


# A Key to Methamphetamine-Related Literature

Version 1.0.1  
(January 2007)



Compiled by: **Mark R. Hammer**  
Division of HIV Prevention  
AIDS Institute  
New York State Department of Health  
(212) 417-4669  
[mrh01@health.state.ny.us](mailto:mrh01@health.state.ny.us)

## A Key to Methamphetamine-Related Literature

---

### Document Description

This document is a comprehensive, thematic index of methamphetamine-related journal articles. In its electronic format, it contains links from cited articles to [PubMed](#), a resource of the [National Library of Medicine](#) maintained by the [National Center for Biotechnology Information](#). *A Key to Methamphetamine-Related Literature* is posted on the [New York State Department of Health's](#) web site at the following URL:  
[http://www.nyhealth.gov/diseases/aids/harm\\_reduction/crystalmeth/docs/meth\\_literature\\_index.pdf](http://www.nyhealth.gov/diseases/aids/harm_reduction/crystalmeth/docs/meth_literature_index.pdf).

### Instructions for Use

#### Viewing the Document

This document is best viewed with Adobe Reader<sup>®</sup>, which is freely available at the following web location: <http://www.adobe.com/products/acrobat/readstep2.html>. **PLEASE NOTE: Because of the large size of *A Key to Methamphetamine-Related Literature*, you are encouraged to download it, store it on your computer and view it directly through the Adobe Reader<sup>®</sup> rather than through a browser extension or add-on.**

#### Navigating the Document

There are two guides for navigating through *A Key to Methamphetamine-Related Literature*: 1) the [Grouped Themes](#); and 2) the more comprehensive [Indexed Terms](#). These tools may be accessed either directly from the body of the document or via the Adobe Reader<sup>®</sup> Bookmarks. If the Bookmarks are not already visible on the left of your screen, you can view them by selecting View/Navigation Tabs/Bookmarks. There are also extensive cross references throughout the document.

#### External Links and Resources

In order to access external links and resources, you must have an Internet connection and a browser. If you select a citation in this document with your mouse, you will be linked in most cases to PubMed where you will find an abstract for the article. From the PubMed site you may be able to link out conveniently to other resources, including the full text of the selected article, if you have an electronic subscription to the journal in which it appears. For more information regarding PubMed, you may want to consult PubMed's [Help](#) or its [Tutorial](#). For articles which are not in PubMed, an attempt has been made in this document to provide links to publisher sites.

### Contact Information

Recommendations for the improvement of this document or other comments may be made to the compiler, Mark Hammer, at [mrh01@health.state.ny.us](mailto:mrh01@health.state.ny.us). No requests for the full text of articles nor for hardcopy of this document will be honored.

### Disclaimer

The State of New York does not warrant or assume any legal liability or responsibility for the accuracy, completeness, or usefulness of any information contained in this document. Reference in this document to the works of others does not imply any recommendation or endorsement of those works. Similarly, the absence of reference to other works does not imply any qualitative assessment of them.. Nothing in this document constitutes advice with respect to the diagnosis or treatment of medical, psychological or substance use conditions. Persons seeking such advice should consult with appropriate professionals.

### Acknowledgements

This work would not have been possible without the resources of three extraordinary libraries: the [National Library of Medicine](#), the [New York State Library](#) and the [Herbert W. Dickerman Library](#) in the [New York State Department of Health's Wadsworth Center](#).

The methamphetamine molecule incorporated in the cover image is courtesy of [erowid.org](http://erowid.org).

# GROUPED THEMES

## Human Studies

GROUPED THEMES (human studies)

### BEHAVIORAL CORRELATES

Aggression and Violence  
Amotivational Syndrome  
Appetite and Feeding  
Binge Use  
Compulsivity

Hyperactivity  
Impulsivity  
Psychomotor Task Performance  
Relapse

Self-Inflicted Injury and Self-Mutilation  
Sexual Risk Behaviors  
Sleep  
Stereotypic Behaviors

### BIOLOGICAL INFLUENCES

Aging and Age Factors  
Genetic Factors

Pharmacokinetics and Pharmacodynamics

Pregnancy  
Sex Differences

### BRAIN

Blood Flow  
Distribution of Methamphetamine  
Electrical Activity  
Glucose Metabolism  
Hepatitis C

HIV  
Imaging  
Lipids  
Neurological Development and Adaptations  
Neurotoxicity

Neurotransmitters  
Pharmacokinetics and Pharmacodynamics  
Reward System  
Seizures

### COMMUNITY

Children, Methamphetamine Endangered  
Child Welfare System  
Circuit Parties and Raves  
Crime  
Ethnography  
Historical Overview

Hospital Utilization  
Internet  
Methamphetamine Laboratories and Manufacture  
Methamphetamine Trafficking and Sale  
Occupational Exposure

Pharmacies  
Precursor Regulation  
Prevalence of Methamphetamine Use  
Prevention of Methamphetamine Use

### HIV

Antiretroviral Therapy  
Brain, HIV and  
Condoms  
HIV Counseling and Testing  
HIV Disclosure

HIV-Positive Individuals  
HIV Prevention  
HIV Replication  
Methamphetamine Interactions with HIV

Sexually Transmitted Diseases  
Sexual Risk Behaviors  
Treatment Adherence

### LEGAL ISSUES

Children, Methamphetamine-endangered  
Child Welfare System  
Crime  
Drug Courts and Court-Mandated Treatment

Incarceration, Alternatives to Incarceration and Incarcerated Individuals  
Law Enforcement  
Methamphetamine Laboratories and Manufacture

Methamphetamine Trafficking and Sale  
Precursor Regulation  
Policy Making

## A Key to Methamphetamine-Related Literature

---

### MEDICAL ISSUES

Antiretroviral Therapy	Hyperthermia	Seizures
Bone Density	Immune Function	Self-Inflicted Injury and Self-Mutilation
Brain Hemorrhages and Strokes	Kidney Function and Disease	Sexually Transmitted Diseases
Burn Injuries	Lead Poisoning	Skin and Soft Tissue Diseases and Disorders
Cardiovascular Effects and Disease	Liver Disease	Spinal Cord Injuries
Corticosterone	Medical Care	Syringe Exchange and Syringe Access
Dental and Oral Health	Medical Uses	Testosterone
Emergency Care	Metabolic Acidosis	Traditional Chinese Medicine
Estrogen	Mortality, Methamphetamine-Associated	Urinary Conditions
Eye Conditions and Injuries	Movement Disorders	Vaccination (hepatitis A)
Gastrointestinal System	Nutrition	Vaccination (hepatitiB)
Health Status	Obesity	Vaccination (pertussis)
Hepatitis A	Occupational Exposure	Vascular Disease
Hepatitis B	Overdose	Vision and Visual Stimuli
Hepatitis C	Pharmacies	Withdrawal
HIV	Pregnancy	
Hospital Utilization	Pulmonary and Thoracic Disease	
Hypertension	Rhabdomyolysis	

### NEUROLOGICAL, COGNITIVE AND PSYCHOLOGICAL ISSUES

Aggression and Violence	Hyperactivity	Psychosis
Attention Deficit Hyperactivity Disorder	Impulsivity	Psychotherapy
Attention Deficits	Memory	Reward System
Bipolar Disorder	Mental Health and Illness	Schizophrenia
Brain, Electrical Activity in	Methamphetamine Abstinence Syndrome	Seizures
Brain, Glucose Metabolism in	Mood	Self-Inflicted Injury and Self-Mutilation
Brain Hemorrhages and Strokes	Motivations for Non-Use and Use Cessation	Self-Perception
Brain Imaging	Motivations for Use	Sexual Compulsivity
Cognition	Neurological Development and Adaptations	Sound and Auditory Stimuli
Compulsivity	Neurotoxicity	Speech
Craving	Panic Disorder	Spinal Cord Injuries
Decision-Making and Judgment	Parkinsonism and Parkinson's Disease	Stereotypic Behaviors
Dependence and Addiction	Pharmacokinetics and Pharmacodynamics	Stress
Depression	Psychomotor Task Performance	Suicide and Suicidal Ideation
Fear and Paranoia		Tolerance
Flashbacks		Vision and Visual Stimuli
Hallucinations		
HIV Brain Disease		

### NEUROTRANSMITTERS AND THEIR METABOLISM

Acetylcholine	Dopamine Transporters	Norepinephrine
Dopamine and Dopamine Metabolism	GABA	Opioid Peptides and Receptors
Dopamine Depletion	Glutamate	Serotonin and Serotonin Metabolism
Dopamine Receptors	Monoamine Transport Function	
	Nitric Oxide	

**OTHER SUBSTANCES**

Adulterated and Contaminated Substances	Erectile Dysfunction Drugs	Methylphenidate (Ritalin™)
Alcohol	Flunitrazepam (Rohypnol™)	Nicotine and Tobacco
Amyl Nitrite	GHB	Psilocybin
Benzodiazepines	Heroin and Other Opioids	Polydrug Use
Caffeine	Ketamine	Recreational and Club Drugs
Cocaine	LSD	Testosterone
	Marijuana	

**POPULATIONS**

African-Americans/Blacks (US)	Homeless Populations	Rural Populations
Aging and Age Factors	Immigrants	Sex Differences
Asians and Pacific Islanders (US)	Incarcerated Individuals	Smokers
Commercial Sex Workers	Injectors	Snorters
Ethnography	Lesbians/Women Who Have Sex with Women	Socioeconomic Factors
Former Methamphetamine Users	Men	Transgendered Individuals
Gay Men/Men Who Have Sex with Men	Military	Treatment, Methamphetamine Users in
Heterosexuals	Native Americans/First Peoples/Aboriginal North Americans	Women
Hispanics	Race and Ethnicity	Young People
HIV-Positive Individuals		

**POPULATIONS—GEOGRAPHY-BASED (UNITED STATES)**

Alabama	Maryland	Oklahoma
Arizona	Massachusetts	Oregon
Arkansas	Michigan	South Dakota
California	Minnesota	Tennessee
Colorado	Missouri	Texas
Florida	Montana	United States Regional Differences
Georgia	Nebraska	Utah
Guam	Nevada	Washington State
Hawaii	New Jersey	Wisconsin
Illinois	New Mexico	Wyoming
Indiana	New York	
Iowa	North Dakota	
Kentucky	Ohio	

**POPULATIONS—GEOGRAPHY-BASED (OUTSIDE OF UNITED STATES)**

Africa	Finland	Pakistan
Asia	Germany	Philippines
Australia	Greece	Poland
Austria	Hong Kong	Portugal
Belgium	Ireland	Russia
Brazil	Italy	Slovak Republic
Burma	Japan	South Africa
Cambodia	Korea	Spain
Canada	Laos	Sweden
China	Latvia	Taiwan
Czech Republic	Lithuania	Thailand
Denmark	Mexico	Tijuana
Estonia	Netherlands	United Kingdom
Europe	New Zealand	

## **A Key to Methamphetamine-Related Literature**

---

### **TREATMENT**

Acupuncture  
Contingency Management  
Drug Courts and Court-Mandated Treatment  
Harm Reduction  
Matrix Model  
Methadone Maintenance

Pharmacological Interventions  
Psychotherapy  
Treatment, Cognitive and Behavioral  
Treatment, Methamphetamine Users in  
Treatment Outcomes

Treatment Preferences of Methamphetamine Users  
Treatment Readiness  
Treatment Utilization  
Twelve Step and Support Groups

### **USAGE**

Binge Use  
Dependence and Addiction  
Disclosure of Methamphetamine Use  
Initiation of Methamphetamine Use  
Injection of Methamphetamine  
Medical Uses

Motivations for Non-Use and Use Cessation  
Motivations for Use  
Oral Administration  
Prevalence of Methamphetamine Use  
Prevention of Methamphetamine Use

Rectal Administration  
Relapse  
Self-Regulation  
Smoking Methamphetamine  
Snorting Methamphetamine  
Tolerance  
Usage Patterns and Dosing

# GROUPED THEMES

## NON-HUMAN STUDIES

### BEHAVIORAL AND COGNITIVE RESPONSES

Aggression and Violence	Craving	Self-Inflicted Injury and Self-Mutilation
Appetite and Feeding	Drinking Behavior	Sleep
Avoidance Behaviors	Exploratory Behaviors	Social Behaviors and Environments
Behavioral Responses (comprehensive listing)	Hyperactivity	Sound and Auditory Stimuli
Binge Use	Psychomotor Task Performance	Stereotypic Behaviors
Circadian Rhythms	Reproductive Behaviors	Timing and Clock Speed
Cognition	Reward System	Vision and Visual Stimuli
Conditioned Place Preference	Self-Administration of Methamphetamine	

### BIOLOGICAL INFLUENCES

Aging and Age Factors	Pharmacokinetics and Pharmacodynamics	Pregnancy
Genetic Factors		Sex Differences

### BRAIN

Ascorbic Acid	Hemorrhages and Strokes	Protein Expression
Blood Flow	HIV	Reward System
Electrical Activity	Imaging	Seizures
Glucose Metabolism	Lipids	

### DEPENDENCY

Conditioned Place Preference	Self-Administration of Methamphetamine	Withdrawal
Craving	Tolerance	
Reward System		

### DOSING AND ROUTES OF ADMINISTRATION

Smoking Methamphetamine	Usage Patterns and Dosing
-------------------------	---------------------------

### EXTERNAL INFLUENCES

Anesthesia	Social Behaviors and Environments	Stress
Pharmacological Interventions		

### HUMAN DISEASES (ANIMAL MODELS)

Bipolar Disorder	Huntington's Disease	Psychosis
Brain Hemorrhages and Strokes	Movement Disorders	Schizophrenia
HIV/Methamphetamine Interactions	Parkinsonism and Parkinson's Disease	

## A Key to Methamphetamine-Related Literature

---

### METABOLIC, HORMONAL AND IMMUNE FUNCTIONS

Brain, Glucose Metabolism in  
Brain Imaging  
Corticosterone

Estrogen  
Immune Function  
Insulin Levels

Liver, Metabolism in  
Sex Differences  
Testosterone

### NEUROTRANSMITTERS AND THEIR METABOLISM

Acetylcholine  
Aspartate  
Brain Imaging  
Benzodiazepine Receptors  
Dopamine and Dopamine  
Metabolism  
Dopamine Depletion  
Dopamine Receptors

Dopamine Transporters  
GABA  
Glutamate  
Glutamate Receptors  
Histamine  
Monoamine Transport Function  
Neurological Development and  
Adaptations

Neurotoxicity  
Nitric Oxide  
Norepinephrine  
Opioid Peptides and Receptors  
Serotonin and Serotonin  
Metabolism  
Substance P  
Tachykinin

### ORGAN SYSTEMS AND STRUCTURES

Brain Imaging  
Cardiovascular Effects and  
Disease  
Cartilage  
Eye Conditions and Injuries  
Fat Cells

Kidney Function and Disease  
Liver, Metabolism in  
Muscles  
Neurological Development and  
Adaptations  
Neurotoxicity

Pulmonary Effects and Thoracic  
Disease  
Reproductive System  
Vascular Effects and Disease

### OTHER SUBSTANCES

Alcohol  
Caffeine  
Cocaine  
Heroin and Other Opioids

Ketamine  
Marijuana and Cannabinoids  
MDMA  
Methylphenidate

Nicotine and Tobacco  
Pharmacological Interventions  
Phencyclidine  
Polydrug Use

### PHYSIOLOGICAL RESPONSES

Cardiovascular Effects and  
Disease  
Hypertension  
Hyperthermia

Neurological Development and  
Adaptations  
Neurotoxicity

Pharmacokinetics and  
Pharmacodynamics  
Seizures  
Tremors

### TREATMENT

Acupuncture

Pharmacological Interventions



**I N D E X E D T E R M S**

**I N D E X E D T E R M S**

Abstinence..... 1

Acetylcholine ..... 1

Acetylcholine (animals) ..... 1

Acupuncture..... 2

Acupuncture (animals)..... 2

Addiction..... 2

Adolescents ..... 2

Adulterated and Contaminated Substances ..... 2

Africa ..... 3

African-Americans/Blacks (US) ..... 4

Aggression and Violence ..... 4

Aggression and Violence (animals) ..... 5

Aging and Age Factors ..... 6

Aging and Age Factors (animals) ..... 8

Alabama ..... 9

Alcohol..... 9

Alcohol (animals)..... 12

American Indians ..... 13

Amotivational Syndrome ..... 13

Amyl Nitrite ..... 13

Anesthesia ..... 14

Anesthesia (animals) ..... 14

Antiretroviral Therapy ..... 14

Appetite and Feeding ..... 14

Appetite and Feeding (animals) ..... 15

Arcata, CA (US)..... 16

Arizona (US)..... 16

Arkansas (US)..... 17

Asia ..... 17

Asians and Pacific Islanders (US)..... 23

Aspartate (animals) ..... 24

Atlanta, GA (US) ..... 24

Attention Deficit Hyperactivity Disorder..... 24

Attention Deficits ..... 24

Australia ..... 25

Austria..... 26

Automobiles ..... 27

Avoidance Behaviors (animals) ..... 27

## A Key to Methamphetamine-Related Literature

---

<b>I N D E X E D  T E R M S</b>	Baltimore, MD (US) .....	30
	Behavioral Interventions .....	30
	Behavioral Responses (animals) .....	30
	Belgium .....	56
	Benzodiazepine Receptors (animals) .....	56
	Benzodiazepines .....	57
	Benzodiazepines (animals) .....	57
	Berkeley, CA (US) .....	57
	Binge Use .....	57
	Binge Use (animals) .....	57
	Bipolar Disorder .....	59
	Bipolar Disorder (animal models) .....	59
	Bisexual Men .....	60
	Blacks .....	60
	Blood Glucose (animals) .....	60
	Blood Pressure .....	60
	Body Temperature .....	60
	Bone Density .....	60
	Boston, MA (US) .....	60
	Brain, Ascorbic Acid Release in (animals) .....	60
	Brain, Blood Flow in .....	60
	Brain, Blood Flow in (animals) .....	61
	Brain, Distributinon of Methamphetamine in .....	61
	Brain, Electrical Activity in .....	61
	Brain, Electrical Activity in (animals) .....	62
	Brain, Glucose Metabolism in .....	63
	Brain, Glucose Metabolism in (animals) .....	64
	Brain, Hepatitis C and .....	64
	Brain, HIV and .....	65
	Brain, HIV and (animal models) .....	65
	Brain, Lipids in .....	65
	Brain, Lipids in (animals) .....	66
	Brain, Neuroadaptations in .....	66
	Brain, Neurotoxicity in .....	66
	Brain, Phospholipids in .....	66
	Brain, Protein Expression in .....	66
	Brain, Protein Expression in (animals) .....	66
	Brain, Seizures in .....	67
	Brain Hemorrhages and Strokes .....	67
	Brain Hemorrhages and Strokes (animals) .....	68
	Brain Imaging .....	69
	Brain Imaging (animals) .....	72

Brazil.....	75
British Columbia, Canada.....	75
Burma.....	75
Burn Injuries.....	75
Caffeine.....	76
Caffeine (animals).....	76
California (US).....	76
Cambodia.....	82
Canada.....	82
Cardiovascular Effects and Disease.....	83
Cardiovascular Effects and Disease (animals).....	85
Cartilage (animals).....	86
Catecholamines.....	86
Chemical Structure.....	87
Chicago, IL (US).....	87
Childhood Attention Deficit Hyperactivity Disorder.....	88
Children, Methamphetamine-Endangered.....	88
Children, Methamphetamine Ingestion by.....	88
Child Welfare System.....	89
China.....	89
Circadian Rhythms.....	90
Circadian Rhythms (animals).....	90
Circuit Parties and Raves.....	92
Clandestine Drug Laboratories.....	93
Clock Speed.....	93
Club Drugs.....	93
Cocaine.....	93
Cocaine (animals).....	96
Cognition.....	99
Cognition (animals).....	102
Colorado (US).....	105
Commercial Sex Work and Sex Workers.....	106
Compulsivity.....	107
Conditioned Place Preference (animals).....	107
Condoms.....	109
Contingency Management.....	110
Coordination.....	110
Corticosterone.....	110
Corticosterone (animals).....	110
Craving.....	111
Craving (animals).....	112
Crime.....	113

## A Key to Methamphetamine-Related Literature

---

<b>I N D E X E D  T E R M S</b>	Czech Republic .....	114
	Dallas, TX (US) .....	114
	Dangerousness .....	114
	Deaths .....	114
	Decision-Making and Judgment .....	114
	Denmark .....	115
	Dental and Oral Health .....	115
	Denver, CO (US) .....	116
	Dependence and Addiction .....	116
	Depression .....	119
	Dermatology .....	120
	Des Moines, IA (US) .....	120
	Disclosure of HIV Status .....	121
	Disclosure of Methamphetamine Use .....	121
	Dopamine and Dopamine Metabolism .....	121
	Dopamine and Dopamine Metabolism (animals) .....	125
	Dopamine Depletion .....	139
	Dopamine Depletion (animals) .....	140
	Dopamine Receptors .....	143
	Dopamine Receptors (animals) .....	145
	Dopamine Transporters .....	148
	Dopamine Transporters (animals) .....	149
	Dosing .....	152
	Drinking Behavior (animals) .....	152
	Driving .....	152
	Drug Courts and Court-Mandated Treatment .....	153
	Drug Dealing .....	153
	Eating Disorders .....	153
	Ecstasy .....	153
	Education Level .....	153
	Electroencephalograms (EEGs) .....	154
	El Paso, TX (US) .....	154
	Emergency Care .....	155
	Epidemiology .....	157
	Epinephrine (animals) .....	157
	Erectile Dysfunction Drugs .....	157
	Estonia .....	157
	Estrogen .....	157
	Estrogen (animals) .....	158
	Ethanol .....	158
Ethnography .....	158	
Europe .....	159	

Exploratory Behaviors (animals) .....	160
Eye Conditions and Injuries .....	162
Eye Conditions and Injuries (animals) .....	163
Fatalities .....	163
Fat Cells (animals) .....	163
Fear and Paranoia .....	163
Feeding .....	164
Finland .....	164
Flashbacks .....	164
Florida (US) .....	165
Flunitrazepam (Rohypnol™) .....	165
Food Deprivation .....	165
Former Methamphetamine Users .....	165
Fresno, CA (US) .....	167
GABA (Gamma Aminobutyric Acid) .....	167
GABA (Gamma Aminobutyric Acid) (animals) .....	168
Gamma Hydroxybutyrate .....	170
Gastrointestinal System .....	170
Gay Men/Men Who Have Sex with Men .....	170
Genetic Factors .....	175
Genetic Factors (animals) .....	177
Georgia (US) .....	181
Germany .....	181
GHB (Gamma Hydroxybutyrate) .....	181
Glucose .....	182
Glutamate .....	182
Glutamate (animals) .....	182
Glutamate Receptors (animals) .....	186
Greece .....	187
Guam (US) .....	187
HAART .....	188
Hallucinations .....	188
Harm Reduction .....	188
Hawaii (US) .....	189
Health Status .....	190
Hearing .....	190
Hepatitis A .....	190
Hepatitis B .....	190
Hepatitis C .....	191
Heroin and Other Opioids .....	191
Heroin and Other Opioids (animals) .....	193
Heterosexuals .....	195

## A Key to Methamphetamine-Related Literature

---

<b>I N D E X E D  T E R M S</b>	Hispanics/Latinos/Latinas (US) .....	196
	Histamine (animals) .....	197
	Historical Overview .....	198
	HIV, Methamphetamine Interactions with.....	198
	HIV, Methamphetamine Interactions with (animal models).....	199
	HIV Antiretroviral Therapy .....	200
	HIV Brain Disease .....	200
	HIV Counseling and Testing.....	200
	HIV Disclosure .....	200
	HIV-Positive Individuals .....	200
	HIV Prevention .....	203
	HIV Replication .....	205
	Homeless Populations .....	205
	Hong Kong.....	206
	Honolulu, HI (US).....	206
	Hospital Utilization.....	206
	Houston, TX (US).....	207
	Huntington’s Disease (animal models) .....	207
	Hyperactivity.....	207
	Hyperactivity (animals).....	207
	Hypertension .....	212
	Hypertension (animals).....	213
	Hyperthermia .....	213
	Hyperthermia (animals) .....	214
	Illinois (US) .....	216
	Immigrants (US) .....	216
	Immune Function .....	216
	Immune Function (animals) .....	217
	Impulsivity .....	217
	Impurities .....	217
	Incarceration, Alternatives to .....	217
	Incarceration and Incarcerated Individuals .....	218
	India .....	218
	Indiana (US).....	218
	Initiation of Methamphetamine Use.....	218
	Injection of Methamphetamine .....	219
	Insulin Levels (animals).....	223
	Internet .....	223
	Iowa (US).....	224
	Ireland .....	224
	Italy .....	224
Japan .....	224	

Juarez, Ciudad (Mexico) .....	228
Judgment .....	228
Kentucky (US) .....	228
Ketamine .....	229
Ketamine (animals) .....	229
Kidney Function and Disease .....	229
Kidney Function and Disease (animals) .....	230
Korea .....	230
Laboratories .....	230
Laos .....	230
Latinos .....	230
Latvia .....	230
Law Enforcement .....	230
Lead Poisoning .....	231
Learning .....	231
Lesbians/ Women Who Have Sex with Women .....	231
Lithuania .....	231
Liver, Metabolism in (animals) .....	232
Liver Disease .....	232
Liver Transplantation .....	233
Los Angeles, CA (US) .....	233
LSD (Lysergic Acid Diethylamide) .....	234
Manufacture .....	235
Lungs .....	235
Marijuana and Cannabinoids .....	235
Marijuana and Cannabinoids (animals) .....	236
Maryland (US) .....	236
Massachusetts (US) .....	237
Matrix Model .....	237
MDMA (3, 4-methylenedioxyamphetamine) .....	237
MDMA (3, 4-methylenedioxyamphetamine) (animals) .....	239
Medical Care .....	240
Medical Uses .....	241
Memory .....	243
Men .....	244
Mental Health and Illness .....	244
Metabolic Acidosis .....	250
Methadone Maintenance Treatment .....	250
Methamphetamine, Medical Uses for .....	250
Methamphetamine Abstinence Syndrome .....	250
Methamphetamine Laboratories and Manufacture .....	251
Methamphetamine Psychosis .....	252

## A Key to Methamphetamine-Related Literature

---

<b>I N D E X E D  T E R M S</b>	Methamphetamine Toxicity .....	252
	Methamphetamine Trafficking and Sale .....	252
	Methylphenidate (Ritalin™) .....	253
	Methylphenidate (Ritalin™) (animals) .....	254
	Mexico .....	255
	Miami, FL (US) .....	256
	Michigan (US) .....	256
	Military .....	256
	Milwaukee, WI (US).....	256
	Minnesota (US).....	256
	Missouri (US).....	256
	Monoamine Transport Function.....	256
	Monoamine Transport Function (animals).....	257
	Montana (US).....	257
	Mood.....	258
	Morphine.....	259
	Mortality, Methamphetamine-Associated.....	259
	Motivations for Non-Use and Use Cessation.....	261
	Motivations for Use .....	262
	Movement Disorders.....	262
	Movement Disorders (animals).....	263
	Muscles (animals) .....	263
	Nasal Administration .....	263
	Native Americans/First Peoples/Aboriginal North Americans .....	263
	Nebraska (US).....	263
	Needle Exchange.....	263
	Neighborhood Disadvantage.....	263
	Netherlands .....	263
	Neuroimaging .....	264
	Neurological Development and Adaptations .....	264
	Neurological Development and Adaptations (animals) .....	264
	Neurotoxicity .....	267
	Neurotoxicity (animals) .....	270
	Nevada (US).....	285
	New Jersey (US) .....	285
	New Mexico (US).....	286
	New York, NY (US) .....	286
	New York State (excluding New York City) (US) .....	287
	New Zealand.....	287
	Nicotine and Tobacco .....	287
	Nicotine and Tobacco (animals) .....	288
Night Shifts.....	288	



Nitric Oxide .....	288
Nitric Oxide (animals) .....	289
Norepinephrine .....	289
Norepinephrine (animals) .....	290
North Dakota (US).....	291
Norway.....	291
Nutrition.....	291
Obesity .....	292
Obesity (animals) .....	292
Obsessive-Compulsive Disorder .....	292
Occupational Exposure .....	292
Oceania .....	292
Ohio (US).....	292
Oklahoma (US) .....	293
Older Persons .....	293
Opioid Peptides and Receptors .....	293
Opioid Peptides and Receptors (animals) .....	293
Opioids.....	293
Oral Administration .....	293
Oral Health.....	294
Oregon (US).....	294
Overdose .....	295
Overdose (animals) .....	295
Pakistan .....	295
Panic Disorder.....	296
Paranoia .....	296
Parkinsonism and Parkinson’s Disease .....	296
Parkinsonism and Parkinson’s Disease (animal models) .....	296
Party Drugs .....	298
PCP .....	298
Pennsylvania (US).....	298
Pertussis .....	298
Pharmaceutical Formulations .....	298
Pharmacies .....	298
Pharmacokinetics and Pharmacodynamics .....	298
Pharmacokinetics and Pharmacodynamics (animals) .....	300
Pharmacological Interventions .....	301
Pharmacological Interventions (animals) .....	304
Phencyclidine (animals).....	316
Philadelphia, PA .....	316
Philippines.....	316
Phoenix, AZ (US) .....	317

## A Key to Methamphetamine-Related Literature

---

<b>I N D E X E D  T E R M S</b>	Phospholipids.....	317
	Place Preference.....	317
	Plasticity.....	317
	Pleasure and Pleasure-Seeking Behaviors.....	317
	Poland.....	318
	Policy Making.....	318
	Polydrug Use.....	318
	Polydrug Use (animals).....	320
	Portland, OR (US).....	321
	Poppers.....	321
	Portugal.....	321
	Poverty.....	321
	Precursor Regulation.....	321
	Pregnancy.....	321
	Pregnancy (animals).....	323
	Prevalence of Methamphetamine Use.....	325
	Prevention of Methamphetamine Use.....	327
	Primary Care.....	328
	Prison.....	328
	Prostitution.....	328
	Psilocybin.....	328
	Psychomotor Task Performance.....	328
	Psychomotor Task Performance (animals).....	329
	Psychosis.....	329
	Psychosis (animal models).....	333
	Psychotherapy.....	333
	Pulmonary Effects and Thoracic Disease.....	333
	Pulmonary Effects and Thoracic Disease (animals).....	334
	Race and Ethnicity.....	334
	Raves.....	336
	Reasons for Use.....	336
	Recreational and Club Drugs.....	336
	Rectal Administration.....	337
	Relapse.....	337
	Relapse (animals).....	338
	Religion and Spirituality.....	338
	Repeated Behaviors.....	338
	Reproductive Behaviors (animals).....	338
	Reproductive System (animals).....	338
	Respiratory Disease.....	338
Review Articles.....	338	
Reward System.....	348	

Reward System (animals) .....	349
Rhabdomyolysis .....	350
Ritalin .....	350
Riverside, CA (US) .....	350
Rohypnol™ .....	351
Rural Populations .....	351
Russia .....	351
Sacramento, CA (US) .....	351
Sale .....	352
San Antonio, TX (US) .....	352
San Diego, CA (US) .....	352
San Francisco, CA (US) .....	353
San Jose, CA (US) .....	355
Santa Cruz, CA (US) .....	355
Schizophrenia .....	355
Schizophrenia (animal models) .....	356
Seattle, WA (US) .....	357
Seizures .....	358
Seizures (animals) .....	358
Self-Administration of Methamphetamine .....	358
Self-Administration of Methamphetamine (animals) .....	358
Self-Inflicted Injury and Self-Mutilation .....	361
Self-Inflicted Injury and Self-Mutilation (animals) .....	361
Self-Perception .....	361
Self-Regulation .....	361
Sensation Seeking .....	362
Serotonin and Serotonin Metabolism .....	362
Serotonin and Serotonin Metabolism (animals) .....	363
Setting .....	366
Sex Differences .....	366
Sex Differences (animals) .....	369
Sexual Arousal and Sexual Experiences .....	370
Sexual Compulsivity .....	370
Sexuality .....	370
Sexually Transmitted Diseases .....	370
Sexual Risk Behaviors .....	371
Sex Work .....	377
Skin and Soft Tissue Diseases and Disorders .....	377
Sleep .....	377
Sleep (animals) .....	378
Slovak Republic .....	379
Smoking Methamphetamine .....	379

## A Key to Methamphetamine-Related Literature

---

<b>I N D E X E D  T E R M S</b>	Smoking Methamphetamine (animals) .....	380
	Snorting Methamphetamine .....	380
	Social Behaviors and Environments (animals) .....	381
	Socioeconomic Factors .....	382
	Sound and Auditory Stimuli.....	384
	Sound and Auditory Stimuli (animals).....	384
	South Africa .....	384
	South Dakota (US).....	384
	Spain .....	384
	Speech.....	385
	Spinal Cord Injuries .....	385
	Stereotypic Behaviors .....	385
	Stereotypic Behaviors (animals) .....	385
	Stigma .....	392
	Stress .....	392
	Stress (animals).....	392
	Strokes .....	393
	Substance P (animals).....	393
	Suicide and Suicidal Ideation.....	393
	Supervised Smoking Facilities.....	394
	Support Groups .....	394
	Surgery.....	394
	Sweden.....	394
	Syringe Exchange and Syringe Access .....	394
	Tachykinin (animals) .....	395
	Tacoma, WA (US) .....	395
	Taiwan .....	395
	Teeth .....	396
	Temperature of Body (animals).....	396
	Tennessee (US).....	397
	Testosterone .....	397
	Testosterone (animals).....	397
	Texas (US) .....	397
	Thailand .....	398
	Therapeutic Uses.....	399
	Tijuana (Mexico).....	399
	Timing and Clock Speed (animals).....	399
	Tobacco.....	399
	Tolerance.....	399
	Tolerance (animals).....	400
Toronto, ON (Canada) .....	401	
Traditional Chinese Medicine .....	401	

Trafficking .....	401
Transgendered Individuals .....	401
Trauma .....	401
Treatment .....	401
Treatment, Cognitive and Behavioral .....	401
Treatment, Methamphetamine Users in .....	403
Treatment (HIV) Adherence .....	406
Treatment Outcomes .....	406
Treatment Preferences of Methamphetamine Users.....	407
Treatment Readiness .....	408
Treatment Utilization .....	408
Tremors .....	408
Tremors (animals) .....	409
Tulsa, OK (US) .....	409
Tuscon, AZ (US).....	409
Twelve Step and Support Groups .....	409
United Kingdom.....	409
United States Regional Variations .....	409
Urinary Conditions.....	410
Usage Patterns and Dosing.....	410
Usage Patterns and Dosing (animals).....	412
Utah (US).....	416
Vaccination, Drug Treatment.....	416
Vaccination, Hepatitis A.....	416
Vaccination, Hepatitis B .....	416
Vaccination, Pertussis .....	416
Vancouver, BC (Canda).....	416
Vascular Effects and Disease .....	417
Vascular Effects and Disease (animals).....	417
Viagra™ .....	418
Victoria, BC (Canada).....	418
Violence .....	418
Vision and Visual Stimuli .....	418
Vision and Visual Stimuli (animals).....	418
Washington State (US).....	418
Wisconsin (US).....	419
Withdrawal.....	419
Withdrawal (animals).....	419
Women.....	420
Workplace .....	421
Wyoming (US).....	421
Young People.....	421



# C I T A T I O N S

## Abstinence

*See Former Methamphetamine Users; Methamphetamine Abstinence Syndrome*

## Acetylcholine

Holman, R. B., G. R. Elliott, et al. (1975). "Neuroregulators and sleep mechanisms." *Annu Rev Med* 26: 499-520.

Siegal, D., J. Erickson, et al. (2004). "Brain vesicular acetylcholine transporter in human users of drugs of abuse." *Synapse* 52(4): 223-32.

## Acetylcholine (animals)

Busche, A., A. Bagorda, et al. (2006). "The maturation of the acetylcholine system in the dentate gyrus of gerbils (*Meriones unguiculatus*) is affected by epigenetic factors." *J Neural Transm* 113(2): 113-24.

Callaway, J. K., R. G. King, et al. (1990). "Methoxyphenamine inhibits histamine-induced bronchoconstriction in anaesthetized guinea-pigs and histamine-induced contractions of guinea-pig ileum in vitro." *Arch Int Pharmacodyn Ther* 308: 86-94.

Fathi, M. M. (1983). "Effect of drugs on brain acetylcholine level in *Gerbillus pyramidum*." *Comp Biochem Physiol C* 74(1): 15-21.

Fox, G. B., T. A. Esbenshade, et al. (2005). "Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzotrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist." *J Pharmacol Exp Ther* 313(1): 176-90.

Glick, S. D., I. M. Maisonneuve, et al. (2002). "Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration." *Eur J Pharmacol* 438(1-2): 99-105.

Grisel, J. E., J. K. Belknap, et al. (1997). "Quantitative trait loci affecting methamphetamine responses in BXD recombinant inbred mouse strains." *J Neurosci* 17(2): 745-54.

Hashimoto, T., N. Fukuda, et al. (1983). "Effects of TRH and an analog, DN-1417 on the activities of single neurons in the nucleus accumbens, cerebral cortex and caudate-putamen of rats." *Kurume Med J* 30 Suppl: S19-27.

Holman, R. B., G. R. Elliott, et al. (1975). "Neuroregulators and sleep mechanisms." *Annu Rev Med* 26: 499-520.

Ikarashi, Y., A. Takahashi, et al. (1997). "Regulation of dopamine D1 and D2 receptors on striatal acetylcholine release in rats." *Brain Res Bull* 43(1): 107-15.

Isa, Y. (1995). "[Repeated MK-801 administration but not methamphetamine produces up-regulation of muscarinic acetylcholine receptors in mice]." *Masui* 44(12): 1648-53.

Iwata, H., A. Baba, et al. (1974). "Role of thiamine metabolism in the central nervous system. II. Effects of various agents on thiamine triphosphatase activity in rat brain." *Jpn J Pharmacol* 24(6): 825-9.

Kim, J. S., R. Hassler, et al. (1970). "Abnormal movements and rigidity induced by harmaline in relation to striatal acetylcholine, serotonin, and dopamine." *Exp Neurol* 29(2): 189-200.

Kuczynski, R. and D. S. Segal (2001). "Caudate-putamen and nucleus accumbens extracellular acetylcholine responses to methamphetamine binges." *Brain Res* 923(1-2): 32-8.

Kumagai, H. (1963). "Central effect of some vasoactive substances as observed by the cross-circulation in the dog." *Jpn Heart J* 186: 462-8.

Lehmann, K., B. Hundsdorfer, et al. (2004). "The acetylcholine fiber density of the neocortex is altered by isolated rearing and early methamphetamine intoxication in rodents." *Exp Neurol* 189(1): 131-40.

Lobo, L. L., R. de Medeiros, et al. (1995). "Atropine increases pilocarpine-induced yawning behavior in paradoxical sleep deprived rats." *Pharmacol Biochem Behav* 52(3): 485-8.

McGeer, P. L., D. S. Grewaal, et al. (1974). "Influence of noncholinergic drugs on rat striatal acetylcholine levels." *Brain Res* 80(2): 211-7.

- Miyata, H., K. Ando, et al. (1991). "[Studies on the involvement of the nucleus accumbens in the discriminative effects of nicotine in rats]." *Nippon Yakurigaku Zasshi* 98(5): 389-97.
- Nomura, T. and T. Nishizaki (1997). "Methamphetamine modulates ACh-evoked currents in *Xenopus* oocytes expressing the rat alpha7 receptors." *Neurosci Lett* 239(2-3): 73-6.
- Oka, T. and E. Hosoya (1977). "The different effect of humoral modulators on the morphine- and central nervous system stimulant-induced hyperactivity of rats." *Neuropharmacology* 16(2): 115-9.
- Okada, M. (1991). "Effects of a new thyrotropin releasing hormone analogue, YM-14673, on the in vivo release of acetylcholine as measured by intracerebral dialysis in rats." *J Neurochem* 56(5): 1544-7.
- Pace, C. J., S. D. Glick, et al. (2004). "Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration." *Eur J Pharmacol* 492(2-3): 159-67.
- Taguchi, K., J. Atobe, et al. (1998). "The effect of methamphetamine on the release of acetylcholine in the rat striatum." *Eur J Pharmacol* 360(2-3): 131-7.
- Takamatsu, Y., Y. Yamanishi, et al. (2006). "Differential effects of donepezil on methamphetamine and cocaine dependencies." *Ann N Y Acad Sci* 1074: 418-26.
- Toyota, H., C. Dugovic, et al. (2002). "Behavioral characterization of mice lacking histamine H(3) receptors." *Mol Pharmacol* 62(2): 389-97.
- Tsai, T. H. and C. F. Chen (1994). "Simultaneous measurement of acetylcholine and monoamines by two serial on-line microdialysis systems: Effects of methamphetamine on neurotransmitters release from the striatum of freely moving rats." *Neurosci Lett* 166(2): 175-7.
- Varner, K. J., B. A. Ogden, et al. (2002). "Cardiovascular responses elicited by the "binge" administration of methamphetamine." *J Pharmacol Exp Ther* 301(1): 152-9.

### Acupuncture

- Russell, L. C., B. Sharp and B. Gilbertson (2000). "Acupuncture for addicted patients with chronic histories of arrest. A pilot study of the consortium treatment center." *J Subst Abuse Treat* 19(2): 199-205.
- Shuaib, B. M. (1976). "Acupuncture treatment of drug dependence in Pakistan." *Am J Chin Med (Gard City N Y)* 4(4): 403-7.

### Acupuncture (animals)

- Liang, X. B., Y. Luo, et al. (2003). "Electro-acupuncture improves behavior and upregulates GDNF mRNA in MFB transected rats." *Neuroreport* 14(8): 1177-81.
- Tian, D. R., X. D. Li, et al. (2005). "Up-regulation of the expression of cocaine and amphetamine-regulated transcript peptide by electroacupuncture in the arcuate nucleus of diet-induced obese rats." *Neurosci Lett* 383(1-2): 17-21.

### Addiction

*See Dependence and Addiction*

### Adolescents

*See Young People*

### Adulterated and Contaminated Substances

- Allcott, J. V., 3rd, R. A. Barnhart, et al. (1987). "Acute lead poisoning in two users of illicit methamphetamine." *JAMA* 258(4): 510-1.
- Anonymous (1990). "From the Centers for Disease Control. Lead poisoning associated with intravenous-methamphetamine use--Oregon, 1988." *JAMA* 263(6): 797-8.
- Anonymous (1989). "Lead poisoning associated with intravenous-methamphetamine use--Oregon, 1988." *MMWR Morb Mortal Wkly Rep* 38(48): 830-1.
- Burton, B. T. (1991). "Heavy metal and organic contaminants associated with illicit methamphetamine production." *NIDA Res Monogr* 115: 47-59.
- Cheng, J. Y., M. F. Chan, et al. (2006). "Impurity profiling of ecstasy tablets seized in Hong Kong by gas chromatography-mass spectrometry." *Forensic Sci Int* 162(1-3): 87-94.
- Cole, J. C., M. Bailey, et al. (2002). "The content of ecstasy tablets: Implications for the study of their long-term effects." *Addiction* 97(12): 1531-6.



- Dayrit, F. M. and M. C. Dumlao (2004). "Impurity profiling of methamphetamine hydrochloride drugs seized in the Philippines." *Forensic Sci Int* 144(1): 29-36.
- Deloach-Banta, L. J. (1994). "Lichenoid drug eruption: Crystal methamphetamine or adulterants?" *Cutis* 53(2): 97-8.
- Inoue, H., T. Kanamori, et al. (2003). "Methamphetamine impurity profiling using a 0.32 mm i.d. nonpolar capillary column." *Forensic Sci Int* 135(1): 42-7.
- Irvine, R. J., M. Keane, et al. (2006). "Plasma drug concentrations and physiological measures in 'dance party' participants." *Neuropsychopharmacology* 31(2): 424-30.
- Kalasinsky, K. S., J. Hugel, et al. (2004). "Use of MDA (the "love drug") and methamphetamine in Toronto by unsuspecting users of ecstasy (MDMA)." *J Forensic Sci* 49(5): 1106-12.
- Klatt, E. C., S. Montgomery, et al. (1986). "Misrepresentation of stimulant street drugs: A decade of experience in an analysis program." *J Toxicol Clin Toxicol* 24(5): 441-50.
- Ku, Y. R., Y. S. Chang, et al. (1999). "Analysis and confirmation of synthetic anorexics in adulterated traditional Chinese medicines by high-performance capillary electrophoresis." *J Chromatogr A* 848(1-2): 537-43.
- Kuwayama, K., H. Inoue, et al. (2006). "Contribution of thermal desorption and liquid-liquid extraction for identification and profiling of impurities in methamphetamine by gas chromatography-mass spectrometry." *Forensic Sci Int*.
- Kuwayama, K., K. Tsujikawa, et al. (2006). "Identification of impurities and the statistical classification of methamphetamine using headspace solid phase microextraction and gas chromatography-mass spectrometry." *Forensic Sci Int* 160(1): 44-52.
- Lambrechts, M. and K. E. Rasmussen (1984). "Leuckart-specific impurities in amphetamine and methamphetamine seized in Norway." *Bull Narc* 36(1): 47-57.
- Lee, J. S., E. Y. Han, et al. (2006). "Analysis of the impurities in the methamphetamine synthesized by three different methods from ephedrine and pseudoephedrine." *Forensic Sci Int* 161(2-3): 209-215.
- Mitrevski, B. and Z. Zdravkovski (2005). "Rapid and simple method for direct determination of several amphetamines in seized tablets by GC-FID." *Forensic Sci Int* 152(2-3): 199-203.
- Moore, K. A., T. Mirshahi, et al. (1996). "Pharmacological characterization of BNMPA (alpha-benzyl-N-methylphenethylamine), an impurity of illicit methamphetamine synthesis." *Eur J Pharmacol* 311(2-3): 133-9.
- Moore, K. A., A. H. Lichtman, et al. (1995). "Alpha-Benzyl-N-methylphenethylamine (BNMPA), an impurity of illicit methamphetamine synthesis: pharmacological evaluation and interaction with methamphetamine." *Drug Alcohol Depend* 39(2): 83-9.
- Norton, R. L., B. T. Burton, et al. (1996). "Blood lead of intravenous drug users." *J Toxicol Clin Toxicol* 34(4): 425-30.
- Puthaviriyakorn, V., N. Siriviriyasomboon, et al. (2002). "Identification of impurities and statistical classification of methamphetamine tablets (Ya-Ba) seized in Thailand." *Forensic Sci Int* 126(2): 105-13.
- Qi, Y., I. D. Evans, et al. (2006). "Australian Federal Police seizures of illicit crystalline methamphetamine ('ice') 1998-2002: Impurity analysis." *Forensic Sci Int* 164(2-3): 201-10.
- Qi, Y., I. Evans, et al. (2006). "New impurity profiles of recent Australian imported 'ice': Methamphetamine impurity profiling and the identification of (pseudo)ephedrine and Leuckart specific marker compounds." *Forensic Sci Int*.
- Sasaki, T. and Y. Makino (2006). "Effective injection in pulsed splitless mode for impurity profiling of methamphetamine crystal by GC or GC/MS." *Forensic Sci Int* 160(1): 1-10.
- Suzuki, S., H. Tsuchihashi, et al. (1988). "Analyses of impurities in methamphetamine by inductively coupled plasma mass spectrometry and ion chromatography." *J Chromatogr* 437(1): 322-7.
- Teng, S. F., S. C. Wu, et al. (2006). "Characteristics and trends of 3,4-methylenedioxymethamphetamine (MDMA) tablets found in Taiwan from 2002 to February 2005." *Forensic Sci Int* 161(2-3): 202-8.
- Varner, K. J., N. D. Hein, et al. (2001). "Chloroephedrine: contaminant of methamphetamine synthesis with cardiovascular activity." *Drug Alcohol Depend* 64(3): 299-307.
- Windahl, K. L., M. J. McTigue, et al. (1995). "Investigation of the impurities found in methamphetamine synthesised from pseudoephedrine by reduction with hydriodic acid and red phosphorus." *Forensic Sci Int* 76(2): 97-114.

## Africa

- Bateman, C. (2006). "'Tik' causing a health crisis." *S Afr Med J* 96(8): 672, 674.
- Morris, K. and C. Parry (2006). "South African methamphetamine boom could fuel further HIV." *Lancet Infect Dis* 6(8): 471.
- Parry, C. D., A. Pluddemann, et al. (2005). "Cannabis and other drug use among trauma patients in three South African cities, 1999-2001." *S Afr Med J* 95(6): 429-32.
- Parry, C. D., B. Myers, et al. (2004). "Drug policy for methamphetamine use urgently needed." *S Afr Med J* 94(12): 964-5.

Simbayi, L. C., S. C. Kalichman, et al. (2006). "Methamphetamine use and sexual risks for HIV infection in Cape Town, South Africa." *Journal of Substance Use* 11(4): 291-300.

### African-Americans/Blacks (US)

Arria, A. M., C. Derauf, et al. (2006). "Methamphetamine and other substance use during pregnancy: Preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study." *Matern Child Health J* 10(3): 293-302.

Brecht, M. L., L. Greenwell, et al. (2007). "Substance use pathways to methamphetamine use among treated users." *Addict Behav* 32(1): 24-38.

Brecht, M. L., L. Greenwell, et al. (2005). "Methamphetamine treatment: Trends and predictors of retention and completion in a large state treatment system (1992-2002)." *J Subst Abuse Treat* 29(4): 295-306.

Chiappelli, F., P. Shapshak, et al. (2006). "Cellular immunology in HIV-1 positive African American women using alcohol and cocaine." *Front Biosci* 11: 2434-41.

Goldsamt, L. A., J. O'Brien, et al. (2005). "The relationship between club drug use and other drug use: A survey of New York City middle school students." *Subst Use Misuse* 40(9): 1539-55.

Herman-Stahl, M. A., C. P. Krebs, et al. (2006). "Risk and protective factors for methamphetamine use and nonmedical use of prescription stimulants among young adults aged 18 to 25." *Addict Behav*.

Herman-Stahl, M. A., C. P. Krebs, et al. (2006). "Risk and protective factors for nonmedical use of prescription stimulants and methamphetamine among adolescents." *J Adolesc Health* 39(3): 374-80.

Ide, S., H. Kobayashi, et al. (2004). "Gene polymorphisms of the mu opioid receptor in methamphetamine abusers." *Ann N Y Acad Sci* 1025: 316-24.

Irwin, T. W. and J. Morgenstern (2005). "Drug-use patterns among men who have sex with men presenting for alcohol treatment: Differences in ethnic and sexual identity." *J Urban Health*.

Maglione, M., B. Chao, et al. (1998). "Methamphetamine abuse in California: Correlates of injection use." *AIDS and Behavior* 2(3): 257-261.

Nyamathi, A. M., E. L. Dixon, et al. (2006). "Hepatitis C virus infection among homeless men referred from a community clinic." *West J Nurs Res* 28(4): 475-88.

Oetting, E. R., J. L. Deffenbacher, et al. (2000). "Methamphetamine use by high school students: Recent trends, gender and ethnicity differences, and use of other drugs." *Journal of Child and Adolescent Substance Abuse* 10(1): 33-50.

Ompad, D. C., S. Galea, et al. (2004). "Club drug use among minority substance users in New York City." *J Psychoactive Drugs* 36(3): 397-9.

Richard, A. J., V. Mosier, et al. (2002). "New syringe acquisition and multi-person use of syringes among illegal drug users." *J Public Health Policy* 23(3): 324-43.

Schermer, C. R. and D. H. Wisner (1999). "Methamphetamine use in trauma patients: A population-based study." *J Am Coll Surg* 189(5): 442-9.

Sexton, R. L., R. G. Carlson, et al. (2005). "Barriers and pathways to diffusion of methamphetamine use among African Americans in the rural South: Preliminary ethnographic findings." *J Ethn Subst Abuse* 4(1): 77-103.

Simon, S. L., C. P. Domier, et al. (2002). "Cognitive performance of current methamphetamine and cocaine abusers." *J Addict Dis* 21(1): 61-74.

Somlai, A. M., J. A. Kelly, et al. (2003). "Predictors of HIV sexual risk behaviors in a community sample of injection drug-using men and women." *AIDS Behav* 7(4): 383-93.

Wohl, A. R., D. F. Johnson, et al. (2002). "HIV risk behaviors among African American men in Los Angeles County who self-identify as heterosexual." *J Acquir Immune Defic Syndr* 31(3): 354-60.

Wu, L. T., D. J. Pilowsky, et al. (2004). "Injection drug use among stimulant users in a national sample." *Am J Drug Alcohol Abuse* 30(1): 61-83.

### Aggression and Violence

*See also* Self-Inflicted Injury and Self-Mutilation; Suicide and Suicidal Ideation; Trauma

Assael, L. A. (2005). "Methamphetamine: An epidemic of oral health neglect, loss of access to care, abuse, and violence." *J Oral Maxillofac Surg* 63(9): 1253-4.

Austin, A. A. (2004). "Alcohol, tobacco, other drug use, and violent behavior among Native Hawaiians: Ethnic pride and resilience." *Subst Use Misuse* 39(5): 721-46.

Baskin-Sommers, A. and I. Sommers (2006). "The co-occurrence of substance use and high-risk behaviors." *J Adolesc Health* 38(5): 609-11.

- Brecht, M. L., A. O'Brien, et al. (2004). "Methamphetamine use behaviors and gender differences." *Addict Behav* 29(1): 89-106.
- Cartier, J., D. Farabee, et al. (2006). "Methamphetamine use, self-reported violent crime, and recidivism among offenders in California who abuse substances." *J Interpers Violence* 21(4): 435-45.
- Cohen, J. B., A. Dickow, et al. (2003). "Abuse and violence history of men and women in treatment for methamphetamine dependence." *Am J Addict* 12(5): 377-85.
- Cretzmeyer, M., M. V. Sarrazin, et al. (2003). "Treatment of methamphetamine abuse: Research findings and clinical directions." *J Subst Abuse Treat* 24(3): 267-77.
- Friese, G. (2006). "The methamphetamine crisis. What EMS providers need to know to stay safe and treat patients." *Emerg Med Serv* 35(3): 55-64.
- Grella, C. E., Y. I. Hser, et al. (2006). "Mothers in substance abuse treatment: Differences in characteristics based on involvement with child welfare services." *Child Abuse Negl* 30(1): 55-73.
- Hall, W., J. Hando, et al. (1996). "Psychological morbidity and route of administration among amphetamine users in Sydney, Australia." *Addiction* 91(1): 81-7.
- Jansen, K. L. and L. Theron (2006). "Ecstasy (MDMA), methamphetamine, and date rape (drug-facilitated sexual assault): A consideration of the issues." *J Psychoactive Drugs* 38(1): 1-12.
- Logan, B. K., C. L. Fligner, et al. (1998). "Cause and manner of death in fatalities involving methamphetamine." *J Forensic Sci* 43(1): 28-34.
- Maxwell, J. C. (2005). "Emerging research on methamphetamine." *Curr Opin Psychiatry* 18(3): 235-42.
- Miura, H., M. Fujiki, et al. (2006). "Prevalence and profile of methamphetamine users in adolescents at a juvenile classification home." *Psychiatry Clin Neurosci* 60(3): 352-7.
- Mukasa, H., J. Nakamura, et al. (1990). "Platelet monoamine oxidase activity and personality traits in alcoholics and methamphetamine dependents." *Drug Alcohol Depend* 26(3): 251-4.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.
- Richards, J. R., S. W. Bretz, et al. (1999). "Methamphetamine abuse and emergency department utilization." *West J Med* 170(4): 198-202.
- Schermer, C. R. and D. H. Wisner (1999). "Methamphetamine use in trauma patients: A population-based study." *J Am Coll Surg* 189(5): 442-9.
- Schrauzer, G. N. and E. de Vroey (1994). "Effects of nutritional lithium supplementation on mood. A placebo-controlled study with former drug users." *Biol Trace Elem Res* 40(1): 89-101.
- Sekine, Y., Y. Ouchi, et al. (2006). "Brain serotonin transporter density and aggression in abstinent methamphetamine abusers." *Arch Gen Psychiatry* 63(1): 90-100.
- Senjo, S. R. (2005). "Trafficking in meth: An analysis of the differences between male and female dealers." *J Drug Educ* 35(1): 59-77.
- Sheridan, J., S. Bennett, et al. (2006). "Injury associated with methamphetamine use: A review of the literature." *Harm Reduct J* 3(1): 14.
- Slade, M., L. J. Daniel, et al. (1991). "Application of forensic toxicology to the problem of domestic violence." *J Forensic Sci* 36(3): 708-13.
- Sommers, I., D. Baskin, et al. (2006). "Methamphetamine use among young adults: Health and social consequences." *Addict Behav* 31(8): 1469-76.
- Szuster, R. R. (1990). "Methamphetamine in psychiatric emergencies." *Hawaii Med J* 49(10): 389-91.
- Tominaga, G. T., G. Garcia, et al. (2004). "Toll of methamphetamine on the trauma system." *Arch Surg* 139(8): 844-7.
- Zweben, J. E., J. B. Cohen, et al. (2004). "Psychiatric symptoms in methamphetamine users." *Am J Addict* 13(2): 181-90.

## Aggression and Violence (animals)

- Cheng, J. T. (1986). "Effect of skimmianine on animal behavior." *Arch Int Pharmacodyn Ther* 281(1): 35-43.
- Crowley, T. J., A. J. Stynes, et al. (1974). "Ethanol, methamphetamine, pentobarbital, morphine, and monkey social behavior." *Arch Gen Psychiatry* 31(6): 829-38.
- Crowley, T. J. (1972). "Dose-dependent facilitation or suppression of rat fighting by methamphetamine, phenobarbital, or imipramine." *Psychopharmacologia* 27(3): 213-22.
- Fujiwara, M., Y. Kataoka, et al. (1984). "Irritable aggression induced by delta 9-tetrahydrocannabinol in rats pretreated with 6-hydroxydopamine." *Pharmacol Biochem Behav* 20(3): 457-62.
- Kameyama, T., T. Nabeshima, et al. (1981). "[Pharmacological action of eptazocine (l-1,4-dimethyl-10-hydroxy-2,3,4,5,6,7-hexahydro-1,6-methano-1H-4-benzazon ine). (III) Central action of eptazocine (author's transl)]." *Nippon Yakurigaku Zasshi* 78(6): 629-45.

- Knoll, B. (1977). "The effect of para-Br-methamphetamine on aggressive behaviour [proceedings]." *Act Nerv Super (Praha)* 19(3): 225-6.
- Maeda, H. and S. Maki (1987). "Dopamine agonists produce functional recovery from septal lesions which affect hypothalamic defensive attack in cats." *Brain Res* 407(2): 381-5.
- Maeda, H. and S. Maki (1986). "Dopaminergic facilitation of recovery from amygdaloid lesions which affect hypothalamic defensive attack in cats." *Brain Res* 363(1): 135-40.
- Maeda, H., T. Sato, et al. (1985). "Effects of dopamine agonists on hypothalamic defensive attack in cats." *Physiol Behav* 35(1): 89-92.
- Miczek, K. A. and J. M. O'Donnell (1978). "Intruder-evoked aggression in isolated and nonisolated mice: Effects of psychomotor stimulants and L-dopa." *Psychopharmacology (Berl)* 57(1): 47-55.
- Nishikawa, T. and M. Tanaka (1978). "Altered behavioral responses to intense foot shock in socially-isolated rats." *Pharmacol Biochem Behav* 8(1): 61-7.
- Panksepp, J. (1971). "Drugs and stimulus-bound attack." *Physiol Behav* 6(4): 317-20.
- Richardson, D., A. G. Karczmar, et al. (1972). "Intergeneric behavioral differences among methamphetamine treated mice." *Psychopharmacologia* 25(4): 347-75.
- Sassenrath, E. N. and L. F. Chapman (1976). "Primate social behavior as a method of analysis of drug action: studies with THC in monkeys." *Fed Proc* 35(11): 2238-44.
- Shintomi, K. (1975). "Effects of psychotropic drugs on methamphetamine-induced behavioral excitation in grouped mice." *Eur J Pharmacol* 31(2): 195-206.
- Sofia, R. D. (1969). "Structural relationship and potency of agents which selectively block mouse killing (muricide) behavior in rats." *Life Sci* 8(21): 1201-10.
- Sokolov, B. P. and J. L. Cadet (2006). "Methamphetamine causes alterations in the MAP kinase-related pathways in the brains of mice that display increased aggressiveness." *Neuropsychopharmacology* 31(5): 956-66.
- Sokolov, B. P., C. W. Schindler, et al. (2004). "Chronic methamphetamine increases fighting in mice." *Pharmacol Biochem Behav* 77(2): 319-26.
- Tachikawa, S., T. Takenaka, et al. (1978). "Effects of indenolol (YB-2), a new beta-adrenergic blocking agent, and its dextro isomer on the central nervous system of mice and rabbits." *Arch Int Pharmacodyn Ther* 234(1): 74-87.
- Yamamoto, T., S. Shibata, et al. (1989). "[Behavioral pharmacological properties of the novel antidepressant paroxetine, a selective 5-HT uptake inhibitor]." *Nippon Yakurigaku Zasshi* 94(3): 189-206.
- Yamamoto, T., M. Ohno, et al. (1988). "Anti-serotonin action in combination with noradrenaline-stimulating action is important for inhibiting muricide in midbrain raphe-lesioned rats." *Neuropharmacology* 27(2): 123-7.

### Aging and Age Factors

*See also* Neurological Development and Adaptations; Young People

- Brecht, M. L., L. Greenwell, et al. (2007). "Substance use pathways to methamphetamine use among treated users." *Addict Behav* 32(1): 24-38.
- Brecht, M. L. and C. von Mayrhauser (2002). "Differences between Ecstasy-using and nonusing methamphetamine users." *J Psychoactive Drugs* 34(2): 215-23.
- Colfax, G., T. J. Coates, et al. (2005). "Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of San Francisco men who have sex with men." *J Urban Health* 82(1 Suppl 1): i62-i70.
- Dawson, R., Jr., M. F. Beal, et al. (1995). "Excitotoxins, aging, and environmental neurotoxins: Implications for understanding human neurodegenerative diseases." *Toxicol Appl Pharmacol* 134(1): 1-17.
- Evans, E. and D. Longshore (2004). "Evaluation of the substance abuse and crime prevention act: Treatment clients and program types during the first year of implementation." *J Psychoactive Drugs Suppl*(2): 165-74.
- Fairbairn, N., T. Kerr, et al. (2006). "Increasing use and associated harms of crystal methamphetamine injection in a Canadian setting." *Drug Alcohol Depend*.
- Gibson, D. R., M. H. Leamon, et al. (2002). "Epidemiology and public health consequences of methamphetamine use in California's Central Valley." *J Psychoactive Drugs* 34(3): 313-9.
- Gonzales, R., P. Marinelli-Casey, et al. (2006). "Hepatitis C virus infection among methamphetamine-dependent individuals in outpatient treatment." *J Subst Abuse Treat* 31(2): 195-202.
- Grella, C. E., Y. I. Hser, et al. (2006). "Mothers in substance abuse treatment: Differences in characteristics based on involvement with child welfare services." *Child Abuse Negl* 30(1): 55-73.
- Greenwell, L. and M. L. Brecht (2003). "Self-reported health status among treated methamphetamine users." *Am J Drug Alcohol Abuse* 29(1): 75-104.

- Gustavsen, I., J. Morland, et al. (2006). "Impairment related to blood amphetamine and/or methamphetamine concentrations in suspected drugged drivers." *Accid Anal Prev* 38(3): 490-5.
- Halkitis, P. N. and J. J. Palamar (2006). "GHB use among gay and bisexual men." *Addict Behav* 31(11): 2135-9.
- Harano, M., N. Uchimura, et al. (2004). "A polymorphism of DRD2 gene and brain atrophy in methamphetamine psychosis." *Ann N Y Acad Sci* 1025: 307-15.
- Hawks, D., M. Mitcheson, et al. (1969). "Abuse of methylamphetamine." *Br Med J* 2(5659): 715-21.
- Kroutil, L. A., D. L. Van Brunt, et al. (2006). "Nonmedical use of prescription stimulants in the United States." *Drug Alcohol Depend* 84(2): 135-43.
- Kurtz, S. P. (2005). "Post-circuit blues: Motivations and consequences of crystal meth use among gay men in Miami." *AIDS Behav* 9(1): 63-72.
- Liu, A., P. Kilmarx, et al. (2006). "Sexual initiation, substance use, and sexual behavior and knowledge among vocational students in northern Thailand." *Int Fam Plan Perspect* 32(3): 126-35.
- Maglione, M., B. Chao, et al. (2000). "Correlates of outpatient drug treatment drop-out among methamphetamine users." *J Psychoactive Drugs* 32(2): 221-8.
- Maglione, M., B. Chao, et al. (1998). "Methamphetamine abuse in California: Correlates of injection use." *AIDS and Behavior* 2(3): 257-261.
- McCann, U. D., D. F. Wong, et al. (1998). "Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: Evidence from positron emission tomography studies with [11C]WIN-35,428." *J Neurosci* 18(20): 8417-22.
- Nyamathi, A., W. A. Robbins, et al. (2002). "Presence and predictors of hepatitis C virus RNA in the semen of homeless men." *Biol Res Nurs* 4(1): 22-30.
- Nyamathi, A. M., E. L. Dixon, et al. (2002). "Risk factors for hepatitis C virus infection among homeless adults." *J Gen Intern Med* 17(2): 134-43.
- Parsons, J. T., B. C. Kelly, et al. (2006). "Differences in club drug use between heterosexual and lesbian/bisexual females." *Addict Behav* 31(12): 2344-9.
- Patterson, T. L., S. J. Semple, et al. (2005). "Methamphetamine-using HIV-positive men who have sex with men: Correlates of polydrug use." *J Urban Health* 82(1 Suppl 1): i120-6.
- Pecha, R. E., T. Prindiville, et al. (1996). "Association of cocaine and methamphetamine use with giant gastroduodenal ulcers." *Am J Gastroenterol* 91(12): 2523-7.
- Pugatch, D. L., B. G. Levesque, et al. (2001). "HIV testing among young adults and older adolescents in the setting of acute substance abuse treatment." *Journal of Acquired Immune Deficiency Syndromes: JAIDS*. 27(2): 135-42.
- Reid, L. W., K. W. Elifson, et al. (2007). "Ecstasy and gateway drugs: Initiating the use of ecstasy and other drugs." *Ann Epidemiol* 17(1): 74-80.
- Rose, V. J., H. F. Raymond, et al. (2006). "Assessing the feasibility of harm reduction services for MSM: The late night breakfast buffet study." *Harm Reduct J* 3: 29.
- Selden, L. S. (1991). "Neurotoxicity of methamphetamine: Mechanisms of action and issues related to aging." *NIDA Res Monogr* 115: 24-32.
- Shibata, S., Y. Minamoto, et al. (1994). "Aging impairs methamphetamine-induced free-running and anticipatory locomotor activity rhythms in rats." *Neurosci Lett* 172(1-2): 107-10.
- Simon, S. L., C. P. Domier, et al. (2002). "Cognitive performance of current methamphetamine and cocaine abusers." *J Addict Dis* 21(1): 61-74.
- Simons, J. S., M. N. Oliver, et al. (2005). "Methamphetamine and alcohol abuse and dependence symptoms: Associations with affect lability and impulsivity in a rural treatment population." *Addict Behav* 30(7): 1370-81.
- Suwaki, H., M. Yamasaki, et al. (1992). "A study of longitudinal patterns of substance abuse with special reference to multiple use problems." *Arukoru Kenkyuto Yakubutsu Ison* 27(3): 284-96.
- Tobe, A., Y. Yoshida, et al. (1981). "Pharmacological evaluation of 2-(4-methylaminobutoxy)diphenylmethane hydrochloride (MCI-2016), A new psychotropic drug with antidepressant activity." *Arzneimittelforschung* 31(8): 1278-85.
- Tobe, A. and T. Kobayashi (1976). "Pharmacological studies on triazine derivatives V Sedative and neuroleptic actions of 2-amino-4-[4-(2-hydroxyethyl)-piperazin-1-yl]-6-trifluoromethyl-s-triazine (TR-10)." *Jpn J Pharmacol* 26(5): 559-70.
- Ujike, H. and M. Sato (2004). "Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis." *Ann N Y Acad Sci* 1025: 279-87.
- Wu, L. T., D. J. Pilowsky, et al. (2004). "Injection drug use among stimulant users in a national sample." *Am J Drug Alcohol Abuse* 30(1): 61-83.

Zule, W. A. and D. P. Desmond (1999). "An ethnographic comparison of HIV risk behaviors among heroin and methamphetamine injectors." *Am J Drug Alcohol Abuse* 25(1): 1-23.

### Aging and Age Factors (animals)

*See also* Neurological Development and Adaptations (animals)

- Ali, S. F., R. R. Holson, et al. (1993). "Development of dopamine and N-methyl-D-aspartate systems in rat brain: The effect of prenatal phencyclidine exposure." *Brain Res Dev Brain Res* 73(1): 25-33.
- Anderson, L. I., R. E. Leipheimer, et al. (2005). "Effects of neonatal and prepubertal hormonal manipulations upon estrogen neuroprotection of the nigrostriatal dopaminergic system within female and male mice." *Neuroscience* 130(2): 369-82.
- Bowyer, J. F. (1995). "The role of hyperthermia in amphetamine's interactions with NMDA receptors, nitric oxide, and age to produce neurotoxicity." *Ann N Y Acad Sci* 765: 309-10.
- Bowyer, J. F., B. Gough, et al. (1993). "Effects of a cold environment or age on methamphetamine-induced dopamine release in the caudate putamen of female rats." *Pharmacol Biochem Behav* 44(1): 87-98.
- Brown, J. M., S. Gouty, et al. (2006). "Differential protection against MPTP or methamphetamine toxicity in dopamine neurons by deletion of ppN/OFQ expression." *J Neurochem* 98(2): 495-505.
- Brummelte, S., T. Grund, et al. (2006). "Long-term effects of a single adult methamphetamine challenge: Minor impact on dopamine fibre density in limbic brain areas of gerbils." *Behav Brain Funct* 2: 12.
- Busche, A., D. Polascheck, et al. (2004). "Developmentally induced imbalance of dopaminergic fibre densities in limbic brain regions of gerbils (*Meriones unguiculatus*)." *J Neural Transm* 111(4): 451-63.
- Cappon, G. D., L. L. Morford, et al. (1997). "Ontogeny of methamphetamine-induced neurotoxicity and associated hyperthermic response." *Brain Res Dev Brain Res* 103(2): 155-62.
- D'Almeida, V., R. Camarini, et al. (1995). "Antioxidant defense in rat brain after chronic treatment with anorectic drugs." *Toxicol Lett* 81(2-3): 101-5.
- Estler, C. J. (1975). "Dependence on age of methamphetamine-produced changes in thermoregulation and metabolism." *Experientia* 31(12): 1436-7.
- Facchinetti, F., R. Dall'Olio, et al. (1994). "Long-lasting effects of chronic neonatal blockade of N-methyl-D-aspartate receptor through the competitive antagonist CGP 39551 in rats." *Neuroscience* 60(2): 343-53.
- Fujiwara, Y., Y. Kazahaya, et al. (1987). "Behavioral sensitization to methamphetamine in the rat: an ontogenic study." *Psychopharmacology (Berl)* 91(3): 316-9.
- Fukui, R., P. Svenningsson, et al. (2003). "Effect of methylphenidate on dopamine/DARPP signalling in adult, but not young, mice." *J Neurochem* 87(6): 1391-401.
- Gomes-Da-Silva, J., M. C. Silva, et al. (1998). "Developmental exposure to methamphetamine: A neonatal model in the rat." *Ann N Y Acad Sci* 844: 310-3.
- Imam, S. Z. and S. F. Ali (2001). "Aging increases the susceptibility to methamphetamine-induced dopaminergic neurotoxicity in rats: Correlation with peroxynitrite production and hyperthermia." *J Neurochem* 78(5): 952-9.
- Knoll, J. and I. Miklya (1995). "Enhanced catecholaminergic and serotonergic activity in rat brain from weaning to sexual maturity: Rationale for prophylactic (-)deprenyl (selegiline) medication." *Life Sci* 56(8): 611-20.
- Kokoshka, J. M., A. E. Fleckenstein, et al. (2000). "Age-dependent differential responses of monoaminergic systems to high doses of methamphetamine." *J Neurochem* 75(5): 2095-102.
- Martin, J. C. and D. C. Martin (1981). "Voluntary activity in the aging rat as a function of maternal drug exposure." *Neurobehav Toxicol Teratol* 3(3): 261-4.
- Martin, J. C., D. D. Martin, et al. (1979). "Life span and pathology in offspring following nicotine and methamphetamine exposure." *Exp Aging Res* 5(6): 509-22.
- Martin, J. C., D. C. Martin, et al. (1976). "Growth, development and activity in rat offspring following maternal drug exposure." *Exp Aging Res* 2(3): 235-51.
- Masuo, Y., M. Ishido, et al. (2004). "Motor activity and gene expression in rats with neonatal 6-hydroxydopamine lesions." *J Neurochem* 91(1): 9-19.
- Miller, D. B., J. P. O'Callaghan, et al. (2000). "Age as a susceptibility factor in the striatal dopaminergic neurotoxicity observed in the mouse following substituted amphetamine exposure." *Ann N Y Acad Sci* 914: 194-207.
- Miller, D. B., S. F. Ali, et al. (1998). "The impact of gender and estrogen on striatal dopaminergic neurotoxicity." *Ann N Y Acad Sci* 844: 153-65.

- Neddens, J., F. Bagorda, et al. (2003). "Epigenetic factors differentially influence postnatal maturation of serotonin (5-HT) innervation in cerebral cortex of gerbils: interaction of rearing conditions and early methamphetamine challenge." *Brain Res Dev Brain Res* 146(1-2): 119-30.
- Pu, C., H. W. Broening, et al. (1996). "Effect of methamphetamine on glutamate-positive neurons in the adult and developing rat somatosensory cortex." *Synapse* 23(4): 328-34.
- Pu, C. and C. V. Vorhees (1993). "Developmental dissociation of methamphetamine-induced depletion of dopaminergic terminals and astrocyte reaction in rat striatum." *Brain Res Dev Brain Res* 72(2): 325-8.
- Ricaurte, G. A., I. Irwin, et al. (1987). "Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra." *Brain Res* 403(1): 43-51.
- Sabol, K. E., J. B. Richards, et al. (2000). "The effects of high-dose methamphetamine in the aging rat: Differential reinforcement of low-rate 72-s schedule behavior and neurochemistry." *J Pharmacol Exp Ther* 294(3): 850-63.
- Shibata, S., Y. Minamoto, et al. (1994). "Aging impairs methamphetamine-induced free-running and anticipatory locomotor activity rhythms in rats." *Neurosci Lett* 172(1-2): 107-10.
- Teuchert-Noodt, G. and R. R. Dawirs (1991). "Age-related toxicity in prefrontal cortex and caudate-putamen complex of gerbils (*Meriones unguiculatus*) after a single dose of methamphetamine." *Neuropharmacology* 30(7): 733-43.
- Truong, J. G., D. G. Wilkins, et al. (2005). "Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: Implications for neurotoxicity." *J Pharmacol Exp Ther* 314(3): 1087-92.
- Tsuchida, K., H. Ujike, et al. (1994). "Ontogeny of enhanced striatal dopamine release in rats with methamphetamine-induced behavioral sensitization." *Pharmacol Biochem Behav* 47(1): 161-9.
- Volz, T. J., G. R. Hanson, et al. (2006). "Kinetic analysis of developmental changes in vesicular monoamine transporter-2 function." *Synapse* 60(6): 474-7.
- Vorhees, C. V., T. M. Reed, et al. (2005). "Periadolescent rats (P41-50) exhibit increased susceptibility to D-methamphetamine-induced long-term spatial and sequential learning deficits compared to juvenile (P21-30 or P31-40) or adult rats (P51-60)." *Neurotoxicol Teratol* 27(1): 117-34.
- Vorhees, C. V., S. L. Inman-Wood, et al. (2000). "Adult learning deficits after neonatal exposure to D-methamphetamine: Selective effects on spatial navigation and memory." *J Neurosci* 20(12): 4732-9.
- Vorhees, C. V., K. G. Ahrens, et al. (1994). "Methamphetamine exposure during early postnatal development in rats: . Acoustic startle augmentation and spatial learning deficits." *Psychopharmacology (Berl)* 114(3): 392-401.
- Wagner, G. C. and S. L. Walsh (1991). "Evaluation of the effects of inhibition of monoamine oxidase and senescence on methamphetamine-induced neuronal damage." *Int J Dev Neurosci* 9(2): 171-4.
- Williams, M. T., T. L. Schaefer, et al. (2006). "Ontogeny of the adrenal response to (+)-methamphetamine in neonatal rats: The effect of prior drug exposure." *Stress* 9(3): 153-63.
- Williams, M. T., M. S. Moran, et al. (2004). "Behavioral and growth effects induced by low dose methamphetamine administration during the neonatal period in rats." *Int J Dev Neurosci* 22(5-6): 273-83.
- Williams, M. T., T. L. Blankenmeyer, et al. (2003). "Long-term effects of neonatal methamphetamine exposure in rats on spatial learning in the Barnes maze and on cliff avoidance, corticosterone release, and neurotoxicity in adulthood." *Brain Res Dev Brain Res* 147(1-2): 163-75.

## Alabama

- Davis, G. G. and C. I. Swalwell (1996). "The incidence of acute cocaine or methamphetamine intoxication in deaths due to ruptured cerebral (berry) aneurysms." *J Forensic Sci* 41(4): 626-8.
- Davis, G. G. and C. I. Swalwell (1994). "Acute aortic dissections and ruptured berry aneurysms associated with methamphetamine abuse." *J Forensic Sci* 39(6): 1481-5.
- Kim, J. Y. and M. Fendrich (2002). "Gender differences in juvenile arrestees' drug use, self-reported dependence, and perceived need for treatment." *Psychiatr Serv* 53(1): 70-5.
- McGuinness, T. (2006). "Methamphetamine abuse." *Am J Nurs* 106(12): 54-59.

## Alcohol

*See also* Polydrug Use

- Alhassoon, O. M., R. M. Dupont, et al. (2001). "Regional cerebral blood flow in cocaine- versus methamphetamine-dependent patients with a history of alcoholism." *Int J Neuropsychopharmacol* 4(2): 105-12.
- Arria, A. M., C. Derauf, et al. (2006). "Methamphetamine and other substance use during pregnancy: Preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study." *Matern Child Health J* 10(3): 293-302.

- Austin, A. A. (2004). "Alcohol, tobacco, other drug use, and violent behavior among Native Hawaiians: Ethnic pride and resilience." *Subst Use Misuse* 39(5): 721-46.
- Baker, F. M. and W. F. Haning, 3rd (2001). "Substance abuse and dependence in a public hospital: Hawaii." *Hawaii Med J* 60(2): 35-8.
- Baskin-Sommers, A. and I. Sommers (2006). "The co-occurrence of substance use and high-risk behaviors." *J Adolesc Health* 38(5): 609-11.
- Bellis, M. A., K. E. Hughes, et al. (2007). "Effects of backpacking holidays in Australia on alcohol, tobacco and drug use of UK residents." *BMC Public Health* 7(1): 1.
- Bennett, A. H. and A. Delrio (1980). "Idiopathic rupture of the bladder: association with methamphetamine and alcohol." *J Urol* 124(3): 429-30.
- Bogart, L. M., A. H. Kral, et al. (2005). "Sexual risk among injection drug users recruited from syringe exchange programs in California." *Sex Transm Dis* 32(1): 27-34.
- Booth, B. M., C. Leukefeld, et al. (2006). "Correlates of rural methamphetamine and cocaine users: Results from a multistate community study." *J Stud Alcohol* 67(4): 493-501.
- Brecht, M. L., L. Greenwell, et al. (2007). "Substance use pathways to methamphetamine use among treated users." *Addict Behav* 32(1): 24-38.
- Breen, C., L. Degenhardt, et al. (2006). "Alcohol use and risk taking among regular ecstasy users." *Subst Use Misuse* 41(8): 1095-109.
- Buchi, K. F., S. Zone, K. Langheinrich and M. W. Varner (2003). "Changing prevalence of prenatal substance abuse in Utah." *Obstet Gynecol* 102(1): 27-30.
- Caetano, R. and C. Weisner (1995). "The association between DSM-III-R alcohol dependence, psychological distress and drug use." *Addiction* 90(3): 351-9.
- Chen, C. K., S. K. Lin, et al. (2003). "Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis." *Psychol Med* 33(8): 1407-14.
- Chiappelli, F., P. Shapshak, et al. (2006). "Cellular immunology in HIV-1 positive African American women using alcohol and cocaine." *Front Biosci* 11: 2434-41.
- Colfax, G., E. Vittinghoff, et al. (2004). "Substance use and sexual risk: A participant- and episode-level analysis among a cohort of men who have sex with men." *Am J Epidemiol* 159(10): 1002-12.
- Crabbe, J. C., J. K. Belknap, et al. (1998). "Quantitative trait loci: Mapping drug and alcohol-related genes." *Adv Pharmacol* 42: 1033-7.
- Crosby, G. M., R. D. Stall, et al. (1998). "Alcohol and drug use patterns have declined between generations of younger gay-bisexual men in San Francisco." *Drug Alcohol Depend* 52(3): 177-82.
- Crouch, D. J., M. M. Birky, et al. (1993). "The prevalence of drugs and alcohol in fatally injured truck drivers." *J Forensic Sci* 38(6): 1342-53.
- Dai, F., J. Y. Yang, et al. (2006). "Effect of drug-induced ascorbic acid release in the striatum and the nucleus accumbens in hippocampus-lesioned rats." *Brain Res* 1125(1): 163-70.
- Furr, C. D., J. Delva, et al. (2000). "The suspected association between methamphetamine ('ice') smoking and frequent episodes of alcohol intoxication: Data from the 1993 National Household Survey on Drug Abuse." *Drug Alcohol Depend* 59(1): 89-93.
- Garfein, R. S., W. A. Bower, et al. (2004). "Factors associated with fulminant liver failure during an outbreak among injection drug users with acute hepatitis B." *Hepatology* 40(4): 865-73.
- Goldsamt, L. A., J. O'Brien, et al. (2005). "The relationship between club drug use and other drug use: A survey of New York City middle school students." *Subst Use Misuse* 40(9): 1539-55.
- Grella, C. E., Y. I. Hser, et al. (2006). "Mothers in substance abuse treatment: differences in characteristics based on involvement with child welfare services." *Child Abuse Negl* 30(1): 55-73.
- Halkitis, P. N. and J. J. Palamar (2006). "GHB use among gay and bisexual men." *Addict Behav* 31(11): 2135-9.
- Harajiri, S., H. Kojima, et al. (1986). "Synergism between methamphetamine and alcohol in a case of methamphetamine psychosis." *Kurume Med J* 33(4): 163-5.
- Hawks, D., M. Mitcheson, et al. (1969). "Abuse of methylamphetamine." *Br Med J* 2(5659): 715-21.
- Herman-Stahl, M. A., C. P. Krebs, et al. (2006). "Risk and protective factors for methamphetamine use and nonmedical use of prescription stimulants among young adults aged 18 to 25." *Addict Behav*.
- Herman-Stahl, M. A., C. P. Krebs, et al. (2006). "Risk and protective factors for nonmedical use of prescription stimulants and methamphetamine among adolescents." *J Adolesc Health* 39(3): 374-80.
- Hida, Y., K. Kudo, et al. (1999). "Identification of an alcoholic beverage in which methamphetamine was dissolved." *Leg Med (Tokyo)* 1(1): 44-7.
- Hirshfield, S., R. H. Remien, et al. (2004). "Crystal methamphetamine use predicts incident STD infection among men who have sex with men recruited online: A nested case-control study." *J Med Internet Res* 6(4): e41.



- Hirshfield, S., R. H. Remien, et al. (2004). "Substance use and high-risk sex among men who have sex with men: a national online study in the USA." *AIDS Care* 16(8): 1036-47.
- Hser, Y. I., E. Evans, et al. (2005). "Treatment outcomes among women and men methamphetamine abusers in California." *J Subst Abuse Treat* 28(1): 77-85.
- Irwin, T. W. and J. Morgenstern (2005). "Drug-use patterns among men who have sex with men presenting for alcohol treatment: Differences in ethnic and sexual Identity." *J Urban Health*.
- Johnson, F. G. (1970). "A comparison of short-term treatment effects of intravenous sodium amytal-methedrine and LSD in the alcoholic." *Can Psychiatr Assoc J* 15(5): 493-7.
- Kassebaum, G. and S. M. Chandler (1994). "Polydrug use and self control among men and women in prisons." *J Drug Educ* 24(4): 333-50.
- Katsumata, S., K. Sato, et al. (1993). "Sudden death due presumably to internal use of methamphetamine." *Forensic Sci Int* 62(3): 209-15.
- Kono, J., H. Miyata, et al. (2003). "[Studies on clinical features of nicotine dependence in comparison with those of alcohol and methamphetamine dependence using a two compartment model of drug dependence]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 23(1): 29-42.
- Kono, J., H. Miyata, et al. (2001). "Nicotine, alcohol, methamphetamine, and inhalant dependence: A comparison of clinical features with the use of a new clinical evaluation form." *Alcohol* 24(2): 99-106.
- Lampinen, T. M., D. McGhee, et al. (2006). "Increased risk of "club" drug use among gay and bisexual high school students in British Columbia." *J Adolesc Health* 38(4): 458-61.
- Lawton-Craddock, A., S. J. Nixon, et al. (2003). "Cognitive efficiency in stimulant abusers with and without alcohol dependence." *Alcohol Clin Exp Res* 27(3): 457-64.
- Liu, A., P. Kilmarx, et al. (2006). "Sexual initiation, substance use, and sexual behavior and knowledge among vocational students in northern Thailand." *Int Fam Plan Perspect* 32(3): 126-35.
- Luchansky, B., A. Krupski, et al. (2007). "Treatment response by primary drug of abuse: Does methamphetamine make a difference?" *J Subst Abuse Treat* 32(1): 89-96.
- Marshall, G. A., C. M. Dixon, et al. (1991). "Substance abuse-related spontaneous bladder rupture: Report of 2 cases and review of the literature." *J Urol* 145(1): 135-7.
- Matsumoto, T., A. Kamijo, et al. (2005). "Childhood histories of attention-deficit hyperactivity disorders in Japanese methamphetamine and inhalant abusers: Preliminary report." *Psychiatry Clin Neurosci* 59(1): 102-5.
- Matsumoto, T., A. Kamijo, et al. (2002). "Methamphetamine in Japan: The consequences of methamphetamine abuse as a function of route of administration." *Addiction* 97(7): 809-17.
- Mattison, A. M., M. W. Ross, et al. (2001). "Circuit party attendance, club drug use, and unsafe sex in gay men." *J Subst Abuse* 13(1-2): 119-26.
- Maxwell, J. C. and R. T. Spence (2005). "Profiles of club drug users in treatment." *Subst Use Misuse* 40(9): 1409-26.
- McCaughan, J. A., R. G. Carlson, et al. (2005). "From "Candy Kids" to "Chemi-Kids": A typology of young adults who attend raves in the midwestern United States." *Subst Use Misuse* 40(9): 1503-23.
- Mendelson, J., R. T. Jones, et al. (1995). "Methamphetamine and ethanol interactions in humans." *Clin Pharmacol Ther* 57(5): 559-68.
- Mukasa, H., J. Nakamura, et al. (1990). "Platelet monoamine oxidase activity and personality traits in alcoholics and methamphetamine dependents." *Drug Alcohol Depend* 26(3): 251-4.
- Nath, A., K. F. Hauser, et al. (2002). "Molecular basis for interactions of HIV and drugs of abuse." *J Acquir Immune Defic Syndr* 31 Suppl 2: S62-9.
- Nyamathi, A. M., E. L. Dixon, et al. (2002). "Risk factors for hepatitis C virus infection among homeless adults." *J Gen Intern Med* 17(2): 134-43.
- Nyamathi, A., W. A. Robbins, et al. (2002). "Presence and predictors of hepatitis C virus RNA in the semen of homeless men." *Biol Res Nurs* 4(1): 22-30.
- Oetting, E. R., J. L. Deffenbacher, et al. (2000). "Methamphetamine use by high school students: Recent trends, gender and ethnicity differences, and use of other drugs." *Journal of Child and Adolescent Substance Abuse* 10(1): 33-50.
- Okudaira, K., T. Yabana, et al. (1994). "[Clinical problems of alcoholics with a history of methamphetamine abuse]." *Arukuru Kenkyuto Yakubutsu Ison* 29(3): 185-9.
- Peirce, J. M., N. M. Petry, et al. (2006). "Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: A National Drug Abuse Treatment Clinical Trials Network study." *Arch Gen Psychiatry* 63(2): 201-8.
- Rawson, R., A. Huber, et al. (2000). "Methamphetamine and cocaine users: Differences in characteristics and treatment retention." *J Psychoactive Drugs* 32(2): 233-8.

- Reiber, C., G. Galloway, et al. (2000). "A descriptive analysis of participant characteristics and patterns of substance use in the CSAT methamphetamine treatment project: the first six months." *J Psychoactive Drugs* 32(2): 183-91.
- Reid, L. W., K. W. Elifson, et al. (2007). "Ecstasy and gateway drugs: Initiating the use of ecstasy and other drugs." *Ann Epidemiol* 17(1): 74-80.
- Rockett, I. R., S. L. Putnam, et al. (2006). "Declared and undeclared substance use among emergency department patients: A population-based study." *Addiction* 101(5): 706-712.
- Roll, J. M., N. M. Petry, et al. (2006). "Contingency management for the treatment of methamphetamine use disorders." *Am J Psychiatry* 163(11): 1993-9.
- Rose, V. J., H. F. Raymond, et al. (2006). "Assessing the feasibility of harm reduction services for MSM: The late night breakfast buffet study." *Harm Reduct J* 3: 29.
- Ross, M. W., A. M. Mattison, et al. (2003). "Club drugs and sex on drugs are associated with different motivations for gay circuit party attendance in men." *Subst Use Misuse* 38(8): 1173-83.
- Rothman, R. B., J. S. Partilla, et al. (2000). "Methamphetamine dependence: Medication development efforts based on the dual deficit model of stimulant addiction." *Ann N Y Acad Sci* 914: 71-81.
- Rusch, M., T. M. Lampinen, et al. (2004). "Unprotected anal intercourse associated with recreational drug use among young men who have sex with men depends on partner type and intercourse role." *Sex Transm Dis* 31(8): 492-8.
- Schwilke, E. W., M. I. Sampaio dos Santos, et al. (2006). "Changing patterns of drug and alcohol use in fatally injured drivers in Washington State." *J Forensic Sci* 51(5): 1191-8.
- Semple, S. J., T. L. Patterson, et al. (2004). "A comparison of injection and non-injection methamphetamine-using HIV positive men who have sex with men." *Drug Alcohol Depend* 76(2): 203-12.
- Simons, J. S., M. N. Oliver, et al. (2005). "Methamphetamine and alcohol abuse and dependence symptoms: Associations with affect lability and impulsivity in a rural treatment population." *Addict Behav* 30(7): 1370-81.
- Smith, L. M., L. L. Lagasse, et al. (2006). "The Infant Development, Environment, and Lifestyle Study: Effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth." *Pediatrics* 118(3): 1149-1156.
- Suwaki, H., M. Yamasaki, et al. (1992). "A study of longitudinal patterns of substance abuse with special reference to multiple use problems." *Arukuru Kenkyuto Yakubutsu Ison* 27(3): 284-96.
- Wu, L. T., W. E. Schlenger, et al. (2006). "Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths." *Drug Alcohol Depend* 84(1): 102-13.
- Wu, L. T., D. J. Pilowsky, et al. (2004). "Injection drug use among stimulant users in a national sample." *Am J Drug Alcohol Abuse* 30(1): 61-83.
- Yamamura, T., S. Hisida, et al. (1991). "Alcohol addiction of methamphetamine abusers in Japan." *J Forensic Sci* 36(3): 754-64.
- Yamamura, T., H. Hasegawa, et al. (1987). "[Alcohol intake on methamphetamine abusers]." *Nippon Hoigaku Zasshi* 41(1): 21-30.
- Yamasaki, M., H. Suwaki, et al. (1992). "Patterns of alcohol abuse from the viewpoint of multiple substance abuse." *Arukuru Kenkyuto Yakubutsu Ison* 27(5): 540-52.
- Yamauchi, J., S. Marukawa, et al. (2000). "[Simultaneous administration of ethanol emphasizes the effect of methamphetamine on central nervous system in rat with high alcohol preference]." *Nihon Arukuru Yakubutsu Igakkai Zasshi* 35(1): 28-47.
- Yen, C. F., Y. H. Yang, et al. (2005). "Substance initiation sequences among Taiwanese adolescents using methamphetamine." *Psychiatry Clin Neurosci* 59(6): 683-9.
- Yu, L., C. F. Cherg, et al. (2002). "Melatonin in concentrated ethanol and ethanol alone attenuate methamphetamine-induced dopamine depletions in C57BL/6J mice." *J Neural Transm* 109(12): 1477-90.
- Zule, W. A. and D. P. Desmond (1999). "An ethnographic comparison of HIV risk behaviors among heroin and methamphetamine injectors." *Am J Drug Alcohol Abuse* 25(1): 1-23.

### Alcohol (animals)

- Bergstrom, H. C., A. A. Palmer, et al. (2003). "Reverse selection for differential response to the locomotor stimulant effects of ethanol provides evidence for pleiotropic genetic influence on locomotor response to other drugs of abuse." *Alcohol Clin Exp Res* 27(10): 1535-47.
- Cunningham, C. L. and D. Noble (1992). "Methamphetamine-induced conditioned place preference or aversion depending on dose and presence of drug." *Ann N Y Acad Sci* 654: 431-3.
- Kamens, H. M., S. Burkhart-Kasch, et al. (2006). "Ethanol-related traits in mice selectively bred for differential sensitivity to methamphetamine-induced activation." *Behav Neurosci* 120(6): 1356-66.
- Komura, S., T. Fujimiya, et al. (1996). "Fundamental studies on alcohol dependence and disposition." *Forensic Sci Int* 80(1-2): 99-107.

- Nishiguchi, M., H. Kinoshita, et al. (2002). "[Effects of chronic alcohol administration on changes of extracellular dopamine and serotonin concentration induced by methamphetamine--comparison of two different alcohol preference rat lines]." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 37(6): 555-76.
- Rubinstein, M., T. J. Phillips, et al. (1997). "Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine." *Cell* 90(6): 991-1001.
- Steffensen, S. C., R. S. Lee, et al. (2002). "A novel electroencephalographic analysis method discriminates alcohol effects from those of other sedative/hypnotics." *J Neurosci Methods* 115(2): 145-56.
- Wang, Y., C. H. Jeng, et al. (1995). "Methamphetamine facilitates ethanol-induced depressions in cerebellar Purkinje neurons of prazosin- or DSP4-treated rats." *Psychopharmacology (Berl)* 121(4): 433-41.
- Yamamura, T., S. Hishida, et al. (1992). "Effects of methamphetamine and ethanol on learning and brain neurotransmitters in rats." *Pharmacol Biochem Behav* 42(3): 389-400.
- Yamamura, T., S. Hishida, et al. (1987). "[Interaction of alcohol and methamphetamine with acute high dose administration to rats]." *Arukoru Kenkyuto Yakubutsu Ison* 22(4): 286-99.
- Yamauchi, J., S. Marukawa, et al. (2000). "[Simultaneous administration of ethanol emphasizes the effect of methamphetamine on central nervous system in rat with high alcohol preference]." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 35(1): 28-47.

## American Indians

*See Native Americans/First Peoples/Aboriginal North Americans*

## Amotivational Syndrome

- Ashizawa, T., T. Saito, et al. (1996). "[A case of amotivational syndrome as a residual symptom after methamphetamine abuse]." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 31(5): 451-61.
- Wang, G. J., N. D. Volkow, et al. (2004). "Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence." *Am J Psychiatry* 161(2): 242-8.

## Amyl Nitrite

*See also Polydrug Use*

- Brewer, D. D., M. R. Golden, et al. (2006). "Unsafe sexual behavior and correlates of risk in a probability sample of men who have sex with men in the era of highly active antiretroviral therapy." *Sex Transm Dis* 33(4): 250-5.
- Choi, K. H., D. Operario, et al. (2005). "Substance use, substance choice, and unprotected anal intercourse among young Asian American and Pacific Islander men who have sex with men." *AIDS Educ Prev* 17(5): 418-29.
- Colfax, G., T. J. Coates, et al. (2005). "Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of San Francisco men who have sex with men." *J Urban Health* 82(1 Suppl 1): i62-70.
- Colfax, G., E. Vittinghoff, et al. (2004). "Substance use and sexual risk: A participant- and episode-level analysis among a cohort of men who have sex with men." *Am J Epidemiol* 159(10): 1002-12.
- Colfax, G. N., G. Mansergh, et al. (2001). "Drug use and sexual risk behavior among gay and bisexual men who attend circuit parties: A venue-based comparison." *J Acquir Immune Defic Syndr* 28(4): 373-9.
- Drumright, L. N., S. J. Little, et al. (2006). "Unprotected anal intercourse and substance use among men who have sex with men with recent HIV infection." *J Acquir Immune Defic Syndr* 43(3): 344-50.
- Drumright, L. N., S. A. Strathdee, et al. (2006). "Unprotected anal intercourse and substance use before and after HIV diagnosis among recently HIV-infected men who have sex with men." *Sex Transm Dis*.
- Fernandez, M. I., T. Perrino, et al. (2005). "Surfing new territory: club-drug use and risky sex among Hispanic men who have sex with men recruited on the Internet." *J Urban Health* 82(1 Suppl 1): i79-88.
- Fernandez, M. I., L. M. Varga, et al. (2004). "The Internet as recruitment tool for HIV studies: viable strategy for reaching at-risk Hispanic MSM in Miami?" *AIDS Care* 16(8): 953-63.
- Patterson, T. L., S. J. Semple, et al. (2005). "Methamphetamine-using HIV-positive men who have sex with men: Correlates of polydrug use." *J Urban Health* 82(1 Suppl 1): i120-6.
- Romanelli, F. and K. M. Smith (2004). "Recreational use of sildenafil by HIV-positive and -negative homosexual/bisexual males." *Ann Pharmacother* 38(6): 1024-30.

### Anesthesia

- Derom, R., M. Thiery, et al. (1974). "Effects of spinal anesthesia on the acid-base balance of the human fetus in elective caesarean section." *Acta Anaesthesiol Belg* 25(1): 26-8.
- Jenkins, L. C. and H. B. Graves (1965). "Potential hazards of psychoactive drugs in association with anaesthesia." *Can Anaesth Soc J* 12: 121-8.
- Klein, M. and F. Kramer (2004). "Rave drugs: Pharmacological considerations." *AANA J* 72(1): 61-7.
- Smith, N. T. and A. N. Corbascio (1970). "The use and misuse of pressor agents." *Anesthesiology* 33(1): 58-101.

### Anesthesia (animals)

- Adachi, Y. U., K. Watanabe, et al. (2001). "Halothane potentiates the effect of methamphetamine and nomifensine on extracellular dopamine levels in rat striatum: A microdialysis study." *Br J Anaesth* 86(6): 837-45.
- Adachi, Y., Y. Uchihashi, et al. (2000). "Halothane anesthesia decreases the extracellular level of dopamine in rat striatum: a microdialysis study in vivo." *J Anesth* 14(2): 82-90.
- Callaway, J. K., R. G. King, et al. (1990). "Methoxyphenamine inhibits histamine-induced bronchoconstriction in anaesthetized guinea-pigs and histamine-induced contractions of guinea-pig ileum in vitro." *Arch Int Pharmacodyn Ther* 308: 86-94.
- Mizugaki, M., N. Nakagawa, et al. (2001). "Influence of anesthesia on brain distribution of [(11)C]methamphetamine in monkeys in positron emission tomography (PET) study." *Brain Res* 911(2): 173-5.
- Okuyama, E., S. Nishimura, et al. (1991). "Analgesic principles from *Aralia cordata* Thunb." *Chem Pharm Bull (Tokyo)* 39(2): 405-7.
- Tsukada, H., K. Miyasato, et al. (2002). "Comparative effects of methamphetamine and nicotine on the striatal [(11)C]raclopride binding in unanesthetized monkeys." *Synapse* 45(4): 207-12.

### Antiretroviral Therapy

- Antoniou, T. and A. L. Tseng (2002). "Interactions between recreational drugs and antiretroviral agents." *Ann Pharmacother* 36(10): 1598-1613.
- Brewer, D. D., M. R. Golden, et al. (2006). "Unsafe sexual behavior and correlates of risk in a probability sample of men who have sex with men in the era of highly active antiretroviral therapy." *Sex Transm Dis* 33(4): 250-5.
- Colfax, G. N., E. Vittinghoff, et al. (2007). "Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance." *AIDS* 21(2): 239-241.
- Copeland, A. L. and J. L. Sorensen (2001). "Differences between methamphetamine users and cocaine users in treatment." *Drug Alcohol Depend* 62(1): 91-5.
- Ellis, R. J., M. E. Childers, et al. (2003). "Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy." *J Infect Dis* 188(12): 1820-6.
- Fernandez, M. I., G. S. Bowen, et al. (2005). "High rates of club drug use and risky sexual practices among Hispanic men who have sex with men in Miami, Florida." *Subst Use Misuse* 40(9): 1347-62.
- Ghaziani, A. (2005). "Crystal methamphetamine use and antiretroviral drug resistance: A pilot study of behavioral and clinical correlates." *IAPAC Mon* 11(10): 297-9.
- Hales, G., N. Roth, et al. (2000). "Possible fatal interaction between protease inhibitors and methamphetamine." *Antivir Ther* 5(1): 19.
- Kahraman, A., M. Miller, et al. (2006). "Non-alcoholic fatty liver disease in HIV-positive patients predisposes for acute-on-chronic liver failure: Two cases." *Eur J Gastroenterol Hepatol* 18(1): 101-105.
- Patterson, T. L. and S. J. Semple (2003). "Sexual risk reduction among HIV-positive drug-using men who have sex with men." *J Urban Health* 80(4 Suppl 3): iii77-87.
- Pol, S., P. Lebray and A. Vallet-Pichard (2004). "HIV infection and hepatic enzyme abnormalities: Intricacies of the pathogenic mechanisms." *Clin Infect Dis* 38 Suppl 2: S65-72.
- Pritzker, D., A. Kanungo, et al. (2002). "Designer drugs that are potent inhibitors of CYP2D6." *J Clin Psychopharmacol* 22(3): 330-2.
- Reback, C. J., S. Larkins, et al. (2003). "Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men." *AIDS Care* 15(6): 775-85.

### Appetite and Feeding

*See also Eating Disorders*

- Bray, G. A. (1993). "Use and abuse of appetite-suppressant drugs in the treatment of obesity." *Ann Intern Med* 119(7 Pt 2): 707-13.
- Cloyd, M. L. (1997). "Diet pill metabolizes to d-methamphetamine." *J Occup Environ Med* 39(12): 1135.

- Cookson, J. and T. Silverstone (1986). "The effects of methylamphetamine on mood and appetite in depressed patients: A placebo-controlled study." *Int Clin Psychopharmacol* 1(2): 127-33.
- Dutta, S., J. Morton, et al. (2006). "Methamphetamine use following bariatric surgery in an adolescent." *Obes Surg* 16(6): 780-2.
- Hart, C. L., A. S. Ward, et al. (2001). "Methamphetamine self-administration by humans." *Psychopharmacology (Berl)* 157(1): 75-81.
- Herting, R. L. and G. Dillon (1966). "Acute clinical assay for appetite suppression." *J New Drugs* 6(4): 232-6.
- Johnson, B. A., N. Ait-Daoud, et al. (1999). "Effects of isradipine, a dihydropyridine-class calcium channel antagonist, on d-methamphetamine-induced reduction in hunger." *Prog Neuropsychopharmacol Biol Psychiatry* 23(7): 1227-34.
- LeRiche, W. H. and A. Csima (1967). "Trial of appetite suppressant. Study of a short-acting and sustained release appetite suppressant on patients paired by initial weight." *Appl Ther* 9(3): 260-2.
- Linquette, A. and P. Fossati (1971). "[Hunger control with benzphetamine hydrochloride in the treatment of obesity]." *Lille Med* 16: Suppl 2:620-4.
- Matthews, C. (1970). "Overweight relapse: Effects of training and methamphetamine with pentobarbital." *Curr Ther Res Clin Exp* 12(1): 34-9.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.
- Stark, P. and C. W. Tooty (1967). "Effects of amphetamines on eating elicited by hypothalamic stimulation." *J Pharmacol Exp Ther* 158(2): 272-8.
- Tolstoi, L. G. (1989). "The role of pharmacotherapy in anorexia nervosa and bulimia." *J Am Diet Assoc* 89(11): 1640-6.
- Wada, K. and S. Fukui (1990). "[Relationship between years of methamphetamine use and symptoms of methamphetamine psychosis]." *Arukuru Kenkyuto Yakubutsu Ison* 25(3): 143-58.

## **Appetite and Feeding (animals)**

- Achat-Mendes, C., S. F. Ali, et al. (2005). "Differential effects of amphetamines-induced neurotoxicity on appetitive and aversive Pavlovian conditioning in mice." *Neuropsychopharmacology* 30(6): 1128-37.
- Bittner, S. E., G. C. Wagner, et al. (1981). "Effects of a high-dose treatment of methamphetamine on caudate dopamine and anorexia in rats." *Pharmacol Biochem Behav* 14(4): 481-6.
- Cox, R. H., Jr. and R. P. Maickel (1975). "Differential effects of alphaMT on anorectic and stimulatory action of amphetamines." *Res Commun Chem Pathol Pharmacol* 12(4): 621-6.
- Cox, R. H., Jr. and R. P. Maickel (1972). "Comparison of anorexigenic and behavioral potency of phenylethylamines." *J Pharmacol Exp Ther* 181(1): 1-9.
- Crowley, W. R., G. Ramoz, et al. (2005). "Differential effects of methamphetamine on expression of neuropeptide Y mRNA in hypothalamus and on serum leptin and ghrelin concentrations in ad libitum-fed and schedule-fed rats." *Neuroscience* 132(1): 167-73.
- De Vito, M. J. and G. C. Wagner (1989). "Functional consequences following methamphetamine-induced neuronal damage." *Psychopharmacology (Berl)* 97(4): 432-5.
- Estler, C. J. and M. C. Gabrys (1979). "Swimming capacity of mice after prolonged treatment with psychostimulants. II. Effect of methamphetamine on swimming performance and availability of metabolic substrates." *Psychopharmacology (Berl)* 60(2): 173-6.
- Evans, H. L. (1971). "Behavioral effects of methamphetamine and -methyltyrosine in the rat." *J Pharmacol Exp Ther* 176(1): 244-54.
- Fischman, M. W. and C. R. Schuster (1974). "Tolerance development to chronic methamphetamine intoxication in the rhesus monkey." *Pharmacol Biochem Behav* 2(4): 503-8.
- Ginawi, O. T., A. A. Al-Majed, et al. (2005). "Ondansetron, a selective 5-HT<sub>3</sub> antagonist, antagonizes methamphetamine-induced anorexia in mice." *Pharmacol Res* 51(3): 255-9.
- Ginawi, O. T., O. A. al-Shabanah, et al. (1997). "Increased toxicity of methamphetamine in morphine-dependent mice." *Gen Pharmacol* 28(5): 727-31.
- Johanson, C. E., R. L. Balster, et al. (1976). "Self-administration of psychomotor stimulant drugs: The effects of unlimited access." *Pharmacol Biochem Behav* 4(1): 45-51.
- Kaufmann, S. H., H. P. Hofmann, et al. (1981). "Induction of hyperphagia in rats by intracerebroventricular infusion of sodium pentobarbital. A method for testing anorexigenic compounds." *Arzneimittelforschung* 31(2): 335-7.
- Kita, T., M. Takahashi, et al. (1998). "Methamphetamine-induced changes in activity and water intake during light and dark cycles in rats." *Prog Neuropsychopharmacol Biol Psychiatry* 22(7): 1185-96.
- Krauchi, K., A. Wirz-Justice, et al. (1984). "Hypothalamic alpha 2- and beta-adrenoceptor rhythms are correlated with circadian feeding: evidence from chronic methamphetamine treatment and withdrawal." *Brain Res* 321(1): 83-90.

- Kraeuchi, K., K. Rudolph, et al. (1985). "Similarities in feeding behavior of chronic methamphetamine treated and withdrawn rats to VMH lesioned rats." *Pharmacol Biochem Behav* 23(6): 917-20.
- Leibowitz, S. F. and C. Rossakis (1978). "Analysis of feeding suppression produced by perifornical hypothalamic injection of catecholamines, amphetamines and mazindol." *Eur J Pharmacol* 53(1): 69-81.
- Madden, L. J., C. T. Flynn, et al. (2005). "Modeling human methamphetamine exposure in nonhuman primates: Chronic dosing in the rhesus macaque leads to behavioral and physiological abnormalities." *Neuropsychopharmacology* 30(2): 350-9.
- Maickel, R. P. and S. A. Johnson (1973). "Effects of various anorexigenic agents on open field behavior of rats." *Res Commun Chem Pathol Pharmacol* 6(2): 733-9.
- Martin, J. C., D. C. Martin, et al. (1983). "Saccharin preferences in food deprived aging rats are altered as a function of perinatal drug exposure." *Physiol Behav* 30(6): 853-8.
- Matsuda, Y. (1966). "Effects of some centrally acting drugs on food intake of normal and hypothalamus-lesioned rats." *Jpn J Pharmacol* 16(3): 276-86.
- Mattei, R. and E. A. Carlini (1996). "A comparative study of the anorectic and behavioral effects of fenproporex on male and female rats." *Braz J Med Biol Res* 29(8): 1025-30.
- Morimasa, T., A. Wirz-Justice, et al. (1987). "Chronic methamphetamine and its withdrawal modify behavioral and neuroendocrine circadian rhythms." *Physiol Behav* 39(6): 699-705.
- Ono, M., S. Shibata, et al. (1996). "Effect of the noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 on food-anticipatory activity rhythm in the rat." *Physiol Behav* 59(4-5): 585-9.
- Pecoraro, N., A. E. Kosobud, et al. (2000). "Long T methamphetamine schedules produce circadian ensuing drug activity in rats." *Physiol Behav* 71(1-2): 95-106.
- Preston, K. L., G. C. Wagner, et al. (1984). "Effects of methamphetamine on atropine-induced conditioned gustatory avoidance." *Pharmacol Biochem Behav* 20(4): 601-7.
- Richardson, D., A. G. Karczmar, et al. (1972). "Intergeneric behavioral differences among methamphetamine treated mice." *Psychopharmacologia* 25(4): 347-75.
- Rietveld, W. J., J. Korving, et al. (1987). "The circadian control of behavior in the rat affected by the chronic application of methamphetamine." *Prog Clin Biol Res* 227B: 513-7.
- Saito, M., M. Terada, et al. (1995). "[Effects of the long-term administration of methamphetamine on body weight, food intake, blood biochemistry and estrous cycle in rats]." *Exp Anim* 43(5): 747-54.
- Seiden, L. S., W. L. Woolverton, et al. (1993). "Behavioral consequences of partial monoamine depletion in the CNS after methamphetamine-like drugs: The conflict between pharmacology and toxicology." *NIDA Res Monogr* 136: 34-46; discussion 46-52.
- Stark, P. and C. W. Tooty (1967). "Effects of amphetamines on eating elicited by hypothalamic stimulation." *J Pharmacol Exp Ther* 158(2): 272-8.
- Stolerman, I. P. and D. D'Mello G (1978). "Amphetamine-induced hypodipsia and its implications for conditioned taste aversion in rats." *Pharmacol Biochem Behav* 8(4): 333-8.
- Tang, A. H. and J. D. Kirch (1971). "Appetite suppression and central nervous system stimulation in the rhesus monkey." *Psychopharmacologia* 21(2): 139-46.
- Uchihashi, Y., H. Kuribara, et al. (1994). "Long-continuous observation of the effects of methamphetamine on wheel-running and drinking in mice." *Prog Neuropsychopharmacol Biol Psychiatry* 18(2): 397-407.
- Wallach, M. B., M. Dawber, et al. (1977). "A new anorexigen assay: Stress-induced hyperphagia in rats." *Pharmacol Biochem Behav* 6(5): 529-31.
- Yokel, R. A. and R. Pickens (1973). "Self-administration of optical isomers of amphetamine and methylamphetamine by rats." *J Pharmacol Exp Ther* 187(1): 27-33.

### Arcata, CA (US)

- Gleghorn, A. A., R. Marx, et al. (1998). "Association between drug use patterns and HIV risks among homeless, runaway, and street youth in northern California." *Drug Alcohol Depend* 51(3): 219-27.

### Arizona (US)

*See also Phoenix*

- Cunningham, J. K. and L. M. Liu (2005). "Impacts of federal precursor chemical regulations on methamphetamine arrests." *Addiction* 100(4): 479-88.

- Glittenberg, J. and C. Anderson (1999). "Methamphetamines: Use and trafficking in the Tucson-Nogales area." *Subst Use Misuse* 34(14): 1977-89.
- Huff, C. (2006). "Crystal crush." *Hosp Health Netw* 80(10): 59-60, 62, 64.
- Kim, J. Y. and M. Fendrich (2002). "Gender differences in juvenile arrestees' drug use, self-reported dependence, and perceived need for treatment." *Psychiatr Serv* 53(1): 70-5.
- Kashani, J. and A. M. Ruha (2004). "Methamphetamine toxicity secondary to intravaginal body stuffing." *J Toxicol Clin Toxicol* 42(7): 987-9.
- Kolecki, P. (1998). "Inadvertent methamphetamine poisoning in pediatric patients." *Pediatr Emerg Care* 14(6): 385-7.
- Maxwell, J. C., P. Cravioto, et al. (2006). "Drug use and risk of HIV/AIDS on the Mexico-USA border: A comparison of treatment admissions in both countries." *Drug Alcohol Depend* 82 Suppl 1: S85-93.
- Nagorka, A. R. and P. S. Bergeson (1998). "Infant methamphetamine toxicity posing as scorpion envenomation." *Pediatr Emerg Care* 14(5): 350-1.
- Ruha, A. M. and M. C. Yarema (2006). "Pharmacologic treatment of acute pediatric methamphetamine toxicity." *Pediatr Emerg Care* 22(12): 782-5.

## Arkansas (US)

- Booth, B. M., C. Leukefeld, et al. (2006). "Correlates of rural methamphetamine and cocaine users: Results from a multistate community study." *J Stud Alcohol* 67(4): 493-501.
- Boulard, G. (2005). "The meth menace: Battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.
- Farst, K., J. M. Duncan, et al. (2006). "Methamphetamine exposure presenting as caustic ingestions in children." *Ann Emerg Med*.
- Penn, C. L. (2006). "Meth abuse in Arkansas." *J Ark Med Soc* 102(8): 218-9.

## Asia

- Ago, M., K. Ago, et al. (2006). "Toxicological and histopathological analysis of a patient who died nine days after a single intravenous dose of methamphetamine: A case report." *Leg Med (Tokyo)* 8(4): 235-9.
- Ahmad, K. (2003). "Asia grapples with spreading amphetamine abuse." *Lancet* 361(9372): 1878-9.
- Akiyama, K. (2006). "Longitudinal clinical course following pharmacological treatment of methamphetamine psychosis which persists after long-term abstinence." *Ann N Y Acad Sci* 1074: 125-34.
- Ando, E., M. Hayashida, et al. (2004). "[GC-MS analysis of methamphetamine and amphetamine in hair of Thai drug addicts]." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 39(3): 168-79.
- Aoyama, N., N. Takahashi, et al. (2006). "Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder." *Alcohol Clin Exp Res* 30(10): 1644-9.
- Ashizawa, T., T. Saito, et al. (1996). "[A case of amotivational syndrome as a residual symptom after methamphetamine abuse]." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 31(5): 451-61.
- Barr, A. M., W. J. Panenka, et al. (2006). "The need for speed: An update on methamphetamine addiction." *J Psychiatry Neurosci* 31(5): 301-313.
- Barrett, M. E. (2003). "Correlates of illicit drug use in Karen villages in Northern Thailand." *Subst Use Misuse* 38(11-13): 1615-49.
- Beyrer, C., M. H. Razak, et al. (2004). "Methamphetamine users in northern Thailand: Changing demographics and risks for HIV and STD among treatment-seeking substance abusers." *Int J STD AIDS* 15(10): 697-704.
- Buavirat, A., K. Page-Shafer, et al. (2003). "Risk of prevalent HIV infection associated with incarceration among injecting drug users in Bangkok, Thailand: Case-control study." *BMJ* 326(7384): 308.
- Chan, P., J. H. Chen, et al. (1994). "Fatal and nonfatal methamphetamine intoxication in the intensive care unit." *J Toxicol Clin Toxicol* 32(2): 147-55.
- Chen, C. K., S. K. Lin, et al. (2005). "Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis." *Am J Med Genet B Neuropsychiatr Genet* 136(1): 87-91.
- Chen, C. K., X. Hu, et al. (2004). "Association analysis of dopamine D2-like receptor genes and methamphetamine abuse." *Psychiatr Genet* 14(4): 223-226.
- Chen, C. K., S. K. Lin, et al. (2003). "Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis." *Psychol Med* 33(8): 1407-14.
- Cheng, J. Y., M. F. Chan, et al. (2006). "Impurity profiling of ecstasy tablets seized in Hong Kong by gas chromatography-mass spectrometry." *Forensic Sci Int* 162(1-3): 87-94.

- Cheng, J. Y., D. T. Chan, et al. (2005). "An epidemiological study on alcohol/drugs related fatal traffic crash cases of deceased drivers in Hong Kong between 1996 and 2000." *Forensic Sci Int* 153(2-3): 196-201.
- Cheng, C. Y., C. J. Hong, et al. (2005). "Brain-derived neurotrophic factor (Val66Met) genetic polymorphism is associated with substance abuse in males." *Brain Res Mol Brain Res* 140(1-2): 86-90.
- Chiang, S. C., H. Y. Chan, et al. (2006). "Recidivism among male subjects incarcerated for illicit drug use in Taiwan." *Psychiatry Clin Neurosci* 60(4): 444-51.
- Cho, B. I. (1991). "Trends and patterns of methamphetamine abuse in the Republic of Korea." *NIDA Res Monogr* 115: 99-108.
- Chomchai, C., N. Na Manorom, et al. (2004). "Methamphetamine abuse during pregnancy and its health impact on neonates born at Siriraj Hospital, Bangkok, Thailand." *Southeast Asian J Trop Med Public Health* 35(1): 228-31.
- Chung, H., M. Park, et al. (2004). "Recent trends of drug abuse and drug-associated deaths in Korea." *Ann N Y Acad Sci* 1025: 458-64.
- Chung, H. (1998). "Drug abuse trends and epidemiological aspects of drug associated deaths in Korea." *J Toxicol Sci* 23 Suppl 2: 197-200.
- Edakubo, T., T. Kaneko, et al. (1991). "[Secondary development of psychological dependence in a methamphetamine dependent]." *Arukuru Kenkyuto Yakubutsu Ison* 26(2): 96-104.
- Farrell, M., J. Marsden, et al. (2002). "Methamphetamine: Drug use and psychoses becomes a major public health issue in the Asia Pacific region." *Addiction* 97(7): 771-2.
- Fukunaga, T., Y. Mizoi, et al. (1987). "Methamphetamine concentrations in blood, urine, and organs of fatal cases after abuse." *Nippon Hoigaku Zasshi* 41(4): 328-34.
- Greberman, S. B. and K. Wada (1994). "Social and legal factors related to drug abuse in the United States and Japan." *Public Health Rep* 109(6): 731-7.
- German, D., S. G. Sherman, et al. (2006). "Motivations for methamphetamine cessation among young people in northern Thailand." *Addiction* 101(8): 1143-52.
- Harajiri, S., H. Kojima, et al. (1986). "Synergism between methamphetamine and alcohol in a case of methamphetamine psychosis." *Kurume Med J* 33(4): 163-5.
- Harano, M., N. Uchimura, et al. (2004). "A polymorphism of DRD2 gene and brain atrophy in methamphetamine psychosis." *Ann N Y Acad Sci* 1025: 307-15.
- Hashimoto, T., K. Hashimoto, et al. (2005). "A functional glutathione S-transferase P1 gene polymorphism is associated with methamphetamine-induced psychosis in Japanese population." *Am J Med Genet B Neuropsychiatr Genet* 135(1): 5-9.
- Hida, Y., K. Kudo, et al. (1999). "Identification of an alcoholic beverage in which methamphetamine was dissolved." *Leg Med (Tokyo)* 1(1): 44-7.
- Hirabayashi, N., K. Wada, et al. (2004). "Prevalence of substance abuse among patients with physical diseases seen in an emergency room in Japan." *Am J Addict* 13(4): 398-404.
- Hirabayashi, N. and T. Yukioka (2004). "[Prevalence of substance abuse through biological method among patients with physical diseases seen in an emergency room]." *Nihon Arukuru Yakubutsu Igakkai Zasshi* 39(1): 46-50.
- Hong, C. J., C. Y. Cheng, et al. (2003). "Association study of the dopamine and serotonin transporter genetic polymorphisms and methamphetamine abuse in Chinese males." *J Neural Transm* 110(4): 345-51.
- Horiguchi, T., S. Hori, et al. (1999). "A case of traumatic shock complicated by methamphetamine intoxication." *Intensive Care Med* 25(7): 758-60.
- Ide, S., H. Kobayashi, et al. (2006). "Linkage disequilibrium and association with methamphetamine dependence/psychosis of mu-opioid receptor gene polymorphisms." *Pharmacogenomics J* 6(3): 179-88.
- Ide, S., H. Kobayashi, et al. (2004). "Gene polymorphisms of the mu opioid receptor in methamphetamine abusers." *Ann N Y Acad Sci* 1025: 316-24.
- Ikeda, M., N. Iwata, et al. (2006). "Positive association of AKT1 haplotype to Japanese methamphetamine use disorder." *Int J Neuropsychopharmacol* 9(1): 77-81.
- Inada, T., Y. Iijima, et al. (2004). "No association found between the type 1 sigma receptor gene polymorphisms and methamphetamine abuse in the Japanese population: a collaborative study by the Japanese Genetics Initiative for Drug Abuse." *Ann N Y Acad Sci* 1025: 27-33.
- Imanishi, M., T. Sakai, et al. (1997). "[Cerebral infarction due to bacterial emboli associated with methamphetamine abuse]." *No To Shinkei* 49(6): 537-40.
- Inamasu, J., Y. Nakamura, et al. (2003). "Subcortical hemorrhage caused by methamphetamine abuse: Efficacy of the triage system in the differential diagnosis--case report." *Neurol Med Chir (Tokyo)* 43(2): 82-4.
- Inoue, H., N. Ikeda, et al. (2006). "Methamphetamine-related sudden death with a concentration which was of a 'toxic level'." *Leg Med (Tokyo)* 8(3): 150-5.



- Ishigami, A., S. Kubo, et al. (2003). "The application of immunohistochemical findings in the diagnosis in methamphetamine-related death-two forensic autopsy cases." *J Med Invest* 50(1-2): 112-6.
- Ishigami, A., I. Tokunaga, et al. (2003). "Immunohistochemical study of myoglobin and oxidative injury-related markers in the kidney of methamphetamine abusers." *Leg Med (Tokyo)* 5(1): 42-8.
- Itoh, K., K. Hashimoto, et al. (2005). "Association study between brain-derived neurotrophic factor gene polymorphisms and methamphetamine abusers in Japan." *Am J Med Genet B Neuropsychiatr Genet* 132(1): 70-3.
- Iwanami, A., D. Kuwakado, et al. (1997). "Relapse of panic disorder induced by a single intravenous methamphetamine injection." *J Anxiety Disord* 11(1): 113-6.
- Iwanami, A., N. Kato, et al. (1991). "P300 in methamphetamine psychosis." *Biol Psychiatry* 30(7): 726-30.
- Iwata, N., T. Inada, et al. (2004). "No association is found between the candidate genes of t-PA/plasminogen system and Japanese methamphetamine-related disorder: A collaborative study by the Japanese Genetics Initiative for Drug Abuse." *Ann N Y Acad Sci* 1025: 34-8.
- Jittiwutikarn, J., S. Thongsawat, et al. (2006). "Hepatitis C infection among drug users in northern Thailand." *Am J Trop Med Hyg* 74(6): 1111-6.
- Joe Laidler, K. A. (2005). "The rise of club drugs in a heroin society: The case of Hong Kong." *Subst Use Misuse* 40(9-10): 1257-78.
- Kamijo, Y., K. Soma, M. Nishida, A. Namera and T. Ohwada (2002). "Acute liver failure following intravenous methamphetamine." *Vet Hum Toxicol* 44(4): 216-7.
- Kato, M. (1983). "A birds eye view of the present state of drug abuse in Japan." *Drug Alcohol Depend* 11(1): 55-6.
- Katsumata, S., K. Sato, et al. (1993). "Sudden death due presumably to internal use of methamphetamine." *Forensic Sci Int* 62(3): 209-15.
- Katsuragawa, Y. (1999). "Effect of methamphetamine abuse on the bone quality of the calcaneus." *Forensic Sci Int* 101(1): 43-8.
- Kobayashi, H., H. Hata, et al. (2006). "Association analysis of delta-opioid receptor gene polymorphisms in methamphetamine dependence/psychosis." *Am J Med Genet B Neuropsychiatr Genet* 141(5): 482-6.
- Kobayashi, H., S. Ide, et al. (2004). "Study of association between alpha-synuclein gene polymorphism and methamphetamine psychosis/dependence." *Ann N Y Acad Sci* 1025: 325-34.
- Koizumi, H., K. Hashimoto, et al. (2004). "Association between the glutathione S-transferase M1 gene deletion and female methamphetamine abusers." *Am J Med Genet B Neuropsychiatr Genet* 126(1): 43-5.
- Kojima, T., E. Matsushima, et al. (1990). "Eye movements in acute, chronic, and remitted schizophrenics." *Biol Psychiatry* 27(9): 975-89.
- Kojima, T., I. Une, et al. (1984). "A fatal methamphetamine poisoning associated with hyperpyrexia." *Forensic Sci Int* 24(1): 87-93.
- Kojima, T., M. Yashiki, et al. (1984). "Articles found in the possession of a methamphetamine abuser." *Forensic Sci Int* 26(3): 207-14.
- Komokata, T., S. Nishida, et al. (2003). "The impact of donor chemical overdose on the outcome of liver transplantation." *Transplantation* 76(4): 705-8.
- Ku, Y. R., Y. S. Chang, et al. (1999). "Analysis and confirmation of synthetic anorexics in adulterated traditional Chinese medicines by high-performance capillary electrophoresis." *J Chromatogr A* 848(1-2): 537-43.
- Kulsudjarit, K. (2004). "Drug problem in southeast and southwest Asia." *Ann N Y Acad Sci* 1025: 446-57.
- Kuwata, T. and H. Suwaki (1998). "[A clinical study of substance dependence patients combined with other psychiatric disorders]." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 33(5): 574-86.
- Kuwayama, K., H. Inoue, et al. (2006). "Contribution of thermal desorption and liquid-liquid extraction for identification and profiling of impurities in methamphetamine by gas chromatography-mass spectrometry." *Forensic Sci Int*.
- Li, T., C. K. Chen, et al. (2004). "Association analysis of the DRD4 and COMT genes in methamphetamine abuse." *Am J Med Genet* 129B(1): 120-4.
- Lin, S. K., D. Ball, et al. (2004). "Psychiatric comorbidity and gender differences of persons incarcerated for methamphetamine abuse in Taiwan." *Psychiatry Clin Neurosci* 58(2): 206-12.
- Lin, S. K., C. K. Chen, et al. (2003). "Gender-specific contribution of the GABA(A) subunit genes on 5q33 in methamphetamine use disorder." *Pharmacogenomics J* 3(6): 349-55.
- Liu, A., P. Kilmarx, et al. (2006). "Sexual initiation, substance use, and sexual behavior and knowledge among vocational students in northern Thailand." *Int Fam Plan Perspect* 32(3): 126-35.
- Liu, H. C., C. K. Chen, et al. (2006). "Association between dopamine receptor D1 A-48G polymorphism and methamphetamine abuse." *Psychiatry Clin Neurosci* 60(2): 226-31.
- Liu, H. C., S. K. Lin, et al. (2004). "DAT polymorphism and diverse clinical manifestations in methamphetamine abusers." *Psychiatr Genet* 14(1): 33-7.

- Matoba, R., S. Onishi, et al. (1984). "[Sudden death in methamphetamine abusers: a histological study of the heart]." *Nippon Hoigaku Zasshi* 38(2): 199-205.
- Matsumoto, T., A. Kamijo, et al. (2005). "Childhood histories of attention-deficit hyperactivity disorders in Japanese methamphetamine and inhalant abusers: Preliminary report." *Psychiatry Clin Neurosci* 59(1): 102-5.
- Matsumoto, T., A. Yamaguchi, et al. (2005). "Drug preferences in illicit drug abusers with a childhood tendency of attention deficit/hyperactivity disorder: A study using the Wender Utah Rating Scale in a Japanese prison." *Psychiatry Clin Neurosci* 59(3): 311-8.
- Matsumoto, T., A. Kamijo, et al. (2002). "Methamphetamine in Japan: The consequences of methamphetamine abuse as a function of route of administration." *Addiction* 97(7): 809-17.
- Maxwell, J. C. (2005). "Emerging research on methamphetamine." *Curr Opin Psychiatry* 18(3): 235-42.
- McGrath, C. and B. Chan (2005). "Oral health sensations associated with illicit drug abuse." *Br Dent J* 198(3): 159-62; discussion 147; quiz 174.
- McGregor, C., M. Srisurapanont, et al. (2005). "The nature, time course and severity of methamphetamine withdrawal." *Addiction* 100(9): 1320-9.
- Mikami, T., N. Naruse, et al. (2003). "Determining vulnerability to schizophrenia in methamphetamine psychosis using exploratory eye movements." *Psychiatry Clin Neurosci* 57(4): 433-40.
- Miura, H., M. Fujiki, et al. (2006). "Prevalence and profile of methamphetamine users in adolescents at a juvenile classification home." *Psychiatry Clin Neurosci* 60(3): 352-7.
- Miyata, H., J. Kono, et al. (2004). "Clinical features of nicotine dependence compared with those of alcohol, methamphetamine, and inhalant dependence." *Ann N Y Acad Sci* 1025: 481-8.
- Mori, A., H. Suzuki, et al. (1992). "[Three cases of acute methamphetamine intoxication--Analysis of optically active methamphetamine]." *Nippon Hoigaku Zasshi* 46(4): 266-70.
- Morio, A., H. Ujike, et al. (2006). "No association between CART (cocaine- and amphetamine-regulated transcript) gene and methamphetamine dependence." *Ann N Y Acad Sci* 1074: 411-7.
- Morita, Y., H. Ujike, et al. (2005). "A nonsynonymous polymorphism in the human fatty acid amide hydrolase gene did not associate with either methamphetamine dependence or schizophrenia." *Neurosci Lett* 376(3): 182-7.
- Morita, Y., H. Ujike, et al. (2005). "The X-box binding protein 1 (XBP1) gene is not associated with methamphetamine dependence." *Neurosci Lett* 383(1-2): 194-8.
- Moriya, F. and Y. Hashimoto (2002). "A case of fatal hemorrhage in the cerebral ventricles following intravenous use of methamphetamine." *Forensic Sci Int* 129(2): 104-9.
- Mukasa, H., J. Nakamura, et al. (1990). "Platelet monoamine oxidase activity and personality traits in alcoholics and methamphetamine dependents." *Drug Alcohol Depend* 26(3): 251-4.
- Nagata, T., J. Oshima, et al. (2003). "Repetitive self-mutilation among Japanese eating disorder patients with drug use disorder: Comparison with patients with methamphetamine use disorder." *J Nerv Ment Dis* 191(5): 319-23.
- Nagata, T., Y. Kawarada, et al. (2002). "Drug use disorders in Japanese eating disorder patients." *Psychiatry Res* 109(2): 181-91.
- Nakamura, K., C. K. Chen, et al. (2006). "Association analysis of SOD2 variants with methamphetamine psychosis in Japanese and Taiwanese populations." *Hum Genet* 120(2): 243-52.
- Nakano, Y., K. Kaneko, et al. (2003). "A patient with self-inflicted injuries of the cervical vertebrae and spinal cord." *Arch Orthop Trauma Surg* 123(7): 379-81.
- Nakatani, Y. and T. Hara (1998). "Disturbance of consciousness due to methamphetamine abuse. A study of 2 patients." *Psychopathology* 31(3): 131-7.
- Newton, P. N., W. Chierakul, et al. (2003). "Malaria and amphetamine 'horse tablets' in Thailand." *Trop Med Int Health* 8(1): 17-8.
- Nishida, N., N. Ikeda, et al. (2003). "Sudden unexpected death of a methamphetamine abuser with cardiopulmonary abnormalities: A case report." *Med Sci Law* 43(3): 267-71.
- Nishiyama, T., M. Ikeda, et al. (2005). "Haplotype association between GABAA receptor gamma2 subunit gene (GABRG2) and methamphetamine use disorder." *Pharmacogenomics J* 5(2): 89-95.
- Nomura, A., H. Ujike, et al. (2006). "Genetic variant of prodynorphin gene is risk factor for methamphetamine dependence." *Neurosci Lett* 400(1-2): 158-62.
- Obert, J. L., E. D. London, et al. (2002). "Incorporating brain research findings into standard treatment: An example using the Matrix Model." *J Subst Abuse Treat* 23(2): 107-13.
- Ogai, Y., A. Haraguchi, et al. (2005). "[Control of craving for methamphetamine: Development of scales for dependence and search for medicines for treatment]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 25(5): 227-33.
- Ohgake, S., K. Hashimoto, et al. (2005). "Functional polymorphism of the NQO2 gene is associated with methamphetamine psychosis." *Addict Biol* 10(2): 145-8.

- Okudaira, K., T. Yabana, et al. (1994). "[Clinical problems of alcoholics with a history of methamphetamine abuse]." *Arukoru Kenkyuto Yakubutsu Ison* 29(3): 185-9.
- Ozaki, S. and K. Wada (2006). "Characteristics of methylphenidate dependence syndrome in psychiatric hospital settings." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 41(2): 89-99.
- Poshyachinda, V. (1993). "Drug injecting and HIV infection among the population of drug abusers in Asia." *Bull Narc* 45(1): 77-90.
- Puthaviriyakorn, V., N. Siriviriyasomboon, et al. (2002). "Identification of impurities and statistical classification of methamphetamine tablets (Ya-Ba) seized in Thailand." *Forensic Sci Int* 126(2): 105-13.
- Razak, M. H., J. Jittiwutikarn, et al. (2003). "HIV prevalence and risks among injection and noninjection drug users in northern Thailand: Need for comprehensive HIV prevention programs." *J Acquir Immune Defic Syndr* 33(2): 259-66.
- Saito, A., Y. Fujikura-Ouchi, et al. (2007). "Association study of putative promoter polymorphisms in the neuroplastin gene and schizophrenia." *Neurosci Lett* 411(3): 168-73.
- Sato, M. (2002). "[Basic and clinical studies on methamphetamine-related psychosis]." *Seishin Shinkeigaku Zasshi* 104(3): 179-90.
- Sato, M., Y. Numachi, et al. (1992). "Relapse of paranoid psychotic state in methamphetamine model of schizophrenia." *Schizophr Bull* 18(1): 115-22.
- Sato, M. (1992). "A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis." *Ann N Y Acad Sci* 654: 160-70.
- Sato, M., C. C. Chen, et al. (1983). "Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis." *Biol Psychiatry* 18(4): 429-40.
- Sattah, M. V., S. Supawitkul, et al. (2002). "Prevalence of and risk factors for methamphetamine use in northern Thai youth: Results of an audio-computer-assisted self-interviewing survey with urine testing." *Addiction* 97(7): 801-8.
- Sekine, Y., Y. Ouchi, et al. (2006). "Brain serotonin transporter density and aggression in abstinent methamphetamine abusers." *Arch Gen Psychiatry* 63(1): 90-100.
- Sexton, R. L., R. G. Carlson, et al. (2005). "Barriers and pathways to diffusion of methamphetamine use among African Americans in the rural South: Preliminary ethnographic findings." *J Ethn Subst Abuse* 4(1): 77-103.
- Shaw, K. P. (1999). "Human methamphetamine-related fatalities in Taiwan during 1991-1996." *J Forensic Sci* 44(1): 27-31.
- Shibata, S., K. Mori, et al. (1991). "Subarachnoid and intracerebral hemorrhage associated with necrotizing angitis due to methamphetamine abuse—an autopsy case." *Neurol Med Chir (Tokyo)* 31(1): 49-52.
- Shibata, S., K. Mori, et al. (1988). "[An autopsy case of subarachnoid and intracerebral hemorrhage and necrotizing angitis associated with methamphetamine abuse]." *No To Shinkei* 40(11): 1089-94.
- Shimazono, Y. and E. Matsushima (1995). "Behavioral and neuroimaging studies on schizophrenia in Japan." *Psychiatry Clin Neurosci* 49(1): 3-11.
- Shuaib, B. M. (1976). "Acupuncture treatment of drug dependence in Pakistan." *Am J Chin Med (Gard City N Y)* 4(4): 403-7.
- Simbulan, N. P., A. S. Aguilar, et al. (2001). "High-risk behaviors and the prevalence of sexually transmitted diseases among women prisoners at the women state penitentiary in Metro Manila." *Soc Sci Med* 52(4): 599-608.
- Srirak, N., S. Kawichai, et al. (2005). "HIV infection among female drug users in Northern Thailand." *Drug Alcohol Depend* 78(2): 141-5.
- Sribanditmongkol, P., M. Chokjamsai, et al. (2000). "Methamphetamine overdose and fatality: 2 cases report." *J Med Assoc Thai* 83(9): 1120-3.
- Srisurapanont, M., R. Ali, et al. (2003). "Psychotic symptoms in methamphetamine psychotic in-patients." *Int J Neuropsychopharmacol* 6(4): 347-52.
- Sung, Y. H., S. C. Cho, et al. (2006). "Relationship between N-acetyl-aspartate in gray and white matter of abstinent methamphetamine abusers and their history of drug abuse: A proton magnetic resonance spectroscopy study." *Drug Alcohol Depend*.
- Suwaki, H., M. Yamasaki, et al. (1992). "A study of longitudinal patterns of substance abuse with special reference to multiple use problems." *Arukoru Kenkyuto Yakubutsu Ison* 27(3): 284-96.
- Suwanwela, C. and V. Poshyachinda (1986). "Drug abuse in Asia." *Bull Narc* 38(1-2): 41-53.
- Suzuki, A., K. Nakamura, et al. (2006). "An association study between catechol-O-methyl transferase gene polymorphism and methamphetamine psychotic disorder." *Psychiatr Genet* 16(4): 133-8.
- Takasaki, T., N. Nishida, et al. (2003). "Unexpected death due to right-sided infective endocarditis in a methamphetamine abuser." *Leg Med (Tokyo)* 5(1): 65-8.
- Teng, S. F., S. C. Wu, et al. (2006). "Characteristics and trends of 3,4-methylenedioxymethamphetamine (MDMA) tablets found in Taiwan from 2002 to February 2005." *Forensic Sci Int* 161(2-3): 202-8.
- Tohara, S., A. Kato, et al. (1990). "[Methamphetamine abuse by smoking]." *Arukoru Kenkyuto Yakubutsu Ison* 25(6): 467-74.

- Tsai, S. J., C. Y. Cheng, et al. (2002). "No association for D2 and D4 dopamine receptor polymorphisms and methamphetamine abuse in Chinese males." *Psychiatr Genet* 12(1): 29-33.
- Ujike, H. and M. Sato (2004). "Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis." *Ann N Y Acad Sci* 1025: 279-87.
- van Griensvan, F., J. Keawkungwal, et al. (2004). "Lack of increased HIV risk behavior among injection drug users participating in the AIDS VAX B/E HIV vaccine trial in Bangkok, Thailand." *AIDS* 18(2): 295-301.
- van Griensven, F., S. Supawitkul, et al. (2001). "Rapid assessment of sexual behavior, drug use, human immunodeficiency virus, and sexually transmitted diseases in northern Thai youth using audio-computer-assisted self-interviewing and noninvasive specimen collection." *Pediatrics* 108(1): E13.
- Verachai, V., T. Phutiprawan, et al. (2005). "HIV infection among substance abusers in Thanyarak Institute On Drug Abuse, Thailand, 1987-2002." *J Med Assoc Thai* 88(1): 76-9.
- Verachai, V., T. Phutiprawan, et al. (2002). "Prevalence and genotypes of hepatitis C virus infection among drug addicts and blood donors in Thailand." *Southeast Asian J Trop Med Public Health* 33(4): 849-51.
- Verachai, V., S. Dechongkit, et al. (2001). "Drug addicts treatment for ten years in Thanyarak Hospital (1989-1998)." *J Med Assoc Thai* 84(1): 24-9.
- Vitsupakorn, K., S. Teerawatsakul, et al. (2003). "The validity of peer responses as a tool for screening at-risk students: a preliminary analysis." *Southeast Asian J Trop Med Public Health* 34(3): 682-6.
- Vongsheree, S., P. Sri-Ngam, et al. (2001). "High HIV-1 prevalence among methamphetamine users in central Thailand, 1999-2000." *J Med Assoc Thai* 84(9): 1263-7.
- Wada, K. (2004). "[HCV infection among narcotics/methamphetamine abusers]." *Nippon Rinsho* 62 Suppl 7(Pt 1): 326-9.
- Wada, K., S. B. Greberman, et al. (1999). "HIV and HCV infection among drug users in Japan." *Addiction* 94(7): 1063-9.
- Wada, K. (1994). "Cocaine abuse in Japan." *Arukuru Kenkyuto Yakubutsu Ison* 29(2): 83-91.
- Yamamoto, J. (2004). "Recent trends of drug abuse in Japan." *Ann N Y Acad Sci* 1025: 430-8.
- Yamamoto, K., H. Watanabe, et al. (1991). "[3 fatalities after communal use of methamphetamine]." *Arch Kriminol* 188(3-4): 72-6.
- Yamamura, T., H. Hasegawa, et al. (1987). "[Alcohol intake on methamphetamine abusers]." *Nippon Hoigaku Zasshi* 41(1): 21-30.
- Yamasaki, M., H. Suwaki, et al. (1992). "Patterns of alcohol abuse from the viewpoint of multiple substance abuse." *Arukuru Kenkyuto Yakubutsu Ison* 27(5): 540-52.
- Yen, C. F. and M. Y. Chong (2006). "Comorbid psychiatric disorders, sex, and methamphetamine use in adolescents: A case-control study." *Compr Psychiatry* 47(3): 215-20.
- Yen, C. F. and Y. C. Su (2006). "The associations of early-onset methamphetamine use with psychiatric morbidity among Taiwanese adolescents." *Subst Use Misuse* 41(1): 35-44.
- Yen, C. F., Y. H. Yang, et al. (2006). "Correlates of methamphetamine use for Taiwanese adolescents." *Psychiatry Clin Neurosci* 60(2): 160-7.
- Yen, C. F. and Y. P. Chang (2005). "Relapse antecedents for methamphetamine use and related factors in Taiwanese adolescents." *Psychiatry Clin Neurosci* 59(1): 77-82.
- Yen, C. F., C. H. Ko, et al. (2005). "Areca quid chewing and methamphetamine use in Taiwanese adolescents." *Public Health* 119(1): 50-4.
- Yen, C. F. and B. L. Shieh (2005). "Suicidal ideation and correlates in Taiwanese adolescent methamphetamine users." *J Nerv Ment Dis* 193(7): 444-9.
- Yen, C. F., Y. H. Yang, et al. (2005). "Substance initiation sequences among Taiwanese adolescents using methamphetamine." *Psychiatry Clin Neurosci* 59(6): 683-9.
- Yen, C. F. (2004). "Relationship between methamphetamine use and risky sexual behavior in adolescents." *Kaohsiung J Med Sci* 20(4): 160-5.
- Yoon, S. J., C. U. Pae, et al. (2005). "Ghrelin precursor gene polymorphism and methamphetamine dependence in the Korean population." *Neurosci Res* 53(4): 391-5.
- Yoshizawa, H. (2002). "Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: Projection to other countries in the foreseeable future." *Oncology* 62 Suppl 1: 8-17.
- Yui, K., K. Goto and S. Ikemoto (2004). "The role of noradrenergic and dopaminergic hyperactivity in the development of spontaneous recurrence of methamphetamine psychosis and susceptibility to episode recurrence." *Ann N Y Acad Sci* 1025: 296-306.
- Yui, K., S. Ikemoto, et al. (2003). "Susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosis." *J Clin Psychopharmacol* 23(5): 525-8.
- Yui, K., S. Ikemoto, et al. (2002). "Factors for susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosis." *Ann N Y Acad Sci* 965: 292-304.

- Yui, K., S. Ikemoto, et al. (2002). "Spontaneous recurrence of methamphetamine-induced paranoid-hallucinatory states in female subjects: Susceptibility to psychotic states and implications for relapse of schizophrenia." *Pharmacopsychiatry* 35(2): 62-71.
- Yui, K., K. Goto, et al. (2001). "Susceptibility to subsequent episodes of spontaneous recurrence of methamphetamine psychosis." *Drug Alcohol Depend* 64(2): 133-42.
- Yui, K., K. Goto, et al. (2000). "Stress induced spontaneous recurrence of methamphetamine psychosis: The relation between stressful experiences and sensitivity to stress." *Drug Alcohol Depend* 58(1-2): 67-75.
- Yui, K., K. Goto, et al. (2000). "Increased sensitivity to stress in spontaneous recurrence of methamphetamine psychosis: noradrenergic hyperactivity with contribution from dopaminergic hyperactivity." *J Clin Psychopharmacol* 20(2): 165-74.
- Yui, K., T. Ishiguro, et al. (1999). "Spontaneous recurrence of methamphetamine psychosis: increased sensitivity to stress associated with noradrenergic hyperactivity and dopaminergic change." *Eur Arch Psychiatry Clin Neurosci* 249(2): 103-11.
- Yui, K., T. Ishiguro, et al. (1998). "Factors affecting the development of spontaneous recurrence of methamphetamine psychosis." *Acta Psychiatr Scand* 97(3): 220-7.
- Yui, K., K. Goto, S. Ikemoto and T. Ishiguro (1997). "Monoamine neurotransmitter metabolites and spontaneous recurrence of methamphetamine psychosis." *Brain Res Bull* 43(1): 25-33.
- Yui, K., K. Goto, et al. (1997). "Noradrenergic activity and spontaneous recurrence of methamphetamine psychosis." *Drug Alcohol Depend* 44(2-3): 183-7.
- Yui, K., T. Ishiguro, et al. (1997). "Precipitating factors in spontaneous recurrence of methamphetamine psychosis." *Psychopharmacology (Berl)* 134(3): 303-8.
- Yui, K., K. Goto, et al. (1997). "Noradrenergic activity and spontaneous recurrence of methamphetamine psychosis." *Drug Alcohol Depend* 44(2-3): 183-7.
- Yukitake, A. (1983). "Amphetamine psychosis in Tokyo--Its clinical features and social problems." *Folia Psychiatr Neurol Jpn* 37(2): 115-20.
- Zhu, B. L., T. Ishikawa, et al. (2006). "Postmortem cardiac troponin T levels in the blood and pericardial fluid. Part 1. Analysis with special regard to traumatic causes of death." *Leg Med (Tokyo)* 8(2): 86-93.
- Zhu, B. L., T. Ishikawa, et al. (2005). "Evaluation of postmortem serum calcium and magnesium levels in relation to the causes of death in forensic autopsy." *Forensic Sci Int* 155(1): 18-23.
- Zhu, B. L., S. Oritani, et al. (2000). "Methamphetamine-related fatalities in forensic autopsy during 5 years in the southern half of Osaka city and surrounding areas." *Forensic Sci Int* 113(1-3): 443-7.

## Asians and Pacific Islanders (US)

*See also* Guam; Hawaii

- Austin, A. A. (2004). "Alcohol, tobacco, other drug use, and violent behavior among Native Hawaiians: Ethnic pride and resilience." *Subst Use Misuse* 39(5): 721-46.
- Choi, K. H., D. Operario, et al. (2005). "Substance use, substance choice, and unprotected anal intercourse among young Asian American and Pacific Islander men who have sex with men." *AIDS Educ Prev* 17(5): 418-29.
- Freese, T. E., J. Obert, et al. (2000). "Methamphetamine abuse: Issues for special populations." *J Psychoactive Drugs* 32(2): 177-82.
- Goldsamt, L. A., J. O'Brien, et al. (2005). "The relationship between club drug use and other drug use: A survey of New York City middle school students." *Subst Use Misuse* 40(9): 1539-55.
- Lampinen, T. M., D. McGhee, et al. (2006). "Increased risk of "club" drug use among gay and bisexual high school students in British Columbia." *J Adolesc Health* 38(4): 458-61.
- Nemoto, T., D. Operario, et al. (2002). "Risk behaviors of Filipino methamphetamine users in San Francisco: Implications for prevention and treatment of drug use and HIV." *Public Health Rep* 117 Suppl 1: S30-8.
- Oetting, E. R., J. L. Deffenbacher, et al. (2000). "Methamphetamine use by high school students: Recent trends, gender and ethnicity differences, and use of other drugs." *Journal of Child and Adolescent Substance Abuse* 10(1): 33-50.
- Operario, D. and T. Nemoto (2005). "Sexual risk behavior and substance use among a sample of Asian Pacific Islander transgendered women." *AIDS Educ Prev* 17(5): 430-43.
- Ramamoorthy, Y., R. F. Tyndale, et al. (2001). "Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates." *Pharmacogenetics* 11(6): 477-87.
- Storr, C. L., A. M. Arria, et al. (2004). "Neighborhood environment and opportunity to try methamphetamine ("ice") and marijuana: Evidence from Guam in the Western Pacific region of Micronesia." *Subst Use Misuse* 39(2): 253-76.

### Aspartate (animals)

Pu, C. and C. V. Vorhees (1993). "Developmental dissociation of methamphetamine-induced depletion of dopaminergic terminals and astrocyte reaction in rat striatum." *Brain Res Dev Brain Res* 72(2): 325-8.

### Atlanta, GA (US)

Reid, L. W., K. W. Elifson, et al. (2007). "Ecstasy and gateway drugs: Initiating the use of ecstasy and other drugs." *Ann Epidemiol* 17(1): 74-80.

### Attention Deficit Hyperactivity Disorder

*See also* Childhood Attention Deficit Hyperactivity Disorder; Hyperactivity

Gordon, S. M., F. Tulak, et al. (2004). "Prevalence and characteristics of adolescents patients with co-occurring ADHD and substance dependence." *J Addict Dis* 23(4): 31-40.

Greenhill, L. L. (2006). "The science of stimulant abuse." *Pediatr Ann* 35(8): 552-6.

Halpern, J. H. (1999). "Treatment of attention-deficit/hyperactivity disorder." *JAMA* 281(16): 1491.

Jaffe, C., K. R. Bush, et al. (2005). "A comparison of methamphetamine-dependent inpatients childhood attention deficit hyperactivity disorder symptomatology." *J Addict Dis* 24(3): 133-52.

Kalbag, A. S. and F. R. Levin (2005). "Adult ADHD and substance abuse: Diagnostic and treatment issues." *Subst Use Misuse* 40(13-14): 1955-81.

Kroutil, L. A., D. L. Van Brunt, et al. (2006). "Nonmedical use of prescription stimulants in the United States." *Drug Alcohol Depend* 84(2): 135-43.

Lin, S. J., S. Y. Crawford, et al. (2005). "Trend and area variation in amphetamine prescription usage among children and adolescents in Michigan." *Soc Sci Med* 60(3): 617-26.

Matsumoto, T., A. Kamijo, et al. (2005). "Childhood histories of attention-deficit hyperactivity disorders in Japanese methamphetamine and inhalant abusers: Preliminary report." *Psychiatry Clin Neurosci* 59(1): 102-5.

Matsumoto, T., A. Yamaguchi, et al. (2005). "Drug preferences in illicit drug abusers with a childhood tendency of attention deficit/hyperactivity disorder: A study using the Wender Utah Rating Scale in a Japanese prison." *Psychiatry Clin Neurosci* 59(3): 311-8.

Popper, C. W. (1997). "Antidepressants in the treatment of attention-deficit/hyperactivity disorder." *J Clin Psychiatry* 58 Suppl 14: 14-29; discussion 30-1.

Sim, T., S. L. Simon, et al. (2002). "Cognitive deficits among methamphetamine users with attention deficit hyperactivity disorder symptomatology." *J Addict Dis* 21(1): 75-89.

Yen, C. F., Y. H. Yang, et al. (2006). "Correlates of methamphetamine use for Taiwanese adolescents." *Psychiatry Clin Neurosci* 60(2): 160-7.

### Attention Deficits

Iwanami, A., R. Kanamori, et al. (1995). "Reduced attention-related negative potentials in methamphetamine psychosis." *J Nerv Ment Dis* 183(11): 693-7.

Johnson, B. A., J. D. Roache, et al. (2007). "Effects of topiramate on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in recently abstinent methamphetamine-dependent individuals." *Prog Neuropsychopharmacol Biol Psychiatry* 31(1): 123-30.

Johnson, B. A., N. Ait-Daoud, et al. (2000). "Effects of isradipine, a dihydropyridine-class calcium channel antagonist, on D-methamphetamine-induced cognitive and physiological changes in humans." *Neuropsychopharmacology* 22(5): 504-12.

Levine, A. J., D. J. Hardy, et al. (2006). "The effect of recent stimulant use on sustained attention in HIV-infected adults." *J Clin Exp Neuropsychol* 28(1): 29-42.

Lundqvist, T. (2005). "Cognitive consequences of cannabis use: Comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions." *Pharmacol Biochem Behav* 81(2): 319-30.

McKetin, R. and N. Solowij (1999). "Event-related potential indices of auditory selective attention in dependent amphetamine users." *Biol Psychiatry* 45(11): 1488-97.

McKetin, R. and R. P. Mattick (1998). "Attention and memory in illicit amphetamine users: Comparison with non-drug-using controls." *Drug Alcohol Depend* 50(2): 181-4.

Nordahl, T. E., R. Salo, et al. (2003). "Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: A review." *J Neuropsychiatry Clin Neurosci* 15(3): 317-25.

- Nordahl, T. E., R. Salo, et al. (2002). "Low N-acetyl-aspartate and high choline in the anterior cingulum of recently abstinent methamphetamine-dependent subjects: A preliminary proton MRS study. *Magnetic resonance spectroscopy*. *Psychiatry Res* 116(1-2): 43-52.
- Salo, R., T. E. Nordahl, et al. (2006). "Attentional control and brain metabolite levels in methamphetamine abusers." *Biol Psychiatry*.
- Salo, R., T. E. Nordahl, et al. (2005). "A dissociation in attentional control: Evidence from methamphetamine dependence." *Biol Psychiatry* 57(3): 310-3.
- Salo, R., T. E. Nordahl, et al. (2002). "Preliminary evidence of reduced cognitive inhibition in methamphetamine-dependent individuals." *Psychiatry Res* 111(1): 65-74.
- Sheridan, J., S. Bennett, et al. (2006). "Injury associated with methamphetamine use: A review of the literature." *Harm Reduct J* 3(1): 14.
- Silber, B. Y., R. J. Croft, et al. (2006). "The acute effects of d-amphetamine and methamphetamine on attention and psychomotor performance." *Psychopharmacology (Berl)* 187(2): 154-69.
- Struthers, J. M. and R. L. Hansen (1992). "Visual recognition memory in drug-exposed infants." *J Dev Behav Pediatr* 13(2): 108-11.

## Australia

- Baker, A. and S. Dawe (2005). "Amphetamine use and co-occurring psychological problems: Review of the literature and implications for treatment." *Australian Psychologist* 40(2): 88-95.
- Baker, A., N. K. Lee, et al. (2004). "Drug use patterns and mental health of regular amphetamine users during a reported 'heroin drought'." *Addiction* 99(7): 875-84.
- Bartu, A., N. C. Freeman, et al. (2004). "Mortality in a cohort of opiate and amphetamine users in Perth, Western Australia." *Addiction* 99(1): 53-60.
- Bellis, M. A., K. E. Hughes, et al. (2007). "Effects of backpacking holidays in Australia on alcohol, tobacco and drug use of UK residents." *BMC Public Health* 7(1): 1.
- Breen, C., L. Degenhardt, et al. (2006). "Alcohol use and risk taking among regular ecstasy users." *Subst Use Misuse* 41(8): 1095-109.
- Burcham, J. L., B. Tindall, et al. (1989). "Incidence and risk factors for human immunodeficiency virus seroconversion in a cohort of Sydney homosexual men." *Med J Aust* 150(11): 634-9.
- Caldicott, D. G., P. E. Pigou, et al. (2005). "Clandestine drug laboratories in Australia and the potential for harm." *Aust N Z J Public Health* 29(2): 155-62.
- Darke, S., S. Kaye, et al. (1999). "Transitions between the injection of heroin and amphetamines." *Addiction* 94(12): 1795-803.
- Darke, S. and W. Hall (1995). "Levels and correlates of polydrug use among heroin users and regular amphetamine users." *Drug Alcohol Depend* 39(3): 231-5.
- Darke, S., J. Ross, et al. (1995). "Injecting and sexual risk-taking behaviour among regular amphetamine users." *AIDS Care* 7(1): 19-26.
- Darke, S., J. Cohen, et al. (1994). "Transitions between routes of administration of regular amphetamine users." *Addiction* 89(9): 1077-83.
- Darke, S., J. Ross, et al. (1994). "The use of benzodiazepines among regular amphetamine users." *Addiction* 89(12): 1683-90.
- Darke, S., W. Hall, et al. (1992). "Benzodiazepine use and HIV risk-taking behaviour among injecting drug users." *Drug Alcohol Depend* 31(1): 31-6.
- Day, C., L. Degenhardt, et al. (2006). "Changes in the initiation of heroin use after a reduction in heroin supply." *Drug Alcohol Rev* 25(4): 307-13.
- Degenhardt, L. (2005). "Drug use and risk behaviour among regular ecstasy users: Does sexuality make a difference?" *Culture, Health & Sexuality* 7(6): 599-614.
- Degenhardt, L., C. Day, et al. (2005). "Effects of a sustained heroin shortage in three Australian States." *Addiction* 100(7): 908-20.
- Degenhardt, L. J., E. Conroy, et al. (2005). "The effect of a reduction in heroin supply on fatal and non-fatal drug overdoses in New South Wales, Australia." *Med J Aust* 182(1): 20-3.
- Degenhardt, L., E. Conroy, et al. (2005). "The impact of a reduction in drug supply on demand for and compliance with treatment for drug dependence." *Drug Alcohol Depend* 79(2): 129-35.
- Dore, G. and M. Sweeting (2006). "Drug-induced psychosis associated with crystalline methamphetamine." *Australas Psychiatry* 14(1): 86-9.
- Drummer, O. H., J. Gerostamoulos, et al. (2003). "The incidence of drugs in drivers killed in Australian road traffic crashes." *Forensic Sci Int* 134(2-3): 154-62.
- Hall, W., J. Hando, et al. (1996). "Psychological morbidity and route of administration among amphetamine users in Sydney, Australia." *Addiction* 91(1): 81-7.

- Hall, W., S. Darke, et al. (1993). "Patterns of drug use and risk-taking among injecting amphetamine and opioid drug users in Sydney, Australia." *Addiction* 88(4): 509-16.
- Hando, J., L. Topp, et al. (1997). "Amphetamine-related harms and treatment preferences of regular amphetamine users in Sydney, Australia." *Drug Alcohol Depend* 46(1-2): 105-13.
- Irvine, R. J., M. Keane, et al. (2006). "Plasma drug concentrations and physiological measures in 'dance party' participants." *Neuropsychopharmacology* 31(2): 424-30.
- Kaye, S. and S. Darke (2000). "A comparison of the harms associated with the injection of heroin and amphetamines." *Drug Alcohol Depend* 58(1-2): 189-95.
- Longo, M. C., S. M. Henry-Edwards, et al. (2004). "Impact of the heroin 'drought' on patterns of drug use and drug-related harms." *Drug Alcohol Rev* 23(2): 143-50.
- McKetin, R., J. McLaren, et al. (2006). "The prevalence of psychotic symptoms among methamphetamine users." *Addiction* 101(10): 1473-8.
- McKetin, R., E. Kelly, et al. (2006). "The relationship between crystalline methamphetamine use and methamphetamine dependence." *Drug Alcohol Depend* 85(3): 198-204.
- McKetin, R. and R. P. Mattick (1998). "Attention and memory in illicit amphetamine users: Comparison with non-drug-using controls." *Drug Alcohol Depend* 50(2): 181-4.
- Qi, Y., I. D. Evans, et al. (2006). "Australian Federal Police seizures of illicit crystalline methamphetamine ('ice') 1998-2002: Impurity analysis." *Forensic Sci Int* 164(2-3): 201-10.
- Qi, Y., I. Evans, et al. (2006). "New impurity profiles of recent Australian imported 'ice': Methamphetamine impurity profiling and the identification of (pseudo)ephedrine and Leuckart specific marker compounds." *Forensic Sci Int*.
- Roxburgh, A., L. Degenhardt, et al. (2005). "Drug use and risk behaviours among injecting drug users: A comparison between sex workers and non-sex workers in Sydney, Australia." *Harm Reduct J* 2(1): 7.
- Roxburgh, A., L. Degenhardt, et al. (2004). "Changes in patterns of drug use among injecting drug users following changes in the availability of heroin in New South Wales, Australia." *Drug Alcohol Rev* 23(3): 287-94.
- Shearer, J. and L. R. Gowing (2004). "Pharmacotherapies for problematic psychostimulant use: A review of current research." *Drug Alcohol Rev* 23(2): 203-11.
- Shearer, J., A. Wodak, et al. (2003). "Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence." *Addiction* 98(8): 1137-41.
- Shearer, J., J. Sherman, et al. (2002). "Substitution therapy for amphetamine users." *Drug Alcohol Rev* 21(2): 179-85.
- Sheridan, J., S. Bennett, et al. (2006). "Injury associated with methamphetamine use: A review of the literature." *Harm Reduct J* 3(1): 14.
- Silber, B. Y., K. Papafioti, et al. (2005). "An evaluation of the sensitivity of the standardised field sobriety tests to detect the presence of amphetamine." *Psychopharmacology (Berl)*: 1-7.
- Srisurapanont, M., R. Ali, et al. (2003). "Psychotic symptoms in methamphetamine psychotic in-patients." *Int J Neuropsychopharmacol* 6(4): 347-52.
- Thorberg, F. A. and M. Lyvers (2006). "Negative Mood Regulation (NMR) expectancies, mood, and affect intensity among clients in substance disorder treatment facilities." *Addict Behav* 31(5): 811-20.
- Topp, L., C. Day, et al. (2003). "Changes in patterns of drug injection concurrent with a sustained reduction in the availability of heroin in Australia." *Drug Alcohol Depend* 70(3): 275-86.
- Topp, L., L. Degenhardt, et al. (2002). "The emergence of potent forms of methamphetamine in Sydney, Australia: A case study of the IDRS as a strategic early warning system." *Drug Alcohol Rev* 21(4): 341-348.
- Topp, L. and S. Darke (1997). "The applicability of the dependence syndrome to amphetamine." *Drug Alcohol Depend* 48(2): 113-8.
- White, B., C. Day, et al. (2006). "Prevalence of injecting drug use and associated risk behavior among regular ecstasy users in Australia." *Drug Alcohol Depend* 83(3): 210-7.
- Windahl, K. L., M. J. McTigue, et al. (1995). "Investigation of the impurities found in methamphetamine synthesised from pseudoephedrine by reduction with hydriodic acid and red phosphorus." *Forensic Sci Int* 76(2): 97-114.
- Worth, H. and P. Rawstone (2005). "Crystallizing the HIV epidemic: Methamphetamine, unsafe sex, and gay diseases of the will." *Arch Sex Behav* 34(5): 483-6.

## Austria

- March, J. C., E. Oviedo-Joekes, et al. (2006). "Drugs and social exclusion in ten European cities." *Eur Addict Res* 12(1): 33-41.



## Automobiles

*See Driving*

## Avoidance Behaviors (animals)

*See also Exploratory Behaviors (animals)*

- Achat-Mendes, C., S. F. Ali, et al. (2005). "Differential effects of amphetamines-induced neurotoxicity on appetitive and aversive Pavlovian conditioning in mice." *Neuropsychopharmacology* 30(6): 1128-37.
- Acuff-Smith, K. D., M. A. Schilling, et al. (1996). "Stage-specific effects of prenatal d-methamphetamine exposure on behavioral and eye development in rats." *Neurotoxicol Teratol* 18(2): 199-215.
- Alam, M. R. (1981). "Enhancement of motor-accelerating effect induced by repeated administration of methamphetamine in mice: Involvement of environmental factors." *Jpn J Pharmacol* 31(6): 897-904.
- Anisman, H. and T. G. Waller (1971). "Effects of methamphetamine and shock duration during inescapable shock exposure on subsequent active and passive avoidance." *J Comp Physiol Psychol* 77(1): 143-51.
- Balsara, J. J. and A. G. Chandorkar (1978). "Experimental evaluation of the possible neuroleptic activity of clomipramine." *Indian J Physiol Pharmacol* 22(3): 263-9.
- Barry, H., 3rd and N. E. Miller (1965). "Comparison of drug effects on approach, avoidance, and escape motivation." *J Comp Physiol Psychol* 59: 18-24.
- Bauer, I. and L. Pickenhain (1967). "[Study of habit following injections of methamphetamine, using the method of conditioned avoidance reaction in the rat]." *Psychopharmacologia* 12(1): 78-82.
- Beaton, J. M., J. R. Smythies, et al. (1968). "Behavioural effects of some 4-substituted amphetamines." *Nature* 220(5169): 800-1.
- Bende, M. M., T. R. Bapat, et al. (1990). "Effects of yohimbine on dopamine dependent behaviours in rats and mice." *Indian J Physiol Pharmacol* 34(3): 195-200.
- Booth, D. A., C. W. Pilcher, et al. (1977). "Comparative potencies of amphetamine, fenfluramine and related compounds in taste aversion experiments in rats." *Br J Pharmacol* 61(4): 669-77.
- Cheng, J. T. (1986). "Effect of skimmianine on animal behavior." *Arch Int Pharmacodyn Ther* 281(1): 35-43.
- Cho, D. H., H. M. Lyu, et al. (1991). "Behavioral teratogenicity of methamphetamine." *J Toxicol Sci* 16 Suppl 1: 37-49.
- Cox, R. H., Jr. and R. P. Maickel (1975). "Differential effects of alphaMT on anorectic and stimulatory action of amphetamines." *Res Commun Chem Pathol Pharmacol* 12(4): 621-6.
- Cox, R. H., Jr. and R. P. Maickel (1972). "Comparison of anorexigenic and behavioral potency of phenylethylamines." *J Pharmacol Exp Ther* 181(1): 1-9.
- Dallo, J. (1979). "Possible role of the serotonergic system in the behavioral effect of massed electroconvulsive shock in rat." *Pol J Pharmacol Pharm* 31(4): 271-6.
- Evans, H. L., W. B. Ghiselli, et al. (1973). "Diurnal rhythm in behavioral effects of methamphetamine, p-chloramethamphetamine and scopolamine." *J Pharmacol Exp Ther* 186(1): 10-7.
- Evans, H. L. (1971). "Behavioral effects of methamphetamine and -methyltyrosine in the rat." *J Pharmacol Exp Ther* 176(1): 244-54.
- Furukawa, T., I. Ushizima, et al. (1975). "Modifications by lithium of behavioral responses to methamphetamine and tetrabenazine." *Psychopharmacologia* 42(3): 243-8.
- Furusawa, K., H. Kuribara, et al. (1987). "[Effects of psychotropic drugs by the cumulative-dosing procedure on lever-press and shuttle discrete avoidance responses in mice]." *Yakubutsu Seishin Kodo* 7(2): 313-20.
- Gomita, Y., N. Ogawa, et al. (1985). "Effects of psychotropic drugs on discrimination conditioning in olfactory bulbectomized rats." *Pharmacol Biochem Behav* 22(5): 717-22.
- Goudie, A. J., E. W. Thornton, et al. (1976). "Drug pretreatment effects in drug induced taste aversions: Effects of dose and duration of pretreatment." *Pharmacol Biochem Behav* 4(5): 629-33.
- Gyarmati, Z., J. Timar, et al. (2001). "Behavioural consequences of methamphetamine-induced neurotoxicity in rats." *Neurobiology (Bp)* 9(1): 37-9.
- Hayashi, T., M. Kunihara, et al. (1987). "Behavioral and neurochemical changes produced by postnatal pretreatments with methamphetamine in rats." *Jpn J Pharmacol* 43(1): 17-25.
- Hayashi, T., K. Fujimoto, et al. (1981). "[Variability in the effects of psychotic drugs on conditioned avoidance reactions in rats due to warning stimuli]." *Yakubutsu Seishin Kodo* 1(1): 13-9.
- Ison, J. R., R. H. Page, et al. (1969). "Methamphetamine hydrochloride and reactions to aversive shock and reward decrements." *Psychol Rep* 24(3): 739-45.

- Jadhav, J. H., J. J. Balsara, et al. (1981). "Effect of ethosuximide on dopaminergically mediated behaviours." *Indian J Physiol Pharmacol* 25(3): 274-8.
- Kameyama, T., T. Nabeshima, et al. (1987). "[Behavioral pharmacological action of Ca-4-(3,5-dihydroxy-3-methylpentylamido) butyrate (mevalonic GABA, MV-GABA)]." *Nippon Yakurigaku Zasshi* 89(3): 103-10.
- Kameyama, T., T. Nabeshima, et al. (1981). "[Pharmacological action of eptazocine (1-1,4-dimethyl-10-hydroxy-2,3,4,5,6,7-hexahydro-1,6-methano-1H-4-benzazon ine). (III) Central action of eptazocine (author's transl)]." *Nippon Yakurigaku Zasshi* 78(6): 629-45.
- Kobayashi, K. and H. Sano (2000). "Dopamine deficiency in mice." *Brain Dev* 22 Suppl 1: S54-60.
- Kulkarni, A. S. (1972). "Avoidance acquisition and CNS stimulants." *Naunyn Schmiedebergs Arch Pharmacol* 273(4): 394-400.
- Kulkarni, A. S. (1972). "Selective increase in avoidance responding by methamphetamine in naive rats." *Psychopharmacologia* 24(4): 449-55.
- Kuribara, H. (1994). "Effects of psychotropic drugs on impairment of acquisition of shuttle avoidance produced by pretreatment with pairs of tone signal and shock in mice." *Jpn J Psychiatry Neurol* 48(3): 639-43.
- Kuribara, H. (1993). "Ceruletide, a cholecystokinin-like decapeptide, differentially reduces the stimulant effect of MK-801 and ketamine: Evaluation by discrete shuttle avoidance in mice." *Eur J Pharmacol* 231(1): 7-11.
- Kuribara, H. and Y. Uchihashi (1993). "SCH 23390 equivalently, but YM-09151-2 differentially reduces the stimulant effects of methamphetamine, MK-801 and ketamine: assessment by discrete shuttle avoidance in mice." *Jpn J Pharmacol* 62(1): 111-4.
- Kuribara, H. and S. Tadokoro (1992). "Behavioral effects of cocoa and its main active compound theobromine: evaluation by ambulatory activity and discrete avoidance in mice." *Arukuru Kenkyuto Yakubutsu Ison* 27(2): 168-79.
- Kuribara, H., T. Asahi, et al. (1992). "Behavioral evaluation of psycho-pharmacological and psychotoxic actions of methylxanthines by ambulatory activity and discrete avoidance in mice." *J Toxicol Sci* 17(2): 81-90.
- Kuribara, H. and S. Tadokoro (1991). "[Behavioral effects of febarbamate (MS-543): evaluation by ambulatory activity, active avoidance and passive avoidance in mice]." *Nippon Yakurigaku Zasshi* 98(4): 311-7.
- Kuribara, H. and S. Tadokoro (1991). "Differential antagonism of the stimulant effects of MK-801 and methamphetamine by ceruletide: Evaluation by discrete shuttle avoidance response in mice." *Jpn J Pharmacol* 57(3): 425-9.
- Kuribara, H., T. Asami, et al. (1990). "Effects of ceruletide, administered singly and in combination with central-acting drugs, on discrete shuttle avoidance response in mice." *Jpn J Pharmacol* 54(3): 325-9.
- Kuribara, H. and S. Tadokoro (1989). "[Behavioral effects of NC-1100, 1-(3,4-dimethoxyphenyl)-2-(4-diphenylmethylpiperazinyl) ethanol dihydrochloride--on ambulatory activity, discrete lever-press response and shuttle avoidance response in mice]." *Nippon Yakurigaku Zasshi* 93(4): 245-53.
- Kuribara, H. and S. Tadokoro (1988). "[Effects of buflomedil on ambulatory activity and discrete avoidance responses in mice]." *Nippon Yakurigaku Zasshi* 91(2): 111-9.
- Kuribara, H., S. Tadokoro, et al. (1986). "[Behavioral effects of propentofylline (HWA 285) on ambulatory activity, discrete avoidance response and passive avoidance response in mice]." *Nippon Yakurigaku Zasshi* 87(5): 573-81.
- Kuribara, H. and S. Tadokoro (1985). "Combined effects of methamphetamine and morphine on ambulatory activity in mice and continuous avoidance response in rats." *Yakubutsu Seishin Kodo* 5(3): 271-7.
- Kuribara, H. and S. Tadokoro (1985). "Effects of psychoactive drugs on conditioned avoidance response in Mongolian gerbils (*Meriones unguiculatus*): Comparison with Wistar rats and dd mice." *Pharmacol Biochem Behav* 23(6): 1013-8.
- Kuribara, H. and S. Tadokoro (1984). "[Behavioral effects of amantadine on ambulatory activity and drinking in mice and on continuous and discrete avoidance responses in rats]." *Nippon Yakurigaku Zasshi* 83(2): 147-58.
- Kuribara, H. (1982). "Strain differences to the effects of central acting drugs on Sidman avoidance response in Wistar and Fischer 344 rats." *Pharmacol Biochem Behav* 17(3): 425-9.
- Martin, J. C. (1975). "Effects on offspring of chronic maternal methamphetamine exposure." *Dev Psychobiol* 8(5): 397-404.
- Matsuoka, N., N. Maeda, et al. (1992). "Effect of FR121196, a novel cognitive enhancer, on the memory impairment of rats in passive avoidance and radial arm maze tasks." *J Pharmacol Exp Ther* 263(2): 436-44.
- Metcalf, F. U., Jr., D. F. Peeler, Jr., et al. (1971). "Methamphetamine effects upon avoidance behavior during limbic seizures in the cat." *Psychopharmacologia* 21(4): 390-400.
- Miller, F. P., R. H. Cox, Jr., et al. (1970). "The effects of altered brain norepinephrine levels on continuous avoidance responding and the action of amphetamines." *Neuropharmacology* 9(6): 511-7.
- Moorthy, N. S. and J. J. Balsara (1999). "Effects of flunarizine on dopamine dependent behaviours in rats." *Indian J Med Sci* 53(2): 43-8.
- Nakagawa, T., K. Ukai, et al. (1997). "Effects of dopaminergic agents on reversal of reserpine-induced impairment in conditioned avoidance response in rats." *Pharmacol Biochem Behav* 58(4): 829-36.
- Nishii, K., N. Matsushita, et al. (1998). "Motor and learning dysfunction during postnatal development in mice defective in dopamine neuronal transmission." *J Neurosci Res* 54(4): 450-64.

- Nishimori, T., K. Morino, et al. (1988). "[Effects of cadralazine on the central nervous system]." *Nippon Yakurigaku Zasshi* 91(4): 209-20.
- Oka, M., Y. Noda, et al. (1993). "Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-52 antagonist properties." *J Pharmacol Exp Ther* 264(1): 158-65.
- Parker, L. A. (1995). "Rewarding drugs produce taste avoidance, but not taste aversion." *Neurosci Biobehav Rev* 19(1): 143-57.
- Parker, L. A. (1993). "Taste reactivity responses elicited by cocaine-, phencyclidine-, and methamphetamine-paired sucrose solutions." *Behav Neurosci* 107(1): 118-29.
- Plaznik, A. and W. Kostowski (1979). "Effects of p-bromo-methamphetamine (V-111) on conditioned avoidance behavior in rats with lesioned raphe nuclei." *Pol J Pharmacol Pharm* 31(3): 193-9.
- Plotnikoff, N. (1966). "Magnesium pemoline: Enhancement of learning and memory of a conditioned avoidance response." *Science* 151(711): 703-4.
- Preston, K. L., G. C. Wagner, et al. (1984). "Effects of methamphetamine on atropine-induced conditioned gustatory avoidance." *Pharmacol Biochem Behav* 20(4): 601-7.
- Ranaldi, R., K. G. Anderson, et al. (2000). "Reinforcing and discriminative stimulus effects of RTI 111, a 3-phenyltropane analog, in rhesus monkeys: Interaction with methamphetamine." *Psychopharmacology (Berl)* 153(1): 103-10.
- Sansone, M. and A. Oliverio (1989). "Avoidance facilitation by nootropics." *Prog Neuropsychopharmacol Biol Psychiatry* 13 Suppl: S89-97.
- Sansone, M., M. Ammassari-Teule, et al. (1985). "Interaction between nootropic drugs and methamphetamine on avoidance acquisition but not on locomotor activity in mice." *Arch Int Pharmacodyn Ther* 278(2): 229-35.
- Sansone, M., P. Renzi, et al. (1974). "Effect of methamphetamine on discriminated lever-press avoidance behaviour in hamsters." *Pharmacol Res Commun* 6(2): 187-92.
- Shika, K., C. Nakata, et al. (1977). "[Inhibitory effects of methyl o-(4-hydroxy-3-methoxycinnamoyl) reserpate (CD-3400) on the central nervous system (author's transl)]." *Nippon Yakurigaku Zasshi* 73(7): 717-34.
- Siuciak, J. A., S. A. McCarthy, et al. (2006). "Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: Evidence for altered striatal function." *Neuropharmacology* 51(2): 374-85.
- Stolerman, I. P. and D. D'Mello G (1978). "Amphetamine-induced hypodipsia and its implications for conditioned taste aversion in rats." *Pharmacol Biochem Behav* 8(4): 333-8.
- Takaori, S., N. Yada, et al. (1969). "Effects of psychotropic agents on Sidman avoidance response in good- and poor-performing rats." *Jpn J Pharmacol* 19(4): 587-96.
- Timar, J., S. Gyarmati, et al. (2003). "Behavioural changes in rats treated with a neurotoxic dose regimen of dextrorotatory amphetamine derivatives." *Behav Pharmacol* 14(3): 199-206.
- Umezu, T., H. Kuribara, et al. (1988). "Acquisition process and effects of psychoactive drugs on discrete shuttle avoidance response in Mongolian gerbils (*Meriones unguiculatus*)." *Jpn J Pharmacol* 47(3): 245-52.
- Verhave, T. (1958). "The effect of methamphetamine on operant level and avoidance behavior." *J Exp Anal Behav* 1(3): 207-19.
- Wagner, G. C., R. W. Foltin, et al. (1981). "Dopamine depletion by 6-hydroxydopamine prevents conditioned taste aversion induced by methylamphetamine but not lithium chloride." *Pharmacol Biochem Behav* 14(1): 85-8.
- Walsh, S. L. and G. C. Wagner (1992). "Motor impairments after methamphetamine-induced neurotoxicity in the rat." *J Pharmacol Exp Ther* 263(2): 617-26.
- Watanabe, T., K. Matsushashi, et al. (1985). "[Study on the postnatal neuro-behavioral development in rats treated prenatally with drugs acting on the autonomic nervous systems]." *Nippon Yakurigaku Zasshi* 85(2): 79-90.
- Watanabe, T., K. Matsushashi, et al. (1984). "[Study on the neuro-behavioral development in rats treated neonatally with drugs acting on the autonomic nervous system]." *Nippon Yakurigaku Zasshi* 84(3): 267-82.
- Williams, M. T., T. L. Blankenmeyer, et al. (2003). "Long-term effects of neonatal methamphetamine exposure in rats on spatial learning in the Barnes maze and on cliff avoidance, corticosterone release, and neurotoxicity in adulthood." *Brain Res Dev Brain Res* 147(1-2): 163-75.
- Wolthuis, O. L. (1971). "Experiments with UCB 6215, a drug which enhances acquisition in rats: Its effects compared with those of methamphetamine." *Eur J Pharmacol* 16(3): 283-97.
- Yamamura, T., S. Hishida, et al. (1993). "Effects of daily administration of methamphetamine on multiple active/passive avoidance performance in rats." *Behav Brain Res* 53(1-2): 105-12.
- Yamamura, T., S. Hishida, et al. (1992). "Effects of methamphetamine and ethanol on learning and brain neurotransmitters in rats." *Pharmacol Biochem Behav* 42(3): 389-400.
- Yamamura, M., K. Maeda, et al. (1986). "[Behavioral pharmacological properties of nicergoline. Effects on gross-behavior in rats and monkeys and on DRL response, CER, and CAR in rats]." *Nippon Yakurigaku Zasshi* 87(2): 209-21.

- Yanaura, S., Y. Abe, et al. (1976). "[Conditioning of emotional behavior caused by hypothalamic stimulation (4). Effects of drugs on conditioned avoidance and escape behavior]." *Nippon Yakurigaku Zasshi* 72(6): 701-8.
- Yoshida, S., Y. Numachi, et al. (2000). "The absence of impairment of cliff avoidance reaction induced by subchronic methamphetamine treatment in inbred strains of mice." *Tohoku J Exp Med* 190(3): 205-12.
- Yoshida, S., Y. Numachi, et al. (1998). "Impairment of cliff avoidance reaction induced by subchronic methamphetamine administration and restraint stress: comparison between two inbred strains of rats." *Prog Neuropsychopharmacol Biol Psychiatry* 22(6): 1023-32.
- Yoshida, S., Y. Numachi, et al. (1995). "[Reverse-tolerance phenomenon in methamphetamine-induced behavioral stereotypy and impairment of cliff avoidance reaction after subchronic methamphetamine administration in rats]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 15(5): 397-403.

### Baltimore, MD (US)

- Thiede, H., L. A. Valleroy, et al. (2003). "Regional patterns and correlates of substance use among young men who have sex with men in 7 US urban areas." *Am J Public Health* 93(11): 1915-21.

### Behavioral Interventions

*See Treatment, Cognitive and Behavioral*

### Behavioral Responses (animals)

*See also Aggression and Violence; Appetite and Feeding; Avoidance Behaviors; Circadian Rhythms; Cognition; Conditioned Place Preference; Drinking Behavior; Exploratory Behaviors; Hyperactivity; Psychomotor Task Performance; Self-Administration of Methamphetamine; Self-Inflicted Injury and Self-Mutilation; Sleep; Social Behaviors; Sterotypic Behaviors*

- Abekawa, T., T. Ohmori, et al. (1997). "Effect of no synthesis inhibition on striatal dopamine release and stereotyped behavior induced by a single administration of methamphetamine." *Prog Neuropsychopharmacol Biol Psychiatry* 21(5): 831-8.
- Abekawa, T., T. Ohmori, et al. (1995). "Effects of nitric oxide (NO) synthesis inhibition on the development of supersensitivity to stereotypy and locomotion stimulating effects of methamphetamine." *Brain Res* 679(2): 200-4.
- Abekawa, T., T. Ohmori, et al. (1994). "Effect of NO synthase inhibition on behavioral changes induced by a single administration of methamphetamine." *Brain Res* 666(1): 147-50.
- Achat-Mendes, C., K. L. Anderson, et al. (2006). "Impairment in consolidation of learned place preference following dopaminergic neurotoxicity in mice is ameliorated by N-acetylcysteine but not D1 and D2 dopamine receptor agonists." *Neuropsychopharmacology*.
- Achat-Mendes, C., S. F. Ali, et al. (2005). "Differential effects of amphetamines-induced neurotoxicity on appetitive and aversive Pavlovian conditioning in mice." *Neuropsychopharmacology* 30(6): 1128-37.
- Acevedo, S. F., I. J. de Esch, et al. (2006). "Sex- and histamine-dependent long-term cognitive effects of methamphetamine exposure." *Neuropsychopharmacology*.
- Acuff-Smith, K. D., M. A. Schilling, et al. (1996). "Stage-specific effects of prenatal d-methamphetamine exposure on behavioral and eye development in rats." *Neurotoxicol Teratol* 18(2): 199-215.
- Ago, Y., S. Nakamura, et al. (2006). "Attenuation by the 5-HT(1A) receptor agonist osetozotan of the behavioral effects of single and repeated methamphetamine in mice." *Neuropharmacology* 51(4): 914-22.
- Akita, H., M. Hashimoto, et al. (1990). "[Behavioral characteristics associated with acoustic stimulation and the neurochemical alterations of monoaminergic systems in rat brain at the steady state of repeated methamphetamine administration]." *Nippon Yakurigaku Zasshi* 95(6): 327-33.
- Akiyama, K., H. Ujike, et al. (1998). "Effect of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline on methamphetamine- and cocaine-induced behavioral sensitization." *Pharmacol Biochem Behav* 61(4): 419-26.
- Akiyama, K., T. Ishihara, et al. (1996). "Effect of acute and chronic administration of methamphetamine on activator protein-1 binding activities in the rat brain regions." *Ann N Y Acad Sci* 801: 13-28.
- Akiyama, K., A. Kanzaki, et al. (1994). "Methamphetamine-induced behavioral sensitization and its implications for relapse of schizophrenia." *Schizophr Res* 12(3): 251-7.
- Alam, M. R. (1981). "Enhancement of motor-accelerating effect induced by repeated administration of methamphetamine in mice: Involvement of environmental factors." *Jpn J Pharmacol* 31(6): 897-904.
- Ali, S. F., K. J. Kordsmeier, et al. (1995). "Drug-induced circling preference in rats. Correlation with monoamine levels." *Mol Neurobiol* 11(1-3): 145-54.

- Allan, A. M., R. Galindo, et al. (2001). "Conditioned place preference for cocaine is attenuated in mice over-expressing the 5-HT(3) receptor." *Psychopharmacology (Berl)* 158(1): 18-27.
- Amano, T., H. Matsubayashi, et al. (2002). "[Alteration of neuronal activities following repeated administration of stimulants]." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 37(1): 31-40.
- Anaya-Martinez, V., A. Martinez-Marcos, et al. (2006). "Substantia nigra compacta neurons that innervate the reticular thalamic nucleus in the rat also project to striatum or globus pallidus: Implications for abnormal motor behavior." *Neuroscience* 143(2): 477-86.
- Andretic, R., B. van Swinderen, et al. (2005). "Dopaminergic modulation of arousal in *Drosophila*." *Curr Biol* 15(13): 1165-75.
- Anggadiredja, K., M. Nakamichi, et al. (2004). "Endocannabinoid system modulates relapse to methamphetamine seeking: Possible mediation by the arachidonic acid cascade." *Neuropsychopharmacology* 29(8): 1470-8.
- Anggadiredja, K., K. Sakimura, et al. (2004). "Naltrexone attenuates cue- but not drug-induced methamphetamine seeking: A possible mechanism for the dissociation of primary and secondary reward." *Brain Res* 1021(2): 272-6.
- Anisman, H. and T. G. Waller (1971). "Effects of methamphetamine and shock duration during inescapable shock exposure on subsequent active and passive avoidance." *J Comp Physiol Psychol* 77(1): 143-51.
- Arakawa, O. (1994). "Effects of methamphetamine and methylphenidate on single and paired rat open-field behaviors." *Physiol Behav* 55(3): 441-6.
- Araki, H., T. Yamamoto, et al. (2002). "Effect of methamphetamine and imipramine on cerebral ischemia-induced hyperactivity in Mongolian gerbils." *Jpn J Pharmacol* 88(3): 293-9.
- Araki, H., T. Yamamoto, et al. (2001). "Chronic methamphetamine administration inhibits cerebral ischemia-induced hyperactivity in Mongolian gerbils." *Physiol Behav* 74(1-2): 127-31.
- Araki, H., K. Kawashima, et al. (1984). "The difference in the site of actions of tricyclic antidepressants and methamphetamine on the duration of the immobility in the behavioral despair test." *Jpn J Pharmacol* 35(1): 67-72.
- Armstrong, V., A. Nazarian, et al. (2001). "Effects of acute and repeated methamphetamine treatment on the ultrasonic vocalizations of postnatal rats." *Pharmacol Biochem Behav* 70(2-3): 273-8.
- Asano, Y. and T. Moroji (1974). "Effects of methamphetamine on daily rhythms of hypothalamic norepinephrine, serotonin and plasma corticosterone levels in the rat." *Life Sci* 14(8): 1463-72.
- Atkins, A. L., M. L. Helms, et al. (2001). "Stereotypic behaviors in mice selectively bred for high and low methamphetamine-induced stereotypic chewing." *Psychopharmacology (Berl)* 157(1): 96-104.
- Balsara, J. J., T. R. Bapat, et al. (1985). "Effect of ergometrine on methamphetamine and apomorphine stereotypy in the guinea-pig." *J Pharm Pharmacol* 37(7): 514-7.
- Balsara, J. J., N. V. Nandal, et al. (1984). "Effects of naloxone on methamphetamine and apomorphine stereotypy and on haloperidol catalepsy in rats." *Psychopharmacology (Berl)* 82(3): 237-40.
- Balsara, J. J., N. V. Nandal, et al. (1982). "Experimental evaluation of the antidepressant and neuroleptic activity of maprotiline." *Indian J Physiol Pharmacol* 26(3): 183-95.
- Balsara, J. J., T. R. Bapat, et al. (1982). "Small doses of apomorphine induce catalepsy and antagonize methamphetamine stereotypy in rats." *Psychopharmacology (Berl)* 78(2): 192-4.
- Balsara, J. J., M. P. Muley, et al. (1981). "Effects of baclofen on dopamine-dependent behaviors in mice." *Psychopharmacology (Berl)* 75(4): 396-9.
- Balsara, J. J., J. H. Jadhav, et al. (1979). "Effect of drugs influencing central serotonergic mechanisms on methamphetamine-induced stereotyped behavior in the rat." *Psychopharmacology (Berl)* 64(3): 303-7.
- Balsara, J. J. and A. G. Chandorkar (1978). "Experimental evaluation of the possible neuroleptic activity of clomipramine." *Indian J Physiol Pharmacol* 22(3): 263-9.
- Balster, R. L., M. M. Kilbey, et al. (1976). "Methamphetamine self-administration in the cat." *Psychopharmacologia* 46(3): 229-33.
- Balster, R. L. and C. R. Schuster (1973). "A comparison of d-amphetamine, l-amphetamine, and methamphetamine self-administration in rhesus monkeys." *Pharmacol Biochem Behav* 1(1): 67-71.
- Barr, A. M., W. J. Panenka, et al. (2006). "The need for speed: An update on methamphetamine addiction." *J Psychiatry Neurosci* 31(5): 301-313.
- Barry, H., 3rd and N. E. Miller (1965). "Comparison of drug effects on approach, avoidance, and escape motivation." *J Comp Physiol Psychol* 59: 18-24.
- Bauer, I. and L. Pickenhain (1967). "[Study of habit following injections of methamphetamine, using the method of conditioned avoidance reaction in the rat]." *Psychopharmacologia* 12(1): 78-82.
- Baumann, M. H., J. M. Phillips, et al. (2002). "Preclinical evaluation of GBR12909 decanoate as a long-acting medication for methamphetamine dependence." *Ann N Y Acad Sci* 965: 92-108.
- Beaton, J. M., J. R. Smythies, et al. (1968). "Behavioural effects of some 4-substituted amphetamines." *Nature* 220(5169): 800-1.

- Bedingfield, J. B., L. D. Calder, et al. (1997). "The role of the striatum in the mouse in behavioral sensitization to amphetamine." *Pharmacol Biochem Behav* 56(2): 305-10.
- Bedingfield, J. B., L. D. Calder, et al. (1996). "Comparative behavioral sensitization to stereotypy by direct and indirect dopamine agonists in CF-1 mice." *Psychopharmacology (Berl)* 124(3): 219-25.
- Belcher, A. M., S. J. O'Dell, et al. (2006). "A sensitizing regimen of methamphetamine causes impairments in a novelty preference task of object recognition." *Behav Brain Res* 170(1): 167-72.
- Belcher, A. M., S. J. O'Dell, et al. (2005). "Impaired object recognition memory following methamphetamine, but not p-chloroamphetamine- or d-amphetamine-induced neurotoxicity." *Neuropsychopharmacology* 30(11): 2026-34.
- Bende, M. M., T. R. Bapat, et al. (1990). "Effects of yohimbine on dopamine dependent behaviours in rats and mice." *Indian J Physiol Pharmacol* 34(3): 195-200.
- Bergman, J., S. Yasar, et al. (2001). "Psychomotor stimulant effects of beta-phenylethylamine in monkeys treated with MAO-B inhibitors." *Psychopharmacology (Berl)* 159(1): 21-30.
- Bergstrom, H. C., A. A. Palmer, et al. (2003). "Reverse selection for differential response to the locomotor stimulant effects of ethanol provides evidence for pleiotropic genetic influence on locomotor response to other drugs of abuse." *Alcohol Clin Exp Res* 27(10): 1535-47.
- Berlyne, D. E., I. D. Koenig, et al. (1966). "Novelty, arousal, and the reinforcement of diversive exploration in the rat." *J Comp Physiol Psychol* 62(2): 222-6.
- Bevins, R. A. and J. L. Peterson (2004). "Individual differences in rats' reactivity to novelty and the unconditioned and conditioned locomotor effects of methamphetamine." *Pharmacol Biochem Behav* 79(1): 65-74.
- Birman, S. (2005). "Arousal mechanisms: Speedy flies don't sleep at night." *Curr Biol* 15(13): R511-3.
- Bisagno, V., D. Ferguson, et al. (2002). "Short toxic methamphetamine schedule impairs object recognition task in male rats." *Brain Res* 940(1-2): 95-101.
- Bittner, S. E., G. C. Wagner, et al. (1981). "Effects of a high-dose treatment of methamphetamine on caudate dopamine and anorexia in rats." *Pharmacol Biochem Behav* 14(4): 481-6.
- Blake, B. L., A. M. Muehlmann, et al. (2006). "Nifedipine suppresses self-injurious behaviors in animals." *Dev Neurosci*.
- Bo, P., E. Marchioni, et al. (1991). "Antagonism of EEGraphic and behavioural effects of methamphetamine by selective receptor blockers (SCH 23390 and raclopride) in the rabbit." *Prog Neuropsychopharmacol Biol Psychiatry* 15(6): 803-15.
- Bo, P., A. Giorgetti, et al. (1990). "EEG and behavioural effects of polyamines (spermine and spermidine) on rabbits." *Pharmacol Res* 22(4): 481-91.
- Bondareva, T. S., R. Young, et al. (2002). "Central stimulants as discriminative stimuli. Asymmetric generalization between (-)ephedrine and S(+)-methamphetamine." *Pharmacol Biochem Behav* 74(1): 157-62.
- Booth, D. A., C. W. Pilcher, et al. (1977). "Comparative potencies of amphetamine, fenfluramine and related compounds in taste aversion experiments in rats." *Br J Pharmacol* 61(4): 669-77.
- Brady, A. M., S. D. Glick, et al. (2005). "Selective disruption of nucleus accumbens gating mechanisms in rats behaviorally sensitized to methamphetamine." *J Neurosci* 25(28): 6687-95.
- Braestrup, C. (1977). "Biochemical differentiation of amphetamine vs methylphenidate and nomifensine in rats." *J Pharm Pharmacol* 29(8): 463-70.
- Brennan, K., A. Johnstone, et al. (2006). "Chronic benzylpiperazine (BZP) exposure produces behavioral sensitization and cross-sensitization to methamphetamine (MA)." *Drug Alcohol Depend*.
- Byrnes-Blake, K. A., E. M. Laurenzana, et al. (2005). "Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats." *Eur J Pharmacol* 521(1-3): 86-94.
- Caligiuri, M. P. and C. Buitenhuis (2005). "Do preclinical findings of methamphetamine-induced motor abnormalities translate to an observable clinical phenotype?" *Neuropsychopharmacology* 30(12): 2125-34.
- Camp, D. M., K. E. Browman, et al. (1994). "The effects of methamphetamine and cocaine on motor behavior and extracellular dopamine in the ventral striatum of Lewis versus Fischer 344 rats." *Brain Res* 668(1-2): 180-93.
- Carney, J. M., R. W. Landrum, et al. (1991). "Establishment of chronic intravenous drug self-administration in the C57BL/6J mouse." *Neuroreport* 2(8): 477-80.
- Carney, J. M., B. Tolliver, et al. (1991). "Selective effects of behaviorally active doses of methamphetamine on mRNA expression in the gerbil brain." *Neuropharmacology* 30(9): 1011-9.
- Chen, H. H., Y. K. Yang, et al. (2003). "Methamphetamine-induced conditioned place preference is facilitated by estradiol pretreatment in female mice." *Chin J Physiol* 46(4): 169-74.
- Chen, P. C., C. L. Lao, et al. (2006). "Dual alteration of limbic dopamine D(1) receptor-mediated signalling and the Akt/GSK3 pathway in dopamine D(3) receptor mutants during the development of methamphetamine sensitization." *J Neurochem*.

- Chen, P. C. and J. C. Chen (2005). "Enhanced Cdk5 activity and p35 translocation in the ventral striatum of acute and chronic methamphetamine-treated rats." *Neuropsychopharmacology* 30(3): 538-49.
- Cheng, J. T. (1986). "Effect of skimmianine on animal behavior." *Arch Int Pharmacodyn Ther* 281(1): 35-43.
- Chiu, C. T., T. Ma, et al. (2006). "Methamphetamine-induced behavioral sensitization in mice: Alterations in mu-opioid receptor." *J Biomed Sci* 13(6): 797-811.
- Chiu, C. T., T. Ma, et al. (2005). "Attenuation of methamphetamine-induced behavioral sensitization in mice by systemic administration of naltrexone." *Brain Res Bull* 67(1-2): 100-9.
- Cho, D. H., H. M. Lyu, et al. (1991). "Behavioral teratogenicity of methamphetamine." *J Toxicol Sci* 16 Suppl 1: 37-49.
- Clemens, K. J., J. L. Cornish, et al. (2006). "Intravenous methamphetamine self-administration in rats: Effects of intravenous or intraperitoneal MDMA co-administration." *Pharmacol Biochem Behav* 85(2): 454-63.
- Clemens, K. J., J. L. Cornish, et al. (2007). "Repeated weekly exposure to MDMA, methamphetamine or their combination: Long-term behavioural and neurochemical effects in rats." *Drug Alcohol Depend* 86(2-3): 183-90.
- Clemens, K. J., J. L. Cornish, et al. (2005). "MDMA ('Ecstasy') and methamphetamine combined: Order of administration influences hyperthermic and long-term adverse effects in female rats." *Neuropharmacology* 49(2): 195-207.
- Comings, D. E. and K. Blum (2000). "Reward deficiency syndrome: Genetic aspects of behavioral disorders." *Prog Brain Res* 126: 325-41.
- Consroe, P., B. Jones, et al. (1976). "EEG and behavioral effects of delta9-tetrahydrocannabinol in combination with stimulant drugs in rabbits." *Psychopharmacology (Berl)* 50(1): 47-52.
- Consroe, P. F., B. C. Jones, et al. (1975). "Delta9-tetrahydrocannabinol methamphetamine interaction in the rabbit." *Neuropharmacology* 14(5-6): 377-83.
- Cowen, P. J., D. J. Nutt, et al. (1982). "Repeated administration of subconvulsant doses of GABA antagonist drugs. II. Effect on monoamine-mediated behaviour." *Psychopharmacology (Berl)* 76(1): 88-91.
- Cox, R. H., Jr. and R. P. Maickel (1975). "Differential effects of alphaMT on anorectic and stimulatory action of amphetamines." *Res Commun Chem Pathol Pharmacol* 12(4): 621-6.
- Cox, R. H., Jr. and R. P. Maickel (1972). "Comparison of anorexigenic and behavioral potency of phenylethylamines." *J Pharmacol Exp Ther* 181(1): 1-9.
- Crean, R. D., S. A. Davis, et al. (2006). "Effects of (+/-)3,4-methylenedioxymethamphetamine, (+/-)3,4-methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques." *Neuroscience* 142(2): 515-25.
- Crowley, T. J. (1983). "Substance abuse research in monkey social groups." *Prog Clin Biol Res* 131: 255-75.
- Crowley, T. J., A. J. Stynes, et al. (1974). "Ethanol, methamphetamine, pentobarbital, morphine, and monkey social behavior." *Arch Gen Psychiatry* 31(6): 829-38.
- Crowley, W. R., G. Ramoz, et al. (2005). "Differential effects of methamphetamine on expression of neuropeptide Y mRNA in hypothalamus and on serum leptin and ghrelin concentrations in ad libitum-fed and schedule-fed rats." *Neuroscience* 132(1): 167-73.
- Cunningham, C. L. and D. Noble (1992). "Methamphetamine-induced conditioned place preference or aversion depending on dose and presence of drug." *Ann N Y Acad Sci* 654: 431-3.
- Czoty, P. W., A. Makriyannis, et al. (2004). "Methamphetamine discrimination and in vivo microdialysis in squirrel monkeys." *Psychopharmacology (Berl)* 175(2): 170-8.
- Dallo, J. (1979). "Possible role of the serotonergic system in the behavioral effect of massed electroconvulsive shock in rat." *Pol J Pharmacol Pharm* 31(4): 271-6.
- Dankova, J., R. Boucher, et al. (1977). "Effects of 1694 and other dopaminergic agents on circling behavior." *Eur J Pharmacol* 42(2): 113-21.
- Daberkow, D. P., R. P. Kesner, et al. (2005). "Relation between methamphetamine-induced monoamine depletions in the striatum and sequential motor learning." *Pharmacol Biochem Behav* 81(1): 198-204.
- Dalley, J. W., K. Laane, et al. (2006). "Enduring deficits in sustained visual attention during withdrawal of intravenous methylenedioxymethamphetamine self-administration in rats: Results from a comparative study with d-amphetamine and methamphetamine." *Neuropsychopharmacology*.
- Daniels, J. R., W. D. Wessinger, et al. (2006). "Effects of anti-phencyclidine and anti-(+)-methamphetamine monoclonal antibodies alone and in combination on the discrimination of phencyclidine and (+)-methamphetamine by pigeons." *Psychopharmacology (Berl)* 185(1): 36-44.
- Dankova, J., R. Boucher, et al. (1977). "Effects of 1694 and other dopaminergic agents on circling behavior." *Eur J Pharmacol* 42(2): 113-21.
- Davidson, C., T. H. Lee, et al. (2005). "Acute and chronic continuous methamphetamine have different long-term behavioral and neurochemical consequences." *Neurochem Int* 46(3): 189-203.

- De Vito, M. J. and G. C. Wagner (1989). "Functional consequences following methamphetamine-induced neuronal damage." *Psychopharmacology (Berl)* 97(4): 432-5.
- Dringenberg, H. C., P. Servos, et al. (1992). "Pressure on the snout immobilizes the spontaneously active, scopolaminized, and amphetaminized hyperactive rat." *Behav Brain Res* 50(1-2): 197-9.
- Dwoskin, L. P. and P. A. Crooks (2002). "A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse." *Biochem Pharmacol* 63(2): 89-98.
- Earle, M. L. and J. A. Davies (1991). "The effect of methamphetamine on the release of glutamate from striatal slices." *J Neural Transm Gen Sect* 86(3): 217-22.
- Edgar, D. M. and W. F. Seidel (1997). "Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat." *J Pharmacol Exp Ther* 283(2): 757-69.
- Ehrman, L. A., M. T. Williams, et al. (2006). "Phosphodiesterase 1B differentially modulates the effects of methamphetamine on locomotor activity and spatial learning through DARPP32-dependent pathways: evidence from PDE1B-DARPP32 double-knockout mice." *Genes Brain Behav* 5(7): 540-51.
- Eibergen, R. D. and K. R. Carlson (1976). "Behavioral evidence for dopaminergic supersensitivity following chronic treatment with methadone or chlorpromazine in the guinea pig." *Psychopharmacology (Berl)* 48(2): 139-46.
- Eibergen, R. D. and K. R. Carlson (1976). "Dyskinesias in monkeys: Interaction of methamphetamine with prior methadone treatment." *Pharmacol Biochem Behav* 5(2): 175-87.
- Eibergen, R. D. and K. R. Carlson (1975). "Dyskinesias elicited by methamphetamine: Susceptibility of former methadone-consuming monkeys." *Science* 190(4214): 588-90.
- Ellinwood, E. H., Jr. and M. M. Kilbey (1980). "Fundamental mechanisms underlying altered behavior following chronic administration of psychomotor stimulants." *Biol Psychiatry* 15(5): 749-57.
- Ellinwood, E. H., Jr. and M. M. Kilbey (1975). "Amphetamine stereotypy: the influence of environmental factors and prepotent behavioral patterns on its topography and development." *Biol Psychiatry* 10(1): 3-16.
- Ellinwood, E. H., Jr., A. Sudilovsky, et al. (1974). "Behavior and EEG analysis of chronic amphetamine effect." *Biol Psychiatry* 8(2): 169-76.
- Ellinwood, E. H., Jr., A. Sudilovsky, et al. (1972). "Behavioral analysis of chronic amphetamine intoxication." *Biol Psychiatry* 4(3): 215-30.
- Ellinwood, E. H., Jr. (1971). "Effect of chronic methamphetamine intoxication in Rhesus monkeys." *Biol Psychiatry* 3(1): 25-32.
- Ellison, G. (2002). "Neural degeneration following chronic stimulant abuse reveals a weak link in brain, fasciculus retroflexus, implying the loss of forebrain control circuitry." *Eur Neuropsychopharmacol* 12(4): 287-97.
- Elphick, M. (1989). "Effects of carbamazepine on dopamine function in rodents." *Psychopharmacology (Berl)* 99(4): 532-6.
- Eradiri, O. L. and M. S. Starr (1999). "Striatal dopamine depletion and behavioural sensitization induced by methamphetamine and 3-nitropropionic acid." *Eur J Pharmacol* 386(2-3): 217-26.
- Estabrooke, I. V., M. T. McCarthy, et al. (2001). "Fos expression in orexin neurons varies with behavioral state." *J Neurosci* 21(5): 1656-62.
- Estler, C. J. and M. C. Gabrys (1979). "Swimming capacity of mice after prolonged treatment with psychostimulants. II. Effect of methamphetamine on swimming performance and availability of metabolic substrates." *Psychopharmacology (Berl)* 60(2): 173-6.
- Estler, C. J. and P. Mitznegg (1971). "Influence of methamphetamine on incorporation of glucose into brain glycogen." *Biochem Pharmacol* 20(6): 1331-3.
- Estler, C. J. and H. P. Ammon (1971). "Modification by two beta-adrenergic blocking drugs of the effects of methamphetamine on behaviour and brain metabolism of mice." *J Neurochem* 18(5): 777-9.
- Evans, H. L., W. B. Ghiselli, et al. (1973). "Diurnal rhythm in behavioral effects of methamphetamine, p-chloramethamphetamine and scopolamine." *J Pharmacol Exp Ther* 186(1): 10-7.
- Evans, H. L. (1971). "Behavioral effects of methamphetamine and -methyltyrosine in the rat." *J Pharmacol Exp Ther* 176(1): 244-54.
- Facchinetti, F., R. Dall'Olio, et al. (1994). "Long-lasting effects of chronic neonatal blockade of N-methyl-D-aspartate receptor through the competitive antagonist CGP 39551 in rats." *Neuroscience* 60(2): 343-53.
- Fang, Y. R., T. Abekawa, et al. (2005). "Effect of the protein kinase C inhibitor, staurosporine, on the high dose of methamphetamine-induced behavioral sensitization to dizocilpine (MK-801)." *Psychopharmacology (Berl)* 180(1): 100-6.
- Fantegrossi, W. E., T. Ullrich, et al. (2002). "3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement." *Psychopharmacology (Berl)* 161(4): 356-64.
- Fehm, H. L., R. Holl, et al. (1984). "Evidence for ACTH-unrelated mechanisms in the regulation of cortisol secretion in man." *Klin Wochenschr* 62(1): 19-24.



- Finnegan, K. T., L. Calder, et al. (1993). "Effects of L-type calcium channel antagonists on the serotonin-depleting actions of MDMA in rats." *Brain Res* 603(1): 134-8.
- Fischer, E., J. M. Saavedra, et al. (1968). "Effects of catecholamines, adrenergic substances and their blocking agents on the searching behavior of mice." *Arzneimittelforschung* 18(7): 780-6.
- Fischman, M. W. and C. R. Schuster (1974). "Tolerance development to chronic methamphetamine intoxication in the rhesus monkey." *Pharmacol Biochem Behav* 2(4): 503-8.
- Floran, B., L. Floran, et al. (2004). "Dopamine D4 receptors inhibit depolarization-induced [3H]GABA release in the rat subthalamic nucleus." *Eur J Pharmacol* 498(1-3): 97-102.
- Fog, R. (1972). "On stereotypy and catalepsy: Studies on the effect of amphetamines and neuroleptics in rats." *Acta Neurol Scand Suppl* 50: 3-66.
- Fog, R. (1969). "Stereotyped and non-stereotyped behaviour in rats induced by various stimulant drugs." *Psychopharmacologia* 14(4): 299-304.
- Fox, G. B., T. A. Esbenshade, et al. (2005). "Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzotrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist." *J Pharmacol Exp Ther* 313(1): 176-90.
- Franklin, K. B. and L. J. Herberg (1974). "Self-stimulation and catecholamines: Drug-induced mobilization of the 'reserve'-pool re-establishes responding in catecholamine-depleted rats." *Brain Res* 67(3): 429-37.
- Friedman, S. D., E. Castaneda, et al. (1998). "Long-term monoamine depletion, differential recovery, and subtle behavioral impairment following methamphetamine-induced neurotoxicity." *Pharmacol Biochem Behav* 61(1): 35-44.
- Fujio, M., T. Nakagawa, et al. (2005). "Facilitative effect of a glutamate transporter inhibitor (2S,3S)-3-{3-[4-(trifluoromethyl)benzoylamino]benzyloxy}aspartate on the expression of methamphetamine-induced behavioral sensitization in rats." *J Pharmacol Sci* 99(4): 415-8.
- Fujio, M., T. Nakagawa, et al. (2005). "Gene transfer of GLT-1, a glutamate transporter, into the nucleus accumbens shell attenuates methamphetamine- and morphine-induced conditioned place preference in rats." *Eur J Neurosci* 22(11): 2744-54.
- Fujiwara, Y., Y. Kazahaya, et al. (1987). "Behavioral sensitization to methamphetamine in the rat: an ontogenic study." *Psychopharmacology (Berl)* 91(3): 316-9.
- Fujiwara, Y. (1985). "[Behavioral and neurochemical changes in pups prenatally treated with methamphetamine]." *Yakubutsu Seishin Kodo* 5(3): 251-9.
- Fujiwara, M., Y. Kataoka, et al. (1984). "Irritable aggression induced by delta 9-tetrahydrocannabinol in rats pretreated with 6-hydroxydopamine." *Pharmacol Biochem Behav* 20(3): 457-62.
- Fukuzako, H., I. Nagatomo, et al. (1988). "Alterations of accumbens neuronal activity in freely moving rats following methamphetamine." *Jpn J Psychiatry Neurol* 42(2): 331-5.
- Funakoshi, T., S. Chaki, et al. (2002). "In vitro and in vivo pharmacological profile of 5-[2-[4-(6-fluoro-1H-indole-3-yl)piperidin-1-yl]ethyl]-4-(4-fluorophenyl)thiazole-2-carboxylic acid amide (NRA0562), a novel and putative atypical antipsychotic." *Life Sci* 71(12): 1371-84.
- Furukawa, T., I. Ushizima, et al. (1975). "Modifications by lithium of behavioral responses to methamphetamine and tetrabenazine." *Psychopharmacologia* 42(3): 243-8.
- Furusawa, K., H. Kuribara, et al. (1987). "[Effects of psychotropic drugs by the cumulative-dosing procedure on lever-press and shuttle discrete avoidance responses in mice]." *Yakubutsu Seishin Kodo* 7(2): 313-20.
- Furuya, N. and T. Hirao (1976). "A substrain mouse serologically classified in ddN strain and its behavioral characteristics." *Tohoku J Exp Med* 118(4): 355-63.
- Gada, V. P., V. V. Joshi, et al. (1984). "Antagonism of apomorphine-induced cage climbing behaviour and methamphetamine stereotypy by fenfluramine in mice." *Indian J Physiol Pharmacol* 28(4): 326-30.
- Gasbarri, A., A. Sulli, et al. (1997). "The dopaminergic mesencephalic projections to the hippocampal formation in the rat." *Prog Neuropsychopharmacol Biol Psychiatry* 21(1): 1-22.
- Gasior, M., J. M. Witkin, et al. (2004). "Chlormethiazole potentiates the discriminative stimulus effects of methamphetamine in rats." *Eur J Pharmacol* 494(2-3): 183-9.
- Gatch, M. B., M. Selvig, et al. (2005). "GABAergic modulation of the discriminative stimulus effects of methamphetamine." *Behav Pharmacol* 16(4): 261-6.
- Gehrke, B. J., W. A. Cass, et al. (2006). "Monoamine-depleting doses of methamphetamine in enriched and isolated rats: Consequences for subsequent methamphetamine-induced hyperactivity and reward." *Behav Pharmacol* 17(5-6): 499-508.
- Gehrke, B. J., S. B. Harrod, et al. (2003). "The effect of neurotoxic doses of methamphetamine on methamphetamine-conditioned place preference in rats." *Psychopharmacology (Berl)* 166(3): 249-57.

- Gentry, W. B., E. M. Laurenzana, et al. (2006). "Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats." *Int Immunopharmacol* 6(6): 968-77.
- Gentry, W. B., A. U. Ghafoor, et al. (2004). "(+)-Methamphetamine-induced spontaneous behavior in rats depends on route of (+)METH administration." *Pharmacol Biochem Behav* 79(4): 751-60.
- Ginawi, O. T., A. A. Al-Majed, et al. (2004). "Involvement of some 5-HT receptors in methamphetamine-induced locomotor activity in mice." *J Physiol Pharmacol* 55(2): 357-69.
- Ginawi, O. T., O. A. al-Shabanah, et al. (1997). "Increased toxicity of methamphetamine in morphine-dependent mice." *Gen Pharmacol* 28(5): 727-31.
- Glick, S. D., I. M. Maisonneuve, et al. (2002). "Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration." *Eur J Pharmacol* 438(1-2): 99-105.
- Glick, S. D., I. M. Maisonneuve, et al. (2001). "Comparative effects of dextromethorphan and dextrorphan on morphine, methamphetamine, and nicotine self-administration in rats." *Eur J Pharmacol* 422(1-3): 87-90.
- Glick, S. D., I. M. Maisonneuve, et al. (2000). "18-MC reduces methamphetamine and nicotine self-administration in rats." *Neuroreport* 11(9): 2013-5.
- Glickstein, S. B. and C. Schmauss (2004). "Effect of methamphetamine on cognition and repetitive motor behavior of mice deficient for dopamine D2 and D3 receptors." *Ann N Y Acad Sci* 1025: 110-8.
- Glickstein, S. B. and C. Schmauss (2004). "Focused motor stereotypies do not require enhanced activation of neurons in striosomes." *J Comp Neurol* 469(2): 227-38.
- Glickstein, S. B., P. R. Hof, et al. (2002). "Mice lacking dopamine D2 and D3 receptors have spatial working memory deficits." *J Neurosci* 22(13): 5619-29.
- Goeders, J. E. and N. E. Goeders (2004). "Effects of oxazepam on methamphetamine-induced conditioned place preference." *Pharmacol Biochem Behav* 78(1): 185-8.
- Golembiowska, K. and A. Zylewska (2000). "Effect of adenosine kinase, adenosine deaminase and transport inhibitors on striatal dopamine and stereotypy after methamphetamine administration." *Neuropharmacology* 39(11): 2124-32.
- Gomita, Y., Y. Ichimaru, et al. (1990). "Effects of methamphetamine on regional cerebral glucose utilization in rats with unilateral lesion of substantia nigra." *Jpn J Pharmacol* 53(3): 414-8.
- Gomita, Y., Y. Kataoka, et al. (1983). "Methamphetamine mortality to emotional stimuli administered in the form of affective communication." *Life Sci* 32(9): 941-7.
- Gomita, Y., Y. Kataoka, et al. (1982). "Influence of aggregation on the action of methamphetamine in locomotor activity." *J Pharmacobiodyn* 5(5): 334-9.
- Goudie, A. J., E. W. Thornton, et al. (1976). "Drug pretreatment effects in drug induced taste aversions: Effects of dose and duration of pretreatment." *Pharmacol Biochem Behav* 4(5): 629-33.
- Green, A. R., D. J. Heal, et al. (1977). "Further observations on the effect of repeated electroconvulsive shock on the behavioural responses of rats produced by increases in the functional activity of brain 5-hydroxytryptamine and dopamine." *Psychopharmacology (Berl)* 52(2): 195-200.
- Green, A. R. and P. H. Kelly (1976). "Evidence concerning the involvement of 5-hydroxytryptamine in the locomotor activity produced by amphetamine or tranlycypromine plus L-DOPA." *Br J Pharmacol* 57(1): 141-7.
- Grisel, J. E., J. K. Belknap, et al. (1997). "Quantitative trait loci affecting methamphetamine responses in BXD recombinant inbred mouse strains." *J Neurosci* 17(2): 745-54.
- Gyarmati, Z., J. Timar, et al. (2001). "Behavioural consequences of methamphetamine-induced neurotoxicity in rats." *Neurobiology (Bp)* 9(1): 37-9.
- Hada, H. and K. Miyamoto (1990). "Enhancing effects of sound on methamphetamine-induced behavioral aberrations in the rat: a model of relapse of schizophrenia-like symptoms." *Jpn J Psychiatry Neurol* 44(3): 619-27.
- Halladay, A. K., A. Kusnecov, et al. (2003). "Relationship between methamphetamine-induced dopamine release, hyperthermia, self-injurious behaviour and long term dopamine depletion in BALB/c and C57BL/6 mice." *Pharmacol Toxicol* 93(1): 33-41.
- Hamamura, T., K. Akiyama, et al. (1991). "Co-administration of either a selective D1 or D2 dopamine antagonist with methamphetamine prevents methamphetamine-induced behavioral sensitization and neurochemical change, studied by in vivo intracerebral dialysis." *Brain Res* 546(1): 40-6.
- Harrigan, S. E. and D. A. Downs (1981). "Pharmacological evaluation of narcotic antagonist delivery systems in rhesus monkeys." *NIDA Res Monogr* 28: 77-92.
- Harrigan, S. E. and D. A. Downs (1978). "Continuous intravenous naltrexone effects on morphine self-administration in rhesus monkeys." *J Pharmacol Exp Ther* 204(2): 481-6.

- Harrod, S. B., L. P. Dwoskin, et al. (2004). "Lobeline produces conditioned taste avoidance in rats." *Pharmacol Biochem Behav* 78(1): 1-5.
- Harrod, S. B., L. P. Dwoskin, et al. (2003). "Lobeline does not serve as a reinforcer in rats." *Psychopharmacology (Berl)* 165(4): 397-404.
- Harrod, S. B., L. P. Dwoskin, et al. (2001). "Lobeline attenuates d-methamphetamine self-administration in rats." *J Pharmacol Exp Ther* 298(1): 172-9.
- Hassler, R. and A. Wagner (1975). "Locomotor activity and speed of movements in relation to monoamine-acting drugs." *Int J Neurol* 10(1-4): 80-97.
- Hayase, T., Y. Yamamoto, et al. (2006). "Behavioral effects of ketamine and toxic interactions with psychostimulants." *BMC Neurosci* 7(1): 25.
- Hayase, T., Y. Yamamoto, et al. (2005). "Persistent anxiogenic effects of a single or repeated doses of cocaine and methamphetamine: Interactions with endogenous cannabinoid receptor ligands." *Behav Pharmacol* 16(5-6): 395-404.
- Hayase, T., Y. Yamamoto, et al. (2003). "Brain excitatory amino acid transporters (EAATs) and treatment of methamphetamine toxicity." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 38(6): 498-511.
- Hayashi, T., M. Kunihara, et al. (1987). "Behavioral and neurochemical changes produced by postnatal pretreatments with methamphetamine in rats." *Jpn J Pharmacol* 43(1): 17-25.
- Hayashi, T., K. Fujimoto, et al. (1981). "[Variability in the effects of psychotic drugs on conditioned avoidance reactions in rats due to warning stimuli]." *Yakubutsu Seishin Kodo* 1(1): 13-9.
- He, J., Y. Yang, et al. (2006). "The effects of chronic administration of quetiapine on the methamphetamine-induced recognition memory impairment and dopaminergic terminal deficit in rats." *Behav Brain Res* 172(1): 39-45.
- He, J., H. Xu, et al. (2005). "Chronic administration of quetiapine alleviates the anxiety-like behavioural changes induced by a neurotoxic regimen of dl-amphetamine in rats." *Behav Brain Res* 160(1): 178-87.
- He, S. and K. Grasing (2006). "l-Methamphetamine and selective MAO inhibitors decrease morphine-reinforced and non-reinforced behavior in rats; Insights towards selegiline's mechanism of action." *Pharmacol Biochem Behav*.
- Hess, U. S., S. P. Whalen, et al. (2003). "Ampakines reduce methamphetamine-driven rotation and activate neocortex in a regionally selective fashion." *Neuroscience* 121(2): 509-21.
- Hienz, R. D., S. E. Lukas, et al. (1985). "Effects of d-methamphetamine on auditory and visual reaction times and detection thresholds in the baboon." *Psychopharmacology (Berl)* 85(4): 476-82.
- Higgs, R. A. and R. A. Glennon (1990). "Stimulus properties of ring-methyl amphetamine analogs." *Pharmacol Biochem Behav* 37(4): 835-7.
- Hirabayashi, M. and S. Tadokoro (1992). "Sensitization to ambulation-increasing effects of cocaine after repeated administration in mice-roles of dose and interval of administration as well as experimental environments." *Arukoru Kenkyuto Yakubutsu Ison* 27(1): 91-102.
- Hirabayashi, M., S. Okada, et al. (1991). "Comparison of sensitization to ambulation-increasing effects of cocaine and methamphetamine after repeated administration in mice." *J Pharm Pharmacol* 43(12): 827-30.
- Hirabayashi, M. and S. Okada (1985). "[Development of reverse tolerance to the ambulation-increasing effect of ephedrine after repeated administration in mice]." *Yakubutsu Seishin Kodo* 5(3): 231-41.
- Hirabayashi, M., S. Okada, et al. (1983). "[Characteristics of reverse tolerance to ambulation-increasing effect of methylphenidate after repeated administration in mice]." *Yakubutsu Seishin Kodo* 3(3): 117-26.
- Hirabayashi, M. and M. R. Alam (1981). "Enhancing effect of methamphetamine on ambulatory activity produced by repeated administration in mice." *Pharmacol Biochem Behav* 15(6): 925-32.
- Hirabayashi, M., F. Iwai, et al. (1979). "[Individual differences in the accelerating effect of methamphetamine, d-amphetamine and morphine on ambulatory activity in mice (author's transl)]." *Nippon Yakurigaku Zasshi* 75(7): 683-93.
- Hiranita, T., Y. Nawata, et al. (2006). "Suppression of methamphetamine-seeking behavior by nicotinic agonists." *Proc Natl Acad Sci U S A* 103(22): 8523-7.
- Hiranita, T., K. Anggadiredja, et al. (2004). "Nicotine attenuates relapse to methamphetamine-seeking behavior (craving) in rats." *Ann N Y Acad Sci* 1025: 504-7.
- Hirate, K. and H. Kuribara (1991). "Characteristics of the ambulation-increasing effect of GBR-12909, a selective dopamine uptake inhibitor, in mice." *Jpn J Pharmacol* 55(4): 501-11.
- Hirose, A., T. Kato, et al. (1990). "Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions." *Jpn J Pharmacol* 53(3): 321-9.
- Hiroshige, T., K. Honma, et al. (1991). "SCN-independent circadian oscillators in the rat." *Brain Res Bull* 27(3-4): 441-5.
- Hirota, S., N. Kawashima, et al. (2003). "Neuropharmacological profile of an atypical antipsychotic, NRA0562." *CNS Drug Rev* 9(4): 375-88.

- Hoefler, M. E., S. J. Voskianian, et al. (2006). "Effects of terguride, ropinirole, and acetyl-L-carnitine on methamphetamine withdrawal in the rat." *Pharmacol Biochem Behav* 83(3): 403-9.
- Holman, R. B., G. R. Elliott, et al. (1975). "Neuroregulators and sleep mechanisms." *Annu Rev Med* 26: 499-520.
- Holtzman, S. G. (2001). "Differential interaction of GBR 12909, a dopamine uptake inhibitor, with cocaine and methamphetamine in rats discriminating cocaine." *Psychopharmacology (Berl)* 155(2): 180-6.
- Honda, F., Y. Satoh, et al. (1977). "Dopamine receptor blocking activity of sulpiride in the central nervous system." *Jpn J Pharmacol* 27(3): 397-411.
- Honda, M. (2004). "[The relation between behavioral sensitization and glutamate release on the animal model of methamphetamine-induced psychosis]." *Hokkaido Igaku Zasshi* 79(1): 65-78.
- Honma, S. and K. Honma (1995). "Phase-dependent phase shift of methamphetamine-induced circadian rhythm by haloperidol in SCN-lesioned rats." *Brain Res* 674(2): 283-90.
- Honma, S., N. Kanematsu, et al. (1992). "Entrainment of methamphetamine-induced locomotor activity rhythm to feeding cycles in SCN-lesioned rats." *Physiol Behav* 52(5): 843-50.
- Honma, S. and K. Honma (1992). "Locomotor rhythms induced by methylphenidate in suprachiasmatic nuclei-lesioned rats." *Neurosci Lett* 137(1): 24-8.
- Honma, S., K. Honma, et al. (1991). "Methamphetamine effects on rat circadian clock depend on actograph." *Physiol Behav* 49(4): 787-95.
- Honma, S., K. Honma, et al. (1989). "Methamphetamine induced locomotor rhythm entrains to restricted daily feeding in SCN lesioned rats." *Physiol Behav* 45(5): 1057-65.
- Honma, S., K. Honma, et al. (1988). "Rhythms in behaviors, body temperature and plasma corticosterone in SCN lesioned rats given methamphetamine." *Physiol Behav* 44(2): 247-55.
- Honma, K., S. Honma, et al. (1987). "Activity rhythms in the circadian domain appear in suprachiasmatic nuclei lesioned rats given methamphetamine." *Physiol Behav* 40(6): 767-74.
- Honma, K., S. Honma, et al. (1986). "Disorganization of the rat activity rhythm by chronic treatment with methamphetamine." *Physiol Behav* 38(5): 687-95.
- Honma, K. and S. Honma (1986). "Effects of methamphetamine on development of circadian rhythms in rats." *Brain Dev* 8(4): 397-401.
- Honma, T. and H. Fukushima (1979). "The involvement of serotonergic neurons in the central nervous system as the possible mechanism for slow head-shaking behavior induced by methamphetamine in rats." *Psychopharmacology (Berl)* 65(2): 155-9.
- Hughes, R. N. and A. M. Greig (1976). "Effects of caffeine, methamphetamine and methylphenidate on reactions to novelty and activity in rats." *Neuropharmacology* 15(11): 673-6.
- Hurlbert, M. S., R. I. Gianani, et al. (1999). "Neural transplantation of hNT neurons for Huntington's disease." *Cell Transplant* 8(1): 143-51.
- Ida, I., T. Asami, et al. (1992). "Circadian variation in R-THBP-induced enhancement of the ambulation-increasing effect of methamphetamine on mice." *Jpn J Psychiatry Neurol* 46(4): 941-5.
- Ida, I., T. Asami, et al. (1990). "[Characteristics of antagonism between ceruletide and various central-acting drugs: Investigation by means of ambulatory activity in mice]." *Nippon Yakurigaku Zasshi* 96(6): 333-41.
- Ihara, Y., M. Sato, et al. (1986). "Morphological changes in rat striatal boutons after chronic methamphetamine and haloperidol treatment." *Neurosci Res* 3(5): 403-10.
- Iijima, M., T. Nikaido, et al. (2002). "Methamphetamine-induced, suprachiasmatic nucleus-independent circadian rhythms of activity and mPer gene expression in the striatum of the mouse." *Eur J Neurosci* 16(5): 921-9.
- Inaji, M., T. Okauchi, et al. (2005). "Correlation between quantitative imaging and behavior in unilaterally 6-OHDA-lesioned rats." *Brain Res* 1064(1-2): 136-45.
- Inamasu, J., Y. Nakamura, et al. (2003). "Subcortical hemorrhage caused by methamphetamine abuse: Efficacy of the triage system in the differential diagnosis--case report." *Neurol Med Chir (Tokyo)* 43(2): 82-4.
- Inoue, H., I. Arai, et al. (1996). "NG-nitro-L-arginine methyl ester attenuates the maintenance and expression of methamphetamine-induced behavioral sensitization and enhancement of striatal dopamine release." *J Pharmacol Exp Ther* 277(3): 1424-30.
- Iorio, L. C., A. Barnett, et al. (1983). "SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems." *J Pharmacol Exp Ther* 226(2): 462-8.
- Irwin, S., R. Kinoi, et al. (1971). "Drug effects on distress-evoked behavior in mice: Methodology and drug class comparisons." *Psychopharmacologia* 20(2): 172-85.
- Ishibashi, S., T. Kuroiwa, et al. (2004). "Extrapyramidal motor symptoms versus striatal infarction volume after focal ischemia in mongolian gerbils." *Neuroscience* 127(2): 269-75.

- Ishida, Y., K. Kawai, et al. (2005). "Alteration of striatal [11C]raclopride and 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine uptake precedes development of methamphetamine-induced rotation following unilateral 6-hydroxydopamine lesions of medial forebrain bundle in rats." *Neurosci Lett* 389(1): 30-4.
- Ishida, Y., K. Todaka, et al. (1998). "Methamphetamine induces Fos expression in the striatum and the substantia nigra pars reticulata in a rat model of Parkinson's disease." *Brain Res* 809(1): 107-14.
- Ishida, Y., H. Hashiguchi, et al. (1991). "Effect of intra-amygdala dopaminergic grafts on methamphetamine-induced locomotor activity, extracellular dopamine and dopamine metabolite overflow: A comparison with the effect of intra-accumbens grafts." *Brain Res* 549(2): 342-5.
- Ishida, Y., T. Hashitani, et al. (1990). "Behavioral and biochemical effects of intra-accumbens dopaminergic grafts." *Brain Res Bull* 24(3): 487-92.
- Ishimaru, M., T. Hashimoto, et al. (1995). "Methamphetamine-induced dopaminergic hyperactivity is not accompanied with increase in tyrosine hydroxylase mRNA of the rat midbrain." *Neurosci Lett* 191(1-2): 107-10.
- Ishikawa, A., T. Kadota, et al. (2005). "Essential role of D1 but not D2 receptors in methamphetamine-induced impairment of long-term potentiation in hippocampal-prefrontal cortex pathway." *Eur J Neurosci* 22(7): 1713-9.
- Ison, J. R., R. H. Page, et al. (1969). "Methamphetamine hydrochloride and reactions to aversive shock and reward decrements." *Psychol Rep* 24(3): 739-45.
- Ito, C., K. Onodera, et al. (1997). "Effects of histamine agents on methamphetamine-induced stereotyped behavior and behavioral sensitization in rats." *Psychopharmacology (Berl)* 130(4): 362-7.
- Ito, C., M. Sato, et al. (1996). "The role of the brain histaminergic neuron system in methamphetamine-induced behavioral sensitization in rats." *Ann N Y Acad Sci* 801: 353-60.
- Ito, H. and S. Takaori (1968). "Effects of psychotropic agents on the exploratory behavior of rats in a Y-shaped box." *Jpn J Pharmacol* 18(3): 344-52.
- Ito, K., T. Abekawa, et al. (2006). "Relationship between development of cross-sensitization to MK-801 and delayed increases in glutamate levels in the nucleus accumbens induced by a high dose of methamphetamine." *Psychopharmacology (Berl)* 187(3): 293-302.
- Ito, K., T. Abekawa, et al. (2006). "Valproate blocks high-dose methamphetamine-induced behavioral cross-sensitization to locomotion-inducing effect of dizocilpine (MK-801), but not methamphetamine." *Psychopharmacology (Berl)* 186(4): 525-33.
- Ito, K., T. Ohmori, et al. (2000). "The role of benzodiazepine receptors in the acquisition and expression of behavioral sensitization to methamphetamine." *Pharmacol Biochem Behav* 65(4): 705-10.
- Ito, K., T. Ohmori, et al. (1997). "Clonazepam prevents the development of sensitization to methamphetamine." *Pharmacol Biochem Behav* 58(4): 875-9.
- Ito, S., T. Mori, et al. (2006). "Differential effects of mu-opioid, delta-opioid and kappa-opioid receptor agonists on dopamine receptor agonist-induced climbing behavior in mice." *Behav Pharmacol* 17(8): 691-701.
- Ito, Y., K. Takuma, et al. (2006). "A novel azaindolinone derivative ZSET1446, spiro[imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one, improves methamphetamine-induced impairment of recognition memory in mice by activating extracellular signal-regulated kinase 1/2." *J Pharmacol Exp Ther*.
- Itoh, Y., M. Nishibori, et al. (1984). "Neuronal histamine inhibits methamphetamine-induced locomotor hyperactivity in mice." *Neurosci Lett* 48(3): 305-9.
- Itohi, N., A. Yamatodani, et al. (1990). "Development of a computer program classifying rat sleep stages." *J Neurosci Methods* 31(2): 137-43.
- Itzhak, Y. and S. F. Ali (2006). "Role of nitrenergic system in behavioral and neurotoxic effects of amphetamine analogs." *Pharmacol Ther* 109(1-2): 246-62.
- Itzhak, Y. and S. F. Ali (2002). "Behavioral consequences of methamphetamine-induced neurotoxicity in mice: Relevance to the psychopathology of methamphetamine addiction." *Ann N Y Acad Sci* 965: 127-35.
- Itzhak, Y. and J. L. Martin (2002). "Cocaine-induced conditioned place preference in mice: Induction, extinction and reinstatement by related psychostimulants." *Neuropsychopharmacology* 26(1): 130-4.
- Itzhak, Y., J. L. Martin, et al. (2002). "Methamphetamine-induced dopaminergic neurotoxicity in mice: Long-lasting sensitization to the locomotor stimulation and desensitization to the rewarding effects of methamphetamine." *Prog Neuropsychopharmacol Biol Psychiatry* 26(6): 1177-83.
- Itzhak, Y. and J. L. Martin (2000). "Effect of riluzole and gabapentin on cocaine- and methamphetamine-induced behavioral sensitization in mice." *Psychopharmacology (Berl)* 151(2-3): 226-33.
- Itzhak, Y., C. Gandia, et al. (1998). "Resistance of neuronal nitric oxide synthase-deficient mice to methamphetamine-induced dopaminergic neurotoxicity." *J Pharmacol Exp Ther* 284(3): 1040-7.
- Iwabuchi, K., Y. Kubota, et al. (2004). "Methamphetamine and brain histamine: A study using histamine-related gene knockout mice." *Ann N Y Acad Sci* 1025: 129-34.

- Iwazaki, T., I. S. McGregor, et al. (2006). "Protein expression profile in the striatum of acute methamphetamine-treated rats." *Brain Res* 1097(1): 19-25.
- Izawa, J., K. Yamanashi, et al. (2006). "Differential effects of methamphetamine and cocaine on behavior and extracellular levels of dopamine and 3,4-dihydroxyphenylalanine in the nucleus accumbens of conscious rats." *Eur J Pharmacol* 549(1-3): 84-90.
- Izumi, K., M. Nomoto, et al. (1984). "Phenytoin potentiates methamphetamine-induced behavior in mice." *Pharmacol Biochem Behav* 20(5): 803-6.
- Jadhav, J. H., J. J. Balsara, et al. (1981). "Effect of ethosuximide on dopaminergically mediated behaviours." *Indian J Physiol Pharmacol* 25(3): 274-8.
- Janowsky, A., C. Mah, et al. (2001). "Mapping genes that regulate density of dopamine transporters and correlated behaviors in recombinant inbred mice." *J Pharmacol Exp Ther* 298(2): 634-43.
- Jewett, R. F. and S. Norton (1964). "Measurement of behavior of rats under isolation and observations on preliminary drug effects." *Psychopharmacologia* 6(2): 151-8.
- Johanson, C. E., R. L. Balster, et al. (1976). "Self-administration of psychomotor stimulant drugs: The effects of unlimited access." *Pharmacol Biochem Behav* 4(1): 45-51.
- Johnson, S. A., N. T. Luu, et al. (1999). "Synergistic interactions between ampakines and antipsychotic drugs." *J Pharmacol Exp Ther* 289(1): 392-7.
- Jones, D. N. and S. G. Holtzman (1994). "Influence of naloxone upon motor activity induced by psychomotor stimulant drugs." *Psychopharmacology (Berl)* 114(2): 215-24.
- Joshi, V. V., J. J. Balsara, et al. (1981). "Effect of L-histidine and chlorcyclizine on apomorphine-induced climbing behaviour and methamphetamine stereotypy in mice." *Eur J Pharmacol* 69(4): 499-502.
- Jun, J. H. and C. W. Schindler (2000). "Dextromethorphan alters methamphetamine self-administration in the rat." *Pharmacol Biochem Behav* 67(3): 405-9.
- Kabai, P., A. Liker, et al. (1999). "Methamphetamine-induced stereotypies in newly-hatched decerebrated domestic chicks." *Neurochem Res* 24(12): 1563-9.
- Kadota, T. and K. Kadota (2004). "Neurotoxic morphological changes induced in the medial prefrontal cortex of rats behaviorally sensitized to methamphetamine." *Arch Histol Cytol* 67(3): 241-51.
- Kajii, Y., S. Muraoka, et al. (2003). "A developmentally regulated and psychostimulant-inducible novel rat gene *mrt1* encoding PDZ-PX proteins isolated in the neocortex." *Mol Psychiatry* 8(4): 434-44.
- Kamei, H., T. Nagai, et al. (2006). "Repeated methamphetamine treatment impairs recognition memory through a failure of novelty-induced ERK1/2 activation in the prefrontal cortex of mice." *Biol Psychiatry* 59(1): 75-84.
- Kamens, H. M., S. Burkhart-Kasch, et al. (2005). "Sensitivity to psychostimulants in mice bred for high and low stimulation to methamphetamine." *Genes Brain Behav* 4(2): 110-25.
- Kameyama, T., T. Nabeshima, et al. (1987). "[Behavioral pharmacological action of Ca-4-(3,5-dihydroxy-3-methylpentylamido) butyrate (mevalonic GABA, MV-GABA)]." *Nippon Yakurigaku Zasshi* 89(3): 103-10.
- Kameyama, T., T. Nabeshima, et al. (1981). "[Pharmacological action of eptazocine (1-1,4-dimethyl-10-hydroxy-2,3,4,5,6,7-hexahydro-1,6-methano-1H-4-benzazon ine). (III) Central action of eptazocine (author's transl)]." *Nippon Yakurigaku Zasshi* 78(6): 629-45.
- Kamei, H., T. Nagai, et al. (2006). "Repeated methamphetamine treatment impairs recognition memory through a failure of novelty-induced ERK1/2 activation in the prefrontal cortex of mice." *Biol Psychiatry* 59(1): 75-84.
- Kamens, H. M., S. Burkhart-Kasch, et al. (2006). "Ethanol-related traits in mice selectively bred for differential sensitivity to methamphetamine-induced activation." *Behav Neurosci* 120(6): 1356-66.
- Kamens, H. M., S. Burkhart-Kasch, et al. (2005). "Sensitivity to psychostimulants in mice bred for high and low stimulation to methamphetamine." *Genes Brain Behav* 4(2): 110-25.
- Kaneko, Y., A. Kashiwa, et al. (2006). "Selective serotonin reuptake inhibitors, fluoxetine and paroxetine, attenuate the expression of the established behavioral sensitization induced by methamphetamine." *Neuropsychopharmacology*.
- Karczmar, A. G. and C. L. Scudder (1967). "Behavioral responses to drugs and brain catecholamine levels in mice of different strains and genera." *Fed Proc* 26(4): 1186-91.
- Karler, R., L. D. Calder, et al. (1998). "The role of dopamine and GABA in the frontal cortex of mice in modulating a motor-stimulant effect of amphetamine and cocaine." *Pharmacol Biochem Behav* 60(1): 237-44.
- Karler, R., L. D. Calder, et al. (1998). "The role of dopamine in the mouse frontal cortex: a new hypothesis of behavioral sensitization to amphetamine and cocaine." *Pharmacol Biochem Behav* 61(4): 435-43.
- Karler, R., J. B. Bedingfield, et al. (1997). "The role of the frontal cortex in the mouse in behavioral sensitization to amphetamine." *Brain Res* 757(2): 228-35.

- Karler, R., L. D. Calder, et al. (1995). "The dopaminergic, glutamatergic, GABAergic bases for the action of amphetamine and cocaine." *Brain Res* 671(1): 100-4.
- Karler, R., L. D. Calder, et al. (1994). "A dopaminergic-glutamatergic basis for the action of amphetamine and cocaine." *Brain Res* 658(1-2): 8-14.
- Kashihara, K., Y. Fujiwara, et al. (1984). "[Continuous suppression of methamphetamine-induced supersensitivity by chronic haloperidol administration]." *Seishin Shinkeigaku Zasshi* 86(11): 928-32.
- Kashiwabara, K. (1983). "[A long-term qualitative behavioral change following chronic methamphetamine administration in Japanese monkeys (*Macaca fuscata*)]." *Yakubutsu Seishin Kodo* 3(3): 137-48.
- Kato, K., T. Shishido, et al. (2001). "Glycine reduces novelty- and methamphetamine-induced locomotor activity in neonatal ventral hippocampal damaged rats." *Neuropsychopharmacology* 24(3): 330-2.
- Kato, K., T. Shishido, et al. (2000). "Effects of phencyclidine on behavior and extracellular levels of dopamine and its metabolites in neonatal ventral hippocampal damaged rats." *Psychopharmacology (Berl)* 150(2): 163-9.
- Katsuura, G. and S. Itoh (1982). "Sedative action of cholecystokinin octapeptide on behavioral excitation by thyrotropin releasing hormone and methamphetamine in the rat." *Jpn J Physiol* 32(1): 83-91.
- Kaufmann, S. H., H. P. Hofmann, et al. (1981). "Induction of hyperphagia in rats by intracerebroventricular infusion of sodium pentobarbital. A method for testing anorexigenic compounds." *Arzneimittelforschung* 31(2): 335-7.
- Kawakami, Y., K. Suemaru, et al. (1998). "Repeated mazindol and methamphetamine administration produces cross-sensitization to stereotyped behavior induced by these agents in rats." *Acta Med Okayama* 52(3): 169-71.
- Kawakami, Y., K. Suemaru, et al. (1996). "[Behavioral changes induced by repeated administration of mazindol, an anorexiant, in rats]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 16(4): 139-43.
- Kawamura, T., Y. Ichitani, et al. (2005). "[Rewarding property of nicotine and methamphetamine tested by conditioned place preference in rats: Effect of chronic nicotine pretreatment]." *Shinrigaku Kenkyu* 76(1): 57-62.
- Kelfer, D. A. and A. J. Rosen (1974). "Effects of metamphetamine, pipradrol and methylphenidate on instrumental conditioning and spontaneous motor activity in the immature rat." *Psychopharmacologia* 35(4): 317-26.
- Kelly, P. H. and R. J. Miller (1975). "The interaction of neuroleptic and muscarinic agents with central dopaminergic systems." *Br J Pharmacol* 54(1): 115-21.
- Khanzode, S. D., S. M. Mahakalkar, et al. (1996). "Effect of pre-treatment of some calcium channel blockers on catalepsy and stereotypic behaviour in rats." *Indian J Physiol Pharmacol* 40(2): 159-62.
- Kifune, A. and S. Tadokoro (1991). "[Modification of stereotypy-producing and ambulation-increasing effects following repeated administration of methamphetamine in rats]." *Yakubutsu Seishin Kodo* 11(3): 207-14.
- Kim, H. C., E. J. Shin, et al. (2005). "Pharmacological action of *Panax ginseng* on the behavioral toxicities induced by psychotropic agents." *Arch Pharm Res* 28(9): 995-1001.
- Kim, H. S., Y. T. Hong, et al. (1998). "Inhibition by ginsenosides Rb1 and Rg1 of methamphetamine-induced hyperactivity, conditioned place preference and postsynaptic dopamine receptor supersensitivity in mice." *Gen Pharmacol* 30(5): 783-9.
- Kim, H. S. and C. G. Jang (1997). "MK-801 inhibits methamphetamine-induced conditioned place preference and behavioral sensitization to apomorphine in mice." *Brain Res Bull* 44(3): 221-7.
- Kim, H. S., C. G. Jang, et al. (1996). "Blockade by ginseng total saponin of methamphetamine-induced hyperactivity and conditioned place preference in mice." *Gen Pharmacol* 27(2): 199-204.
- Kim, H. S., J. G. Kang, et al. (1995). "Blockade by ginseng total saponin of the development of methamphetamine reverse tolerance and dopamine receptor supersensitivity in mice." *Planta Med* 61(1): 22-5.
- Kim, J. S., R. Hassler, et al. (1970). "Abnormal movements and rigidity induced by harmaline in relation to striatal acetylcholine, serotonin, and dopamine." *Exp Neurol* 29(2): 189-200.
- Kirkby, R. J., D. S. Bell, et al. (1972). "The effects of methylamphetamine on stereotyped behaviour, activity, startle, and orienting responses." *Psychopharmacologia* 25(1): 41-8.
- Kita, T., Y. Matsunari, et al. (2000). "Methamphetamine-induced striatal dopamine release, behavior changes and neurotoxicity in BALB/c mice." *Int J Dev Neurosci* 18(6): 521-30.
- Kita, T., Y. Matsunari, et al. (2000). "Evaluation of the effects of alpha-phenyl-N-tert-butyl nitron pretreatment on the neurobehavioral effects of methamphetamine." *Life Sci* 67(13): 1559-71.
- Kita, T., M. Takahashi, et al. (1998). "Methamphetamine-induced changes in activity and water intake during light and dark cycles in rats." *Prog Neuropsychopharmacol Biol Psychiatry* 22(7): 1185-96.
- Kitaichi, K., M. Fukuda, et al. (2005). "Behavioral changes following antisense oligonucleotide-induced reduction of organic cation transporter-3 in mice." *Neurosci Lett* 382(1-2): 195-200.
- Kitaichi, K., Y. Morishita, et al. (2003). "Increased plasma concentration and brain penetration of methamphetamine in behaviorally sensitized rats." *Eur J Pharmacol* 464(1): 39-48.

- Kitaichi, K., Y. Morishita, et al. (2001). "[Pharmacokinetic behavioral changes of methamphetamine in methamphetamine-sensitized animal model]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 21(5): 133-44.
- Kitamura, O., S. Wee, et al. (2006). "Escalation of methamphetamine self-administration in rats: A dose-effect function." *Psychopharmacology (Berl)* 186(1): 48-53.
- Kitanaka, N., J. Kitanaka, et al. (2006). "Methamphetamine reward in mice as assessed by conditioned place preference test with Supermex sensors: Effect of subchronic clorgyline pretreatment." *Neurochem Res* 31(6): 805-13.
- Kitanaka, N., J. Kitanaka, et al. (2005). "Inhibition of methamphetamine-induced hyperlocomotion in mice by clorgyline, a monoamine oxidase-a inhibitor, through alteration of the 5-hydroxytryptamine turnover in the striatum." *Neuroscience* 130(2): 295-308.
- Kitanaka, N., J. Kitanaka, et al. (2005). "Repeated clorgyline treatment inhibits methamphetamine-induced behavioral sensitization in mice." *Neurochem Res* 30(4): 445-51.
- Kitanaka, N., J. Kitanaka, et al. (2003). "Behavioral sensitization and alteration in monoamine metabolism in mice after single versus repeated methamphetamine administration." *Eur J Pharmacol* 474(1): 63-70.
- Kitanaka, J., N. Kitanaka, et al. (2003). "Chronic methamphetamine administration reduces histamine-stimulated phosphoinositide hydrolysis in mouse frontal cortex." *Biochem Biophys Res Commun* 300(4): 932-7.
- Kitahama, K. and J. L. Valatz (1979). "Strain differences in amphetamine sensitivity in mice. II. Overcompensation of paradoxical sleep after deprivation in two C57 strains." *Psychopharmacology (Berl)* 66(3): 291-5.
- Kliethermes, C. L., H. M. Kamens, et al. (2006). "Drug reward and intake in lines of mice selectively bred for divergent exploration of a hole board apparatus." *Genes Brain Behav.*
- Kliethermes, C. L. and J. C. Crabbe (2006). "Pharmacological and genetic influences on hole-board behaviors in mice." *Pharmacol Biochem Behav* 85(1): 57-65.
- Knoll, B. (1977). "The effect of para-Br-methamphetamine on aggressive behaviour [proceedings]." *Act Nerv Super (Praha)* 19(3): 225-6.
- Kobayashi, K. and H. Sano (2000). "Dopamine deficiency in mice." *Brain Dev* 22 Suppl 1: S54-60.
- Kobayashi, M., Y. Wakamatsu, et al. (1977). "[Methamphetamine-stereotypies" and brain dopamine levels of rats treated with single or repeated doses of alpha-methyl-para-tyrosine]." *Nippon Yakurigaku Zasshi* 73(6): 695-701.
- Kobayashi, M. and E. Arai (1976). "Effect of cortisone, aldosterone and nialamide on "amphetamine stereotypies" and brain methamphetamine levels of adrenalectomized rats." *Psychopharmacologia* 46(3): 317-24.
- Kobayashi, M., Y. Wakamatsu, et al. (1973). "[Influence of adrenalectomy on emotional behavior and brain methamphetamine concentration in rats--effect of chronic administrations of ACTH]." *Nippon Yakurigaku Zasshi* 69(3): 403-8.
- Kohda, H., M. Funahashi, et al. (1986). "Decrease in d-methamphetamine sensitivity in mice due to ethanol: Apparent inhibitory and stimulatory effects of ethanol on d-methamphetamine-induced locomotor activity." *Pharmacol Biochem Behav* 25(5): 1035-9.
- Koshikawa, N., S. Aoki, et al. (1987). "Sulpiride injection into the dorsal striatum increases methamphetamine-induced gnawing in rats." *Eur J Pharmacol* 133(1): 119-25.
- Koshikawa, N., E. Mori, et al. (1990). "Role of dopamine D-1 and D-2 receptors in the ventral striatum in the turning behaviour of rats." *Eur J Pharmacol* 178(2): 233-7.
- Koshikawa, N., S. Aoki, et al. (1986). "Effects of sulpiride injected into the dorsal striatum and the nucleus accumbens on dopamine-mediated oral stereotypy and hyperlocomotion in rats." *J Nihon Univ Sch Dent* 28(2): 109-16.
- Kosman, M. E. and D. R. Unna (1968). "Effects of chronic administration of the amphetamines and other stimulants on behavior." *Clin Pharmacol Ther* 9(2): 240-54.
- Kosobud, A. E., N. C. Pecoraro, et al. (1998). "Circadian activity precedes daily methamphetamine injections in the rat." *Neurosci Lett* 250(2): 99-102.
- Kraeuchi, K., A. Wirz-Justice, et al. (1986). "Temporal distribution of [3H]-imipramine binding in rat brain regions is not changed by chronic methamphetamine." *Chronobiol Int* 3(2): 127-33.
- Kraeuchi, K., K. Rudolph, et al. (1985). "Similarities in feeding behavior of chronic methamphetamine treated and withdrawn rats to VMH lesioned rats." *Pharmacol Biochem Behav* 23(6): 917-20.
- Krauchi, K., A. Wirz-Justice, et al. (1984). "Hypothalamic alpha 2- and beta-adrenoceptor rhythms are correlated with circadian feeding: evidence from chronic methamphetamine treatment and withdrawal." *Brain Res* 321(1): 83-90.
- Kruzich, P. J. and J. Xi (2006). "Differences in extinction responding and reinstatement of methamphetamine-seeking behavior between Fischer 344 and Lewis rats." *Pharmacol Biochem Behav* 83(3): 391-5.
- Kubota, Y., C. Ito, et al. (2002). "Increased methamphetamine-induced locomotor activity and behavioral sensitization in histamine-deficient mice." *J Neurochem* 83(4): 837-45.
- Kuczenski, R. and D. S. Segal (2002). "Exposure of adolescent rats to oral methylphenidate: Preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine." *J Neurosci* 22(16): 7264-71.
- Kulkarni, A. S. (1972). "Avoidance acquisition and CNS stimulants." *Naunyn Schmiedebergs Arch Pharmacol* 273(4): 394-400.



- Kuo, Y. M., K. C. Liang, et al. (2006). "Cocaine-but not methamphetamine-associated memory requires de novo protein synthesis." *Neurobiol Learn Mem*.
- Kuczenski, R. and D. S. Segal (2002). "Exposure of adolescent rats to oral methylphenidate: Preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine." *J Neurosci* 22(16): 7264-71.
- Kuczenski, R. and D. S. Segal (2001). "Caudate-putamen and nucleus accumbens extracellular acetylcholine responses to methamphetamine binges." *Brain Res* 923(1-2): 32-8.
- Kuczenski, R., D. S. Segal, et al. (1995). "Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine." *J Neurosci* 15(2): 1308-17.
- Kulkarni, A. S. (1972). "Avoidance acquisition and CNS stimulants." *Naunyn Schmiedebergs Arch Pharmacol* 273(4): 394-400.
- Kulkarni, A. S. (1972). "Selective increase in avoidance responding by methamphetamine in naive rats." *Psychopharmacologia* 24(4): 449-55.
- Kuo, Y. M., K. C. Liang, et al. (2007). "Cocaine-but not methamphetamine-associated memory requires de novo protein synthesis." *Neurobiol Learn Mem* 87(1): 93-100.
- Kurachi, M. (2003). "Pathogenesis of schizophrenia: Part II. Temporo-frontal two-step hypothesis." *Psychiatry Clin Neurosci* 57(1): 9-15.
- Kuribara, H. (1998). "Importance of initial environments in the development of ambulatory sensitization to methamphetamine and cocaine in mice." *J Pharm Pharmacol* 50(3): 303-9.
- Kuribara, H. (1997). "Effects of postmethamphetamine treatment with restraint on ambulatory sensitization to methamphetamine in mice." *Brain Res Bull* 43(1): 97-100.
- Kuribara, H. (1996). "Inhibitory effect of restraint on induction of behavioral sensitization to methamphetamine and cocaine in mice." *Pharmacol Biochem Behav* 54(2): 327-31.
- Kuribara, H. (1995). "Haloperidol and restraint differently inhibit the induction of sensitization to the ambulation-increasing effect of methamphetamine in mice." *Nihon Shinkei Seishin Yakurigaku Zasshi* 15(3): 253-63.
- Kuribara, H. (1994). "Effects of psychotropic drugs on impairment of acquisition of shuttle avoidance produced by pretreatment with pairs of tone signal and shock in mice." *Jpn J Psychiatry Neurol* 48(3): 639-43.
- Kuribara, H. (1993). "Ceruletide, a cholecystokinin-like decapeptide, differentially reduces the stimulant effect of MK-801 and ketamine: Evaluation by discrete shuttle avoidance in mice." *Eur J Pharmacol* 231(1): 7-11.
- Kuribara, H. and Y. Uchihashi (1993). "SCH 23390 equivalently, but YM-09151-2 differentially reduces the stimulant effects of methamphetamine, MK-801 and ketamine: assessment by discrete shuttle avoidance in mice." *Jpn J Pharmacol* 62(1): 111-4.
- Kuribara, H. and S. Tadokoro (1992). "Behavioral effects of cocoa and its main active compound theobromine: evaluation by ambulatory activity and discrete avoidance in mice." *Arukuru Kenkyuto Yakubutsu Ison* 27(2): 168-79.
- Kuribara, H., T. Asahi, et al. (1992). "Behavioral evaluation of psycho-pharmacological and psychotoxic actions of methylxanthines by ambulatory activity and discrete avoidance in mice." *J Toxicol Sci* 17(2): 81-90.
- Kuribara, H. and S. Tadokoro (1991). "[Behavioral effects of febarbamate (MS-543): evaluation by ambulatory activity, active avoidance and passive avoidance in mice]." *Nippon Yakurigaku Zasshi* 98(4): 311-7.
- Kuribara, H. and S. Tadokoro (1991). "Differential antagonism of the stimulant effects of MK-801 and methamphetamine by ceruletide: Evaluation by discrete shuttle avoidance response in mice." *Jpn J Pharmacol* 57(3): 425-9.
- Kuribara, H., T. Asami, et al. (1990). "Behavioral study on mergocriptine (CBM36-733) by ambulatory activity in mice: repeated administration and interaction with methamphetamine." *Jpn J Pharmacol* 54(2): 163-70.
- Kuribara, H., T. Asami, et al. (1990). "Effects of ceruletide, administered singly and in combination with central-acting drugs, on discrete shuttle avoidance response in mice." *Jpn J Pharmacol* 54(3): 325-9.
- Kuribara, H. and S. Tadokoro (1989). "[Behavioral effects of NC-1100, 1-(3,4-dimethoxyphenyl)-2-(4-diphenylmethylpiperazinyl) ethanol dihydrochloride--on ambulatory activity, discrete lever-press response and shuttle avoidance response in mice]." *Nippon Yakurigaku Zasshi* 93(4): 245-53.
- Kuribara, H. and S. Tadokoro (1988). "[Effects of buflomedil on ambulatory activity and discrete avoidance responses in mice]." *Nippon Yakurigaku Zasshi* 91(2): 111-9.
- Kuribara, H., S. Tadokoro, et al. (1986). "[Behavioral effects of propentofylline (HWA 285) on ambulatory activity, discrete avoidance response and passive avoidance response in mice]." *Nippon Yakurigaku Zasshi* 87(5): 573-81.
- Kuribara, H. and S. Tadokoro (1985). "Chronopharmacological study on morphine-induced increase in ambulatory activity in mice and methamphetamine sensitivity in morphine-experienced mice." *Yakubutsu Seishin Kodo* 5(3): 279-86.
- Kuribara, H. and S. Tadokoro (1985). "Combined effects of methamphetamine and morphine on ambulatory activity in mice and continuous avoidance response in rats." *Yakubutsu Seishin Kodo* 5(3): 271-7.
- Kuribara, H., H. Haraguchi, et al. (1985). "Comparisons between discrete lever-press and shuttle avoidance responses in mice: acquisition processes and effects of psychoactive drugs." *Jpn J Pharmacol* 38(2): 141-51.

- Kuribara, H. and S. Tadokoro (1985). "Effects of psychoactive drugs on conditioned avoidance response in Mongolian gerbils (*Meriones unguiculatus*): Comparison with Wistar rats and dd mice." *Pharmacol Biochem Behav* 23(6): 1013-8.
- Kuribara, H. and S. Tadokoro (1984). "[Behavioral effects of amantadine on ambulatory activity and drinking in mice and on continuous and discrete avoidance responses in rats]." *Nippon Yakurigaku Zasshi* 83(2): 147-58.
- Kuribara, H. and S. Tadokoro (1984). "Circadian variation in the ambulation-increasing effect of apomorphine after repeated administration in mice." *Yakubutsu Seishin Kodo* 4(3): 231-6.
- Kuribara, H. and S. Tadokoro (1983). "Effect alteration of methamphetamine by amino acids or their salts on ambulatory activity in mice." *J Toxicol Sci* 8(1): 25-36.
- Kuribara, H. and S. Tadokoro (1982). "Circadian variation in methamphetamine- and apomorphine-induced increase in ambulatory activity in mice." *Pharmacol Biochem Behav* 17(6): 1251-6.
- Kuribara, H. (1982). "Strain differences to the effects of central acting drugs on Sidman avoidance response in Wistar and Fischer 344 rats." *Pharmacol Biochem Behav* 17(3): 425-9.
- Kusayama, T. and S. Watanabe (2000). "Reinforcing effects of methamphetamine in planarians." *Neuroreport* 11(11): 2511-3.
- Kuwahara, A., A. Kubota, et al. (1987). "[Drug dependence test on a cerebral insufficiency improver, aniracetam]." *Nippon Yakurigaku Zasshi* 89(1): 33-46.
- Landa, L., K. Slais, et al. (2006). "Involvement of cannabinoid CB1 and CB2 receptor activity in the development of behavioural sensitization to methamphetamine effects in mice." *Neuro Endocrinol Lett* 27(1-2).
- Larson, J., C. N. Quach, et al. (1996). "Effects of an AMPA receptor modulator on methamphetamine-induced hyperactivity in rats." *Brain Res* 738(2): 353-6.
- Laties, V. G. (1975). "The role of discriminative stimuli in modulating drug action." *Fed Proc* 34(9): 1880-8.
- Leibowitz, S. F. and C. Rossakis (1978). "Analysis of feeding suppression produced by perifornical hypothalamic injection of catecholamines, amphetamines and mazindol." *Eur J Pharmacol* 53(1): 69-81.
- Levy Andersen, M., M. Bignotto, et al. (2003). "Facilitation of ejaculation after methamphetamine administration in paradoxical sleep deprived rats." *Brain Res* 978(1-2): 31-7.
- Li, J. X., R. Han, et al. (2005). "Different effects of valproate on methamphetamine- and cocaine-induced behavioral sensitization in mice." *Behav Brain Res* 161(1): 125-32.
- Li, M., W. D. Wessinger, et al. (2005). "Effects of amphetamine-CNS depressant combinations and of other CNS stimulants in four-choice drug discriminations." *J Exp Anal Behav* 84(1): 77-97.
- Li, S. M., Y. H. Ren, et al. (2002). "Effect of 7-nitroindazole on drug-priming reinstatement of D-methamphetamine-induced conditioned place preference." *Eur J Pharmacol* 443(1-3): 205-6.
- Li, S. M., L. L. Yin, et al. (2002). "The effect of 7-nitroindazole on the acquisition and expression of D-methamphetamine-induced place preference in rats." *Eur J Pharmacol* 435(2-3): 217-23.
- Li, S. M., L. L. Yin, et al. (2001). "GABA(B) receptor agonist baclofen attenuates the development and expression of D-methamphetamine-induced place preference in rats." *Life Sci* 70(3): 349-56.
- Liang, J. H., K. Wang, et al. (2006). "Potentiating effect of tramadol on methamphetamine-induced behavioral sensitization in mice." *Psychopharmacology (Berl)*: 1-10.
- Lien, W. H., T. L. Yeh, et al. (2004). "Cycloheximide enhances maintenance of methamphetamine-induced conditioned place preference." *Chin J Physiol* 47(1): 23-30.
- Lobo, L. L., R. de Medeiros, et al. (1995). "Atropine increases pilocarpine-induced yawning behavior in paradoxical sleep deprived rats." *Pharmacol Biochem Behav* 52(3): 485-8.
- Ma, J. and L. S. Leung (2004). "Schizophrenia-like behavioral changes after partial hippocampal kindling." *Brain Res* 997(1): 111-8.
- Ma, J. and L. S. Leung (2000). "Relation between hippocampal gamma waves and behavioral disturbances induced by phencyclidine and methamphetamine." *Behav Brain Res* 111(1-2): 1-11.
- Machiyama, Y. (1992). "Chronic methamphetamine intoxication model of schizophrenia in animals." *Schizophr Bull* 18(1): 107-13.
- Madden, L. J., C. T. Flynn, et al. (2005). "Modeling human methamphetamine exposure in nonhuman primates: Chronic dosing in the rhesus macaque leads to behavioral and physiological abnormalities." *Neuropsychopharmacology* 30(2): 350-9.
- Maeda, H. and S. Maki (1987). "Dopamine agonists produce functional recovery from septal lesions which affect hypothalamic defensive attack in cats." *Brain Res* 407(2): 381-5.
- Maeda, H. and S. Maki (1986). "Dopaminergic facilitation of recovery from amygdaloid lesions which affect hypothalamic defensive attack in cats." *Brain Res* 363(1): 135-40.
- Maeda, H., T. Sato, et al. (1985). "Effects of dopamine agonists on hypothalamic defensive attack in cats." *Physiol Behav* 35(1): 89-92.
- Maeda, T., N. Kiguchi, et al. (2006). "Peroxisome proliferator-activated receptor gamma activation relieves expression of behavioral sensitization to methamphetamine in mice." *Neuropsychopharmacology*.

- Maickel, R. P. and S. A. Johnson (1973). "Effects of various anorexigenic agents on open field behavior of rats." *Res Commun Chem Pathol Pharmacol* 6(2): 733-9.
- Maisonneuve, I. M. and S. D. Glick (2003). "Anti-addictive actions of an iboga alkaloid congener: A novel mechanism for a novel treatment." *Pharmacol Biochem Behav* 75(3): 607-18.
- Martin, J. C., D. C. Martin, et al. (1983). "Saccharin preferences in food deprived aging rats are altered as a function of perinatal drug exposure." *Physiol Behav* 30(6): 853-8.
- Martin, J. C. and D. C. Martin (1981). "Voluntary activity in the aging rat as a function of maternal drug exposure." *Neurobehav Toxicol Teratol* 3(3): 261-4.
- Martin, J. C. (1975). "Effects on offspring of chronic maternal methamphetamine exposure." *Dev Psychobiol* 8(5): 397-404.
- Martin, J. C. and E. H. Ellinwood, Jr. (1973). "Conditioned aversion to a preferred solution following methamphetamine injections." *Psychopharmacologia* 29(3): 253-61.
- Masubuchi, S., S. Honma, et al. (2001). "Circadian activity rhythm in methamphetamine-treated Clock mutant mice." *Eur J Neurosci* 14(7): 1177-80.
- Masubuchi, S., S. Honma, et al. (2000). "Clock genes outside the suprachiasmatic nucleus involved in manifestation of locomotor activity rhythm in rats." *Eur J Neurosci* 12(12): 4206-14.
- Masuda, Y., Y. Matsuda, et al. (1996). "A quantity of stereotyped behavior of ddY mice induced by low-dose methamphetamine." *Exp Anim* 45(3): 279-81.
- Masukawa, Y., T. Suzuki, et al. (1993). "Differential modification of the rewarding effects of methamphetamine and cocaine by opioids and antihistamines." *Psychopharmacology (Berl)* 111(2): 139-43.
- Masuo, Y., M. Ishido, et al. (2004). "Motor activity and gene expression in rats with neonatal 6-hydroxydopamine lesions." *J Neurochem* 91(1): 9-19.
- Matsuda, Y. (1966). "Effects of some centrally acting drugs on food intake of normal and hypothalamus-lesioned rats." *Jpn J Pharmacol* 16(3): 276-86.
- Matsuoka, N., N. Maeda, et al. (1992). "Effect of FR121196, a novel cognitive enhancer, on the memory impairment of rats in passive avoidance and radial arm maze tasks." *J Pharmacol Exp Ther* 263(2): 436-44.
- Mattei, R. and E. A. Carlini (1996). "A comparative study of the anorectic and behavioral effects of fenproporex on male and female rats." *Braz J Med Biol Res* 29(8): 1025-30.
- McDaid, J., C. E. Tedford, et al. (2007). "Nullifying drug-induced sensitization: Behavioral and electrophysiological evaluations of dopaminergic and serotonergic ligands in methamphetamine-sensitized rats." *Drug Alcohol Depend* 86(1): 55-66.
- Matell, M. S., M. Bateson, et al. (2006). "Single-trials analyses demonstrate that increases in clock speed contribute to the methamphetamine-induced horizontal shifts in peak-interval timing functions." *Psychopharmacology (Berl)*.
- McDaid, J., M. P. Graham, et al. (2006). "Methamphetamine-induced sensitization differentially alters pCREB and {Delta}FosB throughout the limbic circuit of the mammalian brain." *Mol Pharmacol* 70(6): 2064-74.
- McMillan, D. E., W. C. Hardwick, et al. (2004). "Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat." *J Pharmacol Exp Ther* 309(3): 1248-55.
- Mechner, F. and M. Latranyi (1963). "Behavioral effects of caffeine, methamphetamine, and methylphenidate in the rat." *J Exp Anal Behav* 6: 331-42.
- Meck, W. H. (2006). "Frontal cortex lesions eliminate the clock speed effect of dopaminergic drugs on interval timing." *Brain Res* 1108(1): 157-67.
- Metcalf, F. U., Jr., D. F. Peeler, Jr., et al. (1971). "Methamphetamine effects upon avoidance behavior during limbic seizures in the cat." *Psychopharmacologia* 21(4): 390-400.
- Mickley, K. R. and D. E. Dluzen (2004). "Dose-response effects of estrogen and tamoxifen upon methamphetamine-induced behavioral responses and neurotoxicity of the nigrostriatal dopaminergic system in female mice." *Neuroendocrinology* 79(6): 305-16.
- Miczek, K. A. and J. M. O'Donnell (1978). "Intruder-evoked aggression in isolated and nonisolated mice: Effects of psychomotor stimulants and L-dopa." *Psychopharmacology (Berl)* 57(1): 47-55.
- Middaugh, L. D. (1989). "Prenatal amphetamine effects on behavior: Possible mediation by brain monoamines." *Ann N Y Acad Sci* 562: 308-18.
- Milesi-Halle, A., H. P. Hendrickson, et al. (2005). "Sex- and dose-dependency in the pharmacokinetics and pharmacodynamics of (+)-methamphetamine and its metabolite (+)-amphetamine in rats." *Toxicol Appl Pharmacol* 209(3): 203-13.
- Miller, D. K., M. M. Dopheide, et al. (2005). "Dietary cadmium exposure attenuates D-amphetamine-evoked [3H]dopamine release from striatal slices and methamphetamine-induced hyperactivity." *Pharmacol Biochem Behav* 80(4): 557-66.
- Miller, F. P., R. H. Cox, Jr., et al. (1970). "The effects of altered brain norepinephrine levels on continuous avoidance responding and the action of amphetamines." *Neuropharmacology* 9(6): 511-7.

- Miczek, K. A. and J. M. O'Donnell (1978). "Intruder-evoked aggression in isolated and nonisolated mice: effects of psychomotor stimulants and L-dopa." *Psychopharmacology (Berl)* 57(1): 47-55.
- Misslin, R., P. Ropartz, et al. (1984). "Impairment of responses to novelty by apomorphine and its antagonism by neuroleptics in mice." *Psychopharmacology (Berl)* 82(1-2): 113-7.
- Misslin, R. and P. Ropartz (1981). "Effects of methamphetamine on novelty-seeking behaviour by mice." *Psychopharmacology (Berl)* 75(1): 39-43.
- Miyamoto, Y., K. Yamada, et al. (2004). "Behavioural adaptations to addictive drugs in mice lacking the NMDA receptor epsilon1 subunit." *Eur J Neurosci* 19(1): 151-8.
- Miyamoto, K. (1990). "Conditioned drug effects of pimozide, haloperidol and chlorpromazine on methamphetamine-induced behavior." *Jpn J Psychiatry Neurol* 44(3): 629-36.
- Miyatake, M., M. Narita, et al. (2005). "Glutamatergic neurotransmission and protein kinase C play a role in neuron-glia communication during the development of methamphetamine-induced psychological dependence." *Eur J Neurosci* 22(6): 1476-88.
- Miyauchi, T., K. Kikuchi, et al. (1981). "Further studies on the potentiating effect of lithium chloride on methamphetamine-induced stereotypy in mice." *Jpn J Pharmacol* 31(1): 61-8.
- Mizoguchi, H., Y. Noda, et al. (2005). "[Evaluation methods for the discriminative stimulus and possible mechanisms of discriminative stimulus effects of methamphetamine in the rat]." *Nippon Yakurigaku Zasshi* 126(1): 17-23.
- Mizoguchi, H., K. Yamada, et al. (2004). "Regulations of methamphetamine reward by extracellular signal-regulated kinase 1/2/ets-like gene-1 signaling pathway via the activation of dopamine receptors." *Mol Pharmacol* 65(5): 1293-301.
- Mizugaki, M. (1996). "[Alterations in brain distribution of methamphetamine in methamphetamine-sensitized animals.]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 16(5): 187-91.
- Mizuno, M., R. S. Malta, Jr., et al. (2004). "Conditioned place preference and locomotor sensitization after repeated administration of cocaine or methamphetamine in rats treated with epidermal growth factor during the neonatal period." *Ann N Y Acad Sci* 1025: 612-8.
- Moffett, M. C. and N. E. Goeders (2007). "CP-154,526, a CRF type-1 receptor antagonist, attenuates the cue- and methamphetamine-induced reinstatement of extinguished methamphetamine-seeking behavior in rats." *Psychopharmacology (Berl)* 190(2): 171-80.
- Moffett, M. C. and N. E. Goeders (2005). "Neither non-contingent electric footshock nor administered corticosterone facilitate the acquisition of methamphetamine self-administration." *Pharmacol Biochem Behav* 80(2): 333-9.
- Moorthy, N. S. and J. J. Balsara (1999). "Effects of flunarizine on dopamine dependent behaviours in rats." *Indian J Med Sci* 53(2): 43-8.
- Mori, T., S. Ito, et al. (2006). "Effects of mu-, delta- and kappa-opioid receptor agonists on methamphetamine-induced self-injurious behavior in mice." *Eur J Pharmacol* 532(1-2): 81-7.
- Mori, A., K. Okuyama, et al. (2002). "Alteration of methamphetamine-induced striatal dopamine release in mnt-1 knockout mice." *Neurosci Res* 43(3): 251-7.
- Mori, T., S. Ito, et al. (2006). "Effects of mu-, delta- and kappa-opioid receptor agonists on methamphetamine-induced self-injurious behavior in mice." *Eur J Pharmacol* 532(1-2): 81-87.
- Morimasa, T., A. Wirz-Justice, et al. (1987). "Chronic methamphetamine and its withdrawal modify behavioral and neuroendocrine circadian rhythms." *Physiol Behav* 39(6): 699-705.
- Morita, T., R. Sonoda, et al. (2000). "Phencyclidine-induced abnormal behaviors in rats as measured by the hole board apparatus." *Psychopharmacology (Berl)* 148(3): 281-8.
- Moriya, T., T. Fukushima, et al. (1996). "Chronic administration of methamphetamine does not affect the suprachiasmatic nucleus-operated circadian pacemaker in rats." *Neurosci Lett* 208(2): 129-32.
- Moriya, T., S. Yamanouchi, et al. (1996). "Involvement of 5-HT1A receptor mechanisms in the inhibitory effects of methamphetamine on photic responses in the rodent suprachiasmatic nucleus." *Brain Res* 740(1-2): 261-7.
- Moroji, T. and Y. Hagino (1987). "Bilateral subdiaphragmatic vagotomy does not prevent the behavioral effects of systematically administered ceruletide in mice." *Neuropeptides* 9(3): 217-24.
- Moroji, T. and Y. Hagino (1986). "A behavioral pharmacological study on CCK-8 related peptides in mice." *Neuropeptides* 8(3): 273-86.
- Morton, A. J., M. A. Hickey, et al. (2001). "Methamphetamine toxicity in mice is potentiated by exposure to loud music." *Neuroreport* 12(15): 3277-81.
- Muley, M. P., M. A. Joshi, et al. (1984). "Effect of bupropion on dopamine and 5-hydroxytryptamine-mediated behaviour in mice." *J Pharm Pharmacol* 36(3): 208-10.
- Muley, M. P., J. J. Balsara, et al. (1979). "Effect of L-histidine pretreatment on methamphetamine induced stereotyped behaviour in rats." *Indian J Physiol Pharmacol* 23(4): 291-6.
- Munzar, P., G. Tanda, et al. (2004). "Histamine h3 receptor antagonists potentiate methamphetamine self-administration and methamphetamine-induced accumbal dopamine release." *Neuropsychopharmacology* 29(4): 705-17.

- Munzar, P., S. W. Kutkat, et al. (2000). "Failure of baclofen to modulate discriminative-stimulus effects of cocaine or methamphetamine in rats." *Eur J Pharmacol* 408(2): 169-74.
- Munzar, P., M. H. Baumann, et al. (1999). "Effects of dopamine and serotonin-releasing agents on methamphetamine discrimination and self-administration in rats." *Psychopharmacology (Berl)* 141(3): 287-96.
- Munzar, P., R. Nosal, et al. (1998). "Potentiation of the discriminative-stimulus effects of methamphetamine by the histamine H3 receptor antagonist thioperamide in rats." *Eur J Pharmacol* 363(2-3): 93-101.
- Muraki, A. (1993). "[Effects of antagonists of NMDA receptor on methamphetamine-induced decrease in the dopamine uptake sites in the rat striatum and on the behavioral sensitization]." *Hokkaido Igaku Zasshi* 68(3): 407-18.
- Nabeshima, T., A. Itoh, et al. (1994). "Effects of subacute administration of methamphetamine and nicotine on locomotor activity in transgenic mice expressing the human tyrosine hydroxylase gene." *J Neural Transm Gen Sect* 97(1): 41-9.
- Nagai, T., Y. Noda, et al. (2005). "The role of tissue plasminogen activator in methamphetamine-related reward and sensitization." *J Neurochem* 92(3): 660-7.
- Nakagawa, M., M. Ohgoh, et al. (2004). "Dopaminergic agonists and muscarinic antagonists improve lateralization in hemiparkinsonian rats in a novel exploratory Y-maze." *J Pharmacol Exp Ther* 309(2): 737-44.
- Nakagawa, T., M. Fujio, et al. (2005). "Effect of MS-153, a glutamate transporter activator, on the conditioned rewarding effects of morphine, methamphetamine and cocaine in mice." *Behav Brain Res* 156(2): 233-9.
- Nakagawa, N., T. Hishinuma, et al. (2003). "Brain and heart specific alteration of methamphetamine (MAP) distribution in MAP-sensitized rat." *Biol Pharm Bull* 26(4): 506-9.
- Nakagawa, T., K. Ukai, et al. (1997). "Effects of dopaminergic agents on reversal of reserpine-induced impairment in conditioned avoidance response in rats." *Pharmacol Biochem Behav* 58(4): 829-36.
- Nakajima, A., K. Yamada, et al. (2004). "Anatomical substrates for the discriminative stimulus effects of methamphetamine in rats." *J Neurochem* 91(2): 308-17.
- Nakajima, H., R. Shigehara, et al. (1981). "[Effect of alpha-methyl-para-tyrosine on "methamphetamine-induced stereotype and hypermotility" of reserpinized rats (author's transl)]." *Nippon Yakurigaku Zasshi* 78(6): 557-69.
- Nakama, M., T. Ochiai, et al. (1972). "Effects of psychotropic drugs on emotional behavior: Exploratory behavior of naive rats in holed open field." *Jpn J Pharmacol* 22(6): 767-75.
- Nakamura, K., Y. Ozawa, et al. (1985). "[Behavioral and pharmacological studies of methamphetamine-induced stereotypy of mice by the open field method]." *Yakugaku Zasshi* 105(8): 775-83.
- Nakamura, K. and Y. Ozawa (1981). "[A metrical analysis of exploratory behavior in mice: effects of methamphetamine and diazepam (author's transl)]." *Nippon Yakurigaku Zasshi* 78(1): 1-8.
- Namima, M., K. Sugihara, et al. (1999). "Quantitative analysis of the effects of lithium on the reverse tolerance and the c-Fos expression induced by methamphetamine in mice." *Brain Res Brain Res Protoc* 4(1): 11-8.
- Narita, M., H. Akai, et al. (2005). "Involvement of mitogen-stimulated p70-S6 kinase in the development of sensitization to the methamphetamine-induced rewarding effect in rats." *Neuroscience* 132(3): 553-60.
- Narita, M., M. Miyatake, et al. (2005). "Long-lasting change in brain dynamics induced by methamphetamine: enhancement of protein kinase C-dependent astrocytic response and behavioral sensitization." *J Neurochem* 93(6): 1383-92.
- Narita, M., H. Akai, et al. (2004). "Implications of protein kinase C in the nucleus accumbens in the development of sensitization to methamphetamine in rats." *Neuroscience* 127(4): 941-8.
- Narita, M., K. Aoki, et al. (2003). "Implication of brain-derived neurotrophic factor in the release of dopamine and dopamine-related behaviors induced by methamphetamine." *Neuroscience* 119(3): 767-75.
- Nash, J. F., Jr. and R. P. Maickel (1985). "Effects of exposure to stressful stimuli on the free-choice consumption of various phenethylamines by rats." *Alcohol Drug Res* 6(6): 403-15.
- Newman, J. L. and M. E. Carroll (2006). "Reinforcing effects of smoked methamphetamine in rhesus monkeys." *Psychopharmacology (Berl)* 188(2): 193-200.
- Nguyen, E. C., K. A. McCracken, et al. (2005). "Involvement of sigma ( $\sigma$ ) receptors in the acute actions of methamphetamine: receptor binding and behavioral studies." *Neuropharmacology* 49(5): 638-45.
- Nikaïdo, T., M. Akiyama, et al. (2001). "Sensitized increase of period gene expression in the mouse caudate/putamen caused by repeated injection of methamphetamine." *Mol Pharmacol* 59(4): 894-900.
- Nishii, K., N. Matsushita, et al. (1998). "Motor and learning dysfunction during postnatal development in mice defective in dopamine neuronal transmission." *J Neurosci Res* 54(4): 450-64.
- Nishikawa, T., N. Mataga, et al. (1983). "Behavioral sensitization and relative hyperresponsiveness of striatal and limbic dopaminergic neurons after repeated methamphetamine treatment." *Eur J Pharmacol* 88(2-3): 195-203.
- Nishikawa, T. and M. Tanaka (1978). "Altered behavioral responses to intense foot shock in socially-isolated rats." *Pharmacol Biochem Behav* 8(1): 61-7.

- Nishimori, T., K. Morino, et al. (1988). "[Effects of cadralazine on the central nervous system]." *Nippon Yakurigaku Zasshi* 91(4): 209-20.
- Nishio, M., Y. Kuroki, et al. (2003). "Role of hippocampal alpha(2A)-adrenergic receptor in methamphetamine-induced hyperlocomotion in the mouse." *Neurosci Lett* 341(2): 156-60.
- Niwa, M., A. Nitta, et al. (2006). "An inducer for glial cell line-derived neurotrophic factor and tumor necrosis factor-alpha protects against methamphetamine-induced rewarding effects and sensitization." *Biol Psychiatry*.
- Noda, Y., Y. Miyamoto, et al. (1998). "Involvement of dopaminergic system in phencyclidine-induced place preference in mice pretreated with phencyclidine repeatedly." *J Pharmacol Exp Ther* 286(1): 44-51.
- Noda, Y. and T. Nabeshima (1998). "Neuronal mechanisms of phencyclidine-induced place aversion and preference in the conditioned place preference task." *Methods Find Exp Clin Pharmacol* 20(7): 607-11.
- Nomura, T. and T. Nishizaki (1997). "Methamphetamine modulates ACh-evoked currents in *Xenopus oocytes* expressing the rat alpha7 receptors." *Neurosci Lett* 239(2-3): 73-6.
- Nomura, Y., S. Ashikari, et al. (1982). "[Effect of dopamine intracerebrally injected by the Valzelli method on methamphetamine-stereotypy and hypermotility]." *Yakubutsu Seishin Kodo* 2(1): 25-37.
- Numachi, Y., S. Yoshida, et al. (2000). "Two inbred strains of rats, Fischer 344 and Lewis, showed differential behavior and brain expression of corticosterone receptor mRNA induced by methamphetamine." *Ann N Y Acad Sci* 914: 33-45.
- Ogawa, H., H. Kuribara, et al. (1976). "Attainment and stability of the performance in differential low rate water reinforcement in rats." *Jpn J Pharmacol* 26(3): 281-90.
- Ogura, H., Y. Furuya, et al. (1998). "Peptide N- and P/Q-type Ca<sup>2+</sup> blockers inhibit stimulant-induced hyperactivity in mice." *Peptides* 19(6): 1017-22.
- Ohmori, T., T. Abekawa, et al. (1997). "[Context-dependent sensitization: reconsideration and a hypothesis]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 17(2): 61-8.
- Ohmori, T., T. Abekawa, et al. (1996). "The role of glutamate in behavioral and neurotoxic effects of methamphetamine." *Neurochem Int* 29(3): 301-7.
- Ohmori, T., T. Abekawa, et al. (1995). "Scopolamine prevents augmentation of stereotypy induced by chronic methamphetamine treatment." *Psychopharmacology (Berl)* 121(2): 158-63.
- Oiwa, Y., R. Yoshimura, et al. (2002). "Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease." *Brain Res* 947(2): 271-83.
- Oka, M., Y. Noda, et al. (1993). "Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties." *J Pharmacol Exp Ther* 264(1): 158-65.
- Oka, T. and E. Hosoya (1977). "The different effect of humoral modulators on the morphine- and central nervous system stimulant-induced hyperactivity of rats." *Neuropharmacology* 16(2): 115-9.
- Okabe, C., H. Takeshima, et al. (2005). "Methamphetamine sensitization in nociceptin receptor knockout mice: Locomotor and c-fos expression." *Eur J Pharmacol* 507(1-3): 57-67.
- Okabe, C. and N. P. Murphy (2004). "Short-term effects of the nociceptin receptor antagonist Compound B on the development of methamphetamine sensitization in mice: A behavioral and c-fos expression mapping study." *Brain Res* 1017(1-2): 1-12.
- Okuda, T., Y. Ito, et al. (2004). "Drug interaction between methamphetamine and antihistamines: Behavioral changes and tissue concentrations of methamphetamine in rats." *Eur J Pharmacol* 505(1-3): 135-44.
- Okuyama, S., N. Kawashima, et al. (1999). "A selective dopamine D4 receptor antagonist, NRA0160: A preclinical neuropharmacological profile." *Life Sci* 65(20): 2109-25.
- Okuyama, S., S. Chaki, et al. (1997). "In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl]pyrrolidin-3-yl]thiazole (NRA0045)." *J Pharmacol Exp Ther* 282(1): 56-63.
- Omata, K. and H. Kawamura (1988). "Effects of methamphetamine upon circadian rhythms in multiple unit activity inside and outside the suprachiasmatic nucleus in the golden hamster (*Mesocricetus auratus*)." *Neurosci Lett* 95(1-3): 218-22.
- O'Neil, M. L., R. Kuczenski, et al. (2006). "Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge." *Synapse* 60(6): 465-73.
- Ono, M., S. Shibata, et al. (1996). "Effect of the noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 on food-anticipatory activity rhythm in the rat." *Physiol Behav* 59(4-5): 585-9.
- Ono, M., A. Watanabe, et al. (1996). "Methamphetamine modifies the photic entraining responses in the rodent suprachiasmatic nucleus via serotonin release." *Neuroscience* 72(1): 213-24.
- Onodera, K., C. Itoh, et al. (1998). "Motor behavioural function for histamine-dopamine interaction in brain." *Inflamm Res* 47 Suppl 1: S30-1.

- Ozaki, N., D. Nakahara, et al. (1991). "The effect of methamphetamine on serotonin and its metabolite in the suprachiasmatic nucleus: A microdialysis study." *J Neural Transm Gen Sect* 86(3): 175-9.
- Ozawa, H. and T. Miyauchi (1977). "Potentiating effect of lithium chloride on methamphetamine-induced stereotypy in mice." *Eur J Pharmacol* 41(2): 213-6.
- Ozawa, K., K. Hashimoto, et al. (2006). "Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: A neurodevelopmental animal model of schizophrenia." *Biol Psychiatry* 59(6): 546-54.
- Ozawa, H. and T. Miyauchi (1977). "Potentiating effect of lithium chloride on methamphetamine-induced stereotypy in mice." *Eur J Pharmacol* 41(2): 213-6.
- Pacchioni, A. M., J. Vallone, et al. (2007). "Nrf2 gene deletion fails to alter psychostimulant-induced behavior or neurotoxicity." *Brain Res* 1127(1): 26-35.
- Pace, C. J., S. D. Glick, et al. (2004). "Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration." *Eur J Pharmacol* 492(2-3): 159-67.
- Palmer, A. A., M. Verbitsky, et al. (2005). "Gene expression differences in mice divergently selected for methamphetamine sensitivity." *Mamm Genome* 16(5): 291-305.
- Panksepp, J. (1971). "Drugs and stimulus-bound attack." *Physiol Behav* 6(4): 317-20.
- Parker, L. A. (1995). "Rewarding drugs produce taste avoidance, but not taste aversion." *Neurosci Biobehav Rev* 19(1): 143-57.
- Parker, L. A. (1993). "Taste reactivity responses elicited by cocaine-, phencyclidine-, and methamphetamine-paired sucrose solutions." *Behav Neurosci* 107(1): 118-29.
- Pecoraro, N., A. E. Kosobud, et al. (2000). "Long T methamphetamine schedules produce circadian ensuing drug activity in rats." *Physiol Behav* 71(1-2): 95-106.
- Peltier, R. L., D. H. Li, et al. (1996). "Chronic d-amphetamine or methamphetamine produces cross-tolerance to the discriminative and reinforcing stimulus effects of cocaine." *J Pharmacol Exp Ther* 277(1): 212-8.
- Pieri, M., L. Pieri, et al. (1975). "A comparison of drug-induced rotation in rats lesioned in the medial forebrain bundle with 5,6-dihydroxytryptamine or 6-hydroxydopamine." *Arch Int Pharmacodyn Ther* 217(1): 118-30.
- Plaznik, A. and W. Kostowski (1979). "Effects of p-bromo-methamphetamine (V-111) on conditioned avoidance behavior in rats with lesioned raphe nuclei." *Pol J Pharmacol Pharm* 31(3): 193-9.
- Plotnikoff, N. and A. V. Evans (1967). "Enhancement of conditioned photic evoked responses in the rabbit by pemoline and magnesium hydroxide." *Int J Neuropsychiatry* 3(3): 263-7.
- Preston, K. L., G. C. Wagner, et al. (1984). "Effects of methamphetamine on atropine-induced conditioned gustatory avoidance." *Pharmacol Biochem Behav* 20(4): 601-7.
- Ranaldi, R. and K. Poeggel (2002). "Baclofen decreases methamphetamine self-administration in rats." *Neuroreport* 13(9): 1107-10.
- Ranaldi, R. and R. A. Wise (2000). "Intravenous self-administration of methamphetamine-heroin (speedball) combinations under a progressive-ratio schedule of reinforcement in rats." *Neuroreport* 11(12): 2621-3.
- Ranaldi, R., K. G. Anderson, et al. (2000). "Reinforcing and discriminative stimulus effects of RTI 111, a 3-phenyltropane analog, in rhesus monkeys: Interaction with methamphetamine." *Psychopharmacology (Berl)* 153(1): 103-10.
- Randrup, A., G. Sorensen, et al. (1988). "Stereotyped behaviour in animals induced by stimulant drugs or by a restricted cage environment: Relation to disintegrated behaviour, brain dopamine and psychiatric disease." *Yakubutsu Seishin Kodo* 8(2): 313-27.
- Rauhut, A. S., N. Neugebauer, et al. (2003). "Effect of bupropion on nicotine self-administration in rats." *Psychopharmacology (Berl)* 169(1): 1-9.
- Razzak, A., M. Fujiwara, et al. (1977). "Possible involvement of a central noradrenergic system in automutilation induced by clonidine in mice." *Jpn J Pharmacol* 27(1): 145-52.
- Rhodes, J. S., A. E. Ryabinin, et al. (2005). "Patterns of brain activation associated with contextual conditioning to methamphetamine in mice." *Behav Neurosci* 119(3): 759-71.
- Richards, J. B., K. E. Sabol, et al. (1990). "Unilateral dopamine depletion causes bilateral deficits in conditioned rotation in rats." *Pharmacol Biochem Behav* 36(2): 217-23.
- Richards, J. B., K. E. Sabol, et al. (1999). "Effects of methamphetamine on the adjusting amount procedure, A model of impulsive behavior in rats." *Psychopharmacology (Berl)* 146(4): 432-9.
- Richardson, D., A. G. Karczmar, et al. (1972). "Intergeneric behavioral differences among methamphetamine treated mice." *Psychopharmacologia* 25(4): 347-75.
- Rietveld, W. J., J. Korving, et al. (1987). "The circadian control of behavior in the rat affected by the chronic application of methamphetamine." *Prog Clin Biol Res* 227B: 513-7.
- Rosenzweig, M. R. and E. L. Bennett (1972). "Cerebral changes in rats exposed individually to an enriched environment." *J Comp Physiol Psychol* 80(2): 304-13.

- Roth, M. E. and M. E. Carroll (2004). "Sex differences in the acquisition of IV methamphetamine self-administration and subsequent maintenance under a progressive ratio schedule in rats." *Psychopharmacology (Berl)* 172(4): 443-9.
- Rothman, R. B., B. E. Blough, et al. (2005). "Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration." *J Pharmacol Exp Ther* 313(3): 1361-9.
- Rubinstein, M., T. J. Phillips, et al. (1997). "Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine." *Cell* 90(6): 991-1001.
- Ruis, J. F., J. P. Buys, et al. (1990). "Effects of T cycles of light/darkness and periodic forced activity on methamphetamine-induced rhythms in intact and SCN-lesioned rats: Explanation by an hourglass-clock model." *Physiol Behav* 47(5): 917-29.
- Saavedra, J. M. and E. Fischer (1970). "Antagonism of beta-phenylethylamine derivatives and serotonin blocking drugs upon serotonin, tryptamine and reserpine behavioral depression in mice." *Arzneimittelforschung* 20(7): 952-7.
- Sabol, K. E., J. B. Richards, et al. (2003). "Effects of stimulus salience and methamphetamine on choice reaction time in the rat: central tendency versus distribution skew." *Behav Pharmacol* 14(7): 489-500.
- Sabol, K. E., J. B. Richards, et al. (2000). "The effects of high-dose methamphetamine in the aging rat: differential reinforcement of low-rate 72-s schedule behavior and neurochemistry." *J Pharmacol Exp Ther* 294(3): 850-63.
- Saito, M., M. Terada, et al. (1995). "[Effects of the long-term administration of methamphetamine on body weight, food intake, blood biochemistry and estrous cycle in rats]." *Exp Anim* 43(5): 747-54.
- Saito, T. R., S. Aoki, et al. (1991). "Effects of methamphetamine on copulatory behavior in male rats." *Jikken Dobutsu* 40(4): 447-52.
- Sakurada, T., K. Onodera, et al. (1975). "Effects of polyamines on the central nervous system." *Jpn J Pharmacol* 25(6): 653-61.
- Sanchez-Alavez, M., L. M. Gombart, et al. (2004). "Physiological and behavioral effects of methamphetamine in a mouse model of endotoxemia: a preliminary study." *Pharmacol Biochem Behav* 77(2): 365-70.
- Sano, H., Y. Yasoshima, et al. (2003). "Conditional ablation of striatal neuronal types containing dopamine D2 receptor disturbs coordination of basal ganglia function." *J Neurosci* 23(27): 9078-88.
- Sano, H., Y. Totsuka, et al. (1982). "[Methamphetamine-stereotypy and hypermotility" in rats chronically treated with reserpine--the effect of intracerebral injection of chlorpromazine]." *Nippon Yakurigaku Zasshi* 80(2): 113-24.
- Sansone, M. and A. Oliverio (1989). "Avoidance facilitation by nootropics." *Prog Neuropsychopharmacol Biol Psychiatry* 13 Suppl: S89-97.
- Sansone, M., M. Ammassari-Teule, et al. (1985). "Interaction between nootropic drugs and methamphetamine on avoidance acquisition but not on locomotor activity in mice." *Arch Int Pharmacodyn Ther* 278(2): 229-35.
- Sansone, M. (1975). "Effects of chlordiazepoxide, CNS stimulants and their combinations on avoidance behaviour in mice." *Arch Int Pharmacodyn Ther* 215(2): 190-6.
- Sansone, M., P. Renzi, et al. (1974). "Effect of methamphetamine on discriminated lever-press avoidance behaviour in hamsters." *Pharmacol Res Commun* 6(2): 187-92.
- Sassenrath, E. N. and L. F. Chapman (1976). "Primate social behavior as a method of analysis of drug action: studies with THC in monkeys." *Fed Proc* 35(11): 2238-44.
- Sato, M. and Y. Fujiwara (1986). "Behavioral and neurochemical changes in pups prenatally exposed to methamphetamine." *Brain Dev* 8(4): 390-6.
- Sato, M. (1983). "Long-lasting hypersensitivity to methamphetamine following amygdaloid kindling in cats: the relationship between limbic epilepsy and the psychotic state." *Biol Psychiatry* 18(5): 525-36.
- Sayers, A. C. and S. L. Handley (1973). "A study of the role of catecholamines in the response to various central stimulants." *Eur J Pharmacol* 23(1): 47-55.
- Schaefer, T. L., L. A. Ehrman, et al. (2006). "Comparison of monoamine and corticosterone levels 24 h following (+)methamphetamine, (+/-)3,4-methylenedioxymethamphetamine, cocaine, (+)fenfluramine or (+/-)methylphenidate administration in the neonatal rat." *J Neurochem* 98(5): 1369-78.
- Schuster, C. R. and M. W. Fischman (1975). "Amphetamine toxicity: Behavioral and neuropathological indexes." *Fed Proc* 34(9): 1845-51.
- Segal, D. S. and R. Kuczenski (2006). "Human methamphetamine pharmacokinetics simulated in the rat: Single daily intravenous administration reveals elements of sensitization and tolerance." *Neuropsychopharmacology* 31(5): 941-55.
- Segal, D. S., R. Kuczenski, et al. (2005). "Prolonged exposure of rats to intravenous methamphetamine: Behavioral and neurochemical characterization." *Psychopharmacology (Berl)* 180(3): 501-12.
- Segal, D. S., R. Kuczenski, et al. (2003). "Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge." *Neuropsychopharmacology* 28(10): 1730-40.
- Segal, D. S. and R. Kuczenski (1997). "Repeated binge exposures to amphetamine and methamphetamine: Behavioral and neurochemical characterization." *J Pharmacol Exp Ther* 282(2): 561-73.



- Seiden, L. S., W. L. Woolverton, et al. (1993). "Behavioral consequences of partial monoamine depletion in the CNS after methamphetamine-like drugs: The conflict between pharmacology and toxicology." *NIDA Res Monogr* 136: 34-46; discussion 46-52.
- Seiden, L. S. and M. S. Kleven (1989). "Methamphetamine and related drugs: Toxicity and resulting behavioral changes in response to pharmacological probes." *NIDA Res Monogr* 94: 146-60.
- Shepard, J. D., D. T. Chuang, et al. (2006). "Effect of methamphetamine self-administration on tyrosine hydroxylase and dopamine transporter levels in mesolimbic and nigrostriatal dopamine pathways of the rat." *Psychopharmacology (Berl)* 185(4): 505-13.
- Shepard, J. D., J. M. Bossert, et al. (2004). "The anxiogenic drug yohimbine reinstates methamphetamine seeking in a rat model of drug relapse." *Biol Psychiatry* 55(11): 1082-9.
- Shibata, S., Y. Minamoto, et al. (1994). "Aging impairs methamphetamine-induced free-running and anticipatory locomotor activity rhythms in rats." *Neurosci Lett* 172(1-2): 107-10.
- Shika, K., C. Nakata, et al. (1977). "[Inhibitory effects of methyl o-(4-hydroxy-3-methoxycinnamoyl) reserpate (CD-3400) on the central nervous system (author's transl)]." *Nippon Yakurigaku Zasshi* 73(7): 717-34.
- Shilling, P. D., R. Kuczenski, et al. (2006). "Differential regulation of immediate-early gene expression in the prefrontal cortex of rats with a high vs low behavioral response to methamphetamine." *Neuropsychopharmacology* 31(11): 2359-67.
- Shimazu, S., A. Minami, et al. (2005). "Antidepressant-like effects of selegiline in the forced swim test." *Eur Neuropsychopharmacol* 15(5): 563-71.
- Shimosato, K., N. Nagao, et al. (2003). "Suppressive effects of trihexyphenidyl on methamphetamine-induced dopamine release as measured by in vivo microdialysis." *Synapse* 49(1): 47-54.
- Shimosato, K., S. Watanabe, et al. (2001). "Differential effects of trihexyphenidyl on place preference conditioning and locomotor stimulant activity of cocaine and methamphetamine." *Naunyn Schmiedebergs Arch Pharmacol* 364(1): 74-80.
- Shimosato, K. and S. Ohkuma (2000). "Simultaneous monitoring of conditioned place preference and locomotor sensitization following repeated administration of cocaine and methamphetamine." *Pharmacol Biochem Behav* 66(2): 285-92.
- Shin, E. J., T. Nabeshima, et al. (2005). "Ginsenosides attenuate methamphetamine-induced behavioral side effects in mice via activation of adenosine A2A receptors: Possible involvements of the striatal reduction in AP-1 DNA binding activity and proenkephalin gene expression." *Behav Brain Res* 158(1): 143-57.
- Shintomi, K. (1975). "Effects of psychotropic drugs on methamphetamine-induced behavioral excitation in grouped mice." *Eur J Pharmacol* 31(2): 195-206.
- Shoblock, J. R., E. B. Sullivan, et al. (2003). "Neurochemical and behavioral differences between d-methamphetamine and d-amphetamine in rats." *Psychopharmacology (Berl)* 165(4): 359-69.
- Shuto, T., M. Kuroiwa, et al. (2006). "Reversal of methamphetamine-induced behavioral sensitization by repeated administration of a dopamine D(1) receptor agonist." *Neuropharmacology*.
- Siuciak, J. A., S. A. McCarthy, et al. (2006). "Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: Evidence for altered striatal function." *Neuropharmacology* 51(2): 374-85.
- Slamberova, R., M. Pometlova, et al. (2006). "Postnatal development of rat pups is altered by prenatal methamphetamine exposure." *Prog Neuropsychopharmacol Biol Psychiatry* 30(1): 82-8.
- Slamberova, R., P. Charousova, et al. (2005). "Maternal behavior is impaired by methamphetamine administered during pre-mating, gestation and lactation." *Reprod Toxicol* 20(1): 103-10.
- Slamberova, R., P. Charousova, et al. (2005). "Methamphetamine administration during gestation impairs maternal behavior." *Dev Psychobiol* 46(1): 57-65.
- Slamberova, R., M. Pometlova, et al. (2005). "Postnatal development of rat pups is altered by prenatal methamphetamine exposure." *Prog Neuropsychopharmacol Biol Psychiatry*.
- Slamberova, R., M. Pometlova, et al. (2005). "Learning in the Place navigation task, not the New-learning task, is altered by prenatal methamphetamine exposure." *Brain Res Dev Brain Res* 157(2): 217-9.
- Slamberova, R. and R. Rokyta (2005). "Occurrence of bicuculline-, NMDA- and kainic acid-induced seizures in prenatally methamphetamine-exposed adult male rats." *Naunyn Schmiedebergs Arch Pharmacol* 372(3): 236-41.
- Sofia, R. D. (1969). "Structural relationship and potency of agents which selectively block mouse killing (muricide) behavior in rats." *Life Sci* 8(21): 1201-10.
- Sokolov, B. P. and J. L. Cadet (2006). "Methamphetamine causes alterations in the MAP kinase-related pathways in the brains of mice that display increased aggressiveness." *Neuropsychopharmacology* 31(5): 956-66.
- Sokolov, B. P., C. W. Schindler, et al. (2004). "Chronic methamphetamine increases fighting in mice." *Pharmacol Biochem Behav* 77(2): 319-26.
- Stark, P. and C. W. Tooty (1967). "Effects of amphetamines on eating elicited by hypothalamic stimulation." *J Pharmacol Exp Ther* 158(2): 272-8.

- Stefanski, R., Z. Justinova, et al. (2004). "Sigma1 receptor upregulation after chronic methamphetamine self-administration in rats: A study with yoked controls." *Psychopharmacology (Berl)* 175(1): 68-75.
- Stefanski, R., B. Ladenheim, et al. (1999). "Neuroadaptations in the dopaminergic system after active self-administration but not after passive administration of methamphetamine." *Eur J Pharmacol* 371(2-3): 123-35.
- Stolerman, I. P. and D. D'Mello G (1978). "Amphetamine-induced hypodipsia and its implications for conditioned taste aversion in rats." *Pharmacol Biochem Behav* 8(4): 333-8.
- Subarnas, A., T. Tadano, et al. (1993). "Pharmacological properties of beta-amyrin palmitate, a novel centrally acting compound, isolated from *Lobelia inflata* leaves." *J Pharm Pharmacol* 45(6): 545-50.
- Sudilovsky, A. (1975). "Effects of disulfiram on the amphetamine-induced behavioral syndrome in the cat as a model of psychosis." *Natl Inst Drug Abuse Res Monogr Ser*(3): 109-35.
- Sukma, M., C. Chaichantipyuth, et al. (2002). "CNS inhibitory effects of barakol, a constituent of *Cassia siamiam Lamk.*" *J Ethnopharmacol* 83(1-2): 87-94.
- Suzuki, T., K. Mizuo, et al. (2003). "Prenatal and neonatal exposure to bisphenol-A enhances the central dopamine D1 receptor-mediated action in mice: enhancement of the methamphetamine-induced abuse state." *Neuroscience* 117(3): 639-44.
- Suzuki, Y., T. Funakoshi, et al. (2002). "In vitro and in vivo pharmacological profile of 4-(4-fluorobenzylidene)-1-[2-[5-(4-fluorophenyl)-1H-pyrazol-4-yl] ethyl] piperidine (NRA0161)." *Life Sci* 71(22): 2603-15.
- Suzuki, T., T. Mori, et al. (1997). "Generalization of D-, L- and DL-chlorpheniramine and zolantidine to the discriminative stimulus effects of cocaine and methamphetamine." *Behav Pharmacol* 8(8): 718-24.
- Suzuki, T. and M. Misawa (1995). "Sertindole antagonizes morphine-, cocaine-, and methamphetamine-induced place preference in the rat." *Life Sci* 57(13): 1277-84.
- Suzuki, T., Y. Shiozaki, et al. (1992). "Effects of calcium antagonists on the cocaine- and methamphetamine-induced conditioned place preference." *Arukuru Kenkyuto Yakubutsu Ison* 27(1): 81-90.
- Suzuki, T., H. J. Fan Chiang, et al. (1987). "Effects of quinidine and cimetidine on methamphetamine stereotypy in rats." *J Pharmacobiodyn* 10(3): 152-5.
- Syme, L. A. and G. J. Syme (1974). "Group instability and the social response to methamphetamine." *Pharmacol Biochem Behav* 2(6): 851-4.
- Syme, L. A. and G. J. Syme (1973). "Effects of chlorpromazine and methamphetamine on sociability in rats." *Psychopharmacologia* 32(1): 81-4.
- Szumliński, K. K., K. D. Lominac, et al. (2005). "Behavioral and neurochemical phenotyping of Homer1 mutant mice: Possible relevance to schizophrenia." *Genes Brain Behav* 4(5): 273-88.
- Szumliński, K. K., M. Y. Balogun, et al. (2000). "Interactions between iboga agents and methamphetamine sensitization: Studies of locomotion and stereotypy in rats." *Psychopharmacology (Berl)* 151(2-3): 234-41.
- Tachikawa, S., T. Takenaka, et al. (1978). "Effects of indenolol (YB-2), a new beta-adrenergic blocking agent, and its dextro isomer on the central nervous system of mice and rabbits." *Arch Int Pharmacodyn Ther* 234(1): 74-87.
- Tadokoro, S. and H. Kuribara (1990). "[Modification of the behavioral effects of drugs after repeated administration--Special reference to the reverse tolerance of amphetamines]." *Nippon Yakurigaku Zasshi* 95(5): 229-38.
- Takahashi, M. and S. Tokuyama (1998). "Pharmacological and physiological effects of ginseng on actions induced by opioids and psychostimulants." *Methods Find Exp Clin Pharmacol* 20(1): 77-84.
- Takamatsu, Y., Y. Yamanishi, et al. (2006). "Differential effects of donepezil on methamphetamine and cocaine dependencies." *Ann N Y Acad Sci* 1074: 418-26.
- Takamatsu, Y., H. Yamamoto, et al. (2006). "Fluoxetine as a potential pharmacotherapy for methamphetamine dependence: Studies in mice." *Ann N Y Acad Sci* 1074: 295-302.
- Takaori, S., N. Yada, et al. (1969). "Effects of psychotropic agents on Sidman avoidance response in good- and poor-performing rats." *Jpn J Pharmacol* 19(4): 587-96.
- Takeda, Y., Y. Takano, et al. (1986). "Effects of cholecystokinin tetra and octa peptides on locomotor activity in mice." *Jpn J Pharmacol* 42(1): 145-9.
- Takeuchi, S., E. Jodo, et al. (1999). "Effects of repeated administration of methamphetamine on P3-like potentials in rats." *Int J Psychophysiol* 32(3): 183-92.
- Takigawa, M., H. Wang, K. Hamada, T. Shiratani and K. Takenouchi (2000). "Directed coherence of EEG on ICSS rats with methamphetamine-induced hyperactivity and stereotyped behavior." *Ann N Y Acad Sci* 914: 311-5.
- Takigawa, M., H. Fukuzako, et al. (1994). "Intracranial self-stimulation and locomotor traces as indicators for evaluating and developing antipsychotic drugs." *Jpn J Psychiatry Neurol* 48(1): 127-32.
- Takigawa, M., K. Ueyama, et al. (1993). "Intracranial self-stimulation and locomotor traces as indicators for evaluating the homopantothenic acid." *Jpn J Psychiatry Neurol* 47(4): 915-20.

- Tang, A. H. and J. D. Kirch (1971). "Appetite suppression and central nervous system stimulation in the rhesus monkey." *Psychopharmacologia* 21(2): 139-46.
- Tataroglu, O., A. J. Davidson, et al. (2006). "The methamphetamine-sensitive circadian oscillator (MASCO) in mice." *J Biol Rhythms* 21(3): 185-94.
- Tatsuta, T., N. Kitanaka, et al. (2006). "Lobeline attenuates methamphetamine-induced stereotypy in adolescent mice." *Neurochem Res* 31(11): 1359-69.
- Tatsuta, T., N. Kitanaka, et al. (2005). "Effects of monoamine oxidase inhibitors on methamphetamine-induced stereotypy in mice and rats." *Neurochem Res* 30(11): 1377-85.
- Thompson, T. and R. Pickens (1970). "Stimulant self-administration by animals: Some comparisons with opiate self-administration." *Fed Proc* 29(1): 6-12.
- Timar, J., S. Gyarmati, et al. (2003). "Behavioural changes in rats treated with a neurotoxic dose regimen of dextrorotatory amphetamine derivatives." *Behav Pharmacol* 14(3): 199-206.
- Tirelli, E., B. Geter-Douglass, et al. (1998). "gamma-Aminobutyric acidA agonists differentially augment gnawing induced by indirect-acting dopamine agonists in C57BL/6J mice." *J Pharmacol Exp Ther* 284(1): 116-24.
- Tobe, A., M. Egawa, et al. (1983). "Effect of 4-(o-benzylphenoxy)-N-methylbutylamine hydrochloride (MCI-2016) on the scopolamine-induced deficit of spontaneous alternation behavior in rats." *Jpn J Pharmacol* 33(4): 775-84.
- Tobe, A. and T. Kobayashi (1976). "Pharmacological studies on triazine derivatives V Sedative and neuroleptic actions of 2-amino-4-[4-(2-hydroxyethyl)-piperazin-1-yl]-6-trifluoromethyl-s-triazine (TR-10)." *Jpn J Pharmacol* 26(5): 559-70.
- Tokuyama, S. and M. Takahashi (2001). "[Pharmacological and physiological effects of ginseng on actions induced by opioids and psychostimulants]." *Nippon Yakurigaku Zasshi* 117(3): 195-201.
- Tokuyama, S., M. Takahashi, et al. (1996). "The effect of ginseng extract on locomotor sensitization and conditioned place preference induced by methamphetamine and cocaine in mice." *Pharmacol Biochem Behav* 54(4): 671-6.
- Toyota, H., C. Dugovic, et al. (2002). "Behavioral characterization of mice lacking histamine H(3) receptors." *Mol Pharmacol* 62(2): 389-97.
- Tsai, S. J. (2007). "Increased central brain-derived neurotrophic factor activity could be a risk factor for substance abuse: Implications for treatment." *Med Hypotheses* 68(2): 410-4.
- Tsuchida, K., H. Ujike, et al. (1994). "Ontogeny of enhanced striatal dopamine release in rats with methamphetamine-induced behavioral sensitization." *Pharmacol Biochem Behav* 47(1): 161-9.
- Tuazon, D. B., T. Suzuki, et al. (1992). "Methylxanthines (caffeine and theophylline) blocked methamphetamine-induced conditioned place preference in mice but enhanced that induced by cocaine." *Ann N Y Acad Sci* 654: 531-3.
- Uchihashi, Y., H. Kuribara, et al. (1994). "Long-continuous observation of the effects of methamphetamine on wheel-running and drinking in mice." *Prog Neuropsychopharmacol Biol Psychiatry* 18(2): 397-407.
- Ujike, H., H. Tsuchida, et al. (1992). "Competitive and non-competitive N-methyl-D-aspartate antagonists fail to prevent the induction of methamphetamine-induced sensitization." *Life Sci* 50(22): 1673-81.
- Umezu, T., H. Kuribara, et al. (1988). "Acquisition process and effects of psychoactive drugs on discrete shuttle avoidance response in Mongolian gerbils (*Meriones unguiculatus*)." *Jpn J Pharmacol* 47(3): 245-52.
- Ungard, J. T., M. Beekman, et al. (2000). "Modification of behavioral effects of drugs in mice by neuroactive steroids." *Psychopharmacology (Berl)* 148(4): 336-43.
- Ushijima, I., K. Yamada, et al. (1984). "Progressive augmentation of locomotor activity in mice by long-term treatment with thyrotropin releasing hormone." *Arch Int Pharmacodyn Ther* 270(1): 29-37.
- Vajragupta, O., P. Boonchoong, et al. (2003). "Manganese-based complexes of radical scavengers as neuroprotective agents." *Bioorg Med Chem* 11(10): 2329-37.
- Vajragupta, O., O. Monthakantirat, et al. (2000). "Chroman amide 12P inhibition of lipid peroxidation and protection against learning and memory impairment." *Life Sci* 67(14): 1725-34.
- Veenstra-Vanderweele, J., A. Qadir, et al. (2005). "Association between the casein kinase 1 epsilon gene region and subjective response to d-amphetamine." *Neuropsychopharmacology*.
- Verhave, T. (1958). "The effect of methamphetamine on operant level and avoidance behavior." *J Exp Anal Behav* 1(3): 207-19.
- Vinklerova, J., J. Novakova, et al. (2002). "Inhibition of methamphetamine self-administration in rats by cannabinoid receptor antagonist AM 251." *J Psychopharmacol* 16(2): 139-43.
- Vorhees, C. V., T. M. Reed, et al. (2005). "Periadolescent rats (P41-50) exhibit increased susceptibility to D-methamphetamine-induced long-term spatial and sequential learning deficits compared to juvenile (P21-30 or P31-40) or adult rats (P51-60)." *Neurotoxicol Teratol* 27(1): 117-34.
- Vorhees, C. V., S. L. Inman-Wood, et al. (2000). "Adult learning deficits after neonatal exposure to D-methamphetamine: Selective effects on spatial navigation and memory." *J Neurosci* 20(12): 4732-9.

- Vorhees, C. V. (1997). "Methods for detecting long-term CNS dysfunction after prenatal exposure to neurotoxins." *Drug Chem Toxicol* 20(4): 387-99.
- Vorhees, C. V., K. G. Ahrens, et al. (1994). "Methamphetamine exposure during early postnatal development in rats: I. Acoustic startle augmentation and spatial learning deficits." *Psychopharmacology (Berl)* 114(3): 392-401.
- Vorhees, C. V., K. G. Ahrens, et al. (1994). "Methamphetamine exposure during early postnatal development in rats: II. Hypoactivity and altered responses to pharmacological challenge." *Psychopharmacology (Berl)* 114(3): 402-8.
- Wagner, G. C., N. Avena, et al. (2004). "Risperidone reduction of amphetamine-induced self-injurious behavior in mice." *Neuropharmacology* 46(5): 700-8.
- Wagner, G. C., R. W. Foltin, et al. (1981). "Dopamine depletion by 6-hydroxydopamine prevents conditioned taste aversion induced by methylamphetamine but not lithium chloride." *Pharmacol Biochem Behav* 14(1): 85-8.
- Wakayama, A., K. Kataoka, et al. (1993). "Evaluation of masked neurological disorders in the chronic stage after middle cerebral artery occlusion in rats--methamphetamine-induced rotation and regional glucose metabolism in basal ganglia." *Neurol Med Chir (Tokyo)* 33(12): 801-8.
- Wallace, T. L., G. A. Gudelsky, et al. (2001). "Alterations in diurnal and nocturnal locomotor activity in rats treated with a monoamine-depleting regimen of methamphetamine or 3,4-methylenedioxymethamphetamine." *Psychopharmacology (Berl)* 153(3): 321-6.
- Wallace, T. L., G. A. Gudelsky, et al. (2001). "Neurotoxic regimen of methamphetamine produces evidence of behavioral sensitization in the rat." *Synapse* 39(1): 1-7.
- Wallace, T. L., G. A. Gudelsky, et al. (1999). "Methamphetamine-induced neurotoxicity alters locomotor activity, stereotypic behavior, and stimulated dopamine release in the rat." *J Neurosci* 19(20): 9141-8.
- Walsh, S. L. and G. C. Wagner (1992). "Motor impairments after methamphetamine-induced neurotoxicity in the rat." *J Pharmacol Exp Ther* 263(2): 617-26.
- Wang, H. D., M. Takigawa, et al. (2002). "A shift in information flow between prefrontal cortex and the ventral tegmental area in methamphetamine-sensitized rats." *Int J Psychophysiol* 44(3): 251-9.
- Wang, H. D., M. Takigawa, et al. (2000). "Reciprocal information flow between prefrontal cortex and ventral tegmental area in an animal model of schizophrenia." *Neuroreport* 11(9): 2007-11.
- Wang, Z. and W. L. Woolverton (2007). "Estimating the relative reinforcing strength of (+/-)-3,4-methylenedioxymethamphetamine (MDMA) and its isomers in rhesus monkeys: Comparison to (+)-methamphetamine." *Psychopharmacology (Berl)* 189(4): 483-8.
- Watanabe, T. and K. Yanai (2001). "Studies on functional roles of the histaminergic neuron system by using pharmacological agents, knockout mice and positron emission tomography." *Tohoku J Exp Med* 195(4): 197-217.
- Watanabe, T., K. Matsushashi, et al. (1985). "[Study on the postnatal neuro-behavioral development in rats treated prenatally with drugs acting on the autonomic nervous systems]." *Nippon Yakurigaku Zasshi* 85(2): 79-90.
- Watanabe, T., K. Matsushashi, et al. (1984). "[Study on the neuro-behavioral development in rats treated neonatally with drugs acting on the autonomic nervous system]." *Nippon Yakurigaku Zasshi* 84(3): 267-82.
- Watanabe, Y., Y. Hori, et al. (1995). "Inhibitory effects of newly synthesized Ser-contained GABA-peptides administered into either caudate putamen or amygdala on methamphetamine-induced hyperactivity." *Nihon Shinkei Seishin Yakurigaku Zasshi* 15(3): 239-46.
- Will, B. E., M. R. Rosenzweig, et al. (1977). "Relatively brief environmental enrichment aids recovery of learning capacity and alters brain measures after postweaning brain lesions in rats." *J Comp Physiol Psychol* 91(1): 33-50.
- Williams, M. T., M. S. Moran, et al. (2004). "Behavioral and growth effects induced by low dose methamphetamine administration during the neonatal period in rats." *Int J Dev Neurosci* 22(5-6): 273-83.
- Williams, M. T., T. L. Blankenmeyer, et al. (2003). "Long-term effects of neonatal methamphetamine exposure in rats on spatial learning in the Barnes maze and on cliff avoidance, corticosterone release, and neurotoxicity in adulthood." *Brain Res Dev Brain Res* 147(1-2): 163-75.
- Witkin, J. M., N. Savtchenko, et al. (1999). "Behavioral, toxic, and neurochemical effects of sydnocarb, a novel psychomotor stimulant: Comparisons with methamphetamine." *J Pharmacol Exp Ther* 288(3): 1298-310.
- Witkin, J. M. (1993). "Blockade of the locomotor stimulant effects of cocaine and methamphetamine by glutamate antagonists." *Life Sci* 53(24): PL405-10.
- Witkin, J. M., G. A. Ricaurte, et al. (1990). "Behavioral effects of N-methylamphetamine and N,N-dimethylamphetamine in rats and squirrel monkeys." *J Pharmacol Exp Ther* 253(2): 466-74.
- Wolf, G., Y. Jacquet, et al. (1978). "Test for oral and postingestional factors mediating differential acceptability of morphine, methamphetamine, and chlordiazepoxide drinking solutions." *Psychopharmacology (Berl)* 60(1): 101-2.
- Wolthuis, O. L., B. Groen, et al. (1994). "A simple automated test to measure exploratory and motor activity of marmosets." *Pharmacol Biochem Behav* 47(4): 879-81.

- Wolthuis, O. L., H. De Vroome, et al. (1975). "Automatically determined effects of lithium, scopolamine and methamphetamine on motor activity of rats." *Pharmacol Biochem Behav* 3(3): 515-8.
- Wolthuis, O. L. (1971). "Experiments with UCB 6215, a drug which enhances acquisition in rats: Its effects compared with those of metamphetamine." *Eur J Pharmacol* 16(3): 283-97.
- Woolverton, W. L., L. Cervo, et al. (1984). "Effects of repeated methamphetamine administration on methamphetamine self-administration in rhesus monkeys." *Pharmacol Biochem Behav* 21(5): 737-41.
- Yamada, K., T. Nagai, et al. (2005). "Drug dependence, synaptic plasticity, and tissue plasminogen activator." *J Pharmacol Sci* 97(2): 157-61.
- Yamada, K., N. Matsuo, et al. (1989). "Dopamine receptor blocking action of a dibenzothiepin derivative isofloxylthepin in rats." *Clin Exp Pharmacol Physiol* 16(2): 109-16.
- Yamada, K. and T. Furukawa (1980). "Behavior of rats and mice administered active metabolites of fluphenazine, 7-hydroxy-fluphenazine and fluphenazine-sulfoxide." *Arch Int Pharmacodyn Ther* 248(1): 76-85.
- Yamamura, M., H. Nakagawa, et al. (1989). "Effects of mafoprazine, a phenylpiperazine derivative, on the central dopaminergic system." *Jpn J Pharmacol* 50(3): 295-305.
- Yamamoto, T., S. Shibata, et al. (1989). "[Behavioral pharmacological properties of the novel antidepressant paroxetine, a selective 5-HT uptake inhibitor]." *Nippon Yakurigaku Zasshi* 94(3): 189-206.
- Yamamoto, T., M. Ohno, et al. (1988). "Anti-serotonin action in combination with noradrenaline-stimulating action is important for inhibiting muricide in midbrain raphe-lesioned rats." *Neuropharmacology* 27(2): 123-7.
- Yamamoto, T. and S. Ueki (1975). "Behavioral effects of 2,5-dimethoxy-4-methylamphetamine (DOM) in rats and mice." *Eur J Pharmacol* 32(02): 156-62.
- Yamamura, T., S. Hishida, et al. (1993). "Effects of daily administration of methamphetamine on multiple active/passive avoidance performance in rats." *Behav Brain Res* 53(1-2): 105-12.
- Yamamura, T., S. Hishida, et al. (1992). "Effects of methamphetamine and ethanol on learning and brain neurotransmitters in rats." *Pharmacol Biochem Behav* 42(3): 389-400.
- Yamamura, M., K. Maeda, et al. (1986). "[Behavioral pharmacological properties of nicergoline. Effects on gross-behavior in rats and monkeys and on DRL response, CER, and CAR in rats]." *Nippon Yakurigaku Zasshi* 87(2): 209-21.
- Yamanaka, Y., R. Takano, et al. (1986). "Methamphetamine-induced behavioral alterations following repeated administration of methamphetamine." *Jpn J Pharmacol* 41(2): 147-54.
- Yamanaka, Y., T. Yamamoto, et al. (1983). "Methamphetamine-induced behavioral effects and releases of brain catecholamines and brain concentrations of methamphetamine in mice." *Jpn J Pharmacol* 33(1): 33-40.
- Yamauchi, J., S. Marukawa, et al. (2000). "[Simultaneous administration of ethanol emphasizes the effect of methamphetamine on central nervous system in rat with high alcohol preference]." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 35(1): 28-47.
- Yamamoto, J. (1998). "Relationship between hippocampal theta-wave frequency and emotional behaviors in rabbits produced with stresses or psychotropic drugs." *Jpn J Pharmacol* 76(1): 125-7.
- Yamamoto, M., Y. Ozawa, et al. (1990). "Central dopaminergic actions of YM-14673, a new TRH analogue, in rodents." *Eur J Pharmacol* 180(2-3): 319-24.
- Yamazaki, Y., N. Shinohara, et al. (2004). "Visual discrimination of normal and drug induced behavior in quails (*Coturnix coturnix japonica*)." *Anim Cogn* 7(2): 128-32.
- Yan, Y., A. Nitta, et al. (2006). "Relapse of methamphetamine-seeking behavior in C57BL/6J mice demonstrated by a reinstatement procedure involving intravenous self-administration." *Behav Brain Res* 168(1): 137-43.
- Yan, Y., T. Mizuno, et al. (2004). "Nefiracetam attenuates methamphetamine-induced discriminative stimulus effects in rats." *Ann N Y Acad Sci* 1025: 274-8.
- Yanagisawa, D., M. Qi, et al. (2006). "Improvement of focal ischemia-induced rat dopaminergic dysfunction by striatal transplantation of mouse embryonic stem cells." *Neurosci Lett* 407(1): 74-9.
- Yanaura, S., Y. Abe, et al. (1976). "[Conditioning of emotional behavior originating at the hypothalamus. (2) Effects of drugs on conflict-induced behavior models]." *Nippon Yakurigaku Zasshi* 72(3): 351-61.
- Yanaura, S., Y. Abe, et al. (1976). "[Conditioning of emotional behavior caused by hypothalamic stimulation (4). Effects of drugs on conditioned avoidance and escape behavior]." *Nippon Yakurigaku Zasshi* 72(6): 701-8.
- Yang, J. (2004). "[The study developments about changes of methamphetamine-induced genes' transcriptions and translations]." *Fa Yi Xue Za Zhi* 20(3): 185-8.
- Yang, P. P., E. Y. Huang, et al. (2006). "Co-administration of dextromethorphan with methamphetamine attenuates methamphetamine-induced rewarding and behavioral sensitization." *J Biomed Sci* 13(5): 695-702.
- Yasar, S., J. Gaal, et al. (2006). "A comparison of drug-seeking behavior maintained by D-amphetamine, L-deprenyl (selegiline), and D-deprenyl under a second-order schedule in squirrel monkeys." *Psychopharmacology (Berl)* 183(4): 413-21.

- Yasar, S., J. Gaal, et al. (2005). "Discriminative stimulus and reinforcing effects of p-fluoro-L-deprenyl in monkeys." *Psychopharmacology (Berl)* 182(1): 95-103.
- Yokel, R. A. and R. Pickens (1973). "Self-administration of optical isomers of amphetamine and methylamphetamine by rats." *J Pharmacol Exp Ther* 187(1): 27-33.
- Yoshida, K., A. Morimoto, et al. (1993). "Cardiovascular, thermal and behavioral sensitization to methamphetamine in freely moving rats." *J Pharmacol Exp Ther* 267(3): 1538-43.
- Yoshida, S., Y. Numachi, et al. (2000). "The absence of impairment of cliff avoidance reaction induced by subchronic methamphetamine treatment in inbred strains of mice." *Tohoku J Exp Med* 190(3): 205-12.
- Yoshida, S., Y. Numachi, et al. (1998). "Impairment of cliff avoidance reaction induced by subchronic methamphetamine administration and restraint stress: comparison between two inbred strains of rats." *Prog Neuropsychopharmacol Biol Psychiatry* 22(6): 1023-32.
- Yoshida, S., Y. Numachi, et al. (1995). "[Reverse-tolerance phenomenon in methamphetamine-induced behavioral stereotypy and impairment of cliff avoidance reaction after subchronic methamphetamine administration in rats]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 15(5): 397-403.
- Yoshimura, K. and K. Yamamoto (1980). "[Neuropharmacological studies on drug dependence (II). Changes in spontaneous motor activity, EEG and brain monoamines during the period of dependence development and of abrupt withdrawal in rats, with special reference to circadian rhythm (author's transl)]." *Nippon Yakurigaku Zasshi* 76(5): 373-411.
- Yui, K. and S. Ikemoto (2004). "[Stress sensitization induced by stressor and methamphetamine]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 24(3): 151-7.
- Yui, K. and T. Miura (1996). "Behavioral responses induced by repeated treatment with methamphetamine alone and in combination with scopolamine in rats." *Neuropsychobiology* 33(1): 21-7.
- Yui, K., T. Miura, et al. (1996). "Effects of repeated treatment with methamphetamine plus scopolamine and methamphetamine on behavioral sensitization and conditioning." *Behav Brain Res* 80(1-2): 169-75.
- Yui, K., T. Miura, et al. (1995). "Comparison of behavioural effects of repeated treatment with methamphetamine plus scopolamine and methamphetamine alone on behavioural sensitization and conditioned response." *J Pharm Pharmacol* 47(10): 852-6.
- Yui, K., T. Miura, et al. (1995). "Methamphetamine plus scopolamine potentiates behavioral sensitization and conditioning." *Eur J Pharmacol* 279(2-3): 135-42.
- Yui, K., T. Miura, et al. (1994). "Stereotyped behavioral responses to an auditory stimulus in the course of repeated treatment with methamphetamine plus scopolamine and methamphetamine in rats." *Nihon Shinkei Seishin Yakurigaku Zasshi* 14(3): 169-78.
- Yui, K. and T. Miura (1991). "[Cholinergic modulation on stereotyped behavior and behavioral hypersensitivity (reverse tolerance) in rats]." *Yakubutsu Seishin Kodo* 11(2): 141-56.
- Zeng, N., A. Nakajima, et al. (2004). "Fos expression associated with the discriminative stimulus effects of methamphetamine in rats." *Ann N Y Acad Sci* 1025: 236-41.
- Zhang, Y., T. M. Loonam, et al. (2001). "Comparison of cocaine- and methamphetamine-evoked dopamine and glutamate overflow in somatodendritic and terminal field regions of the rat brain during acute, chronic, and early withdrawal conditions." *Ann N Y Acad Sci* 937: 93-120.
- Zhao, R. J., R. S. Woo, et al. (2003). "Orphanin FQ/nociceptin blocks methamphetamine place preference in rats." *Neuroreport* 14(18): 2383-5.

### Belgium

- Delbeke, F. T. (1996). "Doping in cyclism: Results of unannounced controls in Flanders (1987-1994)." *Int J Sports Med* 17(6): 434-8.
- March, J. C., E. Oviedo-Joekes, et al. (2006). "Drugs and social exclusion in ten European cities." *Eur Addict Res* 12(1): 33-41.

### Benzodiazepine Receptors (animals)

- Ito, K., T. Ohmori, et al. (2000). "The role of benzodiazepine receptors in the acquisition and expression of behavioral sensitization to methamphetamine." *Pharmacol Biochem Behav* 65(4): 705-10.
- Ito, K. (1999). "The role of gamma-aminobutyric acid (GABA)-benzodiazepine neurotransmission in an animal model of methamphetamine-induced psychosis." *Hokkaido Igaku Zasshi* 74(2): 135-44.
- Ito, K., T. Ohmori, et al. (1997). "Clonazepam prevents the development of sensitization to methamphetamine." *Pharmacol Biochem Behav* 58(4): 875-9.
- Weissman, B. A., R. Brandeis, et al. (2004). "Monitoring drug-induced neurodegeneration by imaging of peripheral benzodiazepine receptors." *Ann N Y Acad Sci* 1025: 584-9.

## Benzodiazepines

- Darke, S., J. Ross, et al. (1994). "The use of benzodiazepines among regular amphetamine users." *Addiction* 89(12): 1683-90.
- Darke, S., W. Hall, et al. (1992). "Benzodiazepine use and HIV risk-taking behaviour among injecting drug users." *Drug Alcohol Depend* 31(1): 31-6.
- Gatch, M. B., M. Selvig, et al. (2005). "GABAergic modulation of the discriminative stimulus effects of methamphetamine." *Behav Pharmacol* 16(4): 261-6.
- Ruha, A. M. and M. C. Yarema (2006). "Pharmacologic treatment of acute pediatric methamphetamine toxicity." *Pediatr Emerg Care* 22(12): 782-5.
- Schwilke, E. W., M. I. Sampaio dos Santos, et al. (2006). "Changing patterns of drug and alcohol use in fatally injured drivers in Washington State." *J Forensic Sci* 51(5): 1191-8.
- Teng, S. F., S. C. Wu, et al. (2006). "Characteristics and trends of 3,4-methylenedioxyamphetamine (MDMA) tablets found in Taiwan from 2002 to February 2005." *Forensic Sci Int* 161(2-3): 202-8.

## Benzodiazepines (animals)

- Goeders, J. E. and N. E. Goeders (2004). "Effects of oxazepam on methamphetamine-induced conditioned place preference." *Pharmacol Biochem Behav* 78(1): 185-8.
- Ito, K., T. Ohmori, et al. (1997). "Clonazepam prevents the development of sensitization to methamphetamine." *Pharmacol Biochem Behav* 58(4): 875-9.
- Kliethermes, C. L. and J. C. Crabbe (2006). "Pharmacological and genetic influences on hole-board behaviors in mice." *Pharmacol Biochem Behav* 85(1): 57-65.
- Koshikawa, N., E. Mori, et al. (1990). "Role of dopamine D-1 and D-2 receptors in the ventral striatum in the turning behaviour of rats." *Eur J Pharmacol* 178(2): 233-7.
- Nakamura, K. and Y. Ozawa (1981). "[A metrical analysis of exploratory behavior in mice: effects of methamphetamine and diazepam (author's transl)]." *Nippon Yakurigaku Zasshi* 78(1): 1-8.
- Razzak, A., M. Fujiwara, et al. (1977). "Possible involvement of a central noradrenergic system in automutilation induced by clonidine in mice." *Jpn J Pharmacol* 27(1): 145-52.
- Richards, J. R., R. W. Derlet, et al. (1997). "Methamphetamine toxicity: Treatment with a benzodiazepine versus a butyrophenone." *Eur J Emerg Med* 4(3): 130-5.

## Berkeley, CA (US)

- Gleghorn, A. A., R. Marx, et al. (1998). "Association between drug use patterns and HIV risks among homeless, runaway, and street youth in northern California." *Drug Alcohol Depend* 51(3): 219-27.
- Kohrs, F. P., C. Mann and R. Greenberg (2004). "The use of amphetamine in gamma-hydroxybutyrate overdose: A case report." *J Psychoactive Drugs* 36(3): 401-2.
- Zweben, J. E., J. B. Cohen, et al. (2000). "Conducting trials in community settings: The provider perspective." *J Psychoactive Drugs* 32(2): 193-9.

## Binge Use

- Comer, S. D., C. L. Hart, et al. (2001). "Effects of repeated oral methamphetamine administration in humans." *Psychopharmacology (Berl)* 155(4): 397-404.
- Halkitis, P. N. and M. T. Shrem (2006). "Psychological differences between binge and chronic methamphetamine using gay and bisexual men." *Addict Behav* 31(3): 549-52.
- Semple, S. J., J. Zians, et al. (2005). "Impulsivity and methamphetamine use." *J Subst Abuse Treat* 29(2): 85-93.
- Semple, S. J., T. L. Patterson, et al. (2003). "Binge use of methamphetamine among HIV-positive men who have sex with men: Pilot data and HIV prevention implications." *AIDS Educ Prev* 15(2): 133-47.
- Sommers, I., D. Baskin, et al. (2006). "Methamphetamine use among young adults: Health and social consequences." *Addict Behav* 31(8): 1469-76.

## Binge Use (animals)

- Cho, A. K., W. P. Melega, et al. (2001). "Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse." *Synapse* 39(2): 161-6.

- Clemens, K. J., J. L. Cornish, et al. (2007). "Repeated weekly exposure to MDMA, methamphetamine or their combination: Long-term behavioural and neurochemical effects in rats." *Drug Alcohol Depend* 86(2-3): 183-90.
- Davidson, C., T. H. Lee, et al. (2005). "Acute and chronic continuous methamphetamine have different long-term behavioral and neurochemical consequences." *Neurochem Int* 46(3): 189-203.
- Kuczenski, R. and D. S. Segal (2001). "Caudate-putamen and nucleus accumbens extracellular acetylcholine responses to methamphetamine binges." *Brain Res* 923(1-2): 32-8.
- Moszczynska, A., S. Turenne, et al. (1998). "Rat striatal levels of the antioxidant glutathione are decreased following binge administration of methamphetamine." *Neurosci Lett* 255(1): 49-52.
- O'Neil, M. L., R. Kuczenski, et al. (2006). "Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge." *Synapse* 60(6): 465-73.
- Sanchez-Alavez, M., L. M. Gombart, et al. (2004). "Physiological and behavioral effects of methamphetamine in a mouse model of endotoxemia: a preliminary study." *Pharmacol Biochem Behav* 77(2): 365-70.
- Segal, D. S., R. Kuczenski, et al. (2005). "Prolonged exposure of rats to intravenous methamphetamine: Behavioral and neurochemical characterization." *Psychopharmacology (Berl)* 180(3): 501-12.
- Segal, D. S., R. Kuczenski, et al. (2003). "Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge." *Neuropsychopharmacology* 28(10): 1730-40.
- Segal, D. S. and R. Kuczenski (1999). "Escalating dose-binge stimulant exposure: Relationship between emergent behavioral profile and differential caudate-putamen and nucleus accumbens dopamine responses." *Psychopharmacology (Berl)* 142(2): 182-92.
- Segal, D. S. and R. Kuczenski (1997). "Repeated binge exposures to amphetamine and methamphetamine: Behavioral and neurochemical characterization." *J Pharmacol Exp Ther* 282(2): 561-73.
- Semba, J., N. Tanaka, et al. (2001). "Neonatal phencyclidine treatment selectively attenuates mesolimbic dopamine function in adult rats as revealed by methamphetamine-induced behavior and c-fos mRNA expression in the brain." *Synapse* 40(1): 11-8.
- Semba, J., H. Watanabe, et al. (2000). "Neonatal treatment with L-name (NG-nitro-L-arginine methyl ester) attenuates stereotyped behavior induced by acute methamphetamine but not development of behavioral sensitization to methamphetamine." *Prog Neuropsychopharmacol Biol Psychiatry* 24(6): 1017-23.
- Shimosato, K. and S. Watanabe (1989). "Modification of behavioral responses to methamphetamine evoked by the stimulant's metabolite p-hydroxynorephedrine in rats." *Pharmacol Biochem Behav* 33(2): 423-9.
- Slamberova, R., P. Charousova, et al. (2005). "Methamphetamine administration during gestation impairs maternal behavior." *Dev Psychobiol* 46(1): 57-65.
- Subarnas, A., T. Tadano, et al. (1993). "Pharmacological properties of beta-amyrin palmitate, a novel centrally acting compound, isolated from *Lobelia inflata* leaves." *J Pharm Pharmacol* 45(6): 545-50.
- Sumiyoshi, T., M. Tsunoda, et al. (2004). "Enhanced locomotor activity in rats with excitotoxic lesions of the entorhinal cortex, a neurodevelopmental animal model of schizophrenia: Behavioral and in vivo microdialysis studies." *Neurosci Lett* 364(2): 124-9.
- Suzuki, H., T. Shishido, et al. (1997). "Changes of behavior and monoamine metabolites in the rat brain after repeated methamphetamine administration: Effects of duration of repeated administration." *Prog Neuropsychopharmacol Biol Psychiatry* 21(2): 359-69.
- Suzuki, T., H. J. Fan Chiang, et al. (1987). "Effects of quinidine and cimetidine on methamphetamine stereotypy in rats." *J Pharmacobiodyn* 10(3): 152-5.
- Suzuki, T., H. J. Chiang, et al. (1986). "Studies on the mechanism of interaction between methamphetamine and quinine in rats." *J Pharmacobiodyn* 9(3): 234-8.
- Szumliński, K. K., M. Y. Balogun, et al. (2000). "Interactions between iboga agents and methamphetamine sensitization: studies of locomotion and stereotypy in rats." *Psychopharmacology (Berl)* 151(2-3): 234-41.
- Tadokoro, S. and H. Kuribara (1990). "[Modification of the behavioral effects of drugs after repeated administration--special reference to the reverse tolerance of amphetamines]." *Nippon Yakurigaku Zasshi* 95(5): 229-38.
- Takahashi, S., T. Miwa, et al. (2000). "Involvement of sigma 1 receptors in methamphetamine-induced behavioral sensitization in rats." *Neurosci Lett* 289(1): 21-4.
- Takigawa, M., H. Wang, et al. (2000). "Directed coherence of EEG on ICSS rats with methamphetamine-induced hyperactivity and stereotyped behavior." *Ann N Y Acad Sci* 914: 311-5.
- Takigawa, M., H. Maeda, et al. (1993). "A dual approach to self-stimulation and locomotor trace affected by chronic methamphetamine treatment for an animal model of schizophrenia." *Can J Physiol Pharmacol* 71(5-6): 321-5.
- Ujike, H., A. Kanzaki, et al. (1992). "Sigma (sigma) antagonist BMY 14802 prevents methamphetamine-induced sensitization." *Life Sci* 50(16): PL129-34.
- Ujike, H., H. Tsuchida, et al. (1992). "Competitive and non-competitive N-methyl-D-aspartate antagonists fail to prevent the induction of methamphetamine-induced sensitization." *Life Sci* 50(22): 1673-81.



- Ujike, H., K. Akiyama, et al. (1990). "D-2 but not D-1 dopamine agonists produce augmented behavioral response in rats after subchronic treatment with methamphetamine or cocaine." *Psychopharmacology (Berl)* 102(4): 459-64.
- Ujike, H., T. Onoue, et al. (1989). "Effects of selective D-1 and D-2 dopamine antagonists on development of methamphetamine-induced behavioral sensitization." *Psychopharmacology (Berl)* 98(1): 89-92.
- Varner, K. J., B. A. Ogden, et al. (2002). "Cardiovascular responses elicited by the "binge" administration of methamphetamine." *J Pharmacol Exp Ther* 301(1): 152-9.
- Wagner, G. C., N. Avena, et al. (2004). "Risperidone reduction of amphetamine-induced self-injurious behavior in mice." *Neuropharmacology* 46(5): 700-8.
- Wakamatsu, Y., M. Iwasaki, et al. (1974). "Proceedings: Influence of L-DOPA on brain noradrenaline contents and stereotypy in methamphetamine-treated rats." *Jpn J Pharmacol* 24(0): s:61.
- Wallace, T. L., G. A. Gudelsky, et al. (2001). "Neurotoxic regimen of methamphetamine produces evidence of behavioral sensitization in the rat." *Synapse* 39(1): 1-7.
- Wallace, T. L., G. A. Gudelsky, et al. (1999). "Methamphetamine-induced neurotoxicity alters locomotor activity, stereotypic behavior, and stimulated dopamine release in the rat." *J Neurosci* 19(20): 9141-8.
- Weihmuller, F. B., S. J. O'Dell, et al. (1991). "MK-801 attenuates the dopamine-releasing but not the behavioral effects of methamphetamine: an in vivo microdialysis study." *Brain Res* 549(2): 230-5.
- Witkin, J. M., N. Savtchenko, et al. (1999). "Behavioral, toxic, and neurochemical effects of sydnocarb, a novel psychomotor stimulant: comparisons with methamphetamine." *J Pharmacol Exp Ther* 288(3): 1298-310.
- Yamauchi, J., S. Marukawa, et al. (2000). "[Simultaneous administration of ethanol emphasizes the effect of methamphetamine on central nervous system in rat with high alcohol preference]." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 35(1): 28-47.
- Yoshida, S., Y. Numachi, et al. (2000). "The absence of impairment of cliff avoidance reaction induced by subchronic methamphetamine treatment in inbred strains of mice." *Tohoku J Exp Med* 190(3): 205-12.
- Yoshida, S., Y. Numachi, et al. (1998). "Impairment of cliff avoidance reaction induced by subchronic methamphetamine administration and restraint stress: Comparison between two inbred strains of rats." *Prog Neuropsychopharmacol Biol Psychiatry* 22(6): 1023-32.
- Yoshida, S., Y. Numachi, et al. (1995). "[Reverse-tolerance phenomenon in methamphetamine-induced behavioral stereotypy and impairment of cliff avoidance reaction after subchronic methamphetamine administration in rats]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 15(5): 397-403.
- Yui, K., T. Miura, et al. (1994). "Stereotyped behavioral responses to an auditory stimulus in the course of repeated treatment with methamphetamine plus scopolamine and methamphetamine in rats." *Nihon Shinkei Seishin Yakurigaku Zasshi* 14(3): 169-78.
- Zhu, J. P., W. Xu, et al. (2006). "Distinct mechanisms mediating methamphetamine-induced neuronal apoptosis and dopamine terminal damage share the neuropeptide substance P in the striatum of mice." *Ann N Y Acad Sci* 1074: 135-48.
- Zhu, J. P., W. Xu, et al. (2006). "Methamphetamine-induced striatal apoptosis in the mouse brain: Comparison of a binge to an acute bolus drug administration." *Neurotoxicology* 27(1): 131-6.

## Bipolar Disorder

- Camacho, A. and H. S. Akiskal (2005). "Proposal for a bipolar-stimulant spectrum: Temperament, diagnostic validation and therapeutic outcomes with mood stabilizers." *J Affect Disord* 85(1-2): 217-30.
- Ogden, C. A., M. E. Rich, et al. (2004). "Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: An expanded convergent functional genomics approach." *Mol Psychiatry* 9(11): 1007-29.
- Won, M., Y. Minabe, et al. (2003). "Manic-switch induced by fluvoxamine in abstinent pure methamphetamine abusers." *J Psychiatry Neurosci* 28(2): 134-5.

## Bipolar Disorder (animal models)

- Ogden, C. A., M. E. Rich, et al. (2004). "Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: An expanded convergent functional genomics approach." *Mol Psychiatry* 9(11): 1007-29.

### **Bisexual Men**

*See* [Gay Men/Men who Have Sex with Men](#)

### **Blacks**

*See* [African-Americans/Blacks \(US\)](#)

### **Blood Glucose (animals)**

*See also* [Insulin Levels \(animals\)](#)

Dickinson, J. E., R. L. Andres, et al. (1994). "The ovine fetal sympathoadrenal response to the maternal administration of methamphetamine." *Am J Obstet Gynecol* 170(5 Pt 1): 1452-7.

Estler, C. J. and M. C. Gabrys (1979). "Swimming capacity of mice after prolonged treatment with psychostimulants. II. Effect of methamphetamine on swimming performance and availability of metabolic substrates." *Psychopharmacology (Berl)* 60(2): 173-6.

Estler, C. J. (1975). "Influence of phenoxybenzamine on methamphetamine-induced changes in locomotor activity, oxygen consumption, body temperature and some metabolic parameters." *Neuropharmacology* 14(10): 779-83.

Estler, C. J. and P. Mitznegg (1971). "Influence of methamphetamine on incorporation of glucose into brain glycogen." *Biochem Pharmacol* 20(6): 1331-3.

Estler, C. J., H. P. Ammon, et al. (1970). "Substrate supply and energy metabolism of skeletal muscle of mice treated with methamphetamine and propranolol." *Biochem Pharmacol* 19(12): 2957-62.

### **Blood Pressure**

*See* [Hypertension](#)

### **Body Temperature**

*See* [Hyperthermia](#); [Hyperthermia \(animals\)](#); [Temperature of Body \(animals\)](#)

### **Bone Density**

[Katsuragawa, Y. \(1999\). "Effect of methamphetamine abuse on the bone quality of the calcaneus." \*Forensic Sci Int\* 101\(1\): 43-8.](#)

### **Boston, MA (US)**

[Koblin, B. A., M. A. Chesney, et al. \(2003\). "High-risk behaviors among men who have sex with men in 6 US cities: Baseline data from the EXPLORE Study." \*Am J Public Health\* 93\(6\): 926-32.](#)

[Seage, G. R., 3rd, K. H. Mayer, et al. \(1998\). "The social context of drinking, drug use, and unsafe sex in the Boston Young Men Study." \*J Acquir Immune Defic Syndr Hum Retrovirol\* 17\(4\): 368-75.](#)

### **Brain, Ascorbic Acid Release in (animals)**

[Dai, F., J. Y. Yang, et al. \(2006\). "Effect of drug-induced ascorbic acid release in the striatum and the nucleus accumbens in hippocampus-lesioned rats." \*Brain Res\* 1125\(1\): 163-70.](#)

[Gu, P. F., C. F. Wu, et al. \(2006\). "Differential effects of drug-induced ascorbic acid release in the striatum and nucleus accumbens of freely moving rats." \*Neurosci Lett\* 399\(1-2\): 79-84.](#)

[Gu, P. F., J. Y. Yang, et al. \(2005\). "Frontal decortication eliminates drug-induced ascorbic acid release in the striatum but not the nucleus accumbens of freely moving rats." \*Brain Res\* 1033\(2\): 194-201.](#)

### **Brain, Blood Flow in**

*See also* [Brain Hemorrhages and Strokes](#)

[Alhassoon, O. M., R. M. Dupont, et al. \(2001\). "Regional cerebral blood flow in cocaine- versus methamphetamine-dependent patients with a history of alcoholism." \*Int J Neuropsychopharmacol\* 4\(2\): 105-12.](#)

[Hwang, J., I. K. Lyoo, et al. \(2006\). "Decreased cerebral blood flow of the right anterior cingulate cortex in long-term and short-term abstinent methamphetamine users." \*Drug Alcohol Depend\* 82\(2\): 177-81.](#)

- Iyo, M., Y. Sekine, et al. (2004). "Neuromechanism of developing methamphetamine psychosis: A neuroimaging study." *Ann N Y Acad Sci* 1025: 288-95.
- Iyo, M., H. Namba, et al. (1997). "Abnormal cerebral perfusion in chronic methamphetamine abusers: A study using 99mTc-HMPAO and SPECT." *Prog Neuropsychopharmacol Biol Psychiatry* 21(5): 789-96.
- Kleinschmidt, A., H. Bruhn, et al. (1999). "Effects of sedation, stimulation, and placebo on cerebral blood oxygenation: A magnetic resonance neuroimaging study of psychotropic drug action." *NMR Biomed* 12(5): 286-92.

## Brain, Blood Flow in (animals)

*See also* Brain Hemorrhages and Strokes (animals)

- Lindvall, O., M. Ingvar, et al. (1981). "Effects of methamphetamine on blood flow in the caudate-putamen after lesions of the nigrostriatal dopaminergic bundle in the rat." *Brain Res* 211(1): 211-6.
- Miura, Y., T. Ito, et al. (1985). "Acute EEG changes in rats by brainstem ischemia and its dopaminergic involvement." *Jpn J Pharmacol* 39(4): 443-51.
- Nishino, H. (1973). "[Regional blood flow in the brain. II. Effects of central stimulants, convulsants and a dissociative anesthetic on regional blood flow in the brain]." *Nippon Yakurigaku Zasshi* 69(6): 843-53.
- Rumbaugh, C. L., H. C. Fang, et al. (1980). "Cerebral CT findings in drug abuse: Clinical and experimental observations." *J Comput Assist Tomogr* 4(3): 330-4.
- Rumbaugh, C. L., H. C. Fang, et al. (1976). "Cerebral microvascular injury in experimental drug abuse." *Invest Radiol* 11(4): 282-94.
- Rumbaugh, C. L., R. T. Bergeron, et al. (1971). "Cerebral vascular changes secondary to amphetamine abuse in the experimental animal." *Radiology* 101(2): 345-51.
- Shiue, C. Y., G. G. Shiue, et al. (1995). "Comparative PET studies of the distribution of (-)-3,4-methylenedioxy-N-[11C]methamphetamine and (-)-[11C]methamphetamine in a monkey brain." *Nucl Med Biol* 22(3): 321-4.

## Brain, Distributinon of Methamphetamine in

- Kalasinaky, K. S., T. Z. Bosy, et al. (2001). "Regional distribution of methamphetamine in autopsied brain of chronic human methamphetamine users." *Forensic Sci Int* 116(2-3): 163-9.

## Brain, Electrical Activity in

- Ellinwood, E. H., Jr., A. Sudilovsky, et al. (1974). "Behavior and EEG analysis of chronic amphetamine effect." *Biol Psychiatry* 8(2): 169-76.
- Iwanami, A., N. Kato, et al. (1991). "P300 in methamphetamine psychosis." *Biol Psychiatry* 30(7): 726-30.
- Iwanami, A., N. Kuroki, et al. (1998). "P3a of event-related potential in chronic methamphetamine dependence." *J Nerv Ment Dis* 186(12): 746-51.
- Iwanami, A., R. Kanamori, et al. (1995). "Reduced attention-related negative potentials in methamphetamine psychosis." *J Nerv Ment Dis* 183(11): 693-7.
- Iwanami, A., I. Suga, et al. (1994). "P300 component of event-related potentials in methamphetamine psychosis and schizophrenia." *Prog Neuropsychopharmacol Biol Psychiatry* 18(3): 465-75.
- Iwanami, A., I. Suga, et al. (1993). "Event-related potentials in methamphetamine psychosis during an auditory discrimination task. A preliminary report." *Eur Arch Psychiatry Clin Neurosci* 242(4): 203-8.
- Iwanami, A., N. Kato, et al. (1991). "P300 in methamphetamine psychosis." *Biol Psychiatry* 30(7): 726-30.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.
- Newton, T. F., A. D. Kalechstein, et al. (2004). "Association between quantitative EEG and neurocognition in methamphetamine-dependent volunteers." *Clin Neurophysiol* 115(1): 194-8.
- Newton, T. F., I. A. Cook, et al. (2003). "Quantitative EEG abnormalities in recently abstinent methamphetamine dependent individuals." *Clin Neurophysiol* 114(3): 410-5.
- Nordahl, T. E., R. Salo, et al. (2003). "Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: A review." *J Neuropsychiatry Clin Neurosci* 15(3): 317-25.
- Takaori, S. and K. Tanabe (1965). "Effects of central depressants and stimulants on EEG alterations induced by carotid cooling and warming." *Jpn J Pharmacol* 15(2): 113-30.

### Brain, Electrical Activity in (animals)

- Andretic, R., B. van Swinderen, et al. (2005). "Dopaminergic modulation of arousal in *Drosophila*." *Curr Biol* 15(13): 1165-75.
- Ban, T. (1968). "Effects of pyretic drugs on spontaneous EEGs in rabbits with the chronically implanted electrodes." *Acta Sch Med Univ Kioto* 40(2): 172-93.
- Binienda, Z., J. A. Sandberg, et al. (1996). "Alterations in electroencephalographic signals and monoamine concentrations in the rat brain following cocaine and methamphetamine treatment." *Ann N Y Acad Sci* 801: 394-400.
- Bo, P., E. Marchioni, et al. (1991). "Antagonism of EEGraphic and behavioural effects of methamphetamine by selective receptor blockers (SCH 23390 and raclopride) in the rabbit." *Prog Neuropsychopharmacol Biol Psychiatry* 15(6): 803-15.
- Bo, P., A. Giorgetti, et al. (1990). "EEG and behavioural effects of polyamines (spermine and spermidine) on rabbits." *Pharmacol Res* 22(4): 481-91.
- Consroe, P., B. Jones, et al. (1976). "EEG and behavioral effects of delta9-tetrahydrocannabinol in combination with stimulant drugs in rabbits." *Psychopharmacology (Berl)* 50(1): 47-52.
- Consroe, P. F., B. C. Jones, et al. (1975). "Delta9-tetrahydrocannabinol methamphetamine interaction in the rabbit." *Neuropharmacology* 14(5-6): 377-83.
- Consroe, P. F. and R. P. White (1972). "Effects of haloperidol and chlorpromazine on central adrenergic and cholinergic mechanisms in rabbits." *Arch Int Pharmacodyn Ther* 198(1): 67-75.
- Dringenberg, H. C., P. Servos, et al. (1992). "Pressure on the snout immobilizes the spontaneously active, scopolaminized, and amphetaminized hyperactive rat." *Behav Brain Res* 50(1-2): 197-9.
- Edgar, D. M. and W. F. Seidel (1997). "Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat." *J Pharmacol Exp Ther* 283(2): 757-69.
- Ellinwood, E. H., Jr., A. Sudilovsky, et al. (1974). "Behavior and EEG analysis of chronic amphetamine effect." *Biol Psychiatry* 8(2): 169-76.
- Ellinwood, E. H., Jr., A. Sudilovsky, et al. (1973). "Olfactory forebrain seizures induced by methamphetamine and disulfiram." *Biol Psychiatry* 7(2): 89-99.
- Ellinwood, E. H., Jr., A. Sudilovsky, et al. (1972). "Behavioral analysis of chronic amphetamine intoxication." *Biol Psychiatry* 4(3): 215-30.
- Estabrooke, I. V., M. T. McCarthy, et al. (2001). "Fos expression in orexin neurons varies with behavioral state." *J Neurosci* 21(5): 1656-62.
- Fujimori, M. and H. E. Himwich (1969). "Electroencephalographic analyses of amphetamine and its methoxy derivatives with reference to their sites of EEG alerting in the rabbit brain." *Int J Neuropharmacol* 8(6): 601-13.
- Gogolak, G., G. Liebeswar, et al. (1969). "Differential action of eserine and methamphetamine on the limbic system." *Arch Int Pharmacodyn Ther* 178(1): 77-84.
- Ishikawa, T. (1963). "[On the effect of addiction and tolerance observed from brain waves in animals, with special reference to continuous administration of morphine and methamphetamine.]." *Nippon Yakurigaku Zasshi* 59: 187-205.
- Ishiyama, J. (1969). "[Analysis of psychotropic drugs on the recruitments of the hippocampus and amygdala]." *Nippon Yakurigaku Zasshi* 65(5): 466-89.
- Jodo, E., Y. Suzuki, et al. (2003). "Different effects of phencyclidine and methamphetamine on firing activity of medial prefrontal cortex neurons in freely moving rats." *Brain Res* 962(1-2): 226-31.
- John, E. R., P. Walker, et al. (1972). "Mathematical identification of brain states applied to classification of drugs." *Int Rev Neurobiol* 15: 273-347.
- Knoll, J., E. S. Vizi, et al. (1970). "Pharmacological studies on para-bromo-methamphetamine (V-111) and LSD." *Acta Physiol Acad Sci Hung* 37(1): 151-70.
- Kopell, B. S., W. K. Wittner, et al. (1974). "The effects of methamphetamine and secobarbital on the contingent negative variation amplitude." *Psychopharmacologia* 34(1): 55-62.
- Kuno, K. (1969). "[Electrophysiological analysis of the effects of physostigmine and methamphetamine on the thalamo-cortical response]." *Nippon Yakurigaku Zasshi* 65(6): 565-85.
- Liebeswar, G., G. Gogolak, et al. (1968). "[Effect of eserine and methylamphetamine on the electrical activity of the hippocampus]." *Naunyn Schmiedebergs Arch Exp Pathol Pharmacol* 260(2): 169-70.
- Ma, J. and L. S. Leung (2000). "Relation between hippocampal gamma waves and behavioral disturbances induced by phencyclidine and methamphetamine." *Behav Brain Res* 111(1-2): 1-11.
- Malitz, S. and M. Kanzler (1970). "Effects of drugs on perception in man." *Res Publ Assoc Res Nerv Ment Dis* 48: 35-53.
- Minabe, Y., K. Emori, et al. (1988). "Effects of chronic treatment of methamphetamine and imipramine on amygdaloid seizure's generation." *Jpn J Psychiatry Neurol* 42(2): 337-43.

- Minabe, Y., Y. Tani, et al. (1987). "Acute effect of some psychotropic drugs on low-frequency amygdaloid kindled seizures." *Biol Psychiatry* 22(12): 1444-50.
- Miura, Y., T. Ito, et al. (1985). "Acute EEG changes in rats by brainstem ischemia and its dopaminergic involvement." *Jpn J Pharmacol* 39(4): 443-51.
- Nakagawa, T., K. Ukai, et al. (2000). "Effect of dopaminergic drugs on the reserpine-induced lowering of hippocampal theta wave frequency in rats." *Nihon Shinkei Seishin Yakurigaku Zasshi* 20(2): 71-6.
- Nordahl, T. E., R. Salo, et al. (2003). "Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: A review." *J Neuropsychiatry Clin Neurosci* 15(3): 317-25.
- Plotnikoff, N. and G. M. Everett (1965). "Potentiation of evoked cortical responses in the rabbit by methamphetamine and antidepressants." *Life Sci* 4(11): 1135-47.
- Ruch-Monachon, M. A., M. Jalfre, et al. (1976). "Drugs and PGO waves in the lateral geniculate body of the curarized cat. V. Miscellaneous compounds. Synopsis of the role of central neurotransmitters on PGO wave activity." *Arch Int Pharmacodyn Ther* 219(2): 326-46.
- Sato, M. (1979). "[An experimental study of onset and relapse mechanisms of the chronic methamphetamine psychosis (author's transl)]." *Seishin Shinkeigaku Zasshi* 81(1): 21-32.
- Steffensen, S. C., R. S. Lee, et al. (2002). "A novel electroencephalographic analysis method discriminates alcohol effects from those of other sedative/hypnotics." *J Neurosci Methods* 115(2): 145-56.
- Takigawa, M., H. Wang, K. Hamada, T. Shiratani and K. Takenouchi (2000). "Directed coherence of EEG on ICSS rats with methamphetamine-induced hyperactivity and stereotyped behavior." *Ann N Y Acad Sci* 914: 311-5.
- Wallach, M. B., W. D. Winters, et al. (1969). "A correlation of EEG, reticular multiple unit activity and gross behavior following various antidepressant agents in the cat. IV." *Electroencephalogr Clin Neurophysiol* 27(6): 563-73.
- Wang, H. D., M. Takigawa, et al. (2002). "A shift in information flow between prefrontal cortex and the ventral tegmental area in methamphetamine-sensitized rats." *Int J Psychophysiol* 44(3): 251-9.
- Wang, H. D., M. Takigawa, et al. (2000). "Reciprocal information flow between prefrontal cortex and ventral tegmental area in an animal model of schizophrenia." *Neuroreport* 11(9): 2007-11.
- Wenzel, J. and M. Muller (1972). "[Effect of methamphetamine on photic evoked potentials of the rat visual cortex]." *Acta Biol Med Ger* 29(3): 463-5.
- White, R. P., H. H. Sewell, Jr., et al. (1965). "Drug-induced dissociation between evoked reticular potentials and the EEG." *Electroencephalogr Clin Neurophysiol* 19: 16-24.
- Wisor, J. P., S. Nishino, et al. (2001). "Dopaminergic role in stimulant-induced wakefulness." *J Neurosci* 21(5): 1787-94.
- Yamaguchi, N., H. Yoshimoto, et al. (1982). "The influence of psychotropic drugs on the animal EEG: Electrophysiological analysis of the effects of psychotropic drugs." *Electroencephalogr Clin Neurophysiol Suppl* 36: 566-76.
- Yamamoto, J. (1998). "Relationship between hippocampal theta-wave frequency and emotional behaviors in rabbits produced with stresses or psychotropic drugs." *Jpn J Pharmacol* 76(1): 125-7.
- Yamamoto, J. (1997). "Cortical and hippocampal EEG power spectra in animal models of schizophrenia produced with methamphetamine, cocaine, and phencyclidine." *Psychopharmacology (Berl)* 131(4): 379-87.
- Yasar, S., J. P. Goldberg, et al. (1996). "Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research." *J Neural Transm Suppl* 48: 61-73.
- Yoshimura, K. and K. Yamamoto (1980). "[Neuropharmacological studies on drug dependence (II). Changes in spontaneous motor activity, EEG and brain monoamines during the period of dependence development and of abrupt withdrawal in rats, with special reference to circadian rhythm (author's transl)]." *Nippon Yakurigaku Zasshi* 76(5): 373-411.

## Brain, Glucose Metabolism in

- Baxter, L. R., Jr., J. M. Schwartz, et al. (1988). "Localization of neurochemical effects of cocaine and other stimulants in the human brain." *J Clin Psychiatry* 49 Suppl: 23-6.
- Goldstein, R. Z., N. D. Volkow, et al. (2002). "The orbitofrontal cortex in methamphetamine addiction: Involvement in fear." *Neuroreport* 13(17): 2253-7.
- Gouzoulis-Mayfrank, E. and J. Daumann (2006). "The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview." *J Psychopharmacol* 20(2): 188-93.
- Gouzoulis-Mayfrank, E., M. Schreckenberger, et al. (1999). "Neurometabolic effects of psilocybin, 3,4-methylenedioxylethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG." *Neuropsychopharmacology* 20(6): 565-81.
- Kim, S. J., I. K. Lyoo, et al. (2005). "Frontal glucose hypometabolism in abstinent methamphetamine users." *Neuropsychopharmacology* 30(7): 1383-91.

- London, E. D., S. M. Berman, et al. (2005). "Cerebral metabolic dysfunction and impaired vigilance in recently abstinent methamphetamine abusers." *Biol Psychiatry* 58(10): 770-8.
- London, E. D., S. L. Simon, et al. (2004). "Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers." *Arch Gen Psychiatry* 61(1): 73-84.
- Peterfy, G., E. J. Pinter, et al. (1976). "Psychosomatic aspects of catecholamine depletion: Comparative studies of metabolic, endocrine and affective changes." *Psychoneuroendocrinology* 1(3): 243-53.
- Smith, L. M., L. Chang, et al. (2001). "Brain proton magnetic resonance spectroscopy in children exposed to methamphetamine in utero." *Neurology* 57(2): 255-60.
- Volkow, N. D., L. Chang, et al. (2001). "Low level of brain dopamine D2 receptors in methamphetamine abusers: Association with metabolism in the orbitofrontal cortex." *Am J Psychiatry* 158(12): 2015-21.
- Volkow, N. D., L. Chang, et al. (2001). "Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers." *Am J Psychiatry* 158(3): 383-9.
- Volkow, N. D., L. Chang, et al. (2001). "Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex." *Am J Psychiatry* 158(12): 2015-21.
- Voytek, B., S. M. Berman, et al. (2005). "Differences in regional brain metabolism associated with marijuana abuse in methamphetamine abusers." *Synapse* 57(2): 113-5.
- Wang, G. J., N. D. Volkow, et al. (2004). "Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence." *Am J Psychiatry* 161(2): 242-8.

### Brain, Glucose Metabolism in (animals)

- Chan, P., D. A. Di Monte, et al. (1994). "Rapid ATP loss caused by methamphetamine in the mouse striatum: Relationship between energy impairment and dopaminergic neurotoxicity." *J Neurochem* 62(6): 2484-7.
- Dickerson, T. J., N. Yamamoto, et al. (2004). "Immunological consequences of methamphetamine protein glycation." *J Am Chem Soc* 126(37): 11446-7.
- Ellison, G. (2002). "Neural degeneration following chronic stimulant abuse reveals a weak link in brain, fasciculus retroflexus, implying the loss of forebrain control circuitry." *Eur Neuropsychopharmacol* 12(4): 287-97.
- Estler, C. J. and H. P. Ammon (1971). "Modification by two beta-adrenergic blocking drugs of the effects of methamphetamine on behaviour and brain metabolism of mice." *J Neurochem* 18(5): 777-9.
- Estler, C. J. and P. Mitznegg (1971). "Influence of methamphetamine on incorporation of glucose into brain glycogen." *Biochem Pharmacol* 20(6): 1331-3.
- Gomita, Y., Y. Ichimaru, et al. (1990). "Effects of methamphetamine on regional cerebral glucose utilization in rats with unilateral lesion of substantia nigra." *Jpn J Pharmacol* 53(3): 414-8.
- Hamamura, M., S. Watanabe, et al. (2004). "Selective changes in the shapes of parasagittal bands of Aldoc (Zebrin) mRNA in the rat vermis of the cerebellum after repeated methamphetamine injections." *Cerebellum* 3(4): 236-47.
- Huang, Y. H., S. J. Tsai, et al. (1999). "Effects of repeated high-dose methamphetamine on local cerebral glucose utilization in rats." *Neuropsychopharmacology* 21(3): 427-34.
- Manning, D. H., R. H. Strang, et al. (1974). "Changes in cerebral carbohydrate metabolism in the rat after acute and chronic treatment with, and withdrawal of, methamphetamine." *Biochem Pharmacol* 23(7): 1205-9.
- McMahon, E. M., J. M. Feldman, et al. (1975). "Further studies of methamphetamine-induced insulin release." *Toxicol Appl Pharmacol* 32(1): 62-72.
- McMahon, E. M., D. K. Andersen, et al. (1971). "Methamphetamine-induced insulin release." *Science* 174(4): 66-8.
- Pontieri, F. E., A. M. Crane, et al. (1990). "Metabolic mapping of the effects of intravenous methamphetamine administration in freely moving rats." *Psychopharmacology (Berl)* 102(2): 175-82.
- Wakayama, A., K. Kataoka, et al. (1993). "Evaluation of masked neurological disorders in the chronic stage after middle cerebral artery occlusion in rats--methamphetamine-induced rotation and regional glucose metabolism in basal ganglia." *Neurol Med Chir (Tokyo)* 33(12): 801-8.

### Brain, Hepatitis C and

- Cherner, M., S. Letendre, et al. (2005). "Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine." *Neurology* 64(8): 1343-7.
- Letendre, S. L., M. Cherner, et al. (2005). "The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: Biological correlates of disease." *AIDS* 19 Suppl 3: S72-8.

- Taylor, M. J., S. L. Letendre, et al. (2004). "Hepatitis C virus infection is associated with reduced white matter N-acetylaspartate in abstinent methamphetamine users." *J Int Neuropsychol Soc* 10(1): 110-3.
- van Gorp, W. G. and C. H. Hinkin (2005). "Triple trouble: Cognitive deficits from hepatitis C, HIV, and methamphetamine." *Neurology* 64(8): 1328-9.

## Brain, HIV and

- Carey, C. L., S. P. Woods, et al. (2006). "Additive deleterious effects of methamphetamine dependence and immunosuppression on neuropsychological functioning in HIV infection." *AIDS Behav* 10(2): 185-90.
- Chana, G., I. P. Everall, et al. (2006). "Cognitive deficits and degeneration of interneurons in HIV+ methamphetamine users." *Neurology* 67(8): 1486-9.
- Everall, I. P., L. A. Hansen, et al. (2005). "The shifting patterns of HIV encephalitis neuropathology." *Neurotox Res* 8(1-2): 51-61.
- Everall, I., S. Salaria, et al. (2005). "Methamphetamine stimulates interferon inducible genes in HIV infected brain." *J Neuroimmunol* 170(1-2): 158-71.
- Gadd, C. (2005). "Crystal meth use worsens HIV-related brain damage." *IAPAC Mon* 11(4): 109.
- Jernigan, T. L., A. C. Gamst, et al. (2005). "Effects of methamphetamine dependence and HIV infection on cerebral morphology." *Am J Psychiatry* 162(8): 1461-72.
- Jones, K. (2005). "Methamphetamine, the brain, HIV, and mental health." *Focus* 20(6): 1-5.
- Langford, D., A. Adame, et al. (2003). "Patterns of selective neuronal damage in methamphetamine-user AIDS patients." *J Acquir Immune Defic Syndr* 34(5): 467-74.
- Nath, A., K. F. Hauser, et al. (2002). "Molecular basis for interactions of HIV and drugs of abuse." *J Acquir Immune Defic Syndr* 31 Suppl 2: S62-9.
- Nath, A., W. F. Maragos, et al. (2001). "Acceleration of HIV dementia with methamphetamine and cocaine." *J Neurovirol* 7(1): 66-71.
- Nath, A., C. Anderson, et al. (2000). "Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia." *J Psychopharmacol* 14(3): 222-7.
- van Gorp, W. G. and C. H. Hinkin (2005). "Triple trouble: Cognitive deficits from hepatitis C, HIV, and methamphetamine." *Neurology* 64(8): 1328-9.

## Brain, HIV and (animal models)

- Cloak, C. C., L. Chang, et al. (2004). "Methamphetamine and AIDS: IHMRS studies in a feline model of human disease." *J Neuroimmunol* 147(1-2): 16-20.
- Flora, G., Y. W. Lee, A. Nath, B. Hennig, W. Maragos and M. Toborek (2003). "Methamphetamine potentiates HIV-1 tat protein-mediated activation of redox-sensitive pathways in discrete regions of the brain." *Exp Neurol* 179(1): 60-70.
- Maragos, W. F., K. L. Young, et al. (2002). "Human immunodeficiency virus-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function." *J Neurochem* 83(4): 955-63.
- Theodore, S., S. Stolberg, et al. (2006). "Human immunodeficiency virus-1 protein tat and methamphetamine interactions." *Ann N Y Acad Sci* 1074: 178-90.
- Theodore, S., W. A. Cass, et al. (2006). "Inhibition of tumor necrosis factor-alpha signaling prevents human immunodeficiency virus-1 protein Tat and methamphetamine interaction." *Neurobiol Dis* 23(3): 663-8.
- Theodore, S., W. A. Cass, et al. (2006). "Involvement of cytokines in human immunodeficiency virus-1 protein Tat and methamphetamine interactions in the striatum." *Exp Neurol* 199(2): 490-8.
- Theodore, S., W. A. Cass, et al. (2006). "Methamphetamine and human immunodeficiency virus protein Tat synergize to destroy dopaminergic terminals in the rat striatum." *Neuroscience* 137(3): 925-35.

## Brain, Lipids in

- Fitzmaurice, P. S., J. Tong, et al. (2006). "Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of methamphetamine." *J Pharmacol Exp Ther* 319(2): 703-9.
- Hayashi, T. and T. P. Su (2005). "The potential role of sigma-1 receptors in lipid transport and lipid raft reconstitution in the brain: Implication for drug abuse." *Life Sci* 77(14): 1612-24.
- Ross, B. M., A. Moszczynska, et al. (2002). "Decreased activity of brain phospholipid metabolic enzymes in human users of cocaine and methamphetamine." *Drug Alcohol Depend* 67(1): 73-9.

### Brain, Lipids in (animals)

- Acikgoz, O., S. Gonenc, et al. (2000). "The effects of single dose of methamphetamine on lipid peroxidation levels in the rat striatum and prefrontal cortex." *Eur Neuropsychopharmacol* 10(5): 415-8.
- Acikgoz, O., S. Gonenc, et al. (1998). "Methamphetamine causes lipid peroxidation and an increase in superoxide dismutase activity in the rat striatum." *Brain Res* 813(1): 200-2.
- Flora, G., Y. W. Lee, et al. (2002). "Methamphetamine-induced TNF-alpha gene expression and activation of AP-1 in discrete regions of mouse brain: Potential role of reactive oxygen intermediates and lipid peroxidation." *Neuromolecular Med* 2(1): 71-85.
- Gluck, M. R., L. Y. Moy, et al. (2001). "Parallel increases in lipid and protein oxidative markers in several mouse brain regions after methamphetamine treatment." *J Neurochem* 79(1): 152-60.
- Park, M. J., S. K. Lee, et al. (2006). "Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity." *Brain Res* 1109(1): 176-82.
- Sodesaki, K. and R. Matoba (1991). "[Changes in lipid peroxides in methamphetamine treated rats]." *Nihon Hoigaku Zasshi* 45(4): 318-22.
- Vajragupta, O., P. Boonchoong, et al. (2003). "Manganese-based complexes of radical scavengers as neuroprotective agents." *Bioorg Med Chem* 11(10): 2329-37.
- Vajragupta, O., O. Monthakantirat, et al. (2000). "Chroman amide 12P inhibition of lipid peroxidation and protection against learning and memory impairment." *Life Sci* 67(14): 1725-34.
- Virmani, A., F. Gaetani, et al. (2005). "Effects of metabolic modifiers such as carnitines, coenzyme Q10, and PUFAs against different forms of neurotoxic insults: Metabolic inhibitors, MPTP, and methamphetamine." *Ann N Y Acad Sci* 1053: 183-91.
- Wells, P. G., Y. Bhuller, et al. (2005). "Molecular and biochemical mechanisms in teratogenesis involving reactive oxygen species." *Toxicol Appl Pharmacol* 207(2 Suppl): 354-66.
- Yamamoto, B. K. and W. Zhu (1998). "The effects of methamphetamine on the production of free radicals and oxidative stress." *J Pharmacol Exp Ther* 287(1): 107-14.

### Brain, Neuroadaptations in

*See Neurological Development and Adaptations; Neurological Development and Adaptations (animals)*

### Brain, Neurotoxicity in

*See Neurotoxicity; Neurotoxicity (animals)*

### Brain, Phospholipids in

- Ross, B. M., A. Moszczynska, et al. (2002). "Decreased activity of brain phospholipid metabolic enzymes in human users of cocaine and methamphetamine." *Drug Alcohol Depend* 67(1): 73-9.

### Brain, Protein Expression in

- Kobayashi, H., H. Hata, et al. (2006). "Association analysis of delta-opioid receptor gene polymorphisms in methamphetamine dependence/psychosis." *Am J Med Genet B Neuropsychiatr Genet* 141(5): 482-6.
- Liu, H. C., S. K. Lin, et al. (2004). "DAT polymorphism and diverse clinical manifestations in methamphetamine abusers." *Psychiatr Genet* 14(1): 33-7.
- Saito, A., Y. Fujikura-Ouchi, et al. (2007). "Association study of putative promoter polymorphisms in the neuroplastin gene and schizophrenia." *Neurosci Lett* 411(3): 168-73.

### Brain, Protein Expression in (animals)

- Akiyama, K. and J. Suemaru (2000). "Effect of acute and chronic administration of methamphetamine on calcium-calmodulin dependent protein kinase II activity in the rat brain." *Ann N Y Acad Sci* 914: 263-74.
- Brown, J. M., S. Gouty, et al. (2006). "Differential protection against MPTP or methamphetamine toxicity in dopamine neurons by deletion of ppN/OFQ expression." *J Neurochem* 98(2): 495-505.
- Cai, N. S., M. T. McCoy, et al. (2006). "Serial analysis of gene expression in the rat striatum following methamphetamine administration." *Ann N Y Acad Sci* 1074: 13-30.
- Cormaci, G., T. Mori, et al. (2007). "Protein kinase A activation down-regulates, whereas extracellular signal-regulated kinase activation up-regulates {sigma}-1 receptors in B-104 cells: Implication for neuroplasticity." *J Pharmacol Exp Ther* 320(1): 202-10.



- Ferrucci, M., C. L. Busceti, et al. (2006). "Effects of methamphetamine on the cerebellar cortex: A preliminary study." *Ann N Y Acad Sci* 1074: 149-53.
- Horner, K. A., S. C. Westwood, et al. (2006). "Multiple high doses of methamphetamine increase the number of preproneuropeptide Y mRNA-expressing neurons in the striatum of rat via a dopamine D1 receptor-dependent mechanism." *J Pharmacol Exp Ther* 319(1): 414-21.
- Ishihara, T., K. Akiyama, et al. (1996). "Activator protein-1 binding activities in discrete regions of rat brain after acute and chronic administration of methamphetamine." *J Neurochem* 67(2): 708-16.
- Ishikawa, K., A. Nitta, et al. (2006). "Effects of single and repeated administration of methamphetamine or morphine on neuroglycan C gene expression in the rat brain." *Int J Neuropsychopharmacol* 9(4): 407-15.
- Iwazaki, T., I. S. McGregor, et al. (2006). "Protein expression profile in the striatum of acute methamphetamine-treated rats." *Brain Res* 1097(1): 19-25.
- Jayanthi, S., X. Deng, et al. (2005). "Calcineurin/NFAT-induced up-regulation of the Fas ligand/Fas death pathway is involved in methamphetamine-induced neuronal apoptosis." *Proc Natl Acad Sci U S A* 102(3): 868-73.
- Kanthasamy, A., V. Anantharam, et al. (2006). "Methamphetamine induces autophagy and apoptosis in a mesencephalic dopaminergic neuronal culture model: role of cathepsin-D in methamphetamine-induced apoptotic cell death." *Ann N Y Acad Sci* 1074: 234-44.
- Kuo, Y. M., K. C. Liang, et al. (2007). "Cocaine-but not methamphetamine-associated memory requires de novo protein synthesis." *Neurobiol Learn Mem* 87(1): 93-100.
- Mauceli, G., C. I. Busceti, et al. (2006). "Overexpression of alpha-synuclein following methamphetamine: Is it good or bad?" *Ann N Y Acad Sci* 1074: 191-7.
- Morio, A., H. Ujike, et al. (2006). "No association between CART (cocaine- and amphetamine-regulated transcript) gene and methamphetamine dependence." *Ann N Y Acad Sci* 1074: 411-7.
- Straiko, M. M., L. M. Coolen, et al. (2007). "The effect of amphetamine analogs on cleaved microtubule-associated protein-tau formation in the rat brain." *Neuroscience* 144(1): 223-31.
- Suzuki, T., K. Mizuo, et al. (2003). "Prenatal and neonatal exposure to bisphenol-A enhances the central dopamine D1 receptor-mediated action in mice: enhancement of the methamphetamine-induced abuse state." *Neuroscience* 117(3): 639-44.
- Wallace, T. L., C. V. Vorhees, et al. (2003). "Methamphetamine enhances the cleavage of the cytoskeletal protein tau in the rat brain." *Neuroscience* 116(4): 1063-8.
- Yamada, K., T. Nagai, et al. (2005). "Drug dependence, synaptic plasticity, and tissue plasminogen activator." *J Pharmacol Sci* 97(2): 157-61.
- Zhang, X., T. H. Lee, et al. (2006). "Methamphetamine induces long-term changes in GABAA receptor alpha2 subunit and GAD67 expression." *Biochem Biophys Res Commun* 351(1): 300-5.

## Brain, Seizures in

*See* Seizures; Seizures (animals)

## Brain Hemorrhages and Strokes

- Ago, M., K. Ago, et al. (2006). "Toxicological and histopathological analysis of a patient who died nine days after a single intravenous dose of methamphetamine: A case report." *Leg Med (Tokyo)* 8(4): 235-9.
- Berankova, K., V. Habrdova, et al. (2005). "Methamphetamine in hair and interpretation of forensic findings in a fatal case." *Forensic Sci Int* 153(1): 93-7.
- Catanzarite, V. A. and D. A. Stein (1995). "'Crystal' and pregnancy--methamphetamine-associated maternal deaths." *West J Med* 162(5): 454-7.
- Davis, G. G. and C. I. Swalwell (1996). "The incidence of acute cocaine or methamphetamine intoxication in deaths due to ruptured cerebral (berry) aneurysms." *J Forensic Sci* 41(4): 626-8.
- Davis, G. G. and C. I. Swalwell (1994). "Acute aortic dissections and ruptured berry aneurysms associated with methamphetamine abuse." *J Forensic Sci* 39(6): 1481-5.
- Delaney, P. and M. Estes (1980). "Intracranial hemorrhage with amphetamine abuse." *Neurology* 30(10): 1125-8.
- Ellis, K. L. and J. Speed (1998). "Pharmacologic management of movement disorder after midbrain haemorrhage." *Brain Inj* 12(7): 623-8.
- Imanishi, M., T. Sakai, et al. (1997). "[Cerebral infarction due to bacterial emboli associated with methamphetamine abuse]." *No To Shinkei* 49(6): 537-40.

- Inamasu, J., Y. Nakamura, et al. (2003). "Subcortical hemorrhage caused by methamphetamine abuse: Efficacy of the triage system in the differential diagnosis--case report." *Neurol Med Chir (Tokyo)* 43(2): 82-4.
- Jimenez-Caballero, P. E. (2006). "[Medullary infarct due to methamphetamine]." *Rev Neurol* 42(10): 635-7.
- Johnson, B. A., L. T. Wells, et al. (2005). "Isradipine decreases the hemodynamic response of cocaine and methamphetamine results from two human laboratory studies: Results from two human laboratory studies." *Am J Hypertens* 18(6): 813-22.
- Karch, S. B., B. G. Stephens, et al. (1999). "Methamphetamine-related deaths in San Francisco: Demographic, pathologic, and toxicologic profiles." *J Forensic Sci* 44(2): 359-68.
- McGee, S. M., D. N. McGee, et al. (2004). "Spontaneous intracerebral hemorrhage related to methamphetamine abuse: Autopsy findings and clinical correlation." *Am J Forensic Med Pathol* 25(4): 334-7.
- Miller, M. A. and T. P. Coon (2006). "Re: Delayed ischemic stroke associated with methamphetamine use." *J Emerg Med* 31(3): 305-6; author reply 306.
- Moriya, F. and Y. Hashimoto (2002). "A case of fatal hemorrhage in the cerebral ventricles following intravenous use of methamphetamine." *Forensic Sci Int* 129(2): 104-9.
- Ogasawara, K., A. Ogawa, et al. (1986). "[Intracerebral hemorrhage and characteristic angiographic changes associated with methamphetamine--a case report]." *No To Shinkei* 38(10): 967-71.
- Ohta, K., M. Mori, et al. (2005). "Delayed ischemic stroke associated with methamphetamine use." *J Emerg Med* 28(2): 165-7.
- Patel, A. N. (1972). "Self-inflicted strokes." *Ann Intern Med* 76(5): 823-4.
- Perez, J. A., Jr., E. L. Arsur, et al. (1999). "Methamphetamine-related stroke: Four cases." *J Emerg Med* 17(3): 469-71.
- Rothrock, J. F., R. Rubenstein, et al. (1988). "Ischemic stroke associated with methamphetamine inhalation." *Neurology* 38(4): 589-92.
- Sachdeva, K. and K. G. Woodward (1989). "Caudal thalamic infarction following intranasal methamphetamine use." *Neurology* 39(2 Pt 1): 305-6.
- Shibata, S., K. Mori, et al. (1991). "Subarachnoid and intracerebral hemorrhage associated with necrotizing angitis due to methamphetamine abuse--an autopsy case." *Neurol Med Chir (Tokyo)* 31(1): 49-52.
- Shibata, S., K. Mori, et al. (1988). "[An autopsy case of subarachnoid and intracerebral hemorrhage and necrotizing angitis associated with methamphetamine abuse]." *No To Shinkei* 40(11): 1089-94.
- Weiss, S. R., R. Raskind, et al. (1970). "Intracerebral and subarachnoid hemorrhage following use of methamphetamine ("speed")." *Int Surg* 53(2): 123-7.
- Yarnell, P. R. (1977). "'Speed': headache and hematoma." *Headache* 17(2): 69-70.
- Yen, D. J., S. J. Wang, et al. (1994). "Stroke associated with methamphetamine inhalation." *Eur Neurol* 34(1): 16-22.
- Yu, Y. J., D. R. Cooper, et al. (1983). "Cerebral angitis and intracerebral hemorrhage associated with methamphetamine abuse. Case report." *J Neurosurg* 58(1): 109-11.
- Zhu, B. L., S. Oritani, et al. (2000). "Methamphetamine-related fatalities in forensic autopsy during 5 years in the southern half of Osaka city and surrounding areas." *Forensic Sci Int* 113(1-3): 443-7.

### Brain Hemorrhages and Strokes (animals)

- Abraimi, J. H., H. N. David, et al. (2005). "Potentially neuroprotective and therapeutic properties of nitrous oxide and xenon." *Ann N Y Acad Sci* 1053: 289-300.
- Imamura, N., H. Hida, et al. (2003). "Neurodegeneration of substantia nigra accompanied with macrophage/microglia infiltration after intrastriatal hemorrhage." *Neurosci Res* 46(3): 289-98.
- Imanishi, M., T. Sakai, et al. (1997). "[Cerebral infarction due to bacterial emboli associated with methamphetamine abuse]." *No To Shinkei* 49(6): 537-40.
- Ishibashi, S., T. Kuroiwa, et al. (2004). "Extrapyramidal motor symptoms versus striatal infarction volume after focal ischemia in mongolian gerbils." *Neuroscience* 127(2): 269-75.
- Miura, Y., T. Ito, et al. (1985). "Acute EEG changes in rats by brainstem ischemia and its dopaminergic involvement." *Jpn J Pharmacol* 39(4): 443-51.
- Nalls, G., A. Disher, et al. (1989). "Subcortical cerebral hemorrhages associated with cocaine abuse: CT and MR findings." *J Comput Assist Tomogr* 13(1): 1-5.
- Rumbaugh, C. L., H. C. Fang, et al. (1976). "Cerebral microvascular injury in experimental drug abuse." *Invest Radiol* 11(4): 282-94.
- Rumbaugh, C. L., R. T. Bergeron, et al. (1971). "Cerebral vascular changes secondary to amphetamine abuse in the experimental animal." *Radiology* 101(2): 345-51.
- Wang, Y., T. Hayashi, et al. (2001). "Methamphetamine potentiates ischemia/reperfusion insults after transient middle cerebral artery ligation." *Stroke* 32(3): 775-82.

Wang, A. M., J. N. Suojanen, et al. (1990). "Cocaine- and methamphetamine-induced acute cerebral vasospasm: An angiographic study in rabbits." *AJNR Am J Neuroradiol* 11(6): 1141-6.

## Brain Imaging

- Bae, S. C., I. K. Lyoo, et al. (2006). "Increased white matter hyperintensities in male methamphetamine abusers." *Drug Alcohol Depend* 81(1): 83-8.
- Bagorda, F., G. Teuchert-Noodt, et al. (2006). "Isolation rearing or methamphetamine traumatization induce a "dysconnection" of prefrontal efferents in gerbils: Implications for schizophrenia." *J Neural Transm* 113(3): 365-79.
- Barr, A. M., W. J. Panenka, et al. (2006). "The need for speed: An update on methamphetamine addiction." *J Psychiatry Neurosci* 31(5): 301-313.
- Baxter, L. R., Jr., J. M. Schwartz, et al. (1988). "Localization of neurochemical effects of cocaine and other stimulants in the human brain." *J Clin Psychiatry* 49 Suppl: 23-6.
- Buffenstein, A., J. Heaster, et al. (1999). "Chronic psychotic illness from methamphetamine." *Am J Psychiatry* 156(4): 662.
- Chang, L. and W. Haning (2006). "Insights from recent positron emission tomographic studies of drug abuse and dependence." *Curr Opin Psychiatry* 19(3): 246-252.
- Chang, L., T. Ernst, et al. (2005). "Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities." *Am J Psychiatry* 162(2): 361-9.
- Chang, L., C. Cloak, et al. (2005). "Enlarged striatum in abstinent methamphetamine abusers: A possible compensatory response." *Biol Psychiatry* 57(9): 967-74.
- Chang, L., L. M. Smith, et al. (2004). "Smaller subcortical volumes and cognitive deficits in children with prenatal methamphetamine exposure." *Psychiatry Res* 132(2): 95-106.
- Chang, L., T. Ernst, et al. (2002). "Perfusion MRI and computerized cognitive test abnormalities in abstinent methamphetamine users." *Psychiatry Res* 114(2): 65-79.
- Chou, Y. H., W. S. Huang, et al. (2007). "Dopamine transporters and cognitive function in methamphetamine abuser after a short abstinence: A SPECT study." *Eur Neuropsychopharmacol* 17(1): 46-52.
- Chung, A., I. K. Lyoo, et al. (2006). "Decreased frontal white-matter integrity in abstinent methamphetamine abusers." *Int J Neuropsychopharmacol*: 1-11.
- Cumming, P., F. Yokoi, et al. (1999). "Pharmacokinetics of radiotracers in human plasma during positron emission tomography." *Synapse* 34(2): 124-34.
- Ellis, K. L. and J. Speed (1998). "Pharmacologic management of movement disorder after midbrain haemorrhage." *Brain Inj* 12(7): 623-8.
- Ernst, T., L. Chang, et al. (2000). "Evidence for long-term neurotoxicity associated with methamphetamine abuse: A 1H MRS study." *Neurology* 54(6): 1344-9.
- Fantegrossi, W. E., W. L. Woolverton, et al. (2004). "Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys." *Neuropsychopharmacology* 29(7): 1270-81.
- Gadd, C. (2005). "Crystal meth use worsens HIV-related brain damage." *IAPAC Mon* 11(4): 109.
- Gillings, N. M., A. D. Gee, et al. (1999). "The synthesis of (R)- and (S)-[N-methyl-11C]beta, beta-difluoromethamphetamine for the investigation of the binding mechanism of biogenic amines in vivo." *Appl Radiat Isot* 50(4): 707-14.
- Goldstein, R. Z., N. D. Volkow, et al. (2002). "The orbitofrontal cortex in methamphetamine addiction: Involvement in fear." *Neuroreport* 13(17): 2253-7.
- Gouzoulis-Mayfrank, E. and J. Daumann (2006). "The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview." *J Psychopharmacol* 20(2): 188-93.
- Gouzoulis-Mayfrank, E., M. Schreckenberger, et al. (1999). "Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDA) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG." *Neuropsychopharmacology* 20(6): 565-81.
- Harano, M., N. Uchimura, et al. (2004). "A polymorphism of DRD2 gene and brain atrophy in methamphetamine psychosis." *Ann N Y Acad Sci* 1025: 307-15.
- Harvey, D. C., G. Lacan, et al. (2000). "Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss." *Brain Res* 871(2): 259-70.
- Hwang, J., I. K. Lyoo, et al. (2006). "Decreased cerebral blood flow of the right anterior cingulate cortex in long-term and short-term abstinent methamphetamine users." *Drug Alcohol Depend* 82(2): 177-81.
- Iyo, M., Y. Sekine, et al. (2004). "Neuromechanism of developing methamphetamine psychosis: A neuroimaging study." *Ann N Y Acad Sci* 1025: 288-95.

- Iyo, M. and Y. Sekine (2003). "[Stimulants related mental disorders]." *Ryoikibetsu Shokogun Shirizu*(40): 507-12.
- Iyo, M., H. Namba, et al. (1997). "Abnormal cerebral perfusion in chronic methamphetamine abusers: a study using 99mTc-HMPAO and SPECT." *Prog Neuropsychopharmacol Biol Psychiatry* 21(5): 789-96.
- Iyo, M., M. Nishio, et al. (1993). "Dopamine D2 and serotonin S2 receptors in susceptibility to methamphetamine psychosis detected by positron emission tomography." *Psychiatry Res* 50(4): 217-31.
- Iyo, M. (1992). "PET dopamine D2 receptors and susceptibility to methamphetamine psychosis." *Clin Neuropharmacol* 15 Suppl 1 Pt A: 652A-653A.
- Jernigan, T. L., A. C. Gamst, et al. (2005). "Effects of methamphetamine dependence and HIV infection on cerebral morphology." *Am J Psychiatry* 162(8): 1461-72.
- Jimenez-Caballero, P. E. (2006). "[Medullary infarct due to methamphetamine]." *Rev Neurol* 42(10): 635-7.
- Johanson, C. E., K. A. Frey, et al. (2006). "Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers." *Psychopharmacology (Berl)* 186(4): 620.
- Johanson, C. E., K. A. Frey, et al. (2006). "Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers." *Psychopharmacology (Berl)* 185(3): 327-38.
- Kim, S. J., I. K. Lyoo, et al. (2006). "Prefrontal grey-matter changes in short-term and long-term abstinent methamphetamine abusers." *Int J Neuropsychopharmacol* 9(2): 221-8.
- Kim, S. J., I. K. Lyoo, et al. (2005). "Frontal glucose hypometabolism in abstinent methamphetamine users." *Neuropsychopharmacology* 30(7): 1383-91.
- Kleinschmidt, A., H. Bruhn, et al. (1999). "Effects of sedation, stimulation, and placebo on cerebral blood oxygenation: A magnetic resonance neuroimaging study of psychotropic drug action." *NMR Biomed* 12(5): 286-92.
- Leeds, N. E., V. Malhotra, et al. (1983). "The radiology of drug addiction affecting the brain." *Semin Roentgenol* 18(3): 227-33.
- London, E. D., S. M. Berman, et al. (2005). "Cerebral metabolic dysfunction and impaired vigilance in recently abstinent methamphetamine abusers." *Biol Psychiatry* 58(10): 770-8.
- London, E. D., S. L. Simon, et al. (2004). "Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers." *Arch Gen Psychiatry* 61(1): 73-84.
- McCann, U. D., D. F. Wong, et al. (1998). "Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: Evidence from positron emission tomography studies with [11C]WIN-35,428." *J Neurosci* 18(20): 8417-22.
- Monterosso, J. R., G. Ainslie, et al. (2006). "Frontoparietal cortical activity of methamphetamine-dependent and comparison subjects performing a delay discounting task." *Hum Brain Mapp*.
- Munro, C. A., M. E. McCaul, et al. (2006). "Sex differences in striatal dopamine release in healthy adults." *Biol Psychiatry* 59(10): 966-74.
- Nalls, G., A. Disher, et al. (1989). "Subcortical cerebral hemorrhages associated with cocaine abuse: CT and MR findings." *J Comput Assist Tomogr* 13(1): 1-5.
- Nath, A., W. F. Maragos, et al. (2001). "Acceleration of HIV dementia with methamphetamine and cocaine." *J Neurovirol* 7(1): 66-71.
- Nordahl, T. E., R. Salo, et al. (2005). "Methamphetamine users in sustained abstinence: A proton magnetic resonance spectroscopy study." *Arch Gen Psychiatry* 62(4): 444-52.
- Nordahl, T. E., R. Salo, et al. (2003). "Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: A review." *J Neuropsychiatry Clin Neurosci* 15(3): 317-25.
- Nordahl, T. E., R. Salo, et al. (2002). "Low N-acetyl-aspartate and high choline in the anterior cingulum of recently abstinent methamphetamine-dependent subjects: A preliminary proton MRS study. Magnetic resonance spectroscopy." *Psychiatry Res* 116(1-2): 43-52.
- Oh, J. S., I. K. Lyoo, et al. (2005). "Shape changes of the corpus callosum in abstinent methamphetamine users." *Neurosci Lett* 384(1-2): 76-81.
- Paulus, M. P., S. F. Tapert, et al. (2005). "Neural activation patterns of methamphetamine-dependent subjects during decision making predict relapse." *Arch Gen Psychiatry* 62(7): 761-8.
- Paulus, M. P., N. Hozack, et al. (2003). "Decision making by methamphetamine-dependent subjects is associated with error-rate-independent decrease in prefrontal and parietal activation." *Biol Psychiatry* 53(1): 65-74.
- Paulus, M. P., N. E. Hozack, et al. (2002). "Behavioral and functional neuroimaging evidence for prefrontal dysfunction in methamphetamine-dependent subjects." *Neuropsychopharmacology* 26(1): 53-63.
- Piccini, P., N. Pavese, et al. (2005). "Factors affecting the clinical outcome after neural transplantation in Parkinson's disease." *Brain* 128(Pt 12): 2977-86.
- Piccini, P., N. Pavese, et al. (2003). "Endogenous dopamine release after pharmacological challenges in Parkinson's disease." *Ann Neurol* 53(5): 647-53.

- Piccini, P., D. J. Brooks, et al. (1999). "Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient." *Nat Neurosci* 2(12): 1137-40.
- Prince, J. A. and L. Oreland (1998). "Mitochondrial activity in the mapping of functional brain changes in schizophrenia." *Restor Neurol Neurosci* 12(2-3): 185-93.
- Rumbaugh, C. L., H. C. Fang, et al. (1980). "Cerebral CT findings in drug abuse: clinical and experimental observations." *J Comput Assist Tomogr* 4(3): 330-4.
- Sachdeva, K. and K. G. Woodward (1989). "Caudal thalamic infarction following intranasal methamphetamine use." *Neurology* 39(2 Pt 1): 305-6.
- Salo, R., T. E. Nordahl, et al. (2006). "Attentional control and brain metabolite levels in methamphetamine abusers." *Biol Psychiatry*.
- Sekine, Y., Y. Ouchi, et al. (2006). "Brain serotonin transporter density and aggression in abstinent methamphetamine abusers." *Arch Gen Psychiatry* 63(1): 90-100.
- Sekine, Y., Y. Minabe, et al. (2003). "Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms." *Am J Psychiatry* 160(9): 1699-701.
- Sekine, Y., Y. Minabe, et al. (2002). "Metabolite alterations in basal ganglia associated with methamphetamine-related psychiatric symptoms. A proton MRS study." *Neuropsychopharmacology* 27(3): 453-61.
- Sekine, Y., M. Iyo, et al. (2001). "Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET." *Am J Psychiatry* 158(8): 1206-14.
- Shibata, S., K. Mori, et al. (1991). "Subarachnoid and intracerebral hemorrhage associated with necrotizing angitis due to methamphetamine abuse--an autopsy case." *Neurol Med Chir (Tokyo)* 31(1): 49-52.
- Shibata, S., K. Mori, et al. (1988). "[An autopsy case of subarachnoid and intracerebral hemorrhage and necrotizing angitis associated with methamphetamine abuse]." *No To Shinkei* 40(11): 1089-94.
- Shimazono, Y. and E. Matsushima (1995). "Behavioral and neuroimaging studies on schizophrenia in Japan." *Psychiatry Clin Neurosci* 49(1): 3-11.
- Smith, L. M., L. Chang, et al. (2001). "Brain proton magnetic resonance spectroscopy in children exposed to methamphetamine in utero." *Neurology* 57(2): 255-60.
- Sung, Y. H., S. C. Cho, et al. (2006). "Relationship between N-acetyl-aspartate in gray and white matter of abstinent methamphetamine abusers and their history of drug abuse: A proton magnetic resonance spectroscopy study." *Drug Alcohol Depend*.
- Taylor, M. J., S. L. Letendre, et al. (2004). "Hepatitis C virus infection is associated with reduced white matter N-acetylaspartate in abstinent methamphetamine users." *J Int Neuropsychol Soc* 10(1): 110-3.
- Thompson, P. M., K. M. Hayashi, et al. (2004). "Structural abnormalities in the brains of human subjects who use methamphetamine." *J Neurosci* 24(26): 6028-36.
- Volkow, N. D., J. S. Fowler and G. J. Wang (2002). "Role of dopamine in drug reinforcement and addiction in humans: Results from imaging studies." *Behav Pharmacol* 13(5-6): 355-66.
- Volkow, N. D., L. Chang, et al. (2001). "Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers." *Am J Psychiatry* 158(3): 377-82.
- Volkow, N. D., L. Chang, et al. (2001). "Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence." *J Neurosci* 21(23): 9414-8.
- Volkow, N. D., L. Chang, et al. (2001). "Low level of brain dopamine D2 receptors in methamphetamine abusers: Association with metabolism in the orbitofrontal cortex." *Am J Psychiatry* 158(12): 2015-21.
- Volkow, N. D., L. Chang, et al. (2001). "Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers." *Am J Psychiatry* 158(3): 383-9.
- Vollm, B. A., I. E. de Araujo, et al. (2004). "Methamphetamine activates reward circuitry in drug naive human subjects." *Neuropsychopharmacology* 29(9): 1715-22.
- Voytek, B., S. M. Berman, et al. (2005). "Differences in regional brain metabolism associated with marijuana abuse in methamphetamine abusers." *Synapse* 57(2): 113-5.
- Wang, G. J., N. D. Volkow, et al. (2004). "Similarity between obesity and drug addiction as assessed by neurofunctional imaging: a concept review." *J Addict Dis* 23(3): 39-53.
- Wang, G. J., N. D. Volkow, et al. (2004). "Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence." *Am J Psychiatry* 161(2): 242-8.
- Wang, G. J., N. D. Volkow, et al. (2004). "Similarity between obesity and drug addiction as assessed by neurofunctional imaging: A concept review." *J Addict Dis* 23(3): 39-53.
- Watanabe, T. and K. Yanai (2001). "Studies on functional roles of the histaminergic neuron system by using pharmacological agents, knockout mice and positron emission tomography." *Tohoku J Exp Med* 195(4): 197-217.

Weissman, B. A., R. Brandeis, et al. (2004). "Monitoring drug-induced neurodegeneration by imaging of peripheral benzodiazepine receptors." *Ann N Y Acad Sci* 1025: 584-9.

Yen, D. J., S. J. Wang, et al. (1994). "Stroke associated with methamphetamine inhalation." *Eur Neurol* 34(1): 16-22.

### Brain Imaging (animals)

Adams, D. H., G. R. Hanson, et al. (2000). "Cocaine and methamphetamine differentially affect opioid peptide mRNA expression in the striatum." *J Neurochem* 75(5): 2061-70.

Armstrong, B. D. and K. K. Noguchi (2004). "The neurotoxic effects of 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine on serotonin, dopamine, and GABA-ergic terminals: an in-vitro autoradiographic study in rats." *Neurotoxicology* 25(6): 905-14.

Angulo, J. A., N. Angulo, et al. (2004). "Antagonists of the neurokinin-1 or dopamine D1 receptors confer protection from methamphetamine on dopamine terminals of the mouse striatum." *Ann N Y Acad Sci* 1025: 171-80.

Baumann, M. H., J. M. Phillips, et al. (2002). "Preclinical evaluation of GBR12909 decanoate as a long-acting medication for methamphetamine dependence." *Ann N Y Acad Sci* 965: 92-108.

Belcher, A. M., S. J. O'Dell, et al. (2005). "Impaired object recognition memory following methamphetamine, but not p-chloroamphetamine- or d-amphetamine-induced neurotoxicity." *Neuropsychopharmacology* 30(11): 2026-34.

Brunswick, D. J., S. Benmansour, et al. (1992). "Effects of high-dose methamphetamine on monoamine uptake sites in rat brain measured by quantitative autoradiography." *Synapse* 11(4): 287-93.

Castel, M. N., P. Morino, et al. (1994). "Up-regulation of neurotensin mRNA in the rat striatum after acute methamphetamine treatment." *Eur J Neurosci* 6(4): 646-56.

Castel, M. N., P. Morino, et al. (1993). "Modulation of the neurotensin striato-nigral pathway by D1 receptors." *Neuroreport* 5(3): 281-4.

Cloak, C. C., L. Chang, et al. (2004). "Methamphetamine and AIDS: IHMS studies in a feline model of human disease." *J Neuroimmunol* 147(1-2): 16-20.

D'Astous, M., T. M. Gajjar, et al. (2004). "Dopamine transporter as a marker of neuroprotection in methamphetamine-lesioned mice treated acutely with estradiol." *Neuroendocrinology* 79(6): 296-304.

Doudet, D. J. and J. E. Holden (2003). "Raclopride studies of dopamine release: Dependence on presynaptic integrity." *Biol Psychiatry* 54(11): 1193-9.

Doudet, D. J. and J. E. Holden (2003). "Sequential versus nonsequential measurement of density and affinity of dopamine d2 receptors with [<sup>11</sup>C]raclopride: Effect of methamphetamine." *J Cereb Blood Flow Metab* 23(12): 1489-94.

Eisch, A. J., S. J. O'Dell, et al. (1996). "Striatal and cortical NMDA receptors are altered by a neurotoxic regimen of methamphetamine." *Synapse* 22(3): 217-25.

Fantegrossi, W. E., W. L. Woolverton, et al. (2004). "Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys." *Neuropsychopharmacology* 29(7): 1270-81.

Fornai, F., P. Lenzi, et al. (2006). "Fine ultrastructure and biochemistry of PC12 cells: A comparative approach to understand neurotoxicity." *Brain Res*.

Fowler, J. S., A. P. Wolf, et al. (1988). "Mechanistic positron emission tomography studies: Demonstration of a deuterium isotope effect in the monoamine oxidase-catalyzed binding of [<sup>11</sup>C]L-deprenyl in living baboon brain." *J Neurochem* 51(5): 1524-34.

Frey, K., M. Kilbourn, et al. (1997). "Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine." *Eur J Pharmacol* 334(2-3): 273-9.

Gifford, A. N., M. H. Park, et al. (2000). "Effect of amphetamine-induced dopamine release on radiotracer binding to D1 and D2 receptors in rat brain striatal slices." *Naunyn Schmiedebergs Arch Pharmacol* 362(4-5): 413-8.

Gomes-da-Silva, J., A. Perez-Rosado, et al. (2000). "Neonatal methamphetamine in the rat: Evidence for gender-specific differences upon tyrosine hydroxylase enzyme in the dopaminergic nigrostriatal system." *Ann N Y Acad Sci* 914: 431-8.

Gomita, Y., Y. Ichimaru, et al. (1990). "Effects of methamphetamine on regional cerebral glucose utilization in rats with unilateral lesion of substantia nigra." *Jpn J Pharmacol* 53(3): 414-8.

Hamamura, M., S. Watanabe, et al. (2004). "Selective changes in the shapes of parasagittal bands of Aldoc (Zebirin) mRNA in the rat vermis of the cerebellum after repeated methamphetamine injections." *Cerebellum* 3(4): 236-47.

Harvey, D. C., G. Lacan, et al. (2000). "Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss." *Brain Res* 871(2): 259-70.

Hashimoto, K., H. Tsukada, et al. (2006). "Protective effects of minocycline on the reduction of dopamine transporters in the striatum after administration of methamphetamine: A positron emission tomography study in conscious monkeys." *Biol Psychiatry*.

Hashimoto, K., H. Tsukada, et al. (2004). "Effects of N-acetyl-L-cysteine on the reduction of brain dopamine transporters in monkey treated with methamphetamine." *Ann N Y Acad Sci* 1025: 231-5.

- Hashimoto, K., H. Tsukada, S. Nishiyama, D. Fukumoto, T. Kakiuchi, E. Shimizu and M. Iyo (2004). "Effects of N-acetyl-L-cysteine on the reduction of brain dopamine transporters in monkey treated with methamphetamine." *Ann N Y Acad Sci* 1025: 231-5.
- Hashimoto, K., H. Tsukada, et al. (2004). "Protective effects of N-acetyl-L-cysteine on the reduction of dopamine transporters in the striatum of monkeys treated with methamphetamine." *Neuropsychopharmacology* 29(11): 2018-23.
- Hashitani, T., K. Mizukawa, et al. (1998). "Dopamine metabolism in the striatum of hemiparkinsonian model rats with dopaminergic grafts." *Neurosci Res* 30(1): 43-52.
- Hess, U. S., S. P. Whalen, et al. (2003). "Ampakines reduce methamphetamine-driven rotation and activate neocortex in a regionally selective fashion." *Neuroscience* 121(2): 509-21.
- Hirata, H., M. Asanuma, et al. (1998). "Melatonin attenuates methamphetamine-induced toxic effects on dopamine and serotonin terminals in mouse brain." *Synapse* 30(2): 150-5.
- Hirata, H. and J. L. Cadet (1997). "p53-knockout mice are protected against the long-term effects of methamphetamine on dopaminergic terminals and cell bodies." *J Neurochem* 69(2): 780-90.
- Hirata, H., B. Ladenheim, et al. (1996). "Autoradiographic evidence for methamphetamine-induced striatal dopaminergic loss in mouse brain: Attenuation in CuZn-superoxide dismutase transgenic mice." *Brain Res* 714(1-2): 95-103.
- Hirata, H., B. Ladenheim, et al. (1995). "Methamphetamine-induced serotonin neurotoxicity is mediated by superoxide radicals." *Brain Res* 677(2): 345-7.
- Huang, Y. H., S. J. Tsai, et al. (1999). "Effects of repeated high-dose methamphetamine on local cerebral glucose utilization in rats." *Neuropsychopharmacology* 21(3): 427-34.
- Inaji, M., T. Okauchi, et al. (2005). "Correlation between quantitative imaging and behavior in unilaterally 6-OHDA-lesioned rats." *Brain Res* 1064(1-2): 136-45.
- Inaji, M., T. Yoshizaki, et al. (2005). "In vivo PET measurements with [11C]PE2I to evaluate fetal mesencephalic transplantations to unilateral 6-OHDA-lesioned rats." *Cell Transplant* 14(9): 655-63.
- Inamasu, J., Y. Nakamura, et al. (2003). "Subcortical hemorrhage caused by methamphetamine abuse: Efficacy of the triage system in the differential diagnosis--case report." *Neurol Med Chir (Tokyo)* 43(2): 82-4.
- Inoue, O., S. Axelsson, et al. (1990). "Effect of reserpine on the brain uptake of carbon 11 methamphetamine and its N-propargyl derivative, deprenyl." *Eur J Nucl Med* 17(3-4): 121-6.
- Ishida, Y., K. Kawai, et al. (2005). "Alteration of striatal [11C]raclopride and 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine uptake precedes development of methamphetamine-induced rotation following unilateral 6-hydroxydopamine lesions of medial forebrain bundle in rats." *Neurosci Lett* 389(1): 30-4.
- Kanzaki, A., K. Akiyama, et al. (1992). "Subchronic methamphetamine treatment enhances ouabain-induced striatal dopamine efflux in vivo." *Brain Res* 569(2): 181-8.
- Klongpanichapak, S., P. Govitrapong, et al. (2006). "Attenuation of cocaine and methamphetamine neurotoxicity by coenzyme Q10." *Neurochem Res* 31(3): 303-11.
- Kondoh, T., M. Bannai, et al. (2005). "6-Hydroxydopamine-induced lesions in a rat model of hemi-Parkinson's disease monitored by magnetic resonance imaging." *Exp Neurol* 192(1): 194-202.
- Kovachich, G. B., C. E. Aronson, et al. (1989). "Effects of high-dose methamphetamine administration on serotonin uptake sites in rat brain measured using [3H]cyanoimipramine autoradiography." *Brain Res* 505(1): 123-9.
- Kurachi, M. (2003). "Pathogenesis of schizophrenia: Part II. Temporo-frontal two-step hypothesis." *Psychiatry Clin Neurosci* 57(1): 9-15.
- Mach, R. H., M. A. Nader, et al. (1997). "Use of positron emission tomography to study the dynamics of psychostimulant-induced dopamine release." *Pharmacol Biochem Behav* 57(3): 477-86.
- Mathis, C. A., Y. Shulgin, et al. (1986). "18F-labelled N,N-dimethylamphetamine analogues for brain imaging studies." *Int J Rad Appl Instrum [A]* 37(8): 865-72.
- McCabe, R. T., J. W. Gibb, et al. (1987). "Autoradiographic analysis of muscarinic cholinergic and serotonergic receptor alterations following methamphetamine treatment." *Brain Res Bull* 19(5): 551-7.
- McCabe, R. T., G. R. Hanson, et al. (1987). "Methamphetamine-induced reduction in D1 and D2 dopamine receptors as evidenced by autoradiography: comparison with tyrosine hydroxylase activity." *Neuroscience* 23(1): 253-61.
- Melega, W. P., G. Lacan, et al. (2000). "Long-term methamphetamine-induced decreases of [(11)C]WIN 35,428 binding in striatum are reduced by GDNF: PET studies in the vervet monkey." *Synapse* 35(4): 243-9.
- Melega, W. P., G. Lacan, et al. (1998). "Dizocilpine and reduced body temperature do not prevent methamphetamine-induced neurotoxicity in the vervet monkey: [11C]WIN 35,428 - positron emission tomography studies." *Neurosci Lett* 258(1): 17-20.
- Melega, W. P., M. J. Raleigh, et al. (1997). "Recovery of striatal dopamine function after acute amphetamine- and methamphetamine-induced neurotoxicity in the vervet monkey." *Brain Res* 766(1-2): 113-20.

- Mizugaki, M., N. Nakagawa, et al. (2001). "Influence of anesthesia on brain distribution of [(11)C]methamphetamine in monkeys in positron emission tomography (PET) study." *Brain Res* 911(2): 173-5.
- Mizugaki, M. (1996). "[Alterations in brain distribution of methamphetamine in methamphetamine-sensitized animals]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 16(5): 187-91.
- Mizugaki, M., H. Nakamura, et al. (1995). "Positron emission tomography (PET) study of the alterations in brain distribution of [11C]methamphetamine in methamphetamine sensitized dog." *Nucl Med Biol* 22(6): 803-7.
- Mizugaki, M., T. Hishinuma, et al. (1993). "Distribution of carbon-11 labeled methamphetamine and the effect of its chronic administration in mice." *Nucl Med Biol* 20(4): 487-92.
- Munro, C. A., M. E. McCaul, et al. (2006). "Sex differences in striatal dopamine release in healthy adults." *Biol Psychiatry* 59(10): 966-74.
- Nakamura, H. (2001). "[Positron emission tomography (PET) study of the alterations in brain pharmacokinetics of methamphetamine in methamphetamine sensitized animals]." *Yakugaku Zasshi* 121(8): 585-91.
- Nakamura, H., T. Hishinuma, et al. (1997). "Effects of haloperidol and cocaine pretreatments on brain distribution and kinetics of [11C]methamphetamine in methamphetamine sensitized dog: application of PET to drug pharmacokinetic study." *Nucl Med Biol* 24(2): 165-9.
- Nakamura, H., T. Hishinuma, et al. (1996). "Positron emission tomography study of the alterations in brain distribution of [11C]methamphetamine in methamphetamine-sensitized dog." *Ann N Y Acad Sci* 801: 401-8.
- Neto, P. R. (2005). "Activation of striatal dopamine receptors by psychostimulants: Chemical anatomy, autonomic and behavioural effects." *Dan Med Bull* 52(3): 114.
- Nonaka, R. and T. Moroji (1990). "Effects of chronic methamphetamine treatment on the binding parameters of [3H]SCH 23390, a selective D1-dopamine receptor ligand, in the rat brain." *Neurosci Lett* 120(1): 109-12.
- O'Dell, S. J., F. B. Weihmuller, et al. (1994). "Excitotoxic striatal lesions protect against subsequent methamphetamine-induced dopamine depletions." *J Pharmacol Exp Ther* 269(3): 1319-25.
- Pontieri, F. E., A. M. Crane, et al. (1990). "Metabolic mapping of the effects of intravenous methamphetamine administration in freely moving rats." *Psychopharmacology (Berl)* 102(2): 175-82.
- Prince, J. A., M. S. Yassin, et al. (1997). "Normalization of cytochrome-c oxidase activity in the rat brain by neuroleptics after chronic treatment with PCP or methamphetamine." *Neuropharmacology* 36(11-12): 1665-78.
- Rahmann, H. (1971). "Different modes of substance flow in the optic tract." *Acta Neuropathol (Berl)* 5: Suppl 5:162-70.
- Rahmann, H. and H. Rosner (1970). "[Autoradiography studies on the mechanism of action of methamphetamine upon the teleost CNS]." *Pflugers Arch* 314(1): 86-96.
- Rumbaugh, C. L., H. C. Fang, et al. (1980). "Cerebral CT findings in drug abuse: Clinical and experimental observations." *J Comput Assist Tomogr* 4(3): 330-4.
- Sato, S., T. Chiba, et al. (2006). "Decline of striatal dopamine release in parkin-deficient mice shown by ex vivo autoradiography." *J Neurosci Res* 84(6): 1350-7.
- Shiue, C. Y., G. G. Shiue, et al. (1995). "Comparative PET studies of the distribution of (-)-3,4-methylenedioxy-N-[11C]methamphetamine and (-)-[11C]methamphetamine in a monkey brain." *Nucl Med Biol* 22(3): 321-4.
- Shiue, C. Y., G. G. Shiue, et al. (1993). "Fluorine-18 and carbon-11 labeled amphetamine analogs--synthesis, distribution, binding characteristics in mice and rats and a PET study in monkey." *Nucl Med Biol* 20(8): 973-81.
- Sirinathsinghji, D. J., S. B. Dunnett, et al. (1990). "Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway--III. Reversal by embryonic nigral dopamine grafts." *Neuroscience* 37(3): 757-66.
- Spina, M. G., G. Grecksch, et al. (2000). "Microtubule-associated protein 2 (MAP2) and c-fos expression in the rat prefrontal cortex following subchronic treatment with substituted amphetamines." *Ann N Y Acad Sci* 914: 65-70.
- Stefanski, R., S. H. Lee, et al. (2002). "Lack of persistent changes in the dopaminergic system of rats withdrawn from methamphetamine self-administration." *Eur J Pharmacol* 439(1-3): 59-68.
- Stefanski, R., B. Ladenheim, et al. (1999). "Neuroadaptations in the dopaminergic system after active self-administration but not after passive administration of methamphetamine." *Eur J Pharmacol* 371(2-3): 123-35.
- Suzuki, T., T. Moroji, et al. (1993). "Autoradiographic localization of CCK-8 binding sites in the rat brain: effects of chronic methamphetamine administration on these sites." *Biol Psychiatry* 34(11): 781-90.
- Suzuki, T. and T. Moroji (1989). "Cholecystokinin binding sites in the rat forebrain: Effects of acute and chronic methamphetamine administration." *J Neural Transm* 77(2-3): 181-95.
- Takaki, M., H. Ujike, et al. (2001). "Two kinds of mitogen-activated protein kinase phosphatases, MKP-1 and MKP-3, are differentially activated by acute and chronic methamphetamine treatment in the rat brain." *J Neurochem* 79(3): 679-88.



- Tien, L. T., I. K. Ho, et al. (2006). "Role of mu-opioid receptor in modulation of preproenkephalin mRNA expression and opioid and dopamine receptor binding in methamphetamine-sensitized mice." *J Neurosci Res*.
- Triarhou, L. C., E. H. Stotz, et al. (1994). "Studies on the striatal dopamine uptake system of weaver mutant mice and effects of ventral mesencephalic grafts." *Neurochem Res* 19(11): 1349-58.
- Tsukada, H., K. Miyasato, et al. (2002). "Comparative effects of methamphetamine and nicotine on the striatal [(11)C]raclopride binding in unanesthetized monkeys." *Synapse* 45(4): 207-12.
- Tsukada, H., N. Harada, et al. (2001). "Facilitation of dopaminergic neural transmission does not affect [(11)C]SCH23390 binding to the striatal D(1) dopamine receptors, but the facilitation enhances phosphodiesterase type-IV activity through D(1) receptors: PET studies in the conscious monkey brain." *Synapse* 42(4): 258-65.
- Tsukada, H., S. Nishiyama, et al. (1999). "Is synaptic dopamine concentration the exclusive factor which alters the in vivo binding of [(11)C]raclopride? PET studies combined with microdialysis in conscious monkeys." *Brain Res* 841(1-2): 160-9.
- Ujike, H., K. Akiyama, et al. (1991). "Lasting increase in D1 dopamine receptors in the lateral part of the substantia nigra pars reticulata after subchronic methamphetamine administration." *Brain Res* 540(1-2): 159-63.
- Villemagne, V. L., D. F. Wong, et al. (1999). "GBR12909 attenuates amphetamine-induced striatal dopamine release as measured by [(11)C]raclopride continuous infusion PET scans." *Synapse* 33(4): 268-73.
- Villemagne, V., J. Yuan, et al. (1998). "Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [(11)C]WIN-35,428 positron emission tomography studies and direct in vitro determinations." *J Neurosci* 18(1): 419-27.
- Wakayama, A., K. Kataoka, et al. (1993). "Evaluation of masked neurological disorders in the chronic stage after middle cerebral artery occlusion in rats--methamphetamine-induced rotation and regional glucose metabolism in basal ganglia." *Neurol Med Chir (Tokyo)* 33(12): 801-8.
- Watanabe, T. and K. Yanai (2001). "Studies on functional roles of the histaminergic neuron system by using pharmacological agents, knockout mice and positron emission tomography." *Tohoku J Exp Med* 195(4): 197-217.
- Weissman, B. A., R. Brandeis, et al. (2004). "Monitoring drug-induced neurodegeneration by imaging of peripheral benzodiazepine receptors." *Ann N Y Acad Sci* 1025: 584-9.
- Yamagata, K., K. Suzuki, et al. (2000). "Activation of an effector immediate-early gene arc by methamphetamine." *Ann N Y Acad Sci* 914: 22-32.
- Yamaguchi, T., Y. Kuraishi, et al. (1991). "Methamphetamine-induced expression of interleukin-1 beta mRNA in the rat hypothalamus." *Neurosci Lett* 128(1): 90-2.
- Yu, J., J. L. Cadet, et al. (2002). "Neurokinin-1 (NK-1) receptor antagonists abrogate methamphetamine-induced striatal dopaminergic neurotoxicity in the murine brain." *J Neurochem* 83(3): 613-22.
- Yu, J., S. Allison, et al. (2002). "Ontogeny of neurokinin-1 receptor mediation of methamphetamine neurotoxicity in the striatum of the mouse brain." *Ann N Y Acad Sci* 965: 247-53.
- Zhu, J. P., W. Xu, et al. (2005). "Disparity in the temporal appearance of methamphetamine-induced apoptosis and depletion of dopamine terminal markers in the striatum of mice." *Brain Res* 1049(2): 171-81.

## Brazil

Wolffenbittel, E. (1963). "[Use And Abuse Of Pervitin]." *Rev Bras Med* 20: 166.

## British Columbia, Canada

*See Vancouver; Victoria*

## Burma

Ahmad, K. (2003). "Asia grapples with spreading amphetamine abuse." *Lancet* 361(9372): 1878-9.

Suwanwela, C. and V. Poshychinda (1986). "Drug abuse in Asia." *Bull Narc* 38(1-2): 41-53.

## Burn Injuries

Charukamnoetkanok, P. and M. D. Wagoner (2004). "Facial and ocular injuries associated with methamphetamine production accidents." *Am J Ophthalmol* 138(5): 875-6.

Danks, R. R., L. A. Wibbenmeyer, et al. (2004). "Methamphetamine-associated burn injuries: A retrospective analysis." *J Burn Care Rehabil* 25(5): 425-9.

- Lee, J. H., C. L. Farley, et al. (2003). "Anhydrous ammonia eye injuries associated with illicit methamphetamine production." *Ann Emerg Med* 41(1): 157.
- Mitka, M. (2005). "Meth lab fires put heat on burn centers." *JAMA* 294(16): 2009-10.
- Santos, A. P., A. K. Wilson, et al. (2005). "Methamphetamine laboratory explosions: A new and emerging burn injury." *J Burn Care Rehabil* 26(3): 228-32.
- Sheridan, J., S. Bennett, et al. (2006). "Injury associated with methamphetamine use: A review of the literature." *Harm Reduct J* 3(1): 14.
- Spann, M. D., G. McGwin, Jr., et al. (2006). "Characteristics of burn patients injured in methamphetamine laboratory explosions." *J Burn Care Res* 27(4): 496-501.
- Swenson, J. R., J. E. Dimsdale, E. Rockwell, W. Carroll and J. Hansbrough (1991). "Drug and alcohol abuse in patients with acute burn injuries." *Psychosomatics* 32(3): 287-93.
- Wada, K., S. B. Greberman, et al. (1999). "HIV and HCV infection among drug users in Japan." *Addiction* 94(7): 1063-9.
- Warner, P., J. P. Connolly, et al. (2003). "The methamphetamine burn patient." *J Burn Care Rehabil* 24(5): 275-8.

### Caffeine

- Teng, S. F., S. C. Wu, et al. (2006). "Characteristics and trends of 3,4-methylenedioxymethamphetamine (MDMA) tablets found in Taiwan from 2002 to February 2005." *Forensic Sci Int* 161(2-3): 202-8.

### Caffeine (animals)

- Delle Donne, K. T. and P. K. Sonsalla (1994). "Protection against methamphetamine-induced neurotoxicity to neostriatal dopaminergic neurons by adenosine receptor activation." *J Pharmacol Exp Ther* 271(3): 1320-6.
- Hughes, R. N. and A. M. Greig (1976). "Effects of caffeine, methamphetamine and methylphenidate on reactions to novelty and activity in rats." *Neuropharmacology* 15(11): 673-6.
- Mechner, F. and M. Latranyi (1963). "Behavioral effects of caffeine, methamphetamine, and methylphenidate in the rat." *J Exp Anal Behav* 6: 331-42.
- Razzak, A., M. Fujiwara, et al. (1977). "Possible involvement of a central noradrenergic system in automutilation induced by clonidine in mice." *Jpn J Pharmacol* 27(1): 145-52.
- Tuazon, D. B., T. Suzuki, et al. (1992). "Methylxanthines (caffeine and theophylline) blocked methamphetamine-induced conditioned place preference in mice but enhanced that induced by cocaine." *Ann N Y Acad Sci* 654: 531-3.

### California (US)

*See also* Arcata; Berkeley; Fresno; Los Angeles; Riverside; Sacramento; San Diego; San Francisco; San Jose; Santa Cruz

- Anglin, M. D., C. Burke, et al. (2000). "History of the methamphetamine problem." *J Psychoactive Drugs* 32(2): 137-41.
- Anonymous (2006). "Methamphetamine use and HIV risk behaviors among heterosexual men--preliminary results from five northern California counties, December 2001-November 2003." *MMWR Morb Mortal Wkly Rep* 55(10): 273-7.
- Arria, A. M., C. Derauf, et al. (2006). "Methamphetamine and other substance use during pregnancy: Preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study." *Matern Child Health J* 10(3): 293-302.
- Bailey, D. N. and R. F. Shaw (1989). "Cocaine- and methamphetamine-related deaths in San Diego County (1987): Homicides and accidental overdoses." *J Forensic Sci* 34(2): 407-22.
- Bailey, D. N. (1987). "Amphetamine detection during toxicology screening of a university medical center patient population." *J Toxicol Clin Toxicol* 25(5): 399-409.
- Baskin-Sommers, A. and I. Sommers (2006). "The co-occurrence of substance use and high-risk behaviors." *J Adolesc Health* 38(5): 609-11.
- Bailey, D. N. (1987). "Amphetamine detection during toxicology screening of a university medical center patient population." *J Toxicol Clin Toxicol* 25(5): 399-409.
- Baskin-Sommers, A. and I. Sommers (2006). "The co-occurrence of substance use and high-risk behaviors." *J Adolesc Health* 38(5): 609-11.
- Binswanger, I. A., A. H. Kral, et al. (2000). "High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Francisco." *Clin Infect Dis* 30(3): 579-81.
- Bluthenthal, R. N., A. H. Kral, et al. (2001). "Trends in HIV seroprevalence and risk among gay and bisexual men who inject drugs in San Francisco, 1988 to 2000." *J Acquir Immune Defic Syndr* 28(3): 264-9.

- Boddiger, D. (2005). "Methamphetamine use linked to rising HIV transmission." *Lancet* 365(9466): 1217-8.
- Bogart, L. M., A. H. Kral, et al. (2005). "Sexual risk among injection drug users recruited from syringe exchange programs in California." *Sex Transm Dis* 32(1): 27-34.
- Boulard, G. (2005). "The meth menace: Battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.
- Brecht, M. L., L. Greenwell, et al. (2007). "Substance use pathways to methamphetamine use among treated users." *Addict Behav* 32(1): 24-38.
- Brecht, M. L., L. Greenwell, et al. (2005). "Methamphetamine treatment: Trends and predictors of retention and completion in a large state treatment system (1992-2002)." *J Subst Abuse Treat* 29(4): 295-306.
- Brecht, M. L., M. D. Anglin, et al. (2005). "Coerced treatment for methamphetamine abuse: Differential patient characteristics and outcomes." *Am J Drug Alcohol Abuse* 31(2): 337-56.
- Brecht, M. L., A. O'Brien, et al. (2004). "Methamphetamine use behaviors and gender differences." *Addict Behav* 29(1): 89-106.
- Brecht, M. L., C. von Mayrhauser, et al. (2000). "Predictors of relapse after treatment for methamphetamine use." *J Psychoactive Drugs* 32(2): 211-20.
- Brouwer, K. C., P. Case, et al. (2006). "Trends in production, trafficking, and consumption of methamphetamine and cocaine in Mexico." *Subst Use Misuse* 41(5): 707-27.
- Buchacz, K., W. McFarland, et al. (2005). "Amphetamine use is associated with increased HIV incidence among men." *AIDS* 19(13): 1423-24.
- Burgess, J. L., D. F. Kovalchick, et al. (2002). "Medical surveillance of clandestine drug laboratory investigators." *J Occup Environ Med* 44(2): 184-9.
- Caetano, R. and C. Weisner (1995). "The association between DSM-III-R alcohol dependence, psychological distress and drug use." *Addiction* 90(3): 351-9.
- Cartier, J., D. Farabee, et al. (2006). "Methamphetamine use, self-reported violent crime, and recidivism among offenders in California who abuse substances." *J Interpers Violence* 21(4): 435-45.
- Catanzarite, V. A. and D. A. Stein (1995). "'Crystal' and pregnancy--methamphetamine-associated maternal deaths." *West J Med* 162(5): 454-7.
- Chesney, M. A., D. C. Barrett, et al. (1998). "Histories of substance use and risk behavior: Precursors to HIV seroconversion in homosexual men." *Am J Public Health* 88(1): 113-6.
- Choi, K. H., D. Operario, et al. (2005). "Substance use, substance choice, and unprotected anal intercourse among young Asian American and Pacific Islander men who have sex with men." *AIDS Educ Prev* 17(5): 418-29.
- Chu, P. L., W. McFarland, et al. (2003). "Viagra use in a community-recruited sample of men who have sex with men, San Francisco." *J Acquir Immune Defic Syndr* 33(2): 191-3.
- Colfax, G. N., E. Vittinghoff, et al. (2007). "Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance." *AIDS* 21(2): 239-241.
- Colfax, G., T. J. Coates, et al. (2005). "Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of San Francisco men who have sex with men." *J Urban Health* 82(1 Suppl 1): i62-70.
- Copeland, A. L. and J. L. Sorensen (2001). "Differences between methamphetamine users and cocaine users in treatment." *Drug Alcohol Depend* 62(1): 91-5.
- Crosby, G. M., R. D. Stall, et al. (1998). "Alcohol and drug use patterns have declined between generations of younger gay-bisexual men in San Francisco." *Drug Alcohol Depend* 52(3): 177-82.
- Cunningham, J. K. and L. M. Liu (2005). "Impacts of federal precursor chemical regulations on methamphetamine arrests." *Addiction* 100(4): 479-88.
- Davis, F. and L. Munoz (1968). "Heads and freaks: Patterns and meanings of drug use among hippies." *J Health Soc Behav* 9(2): 156-64.
- Demetriades, D., G. Gkiokas, et al. (2004). "Alcohol and illicit drugs in traumatic deaths: Prevalence and association with type and severity of injuries." *J Am Coll Surg* 199(5): 687-92.
- Diaz, R. M., A. L. Heckert, et al. (2005). "Reasons for stimulant use among Latino gay men in San Francisco: a comparison between methamphetamine and cocaine users." *J Urban Health* 82(1 Suppl 1): i71-8.
- Domier, C. P., S. L. Simon, et al. (2000). "A comparison of injecting and noninjecting methamphetamine users." *J Psychoactive Drugs* 32(2): 229-32.
- Drumright, L. N., S. J. Little, et al. (2006). "Unprotected anal intercourse and substance use among men who have sex with men with recent HIV infection." *J Acquir Immune Defic Syndr* 43(3): 344-50.
- Drumright, L. N., S. A. Strathdee, et al. (2006). "Unprotected anal intercourse and substance use before and after HIV diagnosis among recently HIV-infected men who have sex with men." *Sex Transm Dis*.

- Duterte, M., S. O'Neil, et al. (2001). "Walking the tightrope: Balancing health and drug use." *J Psychoactive Drugs* 33(2): 173-83.
- Ellis, R. J., M. E. Childers, et al. (2003). "Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy." *J Infect Dis* 188(12): 1820-6.
- Evans, E. and D. Longshore (2004). "Evaluation of the Substance Abuse and Crime Prevention Act: Treatment clients and program types during the first year of implementation." *J Psychoactive Drugs Suppl*(2): 165-74.
- Farabee, D., M. Prendergast and J. Cartier (2002). "Methamphetamine use and HIV risk among substance-abusing offenders in California." *J Psychoactive Drugs* 34(3): 295-300.
- Freese, T. E., J. Obert, et al. (2000). "Methamphetamine abuse: Issues for special populations." *J Psychoactive Drugs* 32(2): 177-82.
- Frosch, D., S. Shoptaw, et al. (1996). "Sexual HIV risk among gay and bisexual male methamphetamine abusers." *J Subst Abuse Treat* 13(6): 483-6.
- Galloway, G. P., J. Newmeyer, et al. (1996). "A controlled trial of imipramine for the treatment of methamphetamine dependence." *J Subst Abuse Treat* 13(6): 493-7.
- Galloway, G. P., J. Newmeyer, T. Knapp, S. A. Stalcup and D. Smith (1994). "Imipramine for the treatment of cocaine and methamphetamine dependence." *J Addict Dis* 13(4): 201-16.
- Gibson, D. R., M. H. Leamon and N. Flynn (2002). "Epidemiology and public health consequences of methamphetamine use in California's Central Valley." *J Psychoactive Drugs* 34(3): 313-9.
- Gleghorn, A. A., R. Marx, et al. (1998). "Association between drug use patterns and HIV risks among homeless, runaway, and street youth in northern California." *Drug Alcohol Depend* 51(3): 219-27.
- Gonzales, R., P. Marinelli-Casey, et al. (2006). "Hepatitis C virus infection among methamphetamine-dependent individuals in outpatient treatment." *J Subst Abuse Treat* 31(2): 195-202.
- Gonzalez Castro, F., E. H. Barrington, et al. (2000). "Cocaine and methamphetamine: Differential addiction rates." *Psychol Addict Behav* 14(4): 390-6.
- Gorbach, P. M., J. T. Galea, et al. (2004). "Don't ask, don't tell: patterns of HIV disclosure among HIV positive men who have sex with men with recent STI practising high risk behaviour in Los Angeles and Seattle." *Sex Transm Infect* 80(6): 512-7.
- Grella, C. E., Y. I. Hser, et al. (2006). "Mothers in substance abuse treatment: Differences in characteristics based on involvement with child welfare services." *Child Abuse Negl* 30(1): 55-73.
- Greenwell, L. and M. L. Brecht (2003). "Self-reported health status among treated methamphetamine users." *Am J Drug Alcohol Abuse* 29(1): 75-104.
- Greenwood, G. L., E. W. White, et al. (2001). "Correlates of heavy substance use among young gay and bisexual men: The San Francisco Young Men's Health Study." *Drug Alcohol Depend* 61(2): 105-12.
- Gurnack, A. M. and W. Paul (1997). "Factors related to perinatal substance abuse in a California county." *Percept Mot Skills* 84(3 Pt 2): 1403-8.
- Hahn, J. A., K. Page-Shafer, et al. (2001). "Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco." *Hepatology* 34(1): 180-7.
- Halkitis, P. N., L. Wilton, et al. (2005). "Barebacking identity among HIV-positive gay and bisexual men: demographic, psychological, and behavioral correlates." *AIDS* 19: S27-S35.
- Hall, J. A., S. W. Henggeler, et al. (1993). "Adolescent substance use during pregnancy." *J Pediatr Psychol* 18(2): 265-71.
- Harris, D. and S. L. Batki (2000). "Stimulant psychosis: Symptom profile and acute clinical course." *Am J Addict* 9(1): 28-37.
- Heinzerling, K. G., A. H. Kral, et al. (2006). "Unmet need for recommended preventive health services among clients of California syringe exchange programs: Implications for quality improvement." *Drug Alcohol Depend* 81(2): 167-78.
- Helschober, B. and M. A. Miller (1991). "Methamphetamine abuse in California." *NIDA Res Monogr* 115: 60-71.
- Hohman, M., R. Oliver, et al. (2004). "Methamphetamine abuse and manufacture: The child welfare response." *Soc Work* 49(3): 373-81.
- Hornbeck, C. L. and R. J. Czarny (1993). "Retrospective analysis of some L-methamphetamine/L-amphetamine urine data." *J Anal Toxicol* 17(1): 23-5.
- Hser, Y. I., C. Teruya, et al. (2003). "Treating drug-abusing offenders. Initial findings from a five-county study on the impact of California's Proposition 36 on the treatment system and patient outcomes." *Eval Rev* 27(5): 479-505.
- Huber, A., R. H. Lord, et al. (2000). "The CSAT methamphetamine treatment program: Research design accommodations for "real world" application." *J Psychoactive Drugs* 32(2): 149-56.
- Huber, A., W. Ling, et al. (1997). "Integrating treatments for methamphetamine abuse: A psychosocial perspective." *J Addict Dis* 16(4): 41-50.
- Israel, J. A. and K. Lee (2002). "Amphetamine usage and genital self-mutilation." *Addiction* 97(9): 1215-8.
- Karch, S. B., B. G. Stephens, et al. (1999). "Methamphetamine-related deaths in San Francisco: Demographic, pathologic, and toxicologic profiles." *J Forensic Sci* 44(2): 359-68.

- Kipke, M. D., S. O'Connor, et al. (1995). "Street youth in Los Angeles. Profile of a group at high risk for human immunodeficiency virus infection." *Arch Pediatr Adolesc Med* 149(5): 513-9.
- Klausner, J. D., C. K. Kent, et al. (2005). "The public health response to epidemic syphilis, San Francisco, 1999-2004." *Sex Transm Dis* 32(10 supplement): S11-S18.
- Klausner, J. D., D. K. Levine, et al. (2004). "Internet-based site-specific interventions for syphilis prevention among gay and bisexual men." *AIDS Care* 16(8): 964-70.
- Koblin, B. A., M. A. Chesney, et al. (2003). "High-risk behaviors among men who have sex with men in 6 US cities: Baseline data from the EXPLORE Study." *Am J Public Health* 93(6): 926-32.
- Kohrs, F. P., C. Mann and R. Greenberg (2004). "The use of amphetamine in gamma-hydroxybutyrate overdose: A case report." *J Psychoactive Drugs* 36(3): 401-2.
- Hahn, J. A., K. Page-Shafer, P. J. Lum, K. Ochoa and A. R. Moss (2001). "Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco." *Hepatology* 34(1): 180-7.
- Hser, Y. I., E. Evans, et al. (2005). "Treatment outcomes among women and men methamphetamine abusers in California." *J Subst Abuse Treat* 28(1): 77-85.
- Hser, Y. I., C. Teruya, et al. (2003). "Treating drug-abusing offenders. Initial findings from a five-county study on the impact of California's Proposition 36 on the treatment system and patient outcomes." *Eval Rev* 27(5): 479-505.
- Jain, N. C., R. D. Budd, et al. (1979). "Frequency of use or abuse of amphetamine-related drugs." *Am J Drug Alcohol Abuse* 6(1): 53-7.
- Jain, N. C., R. D. Budd, et al. (1978). "A survey of drug use among probationers in the Los Angeles area in 1976." *Int J Addict* 13(8): 1319-25.
- Jain, N. C., R. Budd, et al. (1977). "Patterns of drug use among methadone maintenance patients in Los Angeles county." *Bull Narc* 29(2): 45-53.
- Kalechstein, A. D., T. F. Newton, et al. (2000). "Psychiatric comorbidity of methamphetamine dependence in a forensic sample." *J Neuropsychiatry Clin Neurosci* 12(4): 480-4.
- Kim, A. A., C. K. Kent, et al. (2002). "Increased risk of HIV and sexually transmitted disease transmission among gay or bisexual men who use Viagra, San Francisco 2000-2001." *AIDS* 16(10): 1425-8.
- Kim, J. Y. and M. Fendrich (2002). "Gender differences in juvenile arrestees' drug use, self-reported dependence, and perceived need for treatment." *Psychiatr Serv* 53(1): 70-5.
- Kipke, M. D., S. O'Connor, et al. (1995). "Street youth in Los Angeles. Profile of a group at high risk for human immunodeficiency virus infection." *Arch Pediatr Adolesc Med* 149(5): 513-9.
- Klatt, E. C., S. Montgomery, et al. (1986). "Misrepresentation of stimulant street drugs: A decade of experience in an analysis program." *J Toxicol Clin Toxicol* 24(5): 441-50.
- Klausner, J. D., C. K. Kent, et al. (2005). "The public health response to epidemic syphilis, San Francisco, 1999-2004." *Sex Transm Dis* 32(10 supplement): S11-S18.
- Kral, A. H., J. Lorvick, et al. (2005). "HIV prevalence and risk behaviors among men who have sex with men and inject drugs in San Francisco." *J Urban Health* 82(1 Suppl 1): i43-50.
- Kral, A. H., R. N. Bluthenthal, et al. (2001). "Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: Risk-factor analysis." *Lancet* 357(9266): 1397-401.
- Kral, A. H., J. Lorvick, et al. (2000). "Sex- and drug-related risk among populations of younger and older injection drug users in adjacent neighborhoods in San Francisco." *J Acquir Immune Defic Syndr* 24(2): 162-7.
- Kral, A. H., R. N. Bluthenthal, et al. (1999). "Risk factors among IDUs who give injections to or receive injections from other drug users." *Addiction* 94(5): 675-83.
- Kushel, M. B., J. A. Hahn, et al. (2005). "Revolving doors: Imprisonment among the homeless and marginally housed population." *Am J Public Health* 95(10): 1747-52.
- Larkins, S., C. J. Reback, et al. (2005). "Methamphetamine-dependent gay men's disclosure of their HIV status to sexual partners." *AIDS Care* 17(4): 521-32.
- Levine, A. J., D. J. Hardy, et al. (2006). "The effect of recent stimulant use on sustained attention in HIV-infected adults." *J Clin Exp Neuropsychol* 28(1): 29-42.
- Lorvick, J., A. Martinez, et al. (2006). "Sexual and injection risk among women who inject methamphetamine in San Francisco." *J Urban Health* 83(3): 497-505.
- Lum, P. J., C. Sears, et al. (2005). "Injection risk behavior among women syringe exchangers in San Francisco." *Subst Use Misuse* 40(11): 1681-96.
- Maglione, M., B. Chao, et al. (2000). "Correlates of outpatient drug treatment drop-out among methamphetamine users." *J Psychoactive Drugs* 32(2): 221-8.

- Maglione, M., B. Chao, et al. (1998). "Methamphetamine abuse in California: Correlates of injection use." *AIDS and Behavior* 2(3): 257-261.
- Mansergh, G., R. L. Shouse, et al. (2006). "Methamphetamine and sildenafil (Viagra) use are linked to unprotected receptive and insertive anal sex, respectively, in a sample of men who have sex with men." *Sex Transm Infect* 82(2): 131-4.
- Mansergh, G., G. N. Colfax, et al. (2001). "The Circuit Party Men's Health Survey: Findings and implications for gay and bisexual men." *Am J Public Health* 91(6): 953-8.
- Maxwell, J. C., P. Cravioto, et al. (2006). "Drug use and risk of HIV/AIDS on the Mexico-USA border: A comparison of treatment admissions in both countries." *Drug Alcohol Depend* 82 Suppl 1: S85-93.
- Menza, T. W., G. Colfax, et al. (2006). "Interest in a methamphetamine intervention among men who have sex with men." *Sex Transm Dis* 33(9): 565-70.
- Mitchell, S. J., S. R. Morris, et al. (2006). "Methamphetamine use and sexual activity among HIV-infected patients in care--San Francisco, 2004." *AIDS Patient Care STDS* 20(7): 502-10.
- Molitor, F., J. D. Ruiz, et al. (1999). "Methamphetamine use and sexual and injection risk behaviors among out-of-treatment injection drug users." *Am J Drug Alcohol Abuse* 25(3): 475-93.
- Molitor, F., S. R. Truax, J. D. Ruiz and R. K. Sun (1998). "Association of methamphetamine use during sex with risky sexual behaviors and HIV infection among non-injection drug users." *West J Med* 168(2): 93-7.
- Morin, S. F., W. T. Steward, et al. (2005). "Predicting HIV transmission risk among HIV-infected men who have sex with men: Findings from the Healthy Living Project." *J Acquir Immune Defic Syndr* 40(2): 226-235.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.
- Nalls, G., A. Disher, et al. (1989). "Subcortical cerebral hemorrhages associated with cocaine abuse: CT and MR findings." *J Comput Assist Tomogr* 13(1): 1-5.
- Nemoto, T., D. Operario, et al. (2002). "Risk behaviors of Filipino methamphetamine users in San Francisco: Implications for prevention and treatment of drug use and HIV." *Public Health Rep* 117 Suppl 1: S30-8.
- Newmeyer, J. A. (2003). "Patterns and trends of drug use in the San Francisco Bay Area." *J Psychoactive Drugs* 35(Suppl 1): 127-32.
- Newmeyer, J. A. (1988). "The prevalence of drug use in San Francisco in 1987." *J Psychoactive Drugs* 20(2): 185-9.
- Niv, N. and Y. I. Hser (2006). "Drug treatment service utilization and outcomes for Hispanic and white methamphetamine abusers." *Health Serv Res* 41(4 Pt 1): 1242-57.
- Nyamathi, A. M., E. L. Dixon, et al. (2002). "Risk factors for hepatitis C virus infection among homeless adults." *J Gen Intern Med* 17(2): 134-43.
- Nyamathi, A., W. A. Robbins, et al. (2002). "Presence and predictors of hepatitis C virus RNA in the semen of homeless men." *Biol Res Nurs* 4(1): 22-30.
- Ochoa, K. C., P. J. Davidson, et al. (2005). "Heroin overdose among young injection drug users in San Francisco." *Drug Alcohol Depend* 80(3): 297-302.
- Parsons, J. T. and P. N. Halkitis (2002). "Sexual and drug-using practices of HIV-positive men who frequent public and commercial sex environments." *AIDS Care* 14(6): 815-26.
- Peck, J. A., C. J. Reback, et al. (2005). "Sustained reductions in drug use and depression symptoms from treatment for drug abuse in methamphetamine-dependent gay and bisexual men." *J Urban Health* 82(1 Suppl 1): i100-8.
- Peck, J. A., S. Shoptaw, et al. (2005). "HIV-associated medical, behavioral, and psychiatric characteristics of treatment-seeking, methamphetamine-dependent men who have sex with men." *J Addict Dis* 24(3): 115-32.
- Perez, J. A., Jr., E. L. Arsur, et al. (1999). "Methamphetamine-related stroke: Four cases." *J Emerg Med* 17(3): 469-71.
- Poulsen, E. J., M. J. Mannis, et al. (1996). "Keratitis in methamphetamine abusers." *Cornea* 15(5): 477-82.
- Purcell, D. W., S. Moss, et al. (2005). "Illicit substance use, sexual risk, and HIV-positive gay and bisexual men: Differences by serostatus of casual partners." *AIDS* 19: S37-S47.
- Purcell, D. W., R. J. Wolitski, et al. (2005). "Predictors of the use of viagra, testosterone, and antidepressants among HIV-seropositive gay and bisexual men." *AIDS* 19 Suppl 1: S57-66.
- Purcell, D. W., J. T. Parsons, P. N. Halkitis, Y. Mizuno and W. J. Woods (2001). "Substance use and sexual transmission risk behavior of HIV-positive men who have sex with men." *J Subst Abuse* 13(1-2): 185-200.
- Rawson, R. A., R. Gonzales, et al. (2005). "Methamphetamine use among treatment-seeking adolescents in Southern California: Participant characteristics and treatment response." *J Subst Abuse Treat* 29(2): 67-74.
- Rawson, R. A., P. Marinelli-Casey, et al. (2004). "A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence." *Addiction* 99(6): 708-17.
- Rawson, R. A., A. Huber, et al. (2002). "Status of methamphetamine users 2-5 years after outpatient treatment." *J Addict Dis* 21(1): 107-19.

- Reiber, C., G. Galloway, et al. (2000). "A descriptive analysis of participant characteristics and patterns of substance use in the CSAT methamphetamine treatment project: the first six months." *J Psychoactive Drugs* 32(2): 183-91.
- Richards, J. R. and B. T. Brofeldt (2000). "Patterns of tooth wear associated with methamphetamine use." *J Periodontol* 71(8): 1371-4.
- Richards, J. R., S. W. Bretz, et al. (1999). "Methamphetamine abuse and emergency department utilization." *West J Med* 170(4): 198-202.
- Robinson, L. and H. Rempel (2006). "Methamphetamine use and HIV symptom self-management." *J Assoc Nurses AIDS Care* 17(5): 7-14.
- Rose, V. J., H. F. Raymond, et al. (2006). "Assessing the feasibility of harm reduction services for MSM: The late night breakfast buffet study." *Harm Reduct J* 3: 29.
- Schermer, C. R. and D. H. Wisner (1999). "Methamphetamine use in trauma patients: A population-based study." *J Am Coll Surg* 189(5): 442-9.
- Sears, C., J. R. Gudyish, et al. (2001). "Investigation of a secondary syringe exchange program for homeless young adult injection drug users in San Francisco, California, U.S.A." *J Acquir Immune Defic Syndr* 27(2): 193-201.
- Semple, S. J., J. Zians, et al. (2006). "Sexual compulsivity in a sample of HIV-positive methamphetamine-using gay and bisexual men." *AIDS Behav* 10(5): 587-98.
- Semple, S. J., J. Zians, et al. (2006). "Methamphetamine use, impulsivity, and sexual risk behavior among HIV-positive men who have sex with men." *J Addict Dis* 25(4): 105-14.
- Semple, S. J., J. Zians, et al. (2006). "Sexual risk behavior of HIV-positive methamphetamine-using men who have sex with men: The role of partner serostatus and partner type." *Arch Sex Behav* 35(4): 461-71.
- Semple, S. J., I. Grant, et al. (2005). "Negative self-perceptions and sexual risk behavior among heterosexual methamphetamine users." *Substance Use & Misuse* 40(12): 1797-1810.
- Semple, S. J., I. Grant, et al. (2005). "Utilization of drug treatment programs by methamphetamine users: The role of social stigma." *Am J Addict* 14(4): 367-80.
- Semple, S. J., T. L. Patterson and I. Grant (2004). "The context of sexual risk behavior among heterosexual methamphetamine users." *Addict Behav* 29(4): 807-10.
- Semple, S. J., T. L. Patterson, et al. (2004). "A comparison of injection and non-injection methamphetamine-using HIV positive men who have sex with men." *Drug Alcohol Depend* 76(2): 203-12.
- Semple, S. J., T. L. Patterson, et al. (2004). "Determinants of condom use stage of change among heterosexually-identified methamphetamine users." *AIDS Behav* 8(4): 391-400.
- Semple, S. J., I. Grant, et al. (2004). "Female methamphetamine users: Social characteristics and sexual risk behavior." *Women Health* 40(3): 35-50.
- Semple, S. J., T. L. Patterson, et al. (2003). "Binge use of methamphetamine among HIV-positive men who have sex with men: Pilot data and HIV prevention implications." *AIDS Educ Prev* 15(2): 133-47.
- Shoptaw, S., J. D. Klausner, et al. (2006). "A public health response to the methamphetamine epidemic: The implementation of contingency management to treat methamphetamine dependence." *BMC Public Health* 6(1): 214.
- Shoptaw, S. and C. J. Reback (2006). "Associations between methamphetamine use and HIV among men who have sex with men: A model for guiding public policy." *J Urban Health* 83(6): 1151-7.
- Shoptaw, S., C. J. Reback, et al. (2005). "Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men." *Drug Alcohol Depend* 78(2): 125-34.
- Shoptaw, S., C. J. Reback and T. E. Freese (2002). "Patient characteristics, HIV serostatus, and risk behaviors among gay and bisexual males seeking treatment for methamphetamine abuse and dependence in Los Angeles." *J Addict Dis* 21(1): 91-105.
- Slade, M., L. J. Daniel, et al. (1991). "Application of forensic toxicology to the problem of domestic violence." *J Forensic Sci* 36(3): 708-13.
- Smith, D. E. (1969). "Runaways and their health problems in Haight-Ashbury during the summer of 1967." *Am J Public Health Nations Health* 59(11): 2046-50.
- Smith, D. and A. J. Rose (1968). "Observations in the Haight-Ashbury Medical Clinic of San Francisco. Health problems in a "hippie" subculture." *Clin Pediatr (Phila)* 7(6): 313-6.
- Smith, L. M., L. L. Lagasse, et al. (2006). "The Infant Development, Environment, and Lifestyle Study: Effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth." *Pediatrics* 118(3): 1149-1156.
- Sommers, I., D. Baskin, et al. (2006). "Methamphetamine use among young adults: Health and social consequences." *Addict Behav* 31(8): 1469-76.
- Stall, R., J. P. Paul, et al. (2001). "Alcohol use, drug use and alcohol-related problems among men who have sex with men: The Urban Men's Health Study." *Addiction* 96(11): 1589-601.
- Swalwell, C. I. and G. G. Davis (1999). "Methamphetamine as a risk factor for acute aortic dissection." *J Forensic Sci* 44(1): 23-6.

- Thiede, H., L. A. Valleroy, et al. (2003). "Regional patterns and correlates of substance use among young men who have sex with men in 7 US urban areas." *Am J Public Health* 93(11): 1915-21.
- Turnipseed, S. D., J. R. Richards, et al. (2003). "Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after methamphetamine use." *J Emerg Med* 24(4): 369-73.
- Twitchell, G. R., A. Huber, et al. (2002). "Comparison of general and detailed HIV risk assessments among methamphetamine abusers." *AIDS and Behavior* 6(2): 153-162.
- von Mayrhauser, C., M. L. Brecht and M. D. Anglin (2002). "Use ecology and drug use motivations of methamphetamine users admitted to substance abuse treatment facilities in Los Angeles: An emerging profile." *J Addict Dis* 21(1): 45-60.
- Weiser, S. D., S. E. Dilworth, et al. (2006). "Gender-specific correlates of sex trade among homeless and marginally housed individuals in San Francisco." *J Urban Health* 83(4): 736-40.
- Wenzel, S. L., P. A. Ebener, et al. (1996). "Drug-abusing homeless clients in California's substance abuse treatment system." *J Psychoactive Drugs* 28(2): 147-59.
- Willers-Russo, L. J. (1999). "Three fatalities involving phosphine gas, produced as a result of methamphetamine manufacturing." *J Forensic Sci* 44(3): 647-52.
- Wohl, A. R., D. F. Johnson, et al. (2002). "HIV risk behaviors among African American men in Los Angeles County who self-identify as heterosexual." *J Acquir Immune Defic Syndr* 31(3): 354-60.
- Wong, W., J. K. Chaw, et al. (2005). "Risk factors for early syphilis among gay and bisexual men seen in an STD clinic: San Francisco, 2002-2003." *Sex Transm Dis* 32(7): 458-63.
- Yacoubian, G. S., Jr. and R. J. Peters (2004). "Exploring the prevalence and correlates of methamphetamine use: Findings from Sacramento's ADAM program." *J Drug Educ* 34(3): 281-94.
- Zweben, J. E., J. B. Cohen, et al. (2000). "Conducting trials in community settings: The provider perspective." *J Psychoactive Drugs* 32(2): 193-9.

### Cambodia

- Kulsudjarit, K. (2004). "Drug problem in southeast and southwest Asia." *Ann N Y Acad Sci* 1025: 446-57.

### Canada

*See also* Toronto; Vancouver; Victoria

- Barr, A. M., W. J. Panenka, et al. (2006). "The need for speed: An update on methamphetamine addiction." *J Psychiatry Neurosci* 31(5): 301-313.
- Bungay, V., L. Malchy, et al. (2006). "Life with jib: A snapshot of street youth's use of crystal methamphetamine." *Addiction Research and Theory* 14(3): 235-251.
- Collins, C. L., T. Kerr, et al. (2005). "Rationale to evaluate medically supervised safer smoking facilities for non-injection illicit drug users." *Can J Public Health* 96(5): 344-7.
- Collins, C. L., T. Kerr, et al. (2005). "Potential uptake and correlates of willingness to use a supervised smoking facility for noninjection illicit drug use." *J Urban Health* 82(2): 276-84.
- Cox, C. and R. G. Smart (1972). "Social and psychological aspects of speed use. A study of types of speed users in Toronto." *Int J Addict* 7(2): 201-17.
- Cox, C. and R. G. Smart (1970). "The nature and extent of speed use in North America." *Can Med Assoc J* 102(7): 724-9.
- Fairbairn, N., T. Kerr, et al. (2006). "Increasing use and associated harms of crystal methamphetamine injection in a Canadian setting." *Drug Alcohol Depend*.
- Kalasinsky, K. S., J. Hugel, et al. (2004). "Use of MDA (the "love drug") and methamphetamine in Toronto by unsuspecting users of ecstasy (MDMA)." *J Forensic Sci* 49(5): 1106-12.
- Kerr, T., E. Wood, et al. (2005). "High rates of primary care and emergency department use among injection drug users in Vancouver." *J Public Health (Oxf)* 27(1): 62-6.
- Klasser, G. D. and J. Epstein (2005). "Methamphetamine and its impact on dental care." *J Can Dent Assoc* 71(10): 759-62.
- Lampinen, T. M., D. McGhee, et al. (2006). "Increased risk of "club" drug use among gay and bisexual high school students in British Columbia." *J Adolesc Health* 38(4): 458-61.
- Lampinen, T. M., D. McGhee, et al. (2006). "Use of crystal methamphetamine and other club drugs among high school students in Vancouver and Victoria." *BC Medical Journal* 48(1): 22-27.
- Martin, I., T. M. Lampinen, et al. (2006). "Methamphetamine use among marginalized youth in British Columbia." *Can J Public Health* 97(4): 320-4.



- Rusch, M., T. M. Lampinen, A. Schilder and R. S. Hogg (2004). "Unprotected anal intercourse associated with recreational drug use among young men who have sex with men depends on partner type and intercourse role." *Sex Transm Dis* 31(8): 492-8.
- Schilder, A. J., T. M. Lampinen, et al. (2005). "Crystal methamphetamine and ecstasy differ in relation to unsafe sex among young gay men." *Can J Public Health* 96(5): 340-3.
- Stamler, R. T., R. C. Fahlman, et al. (1983). "Recent trends in illicit drug trafficking from the Canadian perspective." *Bull Narc* 35(4): 23-32.
- Wood, E., J. A. Stoltz, et al. (2006). "Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study." *Harm Reduct J* 3: 18.

## Cardiovascular Effects and Disease

*See also* Hypertension; Vascular Disease

- Ago, M., K. Ago, et al. (2006). "Toxicological and histopathological analysis of a patient who died nine days after a single intravenous dose of methamphetamine: A case report." *Leg Med (Tokyo)* 8(4): 235-9.
- Albertson, T. E., R. W. Derlet, et al. (1999). "Methamphetamine and the expanding complications of amphetamines." *West J Med* 170(4): 214-9.
- Angrist, B., J. Corwin, et al. (1987). "Early pharmacokinetics and clinical effects of oral D-amphetamine in normal subjects." *Biol Psychiatry* 22(11): 1357-68.
- Anzalone, B., W. T. Crow, et al. (2002). "If the bubble bursts.... EMS response to aortic aneurysms & dissections." *Jems* 27(1): 84-8, 90-5; quiz 96-7.
- Beebe, D. K. and E. Walley (1995). "Smokable methamphetamine ('ice'): An old drug in a different form." *Am Fam Physician* 51(2): 449-53.
- Berankova, K., V. Habrdova, et al. (2005). "Methamphetamine in hair and interpretation of forensic findings in a fatal case." *Forensic Sci Int* 153(1): 93-7.
- Boddiger, D. (2005). "Metamphetamine use linked to rising HIV transmission." *Lancet* 365(9466): 1217-8.
- Brauer, L. H., J. Ambre, et al. (1996). "Acute tolerance to subjective but not cardiovascular effects of d-amphetamine in normal, healthy men." *J Clin Psychopharmacol* 16(1): 72-6.
- Catanzarite, V. A. and D. A. Stein (1995). "'Crystal' and pregnancy--methamphetamine-associated maternal deaths." *West J Med* 162(5): 454-7.
- Chan, P., J. H. Chen, et al. (1994). "Fatal and nonfatal methamphetamine intoxication in the intensive care unit." *J Toxicol Clin Toxicol* 32(2): 147-55.
- Chin, K. M., R. N. Channick, et al. (2006). "Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?" *Chest* 130(6): 1657-63.
- Cole, J. C., H. R. Sumnall, et al. (2005). "Preliminary evidence of the cardiovascular effects of polysubstance misuse in nightclubs." *J Psychopharmacol* 19(1): 67-70.
- Cook, C. E., A. R. Jeffcoat, et al. (1993). "Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride." *Drug Metab Dispos* 21(4): 717-23.
- Derlet, R. W. and B. Z. Horowitz (1995). "Cardiotoxic drugs." *Emerg Med Clin North Am* 13(4): 771-91.
- Derlet, R. W. and B. Heischouer (1990). "Methamphetamine. Stimulant of the 1990s?" *West J Med* 153(6): 625-8.
- de Wit, H., M. Clark, et al. (1997). "Effects of d-amphetamine in grouped versus isolated humans." *Pharmacol Biochem Behav* 57(1-2): 333-40.
- Farnsworth, T. L., C. H. Brugger and P. Malters (1997). "Myocardial infarction after intranasal methamphetamine." *Am J Health Syst Pharm* 54(5): 586-7.
- Furst, S. R., S. P. Fallon, G. N. Reznik and P. K. Shah (1990). "Myocardial infarction after inhalation of methamphetamine." *N Engl J Med* 323(16): 1147-8.
- Gotway, M. B., S. R. Marder, et al. (2002). "Thoracic complications of illicit drug use: an organ system approach." *Radiographics* 22 Spec No: S119-35.
- Grady, T. A., A. Brooks, et al. (1996). "Biological and behavioral responses to D-amphetamine, alone and in combination with the serotonin<sub>3</sub> receptor antagonist ondansetron, in healthy volunteers." *Psychiatry Res* 64(1): 1-10.
- Guharoy, R., J. Medicis, S. Chol, B. Stalder, K. Kusiowski and A. Allen (1999). "Methamphetamine overdose: Experience with six cases." *Vet Hum Toxicol* 41(1): 28-30.
- Hiroshi, K., K. Akira, et al. (2005). "An autopsy case of infectious endocarditis in a methamphetamine abuser usefulness of microbiological examination." *Soud Lek* 50(2): 18-22.

- Hong, R., E. Matsuyama and K. Nur (1991). "Cardiomyopathy associated with the smoking of crystal methamphetamine." *JAMA* 265(9): 1152-4.
- Inouye, D. S., J. J. Navin, et al. (2004). "Fatal postoperative arrhythmia in a man with a remote history of methamphetamine and cocaine use: A case report." *Hawaii Med J* 63(3): 82-6.
- Irvine, R. J., M. Keane, et al. (2006). "Plasma drug concentrations and physiological measures in 'dance party' participants." *Neuropsychopharmacology* 31(2): 424-30.
- Jacobs, L. J. (1989). "Reversible dilated cardiomyopathy induced by methamphetamine." *Clin Cardiol* 12(12): 725-7.
- Johnson, B. A., L. T. Wells, et al. (2005). "Isradipine decreases the hemodynamic response of cocaine and methamphetamine results from two human laboratory studies: Results from two human laboratory studies." *Am J Hypertens* 18(6): 813-22.
- Johnson, B. A., N. Ait-Daoud, et al. (2000). "Effects of isradipine, a dihydropyridine-class calcium channel antagonist, on D-methamphetamine-induced cognitive and physiological changes in humans." *Neuropsychopharmacology* 22(5): 504-12.
- Karch, S. B., B. G. Stephens, et al. (1999). "Methamphetamine-related deaths in San Francisco: Demographic, pathologic, and toxicologic profiles." *J Forensic Sci* 44(2): 359-68.
- Kashani, J. and A. M. Ruha (2004). "Methamphetamine toxicity secondary to intravaginal body stuffing." *J Toxicol Clin Toxicol* 42(7): 987-9.
- Kolecki, P. (1998). "Inadvertent methamphetamine poisoning in pediatric patients." *Pediatr Emerg Care* 14(6): 385-7.
- Lile, J. A., W. W. Stoops, et al. (2005). "Aripiprazole attenuates the discriminative-stimulus and subject-rated effects of D-amphetamine in humans." *Neuropsychopharmacology* 30(11): 2103-14.
- Logan, B. K., E. L. Weiss, et al. (1996). "Case report: Distribution of methamphetamine in a massive fatal ingestion." *J Forensic Sci* 41(2): 322-3.
- Lynch, J. and M. A. House (1992). "Cardiovascular effects of methamphetamine." *J Cardiovasc Nurs* 6(2): 12-8.
- Martin, W. R., J. W. Sloan, et al. (1971). "Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man." *Clin Pharmacol Ther* 12(2): 245-58.
- Matoba, R. (2001). "[Cardiac lesions in methamphetamine abusers]." *Nippon Hoigaku Zasshi* 55(3): 321-30.
- Matoba, R., S. Onishi, et al. (1984). "[Sudden death in methamphetamine abusers: a histological study of the heart]." *Nippon Hoigaku Zasshi* 38(2): 199-205.
- Meeker, J. E. and P. C. Reynolds (1990). "Postmortem tissue methamphetamine concentrations following selegiline administration." *J Anal Toxicol* 14(5): 330-1.
- Mendelson, J., R. T. Jones, et al. (1995). "Methamphetamine and ethanol interactions in humans." *Clin Pharmacol Ther* 57(5): 559-68.
- Mori, A., H. Suzuki, et al. (1992). "[Three cases of acute methamphetamine intoxication--Analysis of optically active methamphetamine]." *Nippon Hoigaku Zasshi* 46(4): 266-70.
- Newton, T. F., R. De La Garza, 2nd, et al. (2006). "A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline." *Pharmacol Biochem Behav*.
- Newton, T. F., R. De La Garza, 2nd, et al. (2005). "Cocaine and methamphetamine produce different patterns of subjective and cardiovascular effects." *Pharmacol Biochem Behav* 82(1): 90-7.
- Nishida, N., N. Ikeda, et al. (2003). "Sudden unexpected death of a methamphetamine abuser with cardiopulmonary abnormalities: A case report." *Med Sci Law* 43(3): 267-71.
- Pavese, N., O. Rimoldi, et al. (2004). "Cardiovascular effects of methamphetamine in Parkinson's disease patients." *Mov Disord* 19(3): 298-303.
- Perez-Reyes, M., W. R. White, et al. (1991). "Clinical effects of daily methamphetamine administration." *Clin Neuropharmacol* 14(4): 352-8.
- Perez-Reyes, M., W. R. White, et al. (1991). "Clinical effects of methamphetamine vapor inhalation." *Life Sci* 49(13): 953-9.
- Rajs, J. and B. Falconer (1979). "Cardiac lesions in intravenous drug addicts." *Forensic Sci Int* 13(3): 193-209.
- Shibata, S., K. Mori, et al. (1991). "Subarachnoid and intracerebral hemorrhage associated with necrotizing angitis due to methamphetamine abuse--an autopsy case." *Neurol Med Chir (Tokyo)* 31(1): 49-52.
- Shibata, S., K. Mori, et al. (1988). "[An autopsy case of subarachnoid and intracerebral hemorrhage and necrotizing angitis associated with methamphetamine abuse]." *No To Shinkei* 40(11): 1089-94.
- Smith, N. T. and A. N. Corbascio (1970). "The use and misuse of pressor agents." *Anesthesiology* 33(1): 58-101.
- Stafford, C. R., B. M. Bogdanoff, et al. (1975). "Mononeuropathy multiplex as a complication of amphetamine angitis." *Neurology* 25(6): 570-2.
- Stoops, W. W., J. A. Lile, et al. (2006). "A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine." *Drug Alcohol Depend*.

- Swalwell, C. I. and G. G. Davis (1999). "Methamphetamine as a risk factor for acute aortic dissection." *J Forensic Sci* 44(1): 23-6.
- Takasaki, T., N. Nishida, et al. (2003). "Unexpected death due to right-sided infective endocarditis in a methamphetamine abuser." *Leg Med (Tokyo)* 5(1): 65-8.
- Turnipseed, S. D., J. R. Richards, et al. (2003). "Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after methamphetamine use." *J Emerg Med* 24(4): 369-73.
- Wachtel, S. R. and H. de Wit (1999). "Subjective and behavioral effects of repeated d-amphetamine in humans." *Behav Pharmacol* 10(3): 271-81.
- Watts, D. J. and L. McColester (2006). "Methamphetamine-induced myocardial infarction with elevated troponin I." *Am J Emerg Med* 24(1): 132-4.
- Wijetunga, M., R. Bhan, J. Lindsay and S. Karch (2004). "Acute coronary syndrome and crystal methamphetamine use: A case series." *Hawaii Med J* 63(1): 8-13, 25.
- Wijetunga, M., T. Seto, J. Lindsay and I. Schatz (2003). "Crystal methamphetamine-associated cardiomyopathy: Tip of the iceberg?" *J Toxicol Clin Toxicol* 41(7): 981-6.
- Wolkoff, D. A. (1997). "Methamphetamine abuse: An overview for health care professionals." *Hawaii Med J* 56(2): 34-6, 44.
- Wyman, J. F. and J. T. Cody (2005). "Determination of l-methamphetamine: A case history." *J Anal Toxicol* 29(7): 759-61.
- Yu, Q., D. F. Larson, et al. (2003). "Heart disease, methamphetamine and AIDS." *Life Sci* 73(2): 129-40.
- Zhu, B. L., T. Ishikawa, et al. (2006). "Postmortem cardiac troponin T levels in the blood and pericardial fluid. Part 1. Analysis with special regard to traumatic causes of death." *Leg Med (Tokyo)* 8(2): 86-93.
- Zhu, B. L., S. Oritani, et al. (2000). "Methamphetamine-related fatalities in forensic autopsy during 5 years in the southern half of Osaka city and surrounding areas." *Forensic Sci Int* 113(1-3): 443-7.

## Cardiovascular Effects and Disease (animals)

*See also* Hypertension (animals)

- Araki, H., T. Yamamoto, et al. (2002). "Effect of methamphetamine and imipramine on cerebral ischemia-induced hyperactivity in Mongolian gerbils." *Jpn J Pharmacol* 88(3): 293-9.
- Forney, R., R. Martz, et al. (1976). "The combined effect of marihuana and dextroamphetamine." *Ann N Y Acad Sci* 281: 162-70.
- Gentry, W. B., E. M. Laurenzana, et al. (2006). "Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats." *Int Immunopharmacol* 6(6): 968-77.
- He, S. Y., R. Matoba, N. Fujitani, K. Sodesaki and S. Onishi (1996). "Cardiac muscle lesions associated with chronic administration of methamphetamine in rats." *Am J Forensic Med Pathol* 17(2): 155-62.
- He, S. Y., R. Matoba, et al. (1996). "Morphological and morphometric investigation of cardiac lesions after chronic administration of methamphetamine in rats." *Nippon Hoigaku Zasshi* 50(2): 63-71.
- He, S. Y. (1995). "Methamphetamine-induced toxicity in cultured adult rat cardiomyocytes." *Nippon Hoigaku Zasshi* 49(3): 175-86.
- Hilliard, W. G., W. T. Oliver, et al. (1966). "The influence of sympathomimetic amines, monoamine oxidase inhibitors, and antihypertensives upon the energy metabolism in the rat heart." *Can J Physiol Pharmacol* 44(4): 605-13.
- Inoue, H., M. Nakatome, et al. (2004). "Maternal methamphetamine administration during pregnancy influences on fetal rat heart development." *Life Sci* 74(12): 1529-40.
- Ishiguro, Y. and J. P. Morgan (1997). "Biphasic inotropic effects of methamphetamine and methylphenidate on ferret papillary muscles." *J Cardiovasc Pharmacol* 30(6): 744-9.
- Islam, M. N., H. Kuroki, et al. (1995). "Cardiac lesions and their reversibility after long term administration of methamphetamine." *Forensic Sci Int* 75(1): 29-43.
- Kaiho, M. and I. Ishiyama (1989). "Morphological study of acute myocardial lesions experimentally induced by methamphetamine." *Nippon Hoigaku Zasshi* 43(6): 460-8.
- Kalinski, M. I., D. E. Dluzen, et al. (2001). "Methamphetamine produces subsequent reductions in running time to exhaustion in mice." *Brain Res* 921(1-2): 160-4.
- Knoll, J., E. S. Vizi, et al. (1970). "Pharmacological studies on para-bromo-methamphetamine (V-111) and LSD." *Acta Physiol Acad Sci Hung* 37(1): 151-70.
- Matoba, R. (2001). "[Cardiac lesions in methamphetamine abusers]." *Nippon Hoigaku Zasshi* 55(3): 321-30.
- Maeno, Y., M. Iwasa, et al. (2000). "Methamphetamine induces an increase in cell size and reorganization of myofibrils in cultured adult rat cardiomyocytes." *Int J Legal Med* 113(4): 201-7.

- Nakagawa, N., T. Hishinuma, et al. (2003). "Brain and heart specific alteration of methamphetamine (MAP) distribution in MAP-sensitized rat." *Biol Pharm Bull* 26(4): 506-9.
- Rudzik, A. D. and J. N. Eble (1967). "The potentiation of pressor responses to tyramine by a number of amphetamine-like compounds." *Proc Soc Exp Biol Med* 124(2): 655-7.
- Schindler, C. W., J. P. Gilman, et al. (2003). "Reduced cardiovascular effects of methamphetamine following treatment with selegiline." *Drug Alcohol Depend* 72(2): 133-9.
- Schindler, C. W., J. W. Zheng, et al. (1992). "Pharmacological mechanisms in the cardiovascular effects of methamphetamine in conscious squirrel monkeys." *Pharmacol Biochem Behav* 42(4): 791-6.
- Sheridan, R. D., S. R. Turner, et al. (2005). "Effects of seven drugs of abuse on action potential repolarisation in sheep cardiac Purkinje fibres." *Eur J Pharmacol* 511(2-3): 99-107.
- Stek, A. M., R. S. Baker, et al. (1995). "Fetal responses to maternal and fetal methamphetamine administration in sheep." *Am J Obstet Gynecol* 173(5): 1592-8.
- Stek, A. M., B. K. Fisher, et al. (1993). "Maternal and fetal cardiovascular responses to methamphetamine in the pregnant sheep." *Am J Obstet Gynecol* 169(4): 888-97.
- Urabe, M. (1982). "Inhibitory mechanism of methamphetamine in the isolated myocardium of bullfrog." *Arch Int Pharmacodyn Ther* 257(2): 239-54.
- Varner, K. J., B. A. Ogden, et al. (2002). "Cardiovascular responses elicited by the "binge" administration of methamphetamine." *J Pharmacol Exp Ther* 301(1): 152-9.
- Varner, K. J., N. D. Hein, et al. (2001). "Chloroephedrine: Contaminant of methamphetamine synthesis with cardiovascular activity." *Drug Alcohol Depend* 64(3): 299-307.
- Vidrio, H. (1982). "Cardiovascular effects of methamphetamine in dogs treated chronically with the amine." *J Cardiovasc Pharmacol* 4(2): 326-9.
- Welder, A. A. (1992). "A primary culture system of postnatal rat heart cells for the study of cocaine and methamphetamine toxicity." *Toxicol Lett* 60(2): 183-96.
- Yoshida, K., A. Morimoto, et al. (1993). "Cardiovascular, thermal and behavioral sensitization to methamphetamine in freely moving rats." *J Pharmacol Exp Ther* 267(3): 1538-43.
- Yu, Q., S. Montes, et al. (2002). "Effects of chronic methamphetamine exposure on heart function in uninfected and retrovirus-infected mice." *Life Sci* 71(8): 953-65.
- Zolkowska, D., R. B. Rothman, et al. (2006). "Amphetamine analogs increase plasma serotonin: Implications for cardiac and pulmonary disease." *J Pharmacol Exp Ther* 318(2): 604-10.

### Cartilage (animals)

- Kilgore, B. S., L. C. Dickinson, et al. (1979). "Alterations in cartilage metabolism by neurostimulant drugs." *J Pediatr* 94(4): 542-5.

### Catecholamines

*See also Dopamine headings; Epinephrine (animals); Norepinephrine; Norepinephrine (animals)*

- Barr, A. M., W. J. Panenka, et al. (2006). "The need for speed: An update on methamphetamine addiction." *J Psychiatry Neurosci* 31(5): 301-313.
- Batki, S. L. and D. S. Harris (2004). "Quantitative drug levels in stimulant psychosis: Relationship to symptom severity, catecholamines and hyperkinesia." *Am J Addict* 13(5): 461-70.
- Cozzi, N. V., M. K. Sievert, et al. (1999). "Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines." *Eur J Pharmacol* 381(1): 63-9.
- Dickinson, J. E., R. L. Andres, et al. (1994). "The ovine fetal sympathoadrenal response to the maternal administration of methamphetamine." *Am J Obstet Gynecol* 170(5 Pt 1): 1452-7.
- Ferrucci, M., C. L. Busceti, et al. (2006). "Effects of methamphetamine on the cerebellar cortex: A preliminary study." *Ann N Y Acad Sci* 1074: 149-53.
- Fischer, E., J. M. Saavedra, et al. (1968). "Effects of catecholamines, adrenergic substances and their blocking agents on the searching behavior of mice." *Arzneimittelforschung* 18(7): 780-6.
- Fujiwara, M., Y. Kataoka, et al. (1984). "Irritable aggression induced by delta 9-tetrahydrocannabinol in rats pretreated with 6-hydroxydopamine." *Pharmacol Biochem Behav* 20(3): 457-62.
- Gesi, M., G. Lazzeri, et al. (2006). "Inclusion dynamics in PC12 is comparable between amphetamines and MPTP." *Ann N Y Acad Sci* 1074: 315-9.

- Gomes-da-Silva, J., R. de Miguel, et al. (2004). "Effects of neonatal exposure to methamphetamine: Catecholamine levels in brain areas of the developing rat." *Ann N Y Acad Sci* 1025: 602-11.
- Harris, D. S., V. I. Reus, et al. (2006). "Catecholamine response to methamphetamine is related to glucocorticoid levels but not to pleasurable subjective response." *Pharmacopsychiatry* 39(3): 100-8.
- Ishikawa, T. and M. Yamamoto (1979). "Involvement of the cholinergic mechanism in depression of the caudate spindle." *Jpn J Pharmacol* 29(3): 399-403.
- Karczmar, A. G. and C. L. Scudder (1967). "Behavioral responses to drugs and brain catecholamine levels in mice of different strains and genera." *Fed Proc* 26(4): 1186-91.
- Leibowitz, S. F. and C. Rossakis (1978). "Analysis of feeding suppression produced by perifornical hypothalamic injection of catecholamines, amphetamines and mazindol." *Eur J Pharmacol* 53(1): 69-81.
- Masuo, Y., M. Ishido, et al. (2004). "Motor activity and gene expression in rats with neonatal 6-hydroxydopamine lesions." *J Neurochem* 91(1): 9-19.
- Nishii, K., N. Matsushita, et al. (1998). "Motor and learning dysfunction during postnatal development in mice defective in dopamine neuronal transmission." *J Neurosci Res* 54(4): 450-64.
- Pavese, N., O. Rimoldi, et al. (2004). "Cardiovascular effects of methamphetamine in Parkinson's disease patients." *Mov Disord* 19(3): 298-303.
- Peterfy, G., E. J. Pinter, et al. (1976). "Psychosomatic aspects of catecholamine depletion: Comparative studies of metabolic, endocrine and affective changes." *Psychoneuroendocrinology* 1(3): 243-53.
- Sayers, A. C. and S. L. Handley (1973). "A study of the role of catecholamines in the response to various central stimulants." *Eur J Pharmacol* 23(1): 47-55.
- Scheel-Kruger, J. (1971). "Comparative studies of various amphetamine analogues demonstrating different interactions with the metabolism of the catecholamines in the brain." *Eur J Pharmacol* 14(1): 47-59.
- Sulzer, D., M. S. Sonders, et al. (2005). "Mechanisms of neurotransmitter release by amphetamines: A review." *Prog Neurobiol* 75(6): 406-33.
- Taraska, T. and K. T. Finnegan (1997). "Nitric oxide and the neurotoxic effects of methamphetamine and 3,4-methylenedioxymethamphetamine." *J Pharmacol Exp Ther* 280(2): 941-7.
- Yu, Q., D. F. Larson, et al. (2003). "Heart disease, methamphetamine and AIDS." *Life Sci* 73(2): 129-40.

## Chemical Structure

- Barker, W. D. and U. Antia (2006). "A study of the use of Ephedra in the manufacture of methamphetamine." *Forensic Sci Int*.
- Derlet, R. W. and B. Heischouer (1990). "Methamphetamine. Stimulant of the 1990s?" *West J Med* 153(6): 625-8.
- Higgs, R. A. and R. A. Glennon (1990). "Stimulus properties of ring-methyl amphetamine analogs." *Pharmacol Biochem Behav* 37(4): 835-7.
- Jirovsky, D., K. Lemr, et al. (1998). "Methamphetamine--properties and analytical methods of enantiomer determination." *Forensic Sci Int* 96(1): 61-70.
- NTP-CERHR (2005). "NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines." *NTP CEHR Mon*(16): i-III1.
- Sulzer, D., M. S. Sonders, et al. (2005). "Mechanisms of neurotransmitter release by amphetamines: A review." *Prog Neurobiol* 75(6): 406-33.
- Tubergen, M. J., R. J. Lavrich, et al. (2006). "Rotational spectra and conformational structures of 1-phenyl-2-propanol, methamphetamine, and 1-phenyl-2-propanone." *J Phys Chem A Mol Spectrosc Kinet Environ Gen Theory* 110(49): 13188-13194.

## Chicago, IL (US)

- Fendrich, M., J. S. Wislar, T. P. Johnson and A. Hubbell (2003). "A contextual profile of club drug use among adults in Chicago." *Addiction* 98(12): 1693-703.
- Koblin, B. A., M. A. Chesney, et al. (2003). "High-risk behaviors among men who have sex with men in 6 US cities: Baseline data from the EXPLORE Study." *Am J Public Health* 93(6): 926-32.
- Lyons, T., G. Chandra, et al. (2006). "Stimulant use and HIV risk behavior: The influence of peer support group participation." *AIDS Educ Prev* 18(5): 461-73.
- Stall, R., J. P. Paul, et al. (2001). "Alcohol use, drug use and alcohol-related problems among men who have sex with men: The Urban Men's Health Study." *Addiction* 96(11): 1589-601.

### Childhood Attention Deficit Hyperactivity Disorder

- Gordon, S. M., F. Tulak, et al. (2004). "Prevalence and characteristics of adolescents patients with co-occurring ADHD and substance dependence." *J Addict Dis* 23(4): 31-40.
- Jaffe, C., K. R. Bush, et al. (2005). "A comparison of methamphetamine-dependent inpatients childhood attention deficit hyperactivity disorder symptomatology." *J Addict Dis* 24(3): 133-52.
- Lin, S. J., S. Y. Crawford, et al. (2005). "Trend and area variation in amphetamine prescription usage among children and adolescents in Michigan." *Soc Sci Med* 60(3): 617-26.
- Matsumoto, T., A. Kamijo, et al. (2005). "Childhood histories of attention-deficit hyperactivity disorders in Japanese methamphetamine and inhalant abusers: Preliminary report." *Psychiatry Clin Neurosci* 59(1): 102-5.
- Matsumoto, T., A. Yamaguchi, et al. (2005). "Drug preferences in illicit drug abusers with a childhood tendency of attention deficit/hyperactivity disorder: A study using the Wender Utah Rating Scale in a Japanese prison." *Psychiatry Clin Neurosci* 59(3): 311-8.

### Children, Methamphetamine-Endangered

*See also* Children, Methamphetamine Ingestion by; Pregnancy

- Altshuler, S. J. (2005). "Drug-endangered children need a collaborative community response." *Child Welfare* 84(2): 171-90.
- Assael, L. A. (2005). "Methamphetamine: An epidemic of oral health neglect, loss of access to care, abuse, and violence." *J Oral Maxillofac Surg* 63(9): 1253-4.
- Boulard, G. (2005). "The meth menace: Battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.
- Brecht, M. L., M. D. Anglin, et al. (2005). "Coerced treatment for methamphetamine abuse: differential patient characteristics and outcomes." *Am J Drug Alcohol Abuse* 31(2): 337-56.
- Cohen, J. B., A. Dickow, et al. (2003). "Abuse and violence history of men and women in treatment for methamphetamine dependence." *Am J Addict* 12(5): 377-85.
- Colnar, R. (1999). "Methamphetamine affects individuals and communities." *Nebr Nurse* 32(3): 31.
- Davies, J. K. and J. M. Bledsoe (2005). "Prenatal alcohol and drug exposures in adoption." *Pediatr Clin North Am* 52(5): 1369-93, vii.
- Denehy, J. (2006). "The meth epidemic: its effect on children and communities." *J Sch Nurs* 22(2): 63-5.
- Farst, K., J. M. Duncan, et al. (2006). "Methamphetamine exposure presenting as caustic ingestions in children." *Ann Emerg Med*.
- Friese, G. (2006). "The methamphetamine crisis. What EMS providers need to know to stay safe and treat patients." *Emerg Med Serv* 35(3): 55-64.
- Hohman, M., R. Oliver, et al. (2004). "Methamphetamine abuse and manufacture: The child welfare response." *Soc Work* 49(3): 373-81.
- Lewis, D., C. Moore, et al. (1997). "Determination of drug exposure using hair: application to child protective cases." *Forensic Sci Int* 84(1-3): 123-8.
- Lineberry, T. W. and J. M. Bostwick (2006). "Methamphetamine abuse: a perfect storm of complications." *Mayo Clin Proc* 81(1): 77-84.
- Mecham, N. and J. Melini (2002). "Unintentional victims: Development of a protocol for the care of children exposed to chemicals at methamphetamine laboratories." *Pediatr Emerg Care* 18(4): 327-32.
- Oro, A. S. and S. D. Dixon (1987). "Perinatal cocaine and methamphetamine exposure: Maternal and neonatal correlates." *J Pediatr* 111(4): 571-8.
- Penn, C. L. (2006). "Meth abuse in Arkansas." *J Ark Med Soc* 102(8): 218-9.
- Sheridan, J., S. Bennett, et al. (2006). "Injury associated with methamphetamine use: A review of the literature." *Harm Reduct J* 3(1): 14.
- Stewart, J. L. and J. E. Meeker (1997). "Fetal and infant deaths associated with maternal methamphetamine abuse." *J Anal Toxicol* 21(6): 515-7.
- Struthers, J. M. and R. L. Hansen (1992). "Visual recognition memory in drug-exposed infants." *J Dev Behav Pediatr* 13(2): 108-11.

### Children, Methamphetamine Ingestion by

- Gospe, S. M., Jr. (1995). "Transient cortical blindness in an infant exposed to methamphetamine." *Ann Emerg Med* 26(3): 380-2.
- Kolecki, P. (1998). "Inadvertent methamphetamine poisoning in pediatric patients." *Pediatr Emerg Care* 14(6): 385-7.
- Nagorka, A. R. and P. S. Bergeson (1998). "Infant methamphetamine toxicity posing as scorpion envenomation." *Pediatr Emerg Care* 14(5): 350-1.

Ruha, A. M. and M. C. Yarema (2006). "Pharmacologic treatment of acute pediatric methamphetamine toxicity." *Pediatr Emerg Care* 22(12): 782-5.

## Child Welfare System

Brecht, M. L., M. D. Anglin, et al. (2005). "Coerced treatment for methamphetamine abuse: Differential patient characteristics and outcomes." *Am J Drug Alcohol Abuse* 31(2): 337-56.

Grella, C. E., Y. I. Hser, et al. (2006). "Mothers in substance abuse treatment: Differences in characteristics based on involvement with child welfare services." *Child Abuse Negl* 30(1): 55-73.

Hohman, M., R. Oliver, et al. (2004). "Methamphetamine abuse and manufacture: The child welfare response." *Soc Work* 49(3): 373-81.

Lewis, D., C. Moore, et al. (1997). "Determination of drug exposure using hair: application to child protective cases." *Forensic Sci Int* 84(1-3): 123-8.

## China

*See also* Hong Kong; Taiwan

Ahmad, K. (2003). "Asia grapples with spreading amphetamine abuse." *Lancet* 361(9372): 1878-9.

Barr, A. M., W. J. Panenka, et al. (2006). "The need for speed: An update on methamphetamine addiction." *J Psychiatry Neurosci* 31(5): 301-313.

Chen, C. K., S. K. Lin, et al. (2005). "Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis." *Am J Med Genet B Neuropsychiatr Genet* 136(1): 87-91.

Chen, C. K., X. Hu, et al. (2004). "Association analysis of dopamine D2-like receptor genes and methamphetamine abuse." *Psychiatr Genet* 14(4): 223-226.

Chen, C. K., S. K. Lin, et al. (2003). "Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis." *Psychol Med* 33(8): 1407-14.

Cheng, C. Y., C. J. Hong, et al. (2005). "Brain-derived neurotrophic factor (Val66Met) genetic polymorphism is associated with substance abuse in males." *Brain Res Mol Brain Res* 140(1-2): 86-90.

Cheng, J. Y., M. F. Chan, et al. (2006). "Impurity profiling of ecstasy tablets seized in Hong Kong by gas chromatography-mass spectrometry." *Forensic Sci Int* 162(1-3): 87-94.

Cheng, J. Y., D. T. Chan, et al. (2005). "An epidemiological study on alcohol/drugs related fatal traffic crash cases of deceased drivers in Hong Kong between 1996 and 2000." *Forensic Sci Int* 153(2-3): 196-201.

Cheng, W. C., N. L. Poon, et al. (2003). "Chemical profiling of 3,4-methylenedioxymethamphetamine (MDMA) tablets seized in Hong Kong." *J Forensic Sci* 48(6): 1249-59.

Chiang, S. C., H. Y. Chan, et al. (2006). "Recidivism among male subjects incarcerated for illicit drug use in Taiwan." *Psychiatry Clin Neurosci* 60(4): 444-51.

Hong, C. J., C. Y. Cheng, et al. (2003). "Association study of the dopamine and serotonin transporter genetic polymorphisms and methamphetamine abuse in Chinese males." *J Neural Transm* 110(4): 345-51.

Joe Laidler, K. A. (2005). "The rise of club drugs in a heroin society: The case of Hong Kong." *Subst Use Misuse* 40(9-10): 1257-78.

Ku, Y. R., Y. S. Chang, et al. (1999). "Analysis and confirmation of synthetic anorexics in adulterated traditional Chinese medicines by high-performance capillary electrophoresis." *J Chromatogr A* 848(1-2): 537-43.

Li, T., C. K. Chen, et al. (2004). "Association analysis of the DRD4 and COMT genes in methamphetamine abuse." *Am J Med Genet* 129B(1): 120-4.

Lin, S. K., D. Ball, et al. (2004). "Psychiatric comorbidity and gender differences of persons incarcerated for methamphetamine abuse in Taiwan." *Psychiatry Clin Neurosci* 58(2): 206-12.

Lin, S. K., C. K. Chen, et al. (2003). "Gender-specific contribution of the GABA(A) subunit genes on 5q33 in methamphetamine use disorder." *Pharmacogenomics J* 3(6): 349-55.

Liu, H. C., C. K. Chen, et al. (2006). "Association between dopamine receptor D1 A-48G polymorphism and methamphetamine abuse." *Psychiatry Clin Neurosci* 60(2): 226-31.

Liu, H. C., S. K. Lin, et al. (2004). "DAT polymorphism and diverse clinical manifestations in methamphetamine abusers." *Psychiatr Genet* 14(1): 33-7.

Kulsudjarit, K. (2004). "Drug problem in southeast and southwest Asia." *Ann N Y Acad Sci* 1025: 446-57.

McGrath, C. and B. Chan (2005). "Oral health sensations associated with illicit drug abuse." *Br Dent J* 198(3): 159-62; discussion 147; quiz 174.

- Nakamura, K., C. K. Chen, et al. (2006). "Association analysis of SOD2 variants with methamphetamine psychosis in Japanese and Taiwanese populations." *Hum Genet* 120(2): 243-52.
- Shaw, K. P. (1999). "Human methamphetamine-related fatalities in Taiwan during 1991-1996." *J Forensic Sci* 44(1): 27-31.
- Suwanwela, C. and V. Poshychinda (1986). "Drug abuse in Asia." *Bull Narc* 38(1-2): 41-53.
- Teng, S. F., S. C. Wu, et al. (2006). "Characteristics and trends of 3,4-methylenedioxymethamphetamine (MDMA) tablets found in Taiwan from 2002 to February 2005." *Forensic Sci Int* 161(2-3): 202-8.
- Tsai, S. J., C. Y. Cheng, et al. (2002). "No association for D2 and D4 dopamine receptor polymorphisms and methamphetamine abuse in Chinese males." *Psychiatr Genet* 12(1): 29-33.
- Yeh, P. S., A. Yuan, et al. (2001). "Acute respiratory distress syndrome in a woman with heroin and methamphetamine misuse." *J Formos Med Assoc* 100(8): 553-6.
- Yen, C. F. and M. Y. Chong (2006). "Comorbid psychiatric disorders, sex, and methamphetamine use in adolescents: A case-control study." *Compr Psychiatry* 47(3): 215-20.
- Yen, C. F. and Y. C. Su (2006). "The associations of early-onset methamphetamine use with psychiatric morbidity among Taiwanese adolescents." *Subst Use Misuse* 41(1): 35-44.
- Yen, C. F., Y. H. Yang, et al. (2006). "Correlates of methamphetamine use for Taiwanese adolescents." *Psychiatry Clin Neurosci* 60(2): 160-7.
- Yen, C. F. and Y. P. Chang (2005). "Relapse antecedents for methamphetamine use and related factors in Taiwanese adolescents." *Psychiatry Clin Neurosci* 59(1): 77-82.
- Yen, C. F., C. H. Ko, et al. (2005). "Areca quid chewing and methamphetamine use in Taiwanese adolescents." *Public Health* 119(1): 50-4.
- Yen, C. F. and B. L. Shieh (2005). "Suicidal ideation and correlates in Taiwanese adolescent methamphetamine users." *J Nerv Ment Dis* 193(7): 444-9.
- Yen, C. F., Y. H. Yang, et al. (2005). "Substance initiation sequences among Taiwanese adolescents using methamphetamine." *Psychiatry Clin Neurosci* 59(6): 683-9.
- Yen, C. F. (2004). "Relationship between methamphetamine use and risky sexual behavior in adolescents." *Kaohsiung J Med Sci* 20(4): 160-5.

### Circadian Rhythms

- Hart, C. L., M. Haney, et al. (2005). "Combined effects of methamphetamine and zolpidem on performance and mood during simulated night shift work." *Pharmacol Biochem Behav* 81(3): 559-68.
- Hart, C. L., A. S. Ward, et al. (2003). "Methamphetamine attenuates disruptions in performance and mood during simulated night-shift work." *Psychopharmacology (Berl)* 169(1): 42-51.
- Shappell, S. A., G. L. Kearns, et al. (1996). "Chronopharmacokinetics and chronopharmacodynamics of dextromethamphetamine in man." *J Clin Pharmacol* 36(11): 1051-63.
- Yamashita, I., T. Moroji, et al. (1969). "Neuroendocrinological studies in mental disorders and psychotropic drugs. I. On the circadian rhythm of the plasma adrenocortical hormone in mental patients and methamphetamine- and chlorpromazine-treated animals." *Folia Psychiatr Neurol Jpn* 23(2): 143-58.

### Circadian Rhythms (animals)

*See also* Timing and Clock Speed (animals)

- Asano, Y. and T. Moroji (1974). "Effects of methamphetamine on daily rhythms of hypothalamic norepinephrine, serotonin and plasma corticosterone levels in the rat." *Life Sci* 14(8): 1463-72.
- Crean, R. D., S. A. Davis, et al. (2006). "Effects of (+/-)3,4-methylenedioxymethamphetamine, (+/-)3,4-methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques." *Neuroscience* 142(2): 515-25.
- Davidson, C., T. H. Lee, et al. (2005). "Acute and chronic continuous methamphetamine have different long-term behavioral and neurochemical consequences." *Neurochem Int* 46(3): 189-203.
- Evans, H. L., W. B. Ghiselli, et al. (1973). "Diurnal rhythm in behavioral effects of methamphetamine, p-chloramethamphetamine and scopolamine." *J Pharmacol Exp Ther* 186(1): 10-7.
- Estabrooke, I. V., M. T. McCarthy, et al. (2001). "Fos expression in orexin neurons varies with behavioral state." *J Neurosci* 21(5): 1656-62.
- Fehm, H. L., R. Holl, et al. (1984). "Evidence for ACTH-unrelated mechanisms in the regulation of cortisol secretion in man." *Klin Wochenschr* 62(1): 19-24.



- Fujiwara, Y. (1985). "[Behavioral and neurochemical changes in pups prenatally treated with methamphetamine]." *Yakubutsu Seishin Kodo* 5(3): 251-9.
- Furuya, N. and T. Hirao (1976). "A substrain mouse serologically classified in ddN strain and its behavioral characteristics." *Tohoku J Exp Med* 118(4): 355-63.
- Hiroshige, T., K. Honma, et al. (1991). "SCN-independent circadian oscillators in the rat." *Brain Res Bull* 27(3-4): 441-5.
- Honma, S. and K. Honma (1995). "Phase-dependent phase shift of methamphetamine-induced circadian rhythm by haloperidol in SCN-lesioned rats." *Brain Res* 674(2): 283-90.
- Honma, S. and K. Honma (1992). "Locomotor rhythms induced by methylphenidate in suprachiasmatic nuclei-lesioned rats." *Neurosci Lett* 137(1): 24-8.
- Honma, S., N. Kanematsu, et al. (1992). "Entrainment of methamphetamine-induced locomotor activity rhythm to feeding cycles in SCN-lesioned rats." *Physiol Behav* 52(5): 843-50.
- Honma, S., K. Honma, et al. (1991). "Methamphetamine effects on rat circadian clock depend on actograph." *Physiol Behav* 49(4): 787-95.
- Honma, S., K. Honma, et al. (1989). "Methamphetamine induced locomotor rhythm entrains to restricted daily feeding in SCN lesioned rats." *Physiol Behav* 45(5): 1057-65.
- Honma, S., K. Honma, et al. (1988). "Rhythms in behaviors, body temperature and plasma corticosterone in SCN lesioned rats given methamphetamine." *Physiol Behav* 44(2): 247-55.
- Honma, K., S. Honma, et al. (1987). "Activity rhythms in the circadian domain appear in suprachiasmatic nuclei lesioned rats given methamphetamine." *Physiol Behav* 40(6): 767-74.
- Honma, K., S. Honma, et al. (1986). "Disorganization of the rat activity rhythm by chronic treatment with methamphetamine." *Physiol Behav* 38(5): 687-95.
- Honma, K. and S. Honma (1986). "Effects of methamphetamine on development of circadian rhythms in rats." *Brain Dev* 8(4): 397-401.
- Ida, I., T. Asami, et al. (1992). "Circadian variation in R-THBP-induced enhancement of the ambulation-increasing effect of methamphetamine on mice." *Jpn J Psychiatry Neurol* 46(4): 941-5.
- Iijima, M., T. Nikaido, et al. (2002). "Methamphetamine-induced, suprachiasmatic nucleus-independent circadian rhythms of activity and mPer gene expression in the striatum of the mouse." *Eur J Neurosci* 16(5): 921-9.
- Itow, N., A. Yamatodani, et al. (1990). "Development of a computer program classifying rat sleep stages." *J Neurosci Methods* 31(2): 137-43.
- Kita, T., M. Takahashi, et al. (1998). "Methamphetamine-induced changes in activity and water intake during light and dark cycles in rats." *Prog Neuropsychopharmacol Biol Psychiatry* 22(7): 1185-96.
- Kosobud, A. E., N. C. Pecoraro, et al. (1998). "Circadian activity precedes daily methamphetamine injections in the rat." *Neurosci Lett* 250(2): 99-102.
- Krauchi, K., A. Wirz-Justice, et al. (1986). "Temporal distribution of [3H]-imipramine binding in rat brain regions is not changed by chronic methamphetamine." *Chronobiol Int* 3(2): 127-33.
- Krauchi, K., K. Rudolph, et al. (1985). "Similarities in feeding behavior of chronic methamphetamine treated and withdrawn rats to VMH lesioned rats." *Pharmacol Biochem Behav* 23(6): 917-20.
- Krauchi, K., A. Wirz-Justice, et al. (1984). "Hypothalamic alpha 2- and beta-adrenoceptor rhythms are correlated with circadian feeding: evidence from chronic methamphetamine treatment and withdrawal." *Brain Res* 321(1): 83-90.
- Kuczenski, R. and D. S. Segal (2002). "Exposure of adolescent rats to oral methylphenidate: Preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine." *J Neurosci* 22(16): 7264-71.
- Kuribara, H. and S. Tadokoro (1985). "Chronopharmacological study on morphine-induced increase in ambulatory activity in mice and methamphetamine sensitivity in morphine-experienced mice." *Yakubutsu Seishin Kodo* 5(3): 279-86.
- Kuribara, H. and S. Tadokoro (1984). "[Behavioral effects of amantadine on ambulatory activity and drinking in mice and on continuous and discrete avoidance responses in rats]." *Nippon Yakurigaku Zasshi* 83(2): 147-58.
- Kuribara, H. and S. Tadokoro (1984). "Circadian variation in the ambulation-increasing effect of apomorphine after repeated administration in mice." *Yakubutsu Seishin Kodo* 4(3): 231-6.
- Kuribara, H. and S. Tadokoro (1982). "Circadian variation in methamphetamine- and apomorphine-induced increase in ambulatory activity in mice." *Pharmacol Biochem Behav* 17(6): 1251-6.
- Masubuchi, S., S. Honma, et al. (2001). "Circadian activity rhythm in methamphetamine-treated Clock mutant mice." *Eur J Neurosci* 14(7): 1177-80.
- Masubuchi, S., S. Honma, et al. (2000). "Clock genes outside the suprachiasmatic nucleus involved in manifestation of locomotor activity rhythm in rats." *Eur J Neurosci* 12(12): 4206-14.
- Morimasa, T., A. Wirz-Justice, et al. (1987). "Chronic methamphetamine and its withdrawal modify behavioral and neuroendocrine circadian rhythms." *Physiol Behav* 39(6): 699-705.

- Moriya, T., T. Fukushima, et al. (1996). "Chronic administration of methamphetamine does not affect the suprachiasmatic nucleus-operated circadian pacemaker in rats." *Neurosci Lett* 208(2): 129-32.
- Moriya, T., S. Yamanouchi, et al. (1996). "Involvement of 5-HT1A receptor mechanisms in the inhibitory effects of methamphetamine on photic responses in the rodent suprachiasmatic nucleus." *Brain Res* 740(1-2): 261-7.
- Nikaido, T., M. Akiyama, et al. (2001). "Sensitized increase of period gene expression in the mouse caudate/putamen caused by repeated injection of methamphetamine." *Mol Pharmacol* 59(4): 894-900.
- Omata, K. and H. Kawamura (1988). "Effects of methamphetamine upon circadian rhythms in multiple unit activity inside and outside the suprachiasmatic nucleus in the golden hamster (*Mesocricetus auratus*)." *Neurosci Lett* 95(1-3): 218-22.
- Ono, M., S. Shibata, et al. (1996). "Effect of the noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 on food-anticipatory activity rhythm in the rat." *Physiol Behav* 59(4-5): 585-9.
- Ono, M., A. Watanabe, et al. (1996). "Methamphetamine modifies the photic entraining responses in the rodent suprachiasmatic nucleus via serotonin release." *Neuroscience* 72(1): 213-24.
- Ozaki, N., D. Nakahara, et al. (1991). "The effect of methamphetamine on serotonin and its metabolite in the suprachiasmatic nucleus: A microdialysis study." *J Neural Transm Gen Sect* 86(3): 175-9.
- Pecoraro, N., A. E. Kosobud, et al. (2000). "Long T methamphetamine schedules produce circadian ensuing drug activity in rats." *Physiol Behav* 71(1-2): 95-106.
- Rietveld, W. J., J. Korving, et al. (1987). "The circadian control of behavior in the rat affected by the chronic application of methamphetamine." *Prog Clin Biol Res* 227B: 513-7.
- Ruis, J. F., J. P. Buys, et al. (1990). "Effects of T cycles of light/darkness and periodic forced activity on methamphetamine-induced rhythms in intact and SCN-lesioned rats: Explanation by an hourglass-clock model." *Physiol Behav* 47(5): 917-29.
- Sato, M. and Y. Fujiwara (1986). "Behavioral and neurochemical changes in pups prenatally exposed to methamphetamine." *Brain Dev* 8(4): 390-6.
- Shibata, S., Y. Minamoto, et al. (1994). "Aging impairs methamphetamine-induced free-running and anticipatory locomotor activity rhythms in rats." *Neurosci Lett* 172(1-2): 107-10.
- Tataroglu, O., A. J. Davidson, et al. (2006). "The methamphetamine-sensitive circadian oscillator (MASCO) in mice." *J Biol Rhythms* 21(3): 185-94.
- Toyota, H., C. Dugovic, et al. (2002). "Behavioral characterization of mice lacking histamine H(3) receptors." *Mol Pharmacol* 62(2): 389-97.
- Uchihashi, Y., H. Kuribara, et al. (1994). "Long-continuous observation of the effects of methamphetamine on wheel-running and drinking in mice." *Prog Neuropsychopharmacol Biol Psychiatry* 18(2): 397-407.
- Wallace, T. L., G. A. Gudelsky, et al. (2001). "Alterations in diurnal and nocturnal locomotor activity in rats treated with a monoamine-depleting regimen of methamphetamine or 3,4-methylenedioxymethamphetamine." *Psychopharmacology (Berl)* 153(3): 321-6.
- Watanabe, T. and K. Yanai (2001). "Studies on functional roles of the histaminergic neuron system by using pharmacological agents, knockout mice and positron emission tomography." *Tohoku J Exp Med* 195(4): 197-217.
- Yamamoto, H., K. Imai, et al. (2005). "Methamphetamine modulation of gene expression in the brain: analysis using customized cDNA microarray system with the mouse homologues of KIAA genes." *Brain Res Mol Brain Res* 137(1-2): 40-6.
- Yamamoto, H., K. Imai, et al. (2004). "Changes in expression of the mouse homologues of KIAA genes after subchronic methamphetamine treatment." *Ann N Y Acad Sci* 1025: 92-101.
- Yamashita, I., T. Moroji, et al. (1969). "Neuroendocrinological studies in mental disorders and psychotropic drugs. I. On the circadian rhythm of the plasma adrenocortical hormone in mental patients and methamphetamine- and chlorpromazine-treated animals." *Folia Psychiatr Neurol Jpn* 23(2): 143-58.
- Yoshimura, K. and K. Yamamoto (1980). "[Neuropharmacological studies on drug dependence (II). Changes in spontaneous motor activity, EEG and brain monoamines during the period of dependence development and of abrupt withdrawal in rats, with special reference to circadian rhythm (author's transl)]." *Nippon Yakurigaku Zasshi* 76(5): 373-411.
- Yu, L., C. F. Cherg, et al. (2002). "Melatonin in concentrated ethanol and ethanol alone attenuate methamphetamine-induced dopamine depletions in C57BL/6J mice." *J Neural Transm* 109(12): 1477-90.

### Circuit Parties and Raves

*See also* Recreational and Club Drugs

- Colfax, G. N., G. Mansergh, et al. (2001). "Drug use and sexual risk behavior among gay and bisexual men who attend circuit parties: A venue-based comparison." *J Acquir Immune Defic Syndr* 28(4): 373-9.
- Fendrich, M., J. S. Wislar, T. P. Johnson and A. Hubbell (2003). "A contextual profile of club drug use among adults in Chicago." *Addiction* 98(12): 1693-703.

- Ghaziani, A. and T. D. Cook (2005). "Reducing HIV infections at circuit parties: From description to explanation and principles of intervention design." *J Int Assoc Physicians AIDS Care (Chic Ill)* 4(2): 32-46.
- Halkitis, P. N. and J. J. Palamar (2006). "GHB use among gay and bisexual men." *Addict Behav* 31(11): 2135-9.
- Halkitis, P. N., J. T. Parsons, et al. (2001). "A double epidemic: Crystal methamphetamine drug use in relation to HIV transmission among gay men." *J Homosex* 41(2): 17-35.
- Hopfer, C., B. Mendelson, et al. (2006). "Club drug use among youths in treatment for substance abuse." *Am J Addict* 15(1): 94-9.
- Irvine, R. J., M. Keane, et al. (2006). "Plasma drug concentrations and physiological measures in 'dance party' participants." *Neuropsychopharmacology* 31(2): 424-30.
- Joe Laidler, K. A. (2005). "The rise of club drugs in a heroin society: The case of Hong Kong." *Subst Use Misuse* 40(9-10): 1257-78.
- Kelly, B. C., J. T. Parsons, et al. (2006). "Prevalence and predictors of club drug use among club-going young adults in New York City." *J Urban Health* 83(5): 884-895.
- Klein, M. and F. Kramer (2004). "Rave drugs: Pharmacological considerations." *AANA J* 72(1): 61-7.
- Kurtz, S. P. (2005). "Post-circuit blues: Motivations and consequences of crystal meth use among gay men in Miami." *AIDS Behav* 9(1): 63-72.
- Lee, S. J., M. Galanter, et al. (2003). "Circuit parties and patterns of drug use in a subset of gay men." *J Addict Dis* 22(4): 47-60.
- Mansergh, G., G. N. Colfax, et al. (2001). "The Circuit Party Men's Health Survey: Findings and implications for gay and bisexual men." *Am J Public Health* 91(6): 953-8.
- Mattison, A. M., M. W. Ross, et al. (2001). "Circuit party attendance, club drug use, and unsafe sex in gay men." *J Subst Abuse* 13(1-2): 119-26.
- McCaughan, J. A., R. G. Carlson, et al. (2005). "From 'Candy Kids' to 'Chemi-Kids': A typology of young adults who attend raves in the midwestern United States." *Subst Use Misuse* 40(9-10): 1503-23.
- Parks, K. A. and C. L. Kennedy (2004). "Club drugs: Reasons for and consequences of use." *J Psychoactive Drugs* 36(3): 295-302.
- Ross, M. W., A. M. Mattison, et al. (2003). "Club drugs and sex on drugs are associated with different motivations for gay circuit party attendance in men." *Subst Use Misuse* 38(8): 1173-83.
- Rome, E. S. (2001). "It's a rave new world: Rave culture and illicit drug use in the young." *Cleve Clin J Med* 68(6): 541-50.
- Soellner, R. (2005). "Club drug use in Germany." *Subst Use Misuse* 40(9): 1279-93.

## Clandestine Drug Laboratories

*See Methamphetamine Laboratories*

## Clock Speed

*See Circadian Rhythms; Circadian Rhythms (animals); Hyperactivity; Hyperactivity (animals); Timing and Clock Speed (animals)*

## Club Drugs

*See Polydrug Use; Recreational and Club Drugs; and specific substances*

## Cocaine

*See also Polydrug Use*

- Alhassoon, O. M., R. M. Dupont, et al. (2001). "Regional cerebral blood flow in cocaine- versus methamphetamine-dependent patients with a history of alcoholism." *Int J Neuropsychopharmacol* 4(2): 105-12.
- Bailey, D. N. and R. F. Shaw (1989). "Cocaine- and methamphetamine-related deaths in San Diego County (1987): homicides and accidental overdoses." *J Forensic Sci* 34(2): 407-22.
- Barr, A. M., W. J. Panenka, et al. (2006). "The need for speed: An update on methamphetamine addiction." *J Psychiatry Neurosci* 31(5): 301-313.
- Batki, S. L. and D. S. Harris (2004). "Quantitative drug levels in stimulant psychosis: Relationship to symptom severity, catecholamines and hyperkinesia." *Am J Addict* 13(5): 461-70.
- Baxter, L. R., Jr., J. M. Schwartz, et al. (1988). "Localization of neurochemical effects of cocaine and other stimulants in the human brain." *J Clin Psychiatry* 49 Suppl: 23-6.
- Bolding, G., G. Hart, et al. (2006). "Use of crystal methamphetamine among gay men in London." *Addiction* 101(11): 1622-30.

- Booth, B. M., C. Leukefeld, et al. (2006). "Correlates of rural methamphetamine and cocaine users: Results from a multistate community study." *J Stud Alcohol* 67(4): 493-501.
- Brodie, J. D., E. Figueroa, et al. (2005). "Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction." *Synapse* 55(2): 122-5.
- Brouwer, K. C., P. Case, et al. (2006). "Trends in production, trafficking, and consumption of methamphetamine and cocaine in Mexico." *Subst Use Misuse* 41(5): 707-27.
- Buchi, K. F., S. Zone, K. Langheinrich and M. W. Varner (2003). "Changing prevalence of prenatal substance abuse in Utah." *Obstet Gynecol* 102(1): 27-30.
- Chiappelli, F., P. Shapshak, et al. (2006). "Cellular immunology in HIV-1 positive African American women using alcohol and cocaine." *Front Biosci* 11: 2434-41.
- Chin, K. M., R. N. Channick, et al. (2006). "Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?" *Chest* 130(6): 1657-63.
- Colfax, G., T. J. Coates, et al. (2005). "Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of San Francisco men who have sex with men." *J Urban Health* 82(1 Suppl 1): i62-70.
- Colfax, G., E. Vittinghoff, et al. (2004). "Substance use and sexual risk: A participant- and episode-level analysis among a cohort of men who have sex with men." *Am J Epidemiol* 159(10): 1002-12.
- Cook, C. E. (1991). "Pyrolytic characteristics, pharmacokinetics, and bioavailability of smoked heroin, cocaine, phencyclidine, and methamphetamine." *NIDA Res Monogr* 115: 6-23.
- Copeland, A. L. and J. L. Sorensen (2001). "Differences between methamphetamine users and cocaine users in treatment." *Drug Alcohol Depend* 62(1): 91-5.
- Derlet, R. W. and B. Heischouer (1990). "Methamphetamine. Stimulant of the 1990s?" *West J Med* 153(6): 625-8.
- Diaz, R. M., A. L. Heckert, et al. (2005). "Reasons for stimulant use among Latino gay men in San Francisco: a comparison between methamphetamine and cocaine users." *J Urban Health* 82(1 Suppl 1): i71-8.
- Dixon, S. D. (1989). "Effects of transplacental exposure to cocaine and methamphetamine on the neonate." *West J Med* 150(4): 436-42.
- Ellinwood, E. H., Jr. and M. M. Kilbey (1980). "Fundamental mechanisms underlying altered behavior following chronic administration of psychomotor stimulants." *Biol Psychiatry* 15(5): 749-57.
- Fechtner, R. D., A. S. Khouri, et al. (2006). "Short-term treatment of cocaine and/or methamphetamine abuse with vigabatrin: Ocular safety pilot results." *Arch Ophthalmol* 124(9): 1257-62.
- Forrester, M. B. and R. D. Merz (2007). "Risk of selected birth defects with prenatal illicit drug use, Hawaii, 1986-2002." *J Toxicol Environ Health A* 70(1): 7-18.
- Galloway, G. P., J. Newmeyer, et al. (1994). "Imipramine for the treatment of cocaine and methamphetamine dependence." *J Addict Dis* 13(4): 201-16.
- Gotway, M. B., S. R. Marder, et al. (2002). "Thoracic complications of illicit drug use: An organ system approach." *Radiographics* 22 Spec No: S119-35.
- Gonzalez Castro, F., E. H. Barrington, et al. (2000). "Cocaine and methamphetamine: Differential addiction rates." *Psychol Addict Behav* 14(4): 390-6.
- Harris, D. S., V. I. Reus, et al. (2005). "Repeated psychological stress testing in stimulant-dependent patients." *Prog Neuropsychopharmacol Biol Psychiatry* 29(5): 669-77.
- Hirshfield, S., R. H. Remien, et al. (2004). "Crystal methamphetamine use predicts incident STD infection among men who have sex with men recruited online: a nested case-control study." *J Med Internet Res* 6(4): e41.
- Huber, A., W. Ling, et al. (1997). "Integrating treatments for methamphetamine abuse: a psychosocial perspective." *J Addict Dis* 16(4): 41-50.
- Inouye, D. S., J. J. Navin, et al. (2004). "Fatal postoperative arrhythmia in a man with a remote history of methamphetamine and cocaine use: a case report." *Hawaii Med J* 63(3): 82-6.
- Kelly, B. C., J. T. Parsons, et al. (2006). "Prevalence and predictors of club drug use among club-going young adults in New York City." *J Urban Health* 83(5): 884-895.
- Kish, S. J., K. S. Kalasinsky, et al. (1999). "Brain choline acetyltransferase activity in chronic, human users of cocaine, methamphetamine, and heroin." *Mol Psychiatry* 4(1): 26-32.
- Kobayashi, H., S. Ide, et al. (2004). "Study of association between alpha-synuclein gene polymorphism and methamphetamine psychosis/dependence." *Ann N Y Acad Sci* 1025: 325-34.
- Kral, A. H., J. Lorvick, et al. (2005). "HIV prevalence and risk behaviors among men who have sex with men and inject drugs in San Francisco." *J Urban Health* 82(1 Suppl 1): i43-50.
- Lampinen, T. M., D. McGhee, et al. (2006). "Increased risk of "club" drug use among gay and bisexual high school students in British Columbia." *J Adolesc Health* 38(4): 458-61.

- Leeds, N. E., V. Malhotra, et al. (1983). "The radiology of drug addiction affecting the brain." *Semin Roentgenol* 18(3): 227-33.
- Lorvick, J., A. Martinez, et al. (2006). "Sexual and injection risk among women who inject methamphetamine in San Francisco." *J Urban Health* 83(3): 497-505.
- Lyons, T., G. Chandra, et al. (2006). "Stimulant use and HIV risk behavior: The influence of peer support group participation." *AIDS Educ Prev* 18(5): 461-73.
- Johanson, C. E., L. H. Lundahl, et al. (2006). "Intravenous cocaine discrimination in humans." *Exp Clin Psychopharmacol* 14(2): 99-108.
- Johnson, B. A., L. T. Wells, et al. (2005). "Isradipine decreases the hemodynamic response of cocaine and methamphetamine results from two human laboratory studies: Results from two human laboratory studies." *Am J Hypertens* 18(6): 813-22.
- Kelly, B. C., J. T. Parsons, et al. (2006). "Prevalence and predictors of club drug use among club-going young adults in New York City." *J Urban Health* 83(5): 884-895.
- Levine, A. J., D. J. Hardy, et al. (2006). "The effect of recent stimulant use on sustained attention in HIV-infected adults." *J Clin Exp Neuropsychol* 28(1): 29-42.
- Li, J. X., R. Han, et al. (2005). "Different effects of valproate on methamphetamine- and cocaine-induced behavioral sensitization in mice." *Behav Brain Res* 161(1): 125-32.
- Lampinen, T. M., D. McGhee, et al. (2006). "Increased risk of "club" drug use among gay and bisexual high school students in British Columbia." *J Adolesc Health* 38(4): 458-61.
- Lundqvist, T. (2005). "Cognitive consequences of cannabis use: Comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions." *Pharmacol Biochem Behav* 81(2): 319-30.
- Maxwell, J. C., P. Cravioto, et al. (2006). "Drug use and risk of HIV/AIDS on the Mexico-USA border: A comparison of treatment admissions in both countries." *Drug Alcohol Depend* 82 Suppl 1: S85-93.
- McCaughan, J. A., R. G. Carlson, et al. (2005). "From "Candy Kids" to "Chemi-Kids": A typology of young adults who attend raves in the midwestern United States." *Subst Use Misuse* 40(9-10): 1503-23.
- McKetin, R., E. Kelly, et al. (2006). "The relationship between crystalline methamphetamine use and methamphetamine dependence." *Drug Alcohol Depend* 85(3): 198-204.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.
- Nalls, G., A. Disher, et al. (1989). "Subcortical cerebral hemorrhages associated with cocaine abuse: CT and MR findings." *J Comput Assist Tomogr* 13(1): 1-5.
- Nath, A., C. Anderson, et al. (2000). "Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia." *J Psychopharmacol* 14(3): 222-7.
- Nath, A., W. F. Maragos, et al. (2001). "Acceleration of HIV dementia with methamphetamine and cocaine." *J Neurovirol* 7(1): 66-71.
- Newton, T. F., R. De La Garza, 2nd, et al. (2005). "Cocaine and methamphetamine produce different patterns of subjective and cardiovascular effects." *Pharmacol Biochem Behav* 82(1): 90-7.
- Nordahl, T. E., R. Salo, et al. (2003). "Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: A review." *J Neuropsychiatry Clin Neurosci* 15(3): 317-25.
- Obert, J. L., M. J. McCann, et al. (2000). "The Matrix model of outpatient stimulant abuse treatment: History and description." *J Psychoactive Drugs* 32(2): 157-64.
- Oro, A. S. and S. D. Dixon (1987). "Perinatal cocaine and methamphetamine exposure: Maternal and neonatal correlates." *J Pediatr* 111(4): 571-8.
- Parsons, J. T., B. C. Kelly, et al. (2006). "Differences in club drug use between heterosexual and lesbian/bisexual females." *Addict Behav* 31(12): 2344-9.
- Patterson, T. L., S. J. Semple, et al. (2005). "Methamphetamine-using HIV-positive men who have sex with men: Correlates of polydrug use." *J Urban Health* 82(1 Suppl 1): i120-6.
- Pecha, R. E., T. Prindiville, et al. (1996). "Association of cocaine and methamphetamine use with giant gastroduodenal ulcers." *Am J Gastroenterol* 91(12): 2523-7.
- Peirce, J. M., N. M. Petry, et al. (2006). "Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: A National Drug Abuse Treatment Clinical Trials Network study." *Arch Gen Psychiatry* 63(2): 201-8.
- Rawson, R. A., M. J. McCann, et al. (2006). "A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals." *Addiction* 101(2): 267-74.
- Rawson, R. A., A. Washton, et al. (2002). "Drugs and sexual effects: Role of drug type and gender." *J Subst Abuse Treat* 22(2): 103-8.
- Rawson, R., A. Huber, et al. (2000). "Methamphetamine and cocaine users: Differences in characteristics and treatment retention." *J Psychoactive Drugs* 32(2): 233-8.
- Reid, L. W., K. W. Elifson, et al. (2007). "Ecstasy and gateway drugs: Initiating the use of ecstasy and other drugs." *Ann Epidemiol* 17(1): 74-80.

- Riehmman, K. S., M. Y. Iguchi and M. D. Anglin (2002). "Depressive symptoms among amphetamine and cocaine users before and after substance abuse treatment." *Psychol Addict Behav* 16(4): 333-7.
- Roll, J. M., N. M. Petry, et al. (2006). "Contingency management for the treatment of methamphetamine use disorders." *Am J Psychiatry* 163(11): 1993-9.
- Ross, B. M., A. Moszczynska, et al. (2002). "Decreased activity of brain phospholipid metabolic enzymes in human users of cocaine and methamphetamine." *Drug Alcohol Depend* 67(1): 73-9.
- Rothman, R. B., J. S. Partilla, et al. (2000). "Methamphetamine dependence: Medication development efforts based on the dual deficit model of stimulant addiction." *Ann N Y Acad Sci* 914: 71-81.
- Roxburgh, A., L. Degenhardt, et al. (2004). "Changes in patterns of drug use among injecting drug users following changes in the availability of heroin in New South Wales, Australia." *Drug Alcohol Rev* 23(3): 287-94.
- Royo-Isach, J., M. Magrane, et al. (2004). "[Speed users (metamphetamines): a return journey between ecstasy (MDMA) and cocaine. Clinical, preventive and health-care questions]." *Aten Primaria* 34(10): 553-6.
- Schwilke, E. W., M. I. Sampaio dos Santos, et al. (2006). "Changing patterns of drug and alcohol use in fatally injured drivers in Washington State." *J Forensic Sci* 51(5): 1191-8.
- Semple, S. J., T. L. Patterson, et al. (2004). "A comparison of injection and non-injection methamphetamine-using HIV positive men who have sex with men." *Drug Alcohol Depend* 76(2): 203-12.
- Shearer, J., A. Wodak, et al. (2003). "Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence." *Addiction* 98(8): 1137-41.
- Shoptaw, S., C. J. Reback, et al. (1998). "Stimulant abuse treatment as HIV prevention." *J Addict Dis* 17(4): 19-32.
- Siegel, D., J. Erickson, et al. (2004). "Brain vesicular acetylcholine transporter in human users of drugs of abuse." *Synapse* 52(4): 223-32.
- Simon, S. L., K. Richardson, J. Dacey, S. Glynn, C. P. Domier, R. A. Rawson and W. Ling (2002). "A comparison of patterns of methamphetamine and cocaine use." *J Addict Dis* 21(1): 35-44.
- Simon, S. L., C. P. Domier, et al. (2002). "Cognitive performance of current methamphetamine and cocaine abusers." *J Addict Dis* 21(1): 61-74.
- Soellner, R. (2005). "Club drug use in Germany." *Subst Use Misuse* 40(9): 1279-93.
- Struthers, J. M. and R. L. Hansen (1992). "Visual recognition memory in drug-exposed infants." *J Dev Behav Pediatr* 13(2): 108-11.
- Sulzer, D., M. S. Sonders, et al. (2005). "Mechanisms of neurotransmitter release by amphetamines: A review." *Prog Neurobiol* 75(6): 406-33.
- Ujike, H., K. Akiyama, et al. (1990). "D-2 but not D-1 dopamine agonists produce augmented behavioral response in rats after subchronic treatment with methamphetamine or cocaine." *Psychopharmacology (Berl)* 102(4): 459-64.
- Viani, R. M., M. R. Araneta, et al. (2006). "Perinatal HIV counseling and rapid testing in Tijuana, Baja California, Mexico: Seroprevalence and correlates of HIV infection." *J Acquir Immune Defic Syndr* 41(1): 87-92.
- Volkow, N. D., G. J. Wang, et al. (2007). "Stimulant-induced enhanced sexual desire as a potential contributing factor in HIV transmission." *Am J Psychiatry* 164(1): 157-60.
- Wada, K. (1994). "Cocaine abuse in Japan." *Arukoru Kenkyuto Yakubutsu Ison* 29(2): 83-91.
- Wallace, R. T., G. C. Brown, et al. (1992). "Sudden retinal manifestations of intranasal cocaine and methamphetamine abuse." *Am J Ophthalmol* 114(2): 158-60.
- Worsley, J. N., A. Moszczynska, et al. (2000). "Dopamine D1 receptor protein is elevated in nucleus accumbens of human, chronic methamphetamine users." *Mol Psychiatry* 5(6): 664-72.

### Cocaine (animals)

- Adams, D. H., G. R. Hanson, et al. (2000). "Cocaine and methamphetamine differentially affect opioid peptide mRNA expression in the striatum." *J Neurochem* 75(5): 2061-70.
- Ali, S. F., K. J. Kordsmeier, et al. (1995). "Drug-induced circling preference in rats. Correlation with monoamine levels." *Mol Neurobiol* 11(1-3): 145-54.
- Allan, A. M., R. Galindo, et al. (2001). "Conditioned place preference for cocaine is attenuated in mice over-expressing the 5-HT(3) receptor." *Psychopharmacology (Berl)* 158(1): 18-27.
- Balster, R. L., M. M. Kilbey, et al. (1976). "Methamphetamine self-administration in the cat." *Psychopharmacologia* 46(3): 229-33.
- Bondareva, T. S., R. Young, et al. (2002). "Central stimulants as discriminative stimuli. Asymmetric generalization between (-)ephedrine and S(+)-methamphetamine." *Pharmacol Biochem Behav* 74(1): 157-62.
- Carney, J. M., R. W. Landrum, et al. (1991). "Establishment of chronic intravenous drug self-administration in the C57BL/6J mouse." *Neuroreport* 2(8): 477-80.

- Cervinski, M. A., J. D. Foster, et al. (2005). "Psychoactive substrates stimulate dopamine transporter phosphorylation and down-regulation by cocaine-sensitive and protein kinase C-dependent mechanisms." *J Biol Chem* 280(49): 40442-9.
- Chen, H. H., Y. K. Yang, et al. (2003). "Methamphetamine-induced conditioned place preference is facilitated by estradiol pretreatment in female mice." *Chin J Physiol* 46(4): 169-74.
- Chen, R., D. D. Han, et al. (2005). "A triple mutation in the second transmembrane domain of mouse dopamine transporter markedly decreases sensitivity to cocaine and methylphenidate." *J Neurochem* 94(2): 352-9.
- Davidson, C., T. H. Lee, et al. (2005). "Acute and chronic continuous methamphetamine have different long-term behavioral and neurochemical consequences." *Neurochem Int* 46(3): 189-203.
- Ellinwood, E. H., Jr. and M. M. Kilbey (1980). "Fundamental mechanisms underlying altered behavior following chronic administration of psychomotor stimulants." *Biol Psychiatry* 15(5): 749-57.
- Fantegrossi, W. E., W. L. Woolverton, et al. (2004). "Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys." *Neuropsychopharmacology* 29(7): 1270-81.
- Fantegrossi, W. E., T. Ullrich, et al. (2002). "3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: Serotonergic involvement." *Psychopharmacology (Berl)* 161(4): 356-64.
- Fog, R. (1972). "On stereotypy and catalepsy: Studies on the effect of amphetamines and neuroleptics in rats." *Acta Neurol Scand Suppl* 50: 3-66.
- Fog, R. (1969). "Stereotyped and non-stereotyped behaviour in rats induced by various stimulant drugs." *Psychopharmacologia* 14(4): 299-304.
- Hanson, G. R., M. Jensen, et al. (1999). "Distinct features of seizures induced by cocaine and amphetamine analogs." *Eur J Pharmacol* 377(2-3): 167-73.
- Hanson, G. R., N. Singh, et al. (1992). "Responses of limbic and extrapyramidal neurotensin systems to stimulants of abuse. Involvement of dopaminergic mechanisms." *Ann N Y Acad Sci* 668: 165-72.
- Hayase, T., Y. Yamamoto, et al. (2006). "Behavioral effects of ketamine and toxic interactions with psychostimulants." *BMC Neurosci* 7(1): 25.
- Hayase, T., Y. Yamamoto, et al. (2005). "Persistent anxiogenic effects of a single or repeated doses of cocaine and methamphetamine: Interactions with endogenous cannabinoid receptor ligands." *Behav Pharmacol* 16(5-6): 395-404.
- Hayase, T., Y. Yamamoto, et al. (2003). "Brain excitatory amino acid transporters (EAATs) and treatment of methamphetamine toxicity." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 38(6): 498-511.
- Hirabayashi, M. and S. Tadokoro (1992). "Sensitization to ambulation-increasing effects of cocaine after repeated administration in mice-roles of dose and interval of administration as well as experimental environments." *Arukoru Kenkyuto Yakubutsu Ison* 27(1): 91-102.
- Hirabayashi, M., S. Okada, et al. (1991). "Comparison of sensitization to ambulation-increasing effects of cocaine and methamphetamine after repeated administration in mice." *J Pharm Pharmacol* 43(12): 827-30.
- Holtzman, S. G. (2001). "Differential interaction of GBR 12909, a dopamine uptake inhibitor, with cocaine and methamphetamine in rats discriminating cocaine." *Psychopharmacology (Berl)* 155(2): 180-6.
- Horner, K. A., D. H. Adams, et al. (2005). "Blockade of stimulant-induced preprodynorphin mRNA expression in the striatal matrix by serotonin depletion." *Neuroscience* 131(1): 67-77.
- Janowsky, A., C. Mah, et al. (2001). "Mapping genes that regulate density of dopamine transporters and correlated behaviors in recombinant inbred mice." *J Pharmacol Exp Ther* 298(2): 634-43.
- Itzhak, Y. and J. L. Martin (2002). "Cocaine-induced conditioned place preference in mice: Induction, extinction and reinstatement by related psychostimulants." *Neuropsychopharmacology* 26(1): 130-4.
- Itzhak, Y. and J. L. Martin (2000). "Effect of riluzole and gabapentin on cocaine- and methamphetamine-induced behavioral sensitization in mice." *Psychopharmacology (Berl)* 151(2-3): 226-33.
- Itzhak, Y. (1994). "Modulation of the PCP/NMDA receptor complex and sigma binding sites by psychostimulants." *Neurotoxicol Teratol* 16(4): 363-8.
- Izawa, J., K. Yamanashi, et al. (2006). "Differential effects of methamphetamine and cocaine on behavior and extracellular levels of dopamine and 3,4-dihydroxyphenylalanine in the nucleus accumbens of conscious rats." *Eur J Pharmacol* 549(1-3): 84-90.
- Johanson, C. E., R. L. Balster, et al. (1976). "Self-administration of psychomotor stimulant drugs: The effects of unlimited access." *Pharmacol Biochem Behav* 4(1): 45-51.
- Kamens, H. M., S. Burkhart-Kasch, et al. (2005). "Sensitivity to psychostimulants in mice bred for high and low stimulation to methamphetamine." *Genes Brain Behav* 4(2): 110-25.
- Karler, R., L. D. Calder, et al. (1998). "The role of dopamine and GABA in the frontal cortex of mice in modulating a motor-stimulant effect of amphetamine and cocaine." *Pharmacol Biochem Behav* 60(1): 237-44.

- Karler, R., L. D. Calder, et al. (1995). "The dopaminergic, glutamatergic, GABAergic bases for the action of amphetamine and cocaine." *Brain Res* 671(1): 100-4.
- Karler, R., L. D. Calder, et al. (1994). "A dopaminergic-glutamatergic basis for the action of amphetamine and cocaine." *Brain Res* 658(1-2): 8-14.
- Kim, H. C., E. J. Shin, et al. (2005). "Pharmacological action of Panax ginseng on the behavioral toxicities induced by psychotropic agents." *Arch Pharm Res* 28(9): 995-1001.
- Kleven, M. S. and L. S. Seiden (1992). "Repeated injection of cocaine potentiates methamphetamine-induced toxicity to dopamine-containing neurons in rat striatum." *Ann N Y Acad Sci* 654: 464-6.
- Kleven, M. S. and L. S. Seiden (1991). "Repeated injection of cocaine potentiates methamphetamine-induced toxicity to dopamine-containing neurons in rat striatum." *Brain Res* 557(1-2): 340-3.
- Klongpanichapak, S., P. Govitrapong, et al. (2006). "Attenuation of cocaine and methamphetamine neurotoxicity by coenzyme Q10." *Neurochem Res* 31(3): 303-11.
- Kuo, Y. M., K. C. Liang, et al. (2006). "Cocaine-but not methamphetamine-associated memory requires de novo protein synthesis." *Neurobiol Learn Mem*.
- Kuribara, H. and S. Tadokoro (1985). "Effects of psychoactive drugs on conditioned avoidance response in Mongolian gerbils (*Meriones unguiculatus*): Comparison with Wistar rats and dd mice." *Pharmacol Biochem Behav* 23(6): 1013-8.
- Kuwahara, A., A. Kubota, et al. (1987). "[Drug dependence test on a cerebral insufficiency improver, aniracetam]." *Nippon Yakurigaku Zasshi* 89(1): 33-46.
- Li, J. X., R. Han, et al. (2005). "Different effects of valproate on methamphetamine- and cocaine-induced behavioral sensitization in mice." *Behav Brain Res* 161(1): 125-32.
- Li, S. M., B. L. Campbell, et al. (2006). "Interactions of cocaine with dopamine uptake inhibitors or dopamine releasers in rats discriminating cocaine." *J Pharmacol Exp Ther* 317(3): 1088-96.
- Maisonneuve, I. M. and S. D. Glick (2003). "Anti-addictive actions of an iboga alkaloid congener: A novel mechanism for a novel treatment." *Pharmacol Biochem Behav* 75(3): 607-18.
- Masukawa, Y., T. Suzuki, et al. (1993). "Differential modification of the rewarding effects of methamphetamine and cocaine by opioids and antihistamines." *Psychopharmacology (Berl)* 111(2): 139-43.
- McGinty, J. F. (1995). "Introduction to the role of excitatory amino acids in the actions of abused drugs: a symposium presented at the 1993 annual meeting of the College on Problems of Drug Dependence." *Drug Alcohol Depend* 37(2): 91-4.
- Mizuno, M., R. S. Malta, Jr., et al. (2004). "Conditioned place preference and locomotor sensitization after repeated administration of cocaine or methamphetamine in rats treated with epidermal growth factor during the neonatal period." *Ann N Y Acad Sci* 1025: 612-8.
- Mori, T., M. Narita, et al. (2002). "Modulation of the discriminative stimulus effects of cocaine and methamphetamine by the histaminergic system." *Nihon Shinkei Seishin Yakurigaku Zasshi* 22(3): 73-8.
- Munzar, P., S. W. Kutkat, et al. (2000). "Failure of baclofen to modulate discriminative-stimulus effects of cocaine or methamphetamine in rats." *Eur J Pharmacol* 408(2): 169-74.
- Nakagawa, T., M. Fujio, et al. (2005). "Effect of MS-153, a glutamate transporter activator, on the conditioned rewarding effects of morphine, methamphetamine and cocaine in mice." *Behav Brain Res* 156(2): 233-9.
- Nakamura, H., T. Hishinuma, et al. (1997). "Effects of haloperidol and cocaine pretreatments on brain distribution and kinetics of [<sup>11</sup>C]methamphetamine in methamphetamine sensitized dog: application of PET to drug pharmacokinetic study." *Nucl Med Biol* 24(2): 165-9.
- Newman, J. L. and M. E. Carroll (2006). "Reinforcing effects of smoked methamphetamine in rhesus monkeys." *Psychopharmacology (Berl)* 188(2): 193-200.
- Oro, A. S. and S. D. Dixon (1987). "Perinatal cocaine and methamphetamine exposure: Maternal and neonatal correlates." *J Pediatr* 111(4): 571-8.
- Pacchioni, A. M., J. Vallone, et al. (2007). "Nrf2 gene deletion fails to alter psychostimulant-induced behavior or neurotoxicity." *Brain Res* 1127(1): 26-35.
- Parker, L. A. (1995). "Rewarding drugs produce taste avoidance, but not taste aversion." *Neurosci Biobehav Rev* 19(1): 143-57.
- Parker, L. A. (1993). "Taste reactivity responses elicited by cocaine-, phencyclidine-, and methamphetamine-paired sucrose solutions." *Behav Neurosci* 107(1): 118-29.
- Peltier, R. L., D. H. Li, et al. (1996). "Chronic d-amphetamine or methamphetamine produces cross-tolerance to the discriminative and reinforcing stimulus effects of cocaine." *J Pharmacol Exp Ther* 277(1): 212-8.
- Rothman, R. B., B. E. Blough, et al. (2006). "Dual dopamine-5-HT releasers: Potential treatment agents for cocaine addiction." *Trends Pharmacol Sci* 27(12): 612-8.



- Rothman, R. B., B. E. Blough, et al. (2005). "Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration." *J Pharmacol Exp Ther* 313(3): 1361-9.
- Rubinstein, M., T. J. Phillips, et al. (1997). "Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine." *Cell* 90(6): 991-1001.
- Schaefer, T. L., L. A. Ehrman, et al. (2006). "Comparison of monoamine and corticosterone levels 24 h following (+)methamphetamine, (+/-)3,4-methylenedioxymethamphetamine, cocaine, (+)fenfluramine or (+/-)methylphenidate administration in the neonatal rat." *J Neurochem* 98(5): 1369-78.
- Shimosato, K., S. Watanabe, et al. (2001). "Differential effects of trihexyphenidyl on place preference conditioning and locomotor stimulant activity of cocaine and methamphetamine." *Naunyn Schmiedebergs Arch Pharmacol* 364(1): 74-80.
- Shimosato, K. and S. Ohkuma (2000). "Simultaneous monitoring of conditioned place preference and locomotor sensitization following repeated administration of cocaine and methamphetamine." *Pharmacol Biochem Behav* 66(2): 285-92.
- Suzuki, T., T. Mori, et al. (1997). "Generalization of D-, L- and DL-chlorpheniramine and zolantidine to the discriminative stimulus effects of cocaine and methamphetamine." *Behav Pharmacol* 8(8): 718-24.
- Suzuki, T. and M. Misawa (1995). "Sertindole antagonizes morphine-, cocaine-, and methamphetamine-induced place preference in the rat." *Life Sci* 57(13): 1277-84.
- Suzuki, T., Y. Shiozaki, et al. (1992). "Effects of calcium antagonists on the cocaine- and methamphetamine-induced conditioned place preference." *Arukuru Kenkyuto Yakubutsu Ison* 27(1): 81-90.
- Takamatsu, Y., Y. Yamanishi, et al. (2006). "Differential effects of donepezil on methamphetamine and cocaine dependencies." *Ann N Y Acad Sci* 1074: 418-26.
- Tuazon, D. B., T. Suzuki, et al. (1992). "Methylxanthines (caffeine and theophylline) blocked methamphetamine-induced conditioned place preference in mice but enhanced that induced by cocaine." *Ann N Y Acad Sci* 654: 531-3.
- Ugarte, Y. V., K. S. Rau, et al. (2003). "Methamphetamine rapidly decreases mouse vesicular dopamine uptake: Role of hyperthermia and dopamine D2 receptors." *Eur J Pharmacol* 472(3): 165-71.
- Umezumi, T., H. Kuribara, et al. (1988). "Acquisition process and effects of psychoactive drugs on discrete shuttle avoidance response in Mongolian gerbils (*Meriones unguiculatus*)." *Jpn J Pharmacol* 47(3): 245-52.
- Witkin, J. M. (1993). "Blockade of the locomotor stimulant effects of cocaine and methamphetamine by glutamate antagonists." *Life Sci* 53(24): PL405-10.
- Yamamoto, J. (1997). "Cortical and hippocampal EEG power spectra in animal models of schizophrenia produced with methamphetamine, cocaine, and phencyclidine." *Psychopharmacology (Berl)* 131(4): 379-87.
- Yoshimura, K. and K. Yamamoto (1979). "[Neuropharmacological studies on drug dependence (I). Effects due to the difference in strain, sex and drug administration time on physical dependence development and characteristics of withdrawal signs in CNS-affecting drug dependent rats (author's transl)]." *Nippon Yakurigaku Zasshi* 75(8): 805-28.
- Zhang, Y., T. M. Loonam, et al. (2001). "Comparison of cocaine- and methamphetamine-evoked dopamine and glutamate overflow in somatodendritic and terminal field regions of the rat brain during acute, chronic, and early withdrawal conditions." *Ann N Y Acad Sci* 937: 93-120.

## Cognition

*See also* Attention Deficit Hyperactivity Disorder: Attention Deficits: Decision-Making and Judgment; Memory

- Barr, A. M., W. J. Panenka, et al. (2006). "The need for speed: An update on methamphetamine addiction." *J Psychiatry Neurosci* 31(5): 301-313.
- Bechara, A., S. Dolan, et al. (2001). "Decision-making deficits, linked to a dysfunctional ventromedial prefrontal cortex, revealed in alcohol and stimulant abusers." *Neuropsychologia* 39(4): 376-89.
- Carey, C. L., S. P. Woods, et al. (2006). "Additive deleterious effects of methamphetamine dependence and immunosuppression on neuropsychological functioning in HIV infection." *AIDS Behav*: 1-6.
- Chana, G., I. P. Everall, et al. (2006). "Cognitive deficits and degeneration of interneurons in HIV+ methamphetamine users." *Neurology* 67(8): 1486-9.
- Chang, L. and W. Haning (2006). "Insights from recent positron emission tomographic studies of drug abuse and dependence." *Curr Opin Psychiatry* 19(3): 246-252.
- Chang, L., C. Cloak, et al. (2005). "Enlarged striatum in abstinent methamphetamine abusers: A possible compensatory response." *Biol Psychiatry* 57(9): 967-74.
- Chang, L., L. M. Smith, et al. (2004). "Smaller subcortical volumes and cognitive deficits in children with prenatal methamphetamine exposure." *Psychiatry Res* 132(2): 95-106.
- Chang, L., T. Ernst, et al. (2002). "Perfusion MRI and computerized cognitive test abnormalities in abstinent methamphetamine users." *Psychiatry Res* 114(2): 65-79.

- Cherner, M., S. Letendre, et al. (2005). "Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine." *Neurology* 64(8): 1343-7.
- Chou, Y. H., W. S. Huang, et al. (2007). "Dopamine transporters and cognitive function in methamphetamine abuser after a short abstinence: A SPECT study." *Eur Neuropsychopharmacol* 17(1): 46-52.
- Chung, A., I. K. Lyoo, et al. (2006). "Decreased frontal white-matter integrity in abstinent methamphetamine abusers." *Int J Neuropsychopharmacol*: 1-11.
- Cretzmeyer, M., M. V. Sarrazin, et al. (2003). "Treatment of methamphetamine abuse: Research findings and clinical directions." *J Subst Abuse Treat* 24(3): 267-77.
- Deutsch, R., M. Cherner, et al. (2006). "Significance testing of a cluster of multivariate binary variables: Comparison of the tripartite T index to three common similarity measures." *Stat Methods Med Res* 15(3): 285-99.
- Ellis, K. L. and J. Speed (1998). "Pharmacologic management of movement disorder after midbrain haemorrhage." *Brain Inj* 12(7): 623-8.
- Gonzalez, R., J. D. Rippeth, et al. (2004). "Neurocognitive performance of methamphetamine users discordant for history of marijuana exposure." *Drug Alcohol Depend* 76(2): 181-90.
- Gouzoulis-Mayfrank, E., M. Schreckenberger, et al. (1999). "Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [<sup>18</sup>F]FDG." *Neuropsychopharmacology* 20(6): 565-81.
- Everall, I. P., L. A. Hansen, et al. (2005). "The shifting patterns of HIV encephalitis neuropathology." *Neurotox Res* 8(1-2): 51-61.
- Everall, I., S. Salaria, et al. (2005). "Methamphetamine stimulates interferon inducible genes in HIV infected brain." *J Neuroimmunol* 170(1-2): 158-71.
- Hart, C. L., A. S. Ward, et al. (2001). "Methamphetamine self-administration by humans." *Psychopharmacology (Berl)* 157(1): 75-81.
- Hoffman, W. F., M. Moore, et al. (2006). "Neuropsychological function and delay discounting in methamphetamine-dependent individuals." *Psychopharmacology (Berl)* 188(2): 162-70.
- Iwanami, A., R. Kanamori, et al. (1995). "Reduced attention-related negative potentials in methamphetamine psychosis." *J Nerv Ment Dis* 183(11): 693-7.
- Iwanami, A., I. Suga, et al. (1993). "Event-related potentials in methamphetamine psychosis during an auditory discrimination task. A preliminary report." *Eur Arch Psychiatry Clin Neurosci* 242(4): 203-8.
- Jernigan, T. L., A. C. Gamst, et al. (2005). "Effects of methamphetamine dependence and HIV infection on cerebral morphology." *Am J Psychiatry* 162(8): 1461-72.
- Johnson, B. A., J. D. Roache, et al. (2007). "Effects of topiramate on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in recently abstinent methamphetamine-dependent individuals." *Prog Neuropsychopharmacol Biol Psychiatry* 31(1): 123-30.
- Johanson, C. E., K. A. Frey, et al. (2006). "Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers." *Psychopharmacology (Berl)* 186(4): 620.
- Johanson, C. E., K. A. Frey, et al. (2006). "Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers." *Psychopharmacology (Berl)* 185(3): 327-38.
- Johnson, B. A., J. D. Roache, et al. (2005). "Effects of isradipine on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition." *Psychopharmacology (Berl)* 178(2-3): 296-302.
- Johnson, B. A., N. Ait-Daoud, et al. (2000). "Effects of isradipine, a dihydropyridine-class calcium channel antagonist, on D-methamphetamine-induced cognitive and physiological changes in humans." *Neuropsychopharmacology* 22(5): 504-12.
- Kalechstein, A. D., T. F. Newton and M. Green (2003). "Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence." *J Neuropsychiatry Clin Neurosci* 15(2): 215-20.
- Kim, S. J., I. K. Lyoo, et al. (2005). "Prefrontal grey-matter changes in short-term and long-term abstinent methamphetamine abusers." *Int J Neuropsychopharmacol*: 1-8.
- Kim, S. J., I. K. Lyoo, et al. (2005). "Frontal glucose hypometabolism in abstinent methamphetamine users." *Neuropsychopharmacology* 30(7): 1383-91.
- Kirkby, R. J., D. S. Bell, et al. (1972). "The effects of methylamphetamine on stereotyped behaviour, activity, startle, and orienting responses." *Psychopharmacologia* 25(1): 41-8.
- Kish, S. J., K. S. Kalasinsky, et al. (1999). "Brain choline acetyltransferase activity in chronic, human users of cocaine, methamphetamine, and heroin." *Mol Psychiatry* 4(1): 26-32.
- Kopell, B. S. and W. K. Wittner (1968). "The effects of chlorpromazine and methamphetamine on visual signal-from-noise detection." *J Nerv Ment Dis* 147(4): 418-24.
- Kosman, M. E. and D. R. Unna (1968). "Effects of chronic administration of the amphetamines and other stimulants on behavior." *Clin Pharmacol Ther* 9(2): 240-54.

- Lawton-Craddock, A., S. J. Nixon and R. Tivis (2003). "Cognitive efficiency in stimulant abusers with and without alcohol dependence." *Alcohol Clin Exp Res* 27(3): 457-64.
- Lehmann, H. E., P. Black, et al. (1970). "The effect of psychostimulants on psychometric test performance with special reference to conflict avoidance behavior." *Curr Ther Res Clin Exp* 12(6): 390-3.
- Letendre, S. L., M. Cherner, et al. (2005). "The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: Biological correlates of disease." *AIDS* 19 Suppl 3: S72-8.
- Levine, A. J., D. J. Hardy, et al. (2006). "The effect of recent stimulant use on sustained attention in HIV-infected adults." *J Clin Exp Neuropsychol* 28(1): 29-42.
- London, E. D., S. M. Berman, et al. (2005). "Cerebral metabolic dysfunction and impaired vigilance in recently abstinent methamphetamine abusers." *Biol Psychiatry* 58(10): 770-8.
- Lundqvist, T. (2005). "Cognitive consequences of cannabis use: Comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions." *Pharmacol Biochem Behav* 81(2): 319-30.
- Malitz, S. and M. Kanzler (1970). "Effects of drugs on perception in man." *Res Publ Assoc Res Nerv Ment Dis* 48: 35-53.
- Martin Alisky, J. (2006). "Cholinesterase inhibitors might alleviate methamphetamine-induced delusions, hallucinations and cognitive impairment, while reducing craving and addiction." *World J Biol Psychiatry* 7(4): 269.
- McKetin, R. and N. Solowij (1999). "Event-related potential indices of auditory selective attention in dependent amphetamine users." *Biol Psychiatry* 45(11): 1488-97.
- McKetin, R. and R. P. Mattick (1998). "Attention and memory in illicit amphetamine users: Comparison with non-drug-using controls." *Drug Alcohol Depend* 50(2): 181-4.
- Meredith, C. W., C. Jaffe, et al. (2005). "Implications of chronic methamphetamine use: A literature review." *Harv Rev Psychiatry* 13(3): 141-54.
- Mohs, R. C., J. R. Tinklenberg, et al. (1980). "Sensitivity of some human cognitive functions to effects of methamphetamine and secobarbital." *Drug Alcohol Depend* 5(2): 145-50.
- Mohs, R. C., J. R. Tinklenberg, et al. (1978). "Methamphetamine and diphenhydramine effects on the rate of cognitive processing." *Psychopharmacology (Berl)* 59(1): 13-9.
- Monterosso, J. R., G. Ainslie, et al. (2006). "Frontoparietal cortical activity of methamphetamine-dependent and comparison subjects performing a delay discounting task." *Hum Brain Mapp*.
- Monterosso, J. R., A. R. Aron, et al. (2005). "Deficits in response inhibition associated with chronic methamphetamine abuse." *Drug Alcohol Depend* 79(2): 273-7.
- Moszczynska, A., P. Fitzmaurice, et al. (2004). "Why is parkinsonism not a feature of human methamphetamine users?" *Brain* 127(Pt 2): 363-70.
- Nath, A., K. F. Hauser, V. Wojna, R. M. Booze, W. Maragos, M. Prendergast, W. Cass and J. T. Turchan (2002). "Molecular basis for interactions of HIV and drugs of abuse." *J Acquir Immune Defic Syndr* 31 Suppl 2: S62-9.
- Newton, T. F., A. D. Kalechstein, et al. (2004). "Association between quantitative EEG and neurocognition in methamphetamine-dependent volunteers." *Clin Neurophysiol* 115(1): 194-8.
- Newton, T. F., I. A. Cook, et al. (2003). "Quantitative EEG abnormalities in recently abstinent methamphetamine dependent individuals." *Clin Neurophysiol* 114(3): 410-5.
- Newton, T. F., A. D. Kalechstein, S. Duran, N. Vansluis and W. Ling (2004). "Methamphetamine abstinence syndrome: Preliminary findings." *Am J Addict* 13(3): 248-55.
- Nordahl, T. E., R. Salo, et al. (2003). "Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: A review." *J Neuropsychiatry Clin Neurosci* 15(3): 317-25.
- Nordahl, T. E., R. Salo, et al. (2002). "Low N-acetyl-aspartate and high choline in the anterior cingulum of recently abstinent methamphetamine-dependent subjects: A preliminary proton MRS study. Magnetic resonance spectroscopy." *Psychiatry Res* 116(1-2): 43-52.
- Paulus, M. P., S. F. Tapert, et al. (2005). "Neural activation patterns of methamphetamine-dependent subjects during decision making predict relapse." *Arch Gen Psychiatry* 62(7): 761-8.
- Paulus, M. P., N. Hozack, et al. (2003). "Decision making by methamphetamine-dependent subjects is associated with error-rate-independent decrease in prefrontal and parietal activation." *Biol Psychiatry* 53(1): 65-74.
- Paulus, M. P., N. E. Hozack, et al. (2002). "Behavioral and functional neuroimaging evidence for prefrontal dysfunction in methamphetamine-dependent subjects." *Neuropsychopharmacology* 26(1): 53-63.
- Rippeth, J. D., R. K. Heaton, et al. (2004). "Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons." *J Int Neuropsychol Soc* 10(1): 1-14.
- Roberts, C. and A. M. Horton, Jr. (2002). "Derived Trail Making Test indices in a sample of amphetamine abusers: Demographic effects." *Int J Neurosci* 112(5): 575-84.

- Roberts, C. and A. M. Horton, Jr. (2001). "Demographic effects on the Trail Making Test in amphetamine abusers." *Int J Neurosci* 110(3-4): 181-7.
- Rogers, R. D., B. J. Everitt, et al. (1999). "Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: Evidence for monoaminergic mechanisms." *Neuropsychopharmacology* 20(4): 322-39.
- Salo, R., T. E. Nordahl, et al. (2006). "Attentional control and brain metabolite levels in methamphetamine abusers." *Biol Psychiatry*.
- Salo, R., T. E. Nordahl, et al. (2005). "A dissociation in attentional control: Evidence from methamphetamine dependence." *Biol Psychiatry* 57(3): 310-3.
- Salo, R., T. E. Nordahl, et al. (2002). "Preliminary evidence of reduced cognitive inhibition in methamphetamine-dependent individuals." *Psychiatry Res* 111(1): 65-74.
- Shappell, S. A., G. L. Kearns, et al. (1996). "Chronopharmacokinetics and chronopharmacodynamics of dextromethamphetamine in man." *J Clin Pharmacol* 36(11): 1051-63.
- Shimazono, Y. and E. Matsushima (1995). "Behavioral and neuroimaging studies on schizophrenia in Japan." *Psychiatry Clin Neurosci* 49(1): 3-11.
- Silber, B. Y., R. J. Croft, et al. (2006). "The acute effects of d-amphetamine and methamphetamine on attention and psychomotor performance." *Psychopharmacology (Berl)* 187(2): 154-69.
- Sim, T., S. L. Simon, et al. (2002). "Cognitive deficits among methamphetamine users with attention deficit hyperactivity disorder symptomatology." *J Addict Dis* 21(1): 75-89.
- Simon, S. L., J. Dacey, et al. (2004). "The effect of relapse on cognition in abstinent methamphetamine abusers." *J Subst Abuse Treat* 27(1): 59-66.
- Simon, S. L., C. Domier, et al. (2000). "Cognitive impairment in individuals currently using methamphetamine." *Am J Addict* 9(3): 222-31.
- Simon, S. L., C. P. Domier, et al. (2002). "Cognitive performance of current methamphetamine and cocaine abusers." *J Addict Dis* 21(1): 61-74.
- Struthers, J. M. and R. L. Hansen (1992). "Visual recognition memory in drug-exposed infants." *J Dev Behav Pediatr* 13(2): 108-11.
- Thompson, P. M., K. M. Hayashi, et al. (2004). "Structural abnormalities in the brains of human subjects who use methamphetamine." *J Neurosci* 24(26): 6028-36.
- van Gorp, W. G. and C. H. Hinkin (2005). "Triple trouble: cognitive deficits from hepatitis C, HIV, and methamphetamine." *Neurology* 64(8): 1328-9.
- Verdejo-Garcia, A., A. Bechara, et al. (2006). "Executive dysfunction in substance dependent individuals during drug use and abstinence: an examination of the behavioral, cognitive and emotional correlates of addiction." *J Int Neuropsychol Soc* 12(3): 405-15.
- Volkow, N. D., L. Chang, et al. (2001). "Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence." *J Neurosci* 21(23): 9414-8.
- Wang, G. J., N. D. Volkow, et al. (2004). "Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence." *Am J Psychiatry* 161(2): 242-8.
- Wiegmann, D. A., R. R. Stanny, et al. (1996). "Methamphetamine effects on cognitive processing during extended wakefulness." *Int J Aviat Psychol* 6(4): 379-97.
- Woods, S. P., J. D. Rippeth, et al. (2005). "Deficient strategic control of verbal encoding and retrieval in individuals with methamphetamine dependence." *Neuropsychology* 19(1): 35-43.

### Cognition (animals)

*See also* Avoidance Behaviors (animals); Behavioral Responses (animals); Conditioned Place Preference (animals); Exploratory Behaviors (animals); Time, Perception of (animals)

- Acevedo, S. F., I. J. de Esch, et al. (2006). "Sex- and histamine-dependent long-term cognitive effects of methamphetamine exposure." *Neuropsychopharmacology*.
- Achat-Mendes, C., K. L. Anderson, et al. (2006). "Impairment in consolidation of learned place preference following dopaminergic neurotoxicity in mice is ameliorated by N-acetylcysteine but not D1 and D2 dopamine receptor agonists." *Neuropsychopharmacology*.
- Achat-Mendes, C., S. F. Ali, et al. (2005). "Differential effects of amphetamines-induced neurotoxicity on appetitive and aversive Pavlovian conditioning in mice." *Neuropsychopharmacology* 30(6): 1128-37.
- Belcher, A. M., S. J. O'Dell, et al. (2006). "A sensitizing regimen of methamphetamine causes impairments in a novelty preference task of object recognition." *Behav Brain Res* 170(1): 167-72.

- Belcher, A. M., S. J. O'Dell, et al. (2005). "Impaired object recognition memory following methamphetamine, but not p-chloroamphetamine- or d-amphetamine-induced neurotoxicity." *Neuropsychopharmacology* 30(11): 2026-34.
- Bisagno, V., R. Bowman, et al. (2003). "Functional aspects of estrogen neuroprotection." *Endocrine* 21(1): 33-41.
- Bisagno, V., D. Ferguson, et al. (2002). "Short toxic methamphetamine schedule impairs object recognition task in male rats." *Brain Res* 940(1-2): 95-101.
- Buhusi, C. V. and W. H. Meck (2006). "Effect of clozapine on interval timing and working memory for time in the peak-interval procedure with gaps." *Behav Processes*.
- Busche, A., A. Bagorda, et al. (2006). "The maturation of the acetylcholine system in the dentate gyrus of gerbils (*Meriones unguiculatus*) is affected by epigenetic factors." *J Neural Transm* 113(2): 113-24.
- Clemens, K. J., J. L. Cornish, et al. (2007). "Repeated weekly exposure to MDMA, methamphetamine or their combination: Long-term behavioural and neurochemical effects in rats." *Drug Alcohol Depend* 86(2-3): 183-90.
- Kulkarni, A. S. (1972). "Avoidance acquisition and CNS stimulants." *Naunyn Schmiedebergs Arch Pharmacol* 273(4): 394-400.
- Kuo, Y. M., K. C. Liang, et al. (2007). "Cocaine-but not methamphetamine-associated memory requires de novo protein synthesis." *Neurobiol Learn Mem* 87(1): 93-100.
- Daberkow, D. P., R. P. Kesner, et al. (2005). "Relation between methamphetamine-induced monoamine depletions in the striatum and sequential motor learning." *Pharmacol Biochem Behav* 81(1): 198-204.
- Dalley, J. W., K. Laane, et al. (2006). "Enduring deficits in sustained visual attention during withdrawal of intravenous methylenedioxymethamphetamine self-administration in rats: Results from a comparative study with d-amphetamine and methamphetamine." *Neuropsychopharmacology*.
- Ehrman, L. A., M. T. Williams, et al. (2006). "Phosphodiesterase 1B differentially modulates the effects of methamphetamine on locomotor activity and spatial learning through DARPP32-dependent pathways: evidence from PDE1B-DARPP32 double-knockout mice." *Genes Brain Behav* 5(7): 540-51.
- Ellinwood, E. H., Jr. and M. M. Kilbey (1975). "Amphetamine stereotypy: the influence of environmental factors and prepotent behavioral patterns on its topography and development." *Biol Psychiatry* 10(1): 3-16.
- Ellison, G. (2002). "Neural degeneration following chronic stimulant abuse reveals a weak link in brain, fasciculus retroflexus, implying the loss of forebrain control circuitry." *Eur Neuropsychopharmacol* 12(4): 287-97.
- Fox, G. B., T. A. Esbenshade, et al. (2005). "Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzotrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist." *J Pharmacol Exp Ther* 313(1): 176-90.
- Gasbarri, A., A. Sulli, et al. (1997). "The dopaminergic mesencephalic projections to the hippocampal formation in the rat." *Prog Neuropsychopharmacol Biol Psychiatry* 21(1): 1-22.
- Glickstein, S. B. and C. Schmauss (2004). "Effect of methamphetamine on cognition and repetitive motor behavior of mice deficient for dopamine D2 and D3 receptors." *Ann N Y Acad Sci* 1025: 110-8.
- Glickstein, S. B. and C. Schmauss (2004). "Focused motor stereotypies do not require enhanced activation of neurons in striosomes." *J Comp Neurol* 469(2): 227-38.
- Glickstein, S. B., P. R. Hof, et al. (2002). "Mice lacking dopamine D2 and D3 receptors have spatial working memory deficits." *J Neurosci* 22(13): 5619-29.
- Golembiowska, K. and A. Zylewska (2000). "Effect of adenosine kinase, adenosine deaminase and transport inhibitors on striatal dopamine and stereotypy after methamphetamine administration." *Neuropharmacology* 39(11): 2124-32.
- Green, A. R. and P. H. Kelly (1976). "Evidence concerning the involvement of 5-hydroxytryptamine in the locomotor activity produced by amphetamine or tranylecypromine plus L-DOPA." *Br J Pharmacol* 57(1): 141-7.
- Hada, H. and K. Miyamoto (1990). "Enhancing effects of sound on methamphetamine-induced behavioral aberrations in the rat: a model of relapse of schizophrenia-like symptoms." *Jpn J Psychiatry Neurol* 44(3): 619-27.
- Hamamura, T., K. Akiyama, et al. (1991). "Co-administration of either a selective D1 or D2 dopamine antagonist with methamphetamine prevents methamphetamine-induced behavioral sensitization and neurochemical change, studied by in vivo intracerebral dialysis." *Brain Res* 546(1): 40-6.
- He, J., Y. Yang, et al. (2006). "The effects of chronic administration of quetiapine on the methamphetamine-induced recognition memory impairment and dopaminergic terminal deficit in rats." *Behav Brain Res* 172(1): 39-45.
- Hirose, A., T. Kato, et al. (1990). "Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions." *Jpn J Pharmacol* 53(3): 321-9.
- Iorio, L. C., A. Barnett, et al. (1983). "SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems." *J Pharmacol Exp Ther* 226(2): 462-8.
- Ishikawa, A., T. Kadota, et al. (2005). "Essential role of D1 but not D2 receptors in methamphetamine-induced impairment of long-term potentiation in hippocampal-prefrontal cortex pathway." *Eur J Neurosci* 22(7): 1713-9.

- Ito, Y., K. Takuma, et al. (2006). "A novel azaindolizinone derivative ZSET1446, spiro[imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one, improves methamphetamine-induced impairment of recognition memory in mice by activating extracellular signal-regulated kinase 1/2." *J Pharmacol Exp Ther*.
- Jayanthi, S., X. Deng, et al. (2005). "Calcineurin/NFAT-induced up-regulation of the Fas ligand/Fas death pathway is involved in methamphetamine-induced neuronal apoptosis." *Proc Natl Acad Sci U S A* 102(3): 868-73.
- Kamei, H., T. Nagai, et al. (2006). "Repeated methamphetamine treatment impairs recognition memory through a failure of novelty-induced ERK1/2 activation in the prefrontal cortex of mice." *Biol Psychiatry* 59(1): 75-84.
- Kelfer, D. A. and A. J. Rosen (1974). "Effects of metamphetamine, pipradrol and methylphenidate on instrumental conditioning and spontaneous motor activity in the immature rat." *Psychopharmacologia* 35(4): 317-26.
- Kosman, M. E. and D. R. Unna (1968). "Effects of chronic administration of the amphetamines and other stimulants on behavior." *Clin Pharmacol Ther* 9(2): 240-54.
- Kuo, Y. M., K. C. Liang, et al. (2007). "Cocaine-but not methamphetamine-associated memory requires de novo protein synthesis." *Neurobiol Learn Mem* 87(1): 93-100.
- Matell, M. S., M. Bateson, et al. (2006). "Single-trials analyses demonstrate that increases in clock speed contribute to the methamphetamine-induced horizontal shifts in peak-interval timing functions." *Psychopharmacology (Berl)*.
- Matsuoka, N., N. Maeda, et al. (1992). "Effect of FR121196, a novel cognitive enhancer, on the memory impairment of rats in passive avoidance and radial arm maze tasks." *J Pharmacol Exp Ther* 263(2): 436-44.
- Mechner, F. and M. Latranyi (1963). "Behavioral effects of caffeine, methamphetamine, and methylphenidate in the rat." *J Exp Anal Behav* 6: 331-42.
- Meck, W. H. (2006). "Frontal cortex lesions eliminate the clock speed effect of dopaminergic drugs on interval timing." *Brain Res* 1108(1): 157-67.
- Nishii, K., N. Matsushita, et al. (1998). "Motor and learning dysfunction during postnatal development in mice defective in dopamine neuronal transmission." *J Neurosci Res* 54(4): 450-64.
- Ogawa, H., H. Kuribara, et al. (1976). "Attainment and stability of the performance in differential low rate water reinforcement in rats." *Jpn J Pharmacol* 26(3): 281-90.
- Ozawa, K., K. Hashimoto, et al. (2006). "Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: A neurodevelopmental animal model of schizophrenia." *Biol Psychiatry* 59(6): 546-54.
- Preston, K. L., G. C. Wagner, et al. (1984). "Effects of methamphetamine on atropine-induced conditioned gustatory avoidance." *Pharmacol Biochem Behav* 20(4): 601-7.
- Sabol, K. E., J. B. Richards, et al. (2003). "Effects of stimulus salience and methamphetamine on choice reaction time in the rat: central tendency versus distribution skew." *Behav Pharmacol* 14(7): 489-500.
- Sansone, M., M. Ammassari-Teule, et al. (1985). "Interaction between nootropic drugs and methamphetamine on avoidance acquisition but not on locomotor activity in mice." *Arch Int Pharmacodyn Ther* 278(2): 229-35.
- Schaefer, T. L., L. A. Ehrman, et al. (2006). "Comparison of monoamine and corticosterone levels 24 h following (+)methamphetamine, (+/-)3,4-methylenedioxymethamphetamine, cocaine, (+)fenfluramine or (+/-)methylphenidate administration in the neonatal rat." *J Neurochem* 98(5): 1369-78.
- Slamberova, R., M. Pometlova, et al. (2006). "Postnatal development of rat pups is altered by prenatal methamphetamine exposure." *Prog Neuropsychopharmacol Biol Psychiatry* 30(1): 82-8.
- Slamberova, R., M. Pometlova, et al. (2005). "Learning in the place navigation task, not the new-learning task, is altered by prenatal methamphetamine exposure." *Brain Res Dev Brain Res* 157(2): 217-9.
- Timar, J., S. Gyarmati, et al. (2003). "Behavioural changes in rats treated with a neurotoxic dose regimen of dextrorotatory amphetamine derivatives." *Behav Pharmacol* 14(3): 199-206.
- Vajragupta, O., P. Boonchoong, et al. (2003). "Manganese-based complexes of radical scavengers as neuroprotective agents." *Bioorg Med Chem* 11(10): 2329-37.
- Vajragupta, O., O. Monthakantirat, et al. (2000). "Chroman amide 12P inhibition of lipid peroxidation and protection against learning and memory impairment." *Life Sci* 67(14): 1725-34.
- Vorhees, C. V., T. M. Reed, et al. (2005). "Periadolescent rats (P41-50) exhibit increased susceptibility to D-methamphetamine-induced long-term spatial and sequential learning deficits compared to juvenile (P21-30 or P31-40) or adult rats (P51-60)." *Neurotoxicol Teratol* 27(1): 117-34.
- Vorhees, C. V., S. L. Inman-Wood, et al. (2000). "Adult learning deficits after neonatal exposure to D-methamphetamine: Selective effects on spatial navigation and memory." *J Neurosci* 20(12): 4732-9.
- Vorhees, C. V. (1997). "Methods for detecting long-term CNS dysfunction after prenatal exposure to neurotoxins." *Drug Chem Toxicol* 20(4): 387-99.

- Vorhees, C. V., K. G. Ahrens, et al. (1994). "Methamphetamine exposure during early postnatal development in rats: Acoustic startle augmentation and spatial learning deficits." *Psychopharmacology (Berl)* 114(3): 392-401.
- Vorhees, C. V., K. G. Ahrens, et al. (1994). "Methamphetamine exposure during early postnatal development in rats: II. Hypoactivity and altered responses to pharmacological challenge." *Psychopharmacology (Berl)* 114(3): 402-8.
- Will, B. E., M. R. Rosenzweig, et al. (1977). "Relatively brief environmental enrichment aids recovery of learning capacity and alters brain measures after postweaning brain lesions in rats." *J Comp Physiol Psychol* 91(1): 33-50.
- Williams, M. T., M. S. Moran, et al. (2004). "Behavioral and growth effects induced by low dose methamphetamine administration during the neonatal period in rats." *Int J Dev Neurosci* 22(5-6): 273-83.
- Williams, M. T., R. W. Brown, et al. (2004). "Neonatal methamphetamine administration induces region-specific long-term neuronal morphological changes in the rat hippocampus, nucleus accumbens and parietal cortex." *Eur J Neurosci* 19(12): 3165-70.
- Williams, M. T., M. S. Moran, et al. (2003). "Refining the critical period for methamphetamine-induced spatial deficits in the Morris water maze." *Psychopharmacology (Berl)* 168(3): 329-38.
- Williams, M. T., L. L. Morford, et al. (2003). "Developmental D-methamphetamine treatment selectively induces spatial navigation impairments in reference memory in the Morris water maze while sparing working memory." *Synapse* 48(3): 138-48.
- Williams, M. T., T. L. Blankenmeyer, et al. (2003). "Long-term effects of neonatal methamphetamine exposure in rats on spatial learning in the Barnes maze and on cliff avoidance, corticosterone release, and neurotoxicity in adulthood." *Brain Res Dev Brain Res* 147(1-2): 163-75.
- Williams, M. T., C. V. Vorhees, et al. (2002). "Methamphetamine exposure from postnatal day 11 to 20 causes impairments in both behavioral strategies and spatial learning in adult rats." *Brain Res* 958(2): 312-21.
- Williams, M. T., S. L. Inman-Wood, et al. (2000). "Prenatal treatment with methamphetamine induces increases in both corticosterone and ACTH in rats." *Neurotoxicol Teratol* 22(5): 751-9.
- Wolthuis, O. L. (1971). "Experiments with UCB 6215, a drug which enhances acquisition in rats: Its effects compared with those of metamphetamine." *Eur J Pharmacol* 16(3): 283-97.
- Yamamura, T., S. Hishida, et al. (1993). "Effects of daily administration of methamphetamine on multiple active/passive avoidance performance in rats." *Behav Brain Res* 53(1-2): 105-12.
- Yamamura, T., S. Hishida, et al. (1992). "Effects of methamphetamine and ethanol on learning and brain neurotransmitters in rats." *Pharmacol Biochem Behav* 42(3): 389-400.
- Yamazaki, Y., N. Shinohara, et al. (2004). "Visual discrimination of normal and drug induced behavior in quails (*Coturnix coturnix japonica*)." *Anim Cogn* 7(2): 128-32.
- Yasar, S., J. Gaal, et al. (2005). "Discriminative stimulus and reinforcing effects of p-fluoro-L-deprenyl in monkeys." *Psychopharmacology (Berl)* 182(1): 95-103.
- Yoshida, S., Y. Numachi, et al. (1995). "[Reverse-tolerance phenomenon in methamphetamine-induced behavioral stereotypy and impairment of cliff avoidance reaction after subchronic methamphetamine administration in rats]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 15(5): 397-403.

## Colorado (US)

*See also* Denver

- Boulard, G. (2005). "The meth menace: Battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.
- Bull, S. S., P. Piper and C. Rietmeijer (2002). "Men who have sex with men and also inject drugs-profiles of risk related to the synergy of sex and drug injection behaviors." *J Homosex* 42(3): 31-51.
- Hopfer, C., B. Mendelson, et al. (2006). "Club drug use among youths in treatment for substance abuse." *Am J Addict* 15(1): 94-9.
- Huff, C. (2006). "Crystal crush." *Hosp Health Netw* 80(10): 59-60, 62, 64.
- Kim, J. Y. and M. Fendrich (2002). "Gender differences in juvenile arrestees' drug use, self-reported dependence, and perceived need for treatment." *Psychiatr Serv* 53(1): 70-5.
- Koblin, B. A., M. A. Chesney, et al. (2003). "High-risk behaviors among men who have sex with men in 6 US cities: Baseline data from the EXPLORE Study." *Am J Public Health* 93(6): 926-32.
- Van Leeuwen, J. M., C. Hopfer, et al. (2004). "A snapshot of substance abuse among homeless and runaway youth in Denver, Colorado." *J Community Health* 29(3): 217-29.
- Wallace, M. E. and R. Squires (2000). "Fatal massive amphetamine ingestion associated with hyperpyrexia." *J Am Board Fam Pract* 13(4): 302-4.

### Commercial Sex Work and Sex Workers

- Bogart, L. M., A. H. Kral, et al. (2005). "Sexual risk among injection drug users recruited from syringe exchange programs in California." *Sex Transm Dis* 32(1): 27-34.
- Brouwer, K. C., P. Case, et al. (2006). "Trends in production, trafficking, and consumption of methamphetamine and cocaine in Mexico." *Subst Use Misuse* 41(5): 707-27.
- Chomchai, C., N. Na Manorom, P. Watanarungsan, P. Yossuck and S. Chomchai (2004). "Methamphetamine abuse during pregnancy and its health impact on neonates born at Siriraj Hospital, Bangkok, Thailand." *Southeast Asian J Trop Med Public Health* 35(1): 228-31.
- Clatts, M. C., L. Goldsamt, et al. (2005). "Homelessness and drug abuse among young men who have sex with men in New York City: A preliminary epidemiological trajectory." *J Adolesc* 28(2): 201-14.
- Collins, C. L., T. Kerr, et al. (2005). "Potential uptake and correlates of willingness to use a supervised smoking facility for noninjection illicit drug use." *J Urban Health* 82(2): 276-84.
- Cruz, M. F., A. Mantsios, et al. (2006). "A qualitative exploration of gender in the context of injection drug use in two US-Mexico border cities." *AIDS Behav*.
- Darke, S., W. Hall, et al. (1992). "Benzodiazepine use and HIV risk-taking behaviour among injecting drug users." *Drug Alcohol Depend* 31(1): 31-6.
- Kipke, M. D., S. O'Connor, et al. (1995). "Street youth in Los Angeles. Profile of a group at high risk for human immunodeficiency virus infection." *Arch Pediatr Adolesc Med* 149(5): 513-9.
- Kral, A. H., J. Lorvick, et al. (2005). "HIV prevalence and risk behaviors among men who have sex with men and inject drugs in San Francisco." *J Urban Health* 82(1 Suppl 1): i43-50.
- Molitor, F., J. D. Ruiz, et al. (1999). "Methamphetamine use and sexual and injection risk behaviors among out-of-treatment injection drug users." *Am J Drug Alcohol Abuse* 25(3): 475-93.
- Molitor, F., S. R. Truax, J. D. Ruiz and R. K. Sun (1998). "Association of methamphetamine use during sex with risky sexual behaviors and HIV infection among non-injection drug users." *West J Med* 168(2): 93-7.
- Nemoto, T., D. Operario, et al. (2002). "Risk behaviors of Filipino methamphetamine users in San Francisco: Implications for prevention and treatment of drug use and HIV." *Public Health Rep* 117 Suppl 1: S30-8.
- Newman, P. A., F. Rhodes and R. E. Weiss (2004). "Correlates of sex trading among drug-using men who have sex with men." *Am J Public Health* 94(11): 1998-2003.
- Operario, D. and T. Nemoto (2005). "Sexual risk behavior and substance use among a sample of Asian Pacific Islander transgendered women." *AIDS Educ Prev* 17(5): 430-43.
- Reback, C. J. and C. E. Grella (1999). "HIV risk behaviors of gay and bisexual male methamphetamine users contacted through street outreach." *Journal of Drug Issues* 29(1): 155-66.
- Rietmeijer, C. A., R. J. Wolitski, M. Fishbein, N. H. Corby and D. L. Cohn (1998). "Sex hustling, injection drug use, and non-gay identification by men who have sex with men. Associations with high-risk sexual behaviors and condom use." *Sex Transm Dis* 25(7): 353-60.
- Rose, V. J., H. F. Raymond, et al. (2006). "Assessing the feasibility of harm reduction services for MSM: The late night breakfast buffet study." *Harm Reduct J* 3: 29.
- Roxburgh, A., L. Degenhardt, et al. (2005). "Drug use and risk behaviours among injecting drug users: A comparison between sex workers and non-sex workers in Sydney, Australia." *Harm Reduct J* 2(1): 7.
- Srirak, N., S. Kawichai, et al. (2005). "HIV infection among female drug users in Northern Thailand." *Drug Alcohol Depend* 78(2): 141-5.
- van Griensven, F., S. Supawitkul, et al. (2001). "Rapid assessment of sexual behavior, drug use, human immunodeficiency virus, and sexually transmitted diseases in northern Thai youth using audio-computer-assisted self-interviewing and noninvasive specimen collection." *Pediatrics* 108(1): E13.
- Wada, K., S. B. Greberman, et al. (1999). "HIV and HCV infection among drug users in Japan." *Addiction* 94(7): 1063-9.
- Weiser, S. D., S. E. Dilworth, et al. (2006). "Gender-specific correlates of sex trade among homeless and marginally housed individuals in San Francisco." *J Urban Health* 83(4): 736-40.
- Williams, M. L., J. Atkinson, et al. (2005). "Spatial bridging in a network of drug-using male sex workers." *J Urban Health* 82(1 Suppl 1): i35-42.



## Compulsivity

*See also* Impulsivity; Conditioned Place Preference (animals); Sexual Compulsivity; Stereotypic Behaviors; Stereotypic Behaviors (animals)

Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.

Volkow, N. D., L. Chang, et al. (2001). "Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex." *Am J Psychiatry* 158(12): 2015-21.

## Conditioned Place Preference (animals)

Achat-Mendes, C., K. L. Anderson, et al. (2006). "Impairment in consolidation of learned place preference following dopaminergic neurotoxicity in mice is ameliorated by N-acetylcysteine but not D1 and D2 dopamine receptor agonists." *Neuropsychopharmacology*.

Achat-Mendes, C., S. F. Ali, et al. (2005). "Differential effects of amphetamines-induced neurotoxicity on appetitive and aversive Pavlovian conditioning in mice." *Neuropsychopharmacology* 30(6): 1128-37.

Allan, A. M., R. Galindo, et al. (2001). "Conditioned place preference for cocaine is attenuated in mice over-expressing the 5-HT(3) receptor." *Psychopharmacology (Berl)* 158(1): 18-27.

Chen, H. H., Y. K. Yang, et al. (2003). "Methamphetamine-induced conditioned place preference is facilitated by estradiol pretreatment in female mice." *Chin J Physiol* 46(4): 169-74.

Cunningham, C. L. and D. Noble (1992). "Methamphetamine-induced conditioned place preference or aversion depending on dose and presence of drug." *Ann N Y Acad Sci* 654: 431-3.

Fujio, M., T. Nakagawa, et al. (2005). "Gene transfer of GLT-1, a glutamate transporter, into the nucleus accumbens shell attenuates methamphetamine- and morphine-induced conditioned place preference in rats." *Eur J Neurosci* 22(11): 2744-54.

Gehrke, B. J., W. A. Cass, et al. (2006). "Monoamine-depleting doses of methamphetamine in enriched and isolated rats: Consequences for subsequent methamphetamine-induced hyperactivity and reward." *Behav Pharmacol* 17(5-6): 499-508.

Gehrke, B. J., S. B. Harrod, et al. (2003). "The effect of neurotoxic doses of methamphetamine on methamphetamine-conditioned place preference in rats." *Psychopharmacology (Berl)* 166(3): 249-57.

Goeders, J. E. and N. E. Goeders (2004). "Effects of oxazepam on methamphetamine-induced conditioned place preference." *Pharmacol Biochem Behav* 78(1): 185-8.

Itzhak, Y. and S. F. Ali (2002). "Behavioral consequences of methamphetamine-induced neurotoxicity in mice: Relevance to the psychopathology of methamphetamine addiction." *Ann N Y Acad Sci* 965: 127-35.

Itzhak, Y. and J. L. Martin (2002). "Cocaine-induced conditioned place preference in mice: Induction, extinction and reinstatement by related psychostimulants." *Neuropsychopharmacology* 26(1): 130-4.

Itzhak, Y., J. L. Martin, et al. (2002). "Methamphetamine-induced dopaminergic neurotoxicity in mice: Long-lasting sensitization to the locomotor stimulation and desensitization to the rewarding effects of methamphetamine." *Prog Neuropsychopharmacol Biol Psychiatry* 26(6): 1177-83.

Kawamura, T., Y. Ichitani, et al. (2005). "[Rewarding property of nicotine and methamphetamine tested by conditioned place preference in rats: Effect of chronic nicotine pretreatment]." *Shinrigaku Kenkyu* 76(1): 57-62.

Kim, H. C., E. J. Shin, et al. (2005). "Pharmacological action of Panax ginseng on the behavioral toxicities induced by psychotropic agents." *Arch Pharm Res* 28(9): 995-1001.

Kim, H. S., Y. T. Hong, et al. (1998). "Inhibition by ginsenosides Rb1 and Rg1 of methamphetamine-induced hyperactivity, conditioned place preference and postsynaptic dopamine receptor supersensitivity in mice." *Gen Pharmacol* 30(5): 783-9.

Kim, H. S. and C. G. Jang (1997). "MK-801 inhibits methamphetamine-induced conditioned place preference and behavioral sensitization to apomorphine in mice." *Brain Res Bull* 44(3): 221-7.

Kim, H. S., C. G. Jang, et al. (1996). "Blockade by ginseng total saponin of methamphetamine-induced hyperactivity and conditioned place preference in mice." *Gen Pharmacol* 27(2): 199-204.

Kitanaka, N., J. Kitanaka, et al. (2006). "Methamphetamine reward in mice as assessed by conditioned place preference test with Supermex sensors: Effect of subchronic clorgyline pretreatment." *Neurochem Res* 31(6): 805-13.

Kliethermes, C. L., H. M. Kamens, et al. (2006). "Drug reward and intake in lines of mice selectively bred for divergent exploration of a hole board apparatus." *Genes Brain Behav*.

Kliethermes, C. L. and J. C. Crabbe (2006). "Pharmacological and genetic influences on hole-board behaviors in mice." *Pharmacol Biochem Behav* 85(1): 57-65.

Kuo, Y. M., K. C. Liang, et al. (2007). "Cocaine-but not methamphetamine-associated memory requires de novo protein synthesis." *Neurobiol Learn Mem* 87(1): 93-100.

Kusayama, T. and S. Watanabe (2000). "Reinforcing effects of methamphetamine in planarians." *Neuroreport* 11(11): 2511-3.

- Li, S. M., Y. H. Ren, et al. (2002). "Effect of 7-nitroindazole on drug-priming reinstatement of D-methamphetamine-induced conditioned place preference." *Eur J Pharmacol* 443(1-3): 205-6.
- Li, S. M., L. L. Yin, et al. (2002). "The effect of 7-nitroindazole on the acquisition and expression of D-methamphetamine-induced place preference in rats." *Eur J Pharmacol* 435(2-3): 217-23.
- Li, S. M., L. L. Yin, et al. (2001). "GABA(B) receptor agonist baclofen attenuates the development and expression of d-methamphetamine-induced place preference in rats." *Life Sci* 70(3): 349-56.
- Lien, W. H., T. L. Yeh, et al. (2004). "Cycloheximide enhances maintenance of methamphetamine-induced conditioned place preference." *Chin J Physiol* 47(1): 23-30.
- Masukawa, Y., T. Suzuki, et al. (1993). "Differential modification of the rewarding effects of methamphetamine and cocaine by opioids and antihistamines." *Psychopharmacology (Berl)* 111(2): 139-43.
- Miyatake, M., M. Narita, et al. (2005). "Glutamatergic neurotransmission and protein kinase C play a role in neuron-glia communication during the development of methamphetamine-induced psychological dependence." *Eur J Neurosci* 22(6): 1476-88.
- Mizoguchi, H., K. Yamada, et al. (2004). "Regulations of methamphetamine reward by extracellular signal-regulated kinase 1/2/ets-like gene-1 signaling pathway via the activation of dopamine receptors." *Mol Pharmacol* 65(5): 1293-301.
- Mizuno, M., R. S. Malta, Jr., et al. (2004). "Conditioned place preference and locomotor sensitization after repeated administration of cocaine or methamphetamine in rats treated with epidermal growth factor during the neonatal period." *Ann N Y Acad Sci* 1025: 612-8.
- Nagai, T., Y. Noda, et al. (2005). "The role of tissue plasminogen activator in methamphetamine-related reward and sensitization." *J Neurochem* 92(3): 660-7.
- Nakagawa, T., M. Fujio, et al. (2005). "Effect of MS-153, a glutamate transporter activator, on the conditioned rewarding effects of morphine, methamphetamine and cocaine in mice." *Behav Brain Res* 156(2): 233-9.
- Narita, M., H. Akai, et al. (2005). "Involvement of mitogen-stimulated p70-S6 kinase in the development of sensitization to the methamphetamine-induced rewarding effect in rats." *Neuroscience* 132(3): 553-60.
- Narita, M., H. Akai, et al. (2004). "Implications of protein kinase C in the nucleus accumbens in the development of sensitization to methamphetamine in rats." *Neuroscience* 127(4): 941-8.
- Niwa, M., A. Nitta, et al. (2006). "An inducer for glial cell line-derived neurotrophic factor and tumor necrosis factor-alpha protects against methamphetamine-induced rewarding effects and sensitization." *Biol Psychiatry*.
- Noda, Y., Y. Miyamoto, et al. (1998). "Involvement of dopaminergic system in phencyclidine-induced place preference in mice pretreated with phencyclidine repeatedly." *J Pharmacol Exp Ther* 286(1): 44-51.
- Noda, Y. and T. Nabeshima (1998). "Neuronal mechanisms of phencyclidine-induced place aversion and preference in the conditioned place preference task." *Methods Find Exp Clin Pharmacol* 20(7): 607-11.
- Okabe, C. and N. P. Murphy (2004). "Short-term effects of the nociceptin receptor antagonist Compound B on the development of methamphetamine sensitization in mice: A behavioral and c-fos expression mapping study." *Brain Res* 1017(1-2): 1-12.
- Shimosato, K., N. Nagao, et al. (2003). "Suppressive effects of trihexyphenidyl on methamphetamine-induced dopamine release as measured by in vivo microdialysis." *Synapse* 49(1): 47-54.
- Shimosato, K., S. Watanabe, et al. (2001). "Differential effects of trihexyphenidyl on place preference conditioning and locomotor stimulant activity of cocaine and methamphetamine." *Naunyn Schmiedebergs Arch Pharmacol* 364(1): 74-80.
- Shimosato, K. and S. Ohkuma (2000). "Simultaneous monitoring of conditioned place preference and locomotor sensitization following repeated administration of cocaine and methamphetamine." *Pharmacol Biochem Behav* 66(2): 285-92.
- Shin, E. J., T. Nabeshima, et al. (2005). "Ginsenosides attenuate methamphetamine-induced behavioral side effects in mice via activation of adenosine A2A receptors: Possible involvements of the striatal reduction in AP-1 DNA binding activity and proenkephalin gene expression." *Behav Brain Res* 158(1): 143-57.
- Stefanski, R., Z. Justinova, et al. (2004). "Sigma 1 receptor upregulation after chronic methamphetamine self-administration in rats: A study with yoked controls." *Psychopharmacology (Berl)* 175(1): 68-75.
- Suzuki, T. and M. Misawa (1995). "Sertindole antagonizes morphine-, cocaine-, and methamphetamine-induced place preference in the rat." *Life Sci* 57(13): 1277-84.
- Suzuki, T., Y. Shiozaki, et al. (1992). "Effects of calcium antagonists on the cocaine- and methamphetamine-induced conditioned place preference." *Arukuru Kenkyuto Yakubutsu Ison* 27(1): 81-90.
- Takahashi, M. and S. Tokuyama (1998). "Pharmacological and physiological effects of ginseng on actions induced by opioids and psychostimulants." *Methods Find Exp Clin Pharmacol* 20(1): 77-84.
- Takamatsu, Y., Y. Yamanishi, et al. (2006). "Differential effects of donepezil on methamphetamine and cocaine dependencies." *Ann N Y Acad Sci* 1074: 418-26.
- Takamatsu, Y., H. Yamamoto, et al. (2006). "Fluoxetine as a potential pharmacotherapy for methamphetamine dependence: Studies in mice." *Ann N Y Acad Sci* 1074: 295-302.

- Tokuyama, S. and M. Takahashi (2001). "[Pharmacological and physiological effects of ginseng on actions induced by opioids and psychostimulants]." *Nippon Yakurigaku Zasshi* 117(3): 195-201.
- Tokuyama, S., M. Takahashi, et al. (1996). "The effect of ginseng extract on locomotor sensitization and conditioned place preference induced by methamphetamine and cocaine in mice." *Pharmacol Biochem Behav* 54(4): 671-6.
- Tsai, S. J. (2007). "Increased central brain-derived neurotrophic factor activity could be a risk factor for substance abuse: Implications for treatment." *Med Hypotheses* 68(2): 410-4.
- Tuazon, D. B., T. Suzuki, et al. (1992). "Methylxanthines (caffeine and theophylline) blocked methamphetamine-induced conditioned place preference in mice but enhanced that induced by cocaine." *Ann N Y Acad Sci* 654: 531-3.
- Yamada, K., T. Nagai, et al. (2005). "Drug dependence, synaptic plasticity, and tissue plasminogen activator." *J Pharmacol Sci* 97(2): 157-61.
- Yang, P. P., E. Y. Huang, et al. (2006). "Co-administration of dextromethorphan with methamphetamine attenuates methamphetamine-induced rewarding and behavioral sensitization." *J Biomed Sci* 13(5): 695-702.
- Zhao, R. J., R. S. Woo, et al. (2003). "Orphanin FQ/nociceptin blocks methamphetamine place preference in rats." *Neuroreport* 14(18): 2383-5.

## Condoms

*See also* Sexual Risk Behaviors

- Benotsch, E. G., S. Kalichman, et al. (2002). "Men who have met sex partners via the Internet: Prevalence, predictors, and implications for HIV prevention." *Arch Sex Behav* 31(2): 177-83.
- Bogart, L. M., A. H. Kral, et al. (2005). "Sexual risk among injection drug users recruited from syringe exchange programs in California." *Sex Transm Dis* 32(1): 27-34.
- Bull, S. S., P. Piper and C. Rietmeijer (2002). "Men who have sex with men and also inject drugs-profiles of risk related to the synergy of sex and drug injection behaviors." *J Homosex* 42(3): 31-51.
- Frosch, D., S. Shoptaw, et al. (1996). "Sexual HIV risk among gay and bisexual male methamphetamine abusers." *J Subst Abuse Treat* 13(6): 483-6.
- Mansergh, G., R. L. Shouse, et al. (2006). "Methamphetamine and sildenafil (Viagra) use are linked to unprotected receptive and insertive anal sex, respectively, in a sample of men who have sex with men." *Sex Transm Infect* 82(2): 131-4.
- Molitor, F., J. D. Ruiz, et al. (1999). "Methamphetamine use and sexual and injection risk behaviors among out-of-treatment injection drug users." *Am J Drug Alcohol Abuse* 25(3): 475-93.
- Molitor, F., S. R. Truax, J. D. Ruiz and R. K. Sun (1998). "Association of methamphetamine use during sex with risky sexual behaviors and HIV infection among non-injection drug users." *West J Med* 168(2): 93-7.
- Reback, C. J., S. Larkins and S. Shoptaw (2004). "Changes in the meaning of sexual risk behaviors among gay and bisexual male methamphetamine abusers before and after drug treatment." *AIDS Behav* 8(1): 87-98.
- Rose, V. J., H. F. Raymond, et al. (2006). "Assessing the feasibility of harm reduction services for MSM: The late night breakfast buffet study." *Harm Reduct J* 3: 29.
- Semple, S. J., T. L. Patterson and I. Grant (2004). "The context of sexual risk behavior among heterosexual methamphetamine users." *Addict Behav* 29(4): 807-10.
- Semple, S. J., T. L. Patterson, et al. (2004). "Determinants of condom use stage of change among heterosexually-identified methamphetamine users." *AIDS Behav* 8(4): 391-400.
- Semple, S. J., I. Grant, et al. (2004). "Female methamphetamine users: Social characteristics and sexual risk behavior." *Women Health* 40(3): 35-50.
- Semple, S. J., T. L. Patterson and I. Grant (2002). "Motivations associated with methamphetamine use among HIV+ men who have sex with men." *J Subst Abuse Treat* 22(3): 149-56.
- Shernoff, M. (2006). "Condomless sex: Gay men, barebacking, and harm reduction." *Soc Work* 51(2): 106-13.
- Shoptaw, S. and C. J. Reback (2006). "Associations between methamphetamine use and HIV among men who have sex with men: A model for guiding public policy." *J Urban Health* 83(6): 1151-7.
- Stone, E., P. Heagerty, et al. (1999). "Correlates of condom failure in a sexually active cohort of men who have sex with men." *J Acquir Immune Defic Syndr Hum Retrovirol* 20(5): 495-501.
- Zule, W. A. and D. P. Desmond (1999). "An ethnographic comparison of HIV risk behaviors among heroin and methamphetamine injectors." *Am J Drug Alcohol Abuse* 25(1): 1-23.

### Contingency Management

- Galloway, G. P., P. Marinelli-Casey, et al. (2000). "Treatment-as-usual in the methamphetamine treatment project." *J Psychoactive Drugs* 32(2): 165-75.
- Higgins, S. T. (2006). "Extending contingency management to the treatment of methamphetamine use disorders." *Am J Psychiatry* 163(11): 1870-2.
- Menza, T. W., G. Colfax, et al. (2006). "Interest in a methamphetamine intervention among men who have sex with men." *Sex Transm Dis* 33(9): 565-70.
- Peck, J. A., C. J. Reback, et al. (2005). "Sustained reductions in drug use and depression symptoms from treatment for drug abuse in methamphetamine-dependent gay and bisexual men." *J Urban Health* 82(1 Suppl 1): i100-8.
- Peirce, J. M., N. M. Petry, et al. (2006). "Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: A National Drug Abuse Treatment Clinical Trials Network study." *Arch Gen Psychiatry* 63(2): 201-8.
- Petry, N. M., K. B. Kolodner, et al. (2006). "Prize-based contingency management does not increase gambling." *Drug Alcohol Depend* 83(3): 269-73.
- Petry, N. M., J. M. Peirce, et al. (2005). "Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: a national drug abuse treatment clinical trials network study." *Arch Gen Psychiatry* 62(10): 1148-56.
- Rawson, R. A., M. J. McCann, et al. (2006). "A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals." *Addiction* 101(2): 267-74.
- Rawson, R. A., R. Gonzales, et al. (2002). "Treatment of methamphetamine use disorders: An update." *J Subst Abuse Treat* 23(2): 145-50.
- Roll, J. M., A. Huber, et al. (2006). "A comparison of five reinforcement schedules for use in contingency management-based treatment of methamphetamine abuse." *Psychological Record* 56(1): 67-81.
- Roll, J. M., N. M. Petry, et al. (2006). "Contingency management for the treatment of methamphetamine use disorders." *Am J Psychiatry* 163(11): 1993-9.
- Roll, J. M. and S. Shoptaw (2006). "Contingency management: Schedule effects." *Psychiatry Res* 144(1): 91-3.
- Shoptaw, S., A. Huber, et al. (2006). "Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence." *Drug Alcohol Depend* 85(1): 12-18.
- Shoptaw, S., J. D. Klausner, et al. (2006). "A public health response to the methamphetamine epidemic: The implementation of contingency management to treat methamphetamine dependence." *BMC Public Health* 6(1): 214.
- Shoptaw, S., C. J. Reback, et al. (2005). "Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men." *Drug Alcohol Depend* 78(2): 125-34.

### Coordination

*See Psychomotor Task Performance*

### Corticosterone

- Fehm, H. L., R. Holl, et al. (1984). "Evidence for ACTH-unrelated mechanisms in the regulation of cortisol secretion in man." *Klin Wochenschr* 62(1): 19-24.
- Harris, D. S., V. I. Reus, et al. (2003). "Altering cortisol level does not change the pleasurable effects of methamphetamine in humans." *Neuropsychopharmacology* 28(9): 1677-84.
- Yamashita, I., T. Moroji, et al. (1969). "Neuroendocrinological studies in mental disorders and psychotropic drugs. I. On the circadian rhythm of the plasma adrenocortical hormone in mental patients and methamphetamine- and chlorpromazine-treated animals." *Folia Psychiatr Neurol Jpn* 23(2): 143-58.

### Corticosterone (animals)

- Asano, Y. and T. Moroji (1974). "Effects of methamphetamine on daily rhythms of hypothalamic norepinephrine, serotonin and plasma corticosterone levels in the rat." *Life Sci* 14(8): 1463-72.
- Honma, S., K. Honma, et al. (1988). "Rhythms in behaviors, body temperature and plasma corticosterone in SCN lesioned rats given methamphetamine." *Physiol Behav* 44(2): 247-55.
- Krauchi, K., A. Wirz-Justice, et al. (1984). "Hypothalamic alpha 2- and beta-adrenoceptor rhythms are correlated with circadian feeding: evidence from chronic methamphetamine treatment and withdrawal." *Brain Res* 321(1): 83-90.
- Moffett, M. C. and N. E. Goeders (2005). "Neither non-contingent electric footshock nor administered corticosterone facilitate the acquisition of methamphetamine self-administration." *Pharmacol Biochem Behav* 80(2): 333-9.

- Schaefer, T. L., L. A. Ehrman, et al. (2006). "Comparison of monoamine and corticosterone levels 24 h following (+)methamphetamine, (+/-)3,4-methylenedioxymethamphetamine, cocaine, (+)fenfluramine or (+/-)methylphenidate administration in the neonatal rat." *J Neurochem* 98(5): 1369-78.
- Williams, M. T., T. L. Schaefer, et al. (2006). "Ontogeny of the adrenal response to (+)-methamphetamine in neonatal rats: The effect of prior drug exposure." *Stress* 9(3): 153-63.
- Williams, M. T., T. L. Blankenmeyer, et al. (2003). "Long-term effects of neonatal methamphetamine exposure in rats on spatial learning in the Barnes maze and on cliff avoidance, corticosterone release, and neurotoxicity in adulthood." *Brain Res Dev Brain Res* 147(1-2): 163-75.
- Yamashita, I., T. Moroji, et al. (1969). "Neuroendocrinological studies in mental disorders and psychotropic drugs. I. On the circadian rhythm of the plasma adrenocortical hormone in mental patients and methamphetamine- and chlorpromazine-treated animals." *Folia Psychiatr Neurol Jpn* 23(2): 143-58.

## Craving

*See also* Dependence and Addiction; Relapse; Withdrawal

- Brown, E. S., V. A. Nejtck, D. C. Perantie, N. Rajan Thomas and A. J. Rush (2003). "Cocaine and amphetamine use in patients with psychiatric illness: A randomized trial of typical antipsychotic continuation or discontinuation." *J Clin Psychopharmacol* 23(4): 384-8.
- Camacho, A. and H. S. Akiskal (2005). "Proposal for a bipolar-stimulant spectrum: Temperament, diagnostic validation and therapeutic outcomes with mood stabilizers." *J Affect Disord* 85(1-2): 217-30.
- Cho, A. K. and W. P. Melega (2002). "Patterns of methamphetamine abuse and their consequences." *J Addict Dis* 21(1): 21-34.
- Galloway, G. P., J. Newmeyer, T. Knapp, S. A. Stalcup and D. Smith (1996). "A controlled trial of imipramine for the treatment of methamphetamine dependence." *J Subst Abuse Treat* 13(6): 493-7.
- Gillin, J. C., L. Pulvirenti, et al. (1994). "The effects of lisuride on mood and sleep during acute withdrawal in stimulant abusers: A preliminary report." *Biol Psychiatry* 35(11): 843-9.
- Harris, D. S., V. I. Reus, et al. (2005). "Repeated psychological stress testing in stimulant-dependent patients." *Prog Neuropsychopharmacol Biol Psychiatry* 29(5): 669-77.
- Harris, D. S., V. I. Reus, et al. (2003). "Altering cortisol level does not change the pleasurable effects of methamphetamine in humans." *Neuropsychopharmacology* 28(9): 1677-84.
- Hartz, D. T., S. L. Frederick-Osborne, et al. (2001). "Craving predicts use during treatment for methamphetamine dependence: A prospective, repeated-measures, within-subject analysis." *Drug Alcohol Depend* 63(3): 269-76.
- James, D., G. Davies and P. Willner (2004). "The development and initial validation of a questionnaire to measure craving for amphetamine." *Addiction* 99(9): 1181-8.
- Johnson, B. A., J. D. Roache, et al. (2006). "Effects of acute topiramate dosing on methamphetamine-induced subjective mood." *Int J Neuropsychopharmacol*: 1-14.
- Johnson, B. A., J. D. Roache, et al. (2005). "Effects of isradipine, a dihydropyridine-class calcium-channel antagonist, on d-methamphetamine's subjective and reinforcing effects." *Int J Neuropsychopharmacol* 8(2): 203-13.
- Johnson, B. A., J. D. Roache, et al. (1999). "Isradipine, a dihydropyridine-class calcium channel antagonist, attenuates some of d-methamphetamine's positive subjective effects: A preliminary study." *Psychopharmacology (Berl)* 144(3): 295-300.
- McGregor, C., M. Srisurapanont, et al. (2005). "The nature, time course and severity of methamphetamine withdrawal." *Addiction* 100(9): 1320-9.
- Newton, T. F., J. D. Roache, et al. (2006). "Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving." *Neuropsychopharmacology* 31(7): 1537-44.
- Ogai, Y., A. Haraguchi, et al. (2005). "[Control of craving for methamphetamine: Development of scales for dependence and search for medicines for treatment]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 25(5): 227-33.
- Onaivi, E. S., S. F. Ali, et al. (2002). "Ibogaine signals addiction genes and methamphetamine alteration of long-term potentiation." *Ann N Y Acad Sci* 965: 28-46.
- Paulus, M. P., N. E. Hozack, B. E. Zauscher, L. Frank, G. G. Brown, D. L. Braff and M. A. Schuckit (2002). "Behavioral and functional neuroimaging evidence for prefrontal dysfunction in methamphetamine-dependent subjects." *Neuropsychopharmacology* 26(1): 53-63.
- Piasecki, M. P., G. M. Steinagel, et al. (2002). "An exploratory study: The use of paroxetine for methamphetamine craving." *J Psychoactive Drugs* 34(3): 301-4.
- Ross, B. M., A. Moszczynska, et al. (2002). "Decreased activity of brain phospholipid metabolic enzymes in human users of cocaine and methamphetamine." *Drug Alcohol Depend* 67(1): 73-9.

- Rothman, R. B., B. E. Blough, et al. (2002). "Appetite suppressants as agonist substitution therapies for stimulant dependence." *Ann N Y Acad Sci* 965: 109-26.
- Sattar, S. P., S. C. Bhatia, et al. (2004). "Potential benefits of quetiapine in the treatment of substance dependence disorders." *J Psychiatry Neurosci* 29(6): 452-7.
- Sekine, Y., M. Iyo, et al. (2001). "Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET." *Am J Psychiatry* 158(8): 1206-14.
- Vazquez, E. (2005). "Crystal meth recovery. A step-by-step guide." *Posit Aware* 16(5): 20-2, 25.
- Volkow, N. D., J. S. Fowler and G. J. Wang (2002). "Role of dopamine in drug reinforcement and addiction in humans: Results from imaging studies." *Behav Pharmacol* 13(5-6): 355-66.
- Yamamoto, T., K. Anggadiredja, et al. (2004). "New perspectives in the studies on endocannabinoid and cannabis: A role for the endocannabinoid-arachidonic acid pathway in drug reward and long-lasting relapse to drug taking." *J Pharmacol Sci* 96(4): 382-8.

### Craving (animals)

*See also* Conditioned Place Preference (animals); Self-Administration of Methamphetamine (animals)

- Anggadiredja, K., M. Nakamichi, et al. (2004). "Endocannabinoid system modulates relapse to methamphetamine seeking: Possible mediation by the arachidonic acid cascade." *Neuropsychopharmacology* 29(8): 1470-8.
- Anggadiredja, K., K. Sakimura, et al. (2004). "Naltrexone attenuates cue- but not drug-induced methamphetamine seeking: A possible mechanism for the dissociation of primary and secondary reward." *Brain Res* 1021(2): 272-6.
- Carney, J. M., R. W. Landrum, et al. (1991). "Establishment of chronic intravenous drug self-administration in the C57BL/6J mouse." *Neuroreport* 2(8): 477-80.
- Fattore, L., M. S. Spano, et al. (2007). "An endocannabinoid mechanism in relapse to drug seeking: A review of animal studies and clinical perspectives." *Brain Res Brain Res Rev* 53(1): 1-16.
- Harrod, S. B., L. P. Dvoskin, et al. (2001). "Lobeline attenuates d-methamphetamine self-administration in rats." *J Pharmacol Exp Ther* 298(1): 172-9.
- Hiranita, T., Y. Nawata, et al. (2006). "Suppression of methamphetamine-seeking behavior by nicotinic agonists." *Proc Natl Acad Sci U S A* 103(22): 8523-7.
- Hiranita, T., K. Anggadiredja, et al. (2004). "Nicotine attenuates relapse to methamphetamine-seeking behavior (craving) in rats." *Ann N Y Acad Sci* 1025: 504-7.
- Itzhak, Y. and S. F. Ali (2002). "Behavioral consequences of methamphetamine-induced neurotoxicity in mice: Relevance to the psychopathology of methamphetamine addiction." *Ann N Y Acad Sci* 965: 127-35.
- Kruzich, P. J. and J. Xi (2006). "Differences in extinction responding and reinstatement of methamphetamine-seeking behavior between Fischer 344 and Lewis rats." *Pharmacol Biochem Behav* 83(3): 391-5.
- Kuehn, B. M. (2006). "Nicotine, donepezil may dampen meth craving." *JAMA* 296(1): 31.
- Kuo, Y. M., K. C. Liang, et al. (2007). "Cocaine-but not methamphetamine-associated memory requires de novo protein synthesis." *Neurobiol Learn Mem* 87(1): 93-100.
- Li, S. M., L. L. Yin, et al. (2001). "GABA(B) receptor agonist baclofen attenuates the development and expression of d-methamphetamine-induced place preference in rats." *Life Sci* 70(3): 349-56.
- Moffett, M. C. and N. E. Goeders (2007). "CP-154,526, a CRF type-1 receptor antagonist, attenuates the cue-and methamphetamine-induced reinstatement of extinguished methamphetamine-seeking behavior in rats." *Psychopharmacology (Berl)* 190(2): 171-80.
- Parker, L. A. (1995). "Rewarding drugs produce taste avoidance, but not taste aversion." *Neurosci Biobehav Rev* 19(1): 143-57.
- Ranaldi, R. and K. Poeggel (2002). "Baclofen decreases methamphetamine self-administration in rats." *Neuroreport* 13(9): 1107-10.
- Roth, M. E. and M. E. Carroll (2004). "Sex differences in the acquisition of IV methamphetamine self-administration and subsequent maintenance under a progressive ratio schedule in rats." *Psychopharmacology (Berl)* 172(4): 443-9.
- Shepard, J. D., J. M. Bossert, et al. (2004). "The anxiogenic drug yohimbine reinstates methamphetamine seeking in a rat model of drug relapse." *Biol Psychiatry* 55(11): 1082-9.
- Stefanski, R., S. H. Lee, S. Yasar, J. L. Cadet and S. R. Goldberg (2002). "Lack of persistent changes in the dopaminergic system of rats withdrawn from methamphetamine self-administration." *Eur J Pharmacol* 439(1-3): 59-68.
- Yan, Y., A. Nitta, et al. (2006). "Relapse of methamphetamine-seeking behavior in C57BL/6J mice demonstrated by a reinstatement procedure involving intravenous self-administration." *Behav Brain Res* 168(1): 137-43.
- Yasar, S., J. Gaal, et al. (2006). "A comparison of drug-seeking behavior maintained by D-amphetamine, L-deprenyl (selegiline), and D-deprenyl under a second-order schedule in squirrel monkeys." *Psychopharmacology (Berl)* 183(4): 413-21.

**Crime**

- See also* Drug Courts and Court-Mandated Treatment: Incarceration and Incarcerated Individuals; Law Enforcement; Methamphetamine Laboratories and Manufacture; Methamphetamine Trafficking and Sale
- Austin, A. A. (2004). "Alcohol, tobacco, other drug use, and violent behavior among Native Hawaiians: ethnic pride and resilience." *Subst Use Misuse* 39(5): 721-46.
- Bailey, D. N. and R. F. Shaw (1989). "Cocaine- and methamphetamine-related deaths in San Diego County (1987): homicides and accidental overdoses." *J Forensic Sci* 34(2): 407-22.
- Baskin-Sommers, A. and I. Sommers (2006). "The co-occurrence of substance use and high-risk behaviors." *J Adolesc Health* 38(5): 609-11.
- Booth, B. M., C. Leukefeld, et al. (2006). "Correlates of rural methamphetamine and cocaine users: Results from a multistate community study." *J Stud Alcohol* 67(4): 493-501.
- Boulard, G. (2005). "The meth menace: Battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.
- Brecht, M. L., L. Greenwell, et al. (2007). "Substance use pathways to methamphetamine use among treated users." *Addict Behav* 32(1): 24-38.
- Brecht, M. L., M. D. Anglin, et al. (2005). "Coerced treatment for methamphetamine abuse: Differential patient characteristics and outcomes." *Am J Drug Alcohol Abuse* 31(2): 337-56.
- Brecht, M. L., C. von Mayrhauser, et al. (2000). "Predictors of relapse after treatment for methamphetamine use." *J Psychoactive Drugs* 32(2): 211-20.
- Cartier, J., D. Farabee, et al. (2006). "Methamphetamine use, self-reported violent crime, and recidivism among offenders in California who abuse substances." *J Interpers Violence* 21(4): 435-45.
- Chappell, J. S. (1997). "Infrared discrimination of enantiomerically enriched and racemic samples of methamphetamine salts." *Analyst* 122(8): 755-60.
- Chiang, S. C., H. Y. Chan, et al. (2006). "Recidivism among male subjects incarcerated for illicit drug use in Taiwan." *Psychiatry Clin Neurosci* 60(4): 444-51.
- Denehy, J. (2006). "The meth epidemic: Its effect on children and communities." *J Sch Nurs* 22(2): 63-5.
- Domier, C. P., S. L. Simon, et al. (2000). "A comparison of injecting and noninjecting methamphetamine users." *J Psychoactive Drugs* 32(2): 229-32.
- Evans, E. and D. Longshore (2004). "Evaluation of the substance abuse and crime prevention act: treatment clients and program types during the first year of implementation." *J Psychoactive Drugs Suppl* 2: 165-74.
- Fuller, K. (2005). "A dangerous business." *Occup Health Saf* 74(9): 188, 190-1.
- Greberman, S. B. and K. Wada (1994). "Social and legal factors related to drug abuse in the United States and Japan." *Public Health Rep* 109(6): 731-7.
- Grella, C. E., Y. I. Hser, et al. (2006). "Mothers in substance abuse treatment: Differences in characteristics based on involvement with child welfare services." *Child Abuse Negl* 30(1): 55-73.
- Gunter, T. D., D. W. Black, et al. (2004). "Drug and alcohol treatment services effective for methamphetamine abuse." *Ann Clin Psychiatry* 16(4): 195-200.
- Hser, Y. I., C. Teruya, et al. (2003). "Treating drug-abusing offenders. Initial findings from a five-county study on the impact of California's Proposition 36 on the treatment system and patient outcomes." *Eval Rev* 27(5): 479-505.
- Jansen, K. L. and L. Theron (2006). "Ecstasy (MDMA), methamphetamine, and date rape (drug-facilitated sexual assault): A consideration of the issues." *J Psychoactive Drugs* 38(1): 1-12.
- Kashani, J. and A. M. Ruha (2004). "Methamphetamine toxicity secondary to intravaginal body stuffing." *J Toxicol Clin Toxicol* 42(7): 987-9.
- Kim, J. Y. and M. Fendrich (2002). "Gender differences in juvenile arrestees' drug use, self-reported dependence, and perceived need for treatment." *Psychiatr Serv* 53(1): 70-5.
- Matsumoto, T., A. Kamijo, et al. (2002). "Methamphetamine in Japan: the consequences of methamphetamine abuse as a function of route of administration." *Addiction* 97(7): 809-17.
- Miura, H., M. Fujiki, et al. (2006). "Prevalence and profile of methamphetamine users in adolescents at a juvenile classification home." *Psychiatry Clin Neurosci* 60(3): 352-7.
- Oetting, E. R., J. L. Deffenbacher, et al. (2000). "Methamphetamine use by high school students: Recent trends, gender and ethnicity differences, and use of other drugs." *Journal of Child and Adolescent Substance Abuse* 10(1): 33-50.
- Senjo, S. R. (2005). "Trafficking in meth: An analysis of the differences between male and female dealers." *J Drug Educ* 35(1): 59-77.

- Slade, M., L. J. Daniel, et al. (1991). "Application of forensic toxicology to the problem of domestic violence." *J Forensic Sci* 36(3): 708-13.
- Sommers, I., D. Baskin, et al. (2006). "Methamphetamine use among young adults: Health and social consequences." *Addict Behav* 31(8): 1469-76.
- Storr, C. L., A. M. Arria, et al. (2004). "Neighborhood environment and opportunity to try methamphetamine ("ice") and marijuana: Evidence from Guam in the Western Pacific region of Micronesia." *Subst Use Misuse* 39(2): 253-76.

### Czech Republic

- Berankova, K., V. Habrdova, et al. (2005). "Methamphetamine in hair and interpretation of forensic findings in a fatal case." *Forensic Sci Int* 153(1): 93-7.
- Csemy, L., L. Kubicka, et al. (2002). "Drug scene in the Czech Republic and Slovakia during the period of transformation." *Eur Addict Res* 8(4): 159-65.
- Mravcik, V., H. Sebakova, et al. (2000). "[Seroprevalence of viral hepatitis A, B and C in intravenous drug users]." *Epidemiol Mikrobiol Imunol* 49(1): 19-23.
- Popov, P. (1996). "[Stimulants and addiction]." *Ceska Slov Psychiatr* 92 Suppl 1: 70-2.
- Sery, O., V. Vojtova, et al. (2001). "The association study of DRD2, ACE and AGT gene polymorphisms and metamphetamine dependence." *Physiol Res* 50(1): 43-50.
- Toupalik, P., H. Vanerkova, et al. (2002). "[Morphologic findings in chronic abuse of heroin and pervitine]." *Soud Lek* 47(1): 5-11.

### Dallas, TX (US)

- Little, B. B., L. M. Snell, et al. (1988). "Methamphetamine abuse during pregnancy: Outcome and fetal effects." *Obstet Gynecol* 72(4): 541-4.
- Thiede, H., L. A. Valleroy, et al. (2003). "Regional patterns and correlates of substance use among young men who have sex with men in 7 US urban areas." *Am J Public Health* 93(11): 1915-21.

### Dangerousness

- Room, R. (2006). "The dangerousness of drugs." *Addiction* 101(2): 166-8.

### Deaths

*See Mortality, Methamphetamine-Associated*

### Decision-Making and Judgment

- Bechara, A., S. Dolan, et al. (2001). "Decision-making deficits, linked to a dysfunctional ventromedial prefrontal cortex, revealed in alcohol and stimulant abusers." *Neuropsychologia* 39(4): 376-89.
- Chung, A., I. K. Lyoo, et al. (2006). "Decreased frontal white-matter integrity in abstinent methamphetamine abusers." *Int J Neuropsychopharmacol*: 1-11.
- Forney, R. (1977). "Drug impairment reviews: stimulants." *NIDA Res Monogr Series* 11: 73-6.
- Forney, R., R. Martz, et al. (1976). "The combined effect of marihuana and dextroamphetamine." *Ann N Y Acad Sci* 281: 162-70.
- Gustavsen, I., J. Morland, et al. (2005). "Impairment related to blood amphetamine and/or methamphetamine concentrations in suspected drugged drivers." *Accid Anal Prev*.
- Hart, C. L., A. S. Ward, et al. (2001). "Methamphetamine self-administration by humans." *Psychopharmacology (Berl)* 157(1): 75-81.
- Hoffman, W. F., M. Moore, et al. (2006). "Neuropsychological function and delay discounting in methamphetamine-dependent individuals." *Psychopharmacology (Berl)* 188(2): 162-70.
- Logan, B. K. (1996). "Methamphetamine and driving impairment." *J Forensic Sci* 41(3): 457-64.
- Lundqvist, T. (2005). "Cognitive consequences of cannabis use: Comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions." *Pharmacol Biochem Behav* 81(2): 319-30.
- Monterosso, J. R., A. R. Aron, et al. (2005). "Deficits in response inhibition associated with chronic methamphetamine abuse." *Drug Alcohol Depend* 79(2): 273-7.
- Paulus, M. P., S. F. Tapert, et al. (2005). "Neural activation patterns of methamphetamine-dependent subjects during decision making predict relapse." *Arch Gen Psychiatry* 62(7): 761-8.



- Paulus, M. P., N. Hozack, et al. (2003). "Decision making by methamphetamine-dependent subjects is associated with error-rate-independent decrease in prefrontal and parietal activation." *Biol Psychiatry* 53(1): 65-74.
- Paulus, M. P., N. E. Hozack, et al. (2002). "Behavioral and functional neuroimaging evidence for prefrontal dysfunction in methamphetamine-dependent subjects." *Neuropsychopharmacology* 26(1): 53-63.
- Rogers, R. D., B. J. Everitt, et al. (1999). "Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: Evidence for monoaminergic mechanisms." *Neuropsychopharmacology* 20(4): 322-39.
- Salo, R., T. E. Nordahl, et al. (2002). "Preliminary evidence of reduced cognitive inhibition in methamphetamine-dependent individuals." *Psychiatry Res* 111(1): 65-74.
- Sheridan, J., S. Bennett, et al. (2006). "Injury associated with methamphetamine use: A review of the literature." *Harm Reduct J* 3(1): 14.
- Sim, T., S. L. Simon, et al. (2002). "Cognitive deficits among methamphetamine users with attention deficit hyperactivity disorder symptomatology." *J Addict Dis* 21(1): 75-89.
- Verdejo-Garcia, A., A. Bechara, et al. (2006). "Executive dysfunction in substance dependent individuals during drug use and abstinence: an examination of the behavioral, cognitive and emotional correlates of addiction." *J Int Neuropsychol Soc* 12(3): 405-15.

## Denmark

- Johansen, S. S., A. C. Hansen, et al. (2003). "Three fatal cases of PMA and PMMA poisoning in Denmark." *J Anal Toxicol* 27(4): 253-6.

## Dental and Oral Health

- Anonymous (2005). "For the dental patient ... methamphetamine use and oral health." *J Am Dent Assoc* 136(10): 1491.
- Assael, L. A. (2005). "Methamphetamine: An epidemic of oral health neglect, loss of access to care, abuse, and violence." *J Oral Maxillofac Surg* 63(9): 1253-4.
- Curtis, E. K. (2006). "Meth mouth: A review of methamphetamine abuse and its oral manifestations." *Gen Dent* 54(2): 125-9.
- Damm, D. D. and J. E. Fantasia (2006). "Dilapidated dentition." *Gen Dent* 54(3): 223-4.
- Donaldson, M. and J. H. Goodchild (2006). "Oral health of the methamphetamine abuser." *Am J Health Syst Pharm* 63(21): 2078-82.
- Hasan, A. A. and S. Ciancio (2004). "Relationship between amphetamine ingestion and gingival enlargement." *Pediatr Dent* 26(5): 396-400.
- Howe, A. M. (1995). "Methamphetamine and childhood and adolescent caries." *Aust Dent J* 40(5): 340.
- Klasser, G. D. and J. B. Epstein (2006). "The methamphetamine epidemic and dentistry." *Gen Dent* 54(6): 431-9; quiz 440, 448.
- Klasser, G. D. and J. Epstein (2005). "Methamphetamine and its impact on dental care." *J Can Dent Assoc* 71(10): 759-62.
- Lee, C. Y., L. B. Heffez, et al. (1992). "Crystal methamphetamine abuse: A concern to oral and maxillofacial surgeons." *J Oral Maxillofac Surg* 50(10): 1052-4.
- McGrath, C. and B. Chan (2005). "Oral health sensations associated with illicit drug abuse." *Br Dent J* 198(3): 159-62.
- Morales, S. (2006). "Aesthetic reconstruction of "meth mouth"." *Dent Today* 25(5): 86, 88-91;
- Nixon, P. J., C. C. Youngson and A. Beese (2002). "Tooth surface loss: Does recreational drug use contribute?" *Clin Oral Investig* 6(2): 128-30.
- Rhodus, N. L. and J. W. Little (2005). "Methamphetamine abuse and "meth mouth"." *Northwest Dent* 84(5): 29, 31, 33-7.
- Richards, J. R. and B. T. Brofeldt (2000). "Patterns of tooth wear associated with methamphetamine use." *J Periodontol* 71(8): 1371-4.
- Saini, T., P. C. Edwards, et al. (2005). "Etiology of xerostomia and dental caries among methamphetamine abusers." *Oral Health Prev Dent* 3(3): 189-95.
- Shaner, J. W., N. Kimmes, et al. (2006). ""Meth mouth": Rampant caries in methamphetamine abusers." *AIDS Patient Care STDS* 20(3): 146-50.
- Shaner, J. W. (2002). "Caries associated with methamphetamine abuse." *J Mich Dent Assoc* 84(9): 42-7.
- Smart, R. J. and M. Rosenberg (2005). "Methamphetamine abuse: Medical and dental considerations." *J Mass Dent Soc* 54(2): 44-6, 48-9.
- Venker, D. (1999). "Crystal methamphetamine and the dental patient." *Iowa Dent J* 85(4): 34.
- Wynn, R. L. (1997). "Dental considerations of patients taking appetite suppressants." *Gen Dent* 45(4): 324-8, 330-1.

### Denver, CO (US)

- Bull, S. S., P. Piper and C. Rietmeijer (2002). "Men who have sex with men and also inject drugs-profiles of risk related to the synergy of sex and drug injection behaviors." *J Homosex* 42(3): 31-51.
- Hopfer, C., B. Mendelson, et al. (2006). "Club drug use among youths in treatment for substance abuse." *Am J Addict* 15(1): 94-9.
- Kim, J. Y. and M. Fendrich (2002). "Gender differences in juvenile arrestees' drug use, self-reported dependence, and perceived need for treatment." *Psychiatr Serv* 53(1): 70-5.
- Koblin, B. A., M. A. Chesney, et al. (2003). "High-risk behaviors among men who have sex with men in 6 US cities: Baseline data from the EXPLORE Study." *Am J Public Health* 93(6): 926-32.
- Van Leeuwen, J. M., C. Hopfer, et al. (2004). "A snapshot of substance abuse among homeless and runaway youth in Denver, Colorado." *J Community Health* 29(3): 217-29.

### Dependence and Addiction

*See also* Craving

- Aoyama, N., N. Takahashi, et al. (2006). "Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder." *Alcohol Clin Exp Res* 30(10): 1644-9.
- Asanuma, M. and I. Miyazaki (2005). "[Expression profiling of molecules related to abused drug dependence and toxicity]." *Nippon Yakurigaku Zasshi* 126(1): 30-4, 42.
- Barr, A. M., W. J. Panenka, et al. (2006). "The need for speed: An update on methamphetamine addiction." *J Psychiatry Neurosci* 31(5): 301-313.
- Bechara, A., S. Dolan, et al. (2001). "Decision-making deficits, linked to a dysfunctional ventromedial prefrontal cortex, revealed in alcohol and stimulant abusers." *Neuropsychologia* 39(4): 376-89.
- Chang, L. and W. Haning (2006). "Insights from recent positron emission tomographic studies of drug abuse and dependence." *Curr Opin Psychiatry* 19(3): 246-252.
- Chen, C. K., X. Hu, et al. (2004). "Association analysis of dopamine D2-like receptor genes and methamphetamine abuse." *Psychiatr Genet* 14(4): 223-6.
- Cho, A. K. and W. P. Melega (2002). "Patterns of methamphetamine abuse and their consequences." *J Addict Dis* 21(1): 21-34.
- Edakubo, T., T. Kaneko, et al. (1991). "[Secondary development of psychological dependence in a methamphetamine dependent]." *Arukoru Kenkyuto Yakubutsu Ison* 26(2): 96-104.
- Ellison, G. (2002). "Neural degeneration following chronic stimulant abuse reveals a weak link in brain, fasciculus retroflexus, implying the loss of forebrain control circuitry." *Eur Neuropsychopharmacol* 12(4): 287-97.
- Gonzalez Castro, F., E. H. Barrington, et al. (2000). "Cocaine and methamphetamine: Differential addiction rates." *Psychol Addict Behav* 14(4): 390-6.
- Gordon, S. M., F. Tulak, et al. (2004). "Prevalence and characteristics of adolescents patients with co-occurring ADHD and substance dependence." *J Addict Dis* 23(4): 31-40.
- Halkitis, P. N. and M. T. Shrem (2006). "Psychological differences between binge and chronic methamphetamine using gay and bisexual men." *Addict Behav* 31(3): 549-52.
- Hall, W., S. Darke, et al. (1993). "Patterns of drug use and risk-taking among injecting amphetamine and opioid drug users in Sydney, Australia." *Addiction* 88(4): 509-16.
- Hart, C. L., A. S. Ward, et al. (2001). "Methamphetamine self-administration by humans." *Psychopharmacology (Berl)* 157(1): 75-81.
- Ide, S., H. Kobayashi, et al. (2006). "Linkage disequilibrium and association with methamphetamine dependence/psychosis of mu-opioid receptor gene polymorphisms." *Pharmacogenomics J* 6(3): 179-88.
- Ide, S., H. Kobayashi, et al. (2004). "Gene polymorphisms of the mu opioid receptor in methamphetamine abusers." *Ann N Y Acad Sci* 1025: 316-24.
- Ikeda, M., N. Iwata, et al. (2006). "Positive association of AKT1 haplotype to Japanese methamphetamine use disorder." *Int J Neuropsychopharmacol* 9(1): 77-81.
- Itzhak, Y. and S. F. Ali (2002). "Behavioral consequences of methamphetamine-induced neurotoxicity in mice: Relevance to the psychopathology of methamphetamine addiction." *Ann N Y Acad Sci* 965: 127-35.
- Iwanami, A., N. Kuroki, et al. (1998). "P3a of event-related potential in chronic methamphetamine dependence." *J Nerv Ment Dis* 186(12): 746-51.
- Jernigan, T. L., A. C. Gamst, et al. (2005). "Effects of methamphetamine dependence and HIV infection on cerebral morphology." *Am J Psychiatry* 162(8): 1461-72.

- Kalechstein, A. D., T. F. Newton and M. Green (2003). "Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence." *J Neuropsychiatry Clin Neurosci* 15(2): 215-20.
- Kalechstein, A. D., T. F. Newton, et al. (2000). "Psychiatric comorbidity of methamphetamine dependence in a forensic sample." *J Neuropsychiatry Clin Neurosci* 12(4): 480-4.
- Kaye, S. and S. Darke (2000). "A comparison of the harms associated with the injection of heroin and amphetamines." *Drug Alcohol Depend* 58(1-2): 189-95.
- Kim, J. Y. and M. Fendrich (2002). "Gender differences in juvenile arrestees' drug use, self-reported dependence, and perceived need for treatment." *Psychiatr Serv* 53(1): 70-5.
- Kobayashi, H., H. Hata, et al. (2006). "Association analysis of delta-opioid receptor gene polymorphisms in methamphetamine dependence/psychosis." *Am J Med Genet B Neuropsychiatr Genet* 141(5): 482-6.
- Kobayashi, H., S. Ide, et al. (2004). "Study of association between alpha-synuclein gene polymorphism and methamphetamine psychosis/dependence." *Ann N Y Acad Sci* 1025: 325-34.
- Koizumi, H., K. Hashimoto, et al. (2004). "Association between the glutathione S-transferase M1 gene deletion and female methamphetamine abusers." *Am J Med Genet B Neuropsychiatr Genet* 126(1): 43-5.
- Kovacic, P. and A. L. Cooksy (2005). "Unifying mechanism for toxicity and addiction by abused drugs: electron transfer and reactive oxygen species." *Med Hypotheses* 64(2): 357-66.
- Li, T., C. K. Chen, et al. (2004). "Association analysis of the DRD4 and COMT genes in methamphetamine abuse." *Am J Med Genet* 129B(1): 120-4.
- McKetin, R., J. McLaren, et al. (2006). "The prevalence of psychotic symptoms among methamphetamine users." *Addiction* 101(10): 1473-8.
- McKetin, R., E. Kelly, et al. (2006). "The relationship between crystalline methamphetamine use and methamphetamine dependence." *Drug Alcohol Depend* 85(3): 198-204.
- McKetin, R. and N. Solowij (1999). "Event-related potential indices of auditory selective attention in dependent amphetamine users." *Biol Psychiatry* 45(11): 1488-97.
- Mitchell, S. J., S. R. Morris, et al. (2006). "Methamphetamine use and sexual activity among HIV-infected patients in care--San Francisco, 2004." *AIDS Patient Care STDS* 20(7): 502-10.
- Miyata, H., J. Kono, et al. (2004). "Clinical features of nicotine dependence compared with those of alcohol, methamphetamine, and inhalant dependence." *Ann N Y Acad Sci* 1025: 481-8.
- Miyata, H., J. Kono, et al. (2004). "[Studies on clinical characteristics of nicotine dependence using a two compartment model of drug dependence]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 24(2): 61-6.
- Miyatake, M., M. Narita, et al. (2005). "Glutamatergic neurotransmission and protein kinase C play a role in neuron-glia communication during the development of methamphetamine-induced psychological dependence." *Eur J Neurosci* 22(6): 1476-88.
- Morio, A., H. Ujike, et al. (2006). "No association between CART (cocaine- and amphetamine-regulated transcript) gene and methamphetamine dependence." *Ann N Y Acad Sci* 1074: 411-7.
- Morita, Y., H. Ujike, et al. (2005). "A nonsynonymous polymorphism in the human fatty acid amide hydrolase gene did not associate with either methamphetamine dependence or schizophrenia." *Neurosci Lett* 376(3): 182-7.
- Morita, Y., H. Ujike, et al. (2005). "The X-box binding protein 1 (XBP1) gene is not associated with methamphetamine dependence." *Neurosci Lett* 383(1-2): 194-8.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.
- Nakajima, A., K. Yamada, T. Nagai, T. Uchiyama, Y. Miyamoto, T. Mamiya, J. He, A. Nitta, M. Mizuno, M. H. Tran, A. Seto, M. Yoshimura, K. Kitaichi, T. Hasegawa, K. Saito, Y. Yamada, M. Seishima, K. Sekikawa, H. C. Kim and T. Nabeshima (2004). "Role of tumor necrosis factor-alpha in methamphetamine-induced drug dependence and neurotoxicity." *J Neurosci* 24(9): 2212-25.
- Narita, M., M. Miyatake, et al. (2005). "[Implication of glial function in the development of drug dependence associated with synaptic plasticity]." *Nippon Yakurigaku Zasshi* 126(1): 43-8.
- Newton, T. F., A. D. Kalechstein, et al. (2004). "Association between quantitative EEG and neurocognition in methamphetamine-dependent volunteers." *Clin Neurophysiol* 115(1): 194-8.
- Newton, T. F., I. A. Cook, et al. (2003). "Quantitative EEG abnormalities in recently abstinent methamphetamine dependent individuals." *Clin Neurophysiol* 114(3): 410-5.
- Nishiyama, T., M. Ikeda, et al. (2005). "Haplotype association between GABAA receptor gamma2 subunit gene (GABRG2) and methamphetamine use disorder." *Pharmacogenomics J* 5(2): 89-95.
- Niv, N. and Y. I. Hser (2006). "Drug treatment service utilization and outcomes for Hispanic and white methamphetamine abusers." *Health Serv Res* 41(4 Pt 1): 1242-57.

- Nomura, A., H. Ujike, et al. (2006). "Genetic variant of prodynorphin gene is risk factor for methamphetamine dependence." *Neurosci Lett* 400(1-2): 158-62.
- Nordahl, T. E., R. Salo, et al. (2002). "Low N-acetyl-aspartate and high choline in the anterior cingulum of recently abstinent methamphetamine-dependent subjects: A preliminary proton MRS study. *Magnetic resonance spectroscopy.*" *Psychiatry Res* 116(1-2): 43-52.
- Ogai, Y., A. Haraguchi, et al. (2005). "[Control of craving for methamphetamine: Development of scales for dependence and search for medicines for treatment]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 25(5): 227-33.
- Onaivi, E. S., S. F. Ali, et al. (2002). "Ibogaine signals addiction genes and methamphetamine alteration of long-term potentiation." *Ann N Y Acad Sci* 965: 28-46.
- Osugi, T., Y. Aoki, et al. (1994). "[Involvement of gene expression in drug tolerance and dependence]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 14(4): 185-93.
- Ozaki, S. (2004). "[Current situation of substance abuse/dependence in psychiatric hospital settings]." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 39(1): 35-40.
- Paulus, M. P., N. E. Hozack, et al. (2002). "Behavioral and functional neuroimaging evidence for prefrontal dysfunction in methamphetamine-dependent subjects." *Neuropsychopharmacology* 26(1): 53-63.
- Rawson, R. A., P. Marinelli-Casey, et al. (2004). "A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence." *Addiction* 99(6): 708-17.
- Rippeth, J. D., R. K. Heaton, et al. (2004). "Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons." *J Int Neuropsychol Soc* 10(1): 1-14.
- Rothman, R. B., B. E. Blough and M. H. Baumann (2002). "Appetite suppressants as agonist substitution therapies for stimulant dependence." *Ann N Y Acad Sci* 965: 109-26.
- Rothman, R. B., J. S. Partilla, et al. (2000). "Methamphetamine dependence: Medication development efforts based on the dual deficit model of stimulant addiction." *Ann N Y Acad Sci* 914: 71-81.
- Rothman, R. B., J. S. Partilla, et al. (2000). "Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse." *Synapse* 35(3): 222-7.
- Salo, R., T. E. Nordahl, et al. (2002). "Preliminary evidence of reduced cognitive inhibition in methamphetamine-dependent individuals." *Psychiatry Res* 111(1): 65-74.
- Shoptaw, S., J. Peck, et al. (2003). "Psychiatric and substance dependence comorbidities, sexually transmitted diseases, and risk behaviors among methamphetamine-dependent gay and bisexual men seeking outpatient drug abuse treatment." *J Psychoactive Drugs* 35 Suppl 1: 161-8.
- Shoptaw, S., C. J. Reback and T. E. Freese (2002). "Patient characteristics, HIV serostatus, and risk behaviors among gay and bisexual males seeking treatment for methamphetamine abuse and dependence in Los Angeles." *J Addict Dis* 21(1): 91-105.
- Simons, J. S., M. N. Oliver, et al. (2005). "Methamphetamine and alcohol abuse and dependence symptoms: Associations with affect lability and impulsivity in a rural treatment population." *Addict Behav* 30(7): 1370-81.
- Soellner, R. (2005). "Club drug use in Germany." *Subst Use Misuse* 40(9): 1279-93.
- Topp, L. and S. Darke (1997). "The applicability of the dependence syndrome to amphetamine." *Drug Alcohol Depend* 48(2): 113-8.
- Tsai, S. J. (2007). "Increased central brain-derived neurotrophic factor activity could be a risk factor for substance abuse: Implications for treatment." *Med Hypotheses* 68(2): 410-4.
- Ujike, H. and M. Sato (2004). "Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis." *Ann N Y Acad Sci* 1025: 279-87.
- Uitermark, J. and P. D. A. Cohen (2006). "Amphetamine users in Amsterdam: Patterns of use and modes of self-regulation." *Addiction Research & Theory* 14(2): 159-188.
- Uitermark, J. and P. Cohen (2004). Amphetamine users in Amsterdam: Patterns of use and modes of self-regulation, Centrum voor drugsonderzoek.
- Verdejo-Garcia, A., A. Bechara, et al. (2006). "Executive dysfunction in substance dependent individuals during drug use and abstinence: an examination of the behavioral, cognitive and emotional correlates of addiction." *J Int Neuropsychol Soc* 12(3): 405-15.
- Volkow, N. D., L. Chang, et al. (2001). "Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex." *Am J Psychiatry* 158(12): 2015-21.
- Woods, S. P., J. D. Rippeth, et al. (2005). "Deficient strategic control of verbal encoding and retrieval in individuals with methamphetamine dependence." *Neuropsychology* 19(1): 35-43.
- Worsley, J. N., A. Moszczynska, et al. (2000). "Dopamine D1 receptor protein is elevated in nucleus accumbens of human, chronic methamphetamine users." *Mol Psychiatry* 5(6): 664-72.
- Yamada, K., T. Nagai, et al. (2005). "Drug dependence, synaptic plasticity, and tissue plasminogen activator." *J Pharmacol Sci* 97(2): 157-61.

Yamada, K., T. Nagai, et al. (2005). "[Pro- and anti-addictive factors related to drug addiction]." *Nippon Yakurigaku Zasshi* 126(1): 49-53.

## Depression

*See also* Mood

- Akiyama, K. (2006). "Longitudinal clinical course following pharmacological treatment of methamphetamine psychosis which persists after long-term abstinence." *Ann N Y Acad Sci* 1074: 125-34.
- Baker, A. and S. Dawe (2005). "Amphetamine use and co-occurring psychological problems: Review of the literature and implications for treatment." *Australian Psychologist* 40(2): 88-95.
- Baker, A., N. K. Lee, et al. (2004). "Drug use patterns and mental health of regular amphetamine users during a reported 'heroin drought'." *Addiction* 99(7): 875-84.
- Chen, C. K., S. K. Lin, et al. (2003). "Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis." *Psychol Med* 33(8): 1407-14.
- Clatts, M. C., L. Goldsamt, et al. (2005). "Homelessness and drug abuse among young men who have sex with men in New York city: a preliminary epidemiological trajectory." *J Adolesc* 28(2): 201-14.
- Colfax, G., T. J. Coates, et al. (2005). "Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of San Francisco men who have sex with men." *J Urban Health* 82(1 Suppl 1): i62-70.
- Cookson, J. and T. Silverstone (1986). "The effects of methylamphetamine on mood and appetite in depressed patients: A placebo-controlled study." *Int Clin Psychopharmacol* 1(2): 127-33.
- Davidson, C., A. J. Gow, et al. (2001). "Methamphetamine neurotoxicity: Necrotic and apoptotic mechanisms and relevance to human abuse and treatment." *Brain Res Brain Res Rev* 36(1): 1-22.
- Galloway, G. P., J. Newmeyer, et al. (1996). "A controlled trial of imipramine for the treatment of methamphetamine dependence." *J Subst Abuse Treat* 13(6): 493-7.
- Goldstein, D. J., A. H. Rampey, Jr., et al. (1993). "Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction." *J Clin Psychiatry* 54(8): 309-16.
- Hall, W., J. Hando, et al. (1996). "Psychological morbidity and route of administration among amphetamine users in Sydney, Australia." *Addiction* 91(1): 81-7.
- Joosen, M., T. F. Garrity, et al. (2005). "Predictors of current depressive symptoms in a sample of drug court participants." *Subst Use Misuse* 40(8): 1113-25.
- Kalechstein, A. D., T. F. Newton, D. Longshore, M. D. Anglin, W. G. van Gorp and F. H. Gawin (2000). "Psychiatric comorbidity of methamphetamine dependence in a forensic sample." *J Neuropsychiatry Clin Neurosci* 12(4): 480-4.
- Kiloh, L. G., M. Neilson, et al. (1974). "Response of depressed patients to methylamphetamine." *Br J Psychiatry* 125: 496-9.
- Kim, J. Y. and M. Fendrich (2002). "Gender differences in juvenile arrestees' drug use, self-reported dependence, and perceived need for treatment." *Psychiatr Serv* 53(1): 70-5.
- Kurtz, S. P. (2005). "Post-circuit blues: Motivations and consequences of crystal meth use among gay men in Miami." *AIDS Behav* 9(1): 63-72.
- Lampinen, T. M., D. McGhee, et al. (2006). "Increased risk of 'club' drug use among gay and bisexual high school students in British Columbia." *J Adolesc Health* 38(4): 458-61.
- London, E. D., S. L. Simon, et al. (2004). "Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers." *Arch Gen Psychiatry* 61(1): 73-84.
- McGregor, C., M. Srisurapanont, et al. (2005). "The nature, time course and severity of methamphetamine withdrawal." *Addiction* 100(9): 1320-9.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.
- Nakahara, Y. (1995). "Detection and diagnostic interpretation of amphetamines in hair." *Forensic Sci Int* 70(1-3): 135-53.
- Newton, T. F., J. D. Roache, et al. (2005). "Safety of intravenous methamphetamine administration during treatment with bupropion." *Psychopharmacology (Berl)* 182(3): 426-35.
- Newton, T. F., A. D. Kalechstein, S. Duran, N. Vansluis and W. Ling (2004). "Methamphetamine abstinence syndrome: Preliminary findings." *Am J Addict* 13(3): 248-55.
- Peck, J. A., C. J. Reback, et al. (2005). "Sustained reductions in drug use and depression symptoms from treatment for drug abuse in methamphetamine-dependent gay and bisexual men." *J Urban Health* 82(1 Suppl 1): i100-8.
- Peck, J. A., S. Shoptaw, et al. (2005). "HIV-associated medical, behavioral, and psychiatric characteristics of treatment-seeking, methamphetamine-dependent men who have sex with men." *J Addict Dis* 24(3): 115-32.

- Perdue, T., H. Hagan, et al. (2003). "Depression and HIV risk behavior among Seattle-area injection drug users and young men who have sex with men." *AIDS Educ Prev* 15(1): 81-92.
- Rawson, R. A., R. Gonzales, et al. (2005). "Methamphetamine use among treatment-seeking adolescents in Southern California: Participant characteristics and treatment response." *J Subst Abuse Treat* 29(2): 67-74.
- Rawson, R. A., A. Huber, et al. (2002). "Status of methamphetamine users 2-5 years after outpatient treatment." *J Addict Dis* 21(1): 107-19.
- Riehm, K. S., M. Y. Iguchi and M. D. Anglin (2002). "Depressive symptoms among amphetamine and cocaine users before and after substance abuse treatment." *Psychol Addict Behav* 16(4): 333-7.
- Robinson, L. and H. Rempel (2006). "Methamphetamine use and HIV symptom self-management." *J Assoc Nurses AIDS Care* 17(5): 7-14.
- Semple, S. J., J. Zians, et al. (2006). "Methamphetamine use, impulsivity, and sexual risk behavior among HIV-positive men who have sex with men." *J Addict Dis* 25(4): 105-14.
- Semple, S. J., J. Zians, et al. (2005). "Impulsivity and methamphetamine use." *J Subst Abuse Treat* 29(2): 85-93.
- Semple, S. J., I. Grant, et al. (2005). "Negative self-perceptions and sexual risk behavior among heterosexual methamphetamine users." *Substance Use & Misuse* 40(12): 1797-1810.
- Semple, S. J., T. L. Patterson, et al. (2004). "A comparison of injection and non-injection methamphetamine-using HIV positive men who have sex with men." *Drug Alcohol Depend* 76(2): 203-12.
- Shoptaw, S., J. Peck, et al. (2003). "Psychiatric and substance dependence comorbidities, sexually transmitted diseases, and risk behaviors among methamphetamine-dependent gay and bisexual men seeking outpatient drug abuse treatment." *J Psychoactive Drugs* 35 Suppl 1: 161-8.
- Simons, J. S., M. N. Oliver, et al. (2005). "Methamphetamine and alcohol abuse and dependence symptoms: Associations with affect lability and impulsivity in a rural treatment population." *Addict Behav* 30(7): 1370-81.
- Sommers, L., D. Baskin, et al. (2006). "Methamphetamine use among young adults: Health and social consequences." *Addict Behav* 31(8): 1469-76.
- Srisurapanont, M., R. Ali, et al. (2003). "Psychotic symptoms in methamphetamine psychotic in-patients." *Int J Neuropsychopharmacol* 6(4): 347-52.
- Sommers, L., D. Baskin, et al. (2006). "Methamphetamine use among young adults: Health and social consequences." *Addict Behav* 31(8): 1469-76.
- Thorberg, F. A. and M. Lyvers (2006). "Negative Mood Regulation (NMR) expectancies, mood, and affect intensity among clients in substance disorder treatment facilities." *Addict Behav* 31(5): 811-20.
- Urbina, A. and K. Jones (2004). "Crystal methamphetamine, its analogues, and HIV infection: Medical and psychiatric aspects of a new epidemic." *Clin Infect Dis* 38(6): 890-4.
- Won, M., Y. Minabe, Y. Sekine, N. Takei, N. Kondo and N. Mori (2003). "Manic-switch induced by fluvoxamine in abstinent pure methamphetamine abusers." *J Psychiatry Neurosci* 28(2): 134-5.
- Yen, C. F. and Y. C. Su (2006). "The associations of early-onset methamphetamine use with psychiatric morbidity among Taiwanese adolescents." *Subst Use Misuse* 41(1): 35-44.
- Yen, C. F. and B. L. Shieh (2005). "Suicidal ideation and correlates in Taiwanese adolescent methamphetamine users." *J Nerv Ment Dis* 193(7): 444-9.
- Zweben, J. E., J. B. Cohen, et al. (2004). "Psychiatric symptoms in methamphetamine users." *Am J Addict* 13(2): 181-90.

### Dermatology

*See* Burn Injuries; Skin and Soft Tissue Diseases and Disorders

### Des Moines, IA (US)

- Arria, A. M., C. Derauf, et al. (2006). "Methamphetamine and other substance use during pregnancy: Preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study." *Matern Child Health J* 10(3): 293-302.
- Smith, L. M., L. L. Lagasse, et al. (2006). "The Infant Development, Environment, and Lifestyle Study: Effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth." *Pediatrics* 118(3): 1149-1156.

## Disclosure of HIV Status

See HIV Disclosure

## Disclosure of Methamphetamine Use

Rockett, I. R., S. L. Putnam, et al. (2006). "Declared and undeclared substance use among emergency department patients: A population-based study." *Addiction* 101(5): 706-712.

## Dopamine and Dopamine Metabolism

- Aburai, K., U. Ikemoto, et al. (2004). "[Spontaneous recrudescence of psychotic diseases caused by methamphetamine (a stimulant): The stress type and the role of noradrenaline and dopamine systems]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 24(5): 319-20.
- Ajjimaporn, A., J. Swinscoe, et al. (2005). "Metallothionein provides zinc-mediated protective effects against methamphetamine toxicity in SK-N-SH cells." *Brain Res Bull* 67(6): 466-75.
- Berigan, T. (2004). "Amphetamine-like stimulant cessation in an abusing patient treated with bupropion (Tardiev et al. 2004)." *Acta Psychiatr Scand* 110(4): 312; author reply 312.
- Cass, W. A., M. W. Manning, et al. (2000). "Restorative effects of GDNF on striatal dopamine release in rats treated with neurotoxic doses of methamphetamine." *Ann N Y Acad Sci* 914: 127-36.
- Cass, W. A. (1997). "Decreases in evoked overflow of dopamine in rat striatum after neurotoxic doses of methamphetamine." *J Pharmacol Exp Ther* 280(1): 105-13.
- Cass, W. A. (1996). "GDNF selectively protects dopamine neurons over serotonin neurons against the neurotoxic effects of methamphetamine." *J Neurosci* 16(24): 8132-9.
- Chang, L. and W. Haning (2006). "Insights from recent positron emission tomographic studies of drug abuse and dependence." *Curr Opin Psychiatry* 19(3): 246-252.
- Chen, J., C. Wersinger, et al. (2003). "Chronic stimulation of D1 dopamine receptors in human SK-N-MC neuroblastoma cells induces nitric-oxide synthase activation and cytotoxicity." *J Biol Chem* 278(30): 28089-100.
- Chou, Y. H., W. S. Huang, et al. (2007). "Dopamine transporters and cognitive function in methamphetamine abuser after a short abstinence: A SPECT study." *Eur Neuropsychopharmacol* 17(1): 46-52.
- Comings, D. E. and K. Blum (2000). "Reward deficiency syndrome: Genetic aspects of behavioral disorders." *Prog Brain Res* 126: 325-41.
- Davidson, C., A. J. Gow, et al. (2001). "Methamphetamine neurotoxicity: Necrotic and apoptotic mechanisms and relevance to human abuse and treatment." *Brain Res Brain Res Rev* 36(1): 1-22.
- Dluzen, D. E. and J. L. McDermott (2004). "Developmental and genetic influences upon gender differences in methamphetamine-induced nigrostriatal dopaminergic neurotoxicity." *Ann N Y Acad Sci* 1025: 205-20.
- Dryhurst, G. (2001). "Are dopamine, norepinephrine, and serotonin precursors of biologically reactive intermediates involved in the pathogenesis of neurodegenerative brain disorders?" *Adv Exp Med Biol* 500: 373-96.
- D'Souza, U. M., C. Russ, et al. (2004). "Functional effects of a tandem duplication polymorphism in the 5'flanking region of the DRD4 gene." *Biol Psychiatry* 56(9): 691-7.
- Dwoskin, L. P. and P. A. Crooks (2002). "A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse." *Biochem Pharmacol* 63(2): 89-98.
- Ellinwood, E. H., Jr. and M. M. Kilbey (1980). "Fundamental mechanisms underlying altered behavior following chronic administration of psychomotor stimulants." *Biol Psychiatry* 15(5): 749-57.
- Ellison, G. (2002). "Neural degeneration following chronic stimulant abuse reveals a weak link in brain, fasciculus retroflexus, implying the loss of forebrain control circuitry." *Eur Neuropsychopharmacol* 12(4): 287-97.
- Eshleman, A. J., R. A. Henningsen, et al. (1994). "Release of dopamine via the human transporter." *Mol Pharmacol* 45(2): 312-6.
- Fitzmaurice, P. S., J. Tong, et al. (2006). "Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of methamphetamine." *J Pharmacol Exp Ther* 319(2): 703-9.
- Frost, D. O. and J. L. Cadet (2000). "Effects of methamphetamine-induced neurotoxicity on the development of neural circuitry: A hypothesis." *Brain Res Brain Res Rev* 34(3): 103-18.
- Gillin, J. C., L. Pulvirenti, et al. (1994). "The effects of lisuride on mood and sleep during acute withdrawal in stimulant abusers: A preliminary report." *Biol Psychiatry* 35(11): 843-9.
- Guilarte, T. R. (2001). "Is methamphetamine abuse a risk factor in parkinsonism?" *Neurotoxicology* 22(6): 725-31.
- Han, D. D. and H. H. Gu (2006). "Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs." *BMC Pharmacol* 6: 6.

- Harano, M., N. Uchimura, et al. (2004). "A polymorphism of DRD2 gene and brain atrophy in methamphetamine psychosis." *Ann N Y Acad Sci* 1025: 307-15.
- Heller, A., L. Won, et al. (1995). "Examination of developmental neurotoxicity by the use of tissue culture model systems." *Clin Exp Pharmacol Physiol* 22(5): 375-8.
- Holman, R. B., G. R. Elliott, et al. (1975). "Neuroregulators and sleep mechanisms." *Annu Rev Med* 26: 499-520.
- Hong, C. J., C. Y. Cheng, et al. (2003). "Association study of the dopamine and serotonin transporter genetic polymorphisms and methamphetamine abuse in Chinese males." *J Neural Transm* 110(4): 345-51.
- Ishikawa, T., B. L. Zhu, et al. (2006). "Increase in clusterin-containing follicles in the adenohypophysis of drug abusers." *Int J Legal Med*.
- Iyo, M., Y. Sekine and N. Mori (2004). "Neuromechanism of developing methamphetamine psychosis: A neuroimaging study." *Ann N Y Acad Sci* 1025: 288-95.
- Iyo, M. and Y. Sekine (2003). "[Stimulants related mental disorders]." *Ryoikibetsu Shokogun Shirizu*(40): 507-12.
- Iyo, M., M. Nishio, et al. (1993). "Dopamine D2 and serotonin S2 receptors in susceptibility to methamphetamine psychosis detected by positron emission tomography." *Psychiatry Res* 50(4): 217-31.
- Johanson, C. E., K. A. Frey, et al. (2006). "Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers." *Psychopharmacology (Berl)* 185(3): 327-38.
- Johanson, C. E., K. A. Frey, et al. (2006). "Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers." *Psychopharmacology (Berl)* 186(4): 620.
- Johnson, B. A., J. D. Roache, et al. (1999). "Isradipine, a dihydropyridine-class calcium channel antagonist, attenuates some of d-methamphetamine's positive subjective effects: A preliminary study." *Psychopharmacology (Berl)* 144(3): 295-300.
- Kalasinsky, K. S., T. Z. Bosy, et al. (2001). "Regional distribution of methamphetamine in autopsied brain of chronic human methamphetamine users." *Forensic Sci Int* 116(2-3): 163-9.
- Kitamura, O., I. Tokunaga, et al. (2006). "Immunohistochemical investigation of dopaminergic terminal markers and caspase-3 activation in the striatum of human methamphetamine users." *Int J Legal Med*.
- Kobayashi, H., S. Ide, et al. (2004). "Study of association between alpha-synuclein gene polymorphism and methamphetamine psychosis/dependence." *Ann N Y Acad Sci* 1025: 325-34.
- Kobayashi, K. and H. Sano (2000). "Dopamine deficiency in mice." *Brain Dev* 22 Suppl 1: S54-60.
- Li, T., C. K. Chen, et al. (2004). "Association analysis of the DRD4 and COMT genes in methamphetamine abuse." *Am J Med Genet* 129B(1): 120-4.
- Lile, J. A. (2006). "Pharmacological determinants of the reinforcing effects of psychostimulants: Relation to agonist substitution treatment." *Exp Clin Psychopharmacol* 14(1): 20-33.
- Lile, J. A., W. W. Stoops, et al. (2005). "Aripiprazole attenuates the discriminative-stimulus and subject-rated effects of D-amphetamine in humans." *Neuropsychopharmacology* 30(11): 2103-14.
- Liu, H. C., C. K. Chen, et al. (2006). "Association between dopamine receptor D1 A-48G polymorphism and methamphetamine abuse." *Psychiatry Clin Neurosci* 60(2): 226-31.
- Liu, H. C., S. K. Lin, et al. (2004). "DAT polymorphism and diverse clinical manifestations in methamphetamine abusers." *Psychiatr Genet* 14(1): 33-7.
- Maragos, W. F., K. L. Young, et al. (2002). "Human immunodeficiency virus-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function." *J Neurochem* 83(4): 955-63.
- McCann, U. D. and G. A. Ricaurte (2004). "Amphetamine neurotoxicity: Accomplishments and remaining challenges." *Neurosci Biobehav Rev* 27(8): 821-6.
- McCann, U. D., D. F. Wong, et al. (1998). "Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: Evidence from positron emission tomography studies with [<sup>11</sup>C]WIN-35,428." *J Neurosci* 18(20): 8417-22.
- McTavish, S. F., M. H. McPherson, et al. (2001). "Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness." *Br J Psychiatry* 179: 356-60.
- Mirecki, A., P. Fitzmaurice, et al. (2004). "Brain antioxidant systems in human methamphetamine users." *J Neurochem* 89(6): 1396-408.
- Moszczynska, A., P. Fitzmaurice, et al. (2004). "Why is parkinsonism not a feature of human methamphetamine users?" *Brain* 127(Pt 2): 363-70.
- Munro, C. A., M. E. McCaul, et al. (2006). "Sex differences in striatal dopamine release in healthy adults." *Biol Psychiatry* 59(10): 966-74.
- Muratake, T., S. Hayashi, et al. (1995). "The effect on methamphetamine on the mRNA level for 14.3.3 eta chain in the human cultured cells." *Mol Neurobiol* 11(1-3): 223-30.



- Nath, A., W. F. Maragos, et al. (2001). "Acceleration of HIV dementia with methamphetamine and cocaine." *J Neurovirol* 7(1): 66-71.
- Nath, A., C. Anderson, et al. (2000). "Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia." *J Psychopharmacol* 14(3): 222-7.
- Nordahl, T. E., R. Salo, et al. (2005). "Methamphetamine users in sustained abstinence: A proton magnetic resonance spectroscopy study." *Arch Gen Psychiatry* 62(4): 444-52.
- Nordahl, T. E., R. Salo, et al. (2003). "Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: A review." *J Neuropsychiatry Clin Neurosci* 15(3): 317-25.
- Nordahl, T. E., R. Salo, et al. (2002). "Low N-acetyl-aspartate and high choline in the anterior cingulum of recently abstinent methamphetamine-dependent subjects: A preliminary proton MRS study. Magnetic resonance spectroscopy." *Psychiatry Res* 116(1-2): 43-52.
- Ogden, C. A., M. E. Rich, et al. (2004). "Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: An expanded convergent functional genomics approach." *Mol Psychiatry* 9(11): 1007-29.
- Park, S. U., J. V. Ferrer, et al. (2002). "Peroxyntirite inactivates the human dopamine transporter by modification of cysteine 342: potential mechanism of neurotoxicity in dopamine neurons." *J Neurosci* 22(11): 4399-405.
- Pavese, N., O. Rimoldi, et al. (2004). "Cardiovascular effects of methamphetamine in Parkinson's disease patients." *Mov Disord* 19(3): 298-303.
- Piccini, P., N. Pavese, et al. (2005). "Factors affecting the clinical outcome after neural transplantation in Parkinson's disease." *Brain* 128(Pt 12): 2977-86.
- Piccini, P., D. J. Brooks, et al. (1999). "Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient." *Nat Neurosci* 2(12): 1137-40.
- Quinton, M. S. and B. K. Yamamoto (2006). "Causes and consequences of methamphetamine and MDMA toxicity." *AAPS J* 8(2): E337-47.
- Riddle, E. L., A. E. Fleckenstein, et al. (2006). "Mechanisms of methamphetamine-induced dopaminergic neurotoxicity." *AAPS J* 8(2): E413-8.
- Rogers, R. D., B. J. Everitt, et al. (1999). "Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: Evidence for monoaminergic mechanisms." *Neuropsychopharmacology* 20(4): 322-39.
- Ross, B. M., A. Moszczynska, et al. (2002). "Decreased activity of brain phospholipid metabolic enzymes in human users of cocaine and methamphetamine." *Drug Alcohol Depend* 67(1): 73-9.
- Rothman, R. B., N. Vu, et al. (2003). "In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates." *J Pharmacol Exp Ther* 307(1): 138-45.
- Rothman, R. B., J. S. Partilla, et al. (2000). "Methamphetamine dependence: Medication development efforts based on the dual deficit model of stimulant addiction." *Ann N Y Acad Sci* 914: 71-81.
- Sato, M. (2002). "[Basic and clinical studies on methamphetamine-related psychosis]." *Seishin Shinkeigaku Zasshi* 104(3): 179-90.
- Salo, R., T. E. Nordahl, et al. (2002). "Preliminary evidence of reduced cognitive inhibition in methamphetamine-dependent individuals." *Psychiatry Res* 111(1): 65-74.
- Sato, M. (1992). "A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis." *Ann N Y Acad Sci* 654: 160-70.
- Sato, M., Y. Numachi, et al. (1992). "Relapse of paranoid psychotic state in methamphetamine model of schizophrenia." *Schizophr Bull* 18(1): 115-22.
- Sato, M. (1986). "Acute exacerbation of methamphetamine psychosis and lasting dopaminergic supersensitivity--A clinical survey." *Psychopharmacol Bull* 22(3): 751-6.
- Sekine, Y., Y. Minabe, et al. (2003). "Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms." *Am J Psychiatry* 160(9): 1699-701.
- Sekine, Y., M. Iyo, et al. (2001). "Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET." *Am J Psychiatry* 158(8): 1206-14.
- Selden, L. S. (1991). "Neurotoxicity of methamphetamine: Mechanisms of action and issues related to aging." *NIDA Res Monogr* 115: 24-32.
- Sery, O., V. Vojtova, et al. (2001). "The association study of DRD2, ACE and AGT gene polymorphisms and methamphetamine dependence." *Physiol Res* 50(1): 43-50.
- Shimosato, K., N. Nagao, et al. (2003). "Suppressive effects of trihexyphenidyl on methamphetamine-induced dopamine release as measured by in vivo microdialysis." *Synapse* 49(1): 47-54.
- Sriram, K., S. A. Benkovic, D. B. Miller and J. P. O'Callaghan (2002). "Obesity exacerbates chemically induced neurodegeneration." *Neuroscience* 115(4): 1335-46.

- Stoops, W. W. (2006). "Aripiprazole as a potential pharmacotherapy for stimulant dependence: Human laboratory studies with d-amphetamine." *Exp Clin Psychopharmacol* 14(4): 413-21.
- Sulzer, D., M. S. Sonders, et al. (2005). "Mechanisms of neurotransmitter release by amphetamines: A review." *Prog Neurobiol* 75(6): 406-33.
- Tong, J., B. M. Ross, et al. (2003). "Decreased striatal dopamine D1 receptor-stimulated adenylyl cyclase activity in human methamphetamine users." *Am J Psychiatry* 160(5): 896-903.
- Tsai, S. J. (2007). "Increased central brain-derived neurotrophic factor activity could be a risk factor for substance abuse: Implications for treatment." *Med Hypotheses* 68(2): 410-4.
- Tsai, S. J., C. Y. Cheng, et al. (2002). "No association for D2 and D4 dopamine receptor polymorphisms and methamphetamine abuse in Chinese males." *Psychiatr Genet* 12(1): 29-33.
- Turchan, J., C. Anderson, et al. (2001). "Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine." *BMC Neurosci* 2: 3.
- Ujike, H., M. Harano, et al. (2003). "Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis." *Pharmacogenomics J* 3(4): 242-7.
- Veenstra-VanderWeele, J., A. Qaadir, et al. (2006). "Association between the casein kinase 1 epsilon gene region and subjective response to D-amphetamine." *Neuropsychopharmacology* 31(5): 1056-63.
- Villemagne, V., J. Yuan, et al. (1998). "Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [<sup>11</sup>C]WIN-35,428 positron emission tomography studies and direct in vitro determinations." *J Neurosci* 18(1): 419-27.
- Volkow, N. D., L. Chang, et al. (2001). "Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers." *Am J Psychiatry* 158(3): 377-82.
- Volkow, N. D., L. Chang, et al. (2001). "Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence." *J Neurosci* 21(23): 9414-8.
- Volkow, N. D., L. Chang, et al. (2001). "Low level of brain dopamine D2 receptors in methamphetamine abusers: Association with metabolism in the orbitofrontal cortex." *Am J Psychiatry* 158(12): 2015-21.
- Volz, T. J. and J. O. Schenk (2005). "A comprehensive atlas of the topography of functional groups of the dopamine transporter." *Synapse* 58(2): 72-94.
- Wachtel, S. R., A. Ortengren, et al. (2002). "The effects of acute haloperidol or risperidone on subjective responses to methamphetamine in healthy volunteers." *Drug Alcohol Depend* 68(1): 23-33.
- Wang, G. J., N. D. Volkow, et al. (2004). "Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence." *Am J Psychiatry* 161(2): 242-8.
- Wang, G. J., N. D. Volkow, et al. (2004). "Similarity between obesity and drug addiction as assessed by neurofunctional imaging: a concept review." *J Addict Dis* 23(3): 39-53.
- Wilhelm, C. J., R. A. Johnson, et al. (2006). "Hydrogen ion concentration differentiates effects of methamphetamine and dopamine on transporter-mediated efflux." *J Neurochem* 96(4): 1149-59.
- Wilhelm, C. J., R. A. Johnson, et al. (2004). "Effects of methamphetamine and lobeline on vesicular monoamine and dopamine transporter-mediated dopamine release in a cotransfected model system." *J Pharmacol Exp Ther* 310(3): 1142-51.
- Wilson, J. M., K. S. Kalasinsky, et al. (1996). "Striatal dopamine nerve terminal markers in human, chronic methamphetamine users." *Nat Med* 2(6): 699-703.
- Worsley, J. N., A. Moszczynska, et al. (2000). "Dopamine D1 receptor protein is elevated in nucleus accumbens of human, chronic methamphetamine users." *Mol Psychiatry* 5(6): 664-72.
- Wrona, M. Z., Z. Yang, et al. (1997). "Potential new insights into the molecular mechanisms of methamphetamine-induced neurodegeneration." *NIDA Res Monogr* 173: 146-74.
- Yui, K., K. Goto, et al. (2004). "The role of noradrenergic and dopaminergic hyperactivity in the development of spontaneous recurrence of methamphetamine psychosis and susceptibility to episode recurrence." *Ann N Y Acad Sci* 1025: 296-306.
- Yui, K., S. Ikemoto, et al. (2002). "Spontaneous recurrence of methamphetamine-induced paranoid-hallucinatory states in female subjects: Susceptibility to psychotic states and implications for relapse of schizophrenia." *Pharmacopsychiatry* 35(2): 62-71.
- Yui, K., S. Ikemoto, et al. (2000). "Studies of amphetamine or methamphetamine psychosis in Japan: Relation of methamphetamine psychosis to schizophrenia." *Ann N Y Acad Sci* 914: 1-12.
- Yui, K., T. Ishiguro, et al. (2000). "Susceptibility to subsequent episodes in spontaneous recurrence of methamphetamine psychosis." *Ann N Y Acad Sci* 914: 292-302.

**Dopamine and Dopamine Metabolism (animals)**

- Abekawa, T., T. Ohmori, et al. (1997). "Effect of no synthesis inhibition on striatal dopamine release and stereotyped behavior induced by a single administration of methamphetamine." *Prog Neuropsychopharmacol Biol Psychiatry* 21(5): 831-8.
- Abekawa, T., T. Ohmori, et al. (1994). "Effects of repeated administration of a high dose of methamphetamine on dopamine and glutamate release in rat striatum and nucleus accumbens." *Brain Res* 643(1-2): 276-81.
- Achat-Mendes, C., K. L. Anderson, et al. (2006). "Impairment in consolidation of learned place preference following dopaminergic neurotoxicity in mice is ameliorated by N-acetylcysteine but not D1 and D2 dopamine receptor agonists." *Neuropsychopharmacology*.
- Achat-Mendes, C., S. F. Ali, et al. (2005). "Differential effects of amphetamines-induced neurotoxicity on appetitive and aversive Pavlovian conditioning in mice." *Neuropsychopharmacology* 30(6): 1128-37.
- Adams, F. S., F. G. La Rosa, et al. (1996). "Characterization and transplantation of two neuronal cell lines with dopaminergic properties." *Neurochem Res* 21(5): 619-27.
- Akita, H., M. Ogata, et al. (2006). "Nigral injection of antisense oligonucleotides to synaptotagmin I using HVJ-liposome vectors causes disruption of dopamine release in the striatum and impaired skill learning." *Brain Res* 1095(1): 178-89.
- Akiyama, K., A. Kanzaki, et al. (1994). "Methamphetamine-induced behavioral sensitization and its implications for relapse of schizophrenia." *Schizophr Res* 12(3): 251-7.
- Ali, S. F., G. D. Newport, et al. (1996). "Methamphetamine-induced dopaminergic toxicity in mice. Role of environmental temperature and pharmacological agents." *Ann N Y Acad Sci* 801: 187-98.
- Ali, S. F., K. J. Kordsmeier, et al. (1995). "Drug-induced circling preference in rats. Correlation with monoamine levels." *Mol Neurobiol* 11(1-3): 145-54.
- Ali, S. F., G. D. Newport, et al. (1994). "Low environmental temperatures or pharmacologic agents that produce hypothermia decrease methamphetamine neurotoxicity in mice." *Brain Res* 658(1-2): 33-8.
- Ali, S. F., R. R. Holson, et al. (1993). "Development of dopamine and N-methyl-D-aspartate systems in rat brain: The effect of prenatal phencyclidine exposure." *Brain Res Dev Brain Res* 73(1): 25-33.
- Allan, A. M., R. Galindo, et al. (2001). "Conditioned place preference for cocaine is attenuated in mice over-expressing the 5-HT(3) receptor." *Psychopharmacology (Berl)* 158(1): 18-27.
- Amano, T., H. Matsubayashi, et al. (2002). "[Alteration of neuronal activities following repeated administration of stimulants]." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 37(1): 31-40.
- Amano, T., H. Matsubayashi, et al. (1996). "Hypersensitivity of nucleus accumbens neurons to methamphetamine and dopamine following repeated administrations of methamphetamine." *Ann N Y Acad Sci* 801: 136-47.
- Anaya-Martinez, V., A. Martinez-Marcos, et al. (2006). "Substantia nigra compacta neurons that innervate the reticular thalamic nucleus in the rat also project to striatum or globus pallidus: Implications for abnormal motor behavior." *Neuroscience* 143(2): 477-86.
- Anderson, K. L. and Y. Itzhak (2006). "Methamphetamine-induced selective dopaminergic neurotoxicity is accompanied by an increase in striatal nitrate in the mouse." *Ann N Y Acad Sci* 1074: 225-33.
- Anderson, L. I., R. E. Leipheimer, et al. (2005). "Effects of neonatal and prepubertal hormonal manipulations upon estrogen neuroprotection of the nigrostriatal dopaminergic system within female and male mice." *Neuroscience* 130(2): 369-82.
- Andretic, R., B. van Swinderen, et al. (2005). "Dopaminergic modulation of arousal in *Drosophila*." *Curr Biol* 15(13): 1165-75.
- Angulo, J. A., N. Angulo, et al. (2004). "Antagonists of the neurokinin-1 or dopamine D1 receptors confer protection from methamphetamine on dopamine terminals of the mouse striatum." *Ann N Y Acad Sci* 1025: 171-80.
- Arai, I., T. Shimazoe, et al. (1996). "Enhancement of dopamine release from the striatum through metabotropic glutamate receptor activation in methamphetamine sensitized rats." *Brain Res* 729(2): 277-80.
- Armstrong, B. D. and K. K. Noguchi (2004). "The neurotoxic effects of 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine on serotonin, dopamine, and GABA-ergic terminals: an in-vitro autoradiographic study in rats." *Neurotoxicology* 25(6): 905-14.
- Barr, A. M., W. J. Panenka, et al. (2006). "The need for speed: An update on methamphetamine addiction." *J Psychiatry Neurosci* 31(5): 301-313.
- Baumann, M. H., J. M. Phillips, et al. (2002). "Preclinical evaluation of GBR12909 decanoate as a long-acting medication for methamphetamine dependence." *Ann N Y Acad Sci* 965: 92-108.
- Baumgarten, H. G. and L. Lachenmayer (2004). "Serotonin neurotoxins--past and present." *Neurotox Res* 6(7-8): 589-614.
- Betarbet, R., T. B. Sherer, et al. (2002). "Animal models of Parkinson's disease." *Bioessays* 24(4): 308-18.
- Birman, S. (2005). "Arousal mechanisms: Speedy flies don't sleep at night." *Curr Biol* 15(13): R511-3.
- Bagorda, F., G. Teuchert-Noodt, et al. (2006). "Isolation rearing or methamphetamine traumatization induce a "dysconnection" of prefrontal efferents in gerbils: Implications for schizophrenia." *J Neural Transm* 113(3): 365-79.

- Baumann, M. H., J. M. Phillips, et al. (2002). "Preclinical evaluation of GBR12909 decanoate as a long-acting medication for methamphetamine dependence." *Ann N Y Acad Sci* 965: 92-108.
- Bedingfield, J. B., L. D. Calder, et al. (1996). "Comparative behavioral sensitization to stereotypy by direct and indirect dopamine agonists in CF-1 mice." *Psychopharmacology (Berl)* 124(3): 219-25.
- Bennett, B. A., C. K. Hollingsworth, R. S. Martin and J. J. Harp (1998). "Methamphetamine-induced alterations in dopamine transporter function." *Brain Res* 782(1-2): 219-27.
- Bhatt, S. D. and D. E. Dluzen (2005). "Dopamine transporter function differences between male and female CD-1 mice." *Brain Res* 1035(2): 188-95.
- Buhusi, C. V. and W. H. Meck (2006). "Effect of clozapine on interval timing and working memory for time in the peak-interval procedure with gaps." *Behav Processes*.
- Bialek, M., P. Zaremba, et al. (2004). "Neuroprotective role of testosterone in the nervous system." *Pol J Pharmacol* 56(5): 509-18.
- Binienda, Z. K., B. D. Przybyla, et al. (2006). "Effects of L-carnitine pretreatment in methamphetamine and 3-nitropropionic acid-induced neurotoxicity." *Ann N Y Acad Sci* 1074: 74-83.
- Bittner, S. E., G. C. Wagner, et al. (1981). "Effects of a high-dose treatment of methamphetamine on caudate dopamine and anorexia in rats." *Pharmacol Biochem Behav* 14(4): 481-6.
- Boireau, A., F. Bordier, et al. (1995). "Methamphetamine and dopamine neurotoxicity: differential effects of agents interfering with glutamatergic transmission." *Neurosci Lett* 195(1): 9-12.
- Booij, J., K. de Bruin, et al. (2006). "Repeated administration of d-amphetamine induces loss of [(123)I]FP-CIT binding to striatal dopamine transporters in rat brain: A validation study." *Nucl Med Biol* 33(3): 409-11.
- Bowyer, J. F., D. L. Davies, et al. (1994). "Further studies of the role of hyperthermia in methamphetamine neurotoxicity." *J Pharmacol Exp Ther* 268(3): 1571-80.
- Bowyer, J. F., B. Gough, et al. (1993). "Fluoro-gold and pentamidine inhibit the in vitro and in vivo release of dopamine in the striatum of rat." *J Pharmacol Exp Ther* 266(2): 1066-74.
- Bowyer, J. F., B. Gough, et al. (1993). "Effects of a cold environment or age on methamphetamine-induced dopamine release in the caudate putamen of female rats." *Pharmacol Biochem Behav* 44(1): 87-98.
- Bowyer, J. F., A. C. Scallet, et al. (1991). "Interactions of MK-801 with glutamate-, glutamine- and methamphetamine-evoked release of [3H]dopamine from striatal slices." *J Pharmacol Exp Ther* 257(1): 262-70.
- Brauer, L. H. and H. de Wit (1996). "Subjective responses to d-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers." *Biol Psychiatry* 39(1): 26-32.
- Broening, H. W., L. L. Morford, et al. (2005). "Interactions of dopamine D1 and D2 receptor antagonists with D-methamphetamine-induced hyperthermia and striatal dopamine and serotonin reductions." *Synapse* 56(2): 84-93.
- Bronstein, D. M. and J. S. Hong (1995). "Effects of sulpiride and SCH 23390 on methamphetamine-induced changes in body temperature and lethality." *J Pharmacol Exp Ther* 274(2): 943-50.
- Broom, S. L. and B. K. Yamamoto (2005). "Effects of subchronic methamphetamine exposure on basal dopamine and stress-induced dopamine release in the nucleus accumbens shell of rats." *Psychopharmacology (Berl)*: 1-10.
- Brown, J. M., S. Gouty, et al. (2006). "Differential protection against MPTP or methamphetamine toxicity in dopamine neurons by deletion of ppN/OFQ expression." *J Neurochem* 98(2): 495-505.
- Brown, J. M., M. S. Quinton, et al. (2005). "Methamphetamine-induced inhibition of mitochondrial complex II: roles of glutamate and peroxynitrite." *J Neurochem* 95(2): 429-36.
- Brummelte, S., T. Grund, et al. (2006). "Long-term effects of a single adult methamphetamine challenge: Minor impact on dopamine fibre density in limbic brain areas of gerbils." *Behav Brain Funct* 2: 12.
- Brunswick, D. J., S. Benmansour, et al. (1992). "Effects of high-dose methamphetamine on monoamine uptake sites in rat brain measured by quantitative autoradiography." *Synapse* 11(4): 287-93.
- Burrows, K. B., W. L. Nixdorf, et al. (2000). "Central administration of methamphetamine synergizes with metabolic inhibition to deplete striatal monoamines." *J Pharmacol Exp Ther* 292(3): 853-60.
- Burrows, K. B. and C. K. Meshul (1999). "High-dose methamphetamine treatment alters presynaptic GABA and glutamate immunoreactivity." *Neuroscience* 90(3): 833-50.
- Burrows, K. B. and C. K. Meshul (1997). "Methamphetamine alters presynaptic glutamate immunoreactivity in the caudate nucleus and motor cortex." *Synapse* 27(2): 133-44.
- Bustamante, D., Z. B. You, et al. (2002). "Effect of single and repeated methamphetamine treatment on neurotransmitter release in substantia nigra and neostriatum of the rat." *J Neurochem* 83(3): 645-54.
- Cadet, J. L. and C. Brannock (1998). "Free radicals and the pathobiology of brain dopamine systems." *Neurochem Int* 32(2): 117-31.
- Cadet, J. L., S. F. Ali, et al. (1995). "Neurotoxicity, drugs and abuse, and the CuZn-superoxide dismutase transgenic mice." *Mol Neurobiol* 11(1-3): 155-63.

- Cadet, J. L., S. Ali, et al. (1994). "Involvement of oxygen-based radicals in methamphetamine-induced neurotoxicity: Evidence from the use of CuZnSOD transgenic mice." *Ann N Y Acad Sci* 738: 388-91.
- Cadet, J. L. (2001). "Molecular neurotoxicological models of Parkinsonism: Focus on genetic manipulation of mice." *Parkinsonism Relat Disord* 8(2): 85-90.
- Cashman, J. R., Y. N. Xiong, et al. (1999). "N-oxygenation of amphetamine and methamphetamine by the human flavin-containing monooxygenase (form 3): Role in bioactivation and detoxication." *J Pharmacol Exp Ther* 288(3): 1251-60.
- Cass, W. A., M. P. Smith, et al. (2006). "Calcitriol protects against the dopamine- and serotonin-depleting effects of neurotoxic doses of methamphetamine." *Ann N Y Acad Sci* 1074: 261-71.
- Cass, W. A., L. E. Peters, et al. (2006). "Protection by GDNF and other trophic factors against the dopamine-depleting effects of neurotoxic doses of methamphetamine." *Ann N Y Acad Sci* 1074: 272-81.
- Cass, W. A., D. J. Walker, et al. (1999). "Augmented methamphetamine-induced overflow of striatal dopamine 1 day after GDNF administration." *Brain Res* 827(1-2): 104-12.
- Cass, W. A. and M. W. Manning (1999). "Recovery of presynaptic dopaminergic functioning in rats treated with neurotoxic doses of methamphetamine." *J Neurosci* 19(17): 7653-60.
- Cass, W. A., M. W. Manning, et al. (1998). "Effects of neurotoxic doses of methamphetamine on potassium and amphetamine evoked overflow of dopamine in the striatum of awake rats." *Neurosci Lett* 248(3): 175-8.
- Cass, W. A. (1997). "Decreases in evoked overflow of dopamine in rat striatum after neurotoxic doses of methamphetamine." *J Pharmacol Exp Ther* 280(1): 105-13.
- Castel, M. N., P. Morino, et al. (1994). "Up-regulation of neurotensin mRNA in the rat striatum after acute methamphetamine treatment." *Eur J Neurosci* 6(4): 646-56.
- Castel, M. N., P. Morino, et al. (1993). "Modulation of the neurotensin striato-nigral pathway by D1 receptors." *Neuroreport* 5(3): 281-4.
- Cervinski, M. A., J. D. Foster, et al. (2005). "Psychoactive substrates stimulate dopamine transporter phosphorylation and down-regulation by cocaine-sensitive and protein kinase C-dependent mechanisms." *J Biol Chem* 280(49): 40442-9.
- Chen, P. C., C. L. Lao, et al. (2006). "Dual alteration of limbic dopamine D(1) receptor-mediated signalling and the Akt/GSK3 pathway in dopamine D(3) receptor mutants during the development of methamphetamine sensitization." *J Neurochem*.
- Chen, P. C. and J. C. Chen (2005). "Enhanced Cdk5 activity and p35 translocation in the ventral striatum of acute and chronic methamphetamine-treated rats." *Neuropsychopharmacology* 30(3): 538-49.
- Chen, R., D. D. Han, et al. (2005). "A triple mutation in the second transmembrane domain of mouse dopamine transporter markedly decreases sensitivity to cocaine and methylphenidate." *J Neurochem* 94(2): 352-9.
- Choi, H. J., T. M. Yoo, et al. (2002). "Methamphetamine-induced apoptosis in a CNS-derived catecholaminergic cell line." *Mol Cells* 13(2): 221-7.
- Clarkson, E. D., W. M. Zawada, et al. (2001). "IGF-I and bFGF improve dopamine neuron survival and behavioral outcome in parkinsonian rats receiving cultured human fetal tissue strands." *Exp Neurol* 168(1): 183-91.
- Clemens, K. J., J. L. Cornish, et al. (2006). "Intravenous methamphetamine self-administration in rats: Effects of intravenous or intraperitoneal MDMA co-administration." *Pharmacol Biochem Behav* 85(2): 454-63.
- Clemens, K. J., J. L. Cornish, et al. (2005). "MDMA ('Ecstasy') and methamphetamine combined: Order of administration influences hyperthermic and long-term adverse effects in female rats." *Neuropharmacology* 49(2): 195-207.
- Comings, D. E. and K. Blum (2000). "Reward deficiency syndrome: Genetic aspects of behavioral disorders." *Prog Brain Res* 126: 325-41.
- Cooney, C. A., C. K. Wise, L. A. Poirier and S. F. Ali (1998). "Methamphetamine treatment affects blood and liver S-adenosylmethionine (SAM) in mice. Correlation with dopamine depletion in the striatum." *Ann N Y Acad Sci* 844: 191-200.
- Cosi, C., P. Chopin and M. Marien (1996). "Benzamide, an inhibitor of poly(ADP-ribose) polymerase, attenuates methamphetamine-induced dopamine neurotoxicity in the c57b1/6n mouse." *Brain Res* 735(2): 343-8.
- Daberkow, D. P., R. P. Kesner, et al. (2005). "Relation between methamphetamine-induced monoamine depletions in the striatum and sequential motor learning." *Pharmacol Biochem Behav* 81(1): 198-204.
- Dankova, J., R. Boucher, et al. (1977). "Effects of 1694 and other dopaminergic agents on circling behavior." *Eur J Pharmacol* 42(2): 113-21.
- D'Astous, M., K. R. Mickley, et al. (2005). "Differential protective properties of estradiol and tamoxifen against methamphetamine-induced nigrostriatal dopaminergic toxicity in mice." *Neuroendocrinology* 82(2): 111-20.
- D'Astous, M., T. M. Gajjar, et al. (2004). "Dopamine transporter as a marker of neuroprotection in methamphetamine-lesioned mice treated acutely with estradiol." *Neuroendocrinology* 79(6): 296-304.
- Davidson, C., T. H. Lee, et al. (2005). "Acute and chronic continuous methamphetamine have different long-term behavioral and neurochemical consequences." *Neurochem Int* 46(3): 189-203.

- Delle Donne, K. T. and P. K. Sonsalla (1994). "Protection against methamphetamine-induced neurotoxicity to neostriatal dopaminergic neurons by adenosine receptor activation." *J Pharmacol Exp Ther* 271(3): 1320-6.
- Deng, X., B. Ladenheim, et al. (2006). "Methamphetamine administration causes death of dopaminergic neurons in the mouse olfactory bulb." *Biol Psychiatry*.
- Dluzen, D. E. and J. L. McDermott (2006). "Estrogen, testosterone, and methamphetamine toxicity." *Ann N Y Acad Sci* 1074: 282-94.
- Dluzen, D. E. and T. J. Salvaterra (2006). "Sex differences in methamphetamine-evoked striatal dopamine output are abolished following gonadectomy: Comparisons with potassium-evoked output and responses in prepubertal mice." *Neuroendocrinology* 82(2): 78-86.
- Dluzen, D. E. and J. L. McDermott (2004). "Developmental and genetic influences upon gender differences in methamphetamine-induced nigrostriatal dopaminergic neurotoxicity." *Ann N Y Acad Sci* 1025: 205-20.
- Dluzen, D. E., J. L. McDermott, et al. (2001). "Tamoxifen diminishes methamphetamine-induced striatal dopamine depletion in intact female and male mice." *J Neuroendocrinol* 13(7): 618-24.
- Dluzen, D. E. (2000). "Neuroprotective effects of estrogen upon the nigrostriatal dopaminergic system." *J Neurocytol* 29(5-6): 387-99.
- Doudet, D. J., T. J. Ruth, et al. (2006). "Sequential versus nonsequential measurement of density and affinity of dopamine D2 receptors with [(11)C]raclopride: 2: effects of DAT inhibitors." *J Cereb Blood Flow Metab* 26(1): 28-37.
- Doudet, D. J. and J. E. Holden (2003). "Raclopride studies of dopamine release: Dependence on presynaptic integrity." *Biol Psychiatry* 54(11): 1193-9.
- Doudet, D. J. and J. E. Holden (2003). "Sequential versus nonsequential measurement of density and affinity of dopamine d2 receptors with [11c]raclopride: Effect of methamphetamine." *J Cereb Blood Flow Metab* 23(12): 1489-94.
- Dryhurst, G. (2001). "Are dopamine, norepinephrine, and serotonin precursors of biologically reactive intermediates involved in the pathogenesis of neurodegenerative brain disorders?" *Adv Exp Med Biol* 500: 373-96.
- Ehrman, L. A., M. T. Williams, et al. (2006). "Phosphodiesterase 1B differentially modulates the effects of methamphetamine on locomotor activity and spatial learning through DARPP32-dependent pathways: evidence from PDE1B-DARPP32 double-knockout mice." *Genes Brain Behav* 5(7): 540-51.
- Eisch, A. J., S. J. O'Dell, et al. (1996). "Striatal and cortical NMDA receptors are altered by a neurotoxic regimen of methamphetamine." *Synapse* 22(3): 217-25.
- Earle, M. L. and J. A. Davies (1991). "The effect of methamphetamine on the release of glutamate from striatal slices." *J Neural Transm Gen Sect* 86(3): 217-22.
- Eibergen, R. D. and K. R. Carlson (1976). "Behavioral evidence for dopaminergic supersensitivity following chronic treatment with methadone or chlorpromazine in the guinea pig." *Psychopharmacology (Berl)* 48(2): 139-46.
- Eisch, A. J., S. J. O'Dell, et al. (1996). "Striatal and cortical NMDA receptors are altered by a neurotoxic regimen of methamphetamine." *Synapse* 22(3): 217-25.
- Ellinwood, E. H., Jr. and M. M. Kilbey (1980). "Fundamental mechanisms underlying altered behavior following chronic administration of psychomotor stimulants." *Biol Psychiatry* 15(5): 749-57.
- Ellison, G. (2002). "Neural degeneration following chronic stimulant abuse reveals a weak link in brain, fasciculus retroflexus, implying the loss of forebrain control circuitry." *Eur Neuropsychopharmacol* 12(4): 287-97.
- Elphick, M. (1989). "Effects of carbamazepine on dopamine function in rodents." *Psychopharmacology (Berl)* 99(4): 532-6.
- Eradiri, O. L. and M. S. Starr (1999). "Striatal dopamine depletion and behavioural sensitization induced by methamphetamine and 3-nitropropionic acid." *Eur J Pharmacol* 386(2-3): 217-26.
- Escubedo, E., C. Chipana, et al. (2005). "Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum: Involvement of {alpha}7 nicotinic receptors." *J Pharmacol Exp Ther* 315(2): 658-67.
- Eshleman, A. J., R. A. Henningsen, et al. (1994). "Release of dopamine via the human transporter." *Mol Pharmacol* 45(2): 312-6.
- Facchinetti, F., R. Dall'Olio, et al. (1994). "Long-lasting effects of chronic neonatal blockade of N-methyl-D-aspartate receptor through the competitive antagonist CGP 39551 in rats." *Neuroscience* 60(2): 343-53.
- Finnegan, K. T. and T. Taraska (1996). "Effects of glutamate antagonists on methamphetamine and 3,4-methylenedioxymethamphetamine-induced striatal dopamine release in vivo." *J Neurochem* 66(5): 1949-58.
- Fischer, E., J. M. Saavedra, et al. (1968). "Effects of catecholamines, adrenergic substances and their blocking agents on the searching behavior of mice." *Arzneimittelforschung* 18(7): 780-6.
- Fleckenstein, A. E., H. M. Haughey, et al. (1999). "Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function." *Eur J Pharmacol* 382(1): 45-9.
- Floran, B., L. Floran, et al. (2004). "Dopamine D4 receptors inhibit depolarization-induced [3H]GABA release in the rat subthalamic nucleus." *Eur J Pharmacol* 498(1-3): 97-102.
- Fog, R. (1972). "On stereotypy and catalepsy: Studies on the effect of amphetamines and neuroleptics in rats." *Acta Neurol Scand Suppl* 50: 3-66.

- Fog, R. (1969). "Stereotyped and non-stereotyped behaviour in rats induced by various stimulant drugs." *Psychopharmacologia* 14(4): 299-304.
- Fornai, F., P. Lenzi, et al. (2006). "Fine ultrastructure and biochemistry of PC12 cells: A comparative approach to understand neurotoxicity." *Brain Res*.
- Fornai, F., P. Lenzi, et al. (2005). "Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice." *Brain Res Bull* 65(5): 405-13.
- Fornai, F., G. Lazzeri, et al. (2003). "Amphetamines induce ubiquitin-positive inclusions within striatal cells." *Neurol Sci* 24(3): 182-3.
- Fornai, F., M. T. Carri, et al. (2002). "Resistance to striatal dopamine depletion induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice expressing human mutant Cu,Zn superoxide dismutase." *Neurosci Lett* 325(2): 124-8.
- Frankel, P. S., A. J. Hoonakker, et al. (2005). "Differential neurotensin responses to low and high doses of methamphetamine in the terminal regions of striatal efferents." *Eur J Pharmacol* 522(1-3): 47-54.
- Frost, D. O. and J. L. Cadet (2000). "Effects of methamphetamine-induced neurotoxicity on the development of neural circuitry: A hypothesis." *Brain Res Brain Res Rev* 34(3): 103-18.
- Fukui, R., P. Svenningsson, et al. (2003). "Effect of methylphenidate on dopamine/DARPP signalling in adult, but not young, mice." *J Neurochem* 87(6): 1391-401.
- Fuller, R. W., S. K. Hemrick-Luecke, et al. (1992). "Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist." *Neuropharmacology* 31(10): 1027-32.
- Gada, V. P., V. V. Joshi, et al. (1984). "Antagonism of apomorphine-induced cage climbing behaviour and methamphetamine stereotypy by fenfluramine in mice." *Indian J Physiol Pharmacol* 28(4): 326-30.
- Gandolfi, O., R. Rimondini, et al. (1992). "The modulation of dopaminergic transmission in the striatum by MK-801 is independent of presynaptic mechanisms." *Neuropharmacology* 31(11): 1111-4.
- Garcia de Yebenes, J., J. Yebenes, et al. (2000). "Neurotrophic factors in neurodegenerative disorders: Model of Parkinson's disease." *Neurotox Res* 2(2-3): 115-37.
- Gassen, M., I. Lamensdorf, et al. (2003). "Attenuation of methamphetamine induced dopaminergic neurotoxicity by flupirtine: Microdialysis study on dopamine release and free radical generation." *J Neural Transm* 110(2): 171-82.
- Gehrke, B. J., S. B. Harrod, et al. (2003). "The effect of neurotoxic doses of methamphetamine on methamphetamine-conditioned place preference in rats." *Psychopharmacology (Berl)* 166(3): 249-57.
- Geisler, S. and D. S. Zahm (2006). "Neurotensin afferents of the ventral tegmental area in the rat: [1] re-examination of their origins and [2] responses to acute psychostimulant and antipsychotic drug administration." *Eur J Neurosci* 24(1): 116-34.
- Gerasimov, M. R., C. R. Ashby, Jr., et al. (1999). "Gamma-vinyl GABA inhibits methamphetamine, heroin, or ethanol-induced increases in nucleus accumbens dopamine." *Synapse* 34(1): 11-9.
- Gibb, J. W., M. Johnson, et al. (1990). "Neurochemical basis of neurotoxicity." *Neurotoxicology* 11(2): 317-21.
- Gifford, A. N., M. H. Park, et al. (2000). "Effect of amphetamine-induced dopamine release on radiotracer binding to D1 and D2 receptors in rat brain striatal slices." *Naunyn Schmiedebergs Arch Pharmacol* 362(4-5): 413-8.
- Glickstein, S. B., P. R. Hof, et al. (2002). "Mice lacking dopamine D2 and D3 receptors have spatial working memory deficits." *J Neurosci* 22(13): 5619-29.
- Golembiowska, K., J. Konieczny, et al. (2002). "The role of striatal metabotropic glutamate receptors in degeneration of dopamine neurons." *Amino Acids* 23(1-3): 199-205.
- Golembiowska, K. and A. Zylewska (1998). "N6-2-(4-aminophenyl)ethyladenosine (APNEA), a putative adenosine A3 receptor agonist, enhances methamphetamine-induced dopamine outflow in rat striatum." *Pol J Pharmacol* 50(4-5): 299-305.
- Gomes-da-Silva, J., A. Perez-Rosado, et al. (2000). "Neonatal methamphetamine in the rat: Evidence for gender-specific differences upon tyrosine hydroxylase enzyme in the dopaminergic nigrostriatal system." *Ann N Y Acad Sci* 914: 431-8.
- Green, A. R., D. J. Heal, et al. (1977). "Further observations on the effect of repeated electroconvulsive shock on the behavioural responses of rats produced by increases in the functional activity of brain 5-hydroxytryptamine and dopamine." *Psychopharmacology (Berl)* 52(2): 195-200.
- Hamamura, T., K. Akiyama, et al. (1991). "Co-administration of either a selective D1 or D2 dopamine antagonist with methamphetamine prevents methamphetamine-induced behavioral sensitization and neurochemical change, studied by in vivo intracerebral dialysis." *Brain Res* 546(1): 40-6.
- Han, D. D. and H. H. Gu (2006). "Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs." *BMC Pharmacol* 6: 6.
- Hanson, G. R., V. Sandoval, et al. (2004). "Psychostimulants and vesicle trafficking: A novel mechanism and therapeutic implications." *Ann N Y Acad Sci* 1025: 146-50.
- Hanson, G. R., K. S. Rau, et al. (2004). "The methamphetamine experience: A NIDA partnership." *Neuropharmacology* 47 Suppl 1: 92-100.

- Hanson, G. R., L. P. Midgley, et al. (1995). "Response of extrapyramidal and limbic neurotensin systems to phencyclidine treatment." *Eur J Pharmacol* 278(2): 167-73.
- Hanson, G. R., N. Singh, et al. (1995). "The role of NMDA receptor systems in neuropeptide responses to stimulants of abuse." *Drug Alcohol Depend* 37(2): 107-10.
- Hanson, G. R., N. Singh, et al. (1992). "Responses of limbic and extrapyramidal neurotensin systems to stimulants of abuse. Involvement of dopaminergic mechanisms." *Ann N Y Acad Sci* 668: 165-72.
- Hara, M., A. Akaike, et al. (1987). "Acute effects of methamphetamine applied microiontophoretically to nucleus accumbens neurons in rats." *Neurosci Res* 4(4): 279-90.
- Harrod, S. B., L. P. Dvoskin, et al. (2003). "Lobeline does not serve as a reinforcer in rats." *Psychopharmacology (Berl)* 165(4): 397-404.
- Harvey, D. C., G. Lacan, et al. (2000). "Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss." *Brain Res* 871(2): 259-70.
- Harvey, D. C., G. Lacan, et al. (2000). "Regional heterogeneity of dopaminergic deficits in vervet monkey striatum and substantia nigra after methamphetamine exposure." *Exp Brain Res* 133(3): 349-58.
- Hashimoto, K., H. Tsukada, et al. (2006). "Protective effects of minocycline on the reduction of dopamine transporters in the striatum after administration of methamphetamine: A positron emission tomography study in conscious monkeys." *Biol Psychiatry*.
- Hashimoto, K., H. Tsukada, et al. (2004). "Effects of N-acetyl-L-cysteine on the reduction of brain dopamine transporters in monkey treated with methamphetamine." *Ann N Y Acad Sci* 1025: 231-5.
- Hashimoto, K., H. Tsukada, et al. (2004). "Protective effects of N-acetyl-L-cysteine on the reduction of dopamine transporters in the striatum of monkeys treated with methamphetamine." *Neuropsychopharmacology* 29(11): 2018-23.
- Hashitani, T., K. Mizukawa, et al. (1998). "Dopamine metabolism in the striatum of hemiparkinsonian model rats with dopaminergic grafts." *Neurosci Res* 30(1): 43-52.
- Hassler, R. and A. Wagner (1975). "Locomotor activity and speed of movements in relation to monoamine-acting drugs." *Int J Neurol* 10(1-4): 80-97.
- Haughey, H. M., J. M. Brown, et al. (2000). "Differential effects of methamphetamine on Na(+)/Cl(-)-dependent transporters." *Brain Res* 863(1-2): 59-65.
- Hayase, T., Y. Yamamoto, et al. (2003). "Brain excitatory amino acid transporters (EAATs) and treatment of methamphetamine toxicity." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 38(6): 498-511.
- He, J., Y. Yang, et al. (2006). "The effects of chronic administration of quetiapine on the methamphetamine-induced recognition memory impairment and dopaminergic terminal deficit in rats." *Behav Brain Res* 172(1): 39-45.
- Hess, U. S., S. P. Whalen, et al. (2003). "Ampakines reduce methamphetamine-driven rotation and activate neocortex in a regionally selective fashion." *Neuroscience* 121(2): 509-21.
- Higashi, H., K. Inanaga, et al. (1989). "Enhancement of dopamine actions on rat nucleus accumbens neurones in vitro after methamphetamine pre-treatment." *J Physiol* 408: 587-603.
- Hirata, H., M. Asanuma, et al. (1998). "Melatonin attenuates methamphetamine-induced toxic effects on dopamine and serotonin terminals in mouse brain." *Synapse* 30(2): 150-5.
- Hirata, H. and J. L. Cadet (1997). "p53-knockout mice are protected against the long-term effects of methamphetamine on dopaminergic terminals and cell bodies." *J Neurochem* 69(2): 780-90.
- Hirata, H., B. Ladenheim, et al. (1996). "Autoradiographic evidence for methamphetamine-induced striatal dopaminergic loss in mouse brain: Attenuation in CuZn-superoxide dismutase transgenic mice." *Brain Res* 714(1-2): 95-103.
- Hirate, K. and H. Kuribara (1991). "Characteristics of the ambulation-increasing effect of GBR-12909, a selective dopamine uptake inhibitor, in mice." *Jpn J Pharmacol* 55(4): 501-11.
- Holman, R. B., G. R. Elliott, et al. (1975). "Neuroregulators and sleep mechanisms." *Annu Rev Med* 26: 499-520.
- Holtzman, S. G. (2001). "Differential interaction of GBR 12909, a dopamine uptake inhibitor, with cocaine and methamphetamine in rats discriminating cocaine." *Psychopharmacology (Berl)* 155(2): 180-6.
- Hom, D. G., D. Jiang, et al. (1997). "Elevated expression of glutathione peroxidase in PC12 cells results in protection against methamphetamine but not MPTP toxicity." *Brain Res Mol Brain Res* 46(1-2): 154-60.
- Honda, F., Y. Satoh, et al. (1977). "Dopamine receptor blocking activity of sulpiride in the central nervous system." *Jpn J Pharmacol* 27(3): 397-411.
- Honda, M. (2004). "[The relation between behavioral sensitization and glutamate release on the animal model of methamphetamine-induced psychosis]." *Hokkaido Igaku Zasshi* 79(1): 65-78.
- Honma, T. and H. Fukushima (1979). "The involvement of serotonergic neurons in the central nervous system as the possible mechanism for slow head-shaking behavior induced by methamphetamine in rats." *Psychopharmacology (Berl)* 65(2): 155-9.



- Horner, K. A., S. C. Westwood, et al. (2006). "Multiple high doses of methamphetamine increase the number of preproneuropeptide Y mRNA-expressing neurons in the striatum of rat via a dopamine D1 receptor-dependent mechanism." *J Pharmacol Exp Ther* 319(1): 414-21.
- Hurlbert, M. S., R. I. Gianani, et al. (1999). "Neural transplantation of hNT neurons for Huntington's disease." *Cell Transplant* 8(1): 143-51.
- Ikarashi, Y., A. Takahashi, et al. (1997). "Regulation of dopamine D1 and D2 receptors on striatal acetylcholine release in rats." *Brain Res Bull* 43(1): 107-15.
- Imam, S. Z., J. el-Yazal, et al. (2001). "Methamphetamine-induced dopaminergic neurotoxicity: Role of peroxynitrite and neuroprotective role of antioxidants and peroxynitrite decomposition catalysts." *Ann N Y Acad Sci* 939: 366-80.
- Inaji, M., T. Yoshizaki, et al. (2005). "In vivo PET measurements with [11C]PE2I to evaluate fetal mesencephalic transplantations to unilateral 6-OHDA-lesioned rats." *Cell Transplant* 14(9): 655-63.
- Iorio, L. C., A. Barnett, et al. (1983). "SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems." *J Pharmacol Exp Ther* 226(2): 462-8.
- Ishida, Y., K. Kawai, et al. (2005). "Alteration of striatal [11C]raclopride and 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine uptake precedes development of methamphetamine-induced rotation following unilateral 6-hydroxydopamine lesions of medial forebrain bundle in rats." *Neurosci Lett* 389(1): 30-4.
- Ishida, Y., K. Kawai, et al. (2004). "Changes in dopamine D2 receptors and 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine uptake in the brain of 6-hydroxydopamine-lesioned rats." *Neurodegener Dis* 1(2-3): 109-12.
- Ishihara, T., K. Akiyama, et al. (1998). "Enhanced AP-1 binding in brain induced by D1 and D2 agonists in methamphetamine-sensitized rats." *Neuroreport* 9(17): 3913-7.
- Ishikawa, A., T. Kadota, et al. (2005). "Essential role of D1 but not D2 receptors in methamphetamine-induced impairment of long-term potentiation in hippocampal-prefrontal cortex pathway." *Eur J Neurosci* 22(7): 1713-9.
- Ishikawa, K., A. Nitta, et al. (2006). "Effects of single and repeated administration of methamphetamine or morphine on neuroglycan C gene expression in the rat brain." *Int J Neuropsychopharmacol* 9(4): 407-15.
- Ito, K., T. Abekawa, et al. (2006). "Relationship between development of cross-sensitization to MK-801 and delayed increases in glutamate levels in the nucleus accumbens induced by a high dose of methamphetamine." *Psychopharmacology (Berl)* 187(3): 293-302.
- Ito, S., T. Mori, et al. (2006). "Differential effects of mu-opioid, delta-opioid and kappa-opioid receptor agonists on dopamine receptor agonist-induced climbing behavior in mice." *Behav Pharmacol* 17(8): 691-701.
- Itzhak, Y. and S. F. Ali (2006). "Role of nitergic system in behavioral and neurotoxic effects of amphetamine analogs." *Pharmacol Ther* 109(1-2): 246-62.
- Itzhak, Y. and C. Achat-Mendes (2004). "Methamphetamine and MDMA (ecstasy) neurotoxicity: 'Of mice and men'." *IUBMB Life* 56(5): 249-55.
- Itzhak, Y. and S. F. Ali (2002). "Behavioral consequences of methamphetamine-induced neurotoxicity in mice: Relevance to the psychopathology of methamphetamine addiction." *Ann N Y Acad Sci* 965: 127-35.
- Itzhak, Y., J. L. Martin, et al. (2002). "Methamphetamine-induced dopaminergic neurotoxicity in mice: Long-lasting sensitization to the locomotor stimulation and desensitization to the rewarding effects of methamphetamine." *Prog Neuropsychopharmacol Biol Psychiatry* 26(6): 1177-83.
- Itzhak, Y., C. Gandia, et al. (1998). "Resistance of neuronal nitric oxide synthase-deficient mice to methamphetamine-induced dopaminergic neurotoxicity." *J Pharmacol Exp Ther* 284(3): 1040-7.
- Izawa, J., K. Yamanashi, et al. (2006). "Differential effects of methamphetamine and cocaine on behavior and extracellular levels of dopamine and 3,4-dihydroxyphenylalanine in the nucleus accumbens of conscious rats." *Eur J Pharmacol* 549(1-3): 84-90.
- Jadhav, J. H., J. J. Balsara, et al. (1981). "Effect of ethosuximide on dopaminergically mediated behaviours." *Indian J Physiol Pharmacol* 25(3): 274-8.
- Janowsky, A., C. Mah, et al. (2001). "Mapping genes that regulate density of dopamine transporters and correlated behaviors in recombinant inbred mice." *J Pharmacol Exp Ther* 298(2): 634-43.
- Johnson, R. A., A. J. Eshleman, et al. (1998). "[3H]substrate- and cell-specific effects of uptake inhibitors on human dopamine and serotonin transporter-mediated efflux." *Synapse* 30(1): 97-106.
- Joshi, V. V., J. J. Balsara, et al. (1981). "Effect of L-histidine and chlorcyclizine on apomorphine-induced climbing behaviour and methamphetamine stereotypy in mice." *Eur J Pharmacol* 69(4): 499-502.
- Kanzaki, A., K. Akiyama, et al. (1992). "Subchronic methamphetamine treatment enhances ouabain-induced striatal dopamine efflux in vivo." *Brain Res* 569(2): 181-8.
- Kanthasamy, A., V. Anantharam, et al. (2006). "Methamphetamine induces autophagy and apoptosis in a mesencephalic dopaminergic neuronal culture model: role of cathepsin-D in methamphetamine-induced apoptotic cell death." *Ann N Y Acad Sci* 1074: 234-44.

- Karler, R., L. D. Calder, et al. (1998). "The role of dopamine and GABA in the frontal cortex of mice in modulating a motor-stimulant effect of amphetamine and cocaine." *Pharmacol Biochem Behav* 60(1): 237-44.
- Karler, R., L. D. Calder, et al. (1998). "The role of dopamine in the mouse frontal cortex: a new hypothesis of behavioral sensitization to amphetamine and cocaine." *Pharmacol Biochem Behav* 61(4): 435-43.
- Karler, R., L. D. Calder, et al. (1995). "The dopaminergic, glutamatergic, GABAergic bases for the action of amphetamine and cocaine." *Brain Res* 671(1): 100-4.
- Karler, R., L. D. Calder, et al. (1994). "A dopaminergic-glutamatergic basis for the action of amphetamine and cocaine." *Brain Res* 658(1-2): 8-14.
- Kato, K., T. Shishido, et al. (2000). "Effects of phencyclidine on behavior and extracellular levels of dopamine and its metabolites in neonatal ventral hippocampal damaged rats." *Psychopharmacology (Berl)* 150(2): 163-9.
- Kawasaki, T., K. Ishihara, et al. (2006). "Protective effect of the radical scavenger edaravone against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum." *Eur J Pharmacol* 542(1-3): 92-9.
- Kim, H. C., E. J. Shin, et al. (2005). "Pharmacological action of Panax ginseng on the behavioral toxicities induced by psychotropic agents." *Arch Pharm Res* 28(9): 995-1001.
- Kim, S., R. Westphalen, et al. (2000). "Toward development of an in vitro model of methamphetamine-induced dopamine nerve terminal toxicity." *J Pharmacol Exp Ther* 293(2): 625-33.
- Kita, T., G. C. Wagner, et al. (2003). "Current research on methamphetamine-induced neurotoxicity: Animal models of monoamine disruption." *J Pharmacol Sci* 92(3): 178-95.
- Kita, T. and T. Nakashima (2002). "[A recent trend in methamphetamine-induced neurotoxicity]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 22(2): 35-47.
- Kita, T., M. A. Philbert, et al. (1998). "Methamphetamine-induced modification of dopamine metabolism in cultured striatal astrocytes." *Pharmacol Toxicol* 83(1): 36-9.
- Kita, T., G. C. Wagner, et al. (1995). "Effects of pargyline and pyrogallol on the methamphetamine-induced dopamine depletion." *Mol Chem Neuropathol* 24(1): 31-41.
- Kleven, M. S. and L. S. Seiden (1991). "Repeated injection of cocaine potentiates methamphetamine-induced toxicity to dopamine-containing neurons in rat striatum." *Brain Res* 557(1-2): 340-3.
- Kliethermes, C. L. and J. C. Crabbe (2006). "Pharmacological and genetic influences on hole-board behaviors in mice." *Pharmacol Biochem Behav* 85(1): 57-65.
- Kobayashi, H., S. Ide, et al. (2004). "Study of association between alpha-synuclein gene polymorphism and methamphetamine psychosis/dependence." *Ann N Y Acad Sci* 1025: 325-34.
- Kobayashi, K. and H. Sano (2000). "Dopamine deficiency in mice." *Brain Dev* 22 Suppl 1: S54-60.
- Kobayashi, M., Y. Wakamatsu, et al. (1977). "[Methamphetamine-stereotypies" and brain dopamine levels of rats treated with single or repeated doses of alpha-methyl-para-tyrosine]." *Nippon Yakurigaku Zasshi* 73(6): 695-701.
- Koike, K., K. Hashimoto, et al. (2005). "The immunophilin ligand FK506 protects against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum." *Neuropharmacology* 48(3): 391-7.
- Kondo, T., T. Ito, et al. (1994). "Bromocriptine scavenges methamphetamine-induced hydroxyl radicals and attenuates dopamine depletion in mouse striatum." *Ann N Y Acad Sci* 738: 222-9.
- Koshikawa, N., E. Mori, et al. (1990). "Role of dopamine D-1 and D-2 receptors in the ventral striatum in the turning behaviour of rats." *Eur J Pharmacol* 178(2): 233-7.
- Kuczenski, R. and D. S. Segal (2002). "Exposure of adolescent rats to oral methylphenidate: Preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine." *J Neurosci* 22(16): 7264-71.
- Kuhn, D. M. (1999). "Tryptophan hydroxylase regulation. Drug-induced modifications that alter serotonin neuronal function." *Adv Exp Med Biol* 467: 19-27.
- Kunnathur, V., K. Shemisa, et al. (2006). "Sex differences in methamphetamine-evoked striatal dopamine of mice are reversed by nomifensine." *Neurotoxicol Teratol* 28(5): 557-62.
- Kusayama, T. and S. Watanabe (2000). "Reinforcing effects of methamphetamine in planarians." *Neuroreport* 11(11): 2511-3.
- Layer, R. T., L. R. Bland, et al. (1993). "MK-801, but not drugs acting at strychnine-insensitive glycine receptors, attenuate methamphetamine nigrostriatal toxicity." *Brain Res* 625(1): 38-44.
- Lesting, J., J. Neddens, et al. (2005). "Hemisphere-specific effects on serotonin but not dopamine innervation in the nucleus accumbens of gerbils caused by isolated rearing and a single early methamphetamine challenge." *Brain Res* 1035(2): 168-76.
- Li, S. M., B. L. Campbell, et al. (2006). "Interactions of cocaine with dopamine uptake inhibitors or dopamine releasers in rats discriminating cocaine." *J Pharmacol Exp Ther* 317(3): 1088-96.
- Liu, B. and D. E. Dluzen (2006). "Effects of estrogen and related agents upon methamphetamine-induced neurotoxicity within an impaired nigrostriatal dopaminergic system of ovariectomized mice." *Neuroendocrinology* 83(5-6): 295-302.

- Liu, B. and D. E. Dluzen (2006). "Effect of estrogen upon methamphetamine-induced neurotoxicity within the impaired nigrostriatal dopaminergic system." *Synapse* 60(5): 354-61.
- Lockhart, B., A. Roger, et al. (2005). "In vivo neuroprotective effects of the novel imidazolyl nitron free-radical scavenger (Z)-alpha-[2-thiazol-2-yl]imidazol-4-yl]-N-tert-butyl nitron (S34176)." *Eur J Pharmacol* 511(2-3): 127-36.
- Lotharius, J., J. Falsig, et al. (2005). "Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway." *J Neurosci* 25(27): 6329-42.
- Mach, R. H., M. A. Nader, et al. (1997). "Use of positron emission tomography to study the dynamics of psychostimulant-induced dopamine release." *Pharmacol Biochem Behav* 57(3): 477-86.
- Maeda, H. and S. Maki (1987). "Dopamine agonists produce functional recovery from septal lesions which affect hypothalamic defensive attack in cats." *Brain Res* 407(2): 381-5.
- Maeda, H. and S. Maki (1986). "Dopaminergic facilitation of recovery from amygdaloid lesions which affect hypothalamic defensive attack in cats." *Brain Res* 363(1): 135-40.
- Maeda, H., T. Sato, et al. (1985). "Effects of dopamine agonists on hypothalamic defensive attack in cats." *Physiol Behav* 35(1): 89-92.
- Maragos, W. F., K. L. Young, et al. (2002). "Human immunodeficiency virus-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function." *J Neurochem* 83(4): 955-63.
- Maragos, W. F., R. Jakel, et al. (2000). "Methamphetamine toxicity is attenuated in mice that overexpress human manganese superoxide dismutase." *Brain Res* 878(1-2): 218-22.
- Mark, K. A., J. J. Soghomonian, et al. (2004). "High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity." *J Neurosci* 24(50): 11449-56.
- Matell, M. S., M. Bateson, et al. (2006). "Single-trials analyses demonstrate that increases in clock speed contribute to the methamphetamine-induced horizontal shifts in peak-interval timing functions." *Psychopharmacology (Berl)* 188(2): 201-12.
- Marshall, J. F., S. J. O'Dell, et al. (1993). "Dopamine-glutamate interactions in methamphetamine-induced neurotoxicity." *J Neural Transm Gen Sect* 91(2-3): 241-54.
- Mauceli, G., C. I. Busceti, et al. (2006). "Overexpression of alpha-synuclein following methamphetamine: Is it good or bad?" *Ann N Y Acad Sci* 1074: 191-7.
- McCabe, R. T., G. R. Hanson, et al. (1987). "Methamphetamine-induced reduction in D1 and D2 dopamine receptors as evidenced by autoradiography: comparison with tyrosine hydroxylase activity." *Neuroscience* 23(1): 253-61.
- McCann, U. D., D. F. Wong, et al. (1998). "Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428." *J Neurosci* 18(20): 8417-22.
- McDaid, J., C. E. Tedford, et al. (2007). "Nullifying drug-induced sensitization: Behavioral and electrophysiological evaluations of dopaminergic and serotonergic ligands in methamphetamine-sensitized rats." *Drug Alcohol Depend* 86(1): 55-66.
- McGinty, J. F. (1995). "Introduction to the role of excitatory amino acids in the actions of abused drugs: a symposium presented at the 1993 annual meeting of the College on Problems of Drug Dependence." *Drug Alcohol Depend* 37(2): 91-4.
- Meck, W. H. (2006). "Frontal cortex lesions eliminate the clock speed effect of dopaminergic drugs on interval timing." *Brain Res* 1108(1): 157-67.
- Melega, W. P., G. Lacan, et al. (2000). "Long-term methamphetamine-induced decreases of [(11C)WIN 35,428 binding in striatum are reduced by GDNF: PET studies in the vervet monkey." *Synapse* 35(4): 243-9.
- Metzger, R. R., H. M. Haughey, et al. (2000). "Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia." *J Pharmacol Exp Ther* 295(3): 1077-85.
- Miller, D. K., M. M. Dopheide, et al. (2005). "Dietary cadmium exposure attenuates D-amphetamine-evoked [3H]dopamine release from striatal slices and methamphetamine-induced hyperactivity." *Pharmacol Biochem Behav* 80(4): 557-66.
- Miyazaki, I., M. Asanuma, et al. (2006). "Methamphetamine-induced dopaminergic neurotoxicity is regulated by quinone-formation-related molecules." *FASEB J* 20(3): 571-3.
- Mizoguchi, H., K. Yamada, et al. (2004). "Regulations of methamphetamine reward by extracellular signal-regulated kinase 1/2/ets-like gene-1 signaling pathway via the activation of dopamine receptors." *Mol Pharmacol* 65(5): 1293-301.
- Mori, A., K. Okuyama, et al. (2002). "Alteration of methamphetamine-induced striatal dopamine release in mint-1 knockout mice." *Neurosci Res* 43(3): 251-7.
- Moszczynska, A., P. Fitzmaurice, et al. (2004). "Why is parkinsonism not a feature of human methamphetamine users?" *Brain* 127(Pt 2): 363-70.
- Muley, M. P., M. A. Joshi, et al. (1984). "Effect of bupropion on dopamine and 5-hydroxytryptamine-mediated behaviour in mice." *J Pharm Pharmacol* 36(3): 208-10.
- Munro, C. A., M. E. McCaul, et al. (2006). "Sex differences in striatal dopamine release in healthy adults." *Biol Psychiatry* 59(10): 966-74.

- Munzar, P., M. H. Baumann, et al. (1999). "Effects of dopamine and serotonin-releasing agents on methamphetamine discrimination and self-administration in rats." *Psychopharmacology (Berl)* 141(3): 287-96.
- Muraki, A. (1993). "[Effects of antagonists of NMDA receptor on methamphetamine-induced decrease in the dopamine uptake sites in the rat striatum and on the behavioral sensitization]." *Hokkaido Igaku Zasshi* 68(3): 407-18.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.
- Nabeshima, T., A. Itoh, et al. (1994). "Effects of subacute administration of methamphetamine and nicotine on locomotor activity in transgenic mice expressing the human tyrosine hydroxylase gene." *J Neural Transm Gen Sect* 97(1): 41-9.
- Nagai, T., Y. Noda, et al. (2005). "The role of tissue plasminogen activator in methamphetamine-related reward and sensitization." *J Neurochem* 92(3): 660-7.
- Nakajima, H., R. Shigehara, et al. (1981). "[Effect of alpha-methyl-para-tyrosine on "methamphetamine-induced stereotype and hypermotility" of reserpinized rats (author's transl)]." *Nippon Yakurigaku Zasshi* 78(6): 557-69.
- Nakamura, K., Y. Shimokawa, et al. (1978). "[Influence of clonazepam, an anticonvulsant benzodiazepine drug, on the rat brain monoamine containing neurons especially on dopaminergic neurons (author's transl)]." *Nippon Yakurigaku Zasshi* 74(2): 251-65.
- Narita, M., H. Akai, et al. (2004). "Implications of protein kinase C in the nucleus accumbens in the development of sensitization to methamphetamine in rats." *Neuroscience* 127(4): 941-8.
- Nash, J. F. and B. K. Yamamoto (1992). "Methamphetamine neurotoxicity and striatal glutamate release: Comparison to 3,4-methylenedioxymethamphetamine." *Brain Res* 581(2): 237-43.
- Nath, A., C. Anderson, et al. (2000). "Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia." *J Psychopharmacol* 14(3): 222-7.
- Nishii, K., N. Matsushita, et al. (1998). "Motor and learning dysfunction during postnatal development in mice defective in dopamine neuronal transmission." *J Neurosci Res* 54(4): 450-64.
- Nishikawa, T., N. Mataga, et al. (1983). "Behavioral sensitization and relative hyperresponsiveness of striatal and limbic dopaminergic neurons after repeated methamphetamine treatment." *Eur J Pharmacol* 88(2-3): 195-203.
- Nishikawa, T. and M. Tanaka (1978). "Altered behavioral responses to intense foot shock in socially-isolated rats." *Pharmacol Biochem Behav* 8(1): 61-7.
- Niwa, M., A. Nitta, et al. (2006). "An inducer for glial cell line-derived neurotrophic factor and tumor necrosis factor-alpha protects against methamphetamine-induced rewarding effects and sensitization." *Biol Psychiatry*.
- Noda, Y., Y. Miyamoto, et al. (1998). "Involvement of dopaminergic system in phencyclidine-induced place preference in mice pretreated with phencyclidine repeatedly." *J Pharmacol Exp Ther* 286(1): 44-51.
- Nomura, Y., S. Ashikari, et al. (1982). "[Effect of dopamine intracerebrally injected by the Valzelli method on methamphetamine-stereotypy and hypermotility]." *Yakubutsu Seishin Kodo* 2(1): 25-37.
- Nonaka, R. and T. Moroji (1990). "Effects of chronic methamphetamine treatment on the binding parameters of [3H]SCH 23390, a selective D1-dopamine receptor ligand, in the rat brain." *Neurosci Lett* 120(1): 109-12.
- Nordahl, T. E., R. Salo, et al. (2002). "Low N-acetyl-aspartate and high choline in the anterior cingulum of recently abstinent methamphetamine-dependent subjects: a preliminary proton MRS study. Magnetic resonance spectroscopy." *Psychiatry Res* 116(1-2): 43-52.
- O'Dell, S. J., F. B. Weihmuller, et al. (1994). "Excitotoxic striatal lesions protect against subsequent methamphetamine-induced dopamine depletions." *J Pharmacol Exp Ther* 269(3): 1319-25.
- Ogden, C. A., M. E. Rich, et al. (2004). "Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: An expanded convergent functional genomics approach." *Mol Psychiatry* 9(11): 1007-29.
- Oiwa, Y., R. Yoshimura, et al. (2002). "Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease." *Brain Res* 947(2): 271-83.
- Okuyama, S., N. Kawashima, et al. (1999). "A selective dopamine D4 receptor antagonist, NRA0160: A preclinical neuropharmacological profile." *Life Sci* 65(20): 2109-25.
- Okuyama, S., S. Chaki, et al. (1997). "In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl]pyrrolidin-3-yl]thiazole (NRA0045)." *J Pharmacol Exp Ther* 282(1): 56-63.
- O'Neil M, L., R. Kuczenski, et al. (2006). "Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge." *Synapse* 60(6): 465-73.
- Ozawa, H. and T. Miyauchi (1977). "Potentiating effect of lithium chloride on methamphetamine-induced stereotypy in mice." *Eur J Pharmacol* 41(2): 213-6.
- Ozawa, K., K. Hashimoto, et al. (2006). "Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia." *Biol Psychiatry* 59(6): 546-54.

- Pacchioni, A. M., J. Vallone, et al. (2007). "Nrf2 gene deletion fails to alter psychostimulant-induced behavior or neurotoxicity." *Brain Res* 1127(1): 26-35.
- Palmer, A. A., M. Verbitsky, et al. (2005). "Gene expression differences in mice divergently selected for methamphetamine sensitivity." *Mamm Genome* 16(5): 291-305.
- Park, M. J., S. K. Lee, et al. (2006). "Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity." *Brain Res* 1109(1): 176-82.
- Pereira, F. C., E. S. Lourenco, et al. (2006). "Single or multiple injections of methamphetamine increased dopamine turnover but did not decrease tyrosine hydroxylase levels or cleave caspase-3 in caudate-putamen." *Synapse* 60(3): 185-93.
- Perez, F. A., W. R. Curtis, et al. (2005). "Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity." *BMC Neurosci* 6: 71.
- Perez, V. and M. Unzeta (2003). "PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 mice." *Neurochem Int* 42(3): 221-9.
- Piccini, P., D. J. Brooks, et al. (1999). "Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient." *Nat Neurosci* 2(12): 1137-40.
- Pieri, M., L. Pieri, et al. (1975). "A comparison of drug-induced rotation in rats lesioned in the medial forebrain bundle with 5,6-dihydroxytryptamine or 6-hydroxydopamine." *Arch Int Pharmacodyn Ther* 217(1): 118-30.
- Piasecki, M. P., G. M. Steinagel, O. J. Thienhaus and B. S. Kohlenberg (2002). "An exploratory study: The use of paroxetine for methamphetamine craving." *J Psychoactive Drugs* 34(3): 301-4.
- Preston, K. L., G. C. Wagner, et al. (1984). "Effects of methamphetamine on atropine-induced conditioned gustatory avoidance." *Pharmacol Biochem Behav* 20(4): 601-7.
- Pu, C., J. E. Fisher, et al. (1994). "The effects of amfonelic acid, a dopamine uptake inhibitor, on methamphetamine-induced dopaminergic terminal degeneration and astrocytic response in rat striatum." *Brain Res* 649(1-2): 217-24.
- Pu, C. and C. V. Vorhees (1993). "Developmental dissociation of methamphetamine-induced depletion of dopaminergic terminals and astrocyte reaction in rat striatum." *Brain Res Dev Brain Res* 72(2): 325-8.
- Pubill, D., C. Chipana, et al. (2005). "Free radical production induced by methamphetamine in rat striatal synaptosomes." *Toxicol Appl Pharmacol* 204(1): 57-68.
- Rajan, P. D., R. Kekuda, et al. (2000). "Expression of the extraneuronal monoamine transporter in RPE and neural retina." *Curr Eye Res* 20(3): 195-204.
- Randrup, A., G. Sorensen, et al. (1988). "Stereotyped behaviour in animals induced by stimulant drugs or by a restricted cage environment: Relation to disintegrated behaviour, brain dopamine and psychiatric disease." *Yakubutsu Seishin Kodo* 8(2): 313-27.
- Rau, K. S., E. Birdsall, et al. (2006). "Methamphetamine administration reduces hippocampal vesicular monoamine transporter-2 uptake." *J Pharmacol Exp Ther* 318(2): 676-82.
- Rau, K. S., E. Birdsall, et al. (2005). "Bupropion increases striatal vesicular monoamine transport." *Neuropharmacology* 49(6): 820-30.
- Rauhut, A. S., N. Neugebauer, et al. (2003). "Effect of bupropion on nicotine self-administration in rats." *Psychopharmacology (Berl)* 169(1): 1-9.
- Richards, J. B., K. E. Sabol, et al. (1990). "Unilateral dopamine depletion causes bilateral deficits in conditioned rotation in rats." *Pharmacol Biochem Behav* 36(2): 217-23.
- Riddle, E. L., A. E. Fleckenstein, et al. (2006). "Mechanisms of methamphetamine-induced dopaminergic neurotoxicity." *AAPS J* 8(2): E413-8.
- Rubinstein, M., T. J. Phillips, et al. (1997). "Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine." *Cell* 90(6): 991-1001.
- Rothman, R. B., B. E. Blough, et al. (2006). "Dual dopamine-5-HT releasers: Potential treatment agents for cocaine addiction." *Trends Pharmacol Sci* 27(12): 612-8.
- Rothman, R. B., N. Vu, et al. (2003). "In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates." *J Pharmacol Exp Ther* 307(1): 138-45.
- Rothman, R. B., M. H. Baumann, et al. (2001). "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin." *Synapse* 39(1): 32-41.
- Rothman, R. B., J. S. Partilla, et al. (2000). "Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: A pharmacological strategy for treating stimulant abuse." *Synapse* 35(3): 222-7.
- Rubinstein, M., T. J. Phillips, et al. (1997). "Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine." *Cell* 90(6): 991-1001.
- Sabol, K. E., J. T. Roach, et al. (2001). "Long-term effects of a high-dose methamphetamine regimen on subsequent methamphetamine-induced dopamine release in vivo." *Brain Res* 892(1): 122-9.

- Sabol, K. E., J. B. Richards, et al. (2000). "The effects of high-dose methamphetamine in the aging rat: Differential reinforcement of low-rate 72-s schedule behavior and neurochemistry." *J Pharmacol Exp Ther* 294(3): 850-63.
- Salo, R., T. E. Nordahl, et al. (2002). "Preliminary evidence of reduced cognitive inhibition in methamphetamine-dependent individuals." *Psychiatry Res* 111(1): 65-74.
- Sanchez, V., M. Zeini, et al. (2003). "The nNOS inhibitor, AR-R17477AR, prevents the loss of NF68 immunoreactivity induced by methamphetamine in the mouse striatum." *J Neurochem* 85(2): 515-24.
- Sandoval, V., E. L. Riddle, et al. (2003). "Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits." *J Pharmacol Exp Ther* 304(3): 1181-7.
- Sandoval, V., E. L. Riddle, et al. (2001). "Methamphetamine-induced rapid and reversible changes in dopamine transporter function: An in vitro model." *J Neurosci* 21(4): 1413-9.
- Sano, H., Y. Yasoshima, et al. (2003). "Conditional ablation of striatal neuronal types containing dopamine D2 receptor disturbs coordination of basal ganglia function." *J Neurosci* 23(27): 9078-88.
- Sato, S., T. Chiba, et al. (2006). "Decline of striatal dopamine release in parkin-deficient mice shown by ex vivo autoradiography." *J Neurosci Res* 84(6): 1350-7.
- Sato, M., Y. Numachi, et al. (1992). "Relapse of paranoid psychotic state in methamphetamine model of schizophrenia." *Schizophr Bull* 18(1): 115-22.
- Sato, M. (1983). "Long-lasting hypersensitivity to methamphetamine following amygdaloid kindling in cats: the relationship between limbic epilepsy and the psychotic state." *Biol Psychiatry* 18(5): 525-36.
- Scheel-Kruger, J. (1971). "Comparative studies of various amphetamine analogues demonstrating different interactions with the metabolism of the catecholamines in the brain." *Eur J Pharmacol* 14(1): 47-59.
- Schluter, O. M., F. Fornai, et al. (2003). "Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice." *Neuroscience* 118(4): 985-1002.
- Segal, D. S. and R. Kuczenski (2006). "Human methamphetamine pharmacokinetics simulated in the rat: Single daily intravenous administration reveals elements of sensitization and tolerance." *Neuropsychopharmacology* 31(5): 941-55.
- Segal, D. S., R. Kuczenski, et al. (2005). "Prolonged exposure of rats to intravenous methamphetamine: Behavioral and neurochemical characterization." *Psychopharmacology (Berl)* 180(3): 501-12.
- Seiden, L. S., D. L. Commins, et al. (1988). "Neurotoxicity in dopamine and 5-hydroxytryptamine terminal fields: A regional analysis in nigrostriatal and mesolimbic projections." *Ann N Y Acad Sci* 537: 161-72.
- Shepard, J. D., D. T. Chuang, et al. (2006). "Effect of methamphetamine self-administration on tyrosine hydroxylase and dopamine transporter levels in mesolimbic and nigrostriatal dopamine pathways of the rat." *Psychopharmacology (Berl)* 185(4): 505-13.
- Shi, W. X., C. L. Pun, et al. (2004). "Psychostimulants induce low-frequency oscillations in the firing activity of dopamine neurons." *Neuropsychopharmacology* 29(12): 2160-7.
- Shimazoe, T., Y. Doi, et al. (2002). "Both metabotropic glutamate I and II receptors mediate augmentation of dopamine release from the striatum in methamphetamine-sensitized rats." *Jpn J Pharmacol* 89(1): 85-8.
- Shirayama, Y., H. Mitsushio, et al. (2000). "Differential effects of haloperidol on phencyclidine-induced reduction in substance P contents in rat brain regions." *Synapse* 35(4): 292-9.
- Shoblock, J. R., E. B. Sullivan, et al. (2003). "Neurochemical and behavioral differences between d-methamphetamine and d-amphetamine in rats." *Psychopharmacology (Berl)* 165(4): 359-69.
- Singh, N. A., L. P. Midgley, et al. (1991). "N-Methyl-D-aspartate receptors mediate dopamine-induced changes in extrapyramidal and limbic dynorphin systems." *Brain Res* 555(2): 233-8.
- Singh, N. A., L. G. Bush, et al. (1990). "Dopamine-mediated changes in central nervous system neurotensin systems: A role for NMDA receptors." *Eur J Pharmacol* 187(3): 337-44.
- Sirinathsinghji, D. J., S. B. Dunnett, et al. (1990). "Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway--III. Reversal by embryonic nigral dopamine grafts." *Neuroscience* 37(3): 757-66.
- Snyder, G. L., P. B. Allen, et al. (2000). "Regulation of phosphorylation of the GluR1 AMPA receptor in the neostriatum by dopamine and psychostimulants in vivo." *J Neurosci* 20(12): 4480-8.
- Sonsalla, P. K. (1995). "The role of N-methyl-D-aspartate receptors in dopaminergic neuropathology produced by the amphetamines." *Drug Alcohol Depend* 37(2): 101-5.
- Sonsalla, P. K., A. Giovanni, et al. (1992). "Characteristics of dopaminergic neurotoxicity produced by MPTP and methamphetamine." *Ann N Y Acad Sci* 648: 229-38.
- Stadlin, A., J. W. Lau, et al. (1998). "A selective regional response of cultured astrocytes to methamphetamine." *Ann N Y Acad Sci* 844: 108-21.

- Staszewski, R. D. and B. K. Yamamoto (2006). "Methamphetamine-induced spectrin proteolysis in the rat striatum." *J Neurochem* 96(5): 1267-76.
- Stefanski, R., Z. Justinova, et al. (2004). "Sigma 1 receptor upregulation after chronic methamphetamine self-administration in rats: A study with yoked controls." *Psychopharmacology (Berl)* 175(1): 68-75.
- Stefanski, R., S. H. Lee, et al. (2002). "Lack of persistent changes in the dopaminergic system of rats withdrawn from methamphetamine self-administration." *Eur J Pharmacol* 439(1-3): 59-68.
- Stefanski, R., B. Ladenheim, et al. (1999). "Neuroadaptations in the dopaminergic system after active self-administration but not after passive administration of methamphetamine." *Eur J Pharmacol* 371(2-3): 123-35.
- Stephans, S. E., T. S. Whittingham, et al. (1998). "Substrates of energy metabolism attenuate methamphetamine-induced neurotoxicity in striatum." *J Neurochem* 71(2): 613-21.
- Stephans, S. and B. Yamamoto (1996). "Methamphetamines pretreatment and the vulnerability of the striatum to methamphetamine neurotoxicity." *Neuroscience* 72(3): 593-600.
- Stephans, S. E. and B. Y. Yamamoto (1995). "Effect of repeated methamphetamine administrations on dopamine and glutamate efflux in rat prefrontal cortex." *Brain Res* 700(1-2): 99-106.
- Stephans, S. E. and B. K. Yamamoto (1994). "Methamphetamine-induced neurotoxicity: Roles for glutamate and dopamine efflux." *Synapse* 17(3): 203-9.
- Straiko, M. M., L. M. Coolen, et al. (2007). "The effect of amphetamine analogs on cleaved microtubule-associated protein-tau formation in the rat brain." *Neuroscience* 144(1): 223-31.
- Suamaru, J., K. Akiyama, et al. (2000). "Methamphetamine decreases calcium-calmodulin dependent protein kinase II activity in discrete rat brain regions." *Synapse* 36(3): 155-66.
- Sulzer, D., M. S. Sonders, et al. (2005). "Mechanisms of neurotransmitter release by amphetamines: A review." *Prog Neurobiol* 75(6): 406-433.
- Suzuki, T., K. Mizuo, et al. (2003). "Prenatal and neonatal exposure to bisphenol-A enhances the central dopamine D1 receptor-mediated action in mice: Enhancement of the methamphetamine-induced abuse state." *Neuroscience* 117(3): 639-44.
- Takamatsu, Y., H. Yamamoto, et al. (2006). "Fluoxetine as a potential pharmacotherapy for methamphetamine dependence: Studies in mice." *Ann N Y Acad Sci* 1074: 295-302.
- Takano, Y., Y. Sakurai, et al. (1983). "Presynaptic modulation of the release of dopamine from striatal synaptosomes: Differences in the effects of high K<sup>+</sup> stimulation, methamphetamine and nicotinic drugs." *Brain Res* 279(1-2): 330-4.
- Theodore, S., S. Stolberg, et al. (2006). "Human immunodeficiency virus-1 protein tat and methamphetamine interactions." *Ann N Y Acad Sci* 1074: 178-90.
- Theodore, S., W. A. Cass, et al. (2006). "Inhibition of tumor necrosis factor-alpha signaling prevents human immunodeficiency virus-1 protein Tat and methamphetamine interaction." *Neurobiol Dis* 23(3): 663-8.
- Theodore, S., W. A. Cass, et al. (2006). "Involvement of cytokines in human immunodeficiency virus-1 protein Tat and methamphetamine interactions in the striatum." *Exp Neurol* 199(2): 490-8.
- Theodore, S., W. A. Cass, et al. (2006). "Methamphetamine and human immunodeficiency virus protein Tat synergize to destroy dopaminergic terminals in the rat striatum." *Neuroscience* 137(3): 925-35.
- Tien, L. T., I. K. Ho, et al. (2006). "Role of mu-opioid receptor in modulation of preproenkephalin mRNA expression and opioid and dopamine receptor binding in methamphetamine-sensitized mice." *J Neurosci Res*.
- Triarhou, L. C., E. H. Stotz, et al. (1994). "Studies on the striatal dopamine uptake system of weaver mutant mice and effects of ventral mesencephalic grafts." *Neurochem Res* 19(11): 1349-58.
- Truong, J. G., D. G. Wilkins, et al. (2005). "Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: Implications for neurotoxicity." *J Pharmacol Exp Ther* 314(3): 1087-92.
- Tsai, S. J. (2007). "Increased central brain-derived neurotrophic factor activity could be a risk factor for substance abuse: Implications for treatment." *Med Hypotheses* 68(2): 410-4.
- Tsao, L. I., B. Ladenheim, et al. (1998). "Delta opioid peptide [D-Ala<sup>2</sup>,D-leu<sup>5</sup>]enkephalin blocks the long-term loss of dopamine transporters induced by multiple administrations of methamphetamine: Involvement of opioid receptors and reactive oxygen species." *J Pharmacol Exp Ther* 287(1): 322-31.
- Tsuchida, K., H. Ujike, et al. (1994). "Ontogeny of enhanced striatal dopamine release in rats with methamphetamine-induced behavioral sensitization." *Pharmacol Biochem Behav* 47(1): 161-9.
- Tsukada, H., N. Harada, et al. (2001). "Facilitation of dopaminergic neural transmission does not affect [(11)C]SCH23390 binding to the striatal D(1) dopamine receptors, but the facilitation enhances phosphodiesterase type-IV activity through D(1) receptors: PET studies in the conscious monkey brain." *Synapse* 42(4): 258-65.
- Tsukada, H., S. Nishiyama, et al. (1999). "Is synaptic dopamine concentration the exclusive factor which alters the in vivo binding of [11C]raclopride? PET studies combined with microdialysis in conscious monkeys." *Brain Res* 841(1-2): 160-9.

- Ugarte, Y. V., K. S. Rau, et al. (2003). "Methamphetamine rapidly decreases mouse vesicular dopamine uptake: Role of hyperthermia and dopamine D2 receptors." *Eur J Pharmacol* 472(3): 165-71.
- Veenstra-VanderWeele, J., A. Qaadir, et al. (2006). "Association between the casein kinase 1 epsilon gene region and subjective response to D-amphetamine." *Neuropsychopharmacology* 31(5): 1056-63.
- Villemagne, V., J. Yuan, et al. (1998). "Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [<sup>11</sup>C]WIN-35,428 positron emission tomography studies and direct in vitro determinations." *J Neurosci* 18(1): 419-27.
- Volkow, N. D., J. S. Fowler and G. J. Wang (2002). "Role of dopamine in drug reinforcement and addiction in humans: Results from imaging studies." *Behav Pharmacol* 13(5-6): 355-66.
- Vollm, B. A., I. E. de Araujo, P. J. Cowen, E. T. Rolls, M. L. Kringselbach, K. A. Smith, P. Jezzard, R. J. Heal and P. M. Matthews (2004). "Methamphetamine activates reward circuitry in drug naive human subjects." *Neuropsychopharmacology* 29(9): 1715-22.
- Volz, T. J., G. R. Hanson, et al. (2006). "Kinetic analysis of developmental changes in vesicular monoamine transporter-2 function." *Synapse* 60(6): 474-7.
- Volz, T. J., G. R. Hanson, et al. (2006). "Measurement of kinetically resolved vesicular dopamine uptake and efflux using rotating disk electrode voltammetry." *J Neurosci Methods* 155(1): 109-15.
- Volz, T. J. and J. O. Schenk (2005). "A comprehensive atlas of the topography of functional groups of the dopamine transporter." *Synapse* 58(2): 72-94.
- Wachtel, S. R., A. Ortengren, et al. (2002). "The effects of acute haloperidol or risperidone on subjective responses to methamphetamine in healthy volunteers." *Drug Alcohol Depend* 68(1): 23-33.
- Wall, S. C., H. Gu, et al. (1995). "Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamine specificity for inhibition and efflux." *Mol Pharmacol* 47(3): 544-50.
- Wallace, T. L., C. V. Vorhees, et al. (2001). "Effects of lubeluzole on the methamphetamine-induced increase in extracellular glutamate and the long-term depletion of striatal dopamine." *Synapse* 40(2): 95-101.
- Wang, G. J., N. D. Volkow, et al. (2004). "Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence." *Am J Psychiatry* 161(2): 242-8.
- Wang, J. Q. and J. F. McGinty (1995). "Differential effects of D1 and D2 dopamine receptor antagonists on acute amphetamine- or methamphetamine-induced up-regulation of zif/268 mRNA expression in rat forebrain." *J Neurochem* 65(6): 2706-15.
- Wilhelm, C. J., R. A. Johnson, et al. (2006). "Hydrogen ion concentration differentiates effects of methamphetamine and dopamine on transporter-mediated efflux." *J Neurochem* 96(4): 1149-59.
- Wilson, J. M., K. S. Kalasinsky, et al. (1996). "Striatal dopamine nerve terminal markers in human, chronic methamphetamine users." *Nat Med* 2(6): 699-703.
- Wisor, J. P., S. Nishino, et al. (2001). "Dopaminergic role in stimulant-induced wakefulness." *J Neurosci* 21(5): 1787-94.
- Wrona, M. Z., Z. Yang, et al. (1997). "Potential new insights into the molecular mechanisms of methamphetamine-induced neurodegeneration." *NIDA Res Monogr* 173: 146-74.
- Wu, P. H., Y. C. Shen, et al. (2006). "Baicalein attenuates methamphetamine-induced loss of dopamine transporter in mouse striatum." *Toxicology* 226(2-3): 238-45.
- Xie, T., U. D. McCann, et al. (2000). "Effect of temperature on dopamine transporter function and intracellular accumulation of methamphetamine: implications for methamphetamine-induced dopaminergic neurotoxicity." *J Neurosci* 20(20): 7838-45.
- Xu, W., J. P. Zhu, et al. (2005). "Induction of striatal pre- and postsynaptic damage by methamphetamine requires the dopamine receptors." *Synapse* 58(2): 110-21.
- Yamada, K., T. Nagai, et al. (2005). "[Pro- and anti-addictive factors related to drug addiction]." *Nippon Yakurigaku Zasshi* 126(1): 49-53.
- Yamada, K., N. Matsuo, et al. (1989). "Dopamine receptor blocking action of a dibenzothiepin derivative isofloxythepin in rats." *Clin Exp Pharmacol Physiol* 16(2): 109-16.
- Yamagata, K., K. Suzuki, et al. (2000). "Activation of an effector immediate-early gene arc by methamphetamine." *Ann N Y Acad Sci* 914: 22-32.
- Yamamoto, B. K. and M. G. Bankson (2005). "Amphetamine neurotoxicity: cause and consequence of oxidative stress." *Crit Rev Neurobiol* 17(2): 87-118.
- Yamamoto, B. K. and W. Zhu (1998). "The effects of methamphetamine on the production of free radicals and oxidative stress." *J Pharmacol Exp Ther* 287(1): 107-14.
- Yamamoto, H., N. Kitamura, et al. (1999). "Differential changes in glutamatergic transmission via N-methyl-D-aspartate receptors in the hippocampus and striatum of rats behaviourally sensitized to methamphetamine." *Int J Neuropsychopharmacol* 2(3): 155-163.



- Yamamoto, M., Y. Ozawa, et al. (1990). "Central dopaminergic actions of YM-14673, a new TRH analogue, in rodents." *Eur J Pharmacol* 180(2-3): 319-24.
- Yanagisawa, D., M. Qi, et al. (2006). "Improvement of focal ischemia-induced rat dopaminergic dysfunction by striatal transplantation of mouse embryonic stem cells." *Neurosci Lett* 407(1): 74-9.
- Yang, S. N. (2000). "Sustained enhancement of AMPA receptor- and NMDA receptor-mediated currents induced by dopamine D1/D5 receptor activation in the hippocampus: An essential role of postsynaptic Ca<sup>2+</sup>." *Hippocampus* 10(1): 57-63.
- Yu, J., S. Allison, et al. (2002). "Ontogeny of neurokinin-1 receptor mediation of methamphetamine neurotoxicity in the striatum of the mouse brain." *Ann N Y Acad Sci* 965: 247-53.
- Yu, L., C. F. Chergo, et al. (2002). "Melatonin in concentrated ethanol and ethanol alone attenuate methamphetamine-induced dopamine depletions in C57BL/6J mice." *J Neural Transm* 109(12): 1477-90.
- Yu, L., Y. M. Kuo, et al. (2001). "Opioid peptides alleviated while naloxone potentiated methamphetamine-induced striatal dopamine depletion in mice." *J Neural Transm* 108(11): 1231-7.
- Yu, L. and P. C. Liao (2000). "Estrogen and progesterone distinctively modulate methamphetamine-induced dopamine and serotonin depletions in C57BL/6J mice." *J Neural Transm* 107(10): 1139-47.
- Yu, L. and P. C. Liao (2000). "Sexual differences and estrous cycle in methamphetamine-induced dopamine and serotonin depletions in the striatum of mice." *J Neural Transm* 107(4): 419-27.
- Yui, K., K. Goto, et al. (2001). "Susceptibility to subsequent episodes of spontaneous recurrence of methamphetamine psychosis." *Drug Alcohol Depend* 64(2): 133-42.
- Yui, K., K. Goto, S. Ikemoto and T. Ishiguro (1997). "Monoamine neurotransmitter metabolites and spontaneous recurrence of methamphetamine psychosis." *Brain Res Bull* 43(1): 25-33.
- Yu, Y. L. and G. C. Wagner (1994). "Influence of gonadal hormones on sexual differences in sensitivity to methamphetamine-induced neurotoxicity." *J Neural Transm Park Dis Dement Sect* 8(3): 215-21.
- Zaczek, R., S. Culp, et al. (1991). "Interactions of [3H]amphetamine with rat brain synaptosomes. II. Active transport." *J Pharmacol Exp Ther* 257(2): 830-5.
- Zhang, L., K. Kitaichi, et al. (2006). "Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine." *Prog Neuropsychopharmacol Biol Psychiatry* 30(8): 1381-93.
- Zhang, Y., T. M. Loonam, et al. (2001). "Comparison of cocaine- and methamphetamine-evoked dopamine and glutamate overflow in somatodendritic and terminal field regions of the rat brain during acute, chronic, and early withdrawal conditions." *Ann N Y Acad Sci* 937: 93-120.
- Zhao, R. J., R. S. Woo, et al. (2003). "Orphanin FQ/nociceptin blocks methamphetamine place preference in rats." *Neuroreport* 14(18): 2383-5.
- Zhou, J. L., J. H. Liang, et al. (2004). "Inhibition of methamphetamine-induced apoptosis by the calcium channel blocker verapamil in rat cerebellar neurons." *Beijing Da Xue Xue Bao* 36(4): 361-5.
- Zhu, J. P., W. Xu, et al. (2006). "Distinct mechanisms mediating methamphetamine-induced neuronal apoptosis and dopamine terminal damage share the neuropeptide substance P in the striatum of mice." *Ann N Y Acad Sci* 1074: 135-48.
- Zhu, J. P., W. Xu, et al. (2006). "Methamphetamine-induced striatal apoptosis in the mouse brain: Comparison of a binge to an acute bolus drug administration." *Neurotoxicology* 27(1): 131-6.
- Zhu, J. P., W. Xu, et al. (2005). "Disparity in the temporal appearance of methamphetamine-induced apoptosis and depletion of dopamine terminal markers in the striatum of mice." *Brain Res* 1049(2): 171-81.

## Dopamine Depletion

- Fitzmaurice, P. S., J. Tong, et al. (2006). "Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of methamphetamine." *J Pharmacol Exp Ther* 319(2): 703-9.
- Gillin, J. C., L. Pulvirenti, et al. (1994). "The effects of lisuride on mood and sleep during acute withdrawal in stimulant abusers: A preliminary report." *Biol Psychiatry* 35(11): 843-9.
- Guilarte, T. R. (2001). "Is methamphetamine abuse a risk factor in parkinsonism?" *Neurotoxicology* 22(6): 725-31.
- Kitamura, O., I. Tokunaga, et al. (2006). "Immunohistochemical investigation of dopaminergic terminal markers and caspase-3 activation in the striatum of human methamphetamine users." *Int J Legal Med*.
- McCann, U. D. and G. A. Ricaurte (2004). "Amphetamine neurotoxicity: Accomplishments and remaining challenges." *Neurosci Biobehav Rev* 27(8): 821-6.
- Mirecki, A., P. Fitzmaurice, et al. (2004). "Brain antioxidant systems in human methamphetamine users." *J Neurochem* 89(6): 1396-408.
- Moszczynska, A., P. Fitzmaurice, et al. (2004). "Why is parkinsonism not a feature of human methamphetamine users?" *Brain* 127(Pt 2): 363-70.

Wilson, J. M., K. S. Kalasinsky, et al. (1996). "Striatal dopamine nerve terminal markers in human, chronic methamphetamine users." *Nat Med* 2(6): 699-703.

### Dopamine Depletion (animals)

- Anderson, K. L. and Y. Itzhak (2006). "Methamphetamine-induced selective dopaminergic neurotoxicity is accompanied by an increase in striatal nitrate in the mouse." *Ann N Y Acad Sci* 1074: 225-33.
- Armstrong, B. D. and K. K. Noguchi (2004). "The neurotoxic effects of 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine on serotonin, dopamine, and GABA-ergic terminals: an in-vitro autoradiographic study in rats." *Neurotoxicology* 25(6): 905-14.
- Barr, A. M., W. J. Panenka, et al. (2006). "The need for speed: An update on methamphetamine addiction." *J Psychiatry Neurosci* 31(5): 301-313.
- Boireau, A., F. Bordier, et al. (1995). "Methamphetamine and dopamine neurotoxicity: differential effects of agents interfering with glutamatergic transmission." *Neurosci Lett* 195(1): 9-12.
- Bowyer, J. F., D. L. Davies, et al. (1994). "Further studies of the role of hyperthermia in methamphetamine neurotoxicity." *J Pharmacol Exp Ther* 268(3): 1571-80.
- Broening, H. W., L. L. Morford, et al. (2005). "Interactions of dopamine D1 and D2 receptor antagonists with D-methamphetamine-induced hyperthermia and striatal dopamine and serotonin reductions." *Synapse* 56(2): 84-93.
- Brown, J. M., M. S. Quinton, et al. (2005). "Methamphetamine-induced inhibition of mitochondrial complex II: roles of glutamate and peroxynitrite." *J Neurochem* 95(2): 429-36.
- Brummelte, S., T. Grund, et al. (2006). "Long-term effects of a single adult methamphetamine challenge: Minor impact on dopamine fibre density in limbic brain areas of gerbils." *Behav Brain Funct* 2: 12.
- Burrows, K. B., W. L. Nixdorf, et al. (2000). "Central administration of methamphetamine synergizes with metabolic inhibition to deplete striatal monoamines." *J Pharmacol Exp Ther* 292(3): 853-60.
- Burrows, K. B. and C. K. Meshul (1999). "High-dose methamphetamine treatment alters presynaptic GABA and glutamate immunoreactivity." *Neuroscience* 90(3): 833-50.
- Burrows, K. B. and C. K. Meshul (1997). "Methamphetamine alters presynaptic glutamate immunoreactivity in the caudate nucleus and motor cortex." *Synapse* 27(2): 133-44.
- Bustamante, D., Z. B. You, et al. (2002). "Effect of single and repeated methamphetamine treatment on neurotransmitter release in substantia nigra and neostriatum of the rat." *J Neurochem* 83(3): 645-54.
- Cadet, J. L., S. F. Ali, et al. (1995). "Neurotoxicity, drugs and abuse, and the CuZn-superoxide dismutase transgenic mice." *Mol Neurobiol* 11(1-3): 155-63.
- Cass, W. A., M. P. Smith, et al. (2006). "Calcitriol protects against the dopamine- and serotonin-depleting effects of neurotoxic doses of methamphetamine." *Ann N Y Acad Sci* 1074: 261-71.
- Cass, W. A., L. E. Peters, et al. (2006). "Protection by GDNF and other trophic factors against the dopamine-depleting effects of neurotoxic doses of methamphetamine." *Ann N Y Acad Sci* 1074: 272-81.
- Clemens, K. J., J. L. Cornish, et al. (2005). "MDMA ('Ecstasy') and methamphetamine combined: Order of administration influences hyperthermic and long-term adverse effects in female rats." *Neuropharmacology* 49(2): 195-207.
- Cooney, C. A., C. K. Wise, L. A. Poirier and S. F. Ali (1998). "Methamphetamine treatment affects blood and liver S-adenosylmethionine (SAM) in mice. Correlation with dopamine depletion in the striatum." *Ann N Y Acad Sci* 844: 191-200.
- Daberkow, D. P., R. P. Kesner, et al. (2005). "Relation between methamphetamine-induced monoamine depletions in the striatum and sequential motor learning." *Pharmacol Biochem Behav* 81(1): 198-204.
- D'Astous, M., T. M. Gajjar, et al. (2004). "Dopamine transporter as a marker of neuroprotection in methamphetamine-lesioned mice treated acutely with estradiol." *Neuroendocrinology* 79(6): 296-304.
- Davidson, C., T. H. Lee, et al. (2005). "Acute and chronic continuous methamphetamine have different long-term behavioral and neurochemical consequences." *Neurochem Int* 46(3): 189-203.
- Deng, X., B. Ladenheim, et al. (2006). "Methamphetamine administration causes death of dopaminergic neurons in the mouse olfactory bulb." *Biol Psychiatry*.
- Dluzen, D. E. and J. L. McDermott (2006). "Estrogen, testosterone, and methamphetamine toxicity." *Ann N Y Acad Sci* 1074: 282-94.
- Dluzen, D. E. and T. J. Salvaterra (2006). "Sex differences in methamphetamine-evoked striatal dopamine output are abolished following gonadectomy: Comparisons with potassium-evoked output and responses in prepubertal mice." *Neuroendocrinology* 82(2): 78-86.
- Dluzen, D. E., J. L. McDermott, et al. (2001). "Tamoxifen diminishes methamphetamine-induced striatal dopamine depletion in intact female and male mice." *J Neuroendocrinol* 13(7): 618-24.

- Eradiri, O. L. and M. S. Starr (1999). "Striatal dopamine depletion and behavioural sensitization induced by methamphetamine and 3-nitropropionic acid." *Eur J Pharmacol* 386(2-3): 217-26.
- Finnegan, K. T. and T. Taraska (1996). "Effects of glutamate antagonists on methamphetamine and 3,4-methylenedioxymethamphetamine-induced striatal dopamine release in vivo." *J Neurochem* 66(5): 1949-58.
- Fornai, F., P. Lenzi, et al. (2005). "Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice." *Brain Res Bull* 65(5): 405-13.
- Fornai, F., M. T. Carri, et al. (2002). "Resistance to striatal dopamine depletion induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice expressing human mutant Cu,Zn superoxide dismutase." *Neurosci Lett* 325(2): 124-8.
- Fuller, R. W., S. K. Hemrick-Luecke, et al. (1992). "Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist." *Neuropharmacology* 31(10): 1027-32.
- Gassen, M., I. Lamensdorf, et al. (2003). "Attenuation of methamphetamine induced dopaminergic neurotoxicity by flupirtine: Microdialysis study on dopamine release and free radical generation." *J Neural Transm* 110(2): 171-82.
- Gibb, J. W., M. Johnson, et al. (1990). "Neurochemical basis of neurotoxicity." *Neurotoxicology* 11(2): 317-21.
- Hanson, G. R., V. Sandoval, E. Riddle and A. E. Fleckenstein (2004). "Psychostimulants and vesicle trafficking: A novel mechanism and therapeutic implications." *Ann N Y Acad Sci* 1025: 146-50.
- Haughey, H. M., J. M. Brown, et al. (2000). "Differential effects of methamphetamine on Na(+)/Cl(-)-dependent transporters." *Brain Res* 863(1-2): 59-65.
- Hess, U. S., S. P. Whalen, et al. (2003). "Ampakines reduce methamphetamine-driven rotation and activate neocortex in a regionally selective fashion." *Neuroscience* 121(2): 509-21.
- Hirata, H., B. Ladenheim, et al. (1996). "Autoradiographic evidence for methamphetamine-induced striatal dopaminergic loss in mouse brain: Attenuation in CuZn-superoxide dismutase transgenic mice." *Brain Res* 714(1-2): 95-103.
- Hom, D. G., D. Jiang, et al. (1997). "Elevated expression of glutathione peroxidase in PC12 cells results in protection against methamphetamine but not MPTP toxicity." *Brain Res Mol Brain Res* 46(1-2): 154-60.
- Imam, S. Z., J. el-Yazal, et al. (2001). "Methamphetamine-induced dopaminergic neurotoxicity: Role of peroxynitrite and neuroprotective role of antioxidants and peroxynitrite decomposition catalysts." *Ann N Y Acad Sci* 939: 366-80.
- Ito, K., T. Abekawa, et al. (2006). "Relationship between development of cross-sensitization to MK-801 and delayed increases in glutamate levels in the nucleus accumbens induced by a high dose of methamphetamine." *Psychopharmacology (Berl)* 187(3): 293-302.
- Itzhak, Y. and S. F. Ali (2006). "Role of nitrenergic system in behavioral and neurotoxic effects of amphetamine analogs." *Pharmacol Ther* 109(1-2): 246-62.
- Itzhak, Y. and C. Achat-Mendes (2004). "Methamphetamine and MDMA (ecstasy) neurotoxicity: 'Of mice and men'." *IUBMB Life* 56(5): 249-55.
- Itzhak, Y. and S. F. Ali (2002). "Behavioral consequences of methamphetamine-induced neurotoxicity in mice: Relevance to the psychopathology of methamphetamine addiction." *Ann N Y Acad Sci* 965: 127-35.
- Itzhak, Y., J. L. Martin, et al. (2002). "Methamphetamine-induced dopaminergic neurotoxicity in mice: Long-lasting sensitization to the locomotor stimulation and desensitization to the rewarding effects of methamphetamine." *Prog Neuropsychopharmacol Biol Psychiatry* 26(6): 1177-83.
- Itzhak, Y., C. Gandia, et al. (1998). "Resistance of neuronal nitric oxide synthase-deficient mice to methamphetamine-induced dopaminergic neurotoxicity." *J Pharmacol Exp Ther* 284(3): 1040-7.
- Kanthsamy, A., V. Anantharam, et al. (2006). "Methamphetamine induces autophagy and apoptosis in a mesencephalic dopaminergic neuronal culture model: role of cathepsin-D in methamphetamine-induced apoptotic cell death." *Ann N Y Acad Sci* 1074: 234-44.
- Kawasaki, T., K. Ishihara, et al. (2006). "Protective effect of the radical scavenger edaravone against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum." *Eur J Pharmacol* 542(1-3): 92-9.
- Kim, S., R. Westphalen, et al. (2000). "Toward development of an in vitro model of methamphetamine-induced dopamine nerve terminal toxicity." *J Pharmacol Exp Ther* 293(2): 625-33.
- Kita, T., M. Takahashi, et al. (1998). "Methamphetamine-induced changes in activity and water intake during light and dark cycles in rats." *Prog Neuropsychopharmacol Biol Psychiatry* 22(7): 1185-96.
- Kita, T., G. C. Wagner, et al. (1995). "Effects of pargyline and pyrogallol on the methamphetamine-induced dopamine depletion." *Mol Chem Neuropathol* 24(1): 31-41.
- Kleven, M. S. and L. S. Seiden (1992). "Repeated injection of cocaine potentiates methamphetamine-induced toxicity to dopamine-containing neurons in rat striatum." *Ann N Y Acad Sci* 654: 464-6.
- Kleven, M. S. and L. S. Seiden (1991). "Repeated injection of cocaine potentiates methamphetamine-induced toxicity to dopamine-containing neurons in rat striatum." *Brain Res* 557(1-2): 340-3.

- Kobayashi, K. and H. Sano (2000). "Dopamine deficiency in mice." *Brain Dev* 22 Suppl 1: S54-60.
- Koike, K., K. Hashimoto, et al. (2005). "The immunophilin ligand FK506 protects against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum." *Neuropharmacology* 48(3): 391-7.
- Kondo, T., T. Ito, et al. (1994). "Bromocriptine scavenges methamphetamine-induced hydroxyl radicals and attenuates dopamine depletion in mouse striatum." *Ann N Y Acad Sci* 738: 222-9.
- Kunnathur, V., K. Shemisa, et al. (2006). "Sex differences in methamphetamine-evoked striatal dopamine of mice are reversed by nomifensine." *Neurotoxicol Teratol* 28(5): 557-62.
- Layer, R. T., L. R. Bland, et al. (1993). "MK-801, but not drugs acting at strychnine-insensitive glycine receptors, attenuate methamphetamine nigrostriatal toxicity." *Brain Res* 625(1): 38-44.
- Lesting, J., J. Neddens, et al. (2005). "Hemisphere-specific effects on serotonin but not dopamine innervation in the nucleus accumbens of gerbils caused by isolated rearing and a single early methamphetamine challenge." *Brain Res* 1035(2): 168-76.
- Lockhart, B., A. Roger, et al. (2005). "In vivo neuroprotective effects of the novel imidazolyl nitron free-radical scavenger (Z)-alpha-[2-thiazol-2-yl]imidazol-4-yl]-N-tert-butyl nitron (S34176)." *Eur J Pharmacol* 511(2-3): 127-36.
- Maragos, W. F., K. L. Young, et al. (2002). "Human immunodeficiency virus-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function." *J Neurochem* 83(4): 955-63.
- Maragos, W. F., R. Jakel, et al. (2000). "Methamphetamine toxicity is attenuated in mice that overexpress human manganese superoxide dismutase." *Brain Res* 878(1-2): 218-22.
- Mark, K. A., J. J. Soghomonian, et al. (2004). "High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity." *J Neurosci* 24(50): 11449-56.
- Mauceli, G., C. I. Busceti, et al. (2006). "Overexpression of alpha-synuclein following methamphetamine: Is it good or bad?" *Ann N Y Acad Sci* 1074: 191-7.
- Meck, W. H. (2006). "Frontal cortex lesions eliminate the clock speed effect of dopaminergic drugs on interval timing." *Brain Res* 1108(1): 157-67.
- Miyazaki, I., M. Asanuma, et al. (2006). "Methamphetamine-induced dopaminergic neurotoxicity is regulated by quinone-formation-related molecules." *FASEB J* 20(3): 571-3.
- O'Dell, S. J., F. B. Weihmuller, et al. (1994). "Excitotoxic striatal lesions protect against subsequent methamphetamine-induced dopamine depletions." *J Pharmacol Exp Ther* 269(3): 1319-25.
- Pacchioni, A. M., J. Vallone, et al. (2007). "Nrf2 gene deletion fails to alter psychostimulant-induced behavior or neurotoxicity." *Brain Res* 1127(1): 26-35.
- Pereira, F. C., E. S. Lourenco, et al. (2006). "Single or multiple injections of methamphetamine increased dopamine turnover but did not decrease tyrosine hydroxylase levels or cleave caspase-3 in caudate-putamen." *Synapse* 60(3): 185-93.
- Perez, V. and M. Unzeta (2003). "PF 9601N [N-(2-propynyl)-2-(5-benzoyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 mice." *Neurochem Int* 42(3): 221-9.
- Pu, C., J. E. Fisher, et al. (1994). "The effects of amfonelic acid, a dopamine uptake inhibitor, on methamphetamine-induced dopaminergic terminal degeneration and astrocytic response in rat striatum." *Brain Res* 649(1-2): 217-24.
- Pu, C. and C. V. Vorhees (1993). "Developmental dissociation of methamphetamine-induced depletion of dopaminergic terminals and astrocyte reaction in rat striatum." *Brain Res Dev Brain Res* 72(2): 325-8.
- Randrup, A., G. Sorensen, et al. (1988). "Stereotyped behaviour in animals induced by stimulant drugs or by a restricted cage environment: relation to disintegrated behaviour, brain dopamine and psychiatric disease." *Yakubutsu Seishin Kodo* 8(2): 313-27.
- Richards, J. B., K. E. Sabol, et al. (1990). "Unilateral dopamine depletion causes bilateral deficits in conditioned rotation in rats." *Pharmacol Biochem Behav* 36(2): 217-23.
- Riddle, E. L., A. E. Fleckenstein, et al. (2006). "Mechanisms of methamphetamine-induced dopaminergic neurotoxicity." *AAPS J* 8(2): E413-8.
- Rothman, R. B., B. E. Blough, et al. (2002). "Appetite suppressants as agonist substitution therapies for stimulant dependence." *Ann N Y Acad Sci* 965: 109-26.
- Rothman, R. B., J. S. Partilla, et al. (2000). "Methamphetamine dependence: Medication development efforts based on the dual deficit model of stimulant addiction." *Ann N Y Acad Sci* 914: 71-81.
- Sanchez, V., M. Zeini, et al. (2003). "The nNOS inhibitor, AR-R17477AR, prevents the loss of NF68 immunoreactivity induced by methamphetamine in the mouse striatum." *J Neurochem* 85(2): 515-24.
- Seiden, L. S., D. L. Commins, et al. (1988). "Neurotoxicity in dopamine and 5-hydroxytryptamine terminal fields: A regional analysis in nigrostriatal and mesolimbic projections." *Ann N Y Acad Sci* 537: 161-72.
- Shoblock, J. R., E. B. Sullivan, et al. (2003). "Neurochemical and behavioral differences between d-methamphetamine and d-amphetamine in rats." *Psychopharmacology (Berl)* 165(4): 359-69.

- Sonsalla, P. K., D. S. Albers, et al. (1998). "Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism." *Amino Acids* 14(1-3): 69-74.
- Sonsalla, P. K. (1995). "The role of N-methyl-D-aspartate receptors in dopaminergic neuropathology produced by the amphetamines." *Drug Alcohol Depend* 37(2): 101-5.
- Sonsalla, P. K., A. Giovanni, et al. (1992). "Characteristics of dopaminergic neurotoxicity produced by MPTP and methamphetamine." *Ann N Y Acad Sci* 648: 229-38.
- Staszewski, R. D. and B. K. Yamamoto (2006). "Methamphetamine-induced spectrin proteolysis in the rat striatum." *J Neurochem* 96(5): 1267-76.
- Stephans, S. E., T. S. Whittingham, et al. (1998). "Substrates of energy metabolism attenuate methamphetamine-induced neurotoxicity in striatum." *J Neurochem* 71(2): 613-21.
- Stephans, S. and B. Yamamoto (1996). "Methamphetamines pretreatment and the vulnerability of the striatum to methamphetamine neurotoxicity." *Neuroscience* 72(3): 593-600.
- Stephans, S. E. and B. Y. Yamamoto (1995). "Effect of repeated methamphetamine administrations on dopamine and glutamate efflux in rat prefrontal cortex." *Brain Res* 700(1-2): 99-106.
- Stephans, S. E. and B. K. Yamamoto (1994). "Methamphetamine-induced neurotoxicity: Roles for glutamate and dopamine efflux." *Synapse* 17(3): 203-9.
- Straiko, M. M., L. M. Coolen, et al. (2007). "The effect of amphetamine analogs on cleaved microtubule-associated protein-tau formation in the rat brain." *Neuroscience* 144(1): 223-31.
- Theodore, S., S. Stolberg, et al. (2006). "Human immunodeficiency virus-1 protein tat and methamphetamine interactions." *Ann N Y Acad Sci* 1074: 178-90.
- Theodore, S., W. A. Cass, et al. (2006). "Inhibition of tumor necrosis factor-alpha signaling prevents human immunodeficiency virus-1 protein Tat and methamphetamine interaction." *Neurobiol Dis* 23(3): 663-8.
- Theodore, S., W. A. Cass, et al. (2006). "Involvement of cytokines in human immunodeficiency virus-1 protein Tat and methamphetamine interactions in the striatum." *Exp Neurol* 199(2): 490-8.
- Theodore, S., W. A. Cass, et al. (2006). "Methamphetamine and human immunodeficiency virus protein Tat synergize to destroy dopaminergic terminals in the rat striatum." *Neuroscience* 137(3): 925-35.
- Truong, J. G., D. G. Wilkins, et al. (2005). "Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: Implications for neurotoxicity." *J Pharmacol Exp Ther* 314(3): 1087-92.
- Wallace, T. L., C. V. Vorhees, et al. (2001). "Effects of lubeluzole on the methamphetamine-induced increase in extracellular glutamate and the long-term depletion of striatal dopamine." *Synapse* 40(2): 95-101.
- Yamamoto, B. K. and M. G. Bankson (2005). "Amphetamine neurotoxicity: cause and consequence of oxidative stress." *Crit Rev Neurobiol* 17(2): 87-118.
- Yamamoto, B. K. and W. Zhu (1998). "The effects of methamphetamine on the production of free radicals and oxidative stress." *J Pharmacol Exp Ther* 287(1): 107-14.
- Yu, J., S. Allison, et al. (2002). "Ontogeny of neurokinin-1 receptor mediation of methamphetamine neurotoxicity in the striatum of the mouse brain." *Ann N Y Acad Sci* 965: 247-53.
- Yu, L., C. F. Cherg, et al. (2002). "Melatonin in concentrated ethanol and ethanol alone attenuate methamphetamine-induced dopamine depletions in C57BL/6J mice." *J Neural Transm* 109(12): 1477-90.
- Yu, L., Y. M. Kuo, et al. (2001). "Opioid peptides alleviated while naloxone potentiated methamphetamine-induced striatal dopamine depletion in mice." *J Neural Transm* 108(11): 1231-7.
- Yu, L. and P. C. Liao (2000). "Estrogen and progesterone distinctively modulate methamphetamine-induced dopamine and serotonin depletions in C57BL/6J mice." *J Neural Transm* 107(10): 1139-47.
- Yu, L. and P. C. Liao (2000). "Sexual differences and estrous cycle in methamphetamine-induced dopamine and serotonin depletions in the striatum of mice." *J Neural Transm* 107(4): 419-27.
- Yu, Y. L. and G. C. Wagner (1994). "Influence of gonadal hormones on sexual differences in sensitivity to methamphetamine-induced neurotoxicity." *J Neural Transm Park Dis Dement Sect* 8(3): 215-21.
- Zhu, J. P., W. Xu, et al. (2006). "Distinct mechanisms mediating methamphetamine-induced neuronal apoptosis and dopamine terminal damage share the neuropeptide substance P in the striatum of mice." *Ann N Y Acad Sci* 1074: 135-48.

## Dopamine Receptors

- Chang, L. and W. Haning (2006). "Insights from recent positron emission tomographic studies of drug abuse and dependence." *Curr Opin Psychiatry* 19(3): 246-252.

- Chen, C. K., X. Hu, et al. (2004). "Association analysis of dopamine D2-like receptor genes and methamphetamine abuse." *Psychiatr Genet* 14(4): 223-6.
- Chen, J., C. Wersinger, et al. (2003). "Chronic stimulation of D1 dopamine receptors in human SK-N-MC neuroblastoma cells induces nitric-oxide synthase activation and cytotoxicity." *J Biol Chem* 278(30): 28089-100.
- Comings, D. E. and K. Blum (2000). "Reward deficiency syndrome: Genetic aspects of behavioral disorders." *Prog Brain Res* 126: 325-41.
- D'Souza, U. M., C. Russ, et al. (2004). "Functional effects of a tandem duplication polymorphism in the 5'flanking region of the DRD4 gene." *Biol Psychiatry* 56(9): 691-7.
- Ellinwood, E. H., Jr. and M. M. Kilbey (1980). "Fundamental mechanisms underlying altered behavior following chronic administration of psychomotor stimulants." *Biol Psychiatry* 15(5): 749-57.
- Harano, M., N. Uchimura, et al. (2004). "A polymorphism of DRD2 gene and brain atrophy in methamphetamine psychosis." *Ann N Y Acad Sci* 1025: 307-15.
- Iyo, M., Y. Sekine, et al. (2004). "Neuromechanism of developing methamphetamine psychosis: A neuroimaging study." *Ann N Y Acad Sci* 1025: 288-95.
- Iyo, M., M. Nishio, et al. (1993). "Dopamine D2 and serotonin S2 receptors in susceptibility to methamphetamine psychosis detected by positron emission tomography." *Psychiatry Res* 50(4): 217-31.
- Iyo, M. (1992). "PET dopamine D2 receptors and susceptibility to methamphetamine psychosis." *Clin Neuropharmacol* 15 Suppl 1 Pt A: 652A-653A.
- Li, T., C. K. Chen, et al. (2004). "Association analysis of the DRD4 and COMT genes in methamphetamine abuse." *Am J Med Genet* 129B(1): 120-4.
- Lile, J. A., W. W. Stoops, et al. (2005). "Aripiprazole attenuates the discriminative-stimulus and subject-rated effects of D-amphetamine in humans." *Neuropsychopharmacology* 30(11): 2103-14.
- Liu, H. C., C. K. Chen, et al. (2006). "Association between dopamine receptor D1 A-48G polymorphism and methamphetamine abuse." *Psychiatry Clin Neurosci* 60(2): 226-31.
- Munro, C. A., M. E. McCaul, et al. (2006). "Sex differences in striatal dopamine release in healthy adults." *Biol Psychiatry* 59(10): 966-74.
- Piccini, P., D. J. Brooks, et al. (1999). "Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient." *Nat Neurosci* 2(12): 1137-40.
- Ross, B. M., A. Moszczynska, et al. (2002). "Decreased activity of brain phospholipid metabolic enzymes in human users of cocaine and methamphetamine." *Drug Alcohol Depend* 67(1): 73-9.
- Sato, M. (1992). "A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis." *Ann N Y Acad Sci* 654: 160-70.
- Sato, M. (1986). "Acute exacerbation of methamphetamine psychosis and lasting dopaminergic supersensitivity--A clinical survey." *Psychopharmacol Bull* 22(3): 751-6.
- Sery, O., V. Vojtova, et al. (2001). "The association study of DRD2, ACE and AGT gene polymorphisms and metamphetamine dependence." *Physiol Res* 50(1): 43-50.
- Stoops, W. W. (2006). "Aripiprazole as a potential pharmacotherapy for stimulant dependence: Human laboratory studies with d-amphetamine." *Exp Clin Psychopharmacol* 14(4): 413-21.
- Tong, J., B. M. Ross, et al. (2003). "Decreased striatal dopamine D1 receptor-stimulated adenylyl cyclase activity in human methamphetamine users." *Am J Psychiatry* 160(5): 896-903.
- Tsai, S. J., C. Y. Cheng, et al. (2002). "No association for D2 and D4 dopamine receptor polymorphisms and methamphetamine abuse in Chinese males." *Psychiatr Genet* 12(1): 29-33.
- Turchan, J., C. Anderson, et al. (2001). "Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine." *BMC Neurosci* 2: 3.
- Volkow, N. D., L. Chang, et al. (2001). "Low level of brain dopamine D2 receptors in methamphetamine abusers: Association with metabolism in the orbitofrontal cortex." *Am J Psychiatry* 158(12): 2015-21.
- Wachtel, S. R., A. Ortengren, et al. (2002). "The effects of acute haloperidol or risperidone on subjective responses to methamphetamine in healthy volunteers." *Drug Alcohol Depend* 68(1): 23-33.
- Wang, G. J., N. D. Volkow, et al. (2004). "Similarity between obesity and drug addiction as assessed by neurofunctional imaging: A concept review." *J Addict Dis* 23(3): 39-53.
- Worsley, J. N., A. Moszczynska, et al. (2000). "Dopamine D1 receptor protein is elevated in nucleus accumbens of human, chronic methamphetamine users." *Mol Psychiatry* 5(6): 664-72.

## Dopamine Receptors (animals)

- Achat-Mendes, C., K. L. Anderson, et al. (2006). "Impairment in consolidation of learned place preference following dopaminergic neurotoxicity in mice is ameliorated by N-acetylcysteine but not D1 and D2 dopamine receptor agonists." *Neuropsychopharmacology*.
- Adams, F. S., F. G. La Rosa, et al. (1996). "Characterization and transplantation of two neuronal cell lines with dopaminergic properties." *Neurochem Res* 21(5): 619-27.
- Akiyama, K., A. Kanzaki, et al. (1994). "Methamphetamine-induced behavioral sensitization and its implications for relapse of schizophrenia." *Schizophr Res* 12(3): 251-7.
- Allan, A. M., R. Galindo, et al. (2001). "Conditioned place preference for cocaine is attenuated in mice over-expressing the 5-HT(3) receptor." *Psychopharmacology (Berl)* 158(1): 18-27.
- Amano, T., H. Matsubayashi, et al. (2002). "[Alteration of neuronal activities following repeated administration of stimulants]." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 37(1): 31-40.
- Angulo, J. A., N. Angulo, et al. (2004). "Antagonists of the neurokinin-1 or dopamine D1 receptors confer protection from methamphetamine on dopamine terminals of the mouse striatum." *Ann N Y Acad Sci* 1025: 171-80.
- Baumann, M. H., J. M. Phillips, et al. (2002). "Preclinical evaluation of GBR12909 decanoate as a long-acting medication for methamphetamine dependence." *Ann N Y Acad Sci* 965: 92-108.
- Bedingfield, J. B., L. D. Calder, et al. (1996). "Comparative behavioral sensitization to stereotypy by direct and indirect dopamine agonists in CF-1 mice." *Psychopharmacology (Berl)* 124(3): 219-25.
- Binienda, Z. K., B. D. Przybyla, et al. (2006). "Effects of L-carnitine pretreatment in methamphetamine and 3-nitropropionic acid-induced neurotoxicity." *Ann N Y Acad Sci* 1074: 74-83.
- Broening, H. W., L. L. Morford, et al. (2005). "Interactions of dopamine D1 and D2 receptor antagonists with D-methamphetamine-induced hyperthermia and striatal dopamine and serotonin reductions." *Synapse* 56(2): 84-93.
- Bronstein, D. M. and J. S. Hong (1995). "Effects of sulpiride and SCH 23390 on methamphetamine-induced changes in body temperature and lethality." *J Pharmacol Exp Ther* 274(2): 943-50.
- Castel, M. N., P. Morino, et al. (1994). "Up-regulation of neurotensin mRNA in the rat striatum after acute methamphetamine treatment." *Eur J Neurosci* 6(4): 646-56.
- Castel, M. N., P. Morino, et al. (1993). "Modulation of the neurotensin striato-nigral pathway by D1 receptors." *Neuroreport* 5(3): 281-4.
- Chen, P. C., C. L. Lao, et al. (2006). "Dual alteration of limbic dopamine D(1) receptor-mediated signalling and the Akt/GSK3 pathway in dopamine D(3) receptor mutants during the development of methamphetamine sensitization." *J Neurochem*.
- Comings, D. E. and K. Blum (2000). "Reward deficiency syndrome: Genetic aspects of behavioral disorders." *Prog Brain Res* 126: 325-41.
- Doudet, D. J., T. J. Ruth, et al. (2006). "Sequential versus nonsequential measurement of density and affinity of dopamine D2 receptors with [(11)C]raclopride: 2: effects of DAT inhibitors." *J Cereb Blood Flow Metab* 26(1): 28-37.
- Doudet, D. J. and J. E. Holden (2003). "Raclopride studies of dopamine release: Dependence on presynaptic integrity." *Biol Psychiatry* 54(11): 1193-9.
- Doudet, D. J. and J. E. Holden (2003). "Sequential versus nonsequential measurement of density and affinity of dopamine d2 receptors with [11c]raclopride: Effect of methamphetamine." *J Cereb Blood Flow Metab* 23(12): 1489-94.
- Ehrman, L. A., M. T. Williams, et al. (2006). "Phosphodiesterase 1B differentially modulates the effects of methamphetamine on locomotor activity and spatial learning through DARPP32-dependent pathways: evidence from PDE1B-DARPP32 double-knockout mice." *Genes Brain Behav* 5(7): 540-51.
- Elphick, M. (1989). "Effects of carbamazepine on dopamine function in rodents." *Psychopharmacology (Berl)* 99(4): 532-6.
- Facchinetti, F., R. Dall'Olio, et al. (1994). "Long-lasting effects of chronic neonatal blockade of N-methyl-D-aspartate receptor through the competitive antagonist CGP 39551 in rats." *Neuroscience* 60(2): 343-53.
- Floran, B., L. Floran, et al. (2004). "Dopamine D4 receptors inhibit depolarization-induced [3H]GABA release in the rat subthalamic nucleus." *Eur J Pharmacol* 498(1-3): 97-102.
- Fukui, R., P. Svenningsson, et al. (2003). "Effect of methylphenidate on dopamine/DARPP signalling in adult, but not young, mice." *J Neurochem* 87(6): 1391-401.
- Gada, V. P., V. V. Joshi, et al. (1984). "Antagonism of apomorphine-induced cage climbing behaviour and methamphetamine stereotypy by fenfluramine in mice." *Indian J Physiol Pharmacol* 28(4): 326-30.
- Gifford, A. N., M. H. Park, et al. (2000). "Effect of amphetamine-induced dopamine release on radiotracer binding to D1 and D2 receptors in rat brain striatal slices." *Naunyn Schmiedebergs Arch Pharmacol* 362(4-5): 413-8.
- Glickstein, S. B., P. R. Hof, et al. (2002). "Mice lacking dopamine D2 and D3 receptors have spatial working memory deficits." *J Neurosci* 22(13): 5619-29.

- Hamamura, T., K. Akiyama, et al. (1991). "Co-administration of either a selective D1 or D2 dopamine antagonist with methamphetamine prevents methamphetamine-induced behavioral sensitization and neurochemical change, studied by in vivo intracerebral dialysis." *Brain Res* 546(1): 40-6.
- Hanson, G. R., N. Singh, et al. (1995). "The role of NMDA receptor systems in neuropeptide responses to stimulants of abuse." *Drug Alcohol Depend* 37(2): 107-10.
- Hanson, G. R., N. Singh, et al. (1992). "Responses of limbic and extrapyramidal neurotensin systems to stimulants of abuse. Involvement of dopaminergic mechanisms." *Ann N Y Acad Sci* 668: 165-72.
- He, J., Y. Yang, et al. (2006). "The effects of chronic administration of quetiapine on the methamphetamine-induced recognition memory impairment and dopaminergic terminal deficit in rats." *Behav Brain Res* 172(1): 39-45.
- Hess, U. S., S. P. Whalen, et al. (2003). "Ampakines reduce methamphetamine-driven rotation and activate neocortex in a regionally selective fashion." *Neuroscience* 121(2): 509-21.
- Higashi, H., K. Inanaga, et al. (1989). "Enhancement of dopamine actions on rat nucleus accumbens neurones in vitro after methamphetamine pre-treatment." *J Physiol* 408: 587-603.
- Honda, F., Y. Satoh, et al. (1977). "Dopamine receptor blocking activity of sulpiride in the central nervous system." *Jpn J Pharmacol* 27(3): 397-411.
- Horner, K. A., S. C. Westwood, et al. (2006). "Multiple high doses of methamphetamine increase the number of preproneuropeptide Y mRNA-expressing neurons in the striatum of rat via a dopamine D1 receptor-dependent mechanism." *J Pharmacol Exp Ther* 319(1): 414-21.
- Hurlbert, M. S., R. I. Gianani, et al. (1999). "Neural transplantation of hNT neurons for Huntington's disease." *Cell Transplant* 8(1): 143-51.
- Ikarashi, Y., A. Takahashi, et al. (1997). "Regulation of dopamine D1 and D2 receptors on striatal acetylcholine release in rats." *Brain Res Bull* 43(1): 107-15.
- Iorio, L. C., A. Barnett, et al. (1983). "SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems." *J Pharmacol Exp Ther* 226(2): 462-8.
- Ishida, Y., K. Kawai, et al. (2005). "Alteration of striatal [11C]raclopride and 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine uptake precedes development of methamphetamine-induced rotation following unilateral 6-hydroxydopamine lesions of medial forebrain bundle in rats." *Neurosci Lett* 389(1): 30-4.
- Ishida, Y., K. Kawai, et al. (2004). "Changes in dopamine D2 receptors and 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine uptake in the brain of 6-hydroxydopamine-lesioned rats." *Neurodegener Dis* 1(2-3): 109-12.
- Ishihara, T., K. Akiyama, et al. (1998). "Enhanced AP-1 binding in brain induced by D1 and D2 agonists in methamphetamine-sensitized rats." *Neuroreport* 9(17): 3913-7.
- Ishikawa, A., T. Kadota, et al. (2005). "Essential role of D1 but not D2 receptors in methamphetamine-induced impairment of long-term potentiation in hippocampal-prefrontal cortex pathway." *Eur J Neurosci* 22(7): 1713-9.
- Ishikawa, K., A. Nitta, et al. (2006). "Effects of single and repeated administration of methamphetamine or morphine on neuroglycan C gene expression in the rat brain." *Int J Neuropsychopharmacol* 9(4): 407-15.
- Ito, S., T. Mori, et al. (2006). "Differential effects of mu-opioid, delta-opioid and kappa-opioid receptor agonists on dopamine receptor agonist-induced climbing behavior in mice." *Behav Pharmacol* 17(8): 691-701.
- Itzhak, Y. and S. F. Ali (2006). "Role of nitrenergic system in behavioral and neurotoxic effects of amphetamine analogs." *Pharmacol Ther* 109(1-2): 246-62.
- Jadhav, J. H., J. J. Balsara, et al. (1981). "Effect of ethosuximide on dopaminergically mediated behaviours." *Indian J Physiol Pharmacol* 25(3): 274-8.
- Joshi, V. V., J. J. Balsara, et al. (1981). "Effect of L-histidine and chlorcyclizine on apomorphine-induced climbing behaviour and methamphetamine stereotypy in mice." *Eur J Pharmacol* 69(4): 499-502.
- Karler, R., L. D. Calder, et al. (1998). "The role of dopamine and GABA in the frontal cortex of mice in modulating a motor-stimulant effect of amphetamine and cocaine." *Pharmacol Biochem Behav* 60(1): 237-44.
- Karler, R., L. D. Calder, et al. (1998). "The role of dopamine in the mouse frontal cortex: a new hypothesis of behavioral sensitization to amphetamine and cocaine." *Pharmacol Biochem Behav* 61(4): 435-43.
- Karler, R., L. D. Calder, et al. (1995). "The dopaminergic, glutamatergic, GABAergic bases for the action of amphetamine and cocaine." *Brain Res* 671(1): 100-4.
- Karler, R., L. D. Calder, et al. (1994). "A dopaminergic-glutamatergic basis for the action of amphetamine and cocaine." *Brain Res* 658(1-2): 8-14.
- Kim, H. C., E. J. Shin, et al. (2005). "Pharmacological action of Panax ginseng on the behavioral toxicities induced by psychotropic agents." *Arch Pharm Res* 28(9): 995-1001.



- Koshikawa, N., E. Mori, et al. (1990). "Role of dopamine D-1 and D-2 receptors in the ventral striatum in the turning behaviour of rats." *Eur J Pharmacol* 178(2): 233-7.
- Kusayama, T. and S. Watanabe (2000). "Reinforcing effects of methamphetamine in planarians." *Neuroreport* 11(11): 2511-3.
- Mach, R. H., M. A. Nader, et al. (1997). "Use of positron emission tomography to study the dynamics of psychostimulant-induced dopamine release." *Pharmacol Biochem Behav* 57(3): 477-86.
- McCabe, R. T., G. R. Hanson, et al. (1987). "Methamphetamine-induced reduction in D1 and D2 dopamine receptors as evidenced by autoradiography: comparison with tyrosine hydroxylase activity." *Neuroscience* 23(1): 253-61.
- McCann, U. D., D. F. Wong, et al. (1998). "Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428." *J Neurosci* 18(20): 8417-22.
- Melega, W. P., G. Lacan, et al. (2000). "Long-term methamphetamine-induced decreases of [(11C)WIN 35,428 binding in striatum are reduced by GDNF: PET studies in the vervet monkey." *Synapse* 35(4): 243-9.
- Mizoguchi, H., K. Yamada, et al. (2004). "Regulations of methamphetamine reward by extracellular signal-regulated kinase 1/2/ets-like gene-1 signaling pathway via the activation of dopamine receptors." *Mol Pharmacol* 65(5): 1293-301.
- Muley, M. P., M. A. Joshi, et al. (1984). "Effect of bupropion on dopamine and 5-hydroxytryptamine-mediated behaviour in mice." *J Pharm Pharmacol* 36(3): 208-10.
- Muraki, A. (1993). "[Effects of antagonists of NMDA receptor on methamphetamine-induced decrease in the dopamine uptake sites in the rat striatum and on the behavioral sensitization]." *Hokkaido Igaku Zasshi* 68(3): 407-18.
- Nagai, T., Y. Noda, et al. (2005). "The role of tissue plasminogen activator in methamphetamine-related reward and sensitization." *J Neurochem* 92(3): 660-7.
- Noda, Y., Y. Miyamoto, et al. (1998). "Involvement of dopaminergic system in phencyclidine-induced place preference in mice pretreated with phencyclidine repeatedly." *J Pharmacol Exp Ther* 286(1): 44-51.
- Nonaka, R. and T. Moroji (1990). "Effects of chronic methamphetamine treatment on the binding parameters of [3H]SCH 23390, a selective D1-dopamine receptor ligand, in the rat brain." *Neurosci Lett* 120(1): 109-12.
- Okuyama, S., N. Kawashima, et al. (1999). "A selective dopamine D4 receptor antagonist, NRA0160: A preclinical neuropharmacological profile." *Life Sci* 65(20): 2109-25.
- Okuyama, S., S. Chaki, et al. (1997). "In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl]pyrrolidin-3-yl]thiazole (NRA0045)." *J Pharmacol Exp Ther* 282(1): 56-63.
- Palmer, A. A., M. Verbitsky, et al. (2005). "Gene expression differences in mice divergently selected for methamphetamine sensitivity." *Mamm Genome* 16(5): 291-305.
- Pieri, M., L. Pieri, et al. (1975). "A comparison of drug-induced rotation in rats lesioned in the medial forebrain bundle with 5,6-dihydroxytryptamine or 6-hydroxydopamine." *Arch Int Pharmacodyn Ther* 217(1): 118-30.
- Rubinstein, M., T. J. Phillips, et al. (1997). "Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine." *Cell* 90(6): 991-1001.
- Sano, H., Y. Yasoshima, et al. (2003). "Conditional ablation of striatal neuronal types containing dopamine D2 receptor disturbs coordination of basal ganglia function." *J Neurosci* 23(27): 9078-88.
- Sato, S., T. Chiba, et al. (2006). "Decline of striatal dopamine release in parkin-deficient mice shown by ex vivo autoradiography." *J Neurosci Res* 84(6): 1350-7.
- Segal, D. S., R. Kuczenski, et al. (2005). "Prolonged exposure of rats to intravenous methamphetamine: behavioral and neurochemical characterization." *Psychopharmacology (Berl)* 180(3): 501-12.
- Shirayama, Y., H. Mitsushio, et al. (2000). "Differential effects of haloperidol on phencyclidine-induced reduction in substance P contents in rat brain regions." *Synapse* 35(4): 292-9.
- Singh, N. A., L. P. Midgley, et al. (1991). "N-Methyl-D-aspartate receptors mediate dopamine-induced changes in extrapyramidal and limbic dynorphin systems." *Brain Res* 555(2): 233-8.
- Singh, N. A., L. G. Bush, et al. (1990). "Dopamine-mediated changes in central nervous system neurotensin systems: A role for NMDA receptors." *Eur J Pharmacol* 187(3): 337-44.
- Sirinathsinghji, D. J., S. B. Dunnett, et al. (1990). "Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway--III. Reversal by embryonic nigral dopamine grafts." *Neuroscience* 37(3): 757-66.
- Snyder, G. L., P. B. Allen, et al. (2000). "Regulation of phosphorylation of the GluR1 AMPA receptor in the neostriatum by dopamine and psychostimulants in vivo." *J Neurosci* 20(12): 4480-8.
- Stefanski, R., Z. Justinova, et al. (2004). "Sigma 1 receptor upregulation after chronic methamphetamine self-administration in rats: A study with yoked controls." *Psychopharmacology (Berl)* 175(1): 68-75.

- Stefanski, R., S. H. Lee, et al. (2002). "Lack of persistent changes in the dopaminergic system of rats withdrawn from methamphetamine self-administration." *Eur J Pharmacol* 439(1-3): 59-68.
- Stefanski, R., B. Ladenheim, et al. (1999). "Neuroadaptations in the dopaminergic system after active self-administration but not after passive administration of methamphetamine." *Eur J Pharmacol* 371(2-3): 123-35.
- Stephans, S. and B. Yamamoto (1996). "Methamphetamines pretreatment and the vulnerability of the striatum to methamphetamine neurotoxicity." *Neuroscience* 72(3): 593-600.
- Suzuki, T., K. Mizuo, et al. (2003). "Prenatal and neonatal exposure to bisphenol-A enhances the central dopamine D1 receptor-mediated action in mice: Enhancement of the methamphetamine-induced abuse state." *Neuroscience* 117(3): 639-44.
- Tien, L. T., I. K. Ho, et al. (2006). "Role of mu-opioid receptor in modulation of preproenkephalin mRNA expression and opioid and dopamine receptor binding in methamphetamine-sensitized mice." *J Neurosci Res*.
- Tsukada, H., N. Harada, et al. (2001). "Facilitation of dopaminergic neural transmission does not affect [(11)C]SCH23390 binding to the striatal D(1) dopamine receptors, but the facilitation enhances phosphodiesterase type-IV activity through D(1) receptors: PET studies in the conscious monkey brain." *Synapse* 42(4): 258-65.
- Ugarte, Y. V., K. S. Rau, et al. (2003). "Methamphetamine rapidly decreases mouse vesicular dopamine uptake: Role of hyperthermia and dopamine D2 receptors." *Eur J Pharmacol* 472(3): 165-71.
- Ujike, H., K. Akiyama, et al. (1991). "Lasting increase in D1 dopamine receptors in the lateral part of the substantia nigra pars reticulata after subchronic methamphetamine administration." *Brain Res* 540(1-2): 159-63.
- Wang, J. Q. and J. F. McGinty (1995). "Differential effects of D1 and D2 dopamine receptor antagonists on acute amphetamine- or methamphetamine-induced up-regulation of zif/268 mRNA expression in rat forebrain." *J Neurochem* 65(6): 2706-15.
- Xu, W., J. P. Zhu, et al. (2005). "Induction of striatal pre- and postsynaptic damage by methamphetamine requires the dopamine receptors." *Synapse* 58(2): 110-21.
- Yamada, K., N. Matsuo, et al. (1989). "Dopamine receptor blocking action of a dibenzothiepin derivative isofloxythepin in rats." *Clin Exp Pharmacol Physiol* 16(2): 109-16.
- Yamagata, K., K. Suzuki, et al. (2000). "Activation of an effector immediate-early gene arc by methamphetamine." *Ann N Y Acad Sci* 914: 22-32.
- Yang, S. N. (2000). "Sustained enhancement of AMPA receptor- and NMDA receptor-mediated currents induced by dopamine D1/D5 receptor activation in the hippocampus: An essential role of postsynaptic Ca<sup>2+</sup>." *Hippocampus* 10(1): 57-63.
- Zhou, J. L., J. H. Liang, et al. (2004). "Inhibition of methamphetamine-induced apoptosis by the calcium channel blocker verapamil in rat cerebellar neurons." *Beijing Da Xue Xue Bao* 36(4): 361-5.
- Zhu, J. P., W. Xu, et al. (2006). "Distinct mechanisms mediating methamphetamine-induced neuronal apoptosis and dopamine terminal damage share the neuropeptide substance P in the striatum of mice." *Ann N Y Acad Sci* 1074: 135-48.
- Zhu, J. P., W. Xu, et al. (2006). "Methamphetamine-induced striatal apoptosis in the mouse brain: Comparison of a binge to an acute bolus drug administration." *Neurotoxicology* 27(1): 131-6.
- Zhu, J. P., W. Xu, et al. (2005). "Disparity in the temporal appearance of methamphetamine-induced apoptosis and depletion of dopamine terminal markers in the striatum of mice." *Brain Res* 1049(2): 171-81.

### Dopamine Transporters

- Chou, Y. H., W. S. Huang, et al. (2007). "Dopamine transporters and cognitive function in methamphetamine abuser after a short abstinence: A SPECT study." *Eur Neuropsychopharmacol* 17(1): 46-52.
- Davidson, C., A. J. Gow, et al. (2001). "Methamphetamine neurotoxicity: Necrotic and apoptotic mechanisms and relevance to human abuse and treatment." *Brain Res Brain Res Rev* 36(1): 1-22.
- Han, D. D. and H. H. Gu (2006). "Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs." *BMC Pharmacol* 6: 6.
- Hong, C. J., C. Y. Cheng, et al. (2003). "Association study of the dopamine and serotonin transporter genetic polymorphisms and methamphetamine abuse in Chinese males." *J Neural Transm* 110(4): 345-51.
- Iyo, M., Y. Sekine and N. Mori (2004). "Neuromechanism of developing methamphetamine psychosis: A neuroimaging study." *Ann N Y Acad Sci* 1025: 288-95.
- Iyo, M. and Y. Sekine (2003). "[Stimulants related mental disorders]." *Ryoikibetsu Shokogun Shirizu*(40): 507-12.
- Johanson, C. E., K. A. Frey, et al. (2006). "Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers." *Psychopharmacology (Berl)* 186(4): 620.
- Kitamura, O., I. Tokunaga, et al. (2006). "Immunohistochemical investigation of dopaminergic terminal markers and caspase-3 activation in the striatum of human methamphetamine users." *Int J Legal Med*.

- Kobayashi, H., S. Ide, et al. (2004). "Study of association between alpha-synuclein gene polymorphism and methamphetamine psychosis/dependence." *Ann N Y Acad Sci* 1025: 325-34.
- Lile, J. A. (2006). "Pharmacological determinants of the reinforcing effects of psychostimulants: Relation to agonist substitution treatment." *Exp Clin Psychopharmacol* 14(1): 20-33.
- Liu, H. C., S. K. Lin, et al. (2004). "DAT polymorphism and diverse clinical manifestations in methamphetamine abusers." *Psychiatr Genet* 14(1): 33-7.
- Maragos, W. F., K. L. Young, et al. (2002). "Human immunodeficiency virus-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function." *J Neurochem* 83(4): 955-63.
- McCann, U. D., D. F. Wong, et al. (1998). "Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: Evidence from positron emission tomography studies with [<sup>11</sup>C]WIN-35,428." *J Neurosci* 18(20): 8417-22.
- Nordahl, T. E., R. Salo, et al. (2003). "Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: A review." *J Neuropsychiatry Clin Neurosci* 15(3): 317-25.
- Park, S. U., J. V. Ferrer, et al. (2002). "Peroxy-nitrite inactivates the human dopamine transporter by modification of cysteine 342: potential mechanism of neurotoxicity in dopamine neurons." *J Neurosci* 22(11): 4399-405.
- Sato, M. (1992). "A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis." *Ann N Y Acad Sci* 654: 160-70.
- Sekine, Y., Y. Minabe, et al. (2003). "Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms." *Am J Psychiatry* 160(9): 1699-701.
- Sekine, Y., M. Iyo, et al. (2001). "Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET." *Am J Psychiatry* 158(8): 1206-14.
- Sulzer, D., M. S. Sonders, et al. (2005). "Mechanisms of neurotransmitter release by amphetamines: A review." *Prog Neurobiol* 75(6): 406-33.
- Turchan, J., C. Anderson, et al. (2001). "Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine." *BMC Neurosci* 2: 3.
- Ujike, H., M. Harano, et al. (2003). "Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis." *Pharmacogenomics J* 3(4): 242-7.
- Villemagne, V., J. Yuan, et al. (1998). "Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [<sup>11</sup>C]WIN-35,428 positron emission tomography studies and direct in vitro determinations." *J Neurosci* 18(1): 419-27.
- Volkow, N. D., L. Chang, et al. (2001). "Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers." *Am J Psychiatry* 158(3): 377-82.
- Volkow, N. D., L. Chang, et al. (2001). "Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence." *J Neurosci* 21(23): 9414-8.
- Volz, T. J. and J. O. Schenk (2005). "A comprehensive atlas of the topography of functional groups of the dopamine transporter." *Synapse* 58(2): 72-94.
- Wang, G. J., N. D. Volkow, et al. (2004). "Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence." *Am J Psychiatry* 161(2): 242-8.
- Wilhelm, C. J., R. A. Johnson, et al. (2006). "Hydrogen ion concentration differentiates effects of methamphetamine and dopamine on transporter-mediated efflux." *J Neurochem* 96(4): 1149-59.
- Wilhelm, C. J., R. A. Johnson, et al. (2004). "Effects of methamphetamine and lobeline on vesicular monoamine and dopamine transporter-mediated dopamine release in a cotransfected model system." *J Pharmacol Exp Ther* 310(3): 1142-51.

## Dopamine Transporters (animals)

- Allan, A. M., R. Galindo, et al. (2001). "Conditioned place preference for cocaine is attenuated in mice over-expressing the 5-HT(3) receptor." *Psychopharmacology (Berl)* 158(1): 18-27.
- Angulo, J. A., N. Angulo, et al. (2004). "Antagonists of the neurokinin-1 or dopamine D1 receptors confer protection from methamphetamine on dopamine terminals of the mouse striatum." *Ann N Y Acad Sci* 1025: 171-80.
- Baumgarten, H. G. and L. Lachenmayer (2004). "Serotonin neurotoxins--past and present." *Neurotox Res* 6(7-8): 589-614.
- Bennett, B. A., C. K. Hollingsworth, R. S. Martin and J. J. Harp (1998). "Methamphetamine-induced alterations in dopamine transporter function." *Brain Res* 782(1-2): 219-27.
- Bhatt, S. D. and D. E. Dluzen (2005). "Dopamine transporter function differences between male and female CD-1 mice." *Brain Res* 1035(2): 188-95.

- Booij, J., K. de Bruin, et al. (2006). "Repeated administration of d-amphetamine induces loss of [(123)I]FP-CIT binding to striatal dopamine transporters in rat brain: A validation study." *Nucl Med Biol* 33(3): 409-11.
- Cashman, J. R., Y. N. Xiong, et al. (1999). "N-oxygenation of amphetamine and methamphetamine by the human flavin-containing monooxygenase (form 3): Role in bioactivation and detoxication." *J Pharmacol Exp Ther* 288(3): 1251-60.
- Cervinski, M. A., J. D. Foster, et al. (2005). "Psychoactive substrates stimulate dopamine transporter phosphorylation and down-regulation by cocaine-sensitive and protein kinase C-dependent mechanisms." *J Biol Chem* 280(49): 40442-9.
- Chen, P. C. and J. C. Chen (2005). "Enhanced Cdk5 activity and p35 translocation in the ventral striatum of acute and chronic methamphetamine-treated rats." *Neuropsychopharmacology* 30(3): 538-49.
- Chen, R., D. D. Han, et al. (2005). "A triple mutation in the second transmembrane domain of mouse dopamine transporter markedly decreases sensitivity to cocaine and methylphenidate." *J Neurochem* 94(2): 352-9.
- D'Astous, M., T. M. Gajjar, et al. (2004). "Dopamine transporter as a marker of neuroprotection in methamphetamine-lesioned mice treated acutely with estradiol." *Neuroendocrinology* 79(6): 296-304.
- Eisch, A. J., S. J. O'Dell, et al. (1996). "Striatal and cortical NMDA receptors are altered by a neurotoxic regimen of methamphetamine." *Synapse* 22(3): 217-25.
- Fleckenstein, A. E., H. M. Haughey, et al. (1999). "Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function." *Eur J Pharmacol* 382(1): 45-9.
- Han, D. D. and H. H. Gu (2006). "Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs." *BMC Pharmacol* 6: 6.
- Hanson, G. R., N. Singh, et al. (1992). "Responses of limbic and extrapyramidal neurotensin systems to stimulants of abuse. Involvement of dopaminergic mechanisms." *Ann N Y Acad Sci* 668: 165-72.
- Harvey, D. C., G. Lacan, et al. (2000). "Regional heterogeneity of dopaminergic deficits in vervet monkey striatum and substantia nigra after methamphetamine exposure." *Exp Brain Res* 133(3): 349-58.
- Hashimoto, K., H. Tsukada, et al. (2006). "Protective effects of minocycline on the reduction of dopamine transporters in the striatum after administration of methamphetamine: A positron emission tomography study in conscious monkeys." *Biol Psychiatry*.
- Hashimoto, K., H. Tsukada, et al. (2004). "Effects of N-acetyl-L-cysteine on the reduction of brain dopamine transporters in monkey treated with methamphetamine." *Ann N Y Acad Sci* 1025: 231-5.
- Hashimoto, K., H. Tsukada, et al. (2004). "Protective effects of N-acetyl-L-cysteine on the reduction of dopamine transporters in the striatum of monkeys treated with methamphetamine." *Neuropsychopharmacology* 29(11): 2018-23.
- Inaji, M., T. Yoshizaki, et al. (2005). "In vivo PET measurements with [11C]PE2I to evaluate fetal mesencephalic transplantations to unilateral 6-OHDA-lesioned rats." *Cell Transplant* 14(9): 655-63.
- Itzhak, Y. and C. Achat-Mendes (2004). "Methamphetamine and MDMA (ecstasy) neurotoxicity: 'Of mice and men'." *IUBMB Life* 56(5): 249-55.
- Itzhak, Y. and S. F. Ali (2002). "Behavioral consequences of methamphetamine-induced neurotoxicity in mice: Relevance to the psychopathology of methamphetamine addiction." *Ann N Y Acad Sci* 965: 127-35.
- Itzhak, Y., J. L. Martin, et al. (2002). "Methamphetamine-induced dopaminergic neurotoxicity in mice: Long-lasting sensitization to the locomotor stimulation and desensitization to the rewarding effects of methamphetamine." *Prog Neuropsychopharmacol Biol Psychiatry* 26(6): 1177-83.
- Janowsky, A., C. Mah, et al. (2001). "Mapping genes that regulate density of dopamine transporters and correlated behaviors in recombinant inbred mice." *J Pharmacol Exp Ther* 298(2): 634-43.
- Johnson, R. A., A. J. Eshleman, et al. (1998). "[3H]substrate- and cell-specific effects of uptake inhibitors on human dopamine and serotonin transporter-mediated efflux." *Synapse* 30(1): 97-106.
- Kim, S., R. Westphalen, et al. (2000). "Toward development of an in vitro model of methamphetamine-induced dopamine nerve terminal toxicity." *J Pharmacol Exp Ther* 293(2): 625-33.
- Kita, T., G. C. Wagner, et al. (2003). "Current research on methamphetamine-induced neurotoxicity: Animal models of monoamine disruption." *J Pharmacol Sci* 92(3): 178-95.
- Kita, T. and T. Nakashima (2002). "[A recent trend in methamphetamine-induced neurotoxicity]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 22(2): 35-47.
- Kunnathur, V., K. Shemisa, et al. (2006). "Sex differences in methamphetamine-evoked striatal dopamine of mice are reversed by nomifensine." *Neurotoxicol Teratol* 28(5): 557-62.
- Maragos, W. F., K. L. Young, et al. (2002). "Human immunodeficiency virus-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function." *J Neurochem* 83(4): 955-63.
- Melega, W. P., G. Lacan, et al. (2000). "Long-term methamphetamine-induced decreases of [(11)C]WIN 35,428 binding in striatum are reduced by GDNF: PET studies in the vervet monkey." *Synapse* 35(4): 243-9.

- Metzger, R. R., H. M. Haughey, et al. (2000). "Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia." *J Pharmacol Exp Ther* 295(3): 1077-85.
- O'Neil, M. L., R. Kuczenski, et al. (2006). "Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge." *Synapse* 60(6): 465-73.
- Pu, C., J. E. Fisher, et al. (1994). "The effects of amfonelic acid, a dopamine uptake inhibitor, on methamphetamine-induced dopaminergic terminal degeneration and astrocytic response in rat striatum." *Brain Res* 649(1-2): 217-24.
- Rau, K. S., E. Birdsall, et al. (2006). "Methamphetamine administration reduces hippocampal vesicular monoamine transporter-2 uptake." *J Pharmacol Exp Ther* 318(2): 676-82.
- Rau, K. S., E. Birdsall, et al. (2005). "Bupropion increases striatal vesicular monoamine transport." *Neuropharmacology* 49(6): 820-30.
- Rauhut, A. S., N. Neugebauer, et al. (2003). "Effect of bupropion on nicotine self-administration in rats." *Psychopharmacology (Berl)* 169(1): 1-9.
- Rothman, R. B., B. E. Blough, et al. (2006). "Dual dopamine-5-HT releasers: Potential treatment agents for cocaine addiction." *Trends Pharmacol Sci* 27(12): 612-8.
- Rothman, R. B., N. Vu, et al. (2003). "In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates." *J Pharmacol Exp Ther* 307(1): 138-45.
- Sandoval, V., E. L. Riddle, et al. (2003). "Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits." *J Pharmacol Exp Ther* 304(3): 1181-7.
- Sandoval, V., E. L. Riddle, et al. (2001). "Methamphetamine-induced rapid and reversible changes in dopamine transporter function: An in vitro model." *J Neurosci* 21(4): 1413-9.
- Segal, D. S., R. Kuczenski, et al. (2005). "Prolonged exposure of rats to intravenous methamphetamine: behavioral and neurochemical characterization." *Psychopharmacology (Berl)* 180(3): 501-12.
- Shepard, J. D., D. T. Chuang, et al. (2006). "Effect of methamphetamine self-administration on tyrosine hydroxylase and dopamine transporter levels in mesolimbic and nigrostriatal dopamine pathways of the rat." *Psychopharmacology (Berl)* 185(4): 505-13.
- Staszewski, R. D. and B. K. Yamamoto (2006). "Methamphetamine-induced spectrin proteolysis in the rat striatum." *J Neurochem* 96(5): 1267-76.
- Stefanski, R., S. H. Lee, et al. (2002). "Lack of persistent changes in the dopaminergic system of rats withdrawn from methamphetamine self-administration." *Eur J Pharmacol* 439(1-3): 59-68.
- Takamatsu, Y., H. Yamamoto, et al. (2006). "Fluoxetine as a potential pharmacotherapy for methamphetamine dependence: Studies in mice." *Ann N Y Acad Sci* 1074: 295-302.
- Tsao, L. I., B. Ladenheim, et al. (1998). "Delta opioid peptide [D-Ala<sup>2</sup>,D-leu<sup>5</sup>]enkephalin blocks the long-term loss of dopamine transporters induced by multiple administrations of methamphetamine: Involvement of opioid receptors and reactive oxygen species." *J Pharmacol Exp Ther* 287(1): 322-31.
- Tsukada, H., S. Nishiyama, et al. (1999). "Is synaptic dopamine concentration the exclusive factor which alters the in vivo binding of [<sup>11</sup>C]raclopride? PET studies combined with microdialysis in conscious monkeys." *Brain Res* 841(1-2): 160-9.
- Volz, T. J., G. R. Hanson, et al. (2006). "Measurement of kinetically resolved vesicular dopamine uptake and efflux using rotating disk electrode voltammetry." *J Neurosci Methods* 155(1): 109-15.
- Volz, T. J. and J. O. Schenk (2005). "A comprehensive atlas of the topography of functional groups of the dopamine transporter." *Synapse* 58(2): 72-94.
- Wall, S. C., H. Gu, et al. (1995). "Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamine specificity for inhibition and efflux." *Mol Pharmacol* 47(3): 544-50.
- Wilhelm, C. J., R. A. Johnson, et al. (2006). "Hydrogen ion concentration differentiates effects of methamphetamine and dopamine on transporter-mediated efflux." *J Neurochem* 96(4): 1149-59.
- Wisor, J. P., S. Nishino, et al. (2001). "Dopaminergic role in stimulant-induced wakefulness." *J Neurosci* 21(5): 1787-94.
- Wu, P. H., Y. C. Shen, et al. (2006). "Baicalein attenuates methamphetamine-induced loss of dopamine transporter in mouse striatum." *Toxicology* 226(2-3): 238-45.
- Xie, T., U. D. McCann, et al. (2000). "Effect of temperature on dopamine transporter function and intracellular accumulation of methamphetamine: implications for methamphetamine-induced dopaminergic neurotoxicity." *J Neurosci* 20(20): 7838-45.
- Yamada, K., T. Nagai, et al. (2005). "[Pro- and anti-addictive factors related to drug addiction]." *Nippon Yakurigaku Zasshi* 126(1): 49-53.
- Yu, J., S. Allison, et al. (2002). "Ontogeny of neurokinin-1 receptor mediation of methamphetamine neurotoxicity in the striatum of the mouse brain." *Ann N Y Acad Sci* 965: 247-53.
- Zacsek, R., S. Culp, et al. (1991). "Interactions of [<sup>3</sup>H]amphetamine with rat brain synaptosomes. II. Active transport." *J Pharmacol Exp Ther* 257(2): 830-5.

Zhang, L., K. Kitaichi, et al. (2006). "Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine." *Prog Neuropsychopharmacol Biol Psychiatry* 30(8): 1381-93.

### Dosing

*See Usage Patterns and Dosing ; Usage Patterns and Dosing (animals)*

### Drinking Behavior (animals)

*See also Appetite and Feeding (animals)*

De Vito, M. J. and G. C. Wagner (1989). "Functional consequences following methamphetamine-induced neuronal damage." *Psychopharmacology (Berl)* 97(4): 432-5.

Estler, C. J. and M. C. Gabrys (1979). "Swimming capacity of mice after prolonged treatment with psychostimulants. II. Effect of methamphetamine on swimming performance and availability of metabolic substrates." *Psychopharmacology (Berl)* 60(2): 173-6.

Fischman, M. W. and C. R. Schuster (1974). "Tolerance development to chronic methamphetamine intoxication in the rhesus monkey." *Pharmacol Biochem Behav* 2(4): 503-8.

Glick, S. D., I. M. Maisonneuve, et al. (2001). "Comparative effects of dextromethorphan and dextrorphan on morphine, methamphetamine, and nicotine self-administration in rats." *Eur J Pharmacol* 422(1-3): 87-90.

Kita, T., M. Takahashi, et al. (1998). "Methamphetamine-induced changes in activity and water intake during light and dark cycles in rats." *Prog Neuropsychopharmacol Biol Psychiatry* 22(7): 1185-96.

Rietveld, W. J., J. Korving, et al. (1987). "The circadian control of behavior in the rat affected by the chronic application of methamphetamine." *Prog Clin Biol Res* 227B: 513-7.

Seiden, L. S., W. L. Woolverton, et al. (1993). "Behavioral consequences of partial monoamine depletion in the CNS after methamphetamine-like drugs: The conflict between pharmacology and toxicology." *NIDA Res Monogr* 136: 34-46; discussion 46-52.

Stolerman, I. P. and D. D'Mello G (1978). "Amphetamine-induced hypodipsia and its implications for conditioned taste aversion in rats." *Pharmacol Biochem Behav* 8(4): 333-8.

Wallach, M. B., M. Dawber, et al. (1977). "A new anorexigen assay: Stress-induced hyperphagia in rats." *Pharmacol Biochem Behav* 6(5): 529-31.

Yokel, R. A. and R. Pickens (1973). "Self-administration of optical isomers of amphetamine and methylamphetamine by rats." *J Pharmacol Exp Ther* 187(1): 27-33.

### Driving

Baskin-Sommers, A. and I. Sommers (2006). "The co-occurrence of substance use and high-risk behaviors." *J Adolesc Health* 38(5): 609-11.

Cheng, J. Y., D. T. Chan, et al. (2005). "An epidemiological study on alcohol/drugs related fatal traffic crash cases of deceased drivers in Hong Kong between 1996 and 2000." *Forensic Sci Int* 153(2-3): 196-201.

Concheiro, M., A. D. Castro, et al. (2006). "Determination of drugs of abuse and their metabolites in human plasma by liquid chromatography-mass spectrometry An application to 156 road fatalities." *J Chromatogr B Analyt Technol Biomed Life Sci*.

Couper, F. J., M. Pemberton, et al. (2002). "Prevalence of drug use in commercial tractor-trailer drivers." *J Forensic Sci* 47(3): 562-7.

Crouch, D. J., M. M. Birky, et al. (1993). "The prevalence of drugs and alcohol in fatally injured truck drivers." *J Forensic Sci* 38(6): 1342-53.

Drummer, O. H., J. Gerostamoulos, et al. (2003). "The incidence of drugs in drivers killed in Australian road traffic crashes." *Forensic Sci Int* 134(2-3): 154-62.

Forney, R. (1977). "Drug impairment reviews: Stimulants." *NIDA Res Monogr Series* 11: 73-6.

Forney, R., R. Martz, et al. (1976). "The combined effect of marijuana and dextroamphetamine." *Ann N Y Acad Sci* 281: 162-70.

Gustavsen, I., J. Morland, et al. (2006). "Impairment related to blood amphetamine and/or methamphetamine concentrations in suspected drugged drivers." *Accid Anal Prev* 38(3): 490-5.

Jones, A. W. and L. Karlsson (2005). "Relation between blood- and urine-amphetamine concentrations in impaired drivers as influenced by urinary pH and creatinine." *Hum Exp Toxicol* 24(12): 615-22.

Logan, B. K., C. L. Fligner, et al. (1998). "Cause and manner of death in fatalities involving methamphetamine." *J Forensic Sci* 43(1): 28-34.

Logan, B. K. (1996). "Methamphetamine and driving impairment." *J Forensic Sci* 41(3): 457-64.

- Moeller, M. R. and T. Kraemer (2002). "Drugs of abuse monitoring in blood for control of driving under the influence of drugs." *Ther Drug Monit* 24(2): 210-21.
- Peters, F. T., N. Samyn, et al. (2003). "Concentrations and ratios of amphetamine, methamphetamine, MDA, MDMA, and MDEA enantiomers determined in plasma samples from clinical toxicology and driving under the influence of drugs cases by GC-NICI-MS." *J Anal Toxicol* 27(8): 552-9.
- Schwilke, E. W., M. I. Sampaio dos Santos, et al. (2006). "Changing patterns of drug and alcohol use in fatally injured drivers in Washington State." *J Forensic Sci* 51(5): 1191-8.
- Sheridan, J., S. Bennett, et al. (2006). "Injury associated with methamphetamine use: A review of the literature." *Harm Reduct J* 3(1): 14.
- Silber, B. Y., R. J. Croft, et al. (2006). "The acute effects of d-amphetamine and methamphetamine on attention and psychomotor performance." *Psychopharmacology (Berl)* 187(2): 154-69.
- Silber, B. Y., K. Papafotiou, et al. (2005). "An evaluation of the sensitivity of the standardised field sobriety tests to detect the presence of amphetamine." *Psychopharmacology (Berl)*: 1-7.
- Schermer, C. R. and D. H. Wisner (1999). "Methamphetamine use in trauma patients: A population-based study." *J Am Coll Surg* 189(5): 442-9.
- Sheridan, J., S. Bennett, et al. (2006). "Injury associated with methamphetamine use: A review of the literature." *Harm Reduct J* 3(1): 14.

## Drug Courts and Court-Mandated Treatment

- Brecht, M. L., M. D. Anglin, et al. (2005). "Coerced treatment for methamphetamine abuse: Differential patient characteristics and outcomes." *Am J Drug Alcohol Abuse* 31(2): 337-56.
- Freese, T. E., J. Obert, et al. (2000). "Methamphetamine abuse: Issues for special populations." *J Psychoactive Drugs* 32(2): 177-82.
- Grella, C. E., Y. I. Hser, et al. (2006). "Mothers in substance abuse treatment: differences in characteristics based on involvement with child welfare services." *Child Abuse Negl* 30(1): 55-73.
- Joosen, M., T. F. Garrity, et al. (2005). "Predictors of current depressive symptoms in a sample of drug court participants." *Subst Use Misuse* 40(8): 1113-25.
- Stoops, W. W., M. S. Tindall, et al. (2005). "Methamphetamine use in nonurban and urban drug court clients." *Int J Offender Ther Comp Criminol* 49(3): 260-76.

## Drug Dealing

*See Methamphetamine Trafficking*

## Eating Disorders

*See also Appetite and Feeding*

- Nagata, T., J. Oshima, et al. (2003). "Repetitive self-mutilation among Japanese eating disorder patients with drug use disorder: comparison with patients with methamphetamine use disorder." *J Nerv Ment Dis* 191(5): 319-23.
- Nagata, T., Y. Kawarada, et al. (2002). "Drug use disorders in Japanese eating disorder patients." *Psychiatry Res* 109(2): 181-91.
- Pope, H. G., Jr. and J. I. Hudson (1986). "Antidepressant drug therapy for bulimia: Current status." *J Clin Psychiatry* 47(7): 339-45.
- Tolstoi, L. G. (1989). "The role of pharmacotherapy in anorexia nervosa and bulimia." *J Am Diet Assoc* 89(11): 1640-6.

## Ecstasy

*See MDMA (3, 4-methylenedioxymethamphetamine); MDMA (3, 4-methylenedioxymethamphetamine) (animals)*

## Education Level

- Atkinson, J., V. L. Brown, et al. (2004). "Personal adjustment and substance abuse problems in a longitudinal study of TANF recipients and the potential need for treatment." *Am J Drug Alcohol Abuse* 30(3): 643-57.
- Arria, A. M., C. Derauf, et al. (2006). "Methamphetamine and other substance use during pregnancy: Preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study." *Matern Child Health J* 10(3): 293-302.
- Baker, F. M. and W. F. Haning, 3rd (2001). "Substance abuse and dependence in a public hospital: Hawaii." *Hawaii Med J* 60(2): 35-8.
- Barrett, M. E. (2003). "Correlates of illicit drug use in Karen villages in Northern Thailand." *Subst Use Misuse* 38(11-13): 1615-49.
- Breen, C., L. Degenhardt, et al. (2006). "Alcohol use and risk taking among regular ecstasy users." *Subst Use Misuse* 41(8): 1095-109.

- Booth, B. M., C. Leukefeld, et al. (2006). "Correlates of rural methamphetamine and cocaine users: Results from a multistate community study." *J Stud Alcohol* 67(4): 493-501.
- Brecht, M. L., L. Greenwell, et al. (2005). "Methamphetamine treatment: Trends and predictors of retention and completion in a large state treatment system (1992-2002)." *J Subst Abuse Treat* 29(4): 295-306.
- Caetano, R. and C. Weisner (1995). "The association between DSM-III-R alcohol dependence, psychological distress and drug use." *Addiction* 90(3): 351-9.
- Cox, C. and R. G. Smart (1972). "Social and psychological aspects of speed use. A study of types of speed users in Toronto." *Int J Addict* 7(2): 201-17.
- Duterte, M., S. O'Neil, et al. (2001). "Walking the tightrope: Balancing health and drug use." *J Psychoactive Drugs* 33(2): 173-83.
- Goldsamt, L. A., J. O'Brien, et al. (2005). "The relationship between club drug use and other drug use: A survey of New York City middle school students." *Subst Use Misuse* 40(9): 1539-55.
- Kushel, M. B., J. A. Hahn, et al. (2005). "Revolving doors: Imprisonment among the homeless and marginally housed population." *Am J Public Health* 95(10): 1747-52.
- Lampinen, T. M., D. McGhee, et al. (2006). "Increased risk of "club" drug use among gay and bisexual high school students in British Columbia." *J Adolesc Health* 38(4): 458-61.
- Matsumoto, T., A. Kamijo, et al. (2002). "Methamphetamine in Japan: the consequences of methamphetamine abuse as a function of route of administration." *Addiction* 97(7): 809-17.
- Niv, N. and Y. I. Hser (2006). "Drug treatment service utilization and outcomes for Hispanic and white methamphetamine abusers." *Health Serv Res* 41(4 Pt 1): 1242-57.
- Operario, D. and T. Nemoto (2005). "Sexual risk behavior and substance use among a sample of Asian Pacific Islander transgendered women." *AIDS Educ Prev* 17(5): 430-43.
- Reiber, C., G. Galloway, et al. (2000). "A descriptive analysis of participant characteristics and patterns of substance use in the CSAT methamphetamine treatment project: The first six months." *J Psychoactive Drugs* 32(2): 183-91.
- Rimsza, M. E. and K. S. Moses (2005). "Substance abuse on the college campus." *Pediatr Clin North Am* 52(1): 307-19, xii.
- Rose, V. J., H. F. Raymond, et al. (2006). "Assessing the feasibility of harm reduction services for MSM: The late night breakfast buffet study." *Harm Reduct J* 3: 29.
- Semple, S. J., J. Zians, et al. (2005). "Impulsivity and methamphetamine use." *J Subst Abuse Treat* 29(2): 85-93.
- Semple, S. J., T. L. Patterson, et al. (2004). "A comparison of injection and non-injection methamphetamine-using HIV positive men who have sex with men." *Drug Alcohol Depend* 76(2): 203-12.
- Semple, S. J., T. L. Patterson, et al. (2003). "Binge use of methamphetamine among HIV-positive men who have sex with men: pilot data and HIV prevention implications." *AIDS Educ Prev* 15(2): 133-47.
- Senjo, S. R. (2005). "Trafficking in meth: An analysis of the differences between male and female dealers." *J Drug Educ* 35(1): 59-77.
- Viani, R. M., M. R. Araneta, et al. (2006). "Perinatal HIV counseling and rapid testing in Tijuana, Baja California, Mexico: Seroprevalence and correlates of HIV infection." *J Acquir Immune Defic Syndr* 41(1): 87-92.
- Wu, L. T., D. J. Pilowsky, et al. (2004). "Injection drug use among stimulant users in a national sample." *Am J Drug Alcohol Abuse* 30(1): 61-83.
- Yen, C. F., Y. H. Yang, et al. (2006). "Correlates of methamphetamine use for Taiwanese adolescents." *Psychiatry Clin Neurosci* 60(2): 160-7.
- Yen, C. F. and Y. P. Chang (2005). "Relapse antecedents for methamphetamine use and related factors in Taiwanese adolescents." *Psychiatry Clin Neurosci* 59(1): 77-82.
- Zule, W. A. and D. P. Desmond (1999). "An ethnographic comparison of HIV risk behaviors among heroin and methamphetamine injectors." *Am J Drug Alcohol Abuse* 25(1): 1-23.

## Electroencephalograms (EEGs)

*See Brain Electrical Activity in; Brain, Electrical Activity in (animals)*

## EI Paso, TX (US)

- Maxwell, J. C., P. Cravioto, et al. (2006). "Drug use and risk of HIV/AIDS on the Mexico-USA border: A comparison of treatment admissions in both countries." *Drug Alcohol Depend* 82 Suppl 1: S85-93.



## Emergency Care

- Anglin, M. D., C. Burke, et al. (2000). "History of the methamphetamine problem." *J Psychoactive Drugs* 32(2): 137-41.
- Anonymous (1995). "Increasing morbidity and mortality associated with abuse of methamphetamine--United States, 1991-1994." *MMWR Morb Mortal Wkly Rep* 44(47): 882-6.
- Anzalone, B., W. T. Crow, et al. (2002). "If the bubble bursts.... EMS response to aortic aneurysms & dissections." *Jems* 27(1): 84-8, 90-5; quiz 96-7.
- Batki, S. L. and D. S. Harris (2004). "Quantitative drug levels in stimulant psychosis: Relationship to symptom severity, catecholamines and hyperkinesia." *Am J Addict* 13(5): 461-70.
- Beebe, D. K. and E. Walley (1995). "Smokable methamphetamine ('ice'): An old drug in a different form." *Am Fam Physician* 51(2): 449-53.
- Burchell, S. A., H. C. Ho, et al. (2000). "Effects of methamphetamine on trauma patients: A cause of severe metabolic acidosis?" *Crit Care Med* 28(6): 2112-5.
- Cantrell, F. L., H. M. Breckenridge, et al. (2006). "Transrectal methamphetamine use: A novel route of exposure." *Ann Intern Med* 145(1): 78-9.
- Chan, P., J. H. Chen, et al. (1994). "Fatal and nonfatal methamphetamine intoxication in the intensive care unit." *J Toxicol Clin Toxicol* 32(2): 147-55.
- Charukamnoetkanok, P. and M. D. Wagoner (2004). "Facial and ocular injuries associated with methamphetamine production accidents." *Am J Ophthalmol* 138(5): 875-6.
- Danks, R. R., L. A. Wibbenmeyer, et al. (2004). "Methamphetamine-associated burn injuries: A retrospective analysis." *J Burn Care Rehabil* 25(5): 425-9.
- Delgado, J. H., M. J. Caruso, et al. (2004). "Acute, transient urinary retention from combined ecstasy and methamphetamine use." *J Emerg Med* 26(2): 173-5.
- Derlet, R. W. and B. Heischouer (1990). "Methamphetamine. Stimulant of the 1990s?" *West J Med* 153(6): 625-8.
- Farst, K., J. M. Duncan, et al. (2006). "Methamphetamine exposure presenting as caustic ingestions in children." *Ann Emerg Med*.
- Friese, G. (2006). "The methamphetamine crisis. What EMS providers need to know to stay safe and treat patients." *Emerg Med Serv* 35(3): 55-64.
- Harris, D. and S. L. Batki (2000). "Stimulant psychosis: Symptom profile and acute clinical course." *Am J Addict* 9(1): 28-37.
- Hendrickson, R. G., B. Z. Horowitz, et al. (2006). "'Parachuting' meth: A novel delivery method for methamphetamine and delayed-onset toxicity from 'body stuffing'." *Clin Toxicol (Phila)* 44(4): 379-82.
- Hirabayashi, N., K. Wada, et al. (2004). "Prevalence of substance abuse among patients with physical diseases seen in an emergency room in Japan." *Am J Addict* 13(4): 398-404.
- Hirabayashi, N. and T. Yukioka (2004). "[Prevalence of substance abuse through biological method among patients with physical diseases seen in an emergency room]." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 39(1): 46-50.
- Horton, D. K., Z. Berkowitz, et al. (2003). "Secondary contamination of ED personnel from hazardous materials events, 1995-2001." *Am J Emerg Med* 21(3): 199-204.
- Huff, C. (2006). "Crystal crush." *Hosp Health Netw* 80(10): 59-60, 62, 64.
- Hutin, Y. J., B. P. Bell, et al. (1999). "Identifying target groups for a potential vaccination program during a hepatitis A communitywide outbreak." *Am J Public Health* 89(6): 918-21.
- Imanishi, M., T. Sakai, et al. (1997). "[Cerebral infarction due to bacterial emboli associated with methamphetamine abuse]." *No To Shinkei* 49(6): 537-40.
- Inamasu, J., Y. Nakamura, et al. (2003). "Subcortical hemorrhage caused by methamphetamine abuse: Efficacy of the triage system in the differential diagnosis--case report." *Neurol Med Chir (Tokyo)* 43(2): 82-4.
- Kerr, T., E. Wood, et al. (2005). "High rates of primary care and emergency department use among injection drug users in Vancouver." *J Public Health (Oxf)* 27(1): 62-6.
- Klein, M. and F. Kramer (2004). "Rave drugs: Pharmacological considerations." *AANA J* 72(1): 61-7.
- Kolecki, P. (1998). "Inadvertent methamphetamine poisoning in pediatric patients." *Pediatr Emerg Care* 14(6): 385-7.
- Kohrs, F. P., C. Mann and R. Greenberg (2004). "The use of amphetamine in gamma-hydroxybutyrate overdose: A case report." *J Psychoactive Drugs* 36(3): 401-2.
- Leamon, M. H., D. R. Gibson, R. D. Canning and L. Benjamin (2002). "Hospitalization of patients with cocaine and amphetamine use disorders from a psychiatric emergency service." *Psychiatr Serv* 53(11): 1461-6.
- Lee, J. H., C. L. Farley, et al. (2003). "Anhydrous ammonia eye injuries associated with illicit methamphetamine production." *Ann Emerg Med* 41(1): 157.

- Lineberry, T. W. and J. M. Bostwick (2006). "Methamphetamine abuse: A perfect storm of complications." *Mayo Clin Proc* 81(1): 77-84.
- Mecham, N. and J. Melini (2002). "Unintentional victims: Development of a protocol for the care of children exposed to chemicals at methamphetamine laboratories." *Pediatr Emerg Care* 18(4): 327-32.
- Miller, M. A. and T. P. Coon (2006). "Re: Delayed ischemic stroke associated with methamphetamine use." *J Emerg Med* 31(3): 305-6; author reply 306.
- Mitka, M. (2005). "Meth lab fires put heat on burn centers." *JAMA* 294(16): 2009-10.
- Nagorka, A. R. and P. S. Bergeson (1998). "Infant methamphetamine toxicity posing as scorpion envenomation." *Pediatr Emerg Care* 14(5): 350-1.
- Nakano, Y., K. Kaneko, et al. (2003). "A patient with self-inflicted injuries of the cervical vertebrae and spinal cord." *Arch Orthop Trauma Surg* 123(7): 379-81.
- Parry, C. D., A. Pluddemann, et al. (2005). "Cannabis and other drug use among trauma patients in three South African cities, 1999-2001." *S Afr Med J* 95(6): 429-32.
- Penn, C. L. (2006). "Meth abuse in Arkansas." *J Ark Med Soc* 102(8): 218-9.
- Pittman, H. J. (2005). "Methamphetamine overdose." *Nursing* 35(4): 88.
- Prosser, J. M., M. Naim, et al. (2006). "A 14-year-old girl with agitation and hyperthermia." *Pediatr Emerg Care* 22(9): 676-9.
- Richards, J. R. (2000). "Rhabdomyolysis and drugs of abuse." *J Emerg Med* 19(1): 51-6.
- Richards, J. R., S. W. Bretz, et al. (1999). "Methamphetamine abuse and emergency department utilization." *West J Med* 170(4): 198-202.
- Richards, J. R., E. B. Johnson, et al. (1999). "Methamphetamine abuse and rhabdomyolysis in the ED: A 5-year study." *Am J Emerg Med* 17(7): 681-5.
- Richards, J. R., R. W. Derlet, et al. (1997). "Methamphetamine toxicity: Treatment with a benzodiazepine versus a butyrophenone." *Eur J Emerg Med* 4(3): 130-5.
- Rockett, I. R., S. L. Putnam, et al. (2006). "Declared and undeclared substance use among emergency department patients: A population-based study." *Addiction* 101(5): 706-712.
- Ruha, A. M. and M. C. Yarema (2006). "Pharmacologic treatment of acute pediatric methamphetamine toxicity." *Pediatr Emerg Care* 22(12): 782-5.
- Rusyniak, D. E. and J. E. Sprague (2005). "Toxin-induced hyperthermic syndromes." *Med Clin North Am* 89(6): 1277-96.
- Santos, A. P., A. K. Wilson, et al. (2005). "Methamphetamine laboratory explosions: A new and emerging burn injury." *J Burn Care Rehabil* 26(3): 228-32.
- Sheridan, J., S. Bennett, et al. (2006). "Injury associated with methamphetamine use: A review of the literature." *Harm Reduct J* 3(1): 14.
- Spann, M. D., G. McGwin, Jr., et al. (2006). "Characteristics of burn patients injured in methamphetamine laboratory explosions." *J Burn Care Res* 27(4): 496-501.
- Swenson, J. R., J. E. Dimsdale, E. Rockwell, W. Carroll and J. Hansbrough (1991). "Drug and alcohol abuse in patients with acute burn injuries." *Psychosomatics* 32(3): 287-93.
- Szuster, R. R. (1990). "Methamphetamine in psychiatric emergencies." *Hawaii Med J* 49(10): 389-91.
- Tominaga, G. T., G. Garcia, et al. (2004). "Toll of methamphetamine on the trauma system." *Arch Surg* 139(8): 844-7.
- Turnipseed, S. D., J. R. Richards, et al. (2003). "Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after methamphetamine use." *J Emerg Med* 24(4): 369-73.
- Wada, K., S. B. Greberman, et al. (1999). "HIV and HCV infection among drug users in Japan." *Addiction* 94(7): 1063-9.
- Warner, P., J. P. Connolly, et al. (2003). "The methamphetamine burn patient." *J Burn Care Rehabil* 24(5): 275-8.
- Watts, D. J. and L. McCollester (2006). "Methamphetamine-induced myocardial infarction with elevated troponin I." *Am J Emerg Med* 24(1): 132-4.
- Weinbroum, A. A. (2003). "Importance of early identification of methylenedioxymethamphetamine ('ecstasy') ingestion in victims of motor vehicle accidents." *Eur J Emerg Med* 10(1): 19-22.

## Epidemiology

See [Aging and Age Factors](#); [Prevalence of Methamphetamine Use](#); [Race and Ethnicity](#); [Sex Differences](#); [Socioeconomic Factors](#); and [specific populations, continents, countries, states and cities](#)

## Epinephrine (animals)

Fischer, E., J. M. Saavedra, et al. (1968). "Effects of catecholamines, adrenergic substances and their blocking agents on the searching behavior of mice." *Arzneimittelforschung* 18(7): 780-6.

## Erectile Dysfunction Drugs

- Brewer, D. D., M. R. Golden, et al. (2006). "Unsafe sexual behavior and correlates of risk in a probability sample of men who have sex with men in the era of highly active antiretroviral therapy." *Sex Transm Dis* 33(4): 250-5.
- Chu, P. L., W. McFarland, et al. (2003). "Viagra use in a community-recruited sample of men who have sex with men, San Francisco." *J Acquir Immune Defic Syndr* 33(2): 191-3.
- Colfax, G. N., G. Mansergh, et al. (2001). "Drug use and sexual risk behavior among gay and bisexual men who attend circuit parties: A venue-based comparison." *J Acquir Immune Defic Syndr* 28(4): 373-9.
- Drumright, L. N., S. J. Little, et al. (2006). "Unprotected anal intercourse and substance use among men who have sex with men with recent HIV infection." *J Acquir Immune Defic Syndr* 43(3): 344-50.
- Drumright, L. N., S. A. Strathdee, et al. (2006). "Unprotected anal intercourse and substance use before and after HIV diagnosis among recently HIV-infected men who have sex with men." *Sex Transm Dis*.
- Fernandez, M. I., T. Perrino, et al. (2005). "Surfing new territory: club-drug use and risky sex among Hispanic men who have sex with men recruited on the Internet." *J Urban Health* 82(1 Suppl 1): i79-88.
- Herman-Stahl, M. A., C. P. Krebs, et al. (2006). "Risk and protective factors for methamphetamine use and nonmedical use of prescription stimulants among young adults aged 18 to 25." *Addict Behav*.
- Hirshfield, S., R. H. Remien, et al. (2004). "Crystal methamphetamine use predicts incident STD infection among men who have sex with men recruited online: A nested case-control study." *J Med Internet Res* 6(4): e41.
- Hirshfield, S., R. H. Remien, et al. (2004). "Substance use and high-risk sex among men who have sex with men: a national online study in the USA." *AIDS Care* 16(8): 1036-47.
- Kim, A. A., C. K. Kent, et al. (2002). "Increased risk of HIV and sexually transmitted disease transmission among gay or bisexual men who use Viagra, San Francisco 2000-2001." *AIDS* 16(10): 1425-8.
- Klausner, J. D., C. K. Kent, et al. (2005). "The public health response to epidemic syphilis, San Francisco, 1999-2004." *Sex Transm Dis* 32(10 Suppl): S11-8.
- Mansergh, G., R. L. Shouse, et al. (2006). "Methamphetamine and sildenafil (Viagra) use are linked to unprotected receptive and insertive anal sex, respectively, in a sample of men who have sex with men." *Sex Transm Infect* 82(2): 131-4.
- Mansergh, G., G. N. Colfax, et al. (2001). "The Circuit Party Men's Health Survey: Findings and implications for gay and bisexual men." *Am J Public Health* 91(6): 953-8.
- Purcell, D. W., R. J. Wolitski, et al. (2005). "Predictors of the use of viagra, testosterone, and antidepressants among HIV-seropositive gay and bisexual men." *AIDS* 19 Suppl 1: S57-66.
- Romanelli, F. and K. M. Smith (2004). "Recreational use of sildenafil by HIV-positive and -negative homosexual/bisexual males." *Ann Pharmacother* 38(6): 1024-30.
- Swearingen, S. G. and J. D. Klausner (2005). "Sildenafil use, sexual risk behavior, and risk for sexually transmitted diseases, including HIV infection." *Am J Med* 118(6): 571-7.
- Wong, W., J. K. Chaw, et al. (2005). "Risk factors for early syphilis among gay and bisexual men seen in an STD clinic: San Francisco, 2002-2003." *Sex Transm Dis* 32(7): 458-63.

## Estonia

Lagerspetz, M. and J. Moskalewicz (2002). "Drugs in the postsocialist transitions of Estonia, Latvia, Lithuania and Poland." *Eur Addict Res* 8(4): 177-83.

## Estrogen

Turchan, J., C. Anderson, et al. (2001). "Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine." *BMC Neurosci* 2: 3.

### Estrogen (animals)

- Anderson, L. I., R. E. Leipheimer, et al. (2005). "Effects of neonatal and prepubertal hormonal manipulations upon estrogen neuroprotection of the nigrostriatal dopaminergic system within female and male mice." *Neuroscience* 130(2): 369-82.
- Bae, S. C., I. K. Lyoo, et al. (2006). "Increased white matter hyperintensities in male methamphetamine abusers." *Drug Alcohol Depend* 81(1): 83-8.
- Bisagno, V., R. Bowman, et al. (2003). "Functional aspects of estrogen neuroprotection." *Endocrine* 21(1): 33-41.
- Chen, H. H., Y. K. Yang, et al. (2003). "Methamphetamine-induced conditioned place preference is facilitated by estradiol pretreatment in female mice." *Chin J Physiol* 46(4): 169-74.
- D'Astous, M., K. R. Mickley, et al. (2005). "Differential protective properties of estradiol and tamoxifen against methamphetamine-induced nigrostriatal dopaminergic toxicity in mice." *Neuroendocrinology* 82(2): 111-20.
- D'Astous, M., T. M. Gajjar, et al. (2004). "Dopamine transporter as a marker of neuroprotection in methamphetamine-lesioned mice treated acutely with estradiol." *Neuroendocrinology* 79(6): 296-304.
- Dluzen, D. E. and J. L. McDermott (2006). "Estrogen, testosterone, and methamphetamine toxicity." *Ann N Y Acad Sci* 1074: 282-94.
- Dluzen, D. E. and T. J. Salvaterra (2006). "Sex differences in methamphetamine-evoked striatal dopamine output are abolished following gonadectomy: Comparisons with potassium-evoked output and responses in prepubertal mice." *Neuroendocrinology* 82(2): 78-86.
- Dluzen, D. E. and K. R. Mickley (2005). "Gender differences in modulatory effects of tamoxifen upon the nigrostriatal dopaminergic system." *Pharmacol Biochem Behav* 80(1): 27-33.
- Dluzen, D. E. and J. L. McDermott (2004). "Developmental and genetic influences upon gender differences in methamphetamine-induced nigrostriatal dopaminergic neurotoxicity." *Ann N Y Acad Sci* 1025: 205-20.
- Dluzen, D. E. and J. L. McDermott (2002). "Estrogen, anti-estrogen, and gender: differences in methamphetamine neurotoxicity." *Ann N Y Acad Sci* 965: 136-56.
- Dluzen, D. E., J. L. McDermott, et al. (2001). "Tamoxifen diminishes methamphetamine-induced striatal dopamine depletion in intact female and male mice." *J Neuroendocrinol* 13(7): 618-24.
- Dluzen, D. E. (2000). "Neuroprotective effects of estrogen upon the nigrostriatal dopaminergic system." *J Neurocytol* 29(5-6): 387-99.
- Liu, B. and D. E. Dluzen (2006). "Effects of estrogen and related agents upon methamphetamine-induced neurotoxicity within an impaired nigrostriatal dopaminergic system of ovariectomized mice." *Neuroendocrinology* 83(5-6): 295-302.
- Liu, B. and D. E. Dluzen (2006). "Effect of estrogen upon methamphetamine-induced neurotoxicity within the impaired nigrostriatal dopaminergic system." *Synapse* 60(5): 354-61.
- Mickley, K. R. and D. E. Dluzen (2004). "Dose-response effects of estrogen and tamoxifen upon methamphetamine-induced behavioral responses and neurotoxicity of the nigrostriatal dopaminergic system in female mice." *Neuroendocrinology* 79(6): 305-16.
- Miller, D. B., S. F. Ali, et al. (1998). "The impact of gender and estrogen on striatal dopaminergic neurotoxicity." *Ann N Y Acad Sci* 844: 153-65.
- Slamberova, R. (2005). "Flurothyl seizures susceptibility is increased in prenatally methamphetamine-exposed adult male and female rats." *Epilepsy Res* 65(1-2): 121-4.
- Yu, L., Y. Kuo, et al. (2002). "Ovarian hormones do not attenuate methamphetamine-induced dopaminergic neurotoxicity in mice gonadectomized at 4 weeks postpartum." *Neuroendocrinology* 75(5): 282-7.
- Yu, L. and P. C. Liao (2000). "Sexual differences and estrous cycle in methamphetamine-induced dopamine and serotonin depletions in the striatum of mice." *J Neural Transm* 107(4): 419-27.
- Yu, L. and P. C. Liao (2000). "Estrogen and progesterone distinctively modulate methamphetamine-induced dopamine and serotonin depletions in C57BL/6J mice." *J Neural Transm* 107(10): 1139-47.
- Yu, Y. L. and G. C. Wagner (1994). "Influence of gonadal hormones on sexual differences in sensitivity to methamphetamine-induced neurotoxicity." *J Neural Transm Park Dis Dement Sect* 8(3): 215-21.

### Ethanol

*See Alcohol; Alcohol (animals)*

### Ethnography

- Austin, A. A. (2004). "Alcohol, tobacco, other drug use, and violent behavior among Native Hawaiians: Ethnic pride and resilience." *Subst Use Misuse* 39(5): 721-46.
- Barrett, M. E. (2003). "Correlates of illicit drug use in Karen villages in Northern Thailand." *Subst Use Misuse* 38(11-13): 1615-49.

- Bungay, V., L. Malchy, et al. (2006). "Life with jib: A snapshot of street youth's use of crystal methamphetamine." *Addiction Research and Theory* 14(3): 235-251.
- Clatts, M. C., D. L. Welle, et al. (2001). "Reconceptualizing the interaction of drug and sexual risk among MSM speed users: Notes toward an ethno-epidemiology." *AIDS and Behavior* 5(2): 115-130.
- Cox, C. and R. G. Smart (1972). "Social and psychological aspects of speed use. A study of types of speed users in Toronto." *Int J Addict* 7(2): 201-17.
- Cruz, M. F., A. Mantsios, et al. (2006). "A qualitative exploration of gender in the context of injection drug use in two US-Mexico border cities." *AIDS Behav.*
- Davis, F. and L. Munoz (1968). "Heads and freaks: Patterns and meanings of drug use among hippies." *J Health Soc Behav* 9(2): 156-64.
- Gorman, E. M. and R. T. Carroll (2000). "Substance abuse and HIV: Considerations with regard to methamphetamines and other recreational drugs for nursing practice and research." *J Assoc Nurses AIDS Care* 11(2): 51-62.
- Gorman, E. M., B. D. Barr, A. Hansen, B. Robertson and C. Green (1997). "Speed, sex, gay men, and HIV: Ecological and community perspectives." *Med Anthropol Q* 11(4): 505-15.
- Gorman, E. M., P. Morgan, et al. (1995). "Qualitative research considerations and other issues in the study of methamphetamine use among men who have sex with other men." *NIDA Res Monogr* 157: 156-81.
- Greberman, S. B. and K. Wada (1994). "Social and legal factors related to drug abuse in the United States and Japan." *Public Health Rep* 109(6): 731-7.
- Green, A. I. and P. N. Halkitis (2006). "Crystal methamphetamine and sexual sociality in an urban gay subculture: An elective affinity." *Cult Health Sex* 8(4): 317-33.
- Lyons, T., G. Chandra, et al. (2006). "Stimulant use and HIV risk behavior: The influence of peer support group participation." *AIDS Educ Prev* 18(5): 461-73.
- McCaughan, J. A., R. G. Carlson, et al. (2005). "From "Candy Kids" to "Chemi-Kids": A typology of young adults who attend raves in the midwestern United States." *Subst Use Misuse* 40(9-10): 1503-23.
- Robinson, L. and H. Rempel (2006). "Methamphetamine use and HIV symptom self-management." *J Assoc Nurses AIDS Care* 17(5): 7-14.
- Sexton, R. L., R. G. Carlson, et al. (2005). "Barriers and pathways to diffusion of methamphetamine use among African Americans in the rural South: Preliminary ethnographic findings." *J Ethn Subst Abuse* 4(1): 77-103.
- Siegal, H. A., P. J. Draus, et al. (2006). "Perspectives on health among adult users of illicit stimulant drugs in rural Ohio." *J Rural Health* 22(2): 169-73.
- Soellner, R. (2005). "Club drug use in Germany." *Subst Use Misuse* 40(9-10): 1279-93.
- Sommers, I., D. Baskin, et al. (2006). "Methamphetamine use among young adults: Health and social consequences." *Addict Behav* 31(8): 1469-76.
- Storr, C. L., A. M. Arria, et al. (2004). "Neighborhood environment and opportunity to try methamphetamine ("ice") and marijuana: Evidence from Guam in the Western Pacific region of Micronesia." *Subst Use Misuse* 39(2): 253-76.
- von Mayrhauser, C., M. L. Brecht and M. D. Anglin (2002). "Use ecology and drug use motivations of methamphetamine users admitted to substance abuse treatment facilities in Los Angeles: An emerging profile." *J Addict Dis* 21(1): 45-60.
- Zule, W. A. and D. P. Desmond (1999). "An ethnographic comparison of HIV risk behaviors among heroin and methamphetamine injectors." *Am J Drug Alcohol Abuse* 25(1): 1-23.

## Europe

- Berankova, K., V. Habrdova, et al. (2005). "Methamphetamine in hair and interpretation of forensic findings in a fatal case." *Forensic Sci Int* 153(1): 93-7.
- Bingham, C., M. Beaman, et al. (1998). "Necrotizing renal vasculopathy resulting in chronic renal failure after ingestion of methamphetamine and 3,4-methylenedioxymethamphetamine ('ecstasy')." *Nephrol Dial Transplant* 13(10): 2654-5.
- Bobkov, A. F., L. M. Selimova, et al. (2005). "Human immunodeficiency virus type 1 in illicit-drug solutions used intravenously retains infectivity." *J Clin Microbiol* 43(4): 1937-9.
- Bolding, G., G. Hart, et al. (2006). "Use of crystal methamphetamine among gay men in London." *Addiction* 101(11): 1622-30.
- Christophersen, A. S. (2000). "Amphetamine designer drugs - An overview and epidemiology." *Toxicol Lett* 112-113: 127-31.
- Cole, J. C., H. R. Sumnall, et al. (2005). "Preliminary evidence of the cardiovascular effects of polysubstance misuse in nightclubs." *J Psychopharmacol* 19(1): 67-70.
- Csemy, L., L. Kubicka, et al. (2002). "Drug scene in the Czech Republic and Slovakia during the period of transformation." *Eur Addict Res* 8(4): 159-65.
- Delbeke, F. T. (1996). "Doping in cyclism: Results of unannounced controls in Flanders (1987-1994)." *Int J Sports Med* 17(6): 434-8.

- Grinde, B., K. Stene-Johansen, et al. (1997). "Characterisation of an epidemic of hepatitis A virus involving intravenous drug abusers--infection by needle sharing?" *J Med Virol* 53(1): 69-75.
- Gustavsen, I., J. Morland, et al. (2005). "Impairment related to blood amphetamine and/or methamphetamine concentrations in suspected drugged drivers." *Accid Anal Prev*.
- Hartel-Petri, R., R. Rodler, et al. (2005). "[Increasing prevalence of amphetamine--and methamphetamine-induced psychosis]." *Psychiatr Prax* 32(1): 13-7.
- Hawks, D., M. Mitcheson, et al. (1969). "Abuse of methylamphetamine." *Br Med J* 2(5659): 715-21.
- Jimenez-Caballero, P. E. (2006). "[Medullary infarct due to methamphetamine]." *Rev Neurol* 42(10): 635-7.
- Johansen, S. S., A. C. Hansen, et al. (2003). "Three fatal cases of PMA and PMMA poisoning in Denmark." *J Anal Toxicol* 27(4): 253-6.
- Jones, A. W. and L. Karlsson (2005). "Relation between blood- and urine-amphetamine concentrations in impaired drivers as influenced by urinary pH and creatinine." *Hum Exp Toxicol* 24(12): 615-22.
- Jonsson, J., R. Kronstrand, et al. (1996). "A convenient derivatization method for the determination of amphetamine and related drugs in urine." *J Forensic Sci* 41(1): 148-51.
- Kahraman, A., M. Miller, et al. (2006). "Non-alcoholic fatty liver disease in HIV-positive patients predisposes for acute-on-chronic liver failure: Two cases." *Eur J Gastroenterol Hepatol* 18(1): 101-105.
- Lagerspetz, M. and J. Moskalewicz (2002). "Drugs in the postsocialist transitions of Estonia, Latvia, Lithuania and Poland." *Eur Addict Res* 8(4): 177-83.
- Lambrechts, M. and K. E. Rasmussen (1984). "Leuckart-specific impurities in amphetamine and methamphetamine seized in Norway." *Bull Narc* 36(1): 47-57.
- Leino, T., P. Leinikki, et al. (1997). "Hepatitis A outbreak amongst intravenous amphetamine abusers in Finland." *Scand J Infect Dis* 29(3): 213-6.
- March, J. C., E. Oviedo-Joekes, et al. (2006). "Drugs and social exclusion in ten European cities." *Eur Addict Res* 12(1): 33-41.
- Meyer, U. (2005). "[Fritz Hauschild (1908-1974) and drug research in the 'German Democratic Republic' (GDR)]." *Pharmazie* 60(6): 468-72.
- Moeller, M. R. and T. Kraemer (2002). "Drugs of abuse monitoring in blood for control of driving under the influence of drugs." *Ther Drug Monit* 24(2): 210-21.
- Mravcik, V., H. Sebakova, et al. (2000). "[Seroprevalence of viral hepatitis A, B and C in intravenous drug users]." *Epidemiol Mikrobiol Imunol* 49(1): 19-23.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.
- Popov, P. (1996). "[Stimulants and addiction]." *Ceska Slov Psychiatr* 92 Suppl 1: 70-2.
- Raikos, N., H. Tsoukali, et al. (2002). "Amphetamine derivative related deaths in northern Greece." *Forensic Sci Int* 128(1-2): 31-4.
- Romhild, W., D. Krause, et al. (2003). "LC-MS/MS analysis of pholedrine in a fatal intoxication case." *Forensic Sci Int* 133(1-2): 101-6.
- Royo-Isach, J., M. Magrane, et al. (2004). "[Speed users (metamphetamines): a return journey between ecstasy (MDMA) and cocaine. Clinical, preventive and health-care questions]." *Aten Primaria* 34(10): 553-6.
- Sery, O., V. Vojtova, et al. (2001). "The association study of DRD2, ACE and AGT gene polymorphisms and metamphetamine dependence." *Physiol Res* 50(1): 43-50.
- Smirnov, A. V. (1990). "[Psychomotor stimulants as agents for enhancing work capacity]." *Farmakol Toksikol* 53(4): 72-7.
- Soellner, R. (2005). "Club drug use in Germany." *Subst Use Misuse* 40(9): 1279-93.
- Toupalik, P., H. Vanerkova, et al. (2002). "[Morphologic findings in chronic abuse of heroin and pervitine]." *Soud Lek* 47(1): 5-11.
- Uitermark, J. and P. D. A. Cohen (2006). "Amphetamine users in Amsterdam: Patterns of use and modes of self-regulation." *Addiction Research & Theory* 14(2): 159-188.
- Uitermark, J. and P. Cohen (2004). Amphetamine users in Amsterdam: Patterns of use and modes of self-regulation, Centrum voor drugsonderzoek.

### Exploratory Behaviors (animals)

*See also* Avoidance Behaviors (animals)

- Arakawa, O. (1994). "Effects of methamphetamine and methylphenidate on single and paired rat open-field behaviors." *Physiol Behav* 55(3): 441-6.
- Balsara, J. J., N. V. Nandal, et al. (1982). "Experimental evaluation of the antidepressant and neuroleptic activity of maprotiline." *Indian J Physiol Pharmacol* 26(3): 183-95.

- Balsara, J. J. and A. G. Chandorkar (1978). "Experimental evaluation of the possible neuroleptic activity of clomipramine." *Indian J Physiol Pharmacol* 22(3): 263-9.
- Baumann, M. H., J. M. Phillips, et al. (2002). "Preclinical evaluation of GBR12909 decanoate as a long-acting medication for methamphetamine dependence." *Ann N Y Acad Sci* 965: 92-108.
- Belcher, A. M., S. J. O'Dell, et al. (2006). "A sensitizing regimen of methamphetamine causes impairments in a novelty preference task of object recognition." *Behav Brain Res* 170(1): 167-72.
- Berlyne, D. E., I. D. Koenig, et al. (1966). "Novelty, arousal, and the reinforcement of diversive exploration in the rat." *J Comp Physiol Psychol* 62(2): 222-6.
- Bevins, R. A. and J. L. Peterson (2004). "Individual differences in rats' reactivity to novelty and the unconditioned and conditioned locomotor effects of methamphetamine." *Pharmacol Biochem Behav* 79(1): 65-74.
- Bisagno, V., D. Ferguson, et al. (2002). "Short toxic methamphetamine schedule impairs object recognition task in male rats." *Brain Res* 940(1-2): 95-101.
- Cheng, J. T. (1986). "Effect of skimmianine on animal behavior." *Arch Int Pharmacodyn Ther* 281(1): 35-43.
- Comings, D. E. and K. Blum (2000). "Reward deficiency syndrome: Genetic aspects of behavioral disorders." *Prog Brain Res* 126: 325-41.
- Consroe, P. F., B. C. Jones, et al. (1975). "Delta9-tetrahydrocannabinol methamphetamine interaction in the rabbit." *Neuropharmacology* 14(5-6): 377-83.
- Ellinwood, E. H., Jr. (1971). "Effect of chronic methamphetamine intoxication in Rhesus monkeys." *Biol Psychiatry* 3(1): 25-32.
- Fischer, E., J. M. Saavedra, et al. (1968). "Effects of catecholamines, adrenergic substances and their blocking agents on the searching behavior of mice." *Arzneimittelforschung* 18(7): 780-6.
- Fukuzako, H., I. Nagatomo, et al. (1988). "Alterations of accumbens neuronal activity in freely moving rats following methamphetamine." *Jpn J Psychiatry Neurol* 42(2): 331-5.
- He, J., Y. Yang, et al. (2006). "The effects of chronic administration of quetiapine on the methamphetamine-induced recognition memory impairment and dopaminergic terminal deficit in rats." *Behav Brain Res* 172(1): 39-45.
- Hughes, R. N. and A. M. Greig (1976). "Effects of caffeine, methamphetamine and methylphenidate on reactions to novelty and activity in rats." *Neuropharmacology* 15(11): 673-6.
- Ibuka, N. (1972). "[Effects of methamphetamine on visual exploratory behavior and spontaneous motor activity of rhesus monkeys in bar-pressing]." *Shinrigaku Kenkyu* 43(5): 277-82.
- Ihara, Y., M. Sato, et al. (1986). "Morphological changes in rat striatal boutons after chronic methamphetamine and haloperidol treatment." *Neurosci Res* 3(5): 403-10.
- Ito, H. and S. Takaori (1968). "Effects of psychotropic agents on the exploratory behavior of rats in a Y-shaped box." *Jpn J Pharmacol* 18(3): 344-52.
- Ito, Y., K. Takuma, et al. (2006). "A novel azaindolinone derivative ZSET1446, spiro[imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one, improves methamphetamine-induced impairment of recognition memory in mice by activating extracellular signal-regulated kinase 1/2." *J Pharmacol Exp Ther*.
- Kamei, H., T. Nagai, et al. (2006). "Repeated methamphetamine treatment impairs recognition memory through a failure of novelty-induced ERK1/2 activation in the prefrontal cortex of mice." *Biol Psychiatry* 59(1): 75-84.
- Kirkby, R. J., D. S. Bell, et al. (1972). "The effects of methylamphetamine on stereotyped behaviour, activity, startle, and orienting responses." *Psychopharmacologia* 25(1): 41-8.
- Kliethermes, C. L., H. M. Kamens, et al. (2006). "Drug reward and intake in lines of mice selectively bred for divergent exploration of a hole board apparatus." *Genes Brain Behav*.
- Kliethermes, C. L. and J. C. Crabbe (2006). "Pharmacological and genetic influences on hole-board behaviors in mice." *Pharmacol Biochem Behav* 85(1): 57-65.
- Masuda, Y., Y. Matsuda, et al. (1996). "A quantity of stereotyped behavior of ddY mice induced by low-dose methamphetamine." *Exp Anim* 45(3): 279-81.
- Misslin, R., P. Ropartz, et al. (1984). "Impairment of responses to novelty by apomorphine and its antagonism by neuroleptics in mice." *Psychopharmacology (Berl)* 82(1-2): 113-7.
- Misslin, R. and P. Ropartz (1981). "Effects of methamphetamine on novelty-seeking behaviour by mice." *Psychopharmacology (Berl)* 75(1): 39-43.
- Morita, T., R. Sonoda, et al. (2000). "Phencyclidine-induced abnormal behaviors in rats as measured by the hole board apparatus." *Psychopharmacology (Berl)* 148(3): 281-8.
- Nakagawa, M., M. Ohgoh, et al. (2004). "Dopaminergic agonists and muscarinic antagonists improve lateralization in hemiparkinsonian rats in a novel exploratory Y-maze." *J Pharmacol Exp Ther* 309(2): 737-44.

- Nakama, M., T. Ochiai, et al. (1972). "Effects of psychotropic drugs on emotional behavior: Exploratory behavior of naive rats in holed open field." *Jpn J Pharmacol* 22(6): 767-75.
- Nakamura, K. and Y. Ozawa (1981). "[A metrical analysis of exploratory behavior in mice: effects of methamphetamine and diazepam (author's transl)]." *Nippon Yakurigaku Zasshi* 78(1): 1-8.
- Narita, M., K. Aoki, et al. (2003). "Implication of brain-derived neurotrophic factor in the release of dopamine and dopamine-related behaviors induced by methamphetamine." *Neuroscience* 119(3): 767-75.
- Nishikawa, T. and M. Tanaka (1978). "Altered behavioral responses to intense foot shock in socially-isolated rats." *Pharmacol Biochem Behav* 8(1): 61-7.
- Ozawa, K., K. Hashimoto, et al. (2006). "Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: A neurodevelopmental animal model of schizophrenia." *Biol Psychiatry* 59(6): 546-54.
- Richardson, D., A. G. Karczmar, et al. (1972). "Intergeneric behavioral differences among methamphetamine treated mice." *Psychopharmacologia* 25(4): 347-75.
- Rosenzweig, M. R. and E. L. Bennett (1972). "Cerebral changes in rats exposed individually to an enriched environment." *J Comp Physiol Psychol* 80(2): 304-13.
- Saavedra, J. M. and E. Fischer (1970). "Antagonism of beta-phenylethylamine derivatives and serotonin blocking drugs upon serotonin, tryptamine and reserpine behavioral depression in mice." *Arzneimittelforschung* 20(7): 952-7.
- Szumliński, K. K., K. D. Lominac, et al. (2005). "Behavioral and neurochemical phenotyping of Homer1 mutant mice: possible relevance to schizophrenia." *Genes Brain Behav* 4(5): 273-88.
- Takeda, Y., Y. Takano, et al. (1986). "Effects of cholecystokinin tetra and octa peptides on locomotor activity in mice." *Jpn J Pharmacol* 42(1): 145-9.
- Tobe, A., M. Egawa, et al. (1983). "Effect of 4-(o-benzylphenoxy)-N-methylbutylamine hydrochloride (MCI-2016) on the scopolamine-induced deficit of spontaneous alternation behavior in rats." *Jpn J Pharmacol* 33(4): 775-84.
- Tobe, A. and T. Kobayashi (1976). "Pharmacological studies on triazine derivatives V Sedative and neuroleptic actions of 2-amino-4-[4-(2-hydroxyethyl)-piperazin-1-yl]-6-trifluoromethyl-s-triazine (TR-10)." *Jpn J Pharmacol* 26(5): 559-70.
- Ushijima, I., K. Yamada, et al. (1984). "Progressive augmentation of locomotor activity in mice by long-term treatment with thyrotropin releasing hormone." *Arch Int Pharmacodyn Ther* 270(1): 29-37.
- Will, B. E., M. R. Rosenzweig, et al. (1977). "Relatively brief environmental enrichment aids recovery of learning capacity and alters brain measures after postweaning brain lesions in rats." *J Comp Physiol Psychol* 91(1): 33-50.
- Wolthuis, O. L., B. Groen, et al. (1994). "A simple automated test to measure exploratory and motor activity of marmosets." *Pharmacol Biochem Behav* 47(4): 879-81.
- Yamada, K. and T. Furukawa (1980). "Behavior of rats and mice administered active metabolites of fluphenazine, 7-hydroxy-fluphenazine and fluphenazine-sulfoxide." *Arch Int Pharmacodyn Ther* 248(1): 76-85.

### Eye Conditions and Injuries

- Charukamnoetkanok, P. and M. D. Wagoner (2004). "Facial and ocular injuries associated with methamphetamine production accidents." *Am J Ophthalmol* 138(5): 875-6.
- Chuck, R. S., J. M. Williams, M. A. Goldberg and A. J. Lubniewski (1996). "Recurrent corneal ulcerations associated with smokeable methamphetamine abuse." *Am J Ophthalmol* 121(5): 571-2.
- Firth, A. Y. (2006). "Ocular effects of criminal drug use." *Can J Ophthalmol* 41(2): 140-6.
- Gospe, S. M., Jr. (1995). "Transient cortical blindness in an infant exposed to methamphetamine." *Ann Emerg Med* 26(3): 380-2.
- Isaak, B. L. and T. J. Liesegang (1983). "Conjunctival and episcleral injection in drug abuse." *Ann Ophthalmol* 15(9): 806-7.
- Kojima, T., E. Matsushima, et al. (1990). "Eye movements in acute, chronic, and remitted schizophrenics." *Biol Psychiatry* 27(9): 975-89.
- Kojima, T., E. Matsushima, et al. (1986). "Visual perception process in amphetamine psychosis and schizophrenia." *Psychopharmacol Bull* 22(3): 768-73.
- Kumar, R. L., P. K. Kaiser, et al. (2006). "Crystalline retinopathy from nasal ingestion of methamphetamine." *Retina* 26(7): 823-4.
- Lee, J. H., C. L. Farley, et al. (2003). "Anhydrous ammonia eye injuries associated with illicit methamphetamine production." *Ann Emerg Med* 41(1): 157.
- McLane, N. J. and D. M. Carroll (1986). "Ocular manifestations of drug abuse." *Surv Ophthalmol* 30(5): 298-313.
- Peczon, J. D. and W. M. Grant (1964). "Sedatives, stimulants, and intraocular pressure in glaucoma." *Arch Ophthalmol* 72: 178-88.
- Poulsen, E. J., M. J. Mannis, et al. (1996). "Keratitis in methamphetamine abusers." *Cornea* 15(5): 477-82.



- Wallace, R. T., G. C. Brown, et al. (1992). "Sudden retinal manifestations of intranasal cocaine and methamphetamine abuse." *Am J Ophthalmol* 114(2): 158-60.
- Wilmarth, S. S., D. R. May, et al. (1983). "Aspergillus endophthalmitis in an intravenous drug user." *Ann Ophthalmol* 15(5): 470-2, 74-6.
- Zeiter, J. H., D. M. Corder, et al. (1992). "Sudden retinal manifestations of intranasal cocaine and methamphetamine abuse." *Am J Ophthalmol* 114(6): 780-1.

## Eye Conditions and Injuries (animals)

- Andretic, R., B. van Swinderen, et al. (2005). "Dopaminergic modulation of arousal in *Drosophila*." *Curr Biol* 15(13): 1165-75.
- Melo, P., V. Z. Moreno, et al. (2006). "Myelination changes in the rat optic nerve after prenatal exposure to methamphetamine." *Brain Res* 1106(1): 21-9.
- Melo, P., L. G. Rodrigues, et al. (2006). "Effects of prenatal exposure to methamphetamine on the development of the rat retina." *Ann N Y Acad Sci* 1074: 590-603.
- Melo, P., L. G. Rodrigues, et al. (2005). "Methamphetamine and lipid peroxidation in the rat retina." *Birth Defects Res A Clin Mol Teratol* 73(6): 455-60.
- Rajan, P. D., R. Kekuda, et al. (2000). "Expression of the extraneuronal monoamine transporter in RPE and neural retina." *Curr Eye Res* 20(3): 195-204.
- Rodrigues, L. G., M. A. Tavares, et al. (2004). "Methamphetamine exacerbates the toxic effect of kainic acid in the adult rat retina." *Neurochem Int* 45(8): 1133-41.

## Fatalities

*See Mortality, Methamphetamine-Associated*

## Fat Cells (animals)

*See also Obesity (animals)*

- D'Almeida, V., R. Camarini, et al. (1995). "Antioxidant defense in rat brain after chronic treatment with anorectic drugs." *Toxicol Lett* 81(2-3): 101-5.
- Falb, A., G. Schmidt, et al. (1966). "[Relations between anorexigenic effect and fatty acid mobilization by methamphetamine]." *Arzneimittelforschung* 16(6): 733-4.

## Fear and Paranoia

*See also Avoidance Behaviors (animals); Psychosis*

- Brecht, M. L., A. O'Brien, et al. (2004). "Methamphetamine use behaviors and gender differences." *Addict Behav* 29(1): 89-106.
- Goldstein, R. Z., N. D. Volkow, et al. (2002). "The orbitofrontal cortex in methamphetamine addiction: Involvement in fear." *Neuroreport* 13(17): 2253-7.
- Hall, W., J. Hando, et al. (1996). "Psychological morbidity and route of administration among amphetamine users in Sydney, Australia." *Addiction* 91(1): 81-7.
- Hartel-Petri, R., R. Rodler, et al. (2005). "[Increasing prevalence of amphetamine--and methamphetamine-induced psychosis]." *Psychiatr Prax* 32(1): 13-7.
- McKetin, R., J. McLaren, et al. (2006). "The prevalence of psychotic symptoms among methamphetamine users." *Addiction* 101(10): 1473-8.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.
- Nakatani, Y. and T. Hara (1998). "Disturbance of consciousness due to methamphetamine abuse. A study of 2 patients." *Psychopathology* 31(3): 131-7.
- Sato, M. (1992). "A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis." *Ann N Y Acad Sci* 654: 160-70.
- Sato, M., Y. Numachi, et al. (1992). "Relapse of paranoid psychotic state in methamphetamine model of schizophrenia." *Schizophr Bull* 18(1): 115-22.
- Sato, M., C. C. Chen, et al. (1983). "Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis." *Biol Psychiatry* 18(4): 429-40.
- Sommers, I., D. Baskin, et al. (2006). "Methamphetamine use among young adults: Health and social consequences." *Addict Behav* 31(8): 1469-76.

- Srisurapanont, M., R. Ali, et al. (2003). "Psychotic symptoms in methamphetamine psychotic in-patients." *Int J Neuropsychopharmacol* 6(4): 347-52.
- Yui, K., S. Ikemoto, et al. (2002). "Factors for susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosis." *Ann N Y Acad Sci* 965: 292-304.
- Yui, K., K. Goto, et al. (1997). "Methamphetamine psychosis: Spontaneous recurrence of paranoid-hallucinatory states and monoamine neurotransmitter function." *J Clin Psychopharmacol* 17(1): 34-43.
- Yui, K., K. Goto, et al. (1996). "Plasma monoamine metabolites and spontaneous recurrence of methamphetamine-induced paranoid-hallucinatory psychosis: Relation of noradrenergic activity to the occurrence of flashbacks." *Psychiatry Res* 63(2-3): 93-107.

### Feeding

*See Appetite and Feeding; Appetite and Feeding (animals)*

### Finland

- Leino, T., P. Leinikki, et al. (1997). "Hepatitis A outbreak amongst intravenous amphetamine abusers in Finland." *Scand J Infect Dis* 29(3): 213-6.

### Flashbacks

*See also Psychosis*

- Edakubo, T., T. Kaneko, et al. (1991). "[Secondary development of psychological dependence in a methamphetamine dependent]." *Arukuru Kenkyuto Yakubutsu Ison* 26(2): 96-104.
- Hartel-Petri, R., R. Rodler, et al. (2005). "[Increasing prevalence of amphetamine--and methamphetamine-induced psychosis]." *Psychiatr Prax* 32(1): 13-7.
- Yui, K., K. Goto and S. Ikemoto (2004). "The role of noradrenergic and dopaminergic hyperactivity in the development of spontaneous recurrence of methamphetamine psychosis and susceptibility to episode recurrence." *Ann N Y Acad Sci* 1025: 296-306.
- Yui, K., S. Ikemoto, et al. (2003). "Susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosis." *J Clin Psychopharmacol* 23(5): 525-8.
- Yui, K., S. Ikemoto, et al. (2002). "Factors for susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosis." *Ann N Y Acad Sci* 965: 292-304.
- Yui, K., S. Ikemoto, et al. (2002). "Spontaneous recurrence of methamphetamine-induced paranoid-hallucinatory states in female subjects: Susceptibility to psychotic states and implications for relapse of schizophrenia." *Pharmacopsychiatry* 35(2): 62-71.
- Yui, K., K. Goto, et al. (2001). "Susceptibility to subsequent episodes of spontaneous recurrence of methamphetamine psychosis." *Drug Alcohol Depend* 64(2): 133-42.
- Yui, K., K. Goto, et al. (2000). "Stress induced spontaneous recurrence of methamphetamine psychosis: The relation between stressful experiences and sensitivity to stress." *Drug Alcohol Depend* 58(1-2): 67-75.
- Yui, K., K. Goto, et al. (2000). "Increased sensitivity to stress in spontaneous recurrence of methamphetamine psychosis: noradrenergic hyperactivity with contribution from dopaminergic hyperactivity." *J Clin Psychopharmacol* 20(2): 165-74.
- Yui, K., T. Ishiguro, et al. (1999). "Spontaneous recurrence of methamphetamine psychosis: increased sensitivity to stress associated with noradrenergic hyperactivity and dopaminergic change." *Eur Arch Psychiatry Clin Neurosci* 249(2): 103-11.
- Yui, K., T. Ishiguro, et al. (1998). "Factors affecting the development of spontaneous recurrence of methamphetamine psychosis." *Acta Psychiatr Scand* 97(3): 220-7.
- Yui, K., K. Goto, S. Ikemoto and T. Ishiguro (1997). "Monoamine neurotransmitter metabolites and spontaneous recurrence of methamphetamine psychosis." *Brain Res Bull* 43(1): 25-33.
- Yui, K., T. Ishiguro, et al. (1997). "Precipitating factors in spontaneous recurrence of methamphetamine psychosis." *Psychopharmacology (Berl)* 134(3): 303-8.
- Yui, K., K. Goto, et al. (1997). "Noradrenergic activity and spontaneous recurrence of methamphetamine psychosis." *Drug Alcohol Depend* 44(2-3): 183-7.
- Yui, K., K. Goto, et al. (1996). "Plasma monoamine metabolites and spontaneous recurrence of methamphetamine-induced paranoid-hallucinatory psychosis: Relation of noradrenergic activity to the occurrence of flashbacks." *Psychiatry Res* 63(2-3): 93-107.
- Yui, K., K. Goto, et al. (1995). "Spontaneous recurrence of methamphetamine psychosis: process and monoamine neurotransmitter function." *Nihon Shinkei Seishin Yakurigaku Zasshi* 15(4): 363-74.

**Florida (US)***See also Miami*

- Fernandez, M. I., G. S. Bowen, et al. (2007). "Crystal methamphetamine: A source of added sexual risk for Hispanic men who have sex with men?" *Drug Alcohol Depend* 86(2-3): 245-52.
- Fernandez, M. I., G. S. Bowen, et al. (2005). "High rates of club drug use and risky sexual practices among Hispanic men who have sex with men in Miami, Florida." *Subst Use Misuse* 40(9): 1347-62.
- Fernandez, M. I., T. Perrino, et al. (2005). "Surfing new territory: club-drug use and risky sex among Hispanic men who have sex with men recruited on the Internet." *J Urban Health* 82(1 Suppl 1): i79-88.
- Fernandez, M. I., L. M. Varga, et al. (2004). "The Internet as recruitment tool for HIV studies: viable strategy for reaching at-risk Hispanic MSM in Miami?" *AIDS Care* 16(8): 953-63.
- Jacobs, L. J. (1989). "Reversible dilated cardiomyopathy induced by methamphetamine." *Clin Cardiol* 12(12): 725-7.
- Kurtz, S. P. (2005). "Post-circuit blues: Motivations and consequences of crystal meth use among gay men in Miami." *AIDS Behav* 9(1): 63-72.
- Thiede, H., L. A. Valleroy, et al. (2003). "Regional patterns and correlates of substance use among young men who have sex with men in 7 US urban areas." *Am J Public Health* 93(11): 1915-21.
- Vong, S., A. E. Fiore, et al. (2005). "Vaccination in the county jail as a strategy to reach high risk adults during a community-based hepatitis A outbreak among methamphetamine drug users." *Vaccine* 23(8): 1021-8.

**Flunitrazepam (Rohypnol™)**

- Wu, L. T., W. E. Schlenger, et al. (2006). "Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths." *Drug Alcohol Depend* 84(1): 102-13.

**Food Deprivation**

- Zacny, J. P. and H. de Wit (1989). "Effects of food deprivation on subjective responses to d-amphetamine in humans." *Pharmacol Biochem Behav* 34(4): 791-5.

**Former Methamphetamine Users***See also Flashbacks; Methamphetamine Abstinence Syndrome; Relapse; Withdrawal*

- Akiyama, K. (2006). "Longitudinal clinical course following pharmacological treatment of methamphetamine psychosis which persists after long-term abstinence." *Ann N Y Acad Sci* 1074: 125-34.
- Bechara, A., S. Dolan, et al. (2001). "Decision-making deficits, linked to a dysfunctional ventromedial prefrontal cortex, revealed in alcohol and stimulant abusers." *Neuropsychologia* 39(4): 376-89.
- Chang, L., C. Cloak, et al. (2005). "Enlarged striatum in abstinent methamphetamine abusers: A possible compensatory response." *Biol Psychiatry* 57(9): 967-74.
- Chang, L., T. Ernst, et al. (2002). "Perfusion MRI and computerized cognitive test abnormalities in abstinent methamphetamine users." *Psychiatry Res* 114(2): 65-79.
- Cho, A. K. and W. P. Melega (2002). "Patterns of methamphetamine abuse and their consequences." *J Addict Dis* 21(1): 21-34.
- Chou, Y. H., W. S. Huang, et al. (2007). "Dopamine transporters and cognitive function in methamphetamine abuser after a short abstinence: A SPECT study." *Eur Neuropsychopharmacol* 17(1): 46-52.
- Chung, A., I. K. Lyoo, et al. (2006). "Decreased frontal white-matter integrity in abstinent methamphetamine abusers." *Int J Neuropsychopharmacol*: 1-11.
- Ellis, R. J., M. E. Childers, et al. (2003). "Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy." *J Infect Dis* 188(12): 1820-6.
- Ernst, T., L. Chang, et al. (2000). "Evidence for long-term neurotoxicity associated with methamphetamine abuse: A 1H MRS study." *Neurology* 54(6): 1344-9.
- Frawley, P. J. and J. W. Smith (1992). "One-year follow-up after multimodal inpatient treatment for cocaine and methamphetamine dependencies." *J Subst Abuse Treat* 9(4): 271-86.
- Goldstein, R. Z., N. D. Volkow, et al. (2002). "The orbitofrontal cortex in methamphetamine addiction: Involvement in fear." *Neuroreport* 13(17): 2253-7.
- Harvey, D. C., G. Lacan, et al. (2000). "Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss." *Brain Res* 871(2): 259-70.

- Hoffman, W. F., M. Moore, et al. (2006). "Neuropsychological function and delay discounting in methamphetamine-dependent individuals." *Psychopharmacology (Berl)* 188(2): 162-70.
- Hwang, J., I. K. Lyoo, et al. (2006). "Decreased cerebral blood flow of the right anterior cingulate cortex in long-term and short-term abstinent methamphetamine users." *Drug Alcohol Depend* 82(2): 177-81.
- Inouye, D. S., J. J. Navin, et al. (2004). "Fatal postoperative arrhythmia in a man with a remote history of methamphetamine and cocaine use: A case report." *Hawaii Med J* 63(3): 82-6.
- Iwanami, A., R. Kanamori, et al. (1995). "Reduced attention-related negative potentials in methamphetamine psychosis." *J Nerv Ment Dis* 183(11): 693-7.
- Iyo, M., Y. Sekine and N. Mori (2004). "Neuromechanism of developing methamphetamine psychosis: A neuroimaging study." *Ann N Y Acad Sci* 1025: 288-95.
- Iyo, M., H. Namba, et al. (1997). "Abnormal cerebral perfusion in chronic methamphetamine abusers: a study using 99mTc-HMPAO and SPECT." *Prog Neuropsychopharmacol Biol Psychiatry* 21(5): 789-96.
- Johnson, B. A., J. D. Roache, et al. (2007). "Effects of topiramate on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in recently abstinent methamphetamine-dependent individuals." *Prog Neuropsychopharmacol Biol Psychiatry* 31(1): 123-30.
- Johanson, C. E., K. A. Frey, et al. (2006). "Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers." *Psychopharmacology (Berl)* 186(4): 620.
- Johanson, C. E., K. A. Frey, et al. (2006). "Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers." *Psychopharmacology (Berl)* 185(3): 327-38.
- Kalechstein, A. D., T. F. Newton and M. Green (2003). "Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence." *J Neuropsychiatry Clin Neurosci* 15(2): 215-20.
- Kim, S. J., I. K. Lyoo, et al. (2006). "Prefrontal grey-matter changes in short-term and long-term abstinent methamphetamine abusers." *Int J Neuropsychopharmacol* 9(2): 221-8.
- Kim, S. J., I. K. Lyoo, et al. (2005). "Frontal glucose hypometabolism in abstinent methamphetamine users." *Neuropsychopharmacology* 30(7): 1383-91.
- London, E. D., S. M. Berman, et al. (2005). "Cerebral metabolic dysfunction and impaired vigilance in recently abstinent methamphetamine abusers." *Biol Psychiatry* 58(10): 770-8.
- London, E. D., S. L. Simon, et al. (2004). "Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers." *Arch Gen Psychiatry* 61(1): 73-84.
- McCann, U. D., D. F. Wong, et al. (1998). "Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: Evidence from positron emission tomography studies with [11C]WIN-35,428." *J Neurosci* 18(20): 8417-22.
- McGregor, C., M. Srisurapanont, et al. (2005). "The nature, time course and severity of methamphetamine withdrawal." *Addiction* 100(9): 1320-9.
- Newton, T. F., A. D. Kalechstein, et al. (2004). "Association between quantitative EEG and neurocognition in methamphetamine-dependent volunteers." *Clin Neurophysiol* 115(1): 194-8.
- Newton, T. F., I. A. Cook, et al. (2003). "Quantitative EEG abnormalities in recently abstinent methamphetamine dependent individuals." *Clin Neurophysiol* 114(3): 410-5.
- Nordahl, T. E., R. Salo, et al. (2005). "Methamphetamine users in sustained abstinence: A proton magnetic resonance spectroscopy study." *Arch Gen Psychiatry* 62(4): 444-52.
- Nordahl, T. E., R. Salo, et al. (2003). "Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: A review." *J Neuropsychiatry Clin Neurosci* 15(3): 317-25.
- Nordahl, T. E., R. Salo, et al. (2002). "Low N-acetyl-aspartate and high choline in the anterior cingulum of recently abstinent methamphetamine-dependent subjects: A preliminary proton MRS study. Magnetic resonance spectroscopy." *Psychiatry Res* 116(1-2): 43-52.
- Oh, J. S., I. K. Lyoo, et al. (2005). "Shape changes of the corpus callosum in abstinent methamphetamine users." *Neurosci Lett* 384(1-2): 76-81.
- Okudaira, K., T. Yabana, et al. (1994). "[Clinical problems of alcoholics with a history of methamphetamine abuse]." *Arukuru Kenkyuto Yakubutsu Ison* 29(3): 185-9.
- Paulus, M. P., S. F. Tapert, et al. (2005). "Neural activation patterns of methamphetamine-dependent subjects during decision making predict relapse." *Arch Gen Psychiatry* 62(7): 761-8.
- Paulus, M. P., N. E. Hozack, B. E. Zauscher, L. Frank, G. G. Brown, D. L. Braff and M. A. Schuckit (2002). "Behavioral and functional neuroimaging evidence for prefrontal dysfunction in methamphetamine-dependent subjects." *Neuropsychopharmacology* 26(1): 53-63.

- Salo, R., T. E. Nordahl, et al. (2006). "Attentional control and brain metabolite levels in methamphetamine abusers." *Biol Psychiatry*.
- Salo, R., T. E. Nordahl, et al. (2002). "Preliminary evidence of reduced cognitive inhibition in methamphetamine-dependent individuals." *Psychiatry Res* 111(1): 65-74.
- Sato, M. (1992). "A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis." *Ann N Y Acad Sci* 654: 160-70.
- Sato, M., Y. Numachi, et al. (1992). "Relapse of paranoid psychotic state in methamphetamine model of schizophrenia." *Schizophr Bull* 18(1): 115-22.
- Sato, M., C. C. Chen, et al. (1983). "Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis." *Biol Psychiatry* 18(4): 429-40.
- Schrauzer, G. N. and E. de Vroey (1994). "Effects of nutritional lithium supplementation on mood. A placebo-controlled study with former drug users." *Biol Trace Elem Res* 40(1): 89-101.
- Sekine, Y., Y. Ouchi, et al. (2006). "Brain serotonin transporter density and aggression in abstinent methamphetamine abusers." *Arch Gen Psychiatry* 63(1): 90-100.
- Sekine, Y., Y. Minabe, et al. (2002). "Metabolite alterations in basal ganglia associated with methamphetamine-related psychiatric symptoms. A proton MRS study." *Neuropsychopharmacology* 27(3): 453-61.
- Sekine, Y., M. Iyo, et al. (2001). "Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET." *Am J Psychiatry* 158(8): 1206-14.
- Simon, S. L., J. Dacey, et al. (2004). "The effect of relapse on cognition in abstinent methamphetamine abusers." *J Subst Abuse Treat* 27(1): 59-66.
- Sung, Y. H., S. C. Cho, et al. (2006). "Relationship between N-acetyl-aspartate in gray and white matter of abstinent methamphetamine abusers and their history of drug abuse: A proton magnetic resonance spectroscopy study." *Drug Alcohol Depend*.
- Taylor, M. J., S. L. Letendre, et al. (2004). "Hepatitis C virus infection is associated with reduced white matter N-acetylaspartate in abstinent methamphetamine users." *J Int Neuropsychol Soc* 10(1): 110-3.
- Verdejo-Garcia, A., A. Bechara, et al. (2006). "Executive dysfunction in substance dependent individuals during drug use and abstinence: an examination of the behavioral, cognitive and emotional correlates of addiction." *J Int Neuropsychol Soc* 12(3): 405-15.
- Volkow, N. D., L. Chang, et al. (2001). "Low level of brain dopamine D2 receptors in methamphetamine abusers: Association with metabolism in the orbitofrontal cortex." *Am J Psychiatry* 158(12): 2015-21.
- Volkow, N. D., L. Chang, et al. (2001). "Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers." *Am J Psychiatry* 158(3): 383-9.
- Volkow, N. D., L. Chang, et al. (2001). "Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence." *J Neurosci* 21(23): 9414-8.
- Walton, M. A., F. G. Castro, et al. (1994). "The role of attributions in abstinence, lapse, and relapse following substance abuse treatment." *Addict Behav* 19(3): 319-31.
- Wang, G. J., N. D. Volkow, et al. (2004). "Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence." *Am J Psychiatry* 161(2): 242-8.
- Wolkoff, D. A. (1997). "Methamphetamine abuse: An overview for health care professionals." *Hawaii Med J* 56(2): 34-6, 44.
- Won, M., Y. Minabe, et al. (2003). "Manic-switch induced by fluvoxamine in abstinent pure methamphetamine abusers." *J Psychiatry Neurosci* 28(2): 134-5.

## Fresno, CA (US)

- Molitor, F., J. D. Ruiz, et al. (1999). "Methamphetamine use and sexual and injection risk behaviors among out-of-treatment injection drug users." *Am J Drug Alcohol Abuse* 25(3): 475-93.

## GABA (Gamma Aminobutyric Acid)

- Brodie, J. D., E. Figueroa, et al. (2005). "Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction." *Synapse* 55(2): 122-5.
- Caligiuri, M. P. and C. Buitenhuis (2005). "Do preclinical findings of methamphetamine-induced motor abnormalities translate to an observable clinical phenotype?" *Neuropsychopharmacology* 30(12): 2125-34.
- Cloak, C. C., L. Chang, et al. (2004). "Methamphetamine and AIDS: IHMRS studies in a feline model of human disease." *J Neuroimmunol* 147(1-2): 16-20.
- Hassler, R. and A. Wagner (1975). "Locomotor activity and speed of movements in relation to monoamine-acting drugs." *Int J Neurol* 10(1-4): 80-97.

- Heinzerling, K. G., S. Shoptaw, et al. (2006). "Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence." *Drug Alcohol Depend* 85(3): 177-184.
- Powrozek, T. A., Y. Sari, et al. (2004). "Neurotransmitters and substances of abuse: Effects on adult neurogenesis." *Curr Neurovasc Res* 1(3): 251-60.

### **GABA (Gamma Aminobutyric Acid) (animals)**

- Armstrong, B. D. and K. K. Noguchi (2004). "The neurotoxic effects of 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine on serotonin, dopamine, and GABA-ergic terminals: an in-vitro autoradiographic study in rats." *Neurotoxicology* 25(6): 905-14.
- Bedingfield, J. B., L. D. Calder, et al. (1997). "The role of the striatum in the mouse in behavioral sensitization to amphetamine." *Pharmacol Biochem Behav* 56(2): 305-10.
- Bergstrom, H. C., A. A. Palmer, et al. (2003). "Reverse selection for differential response to the locomotor stimulant effects of ethanol provides evidence for pleiotropic genetic influence on locomotor response to other drugs of abuse." *Alcohol Clin Exp Res* 27(10): 1535-47.
- Brummelte, S., J. Neddens, et al. (2007). "Alteration in the GABAergic network of the prefrontal cortex in a potential animal model of psychosis." *J Neural Transm*.
- Burrows, K. B. and C. K. Meshul (1999). "High-dose methamphetamine treatment alters presynaptic GABA and glutamate immunoreactivity." *Neuroscience* 90(3): 833-50.
- Bustamante, D., Z. B. You, et al. (2002). "Effect of single and repeated methamphetamine treatment on neurotransmitter release in substantia nigra and neostriatum of the rat." *J Neurochem* 83(3): 645-54.
- Caligiuri, M. P. and C. Buitenhuis (2005). "Do preclinical findings of methamphetamine-induced motor abnormalities translate to an observable clinical phenotype?" *Neuropsychopharmacology* 30(12): 2125-34.
- Cloak, C. C., L. Chang, et al. (2004). "Methamphetamine and AIDS: IHMS studies in a feline model of human disease." *J Neuroimmunol* 147(1-2): 16-20.
- Cowen, P. J., D. J. Nutt, et al. (1982). "Repeated administration of subconvulsant doses of GABA antagonist drugs. II. Effect on monoamine-mediated behaviour." *Psychopharmacology (Berl)* 76(1): 88-91.
- Dawirs, R. R., G. Teuchert-Noodt, et al. (1997). "Pharmacologically induced neural plasticity in the prefrontal cortex of adult gerbils (*Meriones unguiculatus*)." *Eur J Pharmacol* 327(2-3): 117-23.
- Finberg, J. P., T. Takeshima, et al. (1998). "Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor." *Neuroreport* 9(4): 703-7.
- Floran, B., L. Floran, et al. (2004). "Dopamine D4 receptors inhibit depolarization-induced [3H]GABA release in the rat subthalamic nucleus." *Eur J Pharmacol* 498(1-3): 97-102.
- Floran, B., L. Floran, et al. (1997). "D2 receptor-mediated inhibition of GABA release by endogenous dopamine in the rat globus pallidus." *Neurosci Lett* 237(1): 1-4.
- Fornai, F., G. Lazzeri, et al. (2003). "Amphetamines induce ubiquitin-positive inclusions within striatal cells." *Neurol Sci* 24(3): 182-3.
- Gasior, M., J. M. Witkin, et al. (2004). "Chlormethiazole potentiates the discriminative stimulus effects of methamphetamine in rats." *Eur J Pharmacol* 494(2-3): 183-9.
- Gatch, M. B., M. Selvig, et al. (2005). "GABAergic modulation of the discriminative stimulus effects of methamphetamine." *Behav Pharmacol* 16(4): 261-6.
- Gerasimov, M. R., C. R. Ashby, Jr., et al. (1999). "Gamma-vinyl GABA inhibits methamphetamine, heroin, or ethanol-induced increases in nucleus accumbens dopamine." *Synapse* 34(1): 11-9.
- Hanson, G. R., L. P. Midgley, et al. (1995). "Response of extrapyramidal and limbic neurotensin systems to phencyclidine treatment." *Eur J Pharmacol* 278(2): 167-73.
- Hassler, R. and A. Wagner (1975). "Locomotor activity and speed of movements in relation to monoamine-acting drugs." *Int J Neurol* 10(1-4): 80-97.
- Haughey, H. M., J. M. Brown, et al. (2000). "Differential effects of methamphetamine on Na(+)/Cl(-)-dependent transporters." *Brain Res* 863(1-2): 59-65.
- Hotchkiss, A. and J. W. Gibb (1980). "Blockade of methamphetamine-induced depression of tyrosine hydroxylase by GABA transaminase inhibitors." *Eur J Pharmacol* 66(2-3): 201-5.
- Ito, K., T. Ohmori, et al. (2000). "The role of benzodiazepine receptors in the acquisition and expression of behavioral sensitization to methamphetamine." *Pharmacol Biochem Behav* 65(4): 705-10.
- Ito, K. (1999). "The role of gamma-aminobutyric acid (GABA)-benzodiazepine neurotransmission in an animal model of methamphetamine-induced psychosis." *Hokkaido Igaku Zasshi* 74(2): 135-44.

- Ito, K., T. Ohmori, et al. (1997). "Clonazepam prevents the development of sensitization to methamphetamine." *Pharmacol Biochem Behav* 58(4): 875-9.
- Itzhak, Y. and J. L. Martin (2000). "Effect of riluzole and gabapentin on cocaine- and methamphetamine-induced behavioral sensitization in mice." *Psychopharmacology (Berl)* 151(2-3): 226-33.
- Jeng, C. H. and Y. Wang (1998). "Methamphetamine modulates GABA-induced electrophysiological depression by alternating noradrenergic actions in cerebellar Purkinje neurons." *Psychopharmacology (Berl)* 136(2): 132-8.
- Kaiya, H., K. Takeuchi, et al. (1983). "Effects of subchronic treatment of methamphetamine haloperidol on the rat brain levels of GABA, glutamate and aspartate." *Folia Psychiatr Neurol Jpn* 37(1): 107-13.
- Karler, R., L. D. Calder, et al. (1998). "The role of dopamine in the mouse frontal cortex: a new hypothesis of behavioral sensitization to amphetamine and cocaine." *Pharmacol Biochem Behav* 61(4): 435-43.
- Karler, R., L. D. Calder, et al. (1998). "The role of dopamine and GABA in the frontal cortex of mice in modulating a motor-stimulant effect of amphetamine and cocaine." *Pharmacol Biochem Behav* 60(1): 237-44.
- Karler, R., J. B. Bedingfield, et al. (1997). "The role of the frontal cortex in the mouse in behavioral sensitization to amphetamine." *Brain Res* 757(2): 228-35.
- Karler, R., L. D. Calder, et al. (1995). "The dopaminergic, glutamatergic, GABAergic bases for the action of amphetamine and cocaine." *Brain Res* 671(1): 100-4.
- Kubota, Y., C. Ito, et al. (2002). "Increased methamphetamine-induced locomotor activity and behavioral sensitization in histamine-deficient mice." *J Neurochem* 83(4): 837-45.
- Kuribara, H. and S. Tadokoro (1983). "Effect alteration of methamphetamine by amino acids or their salts on ambulatory activity in mice." *J Toxicol Sci* 8(1): 25-36.
- Li, S. M., L. L. Yin, et al. (2001). "GABA(B) receptor agonist baclofen attenuates the development and expression of d-methamphetamine-induced place preference in rats." *Life Sci* 70(3): 349-56.
- Lin, S. K., C. K. Chen, et al. (2003). "Gender-specific contribution of the GABA(A) subunit genes on 5q33 in methamphetamine use disorder." *Pharmacogenomics J* 3(6): 349-55.
- Mark, K. A., J. J. Soghomonian, et al. (2004). "High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity." *J Neurosci* 24(50): 11449-56.
- Masuo, Y., M. Ishido, et al. (2004). "Motor activity and gene expression in rats with neonatal 6-hydroxydopamine lesions." *J Neurochem* 91(1): 9-19.
- Munzar, P., S. W. Kutkat, et al. (2000). "Failure of baclofen to modulate discriminative-stimulus effects of cocaine or methamphetamine in rats." *Eur J Pharmacol* 408(2): 169-74.
- Nishiyama, T., M. Ikeda, et al. (2005). "Haplotype association between GABAA receptor gamma2 subunit gene (GABRG2) and methamphetamine use disorder." *Pharmacogenomics J* 5(2): 89-95.
- Nishizawa, Y., T. Kodama, et al. (1968). "Effect of gamma-aminobutyric acid derivatives, especially homopantothenic acid, on the excitability of the brain." *J Vitaminol (Kyoto)* 14(4): 331-44.
- Nossoll, M., G. Teuchert-Noodt, et al. (1997). "A single dose of methamphetamine in neonatal gerbils affects adult prefrontal gamma-aminobutyric acid innervation." *Eur J Pharmacol* 340(2-3): R3-5.
- Palmer, A. A., M. Verbitsky, et al. (2005). "Gene expression differences in mice divergently selected for methamphetamine sensitivity." *Mamm Genome* 16(5): 291-305.
- Powrozek, T. A., Y. Sari, et al. (2004). "Neurotransmitters and substances of abuse: Effects on adult neurogenesis." *Curr Neurovasc Res* 1(3): 251-60.
- Ranaldi, R. and K. Poeggel (2002). "Baclofen decreases methamphetamine self-administration in rats." *Neuroreport* 13(9): 1107-10.
- Slamberova, R. and R. Rokyta (2005). "Occurrence of bicuculline-, NMDA- and kainic acid-induced seizures in prenatally methamphetamine-exposed adult male rats." *Naunyn Schmiedebergs Arch Pharmacol* 372(3): 236-41.
- Slamberova, R. and R. Rokyta (2005). "Seizure susceptibility in prenatally methamphetamine-exposed adult female rats." *Brain Res* 1060(1-2): 193-7.
- Tirelli, E., B. Geter-Douglass, et al. (1998). "gamma-Aminobutyric acidA agonists differentially augment gnawing induced by indirect-acting dopamine agonists in C57BL/6J mice." *J Pharmacol Exp Ther* 284(1): 116-24.
- Wang, Y., J. Chou, et al. (2000). "Chronic methamphetamine exposure decreases high affinity uptake function in norepinephrine afferents in the cerebellar cortex: An electrophysiological and electrochemical study." *Neuropharmacology* 39(11): 2112-23.
- Wang, Y., C. H. Jeng, et al. (1995). "Methamphetamine facilitates ethanol-induced depressions in cerebellar Purkinje neurons of prazosin- or DSP4-treated rats." *Psychopharmacology (Berl)* 121(4): 433-41.
- Watanabe, Y., Y. Hori, et al. (1995). "Inhibitory effects of newly synthesized Ser-contained GABA-peptides administered into either caudate putamen or amygdala on methamphetamine-induced hyperactivity." *Nihon Shinkei Seishin Yakurigaku Zasshi* 15(3): 239-46.

- Wrona, M. Z., Z. Yang, et al. (1997). "Potential new insights into the molecular mechanisms of methamphetamine-induced neurodegeneration." *NIDA Res Monogr* 173: 146-74.
- Zhang, X., T. H. Lee, et al. (2006). "Methamphetamine induces long-term changes in GABAA receptor alpha2 subunit and GAD67 expression." *Biochem Biophys Res Commun* 351(1): 300-5.
- Zhu, J. P., W. Xu, et al. (2006). "Distinct mechanisms mediating methamphetamine-induced neuronal apoptosis and dopamine terminal damage share the neuropeptide substance P in the striatum of mice." *Ann N Y Acad Sci* 1074: 135-48.
- Zhu, J. P., W. Xu, et al. (2006). "Methamphetamine-induced cell death: Selective vulnerability in neuronal subpopulations of the striatum in mice." *Neuroscience* 140(2): 607-22.

### **Gamma Hydroxybutyrate**

*See* GHB (Gamma Hydroxybutyrate)

### **Gastrointestinal System**

- Brannan, T. A., S. Soundararajan, et al. (2004). "Methamphetamine-associated shock with intestinal infarction." *MedGenMed* 6(4): 6.
- Dirkx, C. A. and E. O. Gerscovich (1998). "Sonographic findings in methamphetamine-induced ischemic colitis." *J Clin Ultrasound* 26(9): 479-82.
- Dutta, S., J. Morton, et al. (2006). "Methamphetamine use following bariatric surgery in an adolescent." *Obes Surg* 16(6): 780-2.
- Forrester, M. B. and R. D. Merz (2006). "Comparison of trends in gastroschisis and prenatal illicit drug use rates." *J Toxicol Environ Health A* 69(13): 1253-9.
- Johnson, T. D. and M. M. Berenson (1991). "Methamphetamine-induced ischemic colitis." *J Clin Gastroenterol* 13(6): 687-9.
- Kolecki, P. (1998). "Inadvertent methamphetamine poisoning in pediatric patients." *Pediatr Emerg Care* 14(6): 385-7.
- Pecha, R. E., T. Prindiville, et al. (1996). "Association of cocaine and methamphetamine use with giant gastroduodenal ulcers." *Am J Gastroenterol* 91(12): 2523-7.

### **Gay Men/Men Who Have Sex with Men**

*See also* Men

- Anonymous (2002). "Methamphetamine use is heightening risks among gay youth. 'club drugs' dull safe-sex sensibilities." *AIDS Alert* 17(10): 121, 123-5.
- Benotsch, E. G., S. Kalichman and M. Cage (2002). "Men who have met sex partners via the Internet: Prevalence, predictors, and implications for HIV prevention." *Arch Sex Behav* 31(2): 177-83.
- Bluthenthal, R. N., A. H. Kral, et al. (2001). "Trends in HIV seroprevalence and risk among gay and bisexual men who inject drugs in San Francisco, 1988 to 2000." *J Acquir Immune Defic Syndr* 28(3): 264-9.
- Boddiger, D. (2005). "Methamphetamine use linked to rising HIV transmission." *Lancet* 365(9466): 1217-8.
- Bolding, G., G. Hart, et al. (2006). "Use of crystal methamphetamine among gay men in London." *Addiction* 101(11): 1622-30.
- Brewer, D. D., M. R. Golden, et al. (2006). "Unsafe sexual behavior and correlates of risk in a probability sample of men who have sex with men in the era of highly active antiretroviral therapy." *Sex Transm Dis* 33(4): 250-5.
- Braine, N., D. C. Des Jarlais, et al. (2005). "HIV risk behavior among amphetamine injectors at U.S. syringe exchange programs." *AIDS Educ Prev* 17(6): 515-24.
- Buchacz, K., W. McFarland, et al. (2005). "Amphetamine use is associated with increased HIV incidence among men." *AIDS* 19(13): 1423-24.
- Bull, S. S., P. Piper and C. Rietmeijer (2002). "Men who have sex with men and also inject drugs-profiles of risk related to the synergy of sex and drug injection behaviors." *J Homosex* 42(3): 31-51.
- Burcham, J. L., B. Tindall, et al. (1989). "Incidence and risk factors for human immunodeficiency virus seroconversion in a cohort of Sydney homosexual men." *Med J Aust* 150(11): 634-9.
- Chesney, M. A., D. C. Barrett, et al. (1998). "Histories of substance use and risk behavior: Precursors to HIV seroconversion in homosexual men." *Am J Public Health* 88(1): 113-6.
- Choi, K. H., D. Operario, et al. (2005). "Substance use, substance choice, and unprotected anal intercourse among young Asian American and Pacific Islander men who have sex with men." *AIDS Educ Prev* 17(5): 418-29.
- Chu, P. L., W. McFarland, et al. (2003). "Viagra use in a community-recruited sample of men who have sex with men, San Francisco." *J Acquir Immune Defic Syndr* 33(2): 191-3.



- Clatts, M. C., L. Goldsamt, et al. (2005). "Homelessness and drug abuse among young men who have sex with men in New York city: A preliminary epidemiological trajectory." *J Adolesc* 28(2): 201-14.
- Clatts, M. C., L. A. Goldsamt, et al. (2005). "Club drug use among young men who have sex with men in NYC: A preliminary epidemiological profile." *Subst Use Misuse* 40(9): 1317-30.
- Clatts, M. C., D. L. Welle, et al. (2001). "Reconceptualizing the interaction of drug and sexual risk among MSM speed users: Notes toward an ethno-epidemiology." *AIDS and Behavior* 5(2): 115-130.
- Colfax, G. N., E. Vittinghoff, et al. (2007). "Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance." *AIDS* 21(2): 239-241.
- Colfax, G. and R. Guzman (2006). "Club drugs and HIV infection: A review." *Clin Infect Dis* 42(10): 1463-9.
- Colfax, G. and S. Shoptaw (2005). "The methamphetamine epidemic: Implications for HIV prevention and treatment." *Curr HIV/AIDS Rep* 2(4): 194-9.
- Colfax, G., T. J. Coates, et al. (2005). "Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of San Francisco men who have sex with men." *J Urban Health* 82(1 Suppl 1): i62-70.
- Colfax, G., E. Vittinghoff, et al. (2004). "Substance use and sexual risk: A participant- and episode-level analysis among a cohort of men who have sex with men." *Am J Epidemiol* 159(10): 1002-12.
- Colfax, G. N., G. Mansergh, et al. (2001). "Drug use and sexual risk behavior among gay and bisexual men who attend circuit parties: A venue-based comparison." *J Acquir Immune Defic Syndr* 28(4): 373-9.
- Crosby, G. M., R. D. Stall, et al. (1998). "Alcohol and drug use patterns have declined between generations of younger gay-bisexual men in San Francisco." *Drug Alcohol Depend* 52(3): 177-82.
- Degenhardt, L. (2005). "Drug use and risk behaviour among regular ecstasy users: Does sexuality make a difference?" *Culture, Health & Sexuality* 7(6): 599-614.
- Diaz, R. M., A. L. Heckert, et al. (2005). "Reasons for stimulant use among Latino gay men in San Francisco: a comparison between methamphetamine and cocaine users." *J Urban Health* 82(1 Suppl 1): i71-8.
- Drumright, L. N., S. J. Little, et al. (2006). "Unprotected anal intercourse and substance use among men who have sex with men with recent HIV infection." *J Acquir Immune Defic Syndr* 43(3): 344-50.
- Drumright, L. N., S. A. Strathdee, et al. (2006). "Unprotected anal intercourse and substance use before and after HIV diagnosis among recently HIV-infected men who have sex with men." *Sex Transm Dis*.
- Fernandez, M. I., G. S. Bowen, et al. (2007). "Crystal methamphetamine: A source of added sexual risk for Hispanic men who have sex with men?" *Drug Alcohol Depend* 86(2-3): 245-52.
- Fernandez, M. I., G. S. Bowen, et al. (2005). "High rates of club drug use and risky sexual practices among Hispanic men who have sex with men in Miami, Florida." *Subst Use Misuse* 40(9): 1347-62.
- Fernandez, M. I., T. Perrino, et al. (2005). "Surfing new territory: club-drug use and risky sex among Hispanic men who have sex with men recruited on the Internet." *J Urban Health* 82(1 Suppl 1): i79-88.
- Fernandez, M. I., L. M. Varga, et al. (2004). "The Internet as recruitment tool for HIV studies: viable strategy for reaching at-risk Hispanic MSM in Miami?" *AIDS Care* 16(8): 953-63.
- Freese, T. E., J. Obert, et al. (2000). "Methamphetamine abuse: Issues for special populations." *J Psychoactive Drugs* 32(2): 177-82.
- Frosch, D., S. Shoptaw, et al. (1996). "Sexual HIV risk among gay and bisexual male methamphetamine abusers." *J Subst Abuse Treat* 13(6): 483-6.
- Gorbach, P. M., J. T. Galea, et al. (2004). "Don't ask, don't tell: patterns of HIV disclosure among HIV positive men who have sex with men with recent STI practising high risk behaviour in Los Angeles and Seattle." *Sex Transm Infect* 80(6): 512-7.
- Gorman, E. M. and R. T. Carroll (2000). "Substance abuse and HIV: Considerations with regard to methamphetamines and other recreational drugs for nursing practice and research." *J Assoc Nurses AIDS Care* 11(2): 51-62.
- Gorman, E. M., B. D. Barr, A. Hansen, B. Robertson and C. Green (1997). "Speed, sex, gay men, and HIV: Ecological and community perspectives." *Med Anthropol Q* 11(4): 505-15.
- Gorman, M. (1996). "Speed use and HIV transmission." *Focus* 11(7): 4-6.
- Gorman, E. M., P. Morgan, et al. (1995). "Qualitative research considerations and other issues in the study of methamphetamine use among men who have sex with other men." *NIDA Res Monogr* 157: 156-81.
- Green, A. I. and P. N. Halkitis (2006). "Crystal methamphetamine and sexual sociality in an urban gay subculture: An elective affinity." *Cult Health Sex* 8(4): 317-33.
- Greenwood, G. L., E. W. White, et al. (2001). "Correlates of heavy substance use among young gay and bisexual men: The San Francisco Young Men's Health Study." *Drug Alcohol Depend* 61(2): 105-12.
- Halkitis, P. N. and J. J. Palamar (2006). "GHB use among gay and bisexual men." *Addict Behav* 31(11): 2135-9.

- Halkitis, P. N. and M. T. Shrem (2006). "Psychological differences between binge and chronic methamphetamine using gay and bisexual men." *Addict Behav* 31(3): 549-52.
- Halkitis, P. N., B. N. Fischgrund, et al. (2005). "Explanations for methamphetamine use among gay and bisexual men in New York City." *Subst Use Misuse* 40(9): 1331-45.
- Halkitis, P. N., K. A. Green, et al. (2005). "Seroconcordant sexual partnerings of HIV-seropositive men who have sex with men." *AIDS* 19: S77-S86.
- Halkitis, P. N., K. A. Green, et al. (2005). "Longitudinal investigation of methamphetamine use among gay and bisexual men in New York City: findings from Project BUMPS." *J Urban Health* 82(1 Suppl 1): i18-25.
- Halkitis, P. N., M. T. Shrem, et al. (2005). "Sexual behavior patterns of methamphetamine-using gay and bisexual men." *Subst Use Misuse* 40(5): 703-19.
- Halkitis, P. N., L. Wilton, et al. (2005). "Barebacking identity among HIV-positive gay and bisexual men: demographic, psychological, and behavioral correlates." *AIDS* 19: S27-S35.
- Halkitis, P. N., J. T. Parsons, et al. (2001). "A double epidemic: Crystal methamphetamine drug use in relation to HIV transmission among gay men." *J Homosex* 41(2): 17-35.
- Herbst, J. H., R. T. Sherba, et al. (2005). "A meta-analytic review of HIV behavioral interventions for reducing sexual risk behavior of men who have sex with men." *J Acquir Immune Defic Syndr* 39(2): 228-41.
- Hirshfield, S., R. H. Remien, M. Humberstone, I. Walavalkar and M. A. Chiasson (2004). "Substance use and high-risk sex among men who have sex with men: A national online study in the USA." *AIDS Care* 16(8): 1036-47.
- Hirshfield, S., R. H. Remien, et al. (2004). "Crystal methamphetamine use predicts incident STD infection among men who have sex with men recruited online: A nested case-control study." *J Med Internet Res* 6(4): e41.
- Ibanez, G. E., D. W. Purcell, et al. (2005). "Sexual risk, substance use, and psychological distress in HIV-positive gay and bisexual men who also inject drugs." *AIDS* 19: S49-S55.
- Irwin, T. W. and J. Morgenstern (2005). "Drug-use patterns among men who have sex with men presenting for alcohol treatment: Differences in ethnic and sexual identity." *J Urban Health*.
- Kelly, B. C., J. T. Parsons, et al. (2006). "Prevalence and predictors of club drug use among club-going young adults in New York City." *J Urban Health* 83(5): 884-895.
- Kim, A. A., C. K. Kent, et al. (2002). "Increased risk of HIV and sexually transmitted disease transmission among gay or bisexual men who use Viagra, San Francisco 2000-2001." *AIDS* 16(10): 1425-8.
- Kipke, M. D., S. O'Connor, et al. (1995). "Street youth in Los Angeles. Profile of a group at high risk for human immunodeficiency virus infection." *Arch Pediatr Adolesc Med* 149(5): 513-9.
- Klausner, J. D., D. K. Levine, et al. (2004). "Internet-based site-specific interventions for syphilis prevention among gay and bisexual men." *AIDS Care* 16(8): 964-70.
- Koblin, B. A., M. A. Chesney, et al. (2003). "High-risk behaviors among men who have sex with men in 6 US cities: Baseline data from the EXPLORE Study." *Am J Public Health* 93(6): 926-32.
- Kral, A. H., J. Lorvick, et al. (2005). "HIV prevalence and risk behaviors among men who have sex with men and inject drugs in San Francisco." *J Urban Health* 82(1 Suppl 1): i43-50.
- Kurtz, S. P. (2005). "Post-circuit blues: Motivations and consequences of crystal meth use among gay men in Miami." *AIDS Behav* 9(1): 63-72.
- Lambert, E., J. Normand, et al. (2005). "Introduction: New dynamics of HIV risk among drug-using men who have sex with men." *J Urban Health* 82(1 Suppl 1): i1-8.
- Lampinen, T. M., D. McGhee, et al. (2006). "Increased risk of "club" drug use among gay and bisexual high school students in British Columbia." *J Adolesc Health* 38(4): 458-61.
- Lampinen, T. M., D. McGhee, et al. (2006). "Use of crystal methamphetamine and other club drugs among high school students in Vancouver and Victoria." *BC Medical Journal* 48(1): 22-27.
- Larkins, S., C. J. Reback, et al. (2005). "Methamphetamine-dependent gay men's disclosure of their HIV status to sexual partners." *AIDS Care* 17(4): 521-32.
- Lee, S. J., M. Galanter, et al. (2003). "Circuit parties and patterns of drug use in a subset of gay men." *J Addict Dis* 22(4): 47-60.
- Lyons, T., G. Chandra, et al. (2006). "Stimulant use and HIV risk behavior: The influence of peer support group participation." *AIDS Educ Prev* 18(5): 461-73.
- Mansergh, G., D. W. Purcell, et al. (2006). "CDC consultation on methamphetamine use and sexual risk behavior for HIV/STD infection: summary and suggestions." *Public Health Rep* 121(2): 127-32.
- Mansergh, G., R. L. Shouse, et al. (2006). "Methamphetamine and sildenafil (Viagra) use are linked to unprotected receptive and insertive anal sex, respectively, in a sample of men who have sex with men." *Sex Transm Infect* 82(2): 131-4.

- Mansergh, G., G. N. Colfax, et al. (2001). "The Circuit Party Men's Health Survey: Findings and implications for gay and bisexual men." *Am J Public Health* 91(6): 953-8.
- Martin, I., T. M. Lampinen, et al. (2006). "Methamphetamine use among marginalized youth in British Columbia." *Can J Public Health* 97(4): 320-4.
- Mattison, A. M., M. W. Ross, et al. (2001). "Circuit party attendance, club drug use, and unsafe sex in gay men." *J Subst Abuse* 13(1-2): 119-26.
- Menza, T. W., G. Colfax, et al. (2006). "Interest in a methamphetamine intervention among men who have sex with men." *Sex Transm Dis* 33(9): 565-70.
- Mitchell, S. J., S. R. Morris, et al. (2006). "Methamphetamine use and sexual activity among HIV-infected patients in care--San Francisco, 2004." *AIDS Patient Care STDS* 20(7): 502-10.
- Molitor, F., S. R. Truax, J. D. Ruiz and R. K. Sun (1998). "Association of methamphetamine use during sex with risky sexual behaviors and HIV infection among non-injection drug users." *West J Med* 168(2): 93-7.
- Morin, S. F., W. T. Steward, et al. (2005). "Predicting HIV transmission risk among HIV-infected men who have sex with men: Findings from the Healthy Living Project." *J Acquir Immune Defic Syndr* 40(2): 226-235.
- Newman, P. A., F. Rhodes and R. E. Weiss (2004). "Correlates of sex trading among drug-using men who have sex with men." *Am J Public Health* 94(11): 1998-2003.
- Newmeyer, J. A. (2003). "Patterns and trends of drug use in the San Francisco Bay Area." *J Psychoactive Drugs* 35(Suppl 1): 127-32.
- Parsons, J. T. and D. S. Bimbi (2006). "Intentional unprotected anal intercourse among men who have sex with men: Barebacking-from behavior to identity." *AIDS Behav*.
- Parsons, J. T. and P. N. Halkitis (2002). "Sexual and drug-using practices of HIV-positive men who frequent public and commercial sex environments." *AIDS Care* 14(6): 815-26.
- Patterson, T. L., S. J. Semple, et al. (2005). "Methamphetamine-using HIV-positive men who have sex with men: Correlates of polydrug use." *J Urban Health* 82(1 Suppl 1): i120-6.
- Patterson, T. L. and S. J. Semple (2003). "Sexual risk reduction among HIV-positive drug-using men who have sex with men." *J Urban Health* 80(4 Suppl 3): iii77-87.
- Paul, J. P., R. Stall and F. Davis (1993). "Sexual risk for HIV transmission among gay/bisexual men in substance-abuse treatment." *AIDS Educ Prev* 5(1): 11-24.
- Peck, J. A., C. J. Reback, et al. (2005). "Sustained reductions in drug use and depression symptoms from treatment for drug abuse in methamphetamine-dependent gay and bisexual men." *J Urban Health* 82(1 Suppl 1): i100-8.
- Peck, J. A., S. Shoptaw, et al. (2005). "HIV-associated medical, behavioral, and psychiatric characteristics of treatment-seeking, methamphetamine-dependent men who have sex with men." *J Addict Dis* 24(3): 115-32.
- Perdue, T., H. Hagan, et al. (2003). "Depression and HIV risk behavior among Seattle-area injection drug users and young men who have sex with men." *AIDS Educ Prev* 15(1): 81-92.
- Purcell, D. W., S. Moss, et al. (2005). "Illicit substance use, sexual risk, and HIV-positive gay and bisexual men: Differences by serostatus of casual partners." *AIDS* 19: S37-S47.
- Purcell, D. W., R. J. Wolitski, et al. (2005). "Predictors of the use of viagra, testosterone, and antidepressants among HIV-seropositive gay and bisexual men." *AIDS* 19 Suppl 1: S57-66.
- Purcell, D. W., J. T. Parsons, P. N. Halkitis, Y. Mizuno and W. J. Woods (2001). "Substance use and sexual transmission risk behavior of HIV-positive men who have sex with men." *J Subst Abuse* 13(1-2): 185-200.
- Reback, C. J., S. Larkins and S. Shoptaw (2004). "Changes in the meaning of sexual risk behaviors among gay and bisexual male methamphetamine abusers before and after drug treatment." *AIDS Behav* 8(1): 87-98.
- Reback, C. J., S. Larkins, et al. (2003). "Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men." *AIDS Care* 15(6): 775-85.
- Reback, C. J. and C. E. Grella (1999). "HIV risk behaviors of gay and bisexual male methamphetamine users contacted through street outreach." *Journal of Drug Issues* 29(1): 155-66.
- Rietmeijer, C. A., R. J. Wolitski, M. Fishbein, N. H. Corby and D. L. Cohn (1998). "Sex hustling, injection drug use, and non-gay identification by men who have sex with men. Associations with high-risk sexual behaviors and condom use." *Sex Transm Dis* 25(7): 353-60.
- Romanelli, F. and K. M. Smith (2004). "Recreational use of sildenafil by HIV-positive and -negative homosexual/bisexual males." *Ann Pharmacother* 38(6): 1024-30.
- Rose, V. J., H. F. Raymond, et al. (2006). "Assessing the feasibility of harm reduction services for MSM: The late night breakfast buffet study." *Harm Reduct J* 3: 29.
- Ross, M. W., A. M. Mattison, et al. (2003). "Club drugs and sex on drugs are associated with different motivations for gay circuit party attendance in men." *Subst Use Misuse* 38(8): 1173-83.

- Rusch, M., T. M. Lampinen, A. Schilder and R. S. Hogg (2004). "Unprotected anal intercourse associated with recreational drug use among young men who have sex with men depends on partner type and intercourse role." *Sex Transm Dis* 31(8): 492-8.
- Schilder, A. J., T. M. Lampinen, et al. (2005). "Crystal methamphetamine and ecstasy differ in relation to unsafe sex among young gay men." *Can J Public Health* 96(5): 340-3.
- Seage, G. R., 3rd, K. H. Mayer, et al. (1998). "The social context of drinking, drug use, and unsafe sex in the Boston Young Men Study." *J Acquir Immune Defic Syndr Hum Retrovirol* 17(4): 368-75.
- Semple, S. J., J. Zians, et al. (2006). "Sexual compulsivity in a sample of HIV-positive methamphetamine-using gay and bisexual men." *AIDS Behav* 10(5): 587-98.
- Semple, S. J., J. Zians, et al. (2006). "Methamphetamine use, impulsivity, and sexual risk behavior among HIV-positive men who have sex with men." *J Addict Dis* 25(4): 105-14.
- Semple, S. J., J. Zians, et al. (2006). "Sexual risk behavior of HIV-positive methamphetamine-using men who have sex with men: The role of partner serostatus and partner type." *Arch Sex Behav* 35(4): 461-71.
- Semple, S. J., T. L. Patterson, et al. (2004). "A comparison of injection and non-injection methamphetamine-using HIV positive men who have sex with men." *Drug Alcohol Depend* 76(2): 203-12.
- Semple, S. J., T. L. Patterson, et al. (2003). "Binge use of methamphetamine among HIV-positive men who have sex with men: Pilot data and HIV prevention implications." *AIDS Educ Prev* 15(2): 133-47.
- Semple, S. J., T. L. Patterson and I. Grant (2002). "Motivations associated with methamphetamine use among HIV+ men who have sex with men." *J Subst Abuse Treat* 22(3): 149-56.
- Sheroff, M. (2006). "Condomless sex: Gay men, barebacking, and harm reduction." *Soc Work* 51(2): 106-13.
- Shoptaw, S. (2006). "Methamphetamine use in urban gay and bisexual populations." *Top HIV Med* 14(2): 84-7.
- Shoptaw, S., J. D. Klausner, et al. (2006). "A public health response to the methamphetamine epidemic: The implementation of contingency management to treat methamphetamine dependence." *BMC Public Health* 6(1): 214.
- Shoptaw, S. and C. J. Reback (2006). "Associations between methamphetamine use and HIV among men who have sex with men: A model for guiding public policy." *J Urban Health* 83(6): 1151-7.
- Shoptaw, S., C. J. Reback, et al. (2005). "Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men." *Drug Alcohol Depend* 78(2): 125-34.
- Shoptaw, S., J. Peck, et al. (2003). "Psychiatric and substance dependence comorbidities, sexually transmitted diseases, and risk behaviors among methamphetamine-dependent gay and bisexual men seeking outpatient drug abuse treatment." *J Psychoactive Drugs* 35 Suppl 1: 161-8.
- Shoptaw, S., C. J. Reback and T. E. Freese (2002). "Patient characteristics, HIV serostatus, and risk behaviors among gay and bisexual males seeking treatment for methamphetamine abuse and dependence in Los Angeles." *J Addict Dis* 21(1): 91-105.
- Stall, R., J. P. Paul, et al. (2001). "Alcohol use, drug use and alcohol-related problems among men who have sex with men: The Urban Men's Health Study." *Addiction* 96(11): 1589-601.
- Stone, E., P. Heagerty, et al. (1999). "Correlates of condom failure in a sexually active cohort of men who have sex with men." *J Acquir Immune Defic Syndr Hum Retrovirol* 20(5): 495-501.
- Sullivan, P. S., A. K. Nakashima, et al. (1998). "Geographic differences in noninjection and injection substance use among HIV-seropositive men who have sex with men: western United States versus other regions. Supplement to HIV/AIDS Surveillance Study Group." *J Acquir Immune Defic Syndr Hum Retrovirol* 19(3): 266-73.
- Swearingen, S. G. and J. D. Klausner (2005). "Sildenafil use, sexual risk behavior, and risk for sexually transmitted diseases, including HIV infection." *Am J Med* 118(6): 571-7.
- Thiede, H., L. A. Valleroy, et al. (2003). "Regional patterns and correlates of substance use among young men who have sex with men in 7 US urban areas." *Am J Public Health* 93(11): 1915-21.
- Twitchell, G. R., A. Huber, et al. (2002). "Comparison of general and detailed HIV risk assessments among methamphetamine abusers." *AIDS and Behavior* 6(2): 153-162.
- Waldo, C. R., W. McFarland, M. H. Katz, D. MacKellar and L. A. Valleroy (2000). "Very young gay and bisexual men are at risk for HIV infection: The San Francisco Bay Area Young Men's Survey II." *J Acquir Immune Defic Syndr* 24(2): 168-74.
- Weiser, S. D., S. E. Dilworth, et al. (2006). "Gender-specific correlates of sex trade among homeless and marginally housed individuals in San Francisco." *J Urban Health* 83(4): 736-40.
- Williams, M. L., J. Atkinson, et al. (2005). "Spatial bridging in a network of drug-using male sex workers." *J Urban Health* 82(1 Suppl 1): i35-42.
- Wohl, A. R., D. F. Johnson, et al. (2002). "HIV risk behaviors among African American men in Los Angeles County who self-identify as heterosexual." *J Acquir Immune Defic Syndr* 31(3): 354-60.
- Wong, W., J. K. Chaw, et al. (2005). "Risk factors for early syphilis among gay and bisexual men seen in an STD clinic: San Francisco, 2002-2003." *Sex Transm Dis* 32(7): 458-63.

- Worth, H. and P. Rawstorne (2005). "Crystallizing the HIV epidemic: Methamphetamine, unsafe sex, and gay diseases of the will." *Arch Sex Behav* 34(5): 483-6.
- Zenilman, J. M. (2005). "Behavioral interventions--rationale, measurement, and effectiveness." *Infect Dis Clin North Am* 19(2): 541-62.

## Genetic Factors

- Aoyama, N., N. Takahashi, et al. (2006). "Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder." *Alcohol Clin Exp Res* 30(10): 1644-9.
- Asanuma, M., I. Miyazaki, Y. Higashi, T. Tsuji and N. Ogawa (2004). "Specific gene expression and possible involvement of inflammation in methamphetamine-induced neurotoxicity." *Ann N Y Acad Sci* 1025: 69-75.
- Barr, A. M., W. J. Panenka, et al. (2006). "The need for speed: An update on methamphetamine addiction." *J Psychiatry Neurosci* 31(5): 301-313.
- Chen, C. K., X. Hu, et al. (2004). "Association analysis of dopamine D2-like receptor genes and methamphetamine abuse." *Psychiatr Genet* 14(4): 223-226.
- Cheng, C. Y., C. J. Hong, et al. (2005). "Brain-derived neurotrophic factor (Val66Met) genetic polymorphism is associated with substance abuse in males." *Brain Res Mol Brain Res* 140(1-2): 86-90.
- Comings, D. E. and K. Blum (2000). "Reward deficiency syndrome: Genetic aspects of behavioral disorders." *Prog Brain Res* 126: 325-41.
- Dluzen, D. E. and J. L. McDermott (2004). "Developmental and genetic influences upon gender differences in methamphetamine-induced nigrostriatal dopaminergic neurotoxicity." *Ann N Y Acad Sci* 1025: 205-20.
- D'Souza, U. M., C. Russ, et al. (2004). "Functional effects of a tandem duplication polymorphism in the 5'flanking region of the DRD4 gene." *Biol Psychiatry* 56(9): 691-7.
- Harano, M., N. Uchimura, et al. (2004). "A polymorphism of DRD2 gene and brain atrophy in methamphetamine psychosis." *Ann N Y Acad Sci* 1025: 307-15.
- Hashimoto, T., K. Hashimoto, et al. (2005). "A functional glutathione S-transferase P1 gene polymorphism is associated with methamphetamine-induced psychosis in Japanese population." *Am J Med Genet B Neuropsychiatr Genet* 135(1): 5-9.
- Hong, C. J., C. Y. Cheng, et al. (2003). "Association study of the dopamine and serotonin transporter genetic polymorphisms and methamphetamine abuse in Chinese males." *J Neural Transm* 110(4): 345-51.
- Ide, S., H. Kobayashi, et al. (2004). "Gene polymorphisms of the mu opioid receptor in methamphetamine abusers." *Ann N Y Acad Sci* 1025: 316-24.
- Ide, S., H. Kobayashi, et al. (2006). "Linkage disequilibrium and association with methamphetamine dependence/psychosis of mu-opioid receptor gene polymorphisms." *Pharmacogenomics J* 6(3): 179-88.
- Ide, S., H. Kobayashi, et al. (2004). "Gene polymorphisms of the mu opioid receptor in methamphetamine abusers." *Ann N Y Acad Sci* 1025: 316-24.
- Ikeda, M., N. Iwata, et al. (2006). "Positive association of AKT1 haplotype to Japanese methamphetamine use disorder." *Int J Neuropsychopharmacol* 9(1): 77-81.
- Inada, T., Y. Iijima, et al. (2004). "No association found between the type 1 sigma receptor gene polymorphisms and methamphetamine abuse in the Japanese population: A collaborative study by the Japanese Genetics Initiative for Drug Abuse." *Ann N Y Acad Sci* 1025: 27-33.
- Itoh, K., K. Hashimoto, et al. (2005). "Association study between brain-derived neurotrophic factor gene polymorphisms and methamphetamine abusers in Japan." *Am J Med Genet B Neuropsychiatr Genet* 132(1): 70-3.
- Iwata, N., T. Inada, et al. (2004). "No association is found between the candidate genes of t-PA/plasminogen system and Japanese methamphetamine-related disorder: A collaborative study by the Japanese Genetics Initiative for Drug Abuse." *Ann N Y Acad Sci* 1025: 34-8.
- Kobayashi, H., H. Hata, et al. (2006). "Association analysis of delta-opioid receptor gene polymorphisms in methamphetamine dependence/psychosis." *Am J Med Genet B Neuropsychiatr Genet* 141(5): 482-6.
- Kobayashi, H., S. Ide, et al. (2004). "Study of association between alpha-synuclein gene polymorphism and methamphetamine psychosis/dependence." *Ann N Y Acad Sci* 1025: 325-34.
- Koizumi, H., K. Hashimoto, et al. (2004). "Association between the glutathione S-transferase M1 gene deletion and female methamphetamine abusers." *Am J Med Genet B Neuropsychiatr Genet* 126(1): 43-5.
- Lessov, C. N., G. E. Swan, et al. (2004). "Genetics and drug use as a complex phenotype." *Subst Use Misuse* 39(10-12): 1515-69.
- Li, T., C. K. Chen, et al. (2004). "Association analysis of the DRD4 and COMT genes in methamphetamine abuse." *Am J Med Genet* 129B(1): 120-4.

- Lin, S. K., C. K. Chen, et al. (2003). "Gender-specific contribution of the GABA(A) subunit genes on 5q33 in methamphetamine use disorder." *Pharmacogenomics J* 3(6): 349-55.
- Liu, H. C., C. K. Chen, et al. (2006). "Association between dopamine receptor D1 A-48G polymorphism and methamphetamine abuse." *Psychiatry Clin Neurosci* 60(2): 226-31.
- Liu, H. C., S. K. Lin, et al. (2004). "DAT polymorphism and diverse clinical manifestations in methamphetamine abusers." *Psychiatr Genet* 14(1): 33-7.
- Mahajan, S. D., Z. Hu, et al. (2006). "Methamphetamine modulates gene expression patterns in monocyte derived mature dendritic cells : Implications for HIV-1 pathogenesis." *Mol Diagn Ther* 10(4): 257-69.
- Miyamoto, Y., K. Yamada, et al. (2004). "Behavioural adaptations to addictive drugs in mice lacking the NMDA receptor epsilon1 subunit." *Eur J Neurosci* 19(1): 151-8.
- Morio, A., H. Ujike, et al. (2006). "No association between CART (cocaine- and amphetamine-regulated transcript) gene and methamphetamine dependence." *Ann N Y Acad Sci* 1074: 411-7.
- Morita, Y., H. Ujike, et al. (2005). "A nonsynonymous polymorphism in the human fatty acid amide hydrolase gene did not associate with either methamphetamine dependence or schizophrenia." *Neurosci Lett* 376(3): 182-7.
- Morita, Y., H. Ujike, et al. (2005). "The X-box binding protein 1 (XBP1) gene is not associated with methamphetamine dependence." *Neurosci Lett* 383(1-2): 194-8.
- Muratake, T., S. Hayashi, et al. (1995). "The effect on methamphetamine on the mRNA level for 14.3.3 eta chain in the human cultured cells." *Mol Neurobiol* 11(1-3): 223-30.
- Nakamura, K., C. K. Chen, et al. (2006). "Association analysis of SOD2 variants with methamphetamine psychosis in Japanese and Taiwanese populations." *Hum Genet* 120(2): 243-52.
- Nishiyama, T., M. Ikeda, et al. (2005). "Haplotype association between GABAA receptor gamma2 subunit gene (GABRG2) and methamphetamine use disorder." *Pharmacogenomics J* 5(2): 89-95.
- Nishio, M., Y. Kuroki, et al. (2003). "Role of hippocampal alpha(2A)-adrenergic receptor in methamphetamine-induced hyperlocomotion in the mouse." *Neurosci Lett* 341(2): 156-60.
- Nomura, A., H. Ujike, et al. (2006). "Genetic variant of prodynorphin gene is risk factor for methamphetamine dependence." *Neurosci Lett* 400(1-2): 158-62.
- Ogden, C. A., M. E. Rich, et al. (2004). "Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: An expanded convergent functional genomics approach." *Mol Psychiatry* 9(11): 1007-29.
- Ohgake, S., K. Hashimoto, et al. (2005). "Functional polymorphism of the NQO2 gene is associated with methamphetamine psychosis." *Addict Biol* 10(2): 145-8.
- Onaivi, E. S., S. F. Ali, et al. (2002). "Ibogaine signals addiction genes and methamphetamine alteration of long-term potentiation." *Ann N Y Acad Sci* 965: 28-46.
- Ramamoorthy, Y., R. F. Tyndale, et al. (2001). "Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates." *Pharmacogenetics* 11(6): 477-87.
- Saito, A., Y. Fujikura-Ouchi, et al. (2007). "Association study of putative promoter polymorphisms in the neuroplastin gene and schizophrenia." *Neurosci Lett* 411(3): 168-73.
- Sellers, E. M. and R. F. Tyndale (2000). "Mimicking gene defects to treat drug dependence." *Ann N Y Acad Sci* 909: 233-46.
- Sery, O., V. Vojtova, et al. (2001). "The association study of DRD2, ACE and AGT gene polymorphisms and methamphetamine dependence." *Physiol Res* 50(1): 43-50.
- Suzuki, A., K. Nakamura, et al. (2006). "An association study between catechol-O-methyl transferase gene polymorphism and methamphetamine psychotic disorder." *Psychiatr Genet* 16(4): 133-8.
- Tsai, S. J. (2006). "Increased central brain-derived neurotrophic factor activity could be a risk factor for substance abuse: Implications for treatment." *Med Hypotheses*.
- Tsai, S. J., C. Y. Cheng, et al. (2002). "No association for D2 and D4 dopamine receptor polymorphisms and methamphetamine abuse in Chinese males." *Psychiatr Genet* 12(1): 29-33.
- Ujike, H., M. Takaki, et al. (2002). "Gene expression related to synaptogenesis, neuritogenesis, and MAP kinase in behavioral sensitization to psychostimulants." *Ann N Y Acad Sci* 965: 55-67.
- Veenstra-Vanderweele, J., A. Qadir, et al. (2006). "Association between the Casein Kinase 1 Epsilon Gene Region and Subjective Response to D-Amphetamine." *Neuropsychopharmacology* 31(5): 1056-63.
- Yoon, S. J., C. U. Pae, et al. (2005). "Ghrelin precursor gene polymorphism and methamphetamine dependence in the Korean population." *Neurosci Res* 53(4): 391-5.

**Genetic Factors (animals)**

- Adams, F. S., F. G. La Rosa, et al. (1996). "Characterization and transplantation of two neuronal cell lines with dopaminergic properties." *Neurochem Res* 21(5): 619-27.
- Bergstrom, H. C., A. A. Palmer, et al. (2003). "Reverse selection for differential response to the locomotor stimulant effects of ethanol provides evidence for pleiotropic genetic influence on locomotor response to other drugs of abuse." *Alcohol Clin Exp Res* 27(10): 1535-47.
- Binienda, Z. K., B. D. Przybyla, et al. (2006). "Effects of L-carnitine pretreatment in methamphetamine and 3-nitropropionic acid-induced neurotoxicity." *Ann N Y Acad Sci* 1074: 74-83.
- Bowyer, J. F., A. R. Pogge, et al. (2007). "A threshold neurotoxic amphetamine exposure inhibits parietal cortex expression of synaptic plasticity-related genes." *Neuroscience* 144(1): 66-76.
- Brown, J. M., S. Gouty, et al. (2006). "Differential protection against MPTP or methamphetamine toxicity in dopamine neurons by deletion of ppN/OFQ expression." *J Neurochem* 98(2): 495-505.
- Cadet, J. L. (2001). "Molecular neurotoxicological models of Parkinsonism: Focus on genetic manipulation of mice." *Parkinsonism Relat Disord* 8(2): 85-90.
- Cadet, J. L., S. F. Ali, et al. (1995). "Neurotoxicity, drugs and abuse, and the CuZn-superoxide dismutase transgenic mice." *Mol Neurobiol* 11(1-3): 155-63.
- Cadet, J. L., S. Ali, et al. (1994). "Involvement of oxygen-based radicals in methamphetamine-induced neurotoxicity: Evidence from the use of CuZnSOD transgenic mice." *Ann N Y Acad Sci* 738: 388-91.
- Cadet, J. L., P. Sheng, et al. (1994). "Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice." *J Neurochem* 62(1): 380-3.
- Cai, N. S., M. T. McCoy, et al. (2006). "Serial analysis of gene expression in the rat striatum following methamphetamine administration." *Ann N Y Acad Sci* 1074: 13-30.
- Carney, J. M., B. Tolliver, et al. (1991). "Selective effects of behaviorally active doses of methamphetamine on mRNA expression in the gerbil brain." *Neuropharmacology* 30(9): 1011-9.
- Chen, R., D. D. Han, et al. (2005). "A triple mutation in the second transmembrane domain of mouse dopamine transporter markedly decreases sensitivity to cocaine and methylphenidate." *J Neurochem* 94(2): 352-9.
- Chen, P. C., C. L. Lao, et al. (2006). "Dual alteration of limbic dopamine D(1) receptor-mediated signalling and the Akt/GSK3 pathway in dopamine D(3) receptor mutants during the development of methamphetamine sensitization." *J Neurochem*.
- Cormaci, G., T. Mori, et al. (2007). "Protein kinase A activation down-regulates, whereas extracellular signal-regulated kinase activation up-regulates  $\sigma$ -1 receptors in B-104 cells: Implication for neuroplasticity." *J Pharmacol Exp Ther* 320(1): 202-10.
- Comings, D. E. and K. Blum (2000). "Reward deficiency syndrome: Genetic aspects of behavioral disorders." *Prog Brain Res* 126: 325-41.
- Crabbe, J. C., J. K. Belknap, et al. (1998). "Quantitative trait loci: Mapping drug and alcohol-related genes." *Adv Pharmacol* 42: 1033-7.
- Dluzen, D. E. and J. L. McDermott (2004). "Developmental and genetic influences upon gender differences in methamphetamine-induced nigrostriatal dopaminergic neurotoxicity." *Ann N Y Acad Sci* 1025: 205-20.
- Ehrman, L. A., M. T. Williams, et al. (2006). "Phosphodiesterase 1B differentially modulates the effects of methamphetamine on locomotor activity and spatial learning through DARPP32-dependent pathways: evidence from PDE1B-DARPP32 double-knockout mice." *Genes Brain Behav* 5(7): 540-51.
- Fornai, F., M. T. Carri, et al. (2002). "Resistance to striatal dopamine depletion induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice expressing human mutant Cu,Zn superoxide dismutase." *Neurosci Lett* 325(2): 124-8.
- Fujio, M., T. Nakagawa, et al. (2005). "Gene transfer of GLT-1, a glutamate transporter, into the nucleus accumbens shell attenuates methamphetamine- and morphine-induced conditioned place preference in rats." *Eur J Neurosci* 22(11): 2744-54.
- Fukumoto, M., M. Iwata, et al. (2005). "Effects of acute administration of methamphetamine on Narp mRNA in rat brain." *Addict Biol* 10(3): 257-9.
- Glickstein, S. B., P. R. Hof, et al. (2002). "Mice lacking dopamine D2 and D3 receptors have spatial working memory deficits." *J Neurosci* 22(13): 5619-29.
- Gomes-da-Silva, J., A. Perez-Rosado, et al. (2002). "Prenatal exposure to methamphetamine in the rat: Ontogeny of tyrosine hydroxylase mRNA expression in mesencephalic dopaminergic neurons." *Ann N Y Acad Sci* 965: 68-77.
- Grisel, J. E., J. K. Belknap, et al. (1997). "Quantitative trait loci affecting methamphetamine responses in BXD recombinant inbred mouse strains." *J Neurosci* 17(2): 745-54.
- Hamamura, M., S. Watanabe, et al. (2004). "Selective changes in the shapes of parasagittal bands of Aldoc (Zebrin) mRNA in the rat vermis of the cerebellum after repeated methamphetamine injections." *Cerebellum* 3(4): 236-47.
- Hirata, H., M. Asanuma, et al. (1998). "Superoxide radicals are mediators of the effects of methamphetamine on Zif268 (Egr-1, NGFI-A) in the brain: Evidence from using CuZn superoxide dismutase transgenic mice." *Brain Res Mol Brain Res* 58(1-2): 209-16.

- Hirata, H. and J. L. Cadet (1997). "Methamphetamine-induced serotonin neurotoxicity is attenuated in p53-knockout mice." *Brain Res* 768(1-2): 345-8.
- Hirata, H. and J. L. Cadet (1997). "p53-knockout mice are protected against the long-term effects of methamphetamine on dopaminergic terminals and cell bodies." *J Neurochem* 69(2): 780-90.
- Hirata, H., B. Ladenheim, et al. (1996). "Autoradiographic evidence for methamphetamine-induced striatal dopaminergic loss in mouse brain: Attenuation in CuZn-superoxide dismutase transgenic mice." *Brain Res* 714(1-2): 95-103.
- Hirata, H., B. Ladenheim, et al. (1996). "Autoradiographic evidence for methamphetamine-induced striatal dopaminergic loss in mouse brain: Attenuation in CuZn-superoxide dismutase transgenic mice." *Brain Res* 714(1-2): 95-103.
- Hom, D. G., D. Jiang, et al. (1997). "Elevated expression of glutathione peroxidase in PC12 cells results in protection against methamphetamine but not MPTP toxicity." *Brain Res Mol Brain Res* 46(1-2): 154-60.
- Horner, K. A., S. C. Westwood, et al. (2006). "Multiple high doses of methamphetamine increase the number of preproneuropeptide Y mRNA-expressing neurons in the striatum of rat via a dopamine D1 receptor-dependent mechanism." *J Pharmacol Exp Ther* 319(1): 414-21.
- Ide, S., H. Kobayashi, et al. (2006). "Linkage disequilibrium and association with methamphetamine dependence/psychosis of mu-opioid receptor gene polymorphisms." *Pharmacogenomics J* 6(3): 179-88.
- Imam, S. Z., M. Oetinger, et al. (2003). "The role of caspase III inhibition in methamphetamine-induced alterations in p53 and bcl-2 expression: Correlation with dopaminergic neurotoxicity." *Ann N Y Acad Sci* 993: 350; discussion 387-93.
- Imam, S. Z., J. el-Yazal, et al. (2001). "Methamphetamine-induced dopaminergic neurotoxicity: Role of peroxynitrite and neuroprotective role of antioxidants and peroxynitrite decomposition catalysts." *Ann N Y Acad Sci* 939: 366-80.
- Imam, S. Z., Y. Itzhak, et al. (2001). "Methamphetamine-induced alteration in striatal p53 and bcl-2 expressions in mice." *Brain Res Mol Brain Res* 91(1-2): 174-8.
- Imam, S. Z., G. D. Newport, et al. (2001). "Peroxynitrite plays a role in methamphetamine-induced dopaminergic neurotoxicity: Evidence from mice lacking neuronal nitric oxide synthase gene or overexpressing copper-zinc superoxide dismutase." *J Neurochem* 76(3): 745-9.
- Isao, T. and K. Akiyama (2004). "Effect of acute and chronic treatment with methamphetamine on mRNA expression of synaptotagmin IV and 25 KDa-synaptic-associated protein in the rat brain." *Psychiatry Clin Neurosci* 58(4): 410-9.
- Ishikawa, K., A. Nitta, et al. (2006). "Effects of single and repeated administration of methamphetamine or morphine on neuroglycan C gene expression in the rat brain." *Int J Neuropsychopharmacol* 9(4): 407-15.
- Itzhak, Y. and S. F. Ali (2006). "Role of nitergic system in behavioral and neurotoxic effects of amphetamine analogs." *Pharmacol Ther* 109(1-2): 246-62.
- Itzhak, Y., C. Gandia, et al. (1998). "Resistance of neuronal nitric oxide synthase-deficient mice to methamphetamine-induced dopaminergic neurotoxicity." *J Pharmacol Exp Ther* 284(3): 1040-7.
- Iwabuchi, K., Y. Kubota, et al. (2004). "Methamphetamine and brain histamine: A study using histamine-related gene knockout mice." *Ann N Y Acad Sci* 1025: 129-34.
- Janowsky, A., C. Mah, et al. (2001). "Mapping genes that regulate density of dopamine transporters and correlated behaviors in recombinant inbred mice." *J Pharmacol Exp Ther* 298(2): 634-43.
- Jayanthi, S., X. Deng, et al. (2001). "Methamphetamine causes differential regulation of pro-death and anti-death Bcl-2 genes in the mouse neocortex." *FASEB J* 15(10): 1745-52.
- Kajii, Y., S. Muraoka, et al. (2003). "A developmentally regulated and psychostimulant-inducible novel rat gene *mrt1* encoding PDZ-PX proteins isolated in the neocortex." *Mol Psychiatry* 8(4): 434-44.
- Kamens, H. M., S. Burkhart-Kasch, et al. (2006). "Ethanol-related traits in mice selectively bred for differential sensitivity to methamphetamine-induced activation." *Behav Neurosci* 120(6): 1356-66.
- Kamens, H. M., S. Burkhart-Kasch, et al. (2005). "Sensitivity to psychostimulants in mice bred for high and low stimulation to methamphetamine." *Genes Brain Behav* 4(2): 110-25.
- Karczmar, A. G. and C. L. Scudder (1967). "Behavioral responses to drugs and brain catecholamine levels in mice of different strains and genera." *Fed Proc* 26(4): 1186-91.
- Kita, T., G. C. Wagner, et al. (2003). "Current research on methamphetamine-induced neurotoxicity: Animal models of monoamine disruption." *J Pharmacol Sci* 92(3): 178-95.
- Kita, T. and T. Nakashima (2002). "[A recent trend in methamphetamine-induced neurotoxicity]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 22(2): 35-47.
- Kitahama, K. and J. L. Valatz (1979). "Strain differences in amphetamine sensitivity in mice. II. Overcompensation of paradoxical sleep after deprivation in two C57 strains." *Psychopharmacology (Berl)* 66(3): 291-5.
- Kliethermes, C. L., H. M. Kamens, et al. (2006). "Drug reward and intake in lines of mice selectively bred for divergent exploration of a hole board apparatus." *Genes Brain Behav*.



- Kodama, M., K. Akiyama, et al. (1998). "A robust increase in expression of arc gene, an effector immediate early gene, in the rat brain after acute and chronic methamphetamine administration." *Brain Res* 796(1-2): 273-83.
- Kruzich, P. J. and J. Xi (2006). "Differences in extinction responding and reinstatement of methamphetamine-seeking behavior between Fischer 344 and Lewis rats." *Pharmacol Biochem Behav* 83(3): 391-5.
- Kubota, Y., C. Ito, et al. (1999). "Transient increases of histamine H1 and H2 receptor mRNA levels in the rat striatum after the chronic administration of methamphetamine." *Neurosci Lett* 275(1): 37-40.
- Kuhn, D. M., D. M. Francescutti-Verbeem, et al. (2006). "Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: Relationship to methamphetamine-induced nerve ending damage." *Ann N Y Acad Sci* 1074: 31-41.
- Kuribara, H. and S. Tadokoro (1985). "Effects of psychoactive drugs on conditioned avoidance response in Mongolian gerbils (*Meriones unguiculatus*): Comparison with Wistar rats and dd mice." *Pharmacol Biochem Behav* 23(6): 1013-8.
- Maragos, W. F., R. Jakel, et al. (2000). "Methamphetamine toxicity is attenuated in mice that overexpress human manganese superoxide dismutase." *Brain Res* 878(1-2): 218-22.
- Masubuchi, S., S. Honma, et al. (2001). "Circadian activity rhythm in methamphetamine-treated Clock mutant mice." *Eur J Neurosci* 14(7): 1177-80.
- Masubuchi, S., S. Honma, et al. (2000). "Clock genes outside the suprachiasmatic nucleus involved in manifestation of locomotor activity rhythm in rats." *Eur J Neurosci* 12(12): 4206-14.
- Masuo, Y., M. Ishido, et al. (2004). "Motor activity and gene expression in rats with neonatal 6-hydroxydopamine lesions." *J Neurochem* 91(1): 9-19.
- Mori, A., K. Okuyama, et al. (2002). "Alteration of methamphetamine-induced striatal dopamine release in mint-1 knockout mice." *Neurosci Res* 43(3): 251-7.
- Nabeshima, T., A. Itoh, et al. (1994). "Effects of subacute administration of methamphetamine and nicotine on locomotor activity in transgenic mice expressing the human tyrosine hydroxylase gene." *J Neural Transm Gen Sect* 97(1): 41-9.
- Nikaïdo, T., M. Akiyama, et al. (2001). "Sensitized increase of period gene expression in the mouse caudate/putamen caused by repeated injection of methamphetamine." *Mol Pharmacol* 59(4): 894-900.
- Nishii, K., N. Matsushita, et al. (1998). "Motor and learning dysfunction during postnatal development in mice defective in dopamine neuronal transmission." *J Neurosci Res* 54(4): 450-64.
- Noailles, P. A., K. G. Becker, et al. (2003). "Methamphetamine-induced gene expression profiles in the striatum of male rat pups exposed to the drug in utero." *Brain Res Dev Brain Res* 147(1-2): 153-62.
- Numachi, Y., S. Yoshida, et al. (2000). "Two inbred strains of rats, Fischer 344 and Lewis, showed differential behavior and brain expression of corticosterone receptor mRNA induced by methamphetamine." *Ann N Y Acad Sci* 914: 33-45.
- Ogden, C. A., M. E. Rich, et al. (2004). "Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: An expanded convergent functional genomics approach." *Mol Psychiatry* 9(11): 1007-29.
- Onaivi, E. S., S. F. Ali, et al. (2002). "Ibogaine signals addiction genes and methamphetamine alteration of long-term potentiation." *Ann N Y Acad Sci* 965: 28-46.
- Osugi, T., Y. Aoki, et al. (1994). "[Involvement of gene expression in drug tolerance and dependence]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 14(4): 185-93.
- Ouchi, Y., Y. Kubota, et al. (2005). "Gene expression profiling in whole cerebral cortices of phencyclidine- or methamphetamine-treated rats." *Brain Res Mol Brain Res* 140(1-2): 142-9.
- Pacchioni, A. M., J. Vallone, et al. (2007). "Nrf2 gene deletion fails to alter psychostimulant-induced behavior or neurotoxicity." *Brain Res* 1127(1): 26-35.
- Palmer, A. A., M. Verbitsky, et al. (2005). "Gene expression differences in mice divergently selected for methamphetamine sensitivity." *Mamm Genome* 16(5): 291-305.
- Palmer, L. C., U. S. Hess, et al. (1997). "Comparison of the effects of an ampakine with those of methamphetamine on aggregate neuronal activity in cortex versus striatum." *Brain Res Mol Brain Res* 46(1-2): 127-35.
- Pennypacker, K. R., X. Yang, et al. (2000). "Long-term induction of Fos-related antigen-2 after methamphetamine-, methylenedioxymethamphetamine-, 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine- and trimethyltin-induced brain injury." *Neuroscience* 101(4): 913-9.
- Perez, F. A., W. R. Curtis, et al. (2005). "Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity." *BMC Neurosci* 6: 71.
- Pillot, C., A. Heron, et al. (2003). "Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, modulates the effects of methamphetamine on neuropeptide mRNA expression in rat striatum." *Eur J Neurosci* 17(2): 307-14.
- Rajan, P. D., R. Kekuda, et al. (2000). "Expression of the extraneuronal monoamine transporter in RPE and neural retina." *Curr Eye Res* 20(3): 195-204.

- Richardson, D., A. G. Karczmar, et al. (1972). "Intergeneric behavioral differences among methamphetamine treated mice." *Psychopharmacologia* 25(4): 347-75.
- Rubinstein, M., T. J. Phillips, et al. (1997). "Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine." *Cell* 90(6): 991-1001.
- Saito, A., Y. Fujikura-Ouchi, et al. (2007). "Association study of putative promoter polymorphisms in the neuroplastin gene and schizophrenia." *Neurosci Lett* 411(3): 168-73.
- Sano, H., Y. Yasoshima, et al. (2003). "Conditional ablation of striatal neuronal types containing dopamine D2 receptor disturbs coordination of basal ganglia function." *J Neurosci* 23(27): 9078-88.
- Sato, S., T. Chiba, et al. (2006). "Decline of striatal dopamine release in parkin-deficient mice shown by ex vivo autoradiography." *J Neurosci Res* 84(6): 1350-7.
- Schluter, O. M., F. Fornai, et al. (2003). "Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice." *Neuroscience* 118(4): 985-1002.
- Sellers, E. M. and R. F. Tyndale (2000). "Mimicking gene defects to treat drug dependence." *Ann N Y Acad Sci* 909: 233-46.
- Shilling, P. D., R. Kuczenski, et al. (2006). "Differential regulation of immediate-early gene expression in the prefrontal cortex of rats with a high vs low behavioral response to methamphetamine." *Neuropsychopharmacology* 31(11): 2359-67.
- Siuciak, J. A., S. A. McCarthy, et al. (2006). "Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: Evidence for altered striatal function." *Neuropharmacology* 51(2): 374-85.
- Sriram, K., D. B. Miller, et al. (2006). "Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: Role of tumor necrosis factor-alpha." *J Neurochem* 96(3): 706-18.
- Staszewski, R. D. and B. K. Yamamoto (2006). "Methamphetamine-induced spectrin proteolysis in the rat striatum." *J Neurochem* 96(5): 1267-76.
- Stumm, G., J. Schlegel, et al. (1999). "Amphetamines induce apoptosis and regulation of bcl-x splice variants in neocortical neurons." *Faseb J* 13(9): 1065-72.
- Suh, Y. J., M. H. Yang, et al. (2006). "GEDA: New knowledge base of gene expression in drug addiction." *J Biochem Mol Biol* 39(4): 441-7.
- Szumliński, K. K., K. D. Lominac, et al. (2005). "Behavioral and neurochemical phenotyping of Homer1 mutant mice: Possible relevance to schizophrenia." *Genes Brain Behav* 4(5): 273-88.
- Theodore, S., S. Stolberg, et al. (2006). "Human immunodeficiency virus-1 protein tat and methamphetamine interactions." *Ann N Y Acad Sci* 1074: 178-90.
- Theodore, S., W. A. Cass, et al. (2006). "Inhibition of tumor necrosis factor-alpha signaling prevents human immunodeficiency virus-1 protein Tat and methamphetamine interaction." *Neurobiol Dis* 23(3): 663-8.
- Theodore, S., W. A. Cass, et al. (2006). "Involvement of cytokines in human immunodeficiency virus-1 protein Tat and methamphetamine interactions in the striatum." *Exp Neurol* 199(2): 490-8.
- Theodore, S., W. A. Cass, et al. (2006). "Methamphetamine and human immunodeficiency virus protein Tat synergize to destroy dopaminergic terminals in the rat striatum." *Neuroscience* 137(3): 925-35.
- Thiriet, N., X. Deng, et al. (2005). "Neuropeptide Y protects against methamphetamine-induced neuronal apoptosis in the mouse striatum." *J Neurosci* 25(22): 5273-9.
- Tien, L. T., I. K. Ho, et al. (2006). "Role of mu-opioid receptor in modulation of preproenkephalin mRNA expression and opioid and dopamine receptor binding in methamphetamine-sensitized mice." *J Neurosci Res*.
- Toyota, H., C. Dugovic, et al. (2002). "Behavioral characterization of mice lacking histamine H(3) receptors." *Mol Pharmacol* 62(2): 389-97.
- Triarhou, L. C., E. H. Stotz, et al. (1994). "Studies on the striatal dopamine uptake system of weaver mutant mice and effects of ventral mesencephalic grafts." *Neurochem Res* 19(11): 1349-58.
- Tsai, S. J. (2006). "Increased central brain-derived neurotrophic factor activity could be a risk factor for substance abuse: Implications for treatment." *Med Hypotheses*.
- Ujike, H., M. Harano, et al. (2003). "Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis." *Pharmacogenomics J* 3(4): 242-7.
- Veenstra-VanderWeele, J., A. Qaadir, et al. (2006). "Association between the casein kinase 1 epsilon gene region and subjective response to D-amphetamine." *Neuropsychopharmacology* 31(5): 1056-63.
- Wells, P. G., Y. Bhuller, et al. (2005). "Molecular and biochemical mechanisms in teratogenesis involving reactive oxygen species." *Toxicol Appl Pharmacol* 207(2 Suppl): 354-66.
- Wilhelm, C. J., R. A. Johnson, et al. (2006). "Hydrogen ion concentration differentiates effects of methamphetamine and dopamine on transporter-mediated efflux." *J Neurochem* 96(4): 1149-59.

- Xie, T., L. Tong, et al. (2002). "Changes in gene expression linked to methamphetamine-induced dopaminergic neurotoxicity." *J Neurosci* 22(1): 274-83.
- Yamada, K., T. Nagai, et al. (2005). "Drug dependence, synaptic plasticity, and tissue plasminogen activator." *J Pharmacol Sci* 97(2): 157-61.
- Yamagata, K., K. Suzuki, et al. (2000). "Activation of an effector immediate-early gene arc by methamphetamine." *Ann N Y Acad Sci* 914: 22-32.
- Yamamoto, H., K. Imai, et al. (2005). "Methamphetamine modulation of gene expression in the brain: Analysis using customized cDNA microarray system with the mouse homologues of KIAA genes." *Brain Res Mol Brain Res* 137(1-2): 40-6.
- Yamamoto, H., K. Imai, et al. (2004). "Changes in expression of the mouse homologues of KIAA genes after subchronic methamphetamine treatment." *Ann N Y Acad Sci* 1025: 92-101.
- Yan, Y., A. Nitta, et al. (2006). "Relapse of methamphetamine-seeking behavior in C57BL/6J mice demonstrated by a reinstatement procedure involving intravenous self-administration." *Behav Brain Res* 168(1): 137-43.
- Yang, J. (2004). "[The study developments about changes of methamphetamine-induced genes' transcriptions and translations]." *Fa Yi Xue Za Zhi* 20(3): 185-8.
- Yoshida, S., Y. Numachi, et al. (2000). "The absence of impairment of cliff avoidance reaction induced by subchronic methamphetamine treatment in inbred strains of mice." *Tohoku J Exp Med* 190(3): 205-12.
- Yoshida, S., Y. Numachi, et al. (1998). "Impairment of cliff avoidance reaction induced by subchronic methamphetamine administration and restraint stress: Comparison between two inbred strains of rats." *Prog Neuropsychopharmacol Biol Psychiatry* 22(6): 1023-32.
- Yu, L. and P. C. Liao (2000). "Estrogen and progesterone distinctively modulate methamphetamine-induced dopamine and serotonin depletions in C57BL/6J mice." *J Neural Transm* 107(10): 1139-47.

## Georgia (US)

- Boulard, G. (2005). "The meth menace: Battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.
- Reid, L. W., K. W. Elifson, et al. (2007). "Ecstasy and gateway drugs: Initiating the use of ecstasy and other drugs." *Ann Epidemiol* 17(1): 74-80.

## Germany

- Hartel-Petri, R., R. Rodler, et al. (2005). "[Increasing prevalence of amphetamine--and methamphetamine-induced psychosis]." *Psychiatr Prax* 32(1): 13-7.
- Kahraman, A., M. Miller, et al. (2006). "Non-alcoholic fatty liver disease in HIV-positive patients predisposes for acute-on-chronic liver failure: Two cases." *Eur J Gastroenterol Hepatol* 18(1): 101-105.
- March, J. C., E. Oviedo-Joekes, et al. (2006). "Drugs and social exclusion in ten European cities." *Eur Addict Res* 12(1): 33-41.
- Meyer, U. (2005). "[Fritz Hauschild (1908-1974) and drug research in the 'German Democratic Republic' (GDR)]." *Pharmazie* 60(6): 468-72.
- Moeller, M. R. and T. Kraemer (2002). "Drugs of abuse monitoring in blood for control of driving under the influence of drugs." *Ther Drug Monit* 24(2): 210-21.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.
- Romhild, W., D. Krause, et al. (2003). "LC-MS/MS analysis of pholedrine in a fatal intoxication case." *Forensic Sci Int* 133(1-2): 101-6.
- Soellner, R. (2005). "Club drug use in Germany." *Subst Use Misuse* 40(9): 1279-93.

## GHB (Gamma Hydroxybutyrate)

*See also Polydrug Use*

- Chew, G. and A. Fernando, 3rd (2004). "Epileptic seizure in GHB withdrawal." *Australas Psychiatry* 12(4): 410-1.
- Drumright, L. N., S. J. Little, et al. (2006). "Unprotected anal intercourse and substance use among men who have sex with men with recent HIV infection." *J Acquir Immune Defic Syndr* 43(3): 344-50.
- Drumright, L. N., S. A. Strathdee, et al. (2006). "Unprotected anal intercourse and substance use before and after HIV diagnosis among recently HIV-infected men who have sex with men." *Sex Transm Dis*.
- Fernandez, M. I., T. Perrino, et al. (2005). "Surfing new territory: club-drug use and risky sex among Hispanic men who have sex with men recruited on the Internet." *J Urban Health* 82(1 Suppl 1): i79-88.

- Ghaziani, A. and T. D. Cook (2005). "Reducing HIV infections at circuit parties: From description to explanation and principles of intervention design." *J Int Assoc Physicians AIDS Care (Chic Ill)* 4(2): 32-46.
- Goldsamt, L. A., J. O'Brien, et al. (2005). "The relationship between club drug use and other drug use: A survey of New York City middle school students." *Subst Use Misuse* 40(9): 1539-55.
- Halkitis, P. N. and J. J. Palamar (2006). "GHB use among gay and bisexual men." *Addict Behav* 31(11): 2135-9.
- Hopfer, C., B. Mendelson, et al. (2006). "Club drug use among youths in treatment for substance abuse." *Am J Addict* 15(1): 94-9.
- Kelly, B. C., J. T. Parsons, et al. (2006). "Prevalence and predictors of club drug use among club-going young adults in New York City." *J Urban Health* 83(5): 884-895.
- Kohrs, F. P., C. Mann and R. Greenberg (2004). "The use of amphetamine in gamma-hydroxybutyrate overdose: A case report." *J Psychoactive Drugs* 36(3): 401-2.
- Lampinen, T. M., D. McGhee, et al. (2006). "Increased risk of "club" drug use among gay and bisexual high school students in British Columbia." *J Adolesc Health* 38(4): 458-61.
- Lampinen, T. M., D. McGhee, et al. (2006). "Use of crystal methamphetamine and other club drugs among high school students in Vancouver and Victoria." *BC Medical Journal* 48(1): 22-27.
- Mansergh, G., G. N. Colfax, et al. (2001). "The Circuit Party Men's Health Survey: Findings and implications for gay and bisexual men." *Am J Public Health* 91(6): 953-8.
- Mattison, A. M., M. W. Ross, et al. (2001). "Circuit party attendance, club drug use, and unsafe sex in gay men." *J Subst Abuse* 13(1-2): 119-26.
- Parsons, J. T., B. C. Kelly, et al. (2006). "Differences in club drug use between heterosexual and lesbian/bisexual females." *Addict Behav* 31(12): 2344-9.
- Ross, M. W., A. M. Mattison, et al. (2003). "Club drugs and sex on drugs are associated with different motivations for gay circuit party attendance in men." *Subst Use Misuse* 38(8): 1173-83.
- Rusch, M., T. M. Lampinen, et al. (2004). "Unprotected anal intercourse associated with recreational drug use among young men who have sex with men depends on partner type and intercourse role." *Sex Transm Dis* 31(8): 492-8.
- Scharf, M. B., D. Brown, et al. (1985). "The effects and effectiveness of gamma-hydroxybutyrate in patients with narcolepsy." *J Clin Psychiatry* 46(6): 222-5.
- Wu, L. T., W. E. Schlenger, et al. (2006). "Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths." *Drug Alcohol Depend* 84(1): 102-13.

### Glucose

*See* Blood, Glucose Metabolism in (animals); Brain, Glucose Metabolism in; Brain, Glucose Metabolism in (animals);

### Glutamate

- Nordahl, T. E., R. Salo, et al. (2003). "Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: A review." *J Neuropsychiatry Clin Neurosci* 15(3): 317-25.
- Powrozek, T. A., Y. Sari, et al. (2004). "Neurotransmitters and substances of abuse: Effects on adult neurogenesis." *Curr Neurovasc Res* 1(3): 251-60.

### Glutamate (animals)

- Abekawa, T. (1997). "[Experimental study of methamphetamine psychosis--role of glutamate and nitric oxide in methamphetamine-induced dopaminergic and serotonergic neurotoxicity in the rat brain]." *Hokkaido Igaku Zasshi* 72(1): 113-26.
- Abekawa, T., T. Ohmori, et al. (1994). "Effects of repeated administration of a high dose of methamphetamine on dopamine and glutamate release in rat striatum and nucleus accumbens." *Brain Res* 643(1-2): 276-81.
- Achat-Mendes, C., K. L. Anderson, et al. (2006). "Impairment in consolidation of learned place preference following dopaminergic neurotoxicity in mice is ameliorated by N-acetylcysteine but not D1 and D2 dopamine receptor agonists." *Neuropsychopharmacology*.
- Ali, S. F., G. D. Newport, et al. (1994). "Low environmental temperatures or pharmacologic agents that produce hypothermia decrease methamphetamine neurotoxicity in mice." *Brain Res* 658(1-2): 33-8.
- Ali, S. F., R. R. Holson, et al. (1993). "Development of dopamine and N-methyl-D-aspartate systems in rat brain: The effect of prenatal phencyclidine exposure." *Brain Res Dev Brain Res* 73(1): 25-33.

- Amano, T., H. Matsubayashi, et al. (1996). "Hypersensitivity of nucleus accumbens neurons to methamphetamine and dopamine following repeated administrations of methamphetamine." *Ann N Y Acad Sci* 801: 136-47.
- Arai, I., T. Shimazoe, et al. (1996). "Enhancement of dopamine release from the striatum through metabotropic glutamate receptor activation in methamphetamine sensitized rats." *Brain Res* 729(2): 277-80.
- Bagorda, F., G. Teuchert-Noodt, et al. (2006). "Isolation rearing or methamphetamine traumatization induce a "dysconnection" of prefrontal efferents in gerbils: Implications for schizophrenia." *J Neural Transm* 113(3): 365-79.
- Berman, S. B. and T. G. Hastings (1997). "Inhibition of glutamate transport in synaptosomes by dopamine oxidation and reactive oxygen species." *J Neurochem* 69(3): 1185-95.
- Bialek, M., P. Zaremba, et al. (2004). "Neuroprotective role of testosterone in the nervous system." *Pol J Pharmacol* 56(5): 509-18.
- Boireau, A., F. Bordier, et al. (1995). "Methamphetamine and dopamine neurotoxicity: Differential effects of agents interfering with glutamatergic transmission." *Neurosci Lett* 195(1): 9-12.
- Bowyer, J. F. (1995). "The role of hyperthermia in amphetamine's interactions with NMDA receptors, nitric oxide, and age to produce neurotoxicity." *Ann N Y Acad Sci* 765: 309-10.
- Bowyer, J. F., B. Gough, et al. (1993). "Effects of a cold environment or age on methamphetamine-induced dopamine release in the caudate putamen of female rats." *Pharmacol Biochem Behav* 44(1): 87-98.
- Bowyer, J. F., A. C. Scallet, et al. (1991). "Interactions of MK-801 with glutamate-, glutamine- and methamphetamine-evoked release of [3H]dopamine from striatal slices." *J Pharmacol Exp Ther* 257(1): 262-70.
- Brown, J. M., M. S. Quinton, et al. (2005). "Methamphetamine-induced inhibition of mitochondrial complex II: Roles of glutamate and peroxynitrite." *J Neurochem* 95(2): 429-36.
- Burrows, K. B., W. L. Nixdorf, et al. (2000). "Central administration of methamphetamine synergizes with metabolic inhibition to deplete striatal monoamines." *J Pharmacol Exp Ther* 292(3): 853-60.
- Burrows, K. B. and C. K. Meshul (1999). "High-dose methamphetamine treatment alters presynaptic GABA and glutamate immunoreactivity." *Neuroscience* 90(3): 833-50.
- Burrows, K. B. and C. K. Meshul (1997). "Methamphetamine alters presynaptic glutamate immunoreactivity in the caudate nucleus and motor cortex." *Synapse* 27(2): 133-44.
- Bustamante, D., Z. B. You, et al. (2002). "Effect of single and repeated methamphetamine treatment on neurotransmitter release in substantia nigra and neostriatum of the rat." *J Neurochem* 83(3): 645-54.
- Cadet, J. L., S. Ali, et al. (1994). "Involvement of oxygen-based radicals in methamphetamine-induced neurotoxicity: Evidence from the use of CuZnSOD transgenic mice." *Ann N Y Acad Sci* 738: 388-91.
- Dai, F., J. Y. Yang, et al. (2006). "Effect of drug-induced ascorbic acid release in the striatum and the nucleus accumbens in hippocampus-lesioned rats." *Brain Res* 1125(1): 163-70.
- Earle, M. L. and J. A. Davies (1991). "The effect of methamphetamine on the release of glutamate from striatal slices." *J Neural Transm Gen Sect* 86(3): 217-22.
- Eisch, A. J., S. J. O'Dell, et al. (1996). "Striatal and cortical NMDA receptors are altered by a neurotoxic regimen of methamphetamine." *Synapse* 22(3): 217-25.
- Facchinetti, F., R. Dall'Olio, et al. (1994). "Long-lasting effects of chronic neonatal blockade of N-methyl-D-aspartate receptor through the competitive antagonist CGP 39551 in rats." *Neuroscience* 60(2): 343-53.
- Fang, Y. R., T. Abekawa, et al. (2005). "Effect of the protein kinase C inhibitor, staurosporine, on the high dose of methamphetamine-induced behavioral sensitization to dizocilpine (MK-801)." *Psychopharmacology (Berl)* 180(1): 100-6.
- Finnegan, K. T. and T. Taraska (1996). "Effects of glutamate antagonists on methamphetamine and 3,4-methylenedioxymethamphetamine-induced striatal dopamine release in vivo." *J Neurochem* 66(5): 1949-58.
- Fornai, F., P. Lenzi, et al. (2005). "Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice." *Brain Res Bull* 65(5): 405-13.
- Fornai, F., G. Lazzeri, et al. (2003). "Amphetamines induce ubiquitin-positive inclusions within striatal cells." *Neurol Sci* 24(3): 182-3.
- Foster, S. B., M. Z. Wrona, et al. (2003). "The parkinsonian neurotoxin 1-methyl-4-phenylpyridinium (MPP(+)) mediates release of l-3,4-dihydroxyphenylalanine (l-DOPA) and inhibition of l-DOPA decarboxylase in the rat striatum: a microdialysis study." *Chem Res Toxicol* 16(10): 1372-84.
- Fujio, M., T. Nakagawa, et al. (2005). "Facilitative effect of a glutamate transporter inhibitor (2S,3S)-3-{3-[4-(trifluoromethyl)benzoylamino]benzyloxy}aspartate on the expression of methamphetamine-induced behavioral sensitization in rats." *J Pharmacol Sci* 99(4): 415-8.
- Fujio, M., T. Nakagawa, et al. (2005). "Gene transfer of GLT-1, a glutamate transporter, into the nucleus accumbens shell attenuates methamphetamine- and morphine-induced conditioned place preference in rats." *Eur J Neurosci* 22(11): 2744-54.
- Gibb, J. W., M. Johnson, et al. (1990). "Neurochemical basis of neurotoxicity." *Neurotoxicology* 11(2): 317-21.

- Golembiowska, K., J. Konieczny, et al. (2002). "The role of striatal metabotropic glutamate receptors in degeneration of dopamine neurons." *Amino Acids* 23(1-3): 199-205.
- Golembiowska, K. and A. Zylewska (1998). "N6-2-(4-aminophenyl)ethyladenosine (APNEA), a putative adenosine A3 receptor agonist, enhances methamphetamine-induced dopamine outflow in rat striatum." *Pol J Pharmacol* 50(4-5): 299-305.
- Grisel, J. E., J. K. Belknap, et al. (1997). "Quantitative trait loci affecting methamphetamine responses in BXD recombinant inbred mouse strains." *J Neurosci* 17(2): 745-54.
- Hamamura, M., S. Watanabe, et al. (2004). "Selective changes in the shapes of parasagittal bands of Aldoc (Zebrin) mRNA in the rat vermis of the cerebellum after repeated methamphetamine injections." *Cerebellum* 3(4): 236-47.
- Hanson, G. R., L. P. Midgley, et al. (1995). "Response of extrapyramidal and limbic neurotensin systems to phencyclidine treatment." *Eur J Pharmacol* 278(2): 167-73.
- Hara, M., A. Akaike, et al. (1987). "Acute effects of methamphetamine applied microiontophoretically to nucleus accumbens neurons in rats." *Neurosci Res* 4(4): 279-90.
- Hayase, T., Y. Yamamoto, et al. (2003). "Brain excitatory amino acid transporters (EAATs) and treatment of methamphetamine toxicity." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 38(6): 498-511.
- Hess, U. S., S. P. Whalen, et al. (2003). "Ampakines reduce methamphetamine-driven rotation and activate neocortex in a regionally selective fashion." *Neuroscience* 121(2): 509-21.
- Higashi, H., K. Inanaga, et al. (1989). "Enhancement of dopamine actions on rat nucleus accumbens neurones in vitro after methamphetamine pre-treatment." *J Physiol* 408: 587-603.
- Honda, M. (2004). "[The relation between behavioral sensitization and glutamate release on the animal model of methamphetamine-induced psychosis]." *Hokkaido Igaku Zasshi* 79(1): 65-78.
- Hotchkiss, A. J., M. E. Morgan, et al. (1979). "The long-term effects of multiple doses of methamphetamine on neostriatal tryptophan hydroxylase, tyrosine hydroxylase, choline acetyltransferase and glutamate decarboxylase activities." *Life Sci* 25(16): 1373-8.
- Ito, K., T. Abekawa, et al. (2006). "Relationship between development of cross-sensitization to MK-801 and delayed increases in glutamate levels in the nucleus accumbens induced by a high dose of methamphetamine." *Psychopharmacology (Berl)* 187(3): 293-302.
- Ito, K., T. Abekawa, et al. (2006). "Valproate blocks high-dose methamphetamine-induced behavioral cross-sensitization to locomotion-inducing effect of dizocilpine (MK-801), but not methamphetamine." *Psychopharmacology (Berl)* 186(4): 525-33.
- Itzhak, Y. and S. F. Ali (2006). "Role of nitrenergic system in behavioral and neurotoxic effects of amphetamine analogs." *Pharmacol Ther* 109(1-2): 246-62.
- Johnson, S. A., N. T. Luu, et al. (1999). "Synergistic interactions between ampakines and antipsychotic drugs." *J Pharmacol Exp Ther* 289(1): 392-7.
- Kaiya, H., K. Takeuchi, et al. (1983). "Effects of subchronic treatment of methamphetamine haloperidol on the rat brain levels of GABA, glutamate and aspartate." *Folia Psychiatr Neurol Jpn* 37(1): 107-13.
- Kim, S., R. Westphalen, et al. (2000). "Toward development of an in vitro model of methamphetamine-induced dopamine nerve terminal toxicity." *J Pharmacol Exp Ther* 293(2): 625-33.
- Kokoshka, J. M., R. R. Metzger, et al. (1998). "Methamphetamine treatment rapidly inhibits serotonin, but not glutamate, transporters in rat brain." *Brain Res* 799(1): 78-83.
- Layer, R. T., L. R. Bland, et al. (1993). "MK-801, but not drugs acting at strychnine-insensitive glycine receptors, attenuate methamphetamine nigrostriatal toxicity." *Brain Res* 625(1): 38-44.
- Lotharius, J., J. Falsig, et al. (2005). "Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway." *J Neurosci* 25(27): 6329-42.
- Manning, D. H., R. H. Strang, et al. (1974). "Changes in cerebral carbohydrate metabolism in the rat after acute and chronic treatment with, and withdrawal of, methamphetamine." *Biochem Pharmacol* 23(7): 1205-9.
- Mark, K. A., J. J. Soghomonian, et al. (2004). "High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity." *J Neurosci* 24(50): 11449-56.
- Marshall, J. F., S. J. O'Dell, et al. (1993). "Dopamine-glutamate interactions in methamphetamine-induced neurotoxicity." *J Neural Transm Gen Sect* 91(2-3): 241-54.
- Masuo, Y., M. Ishido, et al. (2004). "Motor activity and gene expression in rats with neonatal 6-hydroxydopamine lesions." *J Neurochem* 91(1): 9-19.
- McGinty, J. F. (1995). "Introduction to the role of excitatory amino acids in the actions of abused drugs: a symposium presented at the 1993 annual meeting of the College on Problems of Drug Dependence." *Drug Alcohol Depend* 37(2): 91-4.
- Miyamoto, Y., K. Yamada, et al. (2004). "Behavioural adaptations to addictive drugs in mice lacking the NMDA receptor epsilon1 subunit." *Eur J Neurosci* 19(1): 151-8.

- Miyatake, M., M. Narita, et al. (2005). "Glutamatergic neurotransmission and protein kinase C play a role in neuron-glia communication during the development of methamphetamine-induced psychological dependence." *Eur J Neurosci* 22(6): 1476-88.
- Muraki, A. (1993). "[Effects of antagonists of NMDA receptor on methamphetamine-induced decrease in the dopamine uptake sites in the rat striatum and on the behavioral sensitization]." *Hokkaido Igaku Zasshi* 68(3): 407-18.
- Nakagawa, T., M. Fujio, et al. (2005). "Effect of MS-153, a glutamate transporter activator, on the conditioned rewarding effects of morphine, methamphetamine and cocaine in mice." *Behav Brain Res* 156(2): 233-9.
- Nash, J. F. and B. K. Yamamoto (1992). "Methamphetamine neurotoxicity and striatal glutamate release: Comparison to 3,4-methylenedioxymethamphetamine." *Brain Res* 581(2): 237-43.
- Nath, A., C. Anderson, et al. (2000). "Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia." *J Psychopharmacol* 14(3): 222-7.
- Nishino, N., Y. Shirai, et al. (1996). "Increased glutamate transporter (GLT-1) immunoreactivity in the rat striatum after repeated intermittent administration of methamphetamine." *Ann N Y Acad Sci* 801: 310-4.
- O'Dell, S. J., F. B. Weihmuller, et al. (1994). "Excitotoxic striatal lesions protect against subsequent methamphetamine-induced dopamine depletions." *J Pharmacol Exp Ther* 269(3): 1319-25.
- Ohmori, T., T. Abekawa, et al. (1996). "The role of glutamate in the neurotoxic effects of methamphetamine." *Ann N Y Acad Sci* 801: 315-26.
- Ohmori, T., T. Abekawa, et al. (1996). "The role of glutamate in behavioral and neurotoxic effects of methamphetamine." *Neurochem Int* 29(3): 301-7.
- Pacchioni, A. M., J. Vallone, et al. (2007). "Nrf2 gene deletion fails to alter psychostimulant-induced behavior or neurotoxicity." *Brain Res* 1127(1): 26-35.
- Powrozek, T. A., Y. Sari, et al. (2004). "Neurotransmitters and substances of abuse: Effects on adult neurogenesis." *Curr Neurovasc Res* 1(3): 251-60.
- Pu, C., H. W. Broening, et al. (1996). "Effect of methamphetamine on glutamate-positive neurons in the adult and developing rat somatosensory cortex." *Synapse* 23(4): 328-34.
- Pu, C., J. E. Fisher, et al. (1994). "The effects of amfonelic acid, a dopamine uptake inhibitor, on methamphetamine-induced dopaminergic terminal degeneration and astrocytic response in rat striatum." *Brain Res* 649(1-2): 217-24.
- Pu, C. and C. V. Vorhees (1993). "Developmental dissociation of methamphetamine-induced depletion of dopaminergic terminals and astrocyte reaction in rat striatum." *Brain Res Dev Brain Res* 72(2): 325-8.
- Raudensky, J. and B. K. Yamamoto (2006). "Effects of chronic unpredictable stress and methamphetamine on hippocampal glutamate function." *Brain Res*.
- Riddle, E. L., A. E. Fleckenstein, et al. (2006). "Mechanisms of methamphetamine-induced dopaminergic neurotoxicity." *AAPS J* 8(2): E413-8.
- Rocher, C. and A. M. Gardier (2001). "Effects of repeated systemic administration of d-Fenfluramine on serotonin and glutamate release in rat ventral hippocampus: comparison with methamphetamine using in vivo microdialysis." *Naunyn Schmiedebergs Arch Pharmacol* 363(4): 422-8.
- Segura Aguilar, J. and R. M. Kostrzewa (2004). "Neurotoxins and neurotoxic species implicated in neurodegeneration." *Neurotox Res* 6(7-8): 615-30.
- Shirai, Y., O. Shirakawa, et al. (1996). "Increased striatal glutamate transporter by repeated intermittent administration of methamphetamine." *Psychiatry Clin Neurosci* 50(3): 161-4.
- Shoblock, J. R., E. B. Sullivan, et al. (2003). "Neurochemical and behavioral differences between d-methamphetamine and d-amphetamine in rats." *Psychopharmacology (Berl)* 165(4): 359-69.
- Sonsalla, P. K., D. S. Albers, et al. (1998). "Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism." *Amino Acids* 14(1-3): 69-74.
- Stadlin, A., J. W. Lau, et al. (1998). "A selective regional response of cultured astrocytes to methamphetamine." *Ann N Y Acad Sci* 844: 108-21.
- Staszewski, R. D. and B. K. Yamamoto (2006). "Methamphetamine-induced spectrin proteolysis in the rat striatum." *J Neurochem* 96(5): 1267-76.
- Stephans, S. E., T. S. Whittingham, et al. (1998). "Substrates of energy metabolism attenuate methamphetamine-induced neurotoxicity in striatum." *J Neurochem* 71(2): 613-21.
- Stephans, S. and B. Yamamoto (1996). "Methamphetamines pretreatment and the vulnerability of the striatum to methamphetamine neurotoxicity." *Neuroscience* 72(3): 593-600.
- Stephans, S. E. and B. Y. Yamamoto (1995). "Effect of repeated methamphetamine administrations on dopamine and glutamate efflux in rat prefrontal cortex." *Brain Res* 700(1-2): 99-106.

- Stephans, S. E. and B. K. Yamamoto (1994). "Methamphetamine-induced neurotoxicity: Roles for glutamate and dopamine efflux." *Synapse* 17(3): 203-9.
- Szumliński, K. K., K. D. Lominac, et al. (2005). "Behavioral and neurochemical phenotyping of Homer1 mutant mice: possible relevance to schizophrenia." *Genes Brain Behav* 4(5): 273-88.
- Wallace, T. L., C. V. Vorhees, et al. (2001). "Effects of lubeluzole on the methamphetamine-induced increase in extracellular glutamate and the long-term depletion of striatal dopamine." *Synapse* 40(2): 95-101.
- Wardas, J. (2002). "Neuroprotective role of adenosine in the CNS." *Pol J Pharmacol* 54(4): 313-26.
- Witkin, J. M. (1993). "Blockade of the locomotor stimulant effects of cocaine and methamphetamine by glutamate antagonists." *Life Sci* 53(24): PL405-10.
- Yamamoto, B. K. and M. G. Bankson (2005). "Amphetamine neurotoxicity: cause and consequence of oxidative stress." *Crit Rev Neurobiol* 17(2): 87-118.
- Yamamoto, H., N. Kitamura, et al. (1999). "Differential changes in glutamatergic transmission via N-methyl-D-aspartate receptors in the hippocampus and striatum of rats behaviourally sensitized to methamphetamine." *Int J Neuropsychopharmacol* 2(3): 155-163.
- Zhang, Y., T. M. Loonam, et al. (2001). "Comparison of cocaine- and methamphetamine-evoked dopamine and glutamate overflow in somatodendritic and terminal field regions of the rat brain during acute, chronic, and early withdrawal conditions." *Ann N Y Acad Sci* 937: 93-120.

### Glutamate Receptors (animals)

- Ali, S. F., G. D. Newport, et al. (1996). "Methamphetamine-induced dopaminergic toxicity in mice. Role of environmental temperature and pharmacological agents." *Ann N Y Acad Sci* 801: 187-98.
- Ali, S. F., R. R. Holson, et al. (1993). "Development of dopamine and N-methyl-D-aspartate systems in rat brain: The effect of prenatal phencyclidine exposure." *Brain Res Dev Brain Res* 73(1): 25-33.
- Arai, I., T. Shimazoe, et al. (1996). "Enhancement of dopamine release from the striatum through metabotropic glutamate receptor activation in methamphetamine sensitized rats." *Brain Res* 729(2): 277-80.
- Battaglia, G., F. Fornai, et al. (2002). "Selective blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine neurotoxicity." *J Neurosci* 22(6): 2135-41.
- Bowyer, J. F., D. L. Davies, et al. (1994). "Further studies of the role of hyperthermia in methamphetamine neurotoxicity." *J Pharmacol Exp Ther* 268(3): 1571-80.
- Fukumoto, M., M. Iwata, et al. (2005). "Effects of acute administration of methamphetamine on Narp mRNA in rat brain." *Addict Biol* 10(3): 257-9.
- Fuller, R. W., S. K. Hemrick-Luecke, et al. (1992). "Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist." *Neuropharmacology* 31(10): 1027-32.
- Gandolfi, O., R. Rimondini, et al. (1992). "The modulation of dopaminergic transmission in the striatum by MK-801 is independent of presynaptic mechanisms." *Neuropharmacology* 31(11): 1111-4.
- Gibb, J. W., M. Johnson, et al. (1989). "MK-801 attenuates the methamphetamine induced decreased in tryptophan hydroxylase activity." *NIDA Res Monogr* 95: 511.
- Golembiowska, K., J. Konieczny, et al. (2003). "Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats." *Neuropharmacology* 45(4): 484-92.
- Golembiowska, K., J. Konieczny, et al. (2002). "The role of striatal metabotropic glutamate receptors in degeneration of dopamine neurons." *Amino Acids* 23(1-3): 199-205.
- Hanson, G. R., N. Singh, et al. (1995). "The role of NMDA receptor systems in neuropeptide responses to stimulants of abuse." *Drug Alcohol Depend* 37(2): 107-10.
- Hess, U. S., S. P. Whalen, et al. (2003). "Ampakines reduce methamphetamine-driven rotation and activate neocortex in a regionally selective fashion." *Neuroscience* 121(2): 509-21.
- Ishida, Y., K. Todaka, et al. (2002). "Morphological changes in immunopositive cells of ionotropic glutamate receptor subunits during the development of transplanted fetal ventral mesencephalic neurons." *Brain Res* 940(1-2): 79-85.
- Itzhak, Y. (1994). "Modulation of the PCP/NMDA receptor complex and sigma binding sites by psychostimulants." *Neurotoxicol Teratol* 16(4): 363-8.
- Kashiwabara, K., M. Sato, et al. (1984). "Reduction of 3H-kainic acid binding in rat cerebral cortex by chronic methamphetamine administration." *Biol Psychiatry* 19(8): 1173-82.
- Larson, J., C. N. Quach, et al. (1996). "Effects of an AMPA receptor modulator on methamphetamine-induced hyperactivity in rats." *Brain Res* 738(2): 353-6.



- Lockhart, B., A. Roger, et al. (2005). "In vivo neuroprotective effects of the novel imidazolyl nitron free-radical scavenger (Z)-alpha-[2-thiazol-2-yl]imidazol-4-yl]-N-tert-butyl nitron (S34176)." *Eur J Pharmacol* 511(2-3): 127-36.
- Miyatake, M., M. Narita, et al. (2005). "Glutamatergic neurotransmission and protein kinase C play a role in neuron-glia communication during the development of methamphetamine-induced psychological dependence." *Eur J Neurosci* 22(6): 1476-88.
- Moore, K. A., T. Mirshahi, et al. (1996). "Pharmacological characterization of BNMPA (alpha-benzyl-N-methylphenethylamine), an impurity of illicit methamphetamine synthesis." *Eur J Pharmacol* 311(2-3): 133-9.
- Muraki, A. (1993). "[Effects of antagonists of NMDA receptor on methamphetamine-induced decrease in the dopamine uptake sites in the rat striatum and on the behavioral sensitization]." *Hokkaido Igaku Zasshi* 68(3): 407-18.
- Palmer, L. C., U. S. Hess, et al. (1997). "Comparison of the effects of an ampakine with those of methamphetamine on aggregate neuronal activity in cortex versus striatum." *Brain Res Mol Brain Res* 46(1-2): 127-35.
- Rodrigues, L. G., M. A. Tavares, et al. (2004). "Methamphetamine exacerbates the toxic effect of kainic acid in the adult rat retina." *Neurochem Int* 45(8): 1133-41.
- Shimazoe, T., Y. Doi, et al. (2002). "Both metabotropic glutamate I and II receptors mediate augmentation of dopamine release from the striatum in methamphetamine-sensitized rats." *Jpn J Pharmacol* 89(1): 85-8.
- Shoblock, J. R., E. B. Sullivan, et al. (2003). "Neurochemical and behavioral differences between d-methamphetamine and d-amphetamine in rats." *Psychopharmacology (Berl)* 165(4): 359-69.
- Singh, N. A., L. P. Midgley, et al. (1991). "N-Methyl-D-aspartate receptors mediate dopamine-induced changes in extrapyramidal and limbic dynorphin systems." *Brain Res* 555(2): 233-8.
- Singh, N. A., L. G. Bush, et al. (1990). "Dopamine-mediated changes in central nervous system neurotensin systems: A role for NMDA receptors." *Eur J Pharmacol* 187(3): 337-44.
- Snyder, G. L., P. B. Allen, et al. (2000). "Regulation of phosphorylation of the GluR1 AMPA receptor in the neostriatum by dopamine and psychostimulants in vivo." *J Neurosci* 20(12): 4480-8.
- Sonsalla, P. K., D. S. Albers, et al. (1998). "Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism." *Amino Acids* 14(1-3): 69-74.
- Staszewski, R. D. and B. K. Yamamoto (2006). "Methamphetamine-induced spectrin proteolysis in the rat striatum." *J Neurochem* 96(5): 1267-76.
- Stephans, S. and B. Yamamoto (1996). "Methamphetamines pretreatment and the vulnerability of the striatum to methamphetamine neurotoxicity." *Neuroscience* 72(3): 593-600.
- Uemura, K., T. Aki, et al. (2003). "Protein kinase C-epsilon protects PC12 cells against methamphetamine-induced death: Possible involvement of suppression of glutamate receptor." *Life Sci* 72(14): 1595-607.
- Ujike, H., H. Tsuchida, et al. (1992). "Competitive and non-competitive N-methyl-D-aspartate antagonists fail to prevent the induction of methamphetamine-induced sensitization." *Life Sci* 50(22): 1673-81.
- Wardas, J. (2002). "Neuroprotective role of adenosine in the CNS." *Pol J Pharmacol* 54(4): 313-26.
- Witkin, J. M. (1993). "Blockade of the locomotor stimulant effects of cocaine and methamphetamine by glutamate antagonists." *Life Sci* 53(24): PL405-10.
- Yamamoto, H., N. Kitamura, et al. (1999). "Differential changes in glutamatergic transmission via N-methyl-D-aspartate receptors in the hippocampus and striatum of rats behaviourally sensitized to methamphetamine." *Int J Neuropsychopharmacol* 2(3): 155-163.
- Yang, S. N. (2000). "Sustained enhancement of AMPA receptor- and NMDA receptor-mediated currents induced by dopamine D1/D5 receptor activation in the hippocampus: An essential role of postsynaptic Ca<sup>2+</sup>." *Hippocampus* 10(1): 57-63.

## Greece

- Raikos, N., H. Tsoukali, et al. (2002). "Amphetamine derivative related deaths in northern Greece." *Forensic Sci Int* 128(1-2): 31-4.
- March, J. C., E. Oviedo-Joekes, et al. (2006). "Drugs and social exclusion in ten European cities." *Eur Addict Res* 12(1): 33-41.

## Guam (US)

- Storr, C. L., A. M. Arria, et al. (2004). "Neighborhood environment and opportunity to try methamphetamine ("ice") and marijuana: Evidence from Guam in the Western Pacific region of Micronesia." *Subst Use Misuse* 39(2): 253-76.

### HAART

*See Antiretroviral Therapy*

### Hallucinations

*See also Flashbacks; Psychosis*

- Brecht, M. L., A. O'Brien, et al. (2004). "Methamphetamine use behaviors and gender differences." *Addict Behav* 29(1): 89-106.
- Edakubo, T., T. Kaneko, et al. (1991). "[Secondary development of psychological dependence in a methamphetamine dependent]." *Arukoru Kenkyuto Yakubutsu Ison* 26(2): 96-104.
- Hall, W., J. Hando, et al. (1996). "Psychological morbidity and route of administration among amphetamine users in Sydney, Australia." *Addiction* 91(1): 81-7.
- Harris, D. and S. L. Batki (2000). "Stimulant psychosis: Symptom profile and acute clinical course." *Am J Addict* 9(1): 28-37.
- Malitz, S. and M. Kanzler (1970). "Effects of drugs on perception in man." *Res Publ Assoc Res Nerv Ment Dis* 48: 35-53.
- Marschall, M. A., R. F. Dolezal, et al. (1991). "Chronic wounds and delusions of parasitosis in the drug abuser." *Plast Reconstr Surg* 88(2): 328-30.
- Martin, I., T. M. Lampinen, et al. (2006). "Methamphetamine use among marginalized youth in British Columbia." *Can J Public Health* 97(4): 320-4.
- Martin Alisky, J. (2006). "Cholinesterase inhibitors might alleviate methamphetamine-induced delusions, hallucinations and cognitive impairment, while reducing craving and addiction." *World J Biol Psychiatry* 7(4): 269.
- Matsumoto, T., A. Kamijo, et al. (2002). "Methamphetamine in Japan: the consequences of methamphetamine abuse as a function of route of administration." *Addiction* 97(7): 809-17.
- McKetin, R., J. McLaren, et al. (2006). "The prevalence of psychotic symptoms among methamphetamine users." *Addiction* 101(10): 1473-8.
- Nakatani, Y. and T. Hara (1998). "Disturbance of consciousness due to methamphetamine abuse. A study of 2 patients." *Psychopathology* 31(3): 131-7.
- Sato, M. (1992). "A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis." *Ann N Y Acad Sci* 654: 160-70.
- Sommers, I., D. Baskin, et al. (2006). "Methamphetamine use among young adults: Health and social consequences." *Addict Behav* 31(8): 1469-76.
- Srisurapanont, M., R. Ali, et al. (2003). "Psychotic symptoms in methamphetamine psychotic in-patients." *Int J Neuropsychopharmacol* 6(4): 347-52.
- Wada, K. and S. Fukui (1990). "[Relationship between years of methamphetamine use and symptoms of methamphetamine psychosis]." *Arukoru Kenkyuto Yakubutsu Ison* 25(3): 143-58.
- Yui, K., S. Ikemoto, et al. (2002). "Spontaneous recurrence of methamphetamine-induced paranoid-hallucinatory states in female subjects: Susceptibility to psychotic states and implications for relapse of schizophrenia." *Pharmacopsychiatry* 35(2): 62-71.

### Harm Reduction

*See also Syringe Exchange and Syringe Access*

- Baker, F. M. and W. F. Haning, 3rd (2001). "Substance abuse and dependence in a public hospital: Hawaii." *Hawaii Med J* 60(2): 35-8.
- Bungay, V., L. Malchy, et al. (2006). "Life with jib: A snapshot of street youth's use of crystal methamphetamine." *Addiction Research and Theory* 14(3): 235-251.
- Collins, C. L., T. Kerr, et al. (2005). "Rationale to evaluate medically supervised safer smoking facilities for non-injection illicit drug users." *Can J Public Health* 96(5): 344-7.
- Collins, C. L., T. Kerr, et al. (2005). "Potential uptake and correlates of willingness to use a supervised smoking facility for noninjection illicit drug use." *J Urban Health* 82(2): 276-84.
- Darke, S., J. Cohen, et al. (1994). "Transitions between routes of administration of regular amphetamine users." *Addiction* 89(9): 1077-83.
- Donaldson, M. and J. H. Goodchild (2006). "Oral health of the methamphetamine abuser." *Am J Health Syst Pharm* 63(21): 2078-82.
- Duterte, M., S. O'Neil, G. McKearin, P. Sales, T. Murphy and S. Murphy (2001). "Walking the tightrope: Balancing health and drug use." *J Psychoactive Drugs* 33(2): 173-83.
- Hall, W., J. Hando, et al. (1996). "Psychological morbidity and route of administration among amphetamine users in Sydney, Australia." *Addiction* 91(1): 81-7.

- Hando, J., L. Topp, et al. (1997). "Amphetamine-related harms and treatment preferences of regular amphetamine users in Sydney, Australia." *Drug Alcohol Depend* 46(1-2): 105-13.
- Johnson, B. A., L. T. Wells, et al. (2005). "Isradipine decreases the hemodynamic response of cocaine and methamphetamine results from two human laboratory studies: Results from two human laboratory studies." *Am J Hypertens* 18(6): 813-22.
- Kingston, S. and M. Conrad (2004). "Harm reduction for methamphetamine users." *Focus* 19(1): 4-6.
- Lester, B. M., L. Andreozzi, et al. (2004). "Substance use during pregnancy: Time for policy to catch up with research." *Harm Reduct J* 1(1): 5.
- Room, R. (2006). "The dangerousness of drugs." *Addiction* 101(2): 166-8.
- Rose, V. J., H. F. Raymond, et al. (2006). "Assessing the feasibility of harm reduction services for MSM: The late night breakfast buffet study." *Harm Reduct J* 3: 29.
- Sharp, M. (2005). "From condoms to needles and everything in between. Shades of gray with harm reduction." *Posit Aware* 16(4): 20-1.
- Sheridan, J., S. Bennett, et al. (2006). "Injury associated with methamphetamine use: A review of the literature." *Harm Reduct J* 3(1): 14.
- Shernoff, M. (2006). "Condomless sex: gay men, barebacking, and harm reduction." *Soc Work* 51(2): 106-13.
- Tatarsky, A. (2003). "Harm reduction psychotherapy: Extending the reach of traditional substance use treatment." *J Subst Abuse Treat* 25(4): 249-56.
- Wermuth, L. (2000). "Methamphetamine use: Hazards and social influences." *J Drug Educ* 30(4): 423-33.
- Wood, E., J. A. Stoltz, et al. (2006). "Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study." *Harm Reduct J* 3: 18.

## Hawaii (US)

*See also* Honolulu

- Arria, A. M., C. Derauf, et al. (2006). "Methamphetamine and other substance use during pregnancy: Preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study." *Matern Child Health J* 10(3): 293-302.
- Austin, A. A. (2004). "Alcohol, tobacco, other drug use, and violent behavior among Native Hawaiians: Ethnic pride and resilience." *Subst Use Misuse* 39(5): 721-46.
- Baker, F. M. and W. F. Haning, 3rd (2001). "Substance abuse and dependence in a public hospital: Hawaii." *Hawaii Med J* 60(2): 35-8.
- Boulard, G. (2005). "The meth menace: Battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.
- Burchell, S. A., H. C. Ho, et al. (2000). "Effects of methamphetamine on trauma patients: A cause of severe metabolic acidosis?" *Crit Care Med* 28(6): 2112-5.
- Forrester, M. B. and R. D. Merz (2007). "Risk of selected birth defects with prenatal illicit drug use, Hawaii, 1986-2002." *J Toxicol Environ Health A* 70(1): 7-18.
- Forrester, M. B. and R. D. Merz (2006). "Comparison of trends in gastroschisis and prenatal illicit drug use rates." *J Toxicol Environ Health A* 69(13): 1253-9.
- Freese, T. E., J. Obert, et al. (2000). "Methamphetamine abuse: Issues for special populations." *J Psychoactive Drugs* 32(2): 177-82.
- Gonzales, R., P. Marinelli-Casey, et al. (2006). "Hepatitis C virus infection among methamphetamine-dependent individuals in outpatient treatment." *J Subst Abuse Treat* 31(2): 195-202.
- Huber, A., R. H. Lord, et al. (2000). "The CSAT methamphetamine treatment program: Research design accommodations for "real world" application." *J Psychoactive Drugs* 32(2): 149-56.
- Inouye, D. S., J. J. Navin, et al. (2004). "Fatal postoperative arrhythmia in a man with a remote history of methamphetamine and cocaine use: a case report." *Hawaii Med J* 63(3): 82-6.
- Miller, M. A. (1991). "Trends and patterns of methamphetamine smoking in Hawaii." *NIDA Res Monogr* 115: 72-83.
- Nestor, T. A., W. I. Tamamoto, et al. (1989). "Acute pulmonary oedema caused by crystalline methamphetamine." *Lancet* 2(8674): 1277-8.
- Rawson, R. A., P. Marinelli-Casey, et al. (2004). "A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence." *Addiction* 99(6): 708-17.
- Reiber, C., G. Galloway, et al. (2000). "A descriptive analysis of participant characteristics and patterns of substance use in the CSAT methamphetamine treatment project: the first six months." *J Psychoactive Drugs* 32(2): 183-91.
- Smith, L. M., L. L. Lagasse, et al. (2006). "The Infant Development, Environment, and Lifestyle Study: Effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth." *Pediatrics* 118(3): 1149-1156.
- Szuster, R. R. (1990). "Methamphetamine in psychiatric emergencies." *Hawaii Med J* 49(10): 389-91.

- Tominaga, G. T., G. Garcia, et al. (2004). "Toll of methamphetamine on the trauma system." *Arch Surg* 139(8): 844-7.
- Waitzfelder, B. E., C. C. Engel Jr, et al. (1998). "Substance abuse in Hawaii: Perspectives of key local human service organizations." *Subst Abus* 19(1): 7-22.
- Wijetunga, M., R. Bhan, J. Lindsay and S. Karch (2004). "Acute coronary syndrome and crystal methamphetamine use: A case series." *Hawaii Med J* 63(1): 8-13, 25.
- Wolkoff, D. A. (1997). "Methamphetamine abuse: An overview for health care professionals." *Hawaii Med J* 56(2): 34-6, 44.

### Health Status

- Greenwell, L. and M. L. Brecht (2003). "Self-reported health status among treated methamphetamine users." *Am J Drug Alcohol Abuse* 29(1): 75-104.
- Siegal, H. A., P. J. Draus, et al. (2006). "Perspectives on health among adult users of illicit stimulant drugs in rural Ohio." *J Rural Health* 22(2): 169-73.

### Hearing

*See* Sound and Auditory Stimuli; Sound and Auditory Stimuli (animals)

### Hepatitis A

- Grinde, B., K. Stene-Johansen, et al. (1997). "Characterisation of an epidemic of hepatitis A virus involving intravenous drug abusers--infection by needle sharing?" *J Med Virol* 53(1): 69-75.
- Harkess, J., B. Gildon, et al. (1989). "Outbreaks of hepatitis A among illicit drug users, Oklahoma, 1984-87." *Am J Public Health* 79(4): 463-6.
- Hutin, Y. J., K. M. Sabin, et al. (2000). "Multiple modes of hepatitis A virus transmission among methamphetamine users." *Am J Epidemiol* 152(2): 186-92.
- Hutin, Y. J., B. P. Bell, et al. (1999). "Identifying target groups for a potential vaccination program during a hepatitis A communitywide outbreak." *Am J Public Health* 89(6): 918-21.
- Kahraman, A., M. Miller, et al. (2006). "Non-alcoholic fatty liver disease in HIV-positive patients predisposes for acute-on-chronic liver failure: Two cases." *Eur J Gastroenterol Hepatol* 18(1): 101-105.
- Leino, T., P. Leinikki, et al. (1997). "Hepatitis A outbreak amongst intravenous amphetamine abusers in Finland." *Scand J Infect Dis* 29(3): 213-6.
- Mravcik, V., H. Sebakova, et al. (2000). "[Seroprevalence of viral hepatitis A, B and C in intravenous drug users]." *Epidemiol Mikrobiol Imunol* 49(1): 19-23.
- Vong, S., A. E. Fiore, et al. (2005). "Vaccination in the county jail as a strategy to reach high risk adults during a community-based hepatitis A outbreak among methamphetamine drug users." *Vaccine* 23(8): 1021-8.

### Hepatitis B

- Davis, L. E., G. Kalousek, et al. (1970). "Hepatitis associated with illicit use of intravenous methamphetamine." *Public Health Rep* 85(9): 809-13.
- Garfein, R. S., W. A. Bower, et al. (2004). "Factors associated with fulminant liver failure during an outbreak among injection drug users with acute hepatitis B." *Hepatology* 40(4): 865-73.
- Kahraman, A., M. Miller, et al. (2006). "Non-alcoholic fatty liver disease in HIV-positive patients predisposes for acute-on-chronic liver failure: Two cases." *Eur J Gastroenterol Hepatol* 18(1): 101-105.
- Koff, R. S., W. C. Widrich, et al. (1973). "Necrotizing angitis in a methamphetamine user with hepatitis B--angiographic diagnosis, five-month follow-up results and localization of bleeding site." *N Engl J Med* 288(18): 946-7.
- Kral, A. H., R. N. Bluthenthal, et al. (1999). "Risk factors among IDUs who give injections to or receive injections from other drug users." *Addiction* 94(5): 675-83.
- Mravcik, V., H. Sebakova, et al. (2000). "[Seroprevalence of viral hepatitis A, B and C in intravenous drug users]." *Epidemiol Mikrobiol Imunol* 49(1): 19-23.
- Pol, S., P. Lebray, et al. (2004). "HIV infection and hepatic enzyme abnormalities: Intricacies of the pathogenic mechanisms." *Clin Infect Dis* 38 Suppl 2: S65-72.
- Vogt, T. M., J. F. Perz, et al. (2006). "An outbreak of hepatitis B virus infection among methamphetamine injectors: the role of sharing injection drug equipment." *Addiction* 101(5): 726-30.

## Hepatitis C

- Boddiger, D. (2005). "Metamphetamine use linked to rising HIV transmission." *Lancet* 365(9466): 1217-8.
- Cherner, M., S. Letendre, et al. (2005). "Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine." *Neurology* 64(8): 1343-7.
- Gonzales, R., P. Marinelli-Casey, et al. (2006). "Hepatitis C virus infection among methamphetamine-dependent individuals in outpatient treatment." *J Subst Abuse Treat* 31(2): 195-202.
- Grinde, B., K. Stene-Johansen, et al. (1997). "Characterisation of an epidemic of hepatitis A virus involving intravenous drug abusers--infection by needle sharing?" *J Med Virol* 53(1): 69-75.
- Hahn, J. A., K. Page-Shafer, P. J. Lum, K. Ochoa and A. R. Moss (2001). "Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco." *Hepatology* 34(1): 180-7.
- Jittiwutikarn, J., S. Thongsawat, et al. (2006). "Hepatitis C infection among drug users in northern Thailand." *Am J Trop Med Hyg* 74(6): 1111-6.
- Koester, S., J. Glanz, et al. (2005). "Drug sharing among heroin networks: Implications for HIV and hepatitis B and C prevention." *AIDS Behav* 9(1): 27-39.
- Kral, A. H., R. N. Bluthenthal, et al. (1999). "Risk factors among IDUs who give injections to or receive injections from other drug users." *Addiction* 94(5): 675-83.
- Kresina, T. F., J. Normand, et al. (2004). "Addressing the need for treatment paradigms for drug-abusing patients with multiple morbidities." *Clin Infect Dis* 38 Suppl 5: S398-401.
- Letendre, S. L., M. Cherner, et al. (2005). "The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: Biological correlates of disease." *AIDS* 19 Suppl 3: S72-8.
- Mravcik, V., H. Sebakova, et al. (2000). "[Seroprevalence of viral hepatitis A, B and C in intravenous drug users]." *Epidemiol Mikrobiol Immunol* 49(1): 19-23.
- Nyamathi, A. M., E. L. Dixon, et al. (2006). "Hepatitis C virus infection among homeless men referred from a community clinic." *West J Nurs Res* 28(4): 475-88.
- Nyamathi, A. M., E. L. Dixon, et al. (2002). "Risk factors for hepatitis C virus infection among homeless adults." *J Gen Intern Med* 17(2): 134-43.
- Nyamathi, A., W. A. Robbins, et al. (2002). "Presence and predictors of hepatitis C virus RNA in the semen of homeless men." *Biol Res Nurs* 4(1): 22-30.
- Okudaira, K., T. Yabana, et al. (1994). "[Clinical problems of alcoholics with a history of methamphetamine abuse]." *Arukoku Kenkyuto Yakubutsu Ison* 29(3): 185-9.
- Pol, S., P. Lebray, et al. (2004). "HIV infection and hepatic enzyme abnormalities: Intricacies of the pathogenic mechanisms." *Clin Infect Dis* 38 Suppl 2: S65-72.
- Semple, S. J., T. L. Patterson, et al. (2004). "A comparison of injection and non-injection methamphetamine-using HIV positive men who have sex with men." *Drug Alcohol Depend* 76(2): 203-12.
- Taylor, M. J., S. L. Letendre, et al. (2004). "Hepatitis C virus infection is associated with reduced white matter N-acetylaspartate in abstinent methamphetamine users." *J Int Neuropsychol Soc* 10(1): 110-3.
- van Gorp, W. G. and C. H. Hinkin (2005). "Triple trouble: Cognitive deficits from hepatitis C, HIV, and methamphetamine." *Neurology* 64(8): 1328-9.
- Verachai, V., T. Phutiprawan, et al. (2002). "Prevalence and genotypes of hepatitis C virus infection among drug addicts and blood donors in Thailand." *Southeast Asian J Trop Med Public Health* 33(4): 849-51.
- Wada, K. (2004). "[HCV infection among narcotics/methamphetamine abusers]." *Nippon Rinsho* 62 Suppl 7(Pt 1): 326-9.
- Wada, K., S. B. Greberman, et al. (1999). "HIV and HCV infection among drug users in Japan." *Addiction* 94(7): 1063-9.
- Wu, L. T., D. J. Pilowsky, et al. (2004). "Injection drug use among stimulant users in a national sample." *Am J Drug Alcohol Abuse* 30(1): 61-83.
- Yoshizawa, H. (2002). "Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: Projection to other countries in the foreseeable future." *Oncology* 62 Suppl 1: 8-17.

## Heroin and Other Opioids

*See also Polydrug Use*

- Baker, A., N. K. Lee, et al. (2004). "Drug use patterns and mental health of regular amphetamine users during a reported 'heroin drought'." *Addiction* 99(7): 875-84.

- Bartu, A., N. C. Freeman, et al. (2004). "Mortality in a cohort of opiate and amphetamine users in Perth, Western Australia." *Addiction* 99(1): 53-60.
- Bogart, L. M., A. H. Kral, et al. (2005). "Sexual risk among injection drug users recruited from syringe exchange programs in California." *Sex Transm Dis* 32(1): 27-34.
- Booth, B. M., C. Leukefeld, et al. (2006). "Correlates of rural methamphetamine and cocaine users: Results from a multistate community study." *J Stud Alcohol* 67(4): 493-501.
- Cheng, C. Y., C. J. Hong, et al. (2005). "Brain-derived neurotrophic factor (Val66Met) genetic polymorphism is associated with substance abuse in males." *Brain Res Mol Brain Res* 140(1-2): 86-90.
- Cook, C. E. (1991). "Pyrolytic characteristics, pharmacokinetics, and bioavailability of smoked heroin, cocaine, phencyclidine, and methamphetamine." *NIDA Res Monogr* 115: 6-23.
- Darke, S., S. Kaye, et al. (1999). "Transitions between the injection of heroin and amphetamines." *Addiction* 94(12): 1795-803.
- Darke, S. and W. Hall (1995). "Levels and correlates of polydrug use among heroin users and regular amphetamine users." *Drug Alcohol Depend* 39(3): 231-5.
- Day, C., L. Degenhardt, et al. (2006). "Changes in the initiation of heroin use after a reduction in heroin supply." *Drug Alcohol Rev* 25(4): 307-13.
- Degenhardt, L., E. Conroy, et al. (2005). "The impact of a reduction in drug supply on demand for and compliance with treatment for drug dependence." *Drug Alcohol Depend* 79(2): 129-35.
- Degenhardt, L. J., E. Conroy, et al. (2005). "The effect of a reduction in heroin supply on fatal and non-fatal drug overdoses in New South Wales, Australia." *Med J Aust* 182(1): 20-3.
- Degenhardt, L., C. Day, et al. (2005). "Effects of a sustained heroin shortage in three Australian States." *Addiction* 100(7): 908-20.
- Dore, G. and M. Sweeting (2006). "Drug-induced psychosis associated with crystalline methamphetamine." *Australas Psychiatry* 14(1): 86-9.
- Gibson, D. R., M. H. Leamon, et al. (2002). "Epidemiology and public health consequences of methamphetamine use in California's Central Valley." *J Psychoactive Drugs* 34(3): 313-9.
- Gleghorn, A. A., R. Marx, et al. (1998). "Association between drug use patterns and HIV risks among homeless, runaway, and street youth in northern California." *Drug Alcohol Depend* 51(3): 219-27.
- Gotway, M. B., S. R. Marder, et al. (2002). "Thoracic complications of illicit drug use: An organ system approach." *Radiographics* 22 Spec No: S119-35.
- Grella, C. E., Y. I. Hser, et al. (2006). "Mothers in substance abuse treatment: differences in characteristics based on involvement with child welfare services." *Child Abuse Negl* 30(1): 55-73.
- Jittiwutikarn, J., S. Thongsawat, et al. (2006). "Hepatitis C infection among drug users in northern Thailand." *Am J Trop Med Hyg* 74(6): 1111-6.
- Joe Laidler, K. A. (2005). "The rise of club drugs in a heroin society: The case of Hong Kong." *Subst Use Misuse* 40(9-10): 1257-78.
- John, D., C. F. Kwiatkowski, et al. (2001). "Differences among out-of-treatment drug injectors who use stimulants only, opiates only or both: implications for treatment entry." *Drug Alcohol Depend* 64(2): 165-72.
- Kaye, S. and S. Darke (2000). "A comparison of the harms associated with the injection of heroin and amphetamines." *Drug Alcohol Depend* 58(1-2): 189-95.
- Kish, S. J., K. S. Kalasinsky, et al. (1999). "Brain choline acetyltransferase activity in chronic, human users of cocaine, methamphetamine, and heroin." *Mol Psychiatry* 4(1): 26-32.
- Koester, S., J. Glanz, et al. (2005). "Drug sharing among heroin networks: Implications for HIV and hepatitis B and C prevention." *AIDS Behav* 9(1): 27-39.
- Kral, A. H., J. Lorvick, et al. (2005). "HIV prevalence and risk behaviors among men who have sex with men and inject drugs in San Francisco." *J Urban Health* 82(1 Suppl 1): i43-50.
- Lampinen, T. M., D. McGhee, et al. (2006). "Increased risk of 'club' drug use among gay and bisexual high school students in British Columbia." *J Adolesc Health* 38(4): 458-61.
- Lipinski, E. (1972). "Motivation in drug misuse. Some comments on agent, environment, host." *Jama* 219(2): 171-5.
- Longo, M. C., S. M. Henry-Edwards, et al. (2004). "Impact of the heroin 'drought' on patterns of drug use and drug-related harms." *Drug Alcohol Rev* 23(2): 143-50.
- Lorvick, J., A. Martinez, et al. (2006). "Sexual and injection risk among women who inject methamphetamine in San Francisco." *J Urban Health* 83(3): 497-505.
- Lundqvist, T. (2005). "Cognitive consequences of cannabis use: Comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions." *Pharmacol Biochem Behav* 81(2): 319-30.

- Maglione, M., B. Chao, et al. (1998). "Methamphetamine abuse in California: Correlates of injection use." *AIDS and Behavior* 2(3): 257-261.
- Manchikanti, L., K. A. Cash, et al. (2006). "Controlled substance abuse and illicit drug use in chronic pain patients: An evaluation of multiple variables." *Pain Physician* 9(3): 215-25.
- Martin, I., T. M. Lampinen, et al. (2006). "Methamphetamine use among marginalized youth in British Columbia." *Can J Public Health* 97(4): 320-4.
- Maxwell, J. C., P. Cravioto, et al. (2006). "Drug use and risk of HIV/AIDS on the Mexico-USA border: A comparison of treatment admissions in both countries." *Drug Alcohol Depend* 82 Suppl 1: S85-93.
- McKetin, R., E. Kelly, et al. (2006). "The relationship between crystalline methamphetamine use and methamphetamine dependence." *Drug Alcohol Depend* 85(3): 198-204.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.
- Namiki, M., T. Mori, et al. (2005). "Underlying mechanism of combined effect of methamphetamine and morphine on lethality in mice and therapeutic potential of cooling." *J Pharmacol Sci* 99(2): 168-76.
- Nath, A., K. F. Hauser, et al. (2002). "Molecular basis for interactions of HIV and drugs of abuse." *J Acquir Immune Defic Syndr* 31 Suppl 2: S62-9.
- Ochoa, K. C., P. J. Davidson, et al. (2005). "Heroin overdose among young injection drug users in San Francisco." *Drug Alcohol Depend* 80(3): 297-302.
- Patterson, T. L., S. J. Semple, et al. (2005). "Methamphetamine-using HIV-positive men who have sex with men: Correlates of polydrug use." *J Urban Health* 82(1 Suppl 1): i120-6.
- Peirce, J. M., N. M. Petry, et al. (2006). "Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: A National Drug Abuse Treatment Clinical Trials Network study." *Arch Gen Psychiatry* 63(2): 201-8.
- Ranaldi, R. and K. Poeggel (2002). "Baclofen decreases methamphetamine self-administration in rats." *Neuroreport* 13(9): 1107-10.
- Reid, L. W., K. W. Elifson, et al. (2007). "Ecstasy and gateway drugs: Initiating the use of ecstasy and other drugs." *Ann Epidemiol* 17(1): 74-80.
- Rogers, R. D., B. J. Everitt, et al. (1999). "Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: Evidence for monoaminergic mechanisms." *Neuropsychopharmacology* 20(4): 322-39.
- Roxburgh, A., L. Degenhardt, et al. (2004). "Changes in patterns of drug use among injecting drug users following changes in the availability of heroin in New South Wales, Australia." *Drug Alcohol Rev* 23(3): 287-94.
- Schwilke, E. W., M. I. Sampaio dos Santos, et al. (2006). "Changing patterns of drug and alcohol use in fatally injured drivers in Washington State." *J Forensic Sci* 51(5): 1191-8.
- Siegal, D., J. Erickson, et al. (2004). "Brain vesicular acetylcholine transporter in human users of drugs of abuse." *Synapse* 52(4): 223-32.
- Struthers, J. M. and R. L. Hansen (1992). "Visual recognition memory in drug-exposed infants." *J Dev Behav Pediatr* 13(2): 108-11.
- Srirak, N., S. Kawichai, et al. (2005). "HIV infection among female drug users in Northern Thailand." *Drug Alcohol Depend* 78(2): 141-5.
- Topp, L., C. Day, et al. (2003). "Changes in patterns of drug injection concurrent with a sustained reduction in the availability of heroin in Australia." *Drug Alcohol Depend* 70(3): 275-86.
- Weiser, S. D., S. E. Dilworth, et al. (2006). "Gender-specific correlates of sex trade among homeless and marginally housed individuals in San Francisco." *J Urban Health* 83(4): 736-40.
- Worsley, J. N., A. Moszczynska, et al. (2000). "Dopamine D1 receptor protein is elevated in nucleus accumbens of human, chronic methamphetamine users." *Mol Psychiatry* 5(6): 664-72.
- Wu, L. T., D. J. Pilowsky, et al. (2004). "Injection drug use among stimulant users in a national sample." *Am J Drug Alcohol Abuse* 30(1): 61-83.
- Yen, C. F., H. Y. Wu, et al. (2004). "Effects of brief cognitive-behavioral interventions on confidence to resist the urges to use heroin and methamphetamine in relapse-related situations." *J Nerv Ment Dis* 192(11): 788-91.
- Zule, W. A. and D. P. Desmond (1999). "An ethnographic comparison of HIV risk behaviors among heroin and methamphetamine injectors." *Am J Drug Alcohol Abuse* 25(1): 1-23.

## Heroin and Other Opioids (animals)

- Carney, J. M., R. W. Landrum, et al. (1991). "Establishment of chronic intravenous drug self-administration in the C57BL/6J mouse." *Neuroreport* 2(8): 477-80.
- Cunningham, C. L. and D. Noble (1992). "Methamphetamine-induced conditioned place preference or aversion depending on dose and presence of drug." *Ann N Y Acad Sci* 654: 431-3.

- Eibergen, R. D. and K. R. Carlson (1976). "Behavioral evidence for dopaminergic supersensitivity following chronic treatment with methadone or chlorpromazine in the guinea pig." *Psychopharmacology (Berl)* 48(2): 139-46.
- Eibergen, R. D. and K. R. Carlson (1976). "Dyskinesias in monkeys: Interaction of methamphetamine with prior methadone treatment." *Pharmacol Biochem Behav* 5(2): 175-87.
- Eibergen, R. D. and K. R. Carlson (1975). "Dyskinesias elicited by methamphetamine: Susceptibility of former methadone-consuming monkeys." *Science* 190(4214): 588-90.
- Fujio, M., T. Nakagawa, et al. (2005). "Gene transfer of GLT-1, a glutamate transporter, into the nucleus accumbens shell attenuates methamphetamine- and morphine-induced conditioned place preference in rats." *Eur J Neurosci* 22(11): 2744-54.
- Ginawi, O. T., O. A. al-Shabanah, et al. (1997). "Increased toxicity of methamphetamine in morphine-dependent mice." *Gen Pharmacol* 28(5): 727-31.
- Glick, S. D., I. M. Maisonneuve, et al. (2002). "Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration." *Eur J Pharmacol* 438(1-2): 99-105.
- Glick, S. D., I. M. Maisonneuve, et al. (2001). "Comparative effects of dextromethorphan and dextrorphan on morphine, methamphetamine, and nicotine self-administration in rats." *Eur J Pharmacol* 422(1-3): 87-90.
- Goudie, A. J., E. W. Thornton, et al. (1976). "Drug pretreatment effects in drug induced taste aversions: Effects of dose and duration of pretreatment." *Pharmacol Biochem Behav* 4(5): 629-33.
- Harrigan, S. E. and D. A. Downs (1981). "Pharmacological evaluation of narcotic antagonist delivery systems in rhesus monkeys." *NIDA Res Monogr* 28: 77-92.
- Harrigan, S. E. and D. A. Downs (1978). "Continuous intravenous naltrexone effects on morphine self-administration in rhesus monkeys." *J Pharmacol Exp Ther* 204(2): 481-6.
- He, S. and K. Grasing (2006). "l-Methamphetamine and selective MAO inhibitors decrease morphine-reinforced and non-reinforced behavior in rats; Insights towards selegiline's mechanism of action." *Pharmacol Biochem Behav*.
- Hirabayashi, M., F. Iwai, et al. (1979). "[Individual differences in the accelerating effect of methamphetamine, d-amphetamine and morphine on ambulatory activity in mice (author's transl)]." *Nippon Yakurigaku Zasshi* 75(7): 683-93.
- Ishikawa, K., A. Nitta, et al. (2006). "Effects of single and repeated administration of methamphetamine or morphine on neuroglycan C gene expression in the rat brain." *Int J Neuropsychopharmacol* 9(4): 407-15.
- Ishikawa, T. (1963). "[On the effect of addiction and tolerance observed from brain waves in animals, with special reference to continuous administration of morphine and methamphetamine.]." *Nippon Yakurigaku Zasshi* 59: 187-205.
- Ito, S., T. Mori, et al. (2006). "Differential effects of mu-opioid, delta-opioid and kappa-opioid receptor agonists on dopamine receptor agonist-induced climbing behavior in mice." *Behav Pharmacol* 17(8): 691-701.
- Kuribara, H. and S. Tadokoro (1985). "Chronopharmacological study on morphine-induced increase in ambulatory activity in mice and methamphetamine sensitivity in morphine-experienced mice." *Yakubutsu Seishin Kodo* 5(3): 279-86.
- Kuribara, H. and S. Tadokoro (1985). "Combined effects of methamphetamine and morphine on ambulatory activity in mice and continuous avoidance response in rats." *Yakubutsu Seishin Kodo* 5(3): 271-7.
- Kuribara, H. and S. Tadokoro (1985). "Effects of psychoactive drugs on conditioned avoidance response in Mongolian gerbils (*Meriones unguiculatus*): Comparison with Wistar rats and dd mice." *Pharmacol Biochem Behav* 23(6): 1013-8.
- Maisonneuve, I. M. and S. D. Glick (2003). "Anti-addictive actions of an iboga alkaloid congener: A novel mechanism for a novel treatment." *Pharmacol Biochem Behav* 75(3): 607-18.
- Masukawa, Y., T. Suzuki, et al. (1993). "Differential modification of the rewarding effects of methamphetamine and cocaine by opioids and antihistamines." *Psychopharmacology (Berl)* 111(2): 139-43.
- Nakagawa, T., M. Fujio, et al. (2005). "Effect of MS-153, a glutamate transporter activator, on the conditioned rewarding effects of morphine, methamphetamine and cocaine in mice." *Behav Brain Res* 156(2): 233-9.
- Nakama, M., T. Ochiai, et al. (1972). "Effects of psychotropic drugs on emotional behavior: Exploratory behavior of naive rats in holed open field." *Jpn J Pharmacol* 22(6): 767-75.
- Namiki, M., T. Mori, et al. (2005). "Underlying mechanism of combined effect of methamphetamine and morphine on lethality in mice and therapeutic potential of cooling." *J Pharmacol Sci* 99(2): 168-76.
- Narita, M., M. Miyatake, et al. (2006). "Direct evidence of astrocytic modulation in the development of rewarding effects induced by drugs of abuse." *Neuropsychopharmacology* 311(11): 2476-88.
- Oka, T. and E. Hosoya (1977). "The different effect of humoral modulators on the morphine- and central nervous system stimulant-induced hyperactivity of rats." *Neuropharmacology* 16(2): 115-9.
- Pace, C. J., S. D. Glick, et al. (2004). "Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration." *Eur J Pharmacol* 492(2-3): 159-67.
- Parker, L. A. (1995). "Rewarding drugs produce taste avoidance, but not taste aversion." *Neurosci Biobehav Rev* 19(1): 143-57.
- Plevry, B. J. (1971). "Cross tolerance between methylamphetamine and morphine in the mouse." *J Pharm Pharmacol* 23(12): 969-70.



- Ranaldi, R. and R. A. Wise (2000). "Intravenous self-administration of methamphetamine-heroin (speedball) combinations under a progressive-ratio schedule of reinforcement in rats." *Neuroreport* 11(12): 2621-3.
- Suzuki, T. and M. Misawa (1995). "Sertindole antagonizes morphine-, cocaine-, and methamphetamine-induced place preference in the rat." *Life Sci* 57(13): 1277-84.
- Takahashi, M. and S. Tokuyama (1998). "Pharmacological and physiological effects of ginseng on actions induced by opioids and psychostimulants." *Methods Find Exp Clin Pharmacol* 20(1): 77-84.
- Thompson, T. and R. Pickens (1970). "Stimulant self-administration by animals: Some comparisons with opiate self-administration." *Fed Proc* 29(1): 6-12.
- Tokuyama, S. and M. Takahashi (2001). "[Pharmacological and physiological effects of ginseng on actions induced by opioids and psychostimulants]." *Nippon Yakurigaku Zasshi* 117(3): 195-201.
- Wolf, G., Y. Jacquet, et al. (1978). "Test for oral and postingestional factors mediating differential acceptability of morphine, methamphetamine, and chlordiazepoxide drinking solutions." *Psychopharmacology (Berl)* 60(1): 101-2.
- Yamada, K., T. Nagai, et al. (2005). "Drug dependence, synaptic plasticity, and tissue plasminogen activator." *J Pharmacol Sci* 97(2): 157-61.
- Yan, Y., A. Nitta, et al. (2006). "Discriminative-stimulus effects of methamphetamine and morphine in rats are attenuated by cAMP-related compounds." *Behav Brain Res* 173(1): 39-46.

## Heterosexuals

- Anonymous (2006). "Methamphetamine use and HIV risk behaviors among heterosexual men--preliminary results from five northern California counties, December 2001-November 2003." *MMWR Morb Mortal Wkly Rep* 55(10): 273-7.
- Bogart, L. M., A. H. Kral, et al. (2005). "Sexual risk among injection drug users recruited from syringe exchange programs in California." *Sex Transm Dis* 32(1): 27-34.
- Darke, S., J. Ross, et al. (1995). "Injecting and sexual risk-taking behaviour among regular amphetamine users." *AIDS Care* 7(1): 19-26.
- Degenhardt, L. (2005). "Drug use and risk behaviour among regular ecstasy users: Does sexuality make a difference?" *Culture, Health & Sexuality* 7(6): 599-614.
- Farabee, D., M. Prendergast and J. Cartier (2002). "Methamphetamine use and HIV risk among substance-abusing offenders in California." *J Psychoactive Drugs* 34(3): 295-300.
- Gibson, D. R., M. H. Leamon, et al. (2002). "Epidemiology and public health consequences of methamphetamine use in California's Central Valley." *J Psychoactive Drugs* 34(3): 313-9.
- Kelly, B. C., J. T. Parsons, et al. (2006). "Prevalence and predictors of club drug use among club-going young adults in New York City." *J Urban Health* 83(5): 884-895.
- Lampinen, T. M., D. McGhee, et al. (2006). "Increased risk of "club" drug use among gay and bisexual high school students in British Columbia." *J Adolesc Health* 38(4): 458-61.
- Lorvick, J., A. Martinez, et al. (2006). "Sexual and injection risk among women who inject methamphetamine in San Francisco." *J Urban Health* 83(3): 497-505.
- Mansergh, G., D. W. Purcell, et al. (2006). "CDC consultation on methamphetamine use and sexual risk behavior for HIV/STD infection: summary and suggestions." *Public Health Rep* 121(2): 127-32.
- Mitchell, S. J., S. R. Morris, et al. (2006). "Methamphetamine use and sexual activity among HIV-infected patients in care--San Francisco, 2004." *AIDS Patient Care STDS* 20(7): 502-10.
- Molitor, F., J. D. Ruiz, et al. (1999). "Methamphetamine use and sexual and injection risk behaviors among out-of-treatment injection drug users." *Am J Drug Alcohol Abuse* 25(3): 475-93.
- Molitor, F., S. R. Truax, J. D. Ruiz and R. K. Sun (1998). "Association of methamphetamine use during sex with risky sexual behaviors and HIV infection among non-injection drug users." *West J Med* 168(2): 93-7.
- Newmeyer, J. A. (2003). "Patterns and trends of drug use in the San Francisco Bay Area." *J Psychoactive Drugs* 35(Suppl 1): 127-32.
- Parsons, J. T., B. C. Kelly, et al. (2006). "Differences in club drug use between heterosexual and lesbian/bisexual females." *Addict Behav* 31(12): 2344-9.
- Semple, S. J., I. Grant, et al. (2005). "Utilization of drug treatment programs by methamphetamine users: The role of social stigma." *Am J Addict* 14(4): 367-80.
- Semple, S. J., I. Grant, et al. (2005). "Negative self-perceptions and sexual risk behavior among heterosexual methamphetamine users." *Substance Use & Misuse* 40(12): 1797-1810.
- Semple, S. J., J. Zians, et al. (2005). "Impulsivity and methamphetamine use." *J Subst Abuse Treat* 29(2): 85-93.
- Semple, S. J., T. L. Patterson and I. Grant (2004). "The context of sexual risk behavior among heterosexual methamphetamine users." *Addict Behav* 29(4): 807-10.

- Semple, S. J., T. L. Patterson, et al. (2004). "Determinants of condom use stage of change among heterosexually-identified methamphetamine users." *AIDS Behav* 8(4): 391-400.
- Semple, S. J., I. Grant, et al. (2004). "Female methamphetamine users: Social characteristics and sexual risk behavior." *Women Health* 40(3): 35-50.
- Somlai, A. M., J. A. Kelly, T. L. McAuliffe, K. Ksobiech and K. L. Hackl (2003). "Predictors of HIV sexual risk behaviors in a community sample of injection drug-using men and women." *AIDS Behav* 7(4): 383-93.
- Twitchell, G. R., A. Huber, et al. (2002). "Comparison of general and detailed HIV risk assessments among methamphetamine abusers." *AIDS and Behavior* 6(2): 153-162.
- van Griensven, F., S. Supawitkul, et al. (2001). "Rapid assessment of sexual behavior, drug use, human immunodeficiency virus, and sexually transmitted diseases in northern Thai youth using audio-computer-assisted self-interviewing and noninvasive specimen collection." *Pediatrics* 108(1): E13.
- Wohl, A. R., D. F. Johnson, et al. (2002). "HIV risk behaviors among African American men in Los Angeles County who self-identify as heterosexual." *J Acquir Immune Defic Syndr* 31(3): 354-60.

### Hispanics/Latinos/Latinas (US)

- Arria, A. M., C. Derauf, et al. (2006). "Methamphetamine and other substance use during pregnancy: Preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study." *Matern Child Health J* 10(3): 293-302.
- Brecht, M. L., L. Greenwell, et al. (2005). "Methamphetamine treatment: Trends and predictors of retention and completion in a large state treatment system (1992-2002)." *J Subst Abuse Treat* 29(4): 295-306.
- Brecht, M. L., C. von Mayrhauser, et al. (2000). "Predictors of relapse after treatment for methamphetamine use." *J Psychoactive Drugs* 32(2): 211-20.
- Diaz, R. M., A. L. Heckert, et al. (2005). "Reasons for stimulant use among Latino gay men in San Francisco: a comparison between methamphetamine and cocaine users." *J Urban Health* 82(1 Suppl 1): i71-8.
- Fernandez, M. I., G. S. Bowen, et al. (2007). "Crystal methamphetamine: A source of added sexual risk for Hispanic men who have sex with men?" *Drug Alcohol Depend* 86(2-3): 245-52.
- Fernandez, M. I., G. S. Bowen, et al. (2005). "High rates of club drug use and risky sexual practices among Hispanic men who have sex with men in Miami, Florida." *Subst Use Misuse* 40(9): 1347-62.
- Fernandez, M. I., T. Perrino, et al. (2005). "Surfing new territory: club-drug use and risky sex among Hispanic men who have sex with men recruited on the Internet." *J Urban Health* 82(1 Suppl 1): i79-88.
- Fernandez, M. I., L. M. Varga, et al. (2004). "The Internet as recruitment tool for HIV studies: viable strategy for reaching at-risk Hispanic MSM in Miami?" *AIDS Care* 16(8): 953-63.
- Glittenberg, J. and C. Anderson (1999). "Methamphetamines: Use and trafficking in the Tucson-Nogales area." *Subst Use Misuse* 34(14): 1977-89.
- Goldsamt, L. A., J. O'Brien, et al. (2005). "The relationship between club drug use and other drug use: A survey of New York City middle school students." *Subst Use Misuse* 40(9): 1539-55.
- Irwin, T. W. and J. Morgenstern (2005). "Drug-use patterns among men who have sex with men presenting for alcohol treatment: Differences in ethnic and sexual Identity." *J Urban Health*.
- Kurtz, S. P. (2005). "Post-circuit blues: Motivations and consequences of crystal meth use among gay men in Miami." *AIDS Behav* 9(1): 63-72.
- Maglione, M., B. Chao, et al. (1998). "Methamphetamine abuse in California: Correlates of injection use." *AIDS and Behavior* 2(3): 257-261.
- Niv, N. and Y. I. Hser (2006). "Drug treatment service utilization and outcomes for Hispanic and white methamphetamine abusers." *Health Serv Res* 41(4 Pt 1): 1242-57.
- Oetting, E. R., J. L. Deffenbacher, et al. (2000). "Methamphetamine use by high school students: Recent trends, gender and ethnicity differences, and use of other drugs." *Journal of Child and Adolescent Substance Abuse* 10(1): 33-50.
- Ompad, D. C., S. Galea, et al. (2004). "Club drug use among minority substance users in New York City." *J Psychoactive Drugs* 36(3): 397-9.
- Schermer, C. R. and D. H. Wisner (1999). "Methamphetamine use in trauma patients: A population-based study." *J Am Coll Surg* 189(5): 442-9.
- Wu, L. T., D. J. Pilowsky, et al. (2004). "Injection drug use among stimulant users in a national sample." *Am J Drug Alcohol Abuse* 30(1): 61-83.
- Zule, W. A. and D. P. Desmond (1999). "An ethnographic comparison of HIV risk behaviors among heroin and methamphetamine injectors." *Am J Drug Alcohol Abuse* 25(1): 1-23.

**Histamine (animals)**

- Acevedo, S. F., I. J. de Esch, et al. (2006). "Sex- and histamine-dependent long-term cognitive effects of methamphetamine exposure." *Neuropsychopharmacology*.
- Barnett, A., R. I. Taber, et al. (1969). "Activity of antihistamines in laboratory antidepressant tests." *Int J Neuropharmacol* 8(1): 73-9.
- Barnett, A., R. I. Taber, et al. (1969). "Mechanism of action of antihistamines in laboratory antidepressant tests." *Int J Neuropharmacol* 8(4): 353-60.
- Callaway, J. K., R. G. King, et al. (1990). "Methoxyphenamine inhibits histamine-induced bronchoconstriction in anaesthetized guinea-pigs and histamine-induced contractions of guinea-pig ileum in vitro." *Arch Int Pharmacodyn Ther* 308: 86-94.
- Chahl, L. A. and S. R. O'Donnell (1971). "The effect on some receptors of guinea pig trachea of a series of sympathomimetics amines." *Eur J Pharmacol* 16(2): 201-8.
- Dai, H., T. Okuda, et al. (2005). "Blockage of histamine H1 receptor attenuates social isolation-induced disruption of prepulse inhibition: A study in H1 receptor gene knockout mice." *Psychopharmacology (Berl)* 183(3): 285-93.
- Dai, H., H. Okuda, et al. (2004). "Social isolation stress significantly enhanced the disruption of prepulse inhibition in mice repeatedly treated with methamphetamine." *Ann N Y Acad Sci* 1025: 257-66.
- Fox, G. B., T. A. Esbenshade, et al. (2005). "Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzotrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist." *J Pharmacol Exp Ther* 313(1): 176-90.
- Gokhale, S. D., O. D. Gulati, et al. (1966). "Antagonism of the adrenergic neurone blocking action of guanethidine by certain antidepressant and antihistamine drugs." *Arch Int Pharmacodyn Ther* 160(2): 321-9.
- Ito, C., K. Onodera, et al. (1997). "Effects of histamine agents on methamphetamine-induced stereotyped behavior and behavioral sensitization in rats." *Psychopharmacology (Berl)* 130(4): 362-7.
- Ito, C., K. Onodera, et al. (1997). "The effect of methamphetamine on histamine release in the rat hypothalamus." *Psychiatry Clin Neurosci* 51(2): 79-81.
- Ito, C., K. Onodera, et al. (1996). "Effects of dopamine antagonists on neuronal histamine release in the striatum of rats subjected to acute and chronic treatments with methamphetamine." *J Pharmacol Exp Ther* 279(1): 271-6.
- Ito, C., K. Onodera, et al. (1996). "The effect of methamphetamine on histamine level and histidine decarboxylase activity in the rat brain." *Brain Res* 734(1-2): 98-102.
- Ito, C., M. Sato, et al. (1996). "The role of the brain histaminergic neuron system in methamphetamine-induced behavioral sensitization in rats." *Ann N Y Acad Sci* 801: 353-60.
- Itoh, Y., R. Oishi, et al. (1986). "Comparison of effects of phencyclidine and methamphetamine on body temperature in mice: A possible role for histamine neurons in thermoregulation." *Naunyn Schmiedebergs Arch Pharmacol* 332(3): 293-6.
- Itoh, Y., M. Nishibori, et al. (1984). "Neuronal histamine inhibits methamphetamine-induced locomotor hyperactivity in mice." *Neurosci Lett* 48(3): 305-9.
- Iwabuchi, K., Y. Kubota, et al. (2004). "Methamphetamine and brain histamine: A study using histamine-related gene knockout mice." *Ann N Y Acad Sci* 1025: 129-34.
- Joshi, V. V., J. J. Balsara, et al. (1981). "Effect of L-histidine and chlorcyclizine on apomorphine-induced climbing behaviour and methamphetamine stereotypy in mice." *Eur J Pharmacol* 69(4): 499-502.
- Kitanaka, J., N. Kitanaka, et al. (2003). "Chronic methamphetamine administration reduces histamine-stimulated phosphoinositide hydrolysis in mouse frontal cortex." *Biochem Biophys Res Commun* 300(4): 932-7.
- Kubota, Y., C. Ito, et al. (2002). "Increased methamphetamine-induced locomotor activity and behavioral sensitization in histamine-deficient mice." *J Neurochem* 83(4): 837-45.
- Kubota, Y., C. Ito, et al. (1999). "Transient increases of histamine H1 and H2 receptor mRNA levels in the rat striatum after the chronic administration of methamphetamine." *Neurosci Lett* 275(1): 37-40.
- Lau, W. A., R. G. King, et al. (1990). "Methoxyphenamine inhibits basal and histamine-induced nasal congestion in anaesthetized rats." *Br J Pharmacol* 101(2): 394-8.
- Masukawa, Y., T. Suzuki, et al. (1993). "Differential modification of the rewarding effects of methamphetamine and cocaine by opioids and antihistamines." *Psychopharmacology (Berl)* 111(2): 139-43.
- Mori, T., M. Narita, et al. (2002). "Modulation of the discriminative stimulus effects of cocaine and methamphetamine by the histaminergic system." *Nihon Shinkei Seishin Yakurigaku Zasshi* 22(3): 73-8.
- Morisset, S., C. Pilon, et al. (2002). "Acute and chronic effects of methamphetamine on tele-methylhistamine levels in mouse brain: Selective involvement of the D(2) and not D(3) receptor." *J Pharmacol Exp Ther* 300(2): 621-8.
- Muley, M. P., J. J. Balsara, et al. (1979). "Effect of L-histidine pretreatment on methamphetamine induced stereotyped behaviour in rats." *Indian J Physiol Pharmacol* 23(4): 291-6.

- Munzar, P., G. Tanda, et al. (2004). "Histamine h3 receptor antagonists potentiate methamphetamine self-administration and methamphetamine-induced accumbal dopamine release." *Neuropsychopharmacology* 29(4): 705-17.
- Munzar, P., R. Nosal, et al. (1998). "Potentiation of the discriminative-stimulus effects of methamphetamine by the histamine H3 receptor antagonist thioperamide in rats." *Eur J Pharmacol* 363(2-3): 93-101.
- Nair, X. and D. C. Dyer (1974). "Responses of guinea pig umbilical vasculature to vasoactive drugs." *Eur J Pharmacol* 27(3): 294-304.
- Oishi, R. (1988). "[Turnover of brain histamine and its changes by various drugs]." *Nippon Yakurigaku Zasshi* 92(5): 271-81.
- Okuda, T., Y. Ito, et al. (2004). "Drug interaction between methamphetamine and antihistamines: Behavioral changes and tissue concentrations of methamphetamine in rats." *Eur J Pharmacol* 505(1-3): 135-44.
- Onodera, K., C. Itoh, et al. (1998). "Motor behavioural function for histamine-dopamine interaction in brain." *Inflamm Res* 47 Suppl 1: S30-1.
- Patil, P. N., S. Hetey, et al. (1970). "The sensitivity of rabbit aorta, atria and ileum to various agonists after repeated doses of (--)-ephedrine and related amines." *Arch Int Pharmacodyn Ther* 188(2): 257-70.
- Pillot, C., A. Heron, et al. (2003). "Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, modulates the effects of methamphetamine on neuropeptide mRNA expression in rat striatum." *Eur J Neurosci* 17(2): 307-14.
- Rajan, P. D., R. Kekuda, et al. (2000). "Expression of the extraneuronal monoamine transporter in RPE and neural retina." *Curr Eye Res* 20(3): 195-204.
- Suzuki, T., T. Mori, et al. (1997). "Generalization of D-, L- and DL-chlorpheniramine and zolantidine to the discriminative stimulus effects of cocaine and methamphetamine." *Behav Pharmacol* 8(8): 718-24.
- Toyota, H., C. Dugovic, et al. (2002). "Behavioral characterization of mice lacking histamine H(3) receptors." *Mol Pharmacol* 62(2): 389-97.
- Watanabe, T. and K. Yanai (2001). "Studies on functional roles of the histaminergic neuron system by using pharmacological agents, knockout mice and positron emission tomography." *Tohoku J Exp Med* 195(4): 197-217.
- Watanabe, T. and K. Yanai (2001). "Studies on functional roles of the histaminergic neuron system by using pharmacological agents, knockout mice and positron emission tomography." *Tohoku J Exp Med* 195(4): 197-217.
- Watanabe, T. (1997). "[Histaminergic neuron system and neural plasticity]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 17(4): 169-73.

### Historical Overview

- Ahmad, K. (2003). "Asia grapples with spreading amphetamine abuse." *Lancet* 361(9372): 1878-9.
- Anglin, M. D., C. Burke, et al. (2000). "History of the methamphetamine problem." *J Psychoactive Drugs* 32(2): 137-41.
- Derlet, R. W. and B. Heischouer (1990). "Methamphetamine. Stimulant of the 1990s?" *West J Med* 153(6): 625-8.
- Greberman, S. B. and K. Wada (1994). "Social and legal factors related to drug abuse in the United States and Japan." *Public Health Rep* 109(6): 731-7.
- Hanson, G. R., K. S. Rau and A. E. Fleckenstein (2004). "The methamphetamine experience: A NIDA partnership." *Neuropharmacology* 47(Suppl 1): 92-100.
- Harris, L. S. (2001). "Drug dependence studies and regulations: An overview of the past and present." *Nihon Shinkei Seishin Yakurigaku Zasshi* 21(5): 171-4.
- Meyer, U. (2005). "[Fritz Hauschild (1908-1974) and drug research in the 'German Democratic Republic' (GDR)]." *Pharmazie* 60(6): 468-72.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.
- Sulzer, D., M. S. Sonders, et al. (2005). "Mechanisms of neurotransmitter release by amphetamines: A review." *Prog Neurobiol* 75(6): 406-33.
- Suwanwela, C. and V. Poshyachinda (1986). "Drug abuse in Asia." *Bull Narc* 38(1-2): 41-53.

### HIV, Methamphetamine Interactions with

- Bobkov, A. F., L. M. Selimova, et al. (2005). "Human immunodeficiency virus type 1 in illicit-drug solutions used intravenously retains infectivity." *J Clin Microbiol* 43(4): 1937-9.
- Carey, C. L., S. P. Woods, et al. (2006). "Additive deleterious effects of methamphetamine dependence and immunosuppression on neuropsychological functioning in HIV infection." *AIDS Behav* 10(2): 185-90.
- Chana, G., I. P. Overall, et al. (2006). "Cognitive deficits and degeneration of interneurons in HIV+ methamphetamine users." *Neurology* 67(8): 1486-9.
- Chang, L., T. Ernst, et al. (2005). "Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities." *Am J Psychiatry* 162(2): 361-9.

- Cherner, M., S. Letendre, et al. (2005). "Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine." *Neurology* 64(8): 1343-7.
- Conant, K., C. St Hillaire, C. Anderson, D. Galey, J. Wang and A. Nath (2004). "Human immunodeficiency virus type 1 Tat and methamphetamine affect the release and activation of matrix-degrading proteinases." *J Neurovirol* 10(1): 21-8.
- Gadd, C. (2005). "Crystal meth use worsens HIV-related brain damage." *IAPAC Mon* 11(4): 109.
- Everall, I. P., L. A. Hansen, et al. (2005). "The shifting patterns of HIV encephalitis neuropathology." *Neurotox Res* 8(1-2): 51-61.
- Everall, I., S. Salaria, et al. (2005). "Methamphetamine stimulates interferon inducible genes in HIV infected brain." *J Neuroimmunol* 170(1-2): 158-71.
- Jernigan, T. L., A. C. Gamst, et al. (2005). "Effects of methamphetamine dependence and HIV infection on cerebral morphology." *Am J Psychiatry* 162(8): 1461-72.
- Jones, K. (2005). "Methamphetamine, the brain, HIV, and mental health." *Focus* 20(6): 1-5.
- Langford, D., A. Adame, A. Grigorian, I. Grant, J. A. McCutchan, R. J. Ellis, T. D. Marcotte and E. Masliah (2003). "Patterns of selective neuronal damage in methamphetamine-user AIDS patients." *J Acquir Immune Defic Syndr* 34(5): 467-74.
- Levine, A. J., D. J. Hardy, et al. (2006). "The effect of recent stimulant use on sustained attention in HIV-infected adults." *J Clin Exp Neuropsychol* 28(1): 29-42.
- Mahajan, S. D., Z. Hu, et al. (2006). "Methamphetamine modulates gene expression patterns in monocyte derived mature dendritic cells : Implications for HIV-1 pathogenesis." *Mol Diagn Ther* 10(4): 257-69.
- Nath, A., K. F. Hauser, et al. (2002). "Molecular basis for interactions of HIV and drugs of abuse." *J Acquir Immune Defic Syndr* 31 Suppl 2: S62-9.
- Nath, A., W. F. Maragos, et al. (2001). "Acceleration of HIV dementia with methamphetamine and cocaine." *J Neurovirol* 7(1): 66-71.
- Nath, A., C. Anderson, et al. (2000). "Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia." *J Psychopharmacol* 14(3): 222-7.
- Pol, S., P. Lebray, et al. (2004). "HIV infection and hepatic enzyme abnormalities: Intricacies of the pathogenic mechanisms." *Clin Infect Dis* 38 Suppl 2: S65-72.
- Selimova, L. M., T. A. Khanina, et al. (2003). "[Effect of home-made narcotics on infectious activity of HIV-1]." *Vopr Virusol* 48(6): 21-5.
- Urbina, A. and K. Jones (2004). "Crystal methamphetamine, its analogues, and HIV infection: Medical and psychiatric aspects of a new epidemic." *Clin Infect Dis* 38(6): 890-4.
- van Gorp, W. G. and C. H. Hinkin (2005). "Triple trouble: Cognitive deficits from hepatitis C, HIV, and methamphetamine." *Neurology* 64(8): 1328-9.
- Yu, Q., D. F. Larson, et al. (2003). "Heart disease, methamphetamine and AIDS." *Life Sci* 73(2): 129-40.

## HIV, Methamphetamine Interactions with (animal models)

- Ahmad, K. (2002). "Addictive drug increases HIV replication and mutation." *Lancet Infect Dis* 2(8): 456.
- Cass, W. A., M. E. Harned, et al. (2003). "HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat." *Brain Res* 984(1-2): 133-42.
- Cloak, C. C., L. Chang, et al. (2004). "Methamphetamine and AIDS: 1HMRS studies in a feline model of human disease." *J Neuroimmunol* 147(1-2): 16-20.
- Flora, G., Y. W. Lee, A. Nath, B. Hennig, W. Maragos and M. Toborek (2003). "Methamphetamine potentiates HIV-1 tat protein-mediated activation of redox-sensitive pathways in discrete regions of the brain." *Exp Neurol* 179(1): 60-70.
- Gavrilin, M. A., L. E. Mathes and M. Podell (2002). "Methamphetamine enhances cell-associated feline immunodeficiency virus replication in astrocytes." *J Neurovirol* 8(3): 240-9.
- Maragos, W. F., K. L. Young, J. T. Turchan, M. Guseva, J. R. Pauly, A. Nath and W. A. Cass (2002). "Human immunodeficiency virus-1 tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function." *J Neurochem* 83(4): 955-63.
- Phillips, T. R., J. N. Billaud, et al. (2000). "Methamphetamine and HIV-1: Potential interactions and the use of the FIV/cat model." *J Psychopharmacol* 14(3): 244-50.
- Theodore, S., W. A. Cass, et al. (2006). "Inhibition of tumor necrosis factor-alpha signaling prevents human immunodeficiency virus-1 protein Tat and methamphetamine interaction." *Neurobiol Dis* 23(3): 663-8.
- Theodore, S., W. A. Cass, et al. (2006). "Involvement of cytokines in human immunodeficiency virus-1 protein Tat and methamphetamine interactions in the striatum." *Exp Neurol* 199(2): 490-8.
- Theodore, S., W. A. Cass, et al. (2006). "Methamphetamine and human immunodeficiency virus protein Tat synergize to destroy dopaminergic terminals in the rat striatum." *Neuroscience* 137(3): 925-35.

### HIV Antiretroviral Therapy

*See Antiretroviral Therapy*

### HIV Brain Disease

*See Brain, HIV and; Brain, HIV and (animal models)*

### HIV Counseling and Testing

- Buchacz, K., W. McFarland, et al. (2005). "Amphetamine use is associated with increased HIV incidence among men." *AIDS* 19(13): 1423-24.
- Drumright, L. N., S. J. Little, et al. (2006). "Unprotected anal intercourse and substance use among men who have sex with men with recent HIV infection." *J Acquir Immune Defic Syndr* 43(3): 344-50.
- Drumright, L. N., S. A. Strathdee, et al. (2006). "Unprotected anal intercourse and substance use before and after HIV diagnosis among recently HIV-infected men who have sex with men." *Sex Transm Dis*.
- Pugatch, D. L., B. G. Levesque, et al. (2001). "HIV testing among young adults and older adolescents in the setting of acute substance abuse treatment." *Journal of Acquired Immune Deficiency Syndromes: JAIDS*. 27(2): 135-42.
- Rose, V. J., H. F. Raymond, et al. (2006). "Assessing the feasibility of harm reduction services for MSM: The late night breakfast buffet study." *Harm Reduct J* 3: 29.
- Viani, R. M., M. R. Araneta, et al. (2006). "Perinatal HIV counseling and rapid testing in Tijuana, Baja California, Mexico: Seroprevalence and correlates of HIV infection." *J Acquir Immune Defic Syndr* 41(1): 87-92.

### HIV Disclosure

- Gorbach, P. M., J. T. Galea, et al. (2004). "Don't ask, don't tell: patterns of HIV disclosure among HIV positive men who have sex with men with recent STI practising high risk behaviour in Los Angeles and Seattle." *Sex Transm Infect* 80(6): 512-7.
- Larkins, S., C. J. Reback, et al. (2005). "Methamphetamine-dependent gay men's disclosure of their HIV status to sexual partners." *AIDS Care* 17(4): 521-32.
- Purcell, D. W., S. Moss, et al. (2005). "Illicit substance use, sexual risk, and HIV-positive gay and bisexual men: Differences by serostatus of casual partners." *AIDS* 19: S37-S47.
- Semple, S. J., J. Zians, et al. (2006). "Sexual risk behavior of HIV-positive methamphetamine-using men who have sex with men: The role of partner serostatus and partner type." *Arch Sex Behav* 35(4): 461-71.

### HIV-Positive Individuals

- Anonymous (2006). "Investigation of a new diagnosis of multidrug-resistant, dual-tropic HIV-1 infection--New York City, 2005." *MMWR Morb Mortal Wkly Rep* 55(29): 793-6.
- Anonymous (2005). "Meth use increases HIV cases in South Dakota." *AIDS Patient Care STDS* 19(9): 619-20.
- Benotsch, E. G., S. Kalichman, et al. (2002). "Men who have met sex partners via the Internet: Prevalence, predictors, and implications for HIV prevention." *Arch Sex Behav* 31(2): 177-83.
- Bluthenthal, R. N., A. H. Kral, et al. (2001). "Trends in HIV seroprevalence and risk among gay and bisexual men who inject drugs in San Francisco, 1988 to 2000." *J Acquir Immune Defic Syndr* 28(3): 264-9.
- Bogart, L. M., A. H. Kral, et al. (2005). "Sexual risk among injection drug users recruited from syringe exchange programs in California." *Sex Transm Dis* 32(1): 27-34.
- Bolding, G., G. Hart, et al. (2006). "Use of crystal methamphetamine among gay men in London." *Addiction* 101(11): 1622-30.
- Brewer, D. D., M. R. Golden, et al. (2006). "Unsafe sexual behavior and correlates of risk in a probability sample of men who have sex with men in the era of highly active antiretroviral therapy." *Sex Transm Dis* 33(4): 250-5.
- Bull, S. S., P. Piper and C. Rietmeijer (2002). "Men who have sex with men and also inject drugs-profiles of risk related to the synergy of sex and drug injection behaviors." *J Homosex* 42(3): 31-51.
- Burcham, J. L., B. Tindall, et al. (1989). "Incidence and risk factors for human immunodeficiency virus seroconversion in a cohort of Sydney homosexual men." *Med J Aust* 150(11): 634-9.
- Carey, C. L., S. P. Woods, et al. (2006). "Additive deleterious effects of methamphetamine dependence and immunosuppression on neuropsychological functioning in HIV infection." *AIDS Behav* 10(2): 185-90.
- Chana, G., I. P. Overall, et al. (2006). "Cognitive deficits and degeneration of interneurons in HIV+ methamphetamine users." *Neurology* 67(8): 1486-9.

- Chang, L., T. Ernst, et al. (2005). "Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities." *Am J Psychiatry* 162(2): 361-9.
- Cherner, M., S. Letendre, et al. (2005). "Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine." *Neurology* 64(8): 1343-7.
- Chiappelli, F., P. Shapshak, et al. (2006). "Cellular immunology in HIV-1 positive African American women using alcohol and cocaine." *Front Biosci* 11: 2434-41.
- Colfax, G. N., E. Vittinghoff, et al. (2007). "Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance." *AIDS* 21(2): 239-241.
- Colfax, G. and S. Shoptaw (2005). "The methamphetamine epidemic: Implications for HIV prevention and treatment." *Curr HIV/AIDS Rep* 2(4): 194-9.
- Conant, K., C. St Hillaire, C. Anderson, D. Galey, J. Wang and A. Nath (2004). "Human immunodeficiency virus type 1 Tat and methamphetamine affect the release and activation of matrix-degrading proteinases." *J Neurovirol* 10(1): 21-8.
- Drumright, L. N., S. J. Little, et al. (2006). "Unprotected anal intercourse and substance use among men who have sex with men with recent HIV infection." *J Acquir Immune Defic Syndr* 43(3): 344-50.
- Drumright, L. N., S. A. Strathdee, et al. (2006). "Unprotected anal intercourse and substance use before and after HIV diagnosis among recently HIV-infected men who have sex with men." *Sex Transm Dis*.
- Everall, I. P., L. A. Hansen, et al. (2005). "The shifting patterns of HIV encephalitis neuropathology." *Neurotox Res* 8(1-2): 51-61.
- Everall, I., S. Salaria, et al. (2005). "Methamphetamine stimulates interferon inducible genes in HIV infected brain." *J Neuroimmunol* 170(1-2): 158-71.
- Fernandez, M. I., G. S. Bowen, et al. (2007). "Crystal methamphetamine: A source of added sexual risk for Hispanic men who have sex with men?" *Drug Alcohol Depend* 86(2-3): 245-52.
- Gadd, C. (2005). "Crystal meth use worsens HIV-related brain damage." *IAPAC Mon* 11(4): 109.
- Ghaziani, A. (2005). "Crystal methamphetamine use and antiretroviral drug resistance: A pilot study of behavioral and clinical correlates." *IAPAC Mon* 11(10): 297-9.
- Ghaziani, A. and T. D. Cook (2005). "Reducing HIV infections at circuit parties: From description to explanation and principles of intervention design." *J Int Assoc Physicians AIDS Care (Chic Ill)* 4(2): 32-46.
- Gorbach, P. M., J. T. Galea, et al. (2004). "Don't ask, don't tell: patterns of HIV disclosure among HIV positive men who have sex with men with recent STI practising high risk behaviour in Los Angeles and Seattle." *Sex Transm Infect* 80(6): 512-7.
- Gorman, M. (1996). "Speed use and HIV transmission." *Focus* 11(7): 4-6.
- Halkitis, P. N. and J. J. Palamar (2006). "GHB use among gay and bisexual men." *Addict Behav* 31(11): 2135-9.
- Halkitis, P. N., B. N. Fischgrund, et al. (2005). "Explanations for methamphetamine use among gay and bisexual men in New York City." *Subst Use Misuse* 40(9): 1331-45.
- Halkitis, P. N., K. A. Green, et al. (2005). "Seroconcordant sexual partnerings of HIV-seropositive men who have sex with men." *AIDS* 19: S77-S86.
- Halkitis, P. N., K. A. Green, et al. (2005). "Longitudinal investigation of methamphetamine use among gay and bisexual men in New York City: findings from Project BUMPS." *J Urban Health* 82(1 Suppl 1): i18-25.
- Halkitis, P. N., L. Wilton, et al. (2005). "Barebacking identity among HIV-positive gay and bisexual men: demographic, psychological, and behavioral correlates." *AIDS* 19: S27-S35.
- Hirshfield, S., R. H. Remien, et al. (2004). "Crystal methamphetamine use predicts incident STD infection among men who have sex with men recruited online: A nested case-control study." *J Med Internet Res* 6(4): e41.
- Ibanez, G. E., D. W. Purcell, et al. (2005). "Sexual risk, substance use, and psychological distress in HIV-positive gay and bisexual men who also inject drugs." *AIDS* 19: S49-S55.
- Jernigan, T. L., A. C. Gamst, et al. (2005). "Effects of methamphetamine dependence and HIV infection on cerebral morphology." *Am J Psychiatry* 162(8): 1461-72.
- Kahraman, A., M. Miller, et al. (2006). "Non-alcoholic fatty liver disease in HIV-positive patients predisposes for acute-on-chronic liver failure: Two cases." *Eur J Gastroenterol Hepatol* 18(1): 101-105.
- Knight, K. R., D. Purcell, et al. (2005). "Sexual risk taking among HIV-positive injection drug users: Contexts, characteristics, and implications for prevention." *AIDS Educ Prev* 17(1 Suppl A): 76-88.
- Kral, A. H., J. Lorvick, et al. (2005). "HIV prevalence and risk behaviors among men who have sex with men and inject drugs in San Francisco." *J Urban Health* 82(1 Suppl 1): i43-50.
- Kurtz, S. P. (2005). "Post-circuit blues: Motivations and consequences of crystal meth use among gay men in Miami." *AIDS Behav* 9(1): 63-72.

- Langford, D., A. Adame, A. Grigorian, I. Grant, J. A. McCutchan, R. J. Ellis, T. D. Marcotte and E. Masliah (2003). "Patterns of selective neuronal damage in methamphetamine-user AIDS patients." *J Acquir Immune Defic Syndr* 34(5): 467-74.
- Larkins, S., C. J. Reback, et al. (2005). "Methamphetamine-dependent gay men's disclosure of their HIV status to sexual partners." *AIDS Care* 17(4): 521-32.
- Letendre, S. L., M. Cherner, et al. (2005). "The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: Biological correlates of disease." *AIDS* 19 Suppl 3: S72-8.
- Levine, A. J., D. J. Hardy, et al. (2006). "The effect of recent stimulant use on sustained attention in HIV-infected adults." *J Clin Exp Neuropsychol* 28(1): 29-42.
- Lyons, T., G. Chandra, et al. (2006). "Stimulant use and HIV risk behavior: The influence of peer support group participation." *AIDS Educ Prev* 18(5): 461-73.
- Mitchell, S. J., S. R. Morris, et al. (2006). "Methamphetamine use and sexual activity among HIV-infected patients in care--San Francisco, 2004." *AIDS Patient Care STDS* 20(7): 502-10.
- Morin, S. F., W. T. Steward, et al. (2005). "Predicting HIV transmission risk among HIV-infected men who have sex with men: Findings from the healthy living project." *J Acquir Immune Defic Syndr* 40(2): 226-235.
- Nath, A., C. Anderson, et al. (2000). "Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia." *J Psychopharmacol* 14(3): 222-7.
- Patterson, T. L. and S. J. Semple (2003). "Sexual risk reduction among HIV-positive drug-using men who have sex with men." *J Urban Health* 80(4 Suppl 3): iii77-87.
- Pol, S., P. Lebray, et al. (2004). "HIV infection and hepatic enzyme abnormalities: Intricacies of the pathogenic mechanisms." *Clin Infect Dis* 38 Suppl 2: S65-72.
- Nath, A., K. F. Hauser, et al. (2002). "Molecular basis for interactions of HIV and drugs of abuse." *J Acquir Immune Defic Syndr* 31 Suppl 2: S62-9.
- Nath, A., W. F. Maragos, et al. (2001). "Acceleration of HIV dementia with methamphetamine and cocaine." *J Neurovirol* 7(1): 66-71.
- Patterson, T. L., S. J. Semple, et al. (2005). "Methamphetamine-using HIV-positive men who have sex with men: Correlates of polydrug use." *J Urban Health* 82(1 Suppl 1): i120-6.
- Pol, S., P. Lebray and A. Vallet-Pichard (2004). "HIV infection and hepatic enzyme abnormalities: Intricacies of the pathogenic mechanisms." *Clin Infect Dis* 38 Suppl 2: S65-72.
- Purcell, D. W., S. Moss, et al. (2005). "Illicit substance use, sexual risk, and HIV-positive gay and bisexual men: Differences by serostatus of casual partners." *AIDS* 19: S37-S47.
- Purcell, D. W., J. T. Parsons, P. N. Halkitis, Y. Mizuno and W. J. Woods (2001). "Substance use and sexual transmission risk behavior of HIV-positive men who have sex with men." *J Subst Abuse* 13(1-2): 185-200.
- Reback, C. J., S. Larkins, et al. (2003). "Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men." *AIDS Care* 15(6): 775-85.
- Rippeth, J. D., R. K. Heaton, et al. (2004). "Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons." *J Int Neuropsychol Soc* 10(1): 1-14.
- Robinson, L. and H. Rempel (2006). "Methamphetamine use and HIV symptom self-management." *J Assoc Nurses AIDS Care* 17(5): 7-14.
- Romanelli, F. and K. M. Smith (2004). "Recreational use of sildenafil by HIV-positive and -negative homosexual/bisexual males." *Ann Pharmacother* 38(6): 1024-30.
- Rose, V. J., H. F. Raymond, et al. (2006). "Assessing the feasibility of harm reduction services for MSM: The late night breakfast buffet study." *Harm Reduct J* 3: 29.
- Semple, S. J., J. Zians, et al. (2006). "Methamphetamine use, impulsivity, and sexual risk behavior among HIV-positive men who have sex with men." *J Addict Dis* 25(4): 105-14.
- Semple, S. J., J. Zians, et al. (2006). "Sexual compulsivity in a sample of HIV-positive methamphetamine-using gay and bisexual men." *AIDS Behav* 10(5): 587-98.
- Semple, S. J., J. Zians, et al. (2006). "Sexual risk behavior of HIV-positive methamphetamine-using men who have sex with men: The role of partner serostatus and partner type." *Arch Sex Behav* 35(4): 461-71.
- Semple, S. J., T. L. Patterson, et al. (2004). "A comparison of injection and non-injection methamphetamine-using HIV positive men who have sex with men." *Drug Alcohol Depend* 76(2): 203-12.
- Semple, S. J., T. L. Patterson, et al. (2003). "Binge use of methamphetamine among HIV-positive men who have sex with men: Pilot data and HIV prevention implications." *AIDS Educ Prev* 15(2): 133-47.
- Semple, S. J., T. L. Patterson and I. Grant (2002). "Motivations associated with methamphetamine use among HIV+ men who have sex with men." *J Subst Abuse Treat* 22(3): 149-56.



- Shibata, S., K. Mori, et al. (1991). "Subarachnoid and intracerebral hemorrhage associated with necrotizing angitis due to methamphetamine abuse--an autopsy case." *Neurol Med Chir (Tokyo)* 31(1): 49-52.
- Shibata, S., K. Mori, et al. (1988). "[An autopsy case of subarachnoid and intracerebral hemorrhage and necrotizing angitis associated with methamphetamine abuse]." *No To Shinkei* 40(11): 1089-94.
- Shoptaw, S., J. D. Klausner, et al. (2006). "A public health response to the methamphetamine epidemic: The implementation of contingency management to treat methamphetamine dependence." *BMC Public Health* 6(1): 214.
- Shoptaw, S. and C. J. Reback (2006). "Associations between methamphetamine use and HIV among men who have sex with men: A model for guiding public policy." *J Urban Health* 83(6): 1151-7.
- Shoptaw, S., C. J. Reback and T. E. Freese (2002). "Patient characteristics, HIV serostatus, and risk behaviors among gay and bisexual males seeking treatment for methamphetamine abuse and dependence in Los Angeles." *J Addict Dis* 21(1): 91-105.
- Srirak, N., S. Kawichai, et al. (2005). "HIV infection among female drug users in Northern Thailand." *Drug Alcohol Depend* 78(2): 141-5.
- Sullivan, P. S., A. K. Nakashima, et al. (1998). "Geographic differences in noninjection and injection substance use among HIV-seropositive men who have sex with men: western United States versus other regions. Supplement to HIV/AIDS Surveillance Study Group." *J Acquir Immune Defic Syndr Hum Retrovirol* 19(3): 266-73.
- Twitchell, G. R., A. Huber, et al. (2002). "Comparison of general and detailed HIV risk assessments among methamphetamine abusers." *AIDS and Behavior* 6(2): 153-162.
- Urbina, A. and K. Jones (2004). "Crystal methamphetamine, its analogues, and HIV infection: Medical and psychiatric aspects of a new epidemic." *Clin Infect Dis* 38(6): 890-4.
- Wu, L. T., D. J. Pilowsky, et al. (2004). "Injection drug use among stimulant users in a national sample." *Am J Drug Alcohol Abuse* 30(1): 61-83.
- Yu, Q., D. F. Larson and R. R. Watson (2003). "Heart disease, methamphetamine and AIDS." *Life Sci* 73(2): 129-40.

## HIV Prevention

*See also* Injection of Methamphetamine; Sexual Risk Behaviors; Syringe Exchange and Syringe Access

- Anonymous (2006). "Investigation of a new diagnosis of multidrug-resistant, dual-tropic HIV-1 infection--New York City, 2005." *MMWR Morb Mortal Wkly Rep* 55(29): 793-6.
- Anonymous (2005). "Meth use increases HIV cases in South Dakota." *AIDS Patient Care STDS* 19(9): 619-20.
- Benotsch, E. G., S. Kalichman, et al. (2002). "Men who have met sex partners via the Internet: Prevalence, predictors, and implications for HIV prevention." *Arch Sex Behav* 31(2): 177-83.
- Bluthenthal, R. N., A. H. Kral, et al. (2001). "Trends in HIV seroprevalence and risk among gay and bisexual men who inject drugs in San Francisco, 1988 to 2000." *J Acquir Immune Defic Syndr* 28(3): 264-9.
- Buchacz, K., W. McFarland, et al. (2005). "Amphetamine use is associated with increased HIV incidence among men." *AIDS* 19(13): 1423-24.
- Colfax, G. N., E. Vittinghoff, et al. (2007). "Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance." *AIDS* 21(2): 239-241.
- Colfax, G. and S. Shoptaw (2005). "The methamphetamine epidemic: Implications for HIV prevention and treatment." *Curr HIV/AIDS Rep* 2(4): 194-9.
- Colfax, G., T. J. Coates, et al. (2005). "Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of San Francisco men who have sex with men." *J Urban Health* 82(1 Suppl 1): i62-70.
- Chu, P. L., W. McFarland, et al. (2003). "Viagra use in a community-recruited sample of men who have sex with men, San Francisco." *J Acquir Immune Defic Syndr* 33(2): 191-3.
- Drumright, L. N., S. A. Strathdee, et al. (2006). "Unprotected anal intercourse and substance use before and after HIV diagnosis among recently HIV-infected men who have sex with men." *Sex Transm Dis*.
- Fernandez, M. I., L. M. Varga, T. Perrino, J. B. Collazo, F. Subiaul, A. Rehbein, H. Torres, M. Castro and G. S. Bowen (2004). "The Internet as recruitment tool for HIV studies: Viable strategy for reaching at-risk Hispanic MSM in Miami?" *AIDS Care* 16(8): 953-63.
- Ghaziani, A. and T. D. Cook (2005). "Reducing HIV infections at circuit parties: From description to explanation and principles of intervention design." *J Int Assoc Physicians AIDS Care (Chic Ill)* 4(2): 32-46.
- Gorman, M. (1996). "Speed use and HIV transmission." *Focus* 11(7): 4-6.
- Herbst, J. H., R. T. Sherba, et al. (2005). "A meta-analytic review of HIV behavioral interventions for reducing sexual risk behavior of men who have sex with men." *J Acquir Immune Defic Syndr* 39(2): 228-41.

- Kral, A. H., J. Lorvick, et al. (2005). "HIV prevalence and risk behaviors among men who have sex with men and inject drugs in San Francisco." *J Urban Health* 82(1 Suppl 1): i43-50.
- Kral, A. H., R. N. Bluthenthal, et al. (2001). "Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: Risk-factor analysis." *Lancet* 357(9266): 1397-401.
- Knight, K. R., D. Purcell, et al. (2005). "Sexual risk taking among HIV-positive injection drug users: Contexts, characteristics, and implications for prevention." *AIDS Educ Prev* 17(1 Suppl A): 76-88.
- Koblin, B. A., M. A. Chesney, et al. (2003). "High-risk behaviors among men who have sex with men in 6 US cities: Baseline data from the EXPLORE Study." *Am J Public Health* 93(6): 926-32.
- Koester, S., J. Glanz, et al. (2005). "Drug sharing among heroin networks: Implications for HIV and hepatitis B and C prevention." *AIDS Behav* 9(1): 27-39.
- Liu, A., P. Kilmarx, et al. (2006). "Sexual initiation, substance use, and sexual behavior and knowledge among vocational students in northern Thailand." *Int Fam Plan Perspect* 32(3): 126-35.
- Lorvick, J., A. Martinez, et al. (2006). "Sexual and injection risk among women who inject methamphetamine in San Francisco." *J Urban Health* 83(3): 497-505.
- Lum, P. J., C. Sears, et al. (2005). "Injection risk behavior among women syringe exchangers in San Francisco." *Subst Use Misuse* 40(11): 1681-96.
- Lyons, T., G. Chandra, et al. (2006). "Stimulant use and HIV risk behavior: The influence of peer support group participation." *AIDS Educ Prev* 18(5): 461-73.
- Mansergh, G., D. W. Purcell, et al. (2006). "CDC consultation on methamphetamine use and sexual risk behavior for HIV/STD infection: summary and suggestions." *Public Health Rep* 121(2): 127-32.
- Mansergh, G., G. N. Colfax, et al. (2001). "The Circuit Party Men's Health Survey: Findings and implications for gay and bisexual men." *Am J Public Health* 91(6): 953-8.
- Mitchell, S. J., S. R. Morris, et al. (2006). "Methamphetamine use and sexual activity among HIV-infected patients in care--San Francisco, 2004." *AIDS Patient Care STDS* 20(7): 502-10.
- Morin, S. F., W. T. Steward, et al. (2005). "Predicting HIV transmission risk among HIV-infected men who have sex with men: Findings from the healthy living project." *J Acquir Immune Defic Syndr* 40(2): 226-235.
- Patterson, T. L. and S. J. Semple (2003). "Sexual risk reduction among HIV-positive drug-using men who have sex with men." *J Urban Health* 80(4 Suppl 3): iii77-87.
- Razak, M. H., J. Jittiwutikarn, et al. (2003). "HIV prevalence and risks among injection and noninjection drug users in northern Thailand: Need for comprehensive HIV prevention programs." *J Acquir Immune Defic Syndr* 33(2): 259-66.
- Reback, C. J. and C. E. Grella (1999). "HIV risk behaviors of gay and bisexual male methamphetamine users contacted through street outreach." *Journal of Drug Issues* 29(1): 155-66.
- Richard, A. J., V. Mosier, et al. (2002). "New syringe acquisition and multi-person use of syringes among illegal drug users." *J Public Health Policy* 23(3): 324-43.
- Rose, V. J., H. F. Raymond, et al. (2006). "Assessing the feasibility of harm reduction services for MSM: The late night breakfast buffet study." *Harm Reduct J* 3: 29.
- Sears, C., J. R. Guydish, et al. (2001). "Investigation of a secondary syringe exchange program for homeless young adult injection drug users in San Francisco, California, U.S.A." *J Acquir Immune Defic Syndr* 27(2): 193-201.
- Semple, S. J., J. Zians, et al. (2006). "Methamphetamine use, impulsivity, and sexual risk behavior among HIV-positive men who have sex with men." *J Addict Dis* 25(4): 105-14.
- Semple, S. J., I. Grant, et al. (2004). "Female methamphetamine users: Social characteristics and sexual risk behavior." *Women Health* 40(3): 35-50.
- Semple, S. J., T. L. Patterson and I. Grant (2004). "The context of sexual risk behavior among heterosexual methamphetamine users." *Addict Behav* 29(4): 807-10.
- Semple, S. J., J. Zians, et al. (2006). "Sexual risk behavior of HIV-positive methamphetamine-using men who have sex with men: The role of partner serostatus and partner type." *Arch Sex Behav* 35(4): 461-71.
- Semple, S. J., T. L. Patterson, et al. (2004). "Determinants of condom use stage of change among heterosexually-identified methamphetamine users." *AIDS Behav* 8(4): 391-400.
- Semple, S. J., T. L. Patterson, et al. (2003). "Binge use of methamphetamine among HIV-positive men who have sex with men: Pilot data and HIV prevention implications." *AIDS Educ Prev* 15(2): 133-47.
- Shoptaw, S. and C. J. Reback (2006). "Associations between methamphetamine use and HIV among men who have sex with men: A model for guiding public policy." *J Urban Health* 83(6): 1151-7.
- Shoptaw, S., C. J. Reback, et al. (2005). "Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men." *Drug Alcohol Depend* 78(2): 125-34.

- Shoptaw, S., C. J. Reback, et al. (1998). "Stimulant abuse treatment as HIV prevention." *J Addict Dis* 17(4): 19-32.
- Simbayi, L. C., S. C. Kalichman, et al. (2006). "Methamphetamine use and sexual risks for HIV infection in Cape Town, South Africa." *Journal of Substance Use* 11(4): 291-300.
- Simbulan, N. P., A. S. Aguilar, et al. (2001). "High-risk behaviors and the prevalence of sexually transmitted diseases among women prisoners at the women state penitentiary in Metro Manila." *Soc Sci Med* 52(4): 599-608.
- Srirak, N., S. Kawichai, et al. (2005). "HIV infection among female drug users in Northern Thailand." *Drug Alcohol Depend* 78(2): 141-5.
- Twitchell, G. R., A. Huber, et al. (2002). "Comparison of general and detailed HIV risk assessments among methamphetamine abusers." *AIDS and Behavior* 6(2): 153-162.
- Verachai, V., T. Phutiprawan, et al. (2005). "HIV infection among substance abusers in Thanyarak Institute On Drug Abuse, Thailand, 1987-2002." *J Med Assoc Thai* 88(1): 76-9.
- Viani, R. M., M. R. Araneta, et al. (2006). "Perinatal HIV counseling and rapid testing in Tijuana, Baja California, Mexico: Seroprevalence and correlates of HIV infection." *J Acquir Immune Defic Syndr* 41(1): 87-92.
- Volkow, N. D., G. J. Wang, et al. (2007). "Stimulant-induced enhanced sexual desire as a potential contributing factor in HIV transmission." *Am J Psychiatry* 164(1): 157-60.
- Wu, L. T., D. J. Pilowsky, et al. (2004). "Injection drug use among stimulant users in a national sample." *Am J Drug Alcohol Abuse* 30(1): 61-83.
- Zenilman, J. M. (2005). "Behavioral interventions--rationale, measurement, and effectiveness." *Infect Dis Clin North Am* 19(2): 541-62.
- Zule, W. A. and D. P. Desmond (1999). "An ethnographic comparison of HIV risk behaviors among heroin and methamphetamine injectors." *Am J Drug Alcohol Abuse* 25(1): 1-23.

## HIV Replication

- Ellis, R. J., M. E. Childers, et al. (2003). "Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy." *J Infect Dis* 188(12): 1820-6.
- Flora, G., Y. W. Lee, A. Nath, B. Hennig, W. Maragos and M. Toborek (2003). "Methamphetamine potentiates HIV-1 tat protein-mediated activation of redox-sensitive pathways in discrete regions of the brain." *Exp Neurol* 179(1): 60-70.

## Homeless Populations

- Bungay, V., L. Malchy, et al. (2006). "Life with jib: A snapshot of street youth's use of crystal methamphetamine." *Addiction Research and Theory* 14(3): 235-251.
- Clatts, M. C., L. Goldsamt, et al. (2005). "Homelessness and drug abuse among young men who have sex with men in New York city: A preliminary epidemiological trajectory." *J Adolesc* 28(2): 201-14.
- Gleghorn, A. A., R. Marx, et al. (1998). "Association between drug use patterns and HIV risks among homeless, runaway, and street youth in northern California." *Drug Alcohol Depend* 51(3): 219-27.
- Kipke, M. D., S. O'Connor, et al. (1995). "Street youth in Los Angeles. Profile of a group at high risk for human immunodeficiency virus infection." *Arch Pediatr Adolesc Med* 149(5): 513-9.
- Kral, A. H., J. Lorvick, et al. (2000). "Sex- and drug-related risk among populations of younger and older injection drug users in adjacent neighborhoods in San Francisco." *J Acquir Immune Defic Syndr* 24(2): 162-7.
- Kushel, M. B., J. A. Hahn, et al. (2005). "Revolving doors: Imprisonment among the homeless and marginally housed population." *Am J Public Health* 95(10): 1747-52.
- Martin, I., T. M. Lampinen, et al. (2006). "Methamphetamine use among marginalized youth in British Columbia." *Can J Public Health* 97(4): 320-4.
- Nyamathi, A. M., E. L. Dixon, et al. (2006). "Hepatitis C virus infection among homeless men referred from a community clinic." *West J Nurs Res* 28(4): 475-88.
- Nyamathi, A. M., E. L. Dixon, et al. (2002). "Risk factors for hepatitis C virus infection among homeless adults." *J Gen Intern Med* 17(2): 134-43.
- Nyamathi, A., W. A. Robbins, et al. (2002). "Presence and predictors of hepatitis C virus RNA in the semen of homeless men." *Biol Res Nurs* 4(1): 22-30.
- Okudaira, K., T. Yabana, et al. (1994). "[Clinical problems of alcoholics with a history of methamphetamine abuse]." *Arukuru Kenkyuto Yakubutsu Ison* 29(3): 185-9.
- Rose, V. J., H. F. Raymond, et al. (2006). "Assessing the feasibility of harm reduction services for MSM: The late night breakfast buffet study." *Harm Reduct J* 3: 29.

- Sears, C., J. R. Gudyish, et al. (2001). "Investigation of a secondary syringe exchange program for homeless young adult injection drug users in San Francisco, California, U.S.A." *J Acquir Immune Defic Syndr* 27(2): 193-201.
- Semple, S. J., T. L. Patterson, et al. (2004). "A comparison of injection and non-injection methamphetamine-using HIV positive men who have sex with men." *Drug Alcohol Depend* 76(2): 203-12.
- Smith, D. E. (1969). "Runaways and their health problems in Haight-Ashbury during the summer of 1967." *Am J Public Health Nations Health* 59(11): 2046-50.
- Van Leeuwen, J. M., C. Hopfer, et al. (2004). "A snapshot of substance abuse among homeless and runaway youth in Denver, Colorado." *J Community Health* 29(3): 217-29.
- Weiser, S. D., S. E. Dilworth, et al. (2006). "Gender-specific correlates of sex trade among homeless and marginally housed individuals in San Francisco." *J Urban Health* 83(4): 736-40.
- Wenzel, S. L., P. A. Ebener, et al. (1996). "Drug-abusing homeless clients in California's substance abuse treatment system." *J Psychoactive Drugs* 28(2): 147-59.
- Wood, E., J. A. Stoltz, et al. (2006). "Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study." *Harm Reduct J* 3: 18.

### Hong Kong

- Ahmad, K. (2003). "Asia grapples with spreading amphetamine abuse." *Lancet* 361(9372): 1878-9.
- Cheng, J. Y., M. F. Chan, et al. (2006). "Impurity profiling of ecstasy tablets seized in Hong Kong by gas chromatography-mass spectrometry." *Forensic Sci Int* 162(1-3): 87-94.
- Cheng, J. Y., D. T. Chan, et al. (2005). "An epidemiological study on alcohol/drugs related fatal traffic crash cases of deceased drivers in Hong Kong between 1996 and 2000." *Forensic Sci Int* 153(2-3): 196-201.
- Cheng, W. C., N. L. Poon, et al. (2003). "Chemical profiling of 3,4-methylenedioxyamphetamine (MDMA) tablets seized in Hong Kong." *J Forensic Sci* 48(6): 1249-59.
- Joe Laidler, K. A. (2005). "The rise of club drugs in a heroin society: The case of Hong Kong." *Subst Use Misuse* 40(9-10): 1257-78.
- McGrath, C. and B. Chan (2005). "Oral health sensations associated with illicit drug abuse." *Br Dent J* 198(3): 159-62; discussion 147; quiz 174.

### Honolulu, HI (US)

- Arria, A. M., C. Derauf, et al. (2006). "Methamphetamine and other substance use during pregnancy: Preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study." *Matern Child Health J* 10(3): 293-302.
- Gonzales, R., P. Marinelli-Casey, et al. (2006). "Hepatitis C virus infection among methamphetamine-dependent individuals in outpatient treatment." *J Subst Abuse Treat* 31(2): 195-202.
- Smith, L. M., L. L. Lagasse, et al. (2006). "The Infant Development, Environment, and Lifestyle Study: Effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth." *Pediatrics* 118(3): 1149-1156.

### Hospital Utilization

- Anonymous (1995). "Increasing morbidity and mortality associated with abuse of methamphetamine--United States, 1991-1994." *MMWR Morb Mortal Wkly Rep* 44(47): 882-6.
- Danks, R. R., L. A. Wibbenmeyer, L. D. Faucher, K. C. Sihler, G. P. Kealey, P. Chang, M. Amelon and R. W. Lewis, 3rd (2004). "Methamphetamine-associated burn injuries: A retrospective analysis." *J Burn Care Rehabil* 25(5): 425-9.
- Huff, C. (2006). "Crystal crush." *Hosp Health Netw* 80(10): 59-60, 62, 64.
- Hutin, Y. J., B. P. Bell, et al. (1999). "Identifying target groups for a potential vaccination program during a hepatitis A communitywide outbreak." *Am J Public Health* 89(6): 918-21.
- Kerr, T., E. Wood, et al. (2005). "High rates of primary care and emergency department use among injection drug users in Vancouver." *J Public Health (Oxf)* 27(1): 62-6.
- Leamon, M. H., D. R. Gibson, R. D. Canning and L. Benjamin (2002). "Hospitalization of patients with cocaine and amphetamine use disorders from a psychiatric emergency service." *Psychiatr Serv* 53(11): 1461-6.
- Ozaki, S. (2004). "[Current situation of substance abuse/dependence in psychiatric hospital settings]." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 39(1): 35-40.
- Parry, C. D., A. Pluddemann, et al. (2005). "Cannabis and other drug use among trauma patients in three South African cities, 1999-2001." *S Afr Med J* 95(6): 429-32.

- Pecha, R. E., T. Prindiville, et al. (1996). "Association of cocaine and methamphetamine use with giant gastroduodenal ulcers." *Am J Gastroenterol* 91(12): 2523-7.
- Penn, C. L. (2006). "Meth abuse in Arkansas." *J Ark Med Soc* 102(8): 218-9.
- Richards, J. R., S. W. Bretz, et al. (1999). "Methamphetamine abuse and emergency department utilization." *West J Med* 170(4): 198-202.
- Tominaga, G. T., G. Garcia, et al. (2004). "Toll of methamphetamine on the trauma system." *Arch Surg* 139(8): 844-7.
- Turnipseed, S. D., J. R. Richards, et al. (2003). "Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after methamphetamine use." *J Emerg Med* 24(4): 369-73.
- Wermuth, L. (2000). "Methamphetamine use: Hazards and social influences." *J Drug Educ* 30(4): 423-33.

## Houston, TX (US)

- Atkinson, J., V. L. Brown, et al. (2004). "Personal adjustment and substance abuse problems in a longitudinal study of TANF recipients and the potential need for treatment." *Am J Drug Alcohol Abuse* 30(3): 643-57.
- Richard, A. J., V. Mosier, et al. (2002). "New syringe acquisition and multi-person use of syringes among illegal drug users." *J Public Health Policy* 23(3): 324-43.
- Williams, M. L., J. Atkinson, et al. (2005). "Spatial bridging in a network of drug-using male sex workers." *J Urban Health* 82(1 Suppl 1): i35-42.

## Huntington's Disease (animal models)

- Hurlbert, M. S., R. I. Gianani, et al. (1999). "Neural transplantation of hNT neurons for Huntington's disease." *Cell Transplant* 8(1): 143-51.

## Hyperactivity

*See also Attention Deficit Hyperactivity Disorder*

- Batki, S. L. and D. S. Harris (2004). "Quantitative drug levels in stimulant psychosis: Relationship to symptom severity, catecholamines and hyperkinesia." *Am J Addict* 13(5): 461-70.
- Dwoskin, L. P. and P. A. Crooks (2002). "A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse." *Biochem Pharmacol* 63(2): 89-98.
- Yui, K., K. Goto and S. Ikemoto (2004). "The role of noradrenergic and dopaminergic hyperactivity in the development of spontaneous recurrence of methamphetamine psychosis and susceptibility to episode recurrence." *Ann N Y Acad Sci* 1025: 296-306.
- Yui, K., S. Ikemoto, et al. (2002). "Factors for susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosis." *Ann N Y Acad Sci* 965: 292-304.
- Yui, K., K. Goto, et al. (1999). "Increased sensitivity to stress and episode recurrence in spontaneous recurrence of methamphetamine psychosis." *Psychopharmacology (Berl)* 145(3): 267-72.

## Hyperactivity (animals)

- Ago, Y., S. Nakamura, et al. (2006). "Attenuation by the 5-HT(1A) receptor agonist osetozotan of the behavioral effects of single and repeated methamphetamine in mice." *Neuropharmacology* 51(4): 914-22.
- Alam, M. R. (1981). "Enhancement of motor-accelerating effect induced by repeated administration of methamphetamine in mice: Involvement of environmental factors." *Jpn J Pharmacol* 31(6): 897-904.
- Araki, H., T. Yamamoto, et al. (2002). "Effect of methamphetamine and imipramine on cerebral ischemia-induced hyperactivity in Mongolian gerbils." *Jpn J Pharmacol* 88(3): 293-9.
- Araki, H., T. Yamamoto, et al. (2001). "Chronic methamphetamine administration inhibits cerebral ischemia-induced hyperactivity in Mongolian gerbils." *Physiol Behav* 74(1-2): 127-31.
- Bergstrom, H. C., A. A. Palmer, et al. (2003). "Reverse selection for differential response to the locomotor stimulant effects of ethanol provides evidence for pleiotropic genetic influence on locomotor response to other drugs of abuse." *Alcohol Clin Exp Res* 27(10): 1535-47.
- Bevins, R. A. and J. L. Peterson (2004). "Individual differences in rats' reactivity to novelty and the unconditioned and conditioned locomotor effects of methamphetamine." *Pharmacol Biochem Behav* 79(1): 65-74.
- Brennan, K., A. Johnstone, et al. (2006). "Chronic benzylpiperazine (BZP) exposure produces behavioral sensitization and cross-sensitization to methamphetamine (MA)." *Drug Alcohol Depend*.

- Clemens, K. J., J. L. Cornish, et al. (2007). "Repeated weekly exposure to MDMA, methamphetamine or their combination: Long-term behavioural and neurochemical effects in rats." *Drug Alcohol Depend* 86(2-3): 183-90.
- Cowen, P. J., D. J. Nutt, et al. (1982). "Repeated administration of subconvulsant doses of GABA antagonist drugs. II. Effect on monoamine-mediated behaviour." *Psychopharmacology (Berl)* 76(1): 88-91.
- Dringenberg, H. C., P. Servos, et al. (1992). "Pressure on the snout immobilizes the spontaneously active, scopolaminized, and amphetaminized hyperactive rat." *Behav Brain Res* 50(1-2): 197-9.
- Ehrman, L. A., M. T. Williams, et al. (2006). "Phosphodiesterase 1B differentially modulates the effects of methamphetamine on locomotor activity and spatial learning through DARPP32-dependent pathways: evidence from PDE1B-DARPP32 double-knockout mice." *Genes Brain Behav* 5(7): 540-51.
- Elphick, M. (1989). "Effects of carbamazepine on dopamine function in rodents." *Psychopharmacology (Berl)* 99(4): 532-6.
- Eradiri, O. L. and M. S. Starr (1999). "Striatal dopamine depletion and behavioural sensitization induced by methamphetamine and 3-nitropropionic acid." *Eur J Pharmacol* 386(2-3): 217-26.
- Facchinetti, F., R. Dall'Olio, et al. (1994). "Long-lasting effects of chronic neonatal blockade of N-methyl-D-aspartate receptor through the competitive antagonist CGP 39551 in rats." *Neuroscience* 60(2): 343-53.
- Fang, Y. R., T. Abekawa, et al. (2005). "Effect of the protein kinase C inhibitor, staurosporine, on the high dose of methamphetamine-induced behavioral sensitization to dizocilpine (MK-801)." *Psychopharmacology (Berl)* 180(1): 100-6.
- Floran, B., L. Floran, et al. (2004). "Dopamine D4 receptors inhibit depolarization-induced [3H]GABA release in the rat subthalamic nucleus." *Eur J Pharmacol* 498(1-3): 97-102.
- Fox, G. B., T. A. Esbenshade, et al. (2005). "Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzotrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist." *J Pharmacol Exp Ther* 313(1): 176-90.
- Funakoshi, T., S. Chaki, et al. (2002). "In vitro and in vivo pharmacological profile of 5-[2-[4-(6-fluoro-1H-indole-3-yl)piperidin-1-yl]ethyl]-4-(4-fluorophenyl)thiazole-2-carboxylic acid amide (NRA0562), a novel and putative atypical antipsychotic." *Life Sci* 71(12): 1371-84.
- Furukawa, T., I. Ushizima, et al. (1975). "Modifications by lithium of behavioral responses to methamphetamine and tetrabenazine." *Psychopharmacologia* 42(3): 243-8.
- Gehrke, B. J., W. A. Cass, et al. (2006). "Monoamine-depleting doses of methamphetamine in enriched and isolated rats: Consequences for subsequent methamphetamine-induced hyperactivity and reward." *Behav Pharmacol* 17(5-6): 499-508.
- Gentry, W. B., E. M. Laurenzana, et al. (2006). "Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats." *Int Immunopharmacol* 6(6): 968-77.
- Ginawi, O. T., A. A. Al-Majed, et al. (2004). "Involvement of some 5-HT receptors in methamphetamine-induced locomotor activity in mice." *J Physiol Pharmacol* 55(2): 357-69.
- Ginawi, O. T., O. A. al-Shabanah, et al. (1997). "Increased toxicity of methamphetamine in morphine-dependent mice." *Gen Pharmacol* 28(5): 727-31.
- Hirabayashi, M. and S. Tadokoro (1992). "Sensitization to ambulation-increasing effects of cocaine after repeated administration in mice—roles of dose and interval of administration as well as experimental environments." *Arukuru Kenkyuto Yakubutsu Ison* 27(1): 91-102.
- Hirabayashi, M., S. Okada, et al. (1991). "Comparison of sensitization to ambulation-increasing effects of cocaine and methamphetamine after repeated administration in mice." *J Pharm Pharmacol* 43(12): 827-30.
- Hirabayashi, M. and M. R. Alam (1981). "Enhancing effect of methamphetamine on ambulatory activity produced by repeated administration in mice." *Pharmacol Biochem Behav* 15(6): 925-32.
- Hirabayashi, M., F. Iwai, et al. (1979). "[Individual differences in the accelerating effect of methamphetamine, d-amphetamine and morphine on ambulatory activity in mice (author's transl)]." *Nippon Yakurigaku Zasshi* 75(7): 683-93.
- Hirose, A., T. Kato, et al. (1990). "Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions." *Jpn J Pharmacol* 53(3): 321-9.
- Hirota, S., N. Kawashima, et al. (2003). "Neuropharmacological profile of an atypical antipsychotic, NRA0562." *CNS Drug Rev* 9(4): 375-88.
- Ida, I., T. Asami, et al. (1990). "[Characteristics of antagonism between ceruletide and various central-acting drugs: Investigation by means of ambulatory activity in mice]." *Nippon Yakurigaku Zasshi* 96(6): 333-41.
- Ishida, Y., T. Hashitani, et al. (1990). "Behavioral and biochemical effects of intra-accumbens dopaminergic grafts." *Brain Res Bull* 24(3): 487-92.
- Ishimaru, M., T. Hashimoto, et al. (1995). "Methamphetamine-induced dopaminergic hyperactivity is not accompanied with increase in tyrosine hydroxylase mRNA of the rat midbrain." *Neurosci Lett* 191(1-2): 107-10.

- Ito, K., T. Abekawa, et al. (2006). "Relationship between development of cross-sensitization to MK-801 and delayed increases in glutamate levels in the nucleus accumbens induced by a high dose of methamphetamine." *Psychopharmacology (Berl)* 187(3): 293-302.
- Ito, K., T. Abekawa, et al. (2006). "Valproate blocks high-dose methamphetamine-induced behavioral cross-sensitization to locomotion-inducing effect of dizocilpine (MK-801), but not methamphetamine." *Psychopharmacology (Berl)* 186(4): 525-33.
- Ito, K., T. Ohmori, et al. (1997). "Clonazepam prevents the development of sensitization to methamphetamine." *Pharmacol Biochem Behav* 58(4): 875-9.
- Itoh, Y., M. Nishibori, et al. (1984). "Neuronal histamine inhibits methamphetamine-induced locomotor hyperactivity in mice." *Neurosci Lett* 48(3): 305-9.
- Itzhak, Y. and S. F. Ali (2002). "Behavioral consequences of methamphetamine-induced neurotoxicity in mice: Relevance to the psychopathology of methamphetamine addiction." *Ann N Y Acad Sci* 965: 127-35.
- Itzhak, Y. and J. L. Martin (2000). "Effect of riluzole and gabapentin on cocaine- and methamphetamine-induced behavioral sensitization in mice." *Psychopharmacology (Berl)* 151(2-3): 226-33.
- Itzhak, Y., C. Gandia, et al. (1998). "Resistance of neuronal nitric oxide synthase-deficient mice to methamphetamine-induced dopaminergic neurotoxicity." *J Pharmacol Exp Ther* 284(3): 1040-7.
- Iwabuchi, K., Y. Kubota, et al. (2004). "Methamphetamine and brain histamine: A study using histamine-related gene knockout mice." *Ann N Y Acad Sci* 1025: 129-34.
- Iwazaki, T., I. S. McGregor, et al. (2006). "Protein expression profile in the striatum of acute methamphetamine-treated rats." *Brain Res* 1097(1): 19-25.
- Johnson, S. A., N. T. Luu, et al. (1999). "Synergistic interactions between ampakines and antipsychotic drugs." *J Pharmacol Exp Ther* 289(1): 392-7.
- Jones, D. N. and S. G. Holtzman (1994). "Influence of naloxone upon motor activity induced by psychomotor stimulant drugs." *Psychopharmacology (Berl)* 114(2): 215-24.
- Kamens, H. M., S. Burkhart-Kasch, et al. (2006). "Ethanol-related traits in mice selectively bred for differential sensitivity to methamphetamine-induced activation." *Behav Neurosci* 120(6): 1356-66.
- Kamens, H. M., S. Burkhart-Kasch, et al. (2005). "Sensitivity to psychostimulants in mice bred for high and low stimulation to methamphetamine." *Genes Brain Behav* 4(2): 110-25.
- Kameyama, T., T. Nabeshima, et al. (1987). "[Behavioral pharmacological action of Ca-4-(3,5-dihydroxy-3-methylpentylamido) butyrate (mevalonic GABA, MV-GABA)]." *Nippon Yakurigaku Zasshi* 89(3): 103-10.
- Kato, K., T. Shishido, et al. (2001). "Glycine reduces novelty- and methamphetamine-induced locomotor activity in neonatal ventral hippocampal damaged rats." *Neuropsychopharmacology* 24(3): 330-2.
- Kato, K., T. Shishido, et al. (2000). "Effects of phencyclidine on behavior and extracellular levels of dopamine and its metabolites in neonatal ventral hippocampal damaged rats." *Psychopharmacology (Berl)* 150(2): 163-9.
- Katsuura, G. and S. Itoh (1982). "Sedative action of cholecystokinin octapeptide on behavioral excitation by thyrotropin releasing hormone and methamphetamine in the rat." *Jpn J Physiol* 32(1): 83-91.
- Kawakami, Y., K. Suemaru, et al. (1996). "[Behavioral changes induced by repeated administration of mazindol, an anorexiant, in rats]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 16(4): 139-43.
- Kim, H. S., Y. T. Hong, et al. (1998). "Inhibition by ginsenosides Rb1 and Rg1 of methamphetamine-induced hyperactivity, conditioned place preference and postsynaptic dopamine receptor supersensitivity in mice." *Gen Pharmacol* 30(5): 783-9.
- Kim, H. S., C. G. Jang, et al. (1996). "Blockade by ginseng total saponin of methamphetamine-induced hyperactivity and conditioned place preference in mice." *Gen Pharmacol* 27(2): 199-204.
- Kitanaka, N., J. Kitanaka, et al. (2005). "Inhibition of methamphetamine-induced hyperlocomotion in mice by clorgyline, a monoamine oxidase-a inhibitor, through alteration of the 5-hydroxytryptamine turnover in the striatum." *Neuroscience* 130(2): 295-308.
- Kliethermes, C. L. and J. C. Crabbe (2006). "Pharmacological and genetic influences on hole-board behaviors in mice." *Pharmacol Biochem Behav* 85(1): 57-65.
- Kohda, H., M. Funahashi, et al. (1986). "Decrease in d-methamphetamine sensitivity in mice due to ethanol: Apparent inhibitory and stimulatory effects of ethanol on d-methamphetamine-induced locomotor activity." *Pharmacol Biochem Behav* 25(5): 1035-9.
- Koshikawa, N., S. Aoki, et al. (1986). "Effects of sulpiride injected into the dorsal striatum and the nucleus accumbens on dopamine-mediated oral stereotypy and hyperlocomotion in rats." *J Nihon Univ Sch Dent* 28(2): 109-16.
- Kubota, Y., C. Ito, et al. (2002). "Increased methamphetamine-induced locomotor activity and behavioral sensitization in histamine-deficient mice." *J Neurochem* 83(4): 837-45.
- Kuribara, H., T. Asahi, et al. (1992). "Behavioral evaluation of psycho-pharmacological and psychotoxic actions of methylxanthines by ambulatory activity and discrete avoidance in mice." *J Toxicol Sci* 17(2): 81-90.

- Kuribara, H. and S. Tadokoro (1984). "[Behavioral effects of amantadine on ambulatory activity and drinking in mice and on continuous and discrete avoidance responses in rats]." *Nippon Yakurigaku Zasshi* 83(2): 147-58.
- Kuribara, H. and S. Tadokoro (1983). "Effect alteration of methamphetamine by amino acids or their salts on ambulatory activity in mice." *J Toxicol Sci* 8(1): 25-36.
- Kwon, Y. S., T. Nabeshima, et al. (2004). "PAP 9704, a Korean herbal medicine attenuates methamphetamine-induced hyperlocomotion via adenosine A2A receptor stimulation in mice." *Biol Pharm Bull* 27(6): 906-9.
- Landa, L., K. Slais, et al. (2006). "Involvement of cannabinoid CB1 and CB2 receptor activity in the development of behavioural sensitization to methamphetamine effects in mice." *Neuro Endocrinol Lett* 27(1-2).
- Larson, J., C. N. Quach, et al. (1996). "Effects of an AMPA receptor modulator on methamphetamine-induced hyperactivity in rats." *Brain Res* 738(2): 353-6.
- Liang, J. H., K. Wang, et al. (2006). "Potentiating effect of tramadol on methamphetamine-induced behavioral sensitization in mice." *Psychopharmacology (Berl)* 185(1): 1-10.
- Ma, J. and L. S. Leung (2000). "Relation between hippocampal gamma waves and behavioral disturbances induced by phencyclidine and methamphetamine." *Behav Brain Res* 111(1-2): 1-11.
- Masuo, Y., M. Ishido, et al. (2004). "Motor activity and gene expression in rats with neonatal 6-hydroxydopamine lesions." *J Neurochem* 91(1): 9-19.
- Mattei, R. and E. A. Carlini (1996). "A comparative study of the anorectic and behavioral effects of fenproporex on male and female rats." *Braz J Med Biol Res* 29(8): 1025-30.
- Miller, D. K., M. M. Dopheide, et al. (2005). "Dietary cadmium exposure attenuates D-amphetamine-evoked [3H]dopamine release from striatal slices and methamphetamine-induced hyperactivity." *Pharmacol Biochem Behav* 80(4): 557-66.
- Miyamoto, Y., K. Yamada, et al. (2004). "Behavioural adaptations to addictive drugs in mice lacking the NMDA receptor epsilon1 subunit." *Eur J Neurosci* 19(1): 151-8.
- Mizuno, M., R. S. Malta, Jr., et al. (2004). "Conditioned place preference and locomotor sensitization after repeated administration of cocaine or methamphetamine in rats treated with epidermal growth factor during the neonatal period." *Ann N Y Acad Sci* 1025: 612-8.
- Moroji, T. and Y. Hagino (1987). "Bilateral subdiaphragmatic vagotomy does not prevent the behavioral effects of systematically administered ceruletide in mice." *Neuropeptides* 9(3): 217-24.
- Moroji, T. and Y. Hagino (1986). "A behavioral pharmacological study on CCK-8 related peptides in mice." *Neuropeptides* 8(3): 273-86.
- Muraki, A. (1993). "[Effects of antagonists of NMDA receptor on methamphetamine-induced decrease in the dopamine uptake sites in the rat striatum and on the behavioral sensitization]." *Hokkaido Igaku Zasshi* 68(3): 407-18.
- Nabeshima, T., A. Itoh, et al. (1994). "Effects of subacute administration of methamphetamine and nicotine on locomotor activity in transgenic mice expressing the human tyrosine hydroxylase gene." *J Neural Transm Gen Sect* 97(1): 41-9.
- Nagai, T., Y. Noda, et al. (2005). "The role of tissue plasminogen activator in methamphetamine-related reward and sensitization." *J Neurochem* 92(3): 660-7.
- Nakagawa, T., M. Fujio, et al. (2005). "Effect of MS-153, a glutamate transporter activator, on the conditioned rewarding effects of morphine, methamphetamine and cocaine in mice." *Behav Brain Res* 156(2): 233-9.
- Nakajima, H., R. Shigehara, et al. (1981). "[Effect of alpha-methyl-para-tyrosine on "methamphetamine-induced stereotype and hypermotility" of reserpinized rats (author's transl)]." *Nippon Yakurigaku Zasshi* 78(6): 557-69.
- Nakamura, T., E. Okuyama, et al. (1996). "Neurotropic components from star anise (*Illicium verum* Hook. fil.)." *Chem Pharm Bull (Tokyo)* 44(10): 1908-14.
- Narita, M., M. Miyatake, et al. (2005). "Long-lasting change in brain dynamics induced by methamphetamine: enhancement of protein kinase C-dependent astrocytic response and behavioral sensitization." *J Neurochem* 93(6): 1383-92.
- Nguyen, E. C., K. A. McCracken, et al. (2005). "Involvement of sigma ( $\sigma$ ) receptors in the acute actions of methamphetamine: receptor binding and behavioral studies." *Neuropharmacology* 49(5): 638-45.
- Nishii, K., N. Matsushita, et al. (1998). "Motor and learning dysfunction during postnatal development in mice defective in dopamine neuronal transmission." *J Neurosci Res* 54(4): 450-64.
- Nishimori, T., K. Morino, et al. (1988). "[Effects of cadralazine on the central nervous system]." *Nippon Yakurigaku Zasshi* 91(4): 209-20.
- Nishio, M., Y. Kuroki, et al. (2003). "Role of hippocampal alpha(2A)-adrenergic receptor in methamphetamine-induced hyperlocomotion in the mouse." *Neurosci Lett* 341(2): 156-60.
- Nomura, Y., S. Ashikari, et al. (1982). "[Effect of dopamine intracerebrally injected by the Valzelli method on methamphetamine-stereotypy and hypermotility]." *Yakubutsu Seishin Kodo* 2(1): 25-37.
- Ogura, H., Y. Furuya, et al. (1998). "Peptide N- and P/Q-type Ca<sup>2+</sup> blockers inhibit stimulant-induced hyperactivity in mice." *Peptides* 19(6): 1017-22.



- Oka, T. and E. Hosoya (1977). "The different effect of humoral modulators on the morphine- and central nervous system stimulant-induced hyperactivity of rats." *Neuropharmacology* 16(2): 115-9.
- Okabe, C., H. Takeshima, et al. (2005). "Methamphetamine sensitization in nociceptin receptor knockout mice: Locomotor and c-fos expression." *Eur J Pharmacol* 507(1-3): 57-67.
- Okuda, T., Y. Ito, et al. (2004). "Drug interaction between methamphetamine and antihistamines: Behavioral changes and tissue concentrations of methamphetamine in rats." *Eur J Pharmacol* 505(1-3): 135-44.
- Okuyama, S., N. Kawashima, et al. (1999). "A selective dopamine D4 receptor antagonist, NRA0160: A preclinical neuropharmacological profile." *Life Sci* 65(20): 2109-25.
- Okuyama, S., S. Chaki, et al. (1997). "In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl]pyrrolidin-3-yl]thiazole (NRA0045)." *J Pharmacol Exp Ther* 282(1): 56-63.
- Onodera, K., C. Itoh, et al. (1998). "Motor behavioural function for histamine-dopamine interaction in brain." *Inflamm Res* 47 Suppl 1: S30-1.
- Ozawa, K., K. Hashimoto, et al. (2006). "Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: A neurodevelopmental animal model of schizophrenia." *Biol Psychiatry* 59(6): 546-54.
- Pacchioni, A. M., J. Vallone, et al. (2007). "Nrf2 gene deletion fails to alter psychostimulant-induced behavior or neurotoxicity." *Brain Res* 1127(1): 26-35.
- Palmer, A. A., M. Verbitsky, et al. (2005). "Gene expression differences in mice divergently selected for methamphetamine sensitivity." *Mamm Genome* 16(5): 291-305.
- Park, M. J., S. K. Lee, et al. (2006). "Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity." *Brain Res* 1109(1): 176-82.
- Rubinstein, M., T. J. Phillips, et al. (1997). "Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine." *Cell* 90(6): 991-1001.
- Sanchez-Alavez, M., L. M. Gombart, et al. (2004). "Physiological and behavioral effects of methamphetamine in a mouse model of endotoxemia: A preliminary study." *Pharmacol Biochem Behav* 77(2): 365-70.
- Sano, H., Y. Yasoshima, et al. (2003). "Conditional ablation of striatal neuronal types containing dopamine D2 receptor disturbs coordination of basal ganglia function." *J Neurosci* 23(27): 9078-88.
- Sano, H., Y. Totsuka, et al. (1982). "[Methamphetamine-stereotypy and hypermotility] in rats chronically treated with reserpine--the effect of intracerebral injection of chlorpromazine]." *Nippon Yakurigaku Zasshi* 80(2): 113-24.
- Segal, D. S., R. Kuczenski, et al. (2005). "Prolonged exposure of rats to intravenous methamphetamine: Behavioral and neurochemical characterization." *Psychopharmacology (Berl)* 180(3): 501-12.
- Shibata, S., Y. Minamoto, et al. (1994). "Aging impairs methamphetamine-induced free-running and anticipatory locomotor activity rhythms in rats." *Neurosci Lett* 172(1-2): 107-10.
- Shimazu, S., A. Minami, et al. (2005). "Antidepressant-like effects of selegiline in the forced swim test." *Eur Neuropsychopharmacol* 15(5): 563-71.
- Shimosato, K., N. Nagao, et al. (2003). "Suppressive effects of trihexyphenidyl on methamphetamine-induced dopamine release as measured by in vivo microdialysis." *Synapse* 49(1): 47-54.
- Shimosato, K., S. Watanabe, et al. (2001). "Differential effects of trihexyphenidyl on place preference conditioning and locomotor stimulant activity of cocaine and methamphetamine." *Naunyn Schmiedebergs Arch Pharmacol* 364(1): 74-80.
- Shimosato, K. and S. Watanabe (1989). "Modification of behavioral responses to methamphetamine evoked by the stimulant's metabolite p-hydroxynorephedrine in rats." *Pharmacol Biochem Behav* 33(2): 423-9.
- Shin, E. J., T. Nabeshima, et al. (2005). "Ginsenosides attenuate methamphetamine-induced behavioral side effects in mice via activation of adenosine A2A receptors: possible involvements of the striatal reduction in AP-1 DNA binding activity and proenkephalin gene expression." *Behav Brain Res* 158(1): 143-57.
- Shoblock, J. R., E. B. Sullivan, et al. (2003). "Neurochemical and behavioral differences between d-methamphetamine and d-amphetamine in rats." *Psychopharmacology (Berl)* 165(4): 359-69.
- Subarnas, A., T. Tadano, et al. (1993). "Pharmacological properties of beta-amyrin palmitate, a novel centrally acting compound, isolated from *Lobelia inflata* leaves." *J Pharm Pharmacol* 45(6): 545-50.
- Sudilovsky, A. (1975). "Effects of disulfiram on the amphetamine-induced behavioral syndrome in the cat as a model of psychosis." *Natl Inst Drug Abuse Res Monogr Ser*(3): 109-35.
- Sukma, M., C. Chaichantipyuth, et al. (2002). "CNS inhibitory effects of barakol, a constituent of *Cassia siamensis* Lamk." *J Ethnopharmacol* 83(1-2): 87-94.
- Szumliński, K. K., M. Y. Balogun, et al. (2000). "Interactions between iboga agents and methamphetamine sensitization: studies of locomotion and stereotypy in rats." *Psychopharmacology (Berl)* 151(2-3): 234-41.

- Takigawa, M., H. Wang, et al. (2000). "Directed coherence of EEG on ICSS rats with methamphetamine-induced hyperactivity and stereotyped behavior." *Ann N Y Acad Sci* 914: 311-5.
- Takigawa, M., H. Fukuzako, et al. (1994). "Intracranial self-stimulation and locomotor traces as indicators for evaluating and developing antipsychotic drugs." *Jpn J Psychiatry Neurol* 48(1): 127-32.
- Takigawa, M., K. Ueyama, et al. (1993). "Intracranial self-stimulation and locomotor traces as indicators for evaluating the homopantothenic acid." *Jpn J Psychiatry Neurol* 47(4): 915-20.
- Uchihashi, Y., H. Kuribara, et al. (1994). "Long-continuous observation of the effects of methamphetamine on wheel-running and drinking in mice." *Prog Neuropsychopharmacol Biol Psychiatry* 18(2): 397-407.
- Ujike, H., K. Akiyama, et al. (1990). "D-2 but not D-1 dopamine agonists produce augmented behavioral response in rats after subchronic treatment with methamphetamine or cocaine." *Psychopharmacology (Berl)* 102(4): 459-64.
- Ushijima, I., K. Yamada, et al. (1984). "Progressive augmentation of locomotor activity in mice by long-term treatment with thyrotropin releasing hormone." *Arch Int Pharmacodyn Ther* 270(1): 29-37.
- Wallace, T. L., G. A. Gudelsky, et al. (2001). "Alterations in diurnal and nocturnal locomotor activity in rats treated with a monoamine-depleting regimen of methamphetamine or 3,4-methylenedioxymethamphetamine." *Psychopharmacology (Berl)* 153(3): 321-6.
- Wallace, T. L., G. A. Gudelsky, et al. (1999). "Methamphetamine-induced neurotoxicity alters locomotor activity, stereotypic behavior, and stimulated dopamine release in the rat." *J Neurosci* 19(20): 9141-8.
- Wang, H. D., M. Takigawa, et al. (2002). "A shift in information flow between prefrontal cortex and the ventral tegmental area in methamphetamine-sensitized rats." *Int J Psychophysiol* 44(3): 251-9.
- Watanabe, Y., Y. Hori, et al. (1995). "Inhibitory effects of newly synthesized Ser-contained GABA-peptides administered into either caudate putamen or amygdala on methamphetamine-induced hyperactivity." *Nihon Shinkei Seishin Yakurigaku Zasshi* 15(3): 239-46.
- Witkin, J. M. (1993). "Blockade of the locomotor stimulant effects of cocaine and methamphetamine by glutamate antagonists." *Life Sci* 53(24): PL405-10.
- Yamada, K. and T. Furukawa (1980). "Behavior of rats and mice administered active metabolites of fluphenazine, 7-hydroxy-fluphenazine and fluphenazine-sulfoxide." *Arch Int Pharmacodyn Ther* 248(1): 76-85.
- Yamamoto, T. and S. Ueki (1975). "Behavioral effects of 2,5-dimethoxy-4-methylamphetamine (DOM) in rats and mice." *Eur J Pharmacol* 32(02): 156-62.
- Yamanaka, Y., R. Takano, et al. (1986). "Methamphetamine-induced behavioral alterations following repeated administration of methamphetamine." *Jpn J Pharmacol* 41(2): 147-54.
- Yamanaka, Y., T. Yamamoto, et al. (1983). "Methamphetamine-induced behavioral effects and releases of brain catecholamines and brain concentrations of methamphetamine in mice." *Jpn J Pharmacol* 33(1): 33-40.
- Yamazaki, Y., N. Shinohara, et al. (2004). "Visual discrimination of normal and drug induced behavior in quails (*Coturnix coturnix japonica*)." *Anim Cogn* 7(2): 128-32.

## Hypertension

- Catanzarite, V. A. and D. A. Stein (1995). "'Crystal' and pregnancy--methamphetamine-associated maternal deaths." *West J Med* 162(5): 454-7.
- Chin, K. M., R. N. Channick, et al. (2006). "Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?" *Chest* 130(6): 1657-63.
- Gulati, O. D., B. T. Dave, et al. (1966). "Antagonism of adrenergic neuron blockade in hypertensive subjects." *Clin Pharmacol Ther* 7(4): 510-4.
- Irvine, R. J., M. Keane, et al. (2006). "Plasma drug concentrations and physiological measures in 'dance party' participants." *Neuropsychopharmacology* 31(2): 424-30.
- Johnson, B. A., L. T. Wells, et al. (2005). "Isradipine decreases the hemodynamic response of cocaine and methamphetamine results from two human laboratory studies: Results from two human laboratory studies." *Am J Hypertens* 18(6): 813-22.
- Martin, W. R., J. W. Sloan, et al. (1971). "Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man." *Clin Pharmacol Ther* 12(2): 245-58.
- Moriya, F. and Y. Hashimoto (2002). "A case of fatal hemorrhage in the cerebral ventricles following intravenous use of methamphetamine." *Forensic Sci Int* 129(2): 104-9.
- Mendelson, J., R. T. Jones, et al. (1995). "Methamphetamine and ethanol interactions in humans." *Clin Pharmacol Ther* 57(5): 559-68.
- Newton, T. F., R. De La Garza, 2nd, et al. (2005). "Cocaine and methamphetamine produce different patterns of subjective and cardiovascular effects." *Pharmacol Biochem Behav* 82(1): 90-7.

- Pavese, N., O. Rimoldi, et al. (2004). "Cardiovascular effects of methamphetamine in Parkinson's disease patients." *Mov Disord* 19(3): 298-303.
- Perez-Reyes, M., W. R. White, et al. (1991). "Clinical effects of daily methamphetamine administration." *Clin Neuropharmacol* 14(4): 352-8.

## Hypertension (animals)

- Gentry, W. B., E. M. Laurenzana, et al. (2006). "Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats." *Int Immunopharmacol* 6(6): 968-77.
- Knoll, J., E. S. Vizi, et al. (1970). "Pharmacological studies on para-bromo-methamphetamine (V-111) and LSD." *Acta Physiol Acad Sci Hung* 37(1): 151-70.
- Rudzik, A. D. and J. N. Eble (1967). "The potentiation of pressor responses to tyramine by a number of amphetamine-like compounds." *Proc Soc Exp Biol Med* 124(2): 655-7.
- Stek, A. M., R. S. Baker, et al. (1995). "Fetal responses to maternal and fetal methamphetamine administration in sheep." *Am J Obstet Gynecol* 173(5): 1592-8.
- Stek, A. M., B. K. Fisher, et al. (1993). "Maternal and fetal cardiovascular responses to methamphetamine in the pregnant sheep." *Am J Obstet Gynecol* 169(4): 888-97.
- Varner, K. J., B. A. Ogden, et al. (2002). "Cardiovascular responses elicited by the "binge" administration of methamphetamine." *J Pharmacol Exp Ther* 301(1): 152-9.

## Hyperthermia

- Bowyer, J. F., D. L. Davies, et al. (1994). "Further studies of the role of hyperthermia in methamphetamine neurotoxicity." *J Pharmacol Exp Ther* 268(3): 1571-80.
- Cappon, G. D., L. L. Morford and C. V. Vorhees (1997). "Ontogeny of methamphetamine-induced neurotoxicity and associated hyperthermic response." *Brain Res Dev Brain Res* 103(2): 155-62.
- Chan, P., J. H. Chen, et al. (1994). "Fatal and nonfatal methamphetamine intoxication in the intensive care unit." *J Toxicol Clin Toxicol* 32(2): 147-55.
- Cole, J. C., H. R. Sumnall, et al. (2005). "Preliminary evidence of the cardiovascular effects of polysubstance misuse in nightclubs." *J Psychopharmacol* 19(1): 67-70.
- de Wit, H., M. Clark, et al. (1997). "Effects of d-amphetamine in grouped versus isolated humans." *Pharmacol Biochem Behav* 57(1-2): 333-40.
- Irvine, R. J., M. Keane, et al. (2006). "Plasma drug concentrations and physiological measures in 'dance party' participants." *Neuropsychopharmacology* 31(2): 424-30.
- Ishigami, A., S. Kubo, et al. (2003). "The application of immunohistochemical findings in the diagnosis in methamphetamine-related death-two forensic autopsy cases." *J Med Invest* 50(1-2): 112-6.
- Kiyatkin, E. A. (2005). "Brain hyperthermia as physiological and pathological phenomena." *Brain Res Brain Res Rev* 50(1): 27-56.
- Kojima, T., I. Une, et al. (1984). "A fatal methamphetamine poisoning associated with hyperpyrexia." *Forensic Sci Int* 24(1): 87-93.
- Lavoie, G. (1966). "[Hyperpyrexia during general anaesthesia: a case report]." *Can Anaesth Soc J* 13(5): 444-6.
- Martin, W. R., J. W. Sloan, et al. (1971). "Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man." *Clin Pharmacol Ther* 12(2): 245-58.
- Prosser, J. M., M. Naim, et al. (2006). "A 14-year-old girl with agitation and hyperthermia." *Pediatr Emerg Care* 22(9): 676-9.
- Riddle, E. L., A. E. Fleckenstein, et al. (2006). "Mechanisms of methamphetamine-induced dopaminergic neurotoxicity." *AAPS J* 8(2): E413-8.
- Romhild, W., D. Krause, et al. (2003). "LC-MS/MS analysis of pholedrine in a fatal intoxication case." *Forensic Sci Int* 133(1-2): 101-6.
- Rusyniak, D. E. and J. E. Sprague (2005). "Toxin-induced hyperthermic syndromes." *Med Clin North Am* 89(6): 1277-96.
- Urbina, A. and K. Jones (2004). "Crystal methamphetamine, its analogues, and HIV infection: Medical and psychiatric aspects of a new epidemic." *Clin Infect Dis* 38(6): 890-4.
- Wallace, M. E. and R. Squires (2000). "Fatal massive amphetamine ingestion associated with hyperpyrexia." *J Am Board Fam Pract* 13(4): 302-4.

### Hyperthermia (animals)

*See also* Temperature of Body (animals)

- Albers, D. S. and P. K. Sonsalla (1995). "Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents." *J Pharmacol Exp Ther* 275(3): 1104-14.
- Ali, S. F., G. D. Newport, et al. (1996). "Methamphetamine-induced dopaminergic toxicity in mice. Role of environmental temperature and pharmacological agents." *Ann N Y Acad Sci* 801: 187-98.
- Ali, S. F., R. R. Newport, et al. (1995). "Low environmental temperatures or pharmacologic agents that produce hyperthermia decrease methamphetamine neurotoxicity in mice." *Ann N Y Acad Sci* 765: 338.
- Baucum, A. J., 2nd, K. S. Rau, et al. (2004). "Methamphetamine increases dopamine transporter higher molecular weight complex formation via a dopamine- and hyperthermia-associated mechanism." *J Neurosci* 24(13): 3436-43.
- Bowyer, J. F. and S. Ali (2006). "High doses of methamphetamine that cause disruption of the blood-brain barrier in limbic regions produce extensive neuronal degeneration in mouse hippocampus." *Synapse* 60(7): 521-532.
- Bowyer, J. F., R. R. Holson, et al. (2001). "Phenobarbital and dizocilpine can block methamphetamine-induced neurotoxicity in mice by mechanisms that are independent of thermoregulation." *Brain Res* 919(1): 179-83.
- Bowyer, J. F., D. L. Davies, et al. (1994). "Further studies of the role of hyperthermia in methamphetamine neurotoxicity." *J Pharmacol Exp Ther* 268(3): 1571-80.
- Bowyer, J. F., B. Gough, et al. (1993). "Effects of a cold environment or age on methamphetamine-induced dopamine release in the caudate putamen of female rats." *Pharmacol Biochem Behav* 44(1): 87-98.
- Broening, H. W., L. L. Morford, et al. (2005). "Interactions of dopamine D1 and D2 receptor antagonists with D-methamphetamine-induced hyperthermia and striatal dopamine and serotonin reductions." *Synapse* 56(2): 84-93.
- Bronstein, D. M. and J. S. Hong (1995). "Effects of sulpiride and SCH 23390 on methamphetamine-induced changes in body temperature and lethality." *J Pharmacol Exp Ther* 274(2): 943-50.
- Burrows, K. B., W. L. Nixdorf, et al. (2000). "Central administration of methamphetamine synergizes with metabolic inhibition to deplete striatal monoamines." *J Pharmacol Exp Ther* 292(3): 853-60.
- Burrows, K. B. and C. K. Meshul (1999). "High-dose methamphetamine treatment alters presynaptic GABA and glutamate immunoreactivity." *Neuroscience* 90(3): 833-50.
- Cappon, G. D., L. L. Morford and C. V. Vorhees (1997). "Ontogeny of methamphetamine-induced neurotoxicity and associated hyperthermic response." *Brain Res Dev Brain Res* 103(2): 155-62.
- Clemens, K. J., J. L. Cornish, et al. (2007). "Repeated weekly exposure to MDMA, methamphetamine or their combination: Long-term behavioural and neurochemical effects in rats." *Drug Alcohol Depend* 86(2-3): 183-90.
- Clemens, K. J., J. L. Cornish, et al. (2005). "MDMA ('Ecstasy') and methamphetamine combined: Order of administration influences hyperthermic and long-term adverse effects in female rats." *Neuropharmacology* 49(2): 195-207.
- Crean, R. D., S. A. Davis, et al. (2006). "Effects of (+/-)3,4-methylenedioxymethamphetamine, (+/-)3,4-methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques." *Neuroscience* 142(2): 515-25.
- Eyerman, D. J. and B. K. Yamamoto (2005). "Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum." *J Pharmacol Exp Ther* 312(1): 160-9.
- Fukumura, M., G. D. Cappon, H. W. Broening and C. V. Vorhees (1998). "Methamphetamine-induced dopamine and serotonin reductions in neostriatum are not gender specific in rats with comparable hyperthermic responses." *Neurotoxicol Teratol* 20(4): 441-8.
- Gehrke, B. J., W. A. Cass, et al. (2006). "Monoamine-depleting doses of methamphetamine in enriched and isolated rats: Consequences for subsequent methamphetamine-induced hyperactivity and reward." *Behav Pharmacol* 17(5-6): 499-508.
- Ginawi, O. T., O. A. al-Shabanah, et al. (1997). "Increased toxicity of methamphetamine in morphine-dependent mice." *Gen Pharmacol* 28(5): 727-31.
- Golembiowska, K., J. Konieczny, et al. (2003). "Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats." *Neuropharmacology* 45(4): 484-92.
- Halladay, A. K., A. Kusnecov, L. Michna, T. Kita, C. Hara and G. C. Wagner (2003). "Relationship between methamphetamine-induced dopamine release, hyperthermia, self-injurious behaviour and long term dopamine depletion in balb/c and c57bl/6 mice." *Pharmacol Toxicol* 93(1): 33-41.
- He, J., H. Xu, et al. (2005). "Chronic administration of quetiapine alleviates the anxiety-like behavioural changes induced by a neurotoxic regimen of dl-amphetamine in rats." *Behav Brain Res* 160(1): 178-87.
- Imam, S. Z. and S. F. Ali (2001). "Aging increases the susceptibility to methamphetamine-induced dopaminergic neurotoxicity in rats: Correlation with peroxynitrite production and hyperthermia." *J Neurochem* 78(5): 952-9.

- Itoh, Y., R. Oishi, et al. (1986). "Comparison of effects of phencyclidine and methamphetamine on body temperature in mice: A possible role for histamine neurons in thermoregulation." *Naunyn Schmiedebergs Arch Pharmacol* 332(3): 293-6.
- Itzhak, Y., J. L. Martin and S. F. Ail (2000). "nNOS inhibitors attenuate methamphetamine-induced dopaminergic neurotoxicity but not hyperthermia in mice." *Neuroreport* 11(13): 2943-6.
- Janowsky, A., C. Mah, et al. (2001). "Mapping genes that regulate density of dopamine transporters and correlated behaviors in recombinant inbred mice." *J Pharmacol Exp Ther* 298(2): 634-43.
- Johnson-Davis, K. L., A. E. Fleckenstein and D. G. Wilkins (2003). "The role of hyperthermia and metabolism as mechanisms of tolerance to methamphetamine neurotoxicity." *Eur J Pharmacol* 482(1-3): 151-4.
- Kawasaki, T., K. Ishihara, et al. (2006). "Protective effect of the radical scavenger edaravone against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum." *Eur J Pharmacol* 542(1-3): 92-9.
- Kita, T., T. Saraya, et al. (2003). "1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine pretreatment attenuates methamphetamine-induced dopamine toxicity." *Pharmacol Toxicol* 92(2): 71-80.
- Kita, T., Y. Matsunari, et al. (2000). "Methamphetamine-induced striatal dopamine release, behavior changes and neurotoxicity in BALB/c mice." *Int J Dev Neurosci* 18(6): 521-30.
- Kita, T., Y. Matsunari, et al. (2000). "Evaluation of the effects of alpha-phenyl-N-tert-butyl nitron pretreatment on the neurobehavioral effects of methamphetamine." *Life Sci* 67(13): 1559-71.
- Kita, T., S. Paku, et al. (1998). "Methamphetamine-induced neurotoxicity in BALB/c, DBA/2N and C57BL/6N mice." *Neuropharmacology* 37(9): 1177-84.
- Kita, T., M. Takahashi, et al. (1998). "Methamphetamine-induced changes in activity and water intake during light and dark cycles in rats." *Prog Neuropsychopharmacol Biol Psychiatry* 22(7): 1185-96.
- Kiyatkin, E. A. (2005). "Brain hyperthermia as physiological and pathological phenomena." *Brain Res Brain Res Rev* 50(1): 27-56.
- Kokoshka, J. M., A. E. Fleckenstein, D. G. Wilkins and G. R. Hanson (2000). "Age-dependent differential responses of monoaminergic systems to high doses of methamphetamine." *J Neurochem* 75(5): 2095-102.
- Kuperman, D. I., T. E. Freyaldenhoven, L. C. Schmued and S. F. Ali (1997). "Methamphetamine-induced hyperthermia in mice: Examination of dopamine depletion and heat-shock protein induction." *Brain Res* 771(2): 221-7.
- Makisumi, T., K. Yoshida, et al. (1998). "Sympatho-adrenal involvement in methamphetamine-induced hyperthermia through skeletal muscle hypermetabolism." *Eur J Pharmacol* 363(2-3): 107-12.
- Matuszewich, L. and B. K. Yamamoto (2004). "Chronic stress augments the long-term and acute effects of methamphetamine." *Neuroscience* 124(3): 637-46.
- Metzger, R. R., H. M. Haughey, D. G. Wilkins, J. W. Gibb, G. R. Hanson and A. E. Fleckenstein (2000). "Methamphetamine-induced rapid decrease in dopamine transporter function: Role of dopamine and hyperthermia." *J Pharmacol Exp Ther* 295(3): 1077-85.
- Moy, L. Y., D. S. Albers, et al. (1998). "Lowering ambient or core body temperature elevates striatal MPP+ levels and enhances toxicity to dopamine neurons in MPTP-treated mice." *Brain Res* 790(1-2): 264-9.
- Nakamura, T., E. Okuyama, et al. (1996). "Neurotropic components from star anise (*Illicium verum* Hook. fil.)." *Chem Pharm Bull (Tokyo)* 44(10): 1908-14.
- Namiki, M., T. Mori, et al. (2005). "Underlying mechanism of combined effect of methamphetamine and morphine on lethality in mice and therapeutic potential of cooling." *J Pharmacol Sci* 99(2): 168-76.
- O'Callaghan, J. P. and D. B. Miller (1994). "Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse." *J Pharmacol Exp Ther* 270(2): 741-51.
- O'Neil M, L., R. Kuczenski, et al. (2006). "Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge." *Synapse* 60(6): 465-73.
- Park, M. J., S. K. Lee, et al. (2006). "Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity." *Brain Res* 1109(1): 176-82.
- Riddle, E. L., A. E. Fleckenstein, et al. (2006). "Mechanisms of methamphetamine-induced dopaminergic neurotoxicity." *AAPS J* 8(2): E413-8.
- Rusyniak, D. E. and J. E. Sprague (2005). "Toxin-induced hyperthermic syndromes." *Med Clin North Am* 89(6): 1277-96.
- Sanchez-Alavez, M., L. M. Gombart, et al. (2004). "Physiological and behavioral effects of methamphetamine in a mouse model of endotoxemia: A preliminary study." *Pharmacol Biochem Behav* 77(2): 365-70.
- Sanchez, V., M. Zeini, J. Camarero, E. O'Shea, L. Bosca, A. R. Green and M. I. Colado (2003). "The nNOS inhibitor, AR-R17477AR, prevents the loss of NF68 immunoreactivity induced by methamphetamine in the mouse striatum." *J Neurochem* 85(2): 515-24.
- Sprague, J. E., X. Yang, et al. (2007). "Roles of norepinephrine, free fatty acids, thyroid status and skeletal muscle uncoupling protein 3 expression in sympathomimetic-induced thermogenesis." *J Pharmacol Exp Ther* 320(1): 274-80.
- Staszewski, R. D. and B. K. Yamamoto (2006). "Methamphetamine-induced spectrin proteolysis in the rat striatum." *J Neurochem* 96(5): 1267-76.

- Toyota, H., C. Dugovic, et al. (2002). "Behavioral characterization of mice lacking histamine H(3) receptors." *Mol Pharmacol* 62(2): 389-97.
- Ugarte, Y. V., K. S. Rau, et al. (2003). "Methamphetamine rapidly decreases mouse vesicular dopamine uptake: Role of hyperthermia and dopamine D2 receptors." *Eur J Pharmacol* 472(3): 165-71.
- Xie, T., U. D. McCann, et al. (2000). "Effect of temperature on dopamine transporter function and intracellular accumulation of methamphetamine: implications for methamphetamine-induced dopaminergic neurotoxicity." *J Neurosci* 20(20): 7838-45.
- Yamamoto, M., K. Tomioka, et al. (1981). "[Central pharmacological effects of YPG-209 (16(S)-methyl-20-methoxy-prostaglandin E2) (author's transl)]." *Nippon Yakurigaku Zasshi* 77(2): 141-51.
- Yamamura, T., S. Hishida, et al. (1987). "[Interaction of alcohol and methamphetamine with acute high dose administration to rats]." *Arukuru Kenkyuto Yakubutsu Ison* 22(4): 286-99.
- Yoshida, K., A. Morimoto, et al. (1993). "Cardiovascular, thermal and behavioral sensitization to methamphetamine in freely moving rats." *J Pharmacol Exp Ther* 267(3): 1538-43.
- Yu, L., C. F. Cherg, et al. (2002). "Melatonin in concentrated ethanol and ethanol alone attenuate methamphetamine-induced dopamine depletions in C57BL/6J mice." *J Neural Transm* 109(12): 1477-90.
- Yu, X., S. Z. Imam, et al. (1999). "Ibogaine blocked methamphetamine-induced hyperthermia and induction of heat shock protein in mice." *Brain Res* 823(1-2): 213-6.
- Yuan, J., G. Hatzidimitriou, et al. (2005). "Relationship between temperature, dopaminergic neurotoxicity and plasma drug concentrations in methamphetamine-treated squirrel monkeys." *J Pharmacol Exp Ther*.

### Illinois (US)

*See also* Chicago

- Boulard, G. (2005). "The meth menace: Battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.
- Fendrich, M., J. S. Wislar, T. P. Johnson and A. Hubbell (2003). "A contextual profile of club drug use among adults in Chicago." *Addiction* 98(12): 1693-703.
- Koblin, B. A., M. A. Chesney, et al. (2003). "High-risk behaviors among men who have sex with men in 6 US cities: Baseline data from the EXPLORE Study." *Am J Public Health* 93(6): 926-32.
- Levin-Epstein, M. (2006). "Experimenting with treatment in prison." *Behav Healthc* 26(7): 32-3.
- Lyons, T., G. Chandra, et al. (2006). "Stimulant use and HIV risk behavior: The influence of peer support group participation." *AIDS Educ Prev* 18(5): 461-73.
- Stall, R., J. P. Paul, et al. (2001). "Alcohol use, drug use and alcohol-related problems among men who have sex with men: The Urban Men's Health Study." *Addiction* 96(11): 1589-601.

### Immigrants (US)

- Fernandez, M. I., G. S. Bowen, et al. (2007). "Crystal methamphetamine: A source of added sexual risk for Hispanic men who have sex with men?" *Drug Alcohol Depend* 86(2-3): 245-52.
- Maxwell, J. C., P. Cravioto, et al. (2006). "Drug use and risk of HIV/AIDS on the Mexico-USA border: A comparison of treatment admissions in both countries." *Drug Alcohol Depend* 82 Suppl 1: S85-93.
- Oetting, E. R., J. L. Deffenbacher, et al. (2000). "Methamphetamine use by high school students: Recent trends, gender and ethnicity differences, and use of other drugs." *Journal of Child and Adolescent Substance Abuse* 10(1): 33-50.

### Immune Function

*See also* HIV, Methamphetamine Interactions with; HIV Replication

- Cabral, G. A. (2006). "Drugs of abuse, immune modulation, and AIDS." *Journal of NeuroImmune Pharmacology* 1(3): 280-295.
- Chiappelli, F., P. Shapshak, et al. (2006). "Cellular immunology in HIV-1 positive African American women using alcohol and cocaine." *Front Biosci* 11: 2434-41.
- Carey, C. L., S. P. Woods, et al. (2006). "Additive deleterious effects of methamphetamine dependence and immunosuppression on neuropsychological functioning in HIV infection." *AIDS Behav* 10(2): 185-90.
- Mahajan, S. D., Z. Hu, et al. (2006). "Methamphetamine modulates gene expression patterns in monocyte derived mature dendritic cells: Implications for HIV-1 pathogenesis." *Mol Diagn Ther* 10(4): 257-69.
- Yu, Q., D. F. Larson, et al. (2003). "Heart disease, methamphetamine and AIDS." *Life Sci* 73(2): 129-40.

## Immune Function (animals)

- Ahmad, K. (2002). "Addictive drug increases HIV replication and mutation." *Lancet Infect Dis* 2(8): 456.
- Cass, W. A., M. E. Harned, et al. (2003). "HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat." *Brain Res* 984(1-2): 133-42.
- Dickerson, T. J., N. Yamamoto, et al. (2004). "Immunological consequences of methamphetamine protein glycation." *J Am Chem Soc* 126(37): 11446-7.
- Flora, G., Y. W. Lee, A. Nath, B. Hennig, W. Maragos and M. Toborek (2003). "Methamphetamine potentiates HIV-1 tat protein-mediated activation of redox-sensitive pathways in discrete regions of the brain." *Exp Neurol* 179(1): 60-70.
- House, R. V., P. T. Thomas, et al. (1994). "Comparison of immune functional parameters following in vitro exposure to natural and synthetic amphetamines." *Immunopharmacol Immunotoxicol* 16(1): 1-21.
- In, S. W., E. W. Son, et al. (2005). "Methamphetamine administration produces immunomodulation in mice." *J Toxicol Environ Health A* 68(23-24): 2133-45.
- In, S. W., E. W. Son, et al. (2004). "Modulation of murine macrophage function by methamphetamine." *J Toxicol Environ Health A* 67(23-24): 1923-37.
- Maragos, W. F., K. L. Young, J. T. Turchan, M. Guseva, J. R. Pauly, A. Nath and W. A. Cass (2002). "Human immunodeficiency virus-1 tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function." *J Neurochem* 83(4): 955-63.
- Saito, M., T. Yamaguchi, et al. (2006). "Effects of methamphetamine on cortisone concentration, NK cell activity and mitogen response of T-lymphocytes in female Cynomolgus monkeys." *Exp Anim* 55(5): 477-81.
- Yu, Q., D. Zhang, et al. (2002). "Chronic methamphetamine exposure alters immune function in normal and retrovirus-infected mice." *Int Immunopharmacol* 2(7): 951-62.

## Impulsivity

*See also Compulsivity*

- Hoffman, W. F., M. Moore, et al. (2006). "Neuropsychological function and delay discounting in methamphetamine-dependent individuals." *Psychopharmacology (Berl)* 188(2): 162-70.
- Monterosso, J. R., A. R. Aron, et al. (2005). "Deficits in response inhibition associated with chronic methamphetamine abuse." *Drug Alcohol Depend* 79(2): 273-7.
- Patterson, T. L., S. J. Semple, et al. (2005). "Methamphetamine-using HIV-positive men who have sex with men: Correlates of polydrug use." *J Urban Health* 82(1 Suppl 1): i120-6.
- Semple, S. J., J. Zians, et al. (2006). "Methamphetamine use, impulsivity, and sexual risk behavior among HIV-positive men who have sex with men." *J Addict Dis* 25(4): 105-14.
- Semple, S. J., J. Zians, et al. (2005). "Impulsivity and methamphetamine use." *J Subst Abuse Treat* 29(2): 85-93.
- Semple, S. J., T. L. Patterson, et al. (2004). "A comparison of injection and non-injection methamphetamine-using HIV positive men who have sex with men." *Drug Alcohol Depend* 76(2): 203-12.
- Simons, J. S., M. N. Oliver, et al. (2005). "Methamphetamine and alcohol abuse and dependence symptoms: Associations with affect lability and impulsivity in a rural treatment population." *Addict Behav* 30(7): 1370-81.

## Impurities

*See Adulterated and Contaminated Substances*

## Incarceration, Alternatives to

*See also Drug Courts and Court-Mandated Treatment*

- Brecht, M. L., M. D. Anglin, et al. (2005). "Coerced treatment for methamphetamine abuse: Differential patient characteristics and outcomes." *Am J Drug Alcohol Abuse* 31(2): 337-56.
- Evans, E. and D. Longshore (2004). "Evaluation of the Substance Abuse and Crime Prevention Act: Treatment clients and program types during the first year of implementation." *J Psychoactive Drugs Suppl*(2): 165-74.
- Freese, T. E., J. Obert, et al. (2000). "Methamphetamine abuse: Issues for special populations." *J Psychoactive Drugs* 32(2): 177-82.
- Hser, Y. I., C. Teruya, et al. (2003). "Treating drug-abusing offenders. Initial findings from a five-county study on the impact of California's Proposition 36 on the treatment system and patient outcomes." *Eval Rev* 27(5): 479-505.
- Maglione, M., B. Chao, et al. (2000). "Correlates of outpatient drug treatment drop-out among methamphetamine users." *J Psychoactive Drugs* 32(2): 221-8.

### Incarceration and Incarcerated Individuals

- Akiyama, K. (2006). "Longitudinal clinical course following pharmacological treatment of methamphetamine psychosis which persists after long-term abstinence." *Ann N Y Acad Sci* 1074: 125-34.
- Assael, L. A. (2005). "Methamphetamine: An epidemic of oral health neglect, loss of access to care, abuse, and violence." *J Oral Maxillofac Surg* 63(9): 1253-4.
- Buavirat, A., K. Page-Shafer, et al. (2003). "Risk of prevalent HIV infection associated with incarceration among injecting drug users in Bangkok, Thailand: Case-control study." *BMJ* 326(7384): 308.
- Cartier, J., D. Farabee, et al. (2006). "Methamphetamine use, self-reported violent crime, and recidivism among offenders in California who abuse substances." *J Interpers Violence* 21(4): 435-45.
- Chiang, S. C., H. Y. Chan, et al. (2006). "Recidivism among male subjects incarcerated for illicit drug use in Taiwan." *Psychiatry Clin Neurosci* 60(4): 444-51.
- Farabee, D., M. Prendergast and J. Cartier (2002). "Methamphetamine use and HIV risk among substance-abusing offenders in California." *J Psychoactive Drugs* 34(3): 295-300.
- Kalechstein, A. D., T. F. Newton, et al. (2000). "Psychiatric comorbidity of methamphetamine dependence in a forensic sample." *J Neuropsychiatry Clin Neurosci* 12(4): 480-4.
- Kassebaum, G. and S. M. Chandler (1994). "Polydrug use and self control among men and women in prisons." *J Drug Educ* 24(4): 333-50.
- Kushel, M. B., J. A. Hahn, et al. (2005). "Revolving doors: Imprisonment among the homeless and marginally housed population." *Am J Public Health* 95(10): 1747-52.
- Levin-Epstein, M. (2006). "Experimenting with treatment in prison." *Behav Healthc* 26(7): 32-3.
- Lin, S. K., D. Ball, et al. (2004). "Psychiatric comorbidity and gender differences of persons incarcerated for methamphetamine abuse in Taiwan." *Psychiatry Clin Neurosci* 58(2): 206-12.
- Matsumoto, T., A. Yamaguchi, et al. (2005). "Drug preferences in illicit drug abusers with a childhood tendency of attention deficit/hyperactivity disorder: A study using the Wender Utah Rating Scale in a Japanese prison." *Psychiatry Clin Neurosci* 59(3): 311-8.
- Miura, H., M. Fujiki, et al. (2006). "Prevalence and profile of methamphetamine users in adolescents at a juvenile classification home." *Psychiatry Clin Neurosci* 60(3): 352-7.
- Simbulan, N. P., A. S. Aguilar, et al. (2001). "High-risk behaviors and the prevalence of sexually transmitted diseases among women prisoners at the women state penitentiary in Metro Manila." *Soc Sci Med* 52(4): 599-608.
- Stoops, W. W., M. S. Tindall, et al. (2005). "Methamphetamine use in nonurban and urban drug court clients." *Int J Offender Ther Comp Criminol* 49(3): 260-76.
- Vong, S., A. E. Fiore, et al. (2005). "Vaccination in the county jail as a strategy to reach high risk adults during a community-based hepatitis A outbreak among methamphetamine drug users." *Vaccine* 23(8): 1021-8.
- Yacoubian, G. S., Jr. and R. J. Peters (2004). "Exploring the prevalence and correlates of methamphetamine use: Findings from Sacramento's ADAM program." *J Drug Educ* 34(3): 281-94.
- Yui, K., S. Ikemoto, et al. (2002). "Factors for susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosis." *Ann N Y Acad Sci* 965: 292-304.
- Yui, K., K. Goto, et al. (2001). "Susceptibility to subsequent episodes of spontaneous recurrence of methamphetamine psychosis." *Drug Alcohol Depend* 64(2): 133-42.
- Zule, W. A. and D. P. Desmond (1999). "An ethnographic comparison of HIV risk behaviors among heroin and methamphetamine injectors." *Am J Drug Alcohol Abuse* 25(1): 1-23.

### India

- Kulsudjarit, K. (2004). "Drug problem in southeast and southwest Asia." *Ann N Y Acad Sci* 1025: 446-57.

### Indiana (US)

- Kim, J. Y. and M. Fendrich (2002). "Gender differences in juvenile arrestees' drug use, self-reported dependence, and perceived need for treatment." *Psychiatr Serv* 53(1): 70-5.

### Initiation of Methamphetamine Use

- Brecht, M. L., L. Greenwell, et al. (2007). "Substance use pathways to methamphetamine use among treated users." *Addict Behav* 32(1): 24-38.



- Brecht, M. L., A. O'Brien, et al. (2004). "Methamphetamine use behaviors and gender differences." *Addict Behav* 29(1): 89-106.
- Day, C., L. Degenhardt, et al. (2006). "Changes in the initiation of heroin use after a reduction in heroin supply." *Drug Alcohol Rev* 25(4): 307-13.
- Gibson, D. R., M. H. Leamon, et al. (2002). "Epidemiology and public health consequences of methamphetamine use in California's Central Valley." *J Psychoactive Drugs* 34(3): 313-9.
- Lyons, T., G. Chandra, et al. (2006). "Stimulant use and HIV risk behavior: The influence of peer support group participation." *AIDS Educ Prev* 18(5): 461-73.
- Martin, I., T. M. Lampinen, et al. (2006). "Methamphetamine use among marginalized youth in British Columbia." *Can J Public Health* 97(4): 320-4.
- Reid, L. W., K. W. Elifson, et al. (2007). "Ecstasy and gateway drugs: Initiating the use of ecstasy and other drugs." *Ann Epidemiol* 17(1): 74-80.
- Storr, C. L., A. M. Arria, et al. (2004). "Neighborhood environment and opportunity to try methamphetamine ("ice") and marijuana: Evidence from Guam in the Western Pacific region of Micronesia." *Subst Use Misuse* 39(2): 253-76.
- Suwaki, H., M. Yamasaki, et al. (1992). "A study of longitudinal patterns of substance abuse with special reference to multiple use problems." *Arukuru Kenkyuto Yakubutsu Ison* 27(3): 284-96.
- Wood, E., J. A. Stoltz, et al. (2006). "Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study." *Harm Reduct J* 3: 18.
- Wu, L. T., D. J. Pilowsky, et al. (2004). "Injection drug use among stimulant users in a national sample." *Am J Drug Alcohol Abuse* 30(1): 61-83.
- Yen, C. F., Y. H. Yang, et al. (2005). "Substance initiation sequences among Taiwanese adolescents using methamphetamine." *Psychiatry Clin Neurosci* 59(6): 683-9.
- Zule, W. A. and D. P. Desmond (1999). "An ethnographic comparison of HIV risk behaviors among heroin and methamphetamine injectors." *Am J Drug Alcohol Abuse* 25(1): 1-23.

## Injection of Methamphetamine

*See also* Syringe Exchange and Syringe Access

- Ago, M., K. Ago, et al. (2006). "Toxicological and histopathological analysis of a patient who died nine days after a single intravenous dose of methamphetamine: A case report." *Leg Med (Tokyo)* 8(4): 235-9.
- Anonymous (1990). "From the Centers for Disease Control. Lead poisoning associated with intravenous-methamphetamine use--Oregon, 1988." *JAMA* 263(6): 797-8.
- Anonymous (1989). "Lead poisoning associated with intravenous-methamphetamine use--Oregon, 1988." *MMWR Morb Mortal Wkly Rep* 38(48): 830-1.
- Baker, A. and S. Dawe (2005). "Amphetamine use and co-occurring psychological problems: Review of the literature and implications for treatment." *Australian Psychologist* 40(2): 88-95.
- Binswanger, I. A., A. H. Kral, et al. (2000). "High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Francisco." *Clin Infect Dis* 30(3): 579-81.
- Bluthenthal, R. N., A. H. Kral, et al. (2001). "Trends in HIV seroprevalence and risk among gay and bisexual men who inject drugs in San Francisco, 1988 to 2000." *J Acquir Immune Defic Syndr* 28(3): 264-9.
- Bobkov, A. F., L. M. Selimova, et al. (2005). "Human immunodeficiency virus type 1 in illicit-drug solutions used intravenously retains infectivity." *J Clin Microbiol* 43(4): 1937-9.
- Boddiger, D. (2005). "Methamphetamine use linked to rising HIV transmission." *Lancet* 365(9466): 1217-8.
- Bogart, L. M., A. H. Kral, et al. (2005). "Sexual risk among injection drug users recruited from syringe exchange programs in California." *Sex Transm Dis* 32(1): 27-34.
- Braine, N., D. C. Des Jarlais, et al. (2005). "HIV risk behavior among amphetamine injectors at U.S. syringe exchange programs." *AIDS Educ Prev* 17(6): 515-24.
- Braine, N., D. C. Des Jarlais, S. Ahmad, D. Purchase and C. Turner (2004). "Long-term effects of syringe exchange on risk behavior and HIV prevention." *AIDS Educ Prev* 16(3): 264-75.
- Brouwer, K. C., P. Case, et al. (2006). "Trends in production, trafficking, and consumption of methamphetamine and cocaine in Mexico." *Subst Use Misuse* 41(5): 707-27.
- Buavirat, A., K. Page-Shafer, et al. (2003). "Risk of prevalent HIV infection associated with incarceration among injecting drug users in Bangkok, Thailand: Case-control study." *BMJ* 326(7384): 308.
- Buffum, J. C. and A. T. Shulgin (2001). "Overdose of 2.3 grams of intravenous methamphetamine: Case, analysis and patient perspective." *J Psychoactive Drugs* 33(4): 409-12.

- Bull, S. S., P. Piper and C. Rietmeijer (2002). "Men who have sex with men and also inject drugs--profiles of risk related to the synergy of sex and drug injection behaviors." *J Homosex* 42(3): 31-51.
- Clatts, M. C., D. L. Welle, et al. (2001). "Reconceptualizing the interaction of drug and sexual risk among MSM speed users: Notes toward an ethno-epidemiology." *AIDS and Behavior* 5(2): 115-130.
- Cook, C. E., A. R. Jeffcoat, et al. (1993). "Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride." *Drug Metab Dispos* 21(4): 717-23.
- Copeland, A. L. and J. L. Sorensen (2001). "Differences between methamphetamine users and cocaine users in treatment." *Drug Alcohol Depend* 62(1): 91-5.
- Cruz, M. F., A. Mantsios, et al. (2006). "A qualitative exploration of gender in the context of injection drug use in two US-Mexico border cities." *AIDS Behav*.
- Darke, S., S. Kaye, et al. (1999). "Transitions between the injection of heroin and amphetamines." *Addiction* 94(12): 1795-803.
- Darke, S. and W. Hall (1995). "Levels and correlates of polydrug use among heroin users and regular amphetamine users." *Drug Alcohol Depend* 39(3): 231-5.
- Darke, S., J. Ross, et al. (1995). "Injecting and sexual risk-taking behaviour among regular amphetamine users." *AIDS Care* 7(1): 19-26.
- Darke, S., J. Cohen, et al. (1994). "Transitions between routes of administration of regular amphetamine users." *Addiction* 89(9): 1077-83.
- Darke, S., J. Ross, et al. (1994). "The use of benzodiazepines among regular amphetamine users." *Addiction* 89(12): 1683-90.
- Darke, S., W. Hall, et al. (1992). "Benzodiazepine use and HIV risk-taking behaviour among injecting drug users." *Drug Alcohol Depend* 31(1): 31-6.
- Davis, L. E., G. Kalousek, et al. (1970). "Hepatitis associated with illicit use of intravenous methamphetamine." *Public Health Rep* 85(9): 809-13.
- Day, C., L. Degenhardt, et al. (2006). "Changes in the initiation of heroin use after a reduction in heroin supply." *Drug Alcohol Rev* 25(4): 307-13.
- Doherty, M. C., R. S. Garfein, E. Monterroso, D. Brown and D. Vlahov (2000). "Correlates of HIV infection among young adult short-term injection drug users." *AIDS* 14(6): 717-26.
- Domier, C. P., S. L. Simon, et al. (2000). "A comparison of injecting and noninjecting methamphetamine users." *J Psychoactive Drugs* 32(2): 229-32.
- Fairbairn, N., T. Kerr, et al. (2006). "Increasing use and associated harms of crystal methamphetamine injection in a Canadian setting." *Drug Alcohol Depend*.
- Farabee, D., M. Prendergast and J. Cartier (2002). "Methamphetamine use and HIV risk among substance-abusing offenders in California." *J Psychoactive Drugs* 34(3): 295-300.
- Garfein, R. S., W. A. Bower, et al. (2004). "Factors associated with fulminant liver failure during an outbreak among injection drug users with acute hepatitis B." *Hepatology* 40(4): 865-73.
- Gibson, D. R., M. H. Leamon and N. Flynn (2002). "Epidemiology and public health consequences of methamphetamine use in California's Central Valley." *J Psychoactive Drugs* 34(3): 313-9.
- Gleghorn, A. A., R. Marx, et al. (1998). "Association between drug use patterns and HIV risks among homeless, runaway, and street youth in northern California." *Drug Alcohol Depend* 51(3): 219-27.
- Gonzales, R., P. Marinelli-Casey, et al. (2006). "Hepatitis C virus infection among methamphetamine-dependent individuals in outpatient treatment." *J Subst Abuse Treat* 31(2): 195-202.
- Gorman, E. M. and R. T. Carroll (2000). "Substance abuse and HIV: Considerations with regard to methamphetamines and other recreational drugs for nursing practice and research." *J Assoc Nurses AIDS Care* 11(2): 51-62.
- Gorman, E. M., B. D. Barr, A. Hansen, B. Robertson and C. Green (1997). "Speed, sex, gay men, and HIV: Ecological and community perspectives." *Med Anthropol Q* 11(4): 505-15.
- Grinde, B., K. Stene-Johansen, et al. (1997). "Characterisation of an epidemic of hepatitis A virus involving intravenous drug abusers--infection by needle sharing?" *J Med Virol* 53(1): 69-75.
- Hahn, J. A., K. Page-Shafer, P. J. Lum, K. Ochoa and A. R. Moss (2001). "Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco." *Hepatology* 34(1): 180-7.
- Halkitis, P. N., L. Wilton, et al. (2005). "Barebacking identity among HIV-positive gay and bisexual men: demographic, psychological, and behavioral correlates." *AIDS* 19: S27-S35.
- Hall, W., J. Hando, et al. (1996). "Psychological morbidity and route of administration among amphetamine users in Sydney, Australia." *Addiction* 91(1): 81-7.
- Hall, W., S. Darke, et al. (1993). "Patterns of drug use and risk-taking among injecting amphetamine and opioid drug users in Sydney, Australia." *Addiction* 88(4): 509-16.

- Harkess, J., B. Gildon, et al. (1989). "Outbreaks of hepatitis A among illicit drug users, Oklahoma, 1984-87." *Am J Public Health* 79(4): 463-6.
- Heinzerling, K. G., A. H. Kral, et al. (2006). "Unmet need for recommended preventive health services among clients of California syringe exchange programs: Implications for quality improvement." *Drug Alcohol Depend* 81(2): 167-78.
- Hiroshi, K., K. Akira, et al. (2005). "An autopsy case of infectious endocarditis in a methamphetamine abuser usefulness of microbiological examination." *Soud Lek* 50(2): 18-22.
- Hutin, Y. J., K. M. Sabin, et al. (2000). "Multiple modes of hepatitis A virus transmission among methamphetamine users." *Am J Epidemiol* 152(2): 186-92.
- Hwang, W., J. Ralph, et al. (2003). "Incomplete Brown-Sequard syndrome after methamphetamine injection into the neck." *Neurology* 60(12): 2015-6.
- Ibanez, G. E., D. W. Purcell, et al. (2005). "Sexual risk, substance use, and psychological distress in HIV-positive gay and bisexual men who also inject drugs." *AIDS* 19: S49-S55.
- Imanishi, M., T. Sakai, et al. (1997). "[Cerebral infarction due to bacterial emboli associated with methamphetamine abuse]." *No To Shinkei* 49(6): 537-40.
- Isaak, B. L. and T. J. Liesegang (1983). "Conjunctival and episcleral injection in drug abuse." *Ann Ophthalmol* 15(9): 806-7.
- Iwanami, A., D. Kuwakado, et al. (1997). "Relapse of panic disorder induced by a single intravenous methamphetamine injection." *J Anxiety Disord* 11(1): 113-6.
- Jittiwutikarn, J., S. Thongsawat, et al. (2006). "Hepatitis C infection among drug users in northern Thailand." *Am J Trop Med Hyg* 74(6): 1111-6.
- John, D., C. F. Kwiatkowski, et al. (2001). "Differences among out-of-treatment drug injectors who use stimulants only, opiates only or both: implications for treatment entry." *Drug Alcohol Depend* 64(2): 165-72.
- Kamijo, Y., K. Soma, et al. (2002). "Acute liver failure following intravenous methamphetamine." *Vet Hum Toxicol* 44(4): 216-7.
- Kaye, S. and S. Darke (2000). "A comparison of the harms associated with the injection of heroin and amphetamines." *Drug Alcohol Depend* 58(1-2): 189-95.
- Kerr, T., E. Wood, et al. (2005). "High rates of primary care and emergency department use among injection drug users in Vancouver." *J Public Health (Oxf)* 27(1): 62-6.
- Kipke, M. D., S. O'Connor, et al. (1995). "Street youth in Los Angeles. Profile of a group at high risk for human immunodeficiency virus infection." *Arch Pediatr Adolesc Med* 149(5): 513-9.
- Knight, K. R., D. Purcell, et al. (2005). "Sexual risk taking among HIV-positive injection drug users: Contexts, characteristics, and implications for prevention." *AIDS Educ Prev* 17(1 Suppl A): 76-88.
- Koester, S., J. Glanz, et al. (2005). "Drug sharing among heroin networks: Implications for HIV and hepatitis B and C prevention." *AIDS Behav* 9(1): 27-39.
- Kojima, T., M. Yashiki, et al. (1984). "Articles found in the possession of a methamphetamine abuser." *Forensic Sci Int* 26(3): 207-14.
- Kral, A. H., J. Lorvick, et al. (2005). "HIV prevalence and risk behaviors among men who have sex with men and inject drugs in San Francisco." *J Urban Health* 82(1 Suppl 1): i43-50.
- Kral, A. H., R. N. Bluthenthal, et al. (2001). "Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: Risk-factor analysis." *Lancet* 357(9266): 1397-401.
- Kral, A. H., J. Lorvick, et al. (2000). "Sex- and drug-related risk among populations of younger and older injection drug users in adjacent neighborhoods in San Francisco." *J Acquir Immune Defic Syndr* 24(2): 162-7.
- Kral, A. H., R. N. Bluthenthal, et al. (1999). "Risk factors among IDUs who give injections to or receive injections from other drug users." *Addiction* 94(5): 675-83.
- Kresina, T. F., J. Normand, et al. (2004). "Addressing the need for treatment paradigms for drug-abusing patients with multiple morbidities." *Clin Infect Dis* 38 Suppl 5: S398-401.
- Leino, T., P. Leinikki, et al. (1997). "Hepatitis A outbreak amongst intravenous amphetamine abusers in Finland." *Scand J Infect Dis* 29(3): 213-6.
- Lorvick, J., A. Martinez, et al. (2006). "Sexual and injection risk among women who inject methamphetamine in San Francisco." *J Urban Health* 83(3): 497-505.
- Lum, P. J., C. Sears, et al. (2005). "Injection risk behavior among women syringe exchangers in San Francisco." *Subst Use Misuse* 40(11): 1681-96.
- Maglione, M., B. Chao, et al. (1998). "Methamphetamine abuse in California: Correlates of injection use." *AIDS and Behavior* 2(3): 257-261.
- Matsumoto, T., A. Kamijo, et al. (2002). "Methamphetamine in Japan: The consequences of methamphetamine abuse as a function of route of administration." *Addiction* 97(7): 809-17.

- McKetin, R., E. Kelly, et al. (2006). "The relationship between crystalline methamphetamine use and methamphetamine dependence." *Drug Alcohol Depend* 85(3): 198-204.
- Molitor, F., J. D. Ruiz, et al. (1999). "Methamphetamine use and sexual and injection risk behaviors among out-of-treatment injection drug users." *Am J Drug Alcohol Abuse* 25(3): 475-93.
- Moriya, F. and Y. Hashimoto (2002). "A case of fatal hemorrhage in the cerebral ventricles following intravenous use of methamphetamine." *Forensic Sci Int* 129(2): 104-9.
- Mravcik, V., H. Sebakova, et al. (2000). "[Seroprevalence of viral hepatitis A, B and C in intravenous drug users]." *Epidemiol Mikrobiol Imunol* 49(1): 19-23.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.
- Nyamathi, A. M., E. L. Dixon, et al. (2006). "Hepatitis C virus infection among homeless men referred from a community clinic." *West J Nurs Res* 28(4): 475-88.
- Nyamathi, A. M., E. L. Dixon, et al. (2002). "Risk factors for hepatitis C virus infection among homeless adults." *J Gen Intern Med* 17(2): 134-43.
- Ochoa, K. C., P. J. Davidson, et al. (2005). "Heroin overdose among young injection drug users in San Francisco." *Drug Alcohol Depend* 80(3): 297-302.
- Patel, A. N. (1972). "Self-inflicted strokes." *Ann Intern Med* 76(5): 823-4.
- Perdue, T., H. Hagan, et al. (2003). "Depression and HIV risk behavior among Seattle-area injection drug users and young men who have sex with men." *AIDS Educ Prev* 15(1): 81-92.
- Poshyachinda, V. (1993). "Drug injecting and HIV infection among the population of drug abusers in Asia." *Bull Narc* 45(1): 77-90.
- Razak, M. H., J. Jittiwutikarn, et al. (2003). "HIV prevalence and risks among injection and noninjection drug users in northern Thailand: Need for comprehensive HIV prevention programs." *J Acquir Immune Defic Syndr* 33(2): 259-66.
- Richard, A. J., V. Mosier, et al. (2002). "New syringe acquisition and multi-person use of syringes among illegal drug users." *J Public Health Policy* 23(3): 324-43.
- Richards, J. R. and B. T. Brofeldt (2000). "Patterns of tooth wear associated with methamphetamine use." *J Periodontol* 71(8): 1371-4.
- Rietmeijer, C. A., R. J. Wolitski, et al. (1998). "Sex hustling, injection drug use, and non-gay identification by men who have sex with men. Associations with high-risk sexual behaviors and condom use." *Sex Transm Dis* 25(7): 353-60.
- Rose, V. J., H. F. Raymond, et al. (2006). "Assessing the feasibility of harm reduction services for MSM: The late night breakfast buffet study." *Harm Reduct J* 3: 29.
- Roxburgh, A., L. Degenhardt, et al. (2005). "Drug use and risk behaviours among injecting drug users: A comparison between sex workers and non-sex workers in Sydney, Australia." *Harm Reduct J* 2(1): 7.
- Roxburgh, A., L. Degenhardt, et al. (2004). "Changes in patterns of drug use among injecting drug users following changes in the availability of heroin in New South Wales, Australia." *Drug Alcohol Rev* 23(3): 287-94.
- Sears, C., J. R. Gudyish, et al. (2001). "Investigation of a secondary syringe exchange program for homeless young adult injection drug users in San Francisco, California, U.S.A." *J Acquir Immune Defic Syndr* 27(2): 193-201.
- Semple, S. J., T. L. Patterson, et al. (2004). "A comparison of injection and non-injection methamphetamine-using HIV positive men who have sex with men." *Drug Alcohol Depend* 76(2): 203-12.
- Simons, J. S., M. N. Oliver, et al. (2005). "Methamphetamine and alcohol abuse and dependence symptoms: Associations with affect lability and impulsivity in a rural treatment population." *Addict Behav* 30(7): 1370-81.
- Somlai, A. M., J. A. Kelly, T. L. McAuliffe, K. Ksobiech and K. L. Hackl (2003). "Predictors of HIV sexual risk behaviors in a community sample of injection drug-using men and women." *AIDS Behav* 7(4): 383-93.
- Srirak, N., S. Kawichai, et al. (2005). "HIV infection among female drug users in Northern Thailand." *Drug Alcohol Depend* 78(2): 141-5.
- Sullivan, P. S., A. K. Nakashima, et al. (1998). "Geographic differences in noninjection and injection substance use among HIV-seropositive men who have sex with men: western United States versus other regions. Supplement to HIV/AIDS Surveillance Study Group." *J Acquir Immune Defic Syndr Hum Retrovirol* 19(3): 266-73.
- Takasaki, T., N. Nishida, et al. (2003). "Unexpected death due to right-sided infective endocarditis in a methamphetamine abuser." *Leg Med (Tokyo)* 5(1): 65-8.
- Thiede, H., L. A. Valleroy, et al. (2003). "Regional patterns and correlates of substance use among young men who have sex with men in 7 US urban areas." *Am J Public Health* 93(11): 1915-21.
- van Griensvan, F., J. Keawkungwal, et al. (2004). "Lack of increased HIV risk behavior among injection drug users participating in the AIDS-VAX B/E HIV vaccine trial in Bangkok, Thailand." *AIDS* 18(2): 295-301.
- Verachai, V., T. Phutiprawan, et al. (2002). "Prevalence and genotypes of hepatitis C virus infection among drug addicts and blood donors in Thailand." *Southeast Asian J Trop Med Public Health* 33(4): 849-51.

- Viani, R. M., M. R. Araneta, et al. (2006). "Perinatal HIV counseling and rapid testing in Tijuana, Baja California, Mexico: Seroprevalence and correlates of HIV infection." *J Acquir Immune Defic Syndr* 41(1): 87-92.
- Vogt, T. M., J. F. Perz, et al. (2006). "An outbreak of hepatitis B virus infection among methamphetamine injectors: the role of sharing injection drug equipment." *Addiction* 101(5): 726-30.
- Vong, S., A. E. Fiore, et al. (2005). "Vaccination in the county jail as a strategy to reach high risk adults during a community-based hepatitis A outbreak among methamphetamine drug users." *Vaccine* 23(8): 1021-8.
- Wada, K. (2004). "[HCV infection among narcotics/methamphetamine abusers]." *Nippon Rinsho* 62 Suppl 7(Pt 1): 326-9.
- Wada, K., S. B. Greberman, et al. (1999). "HIV and HCV infection among drug users in Japan." *Addiction* 94(7): 1063-9.
- Weiss, S. R., R. Raskind, et al. (1970). "Intracerebral and subarachnoid hemorrhage following use of methamphetamine ("speed")." *Int Surg* 53(2): 123-7.
- Wenzel, S. L., P. A. Ebener, et al. (1996). "Drug-abusing homeless clients in California's substance abuse treatment system." *J Psychoactive Drugs* 28(2): 147-59.
- White, B., C. Day, et al. (2006). "Prevalence of injecting drug use and associated risk behavior among regular ecstasy users in Australia." *Drug Alcohol Depend* 83(3): 210-7.
- Wilmarth, S. S., D. R. May, et al. (1983). "Aspergillus endophthalmitis in an intravenous drug user." *Ann Ophthalmol* 15(5): 470-2, 74-6.
- Wood, E., J. A. Stoltz, et al. (2006). "Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study." *Harm Reduct J* 3: 18.
- Wu, L. T., D. J. Pilowsky, et al. (2004). "Injection drug use among stimulant users in a national sample." *Am J Drug Alcohol Abuse* 30(1): 61-83.
- Yoshizawa, H. (2002). "Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: Projection to other countries in the foreseeable future." *Oncology* 62 Suppl 1: 8-17.
- Zhu, B. L., S. Oritani, et al. (2000). "Methamphetamine-related fatalities in forensic autopsy during 5 years in the southern half of Osaka city and surrounding areas." *Forensic Sci Int* 113(1-3): 443-7.
- Zule, W. A. and D. P. Desmond (1999). "An ethnographic comparison of HIV risk behaviors among heroin and methamphetamine injectors." *Am J Drug Alcohol Abuse* 25(1): 1-23.

## Insulin Levels (animals)

*See also* Blood Glucose (animals)

- Dickinson, J. E., R. L. Andres, et al. (1994). "The ovine fetal sympathoadrenal response to the maternal administration of methamphetamine." *Am J Obstet Gynecol* 170(5 Pt 1): 1452-7.
- McMahon, E. M., J. M. Feldman, et al. (1975). "Further studies of methamphetamine-induced insulin release." *Toxicol Appl Pharmacol* 32(1): 62-72.
- McMahon, E. M., D. K. Andersen, et al. (1971). "Methamphetamine-induced insulin release." *Science* 174(4): 66-8.

## Internet

- Benotsch, E. G., S. Kalichman, et al. (2002). "Men who have met sex partners via the Internet: Prevalence, predictors, and implications for HIV prevention." *Arch Sex Behav* 31(2): 177-83.
- Fernandez, M. I., T. Perrino, et al. (2005). "Surfing new territory: club-drug use and risky sex among Hispanic men who have sex with men recruited on the Internet." *J Urban Health* 82(1 Suppl 1): i79-88.
- Fernandez, M. I., L. M. Varga, T. Perrino, J. B. Collazo, F. Subiaul, A. Rehbein, H. Torres, M. Castro and G. S. Bowen (2004). "The Internet as recruitment tool for HIV studies: Viable strategy for reaching at-risk Hispanic MSM in Miami?" *AIDS Care* 16(8): 953-63.
- Hirshfield, S., R. H. Remien, M. Humberstone, I. Walavalkar and M. A. Chiasson (2004). "Substance use and high-risk sex among men who have sex with men: A national online study in the USA." *AIDS Care* 16(8): 1036-47.
- Hirshfield, S., R. H. Remien, et al. (2004). "Crystal methamphetamine use predicts incident STD infection among men who have sex with men recruited online: A nested case-control study." *J Med Internet Res* 6(4): e41.
- Klausner, J. D., D. K. Levine, et al. (2004). "Internet-based site-specific interventions for syphilis prevention among gay and bisexual men." *AIDS Care* 16(8): 964-70.
- Wong, W., J. K. Chaw, et al. (2005). "Risk factors for early syphilis among gay and bisexual men seen in an STD clinic: San Francisco, 2002-2003." *Sex Transm Dis* 32(7): 458-63.
- Yamamoto, J. (2004). "Recent trends of drug abuse in Japan." *Ann N Y Acad Sci* 1025: 430-8.

### Iowa (US)

*See also* Des Moines

- Arria, A. M., C. Derauf, et al. (2006). "Methamphetamine and other substance use during pregnancy: Preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study." *Matern Child Health J* 10(3): 293-302.
- Boulard, G. (2005). "The meth menace: Battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.
- Charukamnoetkanok, P. and M. D. Wagoner (2004). "Facial and ocular injuries associated with methamphetamine production accidents." *Am J Ophthalmol* 138(5): 875-6.
- Cretzmeyer, M., M. V. Sarrazin, et al. (2003). "Treatment of methamphetamine abuse: Research findings and clinical directions." *J Subst Abuse Treat* 24(3): 267-77.
- Gonzales, R., P. Marinelli-Casey, et al. (2006). "Hepatitis C virus infection among methamphetamine-dependent individuals in outpatient treatment." *J Subst Abuse Treat* 31(2): 195-202.
- Gunter, T. D., D. W. Black, et al. (2004). "Drug and alcohol treatment services effective for methamphetamine abuse." *Ann Clin Psychiatry* 16(4): 195-200.
- Hutin, Y. J., B. P. Bell, et al. (1999). "Identifying target groups for a potential vaccination program during a hepatitis A communitywide outbreak." *Am J Public Health* 89(6): 918-21.
- Lewis, D., C. Moore, et al. (1997). "Determination of drug exposure using hair: Application to child protective cases." *Forensic Sci Int* 84(1-3): 123-8.
- Smith, L. M., L. L. Lagasse, et al. (2006). "The Infant Development, Environment, and Lifestyle Study: Effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth." *Pediatrics* 118(3): 1149-1156.
- Spoth, R. L., S. Clair, et al. (2006). "Long-term effects of universal preventive interventions on methamphetamine use among adolescents." *Arch Pediatr Adolesc Med* 160(9): 876-82.

### Ireland

- March, J. C., E. Oviedo-Joekes, et al. (2006). "Drugs and social exclusion in ten European cities." *Eur Addict Res* 12(1): 33-41.

### Italy

- March, J. C., E. Oviedo-Joekes, et al. (2006). "Drugs and social exclusion in ten European cities." *Eur Addict Res* 12(1): 33-41.

### Japan

- Ago, M., K. Ago, et al. (2006). "Toxicological and histopathological analysis of a patient who died nine days after a single intravenous dose of methamphetamine: A case report." *Leg Med (Tokyo)* 8(4): 235-9.
- Ahmad, K. (2003). "Asia grapples with spreading amphetamine abuse." *Lancet* 361(9372): 1878-9.
- Akiyama, K. (2006). "Longitudinal clinical course following pharmacological treatment of methamphetamine psychosis which persists after long-term abstinence." *Ann N Y Acad Sci* 1074: 125-34.
- Aoyama, N., N. Takahashi, et al. (2006). "Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder." *Alcohol Clin Exp Res* 30(10): 1644-9.
- Ashizawa, T., T. Saito, et al. (1996). "[A case of amotivational syndrome as a residual symptom after methamphetamine abuse]." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 31(5): 451-61.
- Barr, A. M., W. J. Panenka, et al. (2006). "The need for speed: An update on methamphetamine addiction." *J Psychiatry Neurosci* 31(5): 301-313.
- Edakubo, T., T. Kaneko, et al. (1991). "[Secondary development of psychological dependence in a methamphetamine dependent]." *Arukoru Kenkyuto Yakubutsu Ison* 26(2): 96-104.
- Fukunaga, T., Y. Mizoi, et al. (1987). "Methamphetamine concentrations in blood, urine, and organs of fatal cases after abuse." *Nippon Hoigaku Zasshi* 41(4): 328-34.
- Greberman, S. B. and K. Wada (1994). "Social and legal factors related to drug abuse in the United States and Japan." *Public Health Rep* 109(6): 731-7.
- Harajiri, S., H. Kojima, et al. (1986). "Synergism between methamphetamine and alcohol in a case of methamphetamine psychosis." *Kurume Med J* 33(4): 163-5.
- Harano, M., N. Uchimura, et al. (2004). "A polymorphism of DRD2 gene and brain atrophy in methamphetamine psychosis." *Ann N Y Acad Sci* 1025: 307-15.

- Hashimoto, T., K. Hashimoto, et al. (2005). "A functional glutathione S-transferase P1 gene polymorphism is associated with methamphetamine-induced psychosis in Japanese population." *Am J Med Genet B Neuropsychiatr Genet* 135(1): 5-9.
- Hida, Y., K. Kudo, et al. (1999). "Identification of an alcoholic beverage in which methamphetamine was dissolved." *Leg Med (Tokyo)* 1(1): 44-7.
- Hirabayashi, N., K. Wada, et al. (2004). "Prevalence of substance abuse among patients with physical diseases seen in an emergency room in Japan." *Am J Addict* 13(4): 398-404.
- Hirabayashi, N. and T. Yukioka (2004). "[Prevalence of substance abuse through biological method among patients with physical diseases seen in an emergency room]." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 39(1): 46-50.
- Hiroshi, K., K. Akira, et al. (2005). "An autopsy case of infectious endocarditis in a methamphetamine abuser usefulness of microbiological examination." *Soud Lek* 50(2): 18-22.
- Horiguchi, T., S. Hori, et al. (1999). "A case of traumatic shock complicated by methamphetamine intoxication." *Intensive Care Med* 25(7): 758-60.
- Ide, S., H. Kobayashi, et al. (2006). "Linkage disequilibrium and association with methamphetamine dependence/psychosis of mu-opioid receptor gene polymorphisms." *Pharmacogenomics J* 6(3): 179-88.
- Ide, S., H. Kobayashi, et al. (2004). "Gene polymorphisms of the mu opioid receptor in methamphetamine abusers." *Ann N Y Acad Sci* 1025: 316-24.
- Ikeda, M., N. Iwata, et al. (2006). "Positive association of AKT1 haplotype to Japanese methamphetamine use disorder." *Int J Neuropsychopharmacol* 9(1): 77-81.
- Inada, T., Y. Iijima, et al. (2004). "No association found between the type 1 sigma receptor gene polymorphisms and methamphetamine abuse in the Japanese population: a collaborative study by the Japanese Genetics Initiative for Drug Abuse." *Ann N Y Acad Sci* 1025: 27-33.
- Imanishi, M., T. Sakai, et al. (1997). "[Cerebral infarction due to bacterial emboli associated with methamphetamine abuse]." *No To Shinkei* 49(6): 537-40.
- Inamasu, J., Y. Nakamura, et al. (2003). "Subcortical hemorrhage caused by methamphetamine abuse: Efficacy of the triage system in the differential diagnosis--case report." *Neurol Med Chir (Tokyo)* 43(2): 82-4.
- Inoue, H., N. Ikeda, et al. (2006). "Methamphetamine-related sudden death with a concentration which was of a 'toxic level'." *Leg Med (Tokyo)* 8(3): 150-5.
- Ishigami, A., S. Kubo, et al. (2003). "The application of immunohistochemical findings in the diagnosis in methamphetamine-related death-two forensic autopsy cases." *J Med Invest* 50(1-2): 112-6.
- Ishigami, A., I. Tokunaga, et al. (2003). "Immunohistochemical study of myoglobin and oxidative injury-related markers in the kidney of methamphetamine abusers." *Leg Med (Tokyo)* 5(1): 42-8.
- Itoh, K., K. Hashimoto, et al. (2005). "Association study between brain-derived neurotrophic factor gene polymorphisms and methamphetamine abusers in Japan." *Am J Med Genet B Neuropsychiatr Genet* 132(1): 70-3.
- Iwanami, A., D. Kuwakado, et al. (1997). "Relapse of panic disorder induced by a single intravenous methamphetamine injection." *J Anxiety Disord* 11(1): 113-6.
- Iwanami, A., N. Kato, et al. (1991). "P300 in methamphetamine psychosis." *Biol Psychiatry* 30(7): 726-30.
- Iwata, N., T. Inada, et al. (2004). "No association is found between the candidate genes of t-PA/plasminogen system and Japanese methamphetamine-related disorder: A collaborative study by the Japanese Genetics Initiative for Drug Abuse." *Ann N Y Acad Sci* 1025: 34-8.
- Kamijo, Y., K. Soma, M. Nishida, A. Namera and T. Ohwada (2002). "Acute liver failure following intravenous methamphetamine." *Vet Hum Toxicol* 44(4): 216-7.
- Kato, M. (1983). "A birds eye view of the present state of drug abuse in Japan." *Drug Alcohol Depend* 11(1): 55-6.
- Katsumata, S., K. Sato, et al. (1993). "Sudden death due presumably to internal use of methamphetamine." *Forensic Sci Int* 62(3): 209-15.
- Katsuragawa, Y. (1999). "Effect of methamphetamine abuse on the bone quality of the calcaneus." *Forensic Sci Int* 101(1): 43-8.
- Kobayashi, H., H. Hata, et al. (2006). "Association analysis of delta-opioid receptor gene polymorphisms in methamphetamine dependence/psychosis." *Am J Med Genet B Neuropsychiatr Genet* 141(5): 482-6.
- Kobayashi, H., S. Ide, et al. (2004). "Study of association between alpha-synuclein gene polymorphism and methamphetamine psychosis/dependence." *Ann N Y Acad Sci* 1025: 325-34.
- Koizumi, H., K. Hashimoto, et al. (2004). "Association between the glutathione S-transferase M1 gene deletion and female methamphetamine abusers." *Am J Med Genet B Neuropsychiatr Genet* 126(1): 43-5.
- Kojima, T., E. Matsushima, et al. (1990). "Eye movements in acute, chronic, and remitted schizophrenics." *Biol Psychiatry* 27(9): 975-89.
- Kojima, T., I. Une, et al. (1984). "A fatal methamphetamine poisoning associated with hyperpyrexia." *Forensic Sci Int* 24(1): 87-93.

- Kojima, T., M. Yashiki, et al. (1984). "Articles found in the possession of a methamphetamine abuser." *Forensic Sci Int* 26(3): 207-14.
- Komokata, T., S. Nishida, et al. (2003). "The impact of donor chemical overdose on the outcome of liver transplantation." *Transplantation* 76(4): 705-8.
- Kuwata, T. and H. Suwaki (1998). "[A clinical study of substance dependence patients combined with other psychiatric disorders]." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 33(5): 574-86.
- Kuwayama, K., H. Inoue, et al. (2006). "Contribution of thermal desorption and liquid-liquid extraction for identification and profiling of impurities in methamphetamine by gas chromatography-mass spectrometry." *Forensic Sci Int*.
- Matoba, R., S. Onishi, et al. (1984). "[Sudden death in methamphetamine abusers: a histological study of the heart]." *Nippon Hoigaku Zasshi* 38(2): 199-205.
- Matsumoto, T., A. Kamijo, et al. (2005). "Childhood histories of attention-deficit hyperactivity disorders in Japanese methamphetamine and inhalant abusers: Preliminary report." *Psychiatry Clin Neurosci* 59(1): 102-5.
- Matsumoto, T., A. Yamaguchi, et al. (2005). "Drug preferences in illicit drug abusers with a childhood tendency of attention deficit/hyperactivity disorder: A study using the Wender Utah Rating Scale in a Japanese prison." *Psychiatry Clin Neurosci* 59(3): 311-8.
- Matsumoto, T., A. Kamijo, et al. (2002). "Methamphetamine in Japan: The consequences of methamphetamine abuse as a function of route of administration." *Addiction* 97(7): 809-17.
- Mikami, T., N. Naruse, et al. (2003). "Determining vulnerability to schizophrenia in methamphetamine psychosis using exploratory eye movements." *Psychiatry Clin Neurosci* 57(4): 433-40.
- Miura, H., M. Fujiki, et al. (2006). "Prevalence and profile of methamphetamine users in adolescents at a juvenile classification home." *Psychiatry Clin Neurosci* 60(3): 352-7.
- Miyata, H., J. Kono, et al. (2004). "Clinical features of nicotine dependence compared with those of alcohol, methamphetamine, and inhalant dependence." *Ann N Y Acad Sci* 1025: 481-8.
- Mori, A., H. Suzuki, et al. (1992). "[Three cases of acute methamphetamine intoxication--Analysis of optically active methamphetamine]." *Nippon Hoigaku Zasshi* 46(4): 266-70.
- Morio, A., H. Ujike, et al. (2006). "No association between CART (cocaine- and amphetamine-regulated transcript) gene and methamphetamine dependence." *Ann N Y Acad Sci* 1074: 411-7.
- Morita, Y., H. Ujike, et al. (2005). "A nonsynonymous polymorphism in the human fatty acid amide hydrolase gene did not associate with either methamphetamine dependence or schizophrenia." *Neurosci Lett* 376(3): 182-7.
- Morita, Y., H. Ujike, et al. (2005). "The X-box binding protein 1 (XBP1) gene is not associated with methamphetamine dependence." *Neurosci Lett* 383(1-2): 194-8.
- Moriya, F. and Y. Hashimoto (2002). "A case of fatal hemorrhage in the cerebral ventricles following intravenous use of methamphetamine." *Forensic Sci Int* 129(2): 104-9.
- Mukasa, H., J. Nakamura, et al. (1990). "Platelet monoamine oxidase activity and personality traits in alcoholics and methamphetamine dependents." *Drug Alcohol Depend* 26(3): 251-4.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.
- Nagata, T., J. Oshima, et al. (2003). "Repetitive self-mutilation among Japanese eating disorder patients with drug use disorder: Comparison with patients with methamphetamine use disorder." *J Nerv Ment Dis* 191(5): 319-23.
- Nagata, T., Y. Kawarada, et al. (2002). "Drug use disorders in Japanese eating disorder patients." *Psychiatry Res* 109(2): 181-91.
- Nakamura, K., C. K. Chen, et al. (2006). "Association analysis of SOD2 variants with methamphetamine psychosis in Japanese and Taiwanese populations." *Hum Genet* 120(2): 243-52.
- Nakano, Y., K. Kaneko, et al. (2003). "A patient with self-inflicted injuries of the cervical vertebrae and spinal cord." *Arch Orthop Trauma Surg* 123(7): 379-81.
- Nakatani, Y. and T. Hara (1998). "Disturbance of consciousness due to methamphetamine abuse. A study of 2 patients." *Psychopathology* 31(3): 131-7.
- Nishida, N., N. Ikeda, et al. (2003). "Sudden unexpected death of a methamphetamine abuser with cardiopulmonary abnormalities: A case report." *Med Sci Law* 43(3): 267-71.
- Nishiyama, T., M. Ikeda, et al. (2005). "Haplotype association between GABAA receptor gamma2 subunit gene (GABRG2) and methamphetamine use disorder." *Pharmacogenomics J* 5(2): 89-95.
- Nomura, A., H. Ujike, et al. (2006). "Genetic variant of prodynorphin gene is risk factor for methamphetamine dependence." *Neurosci Lett* 400(1-2): 158-62.
- Ogai, Y., A. Haraguchi, et al. (2005). "[Control of craving for methamphetamine: Development of scales for dependence and search for medicines for treatment]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 25(5): 227-33.
- Ohgake, S., K. Hashimoto, et al. (2005). "Functional polymorphism of the NQO2 gene is associated with methamphetamine psychosis." *Addict Biol* 10(2): 145-8.



- Okudaira, K., T. Yabana, et al. (1994). "[Clinical problems of alcoholics with a history of methamphetamine abuse]." *Arukuru Kenkyuto Yakubutsu Ison* 29(3): 185-9.
- Ozaki, S. and K. Wada (2006). "Characteristics of methylphenidate dependence syndrome in psychiatric hospital settings." *Nihon Arukuru Yakubutsu Igakkai Zasshi* 41(2): 89-99.
- Poshyachinda, V. (1993). "Drug injecting and HIV infection among the population of drug abusers in Asia." *Bull Narc* 45(1): 77-90.
- Saito, A., Y. Fujikura-Ouchi, et al. (2007). "Association study of putative promoter polymorphisms in the neuroplastin gene and schizophrenia." *Neurosci Lett* 411(3): 168-73.
- Sato, M. (2002). "[Basic and clinical studies on methamphetamine-related psychosis]." *Seishin Shinkeigaku Zasshi* 104(3): 179-90.
- Sato, M., Y. Numachi, et al. (1992). "Relapse of paranoid psychotic state in methamphetamine model of schizophrenia." *Schizophr Bull* 18(1): 115-22.
- Sato, M. (1992). "A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis." *Ann N Y Acad Sci* 654: 160-70.
- Sato, M., C. C. Chen, et al. (1983). "Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis." *Biol Psychiatry* 18(4): 429-40.
- Sekine, Y., Y. Ouchi, et al. (2006). "Brain serotonin transporter density and aggression in abstinent methamphetamine abusers." *Arch Gen Psychiatry* 63(1): 90-100.
- Shibata, S., K. Mori, et al. (1991). "Subarachnoid and intracerebral hemorrhage associated with necrotizing angiitis due to methamphetamine abuse--an autopsy case." *Neurol Med Chir (Tokyo)* 31(1): 49-52.
- Shimazono, Y. and E. Matsushima (1995). "Behavioral and neuroimaging studies on schizophrenia in Japan." *Psychiatry Clin Neurosci* 49(1): 3-11.
- Srisurapanont, M., R. Ali, et al. (2003). "Psychotic symptoms in methamphetamine psychotic in-patients." *Int J Neuropsychopharmacol* 6(4): 347-52.
- Suwaki, H., M. Yamasaki, et al. (1992). "A study of longitudinal patterns of substance abuse with special reference to multiple use problems." *Arukuru Kenkyuto Yakubutsu Ison* 27(3): 284-96.
- Suwanwela, C. and V. Poshyachinda (1986). "Drug abuse in Asia." *Bull Narc* 38(1-2): 41-53.
- Suzuki, A., K. Nakamura, et al. (2006). "An association study between catechol-O-methyl transferase gene polymorphism and methamphetamine psychotic disorder." *Psychiatr Genet* 16(4): 133-8.
- Takasaki, T., N. Nishida, et al. (2003). "Unexpected death due to right-sided infective endocarditis in a methamphetamine abuser." *Leg Med (Tokyo)* 5(1): 65-8.
- Tohhara, S., A. Kato, et al. (1990). "[Methamphetamine abuse by smoking]." *Arukuru Kenkyuto Yakubutsu Ison* 25(6): 467-74.
- Ujike, H. and M. Sato (2004). "Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis." *Ann N Y Acad Sci* 1025: 279-87.
- Wada, K. (2004). "[HCV infection among narcotics/methamphetamine abusers]." *Nippon Rinsho* 62 Suppl 7(Pt 1): 326-9.
- Wada, K., S. B. Greberman, et al. (1999). "HIV and HCV infection among drug users in Japan." *Addiction* 94(7): 1063-9.
- Wada, K. (1994). "Cocaine abuse in Japan." *Arukuru Kenkyuto Yakubutsu Ison* 29(2): 83-91.
- Yamamoto, J. (2004). "Recent trends of drug abuse in Japan." *Ann N Y Acad Sci* 1025: 430-8.
- Yamamoto, K., H. Watanabe, et al. (1991). "[3 fatalities after communal use of methamphetamine]." *Arch Kriminol* 188(3-4): 72-6.
- Yamamura, T., S. Hisida, et al. (1991). "Alcohol addiction of methamphetamine abusers in Japan." *J Forensic Sci* 36(3): 754-64.
- Yamamura, T., H. Hasegawa, et al. (1987). "[Alcohol intake on methamphetamine abusers]." *Nippon Hoigaku Zasshi* 41(1): 21-30.
- Yamasaki, M., H. Suwaki, et al. (1992). "Patterns of alcohol abuse from the viewpoint of multiple substance abuse." *Arukuru Kenkyuto Yakubutsu Ison* 27(5): 540-52.
- Yoshizawa, H. (2002). "Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: Projection to other countries in the foreseeable future." *Oncology* 62 Suppl 1: 8-17.
- Yui, K., K. Goto and S. Ikemoto (2004). "The role of noradrenergic and dopaminergic hyperactivity in the development of spontaneous recurrence of methamphetamine psychosis and susceptibility to episode recurrence." *Ann N Y Acad Sci* 1025: 296-306.
- Yui, K., S. Ikemoto, et al. (2003). "Susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosis." *J Clin Psychopharmacol* 23(5): 525-8.
- Yui, K., S. Ikemoto, et al. (2002). "Factors for susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosis." *Ann N Y Acad Sci* 965: 292-304.
- Yui, K., S. Ikemoto, et al. (2002). "Spontaneous recurrence of methamphetamine-induced paranoid-hallucinatory states in female subjects: Susceptibility to psychotic states and implications for relapse of schizophrenia." *Pharmacopsychiatry* 35(2): 62-71.

- Yui, K., K. Goto, et al. (2001). "Susceptibility to subsequent episodes of spontaneous recurrence of methamphetamine psychosis." *Drug Alcohol Depend* 64(2): 133-42.
- Yui, K., K. Goto, et al. (2000). "Stress induced spontaneous recurrence of methamphetamine psychosis: The relation between stressful experiences and sensitivity to stress." *Drug Alcohol Depend* 58(1-2): 67-75.
- Yui, K., K. Goto, et al. (2000). "Increased sensitivity to stress in spontaneous recurrence of methamphetamine psychosis: noradrenergic hyperactivity with contribution from dopaminergic hyperactivity." *J Clin Psychopharmacol* 20(2): 165-74.
- Yui, K., T. Ishiguro, et al. (1999). "Spontaneous recurrence of methamphetamine psychosis: increased sensitivity to stress associated with noradrenergic hyperactivity and dopaminergic change." *Eur Arch Psychiatry Clin Neurosci* 249(2): 103-11.
- Yui, K., T. Ishiguro, et al. (1998). "Factors affecting the development of spontaneous recurrence of methamphetamine psychosis." *Acta Psychiatr Scand* 97(3): 220-7.
- Yui, K., K. Goto, S. Ikemoto and T. Ishiguro (1997). "Monoamine neurotransmitter metabolites and spontaneous recurrence of methamphetamine psychosis." *Brain Res Bull* 43(1): 25-33.
- Yui, K., T. Ishiguro, et al. (1997). "Precipitating factors in spontaneous recurrence of methamphetamine psychosis." *Psychopharmacology (Berl)* 134(3): 303-8.
- Yui, K., K. Goto, et al. (1997). "Noradrenergic activity and spontaneous recurrence of methamphetamine psychosis." *Drug Alcohol Depend* 44(2-3): 183-7.
- Yui, K., K. Goto, et al. (1997). "Noradrenergic activity and spontaneous recurrence of methamphetamine psychosis." *Drug Alcohol Depend* 44(2-3): 183-7.
- Yukitake, A. (1983). "Amphetamine psychosis in Tokyo--Its clinical features and social problems." *Folia Psychiatr Neurol Jpn* 37(2): 115-20.
- Zhu, B. L., T. Ishikawa, et al. (2006). "Postmortem cardiac troponin T levels in the blood and pericardial fluid. Part 1. Analysis with special regard to traumatic causes of death." *Leg Med (Tokyo)* 8(2): 86-93.
- Zhu, B. L., T. Ishikawa, et al. (2005). "Evaluation of postmortem serum calcium and magnesium levels in relation to the causes of death in forensic autopsy." *Forensic Sci Int* 155(1): 18-23.
- Zhu, B. L., S. Oritani, et al. (2000). "Methamphetamine-related fatalities in forensic autopsy during 5 years in the southern half of Osaka city and surrounding areas." *Forensic Sci Int* 113(1-3): 443-7.

### Juarez, Ciudad (Mexico)

- Brouwer, K. C., P. Case, et al. (2006). "Trends in production, trafficking, and consumption of methamphetamine and cocaine in Mexico." *Subst Use Misuse* 41(5): 707-27.
- Cruz, M. F., A. Mantsios, et al. (2006). "A qualitative exploration of gender in the context of injection drug use in two US-Mexico border cities." *AIDS Behav*.
- Maxwell, J. C., P. Cravioto, et al. (2006). "Drug use and risk of HIV/AIDS on the Mexico-USA border: A comparison of treatment admissions in both countries." *Drug Alcohol Depend* 82 Suppl 1: S85-93.

### Judgment

*See Decision-Making and Judgment*

### Kentucky (US)

- Booth, B. M., C. Leukefeld, et al. (2006). "Correlates of rural methamphetamine and cocaine users: Results from a multistate community study." *J Stud Alcohol* 67(4): 493-501.
- Joosen, M., T. F. Garrity, et al. (2005). "Predictors of current depressive symptoms in a sample of drug court participants." *Subst Use Misuse* 40(8): 1113-25.
- Nath, A., W. F. Maragos, et al. (2001). "Acceleration of HIV dementia with methamphetamine and cocaine." *J Neurovirol* 7(1): 66-71.
- Sexton, R. L., R. G. Carlson, et al. (2005). "Barriers and pathways to diffusion of methamphetamine use among African Americans in the rural South: Preliminary ethnographic findings." *J Ethn Subst Abuse* 4(1): 77-103.
- Stoops, W. W., M. S. Tindall, et al. (2005). "Methamphetamine use in nonurban and urban drug court clients." *Int J Offender Ther Comp Criminol* 49(3): 260-76.

**Ketamine***See also Polydrug Use*

- Bolding, G., G. Hart, et al. (2006). "Use of crystal methamphetamine among gay men in London." *Addiction* 101(11): 1622-30.
- Colfax, G. N., G. Mansergh, et al. (2001). "Drug use and sexual risk behavior among gay and bisexual men who attend circuit parties: A venue-based comparison." *J Acquir Immune Defic Syndr* 28(4): 373-9.
- Fernandez, M. I., T. Perrino, et al. (2005). "Surfing new territory: club-drug use and risky sex among Hispanic men who have sex with men recruited on the Internet." *J Urban Health* 82(1 Suppl 1): i79-88.
- Goldsamt, L. A., J. O'Brien, et al. (2005). "The relationship between club drug use and other drug use: A survey of New York City middle school students." *Subst Use Misuse* 40(9): 1539-55.
- Hopfer, C., B. Mendelson, et al. (2006). "Club drug use among youths in treatment for substance abuse." *Am J Addict* 15(1): 94-9.
- Halkitis, P. N. and J. J. Palamar (2006). "GHB use among gay and bisexual men." *Addict Behav* 31(11): 2135-9.
- Kelly, B. C., J. T. Parsons, et al. (2006). "Prevalence and predictors of club drug use among club-going young adults in New York City." *J Urban Health* 83(5): 884-895.
- Lampinen, T. M., D. McGhee, et al. (2006). "Increased risk of "club" drug use among gay and bisexual high school students in British Columbia." *J Adolesc Health* 38(4): 458-61.
- Lampinen, T. M., D. McGhee, et al. (2006). "Increased risk of "club" drug use among gay and bisexual high school students in British Columbia." *J Adolesc Health* 38(4): 458-61.
- Mansergh, G., G. N. Colfax, et al. (2001). "The Circuit Party Men's Health Survey: Findings and implications for gay and bisexual men." *Am J Public Health* 91(6): 953-8.
- Martin, I., T. M. Lampinen, et al. (2006). "Methamphetamine use among marginalized youth in British Columbia." *Can J Public Health* 97(4): 320-4.
- Mattison, A. M., M. W. Ross, et al. (2001). "Circuit party attendance, club drug use, and unsafe sex in gay men." *J Subst Abuse* 13(1-2): 119-26.
- McCaughan, J. A., R. G. Carlson, et al. (2005). "From "Candy Kids" to "Chemi-Kids": A typology of young adults who attend raves in the midwestern United States." *Subst Use Misuse* 40(9-10): 1503-23.
- Parsons, J. T., B. C. Kelly, et al. (2006). "Differences in club drug use between heterosexual and lesbian/bisexual females." *Addict Behav* 31(12): 2344-9.
- Patterson, T. L., S. J. Semple, et al. (2005). "Methamphetamine-using HIV-positive men who have sex with men: Correlates of polydrug use." *J Urban Health* 82(1 Suppl 1): i120-6.
- Rusch, M., T. M. Lampinen, et al. (2004). "Unprotected anal intercourse associated with recreational drug use among young men who have sex with men depends on partner type and intercourse role." *Sex Transm Dis* 31(8): 492-8.
- Teng, S. F., S. C. Wu, et al. (2006). "Characteristics and trends of 3,4-methylenedioxymethamphetamine (MDMA) tablets found in Taiwan from 2002 to February 2005." *Forensic Sci Int* 161(2-3): 202-8.
- Wu, L. T., W. E. Schlenger, et al. (2006). "Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths." *Drug Alcohol Depend* 84(1): 102-13.

**Ketamine (animals)**

- Hayase, T., Y. Yamamoto, et al. (2006). "Behavioral effects of ketamine and toxic interactions with psychostimulants." *BMC Neurosci* 7(1): 25.
- Kuribara, H. (1993). "Ceruletide, a cholecystokinin-like decapeptide, differentially reduces the stimulant effect of MK-801 and ketamine: Evaluation by discrete shuttle avoidance in mice." *Eur J Pharmacol* 231(1): 7-11.

**Kidney Function and Disease**

- Ago, M., K. Ago, et al. (2006). "Toxicological and histopathological analysis of a patient who died nine days after a single intravenous dose of methamphetamine: A case report." *Leg Med (Tokyo)* 8(4): 235-9.
- Bingham, C., M. Beaman, et al. (1998). "Necrotizing renal vasculopathy resulting in chronic renal failure after ingestion of methamphetamine and 3,4-methylenedioxymethamphetamine ('ecstasy')." *Nephrol Dial Transplant* 13(10): 2654-5.
- Ishigami, A., I. Tokunaga, et al. (2003). "Immunohistochemical study of myoglobin and oxidative injury-related markers in the kidney of methamphetamine abusers." *Leg Med (Tokyo)* 5(1): 42-8.
- Longstreth, P. L. and M. Korobkin (1976). "Intrarenal arterial aneurysms." *CRC Crit Rev Clin Radiol Nucl Med* 8(1): 129-51.

### Kidney Function and Disease (animals)

Tokunaga, I., S. Kubo, et al. (2006). "Changes in renal function and oxidative damage in methamphetamine-treated rat." *Leg Med (Tokyo)* 8(1): 16-21.

### Korea

Ahmad, K. (2003). "Asia grapples with spreading amphetamine abuse." *Lancet* 361(9372): 1878-9.

Bae, S. C., I. K. Lyoo, et al. (2006). "Increased white matter hyperintensities in male methamphetamine abusers." *Drug Alcohol Depend* 81(1): 83-8.

Cho, B. I. (1991). "Trends and patterns of methamphetamine abuse in the Republic of Korea." *NIDA Res Monogr* 115: 99-108.

Chung, H., M. Park, et al. (2004). "Recent trends of drug abuse and drug-associated deaths in Korea." *Ann N Y Acad Sci* 1025: 458-64.

Chung, H. (1998). "Drug abuse trends and epidemiological aspects of drug associated deaths in Korea." *J Toxicol Sci* 23 Suppl 2: 197-200.

Kim, S. J., I. K. Lyoo, et al. (2006). "Prefrontal grey-matter changes in short-term and long-term abstinent methamphetamine abusers." *Int J Neuropsychopharmacol* 9(2): 221-8.

Poshyachinda, V. (1993). "Drug injecting and HIV infection among the population of drug abusers in Asia." *Bull Narc* 45(1): 77-90.

Sung, Y. H., S. C. Cho, et al. (2006). "Relationship between N-acetyl-aspartate in gray and white matter of abstinent methamphetamine abusers and their history of drug abuse: A proton magnetic resonance spectroscopy study." *Drug Alcohol Depend*.

Yoon, S. J., C. U. Pae, et al. (2005). "Ghrelin precursor gene polymorphism and methamphetamine dependence in the Korean population." *Neurosci Res* 53(4): 391-5.

### Laboratories

*See Methamphetamine Laboratories and Manufacture*

### Laos

Kulsudjarit, K. (2004). "Drug problem in southeast and southwest Asia." *Ann N Y Acad Sci* 1025: 446-57.

### Latinos

*See Hispanics/Latinos/Latinas*

### Latvia

Lagerspetz, M. and J. Moskalewicz (2002). "Drugs in the postsocialist transitions of Estonia, Latvia, Lithuania and Poland." *Eur Addict Res* 8(4): 177-83.

### Law Enforcement

*See also Crime; Drug Courts and Court-Mandated Treatment; Incarceration, Alternatives to; Incarceration and Incarcerated Individuals*

Altshuler, S. J. (2005). "Drug-endangered children need a collaborative community response." *Child Welfare* 84(2): 171-90.

Anonymous (2005). "Anhydrous ammonia thefts and releases associated with illicit methamphetamine production--16 states, January 2000-June 2004." *MMWR Morb Mortal Wkly Rep* 54(14): 359-61.

Boulard, G. (2005). "The meth menace: Battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.

Brecht, M. L., M. D. Anglin, et al. (2005). "Coerced treatment for methamphetamine abuse: Differential patient characteristics and outcomes." *Am J Drug Alcohol Abuse* 31(2): 337-56.

Caldicott, D. G., P. E. Pigou, et al. (2005). "Clandestine drug laboratories in Australia and the potential for harm." *Aust N Z J Public Health* 29(2): 155-62.

Colker, A. C. (2005). "Restricting the sale of pseudoephedrine to prevent methamphetamine production." *NCSL Legisbrief* 13(7): 1-2.

Cunningham, J. K. and L. M. Liu (2005). "Impacts of federal precursor chemical regulations on methamphetamine arrests." *Addiction* 100(4): 479-88.

- Grella, C. E., Y. I. Hser, et al. (2006). "Mothers in substance abuse treatment: differences in characteristics based on involvement with child welfare services." *Child Abuse Negl* 30(1): 55-73.
- Gunter, T. D., D. W. Black, et al. (2004). "Drug and alcohol treatment services effective for methamphetamine abuse." *Ann Clin Psychiatry* 16(4): 195-200.
- Marris, E. (2005). "Police urge speedy action to clean up home drug factories." *Nature* 434(7030): 129.
- O'Halloran, R. L. and L. V. Lewman (1993). "Restraint asphyxiation in excited delirium." *Am J Forensic Med Pathol* 14(4): 289-95.
- Qi, Y., I. D. Evans, et al. (2006). "Australian Federal Police seizures of illicit crystalline methamphetamine ('ice') 1998-2002: Impurity analysis." *Forensic Sci Int* 164(2-3): 201-10.
- Rawson, R. A., M. D. Anglin and W. Ling (2002). "Will the methamphetamine problem go away?" *J Addict Dis* 21(1): 5-19.
- Room, R. (2006). "The dangerousness of drugs." *Addiction* 101(2): 166-8.
- Sheridan, J., S. Bennett, et al. (2006). "Injury associated with methamphetamine use: A review of the literature." *Harm Reduct J* 3(1): 14.
- Silber, B. Y., K. Papafotiou, et al. (2005). "An evaluation of the sensitivity of the standardised field sobriety tests to detect the presence of amphetamine." *Psychopharmacology (Berl)*: 1-7.

## Lead Poisoning

- Allcott, J. V., 3rd, R. A. Barnhart, et al. (1987). "Acute lead poisoning in two users of illicit methamphetamine." *JAMA* 258(4): 510-1.
- Anonymous (1990). "From the Centers for Disease Control. Lead poisoning associated with intravenous-methamphetamine use--Oregon, 1988." *JAMA* 263(6): 797-8.
- Anonymous (1989). "Lead poisoning associated with intravenous-methamphetamine use--Oregon, 1988." *MMWR Morb Mortal Wkly Rep* 38(48): 830-1.
- Burton, B. T. (1991). "Heavy metal and organic contaminants associated with illicit methamphetamine production." *NIDA Res Monogr* 115: 47-59.
- Norton, R. L., B. T. Burton, et al. (1996). "Blood lead of intravenous drug users." *J Toxicol Clin Toxicol* 34(4): 425-30.

## Learning

*See* Avoidance Behaviors (animals); Cognition; Cognition (animals); Conditioned Place Preference (animals)

## Lesbians/ Women Who Have Sex with Women

- Cruz, M. F., A. Mantsios, et al. (2006). "A qualitative exploration of gender in the context of injection drug use in two US-Mexico border cities." *AIDS Behav*.
- Degenhardt, L. (2005). "Drug use and risk behaviour among regular ecstasy users: Does sexuality make a difference?" *Culture, Health & Sexuality* 7(6): 599-614.
- Kelly, B. C., J. T. Parsons, et al. (2006). "Prevalence and predictors of club drug use among club-going young adults in New York City." *J Urban Health* 83(5): 884-895.
- Lampinen, T. M., D. McGhee, et al. (2006). "Increased risk of "club" drug use among gay and bisexual high school students in British Columbia." *J Adolesc Health* 38(4): 458-61.
- Lampinen, T. M., D. McGhee, et al. (2006). "Use of crystal methamphetamine and other club drugs among high school students in Vancouver and Victoria." *BC Medical Journal* 48(1): 22-27.
- Lorvick, J., A. Martinez, et al. (2006). "Sexual and injection risk among women who inject methamphetamine in San Francisco." *J Urban Health* 83(3): 497-505.
- Martin, I., T. M. Lampinen, et al. (2006). "Methamphetamine use among marginalized youth in British Columbia." *Can J Public Health* 97(4): 320-4.
- Mitchell, S. J., S. R. Morris, et al. (2006). "Methamphetamine use and sexual activity among HIV-infected patients in care--San Francisco, 2004." *AIDS Patient Care STDS* 20(7): 502-10.
- Parsons, J. T., B. C. Kelly, et al. (2006). "Differences in club drug use between heterosexual and lesbian/bisexual females." *Addict Behav* 31(12): 2344-9.

## Lithuania

- Lagerspetz, M. and J. Moskalewicz (2002). "Drugs in the postsocialist transitions of Estonia, Latvia, Lithuania and Poland." *Eur Addict Res* 8(4): 177-83.

### Liver, Metabolism in (animals)

- Duncan, J. D., G. Hallstrom, et al. (1983). "Effects of alpha-carbon substituents on the N-demethylation of N-methyl-2-phenethylamines by rat liver microsomes." *Drug Metab Dispos* 11(1): 15-20.
- Eling, T. E. and R. P. DiAugustine (1971). "A role for phospholipids in the binding and metabolism of drugs by hepatic microsomes. Use of the fluorescent hydrophobic probe 1-anilinonaphthalene-8-sulphonate." *Biochem J* 123(4): 539-49.
- Estler, C. J. (1975). "Dependence on age of methamphetamine-produced changes in thermoregulation and metabolism." *Experientia* 31(12): 1436-7.
- Estler, C. J. and M. C. Gabrys (1979). "Swimming capacity of mice after prolonged treatment with psychostimulants. II. Effect of methamphetamine on swimming performance and availability of metabolic substrates." *Psychopharmacology (Berl)* 60(2): 173-6.
- Estler, C. J., H. P. Ammon, et al. (1970). "Substrate supply and energy metabolism of skeletal muscle of mice treated with methamphetamine and propranolol." *Biochem Pharmacol* 19(12): 2957-62.
- Gibson, G. G., T. C. Orton, et al. (1982). "Cytochrome P-450 induction by clofibrate. Purification and properties of a hepatic cytochrome P-450 relatively specific for the 12- and 11-hydroxylation of dodecanoic acid (lauric acid)." *Biochem J* 203(1): 161-8.
- Gibson, G. G. and J. B. Schenkman (1978). "Purification and properties of cytochrome P-450 obtained from liver microsomes of untreated rats by lauric acid affinity chromatography." *J Biol Chem* 253(17): 5957-63.
- Reimann, W. and H. Geuer (1975). "Proceedings: Influence of hyperthermic acting substances on several liver substrates in the rat in vivo." *Naunyn Schmiedebergs Arch Pharmacol* 287 Suppl: R84.
- Weiner, M. (1980). "The kinetics of inhibition of hepatic drug metabolism by prostaglandins in rabbits." *Res Commun Chem Pathol Pharmacol* 29(3): 561-71.

### Liver Disease

*See also* Hepatitis A ; Hepatitis B ; Hepatitis C

- Cherner, M., S. Letendre, et al. (2005). "Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine." *Neurology* 64(8): 1343-7.
- Davis, L. E., G. Kalousek, et al. (1970). "Hepatitis associated with illicit use of intravenous methamphetamine." *Public Health Rep* 85(9): 809-13.
- Garfein, R. S., W. A. Bower, et al. (2004). "Factors associated with fulminant liver failure during an outbreak among injection drug users with acute hepatitis B." *Hepatology* 40(4): 865-73.
- Grinde, B., K. Stene-Johansen, et al. (1997). "Characterisation of an epidemic of hepatitis A virus involving intravenous drug abusers--infection by needle sharing?" *J Med Virol* 53(1): 69-75.
- Hahn, J. A., K. Page-Shafer, P. J. Lum, K. Ochoa and A. R. Moss (2001). "Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco." *Hepatology* 34(1): 180-7.
- Harkess, J., B. Gildon, et al. (1989). "Outbreaks of hepatitis A among illicit drug users, Oklahoma, 1984-87." *Am J Public Health* 79(4): 463-6.
- Kahraman, A., M. Miller, et al. (2006). "Non-alcoholic fatty liver disease in HIV-positive patients predisposes for acute-on-chronic liver failure: Two cases." *Eur J Gastroenterol Hepatol* 18(1): 101-105.
- Kamijo, Y., K. Soma, et al. (2002). "Acute liver failure following intravenous methamphetamine." *Vet Hum Toxicol* 44(4): 216-7.
- Koester, S., J. Glanz, et al. (2005). "Drug sharing among heroin networks: Implications for HIV and hepatitis B and C prevention." *AIDS Behav* 9(1): 27-39.
- Leino, T., P. Leinikki, et al. (1997). "Hepatitis A outbreak amongst intravenous amphetamine abusers in Finland." *Scand J Infect Dis* 29(3): 213-6.
- Nyamathi, A. M., E. L. Dixon, et al. (2002). "Risk factors for hepatitis C virus infection among homeless adults." *J Gen Intern Med* 17(2): 134-43.
- Nyamathi, A., W. A. Robbins, et al. (2002). "Presence and predictors of hepatitis C virus RNA in the semen of homeless men." *Biol Res Nurs* 4(1): 22-30.
- Pol, S., P. Lebray, et al. (2004). "HIV infection and hepatic enzyme abnormalities: Intricacies of the pathogenic mechanisms." *Clin Infect Dis* 38 Suppl 2: S65-72.
- Sanga, M., I. R. Younis, et al. (2005). "Epoxidation of the methamphetamine pyrolysis product, trans-phenylpropene, to trans-phenylpropylene oxide by CYP enzymes and stereoselective glutathione adduct formation." *Toxicol Appl Pharmacol*.
- Taylor, M. J., S. L. Letendre, et al. (2004). "Hepatitis C virus infection is associated with reduced white matter N-acetylaspartate in abstinent methamphetamine users." *J Int Neuropsychol Soc* 10(1): 110-3.

- van Gorp, W. G. and C. H. Hinkin (2005). "Triple trouble: cognitive deficits from hepatitis C, HIV, and methamphetamine." *Neurology* 64(8): 1328-9.
- Verachai, V., T. Phutiprawan, et al. (2002). "Prevalence and genotypes of hepatitis C virus infection among drug addicts and blood donors in Thailand." *Southeast Asian J Trop Med Public Health* 33(4): 849-51.
- Vong, S., A. E. Fiore, et al. (2005). "Vaccination in the county jail as a strategy to reach high risk adults during a community-based hepatitis A outbreak among methamphetamine drug users." *Vaccine* 23(8): 1021-8.
- Yoshizawa, H. (2002). "Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: Projection to other countries in the foreseeable future." *Oncology* 62 Suppl 1: 8-17.
- Zhu, B. L., S. Oritani, et al. (2000). "Methamphetamine-related fatalities in forensic autopsy during 5 years in the southern half of Osaka city and surrounding areas." *Forensic Sci Int* 113(1-3): 443-7.

## Liver Transplantation

- Komokata, T., S. Nishida, et al. (2003). "The impact of donor chemical overdose on the outcome of liver transplantation." *Transplantation* 76(4): 705-8.

## Los Angeles, CA (US)

- Arria, A. M., C. Derauf, et al. (2006). "Methamphetamine and other substance use during pregnancy: Preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study." *Matern Child Health J* 10(3): 293-302.
- Baskin-Sommers, A. and I. Sommers (2006). "The co-occurrence of substance use and high-risk behaviors." *J Adolesc Health* 38(5): 609-11.
- Brecht, M. L., L. Greenwell, et al. (2007). "Substance use pathways to methamphetamine use among treated users." *Addict Behav* 32(1): 24-38.
- Brecht, M. L., M. D. Anglin, et al. (2005). "Coerced treatment for methamphetamine abuse: Differential patient characteristics and outcomes." *Am J Drug Alcohol Abuse* 31(2): 337-56.
- Brecht, M. L., A. O'Brien, et al. (2004). "Methamphetamine use behaviors and gender differences." *Addict Behav* 29(1): 89-106.
- Brecht, M. L., C. von Mayrhauser, et al. (2000). "Predictors of relapse after treatment for methamphetamine use." *J Psychoactive Drugs* 32(2): 211-20.
- Demetriades, D., G. Gkiokas, et al. (2004). "Alcohol and illicit drugs in traumatic deaths: Prevalence and association with type and severity of injuries." *J Am Coll Surg* 199(5): 687-92.
- Drumright, L. N., S. J. Little, et al. (2006). "Unprotected anal intercourse and substance use among men who have sex with men with recent HIV infection." *J Acquir Immune Defic Syndr* 43(3): 344-50.
- Drumright, L. N., S. A. Strathdee, et al. (2006). "Unprotected anal intercourse and substance use before and after HIV diagnosis among recently HIV-infected men who have sex with men." *Sex Transm Dis*.
- Frosch, D., S. Shoptaw, et al. (1996). "Sexual HIV risk among gay and bisexual male methamphetamine abusers." *J Subst Abuse Treat* 13(6): 483-6.
- Gorbach, P. M., J. T. Galea, et al. (2004). "Don't ask, don't tell: patterns of HIV disclosure among HIV positive men who have sex with men with recent STI practising high risk behaviour in Los Angeles and Seattle." *Sex Transm Infect* 80(6): 512-7.
- Greenwell, L. and M. L. Brecht (2003). "Self-reported health status among treated methamphetamine users." *Am J Drug Alcohol Abuse* 29(1): 75-104.
- Jain, N. C., R. D. Budd, et al. (1979). "Frequency of use or abuse of amphetamine-related drugs." *Am J Drug Alcohol Abuse* 6(1): 53-7.
- Jain, N. C., R. D. Budd, et al. (1978). "A survey of drug use among probationers in the Los Angeles area in 1976." *Int J Addict* 13(8): 1319-25.
- Jain, N. C., R. Budd, et al. (1977). "Patterns of drug use among methadone maintenance patients in Los Angeles county." *Bull Narc* 29(2): 45-53.
- Kalechstein, A. D., T. F. Newton, et al. (2000). "Psychiatric comorbidity of methamphetamine dependence in a forensic sample." *J Neuropsychiatry Clin Neurosci* 12(4): 480-4.
- Kipke, M. D., S. O'Connor, et al. (1995). "Street youth in Los Angeles. Profile of a group at high risk for human immunodeficiency virus infection." *Arch Pediatr Adolesc Med* 149(5): 513-9.
- Klatt, E. C., S. Montgomery, et al. (1986). "Misrepresentation of stimulant street drugs: A decade of experience in an analysis program." *J Toxicol Clin Toxicol* 24(5): 441-50.
- Larkins, S., C. J. Reback, et al. (2005). "Methamphetamine-dependent gay men's disclosure of their HIV status to sexual partners." *AIDS Care* 17(4): 521-32.

- Levine, A. J., D. J. Hardy, et al. (2006). "The effect of recent stimulant use on sustained attention in HIV-infected adults." *J Clin Exp Neuropsychol* 28(1): 29-42.
- Morin, S. F., W. T. Steward, et al. (2005). "Predicting HIV transmission risk among HIV-infected men who have sex with men: Findings from the Healthy Living Project." *J Acquir Immune Defic Syndr* 40(2): 226-235.
- Nalls, G., A. Disher, et al. (1989). "Subcortical cerebral hemorrhages associated with cocaine abuse: CT and MR findings." *J Comput Assist Tomogr* 13(1): 1-5.
- Nyamathi, A. M., E. L. Dixon, et al. (2002). "Risk factors for hepatitis C virus infection among homeless adults." *J Gen Intern Med* 17(2): 134-43.
- Nyamathi, A., W. A. Robbins, et al. (2002). "Presence and predictors of hepatitis C virus RNA in the semen of homeless men." *Biol Res Nurs* 4(1): 22-30.
- Peck, J. A., C. J. Reback, et al. (2005). "Sustained reductions in drug use and depression symptoms from treatment for drug abuse in methamphetamine-dependent gay and bisexual men." *J Urban Health* 82(1 Suppl 1): i100-8.
- Peck, J. A., S. Shoptaw, et al. (2005). "HIV-associated medical, behavioral, and psychiatric characteristics of treatment-seeking, methamphetamine-dependent men who have sex with men." *J Addict Dis* 24(3): 115-32.
- Rawson, R. A., R. Gonzales, et al. (2005). "Methamphetamine use among treatment-seeking adolescents in Southern California: Participant characteristics and treatment response." *J Subst Abuse Treat* 29(2): 67-74.
- Rawson, R. A., A. Huber, et al. (2002). "Status of methamphetamine users 2-5 years after outpatient treatment." *J Addict Dis* 21(1): 107-19.
- Shoptaw, S. and C. J. Reback (2006). "Associations between methamphetamine use and HIV among men who have sex with men: A model for guiding public policy." *J Urban Health* 83(6): 1151-7.
- Shoptaw, S., C. J. Reback, et al. (2005). "Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men." *Drug Alcohol Depend* 78(2): 125-34.
- Shoptaw, S., C. J. Reback and T. E. Freese (2002). "Patient characteristics, HIV serostatus, and risk behaviors among gay and bisexual males seeking treatment for methamphetamine abuse and dependence in Los Angeles." *J Addict Dis* 21(1): 91-105.
- Smith, L. M., L. L. Lagasse, et al. (2006). "The Infant Development, Environment, and Lifestyle Study: Effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth." *Pediatrics* 118(3): 1149-1156.
- Sommers, L., D. Baskin, et al. (2006). "Methamphetamine use among young adults: Health and social consequences." *Addict Behav* 31(8): 1469-76.
- Stall, R., J. P. Paul, et al. (2001). "Alcohol use, drug use and alcohol-related problems among men who have sex with men: The Urban Men's Health Study." *Addiction* 96(11): 1589-601.
- Thiede, H., L. A. Valleroy, et al. (2003). "Regional patterns and correlates of substance use among young men who have sex with men in 7 US urban areas." *Am J Public Health* 93(11): 1915-21.
- Twitchell, G. R., A. Huber, et al. (2002). "Comparison of general and detailed HIV risk assessments among methamphetamine abusers." *AIDS and Behavior* 6(2): 153-162.
- von Mayrhauser, C., M. L. Brecht and M. D. Anglin (2002). "Use ecology and drug use motivations of methamphetamine users admitted to substance abuse treatment facilities in Los Angeles: An emerging profile." *J Addict Dis* 21(1): 45-60.
- Wenzel, S. L., P. A. Ebener, et al. (1996). "Drug-abusing homeless clients in California's substance abuse treatment system." *J Psychoactive Drugs* 28(2): 147-59.
- Willers-Russo, L. J. (1999). "Three fatalities involving phosphine gas, produced as a result of methamphetamine manufacturing." *J Forensic Sci* 44(3): 647-52.
- Wohl, A. R., D. F. Johnson, et al. (2002). "HIV risk behaviors among African American men in Los Angeles County who self-identify as heterosexual." *J Acquir Immune Defic Syndr* 31(3): 354-60.
- Zweben, J. E., J. B. Cohen, et al. (2000). "Conducting trials in community settings: The provider perspective." *J Psychoactive Drugs* 32(2): 193-9.

### LSD (Lysergic Acid Diethylamide)

- Kelly, B. C., J. T. Parsons, et al. (2006). "Prevalence and predictors of club drug use among club-going young adults in New York City." *J Urban Health* 83(5): 884-895.
- Lampinen, T. M., D. McGhee, et al. (2006). "Increased risk of "club" drug use among gay and bisexual high school students in British Columbia." *J Adolesc Health* 38(4): 458-61.
- Parsons, J. T., B. C. Kelly, et al. (2006). "Differences in club drug use between heterosexual and lesbian/bisexual females." *Addict Behav* 31(12): 2344-9.



Wu, L. T., W. E. Schlenger, et al. (2006). "Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths." *Drug Alcohol Depend* 84(1): 102-13.

## Manufacture

*See* Methamphetamine Laboratories and Manufacture

## Lungs

*See* Pulmonary Effects and Thoracic Disease; Pulmonary Effects and Thoracic Disease (animals)

## Marijuana and Cannabinoids

*See also* Polydrug Use

- Arria, A. M., C. Derauf, et al. (2006). "Methamphetamine and other substance use during pregnancy: Preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study." *Matern Child Health J* 10(3): 293-302.
- Baskin-Sommers, A. and I. Sommers (2006). "The co-occurrence of substance use and high-risk behaviors." *J Adolesc Health* 38(5): 609-11.
- Bellis, M. A., K. E. Hughes, et al. (2007). "Effects of backpacking holidays in Australia on alcohol, tobacco and drug use of UK residents." *BMC Public Health* 7(1): 1.
- Breen, C., L. Degenhardt, et al. (2006). "Alcohol use and risk taking among regular ecstasy users." *Subst Use Misuse* 41(8): 1095-109.
- Booth, B. M., C. Leukefeld, et al. (2006). "Correlates of rural methamphetamine and cocaine users: Results from a multistate community study." *J Stud Alcohol* 67(4): 493-501.
- Brecht, M. L., L. Greenwell, et al. (2007). "Substance use pathways to methamphetamine use among treated users." *Addict Behav* 32(1): 24-38.
- Drumright, L. N., S. J. Little, et al. (2006). "Unprotected anal intercourse and substance use among men who have sex with men with recent HIV infection." *J Acquir Immune Defic Syndr* 43(3): 344-50.
- Drumright, L. N., S. A. Strathdee, et al. (2006). "Unprotected anal intercourse and substance use before and after HIV diagnosis among recently HIV-infected men who have sex with men." *Sex Transm Dis*.
- Forney, R., R. Martz, et al. (1976). "The combined effect of marijuana and dextroamphetamine." *Ann N Y Acad Sci* 281: 162-70.
- Forrester, M. B. and R. D. Merz (2007). "Risk of selected birth defects with prenatal illicit drug use, Hawaii, 1986-2002." *J Toxicol Environ Health A* 70(1): 7-18.
- Goldsamt, L. A., J. O'Brien, et al. (2005). "The relationship between club drug use and other drug use: A survey of New York City middle school students." *Subst Use Misuse* 40(9): 1539-55.
- Gonzalez, R., J. D. Rippeth, et al. (2004). "Neurocognitive performance of methamphetamine users discordant for history of marijuana exposure." *Drug Alcohol Depend* 76(2): 181-90.
- Gouzoulis-Mayfrank, E. and J. Daumann (2006). "The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview." *J Psychopharmacol* 20(2): 188-93.
- Herman-Stahl, M. A., C. P. Krebs, et al. (2006). "Risk and protective factors for methamphetamine use and nonmedical use of prescription stimulants among young adults aged 18 to 25." *Addict Behav*.
- Herman-Stahl, M. A., C. P. Krebs, et al. (2006). "Risk and protective factors for nonmedical use of prescription stimulants and methamphetamine among adolescents." *J Adolesc Health* 39(3): 374-80.
- Lampinen, T. M., D. McGhee, et al. (2006). "Increased risk of "club" drug use among gay and bisexual high school students in British Columbia." *J Adolesc Health* 38(4): 458-61.
- Lipinski, E. (1972). "Motivation in drug misuse. Some comments on agent, environment, host." *Jama* 219(2): 171-5.
- Liu, A., P. Kilmarx, et al. (2006). "Sexual initiation, substance use, and sexual behavior and knowledge among vocational students in northern Thailand." *Int Fam Plan Perspect* 32(3): 126-35.
- Logan, B. K. (1996). "Methamphetamine and driving impairment." *J Forensic Sci* 41(3): 457-64.
- Luchansky, B., A. Krupski, et al. (2007). "Treatment response by primary drug of abuse: Does methamphetamine make a difference?" *J Subst Abuse Treat* 32(1): 89-96.
- Lundqvist, T. (2005). "Cognitive consequences of cannabis use: Comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions." *Pharmacol Biochem Behav* 81(2): 319-30.
- Manchikanti, L., K. A. Cash, et al. (2006). "Controlled substance abuse and illicit drug use in chronic pain patients: An evaluation of multiple variables." *Pain Physician* 9(3): 215-25.

- Martin, I., T. M. Lampinen, et al. (2006). "Methamphetamine use among marginalized youth in British Columbia." *Can J Public Health* 97(4): 320-4.
- Matsumoto, T., A. Kamijo, et al. (2002). "Methamphetamine in Japan: The consequences of methamphetamine abuse as a function of route of administration." *Addiction* 97(7): 809-17.
- Mattison, A. M., M. W. Ross, et al. (2001). "Circuit party attendance, club drug use, and unsafe sex in gay men." *J Subst Abuse* 13(1-2): 119-26.
- McCaughan, J. A., R. G. Carlson, et al. (2005). "From "Candy Kids" to "Chemi-Kids": A typology of young adults who attend raves in the midwestern United States." *Subst Use Misuse* 40(9-10): 1503-23.
- Oetting, E. R., J. L. Deffenbacher, et al. (2000). "Methamphetamine use by high school students: Recent trends, gender and ethnicity differences, and use of other drugs." *Journal of Child and Adolescent Substance Abuse* 10(1): 33-50.
- Patterson, T. L., S. J. Semple, et al. (2005). "Methamphetamine-using HIV-positive men who have sex with men: Correlates of polydrug use." *J Urban Health* 82(1 Suppl 1): i120-6.
- Rawson, R., A. Huber, et al. (2000). "Methamphetamine and cocaine users: Differences in characteristics and treatment retention." *J Psychoactive Drugs* 32(2): 233-8.
- Reid, L. W., K. W. Elifson, et al. (2007). "Ecstasy and gateway drugs: Initiating the use of ecstasy and other drugs." *Ann Epidemiol* 17(1): 74-80.
- Rockett, I. R., S. L. Putnam, et al. (2006). "Declared and undeclared substance use among emergency department patients: A population-based study." *Addiction* 101(5): 706-712.
- Roll, J. M., N. M. Petry, et al. (2006). "Contingency management for the treatment of methamphetamine use disorders." *Am J Psychiatry* 163(11): 1993-9.
- Schwilke, E. W., M. I. Sampaio dos Santos, et al. (2006). "Changing patterns of drug and alcohol use in fatally injured drivers in Washington State." *J Forensic Sci* 51(5): 1191-8.
- Smith, L. M., L. L. Lagasse, et al. (2006). "The Infant Development, Environment, and Lifestyle Study: Effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth." *Pediatrics* 118(3): 1149-1156.
- Storr, C. L., A. M. Arria, et al. (2004). "Neighborhood environment and opportunity to try methamphetamine ("ice") and marijuana: Evidence from Guam in the Western Pacific region of Micronesia." *Subst Use Misuse* 39(2): 253-76.
- Viani, R. M., M. R. Araneta, et al. (2006). "Perinatal HIV counseling and rapid testing in Tijuana, Baja California, Mexico: Seroprevalence and correlates of HIV infection." *J Acquir Immune Defic Syndr* 41(1): 87-92.
- Voytek, B., S. M. Berman, et al. (2005). "Differences in regional brain metabolism associated with marijuana abuse in methamphetamine abusers." *Synapse* 57(2): 113-5.

### Marijuana and Cannabinoids (animals)

- Anggadiredja, K., M. Nakamichi, et al. (2004). "Endocannabinoid system modulates relapse to methamphetamine seeking: Possible mediation by the arachidonic acid cascade." *Neuropsychopharmacology* 29(8): 1470-8.
- Consroe, P., B. Jones, et al. (1976). "EEG and behavioral effects of delta9-tetrahydrocannabinol in combination with stimulant drugs in rabbits." *Psychopharmacology (Berl)* 50(1): 47-52.
- Consroe, P. F., B. C. Jones, et al. (1975). "Delta9-tetrahydrocannabinol methamphetamine interaction in the rabbit." *Neuropharmacology* 14(5-6): 377-83.
- Forney, R., R. Martz, et al. (1976). "The combined effect of marihuana and dextroamphetamine." *Ann N Y Acad Sci* 281: 162-70.
- Fujiwara, M., Y. Kataoka, et al. (1984). "Irritable aggression induced by delta 9-tetrahydrocannabinol in rats pretreated with 6-hydroxydopamine." *Pharmacol Biochem Behav* 20(3): 457-62.
- Kubena, R. K. and H. Barry, 3rd (1970). "Interactions of delta-tetrahydrocannabinol with barbiturates and methamphetamine." *J Pharmacol Exp Ther* 173(1): 94-100.
- Rumbaugh, C. L., H. C. Fang, et al. (1980). "Cerebral CT findings in drug abuse: Clinical and experimental observations." *J Comput Assist Tomogr* 4(3): 330-4.
- Sassenrath, E. N. and L. F. Chapman (1976). "Primate social behavior as a method of analysis of drug action: studies with THC in monkeys." *Fed Proc* 35(11): 2238-44.

### Maryland (US)

- Thiede, H., L. A. Valleroy, et al. (2003). "Regional patterns and correlates of substance use among young men who have sex with men in 7 US urban areas." *Am J Public Health* 93(11): 1915-21.

**Massachusetts (US)**

- Koblin, B. A., M. A. Chesney, et al. (2003). "High-risk behaviors among men who have sex with men in 6 US cities: Baseline data from the EXPLORE Study." *Am J Public Health* 93(6): 926-32.
- Seage, G. R., 3rd, K. H. Mayer, et al. (1998). "The social context of drinking, drug use, and unsafe sex in the Boston Young Men Study." *J Acquir Immune Defic Syndr Hum Retrovirol* 17(4): 368-75.

**Matrix Model**

- Cretzmeyer, M., M. V. Sarrazin, et al. (2003). "Treatment of methamphetamine abuse: Research findings and clinical directions." *J Subst Abuse Treat* 24(3): 267-77.
- Domier, C. P., S. L. Simon, et al. (2000). "A comparison of injecting and noninjecting methamphetamine users." *J Psychoactive Drugs* 32(2): 229-32.
- Freese, T. E., J. Obert, et al. (2000). "Methamphetamine abuse: Issues for special populations." *J Psychoactive Drugs* 32(2): 177-82.
- Hamilton Brown, A. (2004). "Integrating research and practice in the CSAT Methamphetamine Treatment Project." *J Subst Abuse Treat* 26(2): 103-8.
- Herrell, J. M., J. A. Taylor, et al. (2000). "A multisite study of the effectiveness of methamphetamine treatment: An initiative of the Center for Substance Abuse Treatment." *J Psychoactive Drugs* 32(2): 143-7.
- Huber, A., R. H. Lord, et al. (2000). "The CSAT methamphetamine treatment program: Research design accommodations for "real world" application." *J Psychoactive Drugs* 32(2): 149-56.
- Huber, A., W. Ling, et al. (1997). "Integrating treatments for methamphetamine abuse: A psychosocial perspective." *J Addict Dis* 16(4): 41-50.
- Obert, J. L., A. H. Brown, et al. (2005). "When treatment meets research: Clinical perspectives from the CSAT Methamphetamine Treatment Project." *J Subst Abuse Treat* 28(3): 231-7.
- Obert, J. L., E. D. London, et al. (2002). "Incorporating brain research findings into standard treatment: An example using the Matrix Model." *J Subst Abuse Treat* 23(2): 107-13.
- Obert, J. L., M. J. McCann, et al. (2000). "The Matrix model of outpatient stimulant abuse treatment: History and description." *J Psychoactive Drugs* 32(2): 157-64.
- Peck, J. A., C. J. Reback, et al. (2005). "Sustained reductions in drug use and depression symptoms from treatment for drug abuse in methamphetamine-dependent gay and bisexual men." *J Urban Health* 82(1 Suppl 1): i100-8.
- Peck, J. A., S. Shoptaw, et al. (2005). "HIV-associated medical, behavioral, and psychiatric characteristics of treatment-seeking, methamphetamine-dependent men who have sex with men." *J Addict Dis* 24(3): 115-32.
- Rawson, R. A., R. Gonzales, et al. (2005). "Methamphetamine use among treatment-seeking adolescents in Southern California: Participant characteristics and treatment response." *J Subst Abuse Treat* 29(2): 67-74.
- Rawson, R. A., P. Marinelli-Casey, et al. (2004). "A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence." *Addiction* 99(6): 708-17.
- Rawson, R. A., R. Gonzales, et al. (2002). "Treatment of methamphetamine use disorders: An update." *J Subst Abuse Treat* 23(2): 145-50.
- Reiber, C., G. Galloway, et al. (2000). "A descriptive analysis of participant characteristics and patterns of substance use in the CSAT methamphetamine treatment project: the first six months." *J Psychoactive Drugs* 32(2): 183-91.
- Roll, J. M., N. M. Petry, et al. (2006). "Contingency management for the treatment of methamphetamine use disorders." *Am J Psychiatry* 163(11): 1993-9.
- Shoptaw, S., C. J. Reback, et al. (2005). "Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men." *Drug Alcohol Depend* 78(2): 125-34.
- Shoptaw, S., R. A. Rawson, et al. (1994). "The Matrix model of outpatient stimulant abuse treatment: Evidence of efficacy." *J Addict Dis* 13(4): 129-41.
- Vazquez, E. (2005). "Crystal meth recovery. A step-by-step guide." *Posit Aware* 16(5): 20-2, 25.
- Zweben, J. E., J. B. Cohen, et al. (2000). "Conducting trials in community settings: The provider perspective." *J Psychoactive Drugs* 32(2): 193-9.

**MDMA (3, 4-methylenedioxymethamphetamine)**

*See also Polydrug Use*

- Bellis, M. A., K. E. Hughes, et al. (2007). "Effects of backpacking holidays in Australia on alcohol, tobacco and drug use of UK residents." *BMC Public Health* 7(1): 1.

- Bolding, G., G. Hart, et al. (2006). "Use of crystal methamphetamine among gay men in London." *Addiction* 101(11): 1622-30.
- Breen, C., L. Degenhardt, et al. (2006). "Alcohol use and risk taking among regular ecstasy users." *Subst Use Misuse* 41(8): 1095-109.
- Brecht, M. L. and C. von Mayrhauser (2002). "Differences between Ecstasy-using and nonusing methamphetamine users." *J Psychoactive Drugs* 34(2): 215-23.
- Cheng, J. Y., M. F. Chan, et al. (2006). "Impurity profiling of ecstasy tablets seized in Hong Kong by gas chromatography-mass spectrometry." *Forensic Sci Int* 162(1-3): 87-94.
- Cheng, W. C., N. L. Poon, et al. (2003). "Chemical profiling of 3,4-methylenedioxyamphetamine (MDMA) tablets seized in Hong Kong." *J Forensic Sci* 48(6): 1249-59.
- Choi, K. H., D. Operario, et al. (2005). "Substance use, substance choice, and unprotected anal intercourse among young Asian American and Pacific Islander men who have sex with men." *AIDS Educ Prev* 17(5): 418-29.
- Christophersen, A. S. (2000). "Amphetamine designer drugs - An overview and epidemiology." *Toxicol Lett* 112-113: 127-31.
- Degenhardt, L. (2005). "Drug use and risk behaviour among regular ecstasy users: Does sexuality make a difference?" *Culture, Health & Sexuality* 7(6): 599-614.
- Delgado, J. H., M. J. Caruso, J. C. Waksman, B. Honigman and D. Stillman (2004). "Acute, transient urinary retention from combined ecstasy and methamphetamine use." *J Emerg Med* 26(2): 173-5.
- Fernandez, M. I., T. Perrino, et al. (2005). "Surfing new territory: club-drug use and risky sex among Hispanic men who have sex with men recruited on the Internet." *J Urban Health* 82(1 Suppl 1): i79-88.
- Ghaziani, A. and T. D. Cook (2005). "Reducing HIV infections at circuit parties: From description to explanation and principles of intervention design." *J Int Assoc Physicians AIDS Care (Chic Ill)* 4(2): 32-46.
- Goldsamt, L. A., J. O'Brien, et al. (2005). "The relationship between club drug use and other drug use: A survey of New York City middle school students." *Subst Use Misuse* 40(9): 1539-55.
- Gouzoulis-Mayfrank, E. and J. Daumann (2006). "The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview." *J Psychopharmacol* 20(2): 188-93.
- Gouzoulis-Mayfrank, E., M. Schreckenberger, et al. (1999). "Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG." *Neuropsychopharmacology* 20(6): 565-81.
- Halkitis, P. N. and J. J. Palamar (2006). "GHB use among gay and bisexual men." *Addict Behav* 31(11): 2135-9.
- Heller, A., L. Won, et al. (1995). "Examination of developmental neurotoxicity by the use of tissue culture model systems." *Clin Exp Pharmacol Physiol* 22(5): 375-8.
- Hirshfield, S., R. H. Remien, et al. (2004). "Crystal methamphetamine use predicts incident STD infection among men who have sex with men recruited online: a nested case-control study." *J Med Internet Res* 6(4): e41.
- Hopfer, C., B. Mendelson, et al. (2006). "Club drug use among youths in treatment for substance abuse." *Am J Addict* 15(1): 94-9.
- Irvine, R. J., M. Keane, et al. (2006). "Plasma drug concentrations and physiological measures in 'dance party' participants." *Neuropsychopharmacology* 31(2): 424-30.
- Itzhak, Y. and C. Achat-Mendes (2004). "Methamphetamine and MDMA (ecstasy) neurotoxicity: 'Of mice and men'." *IUBMB Life* 56(5): 249-55.
- Jansen, K. L. and L. Theron (2006). "Ecstasy (MDMA), methamphetamine, and date rape (drug-facilitated sexual assault): A consideration of the issues." *J Psychoactive Drugs* 38(1): 1-12.
- Kalasinsky, K. S., J. Hugel, et al. (2004). "Use of MDA (the "love drug") and methamphetamine in Toronto by unsuspecting users of ecstasy (MDMA)." *J Forensic Sci* 49(5): 1106-12.
- Kelly, B. C., J. T. Parsons, et al. (2006). "Prevalence and predictors of club drug use among club-going young adults in New York City." *J Urban Health* 83(5): 884-895.
- Lampinen, T. M., D. McGhee, et al. (2006). "Increased risk of "club" drug use among gay and bisexual high school students in British Columbia." *J Adolesc Health* 38(4): 458-61.
- Lampinen, T. M., D. McGhee, et al. (2006). "Use of crystal methamphetamine and other club drugs among high school students in Vancouver and Victoria." *BC Medical Journal* 48(1): 22-27.
- Lee, S. J., M. Galanter, et al. (2003). "Circuit parties and patterns of drug use in a subset of gay men." *J Addict Dis* 22(4): 47-60.
- Martin, I., T. M. Lampinen, et al. (2006). "Methamphetamine use among marginalized youth in British Columbia." *Can J Public Health* 97(4): 320-4.
- McCaughan, J. A., R. G. Carlson, et al. (2005). "From "Candy Kids" to "Chemi-Kids": A typology of young adults who attend raves in the midwestern United States." *Subst Use Misuse* 40(9): 1503-23.
- McKetin, R., E. Kelly, et al. (2006). "The relationship between crystalline methamphetamine use and methamphetamine dependence." *Drug Alcohol Depend* 85(3): 198-204.

- Morton, J. (2005). "Ecstasy: Pharmacology and neurotoxicity." *Curr Opin Pharmacol* 5(1): 79-86.
- Parsons, J. T., B. C. Kelly, et al. (2006). "Differences in club drug use between heterosexual and lesbian/bisexual females." *Addict Behav* 31(12): 2344-9.
- Peters, F. T., N. Samyn, et al. (2003). "Concentrations and ratios of amphetamine, methamphetamine, MDA, MDMA, and MDEA enantiomers determined in plasma samples from clinical toxicology and driving under the influence of drugs cases by GC-NICI-MS." *J Anal Toxicol* 27(8): 552-9.
- Quinton, M. S. and B. K. Yamamoto (2006). "Causes and consequences of methamphetamine and MDMA toxicity." *AAPS J* 8(2): E337-47.
- Reid, L. W., K. W. Elifson, et al. (2007). "Ecstasy and gateway drugs: Initiating the use of ecstasy and other drugs." *Ann Epidemiol* 17(1): 74-80.
- Ricaurte, G. A. and U. D. McCann (1992). "Neurotoxic amphetamine analogues: Effects in monkeys and implications for humans." *Ann N Y Acad Sci* 648: 371-82.
- Ross, M. W., A. M. Mattison, et al. (2003). "Club drugs and sex on drugs are associated with different motivations for gay circuit party attendance in men." *Subst Use Misuse* 38(8): 1173-83.
- Royo-Isach, J., M. Magrane, et al. (2004). "[Speed users (metamphetamines): a return journey between ecstasy (MDMA) and cocaine. Clinical, preventive and health-care questions]." *Aten Primaria* 34(10): 553-6.
- Schilder, A. J., T. M. Lampinen, et al. (2005). "Crystal methamphetamine and ecstasy differ in relation to unsafe sex among young gay men." *Can J Public Health* 96(5): 340-3.
- Weinbroum, A. A. (2003). "Importance of early identification of methylenedioxymethamphetamine ('ecstasy') ingestion in victims of motor vehicle accidents." *Eur J Emerg Med* 10(1): 19-22.
- White, B., C. Day, et al. (2006). "Prevalence of injecting drug use and associated risk behavior among regular ecstasy users in Australia." *Drug Alcohol Depend* 83(3): 210-7.
- Wu, L. T., W. E. Schlenger, et al. (2006). "Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths." *Drug Alcohol Depend* 84(1): 102-13.

### MDMA (3, 4-methylenedioxymethamphetamine) (animals)

- Armstrong, B. D. and K. K. Noguchi (2004). "The neurotoxic effects of 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine on serotonin, dopamine, and GABA-ergic terminals: an in-vitro autoradiographic study in rats." *Neurotoxicology* 25(6): 905-14.
- Baumgarten, H. G. and L. Lachenmayer (2004). "Serotonin neurotoxins--past and present." *Neurotox Res* 6(7-8): 589-614.
- Cadet, J. L. and C. Brannock (1998). "Free radicals and the pathobiology of brain dopamine systems." *Neurochem Int* 32(2): 117-31.
- Clemens, K. J., J. L. Cornish, et al. (2007). "Repeated weekly exposure to MDMA, methamphetamine or their combination: Long-term behavioural and neurochemical effects in rats." *Drug Alcohol Depend* 86(2-3): 183-90.
- Clemens, K. J., J. L. Cornish, et al. (2006). "Intravenous methamphetamine self-administration in rats: Effects of intravenous or intraperitoneal MDMA co-administration." *Pharmacol Biochem Behav* 85(2): 454-63.
- Clemens, K. J., J. L. Cornish, et al. (2005). "MDMA ('Ecstasy') and methamphetamine combined: Order of administration influences hyperthermic and long-term adverse effects in female rats." *Neuropharmacology* 49(2): 195-207.
- Cozzi, N. V., M. K. Sievert, et al. (1999). "Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines." *Eur J Pharmacol* 381(1): 63-9.
- Crean, R. D., S. A. Davis, et al. (2006). "Effects of (+/-)3,4-methylenedioxymethamphetamine, (+/-)3,4-methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques." *Neuroscience* 142(2): 515-25.
- Dalley, J. W., K. Laane, et al. (2006). "Enduring deficits in sustained visual attention during withdrawal of intravenous methylenedioxymethamphetamine self-administration in rats: Results from a comparative study with d-amphetamine and methamphetamine." *Neuropsychopharmacology*.
- Ellison, G. (2002). "Neural degeneration following chronic stimulant abuse reveals a weak link in brain, fasciculus retroflexus, implying the loss of forebrain control circuitry." *Eur Neuropsychopharmacol* 12(4): 287-97.
- Fantegrossi, W. E., W. L. Woolverton, et al. (2004). "Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys." *Neuropsychopharmacology* 29(7): 1270-81.
- Fantegrossi, W. E., T. Ullrich, et al. (2002). "3,4-Methylenedioxymethamphetamine (MDMA, 'ecstasy') and its stereoisomers as reinforcers in rhesus monkeys: Serotonergic involvement." *Psychopharmacology (Berl)* 161(4): 356-64.
- Finnegan, K. T. and T. Taraska (1996). "Effects of glutamate antagonists on methamphetamine and 3,4-methylenedioxymethamphetamine-induced striatal dopamine release in vivo." *J Neurochem* 66(5): 1949-58.

- Fornai, F., P. Lenzi, et al. (2005). "Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice." *Brain Res Bull* 65(5): 405-13.
- Fornai, F., G. Lazzeri, et al. (2003). "Amphetamines induce ubiquitin-positive inclusions within striatal cells." *Neurol Sci* 24(3): 182-3.
- Gesi, M., G. Lazzeri, et al. (2006). "Inclusion dynamics in PC12 is comparable between amphetamines and MPTP." *Ann N Y Acad Sci* 1074: 315-9.
- Hanson, G. R., M. Jensen, et al. (1999). "Distinct features of seizures induced by cocaine and amphetamine analogs." *Eur J Pharmacol* 377(2-3): 167-73.
- Holden, C. (2003). "Retraction. Paper on toxic party drug is pulled over vial mix-up." *Science* 301(5639): 1454.
- Itzhak, Y. and C. Achat-Mendes (2004). "Methamphetamine and MDMA (ecstasy) neurotoxicity: 'Of mice and men'." *IUBMB Life* 56(5): 249-55.
- Knight, J. (2003). "Agony for researchers as mix-up forces retraction of ecstasy study." *Nature* 425(6954): 109.
- Nash, J. F. and B. K. Yamamoto (1992). "Methamphetamine neurotoxicity and striatal glutamate release: Comparison to 3,4-methylenedioxymethamphetamine." *Brain Res* 581(2): 237-43.
- Neto, P. R. (2005). "Activation of striatal dopamine receptors by psychostimulants: Chemical anatomy, autonomic and behavioural effects." *Dan Med Bull* 52(3): 114.
- O'Callaghan, J. P. and D. B. Miller (1994). "Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse." *J Pharmacol Exp Ther* 270(2): 741-51.
- Pubill, D., A. M. Canudas, et al. (2003). "Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity." *Naunyn Schmiedebergs Arch Pharmacol* 367(5): 490-9.
- Ricaurte, G. A. and U. D. McCann (1992). "Neurotoxic amphetamine analogues: Effects in monkeys and implications for humans." *Ann N Y Acad Sci* 648: 371-82.
- Schaefer, T. L., L. A. Ehrman, et al. (2006). "Comparison of monoamine and corticosterone levels 24 h following (+)methamphetamine, (+/-)3,4-methylenedioxymethamphetamine, cocaine, (+)fenfluramine or (+/-)methylphenidate administration in the neonatal rat." *J Neurochem* 98(5): 1369-78.
- Seiden, L. S. and K. E. Sabol (1996). "Methamphetamine and methylenedioxymethamphetamine neurotoxicity: Possible mechanisms of cell destruction." *NIDA Res Monogr* 163: 251-76.
- Shiue, C. Y., G. G. Shiue, et al. (1995). "Comparative PET studies of the distribution of (-)-3,4-methylenedioxy-N-[11C]methamphetamine and (-)-[11C]methamphetamine in a monkey brain." *Nucl Med Biol* 22(3): 321-4.
- Sprague, J. E., X. Yang, et al. (2007). "Roles of norepinephrine, free fatty acids, thyroid status and skeletal muscle uncoupling protein 3 expression in sympathomimetic-induced thermogenesis." *J Pharmacol Exp Ther* 320(1): 274-80.
- Straiko, M. M., L. M. Coolen, et al. (2007). "The effect of amphetamine analogs on cleaved microtubule-associated protein-tau formation in the rat brain." *Neuroscience* 144(1): 223-31.
- Taraska, T. and K. T. Finnegan (1997). "Nitric oxide and the neurotoxic effects of methamphetamine and 3,4-methylenedioxymethamphetamine." *J Pharmacol Exp Ther* 280(2): 941-7.
- Wang, Z. and W. L. Woolverton (2007). "Estimating the relative reinforcing strength of (+/-)-3,4-methylenedioxymethamphetamine (MDMA) and its isomers in rhesus monkeys: Comparison to (+)-methamphetamine." *Psychopharmacology (Berl)* 189(4): 483-8.
- Zacny, J. P., R. M. Virus, et al. (1990). "Tolerance and cross-tolerance to 3,4-methylenedioxymethamphetamine (MDMA), methamphetamine and methylenedioxyamphetamine." *Pharmacol Biochem Behav* 35(3): 637-42.

### Medical Care

*See also* Emergency Care; Hospital Utilization; *and specific conditions and organ systems*

- Albertson, T. E., R. W. Derlet and B. E. Van Hoozen (1999). "Methamphetamine and the expanding complications of amphetamines." *West J Med* 170(4): 214-9.
- Antoniou, T. and A. L. Tseng (2002). "Interactions between recreational drugs and antiretroviral agents." *Ann Pharmacother* 36(10): 1598-1613.
- Cunningham, J. K. and L. M. Liu (2005). "Impacts of federal precursor chemical regulations on methamphetamine arrests." *Addiction* 100(4): 479-88.
- Delgado, J. H., M. J. Caruso, J. C. Waksman, B. Honigman and D. Stillman (2004). "Acute, transient urinary retention from combined ecstasy and methamphetamine use." *J Emerg Med* 26(2): 173-5.
- Duterte, M., S. O'Neil, et al. (2001). "Walking the tightrope: Balancing health and drug use." *J Psychoactive Drugs* 33(2): 173-83.
- Ellis, R. J., M. E. Childers, et al. (2003). "Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy." *J Infect Dis* 188(12): 1820-6.

- Fournier, M. E. and S. Levy (2006). "Recent trends in adolescent substance use, primary care screening, and updates in treatment options." *Curr Opin Pediatr* 18(4): 352-8.
- Freese, T. E., K. Miotto and C. J. Reback (2002). "The effects and consequences of selected club drugs." *J Subst Abuse Treat* 23(2): 151-6.
- Hart, C. L., M. Haney, et al. (2005). "Combined effects of methamphetamine and zolpidem on performance and mood during simulated night shift work." *Pharmacol Biochem Behav* 81(3): 559-68.
- Hart, C. L., A. S. Ward, et al. (2003). "Methamphetamine attenuates disruptions in performance and mood during simulated night-shift work." *Psychopharmacology (Berl)* 169(1): 42-51.
- Heinzerling, K. G., A. H. Kral, et al. (2006). "Unmet need for recommended preventive health services among clients of California syringe exchange programs: Implications for quality improvement." *Drug Alcohol Depend* 81(2): 167-78.
- Horiguchi, T., S. Hori, et al. (1999). "A case of traumatic shock complicated by methamphetamine intoxication." *Intensive Care Med* 25(7): 758-60.
- Jenkins, L. C. and H. B. Graves (1965). "Potential hazards of psychoactive drugs in association with anaesthesia." *Can Anaesth Soc J* 12: 121-8.
- Kerr, T., E. Wood, et al. (2005). "High rates of primary care and emergency department use among injection drug users in Vancouver." *J Public Health (Oxf)* 27(1): 62-6.
- Kresina, T. F., J. Normand, J. Khalsa, J. Mitty, T. Flanigan and H. Francis (2004). "Addressing the need for treatment paradigms for drug-abusing patients with multiple morbidities." *Clin Infect Dis* 38(Suppl 5): S398-401.
- Kohrs, F. P., C. Mann and R. Greenberg (2004). "The use of amphetamine in gamma-hydroxybutyrate overdose: A case report." *J Psychoactive Drugs* 36(3): 401-2.
- Lavoie, G. (1966). "[Hyperpyrexia during general anaesthesia: a case report]." *Can Anaesth Soc J* 13(5): 444-6.
- Manchikanti, L., K. A. Cash, et al. (2006). "Controlled substance abuse and illicit drug use in chronic pain patients: An evaluation of multiple variables." *Pain Physician* 9(3): 215-25.
- Reback, C. J., S. Larkins, et al. (2003). "Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men." *AIDS Care* 15(6): 775-85.
- Shoptaw, S., J. Peck, et al. (2003). "Psychiatric and substance dependence comorbidities, sexually transmitted diseases, and risk behaviors among methamphetamine-dependent gay and bisexual men seeking outpatient drug abuse treatment." *J Psychoactive Drugs* 35 Suppl 1: 161-8.
- Turnipseed, S. D., J. R. Richards, J. D. Kirk, D. B. Diercks and E. A. Amsterdam (2003). "Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after methamphetamine use." *J Emerg Med* 24(4): 369-73.
- Urbina, A. and K. Jones (2004). "Crystal methamphetamine, its analogues, and HIV infection: Medical and psychiatric aspects of a new epidemic." *Clin Infect Dis* 38(6): 890-4.
- Warner, P., J. P. Connolly, N. S. Gibran, D. M. Heimbach and L. H. Engrav (2003). "The methamphetamine burn patient." *J Burn Care Rehabil* 24(5): 275-8.

## Medical Uses

- Armstrong, P. A., J. E. Carless, et al. (1973). "The effect of pore size of the inhaler support upon the concentration of volatile drug emerging in the air stream from a nasal inhaler." *J Pharm Pharmacol* 25(1): 35-41.
- Armstrong, P. A., J. E. Carless, et al. (1972). "The influence of the moisture content of the fibrous support of a nasal inhaler upon the concentration of drug in the air stream." *J Pharm Pharmacol* 24(1): 13-9.
- Armstrong, P. A., J. E. Carless, et al. (1971). "The relation between the vapour pressure of a drug and its concentration emerging in the air stream from a nasal inhaler." *J Pharm Pharmacol* 23(7): 473-81.
- Aviado, D. M. (1965). "Pharmacologic Approach to the Treatment of Shock." *Ann Intern Med* 62: 1050-9.
- Carnwath, T., T. Garvey and M. Holland (2002). "The prescription of dexamphetamine to patients with schizophrenia and amphetamine dependence." *J Psychopharmacol* 16(4): 373-7.
- Castaneda, R., N. Sussman, et al. (1999). "A treatment algorithm for attention deficit hyperactivity disorder in cocaine-dependent adults: A one-year private practice study with long-acting stimulants, fluoxetine, and bupropion." *Subst Abuse* 20(1): 59-71.
- Chorpita, B. F. and J. O. Viesselman (2005). "Staying in the clinical ballpark while running the evidence bases." *J Am Acad Child Adolesc Psychiatry* 44(11): 1193-7.
- Cookson, J. and T. Silverstone (1986). "The effects of methylamphetamine on mood and appetite in depressed patients: A placebo-controlled study." *Int Clin Psychopharmacol* 1(2): 127-33.
- Cox, R. H., Jr. and R. P. Maickel (1975). "Differential effects of alphaMT on anorectic and stimulatory action of amphetamines." *Res Commun Chem Pathol Pharmacol* 12(4): 621-6.

- Cox, R. H., Jr. and R. P. Maickel (1972). "Comparison of anorexigenic and behavioral potency of phenylethylamines." *J Pharmacol Exp Ther* 181(1): 1-9.
- Crump, G. P. (1963). "Narcolepsy. A discussion and case presentation." *Proc Wkly Semin Neurol* 15: 6-20.
- Dement, W. C., M. A. Carskadon, et al. (1976). "Narcolepsy. Diagnosis and treatment." *Prim Care* 3(4): 609-23.
- Dement, W. C. (1979). "Narcolepsy--not as rare as we believed!" *Med Times* 107(6): 51-5.
- Doleys, D. M. (1977). "Behavioral treatments for nocturnal enuresis in children: A review of the recent literature." *Psychol Bull* 84(1): 30-54.
- Duffy, J. P. and K. Davison (1968). "A female case of the Kleine-Levin Syndrome." *Br J Psychiatry* 114(506): 77-84.
- Ferrando, R. L., E. McCorvey, Jr., et al. (1988). "Bizarre behavior following the ingestion of levo-desoxyephedrine." *Drug Intell Clin Pharm* 22(3): 214-7.
- Fry, J. M. (1998). "Treatment modalities for narcolepsy." *Neurology* 50(2 Suppl 1): S43-8.
- George, H. R. (1970). "A case of the Kleine-Levin syndrome of long duration." *Br J Psychiatry* 117(540): 521-3.
- Goldstein, D. J., A. H. Rampey, Jr., et al. (1993). "Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction." *J Clin Psychiatry* 54(8): 309-16.
- Grabowski, J., J. Shearer, J. Merrill and S. S. Negus (2004). "Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence." *Addict Behav* 29(7): 1439-64.
- Greenhill, L. L. (2006). "The science of stimulant abuse." *Pediatr Ann* 35(8): 552-6.
- Halpern, J. H. (1999). "Treatment of attention-deficit/hyperactivity disorder." *JAMA* 281(16): 1491.
- Herman-Stahl, M. A., C. P. Krebs, et al. (2006). "Risk and protective factors for nonmedical use of prescription stimulants and methamphetamine among adolescents." *J Adolesc Health* 39(3): 374-80.
- Herting, R. L. and G. Dillon (1966). "Acute clinical assay for appetite suppression." *J New Drugs* 6(4): 232-6.
- Joffe, G. M. and T. Kasnic (1994). "Medical prescription of dextroamphetamine during pregnancy." *J Perinatol* 14(4): 301-3.
- Johnson, F. G. (1970). "A comparison of short-term treatment effects of intravenous sodium amytal-methedrine and LSD in the alcoholic." *Can Psychiatr Assoc J* 15(5): 493-7.
- Kiloh, L. G., M. Neilson, et al. (1974). "Response of depressed patients to methylamphetamine." *Br J Psychiatry* 125: 496-9.
- Kohl, R. L., D. S. Calkins, et al. (1986). "Arousal and stability: the effects of five new sympathomimetic drugs suggest a new principle for the prevention of space motion sickness." *Aviat Space Environ Med* 57(2): 137-43.
- Kroutil, L. A., D. L. Van Brunt, et al. (2006). "Nonmedical use of prescription stimulants in the United States." *Drug Alcohol Depend.*
- LeRiche, W. H. and A. Csimas (1967). "Trial of appetite suppressant. Study of a short-acting and sustained release appetite suppressant on patients paired by initial weight." *Appl Ther* 9(3): 260-2.
- Linquette, A. and P. Fossati (1971). "[Hunger control with benzphetamine hydrochloride in the treatment of obesity]." *Lille Med* 16: Suppl 2:620-4.
- Littner, M., S. F. Johnson, et al. (2001). "Practice parameters for the treatment of narcolepsy: An update for 2000." *Sleep* 24(4): 451-66.
- Matthews, C. (1970). "Overweight relapse: Effects of training and methamphetamine with pentobarbital." *Curr Ther Res Clin Exp* 12(1): 34-9.
- Mitler, M. M. (1994). "Evaluation of treatment with stimulants in narcolepsy." *Sleep* 17(8 Suppl): S103-6.
- Mitler, M. M. (1993). "Daytime sleepiness and cognitive functioning in sleep apnea." *Sleep* 16(8 Suppl): S68-70.
- Mitler, M. M., M. Erman, et al. (1993). "The treatment of excessive somnolence with stimulant drugs." *Sleep* 16(3): 203-6.
- Mitler, M. M., R. Hajdukovic, et al. (1993). "Treatment of narcolepsy with methamphetamine." *Sleep* 16(4): 306-17.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.
- NTP-CERHR (2005). "NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines." *NTP CEHR Mon*(16): i-III1.
- Piccini, P., N. Pavese, et al. (2005). "Factors affecting the clinical outcome after neural transplantation in Parkinson's disease." *Brain* 128(Pt 12): 2977-86.
- Piccini, P., N. Pavese, et al. (2003). "Endogenous dopamine release after pharmacological challenges in Parkinson's disease." *Ann Neurol* 53(5): 647-53.
- Piccini, P., D. J. Brooks, et al. (1999). "Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient." *Nat Neurosci* 2(12): 1137-40.
- Pope, H. G., Jr. and J. I. Hudson (1986). "Antidepressant drug therapy for bulimia: Current status." *J Clin Psychiatry* 47(7): 339-45.
- Popper, C. W. (1997). "Antidepressants in the treatment of attention-deficit/hyperactivity disorder." *J Clin Psychiatry* 58 Suppl 14: 14-29; discussion 30-1.



- Rothman, T. and K. Sward (1956). "Studies in pharmacological psychotherapy. I. Treatment of refractory psychoneuroses and personality disorders with thiopental (pentothal) sodium and methamphetamine (desoxy)." *AMA Arch Neurol Psychiatry* 75(1): 95-105.
- Scharf, M. B., D. Brown, et al. (1985). "The effects and effectiveness of gamma-hydroxybutyrate in patients with narcolepsy." *J Clin Psychiatry* 46(6): 222-5.
- Shearer, J., J. Sherman, et al. (2002). "Substitution therapy for amphetamine users." *Drug Alcohol Rev* 21(2): 179-85.
- Shearer, J., A. Wodak, R. P. Mattick, I. Van Beek, J. Lewis, W. Hall and K. Dolan (2001). "Pilot randomized controlled study of dexamphetamine substitution for amphetamine dependence." *Addiction* 96(9): 1289-96.
- Silver, D., H. E. Lehmann, et al. (1968). "Experimental geriatrics. Selection and prediction of therapeutic responsiveness in geriatric patients." *Can Psychiatr Assoc J* 13(6): 561-3.
- Smirnov, A. V. (1990). "[Psychomotor stimulants as agents for enhancing work capacity]." *Farmakol Toksikol* 53(4): 72-7.
- Stevenson, I., J. Buckman, et al. (1974). "The use of drugs in psychiatric interviews: Some interpretations based on controlled experiments." *Am J Psychiatry* 131(6): 707-10.
- Straker, M. (1953). "Intravenous methamphetamine, adjuvant to psychotherapy." *Am J Psychiatry* 109(11): 853-5.
- Sulzer, D., M. S. Sonders, et al. (2005). "Mechanisms of neurotransmitter release by amphetamines: A review." *Prog Neurobiol* 75(6): 406-33.
- Tola-Arribas, M. A., J. M. Zarco-Tejada, et al. (1997). "[Homer's syndrome secondary to ophthalmic herpes zoster]." *Rev Neurol* 25(148): 1922-4.
- Tolstoi, L. G. (1989). "The role of pharmacotherapy in anorexia nervosa and bulimia." *J Am Diet Assoc* 89(11): 1640-6.
- Wyman, J. F. and J. T. Cody (2005). "Determination of l-methamphetamine: A case history." *J Anal Toxicol* 29(7): 759-61.
- Yoss, R. E., N. J. Moyer, et al. (1969). "The pupillogram and narcolepsy. A method to measure decreased levels of wakefulness." *Neurology* 19(10): 921-8.
- Yoss, R. E. and D. D. Daly (1968). "On the treatment of narcolepsy." *Med Clin North Am* 52(4): 781-7.
- Young, G. C. and R. T. Morgan (1973). "Rapidity of response to the treatment of enuresis." *Dev Med Child Neurol* 15(4): 488-96.
- Young, G. C. and R. K. Turner (1965). "CNS stimulant drugs and conditioning treatment of nocturnal enuresis." *Behav Res Ther* 3(2): 93-101.
- Young, H. B. (1963). "Treatment of hiccup." *Br Med J* 5329: 543-4.

## Memory

*See also* Cognition; Cognition (animals)

- Bechara, A., S. Dolan, et al. (2001). "Decision-making deficits, linked to a dysfunctional ventromedial prefrontal cortex, revealed in alcohol and stimulant abusers." *Neuropsychologia* 39(4): 376-89.
- Chana, G., I. P. Everall, et al. (2006). "Cognitive deficits and degeneration of interneurons in HIV+ methamphetamine users." *Neurology* 67(8): 1486-9.
- Hoffman, W. F., M. Moore, et al. (2006). "Neuropsychological function and delay discounting in methamphetamine-dependent individuals." *Psychopharmacology (Berl)* 188(2): 162-70.
- Lundqvist, T. (2005). "Cognitive consequences of cannabis use: Comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions." *Pharmacol Biochem Behav* 81(2): 319-30.
- McKetin, R. and R. P. Mattick (1998). "Attention and memory in illicit amphetamine users: Comparison with non-drug-using controls." *Drug Alcohol Depend* 50(2): 181-4.
- Meredith, C. W., C. Jaffe, et al. (2005). "Implications of chronic methamphetamine use: A literature review." *Harv Rev Psychiatry* 13(3): 141-54.
- Mohs, R. C., J. R. Tinklenberg, et al. (1980). "Sensitivity of some human cognitive functions to effects of methamphetamine and secobarbital." *Drug Alcohol Depend* 5(2): 145-50.
- Nordahl, T. E., R. Salo, et al. (2003). "Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review." *J Neuropsychiatry Clin Neurosci* 15(3): 317-25.
- Sim, T., S. L. Simon, et al. (2002). "Cognitive deficits among methamphetamine users with attention deficit hyperactivity disorder symptomatology." *J Addict Dis* 21(1): 75-89.
- Simon, S. L., J. Dacey, et al. (2004). "The effect of relapse on cognition in abstinent methamphetamine abusers." *J Subst Abuse Treat* 27(1): 59-66.
- Simon, S. L., C. P. Domier, et al. (2002). "Cognitive performance of current methamphetamine and cocaine abusers." *J Addict Dis* 21(1): 61-74.

- Simon, S. L., C. Domier, et al. (2000). "Cognitive impairment in individuals currently using methamphetamine." *Am J Addict* 9(3): 222-31.
- Struthers, J. M. and R. L. Hansen (1992). "Visual recognition memory in drug-exposed infants." *J Dev Behav Pediatr* 13(2): 108-11.
- Thompson, P. M., K. M. Hayashi, et al. (2004). "Structural abnormalities in the brains of human subjects who use methamphetamine." *J Neurosci* 24(26): 6028-36.
- Volkow, N. D., L. Chang, et al. (2001). "Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence." *J Neurosci* 21(23): 9414-8.
- Wang, G. J., N. D. Volkow, et al. (2004). "Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence." *Am J Psychiatry* 161(2): 242-8.
- Woods, S. P., J. D. Rippeth, et al. (2005). "Deficient strategic control of verbal encoding and retrieval in individuals with methamphetamine dependence." *Neuropsychology* 19(1): 35-43.

### Men

*See also Gay Men/Men who Have Sex with Men; Heterosexuals; Sex Differences; and other populations*

- Anonymous (2006). "Methamphetamine use and HIV risk behaviors among heterosexual men--preliminary results from five northern California counties, December 2001-November 2003." *MMWR Morb Mortal Wkly Rep* 55(10): 273-7.
- Bae, S. C., I. K. Lyoo, et al. (2006). "Increased white matter hyperintensities in male methamphetamine abusers." *Drug Alcohol Depend* 81(1): 83-8.
- Chiang, S. C., H. Y. Chan, et al. (2006). "Recidivism among male subjects incarcerated for illicit drug use in Taiwan." *Psychiatry Clin Neurosci* 60(4): 444-51.
- Mitchell, S. J., S. R. Morris, et al. (2006). "Methamphetamine use and sexual activity among HIV-infected patients in care--San Francisco, 2004." *AIDS Patient Care STDS* 20(7): 502-10.
- Nyamathi, A. M., E. L. Dixon, et al. (2006). "Hepatitis C virus infection among homeless men referred from a community clinic." *West J Nurs Res* 28(4): 475-88.
- Wohl, A. R., D. F. Johnson, et al. (2002). "HIV risk behaviors among African American men in Los Angeles County who self-identify as heterosexual." *J Acquir Immune Defic Syndr* 31(3): 354-60.

### Mental Health and Illness

*See also Attention Deficit Hyperactivity Disorder; Cognition; Depression; Mood; Psychosis*

- Akiyama, K. (2006). "Longitudinal clinical course following pharmacological treatment of methamphetamine psychosis which persists after long-term abstinence." *Ann N Y Acad Sci* 1074: 125-34.
- Baker, A. and S. Dawe (2005). "Amphetamine use and co-occurring psychological problems: Review of the literature and implications for treatment." *Australian Psychologist* 40(2): 88-95.
- Baker, A., N. K. Lee, et al. (2004). "Drug use patterns and mental health of regular amphetamine users during a reported 'heroin drought'." *Addiction* 99(7): 875-84.
- Barr, A. M., W. J. Panenka, et al. (2006). "The need for speed: An update on methamphetamine addiction." *J Psychiatry Neurosci* 31(5): 301-313.
- Batki, S. L. and D. S. Harris (2004). "Quantitative drug levels in stimulant psychosis: Relationship to symptom severity, catecholamines and hyperkinesia." *Am J Addict* 13(5): 461-70.
- Booth, B. M., C. Leukefeld, et al. (2006). "Correlates of rural methamphetamine and cocaine users: Results from a multistate community study." *J Stud Alcohol* 67(4): 493-501.
- Braestrup, C. (1977). "Biochemical differentiation of amphetamine vs methylphenidate and nomifensine in rats." *J Pharm Pharmacol* 29(8): 463-70.
- Brecht, M. L., L. Greenwell, et al. (2005). "Methamphetamine treatment: Trends and predictors of retention and completion in a large state treatment system (1992-2002)." *J Subst Abuse Treat* 29(4): 295-306.
- Brown, E. S., V. A. Nejtck, D. C. Perantie, N. Rajan Thomas and A. J. Rush (2003). "Cocaine and amphetamine use in patients with psychiatric illness: A randomized trial of typical antipsychotic continuation or discontinuation." *J Clin Psychopharmacol* 23(4): 384-8.
- Buffenstein, A., J. Heaster, et al. (1999). "Chronic psychotic illness from methamphetamine." *Am J Psychiatry* 156(4): 662.
- Caetano, R. and C. Weisner (1995). "The association between DSM-III-R alcohol dependence, psychological distress and drug use." *Addiction* 90(3): 351-9.

- Camacho, A. and H. S. Akiskal (2005). "Proposal for a bipolar-stimulant spectrum: Temperament, diagnostic validation and therapeutic outcomes with mood stabilizers." *J Affect Disord* 85(1-2): 217-30.
- Carnwath, T., T. Garvey and M. Holland (2002). "The prescription of dexamphetamine to patients with schizophrenia and amphetamine dependence." *J Psychopharmacol* 16(4): 373-7.
- Chen, C. K., S. K. Lin, et al. (2005). "Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis." *Am J Med Genet B Neuropsychiatr Genet* 136(1): 87-91.
- Chen, C. K., X. Hu, et al. (2004). "Association analysis of dopamine D2-like receptor genes and methamphetamine abuse." *Psychiatr Genet* 14(4): 223-226.
- Chen, C. K., S. K. Lin, et al. (2003). "Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis." *Psychol Med* 33(8): 1407-14.
- Clatts, M. C., L. Goldsamt, et al. (2005). "Homelessness and drug abuse among young men who have sex with men in New York city: a preliminary epidemiological trajectory." *J Adolesc* 28(2): 201-14.
- Colfax, G., T. J. Coates, et al. (2005). "Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of San Francisco men who have sex with men." *J Urban Health* 82(1 Suppl 1): i62-70.
- Cookson, J. and T. Silverstone (1986). "The effects of methylamphetamine on mood and appetite in depressed patients: A placebo-controlled study." *Int Clin Psychopharmacol* 1(2): 127-33.
- Copeland, A. L. and J. L. Sorensen (2001). "Differences between methamphetamine users and cocaine users in treatment." *Drug Alcohol Depend* 62(1): 91-5.
- Davidson, C., A. J. Gow, et al. (2001). "Methamphetamine neurotoxicity: Necrotic and apoptotic mechanisms and relevance to human abuse and treatment." *Brain Res Brain Res Rev* 36(1): 1-22.
- Derlet, R. W. and B. Heischouer (1990). "Methamphetamine. Stimulant of the 1990s?" *West J Med* 153(6): 625-8.
- Dore, G. and M. Sweeting (2006). "Drug-induced psychosis associated with crystalline methamphetamine." *Australas Psychiatry* 14(1): 86-9.
- Edakubo, T., T. Kaneko, et al. (1991). "[Secondary development of psychological dependence in a methamphetamine dependent]." *Arukuru Kenkyuto Yakubutsu Ison* 26(2): 96-104.
- Ellinwood, E. H., Jr., A. Sudilovsky, et al. (1973). "Olfactory forebrain seizures induced by methamphetamine and disulfiram." *Biol Psychiatry* 7(2): 89-99.
- Ellison, G. (2002). "Neural degeneration following chronic stimulant abuse reveals a weak link in brain, fasciculus retroflexus, implying the loss of forebrain control circuitry." *Eur Neuropsychopharmacol* 12(4): 287-97.
- Farrell, M., J. Marsden, et al. (2002). "Methamphetamine: Drug use and psychoses becomes a major public health issue in the Asia Pacific region." *Addiction* 97(7): 771-2.
- Galloway, G. P., J. Newmeyer, et al. (1996). "A controlled trial of imipramine for the treatment of methamphetamine dependence." *J Subst Abuse Treat* 13(6): 493-7.
- Goldstein, D. J., A. H. Rampey, Jr., et al. (1993). "Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction." *J Clin Psychiatry* 54(8): 309-16.
- Gunter, T. D., D. W. Black, et al. (2004). "Drug and alcohol treatment services effective for methamphetamine abuse." *Ann Clin Psychiatry* 16(4): 195-200.
- Halkitis, P. N. and M. T. Shrem (2006). "Psychological differences between binge and chronic methamphetamine using gay and bisexual men." *Addict Behav* 31(3): 549-52.
- Hall, W., J. Hando, et al. (1996). "Psychological morbidity and route of administration among amphetamine users in Sydney, Australia." *Addiction* 91(1): 81-7.
- Hall, W., S. Darke, et al. (1993). "Patterns of drug use and risk-taking among injecting amphetamine and opioid drug users in Sydney, Australia." *Addiction* 88(4): 509-16.
- Harajiri, S., H. Kojima, et al. (1986). "Synergism between methamphetamine and alcohol in a case of methamphetamine psychosis." *Kurume Med J* 33(4): 163-5.
- Harano, M., N. Uchimura, et al. (2004). "A polymorphism of DRD2 gene and brain atrophy in methamphetamine psychosis." *Ann N Y Acad Sci* 1025: 307-15.
- Harris, D. and S. L. Batki (2000). "Stimulant psychosis: Symptom profile and acute clinical course." *Am J Addict* 9(1): 28-37.
- Hartel-Petri, R., R. Rodler, et al. (2005). "[Increasing prevalence of amphetamine--and methamphetamine-induced psychosis]." *Psychiatr Prax* 32(1): 13-7.
- Hashimoto, T., K. Hashimoto, et al. (2005). "A functional glutathione S-transferase P1 gene polymorphism is associated with methamphetamine-induced psychosis in Japanese population." *Am J Med Genet B Neuropsychiatr Genet* 135(1): 5-9.
- Hoffman, W. F., M. Moore, et al. (2006). "Neuropsychological function and delay discounting in methamphetamine-dependent individuals." *Psychopharmacology (Berl)* 188(2): 162-70.

- Ide, S., H. Kobayashi, et al. (2006). "Linkage disequilibrium and association with methamphetamine dependence/psychosis of mu-opioid receptor gene polymorphisms." *Pharmacogenomics J* 6(3): 179-88.
- Ide, S., H. Kobayashi, et al. (2004). "Gene polymorphisms of the mu opioid receptor in methamphetamine abusers." *Ann N Y Acad Sci* 1025: 316-24.
- Ikeda, M., N. Iwata, et al. (2006). "Positive association of AKT1 haplotype to Japanese methamphetamine use disorder." *Int J Neuropsychopharmacol* 9(1): 77-81.
- Inada, T., Y. Iijima, et al. (2004). "No association found between the type 1 sigma receptor gene polymorphisms and methamphetamine abuse in the Japanese population: a collaborative study by the Japanese Genetics Initiative for Drug Abuse." *Ann N Y Acad Sci* 1025: 27-33.
- Iwanami, A., D. Kuwakado, et al. (1997). "Relapse of panic disorder induced by a single intravenous methamphetamine injection." *J Anxiety Disord* 11(1): 113-6.
- Iwanami, A., R. Kanamori, et al. (1995). "Reduced attention-related negative potentials in methamphetamine psychosis." *J Nerv Ment Dis* 183(11): 693-7.
- Iwanami, A., I. Suga, et al. (1994). "P300 component of event-related potentials in methamphetamine psychosis and schizophrenia." *Prog Neuropsychopharmacol Biol Psychiatry* 18(3): 465-75.
- Iwanami, A., I. Suga, et al. (1993). "Event-related potentials in methamphetamine psychosis during an auditory discrimination task. A preliminary report." *Eur Arch Psychiatry Clin Neurosci* 242(4): 203-8.
- Iwanami, A., N. Kato, et al. (1991). "P300 in methamphetamine psychosis." *Biol Psychiatry* 30(7): 726-30.
- Iwata, N., T. Inada, et al. (2004). "No association is found between the candidate genes of t-PA/plasminogen system and Japanese methamphetamine-related disorder: A collaborative study by the Japanese Genetics Initiative for Drug Abuse." *Ann N Y Acad Sci* 1025: 34-8.
- Iyo, M., Y. Sekine and N. Mori (2004). "Neuromechanism of developing methamphetamine psychosis: A neuroimaging study." *Ann N Y Acad Sci* 1025: 288-95.
- Iyo, M., Y. Sekine, et al. (1999). "Methamphetamine-associated obsessional symptoms and effective risperidone treatment: A case report." *J Clin Psychiatry* 60(5): 337-8.
- Iyo, M., M. Nishio, et al. (1993). "Dopamine D2 and serotonin S2 receptors in susceptibility to methamphetamine psychosis detected by positron emission tomography." *Psychiatry Res* 50(4): 217-31.
- Iyo, M. (1992). "PET dopamine D2 receptors and susceptibility to methamphetamine psychosis." *Clin Neuropharmacol* 15 Suppl 1 Pt A: 652A-653A.
- John, D., C. F. Kwiatkowski, et al. (2001). "Differences among out-of-treatment drug injectors who use stimulants only, opiates only or both: implications for treatment entry." *Drug Alcohol Depend* 64(2): 165-72.
- Jones, K. (2005). "Methamphetamine, the brain, HIV, and mental health." *Focus* 20(6): 1-5.
- Joosen, M., T. F. Garrity, et al. (2005). "Predictors of current depressive symptoms in a sample of drug court participants." *Subst Use Misuse* 40(8): 1113-25.
- Kalechstein, A. D., T. F. Newton, et al. (2000). "Psychiatric comorbidity of methamphetamine dependence in a forensic sample." *J Neuropsychiatry Clin Neurosci* 12(4): 480-4.
- Kiloh, L. G., M. Neilson, et al. (1974). "Response of depressed patients to methylamphetamine." *Br J Psychiatry* 125: 496-9.
- Kim, J. Y. and M. Fendrich (2002). "Gender differences in juvenile arrestees' drug use, self-reported dependence, and perceived need for treatment." *Psychiatr Serv* 53(1): 70-5.
- Kobayashi, H., H. Hata, et al. (2006). "Association analysis of delta-opioid receptor gene polymorphisms in methamphetamine dependence/psychosis." *Am J Med Genet B Neuropsychiatr Genet* 141(5): 482-6.
- Kobayashi, H., S. Ide, et al. (2004). "Study of association between alpha-synuclein gene polymorphism and methamphetamine psychosis/dependence." *Ann N Y Acad Sci* 1025: 325-34.
- Kojima, T., E. Matsushima, et al. (1990). "Eye movements in acute, chronic, and remitted schizophrenics." *Biol Psychiatry* 27(9): 975-89.
- Kojima, T., E. Matsushima, et al. (1986). "Visual perception process in amphetamine psychosis and schizophrenia." *Psychopharmacol Bull* 22(3): 768-73.
- Kresina, T. F., J. Normand, J. Khalsa, J. Mitty, T. Flanigan and H. Francis (2004). "Addressing the need for treatment paradigms for drug-abusing patients with multiple morbidities." *Clin Infect Dis* 38(Suppl 5): S398-401.
- Kurtz, S. P. (2005). "Post-circuit blues: Motivations and consequences of crystal meth use among gay men in Miami." *AIDS Behav* 9(1): 63-72.
- Kushel, M. B., J. A. Hahn, et al. (2005). "Revolving doors: Imprisonment among the homeless and marginally housed population." *Am J Public Health* 95(10): 1747-52.

- Lampinen, T. M., D. McGhee, et al. (2006). "Increased risk of "club" drug use among gay and bisexual high school students in British Columbia." *J Adolesc Health* 38(4): 458-61.
- Leamon, M. H., D. R. Gibson, R. D. Canning and L. Benjamin (2002). "Hospitalization of patients with cocaine and amphetamine use disorders from a psychiatric emergency service." *Psychiatr Serv* 53(11): 1461-6.
- Lehmann, H. E. and T. A. Ban (1971). "Effects of psychoactive drugs on conflict avoidance behavior in human subjects." *Act Nerv Super (Praha)* 13(2): 82-5.
- Lehmann, H. E., P. Black, et al. (1970). "The effect of psychostimulants on psychometric test performance with special reference to conflict avoidance behavior." *Curr Ther Res Clin Exp* 12(6): 390-3.
- Lin, S. K., D. Ball, et al. (2004). "Psychiatric comorbidity and gender differences of persons incarcerated for methamphetamine abuse in Taiwan." *Psychiatry Clin Neurosci* 58(2): 206-12.
- Liu, H. C., C. K. Chen, et al. (2006). "Association between dopamine receptor D1 A-48G polymorphism and methamphetamine abuse." *Psychiatry Clin Neurosci* 60(2): 226-31.
- Liu, H. C., S. K. Lin, et al. (2004). "DAT polymorphism and diverse clinical manifestations in methamphetamine abusers." *Psychiatr Genet* 14(1): 33-7.
- London, E. D., S. L. Simon, et al. (2004). "Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers." *Arch Gen Psychiatry* 61(1): 73-84.
- Martin, I., T. M. Lampinen, et al. (2006). "Methamphetamine use among marginalized youth in British Columbia." *Can J Public Health* 97(4): 320-4.
- Martin Alisky, J. (2006). "Cholinesterase inhibitors might alleviate methamphetamine-induced delusions, hallucinations and cognitive impairment, while reducing craving and addiction." *World J Biol Psychiatry* 7(4): 269.
- Matsumoto, T., A. Kamijo, et al. (2002). "Methamphetamine in Japan: The consequences of methamphetamine abuse as a function of route of administration." *Addiction* 97(7): 809-17.
- Maxwell, J. C. and R. T. Spence (2005). "Profiles of club drug users in treatment." *Subst Use Misuse* 40(9): 1409-26.
- McGregor, C., M. Srisurapanont, et al. (2005). "The nature, time course and severity of methamphetamine withdrawal." *Addiction* 100(9): 1320-9.
- McKetin, R., J. McLaren, et al. (2006). "The prevalence of psychotic symptoms among methamphetamine users." *Addiction* 101(10): 1473-8.
- Meredith, C. W., C. Jaffe, et al. (2005). "Implications of chronic methamphetamine use: A literature review." *Harv Rev Psychiatry* 13(3): 141-54.
- Mikami, T., N. Naruse, et al. (2003). "Determining vulnerability to schizophrenia in methamphetamine psychosis using exploratory eye movements." *Psychiatry Clin Neurosci* 57(4): 433-40.
- Miura, H., M. Fujiki, et al. (2006). "Prevalence and profile of methamphetamine users in adolescents at a juvenile classification home." *Psychiatry Clin Neurosci* 60(3): 352-7.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.
- Nakahara, Y. (1995). "Detection and diagnostic interpretation of amphetamines in hair." *Forensic Sci Int* 70(1-3): 135-53.
- Nagata, T., J. Oshima, et al. (2003). "Repetitive self-mutilation among Japanese eating disorder patients with drug use disorder: Comparison with patients with methamphetamine use disorder." *J Nerv Ment Dis* 191(5): 319-23.
- Nakamura, K., C. K. Chen, et al. (2006). "Association analysis of SOD2 variants with methamphetamine psychosis in Japanese and Taiwanese populations." *Hum Genet* 120(2): 243-52.
- Newton, T. F., J. D. Roache, et al. (2005). "Safety of intravenous methamphetamine administration during treatment with bupropion." *Psychopharmacology (Berl)* 182(3): 426-35.
- Newton, T. F., A. D. Kalechstein, S. Duran, N. Vansluis and W. Ling (2004). "Methamphetamine abstinence syndrome: Preliminary findings." *Am J Addict* 13(3): 248-55.
- Ohgake, S., K. Hashimoto, et al. (2005). "Functional polymorphism of the NQO2 gene is associated with methamphetamine psychosis." *Addict Biol* 10(2): 145-8.
- Ozaki, S. and K. Wada (2006). "Characteristics of methylphenidate dependence syndrome in psychiatric hospital settings." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 41(2): 89-99.
- Peck, J. A., C. J. Reback, et al. (2005). "Sustained reductions in drug use and depression symptoms from treatment for drug abuse in methamphetamine-dependent gay and bisexual men." *J Urban Health* 82(1 Suppl 1): i100-8.
- Peck, J. A., S. Shoptaw, et al. (2005). "HIV-associated medical, behavioral, and psychiatric characteristics of treatment-seeking, methamphetamine-dependent men who have sex with men." *J Addict Dis* 24(3): 115-32.
- Perdue, T., H. Hagan, et al. (2003). "Depression and HIV risk behavior among Seattle-area injection drug users and young men who have sex with men." *AIDS Educ Prev* 15(1): 81-92.

- Rawson, R. A., R. Gonzales, et al. (2005). "Methamphetamine use among treatment-seeking adolescents in Southern California: Participant characteristics and treatment response." *J Subst Abuse Treat* 29(2): 67-74.
- Rawson, R. A., A. Huber, et al. (2002). "Status of methamphetamine users 2-5 years after outpatient treatment." *J Addict Dis* 21(1): 107-19.
- Richards, J. R., R. W. Derlet, et al. (1997). "Methamphetamine toxicity: Treatment with a benzodiazepine versus a butyrophenone." *Eur J Emerg Med* 4(3): 130-5.
- Riehm, K. S., M. Y. Iguchi and M. D. Anglin (2002). "Depressive symptoms among amphetamine and cocaine users before and after substance abuse treatment." *Psychol Addict Behav* 16(4): 333-7.
- Rothman, R. B., B. E. Blough and M. H. Baumann (2002). "Appetite suppressants as agonist substitution therapies for stimulant dependence." *Ann N Y Acad Sci* 965: 109-26.
- Rothman, T. and K. Sward (1956). "Studies in pharmacological psychotherapy. I. Treatment of refractory psychoneuroses and personality disorders with thiopental (pentothal) sodium and methamphetamine (desoxy)." *AMA Arch Neurol Psychiatry* 75(1): 95-105.
- Sato, M. (2002). "[Basic and clinical studies on methamphetamine-related psychosis]." *Seishin Shinkeigaku Zasshi* 104(3): 179-90.
- Sato, M., Y. Numachi, et al. (1992). "Relapse of paranoid psychotic state in methamphetamine model of schizophrenia." *Schizophr Bull* 18(1): 115-22.
- Sato, M. (1992). "A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis." *Ann N Y Acad Sci* 654: 160-70.
- Sato, M., Y. Numachi, et al. (1992). "Relapse of paranoid psychotic state in methamphetamine model of schizophrenia." *Schizophr Bull* 18(1): 115-22.
- Sato, M. (1986). "Acute exacerbation of methamphetamine psychosis and lasting dopaminergic supersensitivity--A clinical survey." *Psychopharmacol Bull* 22(3): 751-6.
- Sato, M., C. C. Chen, et al. (1983). "Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis." *Biol Psychiatry* 18(4): 429-40.
- Sato, M. (1979). "[An experimental study of onset and relapse mechanisms of the chronic methamphetamine psychosis (author's transl)]." *Seishin Shinkeigaku Zasshi* 81(1): 21-32.
- Sattar, S. P., S. C. Bhatia, et al. (2004). "Potential benefits of quetiapine in the treatment of substance dependence disorders." *J Psychiatry Neurosci* 29(6): 452-7.
- Sekine, Y., Y. Minabe, et al. (2003). "Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms." *Am J Psychiatry* 160(9): 1699-701.
- Sekine, Y., Y. Minabe, et al. (2002). "Metabolite alterations in basal ganglia associated with methamphetamine-related psychiatric symptoms. A proton MRS study." *Neuropsychopharmacology* 27(3): 453-61.
- Sekine, Y., M. Iyo, et al. (2001). "Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET." *Am J Psychiatry* 158(8): 1206-14.
- Semple, S. J., J. Zians, et al. (2006). "Methamphetamine use, impulsivity, and sexual risk behavior among HIV-positive men who have sex with men." *J Addict Dis* 25(4): 105-14.
- Semple, S. J., J. Zians, et al. (2005). "Impulsivity and methamphetamine use." *J Subst Abuse Treat* 29(2): 85-93.
- Semple, S. J., I. Grant, et al. (2005). "Negative self-perceptions and sexual risk behavior among heterosexual methamphetamine users." *Substance Use & Misuse* 40(12): 1797-1810.
- Semple, S. J., T. L. Patterson, et al. (2004). "A comparison of injection and non-injection methamphetamine-using HIV positive men who have sex with men." *Drug Alcohol Depend* 76(2): 203-12.
- Semple, S. J., T. L. Patterson, et al. (2003). "Binge use of methamphetamine among HIV-positive men who have sex with men: pilot data and HIV prevention implications." *AIDS Educ Prev* 15(2): 133-47.
- Shoptaw, S., J. Peck, et al. (2003). "Psychiatric and substance dependence comorbidities, sexually transmitted diseases, and risk behaviors among methamphetamine-dependent gay and bisexual men seeking outpatient drug abuse treatment." *J Psychoactive Drugs* 35 Suppl 1: 161-8.
- Simons, J. S., M. N. Oliver, et al. (2005). "Methamphetamine and alcohol abuse and dependence symptoms: Associations with affect lability and impulsivity in a rural treatment population." *Addict Behav* 30(7): 1370-81.
- Soellner, R. (2005). "Club drug use in Germany." *Subst Use Misuse* 40(9): 1279-93.
- Sommers, I., D. Baskin, et al. (2006). "Methamphetamine use among young adults: Health and social consequences." *Addict Behav* 31(8): 1469-76.
- Srisurapanont, M., R. Ali, et al. (2003). "Psychotic symptoms in methamphetamine psychotic in-patients." *Int J Neuropsychopharmacol* 6(4): 347-52.

- Srisurapanont, M., P. Kittiratanapaiboon, et al. (2001). "Treatment for amphetamine psychosis." *Cochrane Database Syst Rev*(4): CD003026.
- Sommers, I., D. Baskin, et al. (2006). "Methamphetamine use among young adults: Health and social consequences." *Addict Behav* 31(8): 1469-76.
- Suzuki, A., K. Nakamura, et al. (2006). "An association study between catechol-O-methyl transferase gene polymorphism and methamphetamine psychotic disorder." *Psychiatr Genet* 16(4): 133-8.
- Szuster, R. R. (1990). "Methamphetamine in psychiatric emergencies." *Hawaii Med J* 49(10): 389-91.
- Thirthalli, J. and V. Benegal (2006). "Psychosis among substance users." *Curr Opin Psychiatry* 19(3): 239-45.
- Thorberg, F. A. and M. Lyvers (2006). "Negative Mood Regulation (NMR) expectancies, mood, and affect intensity among clients in substance disorder treatment facilities." *Addict Behav* 31(5): 811-20.
- Tomiyama, G. (1990). "Chronic schizophrenia-like states in methamphetamine psychosis." *Jpn J Psychiatry Neurol* 44(3): 531-9.
- Ujike, H. and M. Sato (2004). "Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis." *Ann N Y Acad Sci* 1025: 279-87.
- Ujike, H., M. Harano, et al. (2003). "Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis." *Pharmacogenomics J* 3(4): 242-7.
- Urbina, A. and K. Jones (2004). "Crystal methamphetamine, its analogues, and HIV infection: Medical and psychiatric aspects of a new epidemic." *Clin Infect Dis* 38(6): 890-4.
- Volkow, N. D. (2001). "Drug abuse and mental illness: Progress in understanding comorbidity." *Am J Psychiatry* 158(8): 1181-3.
- Wada, K., S. B. Greberman, et al. (1999). "HIV and HCV infection among drug users in Japan." *Addiction* 94(7): 1063-9.
- Wada, K. and S. Fukui (1990). "[Relationship between years of methamphetamine use and symptoms of methamphetamine psychosis]." *Arukuru Kenkyuto Yakubutsu Ison* 25(3): 143-58.
- Weiser, S. D., S. E. Dilworth, et al. (2006). "Gender-specific correlates of sex trade among homeless and marginally housed individuals in San Francisco." *J Urban Health* 83(4): 736-40.
- Wolkoff, D. A. (1997). "Methamphetamine abuse: An overview for health care professionals." *Hawaii Med J* 56(2): 34-6, 44.
- Won, M., Y. Minabe, Y. Sekine, N. Takei, N. Kondo and N. Mori (2003). "Manic-switch induced by fluvoxamine in abstinent pure methamphetamine abusers." *J Psychiatry Neurosci* 28(2): 134-5.
- Yamashita, I., T. Moroji, et al. (1969). "Neuroendocrinological studies in mental disorders and psychotropic drugs. I. On the circadian rhythm of the plasma adrenocortical hormone in mental patients and methamphetamine- and chlorpromazine-treated animals." *Folia Psychiatr Neurol Jpn* 23(2): 143-58.
- Yen, C. F. and M. Y. Chong (2006). "Comorbid psychiatric disorders, sex, and methamphetamine use in adolescents: A case-control study." *Compr Psychiatry* 47(3): 215-20.
- Yen, C. F. and Y. C. Su (2006). "The associations of early-onset methamphetamine use with psychiatric morbidity among Taiwanese adolescents." *Subst Use Misuse* 41(1): 35-44.
- Yen, C. F., Y. H. Yang, et al. (2006). "Correlates of methamphetamine use for Taiwanese adolescents." *Psychiatry Clin Neurosci* 60(2): 160-7.
- Yen, C. F. and Y. P. Chang (2005). "Relapse antecedents for methamphetamine use and related factors in Taiwanese adolescents." *Psychiatry Clin Neurosci* 59(1): 77-82.
- Yen, C. F. and B. L. Shieh (2005). "Suicidal ideation and correlates in Taiwanese adolescent methamphetamine users." *J Nerv Ment Dis* 193(7): 444-9.
- Yui, K., K. Goto, et al. (2004). "The role of noradrenergic and dopaminergic hyperactivity in the development of spontaneous recurrence of methamphetamine psychosis and susceptibility to episode recurrence." *Ann N Y Acad Sci* 1025: 296-306.
- Yui, K., S. Ikemoto, et al. (2003). "Susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosis." *J Clin Psychopharmacol* 23(5): 525-8.
- Yui, K., S. Ikemoto, et al. (2002). "Factors for susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosis." *Ann N Y Acad Sci* 965: 292-304.
- Yui, K., S. Ikemoto, et al. (2002). "Spontaneous recurrence of methamphetamine-induced paranoid-hallucinatory states in female subjects: Susceptibility to psychotic states and implications for relapse of schizophrenia." *Pharmacopsychiatry* 35(2): 62-71.
- Yui, K., K. Goto, et al. (2001). "Susceptibility to subsequent episodes of spontaneous recurrence of methamphetamine psychosis." *Drug Alcohol Depend* 64(2): 133-42.
- Yui, K., K. Goto, et al. (2000). "Increased sensitivity to stress in spontaneous recurrence of methamphetamine psychosis: Noradrenergic hyperactivity with contribution from dopaminergic hyperactivity." *J Clin Psychopharmacol* 20(2): 165-74.
- Yui, K., K. Goto, et al. (2000). "Stress induced spontaneous recurrence of methamphetamine psychosis: The relation between stressful experiences and sensitivity to stress." *Drug Alcohol Depend* 58(1-2): 67-75.

- Yui, K., S. Ikemoto, et al. (2000). "Studies of amphetamine or methamphetamine psychosis in Japan: Relation of methamphetamine psychosis to schizophrenia." *Ann N Y Acad Sci* 914: 1-12.
- Yui, K., T. Ishiguro, et al. (2000). "Susceptibility to subsequent episodes in spontaneous recurrence of methamphetamine psychosis." *Ann N Y Acad Sci* 914: 292-302.
- Yui, K., K. Goto, et al. (1999). "Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: The role of sensitization." *Mol Psychiatry* 4(6): 512-23.
- Yui, K., K. Goto, et al. (1999). "Increased sensitivity to stress and episode recurrence in spontaneous recurrence of methamphetamine psychosis." *Psychopharmacology (Berl)* 145(3): 267-72.
- Yui, K., T. Ishiguro, et al. (1999). "Spontaneous recurrence of methamphetamine psychosis: Increased sensitivity to stress associated with noradrenergic hyperactivity and dopaminergic change." *Eur Arch Psychiatry Clin Neurosci* 249(2): 103-11.
- Yui, K., T. Ishiguro, et al. (1998). "Factors affecting the development of spontaneous recurrence of methamphetamine psychosis." *Acta Psychiatr Scand* 97(3): 220-7.
- Yui, K., K. Goto, et al. (1997). "Methamphetamine psychosis: Spontaneous recurrence of paranoid-hallucinatory states and monoamine neurotransmitter function." *J Clin Psychopharmacol* 17(1): 34-43.
- Yui, K., K. Goto, S. Ikemoto and T. Ishiguro (1997). "Monoamine neurotransmitter metabolites and spontaneous recurrence of methamphetamine psychosis." *Brain Res Bull* 43(1): 25-33.
- Yui, K., T. Ishiguro, et al. (1997). "Precipitating factors in spontaneous recurrence of methamphetamine psychosis." *Psychopharmacology (Berl)* 134(3): 303-8.
- Yui, K., K. Goto, et al. (1997). "Noradrenergic activity and spontaneous recurrence of methamphetamine psychosis." *Drug Alcohol Depend* 44(2-3): 183-7.
- Yui, K., K. Goto, et al. (1996). "Plasma monoamine metabolites and spontaneous recurrence of methamphetamine-induced paranoid-hallucinatory psychosis: Relation of noradrenergic activity to the occurrence of flashbacks." *Psychiatry Res* 63(2-3): 93-107.
- Yui, K., K. Goto, et al. (1995). "Spontaneous recurrence of methamphetamine psychosis: Process and monoamine neurotransmitter function." *Nihon Shinkei Seishin Yakurigaku Zasshi* 15(4): 363-74.
- Yukitake, A. (1983). "Amphetamine psychosis in Tokyo--Its clinical features and social problems." *Folia Psychiatr Neurol Jpn* 37(2): 115-20.
- Zweben, J. E., J. B. Cohen, et al. (2004). "Psychiatric symptoms in methamphetamine users." *Am J Addict* 13(2): 181-90.

### Metabolic Acidosis

- Burchell, S. A., H. C. Ho, M. Yu and D. R. Margulies (2000). "Effects of methamphetamine on trauma patients: A cause of severe metabolic acidosis?" *Crit Care Med* 28(6): 2112-5.
- Horiguchi, T., S. Hori, et al. (1999). "A case of traumatic shock complicated by methamphetamine intoxication." *Intensive Care Med* 25(7): 758-60.

### Methadone Maintenance Treatment

- Peirce, J. M., N. M. Petry, et al. (2006). "Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: A National Drug Abuse Treatment Clinical Trials Network study." *Arch Gen Psychiatry* 63(2): 201-8.

### Methamphetamine, Medical Uses for

*See Medical Uses*

### Methamphetamine Abstinence Syndrome

*See also Former Methamphetamine Users*

- Kalechstein, A. D., T. F. Newton and M. Green (2003). "Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence." *J Neuropsychiatry Clin Neurosci* 15(2): 215-20.
- Kim, S. J., I. K. Lyoo, et al. (2005). "Prefrontal grey-matter changes in short-term and long-term abstinent methamphetamine abusers." *Int J Neuropsychopharmacol*: 1-8.
- Kim, S. J., I. K. Lyoo, et al. (2005). "Frontal glucose hypometabolism in abstinent methamphetamine users." *Neuropsychopharmacology* 30(7): 1383-91.
- London, E. D., S. L. Simon, S. M. Berman, M. A. Mandelkern, A. M. Lichtman, J. Bramen, A. K. Shinn, K. Miotto, J. Learn, Y. Dong, J. A. Matochik, V. Kurian, T. Newton, R. Woods, R. Rawson and W. Ling (2004). "Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers." *Arch Gen Psychiatry* 61(1): 73-84.



Newton, T. F., A. D. Kalechstein, S. Duran, N. Vansluis and W. Ling (2004). "Methamphetamine abstinence syndrome: Preliminary findings." *Am J Addict* 13(3): 248-55.

## Methamphetamine Laboratories and Manufacture

*See also* Adulterated and Contaminated Substances; Occupational Exposure; Methamphetamine Trafficking and Sale; Precursor Regulation

- Ahmad, K. (2003). "Asia grapples with spreading amphetamine abuse." *Lancet* 361(9372): 1878-9.
- Allen, A. and T. S. Cantrell (1989). "Synthetic reductions in clandestine amphetamine and methamphetamine laboratories: A review." *Forensic Sci Int* 42(3): 183-199.
- Anglin, M. D., C. Burke, et al. (2000). "History of the methamphetamine problem." *J Psychoactive Drugs* 32(2): 137-41.
- Anonymous (2006). "Cooking up solutions to a cooked up menace: Responses to methamphetamine in a federal system." *Harv Law Rev* 119(8): 2508-29.
- Anonymous (2005). "Anhydrous ammonia thefts and releases associated with illicit methamphetamine production--16 states, January 2000-June 2004." *MMWR Morb Mortal Wkly Rep* 54(14): 359-61.
- Anonymous (2005). "Acute public health consequences of methamphetamine laboratories--16 states, January 2000-June 2004." *MMWR Morb Mortal Wkly Rep* 54(14): 356-9.
- Anonymous (2000). "Public health consequences among first responders to emergency events associated with illicit methamphetamine laboratories--selected states, 1996-1999." *MMWR Morb Mortal Wkly Rep* 49(45): 1021-4.
- Barker, W. D. and U. Antia (2006). "A study of the use of Ephedra in the manufacture of methamphetamine." *Forensic Sci Int*.
- Boulard, G. (2005). "The meth menace: Battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.
- Brouwer, K. C., P. Case, et al. (2006). "Trends in production, trafficking, and consumption of methamphetamine and cocaine in Mexico." *Subst Use Misuse* 41(5): 707-27.
- Burgess, J. L., D. F. Kovalchick, et al. (2002). "Medical surveillance of clandestine drug laboratory investigators." *J Occup Environ Med* 44(2): 184-9.
- Burgess, J. L. (2001). "Phosphine exposure from a methamphetamine laboratory investigation." *J Toxicol Clin Toxicol* 39(2): 165-8.
- Burgess, J. L., S. Barnhart, et al. (1996). "Investigating clandestine drug laboratories: Adverse medical effects in law enforcement personnel." *Am J Ind Med* 30(4): 488-94.
- Burton, B. T. (1991). "Heavy metal and organic contaminants associated with illicit methamphetamine production." *NIDA Res Monogr* 115: 47-59.
- Caldicott, D. G., P. E. Pigou, et al. (2005). "Clandestine drug laboratories in Australia and the potential for harm." *Aust N Z J Public Health* 29(2): 155-62.
- Charukamnoetkanok, P. and M. D. Wagoner (2004). "Facial and ocular injuries associated with methamphetamine production accidents." *Am J Ophthalmol* 138(5): 875-6.
- Colker, A. C. (2005). "Restricting the sale of pseudoephedrine to prevent methamphetamine production." *NCSL Legisbrief* 13(7): 1-2.
- Danks, R. R., L. A. Wibbenmeyer, et al. (2004). "Methamphetamine-associated burn injuries: A retrospective analysis." *J Burn Care Rehabil* 25(5): 425-9.
- Dayrit, F. M. and M. C. Dumlao (2004). "Impurity profiling of methamphetamine hydrochloride drugs seized in the Philippines." *Forensic Sci Int* 144(1): 29-36.
- Derlet, R. W. and B. Heischouer (1990). "Methamphetamine. Stimulant of the 1990s?" *West J Med* 153(6): 625-8.
- Eccles, R. (2006). "Substitution of phenylephrine for pseudoephedrine as a nasal decongestant. An illogical way to control methamphetamine abuse." *Br J Clin Pharmacol*.
- Farst, K., J. M. Duncan, et al. (2006). "Methamphetamine exposure presenting as caustic ingestions in children." *Ann Emerg Med*.
- Frank, R. S. (1983). "The clandestine drug laboratory situation in the United States." *J Forensic Sci* 28(1): 18-31.
- Friese, G. (2006). "The methamphetamine crisis. What EMS providers need to know to stay safe and treat patients." *Emerg Med Serv* 35(3): 55-64.
- Fuller, K. (2005). "A dangerous business." *Occup Health Saf* 74(9): 188, 190-1.
- Goss, J. F. (1998). "Meth labs." *JEMS* 23(1): 50-2, 54, 56 passim.
- Hohman, M., R. Oliver, et al. (2004). "Methamphetamine abuse and manufacture: The child welfare response." *Soc Work* 49(3): 373-81.
- Irvine, G. D. and L. Chin (1991). "The environmental impact and adverse health effects of the clandestine manufacture of methamphetamine." *NIDA Res Monogr* 115: 33-46.

- Knops, L. A., D. M. Northrop, et al. (2006). "Capillary electrophoretic analysis of phosphorus species in clandestine methamphetamine laboratory samples." *J Forensic Sci* 51(1): 82-6.
- Lambrechts, M. and K. E. Rasmussen (1984). "Leuckart-specific impurities in amphetamine and methamphetamine seized in Norway." *Bull Narc* 36(1): 47-57.
- Lee, J. S., E. Y. Han, et al. (2006). "Analysis of the impurities in the methamphetamine synthesized by three different methods from ephedrine and pseudoephedrine." *Forensic Sci Int* 161(2-3): 209-215.
- Lee, J. H., C. L. Farley, et al. (2003). "Anhydrous ammonia eye injuries associated with illicit methamphetamine production." *Ann Emerg Med* 41(1): 157.
- Lineberry, T. W. and J. M. Bostwick (2006). "Methamphetamine abuse: A perfect storm of complications." *Mayo Clin Proc* 81(1): 77-84.
- Marris, E. (2005). "Police urge speedy action to clean up home drug factories." *Nature* 434(7030): 129.
- Mecham, N. and J. Melini (2002). "Unintentional victims: Development of a protocol for the care of children exposed to chemicals at methamphetamine laboratories." *Pediatr Emerg Care* 18(4): 327-32.
- Mitka, M. (2005). "Meth lab fires put heat on burn centers." *JAMA* 294(16): 2009-10.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.
- Person, E. C., J. A. Meyer, et al. (2005). "Structural determination of the principal byproduct of the lithium-ammonia reduction method of methamphetamine manufacture." *J Forensic Sci* 50(1): 87-95.
- Puder, K. S., D. V. Kagan, et al. (1988). "Illicit methamphetamine: analysis, synthesis, and availability." *Am J Drug Alcohol Abuse* 14(4): 463-73.
- Qi, Y., I. D. Evans, et al. (2006). "Australian Federal Police seizures of illicit crystalline methamphetamine ('ice') 1998-2002: Impurity analysis." *Forensic Sci Int* 164(2-3): 201-10.
- Qi, Y., I. Evans, et al. (2006). "New impurity profiles of recent Australian imported 'ice': Methamphetamine impurity profiling and the identification of (pseudo)ephedrine and Leuckart specific marker compounds." *Forensic Sci Int*.
- Romanelli, F. and K. M. Smith (2006). "Clinical effects and management of methamphetamine abuse." *Pharmacotherapy* 26(8): 1148-56.
- Santos, A. P., A. K. Wilson, et al. (2005). "Methamphetamine laboratory explosions: A new and emerging burn injury." *J Burn Care Rehabil* 26(3): 228-32.
- Sheridan, J., S. Bennett, et al. (2006). "Injury associated with methamphetamine use: A review of the literature." *Harm Reduct J* 3(1): 14.
- Spann, M. D., G. McGwin, Jr., et al. (2006). "Characteristics of burn patients injured in methamphetamine laboratory explosions." *J Burn Care Res* 27(4): 496-501.
- Sudakin, D. L. (2005). "Occupational exposure to aluminium phosphide and phosphine gas? A suspected case report and review of the literature." *Hum Exp Toxicol* 24(1): 27-33.
- Tanne, J. H. (2006). "Methamphetamine epidemic hits middle America." *BMJ* 332(7538): 382.
- Vandeveld, N. (2004). "Clandestine methamphetamine labs in Wisconsin." *J Environ Health* 66(7): 46-51.
- Vanek, M. (2002). "Ten steps for EMS survival at clandestine methamphetamine labs." *Emerg Med Serv* 31(4): 92, 96.
- Willers-Russo, L. J. (1999). "Three fatalities involving phosphine gas, produced as a result of methamphetamine manufacturing." *J Forensic Sci* 44(3): 647-52.
- Windahl, K. L., M. J. McTigue, et al. (1995). "Investigation of the impurities found in methamphetamine synthesized from pseudoephedrine by reduction with hydriodic acid and red phosphorus." *Forensic Sci Int* 76(2): 97-114.

### **Methamphetamine Psychosis**

*See Psychosis*

### **Methamphetamine Toxicity**

*See Neurotoxicity; Neurotoxicity (animals)*

### **Methamphetamine Trafficking and Sale**

*See also Adulterated and Contaminated Substances; Methamphetamine Laboratories and Manufacture*

- Boulard, G. (2005). "The meth menace: Battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.
- Brouwer, K. C., P. Case, et al. (2006). "Trends in production, trafficking, and consumption of methamphetamine and cocaine in Mexico." *Subst Use Misuse* 41(5): 707-27.

- Cruz, M. F., A. Mantsios, et al. (2006). "A qualitative exploration of gender in the context of injection drug use in two US-Mexico border cities." *AIDS Behav.*
- Glittenberg, J. and C. Anderson (1999). "Methamphetamines: Use and trafficking in the Tucson-Nogales area." *Subst Use Misuse* 34(14): 1977-89.
- Herman-Stahl, M. A., C. P. Krebs, et al. (2006). "Risk and protective factors for methamphetamine use and nonmedical use of prescription stimulants among young adults aged 18 to 25." *Addict Behav.*
- Hopfer, C., B. Mendelson, et al. (2006). "Club drug use among youths in treatment for substance abuse." *Am J Addict* 15(1): 94-9.
- Inoue, H., T. Kanamori, et al. (2003). "Methamphetamine impurity profiling using a 0.32 mm i.d. nonpolar capillary column." *Forensic Sci Int* 135(1): 42-7.
- Kulsudjarit, K. (2004). "Drug problem in southeast and southwest Asia." *Ann N Y Acad Sci* 1025: 446-57.
- Kushel, M. B., J. A. Hahn, et al. (2005). "Revolving doors: Imprisonment among the homeless and marginally housed population." *Am J Public Health* 95(10): 1747-52.
- Puder, K. S., D. V. Kagan, et al. (1988). "Illicit methamphetamine: analysis, synthesis, and availability." *Am J Drug Alcohol Abuse* 14(4): 463-73.
- Senjo, S. R. (2005). "Trafficking in meth: An analysis of the differences between male and female dealers." *J Drug Educ* 35(1): 59-77.
- Stamler, R. T., R. C. Fahlman, et al. (1983). "Recent trends in illicit drug trafficking from the Canadian perspective." *Bull Narc* 35(4): 23-32.
- Storr, C. L., A. M. Arria, et al. (2004). "Neighborhood environment and opportunity to try methamphetamine ("ice") and marijuana: Evidence from Guam in the Western Pacific region of Micronesia." *Subst Use Misuse* 39(2): 253-76.
- Yamamoto, J. (2004). "Recent trends of drug abuse in Japan." *Ann N Y Acad Sci* 1025: 430-8.

## Methylphenidate (Ritalin™)

- Castaneda, R., N. Sussman, et al. (1999). "A treatment algorithm for attention deficit hyperactivity disorder in cocaine-dependent adults: A one-year private practice study with long-acting stimulants, fluoxetine, and bupropion." *Subst Abuse* 20(1): 59-71.
- Crump, G. P. (1963). "Narcolepsy. A discussion and case presentation." *Proc Wkly Semin Neurol* 15: 6-20.
- Dement, W. C., M. A. Carskadon, et al. (1976). "Narcolepsy. Diagnosis and treatment." *Prim Care* 3(4): 609-23.
- Dement, W. C. (1979). "Narcolepsy--not as rare as we believed!" *Med Times* 107(6): 51-5.
- Estler, C. J. (1973). "[Drug interference and incompatibilities of drugs attacking the central nervous system. 2. Stimulants]." *Fortschr Med* 91(13): 574-6.
- Fry, J. M. (1998). "Treatment modalities for narcolepsy." *Neurology* 50(2 Suppl 1): S43-8.
- Greenhill, L. L. (2006). "The science of stimulant abuse." *Pediatr Ann* 35(8): 552-6.
- Gulati, O. D., B. T. Dave, et al. (1966). "Antagonism of adrenergic neuron blockade in hypertensive subjects." *Clin Pharmacol Ther* 7(4): 510-4.
- Han, D. D. and H. H. Gu (2006). "Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs." *BMC Pharmacol* 6: 6.
- Kishimoto, H. (2003). "[Stimulant dependence]." *Ryoikibetsu Shokogun Shirizu*(40): 505-6.
- Kohl, R. L., D. S. Calkins, et al. (1986). "Arousal and stability: the effects of five new sympathomimetic drugs suggest a new principle for the prevention of space motion sickness." *Aviat Space Environ Med* 57(2): 137-43.
- Kosman, M. E. and D. R. Unna (1968). "Effects of chronic administration of the amphetamines and other stimulants on behavior." *Clin Pharmacol Ther* 9(2): 240-54.
- Ladewig, D. and R. Battagay (1971). "Abuse of anorexics with special reference to newer substances." *Int J Addict* 6(1): 167-72.
- Lin, S. J., S. Y. Crawford, et al. (2005). "Trend and area variation in amphetamine prescription usage among children and adolescents in Michigan." *Soc Sci Med* 60(3): 617-26.
- Littner, M., S. F. Johnson, et al. (2001). "Practice parameters for the treatment of narcolepsy: An update for 2000." *Sleep* 24(4): 451-66.
- Martin, W. R., J. W. Sloan, et al. (1971). "Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man." *Clin Pharmacol Ther* 12(2): 245-58.
- Mitler, M. M. (1994). "Evaluation of treatment with stimulants in narcolepsy." *Sleep* 17(8 Suppl): S103-6.
- Ozaki, S. and K. Wada (2006). "Characteristics of methylphenidate dependence syndrome in psychiatric hospital settings." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 41(2): 89-99.
- Patel, A. N. (1972). "Self-inflicted strokes." *Ann Intern Med* 76(5): 823-4.

- Popper, C. W. (1997). "Antidepressants in the treatment of attention-deficit/hyperactivity disorder." *J Clin Psychiatry* 58 Suppl 14: 14-29; discussion 30-1.
- Volkow, N. D., G. J. Wang, et al. (2007). "Stimulant-induced enhanced sexual desire as a potential contributing factor in HIV transmission." *Am J Psychiatry* 164(1): 157-60.

### Methylphenidate (Ritalin™) (animals)

- Arakawa, O. (1994). "Effects of methamphetamine and methylphenidate on single and paired rat open-field behaviors." *Physiol Behav* 55(3): 441-6.
- Bondareva, T. S., R. Young, et al. (2002). "Central stimulants as discriminative stimuli. Asymmetric generalization between (-)ephedrine and S(+)-methamphetamine." *Pharmacol Biochem Behav* 74(1): 157-62.
- Caldwell, R. W. and L. I. Goldberg (1970). "An evaluation of the vasodilation produced by mephentermine and certain other sympathomimetic amines." *J Pharmacol Exp Ther* 172(2): 297-309.
- Czoty, P. W., A. Makriyannis, et al. (2004). "Methamphetamine discrimination and in vivo microdialysis in squirrel monkeys." *Psychopharmacology (Berl)* 175(2): 170-8.
- Chen, R., D. D. Han, et al. (2005). "A triple mutation in the second transmembrane domain of mouse dopamine transporter markedly decreases sensitivity to cocaine and methylphenidate." *J Neurochem* 94(2): 352-9.
- Fleckenstein, A. E., H. M. Haughey, et al. (1999). "Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function." *Eur J Pharmacol* 382(1): 45-9.
- Floran, B., L. Floran, et al. (2004). "Dopamine D4 receptors inhibit depolarization-induced [3H]GABA release in the rat subthalamic nucleus." *Eur J Pharmacol* 498(1-3): 97-102.
- Fog, R. (1972). "On stereotypy and catalepsy: Studies on the effect of amphetamines and neuroleptics in rats." *Acta Neurol Scand Suppl* 50: 3-66.
- Fog, R. (1969). "Stereotyped and non-stereotyped behaviour in rats induced by various stimulant drugs." *Psychopharmacologia* 14(4): 299-304.
- Franklin, K. B. and L. J. Herberg (1974). "Self-stimulation and catecholamines: Drug-induced mobilization of the 'reserve'-pool re-establishes responding in catecholamine-depleted rats." *Brain Res* 67(3): 429-37.
- Fukui, R., P. Svenningsson, et al. (2003). "Effect of methylphenidate on dopamine/DARPP signalling in adult, but not young, mice." *J Neurochem* 87(6): 1391-401.
- Han, D. D. and H. H. Gu (2006). "Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs." *BMC Pharmacol* 6: 6.
- Hanson, G. R., V. Sandoval, et al. (2004). "Psychostimulants and vesicle trafficking: A novel mechanism and therapeutic implications." *Ann N Y Acad Sci* 1025: 146-50.
- Hasebe, Y., H. Ono, et al. (1989). "Enhancement of spinal monosynaptic reflexes with phenylethylamine and related drugs through descending noradrenergic neurons." *J Pharmacobiodyn* 12(4): 241-5.
- Hasebe, Y., H. Ono, et al. (1989). "The most desirable conformation of phenylethylamine (PEA) moiety stimulating noradrenergic neurons: effects of PEA, methamphetamine, phenelzine, methylphenidate, nomifensine and mazindol on rat spinal reflexes." *Gen Pharmacol* 20(3): 375-9.
- Hirabayashi, M. and S. Okada (1985). "[Development of reverse tolerance to the ambulation-increasing effect of ephedrine after repeated administration in mice]." *Yakubutsu Seishin Kodo* 5(3): 231-41.
- Hirabayashi, M., S. Okada, et al. (1983). "[Characteristics of reverse tolerance to ambulation-increasing effect of methylphenidate after repeated administration in mice]." *Yakubutsu Seishin Kodo* 3(3): 117-26.
- Honma, S. and K. Honma (1992). "Locomotor rhythms induced by methylphenidate in suprachiasmatic nuclei-lesioned rats." *Neurosci Lett* 137(1): 24-8.
- Huang, J. T. and B. T. Ho (1974). "Discriminative stimulus properties of d-amphetamine and related compounds in rats." *Pharmacol Biochem Behav* 2(5): 669-73.
- Hughes, R. N. and A. M. Greig (1976). "Effects of caffeine, methamphetamine and methylphenidate on reactions to novelty and activity in rats." *Neuropharmacology* 15(11): 673-6.
- Ida, I., T. Asami, et al. (1990). "[Characteristics of antagonism between ceruletide and various central-acting drugs: Investigation by means of ambulatory activity in mice]." *Nippon Yakurigaku Zasshi* 96(6): 333-41.
- Ishiguro, Y. and J. P. Morgan (1997). "Biphasic inotropic effects of methamphetamine and methylphenidate on ferret papillary muscles." *J Cardiovasc Pharmacol* 30(6): 744-9.
- Itzhak, Y. and S. F. Ali (2006). "Role of nitergic system in behavioral and neurotoxic effects of amphetamine analogs." *Pharmacol Ther* 109(1-2): 246-62.

- Itzhak, Y. and J. L. Martin (2002). "Cocaine-induced conditioned place preference in mice: Induction, extinction and reinstatement by related psychostimulants." *Neuropsychopharmacology* 26(1): 130-4.
- Itzhak, Y. and J. L. Martin (2000). "Effect of riluzole and gabapentin on cocaine- and methamphetamine-induced behavioral sensitization in mice." *Psychopharmacology (Berl)* 151(2-3): 226-33.
- Jones, D. N. and S. G. Holtzman (1994). "Influence of naloxone upon motor activity induced by psychomotor stimulant drugs." *Psychopharmacology (Berl)* 114(2): 215-24.
- Kaneyuki, T., M. Kohsaka, et al. (1979). "Sex hormones metabolism in the brain: Influence of central acting drugs on 5 alpha-reduction in rat diencephalon." *Endocrinol Jpn* 26(3): 345-51.
- Kelfer, D. A. and A. J. Rosen (1974). "Effects of metamphetamine, pipradrol and methylphenidate on instrumental conditioning and spontaneous motor activity in the immature rat." *Psychopharmacologia* 35(4): 317-26.
- Kilgore, B. S., L. C. Dickinson, et al. (1979). "Alterations in cartilage metabolism by neurostimulant drugs." *J Pediatr* 94(4): 542-5.
- Kosman, M. E. and D. R. Unna (1968). "Effects of chronic administration of the amphetamines and other stimulants on behavior." *Clin Pharmacol Ther* 9(2): 240-54.
- Kuczenski, R. and D. S. Segal (2002). "Exposure of adolescent rats to oral methylphenidate: Preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine." *J Neurosci* 22(16): 7264-71.
- Mach, R. H., M. A. Nader, et al. (1997). "Use of positron emission tomography to study the dynamics of psychostimulant-induced dopamine release." *Pharmacol Biochem Behav* 57(3): 477-86.
- Mechner, F. and M. Latranyi (1963). "Behavioral effects of caffeine, methamphetamine, and methylphenidate in the rat." *J Exp Anal Behav* 6: 331-42.
- Miczek, K. A. and J. M. O'Donnell (1978). "Intruder-evoked aggression in isolated and nonisolated mice: Effects of psychomotor stimulants and L-dopa." *Psychopharmacology (Berl)* 57(1): 47-55.
- Moroji, T. and Y. Hagino (1987). "Bilateral subdiaphragmatic vagotomy does not prevent the behavioral effects of systematically administered ceruletide in mice." *Neuropeptides* 9(3): 217-24.
- Moroji, T. and Y. Hagino (1986). "A behavioral pharmacological study on CCK-8 related peptides in mice." *Neuropeptides* 8(3): 273-86.
- Ogura, H., Y. Furuya, et al. (1998). "Peptide N- and P/Q-type Ca<sup>2+</sup> blockers inhibit stimulant-induced hyperactivity in mice." *Peptides* 19(6): 1017-22.
- Parker, L. A. (1995). "Rewarding drugs produce taste avoidance, but not taste aversion." *Neurosci Biobehav Rev* 19(1): 143-57.
- Preston, K. L., G. C. Wagner, et al. (1984). "Effects of methamphetamine on atropine-induced conditioned gustatory avoidance." *Pharmacol Biochem Behav* 20(4): 601-7.
- Sandoval, V., E. L. Riddle, et al. (2003). "Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits." *J Pharmacol Exp Ther* 304(3): 1181-7.
- Sansone, M. (1975). "Effects of chlordiazepoxide, CNS stimulants and their combinations on avoidance behaviour in mice." *Arch Int Pharmacodyn Ther* 215(2): 190-6.
- Sayers, A. C. and S. L. Handley (1973). "A study of the role of catecholamines in the response to various central stimulants." *Eur J Pharmacol* 23(1): 47-55.
- Schaefer, T. L., L. A. Ehrman, et al. (2006). "Comparison of monoamine and corticosterone levels 24 h following (+)methamphetamine, (+/-)3,4-methylenedioxymethamphetamine, cocaine, (+)fenfluramine or (+/-)methylphenidate administration in the neonatal rat." *J Neurochem* 98(5): 1369-78.
- Scheel-Kruger, J. (1971). "Comparative studies of various amphetamine analogues demonstrating different interactions with the metabolism of the catecholamines in the brain." *Eur J Pharmacol* 14(1): 47-59.
- Shi, W. X., C. L. Pun, et al. (2004). "Psychostimulants induce low-frequency oscillations in the firing activity of dopamine neurons." *Neuropsychopharmacology* 29(12): 2160-7.
- Ugarte, Y. V., K. S. Rau, et al. (2003). "Methamphetamine rapidly decreases mouse vesicular dopamine uptake: Role of hyperthermia and dopamine D2 receptors." *Eur J Pharmacol* 472(3): 165-71.
- Wagner, G. C., C. R. Schuster, et al. (1981). "Neurochemical consequences following administration of CNS stimulants to the neonatal rat." *Pharmacol Biochem Behav* 14(1): 117-9.

## Mexico

- Brouwer, K. C., P. Case, et al. (2006). "Trends in production, trafficking, and consumption of methamphetamine and cocaine in Mexico." *Subst Use Misuse* 41(5): 707-27.
- Cruz, M. F., A. Mantsios, et al. (2006). "A qualitative exploration of gender in the context of injection drug use in two US-Mexico border cities." *AIDS Behav*.

Strathdee, S. A., W. D. Fraga, et al. (2005). ""Vivo para consumirla y la consumo para vivir" ["I live to inject and inject to live"]: High-risk injection behaviors in Tijuana, Mexico." *J Urban Health* 82(3 Suppl 4): iv58-73.

Viani, R. M., M. R. Araneta, et al. (2006). "Perinatal HIV counseling and rapid testing in Tijuana, Baja California, Mexico: Seroprevalence and correlates of HIV infection." *J Acquir Immune Defic Syndr* 41(1): 87-92.

### Miami, FL (US)

Fernandez, M. I., G. S. Bowen, et al. (2007). "Crystal methamphetamine: A source of added sexual risk for Hispanic men who have sex with men?" *Drug Alcohol Depend* 86(2-3): 245-52.

Fernandez, M. I., G. S. Bowen, et al. (2005). "High rates of club drug use and risky sexual practices among Hispanic men who have sex with men in Miami, Florida." *Subst Use Misuse* 40(9): 1347-62.

Fernandez, M. I., T. Perrino, et al. (2005). "Surfing new territory: club-drug use and risky sex among Hispanic men who have sex with men recruited on the Internet." *J Urban Health* 82(1 Suppl 1): i79-88.

Fernandez, M. I., L. M. Varga, et al. (2004). "The Internet as recruitment tool for HIV studies: viable strategy for reaching at-risk Hispanic MSM in Miami?" *AIDS Care* 16(8): 953-63.

Kurtz, S. P. (2005). "Post-circuit blues: Motivations and consequences of crystal meth use among gay men in Miami." *AIDS Behav* 9(1): 63-72.

Thiede, H., L. A. Valleroy, et al. (2003). "Regional patterns and correlates of substance use among young men who have sex with men in 7 US urban areas." *Am J Public Health* 93(11): 1915-21.

### Michigan (US)

Lin, S. J., S. Y. Crawford, et al. (2005). "Trend and area variation in amphetamine prescription usage among children and adolescents in Michigan." *Soc Sci Med* 60(3): 617-26.

### Military

Klette, K. L., A. R. Kettle, et al. (2006). "Prevalence of use study for amphetamine (AMP), methamphetamine (MAMP), 3,4-methylenedioxy-amphetamine (MDA), 3,4-methylenedioxy-methamphetamine (MDMA), and 3,4-methylenedioxy-ethylamphetamine (MDEA) in military entrance processing stations (MEPS) specimens." *J Anal Toxicol* 30(5): 319-22.

### Milwaukee, WI (US)

Morin, S. F., W. T. Steward, et al. (2005). "Predicting HIV transmission risk among HIV-infected men who have sex with men: Findings from the Healthy Living Project." *J Acquir Immune Defic Syndr* 40(2): 226-235.

### Minnesota (US)

Boulard, G. (2005). "The meth menace: Battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.

Folger, D. (2006). "Spreading the word about meth." *Minn Med* 89(6): 50.

Smith, S. D. (2005). "A 'real bad' drug." *Minn Med* 88(8): 6-7.

### Missouri (US)

Gonzales, R., P. Marinelli-Casey, et al. (2006). "Hepatitis C virus infection among methamphetamine-dependent individuals in outpatient treatment." *J Subst Abuse Treat* 31(2): 195-202.

### Monoamine Transport Function

Han, D. D. and H. H. Gu (2006). "Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs." *BMC Pharmacol* 6: 6.

Lile, J. A. (2006). "Pharmacological determinants of the reinforcing effects of psychostimulants: Relation to agonist substitution treatment." *Exp Clin Psychopharmacol* 14(1): 20-33.

Ramamoorthy, J. D., S. Ramamoorthy, et al. (1995). "Human placental monoamine transporters as targets for amphetamines." *Am J Obstet Gynecol* 173(6): 1782-7.

- Wilhelm, C. J., R. A. Johnson, et al. (2004). "Effects of methamphetamine and lobeline on vesicular monoamine and dopamine transporter-mediated dopamine release in a cotransfected model system." *J Pharmacol Exp Ther* 310(3): 1142-51.
- Yui, K., K. Goto, et al. (1996). "Monoamine neurotransmitter function and spontaneous recurrence of methamphetamine psychosis." *Ann N Y Acad Sci* 801: 415-29.

## Monoamine Transport Function (animals)

- Baumgarten, H. G. and L. Lachenmayer (2004). "Serotonin neurotoxins--past and present." *Neurotox Res* 6(7-8): 589-614.
- Bustamante, D., Z. B. You, et al. (2002). "Effect of single and repeated methamphetamine treatment on neurotransmitter release in substantia nigra and neostriatum of the rat." *J Neurochem* 83(3): 645-54.
- Daberkow, D. P., R. P. Kesner, et al. (2005). "Relation between methamphetamine-induced monoamine depletions in the striatum and sequential motor learning." *Pharmacol Biochem Behav* 81(1): 198-204.
- Da Prada, M., H. H. Keller, et al. (1984). "The pharmacology of Parkinson's disease: Basic aspects and recent advances." *Experientia* 40(11): 1165-72.
- Fleckenstein, A. E., J. W. Gibb, et al. (2000). "Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity." *Eur J Pharmacol* 406(1): 1-13.
- Frey, K., M. Kilbourn, et al. (1997). "Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine." *Eur J Pharmacol* 334(2-3): 273-9.
- Friedman, S. D., E. Castaneda, et al. (1998). "Long-term monoamine depletion, differential recovery, and subtle behavioral impairment following methamphetamine-induced neurotoxicity." *Pharmacol Biochem Behav* 61(1): 35-44.
- Fuller, R. W. (1978). "Structure-activity relationships among the halogenated amphetamines." *Ann N Y Acad Sci* 305: 147-59.
- Han, D. D. and H. H. Gu (2006). "Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs." *BMC Pharmacol* 6: 6.
- Kubota, Y., C. Ito, et al. (2002). "Increased methamphetamine-induced locomotor activity and behavioral sensitization in histamine-deficient mice." *J Neurochem* 83(4): 837-45.
- Kupsch, A., J. Sautter, et al. (2001). "Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: Comparison of rasagiline (TVP 1012) with selegiline." *J Neural Transm* 108(8-9): 985-1009.
- Miller, D. K., P. A. Crooks, et al. (2004). "Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters." *J Pharmacol Exp Ther* 310(3): 1035-45.
- Ozawa, H. and T. Miyauchi (1977). "Potentiating effect of lithium chloride on methamphetamine-induced stereotypy in mice." *Eur J Pharmacol* 41(2): 213-6.
- Perez, V. and M. Unzeta (2003). "PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 mice." *Neurochem Int* 42(3): 221-9.
- Rajan, P. D., R. Kekuda, et al. (2000). "Expression of the extraneuronal monoamine transporter in RPE and neural retina." *Curr Eye Res* 20(3): 195-204.
- Rau, K. S., E. Birdsall, et al. (2005). "Bupropion increases striatal vesicular monoamine transport." *Neuropharmacology* 49(6): 820-30.
- Sandoval, V., E. L. Riddle, et al. (2003). "Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits." *J Pharmacol Exp Ther* 304(3): 1181-7.
- Segal, D. S., R. Kuczenski, et al. (2005). "Prolonged exposure of rats to intravenous methamphetamine: Behavioral and neurochemical characterization." *Psychopharmacology (Berl)* 180(3): 501-12.
- Volz, T. J., G. R. Hanson, et al. (2006). "Kinetic analysis of developmental changes in vesicular monoamine transporter-2 function." *Synapse* 60(6): 474-7.
- Wang, Y., J. Chou, et al. (2000). "Chronic methamphetamine exposure decreases high affinity uptake function in norepinephrine afferents in the cerebellar cortex: An electrophysiological and electrochemical study." *Neuropharmacology* 39(11): 2112-23.
- Youdim, M. B., W. Maruyama, et al. (2005). "Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline." *Drugs Today (Barc)* 41(6): 369-91.
- Yu, H., I. J. Kim, et al. (2004). "Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters." *J Med Chem* 47(10): 2624-34.

## Montana (US)

- Boulard, G. (2005). "The meth menace: Battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.

- Garfein, R. S., W. A. Bower, et al. (2004). "Factors associated with fulminant liver failure during an outbreak among injection drug users with acute hepatitis B." *Hepatology* 40(4): 865-73.
- Gonzales, R., P. Marinelli-Casey, et al. (2006). "Hepatitis C virus infection among methamphetamine-dependent individuals in outpatient treatment." *J Subst Abuse Treat* 31(2): 195-202.
- Huber, A., R. H. Lord, et al. (2000). "The CSAT methamphetamine treatment program: Research design accommodations for "real world" application." *J Psychoactive Drugs* 32(2): 149-56.
- Rawson, R. A., P. Marinelli-Casey, et al. (2004). "A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence." *Addiction* 99(6): 708-17.
- Reiber, C., G. Galloway, et al. (2000). "A descriptive analysis of participant characteristics and patterns of substance use in the CSAT methamphetamine treatment project: the first six months." *J Psychoactive Drugs* 32(2): 183-91.

### Mood

*See also* Bipolar Disorder; Depression; Mental Health and Illness

- Akiyama, K. (2006). "Longitudinal clinical course following pharmacological treatment of methamphetamine psychosis which persists after long-term abstinence." *Ann N Y Acad Sci* 1074: 125-34.
- Angrist, B., J. Corwin, et al. (1987). "Early pharmacokinetics and clinical effects of oral D-amphetamine in normal subjects." *Biol Psychiatry* 22(11): 1357-68.
- Brauer, L. H., J. Ambre, et al. (1996). "Acute tolerance to subjective but not cardiovascular effects of d-amphetamine in normal, healthy men." *J Clin Psychopharmacol* 16(1): 72-6.
- Brauer, L. H. and H. de Wit (1996). "Subjective responses to d-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers." *Biol Psychiatry* 39(1): 26-32.
- Camacho, A. and H. S. Akiskal (2005). "Proposal for a bipolar-stimulant spectrum: Temperament, diagnostic validation and therapeutic outcomes with mood stabilizers." *J Affect Disord* 85(1-2): 217-30.
- Clatts, M. C., L. Goldsamt, et al. (2005). "Homelessness and drug abuse among young men who have sex with men in New York city: a preliminary epidemiological trajectory." *J Adolesc* 28(2): 201-14.
- Comer, S. D., C. L. Hart, et al. (2001). "Effects of repeated oral methamphetamine administration in humans." *Psychopharmacology (Berl)* 155(4): 397-404.
- Cookson, J. and T. Silverstone (1986). "The effects of methylamphetamine on mood and appetite in depressed patients: A placebo-controlled study." *Int Clin Psychopharmacol* 1(2): 127-33.
- Derlet, R. W. and B. Heischouer (1990). "Methamphetamine. Stimulant of the 1990s?" *West J Med* 153(6): 625-8.
- de Wit, H., M. Clark, et al. (1997). "Effects of d-amphetamine in grouped versus isolated humans." *Pharmacol Biochem Behav* 57(1-2): 333-40.
- Hart, C. L., M. Haney, et al. (2005). "Combined effects of methamphetamine and zolpidem on performance and mood during simulated night shift work." *Pharmacol Biochem Behav* 81(3): 559-68.
- Harris, D. S., V. I. Reus, et al. (2003). "Altering cortisol level does not change the pleasurable effects of methamphetamine in humans." *Neuropsychopharmacology* 28(9): 1677-84.
- Hart, C. L., A. S. Ward, et al. (2003). "Methamphetamine attenuates disruptions in performance and mood during simulated night-shift work." *Psychopharmacology (Berl)* 169(1): 42-51.
- Hart, C. L., M. Haney, et al. (2002). "Effects of the NMDA antagonist memantine on human methamphetamine discrimination." *Psychopharmacology (Berl)* 164(4): 376-84.
- Hart, C. L., A. S. Ward, et al. (2001). "Methamphetamine self-administration by humans." *Psychopharmacology (Berl)* 157(1): 75-81.
- Iwanami, A., D. Kuwakado, et al. (1997). "Relapse of panic disorder induced by a single intravenous methamphetamine injection." *J Anxiety Disord* 11(1): 113-6.
- Johanson, C. E. and E. H. Uhlenhuth (1980). "Drug preference and mood in humans: d-amphetamine." *Psychopharmacology (Berl)* 71(3): 275-9.
- Johnson, B. A., J. D. Roache, et al. (2006). "Effects of acute topiramate dosing on methamphetamine-induced subjective mood." *Int J Neuropsychopharmacol*: 1-14.
- Johnson, B. A., J. D. Roache, et al. (1999). "Isradipine, a dihydropyridine-class calcium channel antagonist, attenuates some of d-methamphetamine's positive subjective effects: A preliminary study." *Psychopharmacology (Berl)* 144(3): 295-300.
- Kiloh, L. G., M. Neilson, et al. (1974). "Response of depressed patients to methylamphetamine." *Br J Psychiatry* 125: 496-9.
- London, E. D., S. L. Simon, et al. (2004). "Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers." *Arch Gen Psychiatry* 61(1): 73-84.
- Mayfield, D. G. (1973). "The effect of intravenous methamphetamine on mood." *Int J Addict* 8(3): 565-8.



- Nakatani, Y. and T. Hara (1998). "Disturbance of consciousness due to methamphetamine abuse. A study of 2 patients." *Psychopathology* 31(3): 131-7.
- Newton, T. F., A. D. Kalechstein, S. Duran, N. Vansluis and W. Ling (2004). "Methamphetamine abstinence syndrome: Preliminary findings." *Am J Addict* 13(3): 248-55.
- Ogden, C. A., M. E. Rich, et al. (2004). "Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: an expanded convergent functional genomics approach." *Mol Psychiatry* 9(11): 1007-29.
- Perdue, T., H. Hagan, et al. (2003). "Depression and HIV risk behavior among Seattle-area injection drug users and young men who have sex with men." *AIDS Educ Prev* 15(1): 81-92.
- Perez-Reyes, M., W. R. White, et al. (1991). "Clinical effects of daily methamphetamine administration." *Clin Neuropharmacol* 14(4): 352-8.
- Robinson, L. and H. Rempel (2006). "Methamphetamine use and HIV symptom self-management." *J Assoc Nurses AIDS Care* 17(5): 7-14.
- Rothman, R. B., B. E. Blough, et al. (2002). "Appetite suppressants as agonist substitution therapies for stimulant dependence." *Ann N Y Acad Sci* 965: 109-26.
- Rothman, R. B., J. S. Partilla, et al. (2000). "Methamphetamine dependence: Medication development efforts based on the dual deficit model of stimulant addiction." *Ann N Y Acad Sci* 914: 71-81.
- Rothman, R. B., M. H. Baumann, et al. (2001). "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin." *Synapse* 39(1): 32-41.
- Sattar, S. P., S. C. Bhatia, et al. (2004). "Potential benefits of quetiapine in the treatment of substance dependence disorders." *J Psychiatry Neurosci* 29(6): 452-7.
- Schrauzer, G. N. and E. de Vroey (1994). "Effects of nutritional lithium supplementation on mood. A placebo-controlled study with former drug users." *Biol Trace Elem Res* 40(1): 89-101.
- Shoptaw, S., J. Peck, et al. (2003). "Psychiatric and substance dependence comorbidities, sexually transmitted diseases, and risk behaviors among methamphetamine-dependent gay and bisexual men seeking outpatient drug abuse treatment." *J Psychoactive Drugs* 35 Suppl 1: 161-8.
- Simons, J. S., M. N. Oliver, et al. (2005). "Methamphetamine and alcohol abuse and dependence symptoms: Associations with affect lability and impulsivity in a rural treatment population." *Addict Behav* 30(7): 1370-81.
- Soderpalm, A., L. Nikolayev, et al. (2003). "Effects of stress on responses to methamphetamine in humans." *Psychopharmacology (Berl)* 170(2): 188-99.
- Thorberg, F. A. and M. Lyvers (2006). "Negative Mood Regulation (NMR) expectancies, mood, and affect intensity among clients in substance disorder treatment facilities." *Addict Behav* 31(5): 811-20.
- Watson, R., E. Hartmann, et al. (1972). "Amphetamine withdrawal: affective state, sleep patterns, and MHPG excretion." *Am J Psychiatry* 129(3): 263-9.
- Wachtel, S. R., A. Ortengren, et al. (2002). "The effects of acute haloperidol or risperidone on subjective responses to methamphetamine in healthy volunteers." *Drug Alcohol Depend* 68(1): 23-33.
- Wachtel, S. R. and H. de Wit (1999). "Subjective and behavioral effects of repeated d-amphetamine in humans." *Behav Pharmacol* 10(3): 271-81.
- Wilson, J. M., K. S. Kalasinsky, et al. (1996). "Striatal dopamine nerve terminal markers in human, chronic methamphetamine users." *Nat Med* 2(6): 699-703.
- Yen, C. F., Y. H. Yang, et al. (2006). "Correlates of methamphetamine use for Taiwanese adolescents." *Psychiatry Clin Neurosci* 60(2): 160-7.
- Zacny, J. P., B. K. Bodker, et al. (1992). "Effects of setting on the subjective and behavioral effects of d-amphetamine in humans." *Addict Behav* 17(1): 27-33.
- Zacny, J. P. and H. de Wit (1989). "Effects of food deprivation on subjective responses to d-amphetamine in humans." *Pharmacol Biochem Behav* 34(4): 791-5.
- Zweben, J. E., J. B. Cohen, et al. (2004). "Psychiatric symptoms in methamphetamine users." *Am J Addict* 13(2): 181-90.

## Morphine

*See Heroin and Other Opioids; Heroin and Other Opioids (animals)*

## Mortality, Methamphetamine-Associated

- Ago, M., K. Ago, et al. (2006). "Toxicological and histopathological analysis of a patient who died nine days after a single intravenous dose of methamphetamine: A case report." *Leg Med (Tokyo)* 8(4): 235-9.

- Anonymous (1995). "Increasing morbidity and mortality associated with abuse of methamphetamine--United States, 1991-1994." *MMWR Morb Mortal Wkly Rep* 44(47): 882-6.
- Bailey, D. N. and R. F. Shaw (1989). "Cocaine- and methamphetamine-related deaths in San Diego County (1987): Homicides and accidental overdoses." *J Forensic Sci* 34(2): 407-22.
- Bartu, A., N. C. Freeman, et al. (2004). "Mortality in a cohort of opiate and amphetamine users in Perth, Western Australia." *Addiction* 99(1): 53-60.
- Berankova, K., V. Habrdova, et al. (2005). "Methamphetamine in hair and interpretation of forensic findings in a fatal case." *Forensic Sci Int* 153(1): 93-7.
- Catanzarite, V. A. and D. A. Stein (1995). "'Crystal' and pregnancy--methamphetamine-associated maternal deaths." *West J Med* 162(5): 454-7.
- Chan, P., J. H. Chen, et al. (1994). "Fatal and nonfatal methamphetamine intoxication in the intensive care unit." *J Toxicol Clin Toxicol* 32(2): 147-55.
- Cheng, J. Y., D. T. Chan, et al. (2005). "An epidemiological study on alcohol/drugs related fatal traffic crash cases of deceased drivers in Hong Kong between 1996 and 2000." *Forensic Sci Int* 153(2-3): 196-201.
- Chung, H., M. Park, et al. (2004). "Recent trends of drug abuse and drug-associated deaths in Korea." *Ann N Y Acad Sci* 1025: 458-64.
- Chung, H. (1998). "Drug abuse trends and epidemiological aspects of drug associated deaths in Korea." *J Toxicol Sci* 23 Suppl 2: 197-200.
- Concheiro, M., A. D. Castro, et al. (2006). "Determination of drugs of abuse and their metabolites in human plasma by liquid chromatography-mass spectrometry An application to 156 road fatalities." *J Chromatogr B Analyt Technol Biomed Life Sci*.
- Crouch, D. J., M. M. Birky, et al. (1993). "The prevalence of drugs and alcohol in fatally injured truck drivers." *J Forensic Sci* 38(6): 1342-53.
- Davis, G. G. and C. I. Swalwell (1996). "The incidence of acute cocaine or methamphetamine intoxication in deaths due to ruptured cerebral (berry) aneurysms." *J Forensic Sci* 41(4): 626-8.
- Davis, G. G. and C. I. Swalwell (1994). "Acute aortic dissections and ruptured berry aneurysms associated with methamphetamine abuse." *J Forensic Sci* 39(6): 1481-5.
- Demetriades, D., G. Gkiokas, et al. (2004). "Alcohol and illicit drugs in traumatic deaths: Prevalence and association with type and severity of injuries." *J Am Coll Surg* 199(5): 687-92.
- Drummer, O. H., J. Gerostamoulos, et al. (2003). "The incidence of drugs in drivers killed in Australian road traffic crashes." *Forensic Sci Int* 134(2-3): 154-62.
- Fukunaga, T., Y. Mizoi, et al. (1987). "Methamphetamine concentrations in blood, urine, and organs of fatal cases after abuse." *Nippon Hoigaku Zasshi* 41(4): 328-34.
- Glittenberg, J. and C. Anderson (1999). "Methamphetamines: Use and trafficking in the Tucson-Nogales area." *Subst Use Misuse* 34(14): 1977-89.
- Inoue, H., N. Ikeda, et al. (2006). "Methamphetamine-related sudden death with a concentration which was of a 'toxic level'." *Leg Med (Tokyo)* 8(3): 150-5.
- Ishigami, A., S. Kubo, et al. (2003). "The application of immunohistochemical findings in the diagnosis in methamphetamine-related death-two forensic autopsy cases." *J Med Invest* 50(1-2): 112-6.
- Johansen, S. S., A. C. Hansen, et al. (2003). "Three fatal cases of PMA and PMMA poisoning in Denmark." *J Anal Toxicol* 27(4): 253-6.
- Kalasinsky, K. S., T. Z. Bosy, et al. (2001). "Regional distribution of methamphetamine in autopsied brain of chronic human methamphetamine users." *Forensic Sci Int* 116(2-3): 163-9.
- Karch, S. B., B. G. Stephens, et al. (1999). "Methamphetamine-related deaths in San Francisco: Demographic, pathologic, and toxicologic profiles." *J Forensic Sci* 44(2): 359-68.
- Katsumata, S., K. Sato, et al. (1993). "Sudden death due presumably to internal use of methamphetamine." *Forensic Sci Int* 62(3): 209-15.
- Kojima, T., I. Une, et al. (1984). "A fatal methamphetamine poisoning associated with hyperpyrexia." *Forensic Sci Int* 24(1): 87-93.
- Komokata, T., S. Nishida, et al. (2003). "The impact of donor chemical overdose on the outcome of liver transplantation." *Transplantation* 76(4): 705-8.
- Logan, B. K. (2001). "Amphetamines: An update on forensic issues." *J Anal Toxicol* 25(5): 400-4.
- Logan, B. K., C. L. Fligner, et al. (1998). "Cause and manner of death in fatalities involving methamphetamine." *J Forensic Sci* 43(1): 28-34.
- Logan, B. K., E. L. Weiss, et al. (1996). "Case report: Distribution of methamphetamine in a massive fatal ingestion." *J Forensic Sci* 41(2): 322-3.
- Molina, N. M. and S. G. Jejurikar (1999). "Toxicological findings in a fatal ingestion of methamphetamine." *J Anal Toxicol* 23(1): 67-8.

- Mori, A., H. Suzuki, et al. (1992). "[Three cases of acute methamphetamine intoxication--Analysis of optically active methamphetamine]." *Nippon Hoigaku Zasshi* 46(4): 266-70.
- Moriya, F. and Y. Hashimoto (2002). "A case of fatal hemorrhage in the cerebral ventricles following intravenous use of methamphetamine." *Forensic Sci Int* 129(2): 104-9.
- Nishida, N., N. Ikeda, et al. (2003). "Sudden unexpected death of a methamphetamine abuser with cardiopulmonary abnormalities: A case report." *Med Sci Law* 43(3): 267-71.
- Ochoa, K. C., P. J. Davidson, et al. (2005). "Heroin overdose among young injection drug users in San Francisco." *Drug Alcohol Depend* 80(3): 297-302.
- O'Halloran, R. L. and L. V. Lewman (1993). "Restraint asphyxiation in excited delirium." *Am J Forensic Med Pathol* 14(4): 289-95.
- Quan, L., T. Ishikawa, et al. (2005). "Ubiquitin-immunoreactive structures in the midbrain of methamphetamine abusers." *Leg Med (Tokyo)* 7(3): 144-50.
- Raikos, N., H. Tsoukali, et al. (2002). "Amphetamine derivative related deaths in northern Greece." *Forensic Sci Int* 128(1-2): 31-4.
- Rajs, J. and B. Falconer (1979). "Cardiac lesions in intravenous drug addicts." *Forensic Sci Int* 13(3): 193-209.
- Romhild, W., D. Krause, et al. (2003). "LC-MS/MS analysis of pholedrine in a fatal intoxication case." *Forensic Sci Int* 133(1-2): 101-6.
- Schwilke, E. W., M. I. Sampaio dos Santos, et al. (2006). "Changing patterns of drug and alcohol use in fatally injured drivers in Washington State." *J Forensic Sci* 51(5): 1191-8.
- Slade, M., L. J. Daniel, et al. (1991). "Application of forensic toxicology to the problem of domestic violence." *J Forensic Sci* 36(3): 708-13.
- Shaw, K. P. (1999). "Human methamphetamine-related fatalities in Taiwan during 1991-1996." *J Forensic Sci* 44(1): 27-31.
- Sheridan, J., S. Bennett, et al. (2006). "Injury associated with methamphetamine use: A review of the literature." *Harm Reduct J* 3(1): 14.
- Shibata, S., K. Mori, et al. (1991). "Subarachnoid and intracerebral hemorrhage associated with necrotizing angitis due to methamphetamine abuse--an autopsy case." *Neurol Med Chir (Tokyo)* 31(1): 49-52.
- Spann, M. D., G. McGwin, Jr., et al. (2006). "Characteristics of burn patients injured in methamphetamine laboratory explosions." *J Burn Care Res* 27(4): 496-501.
- Sribanditmongkol, P., M. Chokjamsai, et al. (2000). "Methamphetamine overdose and fatality: 2 cases report." *J Med Assoc Thai* 83(9): 1120-3.
- Stewart, J. L. and J. E. Meeker (1997). "Fetal and infant deaths associated with maternal methamphetamine abuse." *J Anal Toxicol* 21(6): 515-7.
- Takasaki, T., N. Nishida, et al. (2003). "Unexpected death due to right-sided infective endocarditis in a methamphetamine abuser." *Leg Med (Tokyo)* 5(1): 65-8.
- Toupalik, P., H. Vanerkova, et al. (2002). "[Morphologic findings in chronic abuse of heroin and pervitine]." *Soud Lek* 47(1): 5-11.
- Wallace, M. E. and R. Squires (2000). "Fatal massive amphetamine ingestion associated with hyperpyrexia." *J Am Board Fam Pract* 13(4): 302-4.
- Wermuth, L. (2000). "Methamphetamine use: Hazards and social influences." *J Drug Educ* 30(4): 423-33.
- Wyman, J. F. and J. T. Cody (2005). "Determination of l-methamphetamine: A case history." *J Anal Toxicol* 29(7): 759-61.
- Yamamoto, K., H. Watanabe, et al. (1991). "[3 fatalities after communal use of methamphetamine]." *Arch Kriminol* 188(3-4): 72-6.
- Zalis, E. G. and L. F. Parmley, Jr. (1963). "Fatal Amphetamine Poisoning." *Arch Intern Med* 112: 822-6.
- Zhu, B. L., T. Ishikawa, et al. (2006). "Postmortem cardiac troponin T levels in the blood and pericardial fluid. Part 1. Analysis with special regard to traumatic causes of death." *Leg Med (Tokyo)* 8(2): 86-93.
- Zhu, B. L., T. Ishikawa, et al. (2005). "Evaluation of postmortem serum calcium and magnesium levels in relation to the causes of death in forensic autopsy." *Forensic Sci Int* 155(1): 18-23.
- Zhu, B. L., S. Oritani, et al. (2000). "Methamphetamine-related fatalities in forensic autopsy during 5 years in the southern half of Osaka city and surrounding areas." *Forensic Sci Int* 113(1-3): 443-7.

## Motivations for Non-Use and Use Cessation

*See also* Treatment Readiness

- Brecht, M. L., M. D. Anglin, et al. (2005). "Coerced treatment for methamphetamine abuse: Differential patient characteristics and outcomes." *Am J Drug Alcohol Abuse* 31(2): 337-56.
- German, D., S. G. Sherman, et al. (2006). "Motivations for methamphetamine cessation among young people in northern Thailand." *Addiction* 101(8): 1143-52.

Wu, L. T., D. J. Pilowsky, et al. (2004). "Injection drug use among stimulant users in a national sample." *Am J Drug Alcohol Abuse* 30(1): 61-83.

### Motivations for Use

Brecht, M. L., L. Greenwell, et al. (2007). "Substance use pathways to methamphetamine use among treated users." *Addict Behav* 32(1): 24-38.

Brecht, M. L., A. O'Brien, et al. (2004). "Methamphetamine use behaviors and gender differences." *Addict Behav* 29(1): 89-106.

Bungay, V., L. Malchy, et al. (2006). "Life with jib: A snapshot of street youth's use of crystal methamphetamine." *Addiction Research and Theory* 14(3): 235-251.

Diaz, R. M., A. L. Heckert, et al. (2005). "Reasons for stimulant use among Latino gay men in San Francisco: a comparison between methamphetamine and cocaine users." *J Urban Health* 82(1 Suppl 1): i71-8.

Fendrich, M., J. S. Wislar, et al. (2003). "A contextual profile of club drug use among adults in Chicago." *Addiction* 98(12): 1693-703.

Green, A. I. and P. N. Halkitis (2006). "Crystal methamphetamine and sexual sociality in an urban gay subculture: an elective affinity." *Cult Health Sex* 8(4): 317-33.

Halkitis, P. N. and M. T. Shrem (2006). "Psychological differences between binge and chronic methamphetamine using gay and bisexual men." *Addict Behav* 31(3): 549-52.

Halkitis, P. N., B. N. Fischgrund, et al. (2005). "Explanations for methamphetamine use among gay and bisexual men in New York City." *Subst Use Misuse* 40(9): 1331-45.

Herman-Stahl, M. A., C. P. Krebs, et al. (2006). "Risk and protective factors for methamphetamine use and nonmedical use of prescription stimulants among young adults aged 18 to 25." *Addict Behav*.

Herman-Stahl, M. A., C. P. Krebs, et al. (2006). "Risk and protective factors for nonmedical use of prescription stimulants and methamphetamine among adolescents." *J Adolesc Health* 39(3): 374-80.

Joe Laidler, K. A. (2005). "The rise of club drugs in a heroin society: The case of Hong Kong." *Subst Use Misuse* 40(9-10): 1257-78.

Kurtz, S. P. (2005). "Post-circuit blues: Motivations and consequences of crystal meth use among gay men in Miami." *AIDS Behav* 9(1): 63-72.

Lipinski, E. (1972). "Motivation in drug misuse. Some comments on agent, environment, host." *Jama* 219(2): 171-5.

Parks, K. A. and C. L. Kennedy (2004). "Club drugs: Reasons for and consequences of use." *J Psychoactive Drugs* 36(3): 295-302.

Robinson, L. and H. Rempel (2006). "Methamphetamine use and HIV symptom self-management." *J Assoc Nurses AIDS Care* 17(5): 7-14.

Ross, M. W., A. M. Mattison, et al. (2003). "Club drugs and sex on drugs are associated with different motivations for gay circuit party attendance in men." *Subst Use Misuse* 38(8): 1173-83.

Schilder, A. J., T. M. Lampinen, et al. (2005). "Crystal methamphetamine and ecstasy differ in relation to unsafe sex among young gay men." *Can J Public Health* 96(5): 340-3.

Semple, S. J., T. L. Patterson and I. Grant (2004). "The context of sexual risk behavior among heterosexual methamphetamine users." *Addict Behav* 29(4): 807-10.

Semple, S. J., T. L. Patterson, et al. (2004). "A comparison of injection and non-injection methamphetamine-using HIV positive men who have sex with men." *Drug Alcohol Depend* 76(2): 203-12.

Semple, S. J., T. L. Patterson and I. Grant (2002). "Motivations associated with methamphetamine use among HIV+ men who have sex with men." *J Subst Abuse Treat* 22(3): 149-56.

von Mayrhauser, C., M. L. Brecht and M. D. Anglin (2002). "Use ecology and drug use motivations of methamphetamine users admitted to substance abuse treatment facilities in Los Angeles: An emerging profile." *J Addict Dis* 21(1): 45-60.

### Movement Disorders

*See also* Parkinsonism and Parkinson's Disease; Psychomotor Task Performance; Tremors; Stereotypic Behaviors

Caligiuri, M. P. and C. Buitenhuis (2005). "Do preclinical findings of methamphetamine-induced motor abnormalities translate to an observable clinical phenotype?" *Neuropsychopharmacology* 30(12): 2125-34.

Ellis, K. L. and J. Speed (1998). "Pharmacologic management of movement disorder after midbrain haemorrhage." *Brain Inj* 12(7): 623-8.

Nath, A., W. F. Maragos, et al. (2001). "Acceleration of HIV dementia with methamphetamine and cocaine." *J Neurovirol* 7(1): 66-71.

## Movement Disorders (animals)

*See also* Parkinsonisms and Parkinson's Disease (animal model); Psychomotor Task Performance (animals); Tremors (animals); Stereotypic Behaviors (animals)

Anaya-Martinez, V., A. Martinez-Marcos, et al. (2006). "Substantia nigra compacta neurons that innervate the reticular thalamic nucleus in the rat also project to striatum or globus pallidus: Implications for abnormal motor behavior." *Neuroscience* 143(2): 477-86.

## Muscles (animals)

*See also* Cardiovascular Effects and Diseases (animals)

Ishiguro, Y. and J. P. Morgan (1997). "Biphasic inotropic effects of methamphetamine and methylphenidate on ferret papillary muscles." *J Cardiovasc Pharmacol* 30(6): 744-9.

## Nasal Administration

*See* Snorting Methamphetamine

## Native Americans/First Peoples/Aboriginal North Americans

Freese, T. E., J. Obert, et al. (2000). "Methamphetamine abuse: Issues for special populations." *J Psychoactive Drugs* 32(2): 177-82.

Garfein, R. S., W. A. Bower, et al. (2004). "Factors associated with fulminant liver failure during an outbreak among injection drug users with acute hepatitis B." *Hepatology* 40(4): 865-73.

Glittenberg, J. and C. Anderson (1999). "Methamphetamines: Use and trafficking in the Tucson-Nogales area." *Subst Use Misuse* 34(14): 1977-89.

Oetting, E. R., J. L. Deffenbacher, et al. (2000). "Methamphetamine use by high school students: Recent trends, gender and ethnicity differences, and use of other drugs." *Journal of Child and Adolescent Substance Abuse* 10(1): 33-50.

Simons, J. S., M. N. Oliver, et al. (2005). "Methamphetamine and alcohol abuse and dependence symptoms: Associations with affect lability and impulsivity in a rural treatment population." *Addict Behav* 30(7): 1370-81.

Wood, E., J. A. Stoltz, et al. (2006). "Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study." *Harm Reduct J* 3: 18.

## Nebraska (US)

Brannan, T. A., S. Soundararajan, et al. (2004). "Methamphetamine-associated shock with intestinal infarction." *MedGenMed* 6(4): 6.

Colnar, R. (1999). "Methamphetamine affects individuals and communities." *Nebr Nurse* 32(3): 31.

## Needle Exchange

*See* Syringe Exchange and Syringe Access

## Neighborhood Disadvantage

Storr, C. L., A. M. Arria, et al. (2004). "Neighborhood environment and opportunity to try methamphetamine ("ice") and marijuana: Evidence from Guam in the Western Pacific region of Micronesia." *Subst Use Misuse* 39(2): 253-76.

## Netherlands

Uitermark, J. and P. D. A. Cohen (2006). "Amphetamine users in Amsterdam: Patterns of use and modes of self-regulation." *Addiction Research & Theory* 14(2): 159-188.

Uitermark, J. and P. Cohen (2004). Amphetamine users in Amsterdam: Patterns of use and modes of self-regulation, Centrum voor drugsonderzoek.

### Neuroimaging

*See* Brain Imaging; Brain Imaging (animals)

### Neurological Development and Adaptations

*See also* Neurotoxicity

- Chang, L., C. Cloak, et al. (2005). "Enlarged striatum in abstinent methamphetamine abusers: A possible compensatory response." *Biol Psychiatry* 57(9): 967-74.
- Chang, L., L. M. Smith, et al. (2004). "Smaller subcortical volumes and cognitive deficits in children with prenatal methamphetamine exposure." *Psychiatry Res* 132(2): 95-106.
- Davies, J. K. and J. M. Bledsoe (2005). "Prenatal alcohol and drug exposures in adoption." *Pediatr Clin North Am* 52(5): 1369-93, vii.
- Frost, D. O. and J. L. Cadet (2000). "Effects of methamphetamine-induced neurotoxicity on the development of neural circuitry: A hypothesis." *Brain Res Brain Res Rev* 34(3): 103-18.
- Jernigan, T. L., A. C. Gamst, et al. (2005). "Effects of methamphetamine dependence and HIV infection on cerebral morphology." *Am J Psychiatry* 162(8): 1461-72.
- Nordahl, T. E., R. Salo, et al. (2005). "Methamphetamine users in sustained abstinence: A proton magnetic resonance spectroscopy study." *Arch Gen Psychiatry* 62(4): 444-52.
- NTP-CERHR (2005). "NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines." NTP CEHR Mon(16): i-III1.
- Oh, J. S., I. K. Lyoo, et al. (2005). "Shape changes of the corpus callosum in abstinent methamphetamine users." *Neurosci Lett* 384(1-2): 76-81.
- Powrozek, T. A., Y. Sari, et al. (2004). "Neurotransmitters and substances of abuse: Effects on adult neurogenesis." *Curr Neurovasc Res* 1(3): 251-60.
- Salo, R., T. E. Nordahl, et al. (2006). "Attentional control and brain metabolite levels in methamphetamine abusers." *Biol Psychiatry*.
- Sevarino, K. A., A. Oliveto, et al. (2000). "Neurobiological adaptations to psychostimulants and opiates as a basis of treatment development." *Ann N Y Acad Sci* 909: 51-87.
- Thompson, P. M., K. M. Hayashi, et al. (2004). "Structural abnormalities in the brains of human subjects who use methamphetamine." *J Neurosci* 24(26): 6028-36.
- Yamada, K., T. Nagai, et al. (2005). "Drug dependence, synaptic plasticity, and tissue plasminogen activator." *J Pharmacol Sci* 97(2): 157-61.

### Neurological Development and Adaptations (animals)

*See also* Neurotoxicity (animals)

- Bagorda, F., G. Teuchert-Noodt, et al. (2006). "Isolation rearing or methamphetamine traumatization induce a "dysconnection" of prefrontal efferents in gerbils: Implications for schizophrenia." *J Neural Transm* 113(3): 365-79.
- Bjorklund, A. and U. Stenevi (1979). "Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants." *Brain Res* 177(3): 555-60.
- Bowyer, J. F., A. R. Pogge, et al. (2007). "A threshold neurotoxic amphetamine exposure inhibits parietal cortex expression of synaptic plasticity-related genes." *Neuroscience* 144(1): 66-76.
- Brady, A. M., S. D. Glick, et al. (2005). "Selective disruption of nucleus accumbens gating mechanisms in rats behaviorally sensitized to methamphetamine." *J Neurosci* 25(28): 6687-95.
- Brummelte, S., T. Grund, et al. (2006). "Long-term effects of a single adult methamphetamine challenge: Minor impact on dopamine fibre density in limbic brain areas of gerbils." *Behav Brain Funct* 2: 12.
- Busche, A., A. Bagorda, et al. (2006). "The maturation of the acetylcholine system in the dentate gyrus of gerbils (*Meriones unguiculatus*) is affected by epigenetic factors." *J Neural Transm* 113(2): 113-24.
- Busche, A., D. Polascheck, et al. (2004). "Developmentally induced imbalance of dopaminergic fibre densities in limbic brain regions of gerbils (*Meriones unguiculatus*)." *J Neural Transm* 111(4): 451-63.
- Busche, A., J. Neddens, et al. (2002). "Differential influence of rearing conditions and methamphetamine on serotonin fibre maturation in the dentate gyrus of gerbils (*Meriones unguiculatus*)." *Dev Neurosci* 24(6): 512-21.
- Butz, M. and G. Teuchert-Noodt (2006). "A simulation model for compensatory plasticity in the prefrontal cortex inducing a cortico-cortical dysconnection in early brain development." *J Neural Transm* 113(5): 695-710.
- Cadet, J. L. and C. Brannock (1998). "Free radicals and the pathobiology of brain dopamine systems." *Neurochem Int* 32(2): 117-31.

- Chen, P. C. and J. C. Chen (2005). "Enhanced Cdk5 activity and p35 translocation in the ventral striatum of acute and chronic methamphetamine-treated rats." *Neuropsychopharmacology* 30(3): 538-49.
- Cormaci, G., T. Mori, et al. (2007). "Protein kinase A activation down-regulates, whereas extracellular signal-regulated kinase activation up-regulates  $\sigma$ -1 receptors in B-104 cells: Implication for neuroplasticity." *J Pharmacol Exp Ther* 320(1): 202-10.
- Cui, C., H. Sakata-Haga, et al. (2006). "Histological brain alterations following prenatal methamphetamine exposure in rats." *Congenit Anom (Kyoto)* 46(4): 180-7.
- Deng, X., B. Ladenheim, et al. (2006). "Methamphetamine administration causes death of dopaminergic neurons in the mouse olfactory bulb." *Biol Psychiatry*.
- Facchinetti, F., R. Dall'Olio, et al. (1994). "Long-lasting effects of chronic neonatal blockade of N-methyl-D-aspartate receptor through the competitive antagonist CGP 39551 in rats." *Neuroscience* 60(2): 343-53.
- Fang, Y. R., T. Abekawa, et al. (2005). "Effect of the protein kinase C inhibitor, staurosporine, on the high dose of methamphetamine-induced behavioral sensitization to dizocilpine (MK-801)." *Psychopharmacology (Berl)* 180(1): 100-6.
- Frost, D. O. and J. L. Cadet (2000). "Effects of methamphetamine-induced neurotoxicity on the development of neural circuitry: A hypothesis." *Brain Res Brain Res Rev* 34(3): 103-18.
- Gomes-da-Silva, J., R. de Miguel, et al. (2004). "Effects of neonatal exposure to methamphetamine: Catecholamine levels in brain areas of the developing rat." *Ann N Y Acad Sci* 1025: 602-11.
- Gomes-da-Silva, J., A. Perez-Rosado, et al. (2002). "Prenatal exposure to methamphetamine in the rat: Ontogeny of tyrosine hydroxylase mRNA expression in mesencephalic dopaminergic neurons." *Ann N Y Acad Sci* 965: 68-77.
- Gomes-da-Silva, J., A. Perez-Rosado, et al. (2000). "Neonatal methamphetamine in the rat: Evidence for gender-specific differences upon tyrosine hydroxylase enzyme in the dopaminergic nigrostriatal system." *Ann N Y Acad Sci* 914: 431-8.
- Gomes-Da-Silva, J., M. C. Silva, et al. (1998). "Developmental exposure to methamphetamine: A neonatal model in the rat." *Ann N Y Acad Sci* 844: 310-3.
- Guilarte, T. R., M. K. Nihei, et al. (2003). "Methamphetamine-induced deficits of brain monoaminergic neuronal markers: Distal axotomy or neuronal plasticity." *Neuroscience* 122(2): 499-513.
- Hildebrandt, K., G. Teuchert-Noodt, et al. (1999). "A single neonatal dose of methamphetamine suppresses dentate granule cell proliferation in adult gerbils which is restored to control values by acute doses of haloperidol." *J Neural Transm* 106(5-6): 549-58.
- Ihara, Y., M. Sato, et al. (1986). "Morphological changes in rat striatal boutons after chronic methamphetamine and haloperidol treatment." *Neurosci Res* 3(5): 403-10.
- Ishikawa, K., A. Nitta, et al. (2006). "Effects of single and repeated administration of methamphetamine or morphine on neuroglycan C gene expression in the rat brain." *Int J Neuropsychopharmacol* 9(4): 407-15.
- Itzhak, Y. and S. F. Ali (2006). "Role of nitergic system in behavioral and neurotoxic effects of amphetamine analogs." *Pharmacol Ther* 109(1-2): 246-62.
- Jeng, W., A. W. Wong, et al. (2005). "Methamphetamine-enhanced embryonic oxidative DNA damage and neurodevelopmental deficits." *Free Radic Biol Med* 39(3): 317-26.
- Kajii, Y., S. Muraoka, et al. (2003). "A developmentally regulated and psychostimulant-inducible novel rat gene *mrt1* encoding PDZ-PX proteins isolated in the neocortex." *Mol Psychiatry* 8(4): 434-44.
- Kitanaka, J., N. Kitanaka, et al. (2003). "Chronic methamphetamine administration reduces histamine-stimulated phosphoinositide hydrolysis in mouse frontal cortex." *Biochem Biophys Res Commun* 300(4): 932-7.
- Lehmann, K., B. Hundsdoerfer, et al. (2004). "The acetylcholine fiber density of the neocortex is altered by isolated rearing and early methamphetamine intoxication in rodents." *Exp Neurol* 189(1): 131-40.
- Lesting, J., J. Neddens, et al. (2005). "Hemisphere-specific effects on serotonin but not dopamine innervation in the nucleus accumbens of gerbils caused by isolated rearing and a single early methamphetamine challenge." *Brain Res* 1035(2): 168-76.
- Mizuno, M., R. S. Malta, Jr., et al. (2004). "Conditioned place preference and locomotor sensitization after repeated administration of cocaine or methamphetamine in rats treated with epidermal growth factor during the neonatal period." *Ann N Y Acad Sci* 1025: 612-8.
- Narita, M., M. Miyatake, et al. (2006). "Direct evidence of astrocytic modulation in the development of rewarding effects induced by drugs of abuse." *Neuropsychopharmacology* 31(11): 2476-88.
- Narita, M., M. Miyatake, et al. (2005). "[Implication of glial function in the development of drug dependence associated with synaptic plasticity]." *Nippon Yakurigaku Zasshi* 126(1): 43-8.
- Narita, M., M. Miyatake, et al. (2005). "Long-lasting change in brain dynamics induced by methamphetamine: Enhancement of protein kinase C-dependent astrocytic response and behavioral sensitization." *J Neurochem* 93(6): 1383-92.
- Neddens, J., R. R. Dawirs, et al. (2004). "Postnatal maturation of cortical serotonin lateral asymmetry in gerbils is vulnerable to both environmental and pharmacological epigenetic challenges." *Brain Res* 1021(2): 200-8.

- Neddens, J., F. Bagorda, et al. (2003). "Epigenetic factors differentially influence postnatal maturation of serotonin (5-HT) innervation in cerebral cortex of gerbils: interaction of rearing conditions and early methamphetamine challenge." *Brain Res Dev Brain Res* 146(1-2): 119-30.
- Neddens, J., J. Lesting, et al. (2002). "An early methamphetamine challenge suppresses the maturation of dopamine fibres in the nucleus accumbens of gerbils: On the significance of rearing conditions." *J Neural Transm* 109(2): 141-55.
- Narita, M., M. Miyatake, et al. (2006). "Direct evidence of astrocytic modulation in the development of rewarding effects induced by drugs of abuse." *Neuropsychopharmacology* 31(11): 2476-88.
- Nishii, K., N. Matsushita, et al. (1998). "Motor and learning dysfunction during postnatal development in mice defective in dopamine neuronal transmission." *J Neurosci Res* 54(4): 450-64.
- Nossoll, M., G. Teuchert-Noodt, et al. (1997). "A single dose of methamphetamine in neonatal gerbils affects adult prefrontal gamma-aminobutyric acid innervation." *Eur J Pharmacol* 340(2-3): R3-5.
- NTP-CERHR (2005). "NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines." NTP CEHR Mon(16): i-III1.
- Ozawa, K., K. Hashimoto, et al. (2006). "Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: A neurodevelopmental animal model of schizophrenia." *Biol Psychiatry* 59(6): 546-54.
- Powrozek, T. A., Y. Sari, et al. (2004). "Neurotransmitters and substances of abuse: Effects on adult neurogenesis." *Curr Neurovasc Res* 1(3): 251-60.
- Pu, C., H. W. Broening, et al. (1996). "Effect of methamphetamine on glutamate-positive neurons in the adult and developing rat somatosensory cortex." *Synapse* 23(4): 328-34.
- Sato, M. and Y. Fujiwara (1986). "Behavioral and neurochemical changes in pups prenatally exposed to methamphetamine." *Brain Dev* 8(4): 390-6.
- Slamberova, R., M. Pometlova, et al. (2006). "Postnatal development of rat pups is altered by prenatal methamphetamine exposure." *Prog Neuropsychopharmacol Biol Psychiatry* 30(1): 82-8.
- Slamberova, R. (2005). "Flurothyl seizures susceptibility is increased in prenatally methamphetamine-exposed adult male and female rats." *Epilepsy Res* 65(1-2): 121-4.
- Slamberova, R. and R. Rokyta (2005). "Occurrence of bicuculline-, NMDA- and kainic acid-induced seizures in prenatally methamphetamine-exposed adult male rats." *Naunyn Schmiedebergs Arch Pharmacol* 372(3): 236-41.
- Slamberova, R. and R. Rokyta (2005). "Seizure susceptibility in prenatally methamphetamine-exposed adult female rats." *Brain Res* 1060(1-2): 193-7.
- Stefanski, R., Z. Justinova, et al. (2004). "Sigma1 receptor upregulation after chronic methamphetamine self-administration in rats: A study with yoked controls." *Psychopharmacology (Berl)* 175(1): 68-75.
- Stefanski, R., S. H. Lee, et al. (2002). "Lack of persistent changes in the dopaminergic system of rats withdrawn from methamphetamine self-administration." *Eur J Pharmacol* 439(1-3): 59-68.
- Stefanski, R., B. Ladenheim, et al. (1999). "Neuroadaptations in the dopaminergic system after active self-administration but not after passive administration of methamphetamine." *Eur J Pharmacol* 371(2-3): 123-35.
- Vorhees, C. V. (1997). "Methods for detecting long-term CNS dysfunction after prenatal exposure to neurotoxins." *Drug Chem Toxicol* 20(4): 387-99.
- Vorhees, C. V., K. G. Ahrens, et al. (1994). "Methamphetamine exposure during early postnatal development in rats: I. Acoustic startle augmentation and spatial learning deficits." *Psychopharmacology (Berl)* 114(3): 392-401.
- Watanabe, T. (1997). "[Histaminergic neuron system and neural plasticity]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 17(4): 169-73.
- Wells, P. G., Y. Bhuller, et al. (2005). "Molecular and biochemical mechanisms in teratogenesis involving reactive oxygen species." *Toxicol Appl Pharmacol* 207(2 Suppl): 354-66.
- Williams, M. T., M. S. Moran, et al. (2004). "Behavioral and growth effects induced by low dose methamphetamine administration during the neonatal period in rats." *Int J Dev Neurosci* 22(5-6): 273-83.
- Williams, M. T., R. W. Brown, et al. (2004). "Neonatal methamphetamine administration induces region-specific long-term neuronal morphological changes in the rat hippocampus, nucleus accumbens and parietal cortex." *Eur J Neurosci* 19(12): 3165-70.
- Williams, M. T., M. S. Moran, et al. (2003). "Refining the critical period for methamphetamine-induced spatial deficits in the Morris water maze." *Psychopharmacology (Berl)* 168(3): 329-38.
- Williams, M. T., T. L. Blankenmeyer, et al. (2003). "Long-term effects of neonatal methamphetamine exposure in rats on spatial learning in the Barnes maze and on cliff avoidance, corticosterone release, and neurotoxicity in adulthood." *Brain Res Dev Brain Res* 147(1-2): 163-75.
- Williams, M. T., C. V. Vorhees, et al. (2002). "Methamphetamine exposure from postnatal day 11 to 20 causes impairments in both behavioral strategies and spatial learning in adult rats." *Brain Res* 958(2): 312-21.



- Williams, M. T., S. L. Inman-Wood, et al. (2000). "Prewaning treatment with methamphetamine induces increases in both corticosterone and ACTH in rats." *Neurotoxicol Teratol* 22(5): 751-9.
- Witte, A. V., F. Bagorda, et al. (2006). "Contralateral prefrontal projections in gerbils mature abnormally after early methamphetamine trauma and isolated rearing." *J Neural Transm*.
- Won, L., N. Bubula, et al. (2002). "Fetal exposure to methamphetamine in utero stimulates development of serotonergic neurons in three-dimensional reaggregate tissue culture." *Synapse* 43(2): 139-44.
- Won, L., P. J. Kontur, et al. (1992). "Acute and persistent effects of methamphetamine on developing monoaminergic neurons in reaggregate tissue culture." *Brain Res* 575(1): 6-12.
- Yamada, K., T. Nagai, et al. (2005). "Drug dependence, synaptic plasticity, and tissue plasminogen activator." *J Pharmacol Sci* 97(2): 157-61.
- Yamagata, K., K. Suzuki, et al. (2000). "Activation of an effector immediate-early gene arc by methamphetamine." *Ann N Y Acad Sci* 914: 22-32.
- Yamamoto, H., K. Imai, et al. (2005). "Methamphetamine modulation of gene expression in the brain: Analysis using customized cDNA microarray system with the mouse homologues of KIAA genes." *Brain Res Mol Brain Res* 137(1-2): 40-6.

## Neurotoxicity

- Abraini, J. H., H. N. David, et al. (2005). "Potentially neuroprotective and therapeutic properties of nitrous oxide and xenon." *Ann N Y Acad Sci* 1053: 289-300.
- Ajjimaporn, A., J. Swinscoe, et al. (2005). "Metallothionein provides zinc-mediated protective effects against methamphetamine toxicity in SK-N-SH cells." *Brain Res Bull* 67(6): 466-475.
- Ali, S. F., S. Z. Imam, et al. (2005). "Role of peroxynitrite in methamphetamine-induced dopaminergic neurodegeneration and neuroprotection by antioxidants and selective NOS Inhibitors." *Ann N Y Acad Sci* 1053: 97-8.
- Anglin, M. D., C. Burke, et al. (2000). "History of the methamphetamine problem." *J Psychoactive Drugs* 32(2): 137-41.
- Asanuma, M. and I. Miyazaki (2005). "[Expression profiling of molecules related to abused drug dependence and toxicity]." *Nippon Yakurigaku Zasshi* 126(1): 30-4, 42.
- Asanuma, M., I. Miyazaki, Y. Higashi, T. Tsuji and N. Ogawa (2004). "Specific gene expression and possible involvement of inflammation in methamphetamine-induced neurotoxicity." *Ann N Y Acad Sci* 1025: 69-75.
- Bae, S. C., I. K. Lyoo, et al. (2006). "Increased white matter hyperintensities in male methamphetamine abusers." *Drug Alcohol Depend* 81(1): 83-8.
- Barr, A. M., W. J. Panenka, et al. (2006). "The need for speed: An update on methamphetamine addiction." *J Psychiatry Neurosci* 31(5): 301-313.
- Baumgarten, H. G. and L. Lachenmayer (2004). "Serotonin neurotoxins--past and present." *Neurotox Res* 6(7-8): 589-614.
- Bialek, M., P. Zaremba, et al. (2004). "Neuroprotective role of testosterone in the nervous system." *Pol J Pharmacol* 56(5): 509-18.
- Bowyer, J. F., D. L. Davies, et al. (1994). "Further studies of the role of hyperthermia in methamphetamine neurotoxicity." *J Pharmacol Exp Ther* 268(3): 1571-80.
- Cadet, J. L., S. Jayanthi, et al. (2003). "Speed kills: Cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis." *FASEB J* 17(13): 1775-88.
- Cadet, J. L. and C. Brannock (1998). "Free radicals and the pathobiology of brain dopamine systems." *Neurochem Int* 32(2): 117-31.
- Caligiuri, M. P. and C. Buitenhuis (2005). "Do preclinical findings of methamphetamine-induced motor abnormalities translate to an observable clinical phenotype?" *Neuropsychopharmacology* 30(12): 2125-34.
- Carey, C. L., S. P. Woods, et al. (2006). "Additive deleterious effects of methamphetamine dependence and immunosuppression on neuropsychological functioning in HIV infection." *AIDS Behav* 10(2): 185-90.
- Chana, G., I. P. Everall, et al. (2006). "Cognitive deficits and degeneration of interneurons in HIV+ methamphetamine users." *Neurology* 67(8): 1486-9.
- Chang, L., T. Ernst, et al. (2005). "Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities." *Am J Psychiatry* 162(2): 361-9.
- Chen, J., C. Wersinger, et al. (2003). "Chronic stimulation of D1 dopamine receptors in human SK-N-MC neuroblastoma cells induces nitric-oxide synthase activation and cytotoxicity." *J Biol Chem* 278(30): 28089-100.
- Cho, A. K. and W. P. Melega (2002). "Patterns of methamphetamine abuse and their consequences." *J Addict Dis* 21(1): 21-34.
- Chung, A., I. K. Lyoo, et al. (2006). "Decreased frontal white-matter integrity in abstinent methamphetamine abusers." *Int J Neuropsychopharmacol*: 1-11.
- Davidson, C., A. J. Gow, et al. (2001). "Methamphetamine neurotoxicity: Necrotic and apoptotic mechanisms and relevance to human abuse and treatment." *Brain Res Brain Res Rev* 36(1): 1-22.

- Dawson, R., Jr., M. F. Beal, et al. (1995). "Excitotoxins, aging, and environmental neurotoxins: Implications for understanding human neurodegenerative diseases." *Toxicol Appl Pharmacol* 134(1): 1-17.
- Deutsch, R., M. Cherner, et al. (2006). "Significance testing of a cluster of multivariate binary variables: Comparison of the tripartite T index to three common similarity measures." *Stat Methods Med Res* 15(3): 285-99.
- Dluzen, D. E. and J. L. McDermott (2004). "Developmental and genetic influences upon gender differences in methamphetamine-induced nigrostriatal dopaminergic neurotoxicity." *Ann N Y Acad Sci* 1025: 205-20.
- Dluzen, D. E. and J. L. McDermott (2002). "Estrogen, anti-estrogen, and gender: Differences in methamphetamine neurotoxicity." *Ann N Y Acad Sci* 965: 136-56.
- Ellison, G. (2002). "Neural degeneration following chronic stimulant abuse reveals a weak link in brain, fasciculus retroflexus, implying the loss of forebrain control circuitry." *Eur Neuropsychopharmacol* 12(4): 287-97.
- Ernst, T., L. Chang, et al. (2000). "Evidence for long-term neurotoxicity associated with methamphetamine abuse: A 1H MRS study." *Neurology* 54(6): 1344-9.
- Everall, I., S. Salaria, et al. (2005). "Methamphetamine stimulates interferon inducible genes in HIV infected brain." *J Neuroimmunol* 170(1-2): 158-71.
- Fitzmaurice, P. S., J. Tong, et al. (2006). "Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of methamphetamine." *J Pharmacol Exp Ther* 319(2): 703-9.
- Frost, D. O. and J. L. Cadet (2000). "Effects of methamphetamine-induced neurotoxicity on the development of neural circuitry: A hypothesis." *Brain Res Brain Res Rev* 34(3): 103-18.
- Gadd, C. (2005). "Crystal meth use worsens HIV-related brain damage." *IAPAC Mon* 11(4): 109.
- Garwood, E. R., W. Bekele, et al. (2006). "Amphetamine exposure is elevated in Parkinson's disease." *Neurotoxicology* 27(6): 1003-6.
- Gibb, J. W., M. Johnson, et al. (1990). "Neurochemical basis of neurotoxicity." *Neurotoxicology* 11(2): 317-21.
- Golembiowska, K., J. Konieczny, et al. (2002). "The role of striatal metabotropic glutamate receptors in degeneration of dopamine neurons: Review article." *Amino Acids* 23(1-3): 199-205.
- Gonzalez, R., J. D. Rippeth, et al. (2004). "Neurocognitive performance of methamphetamine users discordant for history of marijuana exposure." *Drug Alcohol Depend* 76(2): 181-90.
- Guilarte, T. R. (2001). "Is methamphetamine abuse a risk factor in parkinsonism?" *Neurotoxicology* 22(6): 725-31.
- Hanson, G. R., K. S. Rau, et al. (2004). "The methamphetamine experience: A NIDA partnership." *Neuropharmacology* 47 Suppl 1: 92-100.
- Harano, M., N. Uchimura, et al. (2004). "A polymorphism of DRD2 gene and brain atrophy in methamphetamine psychosis." *Ann N Y Acad Sci* 1025: 307-15.
- Heller, A., L. Won, et al. (1995). "Examination of developmental neurotoxicity by the use of tissue culture model systems." *Clin Exp Pharmacol Physiol* 22(5): 375-8.
- Holden, C. (2003). "Retraction. Paper on toxic party drug is pulled over vial mix-up." *Science* 301(5639): 1454.
- Ishikawa, T., B. L. Zhu, et al. (2006). "Increase in clusterin-containing follicles in the adenohypophysis of drug abusers." *Int J Legal Med*.
- Itzhak, Y. and C. Achat-Mendes (2004). "Methamphetamine and MDMA (ecstasy) neurotoxicity: 'Of mice and men'." *IUBMB Life* 56(5): 249-55.
- Johanson, C. E., K. A. Frey, et al. (2006). "Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers." *Psychopharmacology (Berl)* 186(4): 620.
- Kim, D. J., S. Roh, et al. (2005). "High concentrations of plasma brain-derived neurotrophic factor in methamphetamine users." *Neurosci Lett* 388(2): 112-5.
- Kim, S. J., I. K. Lyoo, et al. (2005). "Frontal glucose hypometabolism in abstinent methamphetamine users." *Neuropsychopharmacology* 30(7): 1383-91.
- Kitamura, O., I. Tokunaga, et al. (2006). "Immunohistochemical investigation of dopaminergic terminal markers and caspase-3 activation in the striatum of human methamphetamine users." *Int J Legal Med*.
- Kiyatkin, E. A. (2005). "Brain hyperthermia as physiological and pathological phenomena." *Brain Res Brain Res Rev* 50(1): 27-56.
- Kovacic, P. and A. L. Cooksy (2005). "Unifying mechanism for toxicity and addiction by abused drugs: electron transfer and reactive oxygen species." *Med Hypotheses* 64(2): 357-66.
- Langford, D., A. Adame, A. Grigorian, I. Grant, J. A. McCutchan, R. J. Ellis, T. D. Marcotte and E. Masliah (2003). "Patterns of selective neuronal damage in methamphetamine-user AIDS patients." *J Acquir Immune Defic Syndr* 34(5): 467-74.
- Li, T., C. K. Chen, et al. (2004). "Association analysis of the DRD4 and COMT genes in methamphetamine abuse." *Am J Med Genet* 129B(1): 120-4.

- Lotharius, J., J. Falsig, et al. (2005). "Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway." *J Neurosci* 25(27): 6329-42.
- McCann, U. D. and G. A. Ricaurte (2004). "Amphetamine neurotoxicity: Accomplishments and remaining challenges." *Neurosci Biobehav Rev* 27(8): 821-6.
- Meredith, C. W., C. Jaffe, et al. (2005). "Implications of chronic methamphetamine use: A literature review." *Harv Rev Psychiatry* 13(3): 141-54.
- Mirecki, A., P. Fitzmaurice, et al. (2004). "Brain antioxidant systems in human methamphetamine users." *J Neurochem* 89(6): 1396-408.
- Miyatake, M., M. Narita, et al. (2005). "Glutamatergic neurotransmission and protein kinase C play a role in neuron-glia communication during the development of methamphetamine-induced psychological dependence." *Eur J Neurosci* 22(6): 1476-88.
- Moszczynska, A., P. Fitzmaurice, et al. (2004). "Why is parkinsonism not a feature of human methamphetamine users?" *Brain* 127(Pt 2): 363-70.
- Munro, C. A., M. E. McCaul, et al. (2006). "Sex differences in striatal dopamine release in healthy adults." *Biol Psychiatry* 59(10): 966-74.
- Nath, A., K. F. Hauser, et al. (2002). "Molecular basis for interactions of HIV and drugs of abuse." *J Acquir Immune Defic Syndr* 31 Suppl 2: S62-9.
- Nath, A., C. Anderson, et al. (2000). "Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia." *J Psychopharmacol* 14(3): 222-7.
- Nath, A., W. F. Maragos, M. J. Avison, F. A. Schmitt and J. R. Berger (2001). "Acceleration of HIV dementia with methamphetamine and cocaine." *J Neurovirol* 7(1): 66-71.
- Newton, T. F., A. D. Kalechstein, et al. (2004). "Association between quantitative EEG and neurocognition in methamphetamine-dependent volunteers." *Clin Neurophysiol* 115(1): 194-8.
- Nordahl, T. E., R. Salo, et al. (2003). "Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: A review." *J Neuropsychiatry Clin Neurosci* 15(3): 317-25.
- Park, S. U., J. V. Ferrer, et al. (2002). "Peroxy-nitrite inactivates the human dopamine transporter by modification of cysteine 342: potential mechanism of neurotoxicity in dopamine neurons." *J Neurosci* 22(11): 4399-405.
- Quan, L., T. Ishikawa, et al. (2005). "Ubiquitin-immunoreactive structures in the midbrain of methamphetamine abusers." *Leg Med (Tokyo)* 7(3): 144-50.
- Quinton, M. S. and B. K. Yamamoto (2006). "Causes and consequences of methamphetamine and MDMA toxicity." *AAPS J* 8(2): E337-47.
- Ricaurte, G. A. and U. D. McCann (1992). "Neurotoxic amphetamine analogues: Effects in monkeys and implications for humans." *Ann N Y Acad Sci* 648: 371-82.
- Riddle, E. L., A. E. Fleckenstein, et al. (2006). "Mechanisms of methamphetamine-induced dopaminergic neurotoxicity." *AAPS J* 8(2): E413-8.
- Rippeth, J. D., R. K. Heaton, et al. (2004). "Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons." *J Int Neuropsychol Soc* 10(1): 1-14.
- Sanga, M., I. R. Younis, et al. (2006). "Epoxidation of the methamphetamine pyrolysis product, trans-phenylpropene, to trans-phenylpropylene oxide by CYP enzymes and stereoselective glutathione adduct formation." *Toxicol Appl Pharmacol* 211(2): 148-56.
- Segura Aguilar, J. and R. M. Kostrzewa (2004). "Neurotoxins and neurotoxic species implicated in neurodegeneration." *Neurotox Res* 6(7-8): 615-30.
- Seiden, L. S. and K. E. Sabol (1996). "Methamphetamine and methylenedioxymethamphetamine neurotoxicity: Possible mechanisms of cell destruction." *NIDA Res Monogr* 163: 251-76.
- Sekine, Y., Y. Ouchi, et al. (2006). "Brain serotonin transporter density and aggression in abstinent methamphetamine abusers." *Arch Gen Psychiatry* 63(1): 90-100.
- Sekine, Y., Y. Minabe, et al. (2003). "Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms." *Am J Psychiatry* 160(9): 1699-701.
- Selden, L. S. (1991). "Neurotoxicity of methamphetamine: Mechanisms of action and issues related to aging." *NIDA Res Monogr* 115: 24-32.
- Siegal, D., J. Erickson, et al. (2004). "Brain vesicular acetylcholine transporter in human users of drugs of abuse." *Synapse* 52(4): 223-32.
- Sung, Y. H., S. C. Cho, et al. (2006). "Relationship between N-acetyl-aspartate in gray and white matter of abstinent methamphetamine abusers and their history of drug abuse: A proton magnetic resonance spectroscopy study." *Drug Alcohol Depend*.
- Thompson, P. M., K. M. Hayashi, S. L. Simon, J. A. Geaga, M. S. Hong, Y. Sui, J. Y. Lee, A. W. Toga, W. Ling and E. D. London (2004). "Structural abnormalities in the brains of human subjects who use methamphetamine." *J Neurosci* 24(26): 6028-36.
- Toupalik, P., H. Vanerkova, et al. (2002). "[Morphologic findings in chronic abuse of heroin and pervitine]." *Soud Lek* 47(1): 5-11.

- Turchan, J., C. Anderson, et al. (2001). "Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine." *BMC Neurosci* 2: 3.
- Urbina, A. and K. Jones (2004). "Crystal methamphetamine, its analogues, and HIV infection: Medical and psychiatric aspects of a new epidemic." *Clin Infect Dis* 38(6): 890-4.
- Villemagne, V., J. Yuan, et al. (1998). "Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [<sup>11</sup>C]WIN-35,428 positron emission tomography studies and direct in vitro determinations." *J Neurosci* 18(1): 419-27.
- Virmani, A., F. Gaetani, et al. (2005). "Effects of metabolic modifiers such as carnitines, coenzyme Q10, and PUFAs against different forms of neurotoxic insults: Metabolic inhibitors, MPTP, and methamphetamine." *Ann N Y Acad Sci* 1053: 183-91.
- Volkow, N. D., L. Chang, et al. (2001). "Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers." *Am J Psychiatry* 158(3): 377-82.
- Volkow, N. D., L. Chang, et al. (2001). "Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence." *J Neurosci* 21(23): 9414-8.
- Volkow, N. D., L. Chang, et al. (2001). "Low level of brain dopamine D2 receptors in methamphetamine abusers: Association with metabolism in the orbitofrontal cortex." *Am J Psychiatry* 158(12): 2015-21.
- Volkow, N. D., L. Chang, et al. (2001). "Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers." *Am J Psychiatry* 158(3): 383-9.
- Vorhees, C. V. (1994). "Developmental neurotoxicity induced by therapeutic and illicit drugs." *Environ Health Perspect* 102 Suppl 2: 145-53.
- Wang, G. J., N. D. Volkow, et al. (2004). "Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence." *Am J Psychiatry* 161(2): 242-8.
- Wolkoff, D. A. (1997). "Methamphetamine abuse: An overview for health care professionals." *Hawaii Med J* 56(2): 34-6, 44.
- Wrona, M. Z., Z. Yang, et al. (1997). "Potential new insights into the molecular mechanisms of methamphetamine-induced neurodegeneration." *NIDA Res Monogr* 173: 146-74.

### Neurotoxicity (animals)

- Abekawa, T. (1997). "[Experimental study of methamphetamine psychosis--role of glutamate and nitric oxide in methamphetamine-induced dopaminergic and serotonergic neurotoxicity in the rat brain]." *Hokkaido Igaku Zasshi* 72(1): 113-26.
- Achat-Mendes, C., K. L. Anderson, et al. (2006). "Impairment in consolidation of learned place preference following dopaminergic neurotoxicity in mice is ameliorated by N-acetylcysteine but not D1 and D2 dopamine receptor agonists." *Neuropsychopharmacology*.
- Achat-Mendes, C., S. F. Ali, et al. (2005). "Differential effects of amphetamines-induced neurotoxicity on appetitive and aversive Pavlovian conditioning in mice." *Neuropsychopharmacology* 30(6): 1128-37.
- Acevedo, S. F., I. J. de Esch, et al. (2006). "Sex- and histamine-dependent long-term cognitive effects of methamphetamine exposure." *Neuropsychopharmacology*.
- Acikgoz, O., S. Gonenc, et al. (2000). "The effects of single dose of methamphetamine on lipid peroxidation levels in the rat striatum and prefrontal cortex." *Eur Neuropsychopharmacol* 10(5): 415-8.
- Acikgoz, O., S. Gonenc, et al. (1998). "Methamphetamine causes lipid peroxidation and an increase in superoxide dismutase activity in the rat striatum." *Brain Res* 813(1): 200-2.
- Adams, F. S., F. G. La Rosa, et al. (1996). "Characterization and transplantation of two neuronal cell lines with dopaminergic properties." *Neurochem Res* 21(5): 619-27.
- Albers, D. S. and P. K. Sonsalla (1995). "Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents." *J Pharmacol Exp Ther* 275(3): 1104-14.
- Ali, S. F. (1995). "Lack of mitigation of methamphetamine-induced neurotoxicity by ganglioside GM1 or vitamin E." *Ann N Y Acad Sci* 765: 311.
- Ali, S. F., R. R. Newport, et al. (1995). "Low environmental temperatures or pharmacologic agents that produce hyperthermia decrease methamphetamine neurotoxicity in mice." *Ann N Y Acad Sci* 765: 338.
- Ali, S. F., R. R. Holson, et al. (1993). "Development of dopamine and N-methyl-D-aspartate systems in rat brain: The effect of prenatal phencyclidine exposure." *Brain Res Dev Brain Res* 73(1): 25-33.
- Amano, T., H. Matsubayashi, et al. (1996). "Hypersensitivity of nucleus accumbens neurons to methamphetamine and dopamine following repeated administrations of methamphetamine." *Ann N Y Acad Sci* 801: 136-47.
- Anderson, K. L. and Y. Itzhak (2006). "Methamphetamine-induced selective dopaminergic neurotoxicity is accompanied by an increase in striatal nitrate in the mouse." *Ann N Y Acad Sci* 1074: 225-33.

- Anderson, L. I., R. E. Leipheimer, et al. (2005). "Effects of neonatal and prepubertal hormonal manipulations upon estrogen neuroprotection of the nigrostriatal dopaminergic system within female and male mice." *Neuroscience* 130(2): 369-82.
- Ando, K. (1996). "Test methods for predicting tardive toxicity of therapeutic drugs using laboratory animals." *J Toxicol Sci* 21(1): 105-7.
- Angulo, J. A., N. Angulo and J. Yu (2004). "Antagonists of the neurokinin-1 or dopamine d1 receptors confer protection from methamphetamine on dopamine terminals of the mouse striatum." *Ann N Y Acad Sci* 1025: 171-80.
- Armstrong, B. D. and K. K. Noguchi (2004). "The neurotoxic effects of 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine on serotonin, dopamine, and GABA-ergic terminals: an in-vitro autoradiographic study in rats." *Neurotoxicology* 25(6): 905-14.
- Barr, A. M., W. J. Panenka, et al. (2006). "The need for speed: An update on methamphetamine addiction." *J Psychiatry Neurosci* 31(5): 301-313.
- Battaglia, G., M. G. Farrace, et al. (2006). "Transglutaminase 2 ablation leads to defective function of mitochondrial respiratory complex I affecting neuronal vulnerability in experimental models of extrapyramidal disorders." *J Neurochem*.
- Battaglia, G., F. Fornai, et al. (2002). "Selective blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine neurotoxicity." *J Neurosci* 22(6): 2135-41.
- Baucum, A. J., 2nd, K. S. Rau, et al. (2004). "Methamphetamine increases dopamine transporter higher molecular weight complex formation via a dopamine- and hyperthermia-associated mechanism." *J Neurosci* 24(13): 3436-43.
- Baumgarten, H. G. and L. Lachenmayer (2004). "Serotonin neurotoxins--past and present." *Neurotox Res* 6(7-8): 589-614.
- Belcher, A. M., S. J. O'Dell, et al. (2006). "A sensitizing regimen of methamphetamine causes impairments in a novelty preference task of object recognition." *Behav Brain Res* 170(1): 167-72.
- Belcher, A. M., S. J. O'Dell, et al. (2005). "Impaired object recognition memory following methamphetamine, but not p-chloroamphetamine- or d-amphetamine-induced neurotoxicity." *Neuropsychopharmacology* 30(11): 2026-34.
- Bhatt, S. D. and D. E. Dluzen (2005). "Dopamine transporter function differences between male and female CD-1 mice." *Brain Res* 1035(2): 188-95.
- Bialek, M., P. Zaremba, et al. (2004). "Neuroprotective role of testosterone in the nervous system." *Pol J Pharmacol* 56(5): 509-18.
- Binienda, Z. K., B. D. Przybyla, et al. (2006). "Effects of L-carnitine pretreatment in methamphetamine and 3-nitropropionic acid-induced neurotoxicity." *Ann N Y Acad Sci* 1074: 74-83.
- Bisagno, V., R. Bowman, et al. (2003). "Functional aspects of estrogen neuroprotection." *Endocrine* 21(1): 33-41.
- Bagorda, F., G. Teuchert-Noodt, et al. (2006). "Isolation rearing or methamphetamine traumatization induce a "dysconnection" of prefrontal efferents in gerbils: Implications for schizophrenia." *J Neural Transm* 113(3): 365-79.
- Berman, S. B. and T. G. Hastings (1997). "Inhibition of glutamate transport in synaptosomes by dopamine oxidation and reactive oxygen species." *J Neurochem* 69(3): 1185-95.
- Boireau, A., F. Bordier, et al. (1995). "Methamphetamine and dopamine neurotoxicity: Differential effects of agents interfering with glutamatergic transmission." *Neurosci Lett* 195(1): 9-12.
- Booij, J., K. de Bruin, et al. (2006). "Repeated administration of d-amphetamine induces loss of [(123)I]FP-CIT binding to striatal dopamine transporters in rat brain: A validation study." *Nucl Med Biol* 33(3): 409-11.
- Bowyer, J. F. and S. Ali (2006). "High doses of methamphetamine that cause disruption of the blood-brain barrier in limbic regions produce extensive neuronal degeneration in mouse hippocampus." *Synapse* 60(7): 521-532.
- Bowyer, J. F., R. R. Holson, D. B. Miller and J. P. O'Callaghan (2001). "Phenobarbital and dizocilpine can block methamphetamine-induced neurotoxicity in mice by mechanisms that are independent of thermoregulation." *Brain Res* 919(1): 179-83.
- Bowyer, J. F. (1995). "The role of hyperthermia in amphetamine's interactions with NMDA receptors, nitric oxide, and age to produce neurotoxicity." *Ann N Y Acad Sci* 765: 309-10.
- Bowyer, J. F., D. L. Davies, et al. (1994). "Further studies of the role of hyperthermia in methamphetamine neurotoxicity." *J Pharmacol Exp Ther* 268(3): 1571-80.
- Bowyer, J. F., B. Gough, et al. (1993). "Effects of a cold environment or age on methamphetamine-induced dopamine release in the caudate putamen of female rats." *Pharmacol Biochem Behav* 44(1): 87-98.
- Bowyer, J. F., A. C. Scallet, et al. (1991). "Interactions of MK-801 with glutamate-, glutamine- and methamphetamine-evoked release of [3H]dopamine from striatal slices." *J Pharmacol Exp Ther* 257(1): 262-70.
- Brown, J. M., S. Gouty, et al. (2006). "Differential protection against MPTP or methamphetamine toxicity in dopamine neurons by deletion of ppN/OFQ expression." *J Neurochem* 98(2): 495-505.
- Brown, J. M., M. S. Quinton, et al. (2005). "Methamphetamine-induced inhibition of mitochondrial complex II: roles of glutamate and peroxynitrite." *J Neurochem* 95(2): 429-36.
- Brady, A. M., S. D. Glick, et al. (2005). "Selective disruption of nucleus accumbens gating mechanisms in rats behaviorally sensitized to methamphetamine." *J Neurosci* 25(28): 6687-95.

- Bronstein, D. M. and J. S. Hong (1995). "Effects of sulpiride and SCH 23390 on methamphetamine-induced changes in body temperature and lethality." *J Pharmacol Exp Ther* 274(2): 943-50.
- Brummelte, S., T. Grund, et al. (2006). "Long-term effects of a single adult methamphetamine challenge: Minor impact on dopamine fibre density in limbic brain areas of gerbils." *Behav Brain Funct* 2: 12.
- Burrows, K. B., W. L. Nixdorf, et al. (2000). "Central administration of methamphetamine synergizes with metabolic inhibition to deplete striatal monoamines." *J Pharmacol Exp Ther* 292(3): 853-60.
- Burrows, K. B. and C. K. Meshul (1999). "High-dose methamphetamine treatment alters presynaptic GABA and glutamate immunoreactivity." *Neuroscience* 90(3): 833-50.
- Burrows, K. B. and C. K. Meshul (1997). "Methamphetamine alters presynaptic glutamate immunoreactivity in the caudate nucleus and motor cortex." *Synapse* 27(2): 133-44.
- Byrnes-Blake, K. A., E. M. Laurenzana, et al. (2005). "Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats." *Eur J Pharmacol* 521(1-3): 86-94.
- Cadet, J. L. (2001). "Molecular neurotoxicological models of Parkinsonism: Focus on genetic manipulation of mice." *Parkinsonism Relat Disord* 8(2): 85-90.
- Cadet, J. L. and C. Brannock (1998). "Free radicals and the pathobiology of brain dopamine systems." *Neurochem Int* 32(2): 117-31.
- Cadet, J. L., S. V. Ordonez and J. V. Ordonez (1997). "Methamphetamine induces apoptosis in immortalized neural cells: Protection by the proto-oncogene, bcl-2." *Synapse* 25(2): 176-84.
- Cadet, J. L., S. F. Ali, et al. (1995). "Neurotoxicity, drugs and abuse, and the CuZn-superoxide dismutase transgenic mice." *Mol Neurobiol* 11(1-3): 155-63.
- Cadet, J. L., S. Ali, et al. (1994). "Involvement of oxygen-based radicals in methamphetamine-induced neurotoxicity: Evidence from the use of CuZnSOD transgenic mice." *Ann N Y Acad Sci* 738: 388-91.
- Cadet, J. L., P. Sheng, et al. (1994). "Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice." *J Neurochem* 62(1): 380-3.
- Callahan, B. T., B. J. Cord, J. Yuan, U. D. McCann and G. A. Ricaurte (2001). "Inhibitors of Na(+)/H(+) and Na(+)/Ca(2+) exchange potentiate methamphetamine-induced dopamine neurotoxicity: Possible role of ionic dysregulation in methamphetamine neurotoxicity." *J Neurochem* 77(5): 1348-62.
- Cappon, G. D., C. Pu and C. V. Vorhees (2000). "Time-course of methamphetamine-induced neurotoxicity in rat caudate-putamen after single-dose treatment." *Brain Res* 863(1-2): 106-11.
- Cappon, G. D., L. L. Morford and C. V. Vorhees (1997). "Ontogeny of methamphetamine-induced neurotoxicity and associated hyperthermic response." *Brain Res Dev Brain Res* 103(2): 155-62.
- Carney, J. M., B. Tolliver, et al. (1991). "Selective effects of behaviorally active doses of methamphetamine on mRNA expression in the gerbil brain." *Neuropharmacology* 30(9): 1011-9.
- Cass, W. A., M. P. Smith, et al. (2006). "Calcitriol protects against the dopamine- and serotonin-depleting effects of neurotoxic doses of methamphetamine." *Ann N Y Acad Sci* 1074: 261-71.
- Cass, W. A., L. E. Peters, et al. (2006). "Protection by GDNF and other trophic factors against the dopamine-depleting effects of neurotoxic doses of methamphetamine." *Ann N Y Acad Sci* 1074: 272-81.
- Cass, W. A., M. E. Harned, et al. (2003). "HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat." *Brain Res* 984(1-2): 133-42.
- Cass, W. A. (2000). "Attenuation and recovery of evoked overflow of striatal serotonin in rats treated with neurotoxic doses of methamphetamine." *J Neurochem* 74(3): 1079-85.
- Cass, W. A., M. W. Manning, et al. (2000). "Restorative effects of GDNF on striatal dopamine release in rats treated with neurotoxic doses of methamphetamine." *Ann N Y Acad Sci* 914: 127-36.
- Cass, W. A., D. J. Walker, et al. (1999). "Augmented methamphetamine-induced overflow of striatal dopamine 1 day after GDNF administration." *Brain Res* 827(1-2): 104-12.
- Cass, W. A. and M. W. Manning (1999). "Recovery of presynaptic dopaminergic functioning in rats treated with neurotoxic doses of methamphetamine." *J Neurosci* 19(17): 7653-60.
- Cass, W. A., M. W. Manning, et al. (1998). "Effects of neurotoxic doses of methamphetamine on potassium and amphetamine evoked overflow of dopamine in the striatum of awake rats." *Neurosci Lett* 248(3): 175-8.
- Cass, W. A. (1997). "Decreases in evoked overflow of dopamine in rat striatum after neurotoxic doses of methamphetamine." *J Pharmacol Exp Ther* 280(1): 105-13.
- Cass, W. A. (1996). "GDNF selectively protects dopamine neurons over serotonin neurons against the neurotoxic effects of methamphetamine." *J Neurosci* 16(24): 8132-9.
- Cass, W. A. (1997). "Decreases in evoked overflow of dopamine in rat striatum after neurotoxic doses of methamphetamine." *J Pharmacol Exp Ther* 280(1): 105-13.

- Cassarino, D. S., C. P. Fall, et al. (1998). "Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion." *J Neurochem* 71(1): 295-301.
- Chan, P., D. A. Di Monte, et al. (1994). "Rapid ATP loss caused by methamphetamine in the mouse striatum: Relationship between energy impairment and dopaminergic neurotoxicity." *J Neurochem* 62(6): 2484-7.
- Chen, J., C. Wersinger, et al. (2003). "Chronic stimulation of D1 dopamine receptors in human SK-N-MC neuroblastoma cells induces nitric-oxide synthase activation and cytotoxicity." *J Biol Chem* 278(30): 28089-100.
- Choi, H. J., T. M. Yoo, et al. (2002). "Methamphetamine-induced apoptosis in a CNS-derived catecholaminergic cell line." *Mol Cells* 13(2): 221-7.
- Clemens, K. J., J. L. Cornish, et al. (2007). "Repeated weekly exposure to MDMA, methamphetamine or their combination: Long-term behavioural and neurochemical effects in rats." *Drug Alcohol Depend* 86(2-3): 183-90.
- Clemens, K. J., J. L. Cornish, et al. (2005). "MDMA ('Ecstasy') and methamphetamine combined: Order of administration influences hyperthermic and long-term adverse effects in female rats." *Neuropharmacology* 49(2): 195-207.
- Cloak, C. C., L. Chang, T. Ernst, M. C. Barr, S. Huitron-Resendiz, M. Sanchez-Alavez, T. R. Phillips and S. Henriksen (2004). "Methamphetamine and AIDS: IHMRS studies in a feline model of human disease." *J Neuroimmunol* 147(1-2): 16-20.
- Cosi, C., P. Chopin and M. Marien (1996). "Benzamide, an inhibitor of poly(ADP-ribose) polymerase, attenuates methamphetamine-induced dopamine neurotoxicity in the c57b1/6n mouse." *Brain Res* 735(2): 343-8.
- Crutchfield, K. C. and D. E. Dluzen (2006). "Rotenone produces opposite effects upon mouse striatal dopamine function as a result of environmental temperature." *Neurotox Res* 9(1): 15-21.
- Cui, C., H. Sakata-Haga, et al. (2006). "Histological brain alterations following prenatal methamphetamine exposure in rats." *Congenit Anom (Kyoto)* 46(4): 180-7.
- D'Almeida, V., R. Camarini, et al. (1995). "Antioxidant defense in rat brain after chronic treatment with anorectic drugs." *Toxicol Lett* 81(2-3): 101-5.
- D'Astous, M., K. R. Mickley, et al. (2006). "Differential protective properties of estradiol and tamoxifen against methamphetamine-induced nigrostriatal dopaminergic toxicity in mice." *Neuroendocrinology* 82(2): 111-120.
- D'Astous, M., T. M. Gajjar, D. E. Dluzen and T. Di Paolo (2004). "Dopamine transporter as a marker of neuroprotection in methamphetamine-lesioned mice treated acutely with estradiol." *Neuroendocrinology* 79(6): 296-304.
- Davidson, C., T. H. Lee, et al. (2005). "Acute and chronic continuous methamphetamine have different long-term behavioral and neurochemical consequences." *Neurochem Int* 46(3): 189-203.
- Davidson, C., A. J. Gow, et al. (2001). "Methamphetamine neurotoxicity: Necrotic and apoptotic mechanisms and relevance to human abuse and treatment." *Brain Res Brain Res Rev* 36(1): 1-22.
- Dawirs, R. R., G. Teuchert-Noodt, et al. (1997). "Pharmacologically induced neural plasticity in the prefrontal cortex of adult gerbils (*Meriones unguiculatus*)." *Eur J Pharmacol* 327(2-3): 117-23.
- Delle Donne, K. T. and P. K. Sonsalla (1994). "Protection against methamphetamine-induced neurotoxicity to neostriatal dopaminergic neurons by adenosine receptor activation." *J Pharmacol Exp Ther* 271(3): 1320-6.
- Deng, X., B. Ladenheim, et al. (2006). "Methamphetamine administration causes death of dopaminergic neurons in the mouse olfactory bulb." *Biol Psychiatry*.
- Di Monte, D. A., J. E. Royland, M. W. Jakowec and J. W. Langston (1996). "Role of nitric oxide in methamphetamine neurotoxicity: Protection by 7-nitroindazole, an inhibitor of neuronal nitric oxide synthase." *J Neurochem* 67(6): 2443-50.
- Dluzen, D. E. and J. L. McDermott (2006). "Estrogen, testosterone, and methamphetamine toxicity." *Ann N Y Acad Sci* 1074: 282-94.
- Dluzen, D. E. and T. J. Salvaterra (2006). "Sex differences in methamphetamine-evoked striatal dopamine output are abolished following gonadectomy: Comparisons with potassium-evoked output and responses in prepubertal mice." *Neuroendocrinology* 82(2): 78-86.
- Dluzen, D. E. and J. L. McDermott (2004). "Developmental and genetic influences upon gender differences in methamphetamine-induced nigrostriatal dopaminergic neurotoxicity." *Ann N Y Acad Sci* 1025: 205-20.
- Dluzen, D. E. and J. L. McDermott (2002). "Estrogen, anti-estrogen, and gender: Differences in methamphetamine neurotoxicity." *Ann N Y Acad Sci* 965: 136-56.
- Dluzen, D. E. (2000). "Neuroprotective effects of estrogen upon the nigrostriatal dopaminergic system." *J Neurocytol* 29(5-6): 387-99.
- Eisch, A. J., S. J. O'Dell, et al. (1996). "Striatal and cortical NMDA receptors are altered by a neurotoxic regimen of methamphetamine." *Synapse* 22(3): 217-25.
- Elliott, A. J., E. H. Gold, et al. (1980). "Synthesis of some 5-phenylhexahydroazepino[4,5-b]indoles as potential neuroleptic agents." *J Med Chem* 23(11): 1268-9.
- Ellison, G. (2002). "Neural degeneration following chronic stimulant abuse reveals a weak link in brain, fasciculus retroflexus, implying the loss of forebrain control circuitry." *Eur Neuropsychopharmacol* 12(4): 287-97.

- Eradiri, O. L. and M. S. Starr (1999). "Striatal dopamine depletion and behavioural sensitization induced by methamphetamine and 3-nitropropionic acid." *Eur J Pharmacol* 386(2-3): 217-26.
- Escubedo, E., C. Chipana, et al. (2005). "Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum: Involvement of  $\{\alpha\}7$  nicotinic receptors." *J Pharmacol Exp Ther* 315(2): 658-67.
- Eyerman, D. J. and B. K. Yamamoto (2005). "Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum." *J Pharmacol Exp Ther* 312(1): 160-9.
- Facchinetti, F., R. Dall'Olio, et al. (1994). "Long-lasting effects of chronic neonatal blockade of N-methyl-D-aspartate receptor through the competitive antagonist CGP 39551 in rats." *Neuroscience* 60(2): 343-53.
- Ferrucci, M., C. L. Busceti, et al. (2006). "Effects of methamphetamine on the cerebellar cortex: A preliminary study." *Ann N Y Acad Sci* 1074: 149-53.
- Finberg, J. P., T. Takeshima, et al. (1998). "Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor." *Neuroreport* 9(4): 703-7.
- Flora, G., Y. W. Lee, A. Nath, B. Hennig, W. Maragos and M. Toborek (2003). "Methamphetamine potentiates HIV-1 tat protein-mediated activation of redox-sensitive pathways in discrete regions of the brain." *Exp Neurol* 179(1): 60-70.
- Flora, G., Y. W. Lee, et al. (2002). "Methamphetamine-induced TNF- $\alpha$  gene expression and activation of AP-1 in discrete regions of mouse brain: Potential role of reactive oxygen intermediates and lipid peroxidation." *Neuromolecular Med* 2(1): 71-85.
- Fornai, F., P. Lenzi, et al. (2006). "Fine ultrastructure and biochemistry of PC12 cells: A comparative approach to understand neurotoxicity." *Brain Res*.
- Fornai, F., P. Lenzi, et al. (2005). "Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice." *Brain Res Bull* 65(5): 405-13.
- Fornai, F., G. Lazzeri, et al. (2003). "Amphetamines induce ubiquitin-positive inclusions within striatal cells." *Neurol Sci* 24(3): 182-3.
- Fornai, F., F. Vaglini, et al. (1997). "Species differences in the role of excitatory amino acids in experimental parkinsonism." *Neurosci Biobehav Rev* 21(4): 401-15.
- Foster, S. B., M. Z. Wrona, et al. (2003). "The parkinsonian neurotoxin 1-methyl-4-phenylpyridinium (MPP(+)) mediates release of l-3,4-dihydroxyphenylalanine (l-DOPA) and inhibition of l-DOPA decarboxylase in the rat striatum: a microdialysis study." *Chem Res Toxicol* 16(10): 1372-84.
- Frey, K., M. Kilbourn, et al. (1997). "Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine." *Eur J Pharmacol* 334(2-3): 273-9.
- Friedman, S. D., E. Castaneda, et al. (1998). "Long-term monoamine depletion, differential recovery, and subtle behavioral impairment following methamphetamine-induced neurotoxicity." *Pharmacol Biochem Behav* 61(1): 35-44.
- Frost, D. O. and J. L. Cadet (2000). "Effects of methamphetamine-induced neurotoxicity on the development of neural circuitry: A hypothesis." *Brain Res Brain Res Rev* 34(3): 103-18.
- Fukumura, M., G. D. Cappon, C. Pu, H. W. Broening and C. V. Vorhees (1998). "A single dose model of methamphetamine-induced neurotoxicity in rats: Effects on neostriatal monoamines and glial fibrillary acidic protein." *Brain Res* 806(1): 1-7.
- Fukumura, M., G. D. Cappon, H. W. Broening and C. V. Vorhees (1998). "Methamphetamine-induced dopamine and serotonin reductions in neostriatum are not gender specific in rats with comparable hyperthermic responses." *Neurotoxicol Teratol* 20(4): 441-8.
- Fuller, R. W., S. K. Hemrick-Luecke, et al. (1992). "Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist." *Neuropharmacology* 31(10): 1027-32.
- Gajjar, T. M., L. I. Anderson and D. E. Dluzen (2003). "Acute effects of estrogen upon methamphetamine induced neurotoxicity of the nigrostriatal dopaminergic system." *J Neural Transm* 110(11): 1215-24.
- Garcia de Yebenes, J., J. Yebenes, et al. (2000). "Neurotrophic factors in neurodegenerative disorders: Model of Parkinson's disease." *Neurotox Res* 2(2-3): 115-37.
- Gassen, M., I. Lamensdorf, et al. (2003). "Attenuation of methamphetamine induced dopaminergic neurotoxicity by flupirtine: Microdialysis study on dopamine release and free radical generation." *J Neural Transm* 110(2): 171-82.
- Gavrilin, M. A., L. E. Mathes and M. Podell (2002). "Methamphetamine enhances cell-associated feline immunodeficiency virus replication in astrocytes." *J Neurovirol* 8(3): 240-9.
- Gehrke, B. J., S. B. Harrod, et al. (2003). "The effect of neurotoxic doses of methamphetamine on methamphetamine-conditioned place preference in rats." *Psychopharmacology (Berl)* 166(3): 249-57.
- Gesi, M., G. Lazzeri, et al. (2006). "Inclusion dynamics in PC12 is comparable between amphetamines and MPTP." *Ann N Y Acad Sci* 1074: 315-9.
- Gomes-da-Silva, J., A. Perez-Rosado, et al. (2000). "Neonatal methamphetamine in the rat: Evidence for gender-specific differences upon tyrosine hydroxylase enzyme in the dopaminergic nigrostriatal system." *Ann N Y Acad Sci* 914: 431-8.



- Hirata, H., M. Asanuma, et al. (1998). "Melatonin attenuates methamphetamine-induced toxic effects on dopamine and serotonin terminals in mouse brain." *Synapse* 30(2): 150-5.
- Hirata, H. and J. L. Cadet (1997). "p53-knockout mice are protected against the long-term effects of methamphetamine on dopaminergic terminals and cell bodies." *J Neurochem* 69(2): 780-90.
- Hirata, H., B. Ladenheim, et al. (1996). "Autoradiographic evidence for methamphetamine-induced striatal dopaminergic loss in mouse brain: Attenuation in CuZn-superoxide dismutase transgenic mice." *Brain Res* 714(1-2): 95-103.
- Hirata, H., B. Ladenheim, et al. (1995). "Methamphetamine-induced serotonin neurotoxicity is mediated by superoxide radicals." *Brain Res* 677(2): 345-7.
- Gerlach, M. and P. Riederer (1996). "Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man." *J Neural Transm* 103(8-9): 987-1041.
- Gibb, J. W., M. Johnson, et al. (1990). "Neurochemical basis of neurotoxicity." *Neurotoxicology* 11(2): 317-21.
- Gibb, J. W., M. Johnson, et al. (1989). "MK-801 attenuates the methamphetamine induced decreased in tryptophan hydroxylase activity." *NIDA Res Monogr* 95: 511.
- Ginawi, O. T., O. A. al-Shabanah, et al. (1997). "Increased toxicity of methamphetamine in morphine-dependent mice." *Gen Pharmacol* 28(5): 727-31.
- Gluck, M. R., L. Y. Moy, et al. (2001). "Parallel increases in lipid and protein oxidative markers in several mouse brain regions after methamphetamine treatment." *J Neurochem* 79(1): 152-60.
- Golembiowska, K., J. Konieczny, et al. (2003). "Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats." *Neuropharmacology* 45(4): 484-92.
- Golembiowska, K., J. Konieczny, et al. (2002). "The role of striatal metabotropic glutamate receptors in degeneration of dopamine neurons." *Amino Acids* 23(1-3): 199-205.
- Greenamyre, J. T. and C. F. O'Brien (1991). "N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease." *Arch Neurol* 48(9): 977-81.
- Guilarte, T. R., M. K. Nihei, J. L. McGlothlan and A. S. Howard (2003). "Methamphetamine-induced deficits of brain monoaminergic neuronal markers: Distal axotomy or neuronal plasticity." *Neuroscience* 122(2): 499-513.
- Guilarte, T. R. (2001). "Is methamphetamine abuse a risk factor in parkinsonism?" *Neurotoxicology* 22(6): 725-31.
- Hamamura, M., S. Watanabe, et al. (2004). "Selective changes in the shapes of parasagittal bands of Aldoc (Zebrin) mRNA in the rat vermis of the cerebellum after repeated methamphetamine injections." *Cerebellum* 3(4): 236-47.
- Hanson, G. R., K. S. Rau, et al. (2004). "The methamphetamine experience: A NIDA partnership." *Neuropharmacology* 47 Suppl 1: 92-100.
- Hanson, G. R., V. Sandoval, et al. (2004). "Psychostimulants and vesicle trafficking: A novel mechanism and therapeutic implications." *Ann N Y Acad Sci* 1025: 146-50.
- Hanson, G. R., N. Singh, et al. (1992). "Responses of limbic and extrapyramidal neurotensin systems to stimulants of abuse. Involvement of dopaminergic mechanisms." *Ann N Y Acad Sci* 668: 165-72.
- Harold, C., T. Wallace, et al. (2000). "Methamphetamine selectively alters brain glutathione." *Eur J Pharmacol* 400(1): 99-102.
- Harvey, D. C., G. Lacan, et al. (2000). "Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss." *Brain Res* 871(2): 259-70.
- Harvey, D. C., G. Lacan, et al. (2000). "Regional heterogeneity of dopaminergic deficits in vervet monkey striatum and substantia nigra after methamphetamine exposure." *Exp Brain Res* 133(3): 349-58.
- Hashimoto, K., H. Tsukada, et al. (2006). "Protective effects of minocycline on the reduction of dopamine transporters in the striatum after administration of methamphetamine: A positron emission tomography study in conscious monkeys." *Biol Psychiatry*.
- Hashimoto, K., H. Tsukada, et al. (2004). "Effects of N-acetyl-L-cysteine on the reduction of brain dopamine transporters in monkey treated with methamphetamine." *Ann N Y Acad Sci* 1025: 231-5.
- Hashimoto, K., H. Tsukada, et al. (2004). "Protective effects of N-acetyl-L-cysteine on the reduction of dopamine transporters in the striatum of monkeys treated with methamphetamine." *Neuropsychopharmacology* 29(11): 2018-23.
- Hayase, T., Y. Yamamoto, et al. (2003). "Brain excitatory amino acid transporters (EAATs) and treatment of methamphetamine toxicity." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 38(6): 498-511.
- Hayashi, T., H. Hirata, M. Asanuma, B. Ladenheim, L. I. Tsao, J. L. Cadet and T. P. Su (2001). "Delta opioid peptide [D-Ala<sup>2</sup>, D-Leu<sup>5</sup>]enkephalin causes a near complete blockade of the neuronal damage caused by a single high dose of methamphetamine: Examining the role of p53." *Synapse* 39(4): 305-12.
- He, J., Y. Yang, et al. (2006). "The effects of chronic administration of quetiapine on the methamphetamine-induced recognition memory impairment and dopaminergic terminal deficit in rats." *Behav Brain Res* 172(1): 39-45.

- He, J., H. Xu, et al. (2005). "Chronic administration of quetiapine alleviates the anxiety-like behavioural changes induced by a neurotoxic regimen of dl-amphetamine in rats." *Behav Brain Res* 160(1): 178-87.
- He, J., H. Xu, Y. Yang, X. Zhang and X. M. Li (2004). "Neuroprotective effects of olanzapine on methamphetamine-induced neurotoxicity are associated with an inhibition of hyperthermia and prevention of bcl-2 decrease in rats." *Brain Res* 1018(2): 186-92.
- Hirata, H., M. Asanuma, et al. (1998). "Melatonin attenuates methamphetamine-induced toxic effects on dopamine and serotonin terminals in mouse brain." *Synapse* 30(2): 150-5.
- Hirata, H., M. Asanuma, et al. (1998). "Superoxide radicals are mediators of the effects of methamphetamine on Zif268 (Egr-1, NGFI-A) in the brain: Evidence from using CuZn superoxide dismutase transgenic mice." *Brain Res Mol Brain Res* 58(1-2): 209-16.
- Hirata, H. and J. L. Cadet (1997). "Methamphetamine-induced serotonin neurotoxicity is attenuated in p53-knockout mice." *Brain Res* 768(1-2): 345-8.
- Hirata, H. and J. L. Cadet (1997). "p53-knockout mice are protected against the long-term effects of methamphetamine on dopaminergic terminals and cell bodies." *J Neurochem* 69(2): 780-90.
- Hirata, H., B. Ladenheim, et al. (1996). "Autoradiographic evidence for methamphetamine-induced striatal dopaminergic loss in mouse brain: Attenuation in CuZn-superoxide dismutase transgenic mice." *Brain Res* 714(1-2): 95-103.
- Hirata, H., B. Ladenheim, et al. (1995). "Methamphetamine-induced serotonin neurotoxicity is mediated by superoxide radicals." *Brain Res* 677(2): 345-7.
- Holden, C. (2003). "Retraction. Paper on toxic party drug is pulled over vial mix-up." *Science* 301(5639): 1454.
- Hom, D. G., D. Jiang, et al. (1997). "Elevated expression of glutathione peroxidase in PC12 cells results in protection against methamphetamine but not MPTP toxicity." *Brain Res Mol Brain Res* 46(1-2): 154-60.
- Horner, K. A., S. C. Westwood, et al. (2006). "Multiple, high doses of methamphetamine increase the number of preproneuropeptide Y mRNA-expressing neurons in the striatum of rat via a dopamine D1 receptor-dependent mechanism." *J Pharmacol Exp Ther.*
- Ihara, Y., M. Sato, et al. (1986). "Morphological changes in rat striatal boutons after chronic methamphetamine and haloperidol treatment." *Neurosci Res* 3(5): 403-10.
- Imam, S. Z., J. Jankovic, et al. (2005). "Nitric oxide mediates increased susceptibility to dopaminergic damage in Nurr1 heterozygous mice." *FASEB J* 19(11): 1441-50.
- Imam, S. Z., M. Oetinger, et al. (2003). "The role of caspase III inhibition in methamphetamine-induced alterations in p53 and bcl-2 expression: Correlation with dopaminergic neurotoxicity." *Ann N Y Acad Sci* 993: 350; discussion 387-93.
- Imam, S. Z., G. D. Newport, et al. (2002). "Methamphetamine-induced dopaminergic neurotoxicity and production of peroxynitrite are potentiated in nerve growth factor differentiated pheochromocytoma 12 cells." *Ann N Y Acad Sci* 965: 204-13.
- Imam, S. Z. and S. F. Ali (2001). "Aging increases the susceptibility to methamphetamine-induced dopaminergic neurotoxicity in rats: Correlation with peroxynitrite production and hyperthermia." *J Neurochem* 78(5): 952-9.
- Imam, S. Z., Y. Itzhak, et al. (2001). "Methamphetamine-induced alteration in striatal p53 and bcl-2 expressions in mice." *Brain Res Mol Brain Res* 91(1-2): 174-8.
- Imam, S. Z., G. D. Newport, et al. (2001). "Peroxynitrite plays a role in methamphetamine-induced dopaminergic neurotoxicity: Evidence from mice lacking neuronal nitric oxide synthase gene or overexpressing copper-zinc superoxide dismutase." *J Neurochem* 76(3): 745-9.
- Imam, S. Z., J. el-Yazal, et al. (2001). "Methamphetamine-induced dopaminergic neurotoxicity: Role of peroxynitrite and neuroprotective role of antioxidants and peroxynitrite decomposition catalysts." *Ann N Y Acad Sci* 939: 366-80.
- Imam, S. Z., F. Islam, et al. (2000). "Prevention of dopaminergic neurotoxicity by targeting nitric oxide and peroxynitrite: implications for the prevention of methamphetamine-induced neurotoxic damage." *Ann N Y Acad Sci* 914: 157-71.
- Imam, S. Z., J. P. Crow, et al. (1999). "Methamphetamine generates peroxynitrite and produces dopaminergic neurotoxicity in mice: Protective effects of peroxynitrite decomposition catalyst." *Brain Res* 837(1-2): 15-21.
- Imam, S. Z., G. D. Newport, et al. (1999). "Selenium, an antioxidant, protects against methamphetamine-induced dopaminergic neurotoxicity." *Brain Res* 818(2): 575-8.
- Imamura, N., H. Hida, et al. (2003). "Neurodegeneration of substantia nigra accompanied with macrophage/microglia infiltration after intrastriatal hemorrhage." *Neurosci Res* 46(3): 289-98.
- Ishida, Y., K. Todaka, et al. (1998). "Methamphetamine-induced Fos expression in the substantia nigra pars reticulata in rats with a unilateral 6-OHDA lesion of the nigrostriatal fibers." *Neurosci Res* 30(4): 355-60.
- Ishida, Y., K. Todaka, et al. (1998). "Methamphetamine induces Fos expression in the striatum and the substantia nigra pars reticulata in a rat model of Parkinson's disease." *Brain Res* 809(1): 107-14.
- Ito, K. (1999). "The role of gamma-aminobutyric acid (GABA)-benzodiazepine neurotransmission in an animal model of methamphetamine-induced psychosis." *Hokkaido Igaku Zasshi* 74(2): 135-44.

- Itzhak, Y. and S. F. Ali (2006). "Role of nitregeric system in behavioral and neurotoxic effects of amphetamine analogs." *Pharmacol Ther* 109(1-2): 246-62.
- Itzhak, Y. and C. Achat-Mendes (2004). "Methamphetamine and MDMA (ecstasy) neurotoxicity: 'Of mice and men'." *IUBMB Life* 56(5): 249-55.
- Itzhak, Y. and S. F. Ali (2002). "Behavioral consequences of methamphetamine-induced neurotoxicity in mice: Relevance to the psychopathology of methamphetamine addiction." *Ann N Y Acad Sci* 965: 127-35.
- Itzhak, Y., J. L. Martin, et al. (2002). "Methamphetamine-induced dopaminergic neurotoxicity in mice: Long-lasting sensitization to the locomotor stimulation and desensitization to the rewarding effects of methamphetamine." *Prog Neuropsychopharmacol Biol Psychiatry* 26(6): 1177-83.
- Itzhak, Y., J. L. Martin and S. F. Ail (2000). "nNOS inhibitors attenuate methamphetamine-induced dopaminergic neurotoxicity but not hyperthermia in mice." *Neuroreport* 11(13): 2943-6.
- Itzhak, Y., C. Gandia, et al. (1998). "Resistance of neuronal nitric oxide synthase-deficient mice to methamphetamine-induced dopaminergic neurotoxicity." *J Pharmacol Exp Ther* 284(3): 1040-7.
- Iwashita, A., K. Mihara, S. Yamazaki, S. Matsuura, J. Ishida, H. Yamamoto, K. Hattori, N. Matsuoka and S. Mutoh (2004). "A new poly(ADP-ribose) polymerase inhibitor, FR261529 [2-(4-chlorophenyl)-5-quinoxalinecarboxamide], ameliorates methamphetamine-induced dopaminergic neurotoxicity in mice." *J Pharmacol Exp Ther* 310(3): 1114-24.
- Jayanthi, S., X. Deng, et al. (2005). "Calcineurin/NFAT-induced up-regulation of the Fas ligand/Fas death pathway is involved in methamphetamine-induced neuronal apoptosis." *Proc Natl Acad Sci U S A* 102(3): 868-73.
- Jayanthi, S., X. Deng, et al. (2004). "Methamphetamine induces neuronal apoptosis via cross-talks between endoplasmic reticulum and mitochondria-dependent death cascades." *FASEB J* 18(2): 238-51.
- Jayanthi, S., X. Deng, et al. (2001). "Methamphetamine causes differential regulation of pro-death and anti-death Bcl-2 genes in the mouse neocortex." *FASEB J* 15(10): 1745-52.
- Jeng, W., A. Ramkissoon, et al. (2006). "Prostaglandin H synthase-catalyzed bioactivation of amphetamines to free radical intermediates that cause CNS regional DNA oxidation and nerve terminal degeneration." *FASEB J* 20(6): 638-50.
- Jimenez, A., E. G. Jorda, et al. (2004). "Neurotoxicity of amphetamine derivatives is mediated by caspase pathway activation in rat cerebellar granule cells." *Toxicol Appl Pharmacol* 196(2): 223-34.
- Johnson-Davis, K. L., A. E. Fleckenstein and D. G. Wilkins (2003). "The role of hyperthermia and metabolism as mechanisms of tolerance to methamphetamine neurotoxicity." *Eur J Pharmacol* 482(1-3): 151-4.
- Kashiwabara, K., M. Sato, et al. (1984). "Reduction of 3H-kainic acid binding in rat cerebral cortex by chronic methamphetamine administration." *Biol Psychiatry* 19(8): 1173-82.
- Kanthasamy, A., V. Anantharam, et al. (2006). "Methamphetamine induces autophagy and apoptosis in a mesencephalic dopaminergic neuronal culture model: role of cathepsin-D in methamphetamine-induced apoptotic cell death." *Ann N Y Acad Sci* 1074: 234-44.
- Kawasaki, T., K. Ishihara, et al. (2006). "Protective effect of the radical scavenger edaravone against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum." *Eur J Pharmacol* 542(1-3): 92-9.
- Kim, H., W. Jhoo, et al. (2000). "Selenium deficiency potentiates methamphetamine-induced nigral neuronal loss; Comparison with MPTP model." *Brain Res* 862(1-2): 247-52.
- Kim, H. C., W. K. Jhoo, et al. (1999). "Protection of methamphetamine nigrostriatal toxicity by dietary selenium." *Brain Res* 851(1-2): 76-86.
- Kim, S., R. Westphalen, et al. (2000). "Toward development of an in vitro model of methamphetamine-induced dopamine nerve terminal toxicity." *J Pharmacol Exp Ther* 293(2): 625-33.
- Kita, T., T. Saraya, et al. (2003). "1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine pretreatment attenuates methamphetamine-induced dopamine toxicity." *Pharmacol Toxicol* 92(2): 71-80.
- Kita, T., G. C. Wagner, et al. (2003). "Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption." *J Pharmacol Sci* 92(3): 178-95.
- Kita, T. and T. Nakashima (2002). "[A recent trend in methamphetamine-induced neurotoxicity]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 22(2): 35-47.
- Kita, T., Y. Matsunari, et al. (2000). "Evaluation of the effects of alpha-phenyl-N-tert-butyl nitron pretreatment on the neurobehavioral effects of methamphetamine." *Life Sci* 67(13): 1559-71.
- Kita, T., Y. Matsunari, et al. (2000). "Methamphetamine-induced striatal dopamine release, behavior changes and neurotoxicity in BALB/c mice." *Int J Dev Neurosci* 18(6): 521-30.
- Kita, T., M. Takahashi, et al. (1999). "Hydroxyl radical formation following methamphetamine administration to rats." *Pharmacol Toxicol* 85(3): 133-7.

- Kita, T., S. Paku, et al. (1998). "Methamphetamine-induced neurotoxicity in BALB/c, DBA/2N and C57BL/6N mice." *Neuropharmacology* 37(9): 1177-84.
- Kitaichi, K., Y. Ito, et al. (2004). "The altered disposition of methamphetamine in the model of methamphetamine-induced neurotoxicity." *Ann N Y Acad Sci* 1025: 248-56.
- Kitanaka, J., N. Kitanaka, et al. (2003). "Chronic methamphetamine administration reduces histamine-stimulated phosphoinositide hydrolysis in mouse frontal cortex." *Biochem Biophys Res Commun* 300(4): 932-7.
- Kiyatkin, E. A. (2005). "Brain hyperthermia as physiological and pathological phenomena." *Brain Res Brain Res Rev* 50(1): 27-56.
- Kleven, M. S. and L. S. Seiden (1992). "Methamphetamine-induced neurotoxicity: structure activity relationships." *Ann N Y Acad Sci* 654: 292-301.
- Kleven, M. S. and L. S. Seiden (1992). "Repeated injection of cocaine potentiates methamphetamine-induced toxicity to dopamine-containing neurons in rat striatum." *Ann N Y Acad Sci* 654: 464-6.
- Kleven, M. S. and L. S. Seiden (1991). "Repeated injection of cocaine potentiates methamphetamine-induced toxicity to dopamine-containing neurons in rat striatum." *Brain Res* 557(1-2): 340-3.
- Klongpanichapak, S., P. Govitrapong, et al. (2006). "Attenuation of cocaine and methamphetamine neurotoxicity by coenzyme Q10." *Neurochem Res* 31(3): 303-11.
- Koike, K., K. Hashimoto, et al. (2005). "The immunophilin ligand FK506 protects against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum." *Neuropharmacology* 48(3): 391-7.
- Kokoshka, J. M., A. E. Fleckenstein, D. G. Wilkins and G. R. Hanson (2000). "Age-dependent differential responses of monoaminergic systems to high doses of methamphetamine." *J Neurochem* 75(5): 2095-102.
- Kosman, M. E. and D. R. Unna (1968). "Effects of chronic administration of the amphetamines and other stimulants on behavior." *Clin Pharmacol Ther* 9(2): 240-54.
- Kovachich, G. B., C. E. Aronson, et al. (1989). "Effects of high-dose methamphetamine administration on serotonin uptake sites in rat brain measured using [3H]cyanoimipramine autoradiography." *Brain Res* 505(1): 123-9.
- Kovacic, P. and A. L. Cooksy (2005). "Unifying mechanism for toxicity and addiction by abused drugs: Electron transfer and reactive oxygen species." *Med Hypotheses* 64(2): 357-66.
- Koike, K., K. Hashimoto, et al. (2005). "The immunophilin ligand FK506 protects against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum." *Neuropharmacology* 48(3): 391-7.
- Kuhn, D. M., D. M. Francescutti-Verbeem, et al. (2006). "Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: Relationship to methamphetamine-induced nerve ending damage." *Ann N Y Acad Sci* 1074: 31-41.
- Kunnathur, V., K. Shemisa, et al. (2006). "Sex differences in methamphetamine-evoked striatal dopamine of mice are reversed by nomifensine." *Neurotoxicol Teratol* 28(5): 557-62.
- Kuperman, D. I., T. E. Freyaldenhoven, L. C. Schmued and S. F. Ali (1997). "Methamphetamine-induced hyperthermia in mice: Examination of dopamine depletion and heat-shock protein induction." *Brain Res* 771(2): 221-7.
- Kupsch, A., J. Sautter, et al. (2001). "Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: Comparison of rasagiline (TVP 1012) with selegiline." *J Neural Transm* 108(8-9): 985-1009.
- Ladenheim, B., I. N. Krasnova, X. Deng, J. M. Oyler, A. Poletini, T. H. Moran, M. A. Huestis and J. L. Cadet (2000). "Methamphetamine-induced neurotoxicity is attenuated in transgenic mice with a null mutation for interleukin-6." *Mol Pharmacol* 58(6): 1247-56.
- LaVoie, M. J. and T. G. Hastings (1999). "Peroxy-nitrite- and nitrite-induced oxidation of dopamine: Implications for nitric oxide in dopaminergic cell loss." *J Neurochem* 73(6): 2546-54.
- Layer, R. T., L. R. Bland, et al. (1993). "MK-801, but not drugs acting at strychnine-insensitive glycine receptors, attenuate methamphetamine nigrostriatal toxicity." *Brain Res* 625(1): 38-44.
- Lazzeri, G., P. Lenzi, et al. (2006). "In PC12 cells neurotoxicity induced by methamphetamine is related to proteasome inhibition." *Ann N Y Acad Sci* 1074: 174-7.
- Lesting, J., J. Neddens, et al. (2005). "Hemisphere-specific effects on serotonin but not dopamine innervation in the nucleus accumbens of gerbils caused by isolated rearing and a single early methamphetamine challenge." *Brain Res* 1035(2): 168-76.
- Liao, P. C., Y. M. Kuo, et al. (2005). "Local proteins associated with methamphetamine-induced nigrostriatal dopaminergic neurotoxicity." *J Neurochem* 95(1): 160-8.
- Liao, P. C., Y. M. Kuo, et al. (2003). "Striatal formation of 6-hydroxydopamine in mice treated with pargyline, pyrogallol and methamphetamine." *J Neural Transm* 110(5): 487-94.
- Liu, B. and D. E. Dluzen (2006). "Effects of estrogen and related agents upon methamphetamine-induced neurotoxicity within an impaired nigrostriatal dopaminergic system of ovariectomized mice." *Neuroendocrinology* 83(5-6): 295-302.
- Liu, B. and D. E. Dluzen (2006). "Effect of estrogen upon methamphetamine-induced neurotoxicity within the impaired nigrostriatal dopaminergic system." *Synapse* 60(5): 354-61.

- Lockhart, B., A. Roger, et al. (2005). "In vivo neuroprotective effects of the novel imidazolyl nitron free-radical scavenger (Z)-alpha-[2-thiazol-2-yl]imidazol-4-yl]-N-tert-butyl nitron (S34176)." *Eur J Pharmacol* 511(2-3): 127-36.
- Lockhart, B., N. Bonhomme, et al. (2001). "Protective effect of the antioxidant 6-ethoxy-2,2-pentamethylen-1,2-dihydroquinoline (S 33113) in models of cerebral neurodegeneration." *Eur J Pharmacol* 416(1-2): 59-68.
- Loonam, T. M., P. A. Noailles, et al. (2003). "Substance P and cholecystokinin regulate neurochemical responses to cocaine and methamphetamine in the striatum." *Life Sci* 73(6): 727-39.
- Lotharius, J., J. Falsig, et al. (2005). "Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway." *J Neurosci* 25(27): 6329-42.
- Maggio, R., M. Riva, et al. (1998). "Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors." *J Neurochem* 71(6): 2439-46.
- Maggio, R., M. Riva, et al. (1997). "Striatal increase of neurotrophic factors as a mechanism of nicotine protection in experimental parkinsonism." *J Neural Transm* 104(10): 1113-23.
- Maragos, W. F., K. L. Young, et al. (2002). "Human immunodeficiency virus-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function." *J Neurochem* 83(4): 955-63.
- Maragos, W. F., R. Jakel, et al. (2000). "Methamphetamine toxicity is attenuated in mice that overexpress human manganese superoxide dismutase." *Brain Res* 878(1-2): 218-22.
- Mark, K. A., J. J. Soghomonian, et al. (2004). "High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity." *J Neurosci* 24(50): 11449-56.
- Marshall, J. F., S. J. O'Dell, et al. (1993). "Dopamine-glutamate interactions in methamphetamine-induced neurotoxicity." *J Neural Transm Gen Sect* 91(2-3): 241-54.
- Matuszewich, L. and B. K. Yamamoto (2004). "Chronic stress augments the long-term and acute effects of methamphetamine." *Neuroscience* 124(3): 637-46.
- Matsuzaki, H., K. Namikawa, H. Kiyama, N. Mori and K. Sato (2004). "Brain-derived neurotrophic factor rescues neuronal death induced by methamphetamine." *Biol Psychiatry* 55(1): 52-60.
- Mauceli, G., C. I. Busceti, et al. (2006). "Overexpression of alpha-synuclein following methamphetamine: Is it good or bad?" *Ann N Y Acad Sci* 1074: 191-7.
- McCann, U. D. and G. A. Ricaurte (2004). "Amphetamine neurotoxicity: Accomplishments and remaining challenges." *Neurosci Biobehav Rev* 27(8): 821-6.
- McGinty, J. F. (1995). "Introduction to the role of excitatory amino acids in the actions of abused drugs: a symposium presented at the 1993 annual meeting of the College on Problems of Drug Dependence." *Drug Alcohol Depend* 37(2): 91-4.
- McKinney, P. E., C. Tomaszewski, et al. (1994). "Methamphetamine toxicity prevented by activated charcoal in a mouse model." *Ann Emerg Med* 24(2): 220-3.
- Melega, W. P., G. Lacan, et al. (2000). "Long-term methamphetamine-induced decreases of [(11C)WIN 35,428 binding in striatum are reduced by GDNF: PET studies in the vervet monkey." *Synapse* 35(4): 243-9.
- Melega, W. P., G. Lacan, et al. (1998). "Dizocilpine and reduced body temperature do not prevent methamphetamine-induced neurotoxicity in the vervet monkey: [11C]WIN 35,428 - positron emission tomography studies." *Neurosci Lett* 258(1): 17-20.
- Melega, W. P., M. J. Raleigh, et al. (1997). "Recovery of striatal dopamine function after acute amphetamine- and methamphetamine-induced neurotoxicity in the vervet monkey." *Brain Res* 766(1-2): 113-20.
- Melo, P., L. G. Rodrigues, et al. (2006). "Effects of prenatal exposure to methamphetamine on the development of the rat retina." *Ann N Y Acad Sci* 1074: 590-603.
- Melo, P., V. Z. Moreno, et al. (2006). "Myelination changes in the rat optic nerve after prenatal exposure to methamphetamine." *Brain Res* 1106(1): 21-9.
- Meredith, C. W., C. Jaffe, et al. (2005). "Implications of chronic methamphetamine use: A literature review." *Harv Rev Psychiatry* 13(3): 141-54.
- Meredith, G. E., T. Farrell, et al. (1999). "Immunocytochemical characterization of catecholaminergic neurons in the rat striatum following dopamine-depleting lesions." *Eur J Neurosci* 11(10): 3585-96.
- Metzger, R. R., H. M. Haughey, D. G. Wilkins, J. W. Gibb, G. R. Hanson and A. E. Fleckenstein (2000). "Methamphetamine-induced rapid decrease in dopamine transporter function: Role of dopamine and hyperthermia." *J Pharmacol Exp Ther* 295(3): 1077-85.
- Mickley, K. R. and D. E. Dluzen (2004). "Dose-response effects of estrogen and tamoxifen upon methamphetamine-induced behavioral responses and neurotoxicity of the nigrostriatal dopaminergic system in female mice." *Neuroendocrinology* 79(6): 305-16.
- Miller, D. B. and J. P. O'Callaghan (2003). "Elevated environmental temperature and methamphetamine neurotoxicity." *Environ Res* 92(1): 48-53.
- Miller, D. B., J. P. O'Callaghan, et al. (2000). "Age as a susceptibility factor in the striatal dopaminergic neurotoxicity observed in the mouse following substituted amphetamine exposure." *Ann N Y Acad Sci* 914: 194-207.

- Miller, D. B., S. F. Ali, et al. (1998). "The impact of gender and estrogen on striatal dopaminergic neurotoxicity." *Ann N Y Acad Sci* 844: 153-65.
- Miller, D. B. and J. P. O'Callaghan (1994). "Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse." *J Pharmacol Exp Ther* 270(2): 752-60.
- Miyazaki, I., M. Asanuma, et al. (2006). "Methamphetamine-induced dopaminergic neurotoxicity is regulated by quinone-formation-related molecules." *FASEB J* 20(3): 571-3.
- Moore, K. A., A. H. Lichtman, et al. (1995). "Alpha-Benzyl-N-methylphenethylamine (BNMPA), an impurity of illicit methamphetamine synthesis: pharmacological evaluation and interaction with methamphetamine." *Drug Alcohol Depend* 39(2): 83-9.
- Morton, A. J., M. A. Hickey, et al. (2001). "Methamphetamine toxicity in mice is potentiated by exposure to loud music." *Neuroreport* 12(15): 3277-81.
- Moszczynska, A., S. Turenne, et al. (1998). "Rat striatal levels of the antioxidant glutathione are decreased following binge administration of methamphetamine." *Neurosci Lett* 255(1): 49-52.
- Moy, L. Y., D. S. Albers, et al. (1998). "Lowering ambient or core body temperature elevates striatal MPP+ levels and enhances toxicity to dopamine neurons in MPTP-treated mice." *Brain Res* 790(1-2): 264-9.
- Nakajima, A., K. Yamada, T. Nagai, T. Uchiyama, Y. Miyamoto, T. Mamiya, J. He, A. Nitta, M. Mizuno, M. H. Tran, A. Seto, M. Yoshimura, K. Kitaichi, T. Hasegawa, K. Saito, Y. Yamada, M. Seishima, K. Sekikawa, H. C. Kim and T. Nabeshima (2004). "Role of tumor necrosis factor-alpha in methamphetamine-induced drug dependence and neurotoxicity." *J Neurosci* 24(9): 2212-25.
- Namiki, M., T. Mori, et al. (2005). "Underlying mechanism of combined effect of methamphetamine and morphine on lethality in mice and therapeutic potential of cooling." *J Pharmacol Sci* 99(2): 168-76.
- Nash, J. F. and B. K. Yamamoto (1992). "Methamphetamine neurotoxicity and striatal glutamate release: Comparison to 3,4-methylenedioxymethamphetamine." *Brain Res* 581(2): 237-43.
- Neddens, J., J. Lesting, et al. (2002). "An early methamphetamine challenge suppresses the maturation of dopamine fibres in the nucleus accumbens of gerbils: On the significance of rearing conditions." *J Neural Transm* 109(2): 141-55.
- O'Callaghan, J. P. and D. B. Miller (1994). "Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse." *J Pharmacol Exp Ther* 270(2): 741-51.
- O'Dell, S. J. and J. F. Marshall (2005). "Neurotoxic regimens of methamphetamine induce persistent expression of phospho-c-Jun in somatosensory cortex and substantia nigra." *Synapse* 55(3): 137-47.
- Ogden, C. A., M. E. Rich, et al. (2004). "Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: An expanded convergent functional genomics approach." *Mol Psychiatry* 9(11): 1007-29.
- Ohmori, T., T. Abekawa, et al. (1996). "The role of glutamate in behavioral and neurotoxic effects of methamphetamine." *Neurochem Int* 29(3): 301-7.
- Oiwa, Y., R. Yoshimura, et al. (2002). "Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease." *Brain Res* 947(2): 271-83.
- O'Neil M, L., R. Kuczenski, et al. (2006). "Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge." *Synapse* 60(6): 465-73.
- O'Shea, E., V. Sanchez, et al. (2003). "On the protection against methamphetamine-induced neurotoxicity by benzamide, a PARP inhibitor." *Psychopharmacology (Berl)* 165(3): 317-9.
- Pacchioni, A. M., J. Vallone, et al. (2007). "Nrf2 gene deletion fails to alter psychostimulant-induced behavior or neurotoxicity." *Brain Res* 1127(1): 26-35.
- Park, M. J., S. K. Lee, et al. (2006). "Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity." *Brain Res* 1109(1): 176-82.
- Pereira, F. C., E. S. Lourenco, et al. (2006). "Single or multiple injections of methamphetamine increased dopamine turnover but did not decrease tyrosine hydroxylase levels or cleave caspase-3 in caudate-putamen." *Synapse* 60(3): 185-93.
- Pennypacker, K. R., X. Yang, et al. (2000). "Long-term induction of Fos-related antigen-2 after methamphetamine-, methylenedioxymethamphetamine-, 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine- and trimethyltin-induced brain injury." *Neuroscience* 101(4): 913-9.
- Perez, F. A., W. R. Curtis, et al. (2005). "Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity." *BMC Neurosci* 6: 71.
- Perez, V. and M. Unzeta (2003). "PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 mice." *Neurochem Int* 42(3): 221-9.
- Pieri, M., L. Pieri, et al. (1975). "A comparison of drug-induced rotation in rats lesioned in the medial forebrain bundle with 5,6-dihydroxytryptamine or 6-hydroxydopamine." *Arch Int Pharmacodyn Ther* 217(1): 118-30.

- Pontieri, F. E., A. M. Crane, et al. (1990). "Metabolic mapping of the effects of intravenous methamphetamine administration in freely moving rats." *Psychopharmacology (Berl)* 102(2): 175-82.
- Pu, C., H. W. Broening, et al. (1996). "Effect of methamphetamine on glutamate-positive neurons in the adult and developing rat somatosensory cortex." *Synapse* 23(4): 328-34.
- Pu, C., J. E. Fisher, et al. (1994). "The effects of amfonelic acid, a dopamine uptake inhibitor, on methamphetamine-induced dopaminergic terminal degeneration and astrocytic response in rat striatum." *Brain Res* 649(1-2): 217-24.
- Pu, C. and C. V. Vorhees (1993). "Developmental dissociation of methamphetamine-induced depletion of dopaminergic terminals and astrocyte reaction in rat striatum." *Brain Res Dev Brain Res* 72(2): 325-8.
- Pubill, D., C. Chipana, et al. (2005). "Free radical production induced by methamphetamine in rat striatal synaptosomes." *Toxicol Appl Pharmacol* 204(1): 57-68.
- Pubill, D., A. M. Canudas, et al. (2003). "Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity." *Naunyn Schmiedebergs Arch Pharmacol* 367(5): 490-9.
- Pubill, D., E. Verdaguer, et al. (2002). "Carnosine prevents methamphetamine-induced gliosis but not dopamine terminal loss in rats." *Eur J Pharmacol* 448(2-3): 165-8.
- Rajan, P. D., R. Kekuda, et al. (2000). "Expression of the extraneuronal monoamine transporter in RPE and neural retina." *Curr Eye Res* 20(3): 195-204.
- Ricaurte, G. A. and U. D. McCann (1992). "Neurotoxic amphetamine analogues: Effects in monkeys and implications for humans." *Ann N Y Acad Sci* 648: 371-82.
- Ricaurte, G. A., I. Irwin, et al. (1987). "Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra." *Brain Res* 403(1): 43-51.
- Riddle, E. L., A. E. Fleckenstein, et al. (2006). "Mechanisms of methamphetamine-induced dopaminergic neurotoxicity." *AAPS J* 8(2): E413-8.
- Robinson, T. E., E. Castaneda, et al. (1990). "Compensatory changes in striatal dopamine neurons following recovery from injury induced by 6-OHDA or methamphetamine: A review of evidence from microdialysis studies." *Can J Psychol* 44(2): 253-75.
- Rodrigues, L. G., M. A. Tavares, et al. (2004). "Methamphetamine exacerbates the toxic effect of kainic acid in the adult rat retina." *Neurochem Int* 45(8): 1133-41.
- Ryan, R. E., S. A. Ross, et al. (2001). "Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice." *Br J Pharmacol* 132(8): 1650-6.
- Sabol, K. E., J. T. Roach, S. L. , C. Ferreira and M. M. Preau (2001). "Long-term effects of a high-dose methamphetamine regimen on subsequent methamphetamine-induced dopamine release in vivo." *Brain Res* 892(1): 122-9.
- Sabol, K. E., J. B. Richards, et al. (2000). "The effects of high-dose methamphetamine in the aging rat: Differential reinforcement of low-rate 72-s schedule behavior and neurochemistry." *J Pharmacol Exp Ther* 294(3): 850-63.
- Sanchez, V., M. Zeini, et al. (2003). "The nNOS inhibitor, AR-R17477AR, prevents the loss of NF68 immunoreactivity induced by methamphetamine in the mouse striatum." *J Neurochem* 85(2): 515-24.
- Sanchez-Alavez, M., L. M. Gombart, et al. (2004). "Physiological and behavioral effects of methamphetamine in a mouse model of endotoxemia: A preliminary study." *Pharmacol Biochem Behav* 77(2): 365-70.
- Sanga, M., I. R. Younis, et al. (2006). "Epoxidation of the methamphetamine pyrolysis product, trans-phenylpropene, to trans-phenylpropylene oxide by CYP enzymes and stereoselective glutathione adduct formation." *Toxicol Appl Pharmacol* 211(2): 148-56.
- Sato, S., T. Chiba, et al. (2006). "Decline of striatal dopamine release in parkin-deficient mice shown by ex vivo autoradiography." *J Neurosci Res* 84(6): 1350-7.
- Schluter, O. M., F. Fornai, et al. (2003). "Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice." *Neuroscience* 118(4): 985-1002.
- Schuster, C. R. and M. W. Fischman (1975). "Amphetamine toxicity: Behavioral and neuropathological indexes." *Fed Proc* 34(9): 1845-51.
- Segal, D. S., R. Kuczenski, et al. (2005). "Prolonged exposure of rats to intravenous methamphetamine: Behavioral and neurochemical characterization." *Psychopharmacology (Berl)* 180(3): 501-12.
- Segal, D. S., R. Kuczenski, et al. (2003). "Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge." *Neuropsychopharmacology* 28(10): 1730-40.
- Segura Aguilar, J. and R. M. Kostrzewa (2004). "Neurotoxins and neurotoxic species implicated in neurodegeneration." *Neurotox Res* 6(7-8): 615-30.
- Seiden, L. S. and K. E. Sabol (1996). "Methamphetamine and methylenedioxymethamphetamine neurotoxicity: Possible mechanisms of cell destruction." *NIDA Res Monogr* 163: 251-76.

- Seiden, L. S., W. L. Woolverton, et al. (1993). "Behavioral consequences of partial monoamine depletion in the CNS after methamphetamine-like drugs: The conflict between pharmacology and toxicology." *NIDA Res Monogr* 136: 34-46; discussion 46-52.
- Seiden, L. S., D. L. Commins, et al. (1988). "Neurotoxicity in dopamine and 5-hydroxytryptamine terminal fields: A regional analysis in nigrostriatal and mesolimbic projections." *Ann N Y Acad Sci* 537: 161-72.
- Seiden, L. S. and M. S. Kleven (1989). "Methamphetamine and related drugs: toxicity and resulting behavioral changes in response to pharmacological probes." *NIDA Res Monogr* 94: 146-60.
- Shishido, K., T. Shishido, et al. (2000). "Neurotoxic effect of high dose methamphetamine administration on the hippocampal formation of adult mice: morphometric study using image analyzer." *Neuroreport* 11(9): 1973-5.
- Sodesaki, K. and R. Matoba (1991). "[Changes in lipid peroxides in methamphetamine treated rats]." *Nihon Hoigaku Zasshi* 45(4): 318-22.
- Sonsalla, P. K., D. S. Albers, et al. (1998). "Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism." *Amino Acids* 14(1-3): 69-74.
- Sonsalla, P. K. (1995). "The role of N-methyl-D-aspartate receptors in dopaminergic neuropathology produced by the amphetamines." *Drug Alcohol Depend* 37(2): 101-5.
- Sonsalla, P. K., A. Giovanni, et al. (1992). "Characteristics of dopaminergic neurotoxicity produced by MPTP and methamphetamine." *Ann N Y Acad Sci* 648: 229-38.
- Sriram, K., D. B. Miller, et al. (2006). "Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: Role of tumor necrosis factor-alpha." *J Neurochem* 96(3): 706-18.
- Sriram, K., S. A. Benkovic, D. B. Miller and J. P. O'Callaghan (2002). "Obesity exacerbates chemically induced neurodegeneration." *Neuroscience* 115(4): 1335-46.
- Stadlin, A., J. W. Lau, et al. (1998). "A selective regional response of cultured astrocytes to methamphetamine." *Ann N Y Acad Sci* 844: 108-21.
- Staszewski, R. D. and B. K. Yamamoto (2006). "Methamphetamine-induced spectrin proteolysis in the rat striatum." *J Neurochem* 96(5): 1267-76.
- Stephans, S. E., T. S. Whittingham, et al. (1998). "Substrates of energy metabolism attenuate methamphetamine-induced neurotoxicity in striatum." *J Neurochem* 71(2): 613-21.
- Stephans, S. and B. Yamamoto (1996). "Methamphetamines pretreatment and the vulnerability of the striatum to methamphetamine neurotoxicity." *Neuroscience* 72(3): 593-600.
- Stephans, S. E. and B. Y. Yamamoto (1995). "Effect of repeated methamphetamine administrations on dopamine and glutamate efflux in rat prefrontal cortex." *Brain Res* 700(1-2): 99-106.
- Stephans, S. E. and B. K. Yamamoto (1994). "Methamphetamine-induced neurotoxicity: Roles for glutamate and dopamine efflux." *Synapse* 17(3): 203-9.
- Straiko, M. M., L. M. Coolen, et al. (2007). "The effect of amphetamine analogs on cleaved microtubule-associated protein-tau formation in the rat brain." *Neuroscience* 144(1): 223-31.
- Stumm, G., J. Schlegel, et al. (1999). "Amphetamines induce apoptosis and regulation of bcl-x splice variants in neocortical neurons." *FASEB J* 13(9): 1065-72.
- Su, T. P. (2000). "Delta opioid peptide[D-Ala(2),D-Leu(5)]enkephalin promotes cell survival." *J Biomed Sci* 7(3): 195-9.
- Taraska, T. and K. T. Finnegan (1997). "Nitric oxide and the neurotoxic effects of methamphetamine and 3,4-methylenedioxymethamphetamine." *J Pharmacol Exp Ther* 280(2): 941-7.
- Terleckyj, I. and P. K. Sonsalla (1994). "The sigma receptor ligand (+/-)-BMY 14802 prevents methamphetamine-induced dopaminergic neurotoxicity via interactions at dopamine receptors." *J Pharmacol Exp Ther* 269(1): 44-50.
- Teuchert-Noodt, G. and R. R. Dawirs (1991). "Age-related toxicity in prefrontal cortex and caudate-putamen complex of gerbils (*Meriones unguiculatus*) after a single dose of methamphetamine." *Neuropharmacology* 30(7): 733-43.
- Theodore, S., S. Stolberg, et al. (2006). "Human immunodeficiency virus-1 protein tat and methamphetamine interactions." *Ann N Y Acad Sci* 1074: 178-90.
- Theodore, S., W. A. Cass, et al. (2006). "Inhibition of tumor necrosis factor-alpha signaling prevents human immunodeficiency virus-1 protein Tat and methamphetamine interaction." *Neurobiol Dis* 23(3): 663-8.
- Theodore, S., W. A. Cass, et al. (2006). "Involvement of cytokines in human immunodeficiency virus-1 protein Tat and methamphetamine interactions in the striatum." *Exp Neurol* 199(2): 490-8.
- Theodore, S., W. A. Cass, et al. (2006). "Methamphetamine and human immunodeficiency virus protein Tat synergize to destroy dopaminergic terminals in the rat striatum." *Neuroscience* 137(3): 925-35.
- Thiriet, N., X. Deng, et al. (2005). "Neuropeptide Y protects against methamphetamine-induced neuronal apoptosis in the mouse striatum." *J Neurosci* 25(22): 5273-9.



- Thomas, D. M. and D. M. Kuhn (2005). "MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicity." *Brain Res* 1050(1-2): 190-8.
- Thomas, D. M. and D. M. Kuhn (2005). "Cyclooxygenase-2 is an obligatory factor in methamphetamine-induced neurotoxicity." *J Pharmacol Exp Ther* 313(2): 870-6.
- Thomas, D. M. and D. M. Kuhn (2005). "Attenuated microglial activation mediates tolerance to the neurotoxic effects of methamphetamine." *J Neurochem* 92(4): 790-7.
- Thomas, D. M., P. D. Walker, et al. (2004). "Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation." *J Pharmacol Exp Ther* 311(1): 1-7.
- Timar, J., S. Gyarmati, et al. (2003). "Behavioural changes in rats treated with a neurotoxic dose regimen of dextrorotatory amphetamine derivatives." *Behav Pharmacol* 14(3): 199-206.
- Tolwani, R. J., M. W. Jakowec, et al. (1999). "Experimental models of Parkinson's disease: Insights from many models." *Lab Anim Sci* 49(4): 363-71.
- Tomas-Camardiel, M., M. C. Sanchez-Hidalgo, M. J. Sanchez del Pino, A. Navarro, A. Machado and J. Cano (2002). "Comparative study of the neuroprotective effect of dehydroepiandrosterone and 17beta-estradiol against 1-methyl-4-phenylpyridium toxicity on rat striatum." *Neuroscience* 109(3): 569-84.
- Truong, J. G., D. G. Wilkins, et al. (2005). "Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: Implications for neurotoxicity." *J Pharmacol Exp Ther* 314(3): 1087-92.
- Tsao, L. I., B. Ladenheim, et al. (1998). "Delta opioid peptide [D-Ala2,D-leu5]enkephalin blocks the long-term loss of dopamine transporters induced by multiple administrations of methamphetamine: Involvement of opioid receptors and reactive oxygen species." *J Pharmacol Exp Ther* 287(1): 322-31.
- Vajragupta, O., P. Boonchoong, et al. (2003). "Manganese-based complexes of radical scavengers as neuroprotective agents." *Bioorg Med Chem* 11(10): 2329-37.
- Vajragupta, O., O. Monthakantirat, et al. (2000). "Chroman amide 12P inhibition of lipid peroxidation and protection against learning and memory impairment." *Life Sci* 67(14): 1725-34.
- Villemagne, V., J. Yuan, et al. (1998). "Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations." *J Neurosci* 18(1): 419-27.
- Virmani, A., F. Gaetani, et al. (2005). "Effects of metabolic modifiers such as carnitines, coenzyme Q10, and PUFAs against different forms of neurotoxic insults: Metabolic inhibitors, MPTP, and methamphetamine." *Ann N Y Acad Sci* 1053: 183-91.
- Virmani, A., F. Gaetani, et al. (2003). "Possible mechanism for the neuroprotective effects of L-carnitine on methamphetamine-evoked neurotoxicity." *Ann N Y Acad Sci* 993: 197-207; discussion 287-8.
- Virmani, A., F. Gaetani, S. Imam, Z. Binienda and S. Ali (2002). "The protective role of L-carnitine against neurotoxicity evoked by drug of abuse, methamphetamine, could be related to mitochondrial dysfunction." *Ann N Y Acad Sci* 965: 225-32.
- Vorhees, C. V. (1997). "Methods for detecting long-term CNS dysfunction after prenatal exposure to neurotoxins." *Drug Chem Toxicol* 20(4): 387-99.
- Vorhees, C. V. and C. Pu (1995). "Ontogeny of methamphetamine-induced neurotoxicity in the rat model." *NIDA Res Monogr* 158: 149-71.
- Vilagi, I., J. Takacs, A. Gulyas-Kovacs, I. Banczerowski-Pelyhe and I. Tarnawa (2002). "Protective effect of the antiepileptic drug candidate talampanel against ampa-induced striatal neurotoxicity in neonatal rats." *Brain Res Bull* 59(1): 35-40.
- Virmani, A., F. Gaetani, et al. (2005). "Effects of metabolic modifiers such as carnitines, coenzyme Q10, and PUFAs against different forms of neurotoxic insults: Metabolic inhibitors, MPTP, and methamphetamine." *Ann N Y Acad Sci* 1053: 183-91.
- Virmani, A., F. Gaetani, et al. (2003). "Possible mechanism for the neuroprotective effects of L-carnitine on methamphetamine-evoked neurotoxicity." *Ann N Y Acad Sci* 993: 197-207; discussion 287-8.
- Vorhees, C. V. (1994). "Developmental neurotoxicity induced by therapeutic and illicit drugs." *Environ Health Perspect* 102 Suppl 2: 145-53.
- Wagner, G. C. and S. L. Walsh (1991). "Evaluation of the effects of inhibition of monoamine oxidase and senescence on methamphetamine-induced neuronal damage." *Int J Dev Neurosci* 9(2): 171-4.
- Wagner, G. C., C. R. Schuster, et al. (1981). "Neurochemical consequences following administration of CNS stimulants to the neonatal rat." *Pharmacol Biochem Behav* 14(1): 117-9.
- Wahnschaffe, U. and J. Esslen (1985). "Structural evidence for the neurotoxicity of methylamphetamine in the frontal cortex of gerbils (*Meriones unguiculatus*): A light and electron microscopical study." *Brain Res* 337(2): 299-310.
- Wakayama, A., K. Kataoka, et al. (1993). "Evaluation of masked neurological disorders in the chronic stage after middle cerebral artery occlusion in rats--methamphetamine-induced rotation and regional glucose metabolism in basal ganglia." *Neurol Med Chir (Tokyo)* 33(12): 801-8.

- Wallace, T. L., C. V. Vorhees, et al. (2003). "Methamphetamine enhances the cleavage of the cytoskeletal protein tau in the rat brain." *Neuroscience* 116(4): 1063-8.
- Wallace, T. L., G. A. Gudelsky, et al. (2001). "Neurotoxic regimen of methamphetamine produces evidence of behavioral sensitization in the rat." *Synapse* 39(1): 1-7.
- Wallace, T. L., G. A. Gudelsky, et al. (1999). "Methamphetamine-induced neurotoxicity alters locomotor activity, stereotypic behavior, and stimulated dopamine release in the rat." *J Neurosci* 19(20): 9141-8.
- Walsh, S. L. and G. C. Wagner (1992). "Motor impairments after methamphetamine-induced neurotoxicity in the rat." *J Pharmacol Exp Ther* 263(2): 617-26.
- Wardas, J. (2002). "Neuroprotective role of adenosine in the CNS." *Pol J Pharmacol* 54(4): 313-26.
- Warren, M. W., F. H. Kobeissy, et al. (2005). "Concurrent calpain and caspase-3 mediated proteolysis of alphaII-spectrin and tau in rat brain after methamphetamine exposure: A similar profile to traumatic brain injury." *Life Sci* 78(3): 301-9.
- Watanabe, T. (1997). "[Histaminergic neuron system and neural plasticity]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 17(4): 169-73.
- Wei, Q., O. P. Jurma, et al. (1997). "Increased expression of monoamine oxidase-B results in enhanced neurite degeneration in methamphetamine-treated PC12 cells." *J Neurosci Res* 50(4): 618-26.
- Weissman, B. A., R. Brandeis, et al. (2004). "Monitoring drug-induced neurodegeneration by imaging of peripheral benzodiazepine receptors." *Ann N Y Acad Sci* 1025: 584-9.
- Wells, P. G., Y. Bhuller, et al. (2005). "Molecular and biochemical mechanisms in teratogenesis involving reactive oxygen species." *Toxicol Appl Pharmacol* 207(2 Suppl): 354-66.
- Wilhelm, C. J., R. A. Johnson, et al. (2006). "Hydrogen ion concentration differentiates effects of methamphetamine and dopamine on transporter-mediated efflux." *J Neurochem* 96(4): 1149-59.
- Williams, M. T., T. L. Blankenmeyer, et al. (2003). "Long-term effects of neonatal methamphetamine exposure in rats on spatial learning in the Barnes maze and on cliff avoidance, corticosterone release, and neurotoxicity in adulthood." *Brain Res Dev Brain Res* 147(1-2): 163-75.
- Witkin, J. M., N. Savtchenko, et al. (1999). "Behavioral, toxic, and neurochemical effects of sydnocarb, a novel psychomotor stimulant: comparisons with methamphetamine." *J Pharmacol Exp Ther* 288(3): 1298-310.
- Woolverton, W. L., G. A. Ricaurte, et al. (1989). "Long-term effects of chronic methamphetamine administration in rhesus monkeys." *Brain Res* 486(1): 73-8.
- Wrona, M. Z. and G. Dryhurst (1998). "Oxidation of serotonin by superoxide radical: Implications to neurodegenerative brain disorders." *Chem Res Toxicol* 11(6): 639-50.
- Wrona, M. Z., Z. Yang, et al. (1997). "Potential new insights into the molecular mechanisms of methamphetamine-induced neurodegeneration." *NIDA Res Monogr* 173: 146-74.
- Wu, P. H., Y. C. Shen, et al. (2006). "Baicalein attenuates methamphetamine-induced loss of dopamine transporter in mouse striatum." *Toxicology* 226(2-3): 238-45.
- Xie, T., L. Tong, et al. (2002). "Changes in gene expression linked to methamphetamine-induced dopaminergic neurotoxicity." *J Neurosci* 22(1): 274-83.
- Xie, T., U. D. McCann, et al. (2000). "Effect of temperature on dopamine transporter function and intracellular accumulation of methamphetamine: implications for methamphetamine-induced dopaminergic neurotoxicity." *J Neurosci* 20(20): 7838-45.
- Xu, W., J. P. Zhu, et al. (2005). "Induction of striatal pre- and postsynaptic damage by methamphetamine requires the dopamine receptors." *Synapse* 58(2): 110-21.
- Yamamoto, B. K. and M. G. Bankson (2005). "Amphetamine neurotoxicity: cause and consequence of oxidative stress." *Crit Rev Neurobiol* 17(2): 87-118.
- Yang, J. (2004). "[The study developments about changes of methamphetamine-induced genes' transcriptions and translations]." *Fa Yi Xue Za Zhi* 20(3): 185-8.
- Yang, S. N. (2000). "Sustained enhancement of AMPA receptor- and NMDA receptor-mediated currents induced by dopamine D1/D5 receptor activation in the hippocampus: an essential role of postsynaptic Ca<sup>2+</sup>." *Hippocampus* 10(1): 57-63.
- Yang, Z., M. Z. Wrona, et al. (1997). "5-hydroxy-3-ethylamino-2-oxindole is not formed in rat brain following a neurotoxic dose of methamphetamine: Evidence that methamphetamine does not induce the hydroxyl radical-mediated oxidation of serotonin." *J Neurochem* 68(5): 1929-41.
- Yamamoto, B. K. and W. Zhu (1998). "The effects of methamphetamine on the production of free radicals and oxidative stress." *J Pharmacol Exp Ther* 287(1): 107-14.
- Yamamoto, M., K. Tomioka, et al. (1981). "[Central pharmacological effects of YPG-209 (16(S)-methyl-20-methoxy-prostaglandin E2) (author's transl)]." *Nippon Yakurigaku Zasshi* 77(2): 141-51.
- Yasar, S., J. P. Goldberg, et al. (1996). "Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research." *J Neural Transm Suppl* 48: 61-73.

- Youdim, M. B., O. Bar Am, et al. (2005). "Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition." *J Neurosci Res* 79(1-2): 172-9.
- Youdim, M. B., W. Maruyama, et al. (2005). "Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline." *Drugs Today (Barc)* 41(6): 369-91.
- Yu, J., J. Wang, et al. (2004). "Histological evidence supporting a role for the striatal neurokinin-1 receptor in methamphetamine-induced neurotoxicity in the mouse brain." *Brain Res* 1007(1-2): 124-31.
- Yu, J., S. Allison, et al. (2002). "Ontogeny of neurokinin-1 receptor mediation of methamphetamine neurotoxicity in the striatum of the mouse brain." *Ann N Y Acad Sci* 965: 247-53.
- Yu, J., J. L. Cadet, et al. (2002). "Neurokinin-1 (NK-1) receptor antagonists abrogate methamphetamine-induced striatal dopaminergic neurotoxicity in the murine brain." *J Neurochem* 83(3): 613-22.
- Yu, L., C. F. Cherg and C. Chen (2002). "Melatonin in concentrated ethanol and ethanol alone attenuate methamphetamine-induced dopamine depletions in C57BL/6J mice." *J Neural Transm* 109(12): 1477-90.
- Yu, L., Y. Kuo, et al. (2002). "Ovarian hormones do not attenuate methamphetamine-induced dopaminergic neurotoxicity in mice gonadectomized at 4 weeks postpartum." *Neuroendocrinology* 75(5): 282-7.
- Yu, J., J. L. Cadet and J. A. Angulo (2002). "Neurokinin-1 (NK-1) receptor antagonists abrogate methamphetamine-induced striatal dopaminergic neurotoxicity in the murine brain." *J Neurochem* 83(3): 613-22.
- Yu, L., Y. M. Kuo, et al. (2001). "Opioid peptides alleviated while naloxone potentiated methamphetamine-induced striatal dopamine depletion in mice." *J Neural Transm* 108(11): 1231-7.
- Yu, L. and P. C. Liao (2000). "Estrogen and progesterone distinctively modulate methamphetamine-induced dopamine and serotonin depletions in C57BL/6J mice." *J Neural Transm* 107(10): 1139-47.
- Yu, Y. L. and G. C. Wagner (1994). "Influence of gonadal hormones on sexual differences in sensitivity to methamphetamine-induced neurotoxicity." *J Neural Transm Park Dis Dement Sect* 8(3): 215-21.
- Yuan, J., G. Hatzidimitriou, et al. (2006). "Relationship between temperature, dopaminergic neurotoxicity, and plasma drug concentrations in methamphetamine-treated squirrel monkeys." *J Pharmacol Exp Ther* 316(3): 1210-8.
- Yuan, J., B. T. Callahan, et al. (2001). "Evidence against an essential role of endogenous brain dopamine in methamphetamine-induced dopaminergic neurotoxicity." *J Neurochem* 77(5): 1338-47.
- Zhang, X., T. H. Lee, et al. (2006). "Methamphetamine induces long-term changes in GABAA receptor alpha2 subunit and GAD67 expression." *Biochem Biophys Res Commun* 351(1): 300-5.
- Zhang, L., K. Kitaichi, et al. (2006). "Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine." *Prog Neuropsychopharmacol Biol Psychiatry* 30(8): 1381-93.
- Zhou, J. L., J. H. Liang, et al. (2004). "Nerve growth factor protects R2 cells against neurotoxicity induced by methamphetamine." *Toxicol Lett* 150(2): 221-7.
- Zhou, J. L., J. H. Liang, et al. (2004). "Inhibition of methamphetamine-induced apoptosis by the calcium channel blocker verapamil in rat cerebellar neurons." *Beijing Da Xue Xue Bao* 36(4): 361-5.
- Zhu, J. P., W. Xu, et al. (2006). "Distinct mechanisms mediating methamphetamine-induced neuronal apoptosis and dopamine terminal damage share the neuropeptide substance P in the striatum of mice." *Ann N Y Acad Sci* 1074: 135-48.
- Zhu, J. P., W. Xu, et al. (2006). "Methamphetamine-induced cell death: Selective vulnerability in neuronal subpopulations of the striatum in mice." *Neuroscience* 140(2): 607-22.
- Zhu, J. P., W. Xu, et al. (2006). "Methamphetamine-induced striatal apoptosis in the mouse brain: Comparison of a binge to an acute bolus drug administration." *Neurotoxicology* 27(1): 131-6.
- Zhu, J. P., W. Xu, et al. (2005). "Disparity in the temporal appearance of methamphetamine-induced apoptosis and depletion of dopamine terminal markers in the striatum of mice." *Brain Res* 1049(2): 171-81.

## Nevada (US)

- Cunningham, J. K. and L. M. Liu (2005). "Impacts of federal precursor chemical regulations on methamphetamine arrests." *Addiction* 100(4): 479-88.

## New Jersey (US)

- Boulard, G. (2005). "The meth menace: Battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.

### New Mexico (US)

- Boulard, G. (2005). "The meth menace: Battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.
- Maxwell, J. C., P. Cravioto, et al. (2006). "Drug use and risk of HIV/AIDS on the Mexico-USA border: A comparison of treatment admissions in both countries." *Drug Alcohol Depend* 82 Suppl 1: S85-93.

### New York, NY (US)

- Anonymous (2006). "Investigation of a new diagnosis of multidrug-resistant, dual-tropic HIV-1 infection--New York City, 2005." *MMWR Morb Mortal Wkly Rep* 55(29): 793-6.
- Clatts, M. C., L. Goldsamt, et al. (2005). "Homelessness and drug abuse among young men who have sex with men in New York city: a preliminary epidemiological trajectory." *J Adolesc* 28(2): 201-14.
- Clatts, M. C., L. A. Goldsamt, et al. (2005). "Club drug use among young men who have sex with men in NYC: A preliminary epidemiological profile." *Subst Use Misuse* 40(9): 1317-30.
- Goldsamt, L. A., J. O'Brien, et al. (2005). "The relationship between club drug use and other drug use: A survey of New York City middle school students." *Subst Use Misuse* 40(9): 1539-55.
- Green, A. I. and P. N. Halkitis (2006). "Crystal methamphetamine and sexual sociality in an urban gay subculture: An elective affinity." *Cult Health Sex* 8(4): 317-33.
- Halkitis, P. N. and J. J. Palamar (2006). "GHB use among gay and bisexual men." *Addict Behav* 31(11): 2135-9.
- Halkitis, P. N. and M. T. Shrem (2006). "Psychological differences between binge and chronic methamphetamine using gay and bisexual men." *Addict Behav* 31(3): 549-52.
- Halkitis, P. N., B. N. Fischgrund, et al. (2005). "Explanations for methamphetamine use among gay and bisexual men in New York City." *Subst Use Misuse* 40(9): 1331-45.
- Halkitis, P. N., K. A. Green, et al. (2005). "Seroconcordant sexual partnerings of HIV-seropositive men who have sex with men." *AIDS* 19: S77-S86.
- Halkitis, P. N., K. A. Green, et al. (2005). "Longitudinal investigation of methamphetamine use among gay and bisexual men in New York City: Findings from Project BUMPS." *J Urban Health* 82(1 Suppl 1): i18-25.
- Halkitis, P. N., M. T. Shrem, et al. (2005). "Sexual behavior patterns of methamphetamine-using gay and bisexual men." *Subst Use Misuse* 40(5): 703-19.
- Halkitis, P. N., L. Wilton, et al. (2005). "Barebacking identity among HIV-positive gay and bisexual men: Demographic, psychological, and behavioral correlates." *AIDS* 19: S27-S35.
- Kelly, B. C., J. T. Parsons, et al. (2006). "Prevalence and predictors of club drug use among club-going young adults in New York City." *J Urban Health* 83(5): 884-895.
- Koblin, B. A., M. A. Chesney, et al. (2003). "High-risk behaviors among men who have sex with men in 6 US cities: Baseline data from the EXPLORE Study." *Am J Public Health* 93(6): 926-32.
- Lee, S. J., M. Galanter, et al. (2003). "Circuit parties and patterns of drug use in a subset of gay men." *J Addict Dis* 22(4): 47-60.
- Morin, S. F., W. T. Steward, et al. (2005). "Predicting HIV transmission risk among HIV-infected men who have sex with men: Findings from the healthy living project." *J Acquir Immune Defic Syndr* 40(2): 226-235.
- Ompad, D. C., S. Galea, et al. (2004). "Club drug use among minority substance users in New York City." *J Psychoactive Drugs* 36(3): 397-9.
- Parsons, J. T., B. C. Kelly, et al. (2006). "Differences in club drug use between heterosexual and lesbian/bisexual females." *Addict Behav* 31(12): 2344-9.
- Parsons, J. T. and D. S. Bimbi (2006). "Intentional unprotected anal intercourse among men who have sex with men: Barebacking-from behavior to identity." *AIDS Behav*.
- Parsons, J. T. and P. N. Halkitis (2002). "Sexual and drug-using practices of HIV-positive men who frequent public and commercial sex environments." *AIDS Care* 14(6): 815-26.
- Purcell, D. W., S. Moss, et al. (2005). "Illicit substance use, sexual risk, and HIV-positive gay and bisexual men: Differences by serostatus of casual partners." *AIDS* 19: S37-S47.
- Purcell, D. W., R. J. Wolitski, et al. (2005). "Predictors of the use of viagra, testosterone, and antidepressants among HIV-seropositive gay and bisexual men." *AIDS* 19 Suppl 1: S57-66.
- Purcell, D. W., J. T. Parsons, P. N. Halkitis, Y. Mizuno and W. J. Woods (2001). "Substance use and sexual transmission risk behavior of HIV-positive men who have sex with men." *J Subst Abuse* 13(1-2): 185-200.
- Stall, R., J. P. Paul, et al. (2001). "Alcohol use, drug use and alcohol-related problems among men who have sex with men: The Urban Men's Health Study." *Addiction* 96(11): 1589-601.

Thiede, H., L. A. Valleroy, et al. (2003). "Regional patterns and correlates of substance use among young men who have sex with men in 7 US urban areas." *Am J Public Health* 93(11): 1915-21.

## New York State (excluding New York City) (US)

Boulard, G. (2005). "The meth menace: Battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.

Guharoy, R., J. Medicis, S. Chol, B. Stalder, K. Kusiowski and A. Allen (1999). "Methamphetamine overdose: Experience with six cases." *Vet Hum Toxicol* 41(1): 28-30.

## New Zealand

Dore, G. and M. Sweeting (2006). "Drug-induced psychosis associated with crystalline methamphetamine." *Australas Psychiatry* 14(1): 86-9.

Sheridan, J., S. Bennett, et al. (2006). "Injury associated with methamphetamine use: A review of the literature." *Harm Reduct J* 3(1): 14.

Wilkins, C., M. Pledger, K. Bhatta and S. Casswell (2004). "Patterns of amphetamine use in New Zealand: Findings from the 2001 national drug survey." *N Z Med J* 117(1190): U796.

Wilkins, C., K. Bhatta and S. Casswell (2002). "The emergence of amphetamine use in New Zealand: Findings from the 1998 and 2001 national drug surveys." *N Z Med J* 115(1166): U256.

## Nicotine and Tobacco

Arria, A. M., C. Derauf, et al. (2006). "Methamphetamine and other substance use during pregnancy: Preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study." *Matern Child Health J* 10(3): 293-302.

Bellis, M. A., K. E. Hughes, et al. (2007). "Effects of backpacking holidays in Australia on alcohol, tobacco and drug use of UK residents." *BMC Public Health* 7(1): 1.

Brecht, M. L., L. Greenwell, et al. (2007). "Substance use pathways to methamphetamine use among treated users." *Addict Behav* 32(1): 24-38.

Buchi, K. F., S. Zone, K. Langheinrich and M. W. Varner (2003). "Changing prevalence of prenatal substance abuse in Utah." *Obstet Gynecol* 102(1): 27-30.

Goldsamt, L. A., J. O'Brien, et al. (2005). "The relationship between club drug use and other drug use: A survey of New York City middle school students." *Subst Use Misuse* 40(9): 1539-55.

Goode, E. (1972). "Cigarette smoking and drug use on a college campus." *Int J Addict* 7(1): 133-40.

Kono, J., H. Miyata, et al. (2001). "Nicotine, alcohol, methamphetamine, and inhalant dependence: A comparison of clinical features with the use of a new clinical evaluation form." *Alcohol* 24(2): 99-106.

Lampinen, T. M., D. McGhee, et al. (2006). "Increased risk of "club" drug use among gay and bisexual high school students in British Columbia." *J Adolesc Health* 38(4): 458-61.

Liu, A., P. Kilmarx, et al. (2006). "Sexual initiation, substance use, and sexual behavior and knowledge among vocational students in northern Thailand." *Int Fam Plan Perspect* 32(3): 126-35.

Martin, I., T. M. Lampinen, et al. (2006). "Methamphetamine use among marginalized youth in British Columbia." *Can J Public Health* 97(4): 320-4.

Miyata, H., J. Kono, et al. (2004). "Clinical features of nicotine dependence compared with those of alcohol, methamphetamine, and inhalant dependence." *Ann N Y Acad Sci* 1025: 481-8.

Miyata, H., J. Kono, et al. (2004). "[Studies on clinical characteristics of nicotine dependence using a two compartment model of drug dependence]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 24(2): 61-6.

Rockett, I. R., S. L. Putnam, et al. (2006). "Declared and undeclared substance use among emergency department patients: A population-based study." *Addiction* 101(5): 706-712.

Sekine, H. and Y. Nakahara (1990). "Abuse of smoking methamphetamine mixed with tobacco: II. The formation mechanism of pyrolysis products." *J Forensic Sci* 35(3): 580-90.

Sekine, H. and Y. Nakahara (1987). "Abuse of smoking methamphetamine mixed with tobacco: I. Inhalation efficiency and pyrolysis products of methamphetamine." *J Forensic Sci* 32(5): 1271-80.

Smith, L. M., L. L. Lagasse, et al. (2006). "The Infant Development, Environment, and Lifestyle Study: Effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth." *Pediatrics* 118(3): 1149-1156.

- Wu, L. T., D. J. Pilowsky, et al. (2004). "Injection drug use among stimulant users in a national sample." *Am J Drug Alcohol Abuse* 30(1): 61-83.
- Yen, C. F., Y. H. Yang, et al. (2005). "Substance initiation sequences among Taiwanese adolescents using methamphetamine." *Psychiatry Clin Neurosci* 59(6): 683-9.

### Nicotine and Tobacco (animals)

- Bondy, S. C., S. F. Ali, et al. (2000). "Exposure of mice to tobacco smoke attenuates the toxic effect of methamphetamine on dopamine systems." *Toxicol Lett* 118(1-2): 43-6.
- Dai, F., J. Y. Yang, et al. (2006). "Effect of drug-induced ascorbic acid release in the striatum and the nucleus accumbens in hippocampus-lesioned rats." *Brain Res* 1125(1): 163-70.
- Ellison, G. (2002). "Neural degeneration following chronic stimulant abuse reveals a weak link in brain, fasciculus retroflexus, implying the loss of forebrain control circuitry." *Eur Neuropsychopharmacol* 12(4): 287-97.
- Glick, S. D., I. M. Maisonneuve, et al. (2001). "Comparative effects of dextromethorphan and dextrorphan on morphine, methamphetamine, and nicotine self-administration in rats." *Eur J Pharmacol* 422(1-3): 87-90.
- Glick, S. D., I. M. Maisonneuve, et al. (2000). "18-MC reduces methamphetamine and nicotine self-administration in rats." *Neuroreport* 11(9): 2013-5.
- Hiranita, T., Y. Nawata, et al. (2006). "Suppression of methamphetamine-seeking behavior by nicotinic agonists." *Proc Natl Acad Sci U S A* 103(22): 8523-7.
- Hiranita, T., K. Anggadiredja, et al. (2004). "Nicotine attenuates relapse to methamphetamine-seeking behavior (craving) in rats." *Ann N Y Acad Sci* 1025: 504-7.
- Kawamura, T., Y. Ishitani, et al. (2005). "[Rewarding property of nicotine and methamphetamine tested by conditioned place preference in rats: Effect of chronic nicotine pretreatment]." *Shinrigaku Kenkyu* 76(1): 57-62.
- Maggio, R., M. Riva, et al. (1998). "Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors." *J Neurochem* 71(6): 2439-46.
- Maggio, R., M. Riva, et al. (1997). "Striatal increase of neurotrophic factors as a mechanism of nicotine protection in experimental parkinsonism." *J Neural Transm* 104(10): 1113-23.
- Maisonneuve, I. M. and S. D. Glick (2003). "Anti-addictive actions of an iboga alkaloid congener: A novel mechanism for a novel treatment." *Pharmacol Biochem Behav* 75(3): 607-18.
- Miyata, H., K. Ando, et al. (1991). "[Studies on the involvement of the nucleus accumbens in the discriminative effects of nicotine in rats]." *Nippon Yakurigaku Zasshi* 98(5): 389-97.
- Nabeshima, T., A. Itoh, et al. (1994). "Effects of subacute administration of methamphetamine and nicotine on locomotor activity in transgenic mice expressing the human tyrosine hydroxylase gene." *J Neural Transm Gen Sect* 97(1): 41-9.
- Parker, L. A. (1995). "Rewarding drugs produce taste avoidance, but not taste aversion." *Neurosci Biobehav Rev* 19(1): 143-57.
- Rauhut, A. S., N. Neugebauer, et al. (2003). "Effect of bupropion on nicotine self-administration in rats." *Psychopharmacology (Berl)* 169(1): 1-9.
- Ryan, R. E., S. A. Ross, et al. (2001). "Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice." *Br J Pharmacol* 132(8): 1650-6.
- Takano, Y., Y. Sakurai, et al. (1983). "Presynaptic modulation of the release of dopamine from striatal synaptosomes: differences in the effects of high K<sup>+</sup> stimulation, methamphetamine and nicotinic drugs." *Brain Res* 279(1-2): 330-4.
- Tsukada, H., K. Miyasato, et al. (2002). "Comparative effects of methamphetamine and nicotine on the striatal [(11)C]raclopride binding in unanesthetized monkeys." *Synapse* 45(4): 207-12.

### Night Shifts

*See also* Circadian Rhythms

- Hart, C. L., M. Haney, et al. (2005). "Combined effects of methamphetamine and zolpidem on performance and mood during simulated night shift work." *Pharmacol Biochem Behav* 81(3): 559-68.
- Hart, C. L., A. S. Ward, et al. (2003). "Methamphetamine attenuates disruptions in performance and mood during simulated night-shift work." *Psychopharmacology (Berl)* 169(1): 42-51.

### Nitric Oxide

- Chen, J., C. Wersinger, et al. (2003). "Chronic stimulation of D1 dopamine receptors in human SK-N-MC neuroblastoma cells induces nitric-oxide synthase activation and cytotoxicity." *J Biol Chem* 278(30): 28089-100.

- Nordahl, T. E., R. Salo, et al. (2003). "Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: A review." *J Neuropsychiatry Clin Neurosci* 15(3): 317-25.
- Riddle, E. L., A. E. Fleckenstein, et al. (2006). "Mechanisms of methamphetamine-induced dopaminergic neurotoxicity." *AAPS J* 8(2): E413-8.

## Nitric Oxide (animals)

- Abekawa, T. (1997). "[Experimental study of methamphetamine psychosis--role of glutamate and nitric oxide in methamphetamine-induced dopaminergic and serotonergic neurotoxicity in the rat brain]." *Hokkaido Igaku Zasshi* 72(1): 113-26.
- Bowyer, J. F. (1995). "The role of hyperthermia in amphetamine's interactions with NMDA receptors, nitric oxide, and age to produce neurotoxicity." *Ann N Y Acad Sci* 765: 309-10.
- Brown, J. M., M. S. Quinton, et al. (2005). "Methamphetamine-induced inhibition of mitochondrial complex II: Roles of glutamate and peroxynitrite." *J Neurochem* 95(2): 429-36.
- Chen, J., C. Wersinger, et al. (2003). "Chronic stimulation of D1 dopamine receptors in human SK-N-MC neuroblastoma cells induces nitric-oxide synthase activation and cytotoxicity." *J Biol Chem* 278(30): 28089-100.
- Imam, S. Z., J. el-Yazal, et al. (2001). "Methamphetamine-induced dopaminergic neurotoxicity: Role of peroxynitrite and neuroprotective role of antioxidants and peroxynitrite decomposition catalysts." *Ann N Y Acad Sci* 939: 366-80.
- Itzhak, Y. and S. F. Ali (2006). "Role of nitergic system in behavioral and neurotoxic effects of amphetamine analogs." *Pharmacol Ther* 109(1-2): 246-62.
- Itzhak, Y., J. L. Martin, et al. (2000). "nNOS inhibitors attenuate methamphetamine-induced dopaminergic neurotoxicity but not hyperthermia in mice." *Neuroreport* 11(13): 2943-6.
- Itzhak, Y. and C. Achat-Mendes (2004). "Methamphetamine and MDMA (ecstasy) neurotoxicity: 'Of mice and men'." *IUBMB Life* 56(5): 249-55.
- Itzhak, Y., C. Gandia, et al. (1998). "Resistance of neuronal nitric oxide synthase-deficient mice to methamphetamine-induced dopaminergic neurotoxicity." *J Pharmacol Exp Ther* 284(3): 1040-7.
- Kita, T., G. C. Wagner, et al. (2003). "Current research on methamphetamine-induced neurotoxicity: Animal models of monoamine disruption." *J Pharmacol Sci* 92(3): 178-95.
- Li, S. M., Y. H. Ren, et al. (2002). "Effect of 7-nitroindazole on drug-priming reinstatement of D-methamphetamine-induced conditioned place preference." *Eur J Pharmacol* 443(1-3): 205-6.
- Li, S. M., L. L. Yin, et al. (2002). "The effect of 7-nitroindazole on the acquisition and expression of D-methamphetamine-induced place preference in rats." *Eur J Pharmacol* 435(2-3): 217-23.
- Riddle, E. L., A. E. Fleckenstein, et al. (2006). "Mechanisms of methamphetamine-induced dopaminergic neurotoxicity." *AAPS J* 8(2): E413-8.
- Taraska, T. and K. T. Finnegan (1997). "Nitric oxide and the neurotoxic effects of methamphetamine and 3,4-methylenedioxymethamphetamine." *J Pharmacol Exp Ther* 280(2): 941-7.
- Zhu, J. P., W. Xu, et al. (2006). "Distinct mechanisms mediating methamphetamine-induced neuronal apoptosis and dopamine terminal damage share the neuropeptide substance P in the striatum of mice." *Ann N Y Acad Sci* 1074: 135-48.

## Norepinephrine

- Dryhurst, G. (2001). "Are dopamine, norepinephrine, and serotonin precursors of biologically reactive intermediates involved in the pathogenesis of neurodegenerative brain disorders?" *Adv Exp Med Biol* 500: 373-96.
- Han, D. D. and H. H. Gu (2006). "Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs." *BMC Pharmacol* 6: 6.
- Ramamoorthy, J. D., S. Ramamoorthy, et al. (1995). "Human placental monoamine transporters as targets for amphetamines." *Am J Obstet Gynecol* 173(6): 1782-7.
- Yui, K., K. Goto, et al. (2004). "The role of noradrenergic and dopaminergic hyperactivity in the development of spontaneous recurrence of methamphetamine psychosis and susceptibility to episode recurrence." *Ann N Y Acad Sci* 1025: 296-306.
- Yui, K., S. Ikemoto, et al. (2002). "Factors for susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosis." *Ann N Y Acad Sci* 965: 292-304.
- Yui, K., S. Ikemoto, et al. (2002). "Spontaneous recurrence of methamphetamine-induced paranoid-hallucinatory states in female subjects: Susceptibility to psychotic states and implications for relapse of schizophrenia." *Pharmacopsychiatry* 35(2): 62-71.
- Yui, K., K. Goto, et al. (2001). "Susceptibility to subsequent episodes of spontaneous recurrence of methamphetamine psychosis." *Drug Alcohol Depend* 64(2): 133-42.

- Yui, K., K. Goto, et al. (2000). "Increased sensitivity to stress in spontaneous recurrence of methamphetamine psychosis: Noradrenergic hyperactivity with contribution from dopaminergic hyperactivity." *J Clin Psychopharmacol* 20(2): 165-74.
- Yui, K., T. Ishiguro, et al. (2000). "Susceptibility to subsequent episodes in spontaneous recurrence of methamphetamine psychosis." *Ann N Y Acad Sci* 914: 292-302.
- Yui, K., T. Ishiguro, et al. (1999). "Spontaneous recurrence of methamphetamine psychosis: Increased sensitivity to stress associated with noradrenergic hyperactivity and dopaminergic change." *Eur Arch Psychiatry Clin Neurosci* 249(2): 103-11.
- Yui, K., K. Goto, S. Ikemoto and T. Ishiguro (1997). "Monoamine neurotransmitter metabolites and spontaneous recurrence of methamphetamine psychosis." *Brain Res Bull* 43(1): 25-33.
- Yui, K., T. Ishiguro, et al. (1997). "Precipitating factors in spontaneous recurrence of methamphetamine psychosis." *Psychopharmacology (Berl)* 134(3): 303-8.
- Yui, K., K. Goto, et al. (1996). "Monoamine neurotransmitter function and spontaneous recurrence of methamphetamine psychosis." *Ann N Y Acad Sci* 801: 415-29.
- Yui, K., K. Goto, et al. (1996). "Plasma monoamine metabolites and spontaneous recurrence of methamphetamine-induced paranoid-hallucinatory psychosis: Relation of noradrenergic activity to the occurrence of flashbacks." *Psychiatry Res* 63(2-3): 93-107.

### Norepinephrine (animals)

- Brunswick, D. J., S. Benmansour, et al. (1992). "Effects of high-dose methamphetamine on monoamine uptake sites in rat brain measured by quantitative autoradiography." *Synapse* 11(4): 287-93.
- Cozzi, N. V., M. K. Sievert, et al. (1999). "Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines." *Eur J Pharmacol* 381(1): 63-9.
- Dryhurst, G. (2001). "Are dopamine, norepinephrine, and serotonin precursors of biologically reactive intermediates involved in the pathogenesis of neurodegenerative brain disorders?" *Adv Exp Med Biol* 500: 373-96.
- Fischer, E., J. M. Saavedra, et al. (1968). "Effects of catecholamines, adrenergic substances and their blocking agents on the searching behavior of mice." *Arzneimittelforschung* 18(7): 780-6.
- Han, D. D. and H. H. Gu (2006). "Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs." *BMC Pharmacol* 6: 6.
- Hasebe, Y., H. Ono, et al. (1989). "Enhancement of spinal monosynaptic reflexes with phenylethylamine and related drugs through descending noradrenergic neurons." *J Pharmacobiodyn* 12(4): 241-5.
- Haughey, H. M., J. M. Brown, et al. (2000). "Differential effects of methamphetamine on Na(+)/Cl(-)-dependent transporters." *Brain Res* 863(1-2): 59-65.
- Hirate, K. and H. Kuribara (1991). "Characteristics of the ambulation-increasing effect of GBR-12909, a selective dopamine uptake inhibitor, in mice." *Jpn J Pharmacol* 55(4): 501-11.
- Iwabuchi, K., Y. Kubota, et al. (2004). "Methamphetamine and brain histamine: A study using histamine-related gene knockout mice." *Ann N Y Acad Sci* 1025: 129-34.
- Jeng, C. H. and Y. Wang (1998). "Methamphetamine modulates GABA-induced electrophysiological depression by alternating noradrenergic actions in cerebellar Purkinje neurons." *Psychopharmacology (Berl)* 136(2): 132-8.
- Kuczenski, R. and D. S. Segal (2002). "Exposure of adolescent rats to oral methylphenidate: Preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine." *J Neurosci* 22(16): 7264-71.
- Miller, F. P., R. H. Cox, Jr., et al. (1970). "The effects of altered brain norepinephrine levels on continuous avoidance responding and the action of amphetamines." *Neuropharmacology* 9(6): 511-7.
- Nishikawa, T. and M. Tanaka (1978). "Altered behavioral responses to intense foot shock in socially-isolated rats." *Pharmacol Biochem Behav* 8(1): 61-7.
- Noda, Y., Y. Miyamoto, et al. (1998). "Involvement of dopaminergic system in phencyclidine-induced place preference in mice pretreated with phencyclidine repeatedly." *J Pharmacol Exp Ther* 286(1): 44-51.
- Okuyama, S., S. Chaki, et al. (1997). "In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl]pyrrolidin-3-yl]thiazole (NRA0045)." *J Pharmacol Exp Ther* 282(1): 56-63.
- Pieri, M., L. Pieri, et al. (1975). "A comparison of drug-induced rotation in rats lesioned in the medial forebrain bundle with 5,6-dihydroxytryptamine or 6-hydroxydopamine." *Arch Int Pharmacodyn Ther* 217(1): 118-30.
- Rauhut, A. S., N. Neugebauer, et al. (2003). "Effect of bupropion on nicotine self-administration in rats." *Psychopharmacology (Berl)* 169(1): 1-9.
- Razzak, A., M. Fujiwara, et al. (1977). "Possible involvement of a central noradrenergic system in automutilation induced by clonidine in mice." *Jpn J Pharmacol* 27(1): 145-52.



- Rothman, R. B., N. Vu, et al. (2003). "In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates." *J Pharmacol Exp Ther* 307(1): 138-45.
- Rothman, R. B., M. H. Baumann, et al. (2001). "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin." *Synapse* 39(1): 32-41.
- Rothman, R. B., J. S. Partilla, et al. (2000). "Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse." *Synapse* 35(3): 222-7.
- Scheel-Kruger, J. (1971). "Comparative studies of various amphetamine analogues demonstrating different interactions with the metabolism of the catecholamines in the brain." *Eur J Pharmacol* 14(1): 47-59.
- Shepard, J. D., J. M. Bossert, S. Y. Liu and Y. Shaham (2004). "The anxiogenic drug yohimbine reinstates methamphetamine seeking in a rat model of drug relapse." *Biol Psychiatry* 55(11): 1082-9.
- Shi, W. X., C. L. Pun, et al. (2004). "Psychostimulants induce low-frequency oscillations in the firing activity of dopamine neurons." *Neuropsychopharmacology* 29(12): 2160-7.
- Sprague, J. E., X. Yang, et al. (2007). "Roles of norepinephrine, free fatty acids, thyroid status and skeletal muscle uncoupling protein 3 expression in sympathomimetic-induced thermogenesis." *J Pharmacol Exp Ther* 320(1): 274-80.
- Sulzer, D., M. S. Sonders, et al. (2005). "Mechanisms of neurotransmitter release by amphetamines: A review." *Prog Neurobiol* 75(6): 406-433.
- Wagner, G. C., C. R. Schuster, et al. (1981). "Neurochemical consequences following administration of CNS stimulants to the neonatal rat." *Pharmacol Biochem Behav* 14(1): 117-9.
- Wall, S. C., H. Gu, et al. (1995). "Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: Amphetamine specificity for inhibition and efflux." *Mol Pharmacol* 47(3): 544-50.
- Wang, Y., J. Chou, et al. (2000). "Chronic methamphetamine exposure decreases high affinity uptake function in norepinephrine afferents in the cerebellar cortex: An electrophysiological and electrochemical study." *Neuropharmacology* 39(11): 2112-23.
- Yamanaka, Y., T. Yamamoto, et al. (1983). "Methamphetamine-induced behavioral effects and releases of brain catecholamines and brain concentrations of methamphetamine in mice." *Jpn J Pharmacol* 33(1): 33-40.
- Yui, K., K. Goto and S. Ikemoto (2004). "The role of noradrenergic and dopaminergic hyperactivity in the development of spontaneous recurrence of methamphetamine psychosis and susceptibility to episode recurrence." *Ann N Y Acad Sci* 1025: 296-306.
- Yui, K., K. Goto, et al. (2000). "Increased sensitivity to stress in spontaneous recurrence of methamphetamine psychosis: noradrenergic hyperactivity with contribution from dopaminergic hyperactivity." *J Clin Psychopharmacol* 20(2): 165-74.
- Yui, K., K. Goto, S. Ikemoto and T. Ishiguro (1997). "Monoamine neurotransmitter metabolites and spontaneous recurrence of methamphetamine psychosis." *Brain Res Bull* 43(1): 25-33.
- Yui, K., K. Goto, et al. (1997). "Noradrenergic activity and spontaneous recurrence of methamphetamine psychosis." *Drug Alcohol Depend* 44(2-3): 183-7.

## North Dakota (US)

- Boulard, G. (2005). "The meth menace: Battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.

## Norway

- Christoffersen, A. S. (2000). "Amphetamine designer drugs - An overview and epidemiology." *Toxicol Lett* 112-113: 127-31.
- Grinde, B., K. Stene-Johansen, et al. (1997). "Characterisation of an epidemic of hepatitis A virus involving intravenous drug abusers--infection by needle sharing?" *J Med Virol* 53(1): 69-75.
- Gustavsen, I., J. Morland, et al. (2005). "Impairment related to blood amphetamine and/or methamphetamine concentrations in suspected drugged drivers." *Accid Anal Prev*.
- Lambrechts, M. and K. E. Rasmussen (1984). "Leuckart-specific impurities in amphetamine and methamphetamine seized in Norway." *Bull Narc* 36(1): 47-57.

## Nutrition

*See also* Appetite and Feeding; Appetite and Feeding (animals)

- Duterte, M., S. O'Neil, et al. (2001). "Walking the tightrope: Balancing health and drug use." *J Psychoactive Drugs* 33(2): 173-83.
- Dutta, S., J. Morton, et al. (2006). "Methamphetamine use following bariatric surgery in an adolescent." *Obes Surg* 16(6): 780-2.
- Virmani, A., F. Gaetani, et al. (2005). "Effects of metabolic modifiers such as carnitines, coenzyme Q10, and PUFAs against different forms of neurotoxic insults: Metabolic inhibitors, MPTP, and methamphetamine." *Ann N Y Acad Sci* 1053: 183-91.

### Obesity

- Bray, G. A. (1993). "Use and abuse of appetite-suppressant drugs in the treatment of obesity." *Ann Intern Med* 119(7 Pt 2): 707-13.
- Dutta, S., J. Morton, et al. (2006). "Methamphetamine use following bariatric surgery in an adolescent." *Obes Surg* 16(6): 780-2.
- Herting, R. L. and G. Dillon (1966). "Acute clinical assay for appetite suppression." *J New Drugs* 6(4): 232-6.
- LeRiche, W. H. and A. Csima (1967). "Trial of appetite suppressant. Study of a short-acting and sustained release appetite suppressant on patients paired by initial weight." *Appl Ther* 9(3): 260-2.
- Matthews, C. (1970). "Overweight relapse: Effects of training and methamphetamine with pentobarbital." *Curr Ther Res Clin Exp* 12(1): 34-9.
- Wang, G. J., N. D. Volkow, et al. (2004). "Similarity between obesity and drug addiction as assessed by neurofunctional imaging: A concept review." *J Addict Dis* 23(3): 39-53.

### Obesity (animals)

*See also* Fat Cells (animals)

- Sriram, K., S. A. Benkovic, D. B. Miller and J. P. O'Callaghan (2002). "Obesity exacerbates chemically induced neurodegeneration." *Neuroscience* 115(4): 1335-46.

### Obsessive-Compulsive Disorder

*See also* Stereotypic Behaviors

- Iyo, M., Y. Sekine, et al. (1999). "Methamphetamine-associated obsessional symptoms and effective risperidone treatment: A case report." *J Clin Psychiatry* 60(5): 337-8.

### Occupational Exposure

- Anonymous (2005). "Anhydrous ammonia thefts and releases associated with illicit methamphetamine production--16 states, January 2000-June 2004." *MMWR Morb Mortal Wkly Rep* 54(14): 359-61.
- Anonymous (2000). "Public health consequences among first responders to emergency events associated with illicit methamphetamine laboratories--selected states, 1996-1999." *MMWR Morb Mortal Wkly Rep* 49(45): 1021-4.
- Burgess, J. L. (2001). "Phosphine exposure from a methamphetamine laboratory investigation." *J Toxicol Clin Toxicol* 39(2): 165-8.
- Burgess, J. L., S. Barnhart, et al. (1996). "Investigating clandestine drug laboratories: Adverse medical effects in law enforcement personnel." *Am J Ind Med* 30(4): 488-94.
- Fuller, K. (2005). "A dangerous business." *Occup Health Saf* 74(9): 188, 190-1.
- Goss, J. F. (1998). "Meth labs." *JEMS* 23(1): 50-2, 54, 56 passim.
- Horton, D. K., Z. Berkowitz, et al. (2003). "Secondary contamination of ED personnel from hazardous materials events, 1995-2001." *Am J Emerg Med* 21(3): 199-204.
- Stout, P. R., C. K. Horn, et al. (2006). "Occupational exposure to methamphetamine in workers preparing training aids for drug detection dogs." *J Anal Toxicol* 30(8): 551-3.
- Sudakin, D. L. (2005). "Occupational exposure to aluminium phosphide and phosphine gas? A suspected case report and review of the literature." *Hum Exp Toxicol* 24(1): 27-33.
- Vanek, M. (2002). "Ten steps for EMS survival at clandestine methamphetamine labs." *Emerg Med Serv* 31(4): 92, 96.

### Oceania

*See also* Australia

- Storr, C. L., A. M. Arria, et al. (2004). "Neighborhood environment and opportunity to try methamphetamine ("ice") and marijuana: Evidence from Guam in the Western Pacific region of Micronesia." *Subst Use Misuse* 39(2): 253-76.

### Ohio (US)

- Booth, B. M., C. Leukefeld, et al. (2006). "Correlates of rural methamphetamine and cocaine users: Results from a multistate community study." *J Stud Alcohol* 67(4): 493-501.
- McCaughan, J. A., R. G. Carlson, et al. (2005). "From "Candy Kids" to "Chemi-Kids": A typology of young adults who attend raves in the midwestern United States." *Subst Use Misuse* 40(9): 1503-23.

- Siegal, H. A., P. J. Draus, et al. (2006). "Perspectives on health among adult users of illicit stimulant drugs in rural Ohio." *J Rural Health* 22(2): 169-73.
- Wyman, J. F. and J. T. Cody (2005). "Determination of l-methamphetamine: A case history." *J Anal Toxicol* 29(7): 759-61.

## Oklahoma (US)

*See also* Tulsa

- Arria, A. M., C. Derauf, et al. (2006). "Methamphetamine and other substance use during pregnancy: Preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study." *Matern Child Health J* 10(3): 293-302.
- Boulard, G. (2005). "The meth menace: Battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.
- Harkess, J., B. Gildon, et al. (1989). "Outbreaks of hepatitis A among illicit drug users, Oklahoma, 1984-87." *Am J Public Health* 79(4): 463-6.
- Smith, L. M., L. L. Lagasse, et al. (2006). "The Infant Development, Environment, and Lifestyle Study: Effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth." *Pediatrics* 118(3): 1149-1156.

## Older Persons

*See* Aging and Age Factors

## Opioid Peptides and Receptors

- Ide, S., H. Kobayashi, et al. (2006). "Linkage disequilibrium and association with methamphetamine dependence/psychosis of mu-opioid receptor gene polymorphisms." *Pharmacogenomics J* 6(3): 179-88.
- Ide, S., H. Kobayashi, et al. (2004). "Gene polymorphisms of the mu opioid receptor in methamphetamine abusers." *Ann N Y Acad Sci* 1025: 316-24.
- Kobayashi, H., H. Hata, et al. (2006). "Association analysis of delta-opioid receptor gene polymorphisms in methamphetamine dependence/psychosis." *Am J Med Genet B Neuropsychiatr Genet* 141(5): 482-6.

## Opioid Peptides and Receptors (animals)

- Chiu, C. T., T. Ma, et al. (2006). "Methamphetamine-induced behavioral sensitization in mice: Alterations in mu-opioid receptor." *J Biomed Sci* 13(6): 797-811.
- Ishikawa, K., A. Nitta, et al. (2006). "Effects of single and repeated administration of methamphetamine or morphine on neuroglycan C gene expression in the rat brain." *Int J Neuropsychopharmacol* 9(4): 407-15.
- Kim, H. C., E. J. Shin, et al. (2005). "Pharmacological action of Panax ginseng on the behavioral toxicities induced by psychotropic agents." *Arch Pharm Res* 28(9): 995-1001.
- Mori, T., S. Ito, et al. (2006). "Effects of mu-, delta- and kappa-opioid receptor agonists on methamphetamine-induced self-injurious behavior in mice." *Eur J Pharmacol* 532(1-2): 81-87.
- Su, T. P. (2000). "Delta opioid peptide[D-Ala(2),D-Leu(5)]enkephalin promotes cell survival." *J Biomed Sci* 7(3): 195-9.
- Tien, L. T., I. K. Ho, et al. (2006). "Role of mu-opioid receptor in modulation of preproenkephalin mRNA expression and opioid and dopamine receptor binding in methamphetamine-sensitized mice." *J Neurosci Res*.

## Opioids

*See* Heroin and Other Opioids; Heroin and Other Opioids (animals)

## Oral Administration

- Angrist, B., J. Corwin, et al. (1987). "Early pharmacokinetics and clinical effects of oral D-amphetamine in normal subjects." *Biol Psychiatry* 22(11): 1357-68.
- Beckett, A. H. and E. J. Triggs (1967). "Buccal absorption of basic drugs and its application as an in vivo model of passive drug transfer through lipid membranes." *J Pharm Pharmacol* 19: Suppl:31S-41S.
- Brauer, L. H., J. Ambre, et al. (1996). "Acute tolerance to subjective but not cardiovascular effects of d-amphetamine in normal, healthy men." *J Clin Psychopharmacol* 16(1): 72-6.

- Brauer, L. H. and H. de Wit (1996). "Subjective responses to d-amphetamine alone and after pimozone pretreatment in normal, healthy volunteers." *Biol Psychiatry* 39(1): 26-32.
- Comer, S. D., C. L. Hart, et al. (2001). "Effects of repeated oral methamphetamine administration in humans." *Psychopharmacology (Berl)* 155(4): 397-404.
- Cook, C. E., A. R. Jeffcoat, et al. (1992). "Pharmacokinetics of oral methamphetamine and effects of repeated daily dosing in humans." *Drug Metab Dispos* 20(6): 856-62.
- de Wit, H., M. Clark, et al. (1997). "Effects of d-amphetamine in grouped versus isolated humans." *Pharmacol Biochem Behav* 57(1-2): 333-40.
- Grady, T. A., A. Brooks, et al. (1996). "Biological and behavioral responses to D-amphetamine, alone and in combination with the serotonin<sub>3</sub> receptor antagonist ondansetron, in healthy volunteers." *Psychiatry Res* 64(1): 1-10.
- Hart, C. L., A. S. Ward, et al. (2001). "Methamphetamine self-administration by humans." *Psychopharmacology (Berl)* 157(1): 75-81.
- Hendrickson, R. G., B. Z. Horowitz, et al. (2006). "'Parachuting' meth: A novel delivery method for methamphetamine and delayed-onset toxicity from 'body stuffing'." *Clin Toxicol (Phila)* 44(4): 379-82.
- Johanson, C. E. and E. H. Uhlenhuth (1980). "Drug preference and mood in humans: d-amphetamine." *Psychopharmacology (Berl)* 71(3): 275-9.
- Katsumata, S., K. Sato, et al. (1993). "Sudden death due presumably to internal use of methamphetamine." *Forensic Sci Int* 62(3): 209-15.
- Kim, I., J. M. Oyler, et al. (2004). "Urinary pharmacokinetics of methamphetamine and its metabolite, amphetamine following controlled oral administration to humans." *Ther Drug Monit* 26(6): 664-72.
- Kojima, T., I. Une, M. Yashiki, J. Noda, K. Sakai and K. Yamamoto (1984). "A fatal methamphetamine poisoning associated with hyperpyrexia." *Forensic Sci Int* 24(1): 87-93.
- Logan, B. K., E. L. Weiss, et al. (1996). "Case report: Distribution of methamphetamine in a massive fatal ingestion." *J Forensic Sci* 41(2): 322-3.
- Martin, I., T. M. Lampinen, et al. (2006). "Methamphetamine use among marginalized youth in British Columbia." *Can J Public Health* 97(4): 320-4.
- McKetin, R., E. Kelly, et al. (2006). "The relationship between crystalline methamphetamine use and methamphetamine dependence." *Drug Alcohol Depend* 85(3): 198-204.
- Mitchell, S. J., S. R. Morris, et al. (2006). "Methamphetamine use and sexual activity among HIV-infected patients in care--San Francisco, 2004." *AIDS Patient Care STDS* 20(7): 502-10.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.
- Perez-Reyes, M., W. R. White, et al. (1991). "Clinical effects of daily methamphetamine administration." *Clin Neuropharmacol* 14(4): 352-8.
- Stitzer, M. L., R. R. Griffiths, et al. (1978). "Effects of d-amphetamine on speaking in isolated humans." *Pharmacol Biochem Behav* 9(1): 57-63.
- Zacny, J. P., B. K. Bodker, et al. (1992). "Effects of setting on the subjective and behavioral effects of d-amphetamine in humans." *Addict Behav* 17(1): 27-33.
- Zacny, J. P. and H. de Wit (1989). "Effects of food deprivation on subjective responses to d-amphetamine in humans." *Pharmacol Biochem Behav* 34(4): 791-5.

### Oral Health

*See Dental and Oral Health*

### Oregon (US)

*See also Portland*

- Anonymous (1990). "From the Centers for Disease Control. Lead poisoning associated with intravenous-methamphetamine use--Oregon, 1988." *JAMA* 263(6): 797-8.
- Anonymous (1989). "Lead poisoning associated with intravenous-methamphetamine use--Oregon, 1988." *MMWR Morb Mortal Wkly Rep* 38(48): 830-1.
- Boulard, G. (2005). "The meth menace: Battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.
- Hendrickson, R. G., B. Z. Horowitz, et al. (2006). "'Parachuting' meth: A novel delivery method for methamphetamine and delayed-onset toxicity from 'body stuffing'." *Clin Toxicol (Phila)* 44(4): 379-82.

- Huff, C. (2006). "Crystal crush." *Hosp Health Netw* 80(10): 59-60, 62, 64.
- Kim, J. Y. and M. Fendrich (2002). "Gender differences in juvenile arrestees' drug use, self-reported dependence, and perceived need for treatment." *Psychiatr Serv* 53(1): 70-5.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.
- Schafer, S., H. Gillette, et al. (2006). "A community-wide pertussis outbreak: an argument for universal booster vaccination." *Arch Intern Med* 166(12): 1317-21.

## Overdose

*See also* Mortality, Methamphetamine-Associated

- Ago, M., K. Ago, et al. (2006). "Toxicological and histopathological analysis of a patient who died nine days after a single intravenous dose of methamphetamine: A case report." *Leg Med (Tokyo)* 8(4): 235-9.
- Bailey, D. N. and R. F. Shaw (1989). "Cocaine- and methamphetamine-related deaths in San Diego County (1987): Homicides and accidental overdoses." *J Forensic Sci* 34(2): 407-22.
- Buffum, J. C. and A. T. Shulgin (2001). "Overdose of 2.3 grams of intravenous methamphetamine: Case, analysis and patient perspective." *J Psychoactive Drugs* 33(4): 409-12.
- Chan, P., J. H. Chen, et al. (1994). "Fatal and nonfatal methamphetamine intoxication in the intensive care unit." *J Toxicol Clin Toxicol* 32(2): 147-55.
- Derlet, R. W. and B. Heischouer (1990). "Methamphetamine. Stimulant of the 1990s?" *West J Med* 153(6): 625-8.
- Glittenberg, J. and C. Anderson (1999). "Methamphetamines: Use and trafficking in the Tucson-Nogales area." *Subst Use Misuse* 34(14): 1977-89.
- Guharoy, R., J. Medicis, S. Chol, B. Stalder, K. Kusiowski and A. Allen (1999). "Methamphetamine overdose: Experience with six cases." *Vet Hum Toxicol* 41(1): 28-30.
- Hendrickson, R. G., B. Z. Horowitz, et al. (2006). "'Parachuting' meth: A novel delivery method for methamphetamine and delayed-onset toxicity from 'body stuffing'." *Clin Toxicol (Phila)* 44(4): 379-82.
- Inoue, H., N. Ikeda, et al. (2006). "Methamphetamine-related sudden death with a concentration which was of a 'toxic level'." *Leg Med (Tokyo)* 8(3): 150-5.
- Kashani, J. and A. M. Ruha (2004). "Methamphetamine toxicity secondary to intravaginal body stuffing." *J Toxicol Clin Toxicol* 42(7): 987-9.
- Kohrs, F. P., C. Mann and R. Greenberg (2004). "The use of amphetamine in gamma-hydroxybutyrate overdose: A case report." *J Psychoactive Drugs* 36(3): 401-2.
- Logan, B. K., E. L. Weiss, et al. (1996). "Case report: Distribution of methamphetamine in a massive fatal ingestion." *J Forensic Sci* 41(2): 322-3.
- Ochoa, K. C., P. J. Davidson, et al. (2005). "Heroin overdose among young injection drug users in San Francisco." *Drug Alcohol Depend* 80(3): 297-302.
- Penn, A. S., L. P. Rowland, et al. (1972). "Drugs, coma, and myoglobinuria." *Arch Neurol* 26(4): 336-43.
- Pittman, H. J. (2005). "Methamphetamine overdose." *Nursing* 35(4): 88.
- Sribanditmongkol, P., M. Chokjamsai, et al. (2000). "Methamphetamine overdose and fatality: 2 cases report." *J Med Assoc Thai* 83(9): 1120-3.
- Wallace, M. E. and R. Squires (2000). "Fatal massive amphetamine ingestion associated with hyperpyrexia." *J Am Board Fam Pract* 13(4): 302-4.
- Yamamoto, K., H. Watanabe, et al. (1991). "[3 fatalities after communal use of methamphetamine]." *Arch Kriminol* 188(3-4): 72-6.
- Zalis, E. G. and L. F. Parmley, Jr. (1963). "Fatal Amphetamine Poisoning." *Arch Intern Med* 112: 822-6.
- Zhu, B. L., S. Oritani, et al. (2000). "Methamphetamine-related fatalities in forensic autopsy during 5 years in the southern half of Osaka city and surrounding areas." *Forensic Sci Int* 113(1-3): 443-7.

## Overdose (animals)

- Zalis, E. G., G. Kaplan, et al. (1965). "Acute lethality of the amphetamines in dogs and its antagonism by curare." *Proc Soc Exp Biol Med* 118: 557-61.

## Pakistan

- Shuaib, B. M. (1976). "Acupuncture treatment of drug dependence in Pakistan." *Am J Chin Med (Gard City N Y)* 4(4): 403-7.

### **Panic Disorder**

Iwanami, A., D. Kuwakado, et al. (1997). "Relapse of panic disorder induced by a single intravenous methamphetamine injection." *J Anxiety Disord* 11(1): 113-6.

### **Paranoia**

*See Fear and Paranoia*

### **Parkinsonism and Parkinson's Disease**

Cassarino, D. S., C. P. Fall, et al. (1998). "Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion." *J Neurochem* 71(1): 295-301.

Chrisp, P., G. J. Mammen, et al. (1991). "Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease." *Drugs Aging* 1(3): 228-48.

Garwood, E. R., W. Bekele, et al. (2006). "Amphetamine exposure is elevated in Parkinson's disease." *Neurotoxicology* 27(6): 1003-6.

Gerlach, M. and P. Riederer (1996). "Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man." *J Neural Transm* 103(8-9): 987-1041.

Guilarte, T. R. (2001). "Is methamphetamine abuse a risk factor in parkinsonism?" *Neurotoxicology* 22(6): 725-31.

Lotharius, J., J. Falsig, et al. (2005). "Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway." *J Neurosci* 25(27): 6329-42.

Mandel, S., E. Grunblatt, et al. (2003). "Neuroprotective strategies in Parkinson's disease: An update on progress." *CNS Drugs* 17(10): 729-62.

McCann, U. D., D. F. Wong, et al. (1998). "Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: Evidence from positron emission tomography studies with [<sup>11</sup>C]WIN-35,428." *J Neurosci* 18(20): 8417-22.

Moszczynska, A., P. Fitzmaurice, et al. (2004). "Why is parkinsonism not a feature of human methamphetamine users?" *Brain* 127(Pt 2): 363-70.

Pavese, N., O. Rimoldi, et al. (2004). "Cardiovascular effects of methamphetamine in Parkinson's disease patients." *Mov Disord* 19(3): 298-303.

Piccini, P., N. Pavese, et al. (2005). "Factors affecting the clinical outcome after neural transplantation in Parkinson's disease." *Brain* 128(Pt 12): 2977-86.

Piccini, P., N. Pavese, et al. (2003). "Endogenous dopamine release after pharmacological challenges in Parkinson's disease." *Ann Neurol* 53(5): 647-53.

Piccini, P., D. J. Brooks, et al. (1999). "Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient." *Nat Neurosci* 2(12): 1137-40.

Volkow, N. D., L. Chang, et al. (2001). "Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence." *J Neurosci* 21(23): 9414-8.

### **Parkinsonism and Parkinson's Disease (animal models)**

*See also Tremors (animals)*

Battaglia, G., M. G. Farrace, et al. (2006). "Transglutaminase 2 ablation leads to defective function of mitochondrial respiratory complex I affecting neuronal vulnerability in experimental models of extrapyramidal disorders." *J Neurochem*.

Betarbet, R., T. B. Sherer, et al. (2002). "Animal models of Parkinson's disease." *Bioessays* 24(4): 308-18.

Cadet, J. L. (2001). "Molecular neurotoxicological models of Parkinsonism: Focus on genetic manipulation of mice." *Parkinsonism Relat Disord* 8(2): 85-90.

Cassarino, D. S., C. P. Fall, et al. (1998). "Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion." *J Neurochem* 71(1): 295-301.

Clarkson, E. D., W. M. Zawada, et al. (2001). "IGF-I and bFGF improve dopamine neuron survival and behavioral outcome in parkinsonian rats receiving cultured human fetal tissue strands." *Exp Neurol* 168(1): 183-91.

Da Prada, M., H. H. Keller, et al. (1984). "The pharmacology of Parkinson's disease: Basic aspects and recent advances." *Experientia* 40(11): 1165-72.

- Davidson, C., A. J. Gow, et al. (2001). "Methamphetamine neurotoxicity: Necrotic and apoptotic mechanisms and relevance to human abuse and treatment." *Brain Res Brain Res Rev* 36(1): 1-22.
- Fornai, F., F. Vaglini, et al. (1997). "Species differences in the role of excitatory amino acids in experimental parkinsonism." *Neurosci Biobehav Rev* 21(4): 401-15.
- Foster, S. B., M. Z. Wrona, et al. (2003). "The parkinsonian neurotoxin 1-methyl-4-phenylpyridinium (MPP(+)) mediates release of l-3,4-dihydroxyphenylalanine (l-DOPA) and inhibition of l-DOPA decarboxylase in the rat striatum: a microdialysis study." *Chem Res Toxicol* 16(10): 1372-84.
- Garcia de Yebenes, J., J. Yebenes, et al. (2000). "Neurotrophic factors in neurodegenerative disorders: Model of Parkinson's disease." *Neurotox Res* 2(2-3): 115-37.
- Gerlach, M. and P. Riederer (1996). "Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man." *J Neural Transm* 103(8-9): 987-1041.
- Gesi, M., G. Lazzeri, et al. (2006). "Inclusion dynamics in PC12 is comparable between amphetamines and MPTP." *Ann N Y Acad Sci* 1074: 315-9.
- Golembiowska, K., J. Konieczny, et al. (2002). "The role of striatal metabotropic glutamate receptors in degeneration of dopamine neurons." *Amino Acids* 23(1-3): 199-205.
- Greenamyre, J. T. and C. F. O'Brien (1991). "N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease." *Arch Neurol* 48(9): 977-81.
- Harvey, B. K., A. Mark, et al. (2004). "Neurotrophic effects of bone morphogenetic protein-7 in a rat model of Parkinson's disease." *Brain Res* 1022(1-2): 88-95.
- Harvey, D. C., G. Lacan, et al. (2000). "Regional heterogeneity of dopaminergic deficits in vervet monkey striatum and substantia nigra after methamphetamine exposure." *Exp Brain Res* 133(3): 349-58.
- Hashitani, T., K. Mizukawa, et al. (1998). "Dopamine metabolism in the striatum of hemiparkinsonian model rats with dopaminergic grafts." *Neurosci Res* 30(1): 43-52.
- Inaji, M., T. Okauchi, et al. (2005). "Correlation between quantitative imaging and behavior in unilaterally 6-OHDA-lesioned rats." *Brain Res* 1064(1-2): 136-45.
- Inaji, M., T. Yoshizaki, et al. (2005). "In vivo PET measurements with [<sup>11</sup>C]PE2I to evaluate fetal mesencephalic transplantations to unilateral 6-OHDA-lesioned rats." *Cell Transplant* 14(9): 655-63.
- Inden, M., D. H. Kim, et al. (2005). "Transplantation of mouse embryonic stem cell-derived neurons into the striatum, subthalamic nucleus and substantia nigra, and behavioral recovery in hemiparkinsonian rats." *Neurosci Lett* 387(3): 151-6.
- Ishida, Y., K. Todaka, et al. (1998). "Methamphetamine induces fos expression in the striatum and the substantia nigra pars reticulata in a rat model of Parkinson's disease." *Brain Res* 809(1): 107-14.
- Ishida, Y., I. Kuwahara, et al. (1996). "Dopaminergic transplants suppress L-DOPA-induced Fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease." *Brain Res* 727(1-2): 205-11.
- Kondoh, T., M. Bannai, et al. (2005). "6-Hydroxydopamine-induced lesions in a rat model of hemi-Parkinson's disease monitored by magnetic resonance imaging." *Exp Neurol* 192(1): 194-202.
- Kupsch, A., J. Sautter, et al. (2001). "Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: Comparison of rasagiline (TVP 1012) with selegiline." *J Neural Transm* 108(8-9): 985-1009.
- Lotharius, J., J. Falsig, et al. (2005). "Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway." *J Neurosci* 25(27): 6329-42.
- Maggio, R., M. Riva, et al. (1998). "Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors." *J Neurochem* 71(6): 2439-46.
- Maggio, R., M. Riva, et al. (1997). "Striatal increase of neurotrophic factors as a mechanism of nicotine protection in experimental parkinsonism." *J Neural Transm* 104(10): 1113-23.
- Mandel, S., E. Grunblatt, et al. (2003). "Neuroprotective strategies in Parkinson's disease: An update on progress." *CNS Drugs* 17(10): 729-62.
- Mauceli, G., C. I. Busceti, et al. (2006). "Overexpression of alpha-synuclein following methamphetamine: Is it good or bad?" *Ann N Y Acad Sci* 1074: 191-7.
- Nakagawa, M., M. Ohgoh, et al. (2004). "Dopaminergic agonists and muscarinic antagonists improve lateralization in hemiparkinsonian rats in a novel exploratory Y-maze." *J Pharmacol Exp Ther* 309(2): 737-44.
- Oiwa, Y., R. Yoshimura, et al. (2002). "Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease." *Brain Res* 947(2): 271-83.
- Ossowska, K. (1994). "The role of excitatory amino acids in experimental models of Parkinson's disease." *J Neural Transm Park Dis Dement Sect* 8(1-2): 39-71.

- Sato, S., T. Chiba, et al. (2006). "Decline of striatal dopamine release in parkin-deficient mice shown by ex vivo autoradiography." *J Neurosci Res* 84(6): 1350-7.
- Schluter, O. M., F. Fornai, et al. (2003). "Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice." *Neuroscience* 118(4): 985-1002.
- Sirinathsinghji, D. J., S. B. Dunnett, et al. (1990). "Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway--III. Reversal by embryonic nigral dopamine grafts." *Neuroscience* 37(3): 757-66.
- Tolwani, R. J., M. W. Jakowec, et al. (1999). "Experimental models of Parkinson's disease: Insights from many models." *Lab Anim Sci* 49(4): 363-71.
- Walsh, S. L. and G. C. Wagner (1992). "Motor impairments after methamphetamine-induced neurotoxicity in the rat." *J Pharmacol Exp Ther* 263(2): 617-26.
- Wardas, J. (2002). "Neuroprotective role of adenosine in the CNS." *Pol J Pharmacol* 54(4): 313-26.
- Watanabe, T., K. Matsuhashi, et al. (1984). "[Study on the neuro-behavioral development in rats treated neonatally with drugs acting on the autonomic nervous system]." *Nippon Yakurigaku Zasshi* 84(3): 267-82.

### Party Drugs

*See* Recreational and Club Drugs

### PCP

*See* Phencyclidine (animals)

### Pennsylvania (US)

Prosser, J. M., M. Naim, et al. (2006). "A 14-year-old girl with agitation and hyperthermia." *Pediatr Emerg Care* 22(9): 676-9.

### Pertussis

Schafer, S., H. Gillette, et al. (2006). "A community-wide pertussis outbreak: an argument for universal booster vaccination." *Arch Intern Med* 166(12): 1317-21.

### Pharmaceutical Formulations

Golub, M., L. Costa, et al. (2005). "NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of amphetamine and methamphetamine." *Birth Defects Res B Dev Reprod Toxicol*.

### Pharmacies

*See also* Medical Uses; Precursor Regulation

Anonymous (2006). "Retail sales of scheduled listed chemical products; self-certification of regulated sellers of scheduled listed chemical products. Interim final rule with request for comment." *Fed Regist* 71(186): 56008-27.

Boulard, G. (2005). "The meth menace: Battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.

Donaldson, M. and J. H. Goodchild (2006). "Oral health of the methamphetamine abuser." *Am J Health Syst Pharm* 63(21): 2078-82.

Murty, S. and S. S. Sangsiry (2006). "Pseudoephedrine laws in the US--are we doing enough?" *Ann Pharmacother* 40(6): 1213-5.

### Pharmacokinetics and Pharmacodynamics

Angrist, B., J. Corwin, et al. (1987). "Early pharmacokinetics and clinical effects of oral D-amphetamine in normal subjects." *Biol Psychiatry* 22(11): 1357-68.

Armstrong, P. A., J. E. Carless, et al. (1973). "The effect of pore size of the inhaler support upon the concentration of volatile drug emerging in the air stream from a nasal inhaler." *J Pharm Pharmacol* 25(1): 35-41.

Armstrong, P. A., J. E. Carless, et al. (1972). "The influence of the moisture content of the fibrous support of a nasal inhaler upon the concentration of drug in the air stream." *J Pharm Pharmacol* 24(1): 13-9.



- Armstrong, P. A., J. E. Carless, et al. (1971). "The relation between the vapour pressure of a drug and its concentration emerging in the air stream from a nasal inhaler." *J Pharm Pharmacol* 23(7): 473-81.
- Barr, A. M., W. J. Panenka, et al. (2006). "The need for speed: An update on methamphetamine addiction." *J Psychiatry Neurosci* 31(5): 301-313.
- Beckett, A. H. and G. T. Tucker (1968). "Application of the analogue computer to pharmacokinetic and biopharmaceutical studies with amphetamine-type compounds." *J Pharm Pharmacol* 20(3): 174-93.
- Beckett, A. H. and E. J. Triggs (1967). "Buccal absorption of basic drugs and its application as an in vivo model of passive drug transfer through lipid membranes." *J Pharm Pharmacol* 19: Suppl:31S-41S.
- Caldwell, J. and P. S. Sever (1974). "The biochemical pharmacology of abused drugs. Amphetamines, cocaine, and LSD." *Clin Pharmacol Ther* 16(4): 625-38.
- Cho, A. K. and W. P. Melega (2002). "Patterns of methamphetamine abuse and their consequences." *J Addict Dis* 21(1): 21-34.
- Cho, A. K., W. P. Melega, et al. (2001). "Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse." *Synapse* 39(2): 161-6.
- Cook, C. E., A. R. Jeffcoat, et al. (1993). "Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride." *Drug Metab Dispos* 21(4): 717-23.
- Cook, C. E., A. R. Jeffcoat, et al. (1992). "Pharmacokinetics of oral methamphetamine and effects of repeated daily dosing in humans." *Drug Metab Dispos* 20(6): 856-62.
- Cook, C. E., A. R. Jeffcoat, et al. (1991). "Plasma levels of methamphetamine after smoking of methamphetamine hydrochloride." *NIDA Res Monogr* 105: 578-9.
- Dryhurst, G. (2001). "Are dopamine, norepinephrine, and serotonin precursors of biologically reactive intermediates involved in the pathogenesis of neurodegenerative brain disorders?" *Adv Exp Med Biol* 500: 373-96.
- Fuller, R. W. (1978). "Structure-activity relationships among the halogenated amphetamines." *Ann N Y Acad Sci* 305: 147-59.
- Golub, M., L. Costa, et al. (2005). "NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of amphetamine and methamphetamine." *Birth Defects Res B Dev Reprod Toxicol*.
- Grady, T. A., A. Brooks, et al. (1996). "Biological and behavioral responses to D-amphetamine, alone and in combination with the serotonin<sub>3</sub> receptor antagonist ondansetron, in healthy volunteers." *Psychiatry Res* 64(1): 1-10.
- Greenhill, L. L. (2006). "The science of stimulant abuse." *Pediatr Ann* 35(8): 552-6.
- Gulaboski, R., M. N. Cordeiro, et al. (2006). "Evaluation of the lipophilic properties of opioids, amphetamine-like drugs, and metabolites through electrochemical studies at the interface between two immiscible solutions." *Anal Biochem*.
- Harris, D. S., H. Boxenbaum, E. T. Everhart, G. Sequeira, J. E. Mendelson and R. T. Jones (2003). "The bioavailability of intranasal and smoked methamphetamine." *Clin Pharmacol Ther* 74(5): 475-86.
- Inoue, T. and S. Suzuki (1987). "The metabolism of dimethylamphetamine in rat and man." *Xenobiotica* 17(8): 965-71.
- Kalasinsky, K. S., T. Z. Bosy, et al. (2001). "Regional distribution of methamphetamine in autopsied brain of chronic human methamphetamine users." *Forensic Sci Int* 116(2-3): 163-9.
- Kim, I., J. M. Oyler, et al. (2004). "Urinary pharmacokinetics of methamphetamine and its metabolite, amphetamine following controlled oral administration to humans." *Ther Drug Monit* 26(6): 664-72.
- Kraemer, T. and H. H. Maurer (2002). "Toxicokinetics of amphetamines: Metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives." *Ther Drug Monit* 24(2): 277-89.
- Lile, J. A. (2006). "Pharmacological determinants of the reinforcing effects of psychostimulants: Relation to agonist substitution treatment." *Exp Clin Psychopharmacol* 14(1): 20-33.
- Lile, J. A., W. W. Stoops, et al. (2005). "Aripiprazole attenuates the discriminative-stimulus and subject-rated effects of D-amphetamine in humans." *Neuropsychopharmacology* 30(11): 2103-14.
- Mascher, H. J., C. Kikuta, A. Millendorfer, H. Schiel and G. Ludwig (1997). "Pharmacokinetics and bioequivalence of the main metabolites of selegiline: Desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline." *Int J Clin Pharmacol Ther* 35(1): 9-13.
- McKetin, R., E. Kelly, et al. (2006). "The relationship between crystalline methamphetamine use and methamphetamine dependence." *Drug Alcohol Depend* 85(3): 198-204.
- Mendelson, J., N. Uemura, et al. (2006). "Human pharmacology of the methamphetamine stereoisomers." *Clin Pharmacol Ther* 80(4): 403-20.
- Meng, Y., M. Dukat, D. T. Bridgen, B. R. Martin and A. H. Lichtman (1999). "Pharmacological effects of methamphetamine and other stimulants via inhalation exposure." *Drug Alcohol Depend* 53(2): 111-20.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.

- NTP-CERHR (2005). "NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines." NTP CEHR Mon(16): i-III.
- Peters, F. T., N. Samyn, et al. (2003). "Concentrations and ratios of amphetamine, methamphetamine, MDA, MDMA, and MDEA enantiomers determined in plasma samples from clinical toxicology and driving under the influence of drugs cases by GC-NICI-MS." *J Anal Toxicol* 27(8): 552-9.
- Pritzker, D., A. Kanungo, et al. (2002). "Designer drugs that are potent inhibitors of CYP2D6." *J Clin Psychopharmacol* 22(3): 330-2.
- Ramamoorthy, Y., R. F. Tyndale, et al. (2001). "Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates." *Pharmacogenetics* 11(6): 477-87.
- Sanga, M., I. R. Younis, et al. (2006). "Epoxidation of the methamphetamine pyrolysis product, trans-phenylpropene, to trans-phenylpropylene oxide by CYP enzymes and stereoselective glutathione adduct formation." *Toxicol Appl Pharmacol* 211(2): 148-56.
- Segal, D. S. and R. Kuczenski (2006). "Human methamphetamine pharmacokinetics simulated in the rat: Single daily intravenous administration reveals elements of sensitization and tolerance." *Neuropsychopharmacology* 31(5): 941-55.
- Shappell, S. A., G. L. Kearns, et al. (1996). "Chronopharmacokinetics and chronopharmacodynamics of dextromethamphetamine in man." *J Clin Pharmacol* 36(11): 1051-63.
- Shima, N., H. T. Kamata, et al. (2006). "Urinary excretion of the main metabolites of methamphetamine, including p-hydroxymethamphetamine-sulfate and p-hydroxymethamphetamine-glucuronide, in humans and rats." *Xenobiotica* 36(2-3): 259-67.
- Sulzer, D., M. S. Sonders, et al. (2005). "Mechanisms of neurotransmitter release by amphetamines: A review." *Prog Neurobiol* 75(6): 406-33.

### Pharmacokinetics and Pharmacodynamics (animals)

- Baumgarten, H. G. and L. Lachenmayer (2004). "Serotonin neurotoxins--past and present." *Neurotox Res* 6(7-8): 589-614.
- Byrnes-Blake, K. A., E. M. Laurenzana, et al. (2005). "Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats." *Eur J Pharmacol* 521(1-3): 86-94.
- Cashman, J. R., Y. N. Xiong, et al. (1999). "N-oxygenation of amphetamine and methamphetamine by the human flavin-containing monooxygenase (form 3): Role in bioactivation and detoxication." *J Pharmacol Exp Ther* 288(3): 1251-60.
- Cho, A. K., W. P. Melega, et al. (2001). "Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse." *Synapse* 39(2): 161-6.
- Delle Donne, K. T. and P. K. Sonsalla (1994). "Protection against methamphetamine-induced neurotoxicity to neostriatal dopaminergic neurons by adenosine receptor activation." *J Pharmacol Exp Ther* 271(3): 1320-6.
- Inoue, T. and S. Suzuki (1987). "The metabolism of dimethylamphetamine in rat and man." *Xenobiotica* 17(8): 965-71.
- Inoue, T., S. Suzuki, et al. (1983). "The metabolism of 1-phenyl-2-(N-methyl-N-benzylamino)propane (benzphetamine) in vitro in rat." *Xenobiotica* 13(4): 241-9.
- Kanamori, T., K. Tsujikawa, et al. (2005). "A study of the metabolism of methamphetamine and 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in isolated rat hepatocytes." *Forensic Sci Int* 148(2-3): 131-7.
- Kitaichi, K., Y. Ito, et al. (2004). "The altered disposition of methamphetamine in the model of methamphetamine-induced neurotoxicity." *Ann N Y Acad Sci* 1025: 248-56.
- Kitaichi, K., Y. Morishita, et al. (2003). "Increased plasma concentration and brain penetration of methamphetamine in behaviorally sensitized rats." *Eur J Pharmacol* 464(1): 39-48.
- Kitaichi, K., Y. Morishita, et al. (2001). "[Pharmacokinetic behavioral changes of methamphetamine in methamphetamine-sensitized animal model]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 21(5): 133-44.
- Kitanaka, J., N. Kitanaka, et al. (2003). "Chronic methamphetamine administration reduces histamine-stimulated phosphoinositide hydrolysis in mouse frontal cortex." *Biochem Biophys Res Commun* 300(4): 932-7.
- Knoll, J., E. S. Vizi, et al. (1970). "Pharmacological studies on para-bromo-methamphetamine (V-111) and LSD." *Acta Physiol Acad Sci Hung* 37(1): 151-70.
- Kokoshka, J. M., A. E. Fleckenstein, D. G. Wilkins and G. R. Hanson (2000). "Age-dependent differential responses of monoaminergic systems to high doses of methamphetamine." *J Neurochem* 75(5): 2095-102.
- Lile, J. A. (2006). "Pharmacological determinants of the reinforcing effects of psychostimulants: Relation to agonist substitution treatment." *Exp Clin Psychopharmacol* 14(1): 20-33.
- Magyar, K., K. Tekes, et al. (1981). "The fate of p-bromo-methylamphetamine (V-111) in the body." *Acta Physiol Acad Sci Hung* 57(3): 285-307.

- McMillan, D. E., W. C. Hardwick, et al. (2004). "Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat." *J Pharmacol Exp Ther* 309(3): 1248-55.
- Meng, Y., M. Dukat, et al. (1999). "Pharmacological effects of methamphetamine and other stimulants via inhalation exposure." *Drug Alcohol Depend* 53(2): 111-20.
- Milesi-Halle, A., H. P. Hendrickson, et al. (2005). "Sex- and dose-dependency in the pharmacokinetics and pharmacodynamics of (+)-methamphetamine and its metabolite (+)-amphetamine in rats." *Toxicol Appl Pharmacol* 209(3): 203-13.
- Mizugaki, M. (1996). "[Alterations in brain distribution of methamphetamine in methamphetamine-sensitized animals.]" *Nihon Shinkei Seishin Yakurigaku Zasshi* 16(5): 187-91.
- Mizugaki, M., T. Hishinuma, et al. (1993). "Distribution of carbon-11 labeled methamphetamine and the effect of its chronic administration in mice." *Nucl Med Biol* 20(4): 487-92.
- Nakamura, H., T. Hishinuma, et al. (1997). "Effects of haloperidol and cocaine pretreatments on brain distribution and kinetics of [<sup>11</sup>C]methamphetamine in methamphetamine sensitized dog: application of PET to drug pharmacokinetic study." *Nucl Med Biol* 24(2): 165-9.
- Newman, J. L. and M. E. Carroll (2006). "Reinforcing effects of smoked methamphetamine in rhesus monkeys." *Psychopharmacology (Berl)* 188(2): 193-200.
- Okuda, T., Y. Ito, et al. (2004). "Drug interaction between methamphetamine and antihistamines: Behavioral changes and tissue concentrations of methamphetamine in rats." *Eur J Pharmacol* 505(1-3): 135-44.
- O'Neil M, L., R. Kuczenski, et al. (2006). "Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge." *Synapse* 60(6): 465-73.
- Rahmann, H. (1971). "Different modes of substance flow in the optic tract." *Acta Neuropathol (Berl)* 5: Suppl 5:162-70.
- Rahmann, H. and H. Rosner (1970). "[Autoradiography studies on the mechanism of action of methamphetamine upon the teleost CNS]." *Pflugers Arch* 314(1): 86-96.
- Sakai, T., T. Niwaguchi, et al. (1985). "Distribution and excretion of methamphetamine and its metabolites in rats. III. Time-course of concentrations in blood and bile, and distribution after intravenous administration." *Xenobiotica* 15(1): 31-40.
- Segal, D. S. and R. Kuczenski (2006). "Human methamphetamine pharmacokinetics simulated in the rat: Single daily intravenous administration reveals elements of sensitization and tolerance." *Neuropsychopharmacology* 31(5): 941-55.
- Shilling, P. D., R. Kuczenski, et al. (2006). "Differential regulation of immediate-early gene expression in the prefrontal cortex of rats with a high vs low behavioral response to methamphetamine." *Neuropsychopharmacology* 31(11): 2359-67.
- Shiue, C. Y., G. G. Shiue, et al. (1995). "Comparative PET studies of the distribution of (-)-3,4-methylenedioxy-N-[<sup>11</sup>C]methamphetamine and (-)-[<sup>11</sup>C]methamphetamine in a monkey brain." *Nucl Med Biol* 22(3): 321-4.
- Shiue, C. Y., G. G. Shiue, et al. (1993). "Fluorine-18 and carbon-11 labeled amphetamine analogs--synthesis, distribution, binding characteristics in mice and rats and a PET study in monkey." *Nucl Med Biol* 20(8): 973-81.
- Suzuki, T., H. J. Fan Chiang, et al. (1987). "Effects of quinidine and cimetidine on methamphetamine stereotypy in rats." *J Pharmacobiodyn* 10(3): 152-5.
- Truong, J. G., D. G. Wilkins, et al. (2005). "Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: Implications for neurotoxicity." *J Pharmacol Exp Ther* 314(3): 1087-92.
- Tsukada, H., N. Harada, et al. (2001). "Facilitation of dopaminergic neural transmission does not affect [(11)C]SCH23390 binding to the striatal D(1) dopamine receptors, but the facilitation enhances phosphodiesterase type-IV activity through D(1) receptors: PET studies in the conscious monkey brain." *Synapse* 42(4): 258-65.
- Volz, T. J., G. R. Hanson, et al. (2006). "Measurement of kinetically resolved vesicular dopamine uptake and efflux using rotating disk electrode voltammetry." *J Neurosci Methods* 155(1): 109-15.
- Woolverton, W. L., G. Shybut, et al. (1980). "Structure-activity relationships among some d-N-alkylated amphetamines." *Pharmacol Biochem Behav* 13(6): 869-76.
- Yamamoto, T., R. Takano, et al. (1988). "Reversible inhibition of aromatic hydroxylation of methamphetamine in rat liver microsomal preparations pretreated with methamphetamine." *Biochem Pharmacol* 37(8): 1433-7.
- Yamamoto, T., R. Takano, et al. (1984). "Metabolism of methamphetamine, amphetamine and p-hydroxymethamphetamine by rat-liver microsomal preparations in vitro." *Xenobiotica* 14(11): 867-75.

## Pharmacological Interventions

- Akiyama, K. (2006). "Longitudinal clinical course following pharmacological treatment of methamphetamine psychosis which persists after long-term abstinence." *Ann N Y Acad Sci* 1074: 125-34.
- Barr, A. M., W. J. Panenka, et al. (2006). "The need for speed: An update on methamphetamine addiction." *J Psychiatry Neurosci* 31(5): 301-313.

- Berigan, T. (2004). "Amphetamine-like stimulant cessation in an abusing patient treated with bupropion (Tardiev et al. 2004)." *Acta Psychiatr Scand* 110(4): 312; author reply 312.
- Brauer, L. H. and H. de Wit (1996). "Subjective responses to d-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers." *Biol Psychiatry* 39(1): 26-32.
- Brodie, J. D., E. Figueroa, et al. (2005). "Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction." *Synapse* 55(2): 122-5.
- Dwoskin, L. P. and P. A. Crooks (2002). "A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse." *Biochem Pharmacol* 63(2): 89-98.
- Mark, K. A., J. J. Soghomonian, et al. (2004). "High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity." *J Neurosci* 24(50): 11449-56.
- Carnwath, T., T. Garvey and M. Holland (2002). "The prescription of dexamphetamine to patients with schizophrenia and amphetamine dependence." *J Psychopharmacol* 16(4): 373-7.
- Cretzmeyer, M., M. V. Sarrazin, et al. (2003). "Treatment of methamphetamine abuse: Research findings and clinical directions." *J Subst Abuse Treat* 24(3): 267-77.
- Davidson, C., A. J. Gow, et al. (2001). "Methamphetamine neurotoxicity: Necrotic and apoptotic mechanisms and relevance to human abuse and treatment." *Brain Res Brain Res Rev* 36(1): 1-22.
- Dwoskin, L. P. and P. A. Crooks (2002). "A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse." *Biochem Pharmacol* 63(2): 89-98.
- Ellis, K. L. and J. Speed (1998). "Pharmacologic management of movement disorder after midbrain haemorrhage." *Brain Inj* 12(7): 623-8.
- Fechtner, R. D., A. S. Khouri, et al. (2006). "Short-term treatment of cocaine and/or methamphetamine abuse with vigabatrin: Ocular safety pilot results." *Arch Ophthalmol* 124(9): 1257-62.
- Galloway, G. P., J. Newmeyer, et al. (1996). "A controlled trial of imipramine for the treatment of methamphetamine dependence." *J Subst Abuse Treat* 13(6): 493-7.
- Galloway, G. P., J. Newmeyer, T. Knapp, S. A. Stalcup and D. Smith (1994). "Imipramine for the treatment of cocaine and methamphetamine dependence." *J Addict Dis* 13(4): 201-16.
- Gillin, J. C., L. Pulvirenti, et al. (1994). "The effects of lisuride on mood and sleep during acute withdrawal in stimulant abusers: A preliminary report." *Biol Psychiatry* 35(11): 843-9.
- Gottschalk, P. C., L. K. Jacobsen, et al. (1999). "Current concepts in pharmacotherapy of substance abuse." *Curr Psychiatry Rep* 1(2): 172-8.
- Grabowski, J., J. Shearer, J. Merrill and S. S. Negus (2004). "Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence." *Addict Behav* 29(7): 1439-64.
- Haney, M. and T. R. Kosten (2004). "Therapeutic vaccines for substance dependence." *Expert Rev Vaccines* 3(1): 11-8.
- Harris, D. S., V. I. Reus, et al. (2006). "Catecholamine response to methamphetamine is related to glucocorticoid levels but not to pleasurable subjective response." *Pharmacopsychiatry* 39(3): 100-8.
- Harris, D. S., V. I. Reus, et al. (2003). "Altering cortisol level does not change the pleasurable effects of methamphetamine in humans." *Neuropsychopharmacology* 28(9): 1677-84.
- Hart, C. L., M. Haney, et al. (2002). "Effects of the NMDA antagonist memantine on human methamphetamine discrimination." *Psychopharmacology (Berl)* 164(4): 376-84.
- Heinzerling, K. G., S. Shoptaw, et al. (2006). "Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence." *Drug Alcohol Depend* 85(3): 177-184.
- Iyo, M., Y. Sekine, et al. (1999). "Methamphetamine-associated obsessional symptoms and effective risperidone treatment: A case report." *J Clin Psychiatry* 60(5): 337-8.
- Johnson, B. A., J. D. Roache, et al. (2007). "Effects of topiramate on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in recently abstinent methamphetamine-dependent individuals." *Prog Neuropsychopharmacol Biol Psychiatry* 31(1): 123-30.
- Johnson, B. A., J. D. Roache, et al. (2006). "Effects of acute topiramate dosing on methamphetamine-induced subjective mood." *Int J Neuropsychopharmacol*: 1-14.
- Johnson, B. A., J. D. Roache, et al. (2005). "Effects of isradipine, a dihydropyridine-class calcium-channel antagonist, on d-methamphetamine's subjective and reinforcing effects." *Int J Neuropsychopharmacol* 8(2): 203-13.
- Johnson, B. A., J. D. Roache, et al. (2005). "Effects of isradipine on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition." *Psychopharmacology (Berl)* 178(2-3): 296-302.
- Johnson, B. A., L. T. Wells, et al. (2005). "Isradipine decreases the hemodynamic response of cocaine and methamphetamine results from two human laboratory studies: Results from two human laboratory studies." *Am J Hypertens* 18(6): 813-22.

- Johnson, B. A., N. Ait-Daoud, et al. (1999). "Effects of isradipine, a dihydropyridine-class calcium channel antagonist, on d-methamphetamine-induced reduction in hunger." *Prog Neuropsychopharmacol Biol Psychiatry* 23(7): 1227-34.
- Johnson, B. A., J. D. Roache, et al. (1999). "Isradipine, a dihydropyridine-class calcium channel antagonist, attenuates some of d-methamphetamine's positive subjective effects: A preliminary study." *Psychopharmacology (Berl)* 144(3): 295-300.
- Kosten, T. and S. M. Owens (2005). "Immunotherapy for the treatment of drug abuse." *Pharmacol Ther* 108(1): 76-85.
- Kosten, T. R. and P. G. O'Connor (2003). "Management of drug and alcohol withdrawal." *N Engl J Med* 348(18): 1786-95.
- Levi, M. S. and R. F. Borne (2002). "A review of chemical agents in the pharmacotherapy of addiction." *Curr Med Chem* 9(20): 1807-18.
- Lile, J. A. (2006). "Pharmacological determinants of the reinforcing effects of psychostimulants: Relation to agonist substitution treatment." *Exp Clin Psychopharmacol* 14(1): 20-33.
- Lile, J. A., W. W. Stoops, et al. (2005). "Aripiprazole attenuates the discriminative-stimulus and subject-rated effects of D-amphetamine in humans." *Neuropsychopharmacology* 30(11): 2103-14.
- Ling, W., R. Rawson, et al. (2006). "Management of methamphetamine abuse and dependence." *Curr Psychiatry Rep* 8(5): 345-54.
- Maisonneuve, I. M. and S. D. Glick (2003). "Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment." *Pharmacol Biochem Behav* 75(3): 607-18.
- Mandel, S., O. Weinreb, et al. (2005). "Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives." *Brain Res Brain Res Rev* 48(2): 379-87.
- Martin Alisky, J. (2006). "Cholinesterase inhibitors might alleviate methamphetamine-induced delusions, hallucinations and cognitive impairment, while reducing craving and addiction." *World J Biol Psychiatry* 7(4): 269.
- McTavish, S. F., M. H. McPherson, et al. (2001). "Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness." *Br J Psychiatry* 179: 356-60.
- Meredith, C. W., C. Jaffe, et al. (2005). "Implications of chronic methamphetamine use: A literature review." *Harv Rev Psychiatry* 13(3): 141-54.
- Narita, M., M. Miyatake, et al. (2006). "Direct evidence of astrocytic modulation in the development of rewarding effects induced by drugs of abuse." *Neuropsychopharmacology* 31(11): 2476-88.
- Nath, A., W. F. Maragos, et al. (2001). "Acceleration of HIV dementia with methamphetamine and cocaine." *J Neurovirol* 7(1): 66-71.
- Newton, T. F., R. De La Garza, 2nd, et al. (2006). "A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline." *Pharmacol Biochem Behav*.
- Newton, T. F., J. D. Roache, et al. (2006). "Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving." *Neuropsychopharmacology* 31(7): 1537-44.
- Newton, T. F., J. D. Roache, et al. (2005). "Safety of intravenous methamphetamine administration during treatment with bupropion." *Psychopharmacology (Berl)* 182(3): 426-35.
- Onaivi, E. S., S. F. Ali, et al. (2002). "Ibogaine signals addiction genes and methamphetamine alteration of long-term potentiation." *Ann N Y Acad Sci* 965: 28-46.
- Park, S. U., J. V. Ferrer, et al. (2002). "Peroxyinitrite inactivates the human dopamine transporter by modification of cysteine 342: potential mechanism of neurotoxicity in dopamine neurons." *J Neurosci* 22(11): 4399-405.
- Piasecki, M. P., G. M. Steinagel, et al. (2002). "An exploratory study: The use of paroxetine for methamphetamine craving." *J Psychoactive Drugs* 34(3): 301-4.
- Rawson, R. A., M. J. McCann, et al. (2000). "Addiction pharmacotherapy 2000: New options, new challenges." *J Psychoactive Drugs* 32(4): 371-8.
- Rothman, R. B., B. E. Blough, et al. (2002). "Appetite suppressants as agonist substitution therapies for stimulant dependence." *Ann N Y Acad Sci* 965: 109-26.
- Rothman, R. B., J. S. Partilla, et al. (2000). "Methamphetamine dependence: Medication development efforts based on the dual deficit model of stimulant addiction." *Ann N Y Acad Sci* 914: 71-81.
- Ruha, A. M. and M. C. Yarema (2006). "Pharmacologic treatment of acute pediatric methamphetamine toxicity." *Pediatr Emerg Care* 22(12): 782-5.
- Sattar, S. P., S. C. Bhatia, et al. (2004). "Potential benefits of quetiapine in the treatment of substance dependence disorders." *J Psychiatry Neurosci* 29(6): 452-7.
- Sevarino, K. A., A. Oliveto, et al. (2000). "Neurobiological adaptations to psychostimulants and opiates as a basis of treatment development." *Ann N Y Acad Sci* 909: 51-87.
- Shearer, J. and L. R. Gowing (2004). "Pharmacotherapies for problematic psychostimulant use: A review of current research." *Drug Alcohol Rev* 23(2): 203-11.
- Shearer, J., A. Wodak, et al. (2003). "Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence." *Addiction* 98(8): 1137-41.

- Shearer, J., J. Sherman, et al. (2002). "Substitution therapy for amphetamine users." *Drug Alcohol Rev* 21(2): 179-85.
- Shearer, J., A. Wodak, R. P. Mattick, I. Van Beek, J. Lewis, W. Hall and K. Dolan (2001). "Pilot randomized controlled study of dexamphetamine substitution for amphetamine dependence." *Addiction* 96(9): 1289-96.
- Shoptaw, S., A. Huber, et al. (2006). "Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence." *Drug Alcohol Depend* 85(1): 12-18.
- Srisurapanont, M., N. Jarusuraisin, et al. (2001). "Treatment for amphetamine dependence and abuse." *Cochrane Database Syst Rev*(4): CD003022.
- Srisurapanont, M., N. Jarusuraisin, et al. (2001). "Treatment for amphetamine withdrawal." *Cochrane Database Syst Rev*(4): CD003021.
- Srisurapanont, M., P. Kittiratanapaiboon, et al. (2001). "Treatment for amphetamine psychosis." *Cochrane Database Syst Rev*(4): CD003026.
- Stoops, W. W. (2006). "Aripiprazole as a potential pharmacotherapy for stimulant dependence: human laboratory studies with d-amphetamine." *Exp Clin Psychopharmacol* 14(4): 413-21.
- Stoops, W. W., J. A. Lile, et al. (2006). "A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine." *Drug Alcohol Depend* 84(2): 206-9.
- Tsai, S. J. (2007). "Increased central brain-derived neurotrophic factor activity could be a risk factor for substance abuse: Implications for treatment." *Med Hypotheses* 68(2): 410-4.
- Vocci, F. J., J. Acri, et al. (2005). "Medication development for addictive disorders: The state of the science." *Am J Psychiatry* 162(8): 1432-40.
- Vocci, F. and W. Ling (2005). "Medications development: successes and challenges." *Pharmacol Ther* 108(1): 94-108.
- Wachtel, S. R., A. Ortengren, et al. (2002). "The effects of acute haloperidol or risperidone on subjective responses to methamphetamine in healthy volunteers." *Drug Alcohol Depend* 68(1): 23-33.
- White, R. (2000). "Dexamphetamine substitution in the treatment of amphetamine abuse: An initial investigation." *Addiction* 95(2): 229-38.
- Youdim, M. B., O. Bar Am, et al. (2005). "Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition." *J Neurosci Res* 79(1-2): 172-9.

### Pharmacological Interventions (animals)

- Achat-Mendes, C., K. L. Anderson, et al. (2006). "Impairment in consolidation of learned place preference following dopaminergic neurotoxicity in mice is ameliorated by N-acetylcysteine but not D1 and D2 dopamine receptor agonists." *Neuropsychopharmacology*.
- Acevedo, S. F., I. J. de Esch, et al. (2006). "Sex- and histamine-dependent long-term cognitive effects of methamphetamine exposure." *Neuropsychopharmacology*.
- Ago, Y., S. Nakamura, et al. (2006). "Attenuation by the 5-HT1A receptor agonist osetozotan of the behavioral effects of single and repeated methamphetamine in mice." *Neuropharmacology* 51(4): 914-22.
- Akita, H., M. Ogata, et al. (2006). "Nigral injection of antisense oligonucleotides to synaptotagmin I using HVJ-liposome vectors causes disruption of dopamine release in the striatum and impaired skill learning." *Brain Res* 1095(1): 178-89.
- Ali, S. F., G. D. Newport, et al. (1996). "Methamphetamine-induced dopaminergic toxicity in mice. Role of environmental temperature and pharmacological agents." *Ann N Y Acad Sci* 801: 187-98.
- Ali, S. F. (1995). "Lack of mitigation of methamphetamine-induced neurotoxicity by ganglioside GM1 or vitamin E." *Ann N Y Acad Sci* 765: 311.
- Ali, S. F., G. D. Newport, et al. (1994). "Low environmental temperatures or pharmacologic agents that produce hypothermia decrease methamphetamine neurotoxicity in mice." *Brain Res* 658(1-2): 33-8.
- Anggadiredja, K., M. Nakamichi, et al. (2004). "Endocannabinoid system modulates relapse to methamphetamine seeking: Possible mediation by the arachidonic acid cascade." *Neuropsychopharmacology* 29(8): 1470-8.
- Anggadiredja, K., K. Sakimura, et al. (2004). "Naltrexone attenuates cue- but not drug-induced methamphetamine seeking: A possible mechanism for the dissociation of primary and secondary reward." *Brain Res* 1021(2): 272-6.
- Balsara, J. J., T. R. Bapat, et al. (1985). "Effect of ergometrine on methamphetamine and apomorphine stereotypy in the guinea-pig." *J Pharm Pharmacol* 37(7): 514-7.
- Balsara, J. J., N. V. Nandal, et al. (1984). "Effects of naloxone on methamphetamine and apomorphine stereotypy and on haloperidol catalepsy in rats." *Psychopharmacology (Berl)* 82(3): 237-40.
- Balsara, J. J., N. V. Nandal, et al. (1982). "Experimental evaluation of the antidepressant and neuroleptic activity of maprotiline." *Indian J Physiol Pharmacol* 26(3): 183-95.

- Balsara, J. J., T. R. Bapat, et al. (1982). "Small doses of apomorphine induce catalepsy and antagonize methamphetamine stereotypy in rats." *Psychopharmacology (Berl)* 78(2): 192-4.
- Balsara, J. J., M. P. Muley, et al. (1981). "Effects of baclofen on dopamine-dependent behaviors in mice." *Psychopharmacology (Berl)* 75(4): 396-9.
- Balsara, J. J., J. H. Jadhav, et al. (1979). "Effect of drugs influencing central serotonergic mechanisms on methamphetamine-induced stereotyped behavior in the rat." *Psychopharmacology (Berl)* 64(3): 303-7.
- Balsara, J. J. and A. G. Chandorkar (1978). "Experimental evaluation of the possible neuroleptic activity of clomipramine." *Indian J Physiol Pharmacol* 22(3): 263-9.
- Barnett, A., R. I. Taber, et al. (1969). "Mechanism of action of antihistamines in laboratory antidepressant tests." *Int J Neuropharmacol* 8(4): 353-60.
- Battaglia, G., F. Fornai, et al. (2002). "Selective blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine neurotoxicity." *J Neurosci* 22(6): 2135-41.
- Baumann, M. H., J. M. Phillips, et al. (2002). "Preclinical evaluation of GBR12909 decanoate as a long-acting medication for methamphetamine dependence." *Ann N Y Acad Sci* 965: 92-108.
- Bedingfield, J. B., L. D. Calder, et al. (1997). "The role of the striatum in the mouse in behavioral sensitization to amphetamine." *Pharmacol Biochem Behav* 56(2): 305-10.
- Bergman, J., S. Yasar, et al. (2001). "Psychomotor stimulant effects of beta-phenylethylamine in monkeys treated with MAO-B inhibitors." *Psychopharmacology (Berl)* 159(1): 21-30.
- Berman, S. B. and T. G. Hastings (1997). "Inhibition of glutamate transport in synaptosomes by dopamine oxidation and reactive oxygen species." *J Neurochem* 69(3): 1185-95.
- Bialek, M., P. Zaremba, et al. (2004). "Neuroprotective role of testosterone in the nervous system." *Pol J Pharmacol* 56(5): 509-18.
- Binienda, Z. K., B. D. Przybyla, et al. (2006). "Effects of L-carnitine pretreatment in methamphetamine and 3-nitropropionic acid-induced neurotoxicity." *Ann N Y Acad Sci* 1074: 74-83.
- Bisagno, V., R. Bowman, et al. (2003). "Functional aspects of estrogen neuroprotection." *Endocrine* 21(1): 33-41.
- Blake, B. L., A. M. Muehlmann, et al. (2006). "Nifedipine suppresses self-injurious behaviors in animals." *Dev Neurosci*.
- Bowyer, J. F., R. R. Holson, et al. (2001). "Phenobarbital and dizocilpine can block methamphetamine-induced neurotoxicity in mice by mechanisms that are independent of thermoregulation." *Brain Res* 919(1): 179-83.
- Bowyer, J. F., B. Gough, et al. (1993). "Fluoro-gold and pentamidine inhibit the in vitro and in vivo release of dopamine in the striatum of rat." *J Pharmacol Exp Ther* 266(2): 1066-74.
- Bowyer, J. F., A. C. Scallet, et al. (1991). "Interactions of MK-801 with glutamate-, glutamine- and methamphetamine-evoked release of [3H]dopamine from striatal slices." *J Pharmacol Exp Ther* 257(1): 262-70.
- Brennan, K., A. Johnstone, et al. (2006). "Chronic benzylpiperazine (BZP) exposure produces behavioral sensitization and cross-sensitization to methamphetamine (MA)." *Drug Alcohol Depend*.
- Bronstein, D. M. and J. S. Hong (1995). "Effects of sulpiride and SCH 23390 on methamphetamine-induced changes in body temperature and lethality." *J Pharmacol Exp Ther* 274(2): 943-50.
- Brown, J. M., S. Gouty, et al. (2006). "Differential protection against MPTP or methamphetamine toxicity in dopamine neurons by deletion of ppN/OFQ expression." *J Neurochem* 98(2): 495-505.
- Cass, W. A., M. P. Smith, et al. (2006). "Calcitriol protects against the dopamine- and serotonin-depleting effects of neurotoxic doses of methamphetamine." *Ann N Y Acad Sci* 1074: 261-71.
- Cass, W. A., L. E. Peters, et al. (2006). "Protection by GDNF and other trophic factors against the dopamine-depleting effects of neurotoxic doses of methamphetamine." *Ann N Y Acad Sci* 1074: 272-81.
- Cass, W. A., M. W. Manning, et al. (2000). "Restorative effects of GDNF on striatal dopamine release in rats treated with neurotoxic doses of methamphetamine." *Ann N Y Acad Sci* 914: 127-36.
- Cass, W. A., D. J. Walker, et al. (1999). "Augmented methamphetamine-induced overflow of striatal dopamine 1 day after GDNF administration." *Brain Res* 827(1-2): 104-12.
- Cass, W. A. (1996). "GDNF selectively protects dopamine neurons over serotonin neurons against the neurotoxic effects of methamphetamine." *J Neurosci* 16(24): 8132-9.
- Cassarino, D. S., C. P. Fall, et al. (1998). "Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion." *J Neurochem* 71(1): 295-301.
- Cheng, J. T. (1986). "Effect of skimmianine on animal behavior." *Arch Int Pharmacodyn Ther* 281(1): 35-43.
- Chiu, C. T., T. Ma, et al. (2005). "Attenuation of methamphetamine-induced behavioral sensitization in mice by systemic administration of naltrexone." *Brain Res Bull* 67(1-2): 100-9.

- Clarkson, E. D., W. M. Zawada, et al. (2001). "IGF-I and bFGF improve dopamine neuron survival and behavioral outcome in parkinsonian rats receiving cultured human fetal tissue strands." *Exp Neurol* 168(1): 183-91.
- Cosi, C., P. Chopin and M. Marien (1996). "Benzamide, an inhibitor of poly(ADP-ribose) polymerase, attenuates methamphetamine-induced dopamine neurotoxicity in the c57b1/6n mouse." *Brain Res* 735(2): 343-8.
- Cowen, P. J., D. J. Nutt, et al. (1982). "Repeated administration of subconvulsant doses of GABA antagonist drugs. II. Effect on monoamine-mediated behaviour." *Psychopharmacology (Berl)* 76(1): 88-91.
- D'Almeida, V., R. Camarini, et al. (1995). "Antioxidant defense in rat brain after chronic treatment with anorectic drugs." *Toxicol Lett* 81(2-3): 101-5.
- Danger, Y., C. Gadjou, et al. (2006). "Development of murine monoclonal antibodies to methamphetamine and methamphetamine analogues." *J Immunol Methods* 309(1-2): 1-10.
- Daniels, J. R., W. D. Wessinger, et al. (2006). "Effects of anti-phencyclidine and anti-(+)-methamphetamine monoclonal antibodies alone and in combination on the discrimination of phencyclidine and (+)-methamphetamine by pigeons." *Psychopharmacology (Berl)* 185(1): 36-44.
- Dankova, J., R. Boucher, et al. (1977). "Effects of 1694 and other dopaminergic agents on circling behavior." *Eur J Pharmacol* 42(2): 113-21.
- D'Astous, M., K. R. Mickley, et al. (2006). "Differential protective properties of estradiol and tamoxifen against methamphetamine-induced nigrostriatal dopaminergic toxicity in mice." *Neuroendocrinology* 82(2): 111-120.
- D'Astous, M., T. M. Gajjar, D. E. Dluzen and T. Di Paolo (2004). "Dopamine transporter as a marker of neuroprotection in methamphetamine-lesioned mice treated acutely with estradiol." *Neuroendocrinology* 79(6): 296-304.
- Delle Donne, K. T. and P. K. Sonsalla (1994). "Protection against methamphetamine-induced neurotoxicity to neostriatal dopaminergic neurons by adenosine receptor activation." *J Pharmacol Exp Ther* 271(3): 1320-6.
- Dwoskin, L. P. and P. A. Crooks (2002). "A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse." *Biochem Pharmacol* 63(2): 89-98.
- Ehrman, L. A., M. T. Williams, et al. (2006). "Phosphodiesterase 1B differentially modulates the effects of methamphetamine on locomotor activity and spatial learning through DARPP32-dependent pathways: evidence from PDE1B-DARPP32 double-knockout mice." *Genes Brain Behav* 5(7): 540-51.
- Eibergen, R. D. and K. R. Carlson (1976). "Behavioral evidence for dopaminergic supersensitivity following chronic treatment with methadone or chlorpromazine in the guinea pig." *Psychopharmacology (Berl)* 48(2): 139-46.
- Elliott, A. J., E. H. Gold, et al. (1980). "Synthesis of some 5-phenylhexahydroazepino[4,5-b]indoles as potential neuroleptic agents." *J Med Chem* 23(11): 1268-9.
- Elphick, M. (1989). "Effects of carbamazepine on dopamine function in rodents." *Psychopharmacology (Berl)* 99(4): 532-6.
- Escubedo, E., C. Chipana, et al. (2005). "Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum: Involvement of  $\alpha 7$  nicotinic receptors." *J Pharmacol Exp Ther* 315(2): 658-67.
- Finberg, J. P., T. Takeshima, et al. (1998). "Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor." *Neuroreport* 9(4): 703-7.
- Finnegan, K. T. and T. Taraska (1996). "Effects of glutamate antagonists on methamphetamine and 3,4-methylenedioxymethamphetamine-induced striatal dopamine release in vivo." *J Neurochem* 66(5): 1949-58.
- Floran, B., L. Floran, et al. (2004). "Dopamine D4 receptors inhibit depolarization-induced [3H]GABA release in the rat subthalamic nucleus." *Eur J Pharmacol* 498(1-3): 97-102.
- Floran, B., L. Floran, et al. (1997). "D2 receptor-mediated inhibition of GABA release by endogenous dopamine in the rat globus pallidus." *Neurosci Lett* 237(1): 1-4.
- Fox, G. B., T. A. Esbenshade, et al. (2005). "Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzotrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist." *J Pharmacol Exp Ther* 313(1): 176-90.
- Fuller, R. W., S. K. Hemrick-Luecke, et al. (1992). "Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist." *Neuropharmacology* 31(10): 1027-32.
- Funakoshi, T., S. Chaki, et al. (2002). "In vitro and in vivo pharmacological profile of 5-[2-[4-(6-fluoro-1H-indole-3-yl)piperidin-1-yl]ethyl]-4-(4-fluorophenyl)thiazole-2-carboxylic acid amide (NRA0562), a novel and putative atypical antipsychotic." *Life Sci* 71(12): 1371-84.
- Gada, V. P., V. V. Joshi, et al. (1984). "Antagonism of apomorphine-induced cage climbing behaviour and methamphetamine stereotypy by fenfluramine in mice." *Indian J Physiol Pharmacol* 28(4): 326-30.
- Gajjar, T. M., L. I. Anderson and D. E. Dluzen (2003). "Acute effects of estrogen upon methamphetamine induced neurotoxicity of the nigrostriatal dopaminergic system." *J Neural Transm* 110(11): 1215-24.



- Garcia de Yebenes, J., J. Yebenes, et al. (2000). "Neurotrophic factors in neurodegenerative disorders: Model of Parkinson's disease." *Neurotox Res* 2(2-3): 115-37.
- Gasior, M., J. M. Witkin, et al. (2004). "Chlormethiazole potentiates the discriminative stimulus effects of methamphetamine in rats." *Eur J Pharmacol* 494(2-3): 183-9.
- Gassen, M., I. Lamensdorf, et al. (2003). "Attenuation of methamphetamine induced dopaminergic neurotoxicity by flupirtine: Microdialysis study on dopamine release and free radical generation." *J Neural Transm* 110(2): 171-82.
- Gatch, M. B., M. Selvig, et al. (2005). "GABAergic modulation of the discriminative stimulus effects of methamphetamine." *Behav Pharmacol* 16(4): 261-6.
- Gibb, J. W., M. Johnson, et al. (1989). "MK-801 attenuates the methamphetamine induced decreased in tryptophan hydroxylase activity." *NIDA Res Monogr* 95: 511.
- Ginawi, O. T., A. A. Al-Majed, et al. (2005). "NAN-190, a possible specific antagonist for methamphetamine." *Regul Toxicol Pharmacol* 41(2): 122-7.
- Gentry, W. B., E. M. Laurenzana, et al. (2006). "Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats." *Int Immunopharmacol* 6(6): 968-77.
- Gerasimov, M. R., C. R. Ashby, Jr., et al. (1999). "Gamma-vinyl GABA inhibits methamphetamine, heroin, or ethanol-induced increases in nucleus accumbens dopamine." *Synapse* 34(1): 11-9.
- Ginawi, O. T., A. A. Al-Majed, et al. (2005). "Ondansetron, a selective 5-HT3 antagonist, antagonizes methamphetamine-induced anorexia in mice." *Pharmacol Res* 51(3): 255-9.
- Glick, S. D., I. M. Maisonneuve, et al. (2002). "Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration." *Eur J Pharmacol* 438(1-2): 99-105.
- Glick, S. D., I. M. Maisonneuve, et al. (2001). "Comparative effects of dextromethorphan and dextrorphan on morphine, methamphetamine, and nicotine self-administration in rats." *Eur J Pharmacol* 422(1-3): 87-90.
- Glick, S. D., I. M. Maisonneuve, et al. (2000). "18-MC reduces methamphetamine and nicotine self-administration in rats." *Neuroreport* 11(9): 2013-5.
- Goeders, J. E. and N. E. Goeders (2004). "Effects of oxazepam on methamphetamine-induced conditioned place preference." *Pharmacol Biochem Behav* 78(1): 185-8.
- Golembiowska, K., J. Konieczny, et al. (2003). "Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats." *Neuropharmacology* 45(4): 484-92.
- Golembiowska, K., J. Konieczny, et al. (2002). "The role of striatal metabotropic glutamate receptors in degeneration of dopamine neurons." *Amino Acids* 23(1-3): 199-205.
- Greenamyre, J. T. and C. F. O'Brien (1991). "N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease." *Arch Neurol* 48(9): 977-81.
- Hanson, G. R., V. Sandoval, E. Riddle and A. E. Fleckenstein (2004). "Psychostimulants and vesicle trafficking: A novel mechanism and therapeutic implications." *Ann N Y Acad Sci* 1025: 146-50.
- Harrigan, S. E. and D. A. Downs (1981). "Pharmacological evaluation of narcotic antagonist delivery systems in rhesus monkeys." *NIDA Res Monogr* 28: 77-92.
- Harrigan, S. E. and D. A. Downs (1978). "Continuous intravenous naltrexone effects on morphine self-administration in rhesus monkeys." *J Pharmacol Exp Ther* 204(2): 481-6.
- Harrod, S. B., L. P. Dwoskin, et al. (2004). "Lobeline produces conditioned taste avoidance in rats." *Pharmacol Biochem Behav* 78(1): 1-5.
- Harrod, S. B., L. P. Dwoskin, et al. (2003). "Lobeline does not serve as a reinforcer in rats." *Psychopharmacology (Berl)* 165(4): 397-404.
- Harrod, S. B., L. P. Dwoskin, et al. (2001). "Lobeline attenuates d-methamphetamine self-administration in rats." *J Pharmacol Exp Ther* 298(1): 172-9.
- Harvey, B. K., A. Mark, et al. (2004). "Neurotrophic effects of bone morphogenetic protein-7 in a rat model of Parkinson's disease." *Brain Res* 1022(1-2): 88-95.
- Hashimoto, K., H. Tsukada, et al. (2006). "Protective effects of minocycline on the reduction of dopamine transporters in the striatum after administration of methamphetamine: A positron emission tomography study in conscious monkeys." *Biol Psychiatry*.
- Hashimoto, K., H. Tsukada, et al. (2004). "Effects of N-acetyl-L-cysteine on the reduction of brain dopamine transporters in monkey treated with methamphetamine." *Ann N Y Acad Sci* 1025: 231-5.
- Hashimoto, T., N. Fukuda, et al. (1983). "Effects of TRH and an analog, DN-1417 on the activities of single neurons in the nucleus accumbens, cerebral cortex and caudate-putamen of rats." *Kurume Med J* 30 Suppl: S19-27.

- Hayase, T., Y. Yamamoto, et al. (2003). "Brain excitatory amino acid transporters (EAATs) and treatment of methamphetamine toxicity." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 38(6): 498-511.
- He, J., Y. Yang, et al. (2006). "The effects of chronic administration of quetiapine on the methamphetamine-induced recognition memory impairment and dopaminergic terminal deficit in rats." *Behav Brain Res* 172(1): 39-45.
- He, J., H. Xu, et al. (2005). "Chronic administration of quetiapine alleviates the anxiety-like behavioural changes induced by a neurotoxic regimen of dl-amphetamine in rats." *Behav Brain Res* 160(1): 178-87.
- Hess, U. S., S. P. Whalen, et al. (2003). "Ampakines reduce methamphetamine-driven rotation and activate neocortex in a regionally selective fashion." *Neuroscience* 121(2): 509-21.
- Higashi, H., K. Inanaga, et al. (1989). "Enhancement of dopamine actions on rat nucleus accumbens neurones in vitro after methamphetamine pre-treatment." *J Physiol* 408: 587-603.
- Hildebrandt, K., G. Teuchert-Noodt, et al. (1999). "A single neonatal dose of methamphetamine suppresses dentate granule cell proliferation in adult gerbils which is restored to control values by acute doses of haloperidol." *J Neural Transm* 106(5-6): 549-58.
- Hiranita, T., Y. Nawata, et al. (2006). "Suppression of methamphetamine-seeking behavior by nicotinic agonists." *Proc Natl Acad Sci U S A* 103(22): 8523-7.
- Hiranita, T., K. Anggadiredja, et al. (2004). "Nicotine attenuates relapse to methamphetamine-seeking behavior (craving) in rats." *Ann N Y Acad Sci* 1025: 504-7.
- Hirata, H., M. Asanuma, et al. (1998). "Melatonin attenuates methamphetamine-induced toxic effects on dopamine and serotonin terminals in mouse brain." *Synapse* 30(2): 150-5.
- Hirate, K. and H. Kuribara (1991). "Characteristics of the ambulation-increasing effect of GBR-12909, a selective dopamine uptake inhibitor, in mice." *Jpn J Pharmacol* 55(4): 501-11.
- Hirota, S., N. Kawashima, et al. (2003). "Neuropharmacological profile of an atypical antipsychotic, NRA0562." *CNS Drug Rev* 9(4): 375-88.
- Hoefler, M. E., S. J. Voskanian, et al. (2006). "Effects of terguride, ropinirole, and acetyl-l-carnitine on methamphetamine withdrawal in the rat." *Pharmacol Biochem Behav* 83(3): 403-9.
- Holtzman, S. G. (2001). "Differential interaction of GBR 12909, a dopamine uptake inhibitor, with cocaine and methamphetamine in rats discriminating cocaine." *Psychopharmacology (Berl)* 155(2): 180-6.
- Horner, K. A. and K. A. Keefe (2006). "Regulation of psychostimulant-induced preprodynorphin, c-fos and zif/268 messenger RNA expression in the rat dorsal striatum by mu opioid receptor blockade." *Eur J Pharmacol* 532(1-2): 61-73.
- Honma, T. and H. Fukushima (1979). "The involvement of serotonergic neurons in the central nervous system as the possible mechanism for slow head-shaking behavior induced by methamphetamine in rats." *Psychopharmacology (Berl)* 65(2): 155-9.
- Ida, I., T. Asami, et al. (1990). "[Characteristics of antagonism between ceruletide and various central-acting drugs: Investigation by means of ambulatory activity in mice]." *Nippon Yakurigaku Zasshi* 96(6): 333-41.
- Ihara, Y., M. Sato, et al. (1986). "Morphological changes in rat striatal boutons after chronic methamphetamine and haloperidol treatment." *Neurosci Res* 3(5): 403-10.
- Ikarashi, Y., A. Takahashi, et al. (1997). "Regulation of dopamine D1 and D2 receptors on striatal acetylcholine release in rats." *Brain Res Bull* 43(1): 107-15.
- Imam, S. Z., J. el-Yazal, et al. (2001). "Methamphetamine-induced dopaminergic neurotoxicity: Role of peroxynitrite and neuroprotective role of antioxidants and peroxynitrite decomposition catalysts." *Ann N Y Acad Sci* 939: 366-80.
- Imam, S. Z., F. Islam, et al. (2000). "Prevention of dopaminergic neurotoxicity by targeting nitric oxide and peroxynitrite: Implications for the prevention of methamphetamine-induced neurotoxic damage." *Ann N Y Acad Sci* 914: 157-71.
- Imam, S. Z., G. D. Newport, et al. (1999). "Selenium, an antioxidant, protects against methamphetamine-induced dopaminergic neurotoxicity." *Brain Res* 818(2): 575-8.
- Imam, S. Z., J. P. Crow, et al. (1999). "Methamphetamine generates peroxynitrite and produces dopaminergic neurotoxicity in mice: Protective effects of peroxynitrite decomposition catalyst." *Brain Res* 837(1-2): 15-21.
- Imam, S. Z., G. D. Newport, et al. (1999). "Selenium, an antioxidant, protects against methamphetamine-induced dopaminergic neurotoxicity." *Brain Res* 818(2): 575-8.
- Inoue, H., I. Arai, et al. (1996). "NG-nitro-L-arginine methyl ester attenuates the maintenance and expression of methamphetamine-induced behavioral sensitization and enhancement of striatal dopamine release." *J Pharmacol Exp Ther* 277(3): 1424-30.
- Ito, K., T. Abekawa, et al. (2006). "Valproate blocks high-dose methamphetamine-induced behavioral cross-sensitization to locomotion-inducing effect of dizocilpine (MK-801), but not methamphetamine." *Psychopharmacology (Berl)* 186(4): 525-33.
- Ito, K., T. Ohmori, et al. (2000). "The role of benzodiazepine receptors in the acquisition and expression of behavioral sensitization to methamphetamine." *Pharmacol Biochem Behav* 65(4): 705-10.

- Ito, K., T. Ohmori, et al. (1997). "Clonazepam prevents the development of sensitization to methamphetamine." *Pharmacol Biochem Behav* 58(4): 875-9.
- Ito, Y., K. Takuma, et al. (2006). "A novel azaindolizinone derivative ZSET1446, spiro[imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one, improves methamphetamine-induced impairment of recognition memory in mice by activating extracellular signal-regulated kinase 1/2." *J Pharmacol Exp Ther*.
- Itzhak, Y. and J. L. Martin (2000). "Effect of riluzole and gabapentin on cocaine- and methamphetamine-induced behavioral sensitization in mice." *Psychopharmacology (Berl)* 151(2-3): 226-33.
- Jadhav, J. H., J. J. Balsara, et al. (1981). "Effect of ethosuximide on dopaminergically mediated behaviours." *Indian J Physiol Pharmacol* 25(3): 274-8.
- Johnson, S. A., N. T. Luu, et al. (1999). "Synergistic interactions between ampakines and antipsychotic drugs." *J Pharmacol Exp Ther* 289(1): 392-7.
- Jones, D. N. and S. G. Holtzman (1994). "Influence of naloxone upon motor activity induced by psychomotor stimulant drugs." *Psychopharmacology (Berl)* 114(2): 215-24.
- Joshi, V. V., J. J. Balsara, et al. (1981). "Effect of L-histidine and chlorcyclizine on apomorphine-induced climbing behaviour and methamphetamine stereotypy in mice." *Eur J Pharmacol* 69(4): 499-502.
- Jun, J. H. and C. W. Schindler (2000). "Dextromethorphan alters methamphetamine self-administration in the rat." *Pharmacol Biochem Behav* 67(3): 405-9.
- Kameyama, T., T. Nabeshima, et al. (1987). "[Behavioral pharmacological action of Ca-4-(3,5-dihydroxy-3-methylpentylamido) butyrate (mevalonic GABA, MV-GABA)]." *Nippon Yakurigaku Zasshi* 89(3): 103-10.
- Kaneko, Y., A. Kashiwa, et al. (2006). "Selective serotonin reuptake inhibitors, fluoxetine and paroxetine, attenuate the expression of the established behavioral sensitization induced by methamphetamine." *Neuropsychopharmacology*.
- Kashihara, K., Y. Fujiwara, et al. (1984). "[Continuous suppression of methamphetamine-induced supersensitivity by chronic haloperidol administration]." *Seishin Shinkeigaku Zasshi* 86(11): 928-32.
- Kato, K., T. Shishido, et al. (2001). "Glycine reduces novelty- and methamphetamine-induced locomotor activity in neonatal ventral hippocampal damaged rats." *Neuropsychopharmacology* 24(3): 330-2.
- Kawasaki, T., K. Ishihara, et al. (2006). "Protective effect of the radical scavenger edaravone against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum." *Eur J Pharmacol* 542(1-3): 92-9.
- Kim, H. C., E. J. Shin, et al. (2005). "Pharmacological action of Panax ginseng on the behavioral toxicities induced by psychotropic agents." *Arch Pharm Res* 28(9): 995-1001.
- Kim, H., W. Jhoo, et al. (2000). "Selenium deficiency potentiates methamphetamine-induced nigral neuronal loss; Comparison with MPTP model." *Brain Res* 862(1-2): 247-52.
- Kim, H. C., W. K. Jhoo, et al. (1999). "Protection of methamphetamine nigrostriatal toxicity by dietary selenium." *Brain Res* 851(1-2): 76-86.
- Kim, H. S., Y. T. Hong, et al. (1998). "Inhibition by ginsenosides Rb1 and Rg1 of methamphetamine-induced hyperactivity, conditioned place preference and postsynaptic dopamine receptor supersensitivity in mice." *Gen Pharmacol* 30(5): 783-9.
- Kim, H. S. and C. G. Jang (1997). "MK-801 inhibits methamphetamine-induced conditioned place preference and behavioral sensitization to apomorphine in mice." *Brain Res Bull* 44(3): 221-7.
- Kim, H. S., C. G. Jang, et al. (1996). "Blockade by ginseng total saponin of methamphetamine-induced hyperactivity and conditioned place preference in mice." *Gen Pharmacol* 27(2): 199-204.
- Kim, H. S., J. G. Kang, et al. (1995). "Blockade by ginseng total saponin of the development of methamphetamine reverse tolerance and dopamine receptor supersensitivity in mice." *Planta Med* 61(1): 22-5.
- Kim, S., R. Westphalen, et al. (2000). "Toward development of an in vitro model of methamphetamine-induced dopamine nerve terminal toxicity." *J Pharmacol Exp Ther* 293(2): 625-33.
- Kita, T., T. Saraya, et al. (2003). "1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine pretreatment attenuates methamphetamine-induced dopamine toxicity." *Pharmacol Toxicol* 92(2): 71-80.
- Kita, T., Y. Matsunari, et al. (2000). "Evaluation of the effects of alpha-phenyl-N-tert-butyl nitron pretreatment on the neurobehavioral effects of methamphetamine." *Life Sci* 67(13): 1559-71.
- Kitaichi, K., M. Fukuda, et al. (2005). "Behavioral changes following antisense oligonucleotide-induced reduction of organic cation transporter-3 in mice." *Neurosci Lett* 382(1-2): 195-200.
- Kitanaka, N., J. Kitanaka, et al. (2005). "Repeated clorgyline treatment inhibits methamphetamine-induced behavioral sensitization in mice." *Neurochem Res* 30(4): 445-51.
- Kitanaka, N., J. Kitanaka, et al. (2005). "Inhibition of methamphetamine-induced hyperlocomotion in mice by clorgyline, a monoamine oxidase-a inhibitor, through alteration of the 5-hydroxytryptamine turnover in the striatum." *Neuroscience* 130(2): 295-308.

- Kleven, M. S. and L. S. Seiden (1991). "Repeated injection of cocaine potentiates methamphetamine-induced toxicity to dopamine-containing neurons in rat striatum." *Brain Res* 557(1-2): 340-3.
- Klongpanichapak, S., P. Govitrapong, et al. (2006). "Attenuation of cocaine and methamphetamine neurotoxicity by coenzyme Q10." *Neurochem Res* 31(3): 303-11.
- Koike, K., K. Hashimoto, et al. (2005). "The immunophilin ligand FK506 protects against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum." *Neuropharmacology* 48(3): 391-7.
- Kondo, T., T. Ito, et al. (1994). "Bromocriptine scavenges methamphetamine-induced hydroxyl radicals and attenuates dopamine depletion in mouse striatum." *Ann N Y Acad Sci* 738: 222-9.
- Koshikawa, N., S. Aoki, et al. (1986). "Effects of sulpiride injected into the dorsal striatum and the nucleus accumbens on dopamine-mediated oral stereotypy and hyperlocomotion in rats." *J Nihon Univ Sch Dent* 28(2): 109-16.
- Kosten, T. and S. M. Owens (2005). "Immunotherapy for the treatment of drug abuse." *Pharmacol Ther* 108(1): 76-85.
- Kuehn, B. M. (2006). "Nicotine, donepezil may dampen meth craving." *JAMA* 296(1): 31.
- Kunnathur, V., K. Shemisa, et al. (2006). "Sex differences in methamphetamine-evoked striatal dopamine of mice are reversed by nomifensine." *Neurotoxicol Teratol* 28(5): 557-62.
- Kupsch, A., J. Sautter, et al. (2001). "Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: Comparison of rasagiline (TVP 1012) with selegiline." *J Neural Transm* 108(8-9): 985-1009.
- Kuribara, H. (1993). "Ceruletide, a cholecystokinin-like decapeptide, differentially reduces the stimulant effect of MK-801 and ketamine: Evaluation by discrete shuttle avoidance in mice." *Eur J Pharmacol* 231(1): 7-11.
- Kuribara, H. and Y. Uchihashi (1993). "SCH 23390 equivalently, but YM-09151-2 differentially reduces the stimulant effects of methamphetamine, MK-801 and ketamine: assessment by discrete shuttle avoidance in mice." *Jpn J Pharmacol* 62(1): 111-4.
- Kuribara, H. and S. Tadokoro (1992). "Behavioral effects of cocoa and its main active compound theobromine: evaluation by ambulatory activity and discrete avoidance in mice." *Arukuru Kenkyuto Yakubutsu Ison* 27(2): 168-79.
- Kuribara, H. and S. Tadokoro (1991). "[Behavioral effects of febarbamate (MS-543): evaluation by ambulatory activity, active avoidance and passive avoidance in mice]." *Nippon Yakurigaku Zasshi* 98(4): 311-7.
- Kuribara, H. and S. Tadokoro (1991). "Differential antagonism of the stimulant effects of MK-801 and methamphetamine by ceruletide: Evaluation by discrete shuttle avoidance response in mice." *Jpn J Pharmacol* 57(3): 425-9.
- Kuribara, H., T. Asami, et al. (1990). "Effects of ceruletide, administered singly and in combination with central-acting drugs, on discrete shuttle avoidance response in mice." *Jpn J Pharmacol* 54(3): 325-9.
- Kuribara, H. and S. Tadokoro (1989). "[Behavioral effects of NC-1100, 1-(3,4-dimethoxyphenyl)-2-(4-diphenylmethylpiperazinyl) ethanol dihydrochloride--on ambulatory activity, discrete lever-press response and shuttle avoidance response in mice]." *Nippon Yakurigaku Zasshi* 93(4): 245-53.
- Kuribara, H. and S. Tadokoro (1988). "[Effects of buflomedil on ambulatory activity and discrete avoidance responses in mice]." *Nippon Yakurigaku Zasshi* 91(2): 111-9.
- Kuribara, H., S. Tadokoro, et al. (1986). "[Behavioral effects of propentofylline (HWA 285) on ambulatory activity, discrete avoidance response and passive avoidance response in mice]." *Nippon Yakurigaku Zasshi* 87(5): 573-81.
- Kuribara, H. and S. Tadokoro (1984). "[Behavioral effects of amantadine on ambulatory activity and drinking in mice and on continuous and discrete avoidance responses in rats]." *Nippon Yakurigaku Zasshi* 83(2): 147-58.
- Kuribara, H. and S. Tadokoro (1983). "Effect alteration of methamphetamine by amino acids or their salts on ambulatory activity in mice." *J Toxicol Sci* 8(1): 25-36.
- Kusayama, T. and S. Watanabe (2000). "Reinforcing effects of methamphetamine in planarians." *Neuroreport* 11(11): 2511-3.
- Kuwahara, A., A. Kubota, et al. (1987). "[Drug dependence test on a cerebral insufficiency improver, aniracetam]." *Nippon Yakurigaku Zasshi* 89(1): 33-46.
- Kwon, Y. S., T. Nabeshima, et al. (2004). "PAP 9704, a Korean herbal medicine attenuates methamphetamine-induced hyperlocomotion via adenosine A2A receptor stimulation in mice." *Biol Pharm Bull* 27(6): 906-9.
- Larson, J., C. N. Quach, et al. (1996). "Effects of an AMPA receptor modulator on methamphetamine-induced hyperactivity in rats." *Brain Res* 738(2): 353-6.
- Layer, R. T., L. R. Bland, et al. (1993). "MK-801, but not drugs acting at strychnine-insensitive glycine receptors, attenuate methamphetamine nigrostriatal toxicity." *Brain Res* 625(1): 38-44.
- Li, S. M., Y. H. Ren, et al. (2002). "Effect of 7-nitroindazole on drug-priming reinstatement of D-methamphetamine-induced conditioned place preference." *Eur J Pharmacol* 443(1-3): 205-6.
- Li, S. M., L. L. Yin, et al. (2002). "The effect of 7-nitroindazole on the acquisition and expression of D-methamphetamine-induced place preference in rats." *Eur J Pharmacol* 435(2-3): 217-23.
- Li, S. M., L. L. Yin, et al. (2001). "GABA(B) receptor agonist baclofen attenuates the development and expression of D-methamphetamine-induced place preference in rats." *Life Sci* 70(3): 349-56.

- Liang, J. H., K. Wang, et al. (2006). "Potentiating effect of tramadol on methamphetamine-induced behavioral sensitization in mice." *Psychopharmacology (Berl)*: 1-10.
- Liao, P. C., Y. M. Kuo, et al. (2003). "Striatal formation of 6-hydroxydopamine in mice treated with pargyline, pyrogallol and methamphetamine." *J Neural Transm* 110(5): 487-94.
- Lockhart, B., A. Roger, et al. (2005). "In vivo neuroprotective effects of the novel imidazolyl nitron free-radical scavenger (Z)-alpha-[2-thiazol-2-yl]imidazol-4-yl]-N-tert-butyl nitron (S34176)." *Eur J Pharmacol* 511(2-3): 127-36.
- Lockhart, B., N. Bonhomme, et al. (2001). "Protective effect of the antioxidant 6-ethoxy-2,2-pentamethylen-1,2-dihydroquinoline (S 33113) in models of cerebral neurodegeneration." *Eur J Pharmacol* 416(1-2): 59-68.
- Lotharius, J., J. Falsig, et al. (2005). "Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway." *J Neurosci* 25(27): 6329-42.
- Maeda, T., N. Kiguchi, et al. (2006). "Peroxisome proliferator-activated receptor gamma activation relieves expression of behavioral sensitization to methamphetamine in mice." *Neuropsychopharmacology*.
- Maggio, R., M. Riva, et al. (1998). "Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors." *J Neurochem* 71(6): 2439-46.
- Maggio, R., M. Riva, et al. (1997). "Striatal increase of neurotrophic factors as a mechanism of nicotine protection in experimental parkinsonism." *J Neural Transm* 104(10): 1113-23.
- Maisonneuve, I. M. and S. D. Glick (2003). "Anti-addictive actions of an iboga alkaloid congener: A novel mechanism for a novel treatment." *Pharmacol Biochem Behav* 75(3): 607-18.
- Mandel, S., O. Weinreb, et al. (2005). "Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives." *Brain Res Brain Res Rev* 48(2): 379-87.
- Matsuoka, N., N. Maeda, et al. (1992). "Effect of FR121196, a novel cognitive enhancer, on the memory impairment of rats in passive avoidance and radial arm maze tasks." *J Pharmacol Exp Ther* 263(2): 436-44.
- McKinney, P. E., C. Tomaszewski, et al. (1994). "Methamphetamine toxicity prevented by activated charcoal in a mouse model." *Ann Emerg Med* 24(2): 220-3.
- McDaid, J., C. E. Tedford, et al. (2006). "Nullifying drug-induced sensitization: Behavioral and electrophysiological evaluations of dopaminergic and serotonergic ligands in methamphetamine-sensitized rats." *Drug Alcohol Depend*.
- Melega, W. P., G. Lacan, et al. (1998). "Dizocilpine and reduced body temperature do not prevent methamphetamine-induced neurotoxicity in the vervet monkey: [<sup>11</sup>C]WIN 35,428 - positron emission tomography studies." *Neurosci Lett* 258(1): 17-20.
- Miller, D. K., M. M. Dopheide, et al. (2005). "Dietary cadmium exposure attenuates D-amphetamine-evoked [<sup>3</sup>H]dopamine release from striatal slices and methamphetamine-induced hyperactivity." *Pharmacol Biochem Behav* 80(4): 557-66.
- Miyamoto, K. (1990). "Conditioned drug effects of pimozide, haloperidol and chlorpromazine on methamphetamine-induced behavior." *Jpn J Psychiatry Neurol* 44(3): 629-36.
- Moffett, M. C. and N. E. Goeders (2007). "CP-154,526, a CRF type-1 receptor antagonist, attenuates the cue- and methamphetamine-induced reinstatement of extinguished methamphetamine-seeking behavior in rats." *Psychopharmacology (Berl)* 190(2): 171-80.
- Moorthy, N. S. and J. J. Balsara (1999). "Effects of flunarizine on dopamine dependent behaviours in rats." *Indian J Med Sci* 53(2): 43-8.
- Moroji, T. and Y. Hagino (1986). "A behavioral pharmacological study on CCK-8 related peptides in mice." *Neuropeptides* 8(3): 273-86.
- Moy, L. Y., D. S. Albers, et al. (1998). "Lowering ambient or core body temperature elevates striatal MPP+ levels and enhances toxicity to dopamine neurons in MPTP-treated mice." *Brain Res* 790(1-2): 264-9.
- Muley, M. P., M. A. Joshi, et al. (1984). "Effect of bupropion on dopamine and 5-hydroxytryptamine-mediated behaviour in mice." *J Pharm Pharmacol* 36(3): 208-10.
- Muley, M. P., J. J. Balsara, et al. (1979). "Effect of L-histidine pretreatment on methamphetamine induced stereotyped behaviour in rats." *Indian J Physiol Pharmacol* 23(4): 291-6.
- Munzar, P., G. Tanda, et al. (2004). "Histamine h3 receptor antagonists potentiate methamphetamine self-administration and methamphetamine-induced accumbal dopamine release." *Neuropsychopharmacology* 29(4): 705-17.
- Munzar, P., S. W. Kutkat, et al. (2000). "Failure of baclofen to modulate discriminative-stimulus effects of cocaine or methamphetamine in rats." *Eur J Pharmacol* 408(2): 169-74.
- Munzar, P., M. H. Baumann, et al. (1999). "Effects of dopamine and serotonin-releasing agents on methamphetamine discrimination and self-administration in rats." *Psychopharmacology (Berl)* 141(3): 287-96.
- Muraki, A. (1993). "[Effects of antagonists of NMDA receptor on methamphetamine-induced decrease in the dopamine uptake sites in the rat striatum and on the behavioral sensitization]." *Hokkaido Igaku Zasshi* 68(3): 407-18.
- Myers, C. S., H. Fisher, et al. (1995). "Uridine reduces rotation induced by L-dopa and methamphetamine in 6-OHDA-treated rats." *Pharmacol Biochem Behav* 52(4): 749-53.

- Nakagawa, T., M. Fujio, et al. (2005). "Effect of MS-153, a glutamate transporter activator, on the conditioned rewarding effects of morphine, methamphetamine and cocaine in mice." *Behav Brain Res* 156(2): 233-9.
- Nakajima, H., R. Shigehara, et al. (1981). "[Effect of alpha-methyl-para-tyrosine on "methamphetamine-induced stereotype and hypermotility" of reserpinized rats (author's transl)]." *Nippon Yakurigaku Zasshi* 78(6): 557-69.
- Nakagawa, M., M. Ohgoh, et al. (2004). "Dopaminergic agonists and muscarinic antagonists improve lateralization in hemiparkinsonian rats in a novel exploratory Y-maze." *J Pharmacol Exp Ther* 309(2): 737-44.
- Nakamura, T., E. Okuyama, et al. (1996). "Neurotropic components from star anise (*Illicium verum* Hook. fil.)." *Chem Pharm Bull (Tokyo)* 44(10): 1908-14.
- Nakamura, K., Y. Shimokawa, et al. (1978). "[Influence of clonazepam, an anticonvulsant benzodiazepine drug, on the rat brain monoamine containing neurons especially on dopaminergic neurons (author's transl)]." *Nippon Yakurigaku Zasshi* 74(2): 251-65.
- Nishimori, T., K. Morino, et al. (1988). "[Effects of cadralazine on the central nervous system]." *Nippon Yakurigaku Zasshi* 91(4): 209-20.
- Niwa, M., A. Nitta, et al. (2006). "An inducer for glial cell line-derived neurotrophic factor and tumor necrosis factor-alpha protects against methamphetamine-induced rewarding effects and sensitization." *Biol Psychiatry*.
- Nomura, Y., S. Ashikari, et al. (1982). "[Effect of dopamine intracerebrally injected by the Valzelli method on methamphetamine-stereotypy and hypermotility]." *Yakubutsu Seishin Kodo* 2(1): 25-37.
- Ogura, H., Y. Furuya, et al. (1998). "Peptide N- and P/Q-type Ca<sup>2+</sup> blockers inhibit stimulant-induced hyperactivity in mice." *Peptides* 19(6): 1017-22.
- Oiwa, Y., R. Yoshimura, et al. (2002). "Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease." *Brain Res* 947(2): 271-83.
- Oka, M., Y. Noda, et al. (1993). "Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-5<sub>2</sub> antagonist properties." *J Pharmacol Exp Ther* 264(1): 158-65.
- Okugawa, H., R. Ueda, et al. (1996). "Effect of jinkoh-eremol and agarospirol from agarwood on the central nervous system in mice." *Planta Med* 62(1): 2-6.
- Okuyama, S., N. Kawashima, et al. (1999). "A selective dopamine D4 receptor antagonist, NRA0160: A preclinical neuropharmacological profile." *Life Sci* 65(20): 2109-25.
- Okuyama, S., S. Chaki, et al. (1997). "In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT<sub>2A</sub> receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl]pyrrolidin-3-yl]thiazole (NRA0045)." *J Pharmacol Exp Ther* 282(1): 56-63.
- O'Shea, E., V. Sanchez, et al. (2003). "On the protection against methamphetamine-induced neurotoxicity by benzamide, a PARP inhibitor." *Psychopharmacology (Berl)* 165(3): 317-9.
- Ozawa, H. and T. Miyauchi (1977). "Potentiating effect of lithium chloride on methamphetamine-induced stereotypy in mice." *Eur J Pharmacol* 41(2): 213-6.
- Ozawa, K., K. Hashimoto, et al. (2006). "Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: A neurodevelopmental animal model of schizophrenia." *Biol Psychiatry* 59(6): 546-54.
- Pace, C. J., S. D. Glick, et al. (2004). "Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration." *Eur J Pharmacol* 492(2-3): 159-67.
- Palmer, A. A., M. Verbitsky, et al. (2005). "Gene expression differences in mice divergently selected for methamphetamine sensitivity." *Mamm Genome* 16(5): 291-305.
- Park, M. J., S. K. Lee, et al. (2006). "Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity." *Brain Res* 1109(1): 176-82.
- Perez, V. and M. Unzeta (2003). "PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 mice." *Neurochem Int* 42(3): 221-9.
- Pillot, C., A. Heron, et al. (2003). "Ciproxifan, a histamine H<sub>3</sub>-receptor antagonist/inverse agonist, modulates the effects of methamphetamine on neuropeptide mRNA expression in rat striatum." *Eur J Neurosci* 17(2): 307-14.
- Plotnikoff, N. (1966). "Magnesium pemoline: Enhancement of learning and memory of a conditioned avoidance response." *Science* 151(711): 703-4.
- Pubill, D., E. Verdaguer, et al. (2002). "Carnosine prevents methamphetamine-induced gliosis but not dopamine terminal loss in rats." *Eur J Pharmacol* 448(2-3): 165-8.
- Ranaldi, R. and K. Poeggel (2002). "Baclofen decreases methamphetamine self-administration in rats." *Neuroreport* 13(9): 1107-10.
- Ranaldi, R., K. G. Anderson, et al. (2000). "Reinforcing and discriminative stimulus effects of RTI 111, a 3-phenyltropane analog, in rhesus monkeys: Interaction with methamphetamine." *Psychopharmacology (Berl)* 153(1): 103-10.

- Rauhut, A. S., N. Neugebauer, et al. (2003). "Effect of bupropion on nicotine self-administration in rats." *Psychopharmacology (Berl)* 169(1): 1-9.
- Razzak, A., M. Fujiwara, et al. (1977). "Possible involvement of a central noradrenergic system in automutilation induced by clonidine in mice." *Jpn J Pharmacol* 27(1): 145-52.
- Rothman, R. B., B. E. Blough, et al. (2006). "Dual dopamine-5-HT releasers: Potential treatment agents for cocaine addiction." *Trends Pharmacol Sci* 27(12): 612-8.
- Rothman, R. B., B. E. Blough, et al. (2005). "Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration." *J Pharmacol Exp Ther* 313(3): 1361-9.
- Rothman, R. B., J. S. Partilla, et al. (2000). "Methamphetamine dependence: Medication development efforts based on the dual deficit model of stimulant addiction." *Ann N Y Acad Sci* 914: 71-81.
- Rothman, R. B., J. S. Partilla, et al. (2000). "Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: A pharmacological strategy for treating stimulant abuse." *Synapse* 35(3): 222-7.
- Ruch-Monachon, M. A., M. Jalfre, et al. (1976). "Drugs and PGO waves in the lateral geniculate body of the curarized cat. V. Miscellaneous compounds. Synopsis of the role of central neurotransmitters on PGO wave activity." *Arch Int Pharmacodyn Ther* 219(2): 326-46.
- Ryan, R. E., S. A. Ross, et al. (2001). "Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice." *Br J Pharmacol* 132(8): 1650-6.
- Salo, R., T. E. Nordahl, et al. (2002). "Preliminary evidence of reduced cognitive inhibition in methamphetamine-dependent individuals." *Psychiatry Res* 111(1): 65-74.
- Sandoval, V., E. L. Riddle, et al. (2003). "Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits." *J Pharmacol Exp Ther* 304(3): 1181-7.
- Sano, H., Y. Totsuka, et al. (1982). "[Methamphetamine-stereotypy and hypermotility] in rats chronically treated with reserpine--the effect of intracerebral injection of chlorpromazine]." *Nippon Yakurigaku Zasshi* 80(2): 113-24.
- Sansone, M. and A. Oliverio (1989). "Avoidance facilitation by nootropics." *Prog Neuropsychopharmacol Biol Psychiatry* 13 Suppl: S89-97.
- Sansone, M., M. Ammassari-Teule, et al. (1985). "Interaction between nootropic drugs and methamphetamine on avoidance acquisition but not on locomotor activity in mice." *Arch Int Pharmacodyn Ther* 278(2): 229-35.
- Shika, K., C. Nakata, et al. (1977). "[Inhibitory effects of methyl o-(4-hydroxy-3-methoxycinnamoyl) reserpate (CD-3400) on the central nervous system (author's transl)]." *Nippon Yakurigaku Zasshi* 73(7): 717-34.
- Shimosato, K., N. Nagao, et al. (2003). "Suppressive effects of trihexyphenidyl on methamphetamine-induced dopamine release as measured by in vivo microdialysis." *Synapse* 49(1): 47-54.
- Shimosato, K., S. Watanabe, et al. (2001). "Differential effects of trihexyphenidyl on place preference conditioning and locomotor stimulant activity of cocaine and methamphetamine." *Naunyn Schmiedebergs Arch Pharmacol* 364(1): 74-80.
- Shoblock, J. R., E. B. Sullivan, et al. (2003). "Neurochemical and behavioral differences between d-methamphetamine and d-amphetamine in rats." *Psychopharmacology (Berl)* 165(4): 359-69.
- Shuto, T., M. Kuroiwa, et al. (2006). "Reversal of methamphetamine-induced behavioral sensitization by repeated administration of a dopamine D(1) receptor agonist." *Neuropharmacology*.
- Singh, N. A., L. G. Bush, et al. (1990). "Dopamine-mediated changes in central nervous system neurotensin systems: A role for NMDA receptors." *Eur J Pharmacol* 187(3): 337-44.
- Siuciak, J. A., S. A. McCarthy, et al. (2006). "Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: Evidence for altered striatal function." *Neuropharmacology* 51(2): 374-85.
- Sriram, K., D. B. Miller, et al. (2006). "Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: Role of tumor necrosis factor-alpha." *J Neurochem* 96(3): 706-18.
- Staszewski, R. D. and B. K. Yamamoto (2006). "Methamphetamine-induced spectrin proteolysis in the rat striatum." *J Neurochem* 96(5): 1267-76.
- Stephans, S. E., T. S. Whittingham, et al. (1998). "Substrates of energy metabolism attenuate methamphetamine-induced neurotoxicity in striatum." *J Neurochem* 71(2): 613-21.
- Su, T. P. (2000). "Delta opioid peptide[D-Ala(2),D-Leu(5)]enkephalin promotes cell survival." *J Biomed Sci* 7(3): 195-9.
- Subarnas, A., T. Tadano, et al. (1993). "Pharmacological properties of beta-amyrin palmitate, a novel centrally acting compound, isolated from *Lobelia inflata* leaves." *J Pharm Pharmacol* 45(6): 545-50.
- Sudilovsky, A. (1975). "Effects of disulfiram on the amphetamine-induced behavioral syndrome in the cat as a model of psychosis." *Natl Inst Drug Abuse Res Monogr Ser*(3): 109-35.
- Sukma, M., C. Chaichantipyuth, et al. (2002). "CNS inhibitory effects of barakol, a constituent of *Cassia siamiam Lamk.*" *J Ethnopharmacol* 83(1-2): 87-94.

- Suzuki, T., T. Mori, et al. (1997). "Generalization of D-, L- and DL-chlorpheniramine and zolantidine to the discriminative stimulus effects of cocaine and methamphetamine." *Behav Pharmacol* 8(8): 718-24.
- Suzuki, T. and M. Misawa (1995). "Sertindole antagonizes morphine-, cocaine-, and methamphetamine-induced place preference in the rat." *Life Sci* 57(13): 1277-84.
- Suzuki, T., Y. Shiozaki, et al. (1992). "Effects of calcium antagonists on the cocaine- and methamphetamine-induced conditioned place preference." *Arukuru Kenkyuto Yakubutsu Ison* 27(1): 81-90.
- Suzuki, T., H. J. Fan Chiang, et al. (1987). "Effects of quinidine and cimetidine on methamphetamine stereotypy in rats." *J Pharmacobiodyn* 10(3): 152-5.
- Szumliniski, K. K., M. Y. Balogun, et al. (2000). "Interactions between iboga agents and methamphetamine sensitization: Studies of locomotion and stereotypy in rats." *Psychopharmacology (Berl)* 151(2-3): 234-41.
- Tachikawa, S., T. Takenaka, et al. (1978). "Effects of indenolol (YB-2), a new beta-adrenergic blocking agent, and its dextro isomer on the central nervous system of mice and rabbits." *Arch Int Pharmacodyn Ther* 234(1): 74-87.
- Takahashi, M. and S. Tokuyama (1998). "Pharmacological and physiological effects of ginseng on actions induced by opioids and psychostimulants." *Methods Find Exp Clin Pharmacol* 20(1): 77-84.
- Takamatsu, Y., Y. Yamanishi, et al. (2006). "Differential effects of donepezil on methamphetamine and cocaine dependencies." *Ann N Y Acad Sci* 1074: 418-26.
- Takamatsu, Y., H. Yamamoto, et al. (2006). "Fluoxetine as a potential pharmacotherapy for methamphetamine dependence: Studies in mice." *Ann N Y Acad Sci* 1074: 295-302.
- Takashima, A. and S. Itoh (1989). "Neuropharmacological properties of V-9-M, a putative neuropeptide derived from procholecystokinin, in the rat." *Can J Physiol Pharmacol* 67(3): 223-7.
- Takeda, Y., Y. Takano, et al. (1986). "Effects of cholecystokinin tetra and octa peptides on locomotor activity in mice." *Jpn J Pharmacol* 42(1): 145-9.
- Takigawa, M., H. Fukuzako, et al. (1994). "Intracranial self-stimulation and locomotor traces as indicators for evaluating and developing antipsychotic drugs." *Jpn J Psychiatry Neurol* 48(1): 127-32.
- Takigawa, M., K. Ueyama, et al. (1993). "Intracranial self-stimulation and locomotor traces as indicators for evaluating the homopantothenic acid." *Jpn J Psychiatry Neurol* 47(4): 915-20.
- Tatsuta, T., N. Kitanaka, et al. (2006). "Lobeline attenuates methamphetamine-induced stereotypy in adolescent mice." *Neurochem Res* 31(11): 1359-69.
- Tatsuta, T., N. Kitanaka, et al. (2005). "Effects of monoamine oxidase inhibitors on methamphetamine-induced stereotypy in mice and rats." *Neurochem Res* 30(11): 1377-85.
- Thiriet, N., X. Deng, et al. (2005). "Neuropeptide Y protects against methamphetamine-induced neuronal apoptosis in the mouse striatum." *J Neurosci* 25(22): 5273-9.
- Thomas, D. M. and D. M. Kuhn (2005). "MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicity." *Brain Res* 1050(1-2): 190-8.
- Tobe, A., Y. Yoshida, et al. (1981). "Pharmacological evaluation of 2-(4-methylaminobutoxy)diphenylmethane hydrochloride (MCI-2016), A new psychotropic drug with antidepressant activity." *Arzneimittelforschung* 31(8): 1278-85.
- Tobe, A. and T. Kobayashi (1976). "Pharmacological studies on triazine derivatives V Sedative and neuroleptic actions of 2-amino-4-[4-(2-hydroxyethyl)-piperazin-1-yl]-6-trifluoromethyl-s-triazine (TR-10)." *Jpn J Pharmacol* 26(5): 559-70.
- Tokuyama, S. and M. Takahashi (2001). "[Pharmacological and physiological effects of ginseng on actions induced by opioids and psychostimulants]." *Nippon Yakurigaku Zasshi* 117(3): 195-201.
- Tokuyama, S., M. Takahashi, et al. (1996). "The effect of ginseng extract on locomotor sensitization and conditioned place preference induced by methamphetamine and cocaine in mice." *Pharmacol Biochem Behav* 54(4): 671-6.
- Tsao, L. I., B. Ladenheim, et al. (1998). "Delta opioid peptide [D-Ala<sup>2</sup>,D-leu<sup>5</sup>]enkephalin blocks the long-term loss of dopamine transporters induced by multiple administrations of methamphetamine: involvement of opioid receptors and reactive oxygen species." *J Pharmacol Exp Ther* 287(1): 322-31.
- Uemura, K., T. Aki, et al. (2003). "Protein kinase C-epsilon protects PC12 cells against methamphetamine-induced death: Possible involvement of suppression of glutamate receptor." *Life Sci* 72(14): 1595-607.
- Ungard, J. T., M. Beekman, et al. (2000). "Modification of behavioral effects of drugs in mice by neuroactive steroids." *Psychopharmacology (Berl)* 148(4): 336-43.
- Ushijima, I., K. Yamada, et al. (1984). "Progressive augmentation of locomotor activity in mice by long-term treatment with thyrotropin releasing hormone." *Arch Int Pharmacodyn Ther* 270(1): 29-37.
- Vajragupta, O., P. Boonchoong, et al. (2003). "Manganese-based complexes of radical scavengers as neuroprotective agents." *Bioorg Med Chem* 11(10): 2329-37.



- Vajragupta, O., O. Monthakantirat, et al. (2000). "Chroman amide 12P inhibition of lipid peroxidation and protection against learning and memory impairment." *Life Sci* 67(14): 1725-34.
- Villemagne, V. L., D. F. Wong, et al. (1999). "GBR12909 attenuates amphetamine-induced striatal dopamine release as measured by [(11)C]raclopride continuous infusion PET scans." *Synapse* 33(4): 268-73.
- Vinklerova, J., J. Novakova, et al. (2002). "Inhibition of methamphetamine self-administration in rats by cannabinoid receptor antagonist AM 251." *J Psychopharmacol* 16(2): 139-43.
- Virmani, A., F. Gaetani, et al. (2005). "Effects of metabolic modifiers such as carnitines, coenzyme Q10, and PUFAs against different forms of neurotoxic insults: Metabolic inhibitors, MPTP, and methamphetamine." *Ann N Y Acad Sci* 1053: 183-91.
- Virmani, A., F. Gaetani, et al. (2003). "Possible mechanism for the neuroprotective effects of L-carnitine on methamphetamine-evoked neurotoxicity." *Ann N Y Acad Sci* 993: 197-207; discussion 287-8.
- Wagner, G. C., N. Avena, T. Kita, T. Nakashima, H. Fisher and A. K. Halladay (2004). "Risperidone reduction of amphetamine-induced self-injurious behavior in mice." *Neuropharmacology* 46(5): 700-8.
- Wallace, T. L., C. V. Vorhees, et al. (2001). "Effects of lubeluzole on the methamphetamine-induced increase in extracellular glutamate and the long-term depletion of striatal dopamine." *Synapse* 40(2): 95-101.
- Wang, J. Q. and J. F. McGinty (1995). "Differential effects of D1 and D2 dopamine receptor antagonists on acute amphetamine- or methamphetamine-induced up-regulation of zif/268 mRNA expression in rat forebrain." *J Neurochem* 65(6): 2706-15.
- Wardas, J. (2002). "Neuroprotective role of adenosine in the CNS." *Pol J Pharmacol* 54(4): 313-26.
- Warren, M. W., F. H. Kobeissy, et al. (2005). "Concurrent calpain and caspase-3 mediated proteolysis of alphaII-spectrin and tau in rat brain after methamphetamine exposure: A similar profile to traumatic brain injury." *Life Sci* 78(3): 301-9.
- Watanabe, Y., Y. Hori, et al. (1995). "Inhibitory effects of newly synthesized Ser-contained GABA-peptides administered into either caudate putamen or amygdala on methamphetamine-induced hyperactivity." *Nihon Shinkei Seishin Yakurigaku Zasshi* 15(3): 239-46.
- Wei, Q., O. P. Jurma, et al. (1997). "Increased expression of monoamine oxidase-B results in enhanced neurite degeneration in methamphetamine-treated PC12 cells." *J Neurosci Res* 50(4): 618-26.
- Witkin, J. M. (1993). "Blockade of the locomotor stimulant effects of cocaine and methamphetamine by glutamate antagonists." *Life Sci* 53(24): PL405-10.
- Witkin, J. M., G. A. Ricaurte, et al. (1990). "Behavioral effects of N-methylamphetamine and N,N-dimethylamphetamine in rats and squirrel monkeys." *J Pharmacol Exp Ther* 253(2): 466-74.
- Yamada, K. and T. Furukawa (1980). "Behavior of rats and mice administered active metabolites of fluphenazine, 7-hydroxy-fluphenazine and fluphenazine-sulfoxide." *Arch Int Pharmacodyn Ther* 248(1): 76-85.
- Wu, P. H., Y. C. Shen, et al. (2006). "Baicalein attenuates methamphetamine-induced loss of dopamine transporter in mouse striatum." *Toxicology* 226(2-3): 238-45.
- Yamamura, M., H. Nakagawa, et al. (1989). "Effects of mafoprazine, a phenylpiperazine derivative, on the central dopaminergic system." *Jpn J Pharmacol* 50(3): 295-305.
- Yamamoto, M., K. Tomioka, et al. (1981). "[Central pharmacological effects of YPG-209 (16(S)-methyl-20-methoxy-prostaglandin E2) (author's transl)]." *Nippon Yakurigaku Zasshi* 77(2): 141-51.
- Yamamoto, T., S. Shibata, et al. (1989). "[Behavioral pharmacological properties of the novel antidepressant paroxetine, a selective 5-HT uptake inhibitor]." *Nippon Yakurigaku Zasshi* 94(3): 189-206.
- Yamamoto, T., M. Ohno, et al. (1988). "Anti-serotonin action in combination with noradrenaline-stimulating action is important for inhibiting muricide in midbrain raphe-lesioned rats." *Neuropharmacology* 27(2): 123-7.
- Yan, Y., A. Nitta, et al. (2006). "Discriminative-stimulus effects of methamphetamine and morphine in rats are attenuated by cAMP-related compounds." *Behav Brain Res* 173(1): 39-46.
- Yan, Y., T. Mizuno, et al. (2004). "Nefiracetam attenuates methamphetamine-induced discriminative stimulus effects in rats." *Ann N Y Acad Sci* 1025: 274-8.
- Yang, P. P., E. Y. Huang, et al. (2006). "Co-administration of dextromethorphan with methamphetamine attenuates methamphetamine-induced rewarding and behavioral sensitization." *J Biomed Sci* 13(5): 695-702.
- Yang, J. Y., C. F. Wu, et al. (1999). "Studies on the sedative and hypnotic effects of oleamide in mice." *Arzneimittelforschung* 49(8): 663-7.
- Yasar, S., Z. Justinova, et al. (2006). "Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(r)-(-)-deprenyl]." *J Pharmacol Exp Ther* 317(1): 387-94.
- Yoo, J. H., J. H. Cho, et al. (2006). "Involvement of 5-HT receptors in the development and expression of methamphetamine-induced behavioral sensitization: 5-HT receptor channel and binding study." *J Neurochem* 99(3): 976-88.
- Yu, J., J. L. Cadet, et al. (2002). "Neurokinin-1 (NK-1) receptor antagonists abrogate methamphetamine-induced striatal dopaminergic neurotoxicity in the murine brain." *J Neurochem* 83(3): 613-22.

- Yu, L., C. F. Cherg, et al. (2002). "Melatonin in concentrated ethanol and ethanol alone attenuate methamphetamine-induced dopamine depletions in C57BL/6J mice." *J Neural Transm* 109(12): 1477-90.
- Yu, L., Y. M. Kuo, et al. (2001). "Opioid peptides alleviated while naloxone potentiated methamphetamine-induced striatal dopamine depletion in mice." *J Neural Transm* 108(11): 1231-7.
- Yu, X., S. Z. Imam, et al. (1999). "Ibogaine blocked methamphetamine-induced hyperthermia and induction of heat shock protein in mice." *Brain Res* 823(1-2): 213-6.
- Zhang, L., K. Kitaichi, et al. (2006). "Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine." *Prog Neuropsychopharmacol Biol Psychiatry* 30(8): 1381-93.
- Zhao, R. J., R. S. Woo, et al. (2003). "Orphanin FQ/nociceptin blocks methamphetamine place preference in rats." *Neuroreport* 14(18): 2383-5.
- Zhou, J. L., J. H. Liang, et al. (2004). "Nerve growth factor protects R2 cells against neurotoxicity induced by methamphetamine." *Toxicol Lett* 150(2): 221-7.
- Zhou, J. L., J. H. Liang, et al. (2004). "Inhibition of methamphetamine-induced apoptosis by the calcium channel blocker verapamil in rat cerebellar neurons." *Beijing Da Xue Xue Bao* 36(4): 361-5.

### Phencyclidine (animals)

- Ali, S. F., K. J. Kordsmeier, et al. (1995). "Drug-induced circling preference in rats. Correlation with monoamine levels." *Mol Neurobiol* 11(1-3): 145-54.
- Ali, S. F., R. R. Holson, et al. (1993). "Development of dopamine and N-methyl-D-aspartate systems in rat brain: The effect of prenatal phencyclidine exposure." *Brain Res Dev Brain Res* 73(1): 25-33.
- Ellison, G. (2002). "Neural degeneration following chronic stimulant abuse reveals a weak link in brain, fasciculus retroflexus, implying the loss of forebrain control circuitry." *Eur Neuropsychopharmacol* 12(4): 287-97.
- Hanson, G. R., L. P. Midgley, et al. (1995). "Response of extrapyramidal and limbic neurotensin systems to phencyclidine treatment." *Eur J Pharmacol* 278(2): 167-73.
- Itoh, Y., R. Oishi, et al. (1986). "Comparison of effects of phencyclidine and methamphetamine on body temperature in mice: A possible role for histamine neurons in thermoregulation." *Naunyn Schmiedebergs Arch Pharmacol* 332(3): 293-6.
- Itzhak, Y. and J. L. Martin (2000). "Effect of riluzole and gabapentin on cocaine- and methamphetamine-induced behavioral sensitization in mice." *Psychopharmacology (Berl)* 151(2-3): 226-33.
- Kato, K., T. Shishido, et al. (2000). "Effects of phencyclidine on behavior and extracellular levels of dopamine and its metabolites in neonatal ventral hippocampal damaged rats." *Psychopharmacology (Berl)* 150(2): 163-9.
- Ma, J. and L. S. Leung (2000). "Relation between hippocampal gamma waves and behavioral disturbances induced by phencyclidine and methamphetamine." *Behav Brain Res* 111(1-2): 1-11.
- Morita, T., R. Sonoda, et al. (2000). "Phencyclidine-induced abnormal behaviors in rats as measured by the hole board apparatus." *Psychopharmacology (Berl)* 148(3): 281-8.
- Noda, Y., Y. Miyamoto, et al. (1998). "Involvement of dopaminergic system in phencyclidine-induced place preference in mice pretreated with phencyclidine repeatedly." *J Pharmacol Exp Ther* 286(1): 44-51.
- Noda, Y. and T. Nabeshima (1998). "Neuronal mechanisms of phencyclidine-induced place aversion and preference in the conditioned place preference task." *Methods Find Exp Clin Pharmacol* 20(7): 607-11.
- Parker, L. A. (1995). "Rewarding drugs produce taste avoidance, but not taste aversion." *Neurosci Biobehav Rev* 19(1): 143-57.
- Parker, L. A. (1993). "Taste reactivity responses elicited by cocaine-, phencyclidine-, and methamphetamine-paired sucrose solutions." *Behav Neurosci* 107(1): 118-29.
- Shirayama, Y., H. Mitsushio, et al. (2000). "Differential effects of haloperidol on phencyclidine-induced reduction in substance P contents in rat brain regions." *Synapse* 35(4): 292-9.
- Yamamoto, J. (1997). "Cortical and hippocampal EEG power spectra in animal models of schizophrenia produced with methamphetamine, cocaine, and phencyclidine." *Psychopharmacology (Berl)* 131(4): 379-87.

### Philadelphia, PA

- Prosser, J. M., M. Naim, et al. (2006). "A 14-year-old girl with agitation and hyperthermia." *Pediatr Emerg Care* 22(9): 676-9.

### Philippines

- Ahmad, K. (2003). "Asia grapples with spreading amphetamine abuse." *Lancet* 361(9372): 1878-9.

- Dayrit, F. M. and M. C. Dumlao (2004). "Impurity profiling of methamphetamine hydrochloride drugs seized in the Philippines." *Forensic Sci Int* 144(1): 29-36.
- Kulsudjarit, K. (2004). "Drug problem in southeast and southwest Asia." *Ann N Y Acad Sci* 1025: 446-57.
- Simbulan, N. P., A. S. Aguilar, et al. (2001). "High-risk behaviors and the prevalence of sexually transmitted diseases among women prisoners at the women state penitentiary in Metro Manila." *Soc Sci Med* 52(4): 599-608.
- Srisurapanont, M., R. Ali, et al. (2003). "Psychotic symptoms in methamphetamine psychotic in-patients." *Int J Neuropsychopharmacol* 6(4): 347-52.

## Phoenix, AZ (US)

- Kim, J. Y. and M. Fendrich (2002). "Gender differences in juvenile arrestees' drug use, self-reported dependence, and perceived need for treatment." *Psychiatr Serv* 53(1): 70-5.
- Ruha, A. M. and M. C. Yarema (2006). "Pharmacologic treatment of acute pediatric methamphetamine toxicity." *Pediatr Emerg Care* 22(12): 782-5.

## Phospholipids

*See Brain, Phospholipids in*

## Place Preference

*See Conditioned Place Preference (animals)*

## Plasticity

*See Neurological Development and Adaptations; Neurological Development and Adaptations (animals)*

## Pleasure and Pleasure-Seeking Behaviors

*See also Craving; Sensation Seeking; Sexual Arousal and Sexual Experiences*

- Halkitis, P. N. and M. T. Shrem (2006). "Psychological differences between binge and chronic methamphetamine using gay and bisexual men." *Addict Behav* 31(3): 549-52.
- Halkitis, P. N., K. A. Green, et al. (2005). "Seroconcordant sexual partnerings of HIV-seropositive men who have sex with men." *AIDS* 19: S77-S86.
- Harris, D. S., V. I. Reus, et al. (2006). "Catecholamine response to methamphetamine is related to glucocorticoid levels but not to pleasurable subjective response." *Pharmacopsychiatry* 39(3): 100-8.
- Harris, D. S., V. I. Reus, et al. (2003). "Altering cortisol level does not change the pleasurable effects of methamphetamine in humans." *Neuropsychopharmacology* 28(9): 1677-84.
- Johnson, B. A., J. D. Roache, et al. (2005). "Effects of isradipine, a dihydropyridine-class calcium-channel antagonist, on d-methamphetamine's subjective and reinforcing effects." *Int J Neuropsychopharmacol* 8(2): 203-13.
- Lile, J. A., W. W. Stoops, et al. (2005). "Aripiprazole attenuates the discriminative-stimulus and subject-rated effects of D-amphetamine in humans." *Neuropsychopharmacology* 30(11): 2103-14.
- Lorvick, J., A. Martinez, et al. (2006). "Sexual and injection risk among women who inject methamphetamine in San Francisco." *J Urban Health* 83(3): 497-505.
- Ogden, C. A., M. E. Rich, et al. (2004). "Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: an expanded convergent functional genomics approach." *Mol Psychiatry* 9(11): 1007-29.
- Parks, K. A. and C. L. Kennedy (2004). "Club drugs: Reasons for and consequences of use." *J Psychoactive Drugs* 36(3): 295-302.
- Ross, M. W., A. M. Mattison, et al. (2003). "Club drugs and sex on drugs are associated with different motivations for gay circuit party attendance in men." *Subst Use Misuse* 38(8): 1173-83.
- Semple, S. J., T. L. Patterson, et al. (2004). "A comparison of injection and non-injection methamphetamine-using HIV positive men who have sex with men." *Drug Alcohol Depend* 76(2): 203-12.
- Wachtel, S. R., A. Ortengren, et al. (2002). "The effects of acute haloperidol or risperidone on subjective responses to methamphetamine in healthy volunteers." *Drug Alcohol Depend* 68(1): 23-33.
- Worth, H. and P. Rawstorne (2005). "Crystallizing the HIV epidemic: Methamphetamine, unsafe sex, and gay diseases of the will." *Arch Sex Behav* 34(5): 483-6.

### Poland

Lagerspetz, M. and J. Moskalewicz (2002). "Drugs in the postsocialist transitions of Estonia, Latvia, Lithuania and Poland." *Eur Addict Res* 8(4): 177-83.

### Policy Making

*See also Crime; Law Enforcement; Precursors Regulation and treatment headings*

- Anonymous (2006). "Cooking up solutions to a cooked up menace: Responses to methamphetamine in a federal system." *Harv Law Rev* 119(8): 2508-29.
- Boulard, G. (2005). "The meth menace: battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.
- Collins, C. L., T. Kerr, et al. (2005). "Rationale to evaluate medically supervised safer smoking facilities for non-injection illicit drug users." *Can J Public Health* 96(5): 344-7.
- Lester, B. M., L. Andreozzi, et al. (2004). "Substance use during pregnancy: Time for policy to catch up with research." *Harm Reduct J* 1(1): 5.
- Parry, C. D., B. Myers, et al. (2004). "Drug policy for methamphetamine use urgently needed." *S Afr Med J* 94(12): 964-5.
- Rawson, R. A., M. D. Anglin and W. Ling (2002). "Will the methamphetamine problem go away?" *J Addict Dis* 21(1): 5-19.
- Romanelli, F. and K. M. Smith (2006). "Clinical effects and management of methamphetamine abuse." *Pharmacotherapy* 26(8): 1148-56.
- Room, R. (2006). "The dangerousness of drugs." *Addiction* 101(2): 166-8.
- Shoptaw, S. and C. J. Reback (2006). "Associations between methamphetamine use and HIV among men who have sex with men: A model for guiding public policy." *J Urban Health* 83(6): 1151-7.

### Polydrug Use

*See also specific substances*

- Alhassoon, O. M., R. M. Dupont, et al. (2001). "Regional cerebral blood flow in cocaine- versus methamphetamine-dependent patients with a history of alcoholism." *Int J Neuropsychopharmacol* 4(2): 105-12.
- Breen, C., L. Degenhardt, et al. (2006). "Alcohol use and risk taking among regular ecstasy users." *Subst Use Misuse* 41(8): 1095-109.
- Bennett, A. H. and A. Delrio (1980). "Idiopathic rupture of the bladder: association with methamphetamine and alcohol." *J Urol* 124(3): 429-30.
- Bogart, L. M., A. H. Kral, et al. (2005). "Sexual risk among injection drug users recruited from syringe exchange programs in California." *Sex Transm Dis* 32(1): 27-34.
- Bolding, G., G. Hart, et al. (2006). "Use of crystal methamphetamine among gay men in London." *Addiction* 101(11): 1622-30.
- Booth, B. M., C. Leukefeld, et al. (2006). "Correlates of rural methamphetamine and cocaine users: Results from a multistate community study." *J Stud Alcohol* 67(4): 493-501.
- Brecht, M. L., L. Greenwell, et al. (2007). "Substance use pathways to methamphetamine use among treated users." *Addict Behav* 32(1): 24-38.
- Brecht, M. L., A. O'Brien, et al. (2004). "Methamphetamine use behaviors and gender differences." *Addict Behav* 29(1): 89-106.
- Bungay, V., L. Malchy, et al. (2006). "Life with jib: A snapshot of street youth's use of crystal methamphetamine." *Addiction Research and Theory* 14(3): 235-251.
- Caetano, R. and C. Weisner (1995). "The association between DSM-III-R alcohol dependence, psychological distress and drug use." *Addiction* 90(3): 351-9.
- Chew, G. and A. Fernando, 3rd (2004). "Epileptic seizure in GHB withdrawal." *Australas Psychiatry* 12(4): 410-1.
- Chiappelli, F., P. Shapshak, et al. (2006). "Cellular immunology in HIV-1 positive African American women using alcohol and cocaine." *Front Biosci* 11: 2434-41.
- Clatts, M. C., L. Goldsamt, et al. (2005). "Homelessness and drug abuse among young men who have sex with men in New York city: a preliminary epidemiological trajectory." *J Adolesc* 28(2): 201-14.
- Clatts, M. C., L. A. Goldsamt, et al. (2005). "Club drug use among young men who have sex with men in NYC: A preliminary epidemiological profile." *Subst Use Misuse* 40(9): 1317-30.
- Colfax, G. and R. Guzman (2006). "Club drugs and HIV infection: A review." *Clin Infect Dis* 42(10): 1463-9.
- Colfax, G., T. J. Coates, et al. (2005). "Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of San Francisco men who have sex with men." *J Urban Health* 82(1 Suppl 1): i62-70.

- Colfax, G., E. Vittinghoff, et al. (2004). "Substance use and sexual risk: A participant- and episode-level analysis among a cohort of men who have sex with men." *Am J Epidemiol* 159(10): 1002-12.
- Colfax, G. N., G. Mansergh, et al. (2001). "Drug use and sexual risk behavior among gay and bisexual men who attend circuit parties: A venue-based comparison." *J Acquir Immune Defic Syndr* 28(4): 373-9.
- Darke, S. and W. Hall (1995). "Levels and correlates of polydrug use among heroin users and regular amphetamine users." *Drug Alcohol Depend* 39(3): 231-5.
- Darke, S., J. Ross, et al. (1994). "The use of benzodiazepines among regular amphetamine users." *Addiction* 89(12): 1683-90.
- Darke, S., W. Hall, et al. (1992). "Benzodiazepine use and HIV risk-taking behaviour among injecting drug users." *Drug Alcohol Depend* 31(1): 31-6.
- Delgado, J. H., M. J. Caruso, J. C. Waksman, B. Honigman and D. Stillman (2004). "Acute, transient urinary retention from combined ecstasy and methamphetamine use." *J Emerg Med* 26(2): 173-5.
- Drumright, L. N., S. J. Little, et al. (2006). "Unprotected anal intercourse and substance use among men who have sex with men with recent HIV infection." *J Acquir Immune Defic Syndr* 43(3): 344-50.
- Drumright, L. N., S. A. Strathdee, et al. (2006). "Unprotected anal intercourse and substance use before and after HIV diagnosis among recently HIV-infected men who have sex with men." *Sex Transm Dis*.
- Estler, C. J. (1973). "[Drug interference and incompatibilities of drugs attacking the central nervous system. 2. Stimulants]." *Fortschr Med* 91(13): 574-6.
- Fernandez, M. I., G. S. Bowen, et al. (2007). "Crystal methamphetamine: A source of added sexual risk for Hispanic men who have sex with men?" *Drug Alcohol Depend* 86(2-3): 245-52.
- Fernandez, M. I., G. S. Bowen, et al. (2005). "High rates of club drug use and risky sexual practices among Hispanic men who have sex with men in Miami, Florida." *Subst Use Misuse* 40(9): 1347-62.
- Forney, R., R. Martz, et al. (1976). "The combined effect of marihuana and dextroamphetamine." *Ann N Y Acad Sci* 281: 162-70.
- Furr, C. D., J. Delva, et al. (2000). "The suspected association between methamphetamine ('ice') smoking and frequent episodes of alcohol intoxication: Data from the 1993 National Household Survey on Drug Abuse." *Drug Alcohol Depend* 59(1): 89-93.
- Ghaziani, A. and T. D. Cook (2005). "Reducing HIV infections at circuit parties: From description to explanation and principles of intervention design." *J Int Assoc Physicians AIDS Care (Chic Ill)* 4(2): 32-46.
- Gleghorn, A. A., R. Marx, et al. (1998). "Association between drug use patterns and HIV risks among homeless, runaway, and street youth in northern California." *Drug Alcohol Depend* 51(3): 219-27.
- Gonzalez, R., J. D. Rippeth, et al. (2004). "Neurocognitive performance of methamphetamine users discordant for history of marijuana exposure." *Drug Alcohol Depend* 76(2): 181-90.
- Gorman, E. M. and R. T. Carroll (2000). "Substance abuse and HIV: Considerations with regard to methamphetamines and other recreational drugs for nursing practice and research." *J Assoc Nurses AIDS Care* 11(2): 51-62.
- Gouzoulis-Mayfrank, E. and J. Daumann (2006). "The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview." *J Psychopharmacol* 20(2): 188-93.
- Greenwood, G. L., E. W. White, et al. (2001). "Correlates of heavy substance use among young gay and bisexual men: The San Francisco Young Men's Health Study." *Drug Alcohol Depend* 61(2): 105-12.
- Halkitis, P. N. and J. J. Palamar (2006). "GHB use among gay and bisexual men." *Addict Behav* 31(11): 2135-9.
- Halkitis, P. N., K. A. Green, et al. (2005). "Longitudinal investigation of methamphetamine use among gay and bisexual men in New York City: findings from Project BUMPS." *J Urban Health* 82(1 Suppl 1): i18-25.
- Hopfer, C., B. Mendelson, et al. (2006). "Club drug use among youths in treatment for substance abuse." *Am J Addict* 15(1): 94-9.
- Ibanez, G. E., D. W. Purcell, et al. (2005). "Sexual risk, substance use, and psychological distress in HIV-positive gay and bisexual men who also inject drugs." *AIDS* 19: S49-S55.
- Irvine, R. J., M. Keane, et al. (2006). "Plasma drug concentrations and physiological measures in 'dance party' participants." *Neuropsychopharmacology* 31(2): 424-30.
- Irwin, T. W. and J. Morgenstern (2005). "Drug-use patterns among men who have sex with men presenting for alcohol treatment: Differences in ethnic and sexual identity." *J Urban Health*.
- Joe Laidler, K. A. (2005). "The rise of club drugs in a heroin society: The case of Hong Kong." *Subst Use Misuse* 40(9-10): 1257-78.
- Kassebaum, G. and S. M. Chandler (1994). "Polydrug use and self control among men and women in prisons." *J Drug Educ* 24(4): 333-50.
- Kaye, S. and S. Darke (2000). "A comparison of the harms associated with the injection of heroin and amphetamines." *Drug Alcohol Depend* 58(1-2): 189-95.
- Kelly, B. C., J. T. Parsons, et al. (2006). "Prevalence and predictors of club drug use among club-going young adults in New York City." *J Urban Health* 83(5): 884-895.

- Kohrs, F. P., C. Mann and R. Greenberg (2004). "The use of amphetamine in gamma-hydroxybutyrate overdose: A case report." *J Psychoactive Drugs* 36(3): 401-2.
- Lampinen, T. M., D. McGhee, et al. (2006). "Increased risk of "club" drug use among gay and bisexual high school students in British Columbia." *J Adolesc Health* 38(4): 458-61.
- Lampinen, T. M., D. McGhee, et al. (2006). "Use of crystal methamphetamine and other club drugs among high school students in Vancouver and Victoria." *BC Medical Journal* 48(1): 22-27.
- Lee, S. J., M. Galanter, et al. (2003). "Circuit parties and patterns of drug use in a subset of gay men." *J Addict Dis* 22(4): 47-60.
- Little, B. B., L. M. Snell, et al. (1990). "Patterns of multiple substance abuse during pregnancy: Implications for mother and fetus." *South Med J* 83(5): 507-9, 518.
- Lorvick, J., A. Martinez, et al. (2006). "Sexual and injection risk among women who inject methamphetamine in San Francisco." *J Urban Health* 83(3): 497-505.
- Mansergh, G., G. N. Colfax, et al. (2001). "The Circuit Party Men's Health Survey: Findings and implications for gay and bisexual men." *Am J Public Health* 91(6): 953-8.
- Martin, I., T. M. Lampinen, et al. (2006). "Methamphetamine use among marginalized youth in British Columbia." *Can J Public Health* 97(4): 320-4.
- McCaughan, J. A., R. G. Carlson, et al. (2005). "From "Candy Kids" to "Chemi-Kids": A typology of young adults who attend raves in the midwestern United States." *Subst Use Misuse* 40(9-10): 1503-23.
- McKetin, R., E. Kelly, et al. (2006). "The relationship between crystalline methamphetamine use and methamphetamine dependence." *Drug Alcohol Depend* 85(3): 198-204.
- Ochoa, K. C., P. J. Davidson, et al. (2005). "Heroin overdose among young injection drug users in San Francisco." *Drug Alcohol Depend* 80(3): 297-302.
- Oetting, E. R., J. L. Deffenbacher, et al. (2000). "Methamphetamine use by high school students: Recent trends, gender and ethnicity differences, and use of other drugs." *Journal of Child and Adolescent Substance Abuse* 10(1): 33-50.
- Patterson, T. L., S. J. Semple, et al. (2005). "Methamphetamine-using HIV-positive men who have sex with men: Correlates of polydrug use." *J Urban Health* 82(1 Suppl 1): i120-6.
- Rawson, R. A., A. Washton, et al. (2002). "Drugs and sexual effects: Role of drug type and gender." *J Subst Abuse Treat* 22(2): 103-8.
- Rawson, R., A. Huber, et al. (2000). "Methamphetamine and cocaine users: Differences in characteristics and treatment retention." *J Psychoactive Drugs* 32(2): 233-8.
- Ross, M. W., A. M. Mattison, et al. (2003). "Club drugs and sex on drugs are associated with different motivations for gay circuit party attendance in men." *Subst Use Misuse* 38(8): 1173-83.
- Schwilke, E. W., M. I. Sampaio dos Santos, et al. (2006). "Changing patterns of drug and alcohol use in fatally injured drivers in Washington State." *J Forensic Sci* 51(5): 1191-8.
- Sears, C., J. R. Gudyish, et al. (2001). "Investigation of a secondary syringe exchange program for homeless young adult injection drug users in San Francisco, California, U.S.A." *J Acquir Immune Defic Syndr* 27(2): 193-201.
- Semple, S. J., T. L. Patterson, et al. (2004). "Determinants of condom use stage of change among heterosexually-identified methamphetamine users." *AIDS Behav* 8(4): 391-400.
- Semple, S. J., T. L. Patterson, et al. (2004). "A comparison of injection and non-injection methamphetamine-using HIV positive men who have sex with men." *Drug Alcohol Depend* 76(2): 203-12.
- Siegal, H. A., P. J. Draus, et al. (2006). "Perspectives on health among adult users of illicit stimulant drugs in rural Ohio." *J Rural Health* 22(2): 169-73.
- Smith, L. M., L. L. Lagasse, et al. (2006). "The Infant Development, Environment, and Lifestyle Study: Effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth." *Pediatrics* 118(3): 1149-1156.
- White, B., C. Day, et al. (2006). "Prevalence of injecting drug use and associated risk behavior among regular ecstasy users in Australia." *Drug Alcohol Depend* 83(3): 210-7.
- Wu, L. T., W. E. Schlenger, et al. (2006). "Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths." *Drug Alcohol Depend* 84(1): 102-13.
- Wu, L. T., D. J. Pilowsky, et al. (2004). "Injection drug use among stimulant users in a national sample." *Am J Drug Alcohol Abuse* 30(1): 61-83.

### Polydrug Use (animals)

*See also Pharmacological Interventions (animals); and specific substances*

- Clemens, K. J., J. L. Cornish, et al. (2006). "Intravenous methamphetamine self-administration in rats: Effects of intravenous or intraperitoneal MDMA co-administration." *Pharmacol Biochem Behav* 85(2): 454-63.

- Clemens, K. J., J. L. Cornish, et al. (2005). "MDMA ('Ecstasy') and methamphetamine combined: Order of administration influences hyperthermic and long-term adverse effects in female rats." *Neuropharmacology* 49(2): 195-207.
- Hayase, T., Y. Yamamoto, et al. (2006). "Behavioral effects of ketamine and toxic interactions with psychostimulants." *BMC Neurosci* 7(1): 25.
- Kubena, R. K. and H. Barry, 3rd (1970). "Interactions of delta-tetrahydrocannabinol with barbiturates and methamphetamine." *J Pharmacol Exp Ther* 173(1): 94-100.
- Namiki, M., T. Mori, et al. (2005). "Underlying mechanism of combined effect of methamphetamine and morphine on lethality in mice and therapeutic potential of cooling." *J Pharmacol Sci* 99(2): 168-76.
- Ranaldi, R. and R. A. Wise (2000). "Intravenous self-administration of methamphetamine-heroin (speedball) combinations under a progressive-ratio schedule of reinforcement in rats." *Neuroreport* 11(12): 2621-3.

## Portland, OR (US)

- Hendrickson, R. G., B. Z. Horowitz, et al. (2006). "'Parachuting' meth: A novel delivery method for methamphetamine and delayed-onset toxicity from 'body stuffing'." *Clin Toxicol (Phila)* 44(4): 379-82.
- Kim, J. Y. and M. Fendrich (2002). "Gender differences in juvenile arrestees' drug use, self-reported dependence, and perceived need for treatment." *Psychiatr Serv* 53(1): 70-5.

## Poppers

*See Amyl Nitrite*

## Portugal

- March, J. C., E. Oviedo-Joekes, et al. (2006). "Drugs and social exclusion in ten European cities." *Eur Addict Res* 12(1): 33-41.

## Poverty

- Smith, L. M., L. L. Lagasse, et al. (2006). "The Infant Development, Environment, and Lifestyle Study: Effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth." *Pediatrics* 118(3): 1149-1156.

## Precursor Regulation

- Anonymous (2006). "Cooking up solutions to a cooked up menace: Responses to methamphetamine in a federal system." *Harv Law Rev* 119(8): 2508-29.
- Boulard, G. (2005). "The meth menace: Battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.
- Colker, A. C. (2005). "Restricting the sale of pseudoephedrine to prevent methamphetamine production." *NCSL Legisbrief* 13(7): 1-2.
- Cunningham, J. K. and L. M. Liu (2005). "Impacts of federal precursor chemical regulations on methamphetamine arrests." *Addiction* 100(4): 479-88.
- Cunningham, J. K. and L. M. Liu (2003). "Guidelines for measuring impacts of methamphetamine precursor chemical regulations: A reply to Reuter and Caulkins (2003)." *Addiction* 98(10): 1463-4.
- Cunningham, J. K. and L. M. Liu (2003). "Impacts of federal ephedrine and pseudoephedrine regulations on methamphetamine-related hospital admissions." *Addiction* 98(9): 1229-37.
- Eccles, R. (2006). "Substitution of phenylephrine for pseudoephedrine as a nasal decongestant. An illogical way to control methamphetamine abuse." *Br J Clin Pharmacol*.
- Huff, C. (2006). "Crystal crush." *Hosp Health Netw* 80(10): 59-60, 62, 64.
- Murty, S. and S. S. Sansgiry (2006). "Pseudoephedrine laws in the US--are we doing enough?" *Ann Pharmacother* 40(6): 1213-5.
- Reuter, P. and J. P. Caulkins (2003). "Does precursor regulation make a difference?" *Addiction* 98(9): 1177-9.
- Romanelli, F. and K. M. Smith (2006). "Clinical effects and management of methamphetamine abuse." *Pharmacotherapy* 26(8): 1148-56.
- Storr, C. L., A. M. Arria, et al. (2004). "Neighborhood environment and opportunity to try methamphetamine ('ice') and marijuana: Evidence from Guam in the Western Pacific region of Micronesia." *Subst Use Misuse* 39(2): 253-76.

## Pregnancy

- Anglin, M. D., C. Burke, et al. (2000). "History of the methamphetamine problem." *J Psychoactive Drugs* 32(2): 137-41.

- Arria, A. M., C. Derauf, et al. (2006). "Methamphetamine and other substance use during pregnancy: Preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study." *Matern Child Health J* 10(3): 293-302.
- Bailey, D. N. (1987). "Amphetamine detection during toxicology screening of a university medical center patient population." *J Toxicol Clin Toxicol* 25(5): 399-409.
- Bost, R. O., P. Kemp, et al. (1989). "Tissue distribution of methamphetamine and amphetamine in premature infants." *J Anal Toxicol* 13(5): 300-2.
- Buchi, K. F., S. Zone, K. Langheinrich and M. W. Varner (2003). "Changing prevalence of prenatal substance abuse in Utah." *Obstet Gynecol* 102(1): 27-30.
- Catanzarite, V. A. and D. A. Stein (1995). "'Crystal' and pregnancy--methamphetamine-associated maternal deaths." *West J Med* 162(5): 454-7.
- Chang, L., L. M. Smith, et al. (2004). "Smaller subcortical volumes and cognitive deficits in children with prenatal methamphetamine exposure." *Psychiatry Res* 132(2): 95-106.
- Chomchai, C., N. Na Manorom, et al. (2004). "Methamphetamine abuse during pregnancy and its health impact on neonates born at Siriraj Hospital, Bangkok, Thailand." *Southeast Asian J Trop Med Public Health* 35(1): 228-31.
- Davies, J. K. and J. M. Bledsoe (2005). "Prenatal alcohol and drug exposures in adoption." *Pediatr Clin North Am* 52(5): 1369-93, vii.
- Derom, R., M. Thiery, et al. (1974). "Effects of spinal anesthesia on the acid-base balance of the human fetus in elective caesarean section." *Acta Anaesthesiol Belg* 25(1): 26-8.
- Dixon, S. D. (1989). "Effects of transplacental exposure to cocaine and methamphetamine on the neonate." *West J Med* 150(4): 436-42.
- Dixon, S. D. and R. Bejar (1989). "Echoencephalographic findings in neonates associated with maternal cocaine and methamphetamine use: incidence and clinical correlates." *J Pediatr* 115(5 Pt 1): 770-8.
- Forrester, M. B. and R. D. Merz (2007). "Risk of selected birth defects with prenatal illicit drug use, Hawaii, 1986-2002." *J Toxicol Environ Health A* 70(1): 7-18.
- Forrester, M. B. and R. D. Merz (2006). "Comparison of trends in gastroschisis and prenatal illicit drug use rates." *J Toxicol Environ Health A* 69(13): 1253-9.
- Garcia-Bourmissen, F., B. Rokach, et al. (2006). "Methamphetamine detection in maternal and neonatal hair; Implications for fetal safety." *Arch Dis Child Fetal Neonatal Ed*.
- Golub, M., L. Costa, et al. (2005). "NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of amphetamine and methamphetamine." *Birth Defects Res B Dev Reprod Toxicol*.
- Gurnack, A. M. and W. Paul (1997). "Factors related to perinatal substance abuse in a California county." *Percept Mot Skills* 84(3 Pt 2): 1403-8.
- Hall, J. A., S. W. Henggeler, et al. (1993). "Adolescent substance use during pregnancy." *J Pediatr Psychol* 18(2): 265-71.
- Joffe, G. M. and T. Kasnic (1994). "Medical prescription of dextroamphetamine during pregnancy." *J Perinatol* 14(4): 301-3.
- Lester, B. M., L. Andreozzi, et al. (2004). "Substance use during pregnancy: Time for policy to catch up with research." *Harm Reduct J* 1(1): 5.
- Little, B. B., L. M. Snell, et al. (1990). "Patterns of multiple substance abuse during pregnancy: Implications for mother and fetus." *South Med J* 83(5): 507-9, 518.
- Little, B. B., L. M. Snell, et al. (1988). "Methamphetamine abuse during pregnancy: outcome and fetal effects." *Obstet Gynecol* 72(4): 541-4.
- Montgomery, D., C. Plate, et al. (2006). "Testing for fetal exposure to illicit drugs using umbilical cord tissue vs meconium." *J Perinatol* 26(1): 11-4.
- NTP-CERHR (2005). "NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines." *NTP CEHR Mon*(16): i-III1.
- Oro, A. S. and S. D. Dixon (1987). "Perinatal cocaine and methamphetamine exposure: Maternal and neonatal correlates." *J Pediatr* 111(4): 571-8.
- Plessinger, M. A. (1998). "Prenatal exposure to amphetamines. Risks and adverse outcomes in pregnancy." *Obstet Gynecol Clin North Am* 25(1): 119-38.
- Ramamoorthy, J. D., S. Ramamoorthy, et al. (1995). "Human placental monoamine transporters as targets for amphetamines." *Am J Obstet Gynecol* 173(6): 1782-7.
- Smith, L. M., L. L. Lagasse, et al. (2006). "The Infant Development, Environment, and Lifestyle Study: Effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth." *Pediatrics* 118(3): 1149-1156.
- Smith, L., M. L. Yonekura, et al. (2003). "Effects of prenatal methamphetamine exposure on fetal growth and drug withdrawal symptoms in infants born at term." *J Dev Behav Pediatr* 24(1): 17-23.



- Smith, L. M., L. Chang, et al. (2001). "Brain proton magnetic resonance spectroscopy in children exposed to methamphetamine in utero." *Neurology* 57(2): 255-60.
- Stewart, J. L. and J. E. Meeker (1997). "Fetal and infant deaths associated with maternal methamphetamine abuse." *J Anal Toxicol* 21(6): 515-7.
- Struthers, J. M. and R. L. Hansen (1992). "Visual recognition memory in drug-exposed infants." *J Dev Behav Pediatr* 13(2): 108-11.
- Thadani, P. V. (1995). "Biological mechanisms and perinatal exposure to abused drugs." *Synapse* 19(3): 228-32.
- Viani, R. M., M. R. Araneta, et al. (2006). "Perinatal HIV counseling and rapid testing in Tijuana, Baja California, Mexico: Seroprevalence and correlates of HIV infection." *J Acquir Immune Defic Syndr* 41(1): 87-92.
- Wouldes, T., L. LaGasse, et al. (2004). "Maternal methamphetamine use during pregnancy and child outcome: What do we know?" *N Z Med J* 117(1206): U1180.
- Zimmerman, E. F. (1991). "Substance abuse in pregnancy: Teratogenesis." *Pediatr Ann* 20(10): 541-4, 546-7.

## Pregnancy (animals)

- Acevedo, S. F., I. J. de Esch, et al. (2006). "Sex- and histamine-dependent long-term cognitive effects of methamphetamine exposure." *Neuropsychopharmacology*.
- Cho, D. H., H. M. Lyu, et al. (1991). "Behavioral teratogenicity of methamphetamine." *J Toxicol Sci* 16 Suppl 1: 37-49.
- Cui, C., H. Sakata-Haga, et al. (2006). "Histological brain alterations following prenatal methamphetamine exposure in rats." *Congenit Anom (Kyoto)* 46(4): 180-7.
- Fujiwara, Y. (1985). "[Behavioral and neurochemical changes in pups prenatally treated with methamphetamine]." *Yakubutsu Seishin Kodo* 5(3): 251-9.
- Golub, M., L. Costa, et al. (2005). "NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of amphetamine and methamphetamine." *Birth Defects Res B Dev Reprod Toxicol*.
- Gomes-da-Silva, J., R. de Miguel, et al. (2004). "Effects of neonatal exposure to methamphetamine: Catecholamine levels in brain areas of the developing rat." *Ann N Y Acad Sci* 1025: 602-11.
- Gomes-da-Silva, J., A. Perez-Rosado, et al. (2002). "Prenatal exposure to methamphetamine in the rat: Ontogeny of tyrosine hydroxylase mRNA expression in mesencephalic dopaminergic neurons." *Ann N Y Acad Sci* 965: 68-77.
- Gomes-da-Silva, J., A. Perez-Rosado, et al. (2000). "Neonatal methamphetamine in the rat: Evidence for gender-specific differences upon tyrosine hydroxylase enzyme in the dopaminergic nigrostriatal system." *Ann N Y Acad Sci* 914: 431-8.
- Gomes-Da-Silva, J., M. C. Silva, et al. (1998). "Developmental exposure to methamphetamine: A neonatal model in the rat." *Ann N Y Acad Sci* 844: 310-3.
- Hildebrandt, K., G. Teuchert-Noodt, et al. (1999). "A single neonatal dose of methamphetamine suppresses dentate granule cell proliferation in adult gerbils which is restored to control values by acute doses of haloperidol." *J Neural Transm* 106(5-6): 549-58.
- Inoue, H., M. Nakatome, et al. (2004). "Maternal methamphetamine administration during pregnancy influences on fetal rat heart development." *Life Sci* 74(12): 1529-40.
- Jeng, W., A. W. Wong, et al. (2005). "Methamphetamine-enhanced embryonic oxidative DNA damage and neurodevelopmental deficits." *Free Radic Biol Med* 39(3): 317-26.
- Kolesari, G. L. and S. Kaplan (1979). "Amphetamines reduce embryonic size and produce caudal hematomas during early chick morphogenesis." *Teratology* 20(3): 403-11.
- Martin, J. C., D. C. Martin, et al. (1983). "Saccharin preferences in food deprived aging rats are altered as a function of perinatal drug exposure." *Physiol Behav* 30(6): 853-8.
- Martin, J. C. and D. C. Martin (1981). "Voluntary activity in the aging rat as a function of maternal drug exposure." *Neurobehav Toxicol Teratol* 3(3): 261-4.
- Martin, J. C., D. D. Martin, et al. (1979). "Life span and pathology in offspring following nicotine and methamphetamine exposure." *Exp Aging Res* 5(6): 509-22.
- Martin, J. C., D. C. Martin, et al. (1976). "Growth, development and activity in rat offspring following maternal drug exposure." *Exp Aging Res* 2(3): 235-51.
- Martin, J. C. (1975). "Effects on offspring of chronic maternal methamphetamine exposure." *Dev Psychobiol* 8(5): 397-404.
- Melo, P., V. Z. Moreno, et al. (2006). "Myelination changes in the rat optic nerve after prenatal exposure to methamphetamine." *Brain Res* 1106(1): 21-9.
- Melo, P., L. G. Rodrigues, et al. (2006). "Effects of prenatal exposure to methamphetamine on the development of the rat retina." *Ann N Y Acad Sci* 1074: 590-603.

- Melo, P., V. Z. Moreno, et al. (2006). "Myelination changes in the rat optic nerve after prenatal exposure to methamphetamine." *Brain Res* 1106(1): 21-9.
- Melo, P., L. G. Rodrigues, et al. (2005). "Methamphetamine and lipid peroxidation in the rat retina." *Birth Defects Res A Clin Mol Teratol* 73(6): 455-60.
- Middaugh, L. D. (1989). "Prenatal amphetamine effects on behavior: Possible mediation by brain monoamines." *Ann N Y Acad Sci* 562: 308-18.
- Nair, X. and D. C. Dyer (1974). "Responses of guinea pig umbilical vasculature to vasoactive drugs." *Eur J Pharmacol* 27(3): 294-304.
- Nishii, K., N. Matsushita, et al. (1998). "Motor and learning dysfunction during postnatal development in mice defective in dopamine neuronal transmission." *J Neurosci Res* 54(4): 450-64.
- Noailles, P. A., K. G. Becker, et al. (2003). "Methamphetamine-induced gene expression profiles in the striatum of male rat pups exposed to the drug in utero." *Brain Res Dev Brain Res* 147(1-2): 153-62.
- NTP-CERHR (2005). "NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines." *NTP CEHR Mon*(16): i-III1.
- Oro, A. S. and S. D. Dixon (1987). "Perinatal cocaine and methamphetamine exposure: Maternal and neonatal correlates." *J Pediatr* 111(4): 571-8.
- Ozawa, K., K. Hashimoto, et al. (2006). "Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: A neurodevelopmental animal model of schizophrenia." *Biol Psychiatry* 59(6): 546-54.
- Sato, M. and Y. Fujiwara (1986). "Behavioral and neurochemical changes in pups prenatally exposed to methamphetamine." *Brain Dev* 8(4): 390-6.
- Slamberova, R., M. Pometlova, et al. (2006). "Postnatal development of rat pups is altered by prenatal methamphetamine exposure." *Prog Neuropsychopharmacol Biol Psychiatry* 30(1): 82-8.
- Slamberova, R. and R. Rokyta (2005). "Seizure susceptibility in prenatally methamphetamine-exposed adult female rats." *Brain Res* 1060(1-2): 193-7.
- Slamberova, R. (2005). "Flurothyl seizures susceptibility is increased in prenatally methamphetamine-exposed adult male and female rats." *Epilepsy Res* 65(1-2): 121-4.
- Slamberova, R., P. Charousova, et al. (2005). "Maternal behavior is impaired by methamphetamine administered during pre-mating, gestation and lactation." *Reprod Toxicol* 20(1): 103-10.
- Slamberova, R., P. Charousova, et al. (2005). "Methamphetamine administration during gestation impairs maternal behavior." *Dev Psychobiol* 46(1): 57-65.
- Slamberova, R., M. Pometlova, et al. (2005). "Learning in the place navigation task, not the new-learning task, is altered by prenatal methamphetamine exposure." *Brain Res Dev Brain Res* 157(2): 217-9.
- Slamberova, R. and R. Rokyta (2005). "Occurrence of bicuculline-, NMDA- and kainic acid-induced seizures in prenatally methamphetamine-exposed adult male rats." *Naunyn Schmiedebergs Arch Pharmacol* 372(3): 236-41.
- Slamberova, R. and R. Rokyta (2005). "Seizure susceptibility in prenatally methamphetamine-exposed adult female rats." *Brain Res* 1060(1-2): 193-7.
- Stek, A. M., R. S. Baker, et al. (1995). "Fetal responses to maternal and fetal methamphetamine administration in sheep." *Am J Obstet Gynecol* 173(5): 1592-8.
- Stek, A. M., B. K. Fisher, et al. (1993). "Maternal and fetal cardiovascular responses to methamphetamine in the pregnant sheep." *Am J Obstet Gynecol* 169(4): 888-97.
- Suzuki, T., K. Mizuo, et al. (2003). "Prenatal and neonatal exposure to bisphenol-A enhances the central dopamine D1 receptor-mediated action in mice: Enhancement of the methamphetamine-induced abuse state." *Neuroscience* 117(3): 639-44.
- Thadani, P. V. (1995). "Biological mechanisms and perinatal exposure to abused drugs." *Synapse* 19(3): 228-32.
- Vorhees, C. V. (1997). "Methods for detecting long-term CNS dysfunction after prenatal exposure to neurotoxins." *Drug Chem Toxicol* 20(4): 387-99.
- Vorhees, C. V., K. G. Ahrens, et al. (1994). "Methamphetamine exposure during early postnatal development in rats: II. Hypoactivity and altered responses to pharmacological challenge." *Psychopharmacology (Berl)* 114(3): 402-8.
- Watanabe, T., K. Matsushashi, et al. (1985). "[Study on the postnatal neuro-behavioral development in rats treated prenatally with drugs acting on the autonomic nervous systems]." *Nippon Yakurigaku Zasshi* 85(2): 79-90.
- Wells, P. G., Y. Bhuller, et al. (2005). "Molecular and biochemical mechanisms in teratogenesis involving reactive oxygen species." *Toxicol Appl Pharmacol* 207(2 Suppl): 354-66.
- Won, L., N. Bubula, et al. (2002). "Fetal exposure to methamphetamine in utero stimulates development of serotonergic neurons in three-dimensional reaggregate tissue culture." *Synapse* 43(2): 139-44.
- Won, L., N. Bubula, et al. (2001). "Methamphetamine concentrations in fetal and maternal brain following prenatal exposure." *Neurotoxicol Teratol* 23(4): 349-54.

- Yamamoto, Y., K. Yamamoto, et al. (1995). "Effects of methamphetamine on rat embryos cultured in vitro." *Biol Neonate* 68(1): 33-8.
- Yamamoto, Y., K. Yamamoto, et al. (1992). "Teratogenic effects of methamphetamine in mice." *Nippon Hoigaku Zasshi* 46(2): 126-31.
- Zimmerman, E. F. (1991). "Substance abuse in pregnancy: Teratogenesis." *Pediatr Ann* 20(10): 541-4, 546-7.

## Prevalence of Methamphetamine Use

- Adler, P. T. and L. Lotecka (1973). "Drug use among high school students: Patterns and correlates." *Int J Addict* 8(3): 537-48.
- Ahmad, K. (2003). "Asia grapples with spreading amphetamine abuse." *Lancet* 361(9372): 1878-9.
- Bailey, D. N. (1987). "Amphetamine detection during toxicology screening of a university medical center patient population." *J Toxicol Clin Toxicol* 25(5): 399-409.
- Baker, F. M. and W. F. Haning, 3rd (2001). "Substance abuse and dependence in a public hospital: Hawaii." *Hawaii Med J* 60(2): 35-8.
- Bateman, C. (2006). "'Tik' causing a health crisis." *S Afr Med J* 96(8): 672, 674.
- Bellis, M. A., K. E. Hughes, et al. (2007). "Effects of backpacking holidays in Australia on alcohol, tobacco and drug use of UK residents." *BMC Public Health* 7(1): 1.
- Bolding, G., G. Hart, et al. (2006). "Use of crystal methamphetamine among gay men in London." *Addiction* 101(11): 1622-30.
- Buchi, K. F., S. Zone, K. Langheinrich and M. W. Varner (2003). "Changing prevalence of prenatal substance abuse in Utah." *Obstet Gynecol* 102(1): 27-30.
- Cho, B. I. (1991). "Trends and patterns of methamphetamine abuse in the Republic of Korea." *NIDA Res Monogr* 115: 99-108.
- Choi, K. H., D. Operario, et al. (2005). "Substance use, substance choice, and unprotected anal intercourse among young Asian American and Pacific Islander men who have sex with men." *AIDS Educ Prev* 17(5): 418-29.
- Christophersen, A. S. (2000). "Amphetamine designer drugs - An overview and epidemiology." *Toxicol Lett* 112-113: 127-31.
- Chung, H. (1998). "Drug abuse trends and epidemiological aspects of drug associated deaths in Korea." *J Toxicol Sci* 23 Suppl 2: 197-200.
- Clatts, M. C., L. A. Goldsamt, et al. (2005). "Club drug use among young men who have sex with men in NYC: A preliminary epidemiological profile." *Subst Use Misuse* 40(9): 1317-30.
- Colfax, G. and S. Shoptaw (2005). "The methamphetamine epidemic: Implications for HIV prevention and treatment." *Curr HIV/AIDS Rep* 2(4): 194-9.
- Colfax, G., E. Vittinghoff, et al. (2004). "Substance use and sexual risk: A participant- and episode-level analysis among a cohort of men who have sex with men." *Am J Epidemiol* 159(10): 1002-12.
- Couper, F. J., M. Pemberton, et al. (2002). "Prevalence of drug use in commercial tractor-trailer drivers." *J Forensic Sci* 47(3): 562-7.
- Crouch, D. J., M. M. Birky, et al. (1993). "The prevalence of drugs and alcohol in fatally injured truck drivers." *J Forensic Sci* 38(6): 1342-53.
- Cox, C. and R. G. Smart (1970). "The nature and extent of speed use in North America." *Can Med Assoc J* 102(7): 724-9.
- Crosby, G. M., R. D. Stall, et al. (1998). "Alcohol and drug use patterns have declined between generations of younger gay-bisexual men in San Francisco." *Drug Alcohol Depend* 52(3): 177-82.
- Csemy, L., L. Kubicka, et al. (2002). "Drug scene in the Czech Republic and Slovakia during the period of transformation." *Eur Addict Res* 8(4): 159-65.
- Day, C., L. Degenhardt, et al. (2006). "Changes in the initiation of heroin use after a reduction in heroin supply." *Drug Alcohol Rev* 25(4): 307-13.
- Drumright, L. N., S. J. Little, et al. (2006). "Unprotected anal intercourse and substance use among men who have sex with men with recent HIV infection." *J Acquir Immune Defic Syndr* 43(3): 344-50.
- Farabee, D., M. Prendergast and J. Cartier (2002). "Methamphetamine use and HIV risk among substance-abusing offenders in California." *J Psychoactive Drugs* 34(3): 295-300.
- Fernandez, M. I., G. S. Bowen, et al. (2005). "High rates of club drug use and risky sexual practices among Hispanic men who have sex with men in Miami, Florida." *Subst Use Misuse* 40(9): 1347-62.
- Fendrich, M., J. S. Wislar, T. P. Johnson and A. Hubbell (2003). "A contextual profile of club drug use among adults in Chicago." *Addiction* 98(12): 1693-703.
- Forrester, M. B. and R. D. Merz (2007). "Risk of selected birth defects with prenatal illicit drug use, Hawaii, 1986-2002." *J Toxicol Environ Health A* 70(1): 7-18.
- Forrester, M. B. and R. D. Merz (2006). "Comparison of trends in gastroschisis and prenatal illicit drug use rates." *J Toxicol Environ Health A* 69(13): 1253-9.

- Fournier, M. E. and S. Levy (2006). "Recent trends in adolescent substance use, primary care screening, and updates in treatment options." *Curr Opin Pediatr* 18(4): 352-8.
- Gibson, D. R., M. H. Leamon and N. Flynn (2002). "Epidemiology and public health consequences of methamphetamine use in California's Central Valley." *J Psychoactive Drugs* 34(3): 313-9.
- Glittenberg, J. and C. Anderson (1999). "Methamphetamines: Use and trafficking in the Tucson-Nogales area." *Subst Use Misuse* 34(14): 1977-89.
- Goldsamt, L. A., J. O'Brien, et al. (2005). "The relationship between club drug use and other drug use: A survey of New York City middle school students." *Subst Use Misuse* 40(9): 1539-55.
- Hall, J. A., S. W. Henggeler, et al. (1993). "Adolescent substance use during pregnancy." *J Pediatr Psychol* 18(2): 265-71.
- Hartel-Petri, R., R. Rodler, et al. (2005). "[Increasing prevalence of amphetamine--and methamphetamine-induced psychosis]." *Psychiatr Prax* 32(1): 13-7.
- Helschober, B. and M. A. Miller (1991). "Methamphetamine abuse in California." *NIDA Res Monogr* 115: 60-71.
- Herman-Stahl, M. A., C. P. Krebs, et al. (2006). "Risk and protective factors for methamphetamine use and nonmedical use of prescription stimulants among young adults aged 18 to 25." *Addict Behav.*
- Herman-Stahl, M. A., C. P. Krebs, et al. (2006). "Risk and protective factors for nonmedical use of prescription stimulants and methamphetamine among adolescents." *J Adolesc Health* 39(3): 374-80.
- Hirabayashi, N., K. Wada, et al. (2004). "Prevalence of substance abuse among patients with physical diseases seen in an emergency room in Japan." *Am J Addict* 13(4): 398-404.
- Hopfer, C., B. Mendelson, et al. (2006). "Club drug use among youths in treatment for substance abuse." *Am J Addict* 15(1): 94-9.
- Huff, C. (2006). "Crystal crush." *Hosp Health Netw* 80(10): 59-60, 62, 64.
- Jain, N. C., R. D. Budd, et al. (1979). "Frequency of use or abuse of amphetamine-related drugs." *Am J Drug Alcohol Abuse* 6(1): 53-7.
- Kelly, B. C., J. T. Parsons, et al. (2006). "Prevalence and predictors of club drug use among club-going young adults in New York City." *J Urban Health* 83(5): 884-895.
- Klette, K. L., A. R. Kettle, et al. (2006). "Prevalence of use study for amphetamine (AMP), methamphetamine (MAMP), 3,4-methylenedioxy-amphetamine (MDA), 3,4-methylenedioxy-methamphetamine (MDMA), and 3,4-methylenedioxy-ethylamphetamine (MDEA) in military entrance processing stations (MEPS) specimens." *J Anal Toxicol* 30(5): 319-22.
- Kroutil, L. A., D. L. Van Brunt, et al. (2006). "Nonmedical use of prescription stimulants in the United States." *Drug Alcohol Depend* 84(2): 135-43.
- Kulsudjarit, K. (2004). "Drug problem in southeast and southwest Asia." *Ann N Y Acad Sci* 1025: 446-57.
- Lampinen, T. M., D. McGhee, et al. (2006). "Increased risk of "club" drug use among gay and bisexual high school students in British Columbia." *J Adolesc Health* 38(4): 458-61.
- Lampinen, T. M., D. McGhee, et al. (2006). "Use of crystal methamphetamine and other club drugs among high school students in Vancouver and Victoria." *BC Medical Journal* 48(1): 22-27.
- Lee, S. J., M. Galanter, et al. (2003). "Circuit parties and patterns of drug use in a subset of gay men." *J Addict Dis* 22(4): 47-60.
- Maglione, M., B. Chao, et al. (1998). "Methamphetamine abuse in California: Correlates of injection use." *AIDS and Behavior* 2(3): 257-261.
- Mansergh, G., G. N. Colfax, et al. (2001). "The Circuit Party Men's Health Survey: Findings and implications for gay and bisexual men." *Am J Public Health* 91(6): 953-8.
- March, J. C., E. Oviedo-Joekes, et al. (2006). "Drugs and social exclusion in ten European cities." *Eur Addict Res* 12(1): 33-41.
- Martin, I., T. M. Lampinen, et al. (2006). "Methamphetamine use among marginalized youth in British Columbia." *Can J Public Health* 97(4): 320-4.
- Maxwell, J. C., P. Cravioto, et al. (2006). "Drug use and risk of HIV/AIDS on the Mexico-USA border: A comparison of treatment admissions in both countries." *Drug Alcohol Depend* 82 Suppl 1: S85-93.
- Maxwell, J. C. (2005). "Emerging research on methamphetamine." *Curr Opin Psychiatry* 18(3): 235-42.
- Mitchell, S. J., S. R. Morris, et al. (2006). "Methamphetamine use and sexual activity among HIV-infected patients in care--San Francisco, 2004." *AIDS Patient Care STDS* 20(7): 502-10.
- Miura, H., M. Fujiki, et al. (2006). "Prevalence and profile of methamphetamine users in adolescents at a juvenile classification home." *Psychiatry Clin Neurosci* 60(3): 352-7.
- Newmeyer, J. A. (2003). "Patterns and trends of drug use in the San Francisco Bay Area." *J Psychoactive Drugs* 35(Suppl 1): 127-32.
- Newmeyer, J. A. (1988). "The prevalence of drug use in San Francisco in 1987." *J Psychoactive Drugs* 20(2): 185-9.
- Oetting, E. R., J. L. Deffenbacher, et al. (2000). "Methamphetamine use by high school students: Recent trends, gender and ethnicity differences, and use of other drugs." *Journal of Child and Adolescent Substance Abuse* 10(1): 33-50.

- Ompad, D. C., S. Galea, et al. (2004). "Club drug use among minority substance users in New York City." *J Psychoactive Drugs* 36(3): 397-9.
- Parry, C. D., A. Pluddemann, et al. (2005). "Cannabis and other drug use among trauma patients in three South African cities, 1999-2001." *S Afr Med J* 95(6): 429-32.
- Penn, C. L. (2006). "Meth abuse in Arkansas." *J Ark Med Soc* 102(8): 218-9.
- Rawson, R. A., S. L. Simon and W. Ling (2002). "If a US drug abuse epidemic fails to include a major east coast city, can it be called an epidemic?" *J Addict Dis* 21(1): 1-4.
- Rimsza, M. E. and K. S. Moses (2005). "Substance abuse on the college campus." *Pediatr Clin North Am* 52(1): 307-19, xii.
- Rockett, I. R., S. L. Putnam, et al. (2006). "Declared and undeclared substance use among emergency department patients: A population-based study." *Addiction* 101(5): 706-712.
- Roxburgh, A., L. Degenhardt, et al. (2004). "Changes in patterns of drug use among injecting drug users following changes in the availability of heroin in New South Wales, Australia." *Drug Alcohol Rev* 23(3): 287-94.
- Sattah, M. V., S. Supawitkul, et al. (2002). "Prevalence of and risk factors for methamphetamine use in northern Thai youth: Results of an audio-computer-assisted self-interviewing survey with urine testing." *Addiction* 97(7): 801-8.
- Shoptaw, S. and C. J. Reback (2006). "Associations between methamphetamine use and HIV among men who have sex with men: A model for guiding public policy." *J Urban Health* 83(6): 1151-7.
- Stoops, W. W., M. S. Tindall, et al. (2005). "Methamphetamine use in nonurban and urban drug court clients." *Int J Offender Ther Comp Criminol* 49(3): 260-76.
- Storr, C. L., A. M. Arria, et al. (2004). "Neighborhood environment and opportunity to try methamphetamine ("ice") and marijuana: Evidence from Guam in the Western Pacific region of Micronesia." *Subst Use Misuse* 39(2): 253-76.
- Sullivan, P. S., A. K. Nakashima, et al. (1998). "Geographic differences in noninjection and injection substance use among HIV-seropositive men who have sex with men: western United States versus other regions. Supplement to HIV/AIDS Surveillance Study Group." *J Acquir Immune Defic Syndr Hum Retrovirol* 19(3): 266-73.
- Thiede, H., L. A. Valleroy, et al. (2003). "Regional patterns and correlates of substance use among young men who have sex with men in 7 US urban areas." *Am J Public Health* 93(11): 1915-21.
- Van Leeuwen, J. M., C. Hopfer, S. Hooks, R. White, J. Petersen and J. Pirkopf (2004). "A snapshot of substance abuse among homeless and runaway youth in Denver, Colorado." *J Community Health* 29(3): 217-29.
- Wermuth, L. (2000). "Methamphetamine use: Hazards and social influences." *J Drug Educ* 30(4): 423-33.
- Wu, L. T., W. E. Schlenger, et al. (2006). "Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths." *Drug Alcohol Depend* 84(1): 102-13.
- Wu, L. T., D. J. Pilowsky, et al. (2004). "Injection drug use among stimulant users in a national sample." *Am J Drug Alcohol Abuse* 30(1): 61-83.

## Prevention of Methamphetamine Use

- Anonymous (2006). "Cooking up solutions to a cooked up menace: Responses to methamphetamine in a federal system." *Harv Law Rev* 119(8): 2508-29.
- Boulard, G. (2005). "The meth menace: Battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.
- Colker, A. C. (2005). "Restricting the sale of pseudoephedrine to prevent methamphetamine production." *NCSL Legisbrief* 13(7): 1-2.
- Cunningham, J. K. and L. M. Liu (2005). "Impacts of federal precursor chemical regulations on methamphetamine arrests." *Addiction* 100(4): 479-88.
- Cunningham, J. K. and L. M. Liu (2003). "Guidelines for measuring impacts of methamphetamine precursor chemical regulations: A reply to Reuter and Caulkins (2003)." *Addiction* 98(10): 1463-4.
- Cunningham, J. K. and L. M. Liu (2003). "Impacts of federal ephedrine and pseudoephedrine regulations on methamphetamine-related hospital admissions." *Addiction* 98(9): 1229-37.
- Eccles, R. (2006). "Substitution of phenylephrine for pseudoephedrine as a nasal decongestant. An illogical way to control methamphetamine abuse." *Br J Clin Pharmacol*.
- Folger, D. (2006). "Spreading the word about meth." *Minn Med* 89(6): 50.
- Herman-Stahl, M. A., C. P. Krebs, et al. (2006). "Risk and protective factors for methamphetamine use and nonmedical use of prescription stimulants among young adults aged 18 to 25." *Addict Behav*.
- Herman-Stahl, M. A., C. P. Krebs, et al. (2006). "Risk and protective factors for nonmedical use of prescription stimulants and methamphetamine among adolescents." *J Adolesc Health* 39(3): 374-80.
- Huff, C. (2006). "Crystal crush." *Hosp Health Netw* 80(10): 59-60, 62, 64.

- Murty, S. and S. S. Sansgiry (2006). "Pseudoephedrine laws in the US--are we doing enough?" *Ann Pharmacother* 40(6): 1213-5.
- Reuter, P. and J. P. Caulkins (2003). "Does precursor regulation make a difference?" *Addiction* 98(9): 1177-9.
- Romanelli, F. and K. M. Smith (2006). "Clinical effects and management of methamphetamine abuse." *Pharmacotherapy* 26(8): 1148-56.
- Royo-Isach, J., M. Magrane, et al. (2004). "[Speed users (metamphetamines): a return journey between ecstasy (MDMA) and cocaine. Clinical, preventive and health-care questions]." *Aten Primaria* 34(10): 553-6.
- Spoth, R. L., S. Clair, et al. (2006). "Long-term effects of universal preventive interventions on methamphetamine use among adolescents." *Arch Pediatr Adolesc Med* 160(9): 876-82.
- Storr, C. L., A. M. Arria, et al. (2004). "Neighborhood environment and opportunity to try methamphetamine ("ice") and marijuana: Evidence from Guam in the Western Pacific region of Micronesia." *Subst Use Misuse* 39(2): 253-76.
- Wermuth, L. (2000). "Methamphetamine use: Hazards and social influences." *J Drug Educ* 30(4): 423-33.

### Primary Care

*See Medical Care*

### Prison

*See Incarceration and Incarcerated Individuals*

### Prostitution

*See Commercial Sex Work and Sex Workers*

### Psilocybin

Gouzoulis-Mayfrank, E., M. Schreckenberger, et al. (1999). "Neurometabolic effects of psilocybin, 3,4-methylenedioxylethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [<sup>18</sup>F]FDG." *Neuropsychopharmacology* 20(6): 565-81.

### Psychomotor Task Performance

*See also Movement Disorders*

- Caligiuri, M. P. and C. Buitenhuis (2005). "Do preclinical findings of methamphetamine-induced motor abnormalities translate to an observable clinical phenotype?" *Neuropsychopharmacology* 30(12): 2125-34.
- Couper, F. J., M. Pemberton, et al. (2002). "Prevalence of drug use in commercial tractor-trailer drivers." *J Forensic Sci* 47(3): 562-7.
- Dhawn, B. N., S. K. Bapat, et al. (1969). "Effect of four centrally acting drugs on handwriting." *Jpn J Pharmacol* 19(1): 63-7.
- Ellis, K. L. and J. Speed (1998). "Pharmacologic management of movement disorder after midbrain haemorrhage." *Brain Inj* 12(7): 623-8.
- Forney, R. (1977). "Drug impairment reviews: Stimulants." *NIDA Res Monogr Series* 11: 73-6.
- Forney, R., R. Martz, et al. (1976). "The combined effect of marijuana and dextroamphetamine." *Ann N Y Acad Sci* 281: 162-70.
- Gustavsen, I., J. Morland, et al. (2006). "Impairment related to blood amphetamine and/or methamphetamine concentrations in suspected drugged drivers." *Accid Anal Prev* 38(3): 490-5.
- Hart, C. L., M. Haney, et al. (2005). "Combined effects of methamphetamine and zolpidem on performance and mood during simulated night shift work." *Pharmacol Biochem Behav* 81(3): 559-68.
- Hart, C. L., A. S. Ward, et al. (2003). "Methamphetamine attenuates disruptions in performance and mood during simulated night-shift work." *Psychopharmacology (Berl)* 169(1): 42-51.
- Johnson, B. A., J. D. Roache, et al. (2007). "Effects of topiramate on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in recently abstinent methamphetamine-dependent individuals." *Prog Neuropsychopharmacol Biol Psychiatry* 31(1): 123-30.
- Johnson, B. A., J. D. Roache, et al. (2005). "Effects of isradipine on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition." *Psychopharmacology (Berl)* 178(2-3): 296-302.
- Logan, B. K. (1996). "Methamphetamine and driving impairment." *J Forensic Sci* 41(3): 457-64.
- Meredith, C. W., C. Jaffe, et al. (2005). "Implications of chronic methamphetamine use: A literature review." *Harv Rev Psychiatry* 13(3): 141-54.

- Moeller, M. R. and T. Kraemer (2002). "Drugs of abuse monitoring in blood for control of driving under the influence of drugs." *Ther Drug Monit* 24(2): 210-21.
- Monterosso, J. R., A. R. Aron, et al. (2005). "Deficits in response inhibition associated with chronic methamphetamine abuse." *Drug Alcohol Depend* 79(2): 273-7.
- Nath, A., W. F. Maragos, et al. (2001). "Acceleration of HIV dementia with methamphetamine and cocaine." *J Neurovirol* 7(1): 66-71.
- Nordahl, T. E., R. Salo, et al. (2003). "Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: A review." *J Neuropsychiatry Clin Neurosci* 15(3): 317-25.
- Purtell, D. J. (1965). "Effects of drugs on handwriting." *J Forensic Sci* 10(3): 335-46.
- Schwilke, E. W., M. I. Sampaio dos Santos, et al. (2006). "Changing patterns of drug and alcohol use in fatally injured drivers in Washington State." *J Forensic Sci* 51(5): 1191-8.
- Sheridan, J., S. Bennett, et al. (2006). "Injury associated with methamphetamine use: A review of the literature." *Harm Reduct J* 3(1): 14.
- Silber, B. Y., R. J. Croft, et al. (2006). "The acute effects of d-amphetamine and methamphetamine on attention and psychomotor performance." *Psychopharmacology (Berl)* 187(2): 154-69.
- Silber, B. Y., K. Papafotiou, et al. (2005). "An evaluation of the sensitivity of the standardised field sobriety tests to detect the presence of amphetamine." *Psychopharmacology (Berl)*: 1-7.
- Smirnov, A. V. (1990). "[Psychomotor stimulants as agents for enhancing work capacity]." *Farmakol Toksikol* 53(4): 72-7.
- Srisurapanont, M., R. Ali, et al. (2003). "Psychotic symptoms in methamphetamine psychotic in-patients." *Int J Neuropsychopharmacol* 6(4): 347-52.
- Volkow, N. D., L. Chang, et al. (2001). "Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers." *Am J Psychiatry* 158(3): 377-82.
- Volkow, N. D., L. Chang, et al. (2001). "Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence." *J Neurosci* 21(23): 9414-8.
- Wang, G. J., N. D. Volkow, et al. (2004). "Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence." *Am J Psychiatry* 161(2): 242-8.

## Psychomotor Task Performance (animals)

*See also* Hyperactivity (animals); Sterotypic Behaviors (animals); Tremors (animals)

- Caligiuri, M. P. and C. Buitenhuis (2005). "Do preclinical findings of methamphetamine-induced motor abnormalities translate to an observable clinical phenotype?" *Neuropsychopharmacology* 30(12): 2125-34.
- Dalley, J. W., K. Laane, et al. (2006). "Enduring deficits in sustained visual attention during withdrawal of intravenous methylenedioxymethamphetamine self-administration in rats: Results from a comparative study with d-amphetamine and methamphetamine." *Neuropsychopharmacology*.
- Eibergen, R. D. and K. R. Carlson (1976). "Dyskinesias in monkeys: Interaction of methamphetamine with prior methadone treatment." *Pharmacol Biochem Behav* 5(2): 175-87.
- Eibergen, R. D. and K. R. Carlson (1975). "Dyskinesias elicited by methamphetamine: Susceptibility of former methadone-consuming monkeys." *Science* 190(4214): 588-90.
- Kim, J. S., R. Hassler, et al. (1970). "Abnormal movements and rigidity induced by harmaline in relation to striatal acetylcholine, serotonin, and dopamine." *Exp Neurol* 29(2): 189-200.
- Nishii, K., N. Matsushita, et al. (1998). "Motor and learning dysfunction during postnatal development in mice defective in dopamine neuronal transmission." *J Neurosci Res* 54(4): 450-64.
- Richardson, D., A. G. Karczmar, et al. (1972). "Intergenerational behavioral differences among methamphetamine treated mice." *Psychopharmacologia* 25(4): 347-75.
- Slamberova, R., M. Pometlova, et al. (2006). "Postnatal development of rat pups is altered by prenatal methamphetamine exposure." *Prog Neuropsychopharmacol Biol Psychiatry* 30(1): 82-8.

## Psychosis

*See also* Mental Health and Illness; Schizophrenia

- Akiyama, K. (2006). "Longitudinal clinical course following pharmacological treatment of methamphetamine psychosis which persists after long-term abstinence." *Ann N Y Acad Sci* 1074: 125-34.
- Barr, A. M., W. J. Panenka, et al. (2006). "The need for speed: An update on methamphetamine addiction." *J Psychiatry Neurosci* 31(5): 301-313.

- Batki, S. L. and D. S. Harris (2004). "Quantitative drug levels in stimulant psychosis: Relationship to symptom severity, catecholamines and hyperkinesia." *Am J Addict* 13(5): 461-70.
- Brown, E. S., V. A. Nejtck, D. C. Perantie, N. Rajan Thomas and A. J. Rush (2003). "Cocaine and amphetamine use in patients with psychiatric illness: A randomized trial of typical antipsychotic continuation or discontinuation." *J Clin Psychopharmacol* 23(4): 384-8.
- Buffenstein, A., J. Heaster, et al. (1999). "Chronic psychotic illness from methamphetamine." *Am J Psychiatry* 156(4): 662.
- Chen, C. K., S. K. Lin, et al. (2005). "Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis." *Am J Med Genet B Neuropsychiatr Genet* 136(1): 87-91.
- Chen, C. K., S. K. Lin, P. C. Sham, D. Ball, E. W. Loh, C. C. Hsiao, Y. L. Chiang, S. C. Ree, C. H. Lee and R. M. Murray (2003). "Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis." *Psychol Med* 33(8): 1407-14.
- Chen, C. K., X. Hu, et al. (2004). "Association analysis of dopamine D2-like receptor genes and methamphetamine abuse." *Psychiatr Genet* 14(4): 223-6.
- Derlet, R. W. and B. Heischouer (1990). "Methamphetamine. Stimulant of the 1990s?" *West J Med* 153(6): 625-8.
- Dore, G. and M. Sweeting (2006). "Drug-induced psychosis associated with crystalline methamphetamine." *Australas Psychiatry* 14(1): 86-9.
- Edakubo, T., T. Kaneko, et al. (1991). "[Secondary development of psychological dependence in a methamphetamine dependent]." *Arukuru Kenkyuto Yakubutsu Ison* 26(2): 96-104.
- Ellinwood, E. H., Jr., A. Sudilovsky, et al. (1973). "Olfactory forebrain seizures induced by methamphetamine and disulfiram." *Biol Psychiatry* 7(2): 89-99.
- Ellison, G. (2002). "Neural degeneration following chronic stimulant abuse reveals a weak link in brain, fasciculus retroflexus, implying the loss of forebrain control circuitry." *Eur Neuropsychopharmacol* 12(4): 287-97.
- Hall, W., S. Darke, et al. (1993). "Patterns of drug use and risk-taking among injecting amphetamine and opioid drug users in Sydney, Australia." *Addiction* 88(4): 509-16.
- Harajiri, S., H. Kojima, et al. (1986). "Synergism between methamphetamine and alcohol in a case of methamphetamine psychosis." *Kurume Med J* 33(4): 163-5.
- Harano, M., N. Uchimura, et al. (2004). "A polymorphism of DRD2 gene and brain atrophy in methamphetamine psychosis." *Ann N Y Acad Sci* 1025: 307-15.
- Harris, D. and S. L. Batki (2000). "Stimulant psychosis: Symptom profile and acute clinical course." *Am J Addict* 9(1): 28-37.
- Hartel-Petri, R., R. Rodler, et al. (2005). "[Increasing prevalence of amphetamine--and methamphetamine-induced psychosis]." *Psychiatr Prax* 32(1): 13-7.
- Hashimoto, T., K. Hashimoto, et al. (2005). "A functional glutathione S-transferase P1 gene polymorphism is associated with methamphetamine-induced psychosis in Japanese population." *Am J Med Genet B Neuropsychiatr Genet* 135(1): 5-9.
- Ide, S., H. Kobayashi, et al. (2006). "Linkage disequilibrium and association with methamphetamine dependence/psychosis of mu-opioid receptor gene polymorphisms." *Pharmacogenomics J* 6(3): 179-88.
- Ide, S., H. Kobayashi, et al. (2004). "Gene polymorphisms of the mu opioid receptor in methamphetamine abusers." *Ann N Y Acad Sci* 1025: 316-24.
- Ikeda, M., N. Iwata, et al. (2006). "Positive association of AKT1 haplotype to Japanese methamphetamine use disorder." *Int J Neuropsychopharmacol* 9(1): 77-81.
- Inada, T., Y. Iijima, et al. (2004). "No association found between the type 1 sigma receptor gene polymorphisms and methamphetamine abuse in the Japanese population: a collaborative study by the Japanese Genetics Initiative for Drug Abuse." *Ann N Y Acad Sci* 1025: 27-33.
- Iwanami, A., R. Kanamori, et al. (1995). "Reduced attention-related negative potentials in methamphetamine psychosis." *J Nerv Ment Dis* 183(11): 693-7.
- Iwanami, A., I. Suga, et al. (1994). "P300 component of event-related potentials in methamphetamine psychosis and schizophrenia." *Prog Neuropsychopharmacol Biol Psychiatry* 18(3): 465-75.
- Iwanami, A., I. Suga, et al. (1993). "Event-related potentials in methamphetamine psychosis during an auditory discrimination task. A preliminary report." *Eur Arch Psychiatry Clin Neurosci* 242(4): 203-8.
- Iwanami, A., N. Kato, et al. (1991). "P300 in methamphetamine psychosis." *Biol Psychiatry* 30(7): 726-30.
- Iwata, N., T. Inada, et al. (2004). "No association is found between the candidate genes of t-PA/plasminogen system and Japanese methamphetamine-related disorder: A collaborative study by the Japanese Genetics Initiative for Drug Abuse." *Ann N Y Acad Sci* 1025: 34-8.
- Iyo, M., Y. Sekine and N. Mori (2004). "Neuromechanism of developing methamphetamine psychosis: A neuroimaging study." *Ann N Y Acad Sci* 1025: 288-95.



- Iyo, M., Y. Sekine, et al. (1999). "Methamphetamine-associated obsessional symptoms and effective risperidone treatment: A case report." *J Clin Psychiatry* 60(5): 337-8.
- Iyo, M., M. Nishio, et al. (1993). "Dopamine D2 and serotonin S2 receptors in susceptibility to methamphetamine psychosis detected by positron emission tomography." *Psychiatry Res* 50(4): 217-31.
- Iyo, M. (1992). "PET dopamine D2 receptors and susceptibility to methamphetamine psychosis." *Clin Neuropharmacol* 15 Suppl 1 Pt A: 652A-653A.
- Kobayashi, H., H. Hata, et al. (2006). "Association analysis of delta-opioid receptor gene polymorphisms in methamphetamine dependence/psychosis." *Am J Med Genet B Neuropsychiatr Genet* 141(5): 482-6.
- Kobayashi, H., S. Ide, et al. (2004). "Study of association between alpha-synuclein gene polymorphism and methamphetamine psychosis/dependence." *Ann N Y Acad Sci* 1025: 325-34.
- Kojima, T., E. Matsushima, et al. (1990). "Eye movements in acute, chronic, and remitted schizophrenics." *Biol Psychiatry* 27(9): 975-89.
- Kojima, T., E. Matsushima, et al. (1986). "Visual perception process in amphetamine psychosis and schizophrenia." *Psychopharmacol Bull* 22(3): 768-73.
- Lin, S. K., D. Ball, et al. (2004). "Psychiatric comorbidity and gender differences of persons incarcerated for methamphetamine abuse in Taiwan." *Psychiatry Clin Neurosci* 58(2): 206-12.
- Liu, H. C., C. K. Chen, et al. (2006). "Association between dopamine receptor D1 A-48G polymorphism and methamphetamine abuse." *Psychiatry Clin Neurosci* 60(2): 226-31.
- Liu, H. C., S. K. Lin, et al. (2004). "DAT polymorphism and diverse clinical manifestations in methamphetamine abusers." *Psychiatr Genet* 14(1): 33-7.
- Martin, I., T. M. Lampinen, et al. (2006). "Methamphetamine use among marginalized youth in British Columbia." *Can J Public Health* 97(4): 320-4.
- Martin Alisky, J. (2006). "Cholinesterase inhibitors might alleviate methamphetamine-induced delusions, hallucinations and cognitive impairment, while reducing craving and addiction." *World J Biol Psychiatry* 7(4): 269.
- Matsumoto, T., A. Kamijo, et al. (2002). "Methamphetamine in Japan: The consequences of methamphetamine abuse as a function of route of administration." *Addiction* 97(7): 809-17.
- McKetin, R., J. McLaren, et al. (2006). "The prevalence of psychotic symptoms among methamphetamine users." *Addiction* 101(10): 1473-8.
- Mikami, T., N. Naruse, et al. (2003). "Determining vulnerability to schizophrenia in methamphetamine psychosis using exploratory eye movements." *Psychiatry Clin Neurosci* 57(4): 433-40.
- Morio, A., H. Ujike, et al. (2006). "No association between CART (cocaine- and amphetamine-regulated transcript) gene and methamphetamine dependence." *Ann N Y Acad Sci* 1074: 411-7.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.
- Nakamura, K., C. K. Chen, et al. (2006). "Association analysis of SOD2 variants with methamphetamine psychosis in Japanese and Taiwanese populations." *Hum Genet* 120(2): 243-52.
- Ohgake, S., K. Hashimoto, et al. (2005). "Functional polymorphism of the NQO2 gene is associated with methamphetamine psychosis." *Addict Biol* 10(2): 145-8.
- Ozaki, S. (2004). "[Current situation of substance abuse/dependence in psychiatric hospital settings]." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 39(1): 35-40.
- Richards, J. R., R. W. Derlet, et al. (1997). "Methamphetamine toxicity: Treatment with a benzodiazepine versus a butyrophenone." *Eur J Emerg Med* 4(3): 130-5.
- Sato, M. (2002). "[Basic and clinical studies on methamphetamine-related psychosis]." *Seishin Shinkeigaku Zasshi* 104(3): 179-90.
- Sato, M., Y. Numachi, et al. (1992). "Relapse of paranoid psychotic state in methamphetamine model of schizophrenia." *Schizophr Bull* 18(1): 115-22.
- Sato, M. (1992). "A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis." *Ann N Y Acad Sci* 654: 160-70.
- Sato, M., Y. Numachi, et al. (1992). "Relapse of paranoid psychotic state in methamphetamine model of schizophrenia." *Schizophr Bull* 18(1): 115-22.
- Sato, M. (1986). "Acute exacerbation of methamphetamine psychosis and lasting dopaminergic supersensitivity--A clinical survey." *Psychopharmacol Bull* 22(3): 751-6.
- Sato, M., C. C. Chen, et al. (1983). "Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis." *Biol Psychiatry* 18(4): 429-40.
- Sato, M. (1979). "[An experimental study of onset and relapse mechanisms of the chronic methamphetamine psychosis (author's transl)]." *Seishin Shinkeigaku Zasshi* 81(1): 21-32.

- Sekine, Y., Y. Minabe, et al. (2003). "Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms." *Am J Psychiatry* 160(9): 1699-701.
- Sekine, Y., M. Iyo, et al. (2001). "Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET." *Am J Psychiatry* 158(8): 1206-14.
- Srisurapanont, M., R. Ali, et al. (2003). "Psychotic symptoms in methamphetamine psychotic in-patients." *Int J Neuropsychopharmacol* 6(4): 347-52.
- Srisurapanont, M., P. Kittiratanapaiboon, et al. (2001). "Treatment for amphetamine psychosis." *Cochrane Database Syst Rev*(4): CD003026.
- Suzuki, A., K. Nakamura, et al. (2006). "An association study between catechol-O-methyl transferase gene polymorphism and methamphetamine psychotic disorder." *Psychiatr Genet* 16(4): 133-8.
- Szuster, R. R. (1990). "Methamphetamine in psychiatric emergencies." *Hawaii Med J* 49(10): 389-91.
- Thirthalli, J. and V. Benegal (2006). "Psychosis among substance users." *Curr Opin Psychiatry* 19(3): 239-45.
- Tomiyama, G. (1990). "Chronic schizophrenia-like states in methamphetamine psychosis." *Jpn J Psychiatry Neurol* 44(3): 531-9.
- Ujike, H. and M. Sato (2004). "Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis." *Ann N Y Acad Sci* 1025: 279-87.
- Ujike, H., M. Harano, et al. (2003). "Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis." *Pharmacogenomics J* 3(4): 242-7.
- Volkow, N. D. (2001). "Drug abuse and mental illness: Progress in understanding comorbidity." *Am J Psychiatry* 158(8): 1181-3.
- Wada, K. and S. Fukui (1990). "[Relationship between years of methamphetamine use and symptoms of methamphetamine psychosis]." *Arukoro Kenkyuto Yakubutsu Ison* 25(3): 143-58.
- Yen, C. F. and Y. C. Su (2006). "The associations of early-onset methamphetamine use with psychiatric morbidity among Taiwanese adolescents." *Subst Use Misuse* 41(1): 35-44.
- Yui, K., K. Goto, et al. (2004). "The role of noradrenergic and dopaminergic hyperactivity in the development of spontaneous recurrence of methamphetamine psychosis and susceptibility to episode recurrence." *Ann N Y Acad Sci* 1025: 296-306.
- Yui, K., S. Ikemoto, et al. (2003). "Susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosis." *J Clin Psychopharmacol* 23(5): 525-8.
- Yui, K., S. Ikemoto, et al. (2002). "Factors for susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosis." *Ann N Y Acad Sci* 965: 292-304.
- Yui, K., S. Ikemoto, et al. (2002). "Spontaneous recurrence of methamphetamine-induced paranoid-hallucinatory states in female subjects: Susceptibility to psychotic states and implications for relapse of schizophrenia." *Pharmacopsychiatry* 35(2): 62-71.
- Yui, K., K. Goto, et al. (2001). "Susceptibility to subsequent episodes of spontaneous recurrence of methamphetamine psychosis." *Drug Alcohol Depend* 64(2): 133-42.
- Yui, K., K. Goto, et al. (2000). "Increased sensitivity to stress in spontaneous recurrence of methamphetamine psychosis: Noradrenergic hyperactivity with contribution from dopaminergic hyperactivity." *J Clin Psychopharmacol* 20(2): 165-74.
- Yui, K., K. Goto, et al. (2000). "Stress induced spontaneous recurrence of methamphetamine psychosis: The relation between stressful experiences and sensitivity to stress." *Drug Alcohol Depend* 58(1-2): 67-75.
- Yui, K., S. Ikemoto, et al. (2000). "Studies of amphetamine or methamphetamine psychosis in Japan: Relation of methamphetamine psychosis to schizophrenia." *Ann N Y Acad Sci* 914: 1-12.
- Yui, K., T. Ishiguro, et al. (2000). "Susceptibility to subsequent episodes in spontaneous recurrence of methamphetamine psychosis." *Ann N Y Acad Sci* 914: 292-302.
- Yui, K., K. Goto, et al. (1999). "Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: The role of sensitization." *Mol Psychiatry* 4(6): 512-23.
- Yui, K., K. Goto, et al. (1999). "Increased sensitivity to stress and episode recurrence in spontaneous recurrence of methamphetamine psychosis." *Psychopharmacology (Berl)* 145(3): 267-72.
- Yui, K., T. Ishiguro, et al. (1999). "Spontaneous recurrence of methamphetamine psychosis: Increased sensitivity to stress associated with noradrenergic hyperactivity and dopaminergic change." *Eur Arch Psychiatry Clin Neurosci* 249(2): 103-11.
- Yui, K., T. Ishiguro, et al. (1998). "Factors affecting the development of spontaneous recurrence of methamphetamine psychosis." *Acta Psychiatr Scand* 97(3): 220-7.
- Yui, K., K. Goto, et al. (1997). "Methamphetamine psychosis: Spontaneous recurrence of paranoid-hallucinatory states and monoamine neurotransmitter function." *J Clin Psychopharmacol* 17(1): 34-43.
- Yui, K., K. Goto, S. Ikemoto and T. Ishiguro (1997). "Monoamine neurotransmitter metabolites and spontaneous recurrence of methamphetamine psychosis." *Brain Res Bull* 43(1): 25-33.

- Yui, K., T. Ishiguro, et al. (1997). "Precipitating factors in spontaneous recurrence of methamphetamine psychosis." *Psychopharmacology (Berl)* 134(3): 303-8.
- Yui, K., K. Goto, et al. (1997). "Noradrenergic activity and spontaneous recurrence of methamphetamine psychosis." *Drug Alcohol Depend* 44(2-3): 183-7.
- Yui, K., K. Goto, et al. (1996). "Plasma monoamine metabolites and spontaneous recurrence of methamphetamine-induced paranoid-hallucinatory psychosis: Relation of noradrenergic activity to the occurrence of flashbacks." *Psychiatry Res* 63(2-3): 93-107.
- Yui, K., K. Goto, et al. (1995). "Spontaneous recurrence of methamphetamine psychosis: Process and monoamine neurotransmitter function." *Nihon Shinkei Seishin Yakurigaku Zasshi* 15(4): 363-74.
- Yukitake, A. (1983). "Amphetamine psychosis in Tokyo--Its clinical features and social problems." *Folia Psychiatr Neurol Jpn* 37(2): 115-20.

## Psychosis (animal models)

*See also* Schizophrenia (animal models)

- Brummelte, S., J. Neddens, et al. (2007). "Alteration in the GABAergic network of the prefrontal cortex in a potential animal model of psychosis." *J Neural Transm*.
- Dawirs, R. R. and G. Teuchert-Noodt (2001). "A novel pharmacological concept in an animal model of psychosis." *Acta Psychiatr Scand Suppl*(408): 10-7.
- Ellison, G. (2002). "Neural degeneration following chronic stimulant abuse reveals a weak link in brain, fasciculus retroflexus, implying the loss of forebrain control circuitry." *Eur Neuropsychopharmacol* 12(4): 287-97.
- Honda, M. (2004). "[The relation between behavioral sensitization and glutamate release on the animal model of methamphetamine-induced psychosis]." *Hokkaido Igaku Zasshi* 79(1): 65-78.
- Ide, S., H. Kobayashi, et al. (2006). "Linkage disequilibrium and association with methamphetamine dependence/psychosis of mu-opioid receptor gene polymorphisms." *Pharmacogenomics J* 6(3): 179-88.
- Ito, K. (1999). "The role of gamma-aminobutyric acid (GABA)-benzodiazepine neurotransmission in an animal model of methamphetamine-induced psychosis." *Hokkaido Igaku Zasshi* 74(2): 135-44.
- Kaneko, Y., A. Kashiwa, et al. (2006). "Selective serotonin reuptake inhibitors, fluoxetine and paroxetine, attenuate the expression of the established behavioral sensitization induced by methamphetamine." *Neuropsychopharmacology*.
- Sato, M. (1983). "Long-lasting hypersensitivity to methamphetamine following amygdaloid kindling in cats: the relationship between limbic epilepsy and the psychotic state." *Biol Psychiatry* 18(5): 525-36.
- Shilling, P. D., R. Kuczenski, et al. (2006). "Differential regulation of immediate-early gene expression in the prefrontal cortex of rats with a high vs low behavioral response to methamphetamine." *Neuropsychopharmacology* 31(11): 2359-67.
- Sudilovsky, A. (1975). "Effects of disulfiram on the amphetamine-induced behavioral syndrome in the cat as a model of psychosis." *Natl Inst Drug Abuse Res Monogr Ser*(3): 109-35.

## Psychotherapy

- Lehmann, H. E. and T. A. Ban (1971). "Effects of psychoactive drugs on conflict avoidance behavior in human subjects." *Act Nerv Super (Praha)* 13(2): 82-5.
- Lehmann, H. E., P. Black, et al. (1970). "The effect of psychostimulants on psychometric test performance with special reference to conflict avoidance behavior." *Curr Ther Res Clin Exp* 12(6): 390-3.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.
- Straker, M. (1953). "Intravenous methamphetamine, adjuvant to psychotherapy." *Am J Psychiatry* 109(11): 853-5.
- Tatarsky, A. (2003). "Harm reduction psychotherapy: Extending the reach of traditional substance use treatment." *J Subst Abuse Treat* 25(4): 249-56.

## Pulmonary Effects and Thoracic Disease

- Ago, M., K. Ago, et al. (2006). "Toxicological and histopathological analysis of a patient who died nine days after a single intravenous dose of methamphetamine: A case report." *Leg Med (Tokyo)* 8(4): 235-9.
- Chin, K. M., R. N. Channick, et al. (2006). "Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?" *Chest* 130(6): 1657-63.
- Gotway, M. B., S. R. Marder, et al. (2002). "Thoracic complications of illicit drug use: an organ system approach." *Radiographics* 22 Spec No: S119-35.

- Hong, R., E. Matsuyama and K. Nur (1991). "Cardiomyopathy associated with the smoking of crystal methamphetamine." *JAMA* 265(9): 1152-4.
- Johnson, D. C., A. Petru, et al. (1991). "Foreign body pulmonary granulomas in an abuser of nasally inhaled drugs." *Pediatrics* 88(1): 159-61.
- Mori, A., H. Suzuki, et al. (1992). "[Three cases of acute methamphetamine intoxication--analysis of optically active methamphetamine]." *Nihon Hoigaku Zasshi* 46(4): 266-70.
- Nestor, T. A., W. I. Tamamoto, et al. (1989). "Acute pulmonary oedema caused by crystalline methamphetamine." *Lancet* 2(8674): 1277-8.
- Schafer, S., H. Gillette, et al. (2006). "A community-wide pertussis outbreak: an argument for universal booster vaccination." *Arch Intern Med* 166(12): 1317-21.
- Tashkin, D. P. (2001). "Airway effects of marijuana, cocaine, and other inhaled illicit agents." *Curr Opin Pulm Med* 7(2): 43-61.
- Yeh, P. S., A. Yuan, et al. (2001). "Acute respiratory distress syndrome in a woman with heroin and methamphetamine misuse." *J Formos Med Assoc* 100(8): 553-6.

### **Pulmonary Effects and Thoracic Disease (animals)**

- Callaway, J. K., R. G. King, et al. (1990). "Methoxyphenamine inhibits histamine-induced bronchoconstriction in anaesthetized guinea-pigs and histamine-induced contractions of guinea-pig ileum in vitro." *Arch Int Pharmacodyn Ther* 308: 86-94.
- Zolkowska, D., R. B. Rothman, et al. (2006). "Amphetamine analogs increase plasma serotonin: Implications for cardiac and pulmonary disease." *J Pharmacol Exp Ther* 318(2): 604-10.

### **Race and Ethnicity**

- Arria, A. M., C. Derauf, et al. (2006). "Methamphetamine and other substance use during pregnancy: Preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study." *Matern Child Health J* 10(3): 293-302.
- Austin, A. A. (2004). "Alcohol, tobacco, other drug use, and violent behavior among Native Hawaiians: Ethnic pride and resilience." *Subst Use Misuse* 39(5): 721-46.
- Brecht, M. L., L. Greenwell, et al. (2007). "Substance use pathways to methamphetamine use among treated users." *Addict Behav* 32(1): 24-38.
- Brecht, M. L., L. Greenwell, et al. (2005). "Methamphetamine treatment: Trends and predictors of retention and completion in a large state treatment system (1992-2002)." *J Subst Abuse Treat* 29(4): 295-306.
- Choi, K. H., D. Operario, et al. (2005). "Substance use, substance choice, and unprotected anal intercourse among young Asian American and Pacific Islander men who have sex with men." *AIDS Educ Prev* 17(5): 418-29.
- Diaz, R. M., A. L. Heckert, et al. (2005). "Reasons for stimulant use among Latino gay men in San Francisco: a comparison between methamphetamine and cocaine users." *J Urban Health* 82(1 Suppl 1): i71-8.
- Fernandez, M. I., G. S. Bowen, et al. (2007). "Crystal methamphetamine: A source of added sexual risk for Hispanic men who have sex with men?" *Drug Alcohol Depend* 86(2-3): 245-52.
- Fernandez, M. I., G. S. Bowen, et al. (2005). "High rates of club drug use and risky sexual practices among Hispanic men who have sex with men in Miami, Florida." *Subst Use Misuse* 40(9): 1347-62.
- Fernandez, M. I., T. Perrino, et al. (2005). "Surfing new territory: club-drug use and risky sex among Hispanic men who have sex with men recruited on the Internet." *J Urban Health* 82(1 Suppl 1): i79-88.
- Fernandez, M. I., L. M. Varga, et al. (2004). "The Internet as recruitment tool for HIV studies: viable strategy for reaching at-risk Hispanic MSM in Miami?" *AIDS Care* 16(8): 953-63.
- Freese, T. E., J. Obert, et al. (2000). "Methamphetamine abuse: Issues for special populations." *J Psychoactive Drugs* 32(2): 177-82.
- Goldsamt, L. A., J. O'Brien, et al. (2005). "The relationship between club drug use and other drug use: A survey of New York City middle school students." *Subst Use Misuse* 40(9): 1539-55.
- Green, A. I. and P. N. Halkitis (2006). "Crystal methamphetamine and sexual sociality in an urban gay subculture: An elective affinity." *Cult Health Sex* 8(4): 317-33.
- Herman-Stahl, M. A., C. P. Krebs, et al. (2006). "Risk and protective factors for methamphetamine use and nonmedical use of prescription stimulants among young adults aged 18 to 25." *Addict Behav*.
- Herman-Stahl, M. A., C. P. Krebs, et al. (2006). "Risk and protective factors for nonmedical use of prescription stimulants and methamphetamine among adolescents." *J Adolesc Health* 39(3): 374-80.
- Ide, S., H. Kobayashi, et al. (2004). "Gene polymorphisms of the mu opioid receptor in methamphetamine abusers." *Ann N Y Acad Sci* 1025: 316-24.

- Irwin, T. W. and J. Morgenstern (2005). "Drug-use patterns among men who have sex with men presenting for alcohol treatment: Differences in ethnic and sexual Identity." *J Urban Health*.
- Kelly, B. C., J. T. Parsons, et al. (2006). "Prevalence and predictors of club drug use among club-going young adults in New York City." *J Urban Health* 83(5): 884-895.
- Kurtz, S. P. (2005). "Post-circuit blues: Motivations and consequences of crystal meth use among gay men in Miami." *AIDS Behav* 9(1): 63-72.
- Lampinen, T. M., D. McGhee, et al. (2006). "Increased risk of "club" drug use among gay and bisexual high school students in British Columbia." *J Adolesc Health* 38(4): 458-61.
- Lyons, T., G. Chandra, et al. (2006). "Stimulant use and HIV risk behavior: The influence of peer support group participation." *AIDS Educ Prev* 18(5): 461-73.
- Maglione, M., B. Chao, et al. (1998). "Methamphetamine abuse in California: Correlates of injection use." *AIDS and Behavior* 2(3): 257-261.
- Nemoto, T., D. Operario, et al. (2002). "Risk behaviors of Filipino methamphetamine users in San Francisco: Implications for prevention and treatment of drug use and HIV." *Public Health Rep* 117 Suppl 1: S30-8.
- Niv, N. and Y. I. Hser (2006). "Drug treatment service utilization and outcomes for Hispanic and white methamphetamine abusers." *Health Serv Res* 41(4 Pt 1): 1242-57.
- Nyamathi, A. M., E. L. Dixon, et al. (2006). "Hepatitis C virus infection among homeless men referred from a community clinic." *West J Nurs Res* 28(4): 475-88.
- Oetting, E. R., J. L. Deffenbacher, et al. (2000). "Methamphetamine use by high school students: Recent trends, gender and ethnicity differences, and use of other drugs." *Journal of Child and Adolescent Substance Abuse* 10(1): 33-50.
- Ompad, D. C., S. Galea, et al. (2004). "Club drug use among minority substance users in New York City." *J Psychoactive Drugs* 36(3): 397-9.
- Operario, D. and T. Nemoto (2005). "Sexual risk behavior and substance use among a sample of Asian Pacific Islander transgendered women." *AIDS Educ Prev* 17(5): 430-43.
- Ramamoorthy, Y., R. F. Tyndale, et al. (2001). "Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates." *Pharmacogenetics* 11(6): 477-87.
- Richard, A. J., V. Mosier, et al. (2002). "New syringe acquisition and multi-person use of syringes among illegal drug users." *J Public Health Policy* 23(3): 324-43.
- Schermer, C. R. and D. H. Wisner (1999). "Methamphetamine use in trauma patients: A population-based study." *J Am Coll Surg* 189(5): 442-9.
- Sexton, R. L., R. G. Carlson, et al. (2005). "Barriers and pathways to diffusion of methamphetamine use among African Americans in the rural South: Preliminary ethnographic findings." *J Ethn Subst Abuse* 4(1): 77-103.
- Simon, S. L., C. P. Domier, et al. (2002). "Cognitive performance of current methamphetamine and cocaine abusers." *J Addict Dis* 21(1): 61-74.
- Somlai, A. M., J. A. Kelly, et al. (2003). "Predictors of HIV sexual risk behaviors in a community sample of injection drug-using men and women." *AIDS Behav* 7(4): 383-93.
- Storr, C. L., A. M. Arria, et al. (2004). "Neighborhood environment and opportunity to try methamphetamine ("ice") and marijuana: Evidence from Guam in the Western Pacific region of Micronesia." *Subst Use Misuse* 39(2): 253-76.
- Wohl, A. R., D. F. Johnson, et al. (2002). "HIV risk behaviors among African American men in Los Angeles County who self-identify as heterosexual." *J Acquir Immune Defic Syndr* 31(3): 354-60.
- Wu, L. T., D. J. Pilowsky, et al. (2004). "Injection drug use among stimulant users in a national sample." *Am J Drug Alcohol Abuse* 30(1): 61-83.
- Zule, W. A. and D. P. Desmond (1999). "An ethnographic comparison of HIV risk behaviors among heroin and methamphetamine injectors." *Am J Drug Alcohol Abuse* 25(1): 1-23.

### Raves

*See* Circuit Parties and Raves; Recreational and Club Drugs

### Reasons for Use

*See* Motivations for Use

### Recreational and Club Drugs

*See also* Polydrug Use and specific drugs

- Antoniou, T. and A. L. Tseng (2002). "Interactions between recreational drugs and antiretroviral agents." *Ann Pharmacother* 36(10): 1598-1613.
- Banken, J. A. (2004). "Drug abuse trends among youth in the United States." *Ann N Y Acad Sci* 1025: 465-71.
- Buchanan, J. F. and C. R. Brown (1988). "'Designer drugs'. A problem in clinical toxicology." *Med Toxicol Adverse Drug Exp* 3(1): 1-17.
- Christophersen, A. S. (2000). "Amphetamine designer drugs - An overview and epidemiology." *Toxicol Lett* 112-113: 127-31.
- Clatts, M. C., L. A. Goldsamt, et al. (2005). "Club drug use among young men who have sex with men in NYC: A preliminary epidemiological profile." *Subst Use Misuse* 40(9): 1317-30.
- Cole, J. C., H. R. Sumnall, et al. (2005). "Preliminary evidence of the cardiovascular effects of polysubstance misuse in nightclubs." *J Psychopharmacol* 19(1): 67-70.
- Colfax, G. N., G. Mansergh, et al. (2001). "Drug use and sexual risk behavior among gay and bisexual men who attend circuit parties: A venue-based comparison." *J Acquir Immune Defic Syndr* 28(4): 373-9.
- Fendrich, M., J. S. Wislar, T. P. Johnson and A. Hubbell (2003). "A contextual profile of club drug use among adults in Chicago." *Addiction* 98(12): 1693-703.
- Fernandez, M. I., G. S. Bowen, et al. (2005). "High rates of club drug use and risky sexual practices among Hispanic men who have sex with men in Miami, Florida." *Subst Use Misuse* 40(9): 1347-62.
- Freese, T. E., K. Miotto, et al. (2002). "The effects and consequences of selected club drugs." *J Subst Abuse Treat* 23(2): 151-6.
- Goldsamt, L. A., J. O'Brien, et al. (2005). "The relationship between club drug use and other drug use: A survey of New York City middle school students." *Subst Use Misuse* 40(9): 1539-55.
- Gorman, M. and P. Halkitis (2003). "Methamphetamine and club drug use and HIV." *Focus* 18(7): 5-6.
- Halkitis, P. N. and J. J. Palamar (2006). "GHB use among gay and bisexual men." *Addict Behav* 31(11): 2135-9.
- Hirshfield, S., R. H. Remien, M. Humberstone, I. Walavalkar and M. A. Chiasson (2004). "Substance use and high-risk sex among men who have sex with men: A national online study in the USA." *AIDS Care* 16(8): 1036-47.
- Hopfer, C., B. Mendelson, et al. (2006). "Club drug use among youths in treatment for substance abuse." *Am J Addict* 15(1): 94-9.
- Irvine, R. J., M. Keane, et al. (2006). "Plasma drug concentrations and physiological measures in 'dance party' participants." *Neuropsychopharmacology* 31(2): 424-30.
- Joe Laidler, K. A. (2005). "The rise of club drugs in a heroin society: The case of Hong Kong." *Subst Use Misuse* 40(9-10): 1257-78.
- Kelly, B. C., J. T. Parsons, et al. (2006). "Prevalence and predictors of club drug use among club-going young adults in New York City." *J Urban Health* 83(5): 884-895.
- Klein, M. and F. Kramer (2004). "Rave drugs: Pharmacological considerations." *AANA J* 72(1): 61-7.
- Lampinen, T. M., D. McGhee, et al. (2006). "Increased risk of 'club' drug use among gay and bisexual high school students in British Columbia." *J Adolesc Health* 38(4): 458-61.
- Lampinen, T. M., D. McGhee, et al. (2006). "Use of crystal methamphetamine and other club drugs among high school students in Vancouver and Victoria." *BC Medical Journal* 48(1): 22-27.
- Martin, I., T. M. Lampinen, et al. (2006). "Methamphetamine use among marginalized youth in British Columbia." *Can J Public Health* 97(4): 320-4.
- Lee, S. J., M. Galanter, et al. (2003). "Circuit parties and patterns of drug use in a subset of gay men." *J Addict Dis* 22(4): 47-60.
- Mattison, A. M., M. W. Ross, et al. (2001). "Circuit party attendance, club drug use, and unsafe sex in gay men." *J Subst Abuse* 13(1-2): 119-26.
- Maxwell, J. C. and R. T. Spence (2005). "Profiles of club drug users in treatment." *Subst Use Misuse* 40(9): 1409-26.
- McCaughan, J. A., R. G. Carlson, et al. (2005). "From 'Candy Kids' to 'Chemi-Kids': A typology of young adults who attend raves in the midwestern United States." *Subst Use Misuse* 40(9-10): 1503-23.

- Parsons, J. T., B. C. Kelly, et al. (2006). "Differences in club drug use between heterosexual and lesbian/bisexual females." *Addict Behav* 31(12): 2344-9.
- Rawson, R. A., A. Washton, C. P. Domier and C. Reiber (2002). "Drugs and sexual effects: Role of drug type and gender." *J Subst Abuse Treat* 22(2): 103-8.
- Rome, E. S. (2001). "It's a rave new world: Rave culture and illicit drug use in the young." *Cleve Clin J Med* 68(6): 541-50.
- Ross, M. W., A. M. Mattison, et al. (2003). "Club drugs and sex on drugs are associated with different motivations for gay circuit party attendance in men." *Subst Use Misuse* 38(8): 1173-83.
- Rusch, M., T. M. Lampinen, A. Schilder and R. S. Hogg (2004). "Unprotected anal intercourse associated with recreational drug use among young men who have sex with men depends on partner type and intercourse role." *Sex Transm Dis* 31(8): 492-8.
- Swearingen, S. G. and J. D. Klausner (2005). "Sildenafil use, sexual risk behavior, and risk for sexually transmitted diseases, including HIV infection." *Am J Med* 118(6): 571-7.
- Tellier, P. P. (2002). "Club drugs: Is it all ecstasy?" *Pediatr Ann* 31(9): 550-6.
- Van Leeuwen, J. M., C. Hopfer, S. Hooks, R. White, J. Petersen and J. Pirkopf (2004). "A snapshot of substance abuse among homeless and runaway youth in Denver, Colorado." *J Community Health* 29(3): 217-29.
- Vogtsberger, K. N. (1989). "Designer drugs." *Tex Med* 85(7): 30-2.
- Worth, H. and P. Rawstorne (2005). "Crystallizing the HIV epidemic: Methamphetamine, unsafe sex, and gay diseases of the will." *Arch Sex Behav* 34(5): 483-6.

## Rectal Administration

- Cantrell, F. L., H. M. Breckenridge, et al. (2006). "Transrectal methamphetamine use: A novel route of exposure." *Ann Intern Med* 145(1): 78-9.
- Martin, I., T. M. Lampinen, et al. (2006). "Methamphetamine use among marginalized youth in British Columbia." *Can J Public Health* 97(4): 320-4.
- Menza, T. W., G. Colfax, et al. (2006). "Interest in a methamphetamine intervention among men who have sex with men." *Sex Transm Dis* 33(9): 565-70.
- Mitchell, S. J., S. R. Morris, et al. (2006). "Methamphetamine use and sexual activity among HIV-infected patients in care--San Francisco, 2004." *AIDS Patient Care STDS* 20(7): 502-10.

## Relapse

*See also Craving*

- Brecht, M. L., M. D. Anglin, et al. (2005). "Coerced treatment for methamphetamine abuse: Differential patient characteristics and outcomes." *Am J Drug Alcohol Abuse* 31(2): 337-56.
- Brecht, M. L., C. von Mayrhauser, et al. (2000). "Predictors of relapse after treatment for methamphetamine use." *J Psychoactive Drugs* 32(2): 211-20.
- Chang, L. and W. Haning (2006). "Insights from recent positron emission tomographic studies of drug abuse and dependence." *Curr Opin Psychiatry* 19(3): 246-252.
- Frawley, P. J. and J. W. Smith (1992). "One-year follow-up after multimodal inpatient treatment for cocaine and methamphetamine dependencies." *J Subst Abuse Treat* 9(4): 271-86.
- Paulus, M. P., S. F. Tapert, et al. (2005). "Neural activation patterns of methamphetamine-dependent subjects during decision making predict relapse." *Arch Gen Psychiatry* 62(7): 761-8.
- Simon, S. L., J. Dacey, et al. (2004). "The effect of relapse on cognition in abstinent methamphetamine abusers." *J Subst Abuse Treat* 27(1): 59-66.
- Ujike, H. and M. Sato (2004). "Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis." *Ann N Y Acad Sci* 1025: 279-87.
- Vazquez, E. (2005). "Crystal meth recovery. A step-by-step guide." *Posit Aware* 16(5): 20-2, 25.
- Walton, M. A., F. G. Castro, et al. (1994). "The role of attributions in abstinence, lapse, and relapse following substance abuse treatment." *Addict Behav* 19(3): 319-31.
- Yamamoto, T., K. Anggadiredja, et al. (2004). "New perspectives in the studies on endocannabinoid and cannabis: A role for the endocannabinoid-arachidonic acid pathway in drug reward and long-lasting relapse to drug taking." *J Pharmacol Sci* 96(4): 382-8.
- Yen, C. F. and Y. P. Chang (2005). "Relapse antecedents for methamphetamine use and related factors in Taiwanese adolescents." *Psychiatry Clin Neurosci* 59(1): 77-82.

Yen, C. F., H. Y. Wu, et al. (2004). "Effects of brief cognitive-behavioral interventions on confidence to resist the urges to use heroin and methamphetamine in relapse-related situations." *J Nerv Ment Dis* 192(11): 788-91.

Yui, K., K. Goto, et al. (1999). "Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: The role of sensitization." *Mol Psychiatry* 4(6): 512-23.

### Relapse (animals)

*See Craving (animals); Self-Administration of Methamphetamine (animals)*

### Religion and Spirituality

Herman-Stahl, M. A., C. P. Krebs, et al. (2006). "Risk and protective factors for nonmedical use of prescription stimulants and methamphetamine among adolescents." *J Adolesc Health* 39(3): 374-80.

### Repeated Behaviors

*See Stereotypic Behaviors; Stereotypic Behaviors (animals)*

### Reproductive Behaviors (animals)

Levy Andersen, M., M. Bignotto, et al. (2003). "Facilitation of ejaculation after methamphetamine administration in paradoxical sleep deprived rats." *Brain Res* 978(1-2): 31-7.

Saito, T. R., S. Aoki, et al. (1991). "Effects of methamphetamine on copulatory behavior in male rats." *Jikken Dobutsu* 40(4): 447-52.

### Reproductive System (animals)

*See also Estrogen; Pregnancy ; Testosterone*

Saito, M., M. Terada, et al. (1995). "[Effects of the long-term administration of methamphetamine on body weight, food intake, blood biochemistry and estrous cycle in rats]." *Exp Anim* 43(5): 747-54.

Slamberova, R., M. Pometlova, et al. (2006). "Postnatal development of rat pups is altered by prenatal methamphetamine exposure." *Prog Neuropsychopharmacol Biol Psychiatry* 30(1): 82-8.

Yamamoto, Y., K. Yamamoto, et al. (2002). "Methamphetamine induces apoptosis in seminiferous tubules in male mice testis." *Toxicol Appl Pharmacol* 178(3): 155-60.

Yamamoto, Y., K. Yamamoto, et al. (1999). "Effect of methamphetamine on male mice fertility." *J Obstet Gynaecol Res* 25(5): 353-8.

### Respiratory Disease

*See Pulmonary and Thoracic Disease*

### Review Articles

Akiyama, K., A. Kanzaki, et al. (1994). "Methamphetamine-induced behavioral sensitization and its implications for relapse of schizophrenia." *Schizophr Res* 12(3): 251-7.

Albertson, T. E., R. W. Derlet, et al. (1999). "Methamphetamine and the expanding complications of amphetamines." *West J Med* 170(4): 214-9.

Allen, A. and T. S. Cantrell (1989). "Synthetic reductions in clandestine amphetamine and methamphetamine laboratories: A review." *Forensic Sci Int* 42(3): 183-199.

Ando, K. (1996). "Test methods for predicting tardive toxicity of therapeutic drugs using laboratory animals." *J Toxicol Sci* 21(1): 105-7.

Antoniou, T. and A. L. Tseng (2002). "Interactions between recreational drugs and antiretroviral agents." *Ann Pharmacother* 36(10): 1598-1613.

Asanuma, M. and I. Miyazaki (2005). "[Expression profiling of molecules related to abused drug dependence and toxicity]." *Nippon Yakurigaku Zasshi* 126(1): 30-4, 42.

Bailey, D. N. (1987). "Amphetamine detection during toxicology screening of a university medical center patient population." *J Toxicol Clin Toxicol* 25(5): 399-409.

Baker, A. and S. Dawe (2005). "Amphetamine use and co-occurring psychological problems: Review of the literature and implications for treatment." *Australian Psychologist* 40(2): 88-95.



- Banken, J. A. (2004). "Drug abuse trends among youth in the United States." *Ann N Y Acad Sci* 1025: 465-71.
- Barr, A. M., W. J. Panenka, et al. (2006). "The need for speed: An update on methamphetamine addiction." *J Psychiatry Neurosci* 31(5): 301-313.
- Betarbet, R., T. B. Sherer, et al. (2002). "Animal models of Parkinson's disease." *Bioessays* 24(4): 308-18.
- Beebe, D. K. and E. Walley (1995). "Smokable methamphetamine ('ice'): An old drug in a different form." *Am Fam Physician* 51(2): 449-53.
- Bialek, M., P. Zaremba, et al. (2004). "Neuroprotective role of testosterone in the nervous system." *Pol J Pharmacol* 56(5): 509-18.
- Baumgarten, H. G. and L. Lachenmayer (2004). "Serotonin neurotoxins--past and present." *Neurotox Res* 6(7-8): 589-614.
- Birman, S. (2005). "Arousal mechanisms: Speedy flies don't sleep at night." *Curr Biol* 15(13): R511-3.
- Bisagno, V., R. Bowman, et al. (2003). "Functional aspects of estrogen neuroprotection." *Endocrine* 21(1): 33-41.
- Bonnet, M. H., T. J. Balkin, et al. (2005). "The use of stimulants to modify performance during sleep loss: A review by the sleep deprivation and Stimulant Task Force of the American Academy of Sleep Medicine." *Sleep* 28(9): 1163-87.
- Bray, G. A. (1993). "Use and abuse of appetite-suppressant drugs in the treatment of obesity." *Ann Intern Med* 119(7 Pt 2): 707-13.
- Brouwer, K. C., P. Case, et al. (2006). "Trends in production, trafficking, and consumption of methamphetamine and cocaine in Mexico." *Subst Use Misuse* 41(5): 707-27.
- Buchanan, J. F. and C. R. Brown (1988). "'Designer drugs': A problem in clinical toxicology." *Med Toxicol Adverse Drug Exp* 3(1): 1-17.
- Burchell, S. A., H. C. Ho, et al. (2000). "Effects of methamphetamine on trauma patients: A cause of severe metabolic acidosis?" *Crit Care Med* 28(6): 2112-5.
- Burton, B. T. (1991). "Heavy metal and organic contaminants associated with illicit methamphetamine production." *NIDA Res Monogr* 115: 47-59.
- Cabral, G. A. (2006). "Drugs of abuse, immune modulation, and AIDS." *Journal of NeuroImmune Pharmacology* 1(3): 280-295.
- Cadet, J. L., S. Jayanthi, et al. (2003). "Speed kills: Cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis." *FASEB J* 17(13): 1775-88.
- Cadet, J. L. (2001). "Molecular neurotoxicological models of Parkinsonism: Focus on genetic manipulation of mice." *Parkinsonism Relat Disord* 8(2): 85-90.
- Cadet, J. L. and C. Brannock (1998). "Free radicals and the pathobiology of brain dopamine systems." *Neurochem Int* 32(2): 117-31.
- Cadet, J. L., S. F. Ali, et al. (1995). "Neurotoxicity, drugs and abuse, and the CuZn-superoxide dismutase transgenic mice." *Mol Neurobiol* 11(1-3): 155-63.
- Caldicott, D. G., P. E. Pigou, et al. (2005). "Clandestine drug laboratories in Australia and the potential for harm." *Aust N Z J Public Health* 29(2): 155-62.
- Caldwell, J. and P. S. Sever (1974). "The biochemical pharmacology of abused drugs. Amphetamines, cocaine, and LSD." *Clin Pharmacol Ther* 16(4): 625-38.
- Caligiuri, M. P. and C. Buitenhuis (2005). "Do preclinical findings of methamphetamine-induced motor abnormalities translate to an observable clinical phenotype?" *Neuropsychopharmacology* 30(12): 2125-34.
- Chang, L. and W. Haning (2006). "Insights from recent positron emission tomographic studies of drug abuse and dependence." *Curr Opin Psychiatry* 19(3): 246-252.
- Charukamnoetkanok, P. and M. D. Wagoner (2004). "Facial and ocular injuries associated with methamphetamine production accidents." *Am J Ophthalmol* 138(5): 875-6.
- Cheng, J. Y., D. T. Chan, et al. (2005). "An epidemiological study on alcohol/drugs related fatal traffic crash cases of deceased drivers in Hong Kong between 1996 and 2000." *Forensic Sci Int* 153(2-3): 196-201.
- Cho, A. K. and W. P. Melega (2002). "Patterns of methamphetamine abuse and their consequences." *J Addict Dis* 21(1): 21-34.
- Cho, A. K., W. P. Melega, et al. (2001). "Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse." *Synapse* 39(2): 161-6.
- Cho, B. I. (1991). "Trends and patterns of methamphetamine abuse in the Republic of Korea." *NIDA Res Monogr* 115: 99-108.
- Chrisp, P., G. J. Mammen, et al. (1991). "Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease." *Drugs Aging* 1(3): 228-48.
- Christophersen, A. S. (2000). "Amphetamine designer drugs - An overview and epidemiology." *Toxicol Lett* 112-113: 127-31.
- Chomchai, C., N. Na Manorom, et al. (2004). "Methamphetamine abuse during pregnancy and its health impact on neonates born at Siriraj Hospital, Bangkok, Thailand." *Southeast Asian J Trop Med Public Health* 35(1): 228-31.
- Chung, H., M. Park, et al. (2004). "Recent trends of drug abuse and drug-associated deaths in Korea." *Ann N Y Acad Sci* 1025: 458-64.

- Chung, H. (1998). "Drug abuse trends and epidemiological aspects of drug associated deaths in Korea." *J Toxicol Sci* 23 Suppl 2: 197-200.
- Clatts, M. C., D. L. Welle, et al. (2001). "Reconceptualizing the interaction of drug and sexual risk among MSM speed users: Notes toward an ethno-epidemiology." *AIDS and Behavior* 5(2): 115-130.
- Clemens, K. J., J. L. Cornish, et al. (2006). "Intravenous methamphetamine self-administration in rats: Effects of intravenous or intraperitoneal MDMA co-administration." *Pharmacol Biochem Behav* 85(2): 454-63.
- Cody, J. T. (2002). "Precursor medications as a source of methamphetamine and/or amphetamine positive drug testing results." *J Occup Environ Med* 44(5): 435-50.
- Colfax, G. and R. Guzman (2006). "Club drugs and HIV infection: A review." *Clin Infect Dis* 42(10): 1463-9.
- Collins, C. L., T. Kerr, et al. (2005). "Rationale to evaluate medically supervised safer smoking facilities for non-injection illicit drug users." *Can J Public Health* 96(5): 344-7.
- Comings, D. E. and K. Blum (2000). "Reward deficiency syndrome: Genetic aspects of behavioral disorders." *Prog Brain Res* 126: 325-41.
- Cook, C. E. (1991). "Pyrolytic characteristics, pharmacokinetics, and bioavailability of smoked heroin, cocaine, phencyclidine, and methamphetamine." *NIDA Res Monogr* 115: 6-23.
- Copeland, A. L. and J. L. Sorensen (2001). "Differences between methamphetamine users and cocaine users in treatment." *Drug Alcohol Depend* 62(1): 91-5.
- Cox, C. and R. G. Smart (1970). "The nature and extent of speed use in North America." *Can Med Assoc J* 102(7): 724-9.
- Cretzmeyer, M., M. V. Sarrazin, et al. (2003). "Treatment of methamphetamine abuse: Research findings and clinical directions." *J Subst Abuse Treat* 24(3): 267-77.
- Crouch, D. J., M. M. Birky, et al. (1993). "The prevalence of drugs and alcohol in fatally injured truck drivers." *J Forensic Sci* 38(6): 1342-53.
- Csemy, L., L. Kubicka, et al. (2002). "Drug scene in the Czech Republic and Slovakia during the period of transformation." *Eur Addict Res* 8(4): 159-65.
- Curtis, E. K. (2006). "Meth mouth: A review of methamphetamine abuse and its oral manifestations." *Gen Dent* 54(2): 125-9.
- Danks, R. R., L. A. Wibbenmeyer, et al. (2004). "Methamphetamine-associated burn injuries: A retrospective analysis." *J Burn Care Rehabil* 25(5): 425-9.
- Davidson, C., A. J. Gow, et al. (2001). "Methamphetamine neurotoxicity: Necrotic and apoptotic mechanisms and relevance to human abuse and treatment." *Brain Res Brain Res Rev* 36(1): 1-22.
- Davies, J. K. and J. M. Bledsoe (2005). "Prenatal alcohol and drug exposures in adoption." *Pediatr Clin North Am* 52(5): 1369-93, vii.
- Davis, G. G. and C. I. Swallow (1996). "The incidence of acute cocaine or methamphetamine intoxication in deaths due to ruptured cerebral (berry) aneurysms." *J Forensic Sci* 41(4): 626-8.
- Davis, G. G. and C. I. Swallow (1994). "Acute aortic dissections and ruptured berry aneurysms associated with methamphetamine abuse." *J Forensic Sci* 39(6): 1481-5.
- Dawirs, R. R. and G. Teuchert-Noodt (2001). "A novel pharmacological concept in an animal model of psychosis." *Acta Psychiatr Scand Suppl*(408): 10-7.
- Dawson, R., Jr., M. F. Beal, et al. (1995). "Excitotoxins, aging, and environmental neurotoxins: Implications for understanding human neurodegenerative diseases." *Toxicol Appl Pharmacol* 134(1): 1-17.
- Derlet, R. W. and B. Z. Horowitz (1995). "Cardiotoxic drugs." *Emerg Med Clin North Am* 13(4): 771-91.
- Derlet, R. W. and B. Heischouer (1990). "Methamphetamine. Stimulant of the 1990s?" *West J Med* 153(6): 625-8.
- Dluzen, D. E. and J. L. McDermott (2004). "Developmental and genetic influences upon gender differences in methamphetamine-induced nigrostriatal dopaminergic neurotoxicity." *Ann N Y Acad Sci* 1025: 205-20.
- Dluzen, D. E. and J. L. McDermott (2002). "Estrogen, anti-estrogen, and gender: differences in methamphetamine neurotoxicity." *Ann N Y Acad Sci* 965: 136-56.
- Dluzen, D. E. (2000). "Neuroprotective effects of estrogen upon the nigrostriatal dopaminergic system." *J Neurocytol* 29(5-6): 387-99.
- Doleys, D. M. (1977). "Behavioral treatments for nocturnal enuresis in children: A review of the recent literature." *Psychol Bull* 84(1): 30-54.
- Dryhurst, G. (2001). "Are dopamine, norepinephrine, and serotonin precursors of biologically reactive intermediates involved in the pathogenesis of neurodegenerative brain disorders?" *Adv Exp Med Biol* 500: 373-96.
- Dwoskin, L. P. and P. A. Crooks (2002). "A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse." *Biochem Pharmacol* 63(2): 89-98.
- elSohly, M. A. and A. B. Jones (1995). "Drug testing in the workplace: could a positive test for one of the mandated drugs be for reasons other than illicit use of the drug?" *J Anal Toxicol* 19(6): 450-8.

- Fattore, L., M. S. Spano, et al. (2007). "An endocannabinoid mechanism in relapse to drug seeking: A review of animal studies and clinical perspectives." *Brain Res Brain Res Rev* 53(1): 1-16.
- Fleckenstein, A. E., J. W. Gibb, et al. (2000). "Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity." *Eur J Pharmacol* 406(1): 1-13.
- Fog, R. (1972). "On stereotypy and catalepsy: Studies on the effect of amphetamines and neuroleptics in rats." *Acta Neurol Scand Suppl* 50: 3-66.
- Fornai, F., F. Vaglini, et al. (1997). "Species differences in the role of excitatory amino acids in experimental parkinsonism." *Neurosci Biobehav Rev* 21(4): 401-15.
- Forney, R. (1977). "Drug impairment reviews: Stimulants." *NIDA Res Monogr Series* 11: 73-6.
- Forney, R., R. Martz, et al. (1976). "The combined effect of marihuana and dextroamphetamine." *Ann N Y Acad Sci* 281: 162-70.
- Fournier, M. E. and S. Levy (2006). "Recent trends in adolescent substance use, primary care screening, and updates in treatment options." *Curr Opin Pediatr* 18(4): 352-8.
- Frank, R. S. (1983). "The clandestine drug laboratory situation in the United States." *J Forensic Sci* 28(1): 18-31.
- Freese, T. E., K. Miotto, et al. (2002). "The effects and consequences of selected club drugs." *J Subst Abuse Treat* 23(2): 151-6.
- Friese, G. (2006). "The methamphetamine crisis. What EMS providers need to know to stay safe and treat patients." *Emerg Med Serv* 35(3): 55-64.
- Frost, D. O. and J. L. Cadet (2000). "Effects of methamphetamine-induced neurotoxicity on the development of neural circuitry: A hypothesis." *Brain Res Brain Res Rev* 34(3): 103-18.
- Fry, J. M. (1998). "Treatment modalities for narcolepsy." *Neurology* 50(2 Suppl 1): S43-8.
- Fuller, R. W. (1978). "Structure-activity relationships among the halogenated amphetamines." *Ann N Y Acad Sci* 305: 147-59.
- Gerlach, M. and P. Riederer (1996). "Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man." *J Neural Transm* 103(8-9): 987-1041.
- Geyer, M. A. (1996). "Serotonergic functions in arousal and motor activity." *Behav Brain Res* 73(1-2): 31-5.
- Ghaziani, A. and T. D. Cook (2005). "Reducing HIV infections at circuit parties: From description to explanation and principles of intervention design." *J Int Assoc Physicians AIDS Care (Chic Ill)* 4(2): 32-46.
- Gibb, J. W., M. Johnson, et al. (1990). "Neurochemical basis of neurotoxicity." *Neurotoxicology* 11(2): 317-21.
- Glittenberg, J. and C. Anderson (1999). "Methamphetamines: Use and trafficking in the Tucson-Nogales area." *Subst Use Misuse* 34(14): 1977-89.
- Goldberger, B. A. and E. J. Cone (1994). "Confirmatory tests for drugs in the workplace by gas chromatography-mass spectrometry." *J Chromatogr A* 674(1-2): 73-86.
- Goldstein, D. J., A. H. Rampey, Jr., et al. (1993). "Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction." *J Clin Psychiatry* 54(8): 309-16.
- Golembiowska, K., J. Konieczny, et al. (2002). "The role of striatal metabotropic glutamate receptors in degeneration of dopamine neurons." *Amino Acids* 23(1-3): 199-205.
- Golub, M., L. Costa, et al. (2005). "NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of amphetamine and methamphetamine." *Birth Defects Res B Dev Reprod Toxicol* 74(6): 471-584.
- Gorman, E. M. and R. T. Carroll (2000). "Substance abuse and HIV: Considerations with regard to methamphetamines and other recreational drugs for nursing practice and research." *J Assoc Nurses AIDS Care* 11(2): 51-62.
- Gorman, E. M., P. Morgan, et al. (1995). "Qualitative research considerations and other issues in the study of methamphetamine use among men who have sex with other men." *NIDA Res Monogr* 157: 156-81.
- Gottschalk, P. C., L. K. Jacobsen, et al. (1999). "Current concepts in pharmacotherapy of substance abuse." *Curr Psychiatry Rep* 1(2): 172-8.
- Gotway, M. B., S. R. Marder, et al. (2002). "Thoracic complications of illicit drug use: an organ system approach." *Radiographics* 22 Spec No: S119-35.
- Gouzoulis-Mayfrank, E. and J. Daumann (2006). "The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview." *J Psychopharmacol* 20(2): 188-93.
- Greberman, S. B. and K. Wada (1994). "Social and legal factors related to drug abuse in the United States and Japan." *Public Health Rep* 109(6): 731-7.
- Greenhill, L. L. (2006). "The science of stimulant abuse." *Pediatr Ann* 35(8): 552-6.
- Guilarte, T. R. (2001). "Is methamphetamine abuse a risk factor in parkinsonism?" *Neurotoxicology* 22(6): 725-31.
- Halkitis, P. N., J. T. Parsons, et al. (2001). "A double epidemic: Crystal methamphetamine drug use in relation to HIV transmission among gay men." *J Homosex* 41(2): 17-35.

- Hall, J. N. and P. M. Broderick (1991). "Community networks for response to abuse outbreaks of methamphetamine and its analogs." *NIDA Res Monogr* 115: 109-20.
- Haney, M. and T. R. Kosten (2004). "Therapeutic vaccines for substance dependence." *Expert Rev Vaccines* 3(1): 11-8.
- Hanson, G. R., K. S. Rau, et al. (2004). "The methamphetamine experience: A NIDA partnership." *Neuropharmacology* 47 Suppl 1: 92-100.
- Hanson, G. R., N. Singh, et al. (1992). "Responses of limbic and extrapyramidal neurotensin systems to stimulants of abuse. Involvement of dopaminergic mechanisms." *Ann N Y Acad Sci* 668: 165-72.
- Haroz, R. and M. I. Greenberg (2006). "New drugs of abuse in North America." *Clin Lab Med* 26(1): 147-64, ix.
- Hassler, R. and A. Wagner (1975). "Locomotor activity and speed of movements in relation to monoamine-acting drugs." *Int J Neurol* 10(1-4): 80-97.
- Heller, A., L. Won, et al. (1995). "Examination of developmental neurotoxicity by the use of tissue culture model systems." *Clin Exp Pharmacol Physiol* 22(5): 375-8.
- Helschober, B. and M. A. Miller (1991). "Methamphetamine abuse in California." *NIDA Res Monogr* 115: 60-71.
- Haroz, R. and M. I. Greenberg (2006). "New drugs of abuse in North America." *Clin Lab Med* 26(1): 147-64, ix.
- Holman, R. B., G. R. Elliott, et al. (1975). "Neuroregulators and sleep mechanisms." *Annu Rev Med* 26: 499-520.
- Imam, S. Z., J. el-Yazal, et al. (2001). "Methamphetamine-induced dopaminergic neurotoxicity: role of peroxynitrite and neuroprotective role of antioxidants and peroxynitrite decomposition catalysts." *Ann N Y Acad Sci* 939: 366-80.
- Inoue, H., N. Ikeda, et al. (2006). "Methamphetamine-related sudden death with a concentration which was of a 'toxic level'." *Leg Med (Tokyo)* 8(3): 150-5.
- Irvine, G. D. and L. Chin (1991). "The environmental impact and adverse health effects of the clandestine manufacture of methamphetamine." *NIDA Res Monogr* 115: 33-46.
- Itzhak, Y. and S. F. Ali (2006). "Role of nitrenergic system in behavioral and neurotoxic effects of amphetamine analogs." *Pharmacol Ther* 109(1-2): 246-62.
- Itzhak, Y. and C. Achat-Mendes (2004). "Methamphetamine and MDMA (ecstasy) neurotoxicity: 'Of mice and men'." *IUBMB Life* 56(5): 249-55.
- Iwabuchi, K., Y. Kubota, et al. (2004). "Methamphetamine and brain histamine: A study using histamine-related gene knockout mice." *Ann N Y Acad Sci* 1025: 129-34.
- Iyo, M. and Y. Sekine (2003). "[Stimulants related mental disorders]." *Ryoikibetsu Shokogun Shirizu*(40): 507-12.
- Jirovsky, D., K. Lemr, et al. (1998). "Methamphetamine--properties and analytical methods of enantiomer determination." *Forensic Sci Int* 96(1): 61-70.
- Joffe, G. M. and T. Kasnic (1994). "Medical prescription of dextroamphetamine during pregnancy." *J Perinatol* 14(4): 301-3.
- Kalbag, A. S. and F. R. Levin (2005). "Adult ADHD and substance abuse: Diagnostic and treatment issues." *Subst Use Misuse* 40(13-14): 1955-81.
- Kantak, K. M. (2003). "Vaccines against drugs of abuse: A viable treatment option?" *Drugs* 63(4): 341-52.
- Kishimoto, H. (2003). "[Stimulant dependence]." *Ryoikibetsu Shokogun Shirizu*(40): 505-6.
- Kita, T., G. C. Wagner, et al. (2003). "Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption." *J Pharmacol Sci* 92(3): 178-95.
- Kita, T. and T. Nakashima (2002). "[A recent trend in methamphetamine-induced neurotoxicity]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 22(2): 35-47.
- Kitaichi, K., Y. Morishita, et al. (2001). "[Pharmacokinetic behavioral changes of methamphetamine in methamphetamine-sensitized animal model]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 21(5): 133-44.
- Kiyatkin, E. A. (2005). "Brain hyperthermia as physiological and pathological phenomena." *Brain Res Brain Res Rev* 50(1): 27-56.
- Kiyatkin, E. A. (2004). "Brain hyperthermia during physiological and pathological conditions: causes, mechanisms, and functional implications." *Curr Neurovasc Res* 1(1): 77-90.
- Klein, M. and F. Kramer (2004). "Rave drugs: pharmacological considerations." *AANA J* 72(1): 61-7.
- Kleven, M. S. and L. S. Seiden (1992). "Methamphetamine-induced neurotoxicity: structure activity relationships." *Ann N Y Acad Sci* 654: 292-301.
- Kolecki, P. (1998). "Inadvertent methamphetamine poisoning in pediatric patients." *Pediatr Emerg Care* 14(6): 385-7.
- Kosman, M. E. and D. R. Unna (1968). "Effects of chronic administration of the amphetamines and other stimulants on behavior." *Clin Pharmacol Ther* 9(2): 240-54.
- Kosten, T. R. and P. G. O'Connor (2003). "Management of drug and alcohol withdrawal." *N Engl J Med* 348(18): 1786-95.

- Kraemer, T. and H. H. Maurer (2002). "Toxicokinetics of amphetamines: Metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives." *Ther Drug Monit* 24(2): 277-89.
- Kraemer, T. and H. H. Maurer (1998). "Determination of amphetamine, methamphetamine and amphetamine-derived designer drugs or medicaments in blood and urine." *J Chromatogr B Biomed Sci Appl* 713(1): 163-87.
- Kroutil, L. A., D. L. Van Brunt, et al. (2006). "Nonmedical use of prescription stimulants in the United States." *Drug Alcohol Depend.*
- Kuhn, D. M. (1999). "Tryptophan hydroxylase regulation. Drug-induced modifications that alter serotonin neuronal function." *Adv Exp Med Biol* 467: 19-27.
- Kulsudjarit, K. (2004). "Drug problem in southeast and southwest Asia." *Ann N Y Acad Sci* 1025: 446-57.
- Laties, V. G. (1975). "The role of discriminative stimuli in modulating drug action." *Fed Proc* 34(9): 1880-8.
- Leeds, N. E., V. Malhotra, et al. (1983). "The radiology of drug addiction affecting the brain." *Semin Roentgenol* 18(3): 227-33.
- Lessov, C. N., G. E. Swan, et al. (2004). "Genetics and drug use as a complex phenotype." *Subst Use Misuse* 39(10-12): 1515-69.
- Levi, M. S. and R. F. Borne (2002). "A review of chemical agents in the pharmacotherapy of addiction." *Curr Med Chem* 9(20): 1807-18.
- Lile, J. A. (2006). "Pharmacological determinants of the reinforcing effects of psychostimulants: Relation to agonist substitution treatment." *Exp Clin Psychopharmacol* 14(1): 20-33.
- Lineberry, T. W. and J. M. Bostwick (2006). "Methamphetamine abuse: A perfect storm of complications." *Mayo Clin Proc* 81(1): 77-84.
- Logan, B. K. (2001). "Amphetamines: An update on forensic issues." *J Anal Toxicol* 25(5): 400-4.
- Logan, B. K., C. L. Fligner, et al. (1998). "Cause and manner of death in fatalities involving methamphetamine." *J Forensic Sci* 43(1): 28-34.
- Logan, B. K. (1996). "Methamphetamine and driving impairment." *J Forensic Sci* 41(3): 457-64.
- Longo, M. C., S. M. Henry-Edwards, et al. (2004). "Impact of the heroin 'drought' on patterns of drug use and drug-related harms." *Drug Alcohol Rev* 23(2): 143-50.
- Longstreth, P. L. and M. Korobkin (1976). "Intrarenal arterial aneurysms." *CRC Crit Rev Clin Radiol Nucl Med* 8(1): 129-51.
- Loonam, T. M., P. A. Noailles, et al. (2003). "Substance P and cholecystokinin regulate neurochemical responses to cocaine and methamphetamine in the striatum." *Life Sci* 73(6): 727-39.
- Lundqvist, T. (2005). "Cognitive consequences of cannabis use: Comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions." *Pharmacol Biochem Behav* 81(2): 319-30.
- Malitz, S. and M. Kanzler (1970). "Effects of drugs on perception in man." *Res Publ Assoc Res Nerv Ment Dis* 48: 35-53.
- Mandel, S., E. Grunblatt, et al. (2003). "Neuroprotective strategies in Parkinson's disease: An update on progress." *CNS Drugs* 17(10): 729-62.
- Marschall, M. A., R. F. Dolezal, et al. (1991). "Chronic wounds and delusions of parasitosis in the drug abuser." *Plast Reconstr Surg* 88(2): 328-30.
- Marshall, G. A., C. M. Dixon, et al. (1991). "Substance abuse-related spontaneous bladder rupture: Report of 2 cases and review of the literature." *J Urol* 145(1): 135-7.
- Marschall, M. A., R. F. Dolezal, et al. (1991). "Chronic wounds and delusions of parasitosis in the drug abuser." *Plast Reconstr Surg* 88(2): 328-30.
- Mauceli, G., C. I. Busceti, et al. (2006). "Overexpression of alpha-synuclein following methamphetamine: Is it good or bad?" *Ann N Y Acad Sci* 1074: 191-7.
- Maxwell, J. C. (2005). "Emerging research on methamphetamine." *Curr Opin Psychiatry* 18(3): 235-42.
- McCann, U. D. and G. A. Ricaurte (2004). "Amphetamine neurotoxicity: Accomplishments and remaining challenges." *Neurosci Biobehav Rev* 27(8): 821-6.
- McGee, S. M., D. N. McGee, et al. (2004). "Spontaneous intracerebral hemorrhage related to methamphetamine abuse: Autopsy findings and clinical correlation." *Am J Forensic Med Pathol* 25(4): 334-7.
- McLane, N. J. and D. M. Carroll (1986). "Ocular manifestations of drug abuse." *Surv Ophthalmol* 30(5): 298-313.
- Meredith, C. W., C. Jaffe, et al. (2005). "Implications of chronic methamphetamine use: A literature review." *Harv Rev Psychiatry* 13(3): 141-54.
- Middaugh, L. D. (1989). "Prenatal amphetamine effects on behavior: Possible mediation by brain monoamines." *Ann N Y Acad Sci* 562: 308-18.
- Mieczkowski, T. and R. Newel (2000). "Statistical examination of hair color as a potential biasing factor in hair analysis." *Forensic Sci Int* 107(1-3): 13-38.
- Mitler, M. M., M. Erman, et al. (1993). "The treatment of excessive somnolence with stimulant drugs." *Sleep* 16(3): 203-6.
- Mizoguchi, H., Y. Noda, et al. (2005). "[Evaluation methods for the discriminative stimulus and possible mechanisms of discriminative stimulus effects of methamphetamine in the rat]." *Nippon Yakurigaku Zasshi* 126(1): 17-23.

- Mizugaki, M. (1996). "[Alterations in brain distribution of methamphetamine in methamphetamine-sensitized animals]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 16(5): 187-91.
- Moeller, M. R. and T. Kraemer (2002). "Drugs of abuse monitoring in blood for control of driving under the influence of drugs." *Ther Drug Monit* 24(2): 210-21.
- Moeller, M. R., S. Steinmeyer, et al. (1998). "Determination of drugs of abuse in blood." *J Chromatogr B Biomed Sci Appl* 713(1): 91-109.
- Morgan, J. P. (1992). "Amphetamine and methamphetamine during the 1990s." *Pediatr Rev* 13(9): 330-3.
- Morton, J. (2005). "Ecstasy: Pharmacology and neurotoxicity." *Curr Opin Pharmacol* 5(1): 79-86.
- Mukaida, M. (2003). "[Development of new analytical technologies and their applications for forensic medical examinations]." *Nippon Hoigaku Zasshi* 57(2): 135-44.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.
- Musshoff, F. (2000). "Illegal or legitimate use? Precursor compounds to amphetamine and methamphetamine." *Drug Metab Rev* 32(1): 15-44.
- Nakahara, Y. (1995). "Detection and diagnostic interpretation of amphetamines in hair." *Forensic Sci Int* 70(1-3): 135-53.
- Nakajima, A., K. Yamada, et al. (2003). "[Role of cytokines in drug dependence]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 23(4): 179-82.
- Nakamura, H. (2001). "[Positron emission tomography (PET) study of the alterations in brain pharmacokinetics of methamphetamine in methamphetamine sensitized animals]." *Yakugaku Zasshi* 121(8): 585-91.
- Nakatani, Y. and T. Hara (1998). "Disturbance of consciousness due to methamphetamine abuse. A study of 2 patients." *Psychopathology* 31(3): 131-7.
- Namera, A. (2004). "[Practical analysis of toxic substances useful for clinical toxicology--Methamphetamine]." *Chudoku Kenkyu* 17(3): 281-5.
- Narita, M., M. Miyatake, et al. (2005). "[Implication of glial function in the development of drug dependence associated with synaptic plasticity]." *Nippon Yakurigaku Zasshi* 126(1): 43-8.
- Nath, A., K. F. Hauser, et al. (2002). "Molecular basis for interactions of HIV and drugs of abuse." *J Acquir Immune Defic Syndr* 31 Suppl 2: S62-9.
- Nath, A., C. Anderson, et al. (2000). "Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia." *J Psychopharmacol* 14(3): 222-7.
- Newmeyer, J. A. (2003). "Patterns and trends of drug use in the San Francisco Bay Area." *J Psychoactive Drugs* 35(Suppl 1): 127-32.
- Nordahl, T. E., R. Salo, et al. (2003). "Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: A review." *J Neuropsychiatry Clin Neurosci* 15(3): 317-25.
- NTP-CERHR (2005). "NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines." *NTP CEHR Mon*(16): i-III1.
- Obert, J. L., E. D. London, et al. (2002). "Incorporating brain research findings into standard treatment: An example using the Matrix Model." *J Subst Abuse Treat* 23(2): 107-13.
- Ogai, Y., A. Haraguchi, et al. (2005). "[Control of craving for methamphetamine: Development of scales for dependence and search for medicines for treatment]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 25(5): 227-33.
- Ogasawara, K., A. Ogawa, et al. (1986). "[Intracerebral hemorrhage and characteristic angiographic changes associated with methamphetamine--A case report]." *No To Shinkei* 38(10): 967-71.
- O'Halloran, R. L. and L. V. Lewman (1993). "Restraint asphyxiation in excited delirium." *Am J Forensic Med Pathol* 14(4): 289-95.
- Ohmori, T., T. Abekawa, et al. (1997). "[Context-dependent sensitization: reconsideration and a hypothesis]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 17(2): 61-8.
- Ohmori, T., T. Abekawa, et al. (1996). "The role of glutamate in behavioral and neurotoxic effects of methamphetamine." *Neurochem Int* 29(3): 301-7.
- Onaivi, E. S., S. F. Ali, et al. (2002). "Ibogaine signals addiction genes and methamphetamine alteration of long-term potentiation." *Ann N Y Acad Sci* 965: 28-46.
- Ossowska, K. (1994). "The role of excitatory amino acids in experimental models of Parkinson's disease." *J Neural Transm Park Dis Dement Sect* 8(1-2): 39-71.
- Osugi, T., Y. Aoki, et al. (1994). "[Involvement of gene expression in drug tolerance and dependence]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 14(4): 185-93.
- Parker, L. A. (1995). "Rewarding drugs produce taste avoidance, but not taste aversion." *Neurosci Biobehav Rev* 19(1): 143-57.
- Patterson, T. L. and S. J. Semple (2003). "Sexual risk reduction among HIV-positive drug-using men who have sex with men." *J Urban Health* 80(4 Suppl 3): iii77-87.

- Phillips, T. R., J. N. Billaud, et al. (2000). "Methamphetamine and HIV-1: Potential interactions and the use of the FIV/cat model." *J Psychopharmacol* 14(3): 244-50.
- Pope, H. G., Jr. and J. I. Hudson (1986). "Antidepressant drug therapy for bulimia: Current status." *J Clin Psychiatry* 47(7): 339-45.
- Powrozek, T. A., Y. Sari, et al. (2004). "Neurotransmitters and substances of abuse: Effects on adult neurogenesis." *Curr Neurovasc Res* 1(3): 251-60.
- Plessinger, M. A. (1998). "Prenatal exposure to amphetamines. Risks and adverse outcomes in pregnancy." *Obstet Gynecol Clin North Am* 25(1): 119-38.
- Pope, H. G., Jr. and J. I. Hudson (1986). "Antidepressant drug therapy for bulimia: Current status." *J Clin Psychiatry* 47(7): 339-45.
- Popper, C. W. (1997). "Antidepressants in the treatment of attention-deficit/hyperactivity disorder." *J Clin Psychiatry* 58 Suppl 14: 14-29; discussion 30-1.
- Poshyachinda, V. (1993). "Drug injecting and HIV infection among the population of drug abusers in Asia." *Bull Narc* 45(1): 77-90.
- Powrozek, T. A., Y. Sari, et al. (2004). "Neurotransmitters and substances of abuse: Effects on adult neurogenesis." *Curr Neurovasc Res* 1(3): 251-60.
- Quinton, M. S. and B. K. Yamamoto (2006). "Causes and consequences of methamphetamine and MDMA toxicity." *AAPS J* 8(2): E337-47.
- Randrup, A., G. Sorensen, et al. (1988). "Stereotyped behaviour in animals induced by stimulant drugs or by a restricted cage environment: Relation to disintegrated behaviour, brain dopamine and psychiatric disease." *Yakubutsu Seishin Kodo* 8(2): 313-27.
- Rawson, R. A., R. Gonzales, et al. (2005). "Methamphetamine use among treatment-seeking adolescents in Southern California: Participant characteristics and treatment response." *J Subst Abuse Treat* 29(2): 67-74.
- Rawson, R. A., M. D. Anglin, et al. (2002). "Will the methamphetamine problem go away?" *J Addict Dis* 21(1): 5-19.
- Rawson, R. A. and J. L. Obert (2002). "The substance abuse treatment system in the U.S. What is it? What does it do? Myths and misconceptions." *Occup Med* 17(1): 27-39, iii-iv.
- Rawson, R. A., R. Gonzales, et al. (2002). "Treatment of methamphetamine use disorders: An update." *J Subst Abuse Treat* 23(2): 145-50.
- Rawson, R. A., M. J. McCann, et al. (2000). "Addiction pharmacotherapy 2000: New options, new challenges." *J Psychoactive Drugs* 32(4): 371-8.
- Reback, C. J. and C. E. Grella (1999). "HIV risk behaviors of gay and bisexual male methamphetamine users contacted through street outreach." *Journal of Drug Issues* 29(1): 155-66.
- Ricaurte, G. A. and U. D. McCann (1992). "Neurotoxic amphetamine analogues: Effects in monkeys and implications for humans." *Ann N Y Acad Sci* 648: 371-82.
- Richards, J. R., S. W. Bretz, et al. (1999). "Methamphetamine abuse and emergency department utilization." *West J Med* 170(4): 198-202.
- Riddle, E. L., A. E. Fleckenstein, et al. (2006). "Mechanisms of methamphetamine-induced dopaminergic neurotoxicity." *AAPS J* 8(2): E413-8.
- Rimsza, M. E. and K. S. Moses (2005). "Substance abuse on the college campus." *Pediatr Clin North Am* 52(1): 307-19, xii.
- Robinson, T. E., E. Castaneda, et al. (1990). "Compensatory changes in striatal dopamine neurons following recovery from injury induced by 6-OHDA or methamphetamine: A review of evidence from microdialysis studies." *Can J Psychol* 44(2): 253-75.
- Romanelli, F. and K. M. Smith (2006). "Clinical effects and management of methamphetamine abuse." *Pharmacotherapy* 26(8): 1148-56.
- Romanelli, F. and K. M. Smith (2004). "Recreational use of sildenafil by HIV-positive and -negative homosexual/bisexual males." *Ann Pharmacother* 38(6): 1024-30.
- Rome, E. S. (2001). "It's a rave new world: Rave culture and illicit drug use in the young." *Cleve Clin J Med* 68(6): 541-50.
- Rotheram-Borus, M. J., G. C. Luna, et al. (1994). "Going nowhere fast: Methamphetamine use and HIV infection." *NIDA Res Monogr* 143: 155-82.
- Rothman, R. B., J. S. Partilla, et al. (2000). "Methamphetamine dependence: Medication development efforts based on the dual deficit model of stimulant addiction." *Ann N Y Acad Sci* 914: 71-81.
- Rowland, M. and A. H. Beckett (1966). "The amphetamines: Clinical and pharmacokinetic implications of recent studies of an assay procedure and urinary excretion in man." *Arzneimittelforschung* 16(11): 1369-73.
- Rusyniak, D. E. and J. E. Sprague (2005). "Toxin-induced hyperthermic syndromes." *Med Clin North Am* 89(6): 1277-96.
- Saini, T., P. C. Edwards, et al. (2005). "Etiology of xerostomia and dental caries among methamphetamine abusers." *Oral Health Prev Dent* 3(3): 189-95.
- Sato, M. (2002). "[Basic and clinical studies on methamphetamine-related psychosis]." *Seishin Shinkeigaku Zasshi* 104(3): 179-90.

- Sato, M., Y. Numachi, et al. (1992). "Relapse of paranoid psychotic state in methamphetamine model of schizophrenia." *Schizophr Bull* 18(1): 115-22.
- Sattar, S. P., S. C. Bhatia, et al. (2004). "Potential benefits of quetiapine in the treatment of substance dependence disorders." *J Psychiatry Neurosci* 29(6): 452-7.
- Schermer, C. R. and D. H. Wisner (1999). "Methamphetamine use in trauma patients: A population-based study." *J Am Coll Surg* 189(5): 442-9.
- Schuster, C. R. and M. W. Fischman (1975). "Amphetamine toxicity: Behavioral and neuropathological indexes." *Fed Proc* 34(9): 1845-51.
- Segura Aguilar, J. and R. M. Kostrzewa (2004). "Neurotoxins and neurotoxic species implicated in neurodegeneration." *Neurotox Res* 6(7-8): 615-30.
- Seiden, L. S. and K. E. Sabol (1996). "Methamphetamine and methylenedioxymethamphetamine neurotoxicity: Possible mechanisms of cell destruction." *NIDA Res Monogr* 163: 251-76.
- Selden, L. S. (1991). "Neurotoxicity of methamphetamine: Mechanisms of action and issues related to aging." *NIDA Res Monogr* 115: 24-32.
- Seiden, L. S., D. L. Commins, et al. (1988). "Neurotoxicity in dopamine and 5-hydroxytryptamine terminal fields: A regional analysis in nigrostriatal and mesolimbic projections." *Ann N Y Acad Sci* 537: 161-72.
- Seiden, L. S. and M. S. Kleven (1989). "Methamphetamine and related drugs: Toxicity and resulting behavioral changes in response to pharmacological probes." *NIDA Res Monogr* 94: 146-60.
- Sellers, E. M. and R. F. Tyndale (2000). "Mimicking gene defects to treat drug dependence." *Ann N Y Acad Sci* 909: 233-46.
- Sevarino, K. A., A. Oliveto, et al. (2000). "Neurobiological adaptations to psychostimulants and opiates as a basis of treatment development." *Ann N Y Acad Sci* 909: 51-87.
- Shearer, J. and L. R. Gowing (2004). "Pharmacotherapies for problematic psychostimulant use: A review of current research." *Drug Alcohol Rev* 23(2): 203-11.
- Shearer, J., J. Sherman, et al. (2002). "Substitution therapy for amphetamine users." *Drug Alcohol Rev* 21(2): 179-85.
- Sheridan, J., S. Bennett, et al. (2006). "Injury associated with methamphetamine use: A review of the literature." *Harm Reduct J* 3(1): 14.
- Shimazono, Y. and E. Matsushima (1995). "Behavioral and neuroimaging studies on schizophrenia in Japan." *Psychiatry Clin Neurosci* 49(1): 3-11.
- Shippee, R. L. and D. J. Kippenberger (2000). "Retrospective study of urinalysis for dl-amphetamine and dl-methamphetamine analysis under current Department of Defense guidelines." *J Anal Toxicol* 24(6): 450-2.
- Smirnov, A. V. (1990). "[Psychomotor stimulants as agents for enhancing work capacity]." *Farmakol Toksikol* 53(4): 72-7.
- Smith, D. E., R. B. Seymour, et al. (1992). "Anthology series. I: Smokable drugs." *J Psychoactive Drugs* 24(2): 91-8.
- Smith, N. T. and A. N. Corbascio (1970). "The use and misuse of pressor agents." *Anesthesiology* 33(1): 58-101.
- Sonsalla, P. K., D. S. Albers, et al. (1998). "Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism." *Amino Acids* 14(1-3): 69-74.
- Sonsalla, P. K. (1995). "The role of N-methyl-D-aspartate receptors in dopaminergic neuropathology produced by the amphetamines." *Drug Alcohol Depend* 37(2): 101-5.
- Sonsalla, P. K., A. Giovanni, et al. (1992). "Characteristics of dopaminergic neurotoxicity produced by MPTP and methamphetamine." *Ann N Y Acad Sci* 648: 229-38.
- Srisurapanont, M., N. Jarusuraisin, et al. (2001). "Treatment for amphetamine dependence and abuse." *Cochrane Database Syst Rev*(4): CD003022.
- Srisurapanont, M., N. Jarusuraisin, et al. (2001). "Treatment for amphetamine withdrawal." *Cochrane Database Syst Rev*(4): CD003021.
- Srisurapanont, M., P. Kittiratanapaiboon, et al. (2001). "Treatment for amphetamine psychosis." *Cochrane Database Syst Rev*(4): CD003026.
- Su, T. P. (2000). "Delta opioid peptide[D-Ala(2),D-Leu(5)]enkephalin promotes cell survival." *J Biomed Sci* 7(3): 195-9.
- Sudakin, D. L. (2005). "Occupational exposure to aluminium phosphide and phosphine gas? A suspected case report and review of the literature." *Hum Exp Toxicol* 24(1): 27-33.
- Sulzer, D., M. S. Sonders, et al. (2005). "Mechanisms of neurotransmitter release by amphetamines: A review." *Prog Neurobiol* 75(6): 406-33.
- Suttijitpaisal, P. and K. Ratanabanangkoon (1992). "Immunoassays of amphetamines: immunogen structure vs antibody specificity." *Asian Pac J Allergy Immunol* 10(2): 159-64.
- Suwanwela, C. and V. Poshyachinda (1986). "Drug abuse in Asia." *Bull Narc* 38(1-2): 41-53.
- Swalwell, C. I. and G. G. Davis (1999). "Methamphetamine as a risk factor for acute aortic dissection." *J Forensic Sci* 44(1): 23-6.



- Swearingen, S. G. and J. D. Klausner (2005). "Sildenafil use, sexual risk behavior, and risk for sexually transmitted diseases, including HIV infection." *Am J Med* 118(6): 571-7.
- Swenson, J. R., J. E. Dimsdale, E. Rockwell, W. Carroll and J. Hansbrough (1991). "Drug and alcohol abuse in patients with acute burn injuries." *Psychosomatics* 32(3): 287-93.
- Tadokoro, S. and H. Kuribara (1990). "[Modification of the behavioral effects of drugs after repeated administration--Special reference to the reverse tolerance of amphetamines]." *Nippon Yakurigaku Zasshi* 95(5): 229-38.
- Takahashi, M. and S. Tokuyama (1998). "Pharmacological and physiological effects of ginseng on actions induced by opioids and psychostimulants." *Methods Find Exp Clin Pharmacol* 20(1): 77-84.
- Takayama, N., R. Iio, et al. (2003). "Analysis of methamphetamine and its metabolites in hair." *Biomed Chromatogr* 17(2-3): 74-82.
- Takigawa, M. (1999). "[Mechanism involved in substance dependence--from the view point of the reward system]." *Seishin Shinkeigaku Zasshi* 101(10): 789-93.
- Tashkin, D. P. (2001). "Airway effects of marijuana, cocaine, and other inhaled illicit agents." *Curr Opin Pulm Med* 7(2): 43-61.
- Tellier, P. P. (2002). "Club drugs: Is it all ecstasy?" *Pediatr Ann* 31(9): 550-6.
- Thadani, P. V. (1995). "Biological mechanisms and perinatal exposure to abused drugs." *Synapse* 19(3): 228-32.
- Thirthalli, J. and V. Benegal (2006). "Psychosis among substance users." *Curr Opin Psychiatry* 19(3): 239-45.
- Tokuyama, S. and M. Takahashi (2001). "[Pharmacological and physiological effects of ginseng on actions induced by opioids and psychostimulants]." *Nippon Yakurigaku Zasshi* 117(3): 195-201.
- Tolstoi, L. G. (1989). "The role of pharmacotherapy in anorexia nervosa and bulimia." *J Am Diet Assoc* 89(11): 1640-6.
- Tolwani, R. J., M. W. Jakowec, et al. (1999). "Experimental models of Parkinson's disease: Insights from many models." *Lab Anim Sci* 49(4): 363-71.
- Topp, L., C. Day, et al. (2003). "Changes in patterns of drug injection concurrent with a sustained reduction in the availability of heroin in Australia." *Drug Alcohol Depend* 70(3): 275-86.
- Tsai, S. J. (2007). "Increased central brain-derived neurotrophic factor activity could be a risk factor for substance abuse: Implications for treatment." *Med Hypotheses* 68(2): 410-4.
- Turnipseed, S. D., J. R. Richards, et al. (2003). "Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after methamphetamine use." *J Emerg Med* 24(4): 369-73.
- Ueyama, H. and T. Kumamoto (2001). "[Myopathies in drug addicts]." *Ryoikibetsu Shokogun Shirizu*(36): 267-70.
- Ujike, H. and M. Sato (2004). "Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis." *Ann N Y Acad Sci* 1025: 279-87.
- Ujike, H., M. Takaki, et al. (2002). "Gene expression related to synaptogenesis, neuritogenesis, and MAP kinase in behavioral sensitization to psychostimulants." *Ann N Y Acad Sci* 965: 55-67.
- Urbina, A. and K. Jones (2004). "Crystal methamphetamine, its analogues, and HIV infection: Medical and psychiatric aspects of a new epidemic." *Clin Infect Dis* 38(6): 890-4.
- Vandevenne, M., H. Vandebussche, et al. (2000). "Detection time of drugs of abuse in urine." *Acta Clin Belg* 55(6): 323-33.
- Verachai, V., S. Dechongkit, et al. (2001). "Drug addicts treatment for ten years in Thanyarak Hospital (1989-1998)." *J Med Assoc Thai* 84(1): 24-9.
- Virmani, A., F. Gaetani, et al. (2003). "Possible mechanism for the neuroprotective effects of L-carnitine on methamphetamine-evoked neurotoxicity." *Ann N Y Acad Sci* 993: 197-207; discussion 287-8.
- Vocci, F. J., J. Acri, et al. (2005). "Medication development for addictive disorders: The state of the science." *Am J Psychiatry* 162(8): 1432-40.
- Vogtsberger, K. N. (1989). "Designer drugs." *Tex Med* 85(7): 30-2.
- Volkow, N. D., J. S. Fowler, et al. (2002). "Role of dopamine in drug reinforcement and addiction in humans: Results from imaging studies." *Behav Pharmacol* 13(5-6): 355-66.
- Volz, T. J. and J. O. Schenk (2005). "A comprehensive atlas of the topography of functional groups of the dopamine transporter." *Synapse* 58(2): 72-94.
- Vorhees, C. V. (1997). "Methods for detecting long-term CNS dysfunction after prenatal exposure to neurotoxins." *Drug Chem Toxicol* 20(4): 387-99.
- Vorhees, C. V. and C. Pu (1995). "Ontogeny of methamphetamine-induced neurotoxicity in the rat model." *NIDA Res Monogr* 158: 149-71.
- Vorhees, C. V. (1994). "Developmental neurotoxicity induced by therapeutic and illicit drugs." *Environ Health Perspect* 102 Suppl 2: 145-53.
- Wada, K. (2004). "[HCV infection among narcotics/methamphetamine abusers]." *Nippon Rinsho* 62 Suppl 7(Pt 1): 326-9.

- Wada, K. (1994). "Cocaine abuse in Japan." *Arukuru Kenkyuto Yakubutsu Ison* 29(2): 83-91.
- Wang, G. J., N. D. Volkow, et al. (2004). "Similarity between obesity and drug addiction as assessed by neurofunctional imaging: A concept review." *J Addict Dis* 23(3): 39-53.
- Wardas, J. (2002). "Neuroprotective role of adenosine in the CNS." *Pol J Pharmacol* 54(4): 313-26.
- Warner, P., J. P. Connolly, et al. (2003). "The methamphetamine burn patient." *J Burn Care Rehabil* 24(5): 275-8.
- Watanabe, T. and K. Yanai (2001). "Studies on functional roles of the histaminergic neuron system by using pharmacological agents, knockout mice and positron emission tomography." *Tohoku J Exp Med* 195(4): 197-217.
- Watanabe, T. (1997). "[Histaminergic neuron system and neural plasticity]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 17(4): 169-73.
- Weissman, B. A., R. Brandeis, et al. (2004). "Monitoring drug-induced neurodegeneration by imaging of peripheral benzodiazepine receptors." *Ann N Y Acad Sci* 1025: 584-9.
- Wesson, D. R. and P. Washburn (1990). "Current patterns of drug abuse that involve smoking." *NIDA Res Monogr* 99: 5-11.
- Wijetunga, M., T. Seto, J. Lindsay and I. Schatz (2003). "Crystal methamphetamine-associated cardiomyopathy: Tip of the iceberg?" *J Toxicol Clin Toxicol* 41(7): 981-6.
- Willers-Russo, L. J. (1999). "Three fatalities involving phosphine gas, produced as a result of methamphetamine manufacturing." *J Forensic Sci* 44(3): 647-52.
- Wolkoff, D. A. (1997). "Methamphetamine abuse: An overview for health care professionals." *Hawaii Med J* 56(2): 34-6, 44.
- Wrona, M. Z., Z. Yang, et al. (1997). "Potential new insights into the molecular mechanisms of methamphetamine-induced neurodegeneration." *NIDA Res Monogr* 173: 146-74.
- Wynn, R. L. (1997). "Dental considerations of patients taking appetite suppressants." *Gen Dent* 45(4): 324-8, 330-1.
- Yamada, K., T. Nagai, et al. (2005). "Drug dependence, synaptic plasticity, and tissue plasminogen activator." *J Pharmacol Sci* 97(2): 157-61.
- Yamada, K., T. Nagai, et al. (2005). "[Pro- and anti-addictive factors related to drug addiction]." *Nippon Yakurigaku Zasshi* 126(1): 49-53.
- Yamamoto, B. K. and M. G. Bankson (2005). "Amphetamine neurotoxicity: Cause and consequence of oxidative stress." *Crit Rev Neurobiol* 17(2): 87-118.
- Yamamoto, T., K. Anggadiredja, et al. (2004). "New perspectives in the studies on endocannabinoid and cannabis: A role for the endocannabinoid-arachidonic acid pathway in drug reward and long-lasting relapse to drug taking." *J Pharmacol Sci* 96(4): 382-8.
- Yang, J. (2004). "[The study developments about changes of methamphetamine-induced genes' transcriptions and translations]." *Fa Yi Xue Za Zhi* 20(3): 185-8.
- Yasar, S., J. P. Goldberg, et al. (1996). "Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research." *J Neural Transm Suppl* 48: 61-73.
- Youdim, M. B., O. Bar Am, et al. (2005). "Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition." *J Neurosci Res* 79(1-2): 172-9.
- Yu, Q., D. F. Larson, et al. (2003). "Heart disease, methamphetamine and AIDS." *Life Sci* 73(2): 129-40.
- Yui, K. and S. Ikemoto (2004). "[Stress sensitization induced by stressor and methamphetamine]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 24(3): 151-7.
- Yui, K., S. Ikemoto, et al. (2000). "Studies of amphetamine or methamphetamine psychosis in Japan: Relation of methamphetamine psychosis to schizophrenia." *Ann N Y Acad Sci* 914: 1-12.
- Yui, K., K. Goto, et al. (1999). "Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: The role of sensitization." *Mol Psychiatry* 4(6): 512-23.
- Zenilman, J. M. (2005). "Behavioral interventions--rationale, measurement, and effectiveness." *Infect Dis Clin North Am* 19(2): 541-62.
- Zhang, Y., T. M. Loonam, et al. (2001). "Comparison of cocaine- and methamphetamine-evoked dopamine and glutamate overflow in somatodendritic and terminal field regions of the rat brain during acute, chronic, and early withdrawal conditions." *Ann N Y Acad Sci* 937: 93-120.
- Zimmerman, E. F. (1991). "Substance abuse in pregnancy: Teratogenesis." *Pediatr Ann* 20(10): 541-4, 546-7.

### Reward System

*See also Craving*

- Comings, D. E. and K. Blum (2000). "Reward deficiency syndrome: Genetic aspects of behavioral disorders." *Prog Brain Res* 126: 325-41.

- Ellison, G. (2002). "Neural degeneration following chronic stimulant abuse reveals a weak link in brain, fasciculus retroflexus, implying the loss of forebrain control circuitry." *Eur Neuropsychopharmacol* 12(4): 287-97.
- Hart, C. L., A. S. Ward, et al. (2001). "Methamphetamine self-administration by humans." *Psychopharmacology (Berl)* 157(1): 75-81.
- Johnson, B. A., J. D. Roache, et al. (1999). "Isradipine, a dihydropyridine-class calcium channel antagonist, attenuates some of d-methamphetamine's positive subjective effects: A preliminary study." *Psychopharmacology (Berl)* 144(3): 295-300.
- Kawamura, T., Y. Ichitani, et al. (2005). "[Rewarding property of nicotine and methamphetamine tested by conditioned place preference in rats: Effect of chronic nicotine pretreatment]." *Shinrigaku Kenkyu* 76(1): 57-62.
- Nordahl, T. E., R. Salo, et al. (2002). "Low N-acetyl-aspartate and high choline in the anterior cingulum of recently abstinent methamphetamine-dependent subjects: A preliminary proton MRS study. Magnetic resonance spectroscopy." *Psychiatry Res* 116(1-2): 43-52.
- Onaivi, E. S., S. F. Ali, et al. (2002). "Ibogaine signals addiction genes and methamphetamine alteration of long-term potentiation." *Ann N Y Acad Sci* 965: 28-46.
- Takigawa, M. (1999). "[Mechanism involved in substance dependence--from the view point of the reward system]." *Seishin Shinkeigaku Zasshi* 101(10): 789-93.
- Tsai, S. J. (2007). "Increased central brain-derived neurotrophic factor activity could be a risk factor for substance abuse: Implications for treatment." *Med Hypotheses* 68(2): 410-4.
- Volkow, N. D., J. S. Fowler and G. J. Wang (2002). "Role of dopamine in drug reinforcement and addiction in humans: Results from imaging studies." *Behav Pharmacol* 13(5-6): 355-66.
- Vollm, B. A., I. E. de Araujo, et al. (2004). "Methamphetamine activates reward circuitry in drug naive human subjects." *Neuropsychopharmacology* 29(9): 1715-22.
- Wang, G. J., N. D. Volkow, et al. (2004). "Similarity between obesity and drug addiction as assessed by neurofunctional imaging: A concept review." *J Addict Dis* 23(3): 39-53.
- Yamamoto, T., K. Anggadiredja, et al. (2004). "New perspectives in the studies on endocannabinoid and cannabis: A role for the endocannabinoid-arachidonic acid pathway in drug reward and long-lasting relapse to drug taking." *J Pharmacol Sci* 96(4): 382-8.

## Reward System (animals)

*See also* Conditioned Place Preference; Self-Administration of Methamphetamine

- Ellison, G. (2002). "Neural degeneration following chronic stimulant abuse reveals a weak link in brain, fasciculus retroflexus, implying the loss of forebrain control circuitry." *Eur Neuropsychopharmacol* 12(4): 287-97.
- Geisler, S. and D. S. Zahm (2006). "Neurotensin afferents of the ventral tegmental area in the rat: [1] re-examination of their origins and [2] responses to acute psychostimulant and antipsychotic drug administration." *Eur J Neurosci* 24(1): 116-34.
- Itzhak, Y., J. L. Martin, et al. (2002). "Methamphetamine-induced dopaminergic neurotoxicity in mice: Long-lasting sensitization to the locomotor stimulation and desensitization to the rewarding effects of methamphetamine." *Prog Neuropsychopharmacol Biol Psychiatry* 26(6): 1177-83.
- Kawamura, T., Y. Ichitani, et al. (2005). "[Rewarding property of nicotine and methamphetamine tested by conditioned place preference in rats: Effect of chronic nicotine pretreatment]." *Shinrigaku Kenkyu* 76(1): 57-62.
- Kitanaka, N., J. Kitanaka, et al. (2006). "Methamphetamine reward in mice as assessed by conditioned place preference test with Supermex sensors: Effect of subchronic clorgyline pretreatment." *Neurochem Res* 31(6): 805-13.
- Kliethermes, C. L., H. M. Kamens, et al. (2006). "Drug reward and intake in lines of mice selectively bred for divergent exploration of a hole board apparatus." *Genes Brain Behav*.
- Kusayama, T. and S. Watanabe (2000). "Reinforcing effects of methamphetamine in planarians." *Neuroreport* 11(11): 2511-3.
- Li, S. M., Y. H. Ren, et al. (2002). "Effect of 7-nitroindazole on drug-priming reinstatement of D-methamphetamine-induced conditioned place preference." *Eur J Pharmacol* 443(1-3): 205-6.
- Li, S. M., L. L. Yin, et al. (2002). "The effect of 7-nitroindazole on the acquisition and expression of D-methamphetamine-induced place preference in rats." *Eur J Pharmacol* 435(2-3): 217-23.
- Li, S. M., L. L. Yin, et al. (2001). "GABA(B) receptor agonist baclofen attenuates the development and expression of d-methamphetamine-induced place preference in rats." *Life Sci* 70(3): 349-56.
- Masukawa, Y., T. Suzuki, et al. (1993). "Differential modification of the rewarding effects of methamphetamine and cocaine by opioids and antihistamines." *Psychopharmacology (Berl)* 111(2): 139-43.
- Miyatake, M., M. Narita, et al. (2005). "Glutamatergic neurotransmission and protein kinase C play a role in neuron-glia communication during the development of methamphetamine-induced psychological dependence." *Eur J Neurosci* 22(6): 1476-88.

- Mizoguchi, H., K. Yamada, et al. (2004). "Regulations of methamphetamine reward by extracellular signal-regulated kinase 1/2/ets-like gene-1 signaling pathway via the activation of dopamine receptors." *Mol Pharmacol* 65(5): 1293-301.
- Nagai, T., Y. Noda, et al. (2005). "The role of tissue plasminogen activator in methamphetamine-related reward and sensitization." *J Neurochem* 92(3): 660-7.
- Nakagawa, T., M. Fujio, et al. (2005). "Effect of MS-153, a glutamate transporter activator, on the conditioned rewarding effects of morphine, methamphetamine and cocaine in mice." *Behav Brain Res* 156(2): 233-9.
- Narita, M., M. Miyatake, et al. (2006). "Direct evidence of astrocytic modulation in the development of rewarding effects induced by drugs of abuse." *Neuropsychopharmacology* 31(11): 2476-88.
- Narita, M., H. Akai, et al. (2005). "Involvement of mitogen-stimulated p70-S6 kinase in the development of sensitization to the methamphetamine-induced rewarding effect in rats." *Neuroscience* 132(3): 553-60.
- Narita, M., M. Miyatake, et al. (2005). "Long-lasting change in brain dynamics induced by methamphetamine: Enhancement of protein kinase C-dependent astrocytic response and behavioral sensitization." *J Neurochem* 93(6): 1383-92.
- Narita, M., H. Akai, et al. (2004). "Implications of protein kinase C in the nucleus accumbens in the development of sensitization to methamphetamine in rats." *Neuroscience* 127(4): 941-8.
- Niwa, M., A. Nitta, et al. (2006). "An inducer for glial cell line-derived neurotrophic factor and tumor necrosis factor-alpha protects against methamphetamine-induced rewarding effects and sensitization." *Biol Psychiatry*.
- Okabe, C., H. Takeshima, et al. (2005). "Methamphetamine sensitization in nociceptin receptor knockout mice: Locomotor and c-fos expression." *Eur J Pharmacol* 507(1-3): 57-67.
- Pace, C. J., S. D. Glick, et al. (2004). "Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration." *Eur J Pharmacol* 492(2-3): 159-67.
- Ranaldi, R. and K. Poeggel (2002). "Baclofen decreases methamphetamine self-administration in rats." *Neuroreport* 13(9): 1107-10.
- Takigawa, M. (1999). "[Mechanism involved in substance dependence--from the view point of the reward system]." *Seishin Shinkeigaku Zasshi* 101(10): 789-93.
- Wang, H. D., M. Takigawa, et al. (2002). "A shift in information flow between prefrontal cortex and the ventral tegmental area in methamphetamine-sensitized rats." *Int J Psychophysiol* 44(3): 251-9.
- Yang, P. P., E. Y. Huang, et al. (2006). "Co-administration of dextromethorphan with methamphetamine attenuates methamphetamine-induced rewarding and behavioral sensitization." *J Biomed Sci* 13(5): 695-702.

### Rhabdomyolysis

- Ago, M., K. Ago, et al. (2006). "Toxicological and histopathological analysis of a patient who died nine days after a single intravenous dose of methamphetamine: A case report." *Leg Med (Tokyo)* 8(4): 235-9.
- Kamijo, Y., K. Soma, et al. (2002). "Acute liver failure following intravenous methamphetamine." *Vet Hum Toxicol* 44(4): 216-7.
- Kolecki, P. (1998). "Inadvertent methamphetamine poisoning in pediatric patients." *Pediatr Emerg Care* 14(6): 385-7.
- Richards, J. R. (2000). "Rhabdomyolysis and drugs of abuse." *J Emerg Med* 19(1): 51-6.
- Richards, J. R., E. B. Johnson, et al. (1999). "Methamphetamine abuse and rhabdomyolysis in the ED: A 5-year study." *Am J Emerg Med* 17(7): 681-5.
- Ueyama, H. and T. Kumamoto (2001). "[Myopathies in drug addicts]." *Ryoikibetsu Shokogun Shirizu*(36): 267-70.
- Urbina, A. and K. Jones (2004). "Crystal methamphetamine, its analogues, and HIV infection: Medical and psychiatric aspects of a new epidemic." *Clin Infect Dis* 38(6): 890-4.

### Ritalin

*See Methylphenidate; Methylphenidate (animals)*

### Riverside, CA (US)

- Hser, Y. I., C. Teruya, et al. (2003). "Treating drug-abusing offenders. Initial findings from a five-county study on the impact of California's Proposition 36 on the treatment system and patient outcomes." *Eval Rev* 27(5): 479-505.

**Rohypnol™***See* Flunitrazepam (Rohypnol™)**Rural Populations**

- Austin, A. A. (2004). "Alcohol, tobacco, other drug use, and violent behavior among Native Hawaiians: Ethnic pride and resilience." *Subst Use Misuse* 39(5): 721-46.
- Anonymous (2005). "Meth use increases HIV cases in South Dakota." *AIDS Patient Care STDS* 19(9): 619-20.
- Booth, B. M., C. Leukefeld, et al. (2006). "Correlates of rural methamphetamine and cocaine users: Results from a multistate community study." *J Stud Alcohol* 67(4): 493-501.
- Charukamnoetkanok, P. and M. D. Wagoner (2004). "Facial and ocular injuries associated with methamphetamine production accidents." *Am J Ophthalmol* 138(5): 875-6.
- Cretzmeyer, M., M. V. Sarrazin, et al. (2003). "Treatment of methamphetamine abuse: Research findings and clinical directions." *J Subst Abuse Treat* 24(3): 267-77.
- Danks, R. R., L. A. Wibbenmeyer, L. D. Faucher, K. C. Sihler, G. P. Kealey, P. Chang, M. Amelon and R. W. Lewis, 3rd (2004). "Methamphetamine-associated burn injuries: A retrospective analysis." *J Burn Care Rehabil* 25(5): 425-9.
- Freese, T. E., J. Obert, et al. (2000). "Methamphetamine abuse: Issues for special populations." *J Psychoactive Drugs* 32(2): 177-82.
- Huff, C. (2006). "Crystal crush." *Hosp Health Netw* 80(10): 59-60, 62, 64.
- Joosen, M., T. F. Garrity, et al. (2005). "Predictors of current depressive symptoms in a sample of drug court participants." *Subst Use Misuse* 40(8): 1113-25.
- Lineberry, T. W. and J. M. Bostwick (2006). "Methamphetamine abuse: a perfect storm of complications." *Mayo Clin Proc* 81(1): 77-84.
- McGuinness, T. (2006). "Methamphetamine abuse." *Am J Nurs* 106(12): 54-59.
- Penn, C. L. (2006). "Meth abuse in Arkansas." *J Ark Med Soc* 102(8): 218-9.
- Sexton, R. L., R. G. Carlson, et al. (2005). "Barriers and pathways to diffusion of methamphetamine use among African Americans in the rural South: Preliminary ethnographic findings." *J Ethn Subst Abuse* 4(1): 77-103.
- Siegal, H. A., P. J. Draus, et al. (2006). "Perspectives on health among adult users of illicit stimulant drugs in rural Ohio." *J Rural Health* 22(2): 169-73.
- Simons, J. S., M. N. Oliver, et al. (2005). "Methamphetamine and alcohol abuse and dependence symptoms: Associations with affect lability and impulsivity in a rural treatment population." *Addict Behav* 30(7): 1370-81.
- Spoth, R. L., S. Clair, et al. (2006). "Long-term effects of universal preventive interventions on methamphetamine use among adolescents." *Arch Pediatr Adolesc Med* 160(9): 876-82.
- Stoops, W. W., M. S. Tindall, et al. (2005). "Methamphetamine use in nonurban and urban drug court clients." *Int J Offender Ther Comp Criminol* 49(3): 260-76.
- Storr, C. L., A. M. Arria, et al. (2004). "Neighborhood environment and opportunity to try methamphetamine ("ice") and marijuana: Evidence from Guam in the Western Pacific region of Micronesia." *Subst Use Misuse* 39(2): 253-76.
- Tanne, J. H. (2006). "Methamphetamine epidemic hits middle America." *BMJ* 332(7538): 382.
- Vogt, T. M., J. F. Perz, et al. (2006). "An outbreak of hepatitis B virus infection among methamphetamine injectors: the role of sharing injection drug equipment." *Addiction* 101(5): 726-30.
- Wermuth, L. (2000). "Methamphetamine use: Hazards and social influences." *J Drug Educ* 30(4): 423-33.
- Wu, L. T., D. J. Pilowsky, et al. (2004). "Injection drug use among stimulant users in a national sample." *Am J Drug Alcohol Abuse* 30(1): 61-83.

**Russia**

- Bobkov, A. F., L. M. Selimova, et al. (2005). "Human immunodeficiency virus type 1 in illicit-drug solutions used intravenously retains infectivity." *J Clin Microbiol* 43(4): 1937-9.
- Smirnov, A. V. (1990). "[Psychomotor stimulants as agents for enhancing work capacity]." *Farmakol Toksikol* 53(4): 72-7.

**Sacramento, CA (US)**

- Gibson, D. R., M. H. Leamon and N. Flynn (2002). "Epidemiology and public health consequences of methamphetamine use in California's Central Valley." *J Psychoactive Drugs* 34(3): 313-9.

- Hser, Y. I., C. Teruya, et al. (2003). "Treating drug-abusing offenders. Initial findings from a five-county study on the impact of California's Proposition 36 on the treatment system and patient outcomes." *Eval Rev* 27(5): 479-505.
- Molitor, F., J. D. Ruiz, et al. (1999). "Methamphetamine use and sexual and injection risk behaviors among out-of-treatment injection drug users." *Am J Drug Alcohol Abuse* 25(3): 475-93.
- Poulsen, E. J., M. J. Mannis, et al. (1996). "Keratitis in methamphetamine abusers." *Cornea* 15(5): 477-82.
- Richards, J. R. and B. T. Brofeldt (2000). "Patterns of tooth wear associated with methamphetamine use." *J Periodontol* 71(8): 1371-4.
- Richards, J. R., S. W. Bretz, et al. (1999). "Methamphetamine abuse and emergency department utilization." *West J Med* 170(4): 198-202.
- Schermer, C. R. and D. H. Wisner (1999). "Methamphetamine use in trauma patients: A population-based study." *J Am Coll Surg* 189(5): 442-9.
- Turnipseed, S. D., J. R. Richards, et al. (2003). "Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after methamphetamine use." *J Emerg Med* 24(4): 369-73.
- Yacoubian, G. S., Jr. and R. J. Peters (2004). "Exploring the prevalence and correlates of methamphetamine use: Findings from Sacramento's ADAM program." *J Drug Educ* 34(3): 281-94.

### Sale

*See Methamphetamine Trafficking and Sale*

### San Antonio, TX (US)

- Boulard, G. (2005). "The meth menace: Battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.
- Gonzales, R., P. Marinelli-Casey, et al. (2006). "Hepatitis C virus infection among methamphetamine-dependent individuals in outpatient treatment." *J Subst Abuse Treat* 31(2): 195-202.
- Johnson, B. A., J. D. Roache, et al. (2005). "Effects of isradipine on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition." *Psychopharmacology (Berl)* 178(2-3): 296-302.
- Kim, J. Y. and M. Fendrich (2002). "Gender differences in juvenile arrestees' drug use, self-reported dependence, and perceived need for treatment." *Psychiatr Serv* 53(1): 70-5.
- Zule, W. A. and D. P. Desmond (1999). "An ethnographic comparison of HIV risk behaviors among heroin and methamphetamine injectors." *Am J Drug Alcohol Abuse* 25(1): 1-23.

### San Diego, CA (US)

- Bailey, D. N. and R. F. Shaw (1989). "Cocaine- and methamphetamine-related deaths in San Diego County (1987): Homicides and accidental overdoses." *J Forensic Sci* 34(2): 407-22.
- Bailey, D. N. (1987). "Amphetamine detection during toxicology screening of a university medical center patient population." *J Toxicol Clin Toxicol* 25(5): 399-409.
- Bailey, D. N. (1987). "Amphetamine detection during toxicology screening of a university medical center patient population." *J Toxicol Clin Toxicol* 25(5): 399-409.
- Brouwer, K. C., P. Case, et al. (2006). "Trends in production, trafficking, and consumption of methamphetamine and cocaine in Mexico." *Subst Use Misuse* 41(5): 707-27.
- Catanzarite, V. A. and D. A. Stein (1995). "'Crystal' and pregnancy--methamphetamine-associated maternal deaths." *West J Med* 162(5): 454-7.
- Drumright, L. N., S. J. Little, et al. (2006). "Unprotected anal intercourse and substance use among men who have sex with men with recent HIV infection." *J Acquir Immune Defic Syndr* 43(3): 344-50.
- Drumright, L. N., S. A. Strathdee, et al. (2006). "Unprotected anal intercourse and substance use before and after HIV diagnosis among recently HIV-infected men who have sex with men." *Sex Transm Dis*.
- Ellis, R. J., M. E. Childers, et al. (2003). "Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy." *J Infect Dis* 188(12): 1820-6.
- Gonzales, R., P. Marinelli-Casey, et al. (2006). "Hepatitis C virus infection among methamphetamine-dependent individuals in outpatient treatment." *J Subst Abuse Treat* 31(2): 195-202.
- Hall, J. A., S. W. Henggeler, et al. (1993). "Adolescent substance use during pregnancy." *J Pediatr Psychol* 18(2): 265-71.
- Hornbeck, C. L. and R. J. Czarny (1993). "Retrospective analysis of some L-methamphetamine/L-amphetamine urine data." *J Anal Toxicol* 17(1): 23-5.

- Hser, Y. I., C. Teruya, et al. (2003). "Treating drug-abusing offenders. Initial findings from a five-county study on the impact of California's Proposition 36 on the treatment system and patient outcomes." *Eval Rev* 27(5): 479-505.
- Kalechstein, A. D., T. F. Newton, et al. (2000). "Psychiatric comorbidity of methamphetamine dependence in a forensic sample." *J Neuropsychiatry Clin Neurosci* 12(4): 480-4.
- Molitor, F., J. D. Ruiz, et al. (1999). "Methamphetamine use and sexual and injection risk behaviors among out-of-treatment injection drug users." *Am J Drug Alcohol Abuse* 25(3): 475-93.
- Semple, S. J., J. Zians, et al. (2006). "Sexual compulsivity in a sample of HIV-positive methamphetamine-using gay and bisexual men." *AIDS Behav* 10(5): 587-98.
- Semple, S. J., J. Zians, et al. (2006). "Methamphetamine use, impulsivity, and sexual risk behavior among HIV-positive men who have sex with men." *J Addict Dis* 25(4): 105-14.
- Semple, S. J., J. Zians, et al. (2006). "Sexual risk behavior of HIV-positive methamphetamine-using men who have sex with men: The role of partner serostatus and partner type." *Arch Sex Behav* 35(4): 461-71.
- Semple, S. J., I. Grant, et al. (2005). "Negative self-perceptions and sexual risk behavior among heterosexual methamphetamine users." *Substance Use & Misuse* 40(12): 1797-1810.
- Semple, S. J., I. Grant, et al. (2005). "Utilization of drug treatment programs by methamphetamine users: The role of social stigma." *Am J Addict* 14(4): 367-80.
- Semple, S. J., T. L. Patterson and I. Grant (2004). "The context of sexual risk behavior among heterosexual methamphetamine users." *Addict Behav* 29(4): 807-10.
- Semple, S. J., T. L. Patterson, et al. (2004). "A comparison of injection and non-injection methamphetamine-using HIV positive men who have sex with men." *Drug Alcohol Depend* 76(2): 203-12.
- Semple, S. J., T. L. Patterson, et al. (2004). "Determinants of condom use stage of change among heterosexually-identified methamphetamine users." *AIDS Behav* 8(4): 391-400.
- Semple, S. J., I. Grant, et al. (2004). "Female methamphetamine users: Social characteristics and sexual risk behavior." *Women Health* 40(3): 35-50.
- Semple, S. J., T. L. Patterson, et al. (2003). "Binge use of methamphetamine among HIV-positive men who have sex with men: Pilot data and HIV prevention implications." *AIDS Educ Prev* 15(2): 133-47.
- Swalwell, C. I. and G. G. Davis (1999). "Methamphetamine as a risk factor for acute aortic dissection." *J Forensic Sci* 44(1): 23-6.

## San Francisco, CA (US)

- Anonymous (2006). "Methamphetamine use and HIV risk behaviors among heterosexual men--preliminary results from five northern California counties, December 2001-November 2003." *MMWR Morb Mortal Wkly Rep* 55(10): 273-7.
- Binswanger, I. A., A. H. Kral, et al. (2000). "High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Francisco." *Clin Infect Dis* 30(3): 579-81.
- Bluthenthal, R. N., A. H. Kral, et al. (2001). "Trends in HIV seroprevalence and risk among gay and bisexual men who inject drugs in San Francisco, 1988 to 2000." *J Acquir Immune Defic Syndr* 28(3): 264-9.
- Boddiger, D. (2005). "Methamphetamine use linked to rising HIV transmission." *Lancet* 365(9466): 1217-8.
- Buchacz, K., W. McFarland, et al. (2005). "Amphetamine use is associated with increased HIV incidence among men." *AIDS* 19(13): 1423-24.
- Chesney, M. A., D. C. Barrett, et al. (1998). "Histories of substance use and risk behavior: Precursors to HIV seroconversion in homosexual men." *Am J Public Health* 88(1): 113-6.
- Choi, K. H., D. Operario, et al. (2005). "Substance use, substance choice, and unprotected anal intercourse among young Asian American and Pacific Islander men who have sex with men." *AIDS Educ Prev* 17(5): 418-29.
- Chu, P. L., W. McFarland, et al. (2003). "Viagra use in a community-recruited sample of men who have sex with men, San Francisco." *J Acquir Immune Defic Syndr* 33(2): 191-3.
- Colfax, G. N., E. Vittinghoff, et al. (2007). "Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance." *AIDS* 21(2): 239-241.
- Colfax, G., T. J. Coates, et al. (2005). "Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of San Francisco men who have sex with men." *J Urban Health* 82(1 Suppl 1): i62-70.
- Copeland, A. L. and J. L. Sorensen (2001). "Differences between methamphetamine users and cocaine users in treatment." *Drug Alcohol Depend* 62(1): 91-5.
- Crosby, G. M., R. D. Stall, et al. (1998). "Alcohol and drug use patterns have declined between generations of younger gay-bisexual men in San Francisco." *Drug Alcohol Depend* 52(3): 177-82.
- Davis, F. and L. Munoz (1968). "Heads and freaks: Patterns and meanings of drug use among hippies." *J Health Soc Behav* 9(2): 156-64.

- Diaz, R. M., A. L. Heckert, et al. (2005). "Reasons for stimulant use among Latino gay men in San Francisco: a comparison between methamphetamine and cocaine users." *J Urban Health* 82(1 Suppl 1): i71-8.
- Duterte, M., S. O'Neil, et al. (2001). "Walking the tightrope: Balancing health and drug use." *J Psychoactive Drugs* 33(2): 173-83.
- Galloway, G. P., J. Newmeyer, et al. (1996). "A controlled trial of imipramine for the treatment of methamphetamine dependence." *J Subst Abuse Treat* 13(6): 493-7.
- Galloway, G. P., J. Newmeyer, T. Knapp, S. A. Stalcup and D. Smith (1994). "Imipramine for the treatment of cocaine and methamphetamine dependence." *J Addict Dis* 13(4): 201-16.
- Gleghorn, A. A., R. Marx, et al. (1998). "Association between drug use patterns and HIV risks among homeless, runaway, and street youth in northern California." *Drug Alcohol Depend* 51(3): 219-27.
- Greenwood, G. L., E. W. White, et al. (2001). "Correlates of heavy substance use among young gay and bisexual men: The San Francisco Young Men's Health Study." *Drug Alcohol Depend* 61(2): 105-12.
- Hahn, J. A., K. Page-Shafer, P. J. Lum, K. Ochoa and A. R. Moss (2001). "Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco." *Hepatology* 34(1): 180-7.
- Halkitis, P. N., L. Wilton, et al. (2005). "Barebacking identity among HIV-positive gay and bisexual men: demographic, psychological, and behavioral correlates." *AIDS* 19: S27-S35.
- Harris, D. and S. L. Batki (2000). "Stimulant psychosis: Symptom profile and acute clinical course." *Am J Addict* 9(1): 28-37.
- Hser, Y. I., C. Teruya, et al. (2003). "Treating drug-abusing offenders. Initial findings from a five-county study on the impact of California's Proposition 36 on the treatment system and patient outcomes." *Eval Rev* 27(5): 479-505.
- Israel, J. A. and K. Lee (2002). "Amphetamine usage and genital self-mutilation." *Addiction* 97(9): 1215-8.
- Kalechstein, A. D., T. F. Newton, et al. (2000). "Psychiatric comorbidity of methamphetamine dependence in a forensic sample." *J Neuropsychiatry Clin Neurosci* 12(4): 480-4.
- Karch, S. B., B. G. Stephens, et al. (1999). "Methamphetamine-related deaths in San Francisco: Demographic, pathologic, and toxicologic profiles." *J Forensic Sci* 44(2): 359-68.
- Kim, A. A., C. K. Kent, et al. (2002). "Increased risk of HIV and sexually transmitted disease transmission among gay or bisexual men who use Viagra, San Francisco 2000-2001." *AIDS* 16(10): 1425-8.
- Klausner, J. D., C. K. Kent, et al. (2005). "The public health response to epidemic syphilis, San Francisco, 1999-2004." *Sex Transm Dis* 32(10 supplement): S11-S18.
- Klausner, J. D., D. K. Levine, et al. (2004). "Internet-based site-specific interventions for syphilis prevention among gay and bisexual men." *AIDS Care* 16(8): 964-70.
- Koblin, B. A., M. A. Chesney, et al. (2003). "High-risk behaviors among men who have sex with men in 6 US cities: Baseline data from the EXPLORE Study." *Am J Public Health* 93(6): 926-32.
- Kral, A. H., J. Lorvick, et al. (2005). "HIV prevalence and risk behaviors among men who have sex with men and inject drugs in San Francisco." *J Urban Health* 82(1 Suppl 1): i43-50.
- Kral, A. H., R. N. Bluthenthal, et al. (2001). "Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: Risk-factor analysis." *Lancet* 357(9266): 1397-401.
- Kral, A. H., J. Lorvick, et al. (2000). "Sex- and drug-related risk among populations of younger and older injection drug users in adjacent neighborhoods in San Francisco." *J Acquir Immune Defic Syndr* 24(2): 162-7.
- Kral, A. H., R. N. Bluthenthal, et al. (1999). "Risk factors among IDUs who give injections to or receive injections from other drug users." *Addiction* 94(5): 675-83.
- Kushel, M. B., J. A. Hahn, et al. (2005). "Revolving doors: Imprisonment among the homeless and marginally housed population." *Am J Public Health* 95(10): 1747-52.
- Lorvick, J., A. Martinez, et al. (2006). "Sexual and injection risk among women who inject methamphetamine in San Francisco." *J Urban Health* 83(3): 497-505.
- Lum, P. J., C. Sears, et al. (2005). "Injection risk behavior among women syringe exchangers in San Francisco." *Subst Use Misuse* 40(11): 1681-96.
- Mansergh, G., R. L. Shouse, et al. (2006). "Methamphetamine and sildenafil (Viagra) use are linked to unprotected receptive and insertive anal sex, respectively, in a sample of men who have sex with men." *Sex Transm Infect* 82(2): 131-4.
- Mansergh, G., G. N. Colfax, et al. (2001). "The Circuit Party Men's Health Survey: Findings and implications for gay and bisexual men." *Am J Public Health* 91(6): 953-8.
- Menza, T. W., G. Colfax, et al. (2006). "Interest in a methamphetamine intervention among men who have sex with men." *Sex Transm Dis* 33(9): 565-70.
- Mitchell, S. J., S. R. Morris, et al. (2006). "Methamphetamine use and sexual activity among HIV-infected patients in care--San Francisco, 2004." *AIDS Patient Care STDS* 20(7): 502-10.



- Morin, S. F., W. T. Steward, et al. (2005). "Predicting HIV transmission risk among HIV-infected men who have sex with men: Findings from the healthy living project." *J Acquir Immune Defic Syndr* 40(2): 226-235.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.
- Nemoto, T., D. Operario, et al. (2002). "Risk behaviors of Filipino methamphetamine users in San Francisco: Implications for prevention and treatment of drug use and HIV." *Public Health Rep* 117 Suppl 1: S30-8.
- Newmeyer, J. A. (2003). "Patterns and trends of drug use in the San Francisco Bay Area." *J Psychoactive Drugs* 35(Suppl 1): 127-32.
- Newmeyer, J. A. (1988). "The prevalence of drug use in San Francisco in 1987." *J Psychoactive Drugs* 20(2): 185-9.
- Ochoa, K. C., P. J. Davidson, et al. (2005). "Heroin overdose among young injection drug users in San Francisco." *Drug Alcohol Depend* 80(3): 297-302.
- Parsons, J. T. and P. N. Halkitis (2002). "Sexual and drug-using practices of HIV-positive men who frequent public and commercial sex environments." *AIDS Care* 14(6): 815-26.
- Purcell, D. W., S. Moss, et al. (2005). "Illicit substance use, sexual risk, and HIV-positive gay and bisexual men: Differences by serostatus of casual partners." *AIDS* 19: S37-S47.
- Purcell, D. W., R. J. Wolitski, et al. (2005). "Predictors of the use of viagra, testosterone, and antidepressants among HIV-seropositive gay and bisexual men." *AIDS* 19 Suppl 1: S57-66.
- Purcell, D. W., J. T. Parsons, P. N. Halkitis, Y. Mizuno and W. J. Woods (2001). "Substance use and sexual transmission risk behavior of HIV-positive men who have sex with men." *J Subst Abuse* 13(1-2): 185-200.
- Rose, V. J., H. F. Raymond, et al. (2006). "Assessing the feasibility of harm reduction services for MSM: The late night breakfast buffet study." *Harm Reduct J* 3: 29.
- Sears, C., J. R. Gudyish, et al. (2001). "Investigation of a secondary syringe exchange program for homeless young adult injection drug users in San Francisco, California, U.S.A." *J Acquir Immune Defic Syndr* 27(2): 193-201.
- Slade, M., L. J. Daniel, et al. (1991). "Application of forensic toxicology to the problem of domestic violence." *J Forensic Sci* 36(3): 708-13.
- Shoptaw, S., J. D. Klausner, et al. (2006). "A public health response to the methamphetamine epidemic: The implementation of contingency management to treat methamphetamine dependence." *BMC Public Health* 6(1): 214.
- Smith, D. E. (1969). "Runaways and their health problems in Haight-Ashbury during the summer of 1967." *Am J Public Health Nations Health* 59(11): 2046-50.
- Smith, D. and A. J. Rose (1968). "Observations in the Haight-Ashbury Medical Clinic of San Francisco. Health problems in a "hippie" subculture." *Clin Pediatr (Phila)* 7(6): 313-6.
- Stall, R., J. P. Paul, et al. (2001). "Alcohol use, drug use and alcohol-related problems among men who have sex with men: The Urban Men's Health Study." *Addiction* 96(11): 1589-601.
- Thiede, H., L. A. Valleroy, et al. (2003). "Regional patterns and correlates of substance use among young men who have sex with men in 7 US urban areas." *Am J Public Health* 93(11): 1915-21.
- Weiser, S. D., S. E. Dilworth, et al. (2006). "Gender-specific correlates of sex trade among homeless and marginally housed individuals in San Francisco." *J Urban Health* 83(4): 736-40.
- Wong, W., J. K. Chaw, et al. (2005). "Risk factors for early syphilis among gay and bisexual men seen in an STD clinic: San Francisco, 2002-2003." *Sex Transm Dis* 32(7): 458-63.

## San Jose, CA (US)

- Kim, J. Y. and M. Fendrich (2002). "Gender differences in juvenile arrestees' drug use, self-reported dependence, and perceived need for treatment." *Psychiatr Serv* 53(1): 70-5.

## Santa Cruz, CA (US)

- Gleghorn, A. A., R. Marx, et al. (1998). "Association between drug use patterns and HIV risks among homeless, runaway, and street youth in northern California." *Drug Alcohol Depend* 51(3): 219-27.

## Schizophrenia

*See also* Psychosis

- Akiyama, K., A. Kanzaki, et al. (1994). "Methamphetamine-induced behavioral sensitization and its implications for relapse of schizophrenia." *Schizophr Res* 12(3): 251-7.
- Carnwath, T., T. Garvey and M. Holland (2002). "The prescription of dexamphetamine to patients with schizophrenia and amphetamine dependence." *J Psychopharmacol* 16(4): 373-7.

- Chen, C. K., S. K. Lin, et al. (2005). "Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis." *Am J Med Genet B Neuropsychiatr Genet* 136(1): 87-91.
- Ikeda, M., N. Iwata, et al. (2006). "Positive association of AKT1 haplotype to Japanese methamphetamine use disorder." *Int J Neuropsychopharmacol* 9(1): 77-81.
- Iwanami, A., I. Suga, et al. (1994). "P300 component of event-related potentials in methamphetamine psychosis and schizophrenia." *Prog Neuropsychopharmacol Biol Psychiatry* 18(3): 465-75.
- Kojima, T., E. Matsushima, et al. (1990). "Eye movements in acute, chronic, and remitted schizophrenics." *Biol Psychiatry* 27(9): 975-89.
- Kojima, T., E. Matsushima, et al. (1986). "Visual perception process in amphetamine psychosis and schizophrenia." *Psychopharmacol Bull* 22(3): 768-73.
- Machiyama, Y. (1992). "Chronic methamphetamine intoxication model of schizophrenia in animals." *Schizophr Bull* 18(1): 107-13.
- Mikami, T., N. Naruse, et al. (2003). "Determining vulnerability to schizophrenia in methamphetamine psychosis using exploratory eye movements." *Psychiatry Clin Neurosci* 57(4): 433-40.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.
- Nishiyama, T., M. Ikeda, et al. (2005). "Haplotype association between GABAA receptor gamma2 subunit gene (GABRG2) and methamphetamine use disorder." *Pharmacogenomics J* 5(2): 89-95.
- Prince, J. A. and L. Oreland (1998). "Mitochondrial activity in the mapping of functional brain changes in schizophrenia." *Restor Neurol Neurosci* 12(2-3): 185-93.
- Saito, A., Y. Fujikura-Ouchi, et al. (2007). "Association study of putative promoter polymorphisms in the neuroplastin gene and schizophrenia." *Neurosci Lett* 411(3): 168-73.
- Sato, M. (2002). "[Basic and clinical studies on methamphetamine-related psychosis]." *Seishin Shinkeigaku Zasshi* 104(3): 179-90.
- Sato, M. (1992). "A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis." *Ann N Y Acad Sci* 654: 160-70.
- Sato, M., Y. Numachi, et al. (1992). "Relapse of paranoid psychotic state in methamphetamine model of schizophrenia." *Schizophr Bull* 18(1): 115-22.
- Shimazono, Y. and E. Matsushima (1995). "Behavioral and neuroimaging studies on schizophrenia in Japan." *Psychiatry Clin Neurosci* 49(1): 3-11.
- Tomiya, G. (1990). "Chronic schizophrenia-like states in methamphetamine psychosis." *Jpn J Psychiatry Neurol* 44(3): 531-9.
- Yen, C. F. and Y. C. Su (2006). "The associations of early-onset methamphetamine use with psychiatric morbidity among taiwanese adolescents." *Subst Use Misuse* 41(1): 35-44.
- Yui, K. and S. Ikemoto (2004). "[Stress sensitization induced by stressor and methamphetamine]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 24(3): 151-7.
- Yui, K., S. Ikemoto, et al. (2002). "Spontaneous recurrence of methamphetamine-induced paranoid-hallucinatory states in female subjects: Susceptibility to psychotic states and implications for relapse of schizophrenia." *Pharmacopsychiatry* 35(2): 62-71.
- Yui, K., S. Ikemoto, et al. (2000). "Studies of amphetamine or methamphetamine psychosis in Japan: Relation of methamphetamine psychosis to schizophrenia." *Ann N Y Acad Sci* 914: 1-12.
- Yui, K., K. Goto, et al. (2001). "Susceptibility to subsequent episodes of spontaneous recurrence of methamphetamine psychosis." *Drug Alcohol Depend* 64(2): 133-42.
- Yui, K., K. Goto, et al. (1999). "Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: The role of sensitization." *Mol Psychiatry* 4(6): 512-23.

### Schizophrenia (animal models)

- Ago, Y., S. Nakamura, et al. (2006). "Attenuation by the 5-HT(1A) receptor agonist osetozotan of the behavioral effects of single and repeated methamphetamine in mice." *Neuropharmacology* 51(4): 914-22.
- Akiyama, K., A. Kanzaki, et al. (1994). "Methamphetamine-induced behavioral sensitization and its implications for relapse of schizophrenia." *Schizophr Res* 12(3): 251-7.
- Bagorda, F., G. Teuchert-Noodt, et al. (2006). "Isolation rearing or methamphetamine traumatization induce a "dysconnection" of prefrontal efferents in gerbils: Implications for schizophrenia." *J Neural Transm* 113(3): 365-79.
- Fox, G. B., T. A. Esbenshade, et al. (2005). "Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzotrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist." *J Pharmacol Exp Ther* 313(1): 176-90.
- Hada, H. and K. Miyamoto (1990). "Enhancing effects of sound on methamphetamine-induced behavioral aberrations in the rat: a model of relapse of schizophrenia-like symptoms." *Jpn J Psychiatry Neurol* 44(3): 619-27.

- Hanson, G. R., N. Singh, et al. (1992). "Responses of limbic and extrapyramidal neurotensin systems to stimulants of abuse. Involvement of dopaminergic mechanisms." *Ann N Y Acad Sci* 668: 165-72.
- Hirota, S., N. Kawashima, et al. (2003). "Neuropharmacological profile of an atypical antipsychotic, NRA0562." *CNS Drug Rev* 9(4): 375-88.
- Kaneko, Y., A. Kashiwa, et al. (2006). "Selective serotonin reuptake inhibitors, fluoxetine and paroxetine, attenuate the expression of the established behavioral sensitization induced by methamphetamine." *Neuropsychopharmacology*.
- Kato, K., T. Shishido, et al. (2001). "Glycine reduces novelty- and methamphetamine-induced locomotor activity in neonatal ventral hippocampal damaged rats." *Neuropsychopharmacology* 24(3): 330-2.
- Kurachi, M. (2003). "Pathogenesis of schizophrenia: Part II. Temporo-frontal two-step hypothesis." *Psychiatry Clin Neurosci* 57(1): 9-15.
- Larson, J., C. N. Quach, et al. (1996). "Effects of an AMPA receptor modulator on methamphetamine-induced hyperactivity in rats." *Brain Res* 738(2): 353-6.
- Ma, J. and L. S. Leung (2004). "Schizophrenia-like behavioral changes after partial hippocampal kindling." *Brain Res* 997(1): 111-8.
- Machiyama, Y. (1992). "Chronic methamphetamine intoxication model of schizophrenia in animals." *Schizophr Bull* 18(1): 107-13.
- Mizuno, M., R. S. Malta, Jr., et al. (2004). "Conditioned place preference and locomotor sensitization after repeated administration of cocaine or methamphetamine in rats treated with epidermal growth factor during the neonatal period." *Ann N Y Acad Sci* 1025: 612-8.
- Ozawa, K., K. Hashimoto, et al. (2006). "Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia." *Biol Psychiatry* 59(6): 546-54.
- Palmer, L. C., U. S. Hess, et al. (1997). "Comparison of the effects of an ampakine with those of methamphetamine on aggregate neuronal activity in cortex versus striatum." *Brain Res Mol Brain Res* 46(1-2): 127-35.
- Prince, J. A., M. S. Yassin, et al. (1997). "Normalization of cytochrome-c oxidase activity in the rat brain by neuroleptics after chronic treatment with PCP or methamphetamine." *Neuropharmacology* 36(11-12): 1665-78.
- Sumiyoshi, T., M. Tsunoda, et al. (2004). "Enhanced locomotor activity in rats with excitotoxic lesions of the entorhinal cortex, a neurodevelopmental animal model of schizophrenia: Behavioral and in vivo microdialysis studies." *Neurosci Lett* 364(2): 124-9.
- Szumliński, K. K., K. D. Lominac, et al. (2005). "Behavioral and neurochemical phenotyping of Homer1 mutant mice: Possible relevance to schizophrenia." *Genes Brain Behav* 4(5): 273-88.
- Wang, H. D., M. Takigawa, et al. (2000). "Reciprocal information flow between prefrontal cortex and ventral tegmental area in an animal model of schizophrenia." *Neuroreport* 11(9): 2007-11.

## Seattle, WA (US)

- Brewer, D. D., M. R. Golden, et al. (2006). "Unsafe sexual behavior and correlates of risk in a probability sample of men who have sex with men in the era of highly active antiretroviral therapy." *Sex Transm Dis* 33(4): 250-5.
- Gorbach, P. M., J. T. Galea, et al. (2004). "Don't ask, don't tell: patterns of HIV disclosure among HIV positive men who have sex with men with recent STI practising high risk behaviour in Los Angeles and Seattle." *Sex Transm Infect* 80(6): 512-7.
- Gorman, E. M. and R. T. Carroll (2000). "Substance abuse and HIV: Considerations with regard to methamphetamines and other recreational drugs for nursing practice and research." *J Assoc Nurses AIDS Care* 11(2): 51-62.
- Koblin, B. A., M. A. Chesney, et al. (2003). "High-risk behaviors among men who have sex with men in 6 US cities: Baseline data from the EXPLORE Study." *Am J Public Health* 93(6): 926-32.
- Logan, B. K., C. L. Fligner, et al. (1998). "Cause and manner of death in fatalities involving methamphetamine." *J Forensic Sci* 43(1): 28-34.
- Logan, B. K., E. L. Weiss, et al. (1996). "Case report: Distribution of methamphetamine in a massive fatal ingestion." *J Forensic Sci* 41(2): 322-3.
- Menza, T. W., G. Colfax, et al. (2006). "Interest in a methamphetamine intervention among men who have sex with men." *Sex Transm Dis* 33(9): 565-70.
- Perdue, T., H. Hagan, et al. (2003). "Depression and HIV risk behavior among Seattle-area injection drug users and young men who have sex with men." *AIDS Educ Prev* 15(1): 81-92.
- Smith, J. W. and P. J. Frawley (1993). "Treatment outcome of 600 chemically dependent patients treated in a multimodal inpatient program including aversion therapy and pentothal interviews." *J Subst Abuse Treat* 10(4): 359-69.
- Thiede, H., L. A. Valleroy, et al. (2003). "Regional patterns and correlates of substance use among young men who have sex with men in 7 US urban areas." *Am J Public Health* 93(11): 1915-21.

### Seizures

- Catanzarite, V. A. and D. A. Stein (1995). "'Crystal' and pregnancy--methamphetamine-associated maternal deaths." *West J Med* 162(5): 454-7.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.
- Sommers, I., D. Baskin, et al. (2006). "Methamphetamine use among young adults: Health and social consequences." *Addict Behav* 31(8): 1469-76.

### Seizures (animals)

- Bowyer, J. F. and S. Ali (2006). "High doses of methamphetamine that cause disruption of the blood-brain barrier in limbic regions produce extensive neuronal degeneration in mouse hippocampus." *Synapse* 60(7): 521-532.
- Ellinwood, E. H., Jr., A. Sudilovsky, et al. (1973). "Olfactory forebrain seizures induced by methamphetamine and disulfiram." *Biol Psychiatry* 7(2): 89-99.
- Hanson, G. R., M. Jensen, et al. (1999). "Distinct features of seizures induced by cocaine and amphetamine analogs." *Eur J Pharmacol* 377(2-3): 167-73.
- Janowsky, A., C. Mah, et al. (2001). "Mapping genes that regulate density of dopamine transporters and correlated behaviors in recombinant inbred mice." *J Pharmacol Exp Ther* 298(2): 634-43.
- Ma, J. and L. S. Leung (2004). "Schizophrenia-like behavioral changes after partial hippocampal kindling." *Brain Res* 997(1): 111-8.
- Metcalf, F. U., Jr., D. F. Peeler, Jr., et al. (1971). "Methamphetamine effects upon avoidance behavior during limbic seizures in the cat." *Psychopharmacologia* 21(4): 390-400.
- Minabe, Y., K. Emori, et al. (1988). "Effects of chronic treatment of methamphetamine and imipramine on amygdaloid seizure's generation." *Jpn J Psychiatry Neurol* 42(2): 337-43.
- Minabe, Y., Y. Tani, et al. (1987). "Acute effect of some psychotropic drugs on low-frequency amygdaloid kindled seizures." *Biol Psychiatry* 22(12): 1444-50.
- Sano, H., Y. Yasoshima, et al. (2003). "Conditional ablation of striatal neuronal types containing dopamine D2 receptor disturbs coordination of basal ganglia function." *J Neurosci* 23(27): 9078-88.
- Slamberova, R. and R. Rokyta (2005). "Occurrence of bicuculline-, NMDA- and kainic acid-induced seizures in prenatally methamphetamine-exposed adult male rats." *Naunyn Schmiedebergs Arch Pharmacol* 372(3): 236-41.
- Slamberova, R. and R. Rokyta (2005). "Seizure susceptibility in prenatally methamphetamine-exposed adult female rats." *Brain Res* 1060(1-2): 193-7.
- Wallach, M. B., W. D. Winters, et al. (1969). "A correlation of EEG, reticular multiple unit activity and gross behavior following various antidepressant agents in the cat. IV." *Electroencephalogr Clin Neurophysiol* 27(6): 563-73.
- Yamamoto, M., K. Tomioka, et al. (1981). "[Central pharmacological effects of YPG-209 (16(S)-methyl-20-methoxy-prostaglandin E2) (author's transl)]." *Nippon Yakurigaku Zasshi* 77(2): 141-51.

### Self-Administration of Methamphetamine

- Hart, C. L., A. S. Ward, et al. (2001). "Methamphetamine self-administration by humans." *Psychopharmacology (Berl)* 157(1): 75-81.
- Lile, J. A. (2006). "Pharmacological determinants of the reinforcing effects of psychostimulants: Relation to agonist substitution treatment." *Exp Clin Psychopharmacol* 14(1): 20-33.

### Self-Administration of Methamphetamine (animals)

- Anggadiredja, K., M. Nakamichi, et al. (2004). "Endocannabinoid system modulates relapse to methamphetamine seeking: Possible mediation by the arachidonic acid cascade." *Neuropsychopharmacology* 29(8): 1470-8.
- Anggadiredja, K., K. Sakimura, et al. (2004). "Naltrexone attenuates cue- but not drug-induced methamphetamine seeking: A possible mechanism for the dissociation of primary and secondary reward." *Brain Res* 1021(2): 272-6.
- Balster, R. L., M. M. Kilbey, et al. (1976). "Methamphetamine self-administration in the cat." *Psychopharmacologia* 46(3): 229-33.
- Balster, R. L. and C. R. Schuster (1973). "A comparison of d-amphetamine, l-amphetamine, and methamphetamine self-administration in rhesus monkeys." *Pharmacol Biochem Behav* 1(1): 67-71.
- Bergman, J., S. Yasar, et al. (2001). "Psychomotor stimulant effects of beta-phenylethylamine in monkeys treated with MAO-B inhibitors." *Psychopharmacology (Berl)* 159(1): 21-30.
- Carney, J. M., R. W. Landrum, et al. (1991). "Establishment of chronic intravenous drug self-administration in the C57BL/6J mouse." *Neuroreport* 2(8): 477-80.

- Clemens, K. J., J. L. Cornish, et al. (2006). "Intravenous methamphetamine self-administration in rats: Effects of intravenous or intraperitoneal MDMA co-administration." *Pharmacol Biochem Behav* 85(2): 454-63.
- Dalley, J. W., K. Laane, et al. (2006). "Enduring deficits in sustained visual attention during withdrawal of intravenous methylenedioxymethamphetamine self-administration in rats: Results from a comparative study with d-amphetamine and methamphetamine." *Neuropsychopharmacology*.
- Dwoskin, L. P. and P. A. Crooks (2002). "A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse." *Biochem Pharmacol* 63(2): 89-98.
- Fantegrossi, W. E., W. L. Woolverton, et al. (2004). "Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys." *Neuropsychopharmacology* 29(7): 1270-81.
- Fantegrossi, W. E., T. Ullrich, et al. (2002). "3,4-Methylenedioxymethamphetamine (MDMA, 'ecstasy') and its stereoisomers as reinforcers in rhesus monkeys: Serotonergic involvement." *Psychopharmacology (Berl)* 161(4): 356-64.
- Fattore, L., M. S. Spano, et al. (2007). "An endocannabinoid mechanism in relapse to drug seeking: A review of animal studies and clinical perspectives." *Brain Res Brain Res Rev* 53(1): 1-16.
- Franklin, K. B. and L. J. Herberg (1974). "Self-stimulation and catecholamines: Drug-induced mobilization of the 'reserve'-pool re-establishes responding in catecholamine-depleted rats." *Brain Res* 67(3): 429-37.
- Glick, S. D., I. M. Maisonneuve, et al. (2002). "Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration." *Eur J Pharmacol* 438(1-2): 99-105.
- Glick, S. D., I. M. Maisonneuve, et al. (2001). "Comparative effects of dextromethorphan and dextrorphan on morphine, methamphetamine, and nicotine self-administration in rats." *Eur J Pharmacol* 422(1-3): 87-90.
- Glick, S. D., I. M. Maisonneuve, et al. (2000). "18-MC reduces methamphetamine and nicotine self-administration in rats." *Neuroreport* 11(9): 2013-5.
- Harrigan, S. E. and D. A. Downs (1981). "Pharmacological evaluation of narcotic antagonist delivery systems in rhesus monkeys." *NIDA Res Monogr* 28: 77-92.
- Harrigan, S. E. and D. A. Downs (1978). "Continuous intravenous naltrexone effects on morphine self-administration in rhesus monkeys." *J Pharmacol Exp Ther* 204(2): 481-6.
- Harrod, S. B., L. P. Dwoskin, et al. (2004). "Lobeline produces conditioned taste avoidance in rats." *Pharmacol Biochem Behav* 78(1): 1-5.
- Harrod, S. B., L. P. Dwoskin, et al. (2003). "Lobeline does not serve as a reinforcer in rats." *Psychopharmacology (Berl)* 165(4): 397-404.
- Harrod, S. B., L. P. Dwoskin, et al. (2001). "Lobeline attenuates d-methamphetamine self-administration in rats." *J Pharmacol Exp Ther* 298(1): 172-9.
- Hiranita, T., Y. Nawata, et al. (2006). "Suppression of methamphetamine-seeking behavior by nicotinic agonists." *Proc Natl Acad Sci U S A* 103(22): 8523-7.
- Hiranita, T., K. Anggadiredja, et al. (2004). "Nicotine attenuates relapse to methamphetamine-seeking behavior (craving) in rats." *Ann N Y Acad Sci* 1025: 504-7.
- Holtzman, S. G. (2001). "Differential interaction of GBR 12909, a dopamine uptake inhibitor, with cocaine and methamphetamine in rats discriminating cocaine." *Psychopharmacology (Berl)* 155(2): 180-6.
- Johanson, C. E., R. L. Balster, et al. (1976). "Self-administration of psychomotor stimulant drugs: The effects of unlimited access." *Pharmacol Biochem Behav* 4(1): 45-51.
- Jun, J. H. and C. W. Schindler (2000). "Dextromethorphan alters methamphetamine self-administration in the rat." *Pharmacol Biochem Behav* 67(3): 405-9.
- Kamens, H. M., S. Burkhart-Kasch, et al. (2005). "Sensitivity to psychostimulants in mice bred for high and low stimulation to methamphetamine." *Genes Brain Behav* 4(2): 110-25.
- Kitamura, O., S. Wee, et al. (2006). "Escalation of methamphetamine self-administration in rats: A dose-effect function." *Psychopharmacology (Berl)* 186(1): 48-53.
- Kruzich, P. J. and J. Xi (2006). "Differences in extinction responding and reinstatement of methamphetamine-seeking behavior between Fischer 344 and Lewis rats." *Pharmacol Biochem Behav* 83(3): 391-5.
- Kuwahara, A., A. Kubota, et al. (1987). "[Drug dependence test on a cerebral insufficiency improver, aniracetam]." *Nippon Yakurigaku Zasshi* 89(1): 33-46.
- Lile, J. A. (2006). "Pharmacological determinants of the reinforcing effects of psychostimulants: Relation to agonist substitution treatment." *Exp Clin Psychopharmacol* 14(1): 20-33.
- Maisonneuve, I. M. and S. D. Glick (2003). "Anti-addictive actions of an iboga alkaloid congener: A novel mechanism for a novel treatment." *Pharmacol Biochem Behav* 75(3): 607-18.

- McMillan, D. E., W. C. Hardwick, et al. (2004). "Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat." *J Pharmacol Exp Ther* 309(3): 1248-55.
- Moffett, M. C. and N. E. Goeders (2007). "CP-154,526, a CRF type-1 receptor antagonist, attenuates the cue-and methamphetamine-induced reinstatement of extinguished methamphetamine-seeking behavior in rats." *Psychopharmacology (Berl)* 190(2): 171-80.
- Moffett, M. C. and N. E. Goeders (2005). "Neither non-contingent electric footshock nor administered corticosterone facilitate the acquisition of methamphetamine self-administration." *Pharmacol Biochem Behav* 80(2): 333-9.
- Munzar, P., G. Tanda, et al. (2004). "Histamine h3 receptor antagonists potentiate methamphetamine self-administration and methamphetamine-induced accumbal dopamine release." *Neuropsychopharmacology* 29(4): 705-17.
- Munzar, P., S. W. Kutkat, et al. (2000). "Failure of baclofen to modulate discriminative-stimulus effects of cocaine or methamphetamine in rats." *Eur J Pharmacol* 408(2): 169-74.
- Munzar, P., M. H. Baumann, et al. (1999). "Effects of dopamine and serotonin-releasing agents on methamphetamine discrimination and self-administration in rats." *Psychopharmacology (Berl)* 141(3): 287-96.
- Nash, J. F., Jr. and R. P. Maickel (1985). "Effects of exposure to stressful stimuli on the free-choice consumption of various phenethylamines by rats." *Alcohol Drug Res* 6(6): 403-15.
- Newman, J. L. and M. E. Carroll (2006). "Reinforcing effects of smoked methamphetamine in rhesus monkeys." *Psychopharmacology (Berl)* 188(2): 193-200.
- Pace, C. J., S. D. Glick, et al. (2004). "Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration." *Eur J Pharmacol* 492(2-3): 159-67.
- Peltier, R. L., D. H. Li, et al. (1996). "Chronic d-amphetamine or methamphetamine produces cross-tolerance to the discriminative and reinforcing stimulus effects of cocaine." *J Pharmacol Exp Ther* 277(1): 212-8.
- Ranaldi, R. and K. Poeggel (2002). "Baclofen decreases methamphetamine self-administration in rats." *Neuroreport* 13(9): 1107-10.
- Ranaldi, R. and R. A. Wise (2000). "Intravenous self-administration of methamphetamine-heroin (speedball) combinations under a progressive-ratio schedule of reinforcement in rats." *Neuroreport* 11(12): 2621-3.
- Ranaldi, R., K. G. Anderson, et al. (2000). "Reinforcing and discriminative stimulus effects of RTI 111, a 3-phenyltropane analog, in rhesus monkeys: Interaction with methamphetamine." *Psychopharmacology (Berl)* 153(1): 103-10.
- Rauhut, A. S., N. Neugebauer, et al. (2003). "Effect of bupropion on nicotine self-administration in rats." *Psychopharmacology (Berl)* 169(1): 1-9.
- Roth, M. E. and M. E. Carroll (2004). "Sex differences in the acquisition of IV methamphetamine self-administration and subsequent maintenance under a progressive ratio schedule in rats." *Psychopharmacology (Berl)* 172(4): 443-9.
- Rothman, R. B., B. E. Blough, et al. (2005). "Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration." *J Pharmacol Exp Ther* 313(3): 1361-9.
- Shepard, J. D., D. T. Chuang, et al. (2006). "Effect of methamphetamine self-administration on tyrosine hydroxylase and dopamine transporter levels in mesolimbic and nigrostriatal dopamine pathways of the rat." *Psychopharmacology (Berl)* 185(4): 505-13.
- Shepard, J. D., J. M. Bossert, et al. (2004). "The anxiogenic drug yohimbine reinstates methamphetamine seeking in a rat model of drug relapse." *Biol Psychiatry* 55(11): 1082-9.
- Stefanski, R., Z. Justinova, et al. (2004). "Sigma1 receptor upregulation after chronic methamphetamine self-administration in rats: A study with yoked controls." *Psychopharmacology (Berl)* 175(1): 68-75.
- Stefanski, R., B. Ladenheim, et al. (1999). "Neuroadaptations in the dopaminergic system after active self-administration but not after passive administration of methamphetamine." *Eur J Pharmacol* 371(2-3): 123-35.
- Thompson, T. and R. Pickens (1970). "Stimulant self-administration by animals: Some comparisons with opiate self-administration." *Fed Proc* 29(1): 6-12.
- Vinklerova, J., J. Novakova, et al. (2002). "Inhibition of methamphetamine self-administration in rats by cannabinoid receptor antagonist AM 251." *J Psychopharmacol* 16(2): 139-43.
- Wang, Z. and W. L. Woolverton (2007). "Estimating the relative reinforcing strength of (+/-)-3,4-methylenedioxyamphetamine (MDMA) and its isomers in rhesus monkeys: Comparison to (+)-methamphetamine." *Psychopharmacology (Berl)* 189(4): 483-8.
- Witkin, J. M., N. Savtchenko, et al. (1999). "Behavioral, toxic, and neurochemical effects of sydnocarb, a novel psychomotor stimulant: Comparisons with methamphetamine." *J Pharmacol Exp Ther* 288(3): 1298-310.
- Witkin, J. M., G. A. Ricaurte, et al. (1990). "Behavioral effects of N-methylamphetamine and N,N-dimethylamphetamine in rats and squirrel monkeys." *J Pharmacol Exp Ther* 253(2): 466-74.
- Wolf, G., Y. Jacquet, et al. (1978). "Test for oral and postingestional factors mediating differential acceptability of morphine, methamphetamine, and chlordiazepoxide drinking solutions." *Psychopharmacology (Berl)* 60(1): 101-2.

- Woolverton, W. L., L. Cervo, et al. (1984). "Effects of repeated methamphetamine administration on methamphetamine self-administration in rhesus monkeys." *Pharmacol Biochem Behav* 21(5): 737-41.
- Yan, Y., A. Nitta, et al. (2006). "Relapse of methamphetamine-seeking behavior in C57BL/6J mice demonstrated by a reinstatement procedure involving intravenous self-administration." *Behav Brain Res* 168(1): 137-43.
- Yasar, S., J. Gaal, et al. (2005). "Discriminative stimulus and reinforcing effects of p-fluoro-L-deprenyl in monkeys." *Psychopharmacology (Berl)* 182(1): 95-103.
- Yokel, R. A. and R. Pickens (1973). "Self-administration of optical isomers of amphetamine and methylamphetamine by rats." *J Pharmacol Exp Ther* 187(1): 27-33.

## Self-Inflicted Injury and Self-Mutilation

*See also* Suicide and Suicidal Ideation

- Baskin-Sommers, A. and I. Sommers (2006). "The co-occurrence of substance use and high-risk behaviors." *J Adolesc Health* 38(5): 609-11.
- Ellison, J. M. and D. F. Dobies (1984). "Methamphetamine abuse presenting as dysuria following urethral insertion of tablets." *Ann Emerg Med* 13(3): 198-200.
- Israel, J. A. and K. Lee (2002). "Amphetamine usage and genital self-mutilation." *Addiction* 97(9): 1215-8.
- Nakano, Y., K. Kaneko and Y. Inoue (2003). "A patient with self-inflicted injuries of the cervical vertebrae and spinal cord." *Arch Orthop Trauma Surg* 123(7): 379-81.
- Tominaga, G. T., G. Garcia, et al. (2004). "Toll of methamphetamine on the trauma system." *Arch Surg* 139(8): 844-7.
- Wada, K., S. B. Greberman, et al. (1999). "HIV and HCV infection among drug users in Japan." *Addiction* 94(7): 1063-9.
- Hwang, W., J. Ralph, et al. (2003). "Incomplete Brown-Sequard syndrome after methamphetamine injection into the neck." *Neurology* 60(12): 2015-6.

## Self-Inflicted Injury and Self-Mutilation (animals)

- Blake, B. L., A. M. Muehlmann, et al. (2006). "Nifedipine suppresses self-injurious behaviors in animals." *Dev Neurosci*.
- Halladay, A. K., A. Kusnecov, et al. (2003). "Relationship between methamphetamine-induced dopamine release, hyperthermia, self-injurious behaviour and long term dopamine depletion in BALB/c and C57BL/6 mice." *Pharmacol Toxicol* 93(1): 33-41.
- Kita, T., Y. Matsunari, et al. (2000). "Methamphetamine-induced striatal dopamine release, behavior changes and neurotoxicity in BALB/c mice." *Int J Dev Neurosci* 18(6): 521-30.
- Kita, T., Y. Matsunari, et al. (2000). "Evaluation of the effects of alpha-phenyl-N-tert-butyl nitron pretreatment on the neurobehavioral effects of methamphetamine." *Life Sci* 67(13): 1559-71.
- Mori, T., S. Ito, et al. (2006). "Effects of mu-, delta- and kappa-opioid receptor agonists on methamphetamine-induced self-injurious behavior in mice." *Eur J Pharmacol* 532(1-2): 81-87.
- Razzak, A., M. Fujiwara, et al. (1977). "Possible involvement of a central noradrenergic system in automutilation induced by clonidine in mice." *Jpn J Pharmacol* 27(1): 145-52.
- Sano, H., Y. Totsuka, et al. (1982). "[Methamphetamine-stereotypy and hypermotility] in rats chronically treated with reserpine--the effect of intracerebral injection of chlorpromazine]." *Nippon Yakurigaku Zasshi* 80(2): 113-24.
- Wagner, G. C., N. Avena, et al. (2004). "Risperidone reduction of amphetamine-induced self-injurious behavior in mice." *Neuropharmacology* 46(5): 700-8.

## Self-Perception

- Semple, S. J., I. Grant, et al. (2005). "Negative self-perceptions and sexual risk behavior among heterosexual methamphetamine users." *Substance Use & Misuse* 40(12): 1797-1810.

## Self-Regulation

- Uitermark, J. and P. D. A. Cohen (2006). "Amphetamine users in Amsterdam: Patterns of use and modes of self-regulation." *Addiction Research & Theory* 14(2): 159-188.
- Uitermark, J. and P. Cohen (2004). Amphetamine users in Amsterdam: Patterns of use and modes of self-regulation, Centrum voor drugsonderzoek.

### Sensation Seeking

*See also* Pleasure and Pleasure-Seeking Behaviors; Sexual Arousal and Sexual Experiences

- Brecht, M. L., L. Greenwell, et al. (2007). "Substance use pathways to methamphetamine use among treated users." *Addict Behav* 32(1): 24-38.
- Brecht, M. L., A. O'Brien, et al. (2004). "Methamphetamine use behaviors and gender differences." *Addict Behav* 29(1): 89-106.
- Fendrich, M., J. S. Wislar, et al. (2003). "A contextual profile of club drug use among adults in Chicago." *Addiction* 98(12): 1693-703.
- Herman-Stahl, M. A., C. P. Krebs, et al. (2006). "Risk and protective factors for methamphetamine use and nonmedical use of prescription stimulants among young adults aged 18 to 25." *Addict Behav*.
- Herman-Stahl, M. A., C. P. Krebs, et al. (2006). "Risk and protective factors for nonmedical use of prescription stimulants and methamphetamine among adolescents." *J Adolesc Health* 39(3): 374-80.
- Ross, M. W., A. M. Mattison, et al. (2003). "Club drugs and sex on drugs are associated with different motivations for gay circuit party attendance in men." *Subst Use Misuse* 38(8): 1173-83.

### Serotonin and Serotonin Metabolism

- Baumgarten, H. G. and L. Lachenmayer (2004). "Serotonin neurotoxins--past and present." *Neurotox Res* 6(7-8): 589-614.
- Chang, L. and W. Haning (2006). "Insights from recent positron emission tomographic studies of drug abuse and dependence." *Curr Opin Psychiatry* 19(3): 246-252.
- Cozzi, N. V., M. K. Sievert, et al. (1999). "Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines." *Eur J Pharmacol* 381(1): 63-9.
- Dryhurst, G. (2001). "Are dopamine, norepinephrine, and serotonin precursors of biologically reactive intermediates involved in the pathogenesis of neurodegenerative brain disorders?" *Adv Exp Med Biol* 500: 373-96.
- Ellison, G. (2002). "Neural degeneration following chronic stimulant abuse reveals a weak link in brain, fasciculus retroflexus, implying the loss of forebrain control circuitry." *Eur Neuropsychopharmacol* 12(4): 287-97.
- Fuller, R. W. (1978). "Structure-activity relationships among the halogenated amphetamines." *Ann N Y Acad Sci* 305: 147-59.
- Grady, T. A., A. Brooks, et al. (1996). "Biological and behavioral responses to D-amphetamine, alone and in combination with the serotonin<sub>3</sub> receptor antagonist ondansetron, in healthy volunteers." *Psychiatry Res* 64(1): 1-10.
- Hilber, B., P. Scholze, et al. (2005). "Serotonin-transporter mediated efflux: A pharmacological analysis of amphetamines and non-amphetamines." *Neuropharmacology* 49(6): 811-9.
- Hong, C. J., C. Y. Cheng, et al. (2003). "Association study of the dopamine and serotonin transporter genetic polymorphisms and methamphetamine abuse in Chinese males." *J Neural Transm* 110(4): 345-51.
- Iyo, M., M. Nishio, et al. (1993). "Dopamine D<sub>2</sub> and serotonin S<sub>2</sub> receptors in susceptibility to methamphetamine psychosis detected by positron emission tomography." *Psychiatry Res* 50(4): 217-31.
- Johnson, R. A., A. J. Eshleman, et al. (1998). "[<sup>3</sup>H]substrate- and cell-specific effects of uptake inhibitors on human dopamine and serotonin transporter-mediated efflux." *Synapse* 30(1): 97-106.
- Kim, H. C., E. J. Shin, et al. (2005). "Pharmacological action of Panax ginseng on the behavioral toxicities induced by psychotropic agents." *Arch Pharm Res* 28(9): 995-1001.
- Kuhn, D. M. (1999). "Tryptophan hydroxylase regulation. Drug-induced modifications that alter serotonin neuronal function." *Adv Exp Med Biol* 467: 19-27.
- Lile, J. A. (2006). "Pharmacological determinants of the reinforcing effects of psychostimulants: Relation to agonist substitution treatment." *Exp Clin Psychopharmacol* 14(1): 20-33.
- Nordahl, T. E., R. Salo, et al. (2003). "Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: A review." *J Neuropsychiatry Clin Neurosci* 15(3): 317-25.
- Nordahl, T. E., R. Salo, et al. (2002). "Low N-acetyl-aspartate and high choline in the anterior cingulum of recently abstinent methamphetamine-dependent subjects: A preliminary proton MRS study. Magnetic resonance spectroscopy." *Psychiatry Res* 116(1-2): 43-52.
- Okuyama, S., S. Chaki, et al. (1997). "In vitro and in vivo characterization of the dopamine D<sub>4</sub> receptor, serotonin 5-HT<sub>2A</sub> receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl]pyrrolidin-3-yl]thiazole (NRA0045)." *J Pharmacol Exp Ther* 282(1): 56-63.
- Powrozek, T. A., Y. Sari, et al. (2004). "Neurotransmitters and substances of abuse: Effects on adult neurogenesis." *Curr Neurovasc Res* 1(3): 251-60.



- Quinton, M. S. and B. K. Yamamoto (2006). "Causes and consequences of methamphetamine and MDMA toxicity." *AAPS J* 8(2): E337-47.
- Ramamoorthy, J. D., S. Ramamoorthy, et al. (1995). "Human placental monoamine transporters as targets for amphetamines." *Am J Obstet Gynecol* 173(6): 1782-7.
- Rogers, R. D., B. J. Everitt, et al. (1999). "Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: Evidence for monoaminergic mechanisms." *Neuropsychopharmacology* 20(4): 322-39.
- Rothman, R. B., B. E. Blough, et al. (2006). "Dual dopamine-5-HT releasers: Potential treatment agents for cocaine addiction." *Trends Pharmacol Sci* 27(12): 612-8.
- Salo, R., T. E. Nordahl, et al. (2002). "Preliminary evidence of reduced cognitive inhibition in methamphetamine-dependent individuals." *Psychiatry Res* 111(1): 65-74.
- Selden, L. S. (1991). "Neurotoxicity of methamphetamine: Mechanisms of action and issues related to aging." *NIDA Res Monogr* 115: 24-32.
- Sekine, Y., Y. Ouchi, et al. (2006). "Brain serotonin transporter density and aggression in abstinent methamphetamine abusers." *Arch Gen Psychiatry* 63(1): 90-100.
- Sulzer, D., M. S. Sonders, et al. (2005). "Mechanisms of neurotransmitter release by amphetamines: A review." *Prog Neurobiol* 75(6): 406-433.
- Wachtel, S. R., A. Ortengren, et al. (2002). "The effects of acute haloperidol or risperidone on subjective responses to methamphetamine in healthy volunteers." *Drug Alcohol Depend* 68(1): 23-33.
- Wrona, M. Z. and G. Dryhurst (1998). "Oxidation of serotonin by superoxide radical: Implications to neurodegenerative brain disorders." *Chem Res Toxicol* 11(6): 639-50.
- Wrona, M. Z., Z. Yang, et al. (1997). "Potential new insights into the molecular mechanisms of methamphetamine-induced neurodegeneration." *NIDA Res Monogr* 173: 146-74.
- Yamamoto, B. K. and M. G. Bankson (2005). "Amphetamine neurotoxicity: Cause and consequence of oxidative stress." *Crit Rev Neurobiol* 17(2): 87-118.
- Yui, K., K. Goto, S. Ikemoto and T. Ishiguro (1997). "Monoamine neurotransmitter metabolites and spontaneous recurrence of methamphetamine psychosis." *Brain Res Bull* 43(1): 25-33.

## Serotonin and Serotonin Metabolism (animals)

- Achat-Mendes, C., S. F. Ali, et al. (2005). "Differential effects of amphetamines-induced neurotoxicity on appetitive and aversive Pavlovian conditioning in mice." *Neuropsychopharmacology* 30(6): 1128-37.
- Ago, Y., S. Nakamura, et al. (2006). "Attenuation by the 5-HT(1A) receptor agonist osetozotan of the behavioral effects of single and repeated methamphetamine in mice." *Neuropharmacology* 51(4): 914-22.
- Allan, A. M., R. Galindo, et al. (2001). "Conditioned place preference for cocaine is attenuated in mice over-expressing the 5-HT(3) receptor." *Psychopharmacology (Berl)* 158(1): 18-27.
- Armstrong, B. D. and K. K. Noguchi (2004). "The neurotoxic effects of 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine on serotonin, dopamine, and GABA-ergic terminals: an in-vitro autoradiographic study in rats." *Neurotoxicology* 25(6): 905-14.
- Barnett, A., R. I. Taber, et al. (1969). "Mechanism of action of antihistamines in laboratory antidepressant tests." *Int J Neuropharmacol* 8(4): 353-60.
- Baumann, M. H., J. M. Phillips, et al. (2002). "Preclinical evaluation of GBR12909 decanoate as a long-acting medication for methamphetamine dependence." *Ann N Y Acad Sci* 965: 92-108.
- Baumgarten, H. G. and L. Lachenmayer (2004). "Serotonin neurotoxins--past and present." *Neurotox Res* 6(7-8): 589-614.
- Binienda, Z. K., B. D. Przybyla, et al. (2006). "Effects of L-carnitine pretreatment in methamphetamine and 3-nitropropionic acid-induced neurotoxicity." *Ann N Y Acad Sci* 1074: 74-83.
- Brunswick, D. J., S. Benmansour, et al. (1992). "Effects of high-dose methamphetamine on monoamine uptake sites in rat brain measured by quantitative autoradiography." *Synapse* 11(4): 287-93.
- Burrows, K. B., W. L. Nixdorf, et al. (2000). "Central administration of methamphetamine synergizes with metabolic inhibition to deplete striatal monoamines." *J Pharmacol Exp Ther* 292(3): 853-60.
- Busche, A., A. Bagorda, et al. (2006). "The maturation of the acetylcholine system in the dentate gyrus of gerbils (*Meriones unguiculatus*) is affected by epigenetic factors." *J Neural Transm* 113(2): 113-24.
- Cadet, J. L., S. Ali, et al. (1994). "Involvement of oxygen-based radicals in methamphetamine-induced neurotoxicity: Evidence from the use of CuZnSOD transgenic mice." *Ann N Y Acad Sci* 738: 388-91.

- Cass, W. A., M. P. Smith, et al. (2006). "Calcitriol protects against the dopamine- and serotonin-depleting effects of neurotoxic doses of methamphetamine." *Ann N Y Acad Sci* 1074: 261-71.
- Cass, W. A. (2000). "Attenuation and recovery of evoked overflow of striatal serotonin in rats treated with neurotoxic doses of methamphetamine." *J Neurochem* 74(3): 1079-85.
- Cass, W. A. (1996). "GDNF selectively protects dopamine neurons over serotonin neurons against the neurotoxic effects of methamphetamine." *J Neurosci* 16(24): 8132-9.
- Clemens, K. J., J. L. Cornish, et al. (2006). "Intravenous methamphetamine self-administration in rats: Effects of intravenous or intraperitoneal MDMA co-administration." *Pharmacol Biochem Behav* 85(2): 454-63.
- Cozzi, N. V., M. K. Sievert, et al. (1999). "Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines." *Eur J Pharmacol* 381(1): 63-9.
- Dallo, J. (1979). "Possible role of the serotonergic system in the behavioral effect of massed electroconvulsive shock in rat." *Pol J Pharmacol Pharm* 31(4): 271-6.
- Daberkow, D. P., R. P. Kesner, et al. (2005). "Relation between methamphetamine-induced monoamine depletions in the striatum and sequential motor learning." *Pharmacol Biochem Behav* 81(1): 198-204.
- Dryhurst, G. (2001). "Are dopamine, norepinephrine, and serotonin precursors of biologically reactive intermediates involved in the pathogenesis of neurodegenerative brain disorders?" *Adv Exp Med Biol* 500: 373-96.
- Ellison, G. (2002). "Neural degeneration following chronic stimulant abuse reveals a weak link in brain, fasciculus retroflexus, implying the loss of forebrain control circuitry." *Eur Neuropsychopharmacol* 12(4): 287-97.
- Fantegrossi, W. E., W. L. Woolverton, et al. (2004). "Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys." *Neuropsychopharmacology* 29(7): 1270-81.
- Fantegrossi, W. E., T. Ullrich, et al. (2002). "3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: Serotonergic involvement." *Psychopharmacology (Berl)* 161(4): 356-64.
- Fleckenstein, A. E., H. M. Haughey, et al. (1999). "Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function." *Eur J Pharmacol* 382(1): 45-9.
- Fuller, R. W. (1978). "Structure-activity relationships among the halogenated amphetamines." *Ann N Y Acad Sci* 305: 147-59.
- Geyer, M. A. (1996). "Serotonergic functions in arousal and motor activity." *Behav Brain Res* 73(1-2): 31-5.
- Gibb, J. W., M. Johnson, et al. (1990). "Neurochemical basis of neurotoxicity." *Neurotoxicology* 11(2): 317-21.
- Ginawi, O. T., A. A. Al-Majed, et al. (2005). "NAN-190, a possible specific antagonist for methamphetamine." *Regul Toxicol Pharmacol* 41(2): 122-7.
- Glick, S. D., I. M. Maisonneuve, et al. (2002). "Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration." *Eur J Pharmacol* 438(1-2): 99-105.
- Han, D. D. and H. H. Gu (2006). "Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs." *BMC Pharmacol* 6: 6.
- Haughey, H. M., J. M. Brown, et al. (2000). "Differential effects of methamphetamine on Na(+)/Cl(-)-dependent transporters." *Brain Res* 863(1-2): 59-65.
- Hirata, H., M. Asanuma, et al. (1998). "Melatonin attenuates methamphetamine-induced toxic effects on dopamine and serotonin terminals in mouse brain." *Synapse* 30(2): 150-5.
- Hirata, H. and J. L. Cadet (1997). "Methamphetamine-induced serotonin neurotoxicity is attenuated in p53-knockout mice." *Brain Res* 768(1-2): 345-8.
- Hirata, H., B. Ladenheim, et al. (1995). "Methamphetamine-induced serotonin neurotoxicity is mediated by superoxide radicals." *Brain Res* 677(2): 345-7.
- Honma, T. and H. Fukushima (1979). "The involvement of serotonergic neurons in the central nervous system as the possible mechanism for slow head-shaking behavior induced by methamphetamine in rats." *Psychopharmacology (Berl)* 65(2): 155-9.
- Horner, K. A., D. H. Adams, et al. (2005). "Blockade of stimulant-induced preprodynorphin mRNA expression in the striatal matrix by serotonin depletion." *Neuroscience* 131(1): 67-77.
- Itzhak, Y. and S. F. Ali (2006). "Role of nitrenergic system in behavioral and neurotoxic effects of amphetamine analogs." *Pharmacol Ther* 109(1-2): 246-62.
- Kim, H. C., E. J. Shin, et al. (2005). "Pharmacological action of Panax ginseng on the behavioral toxicities induced by psychotropic agents." *Arch Pharm Res* 28(9): 995-1001.
- Kitanaka, N., J. Kitanaka, et al. (2005). "Inhibition of methamphetamine-induced hyperlocomotion in mice by clorgyline, a monoamine oxidase-a inhibitor, through alteration of the 5-hydroxytryptamine turnover in the striatum." *Neuroscience* 130(2): 295-308.
- Kokoshka, J. M., R. R. Metzger, et al. (1998). "Methamphetamine treatment rapidly inhibits serotonin, but not glutamate, transporters in rat brain." *Brain Res* 799(1): 78-83.

- Kovachich, G. B., C. E. Aronson, et al. (1989). "Effects of high-dose methamphetamine administration on serotonin uptake sites in rat brain measured using [3H]cyanoimipramine autoradiography." *Brain Res* 505(1): 123-9.
- Kuhn, D. M. (1999). "Tryptophan hydroxylase regulation. Drug-induced modifications that alter serotonin neuronal function." *Adv Exp Med Biol* 467: 19-27.
- Lehmann, K., J. Lesting, et al. (2003). "Serotonin fibre densities in subcortical areas: Differential effects of isolated rearing and methamphetamine." *Brain Res Dev Brain Res* 147(1-2): 143-52.
- Lesting, J., J. Neddens, et al. (2005). "Hemisphere-specific effects on serotonin but not dopamine innervation in the nucleus accumbens of gerbils caused by isolated rearing and a single early methamphetamine challenge." *Brain Res* 1035(2): 168-76.
- McCabe, R. T., J. W. Gibb, et al. (1987). "Autoradiographic analysis of muscarinic cholinergic and serotonergic receptor alterations following methamphetamine treatment." *Brain Res Bull* 19(5): 551-7.
- McDaid, J., C. E. Tedford, et al. (2007). "Nullifying drug-induced sensitization: Behavioral and electrophysiological evaluations of dopaminergic and serotonergic ligands in methamphetamine-sensitized rats." *Drug Alcohol Depend* 86(1): 55-66.
- Munzar, P., M. H. Baumann, et al. (1999). "Effects of dopamine and serotonin-releasing agents on methamphetamine discrimination and self-administration in rats." *Psychopharmacology (Berl)* 141(3): 287-96.
- Nash, J. F. and B. K. Yamamoto (1992). "Methamphetamine neurotoxicity and striatal glutamate release: Comparison to 3,4-methylenedioxymethamphetamine." *Brain Res* 581(2): 237-43.
- Nishikawa, T. and M. Tanaka (1978). "Altered behavioral responses to intense foot shock in socially-isolated rats." *Pharmacol Biochem Behav* 8(1): 61-7.
- Noda, Y., Y. Miyamoto, et al. (1998). "Involvement of dopaminergic system in phencyclidine-induced place preference in mice pretreated with phencyclidine repeatedly." *J Pharmacol Exp Ther* 286(1): 44-51.
- Noda, Y. and T. Nabeshima (1998). "Neuronal mechanisms of phencyclidine-induced place aversion and preference in the conditioned place preference task." *Methods Find Exp Clin Pharmacol* 20(7): 607-11.
- Ohmori, T., T. Abekawa, et al. (1996). "The role of glutamate in the neurotoxic effects of methamphetamine." *Ann N Y Acad Sci* 801: 315-26.
- Okuyama, S., S. Chaki, et al. (1997). "In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl]pyrrolidin-3-yl]thiazole (NRA0045)." *J Pharmacol Exp Ther* 282(1): 56-63.
- Ono, M., A. Watanabe, et al. (1996). "Methamphetamine modifies the photic entraining responses in the rodent suprachiasmatic nucleus via serotonin release." *Neuroscience* 72(1): 213-24.
- Ozaki, N., D. Nakahara, et al. (1991). "The effect of methamphetamine on serotonin and its metabolite in the suprachiasmatic nucleus: A microdialysis study." *J Neural Transm Gen Sect* 86(3): 175-9.
- Park, M. J., S. K. Lee, et al. (2006). "Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity." *Brain Res* 1109(1): 176-82.
- Pieri, M., L. Pieri, et al. (1975). "A comparison of drug-induced rotation in rats lesioned in the medial forebrain bundle with 5,6-dihydroxytryptamine or 6-hydroxydopamine." *Arch Int Pharmacodyn Ther* 217(1): 118-30.
- Preston, K. L., G. C. Wagner, et al. (1984). "Effects of methamphetamine on atropine-induced conditioned gustatory avoidance." *Pharmacol Biochem Behav* 20(4): 601-7.
- Rocher, C. and A. M. Gardier (2001). "Effects of repeated systemic administration of d-Fenfluramine on serotonin and glutamate release in rat ventral hippocampus: comparison with methamphetamine using in vivo microdialysis." *Naunyn Schmiedebergs Arch Pharmacol* 363(4): 422-8.
- Rothman, R. B., B. E. Blough, et al. (2006). "Dual dopamine-5-HT releasers: Potential treatment agents for cocaine addiction." *Trends Pharmacol Sci* 27(12): 612-8.
- Rothman, R. B., B. E. Blough, et al. (2002). "Appetite suppressants as agonist substitution therapies for stimulant dependence." *Ann N Y Acad Sci* 965: 109-26.
- Rothman, R. B., J. S. Partilla, et al. (2000). "Methamphetamine dependence: Medication development efforts based on the dual deficit model of stimulant addiction." *Ann N Y Acad Sci* 914: 71-81.
- Rothman, R. B., N. Vu, et al. (2003). "In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates." *J Pharmacol Exp Ther* 307(1): 138-45.
- Rothman, R. B., M. H. Baumann, et al. (2001). "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin." *Synapse* 39(1): 32-41.
- Rothman, R. B., J. S. Partilla, et al. (2000). "Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: A pharmacological strategy for treating stimulant abuse." *Synapse* 35(3): 222-7.
- Saavedra, J. M. and E. Fischer (1970). "Antagonism of beta-phenylethylamine derivatives and serotonin blocking drugs upon serotonin, tryptamine and reserpine behavioral depression in mice." *Arzneimittelforschung* 20(7): 952-7.

- Sabol, K. E., J. B. Richards, et al. (2000). "The effects of high-dose methamphetamine in the aging rat: Differential reinforcement of low-rate 72-s schedule behavior and neurochemistry." *J Pharmacol Exp Ther* 294(3): 850-63.
- Stadlin, A., J. W. Lau, et al. (1998). "A selective regional response of cultured astrocytes to methamphetamine." *Ann N Y Acad Sci* 844: 108-21.
- Staszewski, R. D. and B. K. Yamamoto (2006). "Methamphetamine-induced spectrin proteolysis in the rat striatum." *J Neurochem* 96(5): 1267-76.
- Stephans, S. and B. Yamamoto (1996). "Methamphetamines pretreatment and the vulnerability of the striatum to methamphetamine neurotoxicity." *Neuroscience* 72(3): 593-600.
- Sulzer, D., M. S. Sonders, et al. (2005). "Mechanisms of neurotransmitter release by amphetamines: A review." *Prog Neurobiol* 75(6): 406-433.
- Takamatsu, Y., H. Yamamoto, et al. (2006). "Fluoxetine as a potential pharmacotherapy for methamphetamine dependence: Studies in mice." *Ann N Y Acad Sci* 1074: 295-302.
- Wrona, M. Z., Z. Yang, et al. (1997). "Potential new insights into the molecular mechanisms of methamphetamine-induced neurodegeneration." *NIDA Res Monogr* 173: 146-74.
- Yamamoto, B. K. and M. G. Bankson (2005). "Amphetamine neurotoxicity: Cause and consequence of oxidative stress." *Crit Rev Neurobiol* 17(2): 87-118.
- Yoo, J. H., J. H. Cho, et al. (2006). "Involvement of 5-HT receptors in the development and expression of methamphetamine-induced behavioral sensitization: 5-HT receptor channel and binding study." *J Neurochem* 99(3): 976-88.
- Yu, L. and P. C. Liao (2000). "Sexual differences and estrous cycle in methamphetamine-induced dopamine and serotonin depletions in the striatum of mice." *J Neural Transm* 107(4): 419-27.
- Yu, L. and P. C. Liao (2000). "Estrogen and progesterone distinctively modulate methamphetamine-induced dopamine and serotonin depletions in C57BL/6J mice." *J Neural Transm* 107(10): 1139-47.
- Zolkowska, D., R. B. Rothman, et al. (2006). "Amphetamine analogs increase plasma serotonin: Implications for cardiac and pulmonary disease." *J Pharmacol Exp Ther* 318(2): 604-10.

### Setting

- de Wit, H., M. Clark, et al. (1997). "Effects of d-amphetamine in grouped versus isolated humans." *Pharmacol Biochem Behav* 57(1-2): 333-40.
- Halkitis, P. N., K. A. Green, et al. (2005). "Longitudinal investigation of methamphetamine use among gay and bisexual men in New York City: findings from Project BUMPS." *J Urban Health* 82(1 Suppl 1): i18-25.
- Hopfer, C., B. Mendelson, et al. (2006). "Club drug use among youths in treatment for substance abuse." *Am J Addict* 15(1): 94-9.
- Lessov, C. N., G. E. Swan, et al. (2004). "Genetics and drug use as a complex phenotype." *Subst Use Misuse* 39(10-12): 1515-69.
- Lipinski, E. (1972). "Motivation in drug misuse. Some comments on agent, environment, host." *Jama* 219(2): 171-5.
- Morton, A. J., M. A. Hickey, et al. (2001). "Methamphetamine toxicity in mice is potentiated by exposure to loud music." *Neuroreport* 12(15): 3277-81.
- Ohmori, T., T. Abekawa, et al. (1997). "[Context-dependent sensitization: reconsideration and a hypothesis]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 17(2): 61-8.
- Randrup, A., G. Sorensen, et al. (1988). "Stereotyped behaviour in animals induced by stimulant drugs or by a restricted cage environment: Relation to disintegrated behaviour, brain dopamine and psychiatric disease." *Yakubutsu Seishin Kodo* 8(2): 313-27.
- Stitzer, M. L., R. R. Griffiths, et al. (1978). "Effects of d-amphetamine on speaking in isolated humans." *Pharmacol Biochem Behav* 9(1): 57-63.
- Zacny, J. P., B. K. Bodker, et al. (1992). "Effects of setting on the subjective and behavioral effects of d-amphetamine in humans." *Addict Behav* 17(1): 27-33.

### Sex Differences

*See also* Estrogen; Men; Testosterone; Women

- Bae, S. C., I. K. Lyoo, et al. (2006). "Increased white matter hyperintensities in male methamphetamine abusers." *Drug Alcohol Depend* 81(1): 83-8.
- Bialek, M., P. Zaremba, et al. (2004). "Neuroprotective role of testosterone in the nervous system." *Pol J Pharmacol* 56(5): 509-18.
- Bogart, L. M., A. H. Kral, et al. (2005). "Sexual risk among injection drug users recruited from syringe exchange programs in California." *Sex Transm Dis* 32(1): 27-34.

- Booth, B. M., C. Leukefeld, et al. (2006). "Correlates of rural methamphetamine and cocaine users: Results from a multistate community study." *J Stud Alcohol* 67(4): 493-501.
- Brecht, M. L., L. Greenwell, et al. (2005). "Methamphetamine treatment: Trends and predictors of retention and completion in a large state treatment system (1992-2002)." *J Subst Abuse Treat* 29(4): 295-306.
- Brecht, M. L., A. O'Brien, et al. (2004). "Methamphetamine use behaviors and gender differences." *Addict Behav* 29(1): 89-106.
- Caetano, R. and C. Weisner (1995). "The association between DSM-III-R alcohol dependence, psychological distress and drug use." *Addiction* 90(3): 351-9.
- Chang, L., T. Ernst, et al. (2002). "Perfusion MRI and computerized cognitive test abnormalities in abstinent methamphetamine users." *Psychiatry Res* 114(2): 65-79.
- Chung, A., I. K. Lyoo, et al. (2006). "Decreased frontal white-matter integrity in abstinent methamphetamine abusers." *Int J Neuropsychopharmacol*: 1-11.
- Cohen, J. B., A. Dickow, et al. (2003). "Abuse and violence history of men and women in treatment for methamphetamine dependence." *Am J Addict* 12(5): 377-85.
- Copeland, A. L. and J. L. Sorensen (2001). "Differences between methamphetamine users and cocaine users in treatment." *Drug Alcohol Depend* 62(1): 91-5.
- Cruz, M. F., A. Mantsios, et al. (2006). "A qualitative exploration of gender in the context of injection drug use in two US-Mexico border cities." *AIDS Behav*.
- Darke, S., J. Ross, et al. (1995). "Injecting and sexual risk-taking behaviour among regular amphetamine users." *AIDS Care* 7(1): 19-26.
- Dluzen, D. E. and J. L. McDermott (2004). "Developmental and genetic influences upon gender differences in methamphetamine-induced nigrostriatal dopaminergic neurotoxicity." *Ann N Y Acad Sci* 1025: 205-20.
- Dluzen, D. E. and J. L. McDermott (2002). "Estrogen, anti-estrogen, and gender: differences in methamphetamine neurotoxicity." *Ann N Y Acad Sci* 965: 136-56.
- Evans, E. and D. Longshore (2004). "Evaluation of the substance abuse and crime prevention act: treatment clients and program types during the first year of implementation." *J Psychoactive Drugs Suppl* 2: 165-74.
- Fendrich, M., J. S. Wislar, T. P. Johnson and A. Hubbell (2003). "A contextual profile of club drug use among adults in Chicago." *Addiction* 98(12): 1693-703.
- Goldsamt, L. A., J. O'Brien, et al. (2005). "The relationship between club drug use and other drug use: A survey of New York City middle school students." *Subst Use Misuse* 40(9): 1539-55.
- Golub, M., L. Costa, et al. (2005). "NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of amphetamine and methamphetamine." *Birth Defects Res B Dev Reprod Toxicol* 74(6): 471-584.
- Gonzales, R., P. Marinelli-Casey, et al. (2006). "Hepatitis C virus infection among methamphetamine-dependent individuals in outpatient treatment." *J Subst Abuse Treat* 31(2): 195-202.
- Herman-Stahl, M. A., C. P. Krebs, et al. (2006). "Risk and protective factors for methamphetamine use and nonmedical use of prescription stimulants among young adults aged 18 to 25." *Addict Behav*.
- Herman-Stahl, M. A., C. P. Krebs, et al. (2006). "Risk and protective factors for nonmedical use of prescription stimulants and methamphetamine among adolescents." *J Adolesc Health* 39(3): 374-80.
- Hser, Y. I., E. Evans, et al. (2005). "Treatment outcomes among women and men methamphetamine abusers in California." *J Subst Abuse Treat* 28(1): 77-85.
- Hser, Y. I., C. Teruya, et al. (2003). "Treating drug-abusing offenders. Initial findings from a five-county study on the impact of California's Proposition 36 on the treatment system and patient outcomes." *Eval Rev* 27(5): 479-505.
- Itoh, K., K. Hashimoto, et al. (2005). "Association study between brain-derived neurotrophic factor gene polymorphisms and methamphetamine abusers in Japan." *Am J Med Genet B Neuropsychiatr Genet* 132(1): 70-3.
- Kassebaum, G. and S. M. Chandler (1994). "Polydrug use and self control among men and women in prisons." *J Drug Educ* 24(4): 333-50.
- Kelly, B. C., J. T. Parsons, et al. (2006). "Prevalence and predictors of club drug use among club-going young adults in New York City." *J Urban Health* 83(5): 884-895.
- Kim, J. Y. and M. Fendrich (2002). "Gender differences in juvenile arrestees' drug use, self-reported dependence, and perceived need for treatment." *Psychiatr Serv* 53(1): 70-5.
- Kral, A. H., R. N. Bluthenthal, et al. (2001). "Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: Risk-factor analysis." *Lancet* 357(9266): 1397-401.
- Kim, J. Y. and M. Fendrich (2002). "Gender differences in juvenile arrestees' drug use, self-reported dependence, and perceived need for treatment." *Psychiatr Serv* 53(1): 70-5.
- Kim, S. J., I. K. Lyoo, et al. (2005). "Frontal glucose hypometabolism in abstinent methamphetamine users." *Neuropsychopharmacology* 30(7): 1383-91.

- Kobayashi, H., S. Ide, et al. (2004). "Study of association between alpha-synuclein gene polymorphism and methamphetamine psychosis/dependence." *Ann N Y Acad Sci* 1025: 325-34.
- Koizumi, H., K. Hashimoto, et al. (2004). "Association between the glutathione S-transferase M1 gene deletion and female methamphetamine abusers." *Am J Med Genet B Neuropsychiatr Genet* 126(1): 43-5.
- Lin, S. K., D. Ball, et al. (2004). "Psychiatric comorbidity and gender differences of persons incarcerated for methamphetamine abuse in Taiwan." *Psychiatry Clin Neurosci* 58(2): 206-12.
- Lin, S. K., C. K. Chen, et al. (2003). "Gender-specific contribution of the GABA(A) subunit genes on 5q33 in methamphetamine use disorder." *Pharmacogenomics J* 3(6): 349-55.
- Liu, A., P. Kilmarx, et al. (2006). "Sexual initiation, substance use, and sexual behavior and knowledge among vocational students in northern Thailand." *Int Fam Plan Perspect* 32(3): 126-35.
- Liu, H. C., C. K. Chen, et al. (2006). "Association between dopamine receptor D1 A-48G polymorphism and methamphetamine abuse." *Psychiatry Clin Neurosci* 60(2): 226-31.
- Maglione, M., B. Chao, et al. (2000). "Correlates of outpatient drug treatment drop-out among methamphetamine users." *J Psychoactive Drugs* 32(2): 221-8.
- Maglione, M., B. Chao, et al. (1998). "Methamphetamine abuse in California: Correlates of injection use." *AIDS and Behavior* 2(3): 257-261.
- Mikami, T., N. Naruse, et al. (2003). "Determining vulnerability to schizophrenia in methamphetamine psychosis using exploratory eye movements." *Psychiatry Clin Neurosci* 57(4): 433-40.
- Miura, H., M. Fujiki, et al. (2006). "Prevalence and profile of methamphetamine users in adolescents at a juvenile classification home." *Psychiatry Clin Neurosci* 60(3): 352-7.
- Molitor, F., J. D. Ruiz, et al. (1999). "Methamphetamine use and sexual and injection risk behaviors among out-of-treatment injection drug users." *Am J Drug Alcohol Abuse* 25(3): 475-93.
- Munro, C. A., M. E. McCaul, et al. (2006). "Sex differences in striatal dopamine release in healthy adults." *Biol Psychiatry* 59(10): 966-74.
- Oetting, E. R., J. L. Deffenbacher, et al. (2000). "Methamphetamine use by high school students: Recent trends, gender and ethnicity differences, and use of other drugs." *Journal of Child and Adolescent Substance Abuse* 10(1): 33-50.
- Ohgake, S., K. Hashimoto, et al. (2005). "Functional polymorphism of the NQO2 gene is associated with methamphetamine psychosis." *Addict Biol* 10(2): 145-8.
- Ozaki, S. (2004). "[Current situation of substance abuse/dependence in psychiatric hospital settings]." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 39(1): 35-40.
- Rawson, R. A., R. Gonzales, et al. (2005). "Methamphetamine use among treatment-seeking adolescents in Southern California: Participant characteristics and treatment response." *J Subst Abuse Treat* 29(2): 67-74.
- Rawson, R. A., A. Washton, C. P. Domier and C. Reiber (2002). "Drugs and sexual effects: Role of drug type and gender." *J Subst Abuse Treat* 22(2): 103-8.
- Rawson, R., A. Huber, et al. (2000). "Methamphetamine and cocaine users: Differences in characteristics and treatment retention." *J Psychoactive Drugs* 32(2): 233-8.
- Senjo, S. R. (2005). "Trafficking in meth: An analysis of the differences between male and female dealers." *J Drug Educ* 35(1): 59-77.
- Sery, O., V. Vojtova, et al. (2001). "The association study of DRD2, ACE and AGT gene polymorphisms and metamphetamine dependence." *Physiol Res* 50(1): 43-50.
- Simons, J. S., M. N. Oliver, et al. (2005). "Methamphetamine and alcohol abuse and dependence symptoms: Associations with affect lability and impulsivity in a rural treatment population." *Addict Behav* 30(7): 1370-81.
- Storr, C. L., A. M. Arria, et al. (2004). "Neighborhood environment and opportunity to try methamphetamine ("ice") and marijuana: Evidence from Guam in the Western Pacific region of Micronesia." *Subst Use Misuse* 39(2): 253-76.
- Turchan, J., C. Anderson, et al. (2001). "Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine." *BMC Neurosci* 2: 3.
- Weiser, S. D., S. E. Dilworth, et al. (2006). "Gender-specific correlates of sex trade among homeless and marginally housed individuals in San Francisco." *J Urban Health* 83(4): 736-40.
- Wu, L. T., W. E. Schlenger, et al. (2006). "Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths." *Drug Alcohol Depend* 84(1): 102-13.
- Yen, C. F. and M. Y. Chong (2006). "Comorbid psychiatric disorders, sex, and methamphetamine use in adolescents: A case-control study." *Compr Psychiatry* 47(3): 215-20.
- Yen, C. F. and Y. C. Su (2006). "The associations of early-onset methamphetamine use with psychiatric morbidity among Taiwanese adolescents." *Subst Use Misuse* 41(1): 35-44.

Yen, C. F., Y. H. Yang, et al. (2005). "Substance initiation sequences among Taiwanese adolescents using methamphetamine." *Psychiatry Clin Neurosci* 59(6): 683-9.

## Sex Differences (animals)

*See also* Estrogen (animals); Testosterone (animals)

- Acevedo, S. F., I. J. de Esch, et al. (2006). "Sex- and histamine-dependent long-term cognitive effects of methamphetamine exposure." *Neuropsychopharmacology*.
- Anderson, L. I., R. E. Leipheimer, et al. (2005). "Effects of neonatal and prepubertal hormonal manipulations upon estrogen neuroprotection of the nigrostriatal dopaminergic system within female and male mice." *Neuroscience* 130(2): 369-82.
- Bhatt, S. D. and D. E. Dluzen (2005). "Dopamine transporter function differences between male and female CD-1 mice." *Brain Res* 1035(2): 188-95.
- Bisagno, V., R. Bowman, et al. (2003). "Functional aspects of estrogen neuroprotection." *Endocrine* 21(1): 33-41.
- Chen, H. H., Y. K. Yang, et al. (2003). "Methamphetamine-induced conditioned place preference is facilitated by estradiol pretreatment in female mice." *Chin J Physiol* 46(4): 169-74.
- Dluzen, D. E. and J. L. McDermott (2006). "Estrogen, testosterone, and methamphetamine toxicity." *Ann N Y Acad Sci* 1074: 282-94.
- Dluzen, D. E. and T. J. Salvaterra (2006). "Sex differences in methamphetamine-evoked striatal dopamine output are abolished following gonadectomy: Comparisons with potassium-evoked output and responses in prepubertal mice." *Neuroendocrinology* 82(2): 78-86.
- Dluzen, D. E. and K. R. Mickley (2005). "Gender differences in modulatory effects of tamoxifen upon the nigrostriatal dopaminergic system." *Pharmacol Biochem Behav* 80(1): 27-33.
- Dluzen, D. E. and J. L. McDermott (2004). "Developmental and genetic influences upon gender differences in methamphetamine-induced nigrostriatal dopaminergic neurotoxicity." *Ann N Y Acad Sci* 1025: 205-20.
- Dluzen, D. E. (2004). "The effect of gender and the neurotrophin, BDNF, upon methamphetamine-induced neurotoxicity of the nigrostriatal dopaminergic system in mice." *Neurosci Lett* 359(3): 135-8.
- Dluzen, D. E. and J. L. McDermott (2002). "Estrogen, anti-estrogen, and gender: differences in methamphetamine neurotoxicity." *Ann N Y Acad Sci* 965: 136-56.
- Dluzen, D. E., J. L. McDermott, et al. (2001). "Tamoxifen diminishes methamphetamine-induced striatal dopamine depletion in intact female and male mice." *J Neuroendocrinol* 13(7): 618-24.
- Fukumura, M., G. D. Cappon, H. W. Broening and C. V. Vorhees (1998). "Methamphetamine-induced dopamine and serotonin reductions in neostriatum are not gender specific in rats with comparable hyperthermic responses." *Neurotoxicol Teratol* 20(4): 441-8.
- Gomes-da-Silva, J., A. Perez-Rosado, et al. (2000). "Neonatal methamphetamine in the rat: Evidence for gender-specific differences upon tyrosine hydroxylase enzyme in the dopaminergic nigrostriatal system." *Ann N Y Acad Sci* 914: 431-8.
- Hirata, H., B. Ladenheim, et al. (1996). "Autoradiographic evidence for methamphetamine-induced striatal dopaminergic loss in mouse brain: Attenuation in CuZn-superoxide dismutase transgenic mice." *Brain Res* 714(1-2): 95-103.
- Kamens, H. M., S. Burkhart-Kasch, et al. (2005). "Sensitivity to psychostimulants in mice bred for high and low stimulation to methamphetamine." *Genes Brain Behav* 4(2): 110-25.
- Kaneyuki, T., M. Kohsaka, et al. (1979). "Sex hormones metabolism in the brain: Influence of central acting drugs on 5 alpha-reduction in rat diencephalon." *Endocrinol Jpn* 26(3): 345-51.
- Kunnathur, V., K. Shemisa, et al. (2006). "Sex differences in methamphetamine-evoked striatal dopamine of mice are reversed by nomifensine." *Neurotoxicol Teratol* 28(5): 557-62.
- Liu, B. and D. E. Dluzen (2006). "Effects of estrogen and related agents upon methamphetamine-induced neurotoxicity within an impaired nigrostriatal dopaminergic system of ovariectomized mice." *Neuroendocrinology* 83(5-6): 295-302.
- Liu, B. and D. E. Dluzen (2006). "Effect of estrogen upon methamphetamine-induced neurotoxicity within the impaired nigrostriatal dopaminergic system." *Synapse* 60(5): 354-61.
- Mattei, R. and E. A. Carlini (1996). "A comparative study of the anorectic and behavioral effects of fenproporex on male and female rats." *Braz J Med Biol Res* 29(8): 1025-30.
- Melo, P., V. Z. Moreno, et al. (2006). "Myelination changes in the rat optic nerve after prenatal exposure to methamphetamine." *Brain Res* 1106(1): 21-9.
- Melo, P., L. G. Rodrigues, et al. (2006). "Effects of prenatal exposure to methamphetamine on the development of the rat retina." *Ann N Y Acad Sci* 1074: 590-603.
- Milesi-Halle, A., H. P. Hendrickson, et al. (2005). "Sex- and dose-dependency in the pharmacokinetics and pharmacodynamics of (+)-methamphetamine and its metabolite (+)-amphetamine in rats." *Toxicol Appl Pharmacol* 209(3): 203-13.

- Miller, D. B., S. F. Ali, et al. (1998). "The impact of gender and estrogen on striatal dopaminergic neurotoxicity." *Ann N Y Acad Sci* 844: 153-65.
- Roth, M. E. and M. E. Carroll (2004). "Sex differences in the acquisition of IV methamphetamine self-administration and subsequent maintenance under a progressive ratio schedule in rats." *Psychopharmacology (Berl)* 172(4): 443-9.
- Slamberova, R. (2005). "Flurothyl seizures susceptibility is increased in prenatally methamphetamine-exposed adult male and female rats." *Epilepsy Res* 65(1-2): 121-4.
- Yoshimura, K. and K. Yamamoto (1979). "[Neuropharmacological studies on drug dependence (I). Effects due to the difference in strain, sex and drug administration time on physical dependence development and characteristics of withdrawal signs in CNS-affecting drug dependent rats (author's transl)]." *Nippon Yakurigaku Zasshi* 75(8): 805-28.
- Yu, L., Y. Kuo, et al. (2002). "Ovarian hormones do not attenuate methamphetamine-induced dopaminergic neurotoxicity in mice gonadectomized at 4 weeks postpartum." *Neuroendocrinology* 75(5): 282-7.
- Yu, L. and P. C. Liao (2000). "Sexual differences and estrous cycle in methamphetamine-induced dopamine and serotonin depletions in the striatum of mice." *J Neural Transm* 107(4): 419-27.
- Yu, Y. L. and G. C. Wagner (1994). "Influence of gonadal hormones on sexual differences in sensitivity to methamphetamine-induced neurotoxicity." *J Neural Transm Park Dis Dement Sect* 8(3): 215-21.

### Sexual Arousal and Sexual Experiences

- Diaz, R. M., A. L. Heckert, et al. (2005). "Reasons for stimulant use among Latino gay men in San Francisco: a comparison between methamphetamine and cocaine users." *J Urban Health* 82(1 Suppl 1): i71-8.
- Gibson, D. R., M. H. Leamon, et al. (2002). "Epidemiology and public health consequences of methamphetamine use in California's Central Valley." *J Psychoactive Drugs* 34(3): 313-9.
- Halkitis, P. N., B. N. Fischgrund, et al. (2005). "Explanations for methamphetamine use among gay and bisexual men in New York City." *Subst Use Misuse* 40(9): 1331-45.
- Halkitis, P. N., M. T. Shrem, et al. (2005). "Sexual behavior patterns of methamphetamine-using gay and bisexual men." *Subst Use Misuse* 40(5): 703-19.
- Kurtz, S. P. (2005). "Post-circuit blues: Motivations and consequences of crystal meth use among gay men in Miami." *AIDS Behav* 9(1): 63-72.
- Rawson, R. A., A. Washton, et al. (2002). "Drugs and sexual effects: Role of drug type and gender." *J Subst Abuse Treat* 22(2): 103-8.
- Semple, S. J., I. Grant, et al. (2004). "Female methamphetamine users: Social characteristics and sexual risk behavior." *Women Health* 40(3): 35-50.
- Volkow, N. D., G. J. Wang, et al. (2007). "Stimulant-induced enhanced sexual desire as a potential contributing factor in HIV transmission." *Am J Psychiatry* 164(1): 157-60.

### Sexual Compulsivity

- Parsons, J. T. and D. S. Bimbi (2006). "Intentional unprotected anal intercourse among men who have sex with men: Barebacking-from behavior to identity." *AIDS Behav*.
- Semple, S. J., J. Zians, et al. (2006). "Sexual compulsivity in a sample of HIV-positive methamphetamine-using gay and bisexual men." *AIDS Behav* 10(5): 587-98.

### Sexuality

*See also* Gay Men/Men Who Have Sex with Men; Heterosexuals; Lesbians/Women Who Have Sex with Women

- Kelly, B. C., J. T. Parsons, et al. (2006). "Prevalence and predictors of club drug use among club-going young adults in New York City." *J Urban Health* 83(5): 884-895.
- Weiser, S. D., S. E. Dilworth, et al. (2006). "Gender-specific correlates of sex trade among homeless and marginally housed individuals in San Francisco." *J Urban Health* 83(4): 736-40.

### Sexually Transmitted Diseases

*See also* Sexual Risk Behaviors

- Anonymous (2006). "Methamphetamine use and HIV risk behaviors among heterosexual men--preliminary results from five northern California counties, December 2001-November 2003." *MMWR Morb Mortal Wkly Rep* 55(10): 273-7.
- Beyrer, C., M. H. Razak, et al. (2004). "Methamphetamine users in northern Thailand: Changing demographics and risks for HIV and STD among treatment-seeking substance abusers." *Int J STD AIDS* 15(10): 697-704.



- Boddiger, D. (2005). "Metamphetamine use linked to rising HIV transmission." *Lancet* 365(9466): 1217-8.
- Bogart, L. M., A. H. Kral, et al. (2005). "Sexual risk among injection drug users recruited from syringe exchange programs in California." *Sex Transm Dis* 32(1): 27-34.
- Bolding, G., G. Hart, et al. (2006). "Use of crystal methamphetamine among gay men in London." *Addiction* 101(11): 1622-30.
- Brewer, D. D., M. R. Golden, et al. (2006). "Unsafe sexual behavior and correlates of risk in a probability sample of men who have sex with men in the era of highly active antiretroviral therapy." *Sex Transm Dis* 33(4): 250-5.
- Brouwer, K. C., P. Case, et al. (2006). "Trends in production, trafficking, and consumption of methamphetamine and cocaine in Mexico." *Subst Use Misuse* 41(5): 707-27.
- Colfax, G. and R. Guzman (2006). "Club drugs and HIV infection: A review." *Clin Infect Dis* 42(10): 1463-9.
- Gorbach, P. M., J. T. Galea, et al. (2004). "Don't ask, don't tell: patterns of HIV disclosure among HIV positive men who have sex with men with recent STI practising high risk behaviour in Los Angeles and Seattle." *Sex Transm Infect* 80(6): 512-7.
- Hirshfield, S., R. H. Remien, et al. (2004). "Crystal methamphetamine use predicts incident STD infection among men who have sex with men recruited online: A nested case-control study." *J Med Internet Res* 6(4): e41.
- Kim, A. A., C. K. Kent, et al. (2002). "Increased risk of HIV and sexually transmitted disease transmission among gay or bisexual men who use Viagra, San Francisco 2000-2001." *AIDS* 16(10): 1425-8.
- Kipke, M. D., S. O'Connor, et al. (1995). "Street youth in Los Angeles. Profile of a group at high risk for human immunodeficiency virus infection." *Arch Pediatr Adolesc Med* 149(5): 513-9.
- Klausner, J. D., C. K. Kent, et al. (2005). "The public health response to epidemic syphilis, San Francisco, 1999-2004." *Sex Transm Dis* 32(10 supplement): S11-S18.
- Kresina, T. F., J. Normand, J. Khalsa, J. Mitty, T. Flanigan and H. Francis (2004). "Addressing the need for treatment paradigms for drug-abusing patients with multiple morbidities." *Clin Infect Dis* 38(Suppl 5): S398-401.
- Kurtz, S. P. (2005). "Post-circuit blues: Motivations and consequences of crystal meth use among gay men in Miami." *AIDS Behav* 9(1): 63-72.
- Liu, A., P. Kilmarx, et al. (2006). "Sexual initiation, substance use, and sexual behavior and knowledge among vocational students in northern Thailand." *Int Fam Plan Perspect* 32(3): 126-35.
- Lorvick, J., A. Martinez, et al. (2006). "Sexual and injection risk among women who inject methamphetamine in San Francisco." *J Urban Health* 83(3): 497-505.
- Menza, T. W., G. Colfax, et al. (2006). "Interest in a methamphetamine intervention among men who have sex with men." *Sex Transm Dis* 33(9): 565-70.
- Molitor, F., S. R. Truax, J. D. Ruiz and R. K. Sun (1998). "Association of methamphetamine use during sex with risky sexual behaviors and HIV infection among non-injection drug users." *West J Med* 168(2): 93-7.
- Peck, J. A., S. Shoptaw, et al. (2005). "HIV-associated medical, behavioral, and psychiatric characteristics of treatment-seeking, methamphetamine-dependent men who have sex with men." *J Addict Dis* 24(3): 115-32.
- Rose, V. J., H. F. Raymond, et al. (2006). "Assessing the feasibility of harm reduction services for MSM: The late night breakfast buffet study." *Harm Reduct J* 3: 29.
- Semple, S. J., T. L. Patterson, et al. (2004). "Determinants of condom use stage of change among heterosexually-identified methamphetamine users." *AIDS Behav* 8(4): 391-400.
- Shoptaw, S., J. Peck, et al. (2003). "Psychiatric and substance dependence comorbidities, sexually transmitted diseases, and risk behaviors among methamphetamine-dependent gay and bisexual men seeking outpatient drug abuse treatment." *J Psychoactive Drugs* 35 Suppl 1: 161-8.
- Simbulan, N. P., A. S. Aguilar, et al. (2001). "High-risk behaviors and the prevalence of sexually transmitted diseases among women prisoners at the women state penitentiary in Metro Manila." *Soc Sci Med* 52(4): 599-608.
- van Griensven, F., S. Supawitkul, et al. (2001). "Rapid assessment of sexual behavior, drug use, human immunodeficiency virus, and sexually transmitted diseases in northern Thai youth using audio-computer-assisted self-interviewing and noninvasive specimen collection." *Pediatrics* 108(1): E13.
- Wong, W., J. K. Chaw, et al. (2005). "Risk factors for early syphilis among gay and bisexual men seen in an STD clinic: San Francisco, 2002-2003." *Sex Transm Dis* 32(7): 458-63.
- Zenilman, J. M. (2005). "Behavioral interventions--rationale, measurement, and effectiveness." *Infect Dis Clin North Am* 19(2): 541-62.

## Sexual Risk Behaviors

- Anonymous (2006). "Investigation of a new diagnosis of multidrug-resistant, dual-tropic HIV-1 infection--New York City, 2005." *MMWR Morb Mortal Wkly Rep* 55(29): 793-6.

- Anonymous (2006). "Methamphetamine use and HIV risk behaviors among heterosexual men--preliminary results from five northern California counties, December 2001-November 2003." *MMWR Morb Mortal Wkly Rep* 55(10): 273-7.
- Anonymous (2002). "Methamphetamine use is heightening risks among gay youth. 'club drugs' dull safe-sex sensibilities." *AIDS Alert* 17(10): 121, 123-5.
- Baskin-Sommers, A. and I. Sommers (2006). "The co-occurrence of substance use and high-risk behaviors." *J Adolesc Health* 38(5): 609-11.
- Breen, C., L. Degenhardt, et al. (2006). "Alcohol use and risk taking among regular ecstasy users." *Subst Use Misuse* 41(8): 1095-109.
- Benotsch, E. G., S. Kalichman and M. Cage (2002). "Men who have met sex partners via the Internet: Prevalence, predictors, and implications for HIV prevention." *Arch Sex Behav* 31(2): 177-83.
- Beyrer, C., M. H. Razak, et al. (2004). "Methamphetamine users in northern Thailand: Changing demographics and risks for HIV and STD among treatment-seeking substance abusers." *Int J STD AIDS* 15(10): 697-704.
- Bluthenthal, R. N., A. H. Kral, et al. (2001). "Trends in HIV seroprevalence and risk among gay and bisexual men who inject drugs in San Francisco, 1988 to 2000." *J Acquir Immune Defic Syndr* 28(3): 264-9.
- Bogart, L. M., A. H. Kral, et al. (2005). "Sexual risk among injection drug users recruited from syringe exchange programs in California." *Sex Transm Dis* 32(1): 27-34.
- Bolding, G., G. Hart, et al. (2006). "Use of crystal methamphetamine among gay men in London." *Addiction* 101(11): 1622-30.
- Braine, N., D. C. Des Jarlais, et al. (2005). "HIV risk behavior among amphetamine injectors at U.S. syringe exchange programs." *AIDS Educ Prev* 17(6): 515-24.
- Brewer, D. D., M. R. Golden, et al. (2006). "Unsafe sexual behavior and correlates of risk in a probability sample of men who have sex with men in the era of highly active antiretroviral therapy." *Sex Transm Dis* 33(4): 250-5.
- Brouwer, K. C., P. Case, et al. (2006). "Trends in production, trafficking, and consumption of methamphetamine and cocaine in Mexico." *Subst Use Misuse* 41(5): 707-27.
- Buchacz, K., W. McFarland, et al. (2005). "Amphetamine use is associated with increased HIV incidence among men." *AIDS* 19(13): 1423-24.
- Bull, S. S., P. Piper and C. Rietmeijer (2002). "Men who have sex with men and also inject drugs--profiles of risk related to the synergy of sex and drug injection behaviors." *J Homosex* 42(3): 31-51.
- Burcham, J. L., B. Tindall, et al. (1989). "Incidence and risk factors for human immunodeficiency virus seroconversion in a cohort of Sydney homosexual men." *Med J Aust* 150(11): 634-9.
- Chesney, M. A., D. C. Barrett, et al. (1998). "Histories of substance use and risk behavior: Precursors to HIV seroconversion in homosexual men." *Am J Public Health* 88(1): 113-6.
- Choi, K. H., D. Operario, et al. (2005). "Substance use, substance choice, and unprotected anal intercourse among young Asian American and Pacific Islander men who have sex with men." *AIDS Educ Prev* 17(5): 418-29.
- Chu, P. L., W. McFarland, et al. (2003). "Viagra use in a community-recruited sample of men who have sex with men, San Francisco." *J Acquir Immune Defic Syndr* 33(2): 191-3.
- Clatts, M. C., L. Goldsamt, et al. (2005). "Homelessness and drug abuse among young men who have sex with men in New York city: A preliminary epidemiological trajectory." *J Adolesc* 28(2): 201-14.
- Colfax, G. and R. Guzman (2006). "Club drugs and HIV infection: A review." *Clin Infect Dis* 42(10): 1463-9.
- Colfax, G. and S. Shoptaw (2005). "The methamphetamine epidemic: Implications for HIV prevention and treatment." *Curr HIV/AIDS Rep* 2(4): 194-9.
- Colfax, G., T. J. Coates, et al. (2005). "Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of San Francisco men who have sex with men." *J Urban Health* 82(1 Suppl 1): i62-70.
- Colfax, G., E. Vittinghoff, et al. (2004). "Substance use and sexual risk: A participant- and episode-level analysis among a cohort of men who have sex with men." *Am J Epidemiol* 159(10): 1002-12.
- Colfax, G. N., G. Mansergh, et al. (2001). "Drug use and sexual risk behavior among gay and bisexual men who attend circuit parties: A venue-based comparison." *J Acquir Immune Defic Syndr* 28(4): 373-9.
- Darke, S., J. Ross, et al. (1995). "Injecting and sexual risk-taking behaviour among regular amphetamine users." *AIDS Care* 7(1): 19-26.
- Degenhardt, L. (2005). "Drug use and risk behaviour among regular ecstasy users: Does sexuality make a difference?" *Culture, Health & Sexuality* 7(6): 599-614.
- Doherty, M. C., R. S. Garfein, E. Monterroso, D. Brown and D. Vlahov (2000). "Correlates of HIV infection among young adult short-term injection drug users." *AIDS* 14(6): 717-26.
- Drumright, L. N., S. J. Little, et al. (2006). "Unprotected anal intercourse and substance use among men who have sex with men with recent HIV infection." *J Acquir Immune Defic Syndr* 43(3): 344-50.

- Drumright, L. N., S. A. Strathdee, et al. (2006). "Unprotected anal intercourse and substance use before and after HIV diagnosis among recently HIV-infected men who have sex with men." *Sex Transm Dis*.
- Duterte, M., S. O'Neil, G. McKearin, P. Sales, T. Murphy and S. Murphy (2001). "Walking the tightrope: Balancing health and drug use." *J Psychoactive Drugs* 33(2): 173-83.
- Farabee, D., M. Prendergast and J. Cartier (2002). "Methamphetamine use and HIV risk among substance-abusing offenders in California." *J Psychoactive Drugs* 34(3): 295-300.
- Fernandez, M. I., G. S. Bowen, et al. (2007). "Crystal methamphetamine: A source of added sexual risk for Hispanic men who have sex with men?" *Drug Alcohol Depend* 86(2-3): 245-52.
- Fernandez, M. I., G. S. Bowen, et al. (2005). "High rates of club drug use and risky sexual practices among Hispanic men who have sex with men in Miami, Florida." *Subst Use Misuse* 40(9): 1347-62.
- Fernandez, M. I., T. Perrino, et al. (2005). "Surfing new territory: club-drug use and risky sex among Hispanic men who have sex with men recruited on the Internet." *J Urban Health* 82(1 Suppl 1): i79-88.
- Fernandez, M. I., L. M. Varga, et al. (2004). "The Internet as recruitment tool for HIV studies: viable strategy for reaching at-risk Hispanic MSM in Miami?" *AIDS Care* 16(8): 953-63.
- Frosch, D., S. Shoptaw, et al. (1996). "Sexual HIV risk among gay and bisexual male methamphetamine abusers." *J Subst Abuse Treat* 13(6): 483-6.
- Ghaziani, A. and T. D. Cook (2005). "Reducing HIV infections at circuit parties: From description to explanation and principles of intervention design." *J Int Assoc Physicians AIDS Care (Chic Ill)* 4(2): 32-46.
- Gibson, D. R., M. H. Leamon and N. Flynn (2002). "Epidemiology and public health consequences of methamphetamine use in California's Central Valley." *J Psychoactive Drugs* 34(3): 313-9.
- Gleghorn, A. A., R. Marx, et al. (1998). "Association between drug use patterns and HIV risks among homeless, runaway, and street youth in northern California." *Drug Alcohol Depend* 51(3): 219-27.
- Gorbach, P. M., J. T. Galea, et al. (2004). "Don't ask, don't tell: patterns of HIV disclosure among HIV positive men who have sex with men with recent STI practising high risk behaviour in Los Angeles and Seattle." *Sex Transm Infect* 80(6): 512-7.
- Gorman, E. M. and R. T. Carroll (2000). "Substance abuse and HIV: Considerations with regard to methamphetamines and other recreational drugs for nursing practice and research." *J Assoc Nurses AIDS Care* 11(2): 51-62.
- Gorman, E. M., B. D. Barr, A. Hansen, B. Robertson and C. Green (1997). "Speed, sex, gay men, and HIV: Ecological and community perspectives." *Med Anthropol Q* 11(4): 505-15.
- Gorman, M. (1996). "Speed use and HIV transmission." *Focus* 11(7): 4-6.
- Green, A. I. and P. N. Halkitis (2006). "Crystal methamphetamine and sexual sociality in an urban gay subculture: an elective affinity." *Cult Health Sex* 8(4): 317-33.
- Halkitis, P. N., K. A. Green, et al. (2005). "Seroconcordant sexual partnerings of HIV-seropositive men who have sex with men." *AIDS* 19: S77-S86.
- Halkitis, P. N., K. A. Green, et al. (2005). "Longitudinal investigation of methamphetamine use among gay and bisexual men in New York City: findings from Project BUMPS." *J Urban Health* 82(1 Suppl 1): i18-25.
- Halkitis, P. N., M. T. Shrem, et al. (2005). "Sexual behavior patterns of methamphetamine-using gay and bisexual men." *Subst Use Misuse* 40(5): 703-19.
- Halkitis, P. N., L. Wilton, et al. (2005). "Barebacking identity among HIV-positive gay and bisexual men: demographic, psychological, and behavioral correlates." *AIDS* 19: S27-S35.
- Halkitis, P. N., J. T. Parsons, et al. (2001). "A double epidemic: crystal methamphetamine drug use in relation to HIV transmission among gay men." *J Homosex* 41(2): 17-35.
- Herbst, J. H., R. T. Sherba, et al. (2005). "A meta-analytic review of HIV behavioral interventions for reducing sexual risk behavior of men who have sex with men." *J Acquir Immune Defic Syndr* 39(2): 228-41.
- Hirshfield, S., R. H. Remien, et al. (2004). "Crystal methamphetamine use predicts incident STD infection among men who have sex with men recruited online: A nested case-control study." *J Med Internet Res* 6(4): e41.
- Hirshfield, S., R. H. Remien, M. Humberstone, I. Walavalkar and M. A. Chiasson (2004). "Substance use and high-risk sex among men who have sex with men: A national online study in the USA." *AIDS Care* 16(8): 1036-47.
- Ibanez, G. E., D. W. Purcell, et al. (2005). "Sexual risk, substance use, and psychological distress in HIV-positive gay and bisexual men who also inject drugs." *AIDS* 19: S49-S55.
- Kipke, M. D., S. O'Connor, et al. (1995). "Street youth in Los Angeles. Profile of a group at high risk for human immunodeficiency virus infection." *Arch Pediatr Adolesc Med* 149(5): 513-9.
- Knight, K. R., D. Purcell, et al. (2005). "Sexual risk taking among HIV-positive injection drug users: Contexts, characteristics, and implications for prevention." *AIDS Educ Prev* 17(1 Suppl A): 76-88.

- Koblin, B. A., M. A. Chesney, et al. (2003). "High-risk behaviors among men who have sex with men in 6 US cities: Baseline data from the EXPLORE Study." *Am J Public Health* 93(6): 926-32.
- Kral, A. H., J. Lorvick, et al. (2005). "HIV prevalence and risk behaviors among men who have sex with men and inject drugs in San Francisco." *J Urban Health* 82(1 Suppl 1): i43-50.
- Kral, A. H., R. N. Bluthenthal, et al. (2001). "Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: Risk-factor analysis." *Lancet* 357(9266): 1397-401.
- Kral, A. H., J. Lorvick, et al. (2000). "Sex- and drug-related risk among populations of younger and older injection drug users in adjacent neighborhoods in San Francisco." *J Acquir Immune Defic Syndr* 24(2): 162-7.
- Kurtz, S. P. (2005). "Post-circuit blues: Motivations and consequences of crystal meth use among gay men in Miami." *AIDS Behav* 9(1): 63-72.
- Kushel, M. B., J. A. Hahn, et al. (2005). "Revolving doors: Imprisonment among the homeless and marginally housed population." *Am J Public Health* 95(10): 1747-52.
- Lambert, E., J. Normand, et al. (2005). "Introduction: New dynamics of HIV risk among drug-using men who have sex with men." *J Urban Health* 82(1 Suppl 1): i1-8.
- Larkins, S., C. J. Reback, et al. (2005). "Methamphetamine-dependent gay men's disclosure of their HIV status to sexual partners." *AIDS Care* 17(4): 521-32.
- Lee, S. J., M. Galanter, et al. (2003). "Circuit parties and patterns of drug use in a subset of gay men." *J Addict Dis* 22(4): 47-60.
- Liu, A., P. Kilmarx, et al. (2006). "Sexual initiation, substance use, and sexual behavior and knowledge among vocational students in northern Thailand." *Int Fam Plan Perspect* 32(3): 126-35.
- Lorvick, J., A. Martinez, et al. (2006). "Sexual and injection risk among women who inject methamphetamine in San Francisco." *J Urban Health* 83(3): 497-505.
- Lyons, T., G. Chandra, et al. (2006). "Stimulant use and HIV risk behavior: The influence of peer support group participation." *AIDS Educ Prev* 18(5): 461-73.
- Mansergh, G., D. W. Purcell, et al. (2006). "CDC consultation on methamphetamine use and sexual risk behavior for HIV/STD infection: summary and suggestions." *Public Health Rep* 121(2): 127-32.
- Mansergh, G., R. L. Shouse, et al. (2006). "Methamphetamine and sildenafil (Viagra) use are linked to unprotected receptive and insertive anal sex, respectively, in a sample of men who have sex with men." *Sex Transm Infect* 82(2): 131-4.
- Mansergh, G., G. N. Colfax, et al. (2001). "The Circuit Party Men's Health Survey: Findings and implications for gay and bisexual men." *Am J Public Health* 91(6): 953-8.
- Martin, I., T. M. Lampinen, et al. (2006). "Methamphetamine use among marginalized youth in British Columbia." *Can J Public Health* 97(4): 320-4.
- Mattison, A. M., M. W. Ross, et al. (2001). "Circuit party attendance, club drug use, and unsafe sex in gay men." *J Subst Abuse* 13(1-2): 119-26.
- Menza, T. W., G. Colfax, et al. (2006). "Interest in a methamphetamine intervention among men who have sex with men." *Sex Transm Dis* 33(9): 565-70.
- Mitchell, S. J., S. R. Morris, et al. (2006). "Methamphetamine use and sexual activity among HIV-infected patients in care--San Francisco, 2004." *AIDS Patient Care STDS* 20(7): 502-10.
- Molitor, F., J. D. Ruiz, et al. (1999). "Methamphetamine use and sexual and injection risk behaviors among out-of-treatment injection drug users." *Am J Drug Alcohol Abuse* 25(3): 475-93.
- Molitor, F., S. R. Truax, J. D. Ruiz and R. K. Sun (1998). "Association of methamphetamine use during sex with risky sexual behaviors and HIV infection among non-injection drug users." *West J Med* 168(2): 93-7.
- Morris, K. and C. Parry (2006). "South African methamphetamine boom could fuel further HIV." *Lancet Infect Dis* 6(8): 471.
- Morin, S. F., W. T. Steward, et al. (2005). "Predicting HIV transmission risk among HIV-infected men who have sex with men: Findings from the Healthy Living Project." *J Acquir Immune Defic Syndr* 40(2): 226-235.
- Nemoto, T., D. Operario, et al. (2002). "Risk behaviors of Filipino methamphetamine users in San Francisco: Implications for prevention and treatment of drug use and HIV." *Public Health Rep* 117 Suppl 1: S30-8.
- Newman, P. A., F. Rhodes and R. E. Weiss (2004). "Correlates of sex trading among drug-using men who have sex with men." *Am J Public Health* 94(11): 1998-2003.
- Noble, P., T. Hart, et al. (1972). "Correlates and outcome of illicit drug use by adolescent girls." *Br J Psychiatry* 120(558): 497-504.
- Nyamathi, A., W. A. Robbins, et al. (2002). "Presence and predictors of hepatitis C virus RNA in the semen of homeless men." *Biol Res Nurs* 4(1): 22-30.
- Operario, D. and T. Nemoto (2005). "Sexual risk behavior and substance use among a sample of Asian Pacific Islander transgendered women." *AIDS Educ Prev* 17(5): 430-43.

- Parsons, J. T. and D. S. Bimbi (2006). "Intentional unprotected anal intercourse among men who have sex with men: Barebacking-from behavior to identity." *AIDS Behav.*
- Parsons, J. T. and P. N. Halkitis (2002). "Sexual and drug-using practices of HIV-positive men who frequent public and commercial sex environments." *AIDS Care* 14(6): 815-26.
- Patterson, T. L. and S. J. Semple (2003). "Sexual risk reduction among HIV-positive drug-using men who have sex with men." *J Urban Health* 80(4 Suppl 3): iii77-87.
- Peck, J. A., S. Shoptaw, et al. (2005). "HIV-associated medical, behavioral, and psychiatric characteristics of treatment-seeking, methamphetamine-dependent men who have sex with men." *J Addict Dis* 24(3): 115-32.
- Perdue, T., H. Hagan, et al. (2003). "Depression and HIV risk behavior among Seattle-area injection drug users and young men who have sex with men." *AIDS Educ Prev* 15(1): 81-92.
- Purcell, D. W., S. Moss, et al. (2005). "Illicit substance use, sexual risk, and HIV-positive gay and bisexual men: Differences by serostatus of casual partners." *AIDS* 19: S37-S47.
- Purcell, D. W., J. T. Parsons, P. N. Halkitis, Y. Mizuno and W. J. Woods (2001). "Substance use and sexual transmission risk behavior of HIV-positive men who have sex with men." *J Subst Abuse* 13(1-2): 185-200.
- Rawson, R. A., A. Washton, C. P. Domier and C. Reiber (2002). "Drugs and sexual effects: Role of drug type and gender." *J Subst Abuse Treat* 22(2): 103-8.
- Reback, C. J., S. Larkins and S. Shoptaw (2004). "Changes in the meaning of sexual risk behaviors among gay and bisexual male methamphetamine abusers before and after drug treatment." *AIDS Behav* 8(1): 87-98.
- Reback, C. J. and C. E. Grella (1999). "HIV risk behaviors of gay and bisexual male methamphetamine users contacted through street outreach." *Journal of Drug Issues* 29(1): 155-66.
- Rietmeijer, C. A., R. J. Wolitski, M. Fishbein, N. H. Corby and D. L. Cohn (1998). "Sex hustling, injection drug use, and non-gay identification by men who have sex with men. Associations with high-risk sexual behaviors and condom use." *Sex Transm Dis* 25(7): 353-60.
- Romanelli, F. and K. M. Smith (2004). "Recreational use of sildenafil by HIV-positive and -negative homosexual/bisexual males." *Ann Pharmacother* 38(6): 1024-30.
- Rose, V. J., H. F. Raymond, et al. (2006). "Assessing the feasibility of harm reduction services for MSM: The late night breakfast buffet study." *Harm Reduct J* 3: 29.
- Ross, M. W., A. M. Mattison, et al. (2003). "Club drugs and sex on drugs are associated with different motivations for gay circuit party attendance in men." *Subst Use Misuse* 38(8): 1173-83.
- Rotheram-Borus, M. J., G. C. Luna, et al. (1994). "Going nowhere fast: Methamphetamine use and HIV infection." *NIDA Res Monogr* 143: 155-82.
- Roxburgh, A., L. Degenhardt, et al. (2005). "Drug use and risk behaviours among injecting drug users: A comparison between sex workers and non-sex workers in Sydney, Australia." *Harm Reduct J* 2(1): 7.
- Rusch, M., T. M. Lampinen, A. Schilder and R. S. Hogg (2004). "Unprotected anal intercourse associated with recreational drug use among young men who have sex with men depends on partner type and intercourse role." *Sex Transm Dis* 31(8): 492-8.
- Schilder, A. J., T. M. Lampinen, et al. (2005). "Crystal methamphetamine and ecstasy differ in relation to unsafe sex among young gay men." *Can J Public Health* 96(5): 340-3.
- Seage, G. R., 3rd, K. H. Mayer, et al. (1998). "The social context of drinking, drug use, and unsafe sex in the Boston Young Men Study." *J Acquir Immune Defic Syndr Hum Retrovirol* 17(4): 368-75.
- Semple, S. J., J. Zians, et al. (2006). "Sexual compulsivity in a sample of HIV-positive methamphetamine-using gay and bisexual men." *AIDS Behav* 10(5): 587-98.
- Semple, S. J., J. Zians, et al. (2006). "Methamphetamine use, impulsivity, and sexual risk behavior among HIV-positive men who have sex with men." *J Addict Dis* 25(4): 105-14.
- Semple, S. J., J. Zians, et al. (2006). "Sexual risk behavior of HIV-positive methamphetamine-using men who have sex with men: The role of partner serostatus and partner type." *Arch Sex Behav* 35(4): 461-71.
- Semple, S. J., I. Grant, et al. (2005). "Negative self-perceptions and sexual risk behavior among heterosexual methamphetamine users." *Substance Use & Misuse* 40(12): 1797-1810.
- Semple, S. J., J. Zians, et al. (2005). "Impulsivity and methamphetamine use." *J Subst Abuse Treat* 29(2): 85-93.
- Semple, S. J., T. L. Patterson, et al. (2004). "A comparison of injection and non-injection methamphetamine-using HIV positive men who have sex with men." *Drug Alcohol Depend* 76(2): 203-12.
- Semple, S. J., T. L. Patterson and I. Grant (2004). "The context of sexual risk behavior among heterosexual methamphetamine users." *Addict Behav* 29(4): 807-10.
- Semple, S. J., T. L. Patterson, et al. (2004). "Determinants of condom use stage of change among heterosexually-identified methamphetamine users." *AIDS Behav* 8(4): 391-400.

- Semple, S. J., I. Grant, et al. (2004). "Female methamphetamine users: Social characteristics and sexual risk behavior." *Women Health* 40(3): 35-50.
- Sherhoff, M. (2006). "Condomless sex: Gay men, barebacking, and harm reduction." *Soc Work* 51(2): 106-13.
- Shoptaw, S. and C. J. Reback (2006). "Associations between methamphetamine use and HIV among men who have sex with men: A model for guiding public policy." *J Urban Health* 83(6): 1151-7.
- Shoptaw, S. (2006). "Methamphetamine use in urban gay and bisexual populations." *Top HIV Med* 14(2): 84-7.
- Shoptaw, S., C. J. Reback, et al. (2005). "Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men." *Drug Alcohol Depend* 78(2): 125-34.
- Shoptaw, S., C. J. Reback and T. E. Freese (2002). "Patient characteristics, HIV serostatus, and risk behaviors among gay and bisexual males seeking treatment for methamphetamine abuse and dependence in Los Angeles." *J Addict Dis* 21(1): 91-105.
- Shoptaw, S., C. J. Reback, et al. (1998). "Stimulant abuse treatment as HIV prevention." *J Addict Dis* 17(4): 19-32.
- Simbayi, L. C., S. C. Kalichman, et al. (2006). "Methamphetamine use and sexual risks for HIV infection in Cape Town, South Africa." *Journal of Substance Use* 11(4): 291-300.
- Simbulan, N. P., A. S. Aguilar, et al. (2001). "High-risk behaviors and the prevalence of sexually transmitted diseases among women prisoners at the women state penitentiary in Metro Manila." *Soc Sci Med* 52(4): 599-608.
- Somlai, A. M., J. A. Kelly, T. L. McAuliffe, K. Ksobiech and K. L. Hackl (2003). "Predictors of HIV sexual risk behaviors in a community sample of injection drug-using men and women." *AIDS Behav* 7(4): 383-93.
- Srirak, N., S. Kawichai, et al. (2005). "HIV infection among female drug users in Northern Thailand." *Drug Alcohol Depend* 78(2): 141-5.
- Stone, E., P. Heagerty, et al. (1999). "Correlates of condom failure in a sexually active cohort of men who have sex with men." *J Acquir Immune Defic Syndr Hum Retrovirol* 20(5): 495-501.
- Swearingen, S. G. and J. D. Klausner (2005). "Sildenafil use, sexual risk behavior, and risk for sexually transmitted diseases, including HIV infection." *Am J Med* 118(6): 571-7.
- Twitchell, G. R., A. Huber, et al. (2002). "Comparison of general and detailed HIV risk assessments among methamphetamine abusers." *AIDS and Behavior* 6(2): 153-162.
- van Griensvan, F., J. Keawkungwal, et al. (2004). "Lack of increased HIV risk behavior among injection drug users participating in the AIDS VAX B/E HIV vaccine trial in Bangkok, Thailand." *AIDS* 18(2): 295-301.
- van Griensven, F., S. Supawitkul, et al. (2001). "Rapid assessment of sexual behavior, drug use, human immunodeficiency virus, and sexually transmitted diseases in northern Thai youth using audio-computer-assisted self-interviewing and noninvasive specimen collection." *Pediatrics* 108(1): E13.
- Verachai, V., T. Phutiprawan, et al. (2005). "HIV infection among substance abusers in Thanyarak Institute On Drug Abuse, Thailand, 1987-2002." *J Med Assoc Thai* 88(1): 76-9.
- Viani, R. M., M. R. Araneta, et al. (2006). "Perinatal HIV counseling and rapid testing in Tijuana, Baja California, Mexico: Seroprevalence and correlates of HIV infection." *J Acquir Immune Defic Syndr* 41(1): 87-92.
- Volkow, N. D., G. J. Wang, et al. (2007). "Stimulant-induced enhanced sexual desire as a potential contributing factor in HIV transmission." *Am J Psychiatry* 164(1): 157-60.
- Waldo, C. R., W. McFarland, M. H. Katz, D. MacKellar and L. A. Valleroy (2000). "Very young gay and bisexual men are at risk for HIV infection: The San Francisco Bay Area Young Men's Survey II." *J Acquir Immune Defic Syndr* 24(2): 168-74.
- Williams, M. L., J. Atkinson, et al. (2005). "Spatial bridging in a network of drug-using male sex workers." *J Urban Health* 82(1 Suppl 1): i35-42.
- Wohl, A. R., D. F. Johnson, et al. (2002). "HIV risk behaviors among African American men in Los Angeles County who self-identify as heterosexual." *J Acquir Immune Defic Syndr* 31(3): 354-60.
- Wong, W., J. K. Chaw, et al. (2005). "Risk factors for early syphilis among gay and bisexual men seen in an STD clinic: San Francisco, 2002-2003." *Sex Transm Dis* 32(7): 458-63.
- Worth, H. and P. Rawstorne (2005). "Crystallizing the HIV epidemic: Methamphetamine, unsafe sex, and gay diseases of the will." *Arch Sex Behav* 34(5): 483-6.
- Wu, L. T., D. J. Pilowsky, et al. (2004). "Injection drug use among stimulant users in a national sample." *Am J Drug Alcohol Abuse* 30(1): 61-83.
- Yen, C. F. (2004). "Relationship between methamphetamine use and risky sexual behavior in adolescents." *Kaohsiung J Med Sci* 20(4): 160-5.
- Zenilman, J. M. (2005). "Behavioral interventions--rationale, measurement, and effectiveness." *Infect Dis Clin North Am* 19(2): 541-62.
- Zule, W. A. and D. P. Desmond (1999). "An ethnographic comparison of HIV risk behaviors among heroin and methamphetamine injectors." *Am J Drug Alcohol Abuse* 25(1): 1-23.

**Sex Work**

*See* Commercial Sex Work and Sex Workers

**Skin and Soft Tissue Diseases and Disorders**

*See also* Burn Injuries

- Binswanger, I. A., A. H. Kral, et al. (2000). "High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Francisco." *Clin Infect Dis* 30(3): 579-81.
- Bungay, V., L. Malchy, et al. (2006). "Life with jib: A snapshot of street youth's use of crystal methamphetamine." *Addiction Research and Theory* 14(3): 235-251.
- Deloach-Banta, L. J. (1994). "Lichenoid drug eruption: Crystal methamphetamine or adulterants?" *Cutis* 53(2): 97-8.
- Kerr, T., E. Wood, et al. (2005). "High rates of primary care and emergency department use among injection drug users in Vancouver." *J Public Health (Oxf)* 27(1): 62-66.
- Marschall, M. A., R. F. Dolezal, et al. (1991). "Chronic wounds and delusions of parasitosis in the drug abuser." *Plast Reconstr Surg* 88(2): 328-30.
- Scheinfeld, N. (2003). "Delusions of parasitosis: A case with a review of its course and treatment." *Skinmed* 2(6): 376-8.
- Yaffee, H. S. (1971). "Cutaneous stigmata associated with methedrine (methamphetamine)." *Arch Dermatol* 104(6): 687.

**Sleep**

*See also* Circadian Rhythms

- Bonnet, M. H., T. J. Balkin, et al. (2005). "The use of stimulants to modify performance during sleep loss: A review by the sleep deprivation and Stimulant Task Force of the American Academy of Sleep Medicine." *Sleep* 28(9): 1163-87.
- Comer, S. D., C. L. Hart, et al. (2001). "Effects of repeated oral methamphetamine administration in humans." *Psychopharmacology (Berl)* 155(4): 397-404.
- Crump, G. P. (1963). "Narcolepsy. A discussion and case presentation." *Proc Wkly Semin Neurol* 15: 6-20.
- Dement, W. C., M. A. Carskadon, et al. (1976). "Narcolepsy. Diagnosis and treatment." *Prim Care* 3(4): 609-23.
- Dement, W. C. (1979). "Narcolepsy--not as rare as we believed!" *Med Times* 107(6): 51-5.
- Duffy, J. P. and K. Davison (1968). "A female case of the Kleine-Levin Syndrome." *Br J Psychiatry* 114(506): 77-84.
- Duterte, M., S. O'Neil, et al. (2001). "Walking the tightrope: Balancing health and drug use." *J Psychoactive Drugs* 33(2): 173-83.
- Fry, J. M. (1998). "Treatment modalities for narcolepsy." *Neurology* 50(2 Suppl 1): S43-8.
- George, H. R. (1970). "A case of the Kleine-Levin syndrome of long duration." *Br J Psychiatry* 117(540): 521-3.
- Gillin, J. C., L. Pulvirenti, et al. (1994). "The effects of lisuride on mood and sleep during acute withdrawal in stimulant abusers: A preliminary report." *Biol Psychiatry* 35(11): 843-9.
- Hart, C. L., A. S. Ward, et al. (2003). "Methamphetamine attenuates disruptions in performance and mood during simulated night-shift work." *Psychopharmacology (Berl)* 169(1): 42-51.
- Holman, R. B., G. R. Elliott, et al. (1975). "Neuroregulators and sleep mechanisms." *Annu Rev Med* 26: 499-520.
- Kosman, M. E. and D. R. Unna (1968). "Effects of chronic administration of the amphetamines and other stimulants on behavior." *Clin Pharmacol Ther* 9(2): 240-54.
- Littner, M., S. F. Johnson, et al. (2001). "Practice parameters for the treatment of narcolepsy: an update for 2000." *Sleep* 24(4): 451-66.
- Martin, I., T. M. Lampinen, et al. (2006). "Methamphetamine use among marginalized youth in British Columbia." *Can J Public Health* 97(4): 320-4.
- Martin, W. R., J. W. Sloan, et al. (1971). "Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man." *Clin Pharmacol Ther* 12(2): 245-58.
- McGregor, C., M. Srisurapanont, et al. (2005). "The nature, time course and severity of methamphetamine withdrawal." *Addiction* 100(9): 1320-9.
- Mitler, M. M. (1994). "Evaluation of treatment with stimulants in narcolepsy." *Sleep* 17(8 Suppl): S103-6.
- Mitler, M. M. (1993). "Daytime sleepiness and cognitive functioning in sleep apnea." *Sleep* 16(8 Suppl): S68-70.
- Mitler, M. M., M. Erman, et al. (1993). "The treatment of excessive somnolence with stimulant drugs." *Sleep* 16(3): 203-6.
- Mitler, M. M., R. Hajdukovic, et al. (1993). "Treatment of narcolepsy with methamphetamine." *Sleep* 16(4): 306-17.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.

- Perez-Reyes, M. (1968). "Differences in sedative susceptibility between types of depression. Clinical and neurophysiological significance." *Arch Gen Psychiatry* 19(1): 64-71.
- Reback, C. J., S. Larkins, et al. (2003). "Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men." *AIDS Care* 15(6): 775-85.
- Richards, J. R., R. W. Derlet, et al. (1997). "Methamphetamine toxicity: Treatment with a benzodiazepine versus a butyrophenone." *Eur J Emerg Med* 4(3): 130-5.
- Scharf, M. B., D. Brown, et al. (1985). "The effects and effectiveness of gamma-hydroxybutyrate in patients with narcolepsy." *J Clin Psychiatry* 46(6): 222-5.
- Watson, R., E. Hartmann, et al. (1972). "Amphetamine withdrawal: affective state, sleep patterns, and MHPG excretion." *Am J Psychiatry* 129(3): 263-9.
- Wiegmann, D. A., R. R. Stanny, et al. (1996). "Methamphetamine effects on cognitive processing during extended wakefulness." *Int J Aviat Psychol* 6(4): 379-97.
- Wisor, J. P., S. Nishino, et al. (2001). "Dopaminergic role in stimulant-induced wakefulness." *J Neurosci* 21(5): 1787-94.
- Yoss, R. E., N. J. Moyer, et al. (1969). "The pupillogram and narcolepsy. A method to measure decreased levels of wakefulness." *Neurology* 19(10): 921-8.
- Yoss, R. E. and D. D. Daly (1968). "On the treatment of narcolepsy." *Med Clin North Am* 52(4): 781-7.

### Sleep (animals)

*See also* Circadian Rhythms

- Andretic, R., B. van Swinderen, et al. (2005). "Dopaminergic modulation of arousal in *Drosophila*." *Curr Biol* 15(13): 1165-75.
- Birman, S. (2005). "Arousal mechanisms: Speedy flies don't sleep at night." *Curr Biol* 15(13): R511-3.
- Edgar, D. M. and W. F. Seidel (1997). "Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat." *J Pharmacol Exp Ther* 283(2): 757-69.
- Estabrooke, I. V., M. T. McCarthy, et al. (2001). "Fos expression in orexin neurons varies with behavioral state." *J Neurosci* 21(5): 1656-62.
- Holman, R. B., G. R. Elliott, et al. (1975). "Neuroregulators and sleep mechanisms." *Annu Rev Med* 26: 499-520.
- Ihara, Y., M. Sato, et al. (1986). "Morphological changes in rat striatal boutons after chronic methamphetamine and haloperidol treatment." *Neurosci Res* 3(5): 403-10.
- Juvancz, P. (1981). "The effect of p-bromomethamphetamine (V-111) on sleep on the rat." *Eur J Pharmacol* 70(4): 461-6.
- Kameyama, T., T. Nabeshima, et al. (1987). "[Behavioral pharmacological action of Ca-4-(3,5-dihydroxy-3-methylpentylamido) butyrate (mevalonic GABA, MV-GABA)]." *Nippon Yakurigaku Zasshi* 89(3): 103-10.
- Kanbayashi, T., K. Honda, et al. (2000). "Implication of dopaminergic mechanisms in the wake-promoting effects of amphetamine: a study of D- and L-derivatives in canine narcolepsy." *Neuroscience* 99(4): 651-9.
- Katsuura, G. and S. Itoh (1982). "Sedative action of cholecystokinin octapeptide on behavioral excitation by thyrotropin releasing hormone and methamphetamine in the rat." *Jpn J Physiol* 32(1): 83-91.
- Kitahama, K. and J. L. Valatx (1979). "Strain differences in amphetamine sensitivity in mice. II. Overcompensation of paradoxical sleep after deprivation in two C57 strains." *Psychopharmacology (Berl)* 66(3): 291-5.
- Kosman, M. E. and D. R. Unna (1968). "Effects of chronic administration of the amphetamines and other stimulants on behavior." *Clin Pharmacol Ther* 9(2): 240-54.
- Kubena, R. K. and H. Barry, 3rd (1970). "Interactions of delta-tetrahydrocannabinol with barbiturates and methamphetamine." *J Pharmacol Exp Ther* 173(1): 94-100.
- Levy Andersen, M., M. Bignotto, et al. (2003). "Facilitation of ejaculation after methamphetamine administration in paradoxical sleep deprived rats." *Brain Res* 978(1-2): 31-7.
- Lobo, L. L., R. de Medeiros, et al. (1995). "Atropine increases pilocarpine-induced yawning behavior in paradoxical sleep deprived rats." *Pharmacol Biochem Behav* 52(3): 485-8.
- Moore, R. H. and R. P. White (1975). "Central anticholinergic actions of doxepin in rabbits." *Arch Int Pharmacodyn Ther* 213(1): 113-20.
- Richardson, D., A. G. Karczmar, et al. (1972). "Intergeneric behavioral differences among methamphetamine treated mice." *Psychopharmacologia* 25(4): 347-75.
- Ruis, J. F., J. P. Buys, et al. (1990). "Effects of T cycles of light/darkness and periodic forced activity on methamphetamine-induced rhythms in intact and SCN-lesioned rats: Explanation by an hourglass-clock model." *Physiol Behav* 47(5): 917-29.
- Sakurada, T., K. Onodera, et al. (1975). "Effects of polyamines on the central nervous system." *Jpn J Pharmacol* 25(6): 653-61.



- Sattar, S. P., S. C. Bhatia, et al. (2004). "Potential benefits of quetiapine in the treatment of substance dependence disorders." *J Psychiatry Neurosci* 29(6): 452-7.
- Subarnas, A., T. Tadano, et al. (1993). "Pharmacological properties of beta-amyrin palmitate, a novel centrally acting compound, isolated from *Lobelia inflata* leaves." *J Pharm Pharmacol* 45(6): 545-50.
- Sukma, M., C. Chaichantipyuth, et al. (2002). "CNS inhibitory effects of barakol, a constituent of *Cassia siamiam Lamk.*" *J Ethnopharmacol* 83(1-2): 87-94.
- Takashima, A. and S. Itoh (1989). "Neuropharmacological properties of V-9-M, a putative neuropeptide derived from procholecystokinin, in the rat." *Can J Physiol Pharmacol* 67(3): 223-7.
- Tang, A. H. and J. D. Kirch (1971). "Appetite suppression and central nervous system stimulation in the rhesus monkey." *Psychopharmacologia* 21(2): 139-46.
- Wisor, J. P., W. C. Dement, et al. (2006). "Armodafinil, the R-enantiomer of modafinil: Wake-promoting effects and pharmacokinetic profile in the rat." *Pharmacol Biochem Behav.*
- Wisor, J. P., S. Nishino, et al. (2001). "Dopaminergic role in stimulant-induced wakefulness." *J Neurosci* 21(5): 1787-94.
- Yamaguchi, N., H. Yoshimoto, et al. (1982). "The influence of psychotropic drugs on the animal EEG: electrophysiological analysis of the effects of psychotropic drugs." *Electroencephalogr Clin Neurophysiol Suppl* 36: 566-76.
- Yamashita, I., T. Moroji, et al. (1969). "Neuroendocrinological studies in mental disorders and psychotropic drugs. I. On the circadian rhythm of the plasma adrenocortical hormone in mental patients and methamphetamine- and chlorpromazine-treated animals." *Folia Psychiatr Neurol Jpn* 23(2): 143-58.
- Yang, J. Y., C. F. Wu, et al. (1999). "Studies on the sedative and hypnotic effects of oleamide in mice." *Arzneimittelforschung* 49(8): 663-7.

## Slovak Republic

- Csemy, L., L. Kubicka, et al. (2002). "Drug scene in the Czech Republic and Slovakia during the period of transformation." *Eur Addict Res* 8(4): 159-65.

## Smoking Methamphetamine

- Arria, A. M., C. Derauf, et al. (2006). "Methamphetamine and other substance use during pregnancy: Preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study." *Matern Child Health J* 10(3): 293-302.
- Beebe, D. K. and E. Walley (1995). "Smokable methamphetamine ('ice'): An old drug in a different form." *Am Fam Physician* 51(2): 449-53.
- Catanzarite, V. A. and D. A. Stein (1995). "'Crystal' and pregnancy--methamphetamine-associated maternal deaths." *West J Med* 162(5): 454-7.
- Cho, A. K. and W. P. Melega (2002). "Patterns of methamphetamine abuse and their consequences." *J Addict Dis* 21(1): 21-34.
- Collins, C. L., T. Kerr, et al. (2005). "Rationale to evaluate medically supervised safer smoking facilities for non-injection illicit drug users." *Can J Public Health* 96(5): 344-7.
- Collins, C. L., T. Kerr, et al. (2005). "Potential uptake and correlates of willingness to use a supervised smoking facility for noninjection illicit drug use." *J Urban Health* 82(2): 276-84.
- Cook, C. E., A. R. Jeffcoat, et al. (1993). "Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride." *Drug Metab Dispos* 21(4): 717-23.
- Cook, C. E. (1991). "Pyrolytic characteristics, pharmacokinetics, and bioavailability of smoked heroin, cocaine, phencyclidine, and methamphetamine." *NIDA Res Monogr* 115: 6-23.
- Cook, C. E., A. R. Jeffcoat, et al. (1991). "Plasma levels of methamphetamine after smoking of methamphetamine hydrochloride." *NIDA Res Monogr* 105: 578-9.
- Darke, S., J. Cohen, et al. (1994). "Transitions between routes of administration of regular amphetamine users." *Addiction* 89(9): 1077-83.
- Derlet, R. W. and B. Heischouer (1990). "Methamphetamine. Stimulant of the 1990s?" *West J Med* 153(6): 625-8.
- Furr, C. D., J. Delva, et al. (2000). "The suspected association between methamphetamine ('ice') smoking and frequent episodes of alcohol intoxication: Data from the 1993 National Household Survey on Drug Abuse." *Drug Alcohol Depend* 59(1): 89-93.
- Harris, D. S., H. Boxenbaum, E. T. Everhart, G. Sequeira, J. E. Mendelson and R. T. Jones (2003). "The bioavailability of intranasal and smoked methamphetamine." *Clin Pharmacol Ther* 74(5): 475-86.
- Hong, R., E. Matsuyama and K. Nur (1991). "Cardiomyopathy associated with the smoking of crystal methamphetamine." *JAMA* 265(9): 1152-4.

- Martin, I., T. M. Lampinen, et al. (2006). "Methamphetamine use among marginalized youth in British Columbia." *Can J Public Health* 97(4): 320-4.
- Matsumoto, T., A. Kamijo, et al. (2002). "Methamphetamine in Japan: The consequences of methamphetamine abuse as a function of route of administration." *Addiction* 97(7): 809-17.
- Maxwell, J. C., P. Cravioto, et al. (2006). "Drug use and risk of HIV/AIDS on the Mexico-USA border: A comparison of treatment admissions in both countries." *Drug Alcohol Depend* 82 Suppl 1: S85-93.
- McKetin, R., E. Kelly, et al. (2006). "The relationship between crystalline methamphetamine use and methamphetamine dependence." *Drug Alcohol Depend* 85(3): 198-204.
- Meng, Y., M. Dukat, D. T. Bridgen, B. R. Martin and A. H. Lichtman (1999). "Pharmacological effects of methamphetamine and other stimulants via inhalation exposure." *Drug Alcohol Depend* 53(2): 111-20.
- Mitchell, S. J., S. R. Morris, et al. (2006). "Methamphetamine use and sexual activity among HIV-infected patients in care--San Francisco, 2004." *AIDS Patient Care STDS* 20(7): 502-10.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.
- Nestor, T. A., W. I. Tamamoto, T. H. Kam and T. Schultz (1989). "Crystal methamphetamine-induced acute pulmonary edema: A case report." *Hawaii Med J* 48(11): 457-8, 460.
- Newman, J. L. and M. E. Carroll (2006). "Reinforcing effects of smoked methamphetamine in rhesus monkeys." *Psychopharmacology (Berl)* 188(2): 193-200.
- Perez-Reyes, M., W. R. White, et al. (1991). "Clinical effects of methamphetamine vapor inhalation." *Life Sci* 49(13): 953-9.
- Richards, J. R. and B. T. Brofeldt (2000). "Patterns of tooth wear associated with methamphetamine use." *J Periodontol* 71(8): 1371-4.
- Rothrock, J. F., R. Rubenstein, et al. (1988). "Ischemic stroke associated with methamphetamine inhalation." *Neurology* 38(4): 589-92.
- Sanga, M., I. R. Younis, et al. (2006). "Epoxidation of the methamphetamine pyrolysis product, trans-phenylpropene, to trans-phenylpropylene oxide by CYP enzymes and stereoselective glutathione adduct formation." *Toxicol Appl Pharmacol* 211(2): 148-56.
- Sekine, H. and Y. Nakahara (1990). "Abuse of smoking methamphetamine mixed with tobacco: II. The formation mechanism of pyrolysis products." *J Forensic Sci* 35(3): 580-90.
- Sekine, H. and Y. Nakahara (1987). "Abuse of smoking methamphetamine mixed with tobacco: I. Inhalation efficiency and pyrolysis products of methamphetamine." *J Forensic Sci* 32(5): 1271-80.
- Shakleya, D. M., S. G. Tarr, et al. (2005). "Potential marker for smoked methamphetamine hydrochloride based on a gas chromatography-mass spectrometry quantification method for trans-phenylpropene." *J Anal Toxicol* 29(6): 552-5.
- Smith, D. E., R. B. Seymour, et al. (1992). "Anthology series. I: Smokable drugs." *J Psychoactive Drugs* 24(2): 91-8.
- Tashkin, D. P. (2001). "Airway effects of marijuana, cocaine, and other inhaled illicit agents." *Curr Opin Pulm Med* 7(2): 43-61.
- Tohhara, S., A. Kato, et al. (1990). "[Methamphetamine abuse by smoking]." *Arukuru Kenkyuto Yakubutsu Ison* 25(6): 467-74.
- Vongsheree, S., P. Sri-Ngam, et al. (2001). "High HIV-1 prevalence among methamphetamine users in central Thailand, 1999-2000." *J Med Assoc Thai* 84(9): 1263-7.
- Wesson, D. R. and P. Washburn (1990). "Current patterns of drug abuse that involve smoking." *NIDA Res Monogr* 99: 5-11.
- Wijetunga, M., R. Bhan, J. Lindsay and S. Karch (2004). "Acute coronary syndrome and crystal methamphetamine use: A case series." *Hawaii Med J* 63(1): 8-13, 25.
- Wolkoff, D. A. (1997). "Methamphetamine abuse: An overview for health care professionals." *Hawaii Med J* 56(2): 34-6, 44.
- Yeh, P. S., A. Yuan, et al. (2001). "Acute respiratory distress syndrome in a woman with heroin and methamphetamine misuse." *J Formos Med Assoc* 100(8): 553-6.

### Smoking Methamphetamine (animals)

- Meng, Y., M. Dukat, et al. (1999). "Pharmacological effects of methamphetamine and other stimulants via inhalation exposure." *Drug Alcohol Depend* 53(2): 111-20.
- Newman, J. L. and M. E. Carroll (2006). "Reinforcing effects of smoked methamphetamine in rhesus monkeys." *Psychopharmacology (Berl)* 188(2): 193-200.

### Snorting Methamphetamine

- Arria, A. M., C. Derauf, et al. (2006). "Methamphetamine and other substance use during pregnancy: Preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study." *Matern Child Health J* 10(3): 293-302.
- Banooni, P., L. S. Rickman, et al. (2000). "Pott puffy tumor associated with intranasal methamphetamine." *JAMA* 283(10): 1293.

- Cho, A. K. and W. P. Melega (2002). "Patterns of methamphetamine abuse and their consequences." *J Addict Dis* 21(1): 21-34.
- Darke, S., J. Cohen, et al. (1994). "Transitions between routes of administration of regular amphetamine users." *Addiction* 89(9): 1077-83.
- Farnsworth, T. L., C. H. Brugger and P. Malters (1997). "Myocardial infarction after intranasal methamphetamine." *Am J Health Syst Pharm* 54(5): 586-7.
- Furst, S. R., S. P. Fallon, G. N. Reznik and P. K. Shah (1990). "Myocardial infarction after inhalation of methamphetamine." *N Engl J Med* 323(16): 1147-8.
- Harris, D. S., H. Boxenbaum, E. T. Everhart, G. Sequeira, J. E. Mendelson and R. T. Jones (2003). "The bioavailability of intranasal and smoked methamphetamine." *Clin Pharmacol Ther* 74(5): 475-86.
- Johnson, D. C., A. Petru, et al. (1991). "Foreign body pulmonary granulomas in an abuser of nasally inhaled drugs." *Pediatrics* 88(1): 159-61.
- Kumar, R. L., P. K. Kaiser, et al. (2006). "Crystalline retinopathy from nasal ingestion of methamphetamine." *Retina* 26(7): 823-4.
- McKetin, R., E. Kelly, et al. (2006). "The relationship between crystalline methamphetamine use and methamphetamine dependence." *Drug Alcohol Depend* 85(3): 198-204.
- Mitchell, S. J., S. R. Morris, et al. (2006). "Methamphetamine use and sexual activity among HIV-infected patients in care--San Francisco, 2004." *AIDS Patient Care STDS* 20(7): 502-10.
- Nyamathi, A. M., E. L. Dixon, et al. (2006). "Hepatitis C virus infection among homeless men referred from a community clinic." *West J Nurs Res* 28(4): 475-88.
- Richards, J. R. and B. T. Brofeldt (2000). "Patterns of tooth wear associated with methamphetamine use." *J Periodontol* 71(8): 1371-4.
- Sachdeva, K. and K. G. Woodward (1989). "Caudal thalamic infarction following intranasal methamphetamine use." *Neurology* 39(2 Pt 1): 305-6.
- Storr, C. L., A. M. Arria, et al. (2004). "Neighborhood environment and opportunity to try methamphetamine ("ice") and marijuana: Evidence from Guam in the Western Pacific region of Micronesia." *Subst Use Misuse* 39(2): 253-76.
- Zeiter, J. H., D. M. Corder, et al. (1992). "Sudden retinal manifestations of intranasal cocaine and methamphetamine abuse." *Am J Ophthalmol* 114(6): 780-1.

## Social Behaviors and Environments (animals)

*See also* Aggression and Violence; Avoidance Behaviors; Exploratory Behaviors

- Arakawa, O. (1994). "Effects of methamphetamine and methylphenidate on single and paired rat open-field behaviors." *Physiol Behav* 55(3): 441-6.
- Armstrong, V., A. Nazarian, et al. (2001). "Effects of acute and repeated methamphetamine treatment on the ultrasonic vocalizations of postnatal rats." *Pharmacol Biochem Behav* 70(2-3): 273-8.
- Bagorda, F., G. Teuchert-Noodt, et al. (2006). "Isolation rearing or methamphetamine traumatization induce a "dysconnection" of prefrontal efferents in gerbils: Implications for schizophrenia." *J Neural Transm* 113(3): 365-79.
- Brown, P. L., R. A. Wise, et al. (2003). "Brain hyperthermia is induced by methamphetamine and exacerbated by social interaction." *J Neurosci* 23(9): 3924-9.
- Busche, A., J. Neddens, et al. (2002). "Differential influence of rearing conditions and methamphetamine on serotonin fibre maturation in the dentate gyrus of gerbils (*Meriones unguiculatus*)." *Dev Neurosci* 24(6): 512-21.
- Butz, M. and G. Teuchert-Noodt (2006). "A simulation model for compensatory plasticity in the prefrontal cortex inducing a cortico-cortical dysconnection in early brain development." *J Neural Transm* 113(5): 695-710.
- Crowley, T. J. (1983). "Substance abuse research in monkey social groups." *Prog Clin Biol Res* 131: 255-75.
- Crowley, T. J., A. J. Stynes, et al. (1974). "Ethanol, methamphetamine, pentobarbital, morphine, and monkey social behavior." *Arch Gen Psychiatry* 31(6): 829-38.
- Dai, H., T. Okuda, et al. (2005). "Blockage of histamine H1 receptor attenuates social isolation-induced disruption of prepulse inhibition: A study in H1 receptor gene knockout mice." *Psychopharmacology (Berl)* 183(3): 285-93.
- Dai, H., H. Okuda, et al. (2004). "Social isolation stress significantly enhanced the disruption of prepulse inhibition in mice repeatedly treated with methamphetamine." *Ann N Y Acad Sci* 1025: 257-66.
- Dringenberg, H. C., P. Servos, et al. (1992). "Pressure on the snout immobilizes the spontaneously active, scopolaminized, and amphetaminized hyperactive rat." *Behav Brain Res* 50(1-2): 197-9.
- Ellinwood, E. H., Jr. and M. M. Kilbey (1975). "Amphetamine stereotypy: The influence of environmental factors and prepotent behavioral patterns on its topography and development." *Biol Psychiatry* 10(1): 3-16.
- Evans, M. A., R. D. Harbison, et al. (1976). "Stimulant actions of delta9-tetrahydrocannabinol in mice." *Psychopharmacology (Berl)* 50(3): 245-50.

- Fox, G. B., T. A. Esbenshade, et al. (2005). "Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzotrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist." *J Pharmacol Exp Ther* 313(1): 176-90.
- Gomita, Y., Y. Kataoka, et al. (1983). "Methamphetamine mortality to emotional stimuli administered in the form of affective communication." *Life Sci* 32(9): 941-7.
- Gomita, Y., Y. Kataoka, et al. (1982). "Influence of aggregation on the action of methamphetamine in locomotor activity." *J Pharmacobiodyn* 5(5): 334-9.
- Jewett, R. F. and S. Norton (1964). "Measurement of behavior of rats under isolation and observations on preliminary drug effects." *Psychopharmacologia* 6(2): 151-8.
- Lehmann, K., B. Hundsdorfer, et al. (2004). "The acetylcholine fiber density of the neocortex is altered by isolated rearing and early methamphetamine intoxication in rodents." *Exp Neurol* 189(1): 131-40.
- Lehmann, K., J. Lesting, et al. (2003). "Serotonin fibre densities in subcortical areas: Differential effects of isolated rearing and methamphetamine." *Brain Res Dev Brain Res* 147(1-2): 143-52.
- Lesting, J., J. Neddens, et al. (2005). "Hemisphere-specific effects on serotonin but not dopamine innervation in the nucleus accumbens of gerbils caused by isolated rearing and a single early methamphetamine challenge." *Brain Res* 1035(2): 168-76.
- Maengwyn-Davies, G. D., D. G. Johnson, et al. (1973). "Influence of isolation and of fighting on adrenal tyrosine hydroxylase and phenylethanolamine-N-methyltransferase activities in three strains of mice." *Psychopharmacologia* 28(4): 339-50.
- Miczek, K. A. and J. M. O'Donnell (1978). "Intruder-evoked aggression in isolated and nonisolated mice: Effects of psychomotor stimulants and L-dopa." *Psychopharmacology (Berl)* 57(1): 47-55.
- Neddens, J., R. R. Dawirs, et al. (2004). "Postnatal maturation of cortical serotonin lateral asymmetry in gerbils is vulnerable to both environmental and pharmacological epigenetic challenges." *Brain Res* 1021(2): 200-8.
- Neddens, J., J. Lesting, et al. (2002). "An early methamphetamine challenge suppresses the maturation of dopamine fibres in the nucleus accumbens of gerbils: On the significance of rearing conditions." *J Neural Transm* 109(2): 141-55.
- Rosenzweig, M. R. and E. L. Bennett (1972). "Cerebral changes in rats exposed individually to an enriched environment." *J Comp Physiol Psychol* 80(2): 304-13.
- Sassenrath, E. N. and L. F. Chapman (1976). "Primate social behavior as a method of analysis of drug action: Studies with THC in monkeys." *Fed Proc* 35(11): 2238-44.
- Syme, L. A. and G. J. Syme (1974). "Group instability and the social response to methamphetamine." *Pharmacol Biochem Behav* 2(6): 851-4.
- Syme, L. A. and G. J. Syme (1973). "Effects of chlorpromazine and methamphetamine on sociability in rats." *Psychopharmacologia* 32(1): 81-4.
- Wagner, G. C., J. B. Lucot, et al. (1981). "The ontogeny of aggregation-enhanced toxicity." *Psychopharmacology (Berl)* 75(1): 92-3.

### Socioeconomic Factors

*See also* Educational Levels; Homeless Populations; Neighborhood Disadvantage

- Atkinson, J., V. L. Brown, et al. (2004). "Personal adjustment and substance abuse problems in a longitudinal study of TANF recipients and the potential need for treatment." *Am J Drug Alcohol Abuse* 30(3): 643-57.
- Barrett, M. E. (2003). "Correlates of illicit drug use in Karen villages in Northern Thailand." *Subst Use Misuse* 38(11-13): 1615-49.
- Bateman, C. (2006). "'Tik' causing a health crisis." *S Afr Med J* 96(8): 672, 674.
- Beyrer, C., M. H. Razak, et al. (2004). "Methamphetamine users in northern Thailand: Changing demographics and risks for HIV and STD among treatment-seeking substance abusers." *Int J STD AIDS* 15(10): 697-704.
- Brecht, M. L., L. Greenwell, et al. (2005). "Methamphetamine treatment: Trends and predictors of retention and completion in a large state treatment system (1992-2002)." *J Subst Abuse Treat* 29(4): 295-306.
- Brecht, M. L., A. O'Brien, et al. (2004). "Methamphetamine use behaviors and gender differences." *Addict Behav* 29(1): 89-106.
- Brecht, M. L., C. von Mayrhauser, et al. (2000). "Predictors of relapse after treatment for methamphetamine use." *J Psychoactive Drugs* 32(2): 211-20.
- Bungay, V., L. Malchy, et al. (2006). "Life with jib: A snapshot of street youth's use of crystal methamphetamine." *Addiction Research and Theory* 14(3): 235-251.
- Clatts, M. C., L. Goldsamt, et al. (2005). "Homelessness and drug abuse among young men who have sex with men in New York city: A preliminary epidemiological trajectory." *J Adolesc* 28(2): 201-14.
- Cox, C. and R. G. Smart (1972). "Social and psychological aspects of speed use. A study of types of speed users in Toronto." *Int J Addict* 7(2): 201-17.

- Csemy, L., L. Kubicka, et al. (2002). "Drug scene in the Czech Republic and Slovakia during the period of transformation." *Eur Addict Res* 8(4): 159-65.
- Gleghorn, A. A., R. Marx, et al. (1998). "Association between drug use patterns and HIV risks among homeless, runaway, and street youth in northern California." *Drug Alcohol Depend* 51(3): 219-27.
- Grella, C. E., Y. I. Hser, et al. (2006). "Mothers in substance abuse treatment: Differences in characteristics based on involvement with child welfare services." *Child Abuse Negl* 30(1): 55-73.
- Halkitis, P. N., K. A. Green, et al. (2005). "Longitudinal investigation of methamphetamine use among gay and bisexual men in New York City: Findings from Project BUMPS." *J Urban Health* 82(1 Suppl 1): i18-25.
- Kipke, M. D., S. O'Connor, et al. (1995). "Street youth in Los Angeles. Profile of a group at high risk for human immunodeficiency virus infection." *Arch Pediatr Adolesc Med* 149(5): 513-9.
- Kral, A. H., J. Lorvick, et al. (2000). "Sex- and drug-related risk among populations of younger and older injection drug users in adjacent neighborhoods in San Francisco." *J Acquir Immune Defic Syndr* 24(2): 162-7.
- Kushel, M. B., J. A. Hahn, et al. (2005). "Revolving doors: Imprisonment among the homeless and marginally housed population." *Am J Public Health* 95(10): 1747-52.
- Maglione, M., B. Chao, et al. (2000). "Correlates of outpatient drug treatment drop-out among methamphetamine users." *J Psychoactive Drugs* 32(2): 221-8.
- Mansergh, G., G. N. Colfax, et al. (2001). "The Circuit Party Men's Health Survey: Findings and implications for gay and bisexual men." *Am J Public Health* 91(6): 953-8.
- Martin, I., T. M. Lampinen, et al. (2006). "Methamphetamine use among marginalized youth in British Columbia." *Can J Public Health* 97(4): 320-4.
- Nyamathi, A. M., E. L. Dixon, et al. (2006). "Hepatitis C virus infection among homeless men referred from a community clinic." *West J Nurs Res* 28(4): 475-88.
- Nyamathi, A. M., E. L. Dixon, et al. (2002). "Risk factors for hepatitis C virus infection among homeless adults." *J Gen Intern Med* 17(2): 134-43.
- Nyamathi, A., W. A. Robbins, et al. (2002). "Presence and predictors of hepatitis C virus RNA in the semen of homeless men." *Biol Res Nurs* 4(1): 22-30.
- Okudaira, K., T. Yabana, et al. (1994). "[Clinical problems of alcoholics with a history of methamphetamine abuse]." *Arukuru Kenkyuto Yakubutsu Ison* 29(3): 185-9.
- Oro, A. S. and S. D. Dixon (1987). "Perinatal cocaine and methamphetamine exposure: Maternal and neonatal correlates." *J Pediatr* 111(4): 571-8.
- Patterson, T. L., S. J. Semple, et al. (2005). "Methamphetamine-using HIV-positive men who have sex with men: Correlates of polydrug use." *J Urban Health* 82(1 Suppl 1): i120-6.
- Rawson, R., A. Huber, et al. (2000). "Methamphetamine and cocaine users: Differences in characteristics and treatment retention." *J Psychoactive Drugs* 32(2): 233-8.
- Reiber, C., G. Galloway, et al. (2000). "A descriptive analysis of participant characteristics and patterns of substance use in the CSAT methamphetamine treatment project: the first six months." *J Psychoactive Drugs* 32(2): 183-91.
- Rose, V. J., H. F. Raymond, et al. (2006). "Assessing the feasibility of harm reduction services for MSM: The late night breakfast buffet study." *Harm Reduct J* 3: 29.
- Sears, C., J. R. Gyuish, et al. (2001). "Investigation of a secondary syringe exchange program for homeless young adult injection drug users in San Francisco, California, U.S.A." *J Acquir Immune Defic Syndr* 27(2): 193-201.
- Semple, S. J., T. L. Patterson, et al. (2004). "A comparison of injection and non-injection methamphetamine-using HIV positive men who have sex with men." *Drug Alcohol Depend* 76(2): 203-12.
- Semple, S. J., I. Grant, et al. (2004). "Female methamphetamine users: Social characteristics and sexual risk behavior." *Women Health* 40(3): 35-50.
- Semple, S. J., T. L. Patterson, et al. (2003). "Binge use of methamphetamine among HIV-positive men who have sex with men: Pilot data and HIV prevention implications." *AIDS Educ Prev* 15(2): 133-47.
- Smith, D. E. (1969). "Runaways and their health problems in Haight-Ashbury during the summer of 1967." *Am J Public Health Nations Health* 59(11): 2046-50.
- Smith, L. M., L. L. Lagasse, et al. (2006). "The Infant Development, Environment, and Lifestyle Study: Effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth." *Pediatrics* 118(3): 1149-1156.
- Van Leeuwen, J. M., C. Hopfer, et al. (2004). "A snapshot of substance abuse among homeless and runaway youth in Denver, Colorado." *J Community Health* 29(3): 217-29.
- Weiser, S. D., S. E. Dilworth, et al. (2006). "Gender-specific correlates of sex trade among homeless and marginally housed individuals in San Francisco." *J Urban Health* 83(4): 736-40.

Wermuth, L. (2000). "Methamphetamine use: Hazards and social influences." *J Drug Educ* 30(4): 423-33.

Wood, E., J. A. Stoltz, et al. (2006). "Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study." *Harm Reduct J* 3: 18.

Yukitake, A. (1983). "Amphetamine psychosis in Tokyo--Its clinical features and social problems." *Folia Psychiatr Neurol Jpn* 37(2): 115-20.

### Sound and Auditory Stimuli

Hienz, R. D., S. E. Lukas, et al. (1985). "Effects of d-methamphetamine on auditory and visual reaction times and detection thresholds in the baboon." *Psychopharmacology (Berl)* 85(4): 476-82.

Iwanami, A., N. Kuroki, et al. (1998). "P3a of event-related potential in chronic methamphetamine dependence." *J Nerv Ment Dis* 186(12): 746-51.

Iwanami, A., I. Suga, et al. (1993). "Event-related potentials in methamphetamine psychosis during an auditory discrimination task. A preliminary report." *Eur Arch Psychiatry Clin Neurosci* 242(4): 203-8.

Malitz, S. and M. Kanzler (1970). "Effects of drugs on perception in man." *Res Publ Assoc Res Nerv Ment Dis* 48: 35-53.

McKetin, R. and N. Solowij (1999). "Event-related potential indices of auditory selective attention in dependent amphetamine users." *Biol Psychiatry* 45(11): 1488-97.

Vorhees, C. V. (1997). "Methods for detecting long-term CNS dysfunction after prenatal exposure to neurotoxins." *Drug Chem Toxicol* 20(4): 387-99.

### Sound and Auditory Stimuli (animals)

Akita, H., M. Hashimoto, et al. (1990). "[Behavioral characteristics associated with acoustic stimulation and the neurochemical alterations of monoaminergic systems in rat brain at the steady state of repeated methamphetamine administration]." *Nippon Yakurigaku Zasshi* 95(6): 327-33.

Hada, H. and K. Miyamoto (1990). "Enhancing effects of sound on methamphetamine-induced behavioral aberrations in the rat: A model of relapse of schizophrenia-like symptoms." *Jpn J Psychiatry Neurol* 44(3): 619-27.

Hienz, R. D., S. E. Lukas, et al. (1985). "Effects of d-methamphetamine on auditory and visual reaction times and detection thresholds in the baboon." *Psychopharmacology (Berl)* 85(4): 476-82.

Morton, A. J., M. A. Hickey, et al. (2001). "Methamphetamine toxicity in mice is potentiated by exposure to loud music." *Neuroreport* 12(15): 3277-81.

Yui, K., T. Miura, et al. (1994). "Stereotyped behavioral responses to an auditory stimulus in the course of repeated treatment with methamphetamine plus scopolamine and methamphetamine in rats." *Nihon Shinkei Seishin Yakurigaku Zasshi* 14(3): 169-78.

### South Africa

Bateman, C. (2006). "'Tik' causing a health crisis." *S Afr Med J* 96(8): 672, 674.

Morris, K. and C. Parry (2006). "South African methamphetamine boom could fuel further HIV." *Lancet Infect Dis* 6(8): 471.

Parry, C. D., A. Pluddemann, et al. (2005). "Cannabis and other drug use among trauma patients in three South African cities, 1999-2001." *S Afr Med J* 95(6): 429-32.

Parry, C. D., B. Myers, et al. (2004). "Drug policy for methamphetamine use urgently needed." *S Afr Med J* 94(12): 964-5.

Simbayi, L. C., S. C. Kalichman, et al. (2006). "Methamphetamine use and sexual risks for HIV infection in Cape Town, South Africa." *Journal of Substance Use* 11(4): 291-300.

### South Dakota (US)

Anonymous (2005). "Meth use increases HIV cases in South Dakota." *AIDS Patient Care STDS* 19(9): 619-20.

Boulard, G. (2005). "The meth menace: Battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.

Simons, J. S., M. N. Oliver, et al. (2005). "Methamphetamine and alcohol abuse and dependence symptoms: Associations with affect lability and impulsivity in a rural treatment population." *Addict Behav* 30(7): 1370-81.

### Spain

Jimenez-Caballero, P. E. (2006). "[Medullary infarct due to methamphetamine]." *Rev Neurol* 42(10): 635-7.

- March, J. C., E. Oviedo-Joekes, et al. (2006). "Drugs and social exclusion in ten European cities." *Eur Addict Res* 12(1): 33-41.
- Royo-Isach, J., M. Magrane, et al. (2004). "[Speed users (metamphetamines): a return journey between ecstasy (MDMA) and cocaine. Clinical, preventive and health-care questions]." *Aten Primaria* 34(10): 553-6.

## Speech

- Ellis, K. L. and J. Speed (1998). "Pharmacologic management of movement disorder after midbrain haemorrhage." *Brain Inj* 12(7): 623-8.
- Sim, T., S. L. Simon, et al. (2002). "Cognitive deficits among methamphetamine users with attention deficit hyperactivity disorder symptomatology." *J Addict Dis* 21(1): 75-89.
- Srisurapanont, M., R. Ali, et al. (2003). "Psychotic symptoms in methamphetamine psychotic in-patients." *Int J Neuropsychopharmacol* 6(4): 347-52.
- Stitzer, M. L., R. R. Griffiths, et al. (1978). "Effects of d-amphetamine on speaking in isolated humans." *Pharmacol Biochem Behav* 9(1): 57-63.
- Woods, S. P., J. D. Rippeth, et al. (2005). "Deficient strategic control of verbal encoding and retrieval in individuals with methamphetamine dependence." *Neuropsychology* 19(1): 35-43.

## Spinal Cord Injuries

- Hwang, W., J. Ralph, et al. (2003). "Incomplete Brown-Sequard syndrome after methamphetamine injection into the neck." *Neurology* 60(12): 2015-6.
- Nakano, Y., K. Kaneko and Y. Inoue (2003). "A patient with self-inflicted injuries of the cervical vertebrae and spinal cord." *Arch Orthop Trauma Surg* 123(7): 379-81.

## Stereotypic Behaviors

- Ferrando, R. L., E. McCorvey, Jr., et al. (1988). "Bizarre behavior following the ingestion of levo-desoxyephedrine." *Drug Intell Clin Pharm* 22(3): 214-7.
- Kirkby, R. J., D. S. Bell, et al. (1972). "The effects of methylamphetamine on stereotyped behaviour, activity, startle, and orienting responses." *Psychopharmacologia* 25(1): 41-8.
- Sato, M., Y. Numachi, et al. (1992). "Relapse of paranoid psychotic state in methamphetamine model of schizophrenia." *Schizophr Bull* 18(1): 115-22.

## Stereotypic Behaviors (animals)

- Abekawa, T., T. Ohmori, et al. (1997). "Effect of no synthesis inhibition on striatal dopamine release and stereotyped behavior induced by a single administration of methamphetamine." *Prog Neuropsychopharmacol Biol Psychiatry* 21(5): 831-8.
- Abekawa, T., T. Ohmori, et al. (1995). "Effects of nitric oxide (NO) synthesis inhibition on the development of supersensitivity to stereotypy and locomotion stimulating effects of methamphetamine." *Brain Res* 679(2): 200-4.
- Akiyama, K., A. Kanzaki, et al. (1994). "Methamphetamine-induced behavioral sensitization and its implications for relapse of schizophrenia." *Schizophr Res* 12(3): 251-7.
- Abekawa, T., T. Ohmori, et al. (1994). "Effect of NO synthase inhibition on behavioral changes induced by a single administration of methamphetamine." *Brain Res* 666(1): 147-50.
- Akita, H., M. Hashimoto, et al. (1990). "[Behavioral characteristics associated with acoustic stimulation and the neurochemical alterations of monoaminergic systems in rat brain at the steady state of repeated methamphetamine administration]." *Nippon Yakurigaku Zasshi* 95(6): 327-33.
- Akiyama, K., H. Ujike, et al. (1998). "Effect of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline on methamphetamine- and cocaine-induced behavioral sensitization." *Pharmacol Biochem Behav* 61(4): 419-26.
- Akiyama, K., T. Ishihara, et al. (1996). "Effect of acute and chronic administration of methamphetamine on activator protein-1 binding activities in the rat brain regions." *Ann N Y Acad Sci* 801: 13-28.
- Ali, S. F., K. J. Kordsmeier, et al. (1995). "Drug-induced circling preference in rats. Correlation with monoamine levels." *Mol Neurobiol* 11(1-3): 145-54.
- Anaya-Martinez, V., A. Martinez-Marcos, et al. (2006). "Substantia nigra compacta neurons that innervate the reticular thalamic nucleus in the rat also project to striatum or globus pallidus: Implications for abnormal motor behavior." *Neuroscience* 143(2): 477-86.
- Arai, I., T. Shimazoe, et al. (1996). "Enhancement of dopamine release from the striatum through metabotropic glutamate receptor activation in methamphetamine sensitized rats." *Brain Res* 729(2): 277-80.

- Atkins, A. L., M. L. Helms, et al. (2001). "Stereotypic behaviors in mice selectively bred for high and low methamphetamine-induced stereotypic chewing." *Psychopharmacology (Berl)* 157(1): 96-104.
- Balsara, J. J., T. R. Bapat, et al. (1985). "Effect of ergometrine on methamphetamine and apomorphine stereotypy in the guinea-pig." *J Pharm Pharmacol* 37(7): 514-7.
- Balsara, J. J., N. V. Nandal, et al. (1984). "Effects of naloxone on methamphetamine and apomorphine stereotypy and on haloperidol catalepsy in rats." *Psychopharmacology (Berl)* 82(3): 237-40.
- Balsara, J. J., T. R. Bapat, et al. (1982). "Small doses of apomorphine induce catalepsy and antagonize methamphetamine stereotypy in rats." *Psychopharmacology (Berl)* 78(2): 192-4.
- Balsara, J. J., M. P. Muley, et al. (1981). "Effects of baclofen on dopamine-dependent behaviors in mice." *Psychopharmacology (Berl)* 75(4): 396-9.
- Balsara, J. J., J. H. Jadhav, et al. (1979). "Effect of drugs influencing central serotonergic mechanisms on methamphetamine-induced stereotyped behavior in the rat." *Psychopharmacology (Berl)* 64(3): 303-7.
- Balsara, J. J. and A. G. Chandorkar (1978). "Experimental evaluation of the possible neuroleptic activity of clomipramine." *Indian J Physiol Pharmacol* 22(3): 263-9.
- Batki, S. L. and D. S. Harris (2004). "Quantitative drug levels in stimulant psychosis: Relationship to symptom severity, catecholamines and hyperkinesia." *Am J Addict* 13(5): 461-70.
- Bedingfield, J. B., L. D. Calder, et al. (1997). "The role of the striatum in the mouse in behavioral sensitization to amphetamine." *Pharmacol Biochem Behav* 56(2): 305-10.
- Bedingfield, J. B., L. D. Calder, et al. (1996). "Comparative behavioral sensitization to stereotypy by direct and indirect dopamine agonists in CF-1 mice." *Psychopharmacology (Berl)* 124(3): 219-25.
- Bende, M. M., T. R. Bapat, et al. (1990). "Effects of yohimbine on dopamine dependent behaviours in rats and mice." *Indian J Physiol Pharmacol* 34(3): 195-200.
- Bittner, S. E., G. C. Wagner, et al. (1981). "Effects of a high-dose treatment of methamphetamine on caudate dopamine and anorexia in rats." *Pharmacol Biochem Behav* 14(4): 481-6.
- Braestrup, C. (1977). "Biochemical differentiation of amphetamine vs methylphenidate and nomifensine in rats." *J Pharm Pharmacol* 29(8): 463-70.
- Brennan, K., A. Johnstone, et al. (2006). "Chronic benzylpiperazine (BZP) exposure produces behavioral sensitization and cross-sensitization to methamphetamine (MA)." *Drug Alcohol Depend*.
- Camp, D. M., K. E. Browman, et al. (1994). "The effects of methamphetamine and cocaine on motor behavior and extracellular dopamine in the ventral striatum of Lewis versus Fischer 344 rats." *Brain Res* 668(1-2): 180-93.
- Carney, J. M., B. Tolliver, et al. (1991). "Selective effects of behaviorally active doses of methamphetamine on mRNA expression in the gerbil brain." *Neuropharmacology* 30(9): 1011-9.
- Clemens, K. J., J. L. Cornish, et al. (2007). "Repeated weekly exposure to MDMA, methamphetamine or their combination: Long-term behavioural and neurochemical effects in rats." *Drug Alcohol Depend* 86(2-3): 183-90.
- Consroe, P., B. Jones, et al. (1976). "EEG and behavioral effects of delta9-tetrahydrocannabinol in combination with stimulant drugs in rabbits." *Psychopharmacology (Berl)* 50(1): 47-52.
- Cowen, P. J., D. J. Nutt, et al. (1982). "Repeated administration of subconvulsant doses of GABA antagonist drugs. II. Effect on monoamine-mediated behaviour." *Psychopharmacology (Berl)* 76(1): 88-91.
- Dankova, J., R. Boucher, et al. (1977). "Effects of 1694 and other dopaminergic agents on circling behavior." *Eur J Pharmacol* 42(2): 113-21.
- Earle, M. L. and J. A. Davies (1991). "The effect of methamphetamine on the release of glutamate from striatal slices." *J Neural Transm Gen Sect* 86(3): 217-22.
- Eibergen, R. D. and K. R. Carlson (1976). "Behavioral evidence for dopaminergic supersensitivity following chronic treatment with methadone or chlorpromazine in the guinea pig." *Psychopharmacology (Berl)* 48(2): 139-46.
- Eibergen, R. D. and K. R. Carlson (1976). "Dyskinesias in monkeys: Interaction of methamphetamine with prior methadone treatment." *Pharmacol Biochem Behav* 5(2): 175-87.
- Eibergen, R. D. and K. R. Carlson (1975). "Dyskinesias elicited by methamphetamine: Susceptibility of former methadone-consuming monkeys." *Science* 190(4214): 588-90.
- Ellinwood, E. H., Jr. and M. M. Kilbey (1975). "Amphetamine stereotypy: the influence of environmental factors and prepotent behavioral patterns on its topography and development." *Biol Psychiatry* 10(1): 3-16.
- Eradiri, O. L. and M. S. Starr (1999). "Striatal dopamine depletion and behavioural sensitization induced by methamphetamine and 3-nitropropionic acid." *Eur J Pharmacol* 386(2-3): 217-26.
- Finnegan, K. T., L. Calder, et al. (1993). "Effects of L-type calcium channel antagonists on the serotonin-depleting actions of MDMA in rats." *Brain Res* 603(1): 134-8.



- Fog, R. (1972). "On stereotypy and catalepsy: Studies on the effect of amphetamines and neuroleptics in rats." *Acta Neurol Scand Suppl* 50: 3-66.
- Fog, R. (1969). "Stereotyped and non-stereotyped behaviour in rats induced by various stimulant drugs." *Psychopharmacologia* 14(4): 299-304.
- Fukuzako, H., I. Nagatomo, et al. (1988). "Alterations of accumbens neuronal activity in freely moving rats following methamphetamine." *Jpn J Psychiatry Neurol* 42(2): 331-5.
- Funakoshi, T., S. Chaki, et al. (2002). "In vitro and in vivo pharmacological profile of 5-[2-[4-(6-fluoro-1H-indole-3-yl)piperidin-1-yl]ethyl]-4-(4-fluorophenyl)thiazole-2-carboxylic acid amide (NRA0562), a novel and putative atypical antipsychotic." *Life Sci* 71(12): 1371-84.
- Gada, V. P., V. V. Joshi, et al. (1984). "Antagonism of apomorphine-induced cage climbing behaviour and methamphetamine stereotypy by fenfluramine in mice." *Indian J Physiol Pharmacol* 28(4): 326-30.
- Gentry, W. B., A. U. Ghafoor, et al. (2004). "(+)-Methamphetamine-induced spontaneous behavior in rats depends on route of (+)METH administration." *Pharmacol Biochem Behav* 79(4): 751-60.
- Glickstein, S. B. and C. Schmauss (2004). "Effect of methamphetamine on cognition and repetitive motor behavior of mice deficient for dopamine D2 and D3 receptors." *Ann N Y Acad Sci* 1025: 110-8.
- Gomita, Y., Y. Ichimaru, et al. (1990). "Effects of methamphetamine on regional cerebral glucose utilization in rats with unilateral lesion of substantia nigra." *Jpn J Pharmacol* 53(3): 414-8.
- Grisel, J. E., J. K. Belknap, et al. (1997). "Quantitative trait loci affecting methamphetamine responses in BXD recombinant inbred mouse strains." *J Neurosci* 17(2): 745-54.
- Hayase, T., Y. Yamamoto, et al. (2003). "Brain excitatory amino acid transporters (EAATs) and treatment of methamphetamine toxicity." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 38(6): 498-511.
- Hess, U. S., S. P. Whalen, et al. (2003). "Ampakines reduce methamphetamine-driven rotation and activate neocortex in a regionally selective fashion." *Neuroscience* 121(2): 509-21.
- Hirabayashi, M., S. Okada, et al. (1991). "Comparison of sensitization to ambulation-increasing effects of cocaine and methamphetamine after repeated administration in mice." *J Pharm Pharmacol* 43(12): 827-30.
- Hirabayashi, M., S. Okada, et al. (1983). "[Characteristics of reverse tolerance to ambulation-increasing effect of methylphenidate after repeated administration in mice]." *Yakubutsu Seishin Kodo* 3(3): 117-26.
- Hirabayashi, M. and M. R. Alam (1981). "Enhancing effect of methamphetamine on ambulatory activity produced by repeated administration in mice." *Pharmacol Biochem Behav* 15(6): 925-32.
- Hirabayashi, M., F. Iwai, et al. (1979). "[Individual differences in the accelerating effect of methamphetamine, d-amphetamine and morphine on ambulatory activity in mice (author's transl)]." *Nippon Yakurigaku Zasshi* 75(7): 683-93.
- Honma, T. and H. Fukushima (1979). "The involvement of serotonergic neurons in the central nervous system as the possible mechanism for slow head-shaking behavior induced by methamphetamine in rats." *Psychopharmacology (Berl)* 65(2): 155-9.
- Honda, F., Y. Satoh, et al. (1977). "Dopamine receptor blocking activity of sulpiride in the central nervous system." *Jpn J Pharmacol* 27(3): 397-411.
- Hurlbert, M. S., R. I. Gianani, et al. (1999). "Neural transplantation of hNT neurons for Huntington's disease." *Cell Transplant* 8(1): 143-51.
- Ihara, Y., M. Sato, et al. (1986). "Morphological changes in rat striatal boutons after chronic methamphetamine and haloperidol treatment." *Neurosci Res* 3(5): 403-10.
- Inamasu, J., Y. Nakamura, et al. (2003). "Subcortical hemorrhage caused by methamphetamine abuse: Efficacy of the triage system in the differential diagnosis--case report." *Neurol Med Chir (Tokyo)* 43(2): 82-4.
- Ishida, Y., K. Todaka, et al. (1998). "Methamphetamine induces fos expression in the striatum and the substantia nigra pars reticulata in a rat model of Parkinson's disease." *Brain Res* 809(1): 107-14.
- Ito, C., K. Onodera, et al. (1997). "Effects of histamine agents on methamphetamine-induced stereotyped behavior and behavioral sensitization in rats." *Psychopharmacology (Berl)* 130(4): 362-7.
- Ito, S., T. Mori, et al. (2006). "Differential effects of mu-opioid, delta-opioid and kappa-opioid receptor agonists on dopamine receptor agonist-induced climbing behavior in mice." *Behav Pharmacol* 17(8): 691-701.
- Iwazaki, T., I. S. McGregor, et al. (2006). "Protein expression profile in the striatum of acute methamphetamine-treated rats." *Brain Res* 1097(1): 19-25.
- Izawa, J., K. Yamanashi, et al. (2006). "Differential effects of methamphetamine and cocaine on behavior and extracellular levels of dopamine and 3,4-dihydroxyphenylalanine in the nucleus accumbens of conscious rats." *Eur J Pharmacol* 549(1-3): 84-90.
- Izumi, K., M. Nomoto, et al. (1984). "Phenytoin potentiates methamphetamine-induced behavior in mice." *Pharmacol Biochem Behav* 20(5): 803-6.

- Jadhav, J. H., J. J. Balsara, et al. (1981). "Effect of ethosuximide on dopaminergically mediated behaviours." *Indian J Physiol Pharmacol* 25(3): 274-8.
- Janowsky, A., C. Mah, et al. (2001). "Mapping genes that regulate density of dopamine transporters and correlated behaviors in recombinant inbred mice." *J Pharmacol Exp Ther* 298(2): 634-43.
- Joshi, V. V., J. J. Balsara, et al. (1981). "Effect of L-histidine and chlorcyclizine on apomorphine-induced climbing behaviour and methamphetamine stereotypy in mice." *Eur J Pharmacol* 69(4): 499-502.
- Kabai, P., A. Liker, et al. (1999). "Methamphetamine-induced stereotypies in newly-hatched decerebrated domestic chicks." *Neurochem Res* 24(12): 1563-9.
- Kadota, T. and K. Kadota (2004). "Neurotoxic morphological changes induced in the medial prefrontal cortex of rats behaviorally sensitized to methamphetamine." *Arch Histol Cytol* 67(3): 241-51.
- Karler, R., L. D. Calder, et al. (1998). "The role of dopamine in the mouse frontal cortex: a new hypothesis of behavioral sensitization to amphetamine and cocaine." *Pharmacol Biochem Behav* 61(4): 435-43.
- Karler, R., L. D. Calder, et al. (1998). "The role of dopamine and GABA in the frontal cortex of mice in modulating a motor-stimulant effect of amphetamine and cocaine." *Pharmacol Biochem Behav* 60(1): 237-44.
- Karler, R., J. B. Bedingfield, et al. (1997). "The role of the frontal cortex in the mouse in behavioral sensitization to amphetamine." *Brain Res* 757(2): 228-35.
- Karler, R., L. D. Calder, et al. (1995). "The dopaminergic, glutamatergic, GABAergic bases for the action of amphetamine and cocaine." *Brain Res* 671(1): 100-4.
- Karler, R., L. D. Calder, et al. (1994). "A dopaminergic-glutamatergic basis for the action of amphetamine and cocaine." *Brain Res* 658(1-2): 8-14.
- Kashihara, K., Y. Fujiwara, et al. (1984). "[Continuous suppression of methamphetamine-induced supersensitivity by chronic haloperidol administration]." *Seishin Shinkeigaku Zasshi* 86(11): 928-32.
- Kashiwabara, K. (1983). "[A long-term qualitative behavioral change following chronic methamphetamine administration in Japanese monkeys (*Macaca fuscata*)]." *Yakubutsu Seishin Kodo* 3(3): 137-48.
- Kawakami, Y., K. Suemaru, et al. (1998). "Repeated mazindol and methamphetamine administration produces cross-sensitization to stereotyped behavior induced by these agents in rats." *Acta Med Okayama* 52(3): 169-71.
- Kawakami, Y., K. Suemaru, et al. (1996). "[Behavioral changes induced by repeated administration of mazindol, an anorexiant, in rats]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 16(4): 139-43.
- Khanzode, S. D., S. M. Mahakalkar, et al. (1996). "Effect of pre-treatment of some calcium channel blockers on catalepsy and stereotypic behaviour in rats." *Indian J Physiol Pharmacol* 40(2): 159-62.
- Kifune, A. and S. Tadokoro (1991). "[Modification of stereotypy-producing and ambulation-increasing effects following repeated administration of methamphetamine in rats]." *Yakubutsu Seishin Kodo* 11(3): 207-14.
- Kirkby, R. J., D. S. Bell, et al. (1972). "The effects of methylamphetamine on stereotyped behaviour, activity, startle, and orienting responses." *Psychopharmacologia* 25(1): 41-8.
- Kobayashi, M., Y. Wakamatsu, et al. (1977). "[Methamphetamine-stereotypies" and brain dopamine levels of rats treated with single or repeated doses of alpha-methyl-para-tyrosine]." *Nippon Yakurigaku Zasshi* 73(6): 695-701.
- Kobayashi, M. and E. Arai (1976). "Effect of cortisone, aldosterone and nialamide on "amphetamine stereotypies" and brain methamphetamine levels of adrenalectomized rats." *Psychopharmacologia* 46(3): 317-24.
- Koshikawa, N., E. Mori, et al. (1990). "Role of dopamine D-1 and D-2 receptors in the ventral striatum in the turning behaviour of rats." *Eur J Pharmacol* 178(2): 233-7.
- Koshikawa, N., S. Aoki, et al. (1987). "Sulpiride injection into the dorsal striatum increases methamphetamine-induced gnawing in rats." *Eur J Pharmacol* 133(1): 119-25.
- Koshikawa, N., S. Aoki, et al. (1986). "Effects of sulpiride injected into the dorsal striatum and the nucleus accumbens on dopamine-mediated oral stereotypy and hyperlocomotion in rats." *J Nihon Univ Sch Dent* 28(2): 109-16.
- Kuczenski, R. and D. S. Segal (2001). "Caudate-putamen and nucleus accumbens extracellular acetylcholine responses to methamphetamine binges." *Brain Res* 923(1-2): 32-8.
- Kuczenski, R., D. S. Segal, et al. (1995). "Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine." *J Neurosci* 15(2): 1308-17.
- Larson, J., C. N. Quach, et al. (1996). "Effects of an AMPA receptor modulator on methamphetamine-induced hyperactivity in rats." *Brain Res* 738(2): 353-6.
- Lobo, L. L., R. de Medeiros, et al. (1995). "Atropine increases pilocarpine-induced yawning behavior in paradoxical sleep deprived rats." *Pharmacol Biochem Behav* 52(3): 485-8.
- Machiyama, Y. (1992). "Chronic methamphetamine intoxication model of schizophrenia in animals." *Schizophr Bull* 18(1): 107-13.

- Masuda, Y., Y. Matsuda, et al. (1996). "A quantity of stereotyped behavior of ddY mice induced by low-dose methamphetamine." *Exp Anim* 45(3): 279-81.
- Mattei, R. and E. A. Carlini (1996). "A comparative study of the anorectic and behavioral effects of fenproporex on male and female rats." *Braz J Med Biol Res* 29(8): 1025-30.
- Mickley, K. R. and D. E. Dluzen (2004). "Dose-response effects of estrogen and tamoxifen upon methamphetamine-induced behavioral responses and neurotoxicity of the nigrostriatal dopaminergic system in female mice." *Neuroendocrinology* 79(6): 305-16.
- Miyauchi, T., K. Kikuchi, et al. (1981). "Further studies on the potentiating effect of lithium chloride on methamphetamine-induced stereotypy in mice." *Jpn J Pharmacol* 31(1): 61-8.
- Mizuno, M., R. S. Malta, Jr., et al. (2004). "Conditioned place preference and locomotor sensitization after repeated administration of cocaine or methamphetamine in rats treated with epidermal growth factor during the neonatal period." *Ann N Y Acad Sci* 1025: 612-8.
- Mori, A., K. Okuyama, et al. (2002). "Alteration of methamphetamine-induced striatal dopamine release in mint-1 knockout mice." *Neurosci Res* 43(3): 251-7.
- Morton, A. J., M. A. Hickey, et al. (2001). "Methamphetamine toxicity in mice is potentiated by exposure to loud music." *Neuroreport* 12(15): 3277-81.
- Muley, M. P., M. A. Joshi, et al. (1984). "Effect of bupropion on dopamine and 5-hydroxytryptamine-mediated behaviour in mice." *J Pharm Pharmacol* 36(3): 208-10.
- Muley, M. P., J. J. Balsara, et al. (1979). "Effect of L-histidine pretreatment on methamphetamine induced stereotyped behaviour in rats." *Indian J Physiol Pharmacol* 23(4): 291-6.
- Muraki, A. (1993). "[Effects of antagonists of NMDA receptor on methamphetamine-induced decrease in the dopamine uptake sites in the rat striatum and on the behavioral sensitization]." *Hokkaido Igaku Zasshi* 68(3): 407-18.
- Nakajima, H., R. Shigehara, et al. (1981). "[Effect of alpha-methyl-para-tyrosine on "methamphetamine-induced stereotypy and hypermotility" of reserpinized rats (author's transl)]." *Nippon Yakurigaku Zasshi* 78(6): 557-69.
- Nakamura, K., Y. Ozawa, et al. (1985). "[Behavioral and pharmacological studies of methamphetamine-induced stereotypy of mice by the open field method]." *Yakugaku Zasshi* 105(8): 775-83.
- Nakamura, K. and Y. Ozawa (1981). "[A metrical analysis of exploratory behavior in mice: effects of methamphetamine and diazepam (author's transl)]." *Nippon Yakurigaku Zasshi* 78(1): 1-8.
- Nakamura, K., Y. Shimokawa, et al. (1978). "[Influence of clonazepam, an anticonvulsant benzodiazepine drug, on the rat brain monoamine containing neurons especially on dopaminergic neurons (author's transl)]." *Nippon Yakurigaku Zasshi* 74(2): 251-65.
- Namima, M., K. Sugihara, et al. (1999). "Quantitative analysis of the effects of lithium on the reverse tolerance and the c-Fos expression induced by methamphetamine in mice." *Brain Res Brain Res Protoc* 4(1): 11-8.
- Nishikawa, T., N. Mataga, et al. (1983). "Behavioral sensitization and relative hyperresponsiveness of striatal and limbic dopaminergic neurons after repeated methamphetamine treatment." *Eur J Pharmacol* 88(2-3): 195-203.
- Nomura, Y., S. Ashikari, et al. (1982). "[Effect of dopamine intracerebrally injected by the Valzelli method on methamphetamine-stereotypy and hypermotility]." *Yakubutsu Seishin Kodo* 2(1): 25-37.
- Numachi, Y., S. Yoshida, et al. (2000). "Two inbred strains of rats, Fischer 344 and Lewis, showed differential behavior and brain expression of corticosterone receptor mRNA induced by methamphetamine." *Ann N Y Acad Sci* 914: 33-45.
- Ohmori, T., T. Abekawa, et al. (1995). "Scopolamine prevents augmentation of stereotypy induced by chronic methamphetamine treatment." *Psychopharmacology (Berl)* 121(2): 158-63.
- Oiwa, Y., R. Yoshimura, et al. (2002). "Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease." *Brain Res* 947(2): 271-83.
- Okuyama, S., N. Kawashima, et al. (1999). "A selective dopamine D4 receptor antagonist, NRA0160: A preclinical neuropharmacological profile." *Life Sci* 65(20): 2109-25.
- Okuyama, S., S. Chaki, et al. (1997). "In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl]pyrrolidin-3-yl]thiazole (NRA0045)." *J Pharmacol Exp Ther* 282(1): 56-63.
- O'Neil, M. L., R. Kuczenski, et al. (2006). "Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge." *Synapse* 60(6): 465-73.
- Onodera, K., C. Itoh, et al. (1998). "Motor behavioural function for histamine-dopamine interaction in brain." *Inflamm Res* 47 Suppl 1: S30-1.
- Ozawa, H. and T. Miyauchi (1977). "Potentiating effect of lithium chloride on methamphetamine-induced stereotypy in mice." *Eur J Pharmacol* 41(2): 213-6.

- Pacchioni, A. M., J. Vallone, et al. (2007). "Nrf2 gene deletion fails to alter psychostimulant-induced behavior or neurotoxicity." *Brain Res* 1127(1): 26-35.
- Pieri, M., L. Pieri, et al. (1975). "A comparison of drug-induced rotation in rats lesioned in the medial forebrain bundle with 5,6-dihydroxytryptamine or 6-hydroxydopamine." *Arch Int Pharmacodyn Ther* 217(1): 118-30.
- Randrup, A., G. Sorensen, et al. (1988). "Stereotyped behaviour in animals induced by stimulant drugs or by a restricted cage environment: Relation to disintegrated behaviour, brain dopamine and psychiatric disease." *Yakubutsu Seishin Kodo* 8(2): 313-27.
- Richards, J. B., K. E. Sabol, et al. (1990). "Unilateral dopamine depletion causes bilateral deficits in conditioned rotation in rats." *Pharmacol Biochem Behav* 36(2): 217-23.
- Saito, T. R., S. Aoki, et al. (1991). "Effects of methamphetamine on copulatory behavior in male rats." *Jikken Dobutsu* 40(4): 447-52.
- Sano, H., Y. Totsuka, et al. (1982). "[Methamphetamine-stereotypy and hypermotility" in rats chronically treated with reserpine--the effect of intracerebral injection of chlorpromazine]." *Nippon Yakurigaku Zasshi* 80(2): 113-24.
- Sato, M. (1983). "Long-lasting hypersensitivity to methamphetamine following amygdaloid kindling in cats: the relationship between limbic epilepsy and the psychotic state." *Biol Psychiatry* 18(5): 525-36.
- Sayers, A. C. and S. L. Handley (1973). "A study of the role of catecholamines in the response to various central stimulants." *Eur J Pharmacol* 23(1): 47-55.
- Segal, D. S., R. Kuczenski, et al. (2005). "Prolonged exposure of rats to intravenous methamphetamine: Behavioral and neurochemical characterization." *Psychopharmacology (Berl)* 180(3): 501-12.
- Segal, D. S., R. Kuczenski, et al. (2003). "Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge." *Neuropsychopharmacology* 28(10): 1730-40.
- Segal, D. S. and R. Kuczenski (1999). "Escalating dose-binge stimulant exposure: Relationship between emergent behavioral profile and differential caudate-putamen and nucleus accumbens dopamine responses." *Psychopharmacology (Berl)* 142(2): 182-92.
- Segal, D. S. and R. Kuczenski (1997). "Repeated binge exposures to amphetamine and methamphetamine: Behavioral and neurochemical characterization." *J Pharmacol Exp Ther* 282(2): 561-73.
- Semba, J., N. Tanaka, et al. (2001). "Neonatal phencyclidine treatment selectively attenuates mesolimbic dopamine function in adult rats as revealed by methamphetamine-induced behavior and c-fos mRNA expression in the brain." *Synapse* 40(1): 11-8.
- Semba, J., H. Watanabe, et al. (2000). "Neonatal treatment with L-name (NG-nitro-L-arginine methyl ester) attenuates stereotyped behavior induced by acute methamphetamine but not development of behavioral sensitization to methamphetamine." *Prog Neuropsychopharmacol Biol Psychiatry* 24(6): 1017-23.
- Shilling, P. D., R. Kuczenski, et al. (2006). "Differential regulation of immediate-early gene expression in the prefrontal cortex of rats with a high vs low behavioral response to methamphetamine." *Neuropsychopharmacology* 31(11): 2359-67.
- Shimosato, K. and S. Watanabe (1989). "Modification of behavioral responses to methamphetamine evoked by the stimulant's metabolite p-hydroxynorephedrine in rats." *Pharmacol Biochem Behav* 33(2): 423-9.
- Slamberova, R., P. Charousova, et al. (2005). "Maternal behavior is impaired by methamphetamine administered during pre-mating, gestation and lactation." *Reprod Toxicol* 20(1): 103-10.
- Slamberova, R., P. Charousova, et al. (2005). "Methamphetamine administration during gestation impairs maternal behavior." *Dev Psychobiol* 46(1): 57-65.
- Slamberova, R. and R. Rokyta (2005). "Occurrence of bicuculline-, NMDA- and kainic acid-induced seizures in prenatally methamphetamine-exposed adult male rats." *Naunyn Schmiedebergs Arch Pharmacol* 372(3): 236-41.
- Subarnas, A., T. Tadano, et al. (1993). "Pharmacological properties of beta-amyrin palmitate, a novel centrally acting compound, isolated from *Lobelia inflata* leaves." *J Pharm Pharmacol* 45(6): 545-50.
- Sudilovsky, A. (1975). "Effects of disulfiram on the amphetamine-induced behavioral syndrome in the cat as a model of psychosis." *Natl Inst Drug Abuse Res Monogr Ser*(3): 109-35.
- Sumiyoshi, T., M. Tsunoda, et al. (2004). "Enhanced locomotor activity in rats with excitotoxic lesions of the entorhinal cortex, a neurodevelopmental animal model of schizophrenia: Behavioral and in vivo microdialysis studies." *Neurosci Lett* 364(2): 124-9.
- Suzuki, H., T. Shishido, et al. (1997). "Changes of behavior and monoamine metabolites in the rat brain after repeated methamphetamine administration: Effects of duration of repeated administration." *Prog Neuropsychopharmacol Biol Psychiatry* 21(2): 359-69.
- Suzuki, T., H. J. Fan Chiang, et al. (1987). "Effects of quinidine and cimetidine on methamphetamine stereotypy in rats." *J Pharmacobiodyn* 10(3): 152-5.
- Szumliński, K. K., M. Y. Balogun, et al. (2000). "Interactions between iboga agents and methamphetamine sensitization: studies of locomotion and stereotypy in rats." *Psychopharmacology (Berl)* 151(2-3): 234-41.
- Takahashi, S., T. Miwa, et al. (2000). "Involvement of sigma 1 receptors in methamphetamine-induced behavioral sensitization in rats." *Neurosci Lett* 289(1): 21-4.

- Takigawa, M., H. Wang, et al. (2000). "Directed coherence of EEG on ICSS rats with methamphetamine-induced hyperactivity and stereotyped behavior." *Ann N Y Acad Sci* 914: 311-5.
- Takigawa, M., H. Maeda, et al. (1993). "A dual approach to self-stimulation and locomotor trace affected by chronic methamphetamine treatment for an animal model of schizophrenia." *Can J Physiol Pharmacol* 71(5-6): 321-5.
- Tatsuta, T., N. Kitanaka, et al. (2006). "Lobeline attenuates methamphetamine-induced stereotypy in adolescent mice." *Neurochem Res* 31(11): 1359-69.
- Tatsuta, T., N. Kitanaka, et al. (2005). "Effects of monoamine oxidase inhibitors on methamphetamine-induced stereotypy in mice and rats." *Neurochem Res* 30(11): 1377-85.
- Tadokoro, S. and H. Kuribara (1990). "[Modification of the behavioral effects of drugs after repeated administration--special reference to the reverse tolerance of amphetamines]." *Nippon Yakurigaku Zasshi* 95(5): 229-38.
- Takigawa, M., H. Wang, et al. (2000). "Directed coherence of EEG on ICSS rats with methamphetamine-induced hyperactivity and stereotyped behavior." *Ann N Y Acad Sci* 914: 311-5.
- Tirelli, E., B. Geter-Douglass, et al. (1998). "gamma-Aminobutyric acidA agonists differentially augment gnawing induced by indirect-acting dopamine agonists in C57BL/6J mice." *J Pharmacol Exp Ther* 284(1): 116-24.
- Toyota, H., C. Dugovic, et al. (2002). "Behavioral characterization of mice lacking histamine H(3) receptors." *Mol Pharmacol* 62(2): 389-97.
- Ujike, H., A. Kanzaki, et al. (1992). "Sigma (sigma) antagonist BMY 14802 prevents methamphetamine-induced sensitization." *Life Sci* 50(16): PL129-34.
- Ujike, H., H. Tsuchida, et al. (1992). "Competitive and non-competitive N-methyl-D-aspartate antagonists fail to prevent the induction of methamphetamine-induced sensitization." *Life Sci* 50(22): 1673-81.
- Ujike, H., K. Akiyama, et al. (1990). "D-2 but not D-1 dopamine agonists produce augmented behavioral response in rats after subchronic treatment with methamphetamine or cocaine." *Psychopharmacology (Berl)* 102(4): 459-64.
- Ujike, H., T. Onoue, et al. (1989). "Effects of selective D-1 and D-2 dopamine antagonists on development of methamphetamine-induced behavioral sensitization." *Psychopharmacology (Berl)* 98(1): 89-92.
- Wagner, G. C., N. Avena, et al. (2004). "Risperidone reduction of amphetamine-induced self-injurious behavior in mice." *Neuropharmacology* 46(5): 700-8.
- Wakamatsu, Y., M. Iwasaki, et al. (1974). "Proceedings: Influence of L-DOPA on brain noradrenaline contents and stereotypy in methamphetamine-treated rats." *Jpn J Pharmacol* 24(0): s:61.
- Wakayama, A., K. Kataoka, et al. (1993). "Evaluation of masked neurological disorders in the chronic stage after middle cerebral artery occlusion in rats--methamphetamine-induced rotation and regional glucose metabolism in basal ganglia." *Neurol Med Chir (Tokyo)* 33(12): 801-8.
- Wallace, T. L., G. A. Gudelsky, et al. (2001). "Neurotoxic regimen of methamphetamine produces evidence of behavioral sensitization in the rat." *Synapse* 39(1): 1-7.
- Wallace, T. L., G. A. Gudelsky, et al. (1999). "Methamphetamine-induced neurotoxicity alters locomotor activity, stereotypic behavior, and stimulated dopamine release in the rat." *J Neurosci* 19(20): 9141-8.
- Wang, H. D., M. Takigawa, et al. (2002). "A shift in information flow between prefrontal cortex and the ventral tegmental area in methamphetamine-sensitized rats." *Int J Psychophysiol* 44(3): 251-9.
- Wang, H. D., M. Takigawa, et al. (2000). "Reciprocal information flow between prefrontal cortex and ventral tegmental area in an animal model of schizophrenia." *Neuroreport* 11(9): 2007-11.
- Weihmuller, F. B., S. J. O'Dell, et al. (1991). "MK-801 attenuates the dopamine-releasing but not the behavioral effects of methamphetamine: an in vivo microdialysis study." *Brain Res* 549(2): 230-5.
- Witkin, J. M., N. Savtchenko, et al. (1999). "Behavioral, toxic, and neurochemical effects of sydnocarb, a novel psychomotor stimulant: comparisons with methamphetamine." *J Pharmacol Exp Ther* 288(3): 1298-310.
- Yamada, K. and T. Furukawa (1980). "Behavior of rats and mice administered active metabolites of fluphenazine, 7-hydroxy-fluphenazine and fluphenazine-sulfoxide." *Arch Int Pharmacodyn Ther* 248(1): 76-85.
- Yamamura, M., H. Nakagawa, et al. (1989). "Effects of mafoprazine, a phenylpiperazine derivative, on the central dopaminergic system." *Jpn J Pharmacol* 50(3): 295-305.
- Yamamoto, M., Y. Ozawa, et al. (1990). "Central dopaminergic actions of YM-14673, a new TRH analogue, in rodents." *Eur J Pharmacol* 180(2-3): 319-24.
- Yamamoto, T., S. Shibata, et al. (1989). "[Behavioral pharmacological properties of the novel antidepressant paroxetine, a selective 5-HT uptake inhibitor]." *Nippon Yakurigaku Zasshi* 94(3): 189-206.
- Yamanaka, Y., R. Takano, et al. (1986). "Methamphetamine-induced behavioral alterations following repeated administration of methamphetamine." *Jpn J Pharmacol* 41(2): 147-54.

- Yamauchi, J., S. Marukawa, et al. (2000). "[Simultaneous administration of ethanol emphasizes the effect of methamphetamine on central nervous system in rat with high alcohol preference]." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 35(1): 28-47.
- Yang, P. P., E. Y. Huang, et al. (2006). "Co-administration of dextromethorphan with methamphetamine attenuates methamphetamine-induced rewarding and behavioral sensitization." *J Biomed Sci* 13(5): 695-702.
- Yokel, R. A. and R. Pickens (1973). "Self-administration of optical isomers of amphetamine and methylamphetamine by rats." *J Pharmacol Exp Ther* 187(1): 27-33.
- Yoshida, S., Y. Numachi, et al. (2000). "The absence of impairment of cliff avoidance reaction induced by subchronic methamphetamine treatment in inbred strains of mice." *Tohoku J Exp Med* 190(3): 205-12.
- Yoshida, S., Y. Numachi, et al. (1998). "Impairment of cliff avoidance reaction induced by subchronic methamphetamine administration and restraint stress: comparison between two inbred strains of rats." *Prog Neuropsychopharmacol Biol Psychiatry* 22(6): 1023-32.
- Yoshida, S., Y. Numachi, et al. (1995). "[Reverse-tolerance phenomenon in methamphetamine-induced behavioral stereotypy and impairment of cliff avoidance reaction after subchronic methamphetamine administration in rats]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 15(5): 397-403.
- Yui, K. and T. Miura (1996). "Behavioral responses induced by repeated treatment with methamphetamine alone and in combination with scopolamine in rats." *Neuropsychobiology* 33(1): 21-7.
- Yui, K., T. Miura, et al. (1994). "Stereotyped behavioral responses to an auditory stimulus in the course of repeated treatment with methamphetamine plus scopolamine and methamphetamine in rats." *Nihon Shinkei Seishin Yakurigaku Zasshi* 14(3): 169-78.
- Yui, K. and T. Miura (1991). "[Cholinergic modulation on stereotyped behavior and behavioral hypersensitivity (reverse tolerance) in rats]." *Yakubutsu Seishin Kodo* 11(2): 141-56.

### Stigma

- Semple, S. J., I. Grant, et al. (2005). "Utilization of drug treatment programs by methamphetamine users: The role of social stigma." *Am J Addict* 14(4): 367-80.
- Semple, S. J., T. L. Patterson, et al. (2004). "A comparison of injection and non-injection methamphetamine-using HIV positive men who have sex with men." *Drug Alcohol Depend* 76(2): 203-12.

### Stress

- Harris, D. S., V. I. Reus, et al. (2005). "Repeated psychological stress testing in stimulant-dependent patients." *Prog Neuropsychopharmacol Biol Psychiatry* 29(5): 669-77.
- Ibanez, G. E., D. W. Purcell, et al. (2005). "Sexual risk, substance use, and psychological distress in HIV-positive gay and bisexual men who also inject drugs." *AIDS* 19: S49-S55.
- Soderpalm, A., L. Nikolayev, et al. (2003). "Effects of stress on responses to methamphetamine in humans." *Psychopharmacology (Berl)* 170(2): 188-99.
- Yui, K., K. Goto, et al. (2004). "The role of noradrenergic and dopaminergic hyperactivity in the development of spontaneous recurrence of methamphetamine psychosis and susceptibility to episode recurrence." *Ann N Y Acad Sci* 1025: 296-306.
- Yui, K., K. Goto, et al. (2001). "Susceptibility to subsequent episodes of spontaneous recurrence of methamphetamine psychosis." *Drug Alcohol Depend* 64(2): 133-42.
- Yui, K., K. Goto, et al. (2000). "Stress induced spontaneous recurrence of methamphetamine psychosis: The relation between stressful experiences and sensitivity to stress." *Drug Alcohol Depend* 58(1-2): 67-75.
- Yui, K., K. Goto, et al. (1999). "Increased sensitivity to stress and episode recurrence in spontaneous recurrence of methamphetamine psychosis." *Psychopharmacology (Berl)* 145(3): 267-72.

### Stress (animals)

- Dai, H., T. Okuda, et al. (2005). "Blockage of histamine H1 receptor attenuates social isolation-induced disruption of prepulse inhibition: A study in H1 receptor gene knockout mice." *Psychopharmacology (Berl)* 183(3): 285-93.
- Dai, H., H. Okuda, et al. (2004). "Social isolation stress significantly enhanced the disruption of prepulse inhibition in mice repeatedly treated with methamphetamine." *Ann N Y Acad Sci* 1025: 257-66.
- Irwin, S., R. Kinoi, et al. (1971). "Drug effects on distress-evoked behavior in mice: Methodology and drug class comparisons." *Psychopharmacologia* 20(2): 172-85.
- Ison, J. R., R. H. Page, et al. (1969). "Methamphetamine hydrochloride and reactions to aversive shock and reward decrements." *Psychol Rep* 24(3): 739-45.

- Matuszewich, L. and B. K. Yamamoto (2004). "Chronic stress augments the long-term and acute effects of methamphetamine." *Neuroscience* 124(3): 637-46.
- Nash, J. F., Jr. and R. P. Maickel (1985). "Effects of exposure to stressful stimuli on the free-choice consumption of various phenethylamines by rats." *Alcohol Drug Res* 6(6): 403-15.
- Raudensky, J. and B. K. Yamamoto (2006). "Effects of chronic unpredictable stress and methamphetamine on hippocampal glutamate function." *Brain Res.*
- Yamamoto, J. (1998). "Relationship between hippocampal theta-wave frequency and emotional behaviors in rabbits produced with stresses or psychotropic drugs." *Jpn J Pharmacol* 76(1): 125-7.
- Yui, K. and S. Ikemoto (2004). "[Stress sensitization induced by stressor and methamphetamine]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 24(3): 151-7.

## Strokes

*See* Brain Hemorrhages and Strokes

## Substance P (animals)

- Ogden, C. A., M. E. Rich, et al. (2004). "Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: An expanded convergent functional genomics approach." *Mol Psychiatry* 9(11): 1007-29.
- Yu, J., S. Allison, et al. (2002). "Ontogeny of neurokinin-1 receptor mediation of methamphetamine neurotoxicity in the striatum of the mouse brain." *Ann N Y Acad Sci* 965: 247-53.
- Zhu, J. P., W. Xu, et al. (2006). "Distinct mechanisms mediating methamphetamine-induced neuronal apoptosis and dopamine terminal damage share the neuropeptide substance P in the striatum of mice." *Ann N Y Acad Sci* 1074: 135-48.

## Suicide and Suicidal Ideation

*See also* Self-Inflicted Injury and Mutilation

- Callor, W. B., E. Petersen, et al. (2005). "Preliminary findings of noncompliance with psychotropic medication and prevalence of methamphetamine intoxication associated with suicide completion." *Crisis* 26(2): 78-84.
- Chan, P., J. H. Chen, et al. (1994). "Fatal and nonfatal methamphetamine intoxication in the intensive care unit." *J Toxicol Clin Toxicol* 32(2): 147-55.
- Clatts, M. C., L. Goldsamt, et al. (2005). "Homelessness and drug abuse among young men who have sex with men in New York city: a preliminary epidemiological trajectory." *J Adolesc* 28(2): 201-14.
- Clatts, M. C., L. A. Goldsamt, et al. (2005). "Club drug use among young men who have sex with men in NYC: A preliminary epidemiological profile." *Subst Use Misuse* 40(9): 1317-30.
- Fernandez, M. I., G. S. Bowen, et al. (2007). "Crystal methamphetamine: A source of added sexual risk for Hispanic men who have sex with men?" *Drug Alcohol Depend* 86(2-3): 245-52.
- Goldstein, D. J., A. H. Rampey, Jr., et al. (1993). "Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction." *J Clin Psychiatry* 54(8): 309-16.
- Kalechstein, A. D., T. F. Newton, D. Longshore, M. D. Anglin, W. G. van Gorp and F. H. Gawin (2000). "Psychiatric comorbidity of methamphetamine dependence in a forensic sample." *J Neuropsychiatry Clin Neurosci* 12(4): 480-4.
- Logan, B. K., C. L. Fligner, et al. (1998). "Cause and manner of death in fatalities involving methamphetamine." *J Forensic Sci* 43(1): 28-34.
- Noble, P., T. Hart, et al. (1972). "Correlates and outcome of illicit drug use by adolescent girls." *Br J Psychiatry* 120(558): 497-504.
- Operario, D. and T. Nemoto (2005). "Sexual risk behavior and substance use among a sample of Asian Pacific Islander transgendered women." *AIDS Educ Prev* 17(5): 430-43.
- Rawson, R. A., R. Gonzales, et al. (2005). "Methamphetamine use among treatment-seeking adolescents in Southern California: Participant characteristics and treatment response." *J Subst Abuse Treat* 29(2): 67-74.
- Sheridan, J., S. Bennett, et al. (2006). "Injury associated with methamphetamine use: A review of the literature." *Harm Reduct J* 3(1): 14.
- Yen, C. F. and B. L. Shieh (2005). "Suicidal ideation and correlates in Taiwanese adolescent methamphetamine users." *J Nerv Ment Dis* 193(7): 444-9.
- Zweben, J. E., J. B. Cohen, et al. (2004). "Psychiatric symptoms in methamphetamine users." *Am J Addict* 13(2): 181-90.

### Supervised Smoking Facilities

Collins, C. L., T. Kerr, et al. (2005). "Potential uptake and correlates of willingness to use a supervised smoking facility for noninjection illicit drug use." *J Urban Health* 82(2): 276-84.

### Support Groups

*See* Twelve Step and Support Groups

### Surgery

Dutta, S., J. Morton, et al. (2006). "Methamphetamine use following bariatric surgery in an adolescent." *Obes Surg* 16(6): 780-2.

### Sweden

Jones, A. W. and L. Karlsson (2005). "Relation between blood- and urine-amphetamine concentrations in impaired drivers as influenced by urinary pH and creatinine." *Hum Exp Toxicol* 24(12): 615-22.

Jonsson, J., R. Kronstrand, et al. (1996). "A convenient derivatization method for the determination of amphetamine and related drugs in urine." *J Forensic Sci* 41(1): 148-51.

### Syringe Exchange and Syringe Access

Bobkov, A. F., L. M. Selimova, et al. (2005). "Human immunodeficiency virus type 1 in illicit-drug solutions used intravenously retains infectivity." *J Clin Microbiol* 43(4): 1937-9.

Bogart, L. M., A. H. Kral, et al. (2005). "Sexual risk among injection drug users recruited from syringe exchange programs in California." *Sex Transm Dis* 32(1): 27-34.

Braine, N., D. C. Des Jarlais, et al. (2005). "HIV risk behavior among amphetamine injectors at U.S. syringe exchange programs." *AIDS Educ Prev* 17(6): 515-24.

Braine, N., D. C. Des Jarlais, S. Ahmad, D. Purchase and C. Turner (2004). "Long-term effects of syringe exchange on risk behavior and HIV prevention." *AIDS Educ Prev* 16(3): 264-75.

Buavirat, A., K. Page-Shafer, et al. (2003). "Risk of prevalent HIV infection associated with incarceration among injecting drug users in Bangkok, Thailand: Case-control study." *BMJ* 326(7384): 308.

Darke, S., J. Cohen, et al. (1994). "Transitions between routes of administration of regular amphetamine users." *Addiction* 89(9): 1077-83.

Darke, S., W. Hall, et al. (1992). "Benzodiazepine use and HIV risk-taking behaviour among injecting drug users." *Drug Alcohol Depend* 31(1): 31-6.

Darke, S., J. Ross, et al. (1994). "The use of benzodiazepines among regular amphetamine users." *Addiction* 89(12): 1683-90.

Fairbairn, N., T. Kerr, et al. (2006). "Increasing use and associated harms of crystal methamphetamine injection in a Canadian setting." *Drug Alcohol Depend*.

Hahn, J. A., K. Page-Shafer, P. J. Lum, K. Ochoa and A. R. Moss (2001). "Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco." *Hepatology* 34(1): 180-7.

Hall, W., S. Darke, et al. (1993). "Patterns of drug use and risk-taking among injecting amphetamine and opioid drug users in Sydney, Australia." *Addiction* 88(4): 509-16.

Heinzerling, K. G., A. H. Kral, et al. (2006). "Unmet need for recommended preventive health services among clients of California syringe exchange programs: Implications for quality improvement." *Drug Alcohol Depend* 81(2): 167-78.

Kerr, T., E. Wood, E. Grafstein, T. Ishida, K. Shannon, C. Lai, J. Montaner and M. W. Tyndall (2004). "High rates of primary care and emergency department use among injection drug users in Vancouver." *J Public Health (Oxf)*.

Kral, A. H., J. Lorvick, et al. (2005). "HIV prevalence and risk behaviors among men who have sex with men and inject drugs in San Francisco." *J Urban Health* 82(1 Suppl 1): i43-50.

Kral, A. H., J. Lorvick, et al. (2000). "Sex- and drug-related risk among populations of younger and older injection drug users in adjacent neighborhoods in San Francisco." *J Acquir Immune Defic Syndr* 24(2): 162-7.

Kral, A. H., R. N. Bluthenthal, et al. (1999). "Risk factors among IDUs who give injections to or receive injections from other drug users." *Addiction* 94(5): 675-83.

Lorvick, J., A. Martinez, et al. (2006). "Sexual and injection risk among women who inject methamphetamine in San Francisco." *J Urban Health* 83(3): 497-505.



- Lum, P. J., C. Sears, et al. (2005). "Injection risk behavior among women syringe exchangers in San Francisco." *Subst Use Misuse* 40(11): 1681-96.
- Richard, A. J., V. Mosier, et al. (2002). "New syringe acquisition and multi-person use of syringes among illegal drug users." *J Public Health Policy* 23(3): 324-43.
- Rose, V. J., H. F. Raymond, et al. (2006). "Assessing the feasibility of harm reduction services for MSM: The late night breakfast buffet study." *Harm Reduct J* 3: 29.
- Roxburgh, A., L. Degenhardt, et al. (2005). "Drug use and risk behaviours among injecting drug users: A comparison between sex workers and non-sex workers in Sydney, Australia." *Harm Reduct J* 2(1): 7.
- Sears, C., J. R. Gudyish, et al. (2001). "Investigation of a secondary syringe exchange program for homeless young adult injection drug users in San Francisco, California, U.S.A." *J Acquir Immune Defic Syndr* 27(2): 193-201.
- Wada, K. (2004). "[HCV infection among narcotics/methamphetamine abusers]." *Nippon Rinsho* 62 Suppl 7(Pt 1): 326-9.
- Wu, L. T., D. J. Pilowsky, et al. (2004). "Injection drug use among stimulant users in a national sample." *Am J Drug Alcohol Abuse* 30(1): 61-83.
- Zule, W. A. and D. P. Desmond (1999). "An ethnographic comparison of HIV risk behaviors among heroin and methamphetamine injectors." *Am J Drug Alcohol Abuse* 25(1): 1-23.

## Tachykinin (animals)

- Masuo, Y., M. Ishido, et al. (2004). "Motor activity and gene expression in rats with neonatal 6-hydroxydopamine lesions." *J Neurochem* 91(1): 9-19.

## Tacoma, WA (US)

- Braine, N., D. C. Des Jarlais, S. Ahmad, D. Purchase and C. Turner (2004). "Long-term effects of syringe exchange on risk behavior and HIV prevention." *AIDS Educ Prev* 16(3): 264-75.

## Taiwan

- Ahmad, K. (2003). "Asia grapples with spreading amphetamine abuse." *Lancet* 361(9372): 1878-9.
- Barr, A. M., W. J. Panenka, et al. (2006). "The need for speed: An update on methamphetamine addiction." *J Psychiatry Neurosci* 31(5): 301-313.
- Chan, P., J. H. Chen, et al. (1994). "Fatal and nonfatal methamphetamine intoxication in the intensive care unit." *J Toxicol Clin Toxicol* 32(2): 147-55.
- Chen, C. K., S. K. Lin, et al. (2005). "Morbidity risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis." *Am J Med Genet B Neuropsychiatr Genet* 136(1): 87-91.
- Chen, C. K., X. Hu, et al. (2004). "Association analysis of dopamine D2-like receptor genes and methamphetamine abuse." *Psychiatr Genet* 14(4): 223-226.
- Chen, C. K., S. K. Lin, et al. (2003). "Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis." *Psychol Med* 33(8): 1407-14.
- Cheng, C. Y., C. J. Hong, et al. (2005). "Brain-derived neurotrophic factor (Val66Met) genetic polymorphism is associated with substance abuse in males." *Brain Res Mol Brain Res* 140(1-2): 86-90.
- Chiang, S. C., H. Y. Chan, et al. (2006). "Recidivism among male subjects incarcerated for illicit drug use in Taiwan." *Psychiatry Clin Neurosci* 60(4): 444-51.
- Ku, Y. R., Y. S. Chang, et al. (1999). "Analysis and confirmation of synthetic anorexics in adulterated traditional Chinese medicines by high-performance capillary electrophoresis." *J Chromatogr A* 848(1-2): 537-43.
- Li, T., C. K. Chen, et al. (2004). "Association analysis of the DRD4 and COMT genes in methamphetamine abuse." *Am J Med Genet* 129B(1): 120-4.
- Lin, S. K., D. Ball, et al. (2004). "Psychiatric comorbidity and gender differences of persons incarcerated for methamphetamine abuse in Taiwan." *Psychiatry Clin Neurosci* 58(2): 206-12.
- Lin, S. K., C. K. Chen, et al. (2003). "Gender-specific contribution of the GABA(A) subunit genes on 5q33 in methamphetamine use disorder." *Pharmacogenomics J* 3(6): 349-55.
- Liu, H. C., C. K. Chen, et al. (2006). "Association between dopamine receptor D1 A-48G polymorphism and methamphetamine abuse." *Psychiatry Clin Neurosci* 60(2): 226-31.
- Liu, H. C., S. K. Lin, et al. (2004). "DAT polymorphism and diverse clinical manifestations in methamphetamine abusers." *Psychiatr Genet* 14(1): 33-7.

- Nakamura, K., C. K. Chen, et al. (2006). "Association analysis of SOD2 variants with methamphetamine psychosis in Japanese and Taiwanese populations." *Hum Genet* 120(2): 243-52.
- Shaw, K. P. (1999). "Human methamphetamine-related fatalities in Taiwan during 1991-1996." *J Forensic Sci* 44(1): 27-31.
- Teng, S. F., S. C. Wu, et al. (2006). "Characteristics and trends of 3,4-methylenedioxymethamphetamine (MDMA) tablets found in Taiwan from 2002 to February 2005." *Forensic Sci Int* 161(2-3): 202-8.
- Tsai, S. J., C. Y. Cheng, et al. (2002). "No association for D2 and D4 dopamine receptor polymorphisms and methamphetamine abuse in Chinese males." *Psychiatr Genet* 12(1): 29-33.
- Yeh, P. S., A. Yuan, et al. (2001). "Acute respiratory distress syndrome in a woman with heroin and methamphetamine misuse." *J Formos Med Assoc* 100(8): 553-6.
- Yen, C. F. and M. Y. Chong (2006). "Comorbid psychiatric disorders, sex, and methamphetamine use in adolescents: A case-control study." *Compr Psychiatry* 47(3): 215-20.
- Yen, C. F. and Y. C. Su (2006). "The associations of early-onset methamphetamine use with psychiatric morbidity among Taiwanese adolescents." *Subst Use Misuse* 41(1): 35-44.
- Yen, C. F., Y. H. Yang, et al. (2006). "Correlates of methamphetamine use for Taiwanese adolescents." *Psychiatry Clin Neurosci* 60(2): 160-7.
- Yen, C. F. and Y. P. Chang (2005). "Relapse antecedents for methamphetamine use and related factors in Taiwanese adolescents." *Psychiatry Clin Neurosci* 59(1): 77-82.
- Yen, C. F., C. H. Ko, et al. (2005). "Areca quid chewing and methamphetamine use in Taiwanese adolescents." *Public Health* 119(1): 50-4.
- Yen, C. F. and B. L. Shieh (2005). "Suicidal ideation and correlates in Taiwanese adolescent methamphetamine users." *J Nerv Ment Dis* 193(7): 444-9.
- Yen, C. F., Y. H. Yang, et al. (2005). "Substance initiation sequences among Taiwanese adolescents using methamphetamine." *Psychiatry Clin Neurosci* 59(6): 683-9.
- Yen, C. F. (2004). "Relationship between methamphetamine use and risky sexual behavior in adolescents." *Kaohsiung J Med Sci* 20(4): 160-5.

### Teeth

*See Dental and Oral Health*

### Temperature of Body (animals)

*See also Hyperthermia (animals)*

- Estler, C. J. (1975). "Dependence on age of methamphetamine-produced changes in thermoregulation and metabolism." *Experientia* 31(12): 1436-7.
- Estler, C. J. (1975). "Influence of phenoxybenzamine on methamphetamine-induced changes in locomotor activity, oxygen consumption, body temperature and some metabolic parameters." *Neuropharmacology* 14(10): 779-83.
- Grisel, J. E., J. K. Belknap, et al. (1997). "Quantitative trait loci affecting methamphetamine responses in BXD recombinant inbred mouse strains." *J Neurosci* 17(2): 745-54.
- Itabashi, H. (1969). "[Basic investigations in drug evaluation of CNS-acting drugs. Investigation with regards to drug evaluation of CNS-acting drugs with methamphetamine and variation in body temperature]." *Zasshi Tokyo Ika Daigaku* 27(4): 475-98.
- Itoh, Y., R. Oishi, et al. (1986). "Comparison of effects of phencyclidine and methamphetamine on body temperature in mice: A possible role for histamine neurons in thermoregulation." *Naunyn Schmiedebergs Arch Pharmacol* 332(3): 293-6.
- Melega, W. P., G. Lacan, et al. (1998). "Dizocilpine and reduced body temperature do not prevent methamphetamine-induced neurotoxicity in the vervet monkey: [11C]WIN 35,428 - positron emission tomography studies." *Neurosci Lett* 258(1): 17-20.
- Miller, D. B. and J. P. O'Callaghan (2003). "Elevated environmental temperature and methamphetamine neurotoxicity." *Environ Res* 92(1): 48-53.
- Mohaghegh, R. A., M. E. Soulsby, et al. (1997). "The interaction between the central and peripheral nervous systems in mediating the thermic effect of methamphetamine." *Ann N Y Acad Sci* 813: 197-203.
- Miller, D. B. and J. P. O'Callaghan (1994). "Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse." *J Pharmacol Exp Ther* 270(2): 752-60.
- Moy, L. Y., D. S. Albers, et al. (1998). "Lowering ambient or core body temperature elevates striatal MPP+ levels and enhances toxicity to dopamine neurons in MPTP-treated mice." *Brain Res* 790(1-2): 264-9.

- Namiki, M., T. Mori, et al. (2005). "Underlying mechanism of combined effect of methamphetamine and morphine on lethality in mice and therapeutic potential of cooling." *J Pharmacol Sci* 99(2): 168-76.
- O'Neil, M. L., R. Kuczenski, et al. (2006). "Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge." *Synapse* 60(6): 465-73.
- Park, M. J., S. K. Lee, et al. (2006). "Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity." *Brain Res* 1109(1): 176-82.
- Sanchez, V., M. Zeini, et al. (2003). "The nNOS inhibitor, AR-R17477AR, prevents the loss of NF68 immunoreactivity induced by methamphetamine in the mouse striatum." *J Neurochem* 85(2): 515-24.
- Wallace, T. L., C. V. Vorhees, et al. (2003). "Methamphetamine enhances the cleavage of the cytoskeletal protein tau in the rat brain." *Neuroscience* 116(4): 1063-8.
- Xie, T., U. D. McCann, et al. (2000). "Effect of temperature on dopamine transporter function and intracellular accumulation of methamphetamine: Implications for methamphetamine-induced dopaminergic neurotoxicity." *J Neurosci* 20(20): 7838-45.
- Yamamura, T., S. Hishida, et al. (1987). "[Interaction of alcohol and methamphetamine with acute high dose administration to rats]." *Arukuru Kenkyuto Yakubutsu Ison* 22(4): 286-99.
- Yuan, J., G. Hatzidimitriou, et al. (2006). "Relationship between temperature, dopaminergic neurotoxicity, and plasma drug concentrations in methamphetamine-treated squirrel monkeys." *J Pharmacol Exp Ther* 316(3): 1210-8.

## Tennessee (US)

- Boulard, G. (2005). "The meth menace: battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.

## Testosterone

- Bialek, M., P. Zaremba, et al. (2004). "Neuroprotective role of testosterone in the nervous system." *Pol J Pharmacol* 56(5): 509-18.
- Purcell, D. W., R. J. Wolitski, et al. (2005). "Predictors of the use of viagra, testosterone, and antidepressants among HIV-seropositive gay and bisexual men." *AIDS* 19 Suppl 1: S57-66.

## Testosterone (animals)

- Bialek, M., P. Zaremba, et al. (2004). "Neuroprotective role of testosterone in the nervous system." *Pol J Pharmacol* 56(5): 509-18.
- Dluzen, D. E. and J. L. McDermott (2006). "Estrogen, testosterone, and methamphetamine toxicity." *Ann N Y Acad Sci* 1074: 282-94.
- Kaneyuki, T., M. Kohsaka, et al. (1979). "Sex hormones metabolism in the brain: Influence of central acting drugs on 5 alpha-reduction in rat diencephalon." *Endocrinol Jpn* 26(3): 345-51.

## Texas (US)

*See also* Dallas; El Paso; Houston; San Antonio

- Atkinson, J., V. L. Brown, et al. (2004). "Personal adjustment and substance abuse problems in a longitudinal study of TANF recipients and the potential need for treatment." *Am J Drug Alcohol Abuse* 30(3): 643-57.
- Bost, R. O., P. Kemp, et al. (1989). "Tissue distribution of methamphetamine and amphetamine in premature infants." *J Anal Toxicol* 13(5): 300-2.
- Boulard, G. (2005). "The meth menace: battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.
- Gonzales, R., P. Marinelli-Casey, et al. (2006). "Hepatitis C virus infection among methamphetamine-dependent individuals in outpatient treatment." *J Subst Abuse Treat* 31(2): 195-202.
- Johnson, B. A., J. D. Roache, et al. (2005). "Effects of isradipine on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition." *Psychopharmacology (Berl)* 178(2-3): 296-302.
- Kim, J. Y. and M. Fendrich (2002). "Gender differences in juvenile arrestees' drug use, self-reported dependence, and perceived need for treatment." *Psychiatr Serv* 53(1): 70-5.
- Little, B. B., L. M. Snell, et al. (1988). "Methamphetamine abuse during pregnancy: outcome and fetal effects." *Obstet Gynecol* 72(4): 541-4.
- Maxwell, J. C., P. Cravioto, et al. (2006). "Drug use and risk of HIV/AIDS on the Mexico-USA border: A comparison of treatment admissions in both countries." *Drug Alcohol Depend* 82 Suppl 1: S85-93.
- Maxwell, J. C. and R. T. Spence (2005). "Profiles of club drug users in treatment." *Subst Use Misuse* 40(9): 1409-26.

- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.
- Richard, A. J., V. Mosier, et al. (2002). "New syringe acquisition and multi-person use of syringes among illegal drug users." *J Public Health Policy* 23(3): 324-43.
- Thiede, H., L. A. Valleroy, et al. (2003). "Regional patterns and correlates of substance use among young men who have sex with men in 7 US urban areas." *Am J Public Health* 93(11): 1915-21.
- Williams, M. L., J. Atkinson, et al. (2005). "Spatial bridging in a network of drug-using male sex workers." *J Urban Health* 82(1 Suppl 1): i35-42.
- Zule, W. A. and D. P. Desmond (1999). "An ethnographic comparison of HIV risk behaviors among heroin and methamphetamine injectors." *Am J Drug Alcohol Abuse* 25(1): 1-23.

### Thailand

- Ahmad, K. (2003). "Asia grapples with spreading amphetamine abuse." *Lancet* 361(9372): 1878-9.
- Ando, E., M. Hayashida, et al. (2004). "[GC-MS analysis of methamphetamine and amphetamine in hair of Thai drug addicts]." *Nihon Arukoru Yakubutsu Igakkai Zasshi* 39(3): 168-79.
- Barrett, M. E. (2003). "Correlates of illicit drug use in Karen villages in Northern Thailand." *Subst Use Misuse* 38(11-13): 1615-49.
- Beyrer, C., M. H. Razak, et al. (2004). "Methamphetamine users in northern Thailand: Changing demographics and risks for HIV and STD among treatment-seeking substance abusers." *Int J STD AIDS* 15(10): 697-704.
- Buavirat, A., K. Page-Shafer, et al. (2003). "Risk of prevalent HIV infection associated with incarceration among injecting drug users in Bangkok, Thailand: Case-control study." *BMJ* 326(7384): 308.
- Chomchai, C., N. Na Manorom, et al. (2004). "Methamphetamine abuse during pregnancy and its health impact on neonates born at Siriraj Hospital, Bangkok, Thailand." *Southeast Asian J Trop Med Public Health* 35(1): 228-31.
- German, D., S. G. Sherman, et al. (2006). "Motivations for methamphetamine cessation among young people in northern Thailand." *Addiction* 101(8): 1143-52.
- Jittiwutikarn, J., S. Thongsawat, et al. (2006). "Hepatitis C infection among drug users in northern Thailand." *Am J Trop Med Hyg* 74(6): 1111-6.
- Kulsudjarit, K. (2004). "Drug problem in southeast and southwest Asia." *Ann N Y Acad Sci* 1025: 446-57.
- Liu, A., P. Kilmarx, et al. (2006). "Sexual initiation, substance use, and sexual behavior and knowledge among vocational students in northern Thailand." *Int Fam Plan Perspect* 32(3): 126-35.
- McGregor, C., M. Srisurapanont, et al. (2005). "The nature, time course and severity of methamphetamine withdrawal." *Addiction* 100(9): 1320-9.
- Newton, P. N., W. Chierakul, et al. (2003). "Malaria and amphetamine 'horse tablets' in Thailand." *Trop Med Int Health* 8(1): 17-8.
- Obert, J. L., E. D. London, et al. (2002). "Incorporating brain research findings into standard treatment: An example using the Matrix Model." *J Subst Abuse Treat* 23(2): 107-13.
- Poshyachinda, V. (1993). "Drug injecting and HIV infection among the population of drug abusers in Asia." *Bull Narc* 45(1): 77-90.
- Puthaviriyakorn, V., N. Siriviriyasomboon, et al. (2002). "Identification of impurities and statistical classification of methamphetamine tablets (Ya-Ba) seized in Thailand." *Forensic Sci Int* 126(2): 105-13.
- Razak, M. H., J. Jittiwutikarn, et al. (2003). "HIV prevalence and risks among injection and noninjection drug users in northern Thailand: Need for comprehensive HIV prevention programs." *J Acquir Immune Defic Syndr* 33(2): 259-66.
- Sattah, M. V., S. Supawitkul, et al. (2002). "Prevalence of and risk factors for methamphetamine use in northern Thai youth: Results of an audio-computer-assisted self-interviewing survey with urine testing." *Addiction* 97(7): 801-8.
- Srirak, N., S. Kawichai, et al. (2005). "HIV infection among female drug users in Northern Thailand." *Drug Alcohol Depend* 78(2): 141-5.
- Sribanditmongkol, P., M. Chokjamsai, et al. (2000). "Methamphetamine overdose and fatality: 2 cases report." *J Med Assoc Thai* 83(9): 1120-3.
- Srisurapanont, M., R. Ali, et al. (2003). "Psychotic symptoms in methamphetamine psychotic in-patients." *Int J Neuropsychopharmacol* 6(4): 347-52.
- Suwanwela, C. and V. Poshyachinda (1986). "Drug abuse in Asia." *Bull Narc* 38(1-2): 41-53.
- van Griensvan, F., J. Keawkungwal, et al. (2004). "Lack of increased HIV risk behavior among injection drug users participating in the AIDS VAX B/E HIV vaccine trial in Bangkok, Thailand." *AIDS* 18(2): 295-301.
- van Griensven, F., S. Supawitkul, et al. (2001). "Rapid assessment of sexual behavior, drug use, human immunodeficiency virus, and sexually transmitted diseases in northern Thai youth using audio-computer-assisted self-interviewing and noninvasive specimen collection." *Pediatrics* 108(1): E13.

- Verachai, V., T. Phutiprawan, et al. (2005). "HIV infection among substance abusers in Thanyarak Institute On Drug Abuse, Thailand, 1987-2002." *J Med Assoc Thai* 88(1): 76-9.
- Verachai, V., T. Phutiprawan, et al. (2002). "Prevalence and genotypes of hepatitis C virus infection among drug addicts and blood donors in Thailand." *Southeast Asian J Trop Med Public Health* 33(4): 849-51.
- Verachai, V., S. Dechongkit, et al. (2001). "Drug addicts treatment for ten years in Thanyarak Hospital (1989-1998)." *J Med Assoc Thai* 84(1): 24-9.
- Vitsupakorn, K., S. Teerawatsakul, et al. (2003). "The validity of peer responses as a tool for screening at-risk students: a preliminary analysis." *Southeast Asian J Trop Med Public Health* 34(3): 682-6.
- Vongsheree, S., P. Sri-Ngam, et al. (2001). "High HIV-1 prevalence among methamphetamine users in central Thailand, 1999-2000." *J Med Assoc Thai* 84(9): 1263-7.

## Therapeutic Uses

*See Medical Uses*

## Tijuana (Mexico)

- Brouwer, K. C., P. Case, et al. (2006). "Trends in production, trafficking, and consumption of methamphetamine and cocaine in Mexico." *Subst Use Misuse* 41(5): 707-27.
- Cruz, M. F., A. Mantsios, et al. (2006). "A qualitative exploration of gender in the context of injection drug use in two US-Mexico border cities." *AIDS Behav*.
- Strathdee, S. A., W. D. Fraga, et al. (2005). ""Vivo para consumirla y la consumo para vivir" ["I live to inject and inject to live"]: High-risk injection behaviors in Tijuana, Mexico." *J Urban Health* 82(3 Suppl 4): iv58-73.
- Viani, R. M., M. R. Araneta, et al. (2006). "Perinatal HIV counseling and rapid testing in Tijuana, Baja California, Mexico: Seroprevalence and correlates of HIV infection." *J Acquir Immune Defic Syndr* 41(1): 87-92.

## Timing and Clock Speed (animals)

*See also Circadian Rhythms (animals); Hyperactivity (animals); Stereotypic Behaviors (animals)*

- Buhusi, C. V. and W. H. Meck (2006). "Effect of clozapine on interval timing and working memory for time in the peak-interval procedure with gaps." *Behav Processes*.
- Matell, M. S., M. Bateson, et al. (2006). "Single-trials analyses demonstrate that increases in clock speed contribute to the methamphetamine-induced horizontal shifts in peak-interval timing functions." *Psychopharmacology (Berl)* 188(2): 201-12.
- Meck, W. H. (2006). "Frontal cortex lesions eliminate the clock speed effect of dopaminergic drugs on interval timing." *Brain Res* 1108(1): 157-67.

## Tobacco

*See Nicotine and Tobacco; Nicotine and Tobacco (animals)*

## Tolerance

- Brauer, L. H., J. Ambre, et al. (1996). "Acute tolerance to subjective but not cardiovascular effects of d-amphetamine in normal, healthy men." *J Clin Psychopharmacol* 16(1): 72-6.
- Cho, A. K. and W. P. Melega (2002). "Patterns of methamphetamine abuse and their consequences." *J Addict Dis* 21(1): 21-34.
- Comer, S. D., C. L. Hart, et al. (2001). "Effects of repeated oral methamphetamine administration in humans." *Psychopharmacology (Berl)* 155(4): 397-404.
- Derlet, R. W. and B. Heischouer (1990). "Methamphetamine. Stimulant of the 1990s?" *West J Med* 153(6): 625-8.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.
- Osugi, T., Y. Aoki, et al. (1994). "[Involvement of gene expression in drug tolerance and dependence]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 14(4): 185-93.
- Perez-Reyes, M., W. R. White, et al. (1991). "Clinical effects of daily methamphetamine administration." *Clin Neuropharmacol* 14(4): 352-8.
- Segal, D. S. and R. Kuczenski (2006). "Human methamphetamine pharmacokinetics simulated in the rat: Single daily intravenous administration reveals elements of sensitization and tolerance." *Neuropsychopharmacology* 31(5): 941-55.

- Tadokoro, S. and H. Kuribara (1990). "[Modification of the behavioral effects of drugs after repeated administration--special reference to the reverse tolerance of amphetamines]." *Nippon Yakurigaku Zasshi* 95(5): 229-38.
- Wachtel, S. R. and H. de Wit (1999). "Subjective and behavioral effects of repeated d-amphetamine in humans." *Behav Pharmacol* 10(3): 271-81.

### Tolerance (animals)

- Akita, H., M. Hashimoto, et al. (1990). "[Behavioral characteristics associated with acoustic stimulation and the neurochemical alterations of monoaminergic systems in rat brain at the steady state of repeated methamphetamine administration]." *Nippon Yakurigaku Zasshi* 95(6): 327-33.
- Bittner, S. E., G. C. Wagner, et al. (1981). "Effects of a high-dose treatment of methamphetamine on caudate dopamine and anorexia in rats." *Pharmacol Biochem Behav* 14(4): 481-6.
- Davidson, C., T. H. Lee, et al. (2005). "Acute and chronic continuous methamphetamine have different long-term behavioral and neurochemical consequences." *Neurochem Int* 46(3): 189-203.
- Hirabayashi, M. and S. Okada (1985). "[Development of reverse tolerance to the ambulation-increasing effect of ephedrine after repeated administration in mice]." *Yakubutsu Seishin Kodo* 5(3): 231-41.
- Ishikawa, K., A. Nitta, et al. (2006). "Effects of single and repeated administration of methamphetamine or morphine on neuroglycan C gene expression in the rat brain." *Int J Neuropsychopharmacol* 9(4): 407-15.
- Kuczenski, R. and D. S. Segal (2001). "Caudate-putamen and nucleus accumbens extracellular acetylcholine responses to methamphetamine binges." *Brain Res* 923(1-2): 32-8.
- Namima, M., K. Sugihara, et al. (1999). "Quantitative analysis of the effects of lithium on the reverse tolerance and the c-Fos expression induced by methamphetamine in mice." *Brain Res Brain Res Protoc* 4(1): 11-8.
- Narita, M., M. Miyatake, et al. (2005). "[Implication of glial function in the development of drug dependence associated with synaptic plasticity]." *Nippon Yakurigaku Zasshi* 126(1): 43-8.
- O'Neil, M. L., R. Kuczenski, et al. (2006). "Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge." *Synapse* 60(6): 465-73.
- Peltier, R. L., D. H. Li, et al. (1996). "Chronic d-amphetamine or methamphetamine produces cross-tolerance to the discriminative and reinforcing stimulus effects of cocaine." *J Pharmacol Exp Ther* 277(1): 212-8.
- Pleuvry, B. J. (1971). "Cross tolerance between methylamphetamine and morphine in the mouse." *J Pharm Pharmacol* 23(12): 969-70.
- Sano, H., Y. Yasoshima, et al. (2003). "Conditional ablation of striatal neuronal types containing dopamine D2 receptor disturbs coordination of basal ganglia function." *J Neurosci* 23(27): 9078-88.
- Segal, D. S. and R. Kuczenski (2006). "Human methamphetamine pharmacokinetics simulated in the rat: single daily intravenous administration reveals elements of sensitization and tolerance." *Neuropsychopharmacology* 31(5): 941-55.
- Segal, D. S. and R. Kuczenski (1999). "Escalating dose-binge stimulant exposure: Relationship between emergent behavioral profile and differential caudate-putamen and nucleus accumbens dopamine responses." *Psychopharmacology (Berl)* 142(2): 182-92.
- Tadokoro, S. and H. Kuribara (1990). "[Modification of the behavioral effects of drugs after repeated administration--Special reference to the reverse tolerance of amphetamines]." *Nippon Yakurigaku Zasshi* 95(5): 229-38.
- Takahashi, M. and S. Tokuyama (1998). "Pharmacological and physiological effects of ginseng on actions induced by opioids and psychostimulants." *Methods Find Exp Clin Pharmacol* 20(1): 77-84.
- Takigawa, M., H. Maeda, et al. (1993). "A dual approach to self-stimulation and locomotor trace affected by chronic methamphetamine treatment for an animal model of schizophrenia." *Can J Physiol Pharmacol* 71(5-6): 321-5.
- Thomas, D. M. and D. M. Kuhn (2005). "Attenuated microglial activation mediates tolerance to the neurotoxic effects of methamphetamine." *J Neurochem* 92(4): 790-7.
- Woolverton, W. L., L. Cervo, et al. (1984). "Effects of repeated methamphetamine administration on methamphetamine self-administration in rhesus monkeys." *Pharmacol Biochem Behav* 21(5): 737-41.
- Yoshida, S., Y. Numachi, et al. (1998). "Impairment of cliff avoidance reaction induced by subchronic methamphetamine administration and restraint stress: Comparison between two inbred strains of rats." *Prog Neuropsychopharmacol Biol Psychiatry* 22(6): 1023-32.
- Yoshida, S., Y. Numachi, et al. (1995). "[Reverse-tolerance phenomenon in methamphetamine-induced behavioral stereotypy and impairment of cliff avoidance reaction after subchronic methamphetamine administration in rats]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 15(5): 397-403.
- Zacny, J. P., R. M. Virus, et al. (1990). "Tolerance and cross-tolerance to 3,4-methylenedioxymethamphetamine (MDMA), methamphetamine and methylenedioxyamphetamine." *Pharmacol Biochem Behav* 35(3): 637-42.

**Toronto, ON (Canada)**

- Cox, C. and R. G. Smart (1972). "Social and psychological aspects of speed use. A study of types of speed users in Toronto." *Int J Addict* 7(2): 201-17.
- Kalasinaky, K. S., J. Hugel, et al. (2004). "Use of MDA (the "love drug") and methamphetamine in Toronto by unsuspecting users of ecstasy (MDMA)." *J Forensic Sci* 49(5): 1106-12.

**Traditional Chinese Medicine**

*See also* Acupuncture; Acupuncture (animals)

- Ku, Y. R., Y. S. Chang, et al. (1999). "Analysis and confirmation of synthetic anorexics in adulterated traditional Chinese medicines by high-performance capillary electrophoresis." *J Chromatogr A* 848(1-2): 537-43.

**Trafficking**

*See* Methamphetamine Trafficking and Sale

**Transgendered Individuals**

- Martin, I., T. M. Lampinen, et al. (2006). "Methamphetamine use among marginalized youth in British Columbia." *Can J Public Health* 97(4): 320-4.
- Operario, D. and T. Nemoto (2005). "Sexual risk behavior and substance use among a sample of Asian Pacific Islander transgendered women." *AIDS Educ Prev* 17(5): 430-43.

**Trauma**

*See also* Aggression and Violence; Burn Injuries; Emergency Care; Self-Inflicted Injury and Self-Mutilation; Suicide and Suicidal Ideation

- Burchell, S. A., H. C. Ho, et al. (2000). "Effects of methamphetamine on trauma patients: A cause of severe metabolic acidosis?" *Crit Care Med* 28(6): 2112-5.
- Demetriades, D., G. Gkiokas, et al. (2004). "Alcohol and illicit drugs in traumatic deaths: Prevalence and association with type and severity of injuries." *J Am Coll Surg* 199(5): 687-92.
- Horiguchi, T., S. Hori, et al. (1999). "A case of traumatic shock complicated by methamphetamine intoxication." *Intensive Care Med* 25(7): 758-60.
- Parry, C. D., A. Pluddemann, et al. (2005). "Cannabis and other drug use among trauma patients in three South African cities, 1999-2001." *S Afr Med J* 95(6): 429-32.
- Richards, J. R., S. W. Bretz, E. B. Johnson, S. D. Turnipseed, B. T. Brofeldt and R. W. Derlet (1999). "Methamphetamine abuse and emergency department utilization." *West J Med* 170(4): 198-202.
- Schermer, C. R. and D. H. Wisner (1999). "Methamphetamine use in trauma patients: A population-based study." *J Am Coll Surg* 189(5): 442-9.

**Treatment**

*See* Acupuncture; Drug Courts and Court-Mandated Treatment; Harm Reduction; Methadone Maintenance Treatment; Pharmacological Interventions; Psychotherapy; Twelve-Step Groups; Vaccination, Drug Treatment; *and treatment headings below*

**Treatment, Cognitive and Behavioral**

- Anonymous (2002). "Behavioral intervention for meth-using MSM. Researchers want to spread word." *AIDS Alert* 17(11): 143-4.
- Boulard, G. (2005). "The meth menace: Battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.
- Campos, M. and S. Shoptaw (2005). "Evidence-based treatments for methamphetamine abuse." *Focus* 20(6): 5-6.
- Cretzmeyer, M., M. V. Sarrazin, et al. (2003). "Treatment of methamphetamine abuse: Research findings and clinical directions." *J Subst Abuse Treat* 24(3): 267-77.
- Domier, C. P., S. L. Simon, et al. (2000). "A comparison of injecting and noninjecting methamphetamine users." *J Psychoactive Drugs* 32(2): 229-32.

- Freese, T. E., J. Obert, et al. (2000). "Methamphetamine abuse: Issues for special populations." *J Psychoactive Drugs* 32(2): 177-82.
- Gunter, T. D., D. W. Black, et al. (2004). "Drug and alcohol treatment services effective for methamphetamine abuse." *Ann Clin Psychiatry* 16(4): 195-200.
- Hamilton Brown, A. (2004). "Integrating research and practice in the CSAT Methamphetamine Treatment Project." *J Subst Abuse Treat* 26(2): 103-8.
- Hawke, J. M., N. Jainchill and G. De Leon (2000). "Adolescent amphetamine users in treatment: Client profiles and treatment outcomes." *J Psychoactive Drugs* 32(1): 95-105.
- Herrell, J. M., J. A. Taylor, et al. (2000). "A multisite study of the effectiveness of methamphetamine treatment: An initiative of the Center for Substance Abuse Treatment." *J Psychoactive Drugs* 32(2): 143-7.
- Higgins, S. T. (2006). "Extending contingency management to the treatment of methamphetamine use disorders." *Am J Psychiatry* 163(11): 1870-2.
- Huber, A., R. H. Lord, et al. (2000). "The CSAT methamphetamine treatment program: Research design accommodations for "real world" application." *J Psychoactive Drugs* 32(2): 149-56.
- Huber, A., W. Ling, et al. (1997). "Integrating treatments for methamphetamine abuse: A psychosocial perspective." *J Addict Dis* 16(4): 41-50.
- Maxwell, J. C. (2005). "Emerging research on methamphetamine." *Curr Opin Psychiatry* 18(3): 235-42.
- Menza, T. W., G. Colfax, et al. (2006). "Interest in a methamphetamine intervention among men who have sex with men." *Sex Transm Dis* 33(9): 565-70.
- Niv, N. and Y. I. Hser (2006). "Drug treatment service utilization and outcomes for Hispanic and white methamphetamine abusers." *Health Serv Res* 41(4 Pt 1): 1242-57.
- Obert, J. L., A. H. Brown, et al. (2005). "When treatment meets research: Clinical perspectives from the CSAT Methamphetamine Treatment Project." *J Subst Abuse Treat* 28(3): 231-7.
- Obert, J. L., E. D. London, et al. (2002). "Incorporating brain research findings into standard treatment: An example using the Matrix Model." *J Subst Abuse Treat* 23(2): 107-13.
- Obert, J. L., M. J. McCann, et al. (2000). "The Matrix model of outpatient stimulant abuse treatment: History and description." *J Psychoactive Drugs* 32(2): 157-64.
- Peck, J. A., C. J. Reback, et al. (2005). "Sustained reductions in drug use and depression symptoms from treatment for drug abuse in methamphetamine-dependent gay and bisexual men." *J Urban Health* 82(1 Suppl 1): i100-8.
- Peck, J. A., S. Shoptaw, et al. (2005). "HIV-associated medical, behavioral, and psychiatric characteristics of treatment-seeking, methamphetamine-dependent men who have sex with men." *J Addict Dis* 24(3): 115-32.
- Petry, N. M., J. M. Peirce, et al. (2005). "Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: a national drug abuse treatment clinical trials network study." *Arch Gen Psychiatry* 62(10): 1148-56.
- Petry, N. M., K. B. Kolodner, et al. (2006). "Prize-based contingency management does not increase gambling." *Drug Alcohol Depend* 83(3): 269-73.
- Rawson, R. A., M. J. McCann, et al. (2006). "A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals." *Addiction* 101(2): 267-74.
- Rawson, R. A., R. Gonzales, et al. (2005). "Methamphetamine use among treatment-seeking adolescents in Southern California: Participant characteristics and treatment response." *J Subst Abuse Treat* 29(2): 67-74.
- Rawson, R. A., P. Marinelli-Casey, et al. (2004). "A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence." *Addiction* 99(6): 708-17.
- Rawson, R. A., R. Gonzales, et al. (2002). "Treatment of methamphetamine use disorders: An update." *J Subst Abuse Treat* 23(2): 145-50.
- Rawson, R. A., A. Huber, et al. (2002). "Status of methamphetamine users 2-5 years after outpatient treatment." *J Addict Dis* 21(1): 107-19.
- Reiber, C., G. Galloway, et al. (2000). "A descriptive analysis of participant characteristics and patterns of substance use in the CSAT methamphetamine treatment project: The first six months." *J Psychoactive Drugs* 32(2): 183-91.
- Roll, J. M., A. Huber, et al. (2006). "A comparison of five reinforcement schedules for use in contingency management-based treatment of methamphetamine abuse." *Psychological Record* 56(1): 67-81.
- Roll, J. M., N. M. Petry, et al. (2006). "Contingency management for the treatment of methamphetamine use disorders." *Am J Psychiatry* 163(11): 1993-9.
- Roll, J. M. and S. Shoptaw (2006). "Contingency management: Schedule effects." *Psychiatry Res* 144(1): 91-3.
- Shoptaw, S. and C. J. Reback (2006). "Associations between methamphetamine use and HIV among men who have sex with men: A model for guiding public policy." *J Urban Health* 83(6): 1151-7.



- Shoptaw, S. (2006). "Methamphetamine use in urban gay and bisexual populations." *Top HIV Med* 14(2): 84-7.
- Shoptaw, S., A. Huber, et al. (2006). "Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence." *Drug Alcohol Depend* 85(1): 12-18.
- Shoptaw, S., C. J. Reback, et al. (2005). "Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men." *Drug Alcohol Depend* 78(2): 125-34.
- Shoptaw, S., C. J. Reback, et al. (1998). "Stimulant abuse treatment as HIV prevention." *J Addict Dis* 17(4): 19-32.
- Shoptaw, S., R. A. Rawson, et al. (1994). "The Matrix model of outpatient stimulant abuse treatment: Evidence of efficacy." *J Addict Dis* 13(4): 129-41.
- Smith, T. L., F. R. Volpe, et al. (1999). "Impact of a stimulant-focused enhanced program on the outcome of alcohol- and/or stimulant-dependent men." *Alcohol Clin Exp Res* 23(11): 1772-9.
- Vazquez, E. (2005). "Crystal meth recovery. A step-by-step guide." *Posit Aware* 16(5): 20-2, 25.
- Yen, C. F., H. Y. Wu, et al. (2004). "Effects of brief cognitive-behavioral interventions on confidence to resist the urges to use heroin and methamphetamine in relapse-related situations." *J Nerv Ment Dis* 192(11): 788-91.
- Zweben, J. E., J. B. Cohen, et al. (2000). "Conducting trials in community settings: The provider perspective." *J Psychoactive Drugs* 32(2): 193-9.

## Treatment, Methamphetamine Users in

*See also* Treatment Utilization

- Beyrer, C., M. H. Razak, et al. (2004). "Methamphetamine users in northern Thailand: Changing demographics and risks for HIV and STD among treatment-seeking substance abusers." *Int J STD AIDS* 15(10): 697-704.
- Brecht, M. L., L. Greenwell, et al. (2007). "Substance use pathways to methamphetamine use among treated users." *Addict Behav* 32(1): 24-38.
- Brecht, M. L., M. D. Anglin, et al. (2005). "Coerced treatment for methamphetamine abuse: Differential patient characteristics and outcomes." *Am J Drug Alcohol Abuse* 31(2): 337-56.
- Brecht, M. L., L. Greenwell, et al. (2005). "Methamphetamine treatment: Trends and predictors of retention and completion in a large state treatment system (1992-2002)." *J Subst Abuse Treat* 29(4): 295-306.
- Brecht, M. L., A. O'Brien, et al. (2004). "Methamphetamine use behaviors and gender differences." *Addict Behav* 29(1): 89-106.
- Brouwer, K. C., P. Case, et al. (2006). "Trends in production, trafficking, and consumption of methamphetamine and cocaine in Mexico." *Subst Use Misuse* 41(5): 707-27.
- Buavirat, A., K. Page-Shafer, et al. (2003). "Risk of prevalent HIV infection associated with incarceration among injecting drug users in Bangkok, Thailand: Case-control study." *BMJ* 326(7384): 308.
- Cohen, J. B., A. Dickow, et al. (2003). "Abuse and violence history of men and women in treatment for methamphetamine dependence." *Am J Addict* 12(5): 377-85.
- Copeland, A. L. and J. L. Sorensen (2001). "Differences between methamphetamine users and cocaine users in treatment." *Drug Alcohol Depend* 62(1): 91-5.
- Cretzmeyer, M., M. V. Sarrazin, et al. (2003). "Treatment of methamphetamine abuse: Research findings and clinical directions." *J Subst Abuse Treat* 24(3): 267-77.
- Domier, C. P., S. L. Simon, et al. (2000). "A comparison of injecting and noninjecting methamphetamine users." *J Psychoactive Drugs* 32(2): 229-32.
- Evans, E. and D. Longshore (2004). "Evaluation of the substance abuse and crime prevention act: Treatment clients and program types during the first year of implementation." *J Psychoactive Drugs Suppl*(2): 165-74.
- Fournier, M. E. and S. Levy (2006). "Recent trends in adolescent substance use, primary care screening, and updates in treatment options." *Curr Opin Pediatr* 18(4): 352-8.
- Galloway, G. P., J. Newmeyer, T. Knapp, S. A. Stalcup and D. Smith (1996). "A controlled trial of imipramine for the treatment of methamphetamine dependence." *J Subst Abuse Treat* 13(6): 493-7.
- Galloway, G. P., J. Newmeyer, T. Knapp, S. A. Stalcup and D. Smith (1994). "Imipramine for the treatment of cocaine and methamphetamine dependence." *J Addict Dis* 13(4): 201-16.
- Gonzales, R., P. Marinelli-Casey, et al. (2006). "Hepatitis C virus infection among methamphetamine-dependent individuals in outpatient treatment." *J Subst Abuse Treat* 31(2): 195-202.
- Gonzalez Castro, F., E. H. Barrington, et al. (2000). "Cocaine and methamphetamine: Differential addiction rates." *Psychol Addict Behav* 14(4): 390-6.
- Gordon, S. M., F. Tulak, et al. (2004). "Prevalence and characteristics of adolescents patients with co-occurring ADHD and substance dependence." *J Addict Dis* 23(4): 31-40.

- Greenwell, L. and M. L. Brecht (2003). "Self-reported health status among treated methamphetamine users." *Am J Drug Alcohol Abuse* 29(1): 75-104.
- Grella, C. E., Y. I. Hser, et al. (2006). "Mothers in substance abuse treatment: Differences in characteristics based on involvement with child welfare services." *Child Abuse Negl* 30(1): 55-73.
- Harris, D. S., V. I. Reus, et al. (2005). "Repeated psychological stress testing in stimulant-dependent patients." *Prog Neuropsychopharmacol Biol Psychiatry* 29(5): 669-77.
- Hartz, D. T., S. L. Frederick-Osborne, et al. (2001). "Craving predicts use during treatment for methamphetamine dependence: A prospective, repeated-measures, within-subject analysis." *Drug Alcohol Depend* 63(3): 269-76.
- Hawke, J. M., N. Jainchill and G. De Leon (2000). "Adolescent amphetamine users in treatment: Client profiles and treatment outcomes." *J Psychoactive Drugs* 32(1): 95-105.
- Heinzerling, K. G., S. Shoptaw, et al. (2006). "Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence." *Drug Alcohol Depend* 85(3): 177-184.
- Herrell, J. M., J. A. Taylor, et al. (2000). "A multisite study of the effectiveness of methamphetamine treatment: An initiative of the Center for Substance Abuse Treatment." *J Psychoactive Drugs* 32(2): 143-7.
- Higgins, S. T. (2006). "Extending contingency management to the treatment of methamphetamine use disorders." *Am J Psychiatry* 163(11): 1870-2.
- Hoffman, W. F., M. Moore, et al. (2006). "Neuropsychological function and delay discounting in methamphetamine-dependent individuals." *Psychopharmacology (Berl)* 188(2): 162-70.
- Hopfer, C., B. Mendelson, et al. (2006). "Club drug use among youths in treatment for substance abuse." *Am J Addict* 15(1): 94-9.
- Hser, Y. I., E. Evans, et al. (2005). "Treatment outcomes among women and men methamphetamine abusers in California." *J Subst Abuse Treat* 28(1): 77-85.
- Hser, Y. I., C. Teruya, et al. (2003). "Treating drug-abusing offenders. Initial findings from a five-county study on the impact of California's Proposition 36 on the treatment system and patient outcomes." *Eval Rev* 27(5): 479-505.
- Huber, A., R. H. Lord, et al. (2000). "The CSAT methamphetamine treatment program: Research design accommodations for "real world" application." *J Psychoactive Drugs* 32(2): 149-56.
- Huber, A., W. Ling, et al. (1997). "Integrating treatments for methamphetamine abuse: A psychosocial perspective." *J Addict Dis* 16(4): 41-50.
- Larkins, S., C. J. Reback, et al. (2005). "Methamphetamine-dependent gay men's disclosure of their HIV status to sexual partners." *AIDS Care* 17(4): 521-32.
- Levin-Epstein, M. (2006). "Experimenting with treatment in prison." *Behav Healthc* 26(7): 32-3.
- Luchansky, B., A. Krupski, et al. (2007). "Treatment response by primary drug of abuse: Does methamphetamine make a difference?" *J Subst Abuse Treat* 32(1): 89-96.
- Maglione, M., B. Chao, et al. (2000). "Correlates of outpatient drug treatment drop-out among methamphetamine users." *J Psychoactive Drugs* 32(2): 221-8.
- Maxwell, J. C., P. Cravioto, et al. (2006). "Drug use and risk of HIV/AIDS on the Mexico-USA border: A comparison of treatment admissions in both countries." *Drug Alcohol Depend* 82 Suppl 1: S85-93.
- Maxwell, J. C. and R. T. Spence (2005). "Profiles of club drug users in treatment." *Subst Use Misuse* 40(9): 1409-26.
- McGregor, C., M. Srisurapanont, et al. (2005). "The nature, time course and severity of methamphetamine withdrawal." *Addiction* 100(9): 1320-9.
- Molitor, F., J. D. Ruiz, et al. (1999). "Methamphetamine use and sexual and injection risk behaviors among out-of-treatment injection drug users." *Am J Drug Alcohol Abuse* 25(3): 475-93.
- Niv, N. and Y. I. Hser (2006). "Drug treatment service utilization and outcomes for Hispanic and white methamphetamine abusers." *Health Serv Res* 41(4 Pt 1): 1242-57.
- Nordahl, T. E., R. Salo, et al. (2005). "Methamphetamine users in sustained abstinence: A proton magnetic resonance spectroscopy study." *Arch Gen Psychiatry* 62(4): 444-52.
- Obert, J. L., A. H. Brown, et al. (2005). "When treatment meets research: Clinical perspectives from the CSAT Methamphetamine Treatment Project." *J Subst Abuse Treat* 28(3): 231-7.
- Paul, J. P., R. Stall and F. Davis (1993). "Sexual risk for HIV transmission among gay/bisexual men in substance-abuse treatment." *AIDS Educ Prev* 5(1): 11-24.
- Peck, J. A., C. J. Reback, et al. (2005). "Sustained reductions in drug use and depression symptoms from treatment for drug abuse in methamphetamine-dependent gay and bisexual men." *J Urban Health* 82(1 Suppl 1): i100-8.
- Peck, J. A., S. Shoptaw, et al. (2005). "HIV-associated medical, behavioral, and psychiatric characteristics of treatment-seeking, methamphetamine-dependent men who have sex with men." *J Addict Dis* 24(3): 115-32.

- Peirce, J. M., N. M. Petry, et al. (2006). "Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: A National Drug Abuse Treatment Clinical Trials Network study." *Arch Gen Psychiatry* 63(2): 201-8.
- Petry, N. M., K. B. Kolodner, et al. (2006). "Prize-based contingency management does not increase gambling." *Drug Alcohol Depend* 83(3): 269-73.
- Petry, N. M., J. M. Peirce, et al. (2005). "Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: A national drug abuse treatment clinical trials network study." *Arch Gen Psychiatry* 62(10): 1148-56.
- Pugatch, D. L., B. G. Levesque, et al. (2001). "HIV testing among young adults and older adolescents in the setting of acute substance abuse treatment." *Journal of Acquired Immune Deficiency Syndromes: JAIDS*. 27(2): 135-42.
- Rawson, R. A., R. Gonzales, et al. (2005). "Methamphetamine use among treatment-seeking adolescents in Southern California: Participant characteristics and treatment response." *J Subst Abuse Treat* 29(2): 67-74.
- Rawson, R., A. Huber, et al. (2000). "Methamphetamine and cocaine users: Differences in characteristics and treatment retention." *J Psychoactive Drugs* 32(2): 233-8.
- Rawson, R. A., P. Marinelli-Casey, et al. (2004). "A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence." *Addiction* 99(6): 708-17.
- Rawson, R. A., A. Huber, et al. (2002). "Status of methamphetamine users 2-5 years after outpatient treatment." *J Addict Dis* 21(1): 107-19.
- Rawson, R., A. Huber, et al. (2000). "Methamphetamine and cocaine users: Differences in characteristics and treatment retention." *J Psychoactive Drugs* 32(2): 233-8.
- Reback, C. J., S. Larkins and S. Shoptaw (2004). "Changes in the meaning of sexual risk behaviors among gay and bisexual male methamphetamine abusers before and after drug treatment." *AIDS Behav* 8(1): 87-98.
- Reiber, C., G. Galloway, et al. (2000). "A descriptive analysis of participant characteristics and patterns of substance use in the CSAT methamphetamine treatment project: The first six months." *J Psychoactive Drugs* 32(2): 183-91.
- Riehm, K. S., M. Y. Iguchi and M. D. Anglin (2002). "Depressive symptoms among amphetamine and cocaine users before and after substance abuse treatment." *Psychol Addict Behav* 16(4): 333-7.
- Roll, J. M., A. Huber, et al. (2006). "A comparison of five reinforcement schedules for use in contingency management-based treatment of methamphetamine abuse." *Psychological Record* 56(1): 67-81.
- Roll, J. M., N. M. Petry, et al. (2006). "Contingency management for the treatment of methamphetamine use disorders." *Am J Psychiatry* 163(11): 1993-9.
- Roll, J. M. and S. Shoptaw (2006). "Contingency management: Schedule effects." *Psychiatry Res* 144(1): 91-3.
- Russell, L. C., B. Sharp and B. Gilbertson (2000). "Acupuncture for addicted patients with chronic histories of arrest. A pilot study of the consortium treatment center." *J Subst Abuse Treat* 19(2): 199-205.
- Sattar, S. P., S. C. Bhatia, et al. (2004). "Potential benefits of quetiapine in the treatment of substance dependence disorders." *J Psychiatry Neurosci* 29(6): 452-7.
- Semple, S. J., I. Grant, et al. (2005). "Utilization of drug treatment programs by methamphetamine users: The role of social stigma." *Am J Addict* 14(4): 367-80.
- Shoptaw, S., J. D. Klausner, et al. (2006). "A public health response to the methamphetamine epidemic: The implementation of contingency management to treat methamphetamine dependence." *BMC Public Health* 6(1): 214.
- Shoptaw, S. and C. J. Reback (2006). "Associations between methamphetamine use and HIV among men who have sex with men: A model for guiding public policy." *J Urban Health* 83(6): 1151-7.
- Shoptaw, S., C. J. Reback, et al. (2005). "Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men." *Drug Alcohol Depend* 78(2): 125-34.
- Shoptaw, S., J. Peck, et al. (2003). "Psychiatric and substance dependence comorbidities, sexually transmitted diseases, and risk behaviors among methamphetamine-dependent gay and bisexual men seeking outpatient drug abuse treatment." *J Psychoactive Drugs* 35 Suppl 1: 161-8.
- Shoptaw, S., C. J. Reback, et al. (1998). "Stimulant abuse treatment as HIV prevention." *J Addict Dis* 17(4): 19-32.
- Simons, J. S., M. N. Oliver, et al. (2005). "Methamphetamine and alcohol abuse and dependence symptoms: Associations with affect lability and impulsivity in a rural treatment population." *Addict Behav* 30(7): 1370-81.
- Thorberg, F. A. and M. Lyvers (2006). "Negative Mood Regulation (NMR) expectancies, mood, and affect intensity among clients in substance disorder treatment facilities." *Addict Behav* 31(5): 811-20.
- Verachai, V., T. Phutiprawan, et al. (2005). "HIV infection among substance abusers in Thanyarak Institute On Drug Abuse, Thailand, 1987-2002." *J Med Assoc Thai* 88(1): 76-9.
- Verachai, V., S. Dechongkit, et al. (2001). "Drug addicts treatment for ten years in Thanyarak Hospital (1989-1998)." *J Med Assoc Thai* 84(1): 24-9.

- von Mayrhauser, C., M. L. Brecht and M. D. Anglin (2002). "Use ecology and drug use motivations of methamphetamine users admitted to substance abuse treatment facilities in Los Angeles: An emerging profile." *J Addict Dis* 21(1): 45-60.
- Wenzel, S. L., P. A. Ebener, et al. (1996). "Drug-abusing homeless clients in California's substance abuse treatment system." *J Psychoactive Drugs* 28(2): 147-59.
- Wermuth, L. (2000). "Methamphetamine use: Hazards and social influences." *J Drug Educ* 30(4): 423-33.
- Wu, L. T., D. J. Pilowsky, et al. (2004). "Injection drug use among stimulant users in a national sample." *Am J Drug Alcohol Abuse* 30(1): 61-83.

### Treatment (HIV) Adherence

- Copeland, A. L. and J. L. Sorensen (2001). "Differences between methamphetamine users and cocaine users in treatment." *Drug Alcohol Depend* 62(1): 91-5.
- Reback, C. J., S. Larkins, et al. (2003). "Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men." *AIDS Care* 15(6): 775-85.

### Treatment Outcomes

- Brecht, M. L., M. D. Anglin, et al. (2005). "Coerced treatment for methamphetamine abuse: Differential patient characteristics and outcomes." *Am J Drug Alcohol Abuse* 31(2): 337-56.
- Brecht, M. L., L. Greenwell, et al. (2005). "Methamphetamine treatment: Trends and predictors of retention and completion in a large state treatment system (1992-2002)." *J Subst Abuse Treat* 29(4): 295-306.
- Campos, M. and S. Shoptaw (2005). "Evidence-based treatments for methamphetamine abuse." *Focus* 20(6): 5-6.
- Cretzmeyer, M., M. V. Sarrazin, et al. (2003). "Treatment of methamphetamine abuse: Research findings and clinical directions." *J Subst Abuse Treat* 24(3): 267-77.
- Gunter, T. D., D. W. Black, et al. (2004). "Drug and alcohol treatment services effective for methamphetamine abuse." *Ann Clin Psychiatry* 16(4): 195-200.
- Hartz, D. T., S. L. Frederick-Osborne, et al. (2001). "Craving predicts use during treatment for methamphetamine dependence: A prospective, repeated-measures, within-subject analysis." *Drug Alcohol Depend* 63(3): 269-76.
- Hawke, J. M., N. Jainchill and G. De Leon (2000). "Adolescent amphetamine users in treatment: Client profiles and treatment outcomes." *J Psychoactive Drugs* 32(1): 95-105.
- Herrell, J. M., J. A. Taylor, et al. (2000). "A multisite study of the effectiveness of methamphetamine treatment: An initiative of the Center for Substance Abuse Treatment." *J Psychoactive Drugs* 32(2): 143-7.
- Hser, Y. I., E. Evans, et al. (2005). "Treatment outcomes among women and men methamphetamine abusers in California." *J Subst Abuse Treat* 28(1): 77-85.
- Hser, Y. I., C. Teruya, et al. (2003). "Treating drug-abusing offenders. Initial findings from a five-county study on the impact of California's Proposition 36 on the treatment system and patient outcomes." *Eval Rev* 27(5): 479-505.
- Huber, A., R. H. Lord, et al. (2000). "The CSAT methamphetamine treatment program: Research design accommodations for "real world" application." *J Psychoactive Drugs* 32(2): 149-56.
- Huber, A., W. Ling, et al. (1997). "Integrating treatments for methamphetamine abuse: A psychosocial perspective." *J Addict Dis* 16(4): 41-50.
- Luchansky, B., A. Krupski, et al. (2007). "Treatment response by primary drug of abuse: Does methamphetamine make a difference?" *J Subst Abuse Treat* 32(1): 89-96.
- Maglione, M., B. Chao, et al. (2000). "Correlates of outpatient drug treatment drop-out among methamphetamine users." *J Psychoactive Drugs* 32(2): 221-8.
- Maxwell, J. C. and R. T. Spence (2005). "Profiles of club drug users in treatment." *Subst Use Misuse* 40(9): 1409-26.
- Niv, N. and Y. I. Hser (2006). "Drug treatment service utilization and outcomes for Hispanic and white methamphetamine abusers." *Health Serv Res* 41(4 Pt 1): 1242-57.
- Obert, J. L., A. H. Brown, et al. (2005). "When treatment meets research: Clinical perspectives from the CSAT Methamphetamine Treatment Project." *J Subst Abuse Treat* 28(3): 231-7.
- Obert, J. L., M. J. McCann, et al. (2000). "The Matrix model of outpatient stimulant abuse treatment: History and description." *J Psychoactive Drugs* 32(2): 157-64.
- Peck, J. A., C. J. Reback, et al. (2005). "Sustained reductions in drug use and depression symptoms from treatment for drug abuse in methamphetamine-dependent gay and bisexual men." *J Urban Health* 82(1 Suppl 1): i100-8.

- Peirce, J. M., N. M. Petry, et al. (2006). "Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: A National Drug Abuse Treatment Clinical Trials Network study." *Arch Gen Psychiatry* 63(2): 201-8.
- Petry, N. M., K. B. Kolodner, et al. (2006). "Prize-based contingency management does not increase gambling." *Drug Alcohol Depend* 83(3): 269-73.
- Petry, N. M., J. M. Peirce, et al. (2005). "Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: A national drug abuse treatment clinical trials network study." *Arch Gen Psychiatry* 62(10): 1148-56.
- Rawson, R. A., M. J. McCann, et al. (2006). "A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals." *Addiction* 101(2): 267-74.
- Rawson, R. A., R. Gonzales, et al. (2005). "Methamphetamine use among treatment-seeking adolescents in Southern California: Participant characteristics and treatment response." *J Subst Abuse Treat* 29(2): 67-74.
- Rawson, R. A., P. Marinelli-Casey, et al. (2004). "A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence." *Addiction* 99(6): 708-17.
- Rawson, R. A., A. Huber, et al. (2002). "Status of methamphetamine users 2-5 years after outpatient treatment." *J Addict Dis* 21(1): 107-19.
- Rawson, R., A. Huber, et al. (2000). "Methamphetamine and cocaine users: Differences in characteristics and treatment retention." *J Psychoactive Drugs* 32(2): 233-8.
- Rawson, R. A., P. Marinelli-Casey, et al. (2004). "A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence." *Addiction* 99(6): 708-17.
- Rawson, R. A., A. Huber, et al. (2002). "Status of methamphetamine users 2-5 years after outpatient treatment." *J Addict Dis* 21(1): 107-19.
- Rawson, R., A. Huber, et al. (2000). "Methamphetamine and cocaine users: Differences in characteristics and treatment retention." *J Psychoactive Drugs* 32(2): 233-8.
- Reback, C. J., S. Larkins, et al. (2004). "Changes in the meaning of sexual risk behaviors among gay and bisexual male methamphetamine abusers before and after drug treatment." *AIDS Behav* 8(1): 87-98.
- Riehm, K. S., M. Y. Iguchi and M. D. Anglin (2002). "Depressive symptoms among amphetamine and cocaine users before and after substance abuse treatment." *Psychol Addict Behav* 16(4): 333-7.
- Roll, J. M., A. Huber, et al. (2006). "A comparison of five reinforcement schedules for use in contingency management-based treatment of methamphetamine abuse." *Psychological Record* 56(1): 67-81.
- Roll, J. M., N. M. Petry, et al. (2006). "Contingency management for the treatment of methamphetamine use disorders." *Am J Psychiatry* 163(11): 1993-9.
- Roll, J. M. and S. Shoptaw (2006). "Contingency management: Schedule effects." *Psychiatry Res* 144(1): 91-3.
- Sattar, S. P., S. C. Bhatia, et al. (2004). "Potential benefits of quetiapine in the treatment of substance dependence disorders." *J Psychiatry Neurosci* 29(6): 452-7.
- Shoptaw, S., C. J. Reback, et al. (2005). "Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men." *Drug Alcohol Depend* 78(2): 125-34.
- Shoptaw, S., C. J. Reback, et al. (1998). "Stimulant abuse treatment as HIV prevention." *J Addict Dis* 17(4): 19-32.
- Shoptaw, S., R. A. Rawson, et al. (1994). "The Matrix model of outpatient stimulant abuse treatment: Evidence of efficacy." *J Addict Dis* 13(4): 129-41.
- Smith, J. W. and P. J. Frawley (1993). "Treatment outcome of 600 chemically dependent patients treated in a multimodal inpatient program including aversion therapy and pentothal interviews." *J Subst Abuse Treat* 10(4): 359-69.
- Smith, T. L., F. R. Volpe, et al. (1999). "Impact of a stimulant-focused enhanced program on the outcome of alcohol- and/or stimulant-dependent men." *Alcohol Clin Exp Res* 23(11): 1772-9.
- Verachai, V., S. Dechongkit, et al. (2001). "Drug addicts treatment for ten years in Thanyarak Hospital (1989-1998)." *J Med Assoc Thai* 84(1): 24-9.
- Walton, M. A., F. G. Castro, et al. (1994). "The role of attributions in abstinence, lapse, and relapse following substance abuse treatment." *Addict Behav* 19(3): 319-31.

## Treatment Preferences of Methamphetamine Users

- Brecht, M. L., L. Greenwell, et al. (2005). "Methamphetamine treatment: Trends and predictors of retention and completion in a large state treatment system (1992-2002)." *J Subst Abuse Treat* 29(4): 295-306.
- Hando, J., L. Topp, et al. (1997). "Amphetamine-related harms and treatment preferences of regular amphetamine users in Sydney, Australia." *Drug Alcohol Depend* 46(1-2): 105-13.

Shoptaw, S. and C. J. Reback (2006). "Associations between methamphetamine use and HIV among men who have sex with men: A model for guiding public policy." *J Urban Health* 83(6): 1151-7.

### Treatment Readiness

*See also* Motivations for Non-Use and Use Cessation

German, D., S. G. Sherman, et al. (2006). "Motivations for methamphetamine cessation among young people in northern Thailand." *Addiction* 101(8): 1143-52.

John, D., C. F. Kwiatkowski, et al. (2001). "Differences among out-of-treatment drug injectors who use stimulants only, opiates only or both: Implications for treatment entry." *Drug Alcohol Depend* 64(2): 165-72.

Kim, J. Y. and M. Fendrich (2002). "Gender differences in juvenile arrestees' drug use, self-reported dependence, and perceived need for treatment." *Psychiatr Serv* 53(1): 70-5.

Martin, I., T. M. Lampinen, et al. (2006). "Methamphetamine use among marginalized youth in British Columbia." *Can J Public Health* 97(4): 320-4.

Menza, T. W., G. Colfax, et al. (2006). "Interest in a methamphetamine intervention among men who have sex with men." *Sex Transm Dis* 33(9): 565-70.

Shoptaw, S. and C. J. Reback (2006). "Associations between methamphetamine use and HIV among men who have sex with men: A model for guiding public policy." *J Urban Health* 83(6): 1151-7.

Siegal, H. A., P. J. Draus, et al. (2006). "Perspectives on health among adult users of illicit stimulant drugs in rural Ohio." *J Rural Health* 22(2): 169-73.

Wu, L. T., D. J. Pilowsky, et al. (2004). "Injection drug use among stimulant users in a national sample." *Am J Drug Alcohol Abuse* 30(1): 61-83.

Zule, W. A. and D. P. Desmond (1999). "An ethnographic comparison of HIV risk behaviors among heroin and methamphetamine injectors." *Am J Drug Alcohol Abuse* 25(1): 1-23.

### Treatment Utilization

*See also* Treatment, Methamphetamine Users in

Anonymous (1995). "Increasing morbidity and mortality associated with abuse of methamphetamine--United States, 1991-1994." *MMWR Morb Mortal Wkly Rep* 44(47): 882-6.

Brecht, M. L., M. D. Anglin, et al. (2005). "Coerced treatment for methamphetamine abuse: Differential patient characteristics and outcomes." *Am J Drug Alcohol Abuse* 31(2): 337-56.

Brecht, M. L., L. Greenwell, et al. (2005). "Methamphetamine treatment: Trends and predictors of retention and completion in a large state treatment system (1992-2002)." *J Subst Abuse Treat* 29(4): 295-306.

Hando, J., L. Topp, et al. (1997). "Amphetamine-related harms and treatment preferences of regular amphetamine users in Sydney, Australia." *Drug Alcohol Depend* 46(1-2): 105-13.

Hser, Y. I., C. Teruya, et al. (2003). "Treating drug-abusing offenders. Initial findings from a five-county study on the impact of California's Proposition 36 on the treatment system and patient outcomes." *Eval Rev* 27(5): 479-505.

Niv, N. and Y. I. Hser (2006). "Drug treatment service utilization and outcomes for Hispanic and white methamphetamine abusers." *Health Serv Res* 41(4 Pt 1): 1242-57.

Semple, S. J., I. Grant, et al. (2005). "Utilization of drug treatment programs by methamphetamine users: The role of social stigma." *Am J Addict* 14(4): 367-80.

Verachai, V., S. Dechongkit, et al. (2001). "Drug addicts treatment for ten years in Thanyarak Hospital (1989-1998)." *J Med Assoc Thai* 84(1): 24-9.

Wermuth, L. (2000). "Methamphetamine use: Hazards and social influences." *J Drug Educ* 30(4): 423-33.

### Tremors

*See also* Parkinsonism and Parkinson's Disease

Oro, A. S. and S. D. Dixon (1987). "Perinatal cocaine and methamphetamine exposure: Maternal and neonatal correlates." *J Pediatr* 111(4): 571-8.

**Tremors (animals)**

*See also* Parkinsonism and Parkinson's Disease (animals models)

- Baker, W. W., D. Zivanovic, et al. (1976). "Tremorogenic effects of intracaudate d-amphetamine and their suppression by dopamine." *Arch Int Pharmacodyn Ther* 223(2): 271-81.
- Izumi, K., M. Nomoto, et al. (1984). "Phenytoin potentiates methamphetamine-induced behavior in mice." *Pharmacol Biochem Behav* 20(5): 803-6.
- Johanson, C. E., T. G. Aigner, et al. (1979). "The effects of methamphetamine on fine motor control in rhesus monkeys." *Pharmacol Biochem Behav* 11(3): 273-8.
- McKinney, P. E., C. Tomaszewski, et al. (1994). "Methamphetamine toxicity prevented by activated charcoal in a mouse model." *Ann Emerg Med* 24(2): 220-3.

**Tulsa, OK (US)**

- Arria, A. M., C. Derauf, et al. (2006). "Methamphetamine and other substance use during pregnancy: Preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study." *Matern Child Health J* 10(3): 293-302.
- Smith, L. M., L. L. Lagasse, et al. (2006). "The Infant Development, Environment, and Lifestyle Study: Effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth." *Pediatrics* 118(3): 1149-1156.

**Tucson, AZ (US)**

- Glittenberg, J. and C. Anderson (1999). "Methamphetamines: Use and trafficking in the Tucson-Nogales area." *Subst Use Misuse* 34(14): 1977-89.

**Twelve Step and Support Groups**

- Lyons, T., G. Chandra, et al. (2006). "Stimulant use and HIV risk behavior: The influence of peer support group participation." *AIDS Educ Prev* 18(5): 461-73.
- Smith, J. W. and P. J. Frawley (1993). "Treatment outcome of 600 chemically dependent patients treated in a multimodal inpatient program including aversion therapy and pentothal interviews." *J Subst Abuse Treat* 10(4): 359-69.

**United Kingdom**

- Bellis, M. A., K. E. Hughes, et al. (2007). "Effects of backpacking holidays in Australia on alcohol, tobacco and drug use of UK residents." *BMC Public Health* 7(1): 1.
- Bingham, C., M. Beaman, et al. (1998). "Necrotizing renal vasculopathy resulting in chronic renal failure after ingestion of methamphetamine and 3,4-methylenedioxymethamphetamine ('ecstasy')." *Nephrol Dial Transplant* 13(10): 2654-5.
- Bolding, G., G. Hart, et al. (2006). "Use of crystal methamphetamine among gay men in London." *Addiction* 101(11): 1622-30.
- Cole, J. C., H. R. Sumnall, et al. (2005). "Preliminary evidence of the cardiovascular effects of polysubstance misuse in nightclubs." *J Psychopharmacol* 19(1): 67-70.
- Hawks, D., M. Mitcheson, et al. (1969). "Abuse of methylamphetamine." *Br Med J* 2(5659): 715-21.
- March, J. C., E. Oviedo-Joekes, et al. (2006). "Drugs and social exclusion in ten European cities." *Eur Addict Res* 12(1): 33-41.
- McCarrick, H. (1968). "Methedrine: The new restriction." *Nurs Times* 64(42): 1419.
- Noble, P., T. Hart, et al. (1972). "Correlates and outcome of illicit drug use by adolescent girls." *Br J Psychiatry* 120(558): 497-504.
- White, R. (2000). "Dexamphetamine substitution in the treatment of amphetamine abuse: An initial investigation." *Addiction* 95(2): 229-38.
- Youdim, M. B., O. Bar Am, et al. (2005). "Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition." *J Neurosci Res* 79(1-2): 172-9.

**United States Regional Variations**

- Oetting, E. R., J. L. Deffenbacher, et al. (2000). "Methamphetamine use by high school students: Recent trends, gender and ethnicity differences, and use of other drugs." *Journal of Child and Adolescent Substance Abuse* 10(1): 33-50.
- Rawson, R. A., S. L. Simon and W. Ling (2002). "If a US drug abuse epidemic fails to include a major east coast city, can it be called an epidemic?" *J Addict Dis* 21(1): 1-4.

- Rawson, R. A., R. Gonzales and P. Brethen (2002). "Treatment of methamphetamine use disorders: An update." *J Subst Abuse Treat* 23(2): 145-50.
- Stoops, W. W., M. S. Tindall, et al. (2005). "Methamphetamine use in nonurban and urban drug court clients." *Int J Offender Ther Comp Criminol* 49(3): 260-76.
- Sullivan, P. S., A. K. Nakashima, et al. (1998). "Geographic differences in noninjection and injection substance use among HIV-seropositive men who have sex with men: western United States versus other regions. Supplement to HIV/AIDS Surveillance Study Group." *J Acquir Immune Defic Syndr Hum Retrovirol* 19(3): 266-73.
- Thiede, H., L. A. Valleroy, et al. (2003). "Regional patterns and correlates of substance use among young men who have sex with men in 7 US urban areas." *Am J Public Health* 93(11): 1915-21.
- Wolkoff, D. A. (1997). "Methamphetamine abuse: An overview for health care professionals." *Hawaii Med J* 56(2): 34-6, 44.

### Urinary Conditions

- Bennett, A. H. and A. Delrio (1980). "Idiopathic rupture of the bladder: association with methamphetamine and alcohol." *J Urol* 124(3): 429-30.
- Delgado, J. H., M. J. Caruso, J. C. Waksman, B. Honigman and D. Stillman (2004). "Acute, transient urinary retention from combined ecstasy and methamphetamine use." *J Emerg Med* 26(2): 173-5.
- Doleys, D. M. (1977). "Behavioral treatments for nocturnal enuresis in children: A review of the recent literature." *Psychol Bull* 84(1): 30-54.
- Haddad, F. S. and T. L. Wachtel (1987). "Spontaneous intraperitoneal rupture of the bladder." *Urol Int* 42(6): 467-9.
- Marshall, G. A., C. M. Dixon, et al. (1991). "Substance abuse-related spontaneous bladder rupture: Report of 2 cases and review of the literature." *J Urol* 145(1): 135-7.
- Young, G. C. and R. T. Morgan (1973). "Rapidity of response to the treatment of enuresis." *Dev Med Child Neurol* 15(4): 488-96.
- Young, G. C. and R. K. Turner (1965). "CNS stimulant drugs and conditioning treatment of nocturnal enuresis." *Behav Res Ther* 3(2): 93-101.

### Usage Patterns and Dosing

*See also* Binge Use; Injection of Methamphetamine; Motivations for Non-Use and Use-Cessation; Motivations for Use; Polydrug Use; Rectal Administration; Smoking Methamphetamine; Snorting Methamphetamine

- Batki, S. L. and D. S. Harris (2004). "Quantitative drug levels in stimulant psychosis: Relationship to symptom severity, catecholamines and hyperkinesia." *Am J Addict* 13(5): 461-70.
- Bolding, G., G. Hart, et al. (2006). "Use of crystal methamphetamine among gay men in London." *Addiction* 101(11): 1622-30.
- Brecht, M. L., L. Greenwell, et al. (2007). "Substance use pathways to methamphetamine use among treated users." *Addict Behav* 32(1): 24-38.
- Cho, A. K. and W. P. Melega (2002). "Patterns of methamphetamine abuse and their consequences." *J Addict Dis* 21(1): 21-34.
- Colfax, G. N., E. Vittinghoff, et al. (2007). "Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance." *AIDS* 21(2): 239-241.
- Colfax, G., T. J. Coates, et al. (2005). "Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of San Francisco men who have sex with men." *J Urban Health* 82(1 Suppl 1): i62-70.
- Colfax, G. N., G. Mansergh, et al. (2001). "Drug use and sexual risk behavior among gay and bisexual men who attend circuit parties: A venue-based comparison." *J Acquir Immune Defic Syndr* 28(4): 373-9.
- Comer, S. D., C. L. Hart, et al. (2001). "Effects of repeated oral methamphetamine administration in humans." *Psychopharmacology (Berl)* 155(4): 397-404.
- Darke, S., S. Kaye, et al. (1999). "Transitions between the injection of heroin and amphetamines." *Addiction* 94(12): 1795-803.
- Davidson, C., A. J. Gow, et al. (2001). "Methamphetamine neurotoxicity: Necrotic and apoptotic mechanisms and relevance to human abuse and treatment." *Brain Res Brain Res Rev* 36(1): 1-22.
- Domier, C. P., S. L. Simon, et al. (2000). "A comparison of injecting and noninjecting methamphetamine users." *J Psychoactive Drugs* 32(2): 229-32.
- Dore, G. and M. Sweeting (2006). "Drug-induced psychosis associated with crystalline methamphetamine." *Australas Psychiatry* 14(1): 86-9.
- Ellinwood, E. H., Jr. and M. M. Kilbey (1980). "Fundamental mechanisms underlying altered behavior following chronic administration of psychomotor stimulants." *Biol Psychiatry* 15(5): 749-57.



- Ellison, G. (2002). "Neural degeneration following chronic stimulant abuse reveals a weak link in brain, fasciculus retroflexus, implying the loss of forebrain control circuitry." *Eur Neuropsychopharmacol* 12(4): 287-97.
- Fitzmaurice, P. S., J. Tong, et al. (2006). "Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of methamphetamine." *J Pharmacol Exp Ther* 319(2): 703-9.
- Gibson, D. R., M. H. Leamon, et al. (2002). "Epidemiology and public health consequences of methamphetamine use in California's Central Valley." *J Psychoactive Drugs* 34(3): 313-9.
- Goldsamt, L. A., J. O'Brien, et al. (2005). "The relationship between club drug use and other drug use: A survey of New York City middle school students." *Subst Use Misuse* 40(9): 1539-55.
- Gonzalez Castro, F., E. H. Barrington, et al. (2000). "Cocaine and methamphetamine: Differential addiction rates." *Psychol Addict Behav* 14(4): 390-6.
- Gustavsen, I., J. Morland, et al. (2006). "Impairment related to blood amphetamine and/or methamphetamine concentrations in suspected drugged drivers." *Accid Anal Prev* 38(3): 490-5.
- Halkitis, P. N. and M. T. Shrem (2006). "Psychological differences between binge and chronic methamphetamine using gay and bisexual men." *Addict Behav* 31(3): 549-52.
- Halkitis, P. N., K. A. Green, et al. (2005). "Longitudinal investigation of methamphetamine use among gay and bisexual men in New York City: findings from Project BUMPS." *J Urban Health* 82(1 Suppl 1): i18-25.
- Hall, W., J. Hando, et al. (1996). "Psychological morbidity and route of administration among amphetamine users in Sydney, Australia." *Addiction* 91(1): 81-7.
- Hall, W., S. Darke, et al. (1993). "Patterns of drug use and risk-taking among injecting amphetamine and opioid drug users in Sydney, Australia." *Addiction* 88(4): 509-16.
- Irwin, T. W. and J. Morgenstern (2005). "Drug-use patterns among men who have sex with men presenting for alcohol treatment: Differences in ethnic and sexual identity." *J Urban Health*.
- Kaye, S. and S. Darke (2000). "A comparison of the harms associated with the injection of heroin and amphetamines." *Drug Alcohol Depend* 58(1-2): 189-95.
- Martin, I., T. M. Lampinen, et al. (2006). "Methamphetamine use among marginalized youth in British Columbia." *Can J Public Health* 97(4): 320-4.
- McCaughan, J. A., R. G. Carlson, et al. (2005). "From "Candy Kids" to "Chemi-Kids": A typology of young adults who attend raves in the midwestern United States." *Subst Use Misuse* 40(9-10): 1503-23.
- McKetin, R., E. Kelly, et al. (2006). "The relationship between crystalline methamphetamine use and methamphetamine dependence." *Drug Alcohol Depend* 85(3): 198-204.
- Meredith, C. W., C. Jaffe, et al. (2005). "Implications of chronic methamphetamine use: A literature review." *Harv Rev Psychiatry* 13(3): 141-54.
- Moszczynska, A., S. Turenne, et al. (1998). "Rat striatal levels of the antioxidant glutathione are decreased following binge administration of methamphetamine." *Neurosci Lett* 255(1): 49-52.
- O'Neil, M. L., R. Kuczenski, et al. (2006). "Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge." *Synapse* 60(6): 465-73.
- Peck, J. A., C. J. Reback, et al. (2005). "Sustained reductions in drug use and depression symptoms from treatment for drug abuse in methamphetamine-dependent gay and bisexual men." *J Urban Health* 82(1 Suppl 1): i100-8.
- Rogers, R. D., B. J. Everitt, et al. (1999). "Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: Evidence for monoaminergic mechanisms." *Neuropsychopharmacology* 20(4): 322-39.
- Roxburgh, A., L. Degenhardt, et al. (2005). "Drug use and risk behaviours among injecting drug users: A comparison between sex workers and non-sex workers in Sydney, Australia." *Harm Reduct J* 2(1): 7.
- Semple, S. J., J. Zians, et al. (2006). "Methamphetamine use, impulsivity, and sexual risk behavior among HIV-positive men who have sex with men." *J Addict Dis* 25(4): 105-14.
- Semple, S. J., I. Grant, et al. (2005). "Negative self-perceptions and sexual risk behavior among heterosexual methamphetamine users." *Substance Use & Misuse* 40(12): 1797-1810.
- Semple, S. J., J. Zians, et al. (2005). "Impulsivity and methamphetamine use." *J Subst Abuse Treat* 29(2): 85-93.
- Semple, S. J., T. L. Patterson and I. Grant (2004). "The context of sexual risk behavior among heterosexual methamphetamine users." *Addict Behav* 29(4): 807-10.
- Semple, S. J., T. L. Patterson, et al. (2004). "A comparison of injection and non-injection methamphetamine-using HIV positive men who have sex with men." *Drug Alcohol Depend* 76(2): 203-12.
- Semple, S. J., T. L. Patterson, et al. (2004). "Determinants of condom use stage of change among heterosexually-identified methamphetamine users." *AIDS Behav* 8(4): 391-400.

- Shoptaw, S. and C. J. Reback (2006). "Associations between methamphetamine use and HIV among men who have sex with men: A model for guiding public policy." *J Urban Health* 83(6): 1151-7.
- Siegal, D., J. Erickson, et al. (2004). "Brain vesicular acetylcholine transporter in human users of drugs of abuse." *Synapse* 52(4): 223-32.
- Sommers, L., D. Baskin, et al. (2006). "Methamphetamine use among young adults: Health and social consequences." *Addict Behav* 31(8): 1469-76.
- Sung, Y. H., S. C. Cho, et al. (2006). "Relationship between N-acetyl-aspartate in gray and white matter of abstinent methamphetamine abusers and their history of drug abuse: A proton magnetic resonance spectroscopy study." *Drug Alcohol Depend*.
- Uitermark, J. and P. D. A. Cohen (2006). "Amphetamine users in Amsterdam: Patterns of use and modes of self-regulation." *Addiction Research & Theory* 14(2): 159-188.
- Uitermark, J. and P. Cohen (2004). Amphetamine users in Amsterdam: Patterns of use and modes of self-regulation, Centrum voor drugsonderzoek.
- Wada, K. and S. Fukui (1990). "[Relationship between years of methamphetamine use and symptoms of methamphetamine psychosis]." *Arukuru Kenkyuto Yakubutsu Ison* 25(3): 143-58.
- Wu, L. T., D. J. Pilowsky, et al. (2004). "Injection drug use among stimulant users in a national sample." *Am J Drug Alcohol Abuse* 30(1): 61-83.
- Zule, W. A. and D. P. Desmond (1999). "An ethnographic comparison of HIV risk behaviors among heroin and methamphetamine injectors." *Am J Drug Alcohol Abuse* 25(1): 1-23.

### Usage Patterns and Dosing (animals)

*See also* Binge Use (animals); Polydrug Use (animals); Self-Administration of Methamphetamine (animals)

- Bittner, S. E., G. C. Wagner, et al. (1981). "Effects of a high-dose treatment of methamphetamine on caudate dopamine and anorexia in rats." *Pharmacol Biochem Behav* 14(4): 481-6.
- Brummelte, S., T. Grund, et al. (2006). "Long-term effects of a single adult methamphetamine challenge: Minor impact on dopamine fibre density in limbic brain areas of gerbils." *Behav Brain Funct* 2: 12.
- Bustamante, D., Z. B. You, et al. (2002). "Effect of single and repeated methamphetamine treatment on neurotransmitter release in substantia nigra and neostriatum of the rat." *J Neurochem* 83(3): 645-54.
- Byrnes-Blake, K. A., E. M. Laurenzana, et al. (2005). "Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats." *Eur J Pharmacol* 521(1-3): 86-94.
- Chiu, C. T., T. Ma, et al. (2006). "Methamphetamine-induced behavioral sensitization in mice: Alterations in mu-opioid receptor." *J Biomed Sci* 13(6): 797-811.
- Clemens, K. J., J. L. Cornish, et al. (2007). "Repeated weekly exposure to MDMA, methamphetamine or their combination: Long-term behavioural and neurochemical effects in rats." *Drug Alcohol Depend* 86(2-3): 183-90.
- Clemens, K. J., J. L. Cornish, et al. (2006). "Intravenous methamphetamine self-administration in rats: Effects of intravenous or intraperitoneal MDMA co-administration." *Pharmacol Biochem Behav* 85(2): 454-63.
- Clemens, K. J., J. L. Cornish, et al. (2007). "Repeated weekly exposure to MDMA, methamphetamine or their combination: Long-term behavioural and neurochemical effects in rats." *Drug Alcohol Depend* 86(2-3): 183-90.
- Cunningham, C. L. and D. Noble (1992). "Methamphetamine-induced conditioned place preference or aversion depending on dose and presence of drug." *Ann N Y Acad Sci* 654: 431-3.
- Davidson, C., T. H. Lee, et al. (2005). "Acute and chronic continuous methamphetamine have different long-term behavioral and neurochemical consequences." *Neurochem Int* 46(3): 189-203.
- Davidson, C., A. J. Gow, et al. (2001). "Methamphetamine neurotoxicity: Necrotic and apoptotic mechanisms and relevance to human abuse and treatment." *Brain Res Brain Res Rev* 36(1): 1-22.
- Ellison, G. (2002). "Neural degeneration following chronic stimulant abuse reveals a weak link in brain, fasciculus retroflexus, implying the loss of forebrain control circuitry." *Eur Neuropsychopharmacol* 12(4): 287-97.
- Fukuzako, H., I. Nagatomo, et al. (1988). "Alterations of accumbens neuronal activity in freely moving rats following methamphetamine." *Jpn J Psychiatry Neurol* 42(2): 331-5.
- Gentry, W. B., A. U. Ghafoor, et al. (2004). "(+)-Methamphetamine-induced spontaneous behavior in rats depends on route of (+)METH administration." *Pharmacol Biochem Behav* 79(4): 751-60.
- Glick, S. D., I. M. Maisonneuve, et al. (2001). "Comparative effects of dextromethorphan and dextrorphan on morphine, methamphetamine, and nicotine self-administration in rats." *Eur J Pharmacol* 422(1-3): 87-90.
- Hayase, T., Y. Yamamoto, et al. (2005). "Persistent anxiogenic effects of a single or repeated doses of cocaine and methamphetamine: Interactions with endogenous cannabinoid receptor ligands." *Behav Pharmacol* 16(5-6): 395-404.

- Hirabayashi, M., S. Okada, et al. (1983). "[Characteristics of reverse tolerance to ambulation-increasing effect of methylphenidate after repeated administration in mice]." *Yakubutsu Seishin Kodo* 3(3): 117-26.
- Hirabayashi, M., F. Iwai, et al. (1979). "[Individual differences in the accelerating effect of methamphetamine, d-amphetamine and morphine on ambulatory activity in mice (author's transl)]." *Nippon Yakurigaku Zasshi* 75(7): 683-93.
- Honma, T. and H. Fukushima (1979). "The involvement of serotonergic neurons in the central nervous system as the possible mechanism for slow head-shaking behavior induced by methamphetamine in rats." *Psychopharmacology (Berl)* 65(2): 155-9.
- Horner, K. A., S. C. Westwood, et al. (2006). "Multiple high doses of methamphetamine increase the number of preproneuropeptide Y mRNA-expressing neurons in the striatum of rat via a dopamine D1 receptor-dependent mechanism." *J Pharmacol Exp Ther* 319(1): 414-21.
- Ishikawa, K., A. Nitta, et al. (2006). "Effects of single and repeated administration of methamphetamine or morphine on neuroglycan C gene expression in the rat brain." *Int J Neuropsychopharmacol* 9(4): 407-15.
- Kanthasamy, A., V. Anantharam, et al. (2006). "Methamphetamine induces autophagy and apoptosis in a mesencephalic dopaminergic neuronal culture model: role of cathepsin-D in methamphetamine-induced apoptotic cell death." *Ann N Y Acad Sci* 1074: 234-44.
- Kita, T., Y. Matsunari, et al. (2000). "Methamphetamine-induced striatal dopamine release, behavior changes and neurotoxicity in BALB/c mice." *Int J Dev Neurosci* 18(6): 521-30.
- Kitanaka, N., J. Kitanaka, et al. (2003). "Behavioral sensitization and alteration in monoamine metabolism in mice after single versus repeated methamphetamine administration." *Eur J Pharmacol* 474(1): 63-70.
- Kitamura, O., S. Wee, et al. (2006). "Escalation of methamphetamine self-administration in rats: A dose-effect function." *Psychopharmacology (Berl)* 186(1): 48-53.
- Kobayashi, M., Y. Wakamatsu, et al. (1977). "[Methamphetamine-stereotypies" and brain dopamine levels of rats treated with single or repeated doses of alpha-methyl-para-tyrosine]." *Nippon Yakurigaku Zasshi* 73(6): 695-701.
- Kuczenski, R. and D. S. Segal (2001). "Caudate-putamen and nucleus accumbens extracellular acetylcholine responses to methamphetamine binges." *Brain Res* 923(1-2): 32-8.
- Kuczenski, R., D. S. Segal, et al. (1995). "Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine." *J Neurosci* 15(2): 1308-17.
- Lazzeri, G., P. Lenzi, et al. (2006). "In PC12 cells neurotoxicity induced by methamphetamine is related to proteasome inhibition." *Ann N Y Acad Sci* 1074: 174-7.
- Madden, L. J., C. T. Flynn, et al. (2005). "Modeling human methamphetamine exposure in nonhuman primates: Chronic dosing in the rhesus macaque leads to behavioral and physiological abnormalities." *Neuropsychopharmacology* 30(2): 350-9.
- Muraki, A. (1993). "[Effects of antagonists of NMDA receptor on methamphetamine-induced decrease in the dopamine uptake sites in the rat striatum and on the behavioral sensitization]." *Hokkaido Igaku Zasshi* 68(3): 407-18.
- Masuda, Y., Y. Matsuda, et al. (1996). "A quantity of stereotyped behavior of ddY mice induced by low-dose methamphetamine." *Exp Anim* 45(3): 279-81.
- Matell, M. S., M. Bateson, et al. (2006). "Single-trials analyses demonstrate that increases in clock speed contribute to the methamphetamine-induced horizontal shifts in peak-interval timing functions." *Psychopharmacology (Berl)* 188(2): 201-12.
- Newman, J. L. and M. E. Carroll (2006). "Reinforcing effects of smoked methamphetamine in rhesus monkeys." *Psychopharmacology (Berl)* 188(2): 193-200.
- Nishino, N., Y. Shirai, et al. (1996). "Increased glutamate transporter (GLT-1) immunoreactivity in the rat striatum after repeated intermittent administration of methamphetamine." *Ann N Y Acad Sci* 801: 310-4.
- O'Neil M, L., R. Kuczenski, et al. (2006). "Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge." *Synapse* 60(6): 465-73.
- Pereira, F. C., E. S. Lourenco, et al. (2006). "Single or multiple injections of methamphetamine increased dopamine turnover but did not decrease tyrosine hydroxylase levels or cleave caspase-3 in caudate-putamen." *Synapse* 60(3): 185-93.
- Ranaldi, R. and R. A. Wise (2000). "Intravenous self-administration of methamphetamine-heroin (speedball) combinations under a progressive-ratio schedule of reinforcement in rats." *Neuroreport* 11(12): 2621-3.
- Ranaldi, R., K. G. Anderson, et al. (2000). "Reinforcing and discriminative stimulus effects of RTI 111, a 3-phenyltropane analog, in rhesus monkeys: Interaction with methamphetamine." *Psychopharmacology (Berl)* 153(1): 103-10.
- Roth, M. E. and M. E. Carroll (2004). "Sex differences in the acquisition of IV methamphetamine self-administration and subsequent maintenance under a progressive ratio schedule in rats." *Psychopharmacology (Berl)* 172(4): 443-9.
- Rothman, R. B., M. H. Baumann, et al. (2001). "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin." *Synapse* 39(1): 32-41.
- Sabol, K. E., J. T. Roach, et al. (2001). "Long-term effects of a high-dose methamphetamine regimen on subsequent methamphetamine-induced dopamine release in vivo." *Brain Res* 892(1): 122-9.

- Sanchez-Alavez, M., L. M. Gombart, et al. (2004). "Physiological and behavioral effects of methamphetamine in a mouse model of endotoxemia: a preliminary study." *Pharmacol Biochem Behav* 77(2): 365-70.
- Segal, D. S., R. Kuczenski, et al. (2005). "Prolonged exposure of rats to intravenous methamphetamine: behavioral and neurochemical characterization." *Psychopharmacology (Berl)* 180(3): 501-12.
- Segal, D. S., R. Kuczenski, et al. (2003). "Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge." *Neuropsychopharmacology* 28(10): 1730-40.
- Segal, D. S. and R. Kuczenski (1999). "Escalating dose-binge stimulant exposure: Relationship between emergent behavioral profile and differential caudate-putamen and nucleus accumbens dopamine responses." *Psychopharmacology (Berl)* 142(2): 182-92.
- Segal, D. S. and R. Kuczenski (1997). "Repeated binge exposures to amphetamine and methamphetamine: Behavioral and neurochemical characterization." *J Pharmacol Exp Ther* 282(2): 561-73.
- Semba, J., N. Tanaka, et al. (2001). "Neonatal phencyclidine treatment selectively attenuates mesolimbic dopamine function in adult rats as revealed by methamphetamine-induced behavior and c-fos mRNA expression in the brain." *Synapse* 40(1): 11-8.
- Semba, J., H. Watanabe, et al. (2000). "Neonatal treatment with L-name (NG-nitro-L-arginine methyl ester) attenuates stereotyped behavior induced by acute methamphetamine but not development of behavioral sensitization to methamphetamine." *Prog Neuropsychopharmacol Biol Psychiatry* 24(6): 1017-23.
- Shimosato, K. and S. Watanabe (1989). "Modification of behavioral responses to methamphetamine evoked by the stimulant's metabolite p-hydroxynorephedrine in rats." *Pharmacol Biochem Behav* 33(2): 423-9.
- Slamberova, R., P. Charousova, et al. (2005). "Methamphetamine administration during gestation impairs maternal behavior." *Dev Psychobiol* 46(1): 57-65.
- Stefanski, R., B. Ladenheim, et al. (1999). "Neuroadaptations in the dopaminergic system after active self-administration but not after passive administration of methamphetamine." *Eur J Pharmacol* 371(2-3): 123-35.
- Stephans, S. and B. Yamamoto (1996). "Methamphetamines pretreatment and the vulnerability of the striatum to methamphetamine neurotoxicity." *Neuroscience* 72(3): 593-600.
- Subarnas, A., T. Tadano, et al. (1993). "Pharmacological properties of beta-amyrin palmitate, a novel centrally acting compound, isolated from *Lobelia inflata* leaves." *J Pharm Pharmacol* 45(6): 545-50.
- Suemaru, J., K. Akiyama, et al. (2000). "Methamphetamine decreases calcium-calmodulin dependent protein kinase II activity in discrete rat brain regions." *Synapse* 36(3): 155-66.
- Sumiyoshi, T., M. Tsunoda, et al. (2004). "Enhanced locomotor activity in rats with excitotoxic lesions of the entorhinal cortex, a neurodevelopmental animal model of schizophrenia: Behavioral and in vivo microdialysis studies." *Neurosci Lett* 364(2): 124-9.
- Suzuki, H., T. Shishido, et al. (1997). "Changes of behavior and monoamine metabolites in the rat brain after repeated methamphetamine administration: Effects of duration of repeated administration." *Prog Neuropsychopharmacol Biol Psychiatry* 21(2): 359-69.
- Suzuki, T. and T. Moroji (1989). "Cholecystokinin binding sites in the rat forebrain: Effects of acute and chronic methamphetamine administration." *J Neural Transm* 77(2-3): 181-95.
- Suzuki, T., H. J. Fan Chiang, et al. (1987). "Effects of quinidine and cimetidine on methamphetamine stereotypy in rats." *J Pharmacobiodyn* 10(3): 152-5.
- Suzuki, T., H. J. Chiang, et al. (1986). "Studies on the mechanism of interaction between methamphetamine and quinine in rats." *J Pharmacobiodyn* 9(3): 234-8.
- Szumliński, K. K., M. Y. Balogun, et al. (2000). "Interactions between iboga agents and methamphetamine sensitization: studies of locomotion and stereotypy in rats." *Psychopharmacology (Berl)* 151(2-3): 234-41.
- Tadokoro, S. and H. Kuribara (1990). "[Modification of the behavioral effects of drugs after repeated administration--special reference to the reverse tolerance of amphetamines]." *Nippon Yakurigaku Zasshi* 95(5): 229-38.
- Takahashi, S., T. Miwa, et al. (2000). "Involvement of sigma 1 receptors in methamphetamine-induced behavioral sensitization in rats." *Neurosci Lett* 289(1): 21-4.
- Takaki, M., H. Ujike, et al. (2001). "Two kinds of mitogen-activated protein kinase phosphatases, MKP-1 and MKP-3, are differentially activated by acute and chronic methamphetamine treatment in the rat brain." *J Neurochem* 79(3): 679-88.
- Takigawa, M., H. Wang, et al. (2000). "Directed coherence of EEG on ICSS rats with methamphetamine-induced hyperactivity and stereotyped behavior." *Ann N Y Acad Sci* 914: 311-5.
- Takigawa, M., H. Maeda, et al. (1993). "A dual approach to self-stimulation and locomotor trace affected by chronic methamphetamine treatment for an animal model of schizophrenia." *Can J Physiol Pharmacol* 71(5-6): 321-5.
- Tsukada, H., K. Miyasato, et al. (2002). "Comparative effects of methamphetamine and nicotine on the striatal [(11)C]raclopride binding in unanesthetized monkeys." *Synapse* 45(4): 207-12.
- Ujike, H., A. Kanzaki, et al. (1992). "Sigma (sigma) antagonist BMY 14802 prevents methamphetamine-induced sensitization." *Life Sci* 50(16): PL129-34.

- Ujike, H., H. Tsuchida, et al. (1992). "Competitive and non-competitive N-methyl-D-aspartate antagonists fail to prevent the induction of methamphetamine-induced sensitization." *Life Sci* 50(22): 1673-81.
- Ujike, H., K. Akiyama, et al. (1990). "D-2 but not D-1 dopamine agonists produce augmented behavioral response in rats after subchronic treatment with methamphetamine or cocaine." *Psychopharmacology (Berl)* 102(4): 459-64.
- Ujike, H., T. Onoue, et al. (1989). "Effects of selective D-1 and D-2 dopamine antagonists on development of methamphetamine-induced behavioral sensitization." *Psychopharmacology (Berl)* 98(1): 89-92.
- Varner, K. J., B. A. Ogden, et al. (2002). "Cardiovascular responses elicited by the "binge" administration of methamphetamine." *J Pharmacol Exp Ther* 301(1): 152-9.
- Vinklerova, J., J. Novakova, et al. (2002). "Inhibition of methamphetamine self-administration in rats by cannabinoid receptor antagonist AM 251." *J Psychopharmacol* 16(2): 139-43.
- Wagner, G. C., N. Avena, et al. (2004). "Risperidone reduction of amphetamine-induced self-injurious behavior in mice." *Neuropharmacology* 46(5): 700-8.
- Wakamatsu, Y., M. Iwasaki, et al. (1974). "Proceedings: Influence of L-DOPA on brain noradrenaline contents and stereotypy in methamphetamine-treated rats." *Jpn J Pharmacol* 24(0): s:61.
- Wallace, T. L., G. A. Gudelsky, et al. (2001). "Neurotoxic regimen of methamphetamine produces evidence of behavioral sensitization in the rat." *Synapse* 39(1): 1-7.
- Wallace, T. L., G. A. Gudelsky, et al. (1999). "Methamphetamine-induced neurotoxicity alters locomotor activity, stereotypic behavior, and stimulated dopamine release in the rat." *J Neurosci* 19(20): 9141-8.
- Wang, H. D., M. Takigawa, et al. (2002). "A shift in information flow between prefrontal cortex and the ventral tegmental area in methamphetamine-sensitized rats." *Int J Psychophysiol* 44(3): 251-9.
- Wang, Z. and W. L. Woolverton (2007). "Estimating the relative reinforcing strength of (+/-)-3,4-methylenedioxyamphetamine (MDMA) and its isomers in rhesus monkeys: Comparison to (+)-methamphetamine." *Psychopharmacology (Berl)* 189(4): 483-8.
- Weihmuller, F. B., S. J. O'Dell, et al. (1991). "MK-801 attenuates the dopamine-releasing but not the behavioral effects of methamphetamine: an in vivo microdialysis study." *Brain Res* 549(2): 230-5.
- Williams, M. T., T. L. Schaefer, et al. (2006). "Ontogeny of the adrenal response to (+)-methamphetamine in neonatal rats: The effect of prior drug exposure." *Stress* 9(3): 153-63.
- Witkin, J. M., N. Savtchenko, et al. (1999). "Behavioral, toxic, and neurochemical effects of sydnocarb, a novel psychomotor stimulant: comparisons with methamphetamine." *J Pharmacol Exp Ther* 288(3): 1298-310.
- Yamamoto, H., K. Imai, et al. (2004). "Changes in expression of the mouse homologues of KIAA genes after subchronic methamphetamine treatment." *Ann N Y Acad Sci* 1025: 92-101.
- Yamamura, T., S. Hishida, et al. (1987). "[Interaction of alcohol and methamphetamine with acute high dose administration to rats]." *Arukuru Kenkyuto Yakubutsu Ison* 22(4): 286-99.
- Yamauchi, J., S. Marukawa, et al. (2000). "[Simultaneous administration of ethanol emphasizes the effect of methamphetamine on central nervous system in rat with high alcohol preference]." *Nihon Arukuru Yakubutsu Igakkai Zasshi* 35(1): 28-47.
- Yoshida, S., Y. Numachi, et al. (2000). "The absence of impairment of cliff avoidance reaction induced by subchronic methamphetamine treatment in inbred strains of mice." *Tohoku J Exp Med* 190(3): 205-12.
- Yoshida, S., Y. Numachi, et al. (1998). "Impairment of cliff avoidance reaction induced by subchronic methamphetamine administration and restraint stress: Comparison between two inbred strains of rats." *Prog Neuropsychopharmacol Biol Psychiatry* 22(6): 1023-32.
- Yoshida, S., Y. Numachi, et al. (1995). "[Reverse-tolerance phenomenon in methamphetamine-induced behavioral stereotypy and impairment of cliff avoidance reaction after subchronic methamphetamine administration in rats]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 15(5): 397-403.
- Yui, K., T. Miura, et al. (1994). "Stereotyped behavioral responses to an auditory stimulus in the course of repeated treatment with methamphetamine plus scopolamine and methamphetamine in rats." *Nihon Shinkei Seishin Yakurigaku Zasshi* 14(3): 169-78.
- Zhang, Y., T. M. Loonam, et al. (2001). "Comparison of cocaine- and methamphetamine-evoked dopamine and glutamate overflow in somatodendritic and terminal field regions of the rat brain during acute, chronic, and early withdrawal conditions." *Ann N Y Acad Sci* 937: 93-120.
- Zhu, J. P., W. Xu, et al. (2006). "Distinct mechanisms mediating methamphetamine-induced neuronal apoptosis and dopamine terminal damage share the neuropeptide substance P in the striatum of mice." *Ann N Y Acad Sci* 1074: 135-48.
- Zhu, J. P., W. Xu, et al. (2006). "Methamphetamine-induced striatal apoptosis in the mouse brain: Comparison of a binge to an acute bolus drug administration." *Neurotoxicology* 27(1): 131-6.

### Utah (US)

- Boulard, G. (2005). "The meth menace: Battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.
- Buchi, K. F., S. Zone, K. Langheinrich and M. W. Varner (2003). "Changing prevalence of prenatal substance abuse in Utah." *Obstet Gynecol* 102(1): 27-30.
- Callor, W. B., E. Petersen, et al. (2005). "Preliminary findings of noncompliance with psychotropic medication and prevalence of methamphetamine intoxication associated with suicide completion." *Crisis* 26(2): 78-84.
- Mecham, N. and J. Melini (2002). "Unintentional victims: Development of a protocol for the care of children exposed to chemicals at methamphetamine laboratories." *Pediatr Emerg Care* 18(4): 327-32.

### Vaccination, Drug Treatment

- Haney, M. and T. R. Kosten (2004). "Therapeutic vaccines for substance dependence." *Expert Rev Vaccines* 3(1): 11-8.
- Kantak, K. M. (2003). "Vaccines against drugs of abuse: A viable treatment option?" *Drugs* 63(4): 341-52.
- Kosten, T. and S. M. Owens (2005). "Immunotherapy for the treatment of drug abuse." *Pharmacol Ther.*

### Vaccination, Hepatitis A

- Hutin, Y. J., B. P. Bell, et al. (1999). "Identifying target groups for a potential vaccination program during a hepatitis A communitywide outbreak." *Am J Public Health* 89(6): 918-21.
- Kahraman, A., M. Miller, et al. (2006). "Non-alcoholic fatty liver disease in HIV-positive patients predisposes for acute-on-chronic liver failure: two cases." *Eur J Gastroenterol Hepatol* 18(1): 101-105.
- Vong, S., A. E. Fiore, et al. (2005). "Vaccination in the county jail as a strategy to reach high risk adults during a community-based hepatitis A outbreak among methamphetamine drug users." *Vaccine* 23(8): 1021-8.

### Vaccination, Hepatitis B

- Kahraman, A., M. Miller, et al. (2006). "Non-alcoholic fatty liver disease in HIV-positive patients predisposes for acute-on-chronic liver failure: Two cases." *Eur J Gastroenterol Hepatol* 18(1): 101-105.

### Vaccination, Pertussis

- Schafer, S., H. Gillette, et al. (2006). "A community-wide pertussis outbreak: an argument for universal booster vaccination." *Arch Intern Med* 166(12): 1317-21.

### Vancouver, BC (Canda)

- Barr, A. M., W. J. Panenka, et al. (2006). "The need for speed: An update on methamphetamine addiction." *J Psychiatry Neurosci* 31(5): 301-313.
- Bungay, V., L. Malchy, et al. (2006). "Life with jib: A snapshot of street youth's use of crystal methamphetamine." *Addiction Research and Theory* 14(3): 235-251.
- Collins, C. L., T. Kerr, et al. (2005). "Rationale to evaluate medically supervised safer smoking facilities for non-injection illicit drug users." *Can J Public Health* 96(5): 344-7.
- Collins, C. L., T. Kerr, et al. (2005). "Potential uptake and correlates of willingness to use a supervised smoking facility for noninjection illicit drug use." *J Urban Health* 82(2): 276-84.
- Fairbairn, N., T. Kerr, et al. (2006). "Increasing use and associated harms of crystal methamphetamine injection in a Canadian setting." *Drug Alcohol Depend.*
- Kerr, T., E. Wood, et al. (2005). "High rates of primary care and emergency department use among injection drug users in Vancouver." *J Public Health (Oxf)* 27(1): 62-6.
- Lampinen, T. M., D. McGhee, et al. (2006). "Increased risk of "club" drug use among gay and bisexual high school students in British Columbia." *J Adolesc Health* 38(4): 458-61.
- Lampinen, T. M., D. McGhee, et al. (2006). "Use of crystal methamphetamine and other club drugs among high school students in Vancouver and Victoria." *BC Medical Journal* 48(1): 22-27.
- Martin, I., T. M. Lampinen, et al. (2006). "Methamphetamine use among marginalized youth in British Columbia." *Can J Public Health* 97(4): 320-4.

- Rusch, M., T. M. Lampinen, A. Schilder and R. S. Hogg (2004). "Unprotected anal intercourse associated with recreational drug use among young men who have sex with men depends on partner type and intercourse role." *Sex Transm Dis* 31(8): 492-8.
- Schilder, A. J., T. M. Lampinen, et al. (2005). "Crystal methamphetamine and ecstasy differ in relation to unsafe sex among young gay men." *Can J Public Health* 96(5): 340-3.
- Wood, E., J. A. Stoltz, et al. (2006). "Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study." *Harm Reduct J* 3: 18.

## Vascular Effects and Disease

*See also* Brain Hemorrhages and Strokes; Cardiovascular Effects and Disease

- Anzalone, B., W. T. Crow and S. K. Costalas (2002). "If the bubble bursts.... EMS response to aortic aneurysms & dissections." *JEMS* 27(1): 84-8, 90-5; quiz 96-7.
- Berankova, K., V. Habrdova, et al. (2005). "Methamphetamine in hair and interpretation of forensic findings in a fatal case." *Forensic Sci Int* 153(1): 93-7.
- Brannan, T. A., S. Soundararajan, et al. (2004). "Methamphetamine-associated shock with intestinal infarction." *MedGenMed* 6(4): 6.
- Davis, G. G. and C. I. Swalwell (1996). "The incidence of acute cocaine or methamphetamine intoxication in deaths due to ruptured cerebral (berry) aneurysms." *J Forensic Sci* 41(4): 626-8.
- Davis, G. G. and C. I. Swalwell (1994). "Acute aortic dissections and ruptured berry aneurysms associated with methamphetamine abuse." *J Forensic Sci* 39(6): 1481-5.
- Dirkx, C. A. and E. O. Gerscovich (1998). "Sonographic findings in methamphetamine-induced ischemic colitis." *J Clin Ultrasound* 26(9): 479-82.
- Karch, S. B., B. G. Stephens and C. H. Ho (1999). "Methamphetamine-related deaths in San Francisco: Demographic, pathologic, and toxicologic profiles." *J Forensic Sci* 44(2): 359-68.
- Leithauser, B., A. C. Langheinrich, et al. (2005). "A 22-year-old woman with lower limb arteriopathy. Buerger's disease, or methamphetamine- or cannabis-induced arteritis?" *Heart Vessels* 20(1): 39-43.
- Longstreth, P. L. and M. Korobkin (1976). "Intrarenal arterial aneurysms." *CRC Crit Rev Clin Radiol Nucl Med* 8(1): 129-51.
- McGee, S. M., D. N. McGee, et al. (2004). "Spontaneous intracerebral hemorrhage related to methamphetamine abuse: Autopsy findings and clinical correlation." *Am J Forensic Med Pathol* 25(4): 334-7.
- Wallace, R. T., G. C. Brown, et al. (1992). "Sudden retinal manifestations of intranasal cocaine and methamphetamine abuse." *Am J Ophthalmol* 114(2): 158-60.

## Vascular Effects and Disease (animals)

*See also* Brain Hemorrhages and Strokes (animals); Cardiovascular Effects and Disease (animals)

- Caldwell, R. W. and L. I. Goldberg (1970). "An evaluation of the vasodilation produced by mephentermine and certain other sympathomimetic amines." *J Pharmacol Exp Ther* 172(2): 297-309.
- Cannon, M. S., E. D. Kapes, et al. (1986). "Effects of methamphetamine on arterioles of rat caudate nucleus and midbrain." *Acta Anat (Basel)* 127(3): 226-9.
- Nair, X. and D. C. Dyer (1974). "Responses of guinea pig umbilical vasculature to vasoactive drugs." *Eur J Pharmacol* 27(3): 294-304.
- Patil, P. N., S. Hetey, et al. (1970). "The sensitivity of rabbit aorta, atria and ileum to various agonists after repeated doses of (--) -ephedrine and related amines." *Arch Int Pharmacodyn Ther* 188(2): 257-70.
- Rumbaugh, C. L., H. C. Fang, et al. (1980). "Cerebral CT findings in drug abuse: Clinical and experimental observations." *J Comput Assist Tomogr* 4(3): 330-4.
- Rumbaugh, C. L., H. C. Fang, et al. (1976). "Cerebral microvascular injury in experimental drug abuse." *Invest Radiol* 11(4): 282-94.
- Rumbaugh, C. L., R. T. Bergeron, et al. (1971). "Cerebral vascular changes secondary to amphetamine abuse in the experimental animal." *Radiology* 101(2): 345-51.
- Shybut, G. T., W. R. Richter, et al. (1976). "Absence of pathological changes following intravenous methamphetamine and intra-arterial iothalamate meglumine." *Res Commun Chem Pathol Pharmacol* 15(1): 53-73.

### Viagra™

*See* [Erectile Dysfunction Drugs](#)

### Victoria, BC (Canada)

Lampinen, T. M., D. McGhee, et al. (2006). "Increased risk of "club" drug use among gay and bisexual high school students in British Columbia." *J Adolesc Health* 38(4): 458-61.

Lampinen, T. M., D. McGhee, et al. (2006). "Use of crystal methamphetamine and other club drugs among high school students in Vancouver and Victoria." *BC Medical Journal* 48(1): 22-27.

Martin, I., T. M. Lampinen, et al. (2006). "Methamphetamine use among marginalized youth in British Columbia." *Can J Public Health* 97(4): 320-4.

### Violence

*See* [Aggression and Violence; Self-Inflicted Injury and Self-Mutilation; Suicide and Suicidal Ideation](#)

### Vision and Visual Stimuli

Malitz, S. and M. Kanzler (1970). "Effects of drugs on perception in man." *Res Publ Assoc Res Nerv Ment Dis* 48: 35-53.

*See also* [Eye Conditions and Injuries](#)

### Vision and Visual Stimuli (animals)

Dalley, J. W., K. Laane, et al. (2006). "Enduring deficits in sustained visual attention during withdrawal of intravenous methylenedioxymethamphetamine self-administration in rats: Results from a comparative study with d-amphetamine and methamphetamine." *Neuropsychopharmacology*.

Hienz, R. D., S. E. Lukas, et al. (1985). "Effects of d-methamphetamine on auditory and visual reaction times and detection thresholds in the baboon." *Psychopharmacology (Berl)* 85(4): 476-82.

### Washington State (US)

*See also* [Seattle; Tacoma](#)

Boulard, G. (2005). "The meth menace: Battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.

Brewer, D. D., M. R. Golden, et al. (2006). "Unsafe sexual behavior and correlates of risk in a probability sample of men who have sex with men in the era of highly active antiretroviral therapy." *Sex Transm Dis* 33(4): 250-5.

Braine, N., D. C. Des Jarlais, S. Ahmad, D. Purchase and C. Turner (2004). "Long-term effects of syringe exchange on risk behavior and HIV prevention." *AIDS Educ Prev* 16(3): 264-75.

Couper, F. J., M. Pemberton, et al. (2002). "Prevalence of drug use in commercial tractor-trailer drivers." *J Forensic Sci* 47(3): 562-7.

Gorbach, P. M., J. T. Galea, et al. (2004). "Don't ask, don't tell: patterns of HIV disclosure among HIV positive men who have sex with men with recent STI practising high risk behaviour in Los Angeles and Seattle." *Sex Transm Infect* 80(6): 512-7.

Gorman, E. M. and R. T. Carroll (2000). "Substance abuse and HIV: Considerations with regard to methamphetamines and other recreational drugs for nursing practice and research." *J Assoc Nurses AIDS Care* 11(2): 51-62.

Huff, C. (2006). "Crystal crush." *Hosp Health Netw* 80(10): 59-60, 62, 64.

Koblin, B. A., M. A. Chesney, et al. (2003). "High-risk behaviors among men who have sex with men in 6 US cities: Baseline data from the EXPLORE Study." *Am J Public Health* 93(6): 926-32.

Logan, B. K., C. L. Fligner, et al. (1998). "Cause and manner of death in fatalities involving methamphetamine." *J Forensic Sci* 43(1): 28-34.

Logan, B. K. (1996). "Methamphetamine and driving impairment." *J Forensic Sci* 41(3): 457-64.

Logan, B. K., E. L. Weiss, et al. (1996). "Case report: Distribution of methamphetamine in a massive fatal ingestion." *J Forensic Sci* 41(2): 322-3.

Luchansky, B., A. Krupski, et al. (2007). "Treatment response by primary drug of abuse: Does methamphetamine make a difference?" *J Subst Abuse Treat* 32(1): 89-96.

Menza, T. W., G. Colfax, et al. (2006). "Interest in a methamphetamine intervention among men who have sex with men." *Sex Transm Dis* 33(9): 565-70.



- Perdue, T., H. Hagan, et al. (2003). "Depression and HIV risk behavior among Seattle-area injection drug users and young men who have sex with men." *AIDS Educ Prev* 15(1): 81-92.
- Schwilke, E. W., M. I. Sampaio dos Santos, et al. (2006). "Changing patterns of drug and alcohol use in fatally injured drivers in Washington State." *J Forensic Sci* 51(5): 1191-8.
- Smith, J. W. and P. J. Frawley (1993). "Treatment outcome of 600 chemically dependent patients treated in a multimodal inpatient program including aversion therapy and pentothal interviews." *J Subst Abuse Treat* 10(4): 359-69.
- Soellner, R. (2005). "Club drug use in Germany." *Subst Use Misuse* 40(9): 1279-93.
- Thiede, H., L. A. Valleroy, et al. (2003). "Regional patterns and correlates of substance use among young men who have sex with men in 7 US urban areas." *Am J Public Health* 93(11): 1915-21.

## Wisconsin (US)

*See also Milwaukee*

- Morin, S. F., W. T. Steward, et al. (2005). "Predicting HIV transmission risk among HIV-infected men who have sex with men: Findings from the Healthy Living Project." *J Acquir Immune Defic Syndr* 40(2): 226-235.
- Vandeveld, N. (2004). "Clandestine methamphetamine labs in Wisconsin." *J Environ Health* 66(7): 46-51.

## Withdrawal

- Broom, S. L. and B. K. Yamamoto (2005). "Effects of subchronic methamphetamine exposure on basal dopamine and stress-induced dopamine release in the nucleus accumbens shell of rats." *Psychopharmacology (Berl)*: 1-10.
- Davidson, C., A. J. Gow, et al. (2001). "Methamphetamine neurotoxicity: Necrotic and apoptotic mechanisms and relevance to human abuse and treatment." *Brain Res Brain Res Rev* 36(1): 1-22.
- Gillin, J. C., L. Pulvirenti, et al. (1994). "The effects of lisuride on mood and sleep during acute withdrawal in stimulant abusers: A preliminary report." *Biol Psychiatry* 35(11): 843-9.
- Kosten, T. R. and P. G. O'Connor (2003). "Management of drug and alcohol withdrawal." *N Engl J Med* 348(18): 1786-95.
- McGregor, C., M. Srisurapanont, et al. (2005). "The nature, time course and severity of methamphetamine withdrawal." *Addiction* 100(9): 1320-9.
- Miyata, H., J. Kono, et al. (2004). "[Studies on clinical characteristics of nicotine dependence using a two compartment model of drug dependence]." *Nihon Shinkei Seishin Yakurigaku Zasshi* 24(2): 61-6.
- Murray, J. B. (1998). "Psychophysiological aspects of amphetamine-methamphetamine abuse." *J Psychol* 132(2): 227-37.
- Nordahl, T. E., R. Salo, et al. (2005). "Methamphetamine users in sustained abstinence: A proton magnetic resonance spectroscopy study." *Arch Gen Psychiatry* 62(4): 444-52.
- Nordahl, T. E., R. Salo, et al. (2002). "Low N-acetyl-aspartate and high choline in the anterior cingulum of recently abstinent methamphetamine-dependent subjects: A preliminary proton MRS study. Magnetic resonance spectroscopy." *Psychiatry Res* 116(1-2): 43-52.
- Oro, A. S. and S. D. Dixon (1987). "Perinatal cocaine and methamphetamine exposure: Maternal and neonatal correlates." *J Pediatr* 111(4): 571-8.
- Rothman, R. B., J. S. Partilla, et al. (2000). "Methamphetamine dependence: Medication development efforts based on the dual deficit model of stimulant addiction." *Ann N Y Acad Sci* 914: 71-81.
- Smith, L., M. L. Yonekura, et al. (2003). "Effects of prenatal methamphetamine exposure on fetal growth and drug withdrawal symptoms in infants born at term." *J Dev Behav Pediatr* 24(1): 17-23.
- Srisurapanont, M., N. Jarusuraisin and P. Kittirattanapaiboon (2001). "Treatment for amphetamine withdrawal." *Cochrane Database Syst Rev*(4): CD003021.
- Watson, R., E. Hartmann, et al. (1972). "Amphetamine withdrawal: affective state, sleep patterns, and MHPG excretion." *Am J Psychiatry* 129(3): 263-9.

## Withdrawal (animals)

- Dalley, J. W., K. Laane, et al. (2006). "Enduring deficits in sustained visual attention during withdrawal of intravenous methylenedioxymethamphetamine self-administration in rats: Results from a comparative study with d-amphetamine and methamphetamine." *Neuropsychopharmacology*.
- Davidson, C., T. H. Lee, et al. (2005). "Acute and chronic continuous methamphetamine have different long-term behavioral and neurochemical consequences." *Neurochem Int* 46(3): 189-203.

- Hoefler, M. E., S. J. Voskanian, et al. (2006). "Effects of terguride, ropinirole, and acetyl-L-carnitine on methamphetamine withdrawal in the rat." *Pharmacol Biochem Behav* 83(3): 403-9.
- Krauchi, K., A. Wirz-Justice, et al. (1984). "Hypothalamic alpha 2- and beta-adrenoceptor rhythms are correlated with circadian feeding: evidence from chronic methamphetamine treatment and withdrawal." *Brain Res* 321(1): 83-90.
- Kubota, Y., C. Ito, et al. (1999). "Transient increases of histamine H1 and H2 receptor mRNA levels in the rat striatum after the chronic administration of methamphetamine." *Neurosci Lett* 275(1): 37-40.
- Maeda, T., N. Kiguchi, et al. (2006). "Peroxisome proliferator-activated receptor gamma activation relieves expression of behavioral sensitization to methamphetamine in mice." *Neuropsychopharmacology*.
- Manning, D. H., R. H. Strang, et al. (1974). "Changes in cerebral carbohydrate metabolism in the rat after acute and chronic treatment with, and withdrawal of, methamphetamine." *Biochem Pharmacol* 23(7): 1205-9.
- Morimasa, T., A. Wirz-Justice, et al. (1987). "Chronic methamphetamine and its withdrawal modify behavioral and neuroendocrine circadian rhythms." *Physiol Behav* 39(6): 699-705.
- Shibata, S., Y. Minamoto, et al. (1994). "Aging impairs methamphetamine-induced free-running and anticipatory locomotor activity rhythms in rats." *Neurosci Lett* 172(1-2): 107-10.
- Yoshimura, K. and K. Yamamoto (1980). "[Neuropharmacological studies on drug dependence (II). Changes in spontaneous motor activity, EEG and brain monoamines during the period of dependence development and of abrupt withdrawal in rats, with special reference to circadian rhythm (author's transl)]." *Nippon Yakurigaku Zasshi* 76(5): 373-411.
- Zhang, Y., T. M. Loonam, et al. (2001). "Comparison of cocaine- and methamphetamine-evoked dopamine and glutamate overflow in somatodendritic and terminal field regions of the rat brain during acute, chronic, and early withdrawal conditions." *Ann N Y Acad Sci* 937: 93-120.
- Zhang, Y. and J. A. Angulo (1996). "Contrasting effects of repeated treatment vs. withdrawal of methamphetamine on tyrosine hydroxylase messenger RNA levels in the ventral tegmental area and substantia nigra zona compacta of the rat brain." *Synapse* 24(3): 218-23.

### Women

*See also* Heterosexuals; Lesbians/Women who Have Sex with Women: Pregnancy; Sex Differences; *and other populations*

- Arria, A. M., C. Derauf, et al. (2006). "Methamphetamine and other substance use during pregnancy: Preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study." *Matern Child Health J* 10(3): 293-302.
- Grella, C. E., Y. I. Hser, et al. (2006). "Mothers in substance abuse treatment: Differences in characteristics based on involvement with child welfare services." *Child Abuse Negl* 30(1): 55-73.
- Hser, Y. I., E. Evans, et al. (2005). "Treatment outcomes among women and men methamphetamine abusers in California." *J Subst Abuse Treat* 28(1): 77-85.
- Koizumi, H., K. Hashimoto, et al. (2004). "Association between the glutathione S-transferase M1 gene deletion and female methamphetamine abusers." *Am J Med Genet B Neuropsychiatr Genet* 126(1): 43-5.
- Lampinen, T. M., D. McGhee, et al. (2006). "Use of crystal methamphetamine and other club drugs among high school students in Vancouver and Victoria." *BC Medical Journal* 48(1): 22-27.
- Lorvick, J., A. Martinez, et al. (2006). "Sexual and injection risk among women who inject methamphetamine in San Francisco." *J Urban Health* 83(3): 497-505.
- Lum, P. J., C. Sears, et al. (2005). "Injection risk behavior among women syringe exchangers in San Francisco." *Subst Use Misuse* 40(11): 1681-96.
- Mitchell, S. J., S. R. Morris, et al. (2006). "Methamphetamine use and sexual activity among HIV-infected patients in care--San Francisco, 2004." *AIDS Patient Care STDS* 20(7): 502-10.
- Noble, P., T. Hart, et al. (1972). "Correlates and outcome of illicit drug use by adolescent girls." *Br J Psychiatry* 120(558): 497-504.
- Operario, D. and T. Nemoto (2005). "Sexual risk behavior and substance use among a sample of Asian Pacific Islander transgendered women." *AIDS Educ Prev* 17(5): 430-43.
- Parsons, J. T., B. C. Kelly, et al. (2006). "Differences in club drug use between heterosexual and lesbian/bisexual females." *Addict Behav* 31(12): 2344-9.
- Semple, S. J., I. Grant, et al. (2004). "Female methamphetamine users: Social characteristics and sexual risk behavior." *Women Health* 40(3): 35-50.
- Simbulan, N. P., A. S. Aguilar, et al. (2001). "High-risk behaviors and the prevalence of sexually transmitted diseases among women prisoners at the women state penitentiary in Metro Manila." *Soc Sci Med* 52(4): 599-608.
- Somlai, A. M., J. A. Kelly, et al. (2003). "Predictors of HIV sexual risk behaviors in a community sample of injection drug-using men and women." *AIDS Behav* 7(4): 383-93.

- Srirak, N., S. Kawichai, et al. (2005). "HIV infection among female drug users in Northern Thailand." *Drug Alcohol Depend* 78(2): 141-5.
- Twitchell, G. R., A. Huber, et al. (2002). "Comparison of general and detailed HIV risk assessments among methamphetamine abusers." *AIDS and Behavior* 6(2): 153-162.
- Viani, R. M., M. R. Araneta, et al. (2006). "Perinatal HIV counseling and rapid testing in Tijuana, Baja California, Mexico: Seroprevalence and correlates of HIV infection." *J Acquir Immune Defic Syndr* 41(1): 87-92.
- Yoshimura, K. and K. Yamamoto (1979). "[Neuropharmacological studies on drug dependence (I). Effects due to the difference in strain, sex and drug administration time on physical dependence development and characteristics of withdrawal signs in CNS-affecting drug dependent rats (author's transl)]." *Nippon Yakurigaku Zasshi* 75(8): 805-28.
- Yui, K., S. Ikemoto, et al. (2002). "Spontaneous recurrence of methamphetamine-induced paranoid-hallucinatory states in female subjects: Susceptibility to psychotic states and implications for relapse of schizophrenia." *Pharmacopsychiatry* 35(2): 62-71.
- Yui, K., K. Goto, et al. (1995). "Spontaneous recurrence of methamphetamine psychosis: Process and monoamine neurotransmitter function." *Nihon Shinkei Seishin Yakurigaku Zasshi* 15(4): 363-74.

## Workplace

*See also* Occupational Exposure

- Maxwell, J. C. (2005). "Emerging research on methamphetamine." *Curr Opin Psychiatry* 18(3): 235-42.

## Wyoming (US)

- Boulard, G. (2005). "The meth menace: Battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.
- Vogt, T. M., J. F. Perz, et al. (2006). "An outbreak of hepatitis B virus infection among methamphetamine injectors: the role of sharing injection drug equipment." *Addiction* 101(5): 726-30.

## Young People

*See also* Aging and Age Factors; Childhood Attention-Deficit Hyperactivity Disorder; Children, Methamphetamine-Endangered; Children, Methamphetamine Ingestion by; Child Welfare System

- Adler, P. T. and L. Lotecka (1973). "Drug use among high school students: Patterns and correlates." *Int J Addict* 8(3): 537-48.
- Anonymous (2002). "Methamphetamine use is heightening risks among gay youth. 'club drugs' dull safe-sex sensibilities." *AIDS Alert* 17(10): 121, 123-5.
- Bailey, D. N. (1987). "Amphetamine detection during toxicology screening of a university medical center patient population." *J Toxicol Clin Toxicol* 25(5): 399-409.
- Banken, J. A. (2004). "Drug abuse trends among youth in the United States." *Ann N Y Acad Sci* 1025: 465-71.
- Barrett, M. E. (2003). "Correlates of illicit drug use in Karen villages in Northern Thailand." *Subst Use Misuse* 38(11-13): 1615-49.
- Baskin-Sommers, A. and I. Sommers (2006). "The co-occurrence of substance use and high-risk behaviors." *J Adolesc Health* 38(5): 609-11.
- Bellis, M. A., K. E. Hughes, et al. (2007). "Effects of backpacking holidays in Australia on alcohol, tobacco and drug use of UK residents." *BMC Public Health* 7(1): 1.
- Beyrer, C., M. H. Razak, et al. (2004). "Methamphetamine users in northern Thailand: Changing demographics and risks for HIV and STD among treatment-seeking substance abusers." *Int J STD AIDS* 15(10): 697-704.
- Boulard, G. (2005). "The meth menace: Battling the fast-paced spread of methamphetamine may mean attacking it from several fronts." *State Legis* 31(5): 14-8.
- Braine, N., D. C. Des Jarlais, et al. (2005). "HIV risk behavior among amphetamine injectors at U.S. syringe exchange programs." *AIDS Educ Prev* 17(6): 515-24.
- Braine, N., D. C. Des Jarlais, S. Ahmad, D. Purchase and C. Turner (2004). "Long-term effects of syringe exchange on risk behavior and HIV prevention." *AIDS Educ Prev* 16(3): 264-75.
- Brecht, M. L., L. Greenwell, et al. (2007). "Substance use pathways to methamphetamine use among treated users." *Addict Behav* 32(1): 24-38.
- Bungay, V., L. Malchy, et al. (2006). "Life with jib: A snapshot of street youth's use of crystal methamphetamine." *Addiction Research and Theory* 14(3): 235-251.
- Callor, W. B., E. Petersen, et al. (2005). "Preliminary findings of noncompliance with psychotropic medication and prevalence of methamphetamine intoxication associated with suicide completion." *Crisis* 26(2): 78-84.

- Chorpita, B. F. and J. O. Viesselman (2005). "Staying in the clinical ballpark while running the evidence bases." *J Am Acad Child Adolesc Psychiatry* 44(11): 1193-7.
- Chung, H., M. Park, et al. (2004). "Recent trends of drug abuse and drug-associated deaths in Korea." *Ann N Y Acad Sci* 1025: 458-64.
- Clatts, M. C., L. Goldsamt, et al. (2005). "Homelessness and drug abuse among young men who have sex with men in New York city: A preliminary epidemiological trajectory." *J Adolesc* 28(2): 201-14.
- Clatts, M. C., L. A. Goldsamt, et al. (2005). "Club drug use among young men who have sex with men in NYC: A preliminary epidemiological profile." *Subst Use Misuse* 40(9): 1317-30.
- Colfax, G., T. J. Coates, et al. (2005). "Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of San Francisco men who have sex with men." *J Urban Health* 82(1 Suppl 1): i62-70.
- Crosby, G. M., R. D. Stall, et al. (1998). "Alcohol and drug use patterns have declined between generations of younger gay-bisexual men in San Francisco." *Drug Alcohol Depend* 52(3): 177-82.
- Csemy, L., L. Kubicka, et al. (2002). "Drug scene in the Czech Republic and Slovakia during the period of transformation." *Eur Addict Res* 8(4): 159-65.
- Day, C., L. Degenhardt, et al. (2006). "Changes in the initiation of heroin use after a reduction in heroin supply." *Drug Alcohol Rev* 25(4): 307-13.
- Denehy, J. (2006). "The meth epidemic: Its effect on children and communities." *J Sch Nurs* 22(2): 63-5.
- Doherty, M. C., R. S. Garfein, E. Monterroso, D. Brown and D. Vlahov (2000). "Correlates of HIV infection among young adult short-term injection drug users." *AIDS* 14(6): 717-26.
- Doleys, D. M. (1977). "Behavioral treatments for nocturnal enuresis in children: A review of the recent literature." *Psychol Bull* 84(1): 30-54.
- Duterte, M., S. O'Neil, et al. (2001). "Walking the tightrope: Balancing health and drug use." *J Psychoactive Drugs* 33(2): 173-83.
- Dutta, S., J. Morton, et al. (2006). "Methamphetamine use following bariatric surgery in an adolescent." *Obes Surg* 16(6): 780-2.
- Fairbairn, N., T. Kerr, et al. (2006). "Increasing use and associated harms of crystal methamphetamine injection in a Canadian setting." *Drug Alcohol Depend*.
- Fournier, M. E. and S. Levy (2006). "Recent trends in adolescent substance use, primary care screening, and updates in treatment options." *Curr Opin Pediatr* 18(4): 352-8.
- Gettig, J. P., S. E. Grady, et al. (2006). "Methamphetamine: Putting the brakes on speed." *J Sch Nurs* 22(2): 66-73.
- Gibson, D. R., M. H. Leamon, et al. (2002). "Epidemiology and public health consequences of methamphetamine use in California's Central Valley." *J Psychoactive Drugs* 34(3): 313-9.
- Gleghorn, A. A., R. Marx, et al. (1998). "Association between drug use patterns and HIV risks among homeless, runaway, and street youth in northern California." *Drug Alcohol Depend* 51(3): 219-27.
- Goldsamt, L. A., J. O'Brien, et al. (2005). "The relationship between club drug use and other drug use: A survey of New York City middle school students." *Subst Use Misuse* 40(9): 1539-55.
- Goode, E. (1972). "Cigarette smoking and drug use on a college campus." *Int J Addict* 7(1): 133-40.
- Gordon, S. M., F. Tulak, et al. (2004). "Prevalence and characteristics of adolescents patients with co-occurring ADHD and substance dependence." *J Addict Dis* 23(4): 31-40.
- Greenhill, L. L. (2006). "The science of stimulant abuse." *Pediatr Ann* 35(8): 552-6.
- Hahn, J. A., K. Page-Shafer, P. J. Lum, K. Ochoa and A. R. Moss (2001). "Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco." *Hepatology* 34(1): 180-7.
- Hall, J. A., S. W. Henggeler, et al. (1993). "Adolescent substance use during pregnancy." *J Pediatr Psychol* 18(2): 265-71.
- Hasan, A. A. and S. Ciancio (2004). "Relationship between amphetamine ingestion and gingival enlargement." *Pediatr Dent* 26(5): 396-400.
- Hawke, J. M., N. Jainchill and G. De Leon (2000). "Adolescent amphetamine users in treatment: Client profiles and treatment outcomes." *J Psychoactive Drugs* 32(1): 95-105.
- Herman-Stahl, M. A., C. P. Krebs, et al. (2006). "Risk and protective factors for methamphetamine use and nonmedical use of prescription stimulants among young adults aged 18 to 25." *Addict Behav*.
- Herman-Stahl, M. A., C. P. Krebs, et al. (2006). "Risk and protective factors for nonmedical use of prescription stimulants and methamphetamine among adolescents." *J Adolesc Health* 39(3): 374-80.
- Hopfer, C., B. Mendelson, et al. (2006). "Club drug use among youths in treatment for substance abuse." *Am J Addict* 15(1): 94-9.
- Howe, A. M. (1995). "Methamphetamine and childhood and adolescent caries." *Aust Dent J* 40(5): 340.
- Irvine, R. J., M. Keane, et al. (2006). "Plasma drug concentrations and physiological measures in 'dance party' participants." *Neuropsychopharmacology* 31(2): 424-30.

- Jernigan, T. L., A. C. Gamst, et al. (2005). "Effects of methamphetamine dependence and HIV infection on cerebral morphology." *Am J Psychiatry* 162(8): 1461-72.
- Joe Laidler, K. A. (2005). "The rise of club drugs in a heroin society: The case of Hong Kong." *Subst Use Misuse* 40(9-10): 1257-78.
- Kato, M. (1983). "A birds eye view of the present state of drug abuse in Japan." *Drug Alcohol Depend* 11(1): 55-6.
- Kelly, B. C., J. T. Parsons, et al. (2006). "Prevalence and predictors of club drug use among club-going young adults in New York City." *J Urban Health* 83(5): 884-895.
- Kim, J. Y. and M. Fendrich (2002). "Gender differences in juvenile arrestees' drug use, self-reported dependence, and perceived need for treatment." *Psychiatr Serv* 53(1): 70-5.
- Kipke, M. D., S. O'Connor, et al. (1995). "Street youth in Los Angeles. Profile of a group at high risk for human immunodeficiency virus infection." *Arch Pediatr Adolesc Med* 149(5): 513-9.
- Kohrs, F. P., C. Mann and R. Greenberg (2004). "The use of amphetamine in gamma-hydroxybutyrate overdose: A case report." *J Psychoactive Drugs* 36(3): 401-2.
- Kolecki, P. (1998). "Inadvertent methamphetamine poisoning in pediatric patients." *Pediatr Emerg Care* 14(6): 385-7.
- Kral, A. H., J. Lorvick, et al. (2000). "Sex- and drug-related risk among populations of younger and older injection drug users in adjacent neighborhoods in San Francisco." *J Acquir Immune Defic Syndr* 24(2): 162-7.
- Kroutil, L. A., D. L. Van Brunt, et al. (2006). "Nonmedical use of prescription stimulants in the United States." *Drug Alcohol Depend* 84(2): 135-43.
- Kulsudjarit, K. (2004). "Drug problem in southeast and southwest Asia." *Ann N Y Acad Sci* 1025: 446-57.
- Ladewig, D. and R. Battagay (1971). "Abuse of anorexics with special reference to newer substances." *Int J Addict* 6(1): 167-72.
- Lagerspetz, M. and J. Moskalewicz (2002). "Drugs in the postsocialist transitions of Estonia, Latvia, Lithuania and Poland." *Eur Addict Res* 8(4): 177-83.
- Lampinen, T. M., D. McGhee, et al. (2006). "Increased risk of "club" drug use among gay and bisexual high school students in British Columbia." *J Adolesc Health* 38(4): 458-61.
- Lampinen, T. M., D. McGhee, et al. (2006). "Use of crystal methamphetamine and other club drugs among high school students in Vancouver and Victoria." *BC Medical Journal* 48(1): 22-27.
- Liu, A., P. Kilmarx, et al. (2006). "Sexual initiation, substance use, and sexual behavior and knowledge among vocational students in northern Thailand." *Int Fam Plan Perspect* 32(3): 126-35.
- Martin, I., T. M. Lampinen, et al. (2006). "Methamphetamine use among marginalized youth in British Columbia." *Can J Public Health* 97(4): 320-4.
- Maxwell, J. C. and R. T. Spence (2005). "Profiles of club drug users in treatment." *Subst Use Misuse* 40(9): 1409-26.
- McCaughan, J. A., R. G. Carlson, et al. (2005). "From "Candy Kids" to "Chemi-Kids": A typology of young adults who attend raves in the midwestern United States." *Subst Use Misuse* 40(9): 1503-23.
- Miura, H., M. Fujiki, et al. (2006). "Prevalence and profile of methamphetamine users in adolescents at a juvenile classification home." *Psychiatry Clin Neurosci* 60(3): 352-7.
- Morgan, J. P. (1992). "Amphetamine and methamphetamine during the 1990s." *Pediatr Rev* 13(9): 330-3.
- Noble, P., T. Hart, et al. (1972). "Correlates and outcome of illicit drug use by adolescent girls." *Br J Psychiatry* 120(558): 497-504.
- Ochoa, K. C., P. J. Davidson, et al. (2005). "Heroin overdose among young injection drug users in San Francisco." *Drug Alcohol Depend* 80(3): 297-302.
- Oetting, E. R., J. L. Deffenbacher, et al. (2000). "Methamphetamine use by high school students: Recent trends, gender and ethnicity differences, and use of other drugs." *Journal of Child and Adolescent Substance Abuse* 10(1): 33-50.
- Parks, K. A. and C. L. Kennedy (2004). "Club drugs: Reasons for and consequences of use." *J Psychoactive Drugs* 36(3): 295-302.
- Parsons, J. T., B. C. Kelly, et al. (2006). "Differences in club drug use between heterosexual and lesbian/bisexual females." *Addict Behav* 31(12): 2344-9.
- Perdue, T., H. Hagan, et al. (2003). "Depression and HIV risk behavior among Seattle-area injection drug users and young men who have sex with men." *AIDS Educ Prev* 15(1): 81-92.
- Prosser, J. M., M. Naim, et al. (2006). "A 14-year-old girl with agitation and hyperthermia." *Pediatr Emerg Care* 22(9): 676-9.
- Pugatch, D. L., B. G. Levesque, et al. (2001). "HIV testing among young adults and older adolescents in the setting of acute substance abuse treatment." *Journal of Acquired Immune Deficiency Syndromes: JAIDS*. 27(2): 135-42.x
- Rawson, R. A., R. Gonzales, et al. (2005). "Methamphetamine use among treatment-seeking adolescents in Southern California: Participant characteristics and treatment response." *J Subst Abuse Treat* 29(2): 67-74.
- Reid, L. W., K. W. Elifson, et al. (2007). "Ecstasy and gateway drugs: Initiating the use of ecstasy and other drugs." *Ann Epidemiol* 17(1): 74-80.

- Rimsza, M. E. and K. S. Moses (2005). "Substance abuse on the college campus." *Pediatr Clin North Am* 52(1): 307-19, xii.
- Royo-Isach, J., M. Magrane, et al. (2004). "[Speed users (metamphetamines): a return journey between ecstasy (MDMA) and cocaine. Clinical, preventive and health-care questions]." *Aten Primaria* 34(10): 553-6.
- Rusch, M., T. M. Lampinen, A. Schilder and R. S. Hogg (2004). "Unprotected anal intercourse associated with recreational drug use among young men who have sex with men depends on partner type and intercourse role." *Sex Transm Dis* 31(8): 492-8.
- Sattah, M. V., S. Supawitkul, et al. (2002). "Prevalence of and risk factors for methamphetamine use in northern Thai youth: Results of an audio-computer-assisted self-interviewing survey with urine testing." *Addiction* 97(7): 801-8.
- Schilder, A. J., T. M. Lampinen, et al. (2005). "Crystal methamphetamine and ecstasy differ in relation to unsafe sex among young gay men." *Can J Public Health* 96(5): 340-3.
- Seage, G. R., 3rd, K. H. Mayer, et al. (1998). "The social context of drinking, drug use, and unsafe sex in the Boston Young Men Study." *J Acquir Immune Defic Syndr Hum Retrovirol* 17(4): 368-75.
- Sears, C., J. R. Gudyish, et al. (2001). "Investigation of a secondary syringe exchange program for homeless young adult injection drug users in San Francisco, California, U.S.A." *J Acquir Immune Defic Syndr* 27(2): 193-201.
- Simbayi, L. C., S. C. Kalichman, et al. (2006). "Methamphetamine use and sexual risks for HIV infection in Cape Town, South Africa." *Journal of Substance Use* 11(4): 291-300.
- Simons, J. S., M. N. Oliver, et al. (2005). "Methamphetamine and alcohol abuse and dependence symptoms: Associations with affect lability and impulsivity in a rural treatment population." *Addict Behav* 30(7): 1370-81.
- Smith, D. E. (1969). "Runaways and their health problems in Haight-Ashbury during the summer of 1967." *Am J Public Health Nations Health* 59(11): 2046-50.
- Soellner, R. (2005). "Club drug use in Germany." *Subst Use Misuse* 40(9): 1279-93.
- Sommers, I., D. Baskin, et al. (2006). "Methamphetamine use among young adults: Health and social consequences." *Addict Behav* 31(8): 1469-76.
- Spoth, R. L., S. Clair, et al. (2006). "Long-term effects of universal preventive interventions on methamphetamine use among adolescents." *Arch Pediatr Adolesc Med* 160(9): 876-82.
- Storr, C. L., A. M. Arria, et al. (2004). "Neighborhood environment and opportunity to try methamphetamine ("ice") and marijuana: Evidence from Guam in the Western Pacific region of Micronesia." *Subst Use Misuse* 39(2): 253-76.
- Srirak, N., S. Kawichai, et al. (2005). "HIV infection among female drug users in Northern Thailand." *Drug Alcohol Depend* 78(2): 141-5.
- Suwaki, H., M. Yamasaki, et al. (1992). "A study of longitudinal patterns of substance abuse with special reference to multiple use problems." *Arukuru Kenkyuto Yakubutsu Ison* 27(3): 284-96.
- Tellier, P. P. (2002). "Club drugs: Is it all ecstasy?" *Pediatr Ann* 31(9): 550-6.
- Thiede, H., L. A. Valleroy, et al. (2003). "Regional patterns and correlates of substance use among young men who have sex with men in 7 US urban areas." *Am J Public Health* 93(11): 1915-21.
- van Griensven, F., S. Supawitkul, et al. (2001). "Rapid assessment of sexual behavior, drug use, human immunodeficiency virus, and sexually transmitted diseases in northern Thai youth using audio-computer-assisted self-interviewing and noninvasive specimen collection." *Pediatrics* 108(1): E13.
- Van Leeuwen, J. M., C. Hopfer, et al. (2004). "A snapshot of substance abuse among homeless and runaway youth in Denver, Colorado." *J Community Health* 29(3): 217-29.
- Vitsupakorn, K., S. Teerawatsakul, et al. (2003). "The validity of peer responses as a tool for screening at-risk students: a preliminary analysis." *Southeast Asian J Trop Med Public Health* 34(3): 682-6.
- Waldo, C. R., W. McFarland, M. H. Katz, D. MacKellar and L. A. Valleroy (2000). "Very young gay and bisexual men are at risk for HIV infection: The San Francisco Bay Area Young Men's Survey II." *J Acquir Immune Defic Syndr* 24(2): 168-74.
- Wu, L. T., W. E. Schlenger, et al. (2006). "Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths." *Drug Alcohol Depend* 84(1): 102-13.
- Wu, L. T., D. J. Pilowsky, et al. (2004). "Injection drug use among stimulant users in a national sample." *Am J Drug Alcohol Abuse* 30(1): 61-83.
- Yamamoto, J. (2004). "Recent trends of drug abuse in Japan." *Ann N Y Acad Sci* 1025: 430-8.
- Yen, C. F. and M. Y. Chong (2006). "Comorbid psychiatric disorders, sex, and methamphetamine use in adolescents: A case-control study." *Compr Psychiatry* 47(3): 215-20.
- Yen, C. F. and Y. C. Su (2006). "The associations of early-onset methamphetamine use with psychiatric morbidity among Taiwanese adolescents." *Subst Use Misuse* 41(1): 35-44.
- Yen, C. F., Y. H. Yang, et al. (2006). "Correlates of methamphetamine use for Taiwanese adolescents." *Psychiatry Clin Neurosci* 60(2): 160-7.

- Yen, C. F., C. H. Ko, et al. (2005). "Areca quid chewing and methamphetamine use in Taiwanese adolescents." *Public Health* 119(1): 50-4.
- Yen, C. F. and Y. P. Chang (2005). "Relapse antecedents for methamphetamine use and related factors in Taiwanese adolescents." *Psychiatry Clin Neurosci* 59(1): 77-82.
- Yen, C. F., Y. H. Yang, et al. (2005). "Substance initiation sequences among Taiwanese adolescents using methamphetamine." *Psychiatry Clin Neurosci* 59(6): 683-9.
- Yen, C. F. and B. L. Shieh (2005). "Suicidal ideation and correlates in Taiwanese adolescent methamphetamine users." *J Nerv Ment Dis* 193(7): 444-9.
- Yen, C. F. (2004). "Relationship between methamphetamine use and risky sexual behavior in adolescents." *Kaohsiung J Med Sci* 20(4): 160-5.

